Number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
their O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
hormone O-MISC O-MISC
action O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
study O-MISC O-MISC
demonstrated O-MISC O-MISC
a O-MISC O-MISC
decreased O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
hypercholesterolemic O-MISC O-MISC
subjects O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
an O-MISC O-MISC
elevated O-MISC O-MISC
level O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
myocardial O-MISC O-MISC
infarction O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
lymphocytes O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
GR B-MISC B-MISC
number O-MISC O-MISC
, O-MISC O-MISC
dexamethasone O-MISC O-MISC
inhibited O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
thymidine O-MISC O-MISC
and O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
acetate O-MISC O-MISC
incorporation O-MISC O-MISC
into O-MISC O-MISC
DNA O-MISC O-MISC
and O-MISC O-MISC
cholesterol O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
manner O-MISC O-MISC
as O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
hand O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
decreased O-MISC O-MISC
GR B-MISC B-MISC
number O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
less O-MISC O-MISC
efficient O-MISC O-MISC
dexamethasone O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
incorporation O-MISC O-MISC
of O-MISC O-MISC
labeled O-MISC O-MISC
compounds O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
lymphocytes O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
changed O-MISC O-MISC
only O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
decrease O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
level O-MISC O-MISC
. O-MISC O-MISC

[ O-MISC B-MISC
1 B-MISC I-MISC
, I-MISC I-MISC
25 I-MISC I-MISC
- I-MISC I-MISC
Dihydroxyvitamin I-MISC I-MISC
D3 I-MISC I-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphocyte O-MISC O-MISC
count O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
glomerulonephritis O-MISC O-MISC
] O-MISC O-MISC

Content O-MISC O-MISC
of O-MISC O-MISC
receptors O-MISC O-MISC
to O-MISC O-MISC
hormonal O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
vitamin O-MISC O-MISC
D3 O-MISC O-MISC
, O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
, O-MISC O-MISC
constituted O-MISC O-MISC
27 O-MISC O-MISC
. O-MISC O-MISC
3 O-MISC O-MISC
fmole O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
of O-MISC O-MISC
protein O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
of O-MISC O-MISC
peripheric O-MISC O-MISC
blood O-MISC O-MISC
of O-MISC O-MISC
children O-MISC O-MISC
with O-MISC O-MISC
glomerulonephritis O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
total O-MISC O-MISC
and O-MISC O-MISC
ionized O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
Ca2 O-MISC O-MISC
+ O-MISC O-MISC
was O-MISC O-MISC
decreased O-MISC O-MISC
down O-MISC O-MISC
to O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
04 O-MISC O-MISC
mmole O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
and O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
09 O-MISC O-MISC
mmole O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
parathormone O-MISC O-MISC
( O-MISC O-MISC
PTH O-MISC O-MISC
) O-MISC O-MISC
by O-MISC O-MISC
36 O-MISC O-MISC
% O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
distinct O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
D O-MISC O-MISC
concentration O-MISC O-MISC
( O-MISC O-MISC
lower O-MISC O-MISC
than O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
25 O-MISC O-MISC
ng O-MISC O-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
blood O-MISC O-MISC
; O-MISC O-MISC
content O-MISC O-MISC
of O-MISC O-MISC
cAMP O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
decreased O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
by O-MISC O-MISC
33 O-MISC O-MISC
% O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
time O-MISC O-MISC
, O-MISC O-MISC
total O-MISC O-MISC
content O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
was O-MISC O-MISC
decreased O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
in O-MISC O-MISC
peripheric O-MISC O-MISC
blood O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
with O-MISC O-MISC
I O-MISC O-MISC
- O-MISC O-MISC
hydroxyvitamin O-MISC O-MISC
D3 O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
mg O-MISC O-MISC
daily O-MISC O-MISC
, O-MISC O-MISC
within O-MISC O-MISC
4 O-MISC O-MISC
weeks O-MISC O-MISC
) O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
normalization O-MISC O-MISC
of O-MISC O-MISC
total O-MISC O-MISC
and O-MISC O-MISC
ionized O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
Ca2 O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
of O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
D O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
the O-MISC O-MISC
PTH O-MISC O-MISC
content O-MISC O-MISC
in O-MISC O-MISC
blood O-MISC O-MISC
. O-MISC O-MISC

Concentration O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptors B-MISC O-MISC
to O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
was O-MISC O-MISC
elevated O-MISC O-MISC
up O-MISC O-MISC
to O-MISC O-MISC
39 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
fmole O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
after O-MISC O-MISC
I O-MISC O-MISC
week O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
decreased O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
initial O-MISC O-MISC
level O-MISC O-MISC
24 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
fmole O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
within O-MISC O-MISC
4 O-MISC O-MISC
weeks O-MISC O-MISC
; O-MISC O-MISC
simultaneous O-MISC O-MISC
alteration O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cAMP O-MISC O-MISC
content O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
with O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
D3 O-MISC O-MISC
normalized O-MISC O-MISC
also O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
content O-MISC O-MISC
in O-MISC O-MISC
peripheric O-MISC O-MISC
blood O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
data O-MISC O-MISC
obtained O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
under O-MISC O-MISC
conditions O-MISC O-MISC
of O-MISC O-MISC
glomerulonephritis O-MISC B-MISC
only O-MISC O-MISC
high O-MISC O-MISC
content O-MISC O-MISC
of O-MISC O-MISC
receptors B-MISC B-MISC
to O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
enabled O-MISC O-MISC
to O-MISC O-MISC
perform O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
hormone O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

Tumor O-MISC B-MISC
and O-MISC O-MISC
serum O-MISC B-MISC
beta O-MISC I-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC I-MISC
microglobulin O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
women O-MISC O-MISC
with O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
investigate O-MISC O-MISC
whether O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
beta B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
- I-MISC I-MISC
microglobulin I-MISC I-MISC
( O-MISC O-MISC
beta B-MISC O-MISC
2 I-MISC I-MISC
- I-MISC O-MISC
M I-MISC O-MISC
) O-MISC O-MISC
could O-MISC O-MISC
serve O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
marker O-MISC O-MISC
of O-MISC O-MISC
tumor O-MISC O-MISC
biologic O-MISC O-MISC
behavior O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
authors O-MISC O-MISC
studied O-MISC O-MISC
specimens O-MISC O-MISC
of O-MISC O-MISC
breast O-MISC O-MISC
carcinomas O-MISC O-MISC
from O-MISC O-MISC
60 O-MISC O-MISC
consecutive O-MISC O-MISC
female O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Presence O-MISC O-MISC
of O-MISC O-MISC
beta B-MISC O-MISC
2 I-MISC I-MISC
- I-MISC O-MISC
M I-MISC O-MISC
was O-MISC O-MISC
analyzed O-MISC O-MISC
by O-MISC O-MISC
immunohistochemistry O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
significant O-MISC O-MISC
correlations O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
between O-MISC O-MISC
tumor B-MISC B-MISC
beta I-MISC I-MISC
2 I-MISC I-MISC
- I-MISC O-MISC
M I-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
several O-MISC O-MISC
histologic O-MISC O-MISC
attributes O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
type O-MISC O-MISC
, O-MISC O-MISC
histologic O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
grades O-MISC O-MISC
, O-MISC O-MISC
mitotic O-MISC O-MISC
index O-MISC O-MISC
, O-MISC O-MISC
necrosis O-MISC O-MISC
, O-MISC O-MISC
vascular O-MISC B-MISC
invasion O-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
lymphocytic O-MISC O-MISC
infiltration O-MISC O-MISC
. O-MISC O-MISC

Likewise O-MISC O-MISC
, O-MISC O-MISC
beta B-MISC B-MISC
2 I-MISC I-MISC
- I-MISC I-MISC
M I-MISC I-MISC
was O-MISC O-MISC
not O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
markers O-MISC O-MISC
of O-MISC O-MISC
disease O-MISC O-MISC
extension O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
TNM O-MISC B-MISC
, O-MISC O-MISC
( O-MISC O-MISC
UICC O-MISC O-MISC
, O-MISC O-MISC
classification O-MISC O-MISC
of O-MISC O-MISC
malignant O-MISC O-MISC
tumors O-MISC O-MISC
) O-MISC O-MISC
staging O-MISC O-MISC
and O-MISC O-MISC
axillary O-MISC O-MISC
lymph O-MISC O-MISC
node O-MISC O-MISC
involvement O-MISC O-MISC
or O-MISC O-MISC
with O-MISC O-MISC
estrogen O-MISC O-MISC
, O-MISC O-MISC
progesterone O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
glucocorticoid O-MISC B-MISC
receptor O-MISC I-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
significantly O-MISC O-MISC
positive O-MISC O-MISC
association O-MISC O-MISC
between O-MISC O-MISC
tumor B-MISC O-MISC
beta I-MISC I-MISC
2 I-MISC I-MISC
- I-MISC O-MISC
M I-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
degree O-MISC O-MISC
of O-MISC O-MISC
lymphocytic O-MISC O-MISC
infiltration O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC O-MISC
tissue O-MISC O-MISC
. O-MISC O-MISC

Beta B-MISC O-MISC
2 I-MISC O-MISC
- I-MISC O-MISC
M I-MISC O-MISC
serum O-MISC O-MISC
levels O-MISC O-MISC
were O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
enzyme O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
immunosorbent O-MISC O-MISC
assay O-MISC O-MISC
in O-MISC O-MISC
samples O-MISC O-MISC
from O-MISC O-MISC
22 O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
above O-MISC O-MISC
women O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
some O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
highest O-MISC O-MISC
values O-MISC O-MISC
had O-MISC O-MISC
been O-MISC O-MISC
obtained O-MISC O-MISC
in O-MISC O-MISC
women O-MISC O-MISC
with O-MISC O-MISC
larger O-MISC O-MISC
( O-MISC O-MISC
T4 O-MISC O-MISC
) O-MISC O-MISC
primary O-MISC O-MISC
tumors O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
authors O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
detect O-MISC O-MISC
any O-MISC O-MISC
statistical O-MISC O-MISC
relationship O-MISC O-MISC
between O-MISC O-MISC
beta B-MISC B-MISC
2 I-MISC I-MISC
- I-MISC O-MISC
M I-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC O-MISC
with O-MISC O-MISC
serum O-MISC O-MISC
levels O-MISC O-MISC
or O-MISC O-MISC
between O-MISC O-MISC
serum B-MISC B-MISC
beta I-MISC I-MISC
2 I-MISC I-MISC
- I-MISC O-MISC
M I-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
above O-MISC O-MISC
histologic O-MISC O-MISC
, O-MISC O-MISC
laboratory O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
clinical O-MISC B-MISC
factors O-MISC I-MISC
. O-MISC O-MISC

[ O-MISC O-MISC
Preliminary O-MISC O-MISC
observation O-MISC O-MISC
of O-MISC O-MISC
level O-MISC O-MISC
free B-MISC O-MISC
- I-MISC O-MISC
form I-MISC I-MISC
E I-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
serum O-MISC O-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
childbearing O-MISC O-MISC
- O-MISC O-MISC
aged O-MISC O-MISC
and O-MISC O-MISC
pregnant O-MISC O-MISC
women O-MISC O-MISC
] O-MISC O-MISC

In O-MISC O-MISC
137 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
childbearing O-MISC O-MISC
- O-MISC O-MISC
aged O-MISC O-MISC
and O-MISC O-MISC
pregnant O-MISC O-MISC
women O-MISC O-MISC
, O-MISC O-MISC
free B-MISC O-MISC
form I-MISC O-MISC
E I-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
( O-MISC O-MISC
sE B-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
serum O-MISC O-MISC
were O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
ELISA O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
sE B-MISC B-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
decreased O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
trimester O-MISC O-MISC
, O-MISC O-MISC
slightly O-MISC O-MISC
higher O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
second O-MISC O-MISC
trimester O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
recovered O-MISC O-MISC
to O-MISC O-MISC
normal O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
third O-MISC O-MISC
trimester O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
level O-MISC O-MISC
remained O-MISC O-MISC
lower O-MISC O-MISC
in O-MISC O-MISC
29 O-MISC O-MISC
PIH O-MISC B-MISC
women O-MISC O-MISC
but O-MISC O-MISC
appeared O-MISC O-MISC
higher O-MISC O-MISC
in O-MISC O-MISC
overdue O-MISC O-MISC
pregnancies O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
normal O-MISC O-MISC
3rd O-MISC O-MISC
trimester O-MISC O-MISC
range O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
there O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
relationship O-MISC O-MISC
between O-MISC O-MISC
a O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
and O-MISC O-MISC
pregnancy O-MISC O-MISC
. O-MISC O-MISC

Kappa B-MISC B-MISC
B I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
DNA I-MISC I-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
: O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
human B-MISC B-MISC
interleukin I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Transcriptional O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
interleukin I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) I-MISC I-MISC
gene I-MISC I-MISC
, O-MISC O-MISC
like O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
alpha I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
alpha I-MISC I-MISC
) I-MISC I-MISC
gene I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
modulated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
kappa B-MISC B-MISC
B I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
enhancer I-MISC I-MISC
element I-MISC I-MISC
. O-MISC O-MISC

Mutation O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
kappa B-MISC B-MISC
B I-MISC I-MISC
core I-MISC I-MISC
sequence I-MISC I-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
( O-MISC O-MISC
- O-MISC I-MISC
206 O-MISC I-MISC
to O-MISC I-MISC
- O-MISC I-MISC
195 O-MISC I-MISC
) O-MISC O-MISC
partially O-MISC O-MISC
inhibits O-MISC O-MISC
both O-MISC O-MISC
mitogen O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
I O-MISC O-MISC
Tax O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
transcription B-MISC B-MISC
unit I-MISC I-MISC
and O-MISC O-MISC
blocks O-MISC O-MISC
the O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
two O-MISC O-MISC
inducible B-MISC O-MISC
cellular I-MISC B-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
kappa B-MISC B-MISC
B I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
proteins I-MISC I-MISC
( O-MISC O-MISC
80 O-MISC O-MISC
to O-MISC O-MISC
90 O-MISC O-MISC
and O-MISC O-MISC
50 O-MISC O-MISC
to O-MISC O-MISC
55 O-MISC B-MISC
kilodaltons O-MISC I-MISC
) O-MISC O-MISC
similarly O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
functional O-MISC O-MISC
kappa B-MISC B-MISC
B I-MISC I-MISC
enhancer I-MISC I-MISC
present O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
alpha I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
these O-MISC O-MISC
kappa B-MISC B-MISC
B I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
proteins I-MISC I-MISC
have O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
coordinate O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
growth O-MISC B-MISC
factor O-MISC I-MISC
- O-MISC I-MISC
growth O-MISC I-MISC
factor O-MISC I-MISC
receptor O-MISC I-MISC
gene O-MISC I-MISC
system O-MISC O-MISC
that O-MISC O-MISC
controls O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Novel O-MISC O-MISC
region O-MISC I-MISC
within O-MISC O-MISC
the O-MISC O-MISC
V B-MISC B-MISC
kappa I-MISC I-MISC
gene I-MISC I-MISC
promoter I-MISC I-MISC
is O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
tissue O-MISC O-MISC
and O-MISC O-MISC
stage O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
neoplasms O-MISC O-MISC
. O-MISC O-MISC

Immunoglobulin B-MISC O-MISC
gene I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
transacting I-MISC I-MISC
factors I-MISC I-MISC
have O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
lymphoid O-MISC O-MISC
tissue O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
factors O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
stage O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
genes O-MISC O-MISC
is O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
not O-MISC O-MISC
fully O-MISC O-MISC
understood O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
used O-MISC O-MISC
a O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
neoplasia O-MISC O-MISC
to O-MISC O-MISC
address O-MISC O-MISC
this O-MISC O-MISC
question O-MISC O-MISC
. O-MISC O-MISC

Different O-MISC O-MISC
fragments O-MISC O-MISC
of O-MISC O-MISC
unrearranged B-MISC O-MISC
human I-MISC B-MISC
variable I-MISC I-MISC
region I-MISC I-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
kappa I-MISC I-MISC
gene I-MISC I-MISC
( O-MISC O-MISC
V B-MISC B-MISC
kappa I-MISC I-MISC
) O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
for O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
transcription O-MISC O-MISC
and O-MISC O-MISC
DNA O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
. O-MISC O-MISC

Previously O-MISC O-MISC
described O-MISC O-MISC
enhancement O-MISC O-MISC
of O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
transcription O-MISC O-MISC
that O-MISC O-MISC
was O-MISC O-MISC
only O-MISC O-MISC
seen O-MISC O-MISC
with O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
neoplasms O-MISC O-MISC
corresponding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
late O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
was O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
actions O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
factor O-MISC O-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
DNA O-MISC B-MISC
region O-MISC I-MISC
within O-MISC O-MISC
the O-MISC O-MISC
V B-MISC B-MISC
kappa I-MISC I-MISC
gene I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
region O-MISC O-MISC
is O-MISC O-MISC
located O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
920 O-MISC B-MISC
bp O-MISC I-MISC
fragment O-MISC I-MISC
located O-MISC O-MISC
210 O-MISC B-MISC
bp O-MISC I-MISC
upstream O-MISC I-MISC
from O-MISC O-MISC
the O-MISC O-MISC
coding O-MISC O-MISC
region O-MISC O-MISC
and O-MISC O-MISC
this O-MISC O-MISC
fragment O-MISC O-MISC
represents O-MISC O-MISC
a O-MISC O-MISC
possible O-MISC O-MISC
novel O-MISC O-MISC
DNA O-MISC B-MISC
region O-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
stage O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
tissue O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

[ O-MISC O-MISC
Determination O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids B-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
] O-MISC O-MISC

A O-MISC O-MISC
modified O-MISC O-MISC
method O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
determination O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
is O-MISC O-MISC
suggested O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
principal O-MISC O-MISC
distinction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
method O-MISC O-MISC
is O-MISC O-MISC
standardization O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
lymphocyte O-MISC O-MISC
count O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
sample O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
mln O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
labeled O-MISC O-MISC
hormone B-MISC O-MISC
concentration O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
modification O-MISC O-MISC
saves O-MISC O-MISC
time O-MISC O-MISC
and O-MISC O-MISC
money O-MISC O-MISC
, O-MISC O-MISC
limits O-MISC O-MISC
the O-MISC O-MISC
range O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
data O-MISC O-MISC
variations O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
makes O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
lesser O-MISC O-MISC
volume O-MISC O-MISC
of O-MISC O-MISC
blood O-MISC O-MISC
. O-MISC O-MISC

Examinations O-MISC O-MISC
of O-MISC O-MISC
70 O-MISC O-MISC
children O-MISC O-MISC
aged O-MISC O-MISC
4 O-MISC O-MISC
to O-MISC O-MISC
15 O-MISC O-MISC
suffering O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
nephrotic O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
glomerulonephritis O-MISC O-MISC
have O-MISC O-MISC
made O-MISC O-MISC
it O-MISC O-MISC
possible O-MISC O-MISC
to O-MISC O-MISC
distinguish O-MISC O-MISC
two O-MISC O-MISC
groups O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
: O-MISC O-MISC
with O-MISC O-MISC
relatively O-MISC O-MISC
high O-MISC O-MISC
values O-MISC O-MISC
of O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
X O-MISC O-MISC
= O-MISC O-MISC
6820 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
530 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
30 O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
95 O-MISC O-MISC
, O-MISC O-MISC
t O-MISC O-MISC
= O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
04 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
this O-MISC O-MISC
corresponding O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
clinical O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
hormone B-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
glomerulonephritis O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
with O-MISC O-MISC
relatively O-MISC O-MISC
low O-MISC O-MISC
values O-MISC O-MISC
of O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
X O-MISC O-MISC
= O-MISC O-MISC
1815 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
302 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
40 O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
95 O-MISC O-MISC
, O-MISC O-MISC
t O-MISC O-MISC
= O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
96 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
corresponds O-MISC O-MISC
to O-MISC O-MISC
hormone B-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
glomerulonephritis O-MISC O-MISC
. O-MISC O-MISC

Dynamic O-MISC O-MISC
studies O-MISC O-MISC
have O-MISC O-MISC
not O-MISC O-MISC
shown O-MISC O-MISC
any O-MISC O-MISC
statistically O-MISC O-MISC
significant O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
values O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
permit O-MISC O-MISC
regarding O-MISC O-MISC
the O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
value O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
prognostic O-MISC O-MISC
criterion O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
assessment O-MISC O-MISC
of O-MISC O-MISC
corticosteroid B-MISC O-MISC
therapy O-MISC O-MISC
; O-MISC O-MISC
this O-MISC O-MISC
allows O-MISC O-MISC
a O-MISC O-MISC
wide O-MISC O-MISC
employment O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
described O-MISC O-MISC
method O-MISC O-MISC
in O-MISC O-MISC
practical O-MISC O-MISC
nephrology O-MISC O-MISC
. O-MISC O-MISC

Octamer B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
from O-MISC O-MISC
B O-MISC O-MISC
or O-MISC O-MISC
HeLa O-MISC O-MISC
cells O-MISC O-MISC
stimulate O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immunoglobulin B-MISC B-MISC
heavy I-MISC I-MISC
- I-MISC I-MISC
chain I-MISC I-MISC
promoter I-MISC I-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
specificity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immunoglobulin B-MISC B-MISC
( O-MISC I-MISC
Ig B-MISC I-MISC
) O-MISC I-MISC
heavy O-MISC I-MISC
- O-MISC I-MISC
chain O-MISC I-MISC
and O-MISC I-MISC
light O-MISC I-MISC
- O-MISC I-MISC
chain O-MISC I-MISC
promoters O-MISC I-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
octanucleotide B-MISC O-MISC
( I-MISC I-MISC
OCTA I-MISC B-MISC
) I-MISC I-MISC
element I-MISC I-MISC
, O-MISC O-MISC
ATGCAAAT O-MISC B-MISC
, O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
a O-MISC O-MISC
functional O-MISC O-MISC
component O-MISC O-MISC
of O-MISC O-MISC
other O-MISC O-MISC
RNA B-MISC B-MISC
polymerase I-MISC I-MISC
II I-MISC I-MISC
promoters I-MISC I-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
snRNA O-MISC B-MISC
and O-MISC O-MISC
histone O-MISC I-MISC
H2B O-MISC B-MISC
promoters O-MISC I-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
nuclear B-MISC B-MISC
proteins I-MISC I-MISC
that O-MISC O-MISC
bind O-MISC O-MISC
specifically O-MISC O-MISC
and O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
OCTA B-MISC B-MISC
element I-MISC I-MISC
have O-MISC O-MISC
been O-MISC O-MISC
identified O-MISC O-MISC
. O-MISC O-MISC

NF B-MISC B-MISC
- I-MISC I-MISC
A1 I-MISC I-MISC
is O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
A2 I-MISC I-MISC
is O-MISC O-MISC
essentially O-MISC O-MISC
confined O-MISC O-MISC
to O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
hypothesis O-MISC O-MISC
that O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
A2 I-MISC I-MISC
activates O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ig B-MISC B-MISC
promoter I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
A1 I-MISC I-MISC
mediates O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
responses O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
OCTA B-MISC B-MISC
element I-MISC I-MISC
. O-MISC O-MISC

Extracts O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
BJA O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
, O-MISC O-MISC
contain O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
A2 I-MISC O-MISC
and O-MISC O-MISC
specifically O-MISC O-MISC
transcribe O-MISC O-MISC
Ig B-MISC B-MISC
promoters I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
HeLa O-MISC O-MISC
cells O-MISC O-MISC
transcribed O-MISC O-MISC
the O-MISC O-MISC
Ig B-MISC B-MISC
promoter I-MISC I-MISC
poorly O-MISC O-MISC
. O-MISC O-MISC

Surprisingly O-MISC O-MISC
, O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
affinity O-MISC O-MISC
- O-MISC I-MISC
enriched O-MISC I-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
A2 O-MISC I-MISC
or O-MISC I-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
A1 O-MISC I-MISC
to O-MISC O-MISC
either O-MISC O-MISC
a O-MISC O-MISC
HeLa O-MISC O-MISC
extract O-MISC O-MISC
or O-MISC O-MISC
a O-MISC O-MISC
partially O-MISC O-MISC
purified O-MISC O-MISC
reaction O-MISC O-MISC
system O-MISC O-MISC
specifically O-MISC O-MISC
stimulates O-MISC O-MISC
the O-MISC O-MISC
Ig B-MISC B-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
constitutive O-MISC O-MISC
OCTA B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
factor I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
A1 I-MISC I-MISC
can O-MISC O-MISC
activate O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ig B-MISC B-MISC
promoter I-MISC I-MISC
and O-MISC O-MISC
that O-MISC O-MISC
B O-MISC B-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
promoter O-MISC O-MISC
, O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
partially O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
quantitative O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
OCTA B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

Because O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
A1 I-MISC I-MISC
can O-MISC O-MISC
stimulate O-MISC O-MISC
Ig B-MISC B-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
inability O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
factor O-MISC O-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
the O-MISC O-MISC
Ig B-MISC B-MISC
promoter I-MISC I-MISC
to O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
degree O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
snRNA B-MISC B-MISC
promoters I-MISC I-MISC
probably O-MISC O-MISC
reflects O-MISC O-MISC
a O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
context O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
OCTA B-MISC B-MISC
element I-MISC I-MISC
in O-MISC O-MISC
these O-MISC O-MISC
two O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
promoters B-MISC B-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
putative O-MISC O-MISC
regulator O-MISC O-MISC
of O-MISC O-MISC
early B-MISC B-MISC
T I-MISC I-MISC
cell I-MISC I-MISC
activation I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Molecules O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
antigen O-MISC B-MISC
receptor O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
early B-MISC B-MISC
T I-MISC I-MISC
cell I-MISC I-MISC
activation I-MISC I-MISC
genes I-MISC I-MISC
were O-MISC O-MISC
investigated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
functional O-MISC O-MISC
sequences O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
cell I-MISC I-MISC
activation I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
enhancer I-MISC I-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

One O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
sequences O-MISC O-MISC
forms O-MISC O-MISC
a O-MISC O-MISC
protein O-MISC B-MISC
complex O-MISC I-MISC
, O-MISC O-MISC
NFAT B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
specifically O-MISC O-MISC
with O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
of O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
complex O-MISC O-MISC
appeared O-MISC O-MISC
10 O-MISC O-MISC
to O-MISC O-MISC
25 O-MISC O-MISC
minutes O-MISC O-MISC
before O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

Studies O-MISC O-MISC
with O-MISC O-MISC
inhibitors O-MISC O-MISC
of O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
time O-MISC O-MISC
of O-MISC O-MISC
synthesis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
activator O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
corresponds O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
time O-MISC O-MISC
of O-MISC O-MISC
appearance O-MISC O-MISC
of O-MISC O-MISC
NFAT B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

NFAT B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
or O-MISC O-MISC
a O-MISC O-MISC
very O-MISC O-MISC
similar O-MISC O-MISC
protein O-MISC O-MISC
, O-MISC O-MISC
bound O-MISC O-MISC
functional O-MISC O-MISC
sequences O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
long B-MISC B-MISC
terminal I-MISC I-MISC
repeat I-MISC I-MISC
( O-MISC O-MISC
LTR B-MISC B-MISC
) O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
; O-MISC O-MISC
the O-MISC O-MISC
LTR B-MISC B-MISC
of O-MISC O-MISC
this O-MISC O-MISC
virus O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
stimulated O-MISC O-MISC
during O-MISC O-MISC
early O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
binding B-MISC B-MISC
site I-MISC I-MISC
for O-MISC O-MISC
this O-MISC O-MISC
complex O-MISC O-MISC
activated O-MISC O-MISC
a O-MISC O-MISC
linked O-MISC B-MISC
promoter O-MISC I-MISC
after O-MISC O-MISC
transfection O-MISC O-MISC
into O-MISC O-MISC
antigen O-MISC O-MISC
receptor O-MISC I-MISC
- O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
other O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
characteristics O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
NFAT B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
transmits O-MISC O-MISC
signals O-MISC O-MISC
initiated O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
cell I-MISC I-MISC
antigen I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Characterization O-MISC O-MISC
of O-MISC O-MISC
thyroid B-MISC B-MISC
hormone I-MISC I-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
IM O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
putatively O-MISC O-MISC
identified O-MISC O-MISC
more O-MISC O-MISC
than O-MISC O-MISC
10 O-MISC O-MISC
years O-MISC O-MISC
ago O-MISC O-MISC
, O-MISC O-MISC
thyroid B-MISC B-MISC
hormone I-MISC I-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
tissues O-MISC O-MISC
remain O-MISC O-MISC
poorly O-MISC O-MISC
characterized O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
a O-MISC O-MISC
first O-MISC O-MISC
step O-MISC O-MISC
towards O-MISC O-MISC
understanding O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
thyroid O-MISC O-MISC
hormone O-MISC O-MISC
action O-MISC O-MISC
in O-MISC O-MISC
man O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
characterized O-MISC O-MISC
T3 B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
in O-MISC O-MISC
nuclei O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
lymphoblastoid O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
IM O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
experiments O-MISC O-MISC
at O-MISC O-MISC
37 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
, O-MISC O-MISC
nuclear O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
[ B-MISC O-MISC
125I I-MISC O-MISC
] I-MISC O-MISC
T3 I-MISC O-MISC
was O-MISC O-MISC
saturable O-MISC O-MISC
( O-MISC O-MISC
Kd O-MISC O-MISC
34 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
pmol O-MISC O-MISC
/ O-MISC O-MISC
l O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
of O-MISC O-MISC
finite O-MISC O-MISC
capacity O-MISC O-MISC
( O-MISC O-MISC
approximately O-MISC O-MISC
equal O-MISC O-MISC
to O-MISC O-MISC
350 O-MISC O-MISC
sites O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
binding B-MISC B-MISC
sites I-MISC I-MISC
were O-MISC O-MISC
extracted O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
nuclear O-MISC O-MISC
pellet O-MISC I-MISC
by O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
mol O-MISC O-MISC
/ O-MISC O-MISC
l O-MISC O-MISC
KCl O-MISC O-MISC
and O-MISC O-MISC
sonication O-MISC O-MISC
. O-MISC O-MISC

Separation O-MISC O-MISC
of O-MISC O-MISC
bound O-MISC O-MISC
from O-MISC O-MISC
free O-MISC O-MISC
[ B-MISC O-MISC
125I I-MISC O-MISC
] I-MISC O-MISC
T3 I-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
extracts O-MISC O-MISC
was O-MISC O-MISC
achieved O-MISC O-MISC
using O-MISC O-MISC
the O-MISC O-MISC
calcium O-MISC O-MISC
phosphate O-MISC O-MISC
matrix O-MISC O-MISC
, O-MISC O-MISC
hydroxyapatite O-MISC B-MISC
at O-MISC O-MISC
a O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
3 O-MISC O-MISC
ml O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
150 O-MISC O-MISC
g O-MISC O-MISC
/ O-MISC O-MISC
l O-MISC O-MISC
slurry O-MISC O-MISC
. O-MISC O-MISC

Rectilinear O-MISC O-MISC
Scatchard O-MISC O-MISC
plots O-MISC O-MISC
were O-MISC O-MISC
obtained O-MISC O-MISC
only O-MISC O-MISC
when O-MISC O-MISC
the O-MISC O-MISC
hydroxyapatite O-MISC B-MISC
was O-MISC O-MISC
washed O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
buffer O-MISC O-MISC
containing O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
% O-MISC O-MISC
Triton O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
100 O-MISC O-MISC
. O-MISC O-MISC

Under O-MISC O-MISC
these O-MISC O-MISC
conditions O-MISC O-MISC
T3 B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
were O-MISC O-MISC
present O-MISC O-MISC
at O-MISC O-MISC
a O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
22 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
fmol O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
protein O-MISC O-MISC
and O-MISC O-MISC
showed O-MISC O-MISC
an O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
( O-MISC O-MISC
Kd O-MISC O-MISC
, O-MISC O-MISC
room O-MISC O-MISC
temperature O-MISC O-MISC
) O-MISC O-MISC
140 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
10 O-MISC O-MISC
pmol O-MISC O-MISC
/ O-MISC O-MISC
l O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
same O-MISC O-MISC
assay O-MISC O-MISC
system O-MISC O-MISC
was O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
hierarchy O-MISC O-MISC
of O-MISC O-MISC
affinities O-MISC O-MISC
for O-MISC O-MISC
a O-MISC O-MISC
range O-MISC O-MISC
of O-MISC O-MISC
natural O-MISC O-MISC
and O-MISC O-MISC
synthetic O-MISC O-MISC
analogues O-MISC O-MISC
. O-MISC O-MISC

Calling O-MISC O-MISC
T3 O-MISC O-MISC
100 O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
order O-MISC O-MISC
of O-MISC O-MISC
potencies O-MISC O-MISC
observed O-MISC O-MISC
was O-MISC O-MISC
: O-MISC O-MISC
Triac O-MISC O-MISC
, O-MISC O-MISC
500 O-MISC O-MISC
; O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
diiodo O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
' O-MISC O-MISC
- O-MISC O-MISC
isopropylthyronine O-MISC O-MISC
, O-MISC O-MISC
89 O-MISC O-MISC
; O-MISC O-MISC
T4 O-MISC O-MISC
, O-MISC O-MISC
32 O-MISC O-MISC
; O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
dimethyl O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
' O-MISC O-MISC
isopropylthyronine O-MISC O-MISC
2 O-MISC O-MISC
; O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
T2 O-MISC O-MISC
, O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
rT3 O-MISC O-MISC
, O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
; O-MISC O-MISC
3 O-MISC O-MISC
' O-MISC O-MISC
5 O-MISC O-MISC
' O-MISC O-MISC
- O-MISC O-MISC
T2 O-MISC O-MISC
, O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
T3 B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
present O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
IM O-MISC O-MISC
- O-MISC I-MISC
9 O-MISC I-MISC
lymphocyte O-MISC O-MISC
nuclei O-MISC O-MISC
and O-MISC O-MISC
extracts O-MISC O-MISC
thereof O-MISC O-MISC
are O-MISC O-MISC
thyroid B-MISC B-MISC
hormone I-MISC I-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
cells O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
useful O-MISC O-MISC
tool O-MISC O-MISC
to O-MISC O-MISC
increase O-MISC O-MISC
our O-MISC O-MISC
understanding O-MISC O-MISC
of O-MISC O-MISC
human B-MISC B-MISC
T3 I-MISC I-MISC
receptors I-MISC I-MISC

Definition O-MISC O-MISC
of O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
specific I-MISC I-MISC
DNA I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
factors I-MISC I-MISC
that O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
3 B-MISC B-MISC
' I-MISC I-MISC
- I-MISC I-MISC
silencer I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
CD4 B-MISC O-MISC
+ I-MISC O-MISC
T I-MISC O-MISC
- I-MISC O-MISC
cell I-MISC O-MISC
gene I-MISC O-MISC
Rpt I-MISC O-MISC
- I-MISC O-MISC
1 I-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
region O-MISC B-MISC
3 O-MISC I-MISC
' O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
CD4 B-MISC B-MISC
+ I-MISC I-MISC
T I-MISC I-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
gene I-MISC I-MISC
Rpt I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
encoding O-MISC O-MISC
regulatory O-MISC B-MISC
protein O-MISC I-MISC
T B-MISC O-MISC
- I-MISC O-MISC
lymphocyte I-MISC O-MISC
1 I-MISC O-MISC
) O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
definition O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
silencer B-MISC B-MISC
element I-MISC I-MISC
that O-MISC O-MISC
inhibits O-MISC O-MISC
heterologous B-MISC O-MISC
gene I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
certain O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
or O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
lymphoid O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

Functional O-MISC O-MISC
silencer B-MISC B-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC B-MISC
silencer B-MISC B-MISC
- I-MISC I-MISC
DNA I-MISC I-MISC
- I-MISC I-MISC
protein I-MISC I-MISC
complex I-MISC I-MISC
in O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
with O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
extracts O-MISC O-MISC
. O-MISC O-MISC

Formation O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
complex O-MISC O-MISC
was O-MISC O-MISC
selectively O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
region O-MISC O-MISC
in O-MISC O-MISC
HIV B-MISC O-MISC
- I-MISC O-MISC
1 I-MISC I-MISC
containing O-MISC O-MISC
a O-MISC O-MISC
silencer B-MISC B-MISC
element I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
discuss O-MISC O-MISC
the O-MISC O-MISC
possibility O-MISC O-MISC
that O-MISC O-MISC
DNA B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
factors I-MISC I-MISC
may O-MISC O-MISC
coregulate O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
and O-MISC O-MISC
Rpt O-MISC O-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
through O-MISC O-MISC
a O-MISC O-MISC
common O-MISC O-MISC
transcriptional B-MISC B-MISC
silencer I-MISC I-MISC
element I-MISC I-MISC
. O-MISC O-MISC

Congenital O-MISC O-MISC
immunodeficiencies O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
HLA B-MISC B-MISC
class I-MISC I-MISC
II I-MISC I-MISC
antigens I-MISC I-MISC
on O-MISC O-MISC
lymphocytes O-MISC O-MISC
result O-MISC O-MISC
from O-MISC O-MISC
distinct O-MISC O-MISC
mutations O-MISC O-MISC
in O-MISC O-MISC
trans B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

Coordinate O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
HLA B-MISC B-MISC
class I-MISC I-MISC
II I-MISC I-MISC
gene I-MISC I-MISC
expression O-MISC O-MISC
during O-MISC O-MISC
development O-MISC O-MISC
and O-MISC O-MISC
coinduction O-MISC O-MISC
of O-MISC O-MISC
class B-MISC B-MISC
II I-MISC I-MISC
genes I-MISC I-MISC
by O-MISC O-MISC
soluble B-MISC O-MISC
factors I-MISC I-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
common O-MISC O-MISC
trans B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
control O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
genes O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphoblastoid O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
two O-MISC O-MISC
independent O-MISC O-MISC
class O-MISC O-MISC
II O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
bare O-MISC O-MISC
lymphocyte O-MISC O-MISC
syndrome O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
observed O-MISC O-MISC
a O-MISC O-MISC
drastic O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
transcription O-MISC O-MISC
rates O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
class B-MISC B-MISC
II I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

When O-MISC O-MISC
these O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
are O-MISC O-MISC
fused O-MISC O-MISC
, O-MISC O-MISC
class B-MISC B-MISC
II I-MISC I-MISC
genes I-MISC I-MISC
are O-MISC O-MISC
reexpressed O-MISC O-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
that O-MISC O-MISC
immunodeficiencies O-MISC O-MISC
in O-MISC O-MISC
bare O-MISC O-MISC
lymphocyte O-MISC O-MISC
syndrome O-MISC O-MISC
patients O-MISC O-MISC
are O-MISC O-MISC
the O-MISC O-MISC
result O-MISC O-MISC
of O-MISC O-MISC
two O-MISC O-MISC
distinct O-MISC O-MISC
mutations O-MISC O-MISC
. O-MISC O-MISC

Further O-MISC O-MISC
studies O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
genes O-MISC O-MISC
governing O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
class B-MISC B-MISC
II I-MISC I-MISC
antigens I-MISC I-MISC
fall O-MISC O-MISC
into O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
three O-MISC O-MISC
complementation O-MISC O-MISC
groups O-MISC O-MISC
; O-MISC O-MISC
two O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
were O-MISC O-MISC
previously O-MISC O-MISC
unidentified O-MISC O-MISC
in O-MISC O-MISC
mutant O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
generated O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
the O-MISC O-MISC
identification O-MISC O-MISC
of O-MISC O-MISC
two O-MISC O-MISC
discrete O-MISC O-MISC
complexes O-MISC O-MISC
, O-MISC O-MISC
NFX1 B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
NFX1 B-MISC B-MISC
. I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
that O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
DRA B-MISC B-MISC
X I-MISC I-MISC
consensus I-MISC I-MISC
element I-MISC I-MISC
. O-MISC O-MISC

Though O-MISC O-MISC
the O-MISC O-MISC
mutation O-MISC O-MISC
in O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
one O-MISC O-MISC
mutant O-MISC O-MISC
line O-MISC O-MISC
generated O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
( O-MISC O-MISC
RJ2 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
) O-MISC O-MISC
affects O-MISC O-MISC
products O-MISC O-MISC
functioning O-MISC O-MISC
via O-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
X B-MISC B-MISC
box I-MISC I-MISC
, O-MISC O-MISC
clear O-MISC O-MISC
alterations O-MISC O-MISC
in O-MISC O-MISC
either O-MISC O-MISC
NFX1 B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
or O-MISC O-MISC
NFX1 B-MISC B-MISC
. I-MISC I-MISC
2 I-MISC I-MISC
are O-MISC O-MISC
not O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
any O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mutant O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
vivo O-MISC O-MISC
responsiveness O-MISC O-MISC
to O-MISC O-MISC
glucocorticoid O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
content O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
leukocytes O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
humans O-MISC O-MISC
. O-MISC O-MISC

Dexamethasone O-MISC O-MISC
loading O-MISC O-MISC
tests O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
mg O-MISC O-MISC
dexamethasone O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
, O-MISC O-MISC
iv O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
performed O-MISC O-MISC
in O-MISC O-MISC
18 O-MISC O-MISC
normal O-MISC O-MISC
males O-MISC O-MISC
to O-MISC O-MISC
evaluate O-MISC O-MISC
the O-MISC O-MISC
individual O-MISC O-MISC
responsiveness O-MISC O-MISC
to O-MISC O-MISC
glucocorticoid O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
were O-MISC O-MISC
inter O-MISC O-MISC
- O-MISC O-MISC
individual O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
polymorphonuclear O-MISC O-MISC
leukocyte O-MISC O-MISC
count O-MISC O-MISC
, O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
lymphocyte O-MISC O-MISC
count O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
plasma O-MISC O-MISC
free O-MISC O-MISC
fatty O-MISC O-MISC
acids O-MISC O-MISC
levels O-MISC O-MISC
after O-MISC O-MISC
dexamethasone O-MISC O-MISC
injection O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
maximum O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
polymorphonuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
maximum O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
( O-MISC O-MISC
r O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
7514 O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
0003 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Simultaneous O-MISC O-MISC
measurements O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
content O-MISC O-MISC
by O-MISC O-MISC
whole O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
assay O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
content O-MISC O-MISC
in O-MISC O-MISC
polymorphonuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
linearly O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
corresponding O-MISC O-MISC
lymphocytes O-MISC O-MISC
( O-MISC O-MISC
r O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
9482 O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
0001 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
significant O-MISC O-MISC
correlations O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
maximum O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
polymorphonuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
and O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
content O-MISC O-MISC
in O-MISC O-MISC
polymorphonuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
( O-MISC O-MISC
r O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
7239 O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
0007 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
maximum O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
content O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
( O-MISC O-MISC
r O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
7703 O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
0002 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
individual O-MISC O-MISC
differences O-MISC O-MISC
are O-MISC O-MISC
preserved O-MISC O-MISC
both O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid O-MISC O-MISC
responsiveness O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
content O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
leukocytes O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
humans O-MISC O-MISC
. O-MISC O-MISC

Estradiol O-MISC B-MISC
receptors O-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytosol O-MISC O-MISC
of O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
hepatitis O-MISC O-MISC
B O-MISC O-MISC
virus O-MISC O-MISC
carriers O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
interferon B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

Estradiol B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytosol O-MISC O-MISC
of O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
interferon B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC I-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
on O-MISC O-MISC
estradiol B-MISC O-MISC
receptors I-MISC I-MISC
were O-MISC O-MISC
studied O-MISC O-MISC
in O-MISC O-MISC
asymptomatic O-MISC O-MISC
hepatitis O-MISC O-MISC
B O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
HBV O-MISC O-MISC
) O-MISC O-MISC
carriers O-MISC O-MISC
, O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
hepatitis O-MISC O-MISC
B O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
estradiol B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytosol O-MISC O-MISC
of O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
lower O-MISC O-MISC
in O-MISC O-MISC
asymptomatic O-MISC O-MISC
HBV O-MISC O-MISC
carriers O-MISC O-MISC
and O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
hepatitis O-MISC O-MISC
B O-MISC O-MISC
, O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
normal O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
low O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
cytosol O-MISC O-MISC
estradiol B-MISC O-MISC
receptors I-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
hepatitis O-MISC O-MISC
B O-MISC O-MISC
was O-MISC O-MISC
increased O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
administration O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
when O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
hepatitis O-MISC O-MISC
B O-MISC O-MISC
were O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
cytosol O-MISC O-MISC
estradiol B-MISC O-MISC
receptors I-MISC O-MISC
also O-MISC O-MISC
increased O-MISC O-MISC
by O-MISC O-MISC
increasing O-MISC O-MISC
the O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
previously O-MISC O-MISC
reported O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
response O-MISC O-MISC
of O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
estrogen O-MISC O-MISC
is O-MISC O-MISC
impaired O-MISC O-MISC
in O-MISC O-MISC
HBV O-MISC O-MISC
carriers O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
our O-MISC O-MISC
present O-MISC O-MISC
results O-MISC O-MISC
suggested O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
low O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
estradiol B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytosol O-MISC O-MISC
of O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Association O-MISC O-MISC
of O-MISC O-MISC
increased O-MISC O-MISC
lytic O-MISC O-MISC
effector O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
estrogen B-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
tumor O-MISC O-MISC
- O-MISC O-MISC
bearing O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
. O-MISC O-MISC

Tumor O-MISC O-MISC
- O-MISC O-MISC
bearing O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
were O-MISC O-MISC
assayed O-MISC O-MISC
for O-MISC O-MISC
their O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
( O-MISC O-MISC
NK O-MISC O-MISC
) O-MISC O-MISC
cell O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
activated O-MISC O-MISC
cytotoxic O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
lectin O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
cellular O-MISC O-MISC
cytotoxicity O-MISC O-MISC
( O-MISC O-MISC
LDCC O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Tumor O-MISC O-MISC
- O-MISC O-MISC
bearing O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
NK O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
LDCC O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
healthy O-MISC O-MISC
control O-MISC O-MISC
individuals O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
the O-MISC O-MISC
enhanced O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
LDCC O-MISC O-MISC
were O-MISC O-MISC
closely O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
( O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
31 O-MISC O-MISC
fmol O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
estrogen B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
ER B-MISC B-MISC
) O-MISC O-MISC
content O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
primary O-MISC O-MISC
tumor O-MISC O-MISC
, O-MISC O-MISC
no O-MISC O-MISC
other O-MISC O-MISC
clinical O-MISC O-MISC
or O-MISC O-MISC
histologic O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
either O-MISC O-MISC
parameter O-MISC O-MISC
of O-MISC O-MISC
cytotoxic O-MISC O-MISC
effector O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
found O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
ER B-MISC O-MISC
levels O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
31 O-MISC O-MISC
fmol O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
might O-MISC O-MISC
be O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
increased O-MISC O-MISC
cytotoxic O-MISC O-MISC
effector O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
in O-MISC O-MISC
tumor O-MISC O-MISC
- O-MISC O-MISC
bearing O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
. O-MISC O-MISC

Properties O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
familial O-MISC O-MISC
cortisol O-MISC O-MISC
resistance O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
a O-MISC O-MISC
previous O-MISC O-MISC
report O-MISC O-MISC
of O-MISC O-MISC
two O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
familial O-MISC O-MISC
glucocorticoid O-MISC O-MISC
resistance O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
reduced O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
decreased O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
cultured O-MISC O-MISC
fibroblasts O-MISC O-MISC
but O-MISC O-MISC
normal O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
in O-MISC O-MISC
both O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
peripheral O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
these O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
one O-MISC O-MISC
patient O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
son O-MISC O-MISC
and O-MISC O-MISC
daughter O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
were O-MISC O-MISC
transformed O-MISC O-MISC
with O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
. O-MISC O-MISC

Reduced O-MISC O-MISC
numbers O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
were O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
both O-MISC O-MISC
patients O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
son O-MISC O-MISC
and O-MISC O-MISC
daughter O-MISC O-MISC
had O-MISC O-MISC
normal O-MISC O-MISC
numbers O-MISC O-MISC
and O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
thermal O-MISC O-MISC
stability O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
and O-MISC O-MISC
thermal O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
cytosolic B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
both O-MISC O-MISC
patients O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
normal O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
the O-MISC O-MISC
percentages O-MISC O-MISC
of O-MISC O-MISC
nuclear O-MISC O-MISC
bound O-MISC O-MISC
GR B-MISC B-MISC
were O-MISC O-MISC
similar O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
controls O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
absolute O-MISC O-MISC
amounts O-MISC O-MISC
of O-MISC O-MISC
nuclear O-MISC O-MISC
bound O-MISC O-MISC
GR B-MISC B-MISC
of O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
were O-MISC O-MISC
about O-MISC O-MISC
one O-MISC O-MISC
- O-MISC O-MISC
half O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
abnormal O-MISC O-MISC
properties O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
( O-MISC O-MISC
reduced O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
were O-MISC O-MISC
preserved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
transformed O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Octamer O-MISC B-MISC
transcription O-MISC B-MISC
factors O-MISC I-MISC
1 O-MISC I-MISC
and O-MISC O-MISC
2 O-MISC O-MISC
each O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
two O-MISC O-MISC
different O-MISC O-MISC
functional B-MISC O-MISC
elements I-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
immunoglobulin B-MISC B-MISC
heavy I-MISC I-MISC
- I-MISC I-MISC
chain I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Immunoglobulin B-MISC O-MISC
heavy I-MISC I-MISC
- I-MISC I-MISC
chain I-MISC I-MISC
genes I-MISC I-MISC
contain O-MISC O-MISC
two O-MISC O-MISC
conserved B-MISC B-MISC
sequence I-MISC I-MISC
elements I-MISC I-MISC
5 O-MISC I-MISC
' O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
site O-MISC O-MISC
of O-MISC O-MISC
transcription O-MISC O-MISC
initiation O-MISC O-MISC
: O-MISC O-MISC
the O-MISC O-MISC
octamer O-MISC O-MISC
ATGCAAAT O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
heptamer O-MISC B-MISC
CTCATGA O-MISC B-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
elements O-MISC O-MISC
are O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
normal B-MISC O-MISC
cell I-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
promoter I-MISC I-MISC
function O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
demonstrates O-MISC O-MISC
that O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
ubiquitous B-MISC B-MISC
and I-MISC I-MISC
lymphoid I-MISC I-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
octamer I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
( O-MISC O-MISC
OTF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
OTF B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
) O-MISC O-MISC
interact O-MISC O-MISC
specifically O-MISC O-MISC
with O-MISC O-MISC
each O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
conserved B-MISC B-MISC
sequence I-MISC I-MISC
elements I-MISC I-MISC
, O-MISC O-MISC
forming O-MISC O-MISC
either O-MISC O-MISC
homo B-MISC O-MISC
- I-MISC I-MISC
or I-MISC I-MISC
heterodimeric I-MISC I-MISC
complexes I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
was O-MISC O-MISC
surprising O-MISC O-MISC
, O-MISC O-MISC
since O-MISC O-MISC
the O-MISC O-MISC
heptamer O-MISC B-MISC
and O-MISC I-MISC
octamer O-MISC I-MISC
sequence O-MISC I-MISC
motifs O-MISC I-MISC
bear O-MISC O-MISC
no O-MISC O-MISC
obvious O-MISC O-MISC
similarity O-MISC O-MISC
to O-MISC O-MISC
each O-MISC O-MISC
other O-MISC O-MISC
. O-MISC O-MISC

Binding O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
factor O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
octamer B-MISC B-MISC
element I-MISC I-MISC
occurred O-MISC O-MISC
independently O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
OTF B-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
heptamer B-MISC B-MISC
sequence I-MISC I-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
require O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
intact O-MISC B-MISC
octamer O-MISC B-MISC
motif O-MISC I-MISC
and O-MISC O-MISC
occurred O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
spacing O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
2 B-MISC O-MISC
or I-MISC O-MISC
14 I-MISC O-MISC
base I-MISC I-MISC
pairs I-MISC I-MISC
between O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
elements O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
coordinate O-MISC O-MISC
binding O-MISC O-MISC
resulting O-MISC O-MISC
from O-MISC O-MISC
protein O-MISC O-MISC
- O-MISC O-MISC
protein O-MISC O-MISC
interactions O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
degeneracy O-MISC B-MISC
in O-MISC O-MISC
sequences O-MISC I-MISC
recognized O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
OTFs B-MISC B-MISC
may O-MISC O-MISC
be O-MISC O-MISC
important O-MISC O-MISC
in O-MISC O-MISC
widening O-MISC O-MISC
the O-MISC O-MISC
range O-MISC O-MISC
over O-MISC O-MISC
which O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
modulated O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
establishing O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
specificity O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
lymphoid B-MISC O-MISC
specific I-MISC I-MISC
octamer I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
OTF B-MISC B-MISC
- I-MISC I-MISC
2B I-MISC I-MISC
) O-MISC O-MISC
by O-MISC O-MISC
proteolytic O-MISC O-MISC
clipping O-MISC O-MISC
bandshift O-MISC O-MISC
assay O-MISC O-MISC
( O-MISC O-MISC
PCBA O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
octamer O-MISC B-MISC
sequence O-MISC I-MISC
ATGCAAAT O-MISC O-MISC
is O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
promoters O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
( I-MISC I-MISC
Ig I-MISC I-MISC
) I-MISC I-MISC
heavy I-MISC I-MISC
and I-MISC I-MISC
light I-MISC I-MISC
chain I-MISC I-MISC
genes I-MISC I-MISC
and O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
heavy B-MISC B-MISC
chain I-MISC O-MISC
enhancer I-MISC I-MISC
and O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
determinant O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Ig B-MISC B-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

An O-MISC O-MISC
apparent O-MISC O-MISC
paradox O-MISC O-MISC
is O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
sequence O-MISC O-MISC
serves O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
upstream B-MISC B-MISC
promoter I-MISC I-MISC
or I-MISC I-MISC
enhancer I-MISC B-MISC
element I-MISC I-MISC
in O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
housekeeping B-MISC B-MISC
genes I-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
histone B-MISC B-MISC
H2B I-MISC I-MISC
and I-MISC O-MISC
U I-MISC B-MISC
snRNA I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
differential O-MISC O-MISC
usage O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
regulatory O-MISC B-MISC
sequence O-MISC I-MISC
motif O-MISC I-MISC
is O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
different O-MISC O-MISC
species O-MISC O-MISC
of O-MISC O-MISC
octamer B-MISC B-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
. O-MISC O-MISC

One O-MISC O-MISC
species O-MISC O-MISC
of O-MISC O-MISC
100 O-MISC O-MISC
kd O-MISC O-MISC
, O-MISC O-MISC
designated O-MISC O-MISC
OTF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
is O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
and O-MISC O-MISC
may O-MISC O-MISC
exert O-MISC O-MISC
its O-MISC O-MISC
activating O-MISC O-MISC
function O-MISC O-MISC
only O-MISC O-MISC
when O-MISC O-MISC
it O-MISC O-MISC
can O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
additional O-MISC O-MISC
adjacent O-MISC O-MISC
transcription B-MISC I-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
lymphoid B-MISC B-MISC
cell I-MISC I-MISC
specific I-MISC I-MISC
octamer I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
of O-MISC O-MISC
60 O-MISC B-MISC
kd O-MISC I-MISC
( O-MISC O-MISC
OTF B-MISC B-MISC
- I-MISC I-MISC
2A I-MISC I-MISC
) O-MISC O-MISC
specifically O-MISC O-MISC
stimulates O-MISC O-MISC
Ig B-MISC B-MISC
promoters I-MISC I-MISC
which O-MISC O-MISC
consist O-MISC O-MISC
essentially O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
TATA B-MISC B-MISC
- I-MISC I-MISC
box I-MISC I-MISC
and O-MISC O-MISC
an O-MISC O-MISC
octamer B-MISC B-MISC
sequence I-MISC I-MISC
upstream O-MISC O-MISC
of O-MISC O-MISC
it O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
present O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
yet O-MISC O-MISC
another O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
specific I-MISC I-MISC
octamer I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
of O-MISC O-MISC
75 O-MISC B-MISC
kd O-MISC I-MISC
( O-MISC O-MISC
OTF B-MISC B-MISC
- I-MISC I-MISC
2B I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

From O-MISC O-MISC
several O-MISC O-MISC
findings O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
OTF B-MISC B-MISC
- I-MISC I-MISC
2B I-MISC I-MISC
( O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
OTF B-MISC B-MISC
- I-MISC I-MISC
2A I-MISC I-MISC
) O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
lymphocyte O-MISC O-MISC
line O-MISC O-MISC
that O-MISC O-MISC
can O-MISC O-MISC
not O-MISC O-MISC
respond O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
IgH B-MISC B-MISC
enhancer I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
propose O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
novel B-MISC O-MISC
octamer I-MISC B-MISC
factor I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
long O-MISC O-MISC
range O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
IgH B-MISC B-MISC
enhancer I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
used O-MISC O-MISC
the O-MISC O-MISC
proteolytic O-MISC O-MISC
clipping O-MISC O-MISC
bandshift O-MISC O-MISC
assay O-MISC O-MISC
( O-MISC O-MISC
PCBA O-MISC O-MISC
) O-MISC O-MISC
technique O-MISC O-MISC
to O-MISC O-MISC
distinguish O-MISC O-MISC
the O-MISC O-MISC
three O-MISC O-MISC
different O-MISC O-MISC
forms O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
analysis O-MISC O-MISC
indicates O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
75 O-MISC B-MISC
kd O-MISC I-MISC
- O-MISC I-MISC
species O-MISC I-MISC
OTF B-MISC I-MISC
- I-MISC I-MISC
2B I-MISC I-MISC
is O-MISC O-MISC
closely O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
60 B-MISC B-MISC
kd I-MISC I-MISC
species I-MISC I-MISC
OTF I-MISC B-MISC
- I-MISC I-MISC
2A I-MISC I-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
2 I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
cloned O-MISC O-MISC
murine O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

Possible O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
inhibitory B-MISC B-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
interleukin B-MISC B-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
in O-MISC O-MISC
two O-MISC O-MISC
cytotoxic O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
( O-MISC O-MISC
CTL O-MISC O-MISC
) O-MISC O-MISC
clones O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
studied O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
complete O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
DNA O-MISC O-MISC
synthesis O-MISC O-MISC
by O-MISC O-MISC
dexamethasone O-MISC O-MISC
( O-MISC O-MISC
Dx O-MISC O-MISC
) O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
observed O-MISC O-MISC
when O-MISC O-MISC
IL O-MISC B-MISC
2 O-MISC I-MISC
- O-MISC I-MISC
depleted O-MISC O-MISC
cultures O-MISC O-MISC
of O-MISC O-MISC
CTL O-MISC O-MISC
were O-MISC O-MISC
either O-MISC O-MISC
incubated O-MISC O-MISC
for O-MISC O-MISC
6 O-MISC O-MISC
h O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
hormone B-MISC O-MISC
prior O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
2 I-MISC I-MISC
or O-MISC O-MISC
treated O-MISC O-MISC
simultaneously O-MISC O-MISC
with O-MISC O-MISC
Dx O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
low O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

No O-MISC O-MISC
significant O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
and O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
2 I-MISC I-MISC
receptors I-MISC I-MISC
was O-MISC O-MISC
seen O-MISC O-MISC
after O-MISC O-MISC
6 O-MISC O-MISC
h O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
Dx O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
order O-MISC O-MISC
of O-MISC O-MISC
potency O-MISC O-MISC
observed O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
different O-MISC O-MISC
steroids O-MISC O-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
was O-MISC O-MISC
mediated O-MISC O-MISC
through O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
hormones B-MISC O-MISC
possibly O-MISC O-MISC
involves O-MISC O-MISC
the O-MISC O-MISC
synthesis O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
inhibitory B-MISC B-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
s O-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
since O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
cycloheximide O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
Dx O-MISC O-MISC
prevented O-MISC O-MISC
the O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
DNA O-MISC O-MISC
synthesis O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
supernatant O-MISC O-MISC
from O-MISC O-MISC
Dx O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
CTL O-MISC O-MISC
contained O-MISC O-MISC
a O-MISC O-MISC
nondialyzable O-MISC B-MISC
factor O-MISC I-MISC
which O-MISC O-MISC
inhibited O-MISC O-MISC
DNA O-MISC O-MISC
synthesis O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
CTL O-MISC O-MISC
clones O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
IL B-MISC B-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

Blocking O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
2 I-MISC I-MISC
synthesis O-MISC O-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
formation O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
proposed O-MISC O-MISC
as O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
mechanisms O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
immunosuppression O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
these O-MISC O-MISC
hormones B-MISC O-MISC
may O-MISC O-MISC
also O-MISC O-MISC
affect O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
by O-MISC O-MISC
inhibiting O-MISC O-MISC
IL B-MISC B-MISC
2 I-MISC I-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
and O-MISC O-MISC
purification O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
human B-MISC B-MISC
immunoglobulin I-MISC I-MISC
- I-MISC I-MISC
enhancer I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
) O-MISC O-MISC
that O-MISC O-MISC
activates O-MISC O-MISC
transcription O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
human B-MISC O-MISC
immunodeficiency I-MISC O-MISC
virus I-MISC O-MISC
type I-MISC O-MISC
1 I-MISC I-MISC
promoter I-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
enhancer B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
factor I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
found O-MISC O-MISC
only O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
transcribe O-MISC O-MISC
immunoglobulin B-MISC B-MISC
light I-MISC I-MISC
chain I-MISC I-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
purified O-MISC O-MISC
from O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
of O-MISC O-MISC
Namalwa O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
human O-MISC O-MISC
Burkitt O-MISC O-MISC
lymphoma O-MISC O-MISC
cells O-MISC O-MISC
) O-MISC O-MISC
by O-MISC O-MISC
sequence O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
DNA O-MISC O-MISC
affinity O-MISC O-MISC
chromatography O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
purified O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
has O-MISC O-MISC
been O-MISC O-MISC
identified O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
51 B-MISC O-MISC
- I-MISC O-MISC
kDa I-MISC O-MISC
polypeptide I-MISC O-MISC
by O-MISC O-MISC
UV O-MISC O-MISC
- O-MISC O-MISC
crosslinking O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

` O-MISC O-MISC
` O-MISC O-MISC
Footprint O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
and O-MISC O-MISC
methylation O-MISC O-MISC
- O-MISC O-MISC
interference O-MISC O-MISC
analyses O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
purified O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
has O-MISC O-MISC
a O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
kappa B-MISC B-MISC
light I-MISC I-MISC
chain I-MISC I-MISC
enhancer I-MISC I-MISC
sequence I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
purified O-MISC B-MISC
factor O-MISC I-MISC
activated O-MISC I-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
immunodeficiency I-MISC I-MISC
virus I-MISC I-MISC
type I-MISC I-MISC
I I-MISC I-MISC
promoter I-MISC I-MISC
by O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
upstream B-MISC B-MISC
NF I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC

Lymphocyte O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
depression O-MISC O-MISC
: O-MISC O-MISC
normal O-MISC O-MISC
values O-MISC O-MISC
following O-MISC O-MISC
recovery O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
sites O-MISC I-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
plasma O-MISC O-MISC
cortisol O-MISC O-MISC
concentrations O-MISC O-MISC
were O-MISC O-MISC
measured O-MISC O-MISC
in O-MISC O-MISC
20 O-MISC O-MISC
patients O-MISC O-MISC
who O-MISC O-MISC
had O-MISC O-MISC
recovered O-MISC O-MISC
from O-MISC O-MISC
major O-MISC O-MISC
depressive O-MISC O-MISC
disorder O-MISC O-MISC
and O-MISC O-MISC
20 O-MISC O-MISC
healthy O-MISC O-MISC
control O-MISC O-MISC
subjects O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
sites O-MISC I-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
recovered O-MISC O-MISC
depressed O-MISC O-MISC
group O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
significantly O-MISC O-MISC
different O-MISC O-MISC
from O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
group O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
the O-MISC O-MISC
mean O-MISC O-MISC
plasma O-MISC O-MISC
cortisol O-MISC O-MISC
concentration O-MISC O-MISC
in O-MISC O-MISC
recovered O-MISC O-MISC
depressives O-MISC O-MISC
was O-MISC O-MISC
higher O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
control O-MISC O-MISC
subjects O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
difference O-MISC O-MISC
only O-MISC O-MISC
just O-MISC O-MISC
reached O-MISC O-MISC
significance O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
shows O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
numbers O-MISC O-MISC
which O-MISC O-MISC
occurs O-MISC O-MISC
during O-MISC O-MISC
acute O-MISC O-MISC
depressive O-MISC O-MISC
illness O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
persist O-MISC O-MISC
on O-MISC O-MISC
recovery O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
, O-MISC O-MISC
therefore O-MISC O-MISC
, O-MISC O-MISC
state O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
and O-MISC O-MISC
purification O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
human B-MISC B-MISC
lymphoid I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
octamer I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
OTF B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
that O-MISC O-MISC
activates O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
immunoglobulin B-MISC B-MISC
promoter I-MISC I-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
octamer O-MISC B-MISC
sequence O-MISC I-MISC
5 O-MISC I-MISC
' O-MISC I-MISC
- O-MISC I-MISC
ATGCAAAT O-MISC I-MISC
, O-MISC O-MISC
in O-MISC O-MISC
either O-MISC O-MISC
orientation O-MISC O-MISC
, O-MISC O-MISC
serves O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
upstream B-MISC B-MISC
element I-MISC I-MISC
in O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
promoters B-MISC B-MISC
and O-MISC O-MISC
also O-MISC O-MISC
occurs O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
modular B-MISC B-MISC
enhancer I-MISC I-MISC
element I-MISC I-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
of O-MISC O-MISC
particular O-MISC O-MISC
interest O-MISC O-MISC
in O-MISC O-MISC
immunoglobulin B-MISC B-MISC
genes I-MISC I-MISC
since O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
upstream B-MISC B-MISC
regions I-MISC I-MISC
of O-MISC O-MISC
all O-MISC B-MISC
heavy B-MISC B-MISC
and I-MISC I-MISC
light I-MISC I-MISC
chain I-MISC I-MISC
promoters I-MISC I-MISC
and O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
heavy B-MISC B-MISC
chain I-MISC I-MISC
enhancer I-MISC I-MISC
, O-MISC O-MISC
both O-MISC O-MISC
of O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
here O-MISC O-MISC
the O-MISC O-MISC
chromatographic O-MISC O-MISC
separation O-MISC O-MISC
of O-MISC O-MISC
ubiquitous B-MISC B-MISC
and I-MISC I-MISC
B I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
octamer I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
was O-MISC O-MISC
purified O-MISC O-MISC
to O-MISC O-MISC
homogeneity O-MISC O-MISC
using O-MISC O-MISC
affinity O-MISC O-MISC
chromatography O-MISC O-MISC
and O-MISC O-MISC
consists O-MISC O-MISC
of O-MISC O-MISC
three O-MISC O-MISC
peptides O-MISC O-MISC
of O-MISC O-MISC
62 O-MISC O-MISC
, O-MISC O-MISC
61 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
58 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC B-MISC
kd O-MISC I-MISC
. O-MISC O-MISC

Each O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
polypeptides O-MISC O-MISC
was O-MISC O-MISC
renatured O-MISC O-MISC
after O-MISC O-MISC
SDS O-MISC O-MISC
- O-MISC O-MISC
PAGE O-MISC O-MISC
and O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
octamer O-MISC B-MISC
sequence O-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
specific O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
pure O-MISC B-MISC
B B-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
factor I-MISC I-MISC
was O-MISC O-MISC
indistinguishable O-MISC O-MISC
from O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
affinity B-MISC O-MISC
- I-MISC I-MISC
purified I-MISC I-MISC
ubiquitous I-MISC I-MISC
factor I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
octamer I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
factor I-MISC I-MISC
, O-MISC O-MISC
in O-MISC O-MISC
pure O-MISC O-MISC
form O-MISC O-MISC
, O-MISC O-MISC
activated O-MISC O-MISC
transcription O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
kappa B-MISC B-MISC
light I-MISC I-MISC
chain I-MISC I-MISC
promoter I-MISC I-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
, O-MISC O-MISC
thus O-MISC O-MISC
demonstrating O-MISC O-MISC
that O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
indeed O-MISC O-MISC
a O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
for O-MISC O-MISC
this O-MISC O-MISC
gene O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
ubiquitous B-MISC B-MISC
and I-MISC I-MISC
B I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
octamer I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
factors I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
identified O-MISC O-MISC
several O-MISC O-MISC
additional O-MISC O-MISC
proteins O-MISC O-MISC
, O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
kappa B-MISC B-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Decreased O-MISC O-MISC
deoxyribonucleic O-MISC O-MISC
acid O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complex I-MISC I-MISC
in O-MISC O-MISC
cultured O-MISC O-MISC
skin O-MISC O-MISC
fibroblasts O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
patient O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid O-MISC O-MISC
resistance O-MISC O-MISC
syndrome O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
patient O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
syndrome O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
resistance O-MISC O-MISC
was O-MISC O-MISC
studied O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
27 O-MISC O-MISC
- O-MISC O-MISC
yr O-MISC O-MISC
- O-MISC O-MISC
old O-MISC O-MISC
woman O-MISC O-MISC
initially O-MISC O-MISC
was O-MISC O-MISC
diagnosed O-MISC O-MISC
as O-MISC O-MISC
having O-MISC O-MISC
Cushing O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
disease O-MISC O-MISC
, O-MISC O-MISC
based O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
findings O-MISC O-MISC
of O-MISC O-MISC
high O-MISC O-MISC
plasma O-MISC O-MISC
ACTH O-MISC O-MISC
and O-MISC O-MISC
serum O-MISC O-MISC
cortisol O-MISC O-MISC
levels O-MISC O-MISC
, O-MISC O-MISC
increased O-MISC O-MISC
urinary O-MISC O-MISC
cortisol O-MISC O-MISC
secretion O-MISC O-MISC
, O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
adrenal O-MISC O-MISC
suppression O-MISC O-MISC
with O-MISC O-MISC
dexamethasone O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
bilateral O-MISC O-MISC
adrenal O-MISC O-MISC
hyperplasia O-MISC O-MISC
by O-MISC O-MISC
computed O-MISC O-MISC
tomography O-MISC O-MISC
and O-MISC O-MISC
scintigraphy O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
adrenal O-MISC O-MISC
glands O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
she O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
signs O-MISC O-MISC
or O-MISC O-MISC
symptoms O-MISC O-MISC
of O-MISC O-MISC
Cushing O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
syndrome O-MISC O-MISC
. O-MISC O-MISC

During O-MISC O-MISC
a O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
yr O-MISC O-MISC
follow O-MISC O-MISC
- O-MISC O-MISC
up O-MISC O-MISC
, O-MISC O-MISC
no O-MISC O-MISC
clinical O-MISC O-MISC
abnormalities O-MISC O-MISC
developed O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
hypercortisolism O-MISC O-MISC
persisted O-MISC O-MISC
. O-MISC O-MISC

End O-MISC O-MISC
- O-MISC O-MISC
organ O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
cortisol O-MISC O-MISC
was O-MISC O-MISC
suspected O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
explain O-MISC O-MISC
the O-MISC O-MISC
end O-MISC O-MISC
- O-MISC O-MISC
organ O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
cortisol O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
and O-MISC O-MISC
cultured O-MISC O-MISC
skin O-MISC O-MISC
fibroblasts O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
forearm O-MISC O-MISC
skin O-MISC O-MISC
biopsy O-MISC O-MISC
were O-MISC O-MISC
characterized O-MISC O-MISC
and O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
of O-MISC O-MISC
similar O-MISC O-MISC
studies O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
patient O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
GR B-MISC B-MISC
in O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
assays O-MISC O-MISC
had O-MISC O-MISC
an O-MISC O-MISC
increased O-MISC O-MISC
dissociation O-MISC O-MISC
constant O-MISC O-MISC
( O-MISC O-MISC
Kd O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
cytosol O-MISC O-MISC
of O-MISC O-MISC
cultured O-MISC O-MISC
skin O-MISC O-MISC
fibroblasts O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
decreased O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
thermal O-MISC O-MISC
stability O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
sedimentation O-MISC O-MISC
coefficient O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
sucrose O-MISC O-MISC
density O-MISC O-MISC
gradient O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptors O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytosol O-MISC O-MISC
of O-MISC O-MISC
cultured O-MISC O-MISC
skin O-MISC O-MISC
fibroblasts O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
were O-MISC O-MISC
similar O-MISC O-MISC
. O-MISC O-MISC

GR O-MISC B-MISC
complex O-MISC I-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
analyzed O-MISC O-MISC
by O-MISC O-MISC
DEAE O-MISC B-MISC
- O-MISC O-MISC
cellulose O-MISC O-MISC
chromatography O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
decreased O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
. O-MISC O-MISC

DNA B-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
GR B-MISC B-MISC
complex I-MISC I-MISC
after O-MISC O-MISC
temperature O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
was O-MISC O-MISC
lower O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
. O-MISC O-MISC

Nuclear O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
complexes I-MISC I-MISC
from O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
slightly O-MISC O-MISC
decreased O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
glucocorticoid O-MISC O-MISC
resistance O-MISC O-MISC
was O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
for O-MISC O-MISC
glucocorticoids O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
GR B-MISC B-MISC
complex I-MISC I-MISC
to O-MISC O-MISC
DNA B-MISC O-MISC
. O-MISC O-MISC

Granulocyte B-MISC B-MISC
- I-MISC I-MISC
macrophage I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
. O-MISC O-MISC

Sensitive O-MISC O-MISC
and O-MISC O-MISC
receptor O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
regulation O-MISC O-MISC
by O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
dihydroxyvitamin O-MISC O-MISC
D3 O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
dihydroxyvitamin O-MISC O-MISC
D3 O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
[ O-MISC O-MISC
OH O-MISC O-MISC
] O-MISC O-MISC
2D3 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
most O-MISC O-MISC
hormonally O-MISC O-MISC
active O-MISC O-MISC
metabolite O-MISC O-MISC
of O-MISC O-MISC
vitamin O-MISC O-MISC
D3 O-MISC O-MISC
, O-MISC O-MISC
modulates O-MISC O-MISC
sensitively O-MISC O-MISC
and O-MISC O-MISC
specifically O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
protein O-MISC B-MISC
and O-MISC O-MISC
messenger B-MISC I-MISC
RNA I-MISC I-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
multilineage B-MISC B-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
granulocyte B-MISC I-MISC
- I-MISC O-MISC
macrophage I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC B-MISC
mitogen O-MISC I-MISC
- O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
line O-MISC O-MISC
( O-MISC O-MISC
S O-MISC B-MISC
- O-MISC I-MISC
LB1 O-MISC I-MISC
) O-MISC O-MISC
transformed O-MISC O-MISC
with O-MISC O-MISC
human O-MISC O-MISC
T O-MISC I-MISC
cell O-MISC I-MISC
lymphotropic O-MISC I-MISC
virus O-MISC I-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
transformed O-MISC O-MISC
T O-MISC O-MISC
lymphocyte O-MISC O-MISC
line O-MISC O-MISC
( O-MISC O-MISC
Ab O-MISC O-MISC
- O-MISC O-MISC
VDR O-MISC O-MISC
) O-MISC O-MISC
established O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
patient O-MISC O-MISC
with O-MISC O-MISC
vitamin O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
rickets O-MISC O-MISC
type O-MISC O-MISC
II O-MISC O-MISC
with O-MISC O-MISC
undetectable O-MISC O-MISC
1 B-MISC O-MISC
, I-MISC O-MISC
25 I-MISC I-MISC
( I-MISC I-MISC
OH I-MISC I-MISC
) I-MISC I-MISC
2D3 I-MISC I-MISC
cellular I-MISC I-MISC
receptors I-MISC I-MISC
are O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
can O-MISC O-MISC
occur O-MISC O-MISC
independently O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
2 I-MISC I-MISC
regulation O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
probably O-MISC O-MISC
mediated O-MISC O-MISC
through O-MISC O-MISC
cellular B-MISC B-MISC
1 I-MISC I-MISC
, I-MISC I-MISC
25 I-MISC I-MISC
( I-MISC I-MISC
OH I-MISC I-MISC
) I-MISC I-MISC
2D3 I-MISC I-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
important O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
physiology O-MISC O-MISC
of O-MISC O-MISC
hematopoiesis O-MISC O-MISC
. O-MISC O-MISC

Altered O-MISC O-MISC
interaction O-MISC O-MISC
between O-MISC O-MISC
triiodothyronine O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
nuclear B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
: O-MISC O-MISC
a O-MISC O-MISC
proposed O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
increased O-MISC O-MISC
thyrotropin O-MISC O-MISC
secretion O-MISC O-MISC
in O-MISC O-MISC
corticosteroid O-MISC O-MISC
deficiency O-MISC O-MISC
states O-MISC O-MISC
. O-MISC O-MISC

Thyroid O-MISC O-MISC
hormones O-MISC O-MISC
occasionally O-MISC O-MISC
appear O-MISC O-MISC
less O-MISC O-MISC
effective O-MISC O-MISC
when O-MISC O-MISC
administered O-MISC O-MISC
alone O-MISC O-MISC
to O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
panhypopituitarism O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
manifestations O-MISC O-MISC
suggestive O-MISC O-MISC
of O-MISC O-MISC
hypothyroidism O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
reported O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
suffering O-MISC O-MISC
from O-MISC O-MISC
untreated O-MISC O-MISC
Addison O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
latter O-MISC O-MISC
condition O-MISC O-MISC
, O-MISC O-MISC
thyrotropin O-MISC O-MISC
secretion O-MISC O-MISC
is O-MISC O-MISC
increased O-MISC O-MISC
: O-MISC O-MISC
this O-MISC O-MISC
occurs O-MISC O-MISC
already O-MISC O-MISC
after O-MISC O-MISC
as O-MISC O-MISC
little O-MISC O-MISC
as O-MISC O-MISC
2 O-MISC O-MISC
days O-MISC O-MISC
of O-MISC O-MISC
temporary O-MISC O-MISC
withdrawal O-MISC O-MISC
of O-MISC O-MISC
therapy O-MISC O-MISC
with O-MISC O-MISC
substitution O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
corticosteroids O-MISC O-MISC
while O-MISC O-MISC
circulating O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
thyroid O-MISC O-MISC
hormones O-MISC O-MISC
remain O-MISC O-MISC
within O-MISC O-MISC
normal O-MISC O-MISC
limits O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
possible O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
in O-MISC O-MISC
interaction O-MISC O-MISC
between O-MISC O-MISC
triiodothyronine O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
nuclear B-MISC B-MISC
receptors I-MISC I-MISC
was O-MISC O-MISC
examined O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
circulating O-MISC O-MISC
lymphocytes O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
primary O-MISC O-MISC
or O-MISC O-MISC
secondary O-MISC O-MISC
adrenocortical O-MISC O-MISC
failure O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
receptors O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
decreased O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
more O-MISC O-MISC
than O-MISC O-MISC
50 O-MISC O-MISC
% O-MISC O-MISC
on O-MISC O-MISC
average O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
treatments O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
change O-MISC O-MISC
was O-MISC O-MISC
promptly O-MISC O-MISC
corrected O-MISC O-MISC
upon O-MISC O-MISC
resumption O-MISC O-MISC
of O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC B-MISC
sites O-MISC I-MISC
was O-MISC O-MISC
not O-MISC O-MISC
significantly O-MISC O-MISC
modified O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
influence O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
on O-MISC O-MISC
thyroid B-MISC B-MISC
hormone I-MISC I-MISC
receptors I-MISC I-MISC
discussed O-MISC O-MISC
here O-MISC O-MISC
might O-MISC O-MISC
account O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
clinical O-MISC O-MISC
observations O-MISC O-MISC
mentioned O-MISC O-MISC
above O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
by O-MISC O-MISC
cortisol O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
( O-MISC O-MISC
NK O-MISC O-MISC
) O-MISC O-MISC
cell O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
( O-MISC O-MISC
NK O-MISC O-MISC
) O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
( O-MISC O-MISC
PBM O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
studied O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
using O-MISC O-MISC
a O-MISC O-MISC
direct O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
h O-MISC O-MISC
51Cr O-MISC O-MISC
- O-MISC O-MISC
release O-MISC O-MISC
assay O-MISC O-MISC
and O-MISC O-MISC
K O-MISC O-MISC
562 O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
target O-MISC O-MISC
. O-MISC O-MISC

Preincubation O-MISC O-MISC
for O-MISC O-MISC
20 O-MISC O-MISC
h O-MISC O-MISC
of O-MISC O-MISC
PBM O-MISC O-MISC
cells O-MISC O-MISC
drawn O-MISC O-MISC
from O-MISC O-MISC
healthy O-MISC O-MISC
donors O-MISC O-MISC
with O-MISC O-MISC
1 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
) O-MISC O-MISC
to O-MISC O-MISC
1 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
5 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
cortisol O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
decrease O-MISC O-MISC
of O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
magnitude O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
suppression O-MISC O-MISC
was O-MISC O-MISC
directly O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
steroid O-MISC O-MISC
concentration O-MISC O-MISC
and O-MISC O-MISC
inversely O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
effector O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Cortisol O-MISC O-MISC
was O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
minimize O-MISC O-MISC
the O-MISC O-MISC
enhancement O-MISC O-MISC
of O-MISC O-MISC
NK O-MISC O-MISC
cytotoxicity O-MISC O-MISC
obtainable O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
immune O-MISC O-MISC
interferon O-MISC B-MISC
( O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
significantly O-MISC O-MISC
higher O-MISC O-MISC
suppression O-MISC O-MISC
was O-MISC O-MISC
achieved O-MISC O-MISC
after O-MISC O-MISC
sequential O-MISC O-MISC
exposure O-MISC O-MISC
of O-MISC O-MISC
PBM O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
cortisol O-MISC O-MISC
and O-MISC O-MISC
equimolar O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
prostaglandin O-MISC O-MISC
E2 O-MISC B-MISC
( O-MISC O-MISC
PgE2 O-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
concomitant O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
theophylline O-MISC O-MISC
and O-MISC O-MISC
isobutyl O-MISC O-MISC
- O-MISC O-MISC
methylxanthine O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
enhance O-MISC O-MISC
the O-MISC O-MISC
cortisol O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
suppression O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
PgE2 O-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
inhibition O-MISC O-MISC
significantly O-MISC O-MISC
increased O-MISC O-MISC
after O-MISC O-MISC
exposure O-MISC O-MISC
of O-MISC O-MISC
PBM O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
methyl O-MISC O-MISC
- O-MISC O-MISC
xanthines O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
was O-MISC O-MISC
partially O-MISC O-MISC
or O-MISC O-MISC
totally O-MISC O-MISC
prevented O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
concomitant O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
equimolar O-MISC O-MISC
amounts O-MISC O-MISC
of O-MISC O-MISC
11 O-MISC O-MISC
- O-MISC O-MISC
deoxycortisol O-MISC O-MISC
and O-MISC O-MISC
RU O-MISC O-MISC
486 O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
of O-MISC O-MISC
progesterone O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
NK O-MISC O-MISC
effectors O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
monoclonal B-MISC O-MISC
anti I-MISC I-MISC
- I-MISC I-MISC
human I-MISC I-MISC
corticosteroid I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
globulin I-MISC I-MISC
( I-MISC I-MISC
CBG I-MISC B-MISC
) I-MISC I-MISC
antibody I-MISC I-MISC
produced O-MISC O-MISC
an O-MISC O-MISC
enhancement O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
spontaneous O-MISC O-MISC
NK O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
partial O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
effects O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
endogenous O-MISC O-MISC
glucocorticoids O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
cytotoxicity O-MISC O-MISC
. O-MISC O-MISC

Since O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
was O-MISC O-MISC
additive O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
PgE2 O-MISC B-MISC
and O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
changed O-MISC O-MISC
by O-MISC O-MISC
phosphodiesterase B-MISC O-MISC
inhibitors O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
conceivable O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
hormone O-MISC O-MISC
acts O-MISC O-MISC
at O-MISC O-MISC
a O-MISC O-MISC
level O-MISC O-MISC
different O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
adenylate B-MISC B-MISC
cyclase I-MISC I-MISC
- O-MISC I-MISC
phosphodiesterase B-MISC I-MISC
system O-MISC O-MISC
. O-MISC O-MISC

Data O-MISC O-MISC
obtained O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
antiglucocorticoids O-MISC B-MISC
and O-MISC O-MISC
the O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CBG I-MISC I-MISC
antibody I-MISC I-MISC
are O-MISC O-MISC
compatible O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
both O-MISC O-MISC
of O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
affinity O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
of O-MISC O-MISC
CBG B-MISC B-MISC
in O-MISC O-MISC
mediating O-MISC O-MISC
cortisol O-MISC O-MISC
action O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Interaction O-MISC O-MISC
of O-MISC O-MISC
cell B-MISC B-MISC
- I-MISC I-MISC
type I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
nuclear I-MISC I-MISC
proteins I-MISC I-MISC
with O-MISC O-MISC
immunoglobulin B-MISC B-MISC
VH I-MISC I-MISC
promoter I-MISC I-MISC
region I-MISC I-MISC
sequences I-MISC I-MISC
. O-MISC O-MISC

All O-MISC O-MISC
human B-MISC B-MISC
and I-MISC I-MISC
murine I-MISC I-MISC
immunoglobulin I-MISC I-MISC
heavy I-MISC I-MISC
chain I-MISC I-MISC
variable I-MISC I-MISC
region I-MISC I-MISC
( I-MISC I-MISC
VH I-MISC I-MISC
) I-MISC I-MISC
genes I-MISC I-MISC
contain O-MISC O-MISC
the O-MISC O-MISC
sequence O-MISC O-MISC
ATGCAAAT O-MISC O-MISC
approximately O-MISC O-MISC
70 O-MISC O-MISC
nucleotides O-MISC O-MISC
5 O-MISC O-MISC
' O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
site O-MISC O-MISC
of O-MISC O-MISC
transcription O-MISC O-MISC
initiation O-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
octanucleotide O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
reverse O-MISC O-MISC
orientation O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
light B-MISC B-MISC
chain I-MISC I-MISC
variable I-MISC I-MISC
region I-MISC I-MISC
( I-MISC I-MISC
VL I-MISC B-MISC
) I-MISC I-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
immunoglobulin B-MISC B-MISC
heavy I-MISC I-MISC
chain I-MISC I-MISC
transcriptional I-MISC I-MISC
enhancer I-MISC I-MISC
. O-MISC O-MISC

Transfection O-MISC O-MISC
studies O-MISC O-MISC
have O-MISC O-MISC
established O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
octamer O-MISC B-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
lymphoid O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Octamer B-MISC B-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
fragments I-MISC I-MISC
have O-MISC O-MISC
been O-MISC O-MISC
reported O-MISC O-MISC
to O-MISC O-MISC
bind O-MISC O-MISC
a O-MISC O-MISC
factor O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
; O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
identical O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
B O-MISC O-MISC
lymphoid O-MISC O-MISC
and O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
establish O-MISC O-MISC
that O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
distinct O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
differ O-MISC O-MISC
in O-MISC O-MISC
their O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
octamer B-MISC B-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
fragments I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
also O-MISC O-MISC
detected O-MISC O-MISC
a O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
protein O-MISC O-MISC
interaction O-MISC O-MISC
that O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
specificity O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
determined O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
sequence O-MISC O-MISC
upstream O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
octamer O-MISC B-MISC
participates O-MISC O-MISC
in O-MISC O-MISC
an O-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
nuclear B-MISC B-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
s O-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Preferential O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
HTLV B-MISC O-MISC
- I-MISC I-MISC
I I-MISC I-MISC
LTR I-MISC I-MISC
in O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
extracts O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
producing O-MISC O-MISC
HTLV B-MISC O-MISC
- I-MISC O-MISC
I I-MISC I-MISC
viral I-MISC I-MISC
proteins I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
promoters B-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
adenovirus B-MISC B-MISC
2 I-MISC I-MISC
major I-MISC I-MISC
late I-MISC I-MISC
gene I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
mouse B-MISC B-MISC
beta I-MISC I-MISC
- I-MISC I-MISC
globin I-MISC I-MISC
gene I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
mouse B-MISC B-MISC
immunoglobulin I-MISC I-MISC
VH I-MISC I-MISC
gene I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
LTR B-MISC B-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
T O-MISC I-MISC
- O-MISC I-MISC
lymphotropic O-MISC O-MISC
retrovirus O-MISC O-MISC
type O-MISC O-MISC
I O-MISC O-MISC
were O-MISC O-MISC
tested O-MISC O-MISC
for O-MISC O-MISC
their O-MISC O-MISC
transcription O-MISC O-MISC
activities O-MISC O-MISC
in O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
extracts O-MISC O-MISC
of O-MISC O-MISC
four O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
; O-MISC O-MISC
HeLa O-MISC O-MISC
, O-MISC O-MISC
CESS O-MISC O-MISC
( O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
MT O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
I O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
without O-MISC O-MISC
viral O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
MT O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
( O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
I O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
producing O-MISC O-MISC
viral B-MISC O-MISC
proteins I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

LTR B-MISC B-MISC
was O-MISC O-MISC
preferentially O-MISC O-MISC
transcribed O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
extracts O-MISC O-MISC
of O-MISC O-MISC
MT O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
although O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
three O-MISC O-MISC
genes O-MISC O-MISC
were O-MISC O-MISC
transcribed O-MISC O-MISC
with O-MISC O-MISC
relatively O-MISC O-MISC
constant O-MISC O-MISC
efficiencies O-MISC O-MISC
in O-MISC O-MISC
different O-MISC O-MISC
extracts O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
agree O-MISC O-MISC
well O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
previous O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
studies O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
HTLV B-MISC B-MISC
- I-MISC I-MISC
I I-MISC I-MISC
LTR I-MISC I-MISC
. O-MISC O-MISC

Mixing O-MISC O-MISC
of O-MISC O-MISC
HeLa O-MISC O-MISC
and O-MISC O-MISC
MT O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
extracts O-MISC O-MISC
revealed O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
LTR O-MISC B-MISC
- O-MISC I-MISC
specific O-MISC O-MISC
stimulating O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
MT O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC I-MISC
extracts O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
that O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
conserved O-MISC B-MISC
sequence O-MISC I-MISC
motif O-MISC I-MISC
in O-MISC O-MISC
transcriptional B-MISC O-MISC
control I-MISC I-MISC
elements I-MISC O-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Trans B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
factors I-MISC I-MISC
that O-MISC O-MISC
mediate O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
specific O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
genes I-MISC I-MISC
have O-MISC O-MISC
been O-MISC O-MISC
postulated O-MISC O-MISC
based O-MISC O-MISC
on O-MISC O-MISC
an O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
exogenously O-MISC O-MISC
introduced O-MISC O-MISC
immunoglobulin B-MISC B-MISC
gene I-MISC I-MISC
recombinants I-MISC I-MISC
in O-MISC O-MISC
lymphoid O-MISC O-MISC
and O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
B O-MISC O-MISC
- O-MISC I-MISC
cell O-MISC I-MISC
- O-MISC I-MISC
specific O-MISC I-MISC
, O-MISC O-MISC
cis B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
transcriptional I-MISC I-MISC
regulatory I-MISC I-MISC
elements I-MISC I-MISC
have O-MISC O-MISC
been O-MISC O-MISC
identified O-MISC O-MISC
. O-MISC O-MISC

One O-MISC O-MISC
element O-MISC O-MISC
is O-MISC O-MISC
located O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
intron O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
variable O-MISC B-MISC
( O-MISC I-MISC
V O-MISC I-MISC
) O-MISC I-MISC
and O-MISC I-MISC
constant O-MISC I-MISC
( O-MISC I-MISC
C O-MISC I-MISC
) O-MISC I-MISC
regions O-MISC I-MISC
of O-MISC O-MISC
both O-MISC O-MISC
heavy B-MISC B-MISC
and I-MISC I-MISC
kappa I-MISC I-MISC
light I-MISC I-MISC
- I-MISC I-MISC
chain I-MISC I-MISC
genes I-MISC I-MISC
and O-MISC O-MISC
acts O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
transcriptional O-MISC B-MISC
enhancer O-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
second O-MISC O-MISC
element B-MISC O-MISC
is O-MISC O-MISC
found O-MISC O-MISC
upstream O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
heavy B-MISC B-MISC
and I-MISC I-MISC
kappa I-MISC I-MISC
light I-MISC I-MISC
- I-MISC I-MISC
chain I-MISC I-MISC
gene I-MISC I-MISC
promoters I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
element O-MISC O-MISC
directs O-MISC O-MISC
lymphoid O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
transcription O-MISC O-MISC
even O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
viral B-MISC B-MISC
enhancers I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
sought O-MISC O-MISC
nuclear O-MISC B-MISC
factors O-MISC I-MISC
that O-MISC O-MISC
might O-MISC O-MISC
bind O-MISC O-MISC
specifically O-MISC O-MISC
to O-MISC O-MISC
these O-MISC O-MISC
two O-MISC O-MISC
regulatory B-MISC B-MISC
elements I-MISC I-MISC
by O-MISC O-MISC
application O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
modified O-MISC O-MISC
gel O-MISC O-MISC
electrophoresis O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
here O-MISC O-MISC
the O-MISC O-MISC
identification O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
human B-MISC B-MISC
B I-MISC I-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
nuclear I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC I-MISC
IgNF B-MISC I-MISC
- I-MISC I-MISC
A I-MISC I-MISC
) O-MISC O-MISC
that O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
DNA B-MISC B-MISC
sequences I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
upstream B-MISC O-MISC
regions I-MISC I-MISC
of O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
mouse B-MISC B-MISC
heavy I-MISC I-MISC
and I-MISC I-MISC
kappa I-MISC I-MISC
light I-MISC I-MISC
- I-MISC I-MISC
chain I-MISC I-MISC
gene I-MISC I-MISC
promoters I-MISC I-MISC
and O-MISC O-MISC
also O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
mouse B-MISC B-MISC
heavy I-MISC I-MISC
- I-MISC I-MISC
chain I-MISC I-MISC
gene I-MISC I-MISC
enhancer I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
sequence O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
is O-MISC O-MISC
probably O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
highly O-MISC O-MISC
conserved O-MISC O-MISC
sequence O-MISC O-MISC
motif O-MISC I-MISC
, O-MISC O-MISC
ATTTGCAT O-MISC O-MISC
, O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
three O-MISC O-MISC
transcriptional B-MISC B-MISC
elements I-MISC I-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
factor O-MISC O-MISC
showing O-MISC O-MISC
similar O-MISC O-MISC
binding O-MISC O-MISC
specificity O-MISC O-MISC
to O-MISC O-MISC
IgNF B-MISC B-MISC
- I-MISC I-MISC
A I-MISC I-MISC
is O-MISC O-MISC
also O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
HeLa O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
new O-MISC O-MISC
world O-MISC O-MISC
primates O-MISC O-MISC
as O-MISC O-MISC
animal O-MISC O-MISC
models O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
resistance O-MISC O-MISC
. O-MISC O-MISC

Many O-MISC O-MISC
New O-MISC O-MISC
World O-MISC O-MISC
primate O-MISC B-MISC
species O-MISC I-MISC
have O-MISC O-MISC
greatly O-MISC O-MISC
increased O-MISC O-MISC
plasma O-MISC O-MISC
cortisol O-MISC O-MISC
concentrations O-MISC O-MISC
, O-MISC O-MISC
decreased O-MISC O-MISC
plasma O-MISC O-MISC
cortisol O-MISC O-MISC
binding O-MISC O-MISC
globulin O-MISC O-MISC
capacity O-MISC O-MISC
and O-MISC O-MISC
affinity O-MISC O-MISC
, O-MISC O-MISC
marked O-MISC O-MISC
resistance O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
hypothalamic O-MISC O-MISC
- O-MISC O-MISC
pituitary O-MISC O-MISC
- O-MISC O-MISC
adrenal O-MISC O-MISC
axis O-MISC O-MISC
to O-MISC O-MISC
suppression O-MISC O-MISC
by O-MISC O-MISC
dexamethasone O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
no O-MISC O-MISC
biological O-MISC O-MISC
evidence O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
excess O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
primates O-MISC O-MISC
also O-MISC O-MISC
have O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
circulating O-MISC O-MISC
progesterone O-MISC O-MISC
, O-MISC O-MISC
estrogen O-MISC O-MISC
, O-MISC O-MISC
mineralocorticoid O-MISC O-MISC
, O-MISC O-MISC
androgen O-MISC O-MISC
and O-MISC O-MISC
vitamin O-MISC O-MISC
D O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
glucocorticoid O-MISC O-MISC
target O-MISC O-MISC
tissues O-MISC O-MISC
that O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
examined O-MISC O-MISC
( O-MISC O-MISC
circulating O-MISC O-MISC
mononuclear O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
cultured O-MISC O-MISC
skin O-MISC O-MISC
fibroblasts O-MISC O-MISC
) O-MISC O-MISC
have O-MISC O-MISC
normal O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC O-MISC
with O-MISC O-MISC
decreased O-MISC O-MISC
affinity O-MISC O-MISC
for O-MISC O-MISC
dexamethasone O-MISC O-MISC
. O-MISC O-MISC

Transformation O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphocytes O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
induction O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
that O-MISC O-MISC
observed O-MISC O-MISC
with O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
Old O-MISC O-MISC
World O-MISC O-MISC
primates O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
receptor O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
has O-MISC O-MISC
a O-MISC O-MISC
low O-MISC O-MISC
affinity O-MISC O-MISC
for O-MISC O-MISC
dexamethasone O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
low O-MISC O-MISC
affinity O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
increased O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
specific O-MISC O-MISC
bound O-MISC O-MISC
ligand O-MISC O-MISC
during O-MISC O-MISC
thermal O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Meroreceptor O-MISC O-MISC
generation O-MISC O-MISC
is O-MISC O-MISC
normal O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
molecular O-MISC O-MISC
weight O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
, O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
SDS O-MISC O-MISC
- O-MISC O-MISC
PAGE O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
Old O-MISC O-MISC
World O-MISC O-MISC
primates O-MISC O-MISC
( O-MISC O-MISC
approximately O-MISC O-MISC
92 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
pattern O-MISC O-MISC
per O-MISC O-MISC
se O-MISC O-MISC
, O-MISC O-MISC
examined O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
by O-MISC O-MISC
heating O-MISC O-MISC
cytosol O-MISC O-MISC
and O-MISC O-MISC
performing O-MISC O-MISC
phosphocellulose O-MISC O-MISC
chromatography O-MISC O-MISC
, O-MISC O-MISC
appears O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ratios O-MISC O-MISC
of O-MISC O-MISC
nuclear O-MISC O-MISC
to O-MISC O-MISC
cytosolic B-MISC B-MISC
hormone I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
- I-MISC I-MISC
complexes I-MISC I-MISC
and O-MISC O-MISC
of O-MISC O-MISC
cytosolic O-MISC B-MISC
activated O-MISC O-MISC
to O-MISC O-MISC
unactivated B-MISC B-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
in O-MISC O-MISC
intact O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
Old O-MISC O-MISC
World O-MISC O-MISC
primates O-MISC O-MISC
. O-MISC O-MISC

Results O-MISC O-MISC
from O-MISC O-MISC
mixing O-MISC O-MISC
studies O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
support O-MISC O-MISC
the O-MISC O-MISC
hypothesis O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
binding O-MISC O-MISC
inhibitor O-MISC O-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
a O-MISC O-MISC
deficient O-MISC O-MISC
cytosolic O-MISC O-MISC
positive O-MISC O-MISC
modifier O-MISC O-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
underlies O-MISC O-MISC
the O-MISC O-MISC
findings O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
primates O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
New O-MISC O-MISC
World O-MISC O-MISC
primates O-MISC O-MISC
, O-MISC O-MISC
unlike O-MISC O-MISC
men O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
syndrome O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
cortisol O-MISC O-MISC
resistance O-MISC O-MISC
, O-MISC O-MISC
have O-MISC O-MISC
compensated O-MISC O-MISC
for O-MISC O-MISC
their O-MISC O-MISC
condition O-MISC O-MISC
with O-MISC O-MISC
intra O-MISC O-MISC
- O-MISC O-MISC
adrenal O-MISC O-MISC
and O-MISC O-MISC
mineralocorticoid O-MISC B-MISC
receptor O-MISC I-MISC
adaptations O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
unlike O-MISC O-MISC
Old O-MISC O-MISC
World O-MISC O-MISC
primates O-MISC O-MISC
, O-MISC O-MISC
cortisol O-MISC O-MISC
in O-MISC O-MISC
New O-MISC O-MISC
World O-MISC O-MISC
primates O-MISC O-MISC
has O-MISC O-MISC
only O-MISC O-MISC
weak O-MISC O-MISC
sodium O-MISC O-MISC
- O-MISC O-MISC
retaining O-MISC O-MISC
potency O-MISC O-MISC
because O-MISC O-MISC
the O-MISC O-MISC
aldosterone B-MISC O-MISC
receptor I-MISC I-MISC
has O-MISC O-MISC
a O-MISC O-MISC
low O-MISC O-MISC
affinity O-MISC O-MISC
for O-MISC O-MISC
cortisol O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
common O-MISC O-MISC
element O-MISC O-MISC
that O-MISC O-MISC
would O-MISC O-MISC
explain O-MISC O-MISC
the O-MISC O-MISC
apparent O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
six O-MISC O-MISC
steroid O-MISC O-MISC
hormones O-MISC O-MISC
in O-MISC O-MISC
New O-MISC O-MISC
World O-MISC O-MISC
primates O-MISC O-MISC

Acetylation O-MISC O-MISC
and O-MISC O-MISC
modulation O-MISC O-MISC
of O-MISC O-MISC
erythroid B-MISC B-MISC
Kruppel I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
EKLF B-MISC B-MISC
) O-MISC O-MISC
activity O-MISC O-MISC
by O-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
histone B-MISC B-MISC
acetyltransferases I-MISC I-MISC
. O-MISC O-MISC

Erythroid B-MISC B-MISC
Kruppel I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
EKLF B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
red B-MISC O-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
transcriptional I-MISC I-MISC
activator I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
crucial O-MISC O-MISC
for O-MISC O-MISC
consolidating O-MISC O-MISC
the O-MISC O-MISC
switch O-MISC O-MISC
to O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
adult O-MISC O-MISC
beta O-MISC O-MISC
- O-MISC O-MISC
globin O-MISC B-MISC
expression O-MISC O-MISC
during O-MISC O-MISC
erythroid O-MISC O-MISC
ontogeny O-MISC O-MISC
. O-MISC O-MISC

EKLF B-MISC B-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
integrity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
chromatin O-MISC B-MISC
structure O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
beta B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
globin I-MISC I-MISC
locus I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
it O-MISC O-MISC
interacts O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
positive B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
factor I-MISC I-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
find O-MISC O-MISC
that O-MISC O-MISC
EKLF B-MISC B-MISC
is O-MISC O-MISC
an O-MISC O-MISC
acetylated B-MISC B-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
it O-MISC O-MISC
interacts O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
with O-MISC O-MISC
CBP B-MISC B-MISC
, O-MISC O-MISC
p300 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
P B-MISC B-MISC
/ I-MISC I-MISC
CAF I-MISC I-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
its O-MISC O-MISC
interactions O-MISC O-MISC
with O-MISC O-MISC
these O-MISC O-MISC
histone B-MISC B-MISC
acetyltransferases I-MISC I-MISC
are O-MISC O-MISC
not O-MISC O-MISC
equivalent O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
CBP B-MISC B-MISC
and O-MISC O-MISC
p300 B-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
P B-MISC B-MISC
/ I-MISC I-MISC
CAF I-MISC I-MISC
, O-MISC O-MISC
utilize O-MISC O-MISC
EKLF B-MISC B-MISC
as O-MISC O-MISC
a O-MISC O-MISC
substrate O-MISC O-MISC
for O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
acetylation O-MISC O-MISC
within O-MISC O-MISC
its O-MISC O-MISC
trans O-MISC B-MISC
- O-MISC I-MISC
activation O-MISC I-MISC
region O-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
functional O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
interactions O-MISC O-MISC
are O-MISC O-MISC
that O-MISC O-MISC
CBP B-MISC B-MISC
and O-MISC O-MISC
p300 B-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
P B-MISC B-MISC
/ I-MISC I-MISC
CAF I-MISC I-MISC
, O-MISC O-MISC
enhance O-MISC B-MISC
EKLF B-MISC B-MISC
' O-MISC O-MISC
s O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
beta B-MISC B-MISC
- I-MISC I-MISC
globin I-MISC I-MISC
promoter I-MISC I-MISC
in O-MISC O-MISC
erythroid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
establish O-MISC O-MISC
EKLF B-MISC B-MISC
as O-MISC O-MISC
a O-MISC O-MISC
tissue B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
that O-MISC O-MISC
undergoes O-MISC O-MISC
post O-MISC O-MISC
- O-MISC O-MISC
translational O-MISC O-MISC
acetylation O-MISC O-MISC
and O-MISC O-MISC
suggest O-MISC O-MISC
a O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
EKLF B-MISC B-MISC
is O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
alter O-MISC O-MISC
chromatin O-MISC B-MISC
structure O-MISC O-MISC
and O-MISC O-MISC
induce O-MISC O-MISC
beta O-MISC B-MISC
- O-MISC I-MISC
globin O-MISC I-MISC
expression O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
beta B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
globin I-MISC I-MISC
cluster I-MISC I-MISC
. O-MISC O-MISC

Recognition O-MISC O-MISC
of O-MISC O-MISC
herpes B-MISC B-MISC
simplex I-MISC I-MISC
virus I-MISC I-MISC
type I-MISC I-MISC
2 I-MISC I-MISC
tegument I-MISC I-MISC
proteins I-MISC I-MISC
by O-MISC O-MISC
CD4 O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
infiltrating O-MISC O-MISC
human O-MISC O-MISC
genital O-MISC O-MISC
herpes O-MISC O-MISC
lesions O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
local O-MISC O-MISC
cellular O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
herpes O-MISC O-MISC
simplex O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
HSV O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
important O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
recurrent O-MISC O-MISC
HSV O-MISC O-MISC
infection O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
antiviral O-MISC O-MISC
functions O-MISC O-MISC
of O-MISC O-MISC
infiltrating O-MISC O-MISC
CD4 O-MISC O-MISC
- O-MISC O-MISC
bearing O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
may O-MISC O-MISC
include O-MISC O-MISC
cytotoxicity O-MISC O-MISC
, O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
viral O-MISC O-MISC
growth O-MISC O-MISC
, O-MISC O-MISC
lymphokine O-MISC B-MISC
secretion O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
support O-MISC O-MISC
of O-MISC O-MISC
humoral O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
antigens O-MISC O-MISC
recognized O-MISC O-MISC
by O-MISC O-MISC
many O-MISC O-MISC
HSV O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CD4 O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
localizing O-MISC O-MISC
to O-MISC O-MISC
genital O-MISC O-MISC
HSV O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
lesions O-MISC O-MISC
are O-MISC O-MISC
unknown O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cells O-MISC O-MISC
recognizing O-MISC O-MISC
antigens O-MISC B-MISC
encoded O-MISC O-MISC
within O-MISC O-MISC
map O-MISC O-MISC
units O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
67 O-MISC O-MISC
to O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
73 O-MISC O-MISC
of O-MISC O-MISC
HSV B-MISC O-MISC
DNA I-MISC O-MISC
are O-MISC O-MISC
frequently O-MISC O-MISC
recovered O-MISC O-MISC
from O-MISC O-MISC
herpetic O-MISC O-MISC
lesions O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
cloning O-MISC O-MISC
with O-MISC O-MISC
this O-MISC O-MISC
region O-MISC O-MISC
of O-MISC O-MISC
DNA O-MISC O-MISC
now O-MISC O-MISC
shows O-MISC O-MISC
that O-MISC O-MISC
tegument B-MISC B-MISC
protein I-MISC I-MISC
VP22 B-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
viral B-MISC B-MISC
dUTPase I-MISC I-MISC
, O-MISC O-MISC
encoded O-MISC O-MISC
by O-MISC O-MISC
genes B-MISC B-MISC
UL49 I-MISC B-MISC
and I-MISC O-MISC
UL50 I-MISC B-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
, O-MISC O-MISC
are O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
antigens I-MISC I-MISC
. O-MISC O-MISC

Separate O-MISC O-MISC
epitopes B-MISC B-MISC
in O-MISC O-MISC
VP22 B-MISC B-MISC
were O-MISC O-MISC
defined O-MISC O-MISC
for O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
clones O-MISC O-MISC
from O-MISC O-MISC
each O-MISC O-MISC
of O-MISC O-MISC
three O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Reactivity O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
tegument B-MISC B-MISC
protein I-MISC I-MISC
encoded O-MISC O-MISC
by O-MISC O-MISC
UL21 B-MISC B-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
for O-MISC O-MISC
an O-MISC O-MISC
additional O-MISC O-MISC
patient O-MISC O-MISC
. O-MISC O-MISC

Three O-MISC O-MISC
new O-MISC O-MISC
epitopes O-MISC O-MISC
were O-MISC O-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
VP16 B-MISC B-MISC
, O-MISC O-MISC
a O-MISC O-MISC
tegument B-MISC B-MISC
protein I-MISC I-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
VP22 B-MISC B-MISC
. O-MISC O-MISC

Some O-MISC O-MISC
tegument O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CD4 O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
clones O-MISC O-MISC
exhibited O-MISC O-MISC
cytotoxic O-MISC O-MISC
activity O-MISC O-MISC
against O-MISC O-MISC
HSV O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
herpes B-MISC B-MISC
simplex I-MISC I-MISC
tegument I-MISC I-MISC
proteins I-MISC I-MISC
are O-MISC O-MISC
processed O-MISC O-MISC
for O-MISC O-MISC
antigen O-MISC O-MISC
presentation O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
possible O-MISC O-MISC
candidate O-MISC O-MISC
compounds O-MISC O-MISC
for O-MISC O-MISC
herpes O-MISC O-MISC
simplex O-MISC O-MISC
vaccines O-MISC O-MISC
. O-MISC O-MISC

Fibrinogen B-MISC B-MISC
activates O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
in O-MISC O-MISC
mononuclear O-MISC O-MISC
phagocytes O-MISC O-MISC
. O-MISC O-MISC

Adhesion O-MISC O-MISC
to O-MISC O-MISC
extracellular O-MISC O-MISC
matrices O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
modulate O-MISC O-MISC
leukocyte O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
fully O-MISC O-MISC
understood O-MISC O-MISC
. O-MISC O-MISC

Mononuclear O-MISC O-MISC
phagocytes O-MISC O-MISC
are O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
fibrinous O-MISC O-MISC
provisional O-MISC O-MISC
matrix O-MISC O-MISC
throughout O-MISC O-MISC
migration O-MISC O-MISC
into O-MISC O-MISC
inflammatory O-MISC O-MISC
foci O-MISC O-MISC
, O-MISC O-MISC
so O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
was O-MISC O-MISC
undertaken O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
fibrinogen O-MISC B-MISC
triggers O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

U937 O-MISC O-MISC
cells O-MISC O-MISC
differentiated O-MISC O-MISC
with O-MISC O-MISC
PMA O-MISC O-MISC
in O-MISC O-MISC
nonadherent O-MISC O-MISC
culture O-MISC O-MISC
were O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
express O-MISC O-MISC
two O-MISC O-MISC
fibrinogen B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
integrins I-MISC I-MISC
, O-MISC O-MISC
predominately O-MISC B-MISC
CD11b B-MISC B-MISC
/ I-MISC I-MISC
CD18 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
lesser O-MISC O-MISC
extent O-MISC O-MISC
, O-MISC O-MISC
CD11c B-MISC B-MISC
/ I-MISC I-MISC
CD18 I-MISC I-MISC
. O-MISC O-MISC

Cells O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
fibrinogen B-MISC O-MISC
( O-MISC O-MISC
10 O-MISC O-MISC
- O-MISC O-MISC
100 O-MISC O-MISC
microg O-MISC O-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
Mn2 O-MISC O-MISC
+ O-MISC O-MISC
( O-MISC O-MISC
50 O-MISC O-MISC
microM O-MISC O-MISC
) O-MISC O-MISC
for O-MISC O-MISC
2 O-MISC O-MISC
h O-MISC O-MISC
were O-MISC O-MISC
examined O-MISC O-MISC
by O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
minimal O-MISC O-MISC
in O-MISC O-MISC
unstimulated O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
substantially O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
fibrinogen B-MISC B-MISC
. O-MISC O-MISC

Fibrinogen B-MISC B-MISC
also O-MISC O-MISC
caused O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
SP1 B-MISC B-MISC
or O-MISC O-MISC
cAMP B-MISC B-MISC
response I-MISC I-MISC
element I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( I-MISC I-MISC
CREB I-MISC I-MISC
) I-MISC I-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

Blocking O-MISC O-MISC
mAbs B-MISC B-MISC
against O-MISC O-MISC
CD18 B-MISC B-MISC
and O-MISC O-MISC
CD11b B-MISC B-MISC
abrogated O-MISC O-MISC
fibrinogen B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
, O-MISC O-MISC
U937 O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
transfected O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
plasmid O-MISC B-MISC
containing O-MISC O-MISC
the O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
enhancer I-MISC I-MISC
( O-MISC O-MISC
bearing O-MISC O-MISC
two O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
sites I-MISC I-MISC
) O-MISC O-MISC
coupled O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
chloramphenicol B-MISC B-MISC
acetyltransferase I-MISC I-MISC
( I-MISC I-MISC
CAT I-MISC I-MISC
) I-MISC I-MISC
reporter I-MISC I-MISC
. O-MISC O-MISC

Cells O-MISC O-MISC
were O-MISC O-MISC
subsequently O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
PMA O-MISC O-MISC
for O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
, O-MISC O-MISC
inducing O-MISC O-MISC
CAT O-MISC B-MISC
activity O-MISC O-MISC
by O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
fibrinogen B-MISC O-MISC
/ O-MISC O-MISC
Mn2 O-MISC O-MISC
+ O-MISC O-MISC
for O-MISC O-MISC
2 O-MISC O-MISC
h O-MISC O-MISC
, O-MISC O-MISC
inducing O-MISC O-MISC
CAT O-MISC B-MISC
activity O-MISC O-MISC
by O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC I-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
3 O-MISC O-MISC
) O-MISC O-MISC
costimulation O-MISC O-MISC
with O-MISC O-MISC
fibrinogen B-MISC B-MISC
and O-MISC O-MISC
PMA O-MISC O-MISC
, O-MISC O-MISC
inducing O-MISC O-MISC
5 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
the O-MISC O-MISC
CAT O-MISC B-MISC
activity O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
PMA O-MISC O-MISC
alone O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
contact O-MISC O-MISC
with O-MISC O-MISC
fibrinogen B-MISC B-MISC
- I-MISC I-MISC
derived I-MISC I-MISC
proteins I-MISC I-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
mononuclear O-MISC O-MISC
phagocyte O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
signaling O-MISC O-MISC
through O-MISC O-MISC
CD11b B-MISC B-MISC
/ I-MISC I-MISC
CD18 I-MISC I-MISC
, O-MISC O-MISC
resulting O-MISC O-MISC
in O-MISC O-MISC
selective O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
transcriptional B-MISC B-MISC
regulatory I-MISC I-MISC
factors I-MISC I-MISC
, O-MISC O-MISC
including O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
. O-MISC O-MISC

Peripheral O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
lupus O-MISC O-MISC
express O-MISC O-MISC
estrogen O-MISC B-MISC
receptor O-MISC I-MISC
transcripts O-MISC I-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
those O-MISC O-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
To O-MISC O-MISC
identify O-MISC O-MISC
and O-MISC O-MISC
characterize O-MISC O-MISC
estrogen B-MISC B-MISC
receptor I-MISC I-MISC
( I-MISC I-MISC
ER I-MISC B-MISC
) I-MISC I-MISC
transcripts I-MISC I-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
immune O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
systemic O-MISC O-MISC
lupus O-MISC O-MISC
erythematosus O-MISC O-MISC
( O-MISC O-MISC
SLE O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
healthy O-MISC O-MISC
donors O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Peripheral O-MISC O-MISC
blood O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
prepared O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
SLE O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
healthy O-MISC O-MISC
donors O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
8 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
separated O-MISC O-MISC
into O-MISC O-MISC
CD4 O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC O-MISC
. O-MISC O-MISC

Some O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
estradiol O-MISC O-MISC
, O-MISC O-MISC
PMA O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
ionomycin O-MISC O-MISC
. O-MISC O-MISC

Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
7 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
hybridomas O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
established O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
SLE O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
healthy O-MISC O-MISC
individual O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
source O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
examined O-MISC O-MISC
for O-MISC O-MISC
ER B-MISC B-MISC
mRNA I-MISC I-MISC
by O-MISC O-MISC
reverse O-MISC O-MISC
transcription O-MISC O-MISC
nested O-MISC O-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
. O-MISC O-MISC

Amplified O-MISC O-MISC
cDNA B-MISC B-MISC
were O-MISC O-MISC
sequenced O-MISC O-MISC
by O-MISC O-MISC
standard O-MISC O-MISC
methods O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
In O-MISC O-MISC
all O-MISC O-MISC
cells O-MISC O-MISC
tested O-MISC O-MISC
, O-MISC O-MISC
ER B-MISC B-MISC
mRNA I-MISC I-MISC
was O-MISC O-MISC
expressed O-MISC O-MISC
without O-MISC O-MISC
prior O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Partial O-MISC O-MISC
sequences O-MISC O-MISC
from O-MISC O-MISC
exons B-MISC B-MISC
1 I-MISC I-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
were O-MISC O-MISC
nearly O-MISC O-MISC
identical O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
published O-MISC O-MISC
sequence O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
ER I-MISC I-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

There O-MISC O-MISC
were O-MISC O-MISC
no O-MISC O-MISC
notable O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
ER B-MISC B-MISC
transcripts I-MISC I-MISC
between O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
healthy O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

Variant O-MISC B-MISC
receptor O-MISC I-MISC
transcripts O-MISC I-MISC
lacking O-MISC O-MISC
exon B-MISC B-MISC
5 I-MISC I-MISC
or O-MISC I-MISC
exon B-MISC B-MISC
7 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
encodes O-MISC O-MISC
the O-MISC O-MISC
hormone B-MISC B-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
, O-MISC O-MISC
were O-MISC O-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
majority O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Precise O-MISC O-MISC
deletion O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
exons O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
they O-MISC O-MISC
are O-MISC O-MISC
alternatively O-MISC O-MISC
spliced O-MISC B-MISC
transcripts O-MISC I-MISC
. O-MISC O-MISC

Whether O-MISC O-MISC
the O-MISC O-MISC
detected O-MISC O-MISC
transcripts O-MISC B-MISC
are O-MISC O-MISC
translated O-MISC O-MISC
into O-MISC O-MISC
functional B-MISC B-MISC
receptor I-MISC I-MISC
proteins I-MISC I-MISC
remains O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
determined O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
vitro O-MISC O-MISC
stimulation O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
ER B-MISC B-MISC
mRNA I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
variants O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
correlate O-MISC O-MISC
with O-MISC O-MISC
disease O-MISC O-MISC
activity O-MISC O-MISC
or O-MISC O-MISC
medication O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
Monocytes O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
express O-MISC O-MISC
transcripts O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
normal O-MISC O-MISC
wild B-MISC O-MISC
type I-MISC O-MISC
ER I-MISC B-MISC
and O-MISC O-MISC
the O-MISC O-MISC
hormone B-MISC B-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
variants I-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

DNA O-MISC O-MISC
damaging O-MISC O-MISC
agents O-MISC O-MISC
induce O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Fas B-MISC B-MISC
ligand I-MISC I-MISC
and O-MISC O-MISC
subsequent O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
via O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
and O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Apoptosis O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
DNA O-MISC O-MISC
damage O-MISC O-MISC
and O-MISC O-MISC
other O-MISC O-MISC
stresses O-MISC O-MISC
can O-MISC O-MISC
proceed O-MISC O-MISC
via O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Fas B-MISC B-MISC
ligand I-MISC I-MISC
( O-MISC O-MISC
FasL B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
ligation O-MISC O-MISC
of O-MISC O-MISC
its O-MISC O-MISC
receptor O-MISC O-MISC
, O-MISC O-MISC
Fas O-MISC B-MISC
( O-MISC O-MISC
CD95 O-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
that O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
and I-MISC O-MISC
AP I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
crucially O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
FasL B-MISC B-MISC
expression O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
etoposide O-MISC O-MISC
, O-MISC O-MISC
teniposide O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
UV O-MISC O-MISC
irradiation O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
nondegradable B-MISC O-MISC
mutant I-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
blocked O-MISC O-MISC
both O-MISC O-MISC
FasL B-MISC B-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
apoptosis O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
DNA O-MISC O-MISC
damage O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
Fas O-MISC B-MISC
ligation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
stimuli O-MISC O-MISC
also O-MISC O-MISC
induced O-MISC O-MISC
the O-MISC O-MISC
stress O-MISC O-MISC
- O-MISC O-MISC
activated O-MISC O-MISC
kinase O-MISC I-MISC
pathway O-MISC O-MISC
( O-MISC O-MISC
SAPK O-MISC B-MISC
/ O-MISC I-MISC
JNK O-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
was O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
maximal O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
1 O-MISC B-MISC
. O-MISC I-MISC
2 O-MISC I-MISC
kb O-MISC I-MISC
FasL B-MISC I-MISC
promoter I-MISC I-MISC
responded O-MISC O-MISC
to O-MISC O-MISC
DNA O-MISC O-MISC
damage O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
coexpression O-MISC O-MISC
with O-MISC O-MISC
p65 B-MISC B-MISC
Rel I-MISC I-MISC
or O-MISC O-MISC
Fos B-MISC B-MISC
/ I-MISC I-MISC
Jun I-MISC I-MISC
. O-MISC O-MISC

Mutations O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
relevant O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
and I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
eliminated O-MISC O-MISC
these O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
and O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
contributes O-MISC O-MISC
to O-MISC O-MISC
stress O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
via O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
FasL B-MISC B-MISC
. O-MISC O-MISC

A O-MISC O-MISC
small O-MISC O-MISC
, O-MISC O-MISC
nonpeptidyl O-MISC O-MISC
mimic O-MISC O-MISC
of O-MISC O-MISC
granulocyte B-MISC B-MISC
- I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
[ O-MISC O-MISC
see O-MISC O-MISC
commetns O-MISC O-MISC
] O-MISC O-MISC

A O-MISC O-MISC
nonpeptidyl O-MISC O-MISC
small O-MISC I-MISC
molecule O-MISC I-MISC
SB O-MISC B-MISC
247464 O-MISC O-MISC
, O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
activating O-MISC O-MISC
granulocyte B-MISC B-MISC
- I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
) O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
pathways O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
throughput O-MISC O-MISC
assay O-MISC O-MISC
in O-MISC O-MISC
cultured O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Like O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
, O-MISC O-MISC
SB O-MISC O-MISC
247464 O-MISC O-MISC
induced O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
multiple B-MISC O-MISC
signaling I-MISC B-MISC
proteins I-MISC I-MISC
and O-MISC O-MISC
stimulated O-MISC O-MISC
primary O-MISC O-MISC
murine O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
form O-MISC O-MISC
granulocytic O-MISC O-MISC
colonies O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
also O-MISC O-MISC
elevated O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
neutrophil O-MISC O-MISC
counts O-MISC O-MISC
in O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
extracellular O-MISC B-MISC
domain O-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
murine B-MISC B-MISC
G I-MISC I-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
receptor I-MISC I-MISC
was O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
SB O-MISC B-MISC
247464 O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
compound O-MISC O-MISC
acts O-MISC O-MISC
by O-MISC O-MISC
oligomerizing B-MISC B-MISC
receptor I-MISC I-MISC
chains I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
small O-MISC O-MISC
molecule O-MISC I-MISC
can O-MISC O-MISC
activate O-MISC O-MISC
a O-MISC O-MISC
receptor O-MISC O-MISC
that O-MISC O-MISC
normally O-MISC O-MISC
binds O-MISC O-MISC
a O-MISC O-MISC
relatively O-MISC O-MISC
large O-MISC O-MISC
protein O-MISC O-MISC
ligand O-MISC O-MISC
. O-MISC O-MISC

Minimal O-MISC O-MISC
residual O-MISC O-MISC
disease O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
myelogenous O-MISC O-MISC
leukemia O-MISC O-MISC
with O-MISC O-MISC
PML B-MISC B-MISC
/ I-MISC I-MISC
RAR I-MISC I-MISC
alpha I-MISC I-MISC
or O-MISC I-MISC
AML1 B-MISC B-MISC
/ I-MISC I-MISC
ETO I-MISC I-MISC
mRNA I-MISC I-MISC
and O-MISC O-MISC
phenotypic O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
possible O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
studied O-MISC O-MISC
minimal O-MISC O-MISC
residual O-MISC O-MISC
disease O-MISC O-MISC
( O-MISC O-MISC
MRD O-MISC B-MISC
) O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
AML O-MISC O-MISC
) O-MISC O-MISC
who O-MISC O-MISC
have O-MISC O-MISC
PML B-MISC B-MISC
/ I-MISC I-MISC
RAR I-MISC I-MISC
alpha I-MISC I-MISC
or O-MISC O-MISC
AML1 B-MISC B-MISC
/ I-MISC I-MISC
ETO I-MISC I-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
phenotypic O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
lymphocyte O-MISC O-MISC
subsets O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
antitumor O-MISC O-MISC
immunity O-MISC O-MISC
. O-MISC O-MISC

Eight O-MISC O-MISC
patients O-MISC O-MISC
in O-MISC O-MISC
long O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
( O-MISC O-MISC
LT O-MISC O-MISC
; O-MISC O-MISC
3 O-MISC O-MISC
to O-MISC O-MISC
15 O-MISC O-MISC
years O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
15 O-MISC O-MISC
patients O-MISC O-MISC
in O-MISC O-MISC
short O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
( O-MISC O-MISC
ST O-MISC O-MISC
; O-MISC O-MISC
up O-MISC O-MISC
to O-MISC O-MISC
3 O-MISC O-MISC
years O-MISC O-MISC
) O-MISC O-MISC
remission O-MISC O-MISC
were O-MISC O-MISC
studied O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
the O-MISC O-MISC
reverse O-MISC O-MISC
transcription O-MISC O-MISC
- O-MISC O-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
( O-MISC O-MISC
RT O-MISC O-MISC
) O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
limit O-MISC O-MISC
of O-MISC O-MISC
detection O-MISC O-MISC
was O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
5 O-MISC O-MISC
) O-MISC O-MISC
to O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
for O-MISC O-MISC
PML B-MISC B-MISC
/ I-MISC I-MISC
RAR I-MISC I-MISC
alpha I-MISC I-MISC
transcript I-MISC I-MISC
and O-MISC O-MISC
10 O-MISC I-MISC
( O-MISC O-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
) O-MISC O-MISC
to O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC I-MISC
5 O-MISC I-MISC
) O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
AML1 B-MISC B-MISC
/ I-MISC I-MISC
ETO I-MISC I-MISC
transcript I-MISC I-MISC
. O-MISC O-MISC

Simultaneously O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
lymphocyte O-MISC O-MISC
subsets O-MISC O-MISC
and O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
( O-MISC O-MISC
PB O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
( O-MISC O-MISC
BM O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
investigated O-MISC O-MISC
by O-MISC O-MISC
flow O-MISC O-MISC
cytometric O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

Four O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
eight O-MISC O-MISC
patients O-MISC O-MISC
in O-MISC O-MISC
LT O-MISC O-MISC
and O-MISC O-MISC
7 O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
15 O-MISC O-MISC
patients O-MISC O-MISC
in O-MISC O-MISC
ST O-MISC O-MISC
remission O-MISC O-MISC
were O-MISC O-MISC
MRD O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
all O-MISC O-MISC
MRD O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
patients O-MISC O-MISC
in O-MISC O-MISC
LT O-MISC O-MISC
remission O-MISC O-MISC
are O-MISC O-MISC
still O-MISC O-MISC
until O-MISC O-MISC
now O-MISC O-MISC
event O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
, O-MISC O-MISC
3 O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
7 O-MISC O-MISC
MRD O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
( O-MISC O-MISC
MRD O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
patients O-MISC O-MISC
in O-MISC O-MISC
ST O-MISC B-MISC
remission O-MISC I-MISC
soon O-MISC O-MISC
relapsed O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
total O-MISC O-MISC
populations O-MISC O-MISC
of O-MISC O-MISC
CD4 B-MISC O-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
CD8 B-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD56 B-MISC O-MISC
+ O-MISC O-MISC
[ O-MISC O-MISC
possible O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
and O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
( O-MISC O-MISC
T O-MISC O-MISC
/ O-MISC O-MISC
NK O-MISC O-MISC
) O-MISC O-MISC
populations O-MISC O-MISC
] O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
BM O-MISC O-MISC
of O-MISC O-MISC
ST O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
MRD O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
LT O-MISC O-MISC
patients O-MISC O-MISC
were O-MISC O-MISC
significantly O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
low O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
CD28 O-MISC B-MISC
+ O-MISC O-MISC
population O-MISC O-MISC
showed O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
tendency O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
- O-MISC O-MISC
. O-MISC O-MISC
02 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
T O-MISC O-MISC
/ O-MISC O-MISC
NK O-MISC O-MISC
subsets O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
BM O-MISC O-MISC
of O-MISC O-MISC
MRD O-MISC O-MISC
- O-MISC O-MISC
negative O-MISC O-MISC
( O-MISC O-MISC
MRD O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
LT O-MISC O-MISC
( O-MISC O-MISC
MRD O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
LT O-MISC O-MISC
) O-MISC O-MISC
patients O-MISC O-MISC
showed O-MISC O-MISC
similar O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
normal O-MISC O-MISC
volunteers O-MISC O-MISC
. O-MISC O-MISC

Basically O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
total O-MISC O-MISC
percentage O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD56 O-MISC O-MISC
+ O-MISC O-MISC
cell O-MISC O-MISC
populations O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
BM O-MISC O-MISC
was O-MISC O-MISC
increased O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
following O-MISC O-MISC
order O-MISC O-MISC
: O-MISC O-MISC
MRD O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
LT O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
normal O-MISC O-MISC
volunteers O-MISC O-MISC
, O-MISC O-MISC
MRD O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
LT O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
MRD O-MISC O-MISC
+ O-MISC O-MISC
or O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
ST O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
percentages O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
/ O-MISC O-MISC
NK O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
subsets O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
PB O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
significantly O-MISC O-MISC
different O-MISC O-MISC
among O-MISC O-MISC
these O-MISC O-MISC
groups O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
difference O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
possible O-MISC O-MISC
T O-MISC O-MISC
/ O-MISC O-MISC
NK O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
BM O-MISC O-MISC
may O-MISC O-MISC
strongly O-MISC O-MISC
influence O-MISC O-MISC
clinical O-MISC O-MISC
and O-MISC O-MISC
molecular O-MISC O-MISC
remission O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
still O-MISC O-MISC
remain O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
confirmed O-MISC O-MISC
by O-MISC O-MISC
further O-MISC O-MISC
studies O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
functional O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
tumor O-MISC O-MISC
immunity O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
/ O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
AML O-MISC O-MISC
in O-MISC O-MISC
remission O-MISC O-MISC
. O-MISC O-MISC

Mycobacterium O-MISC O-MISC
tuberculosis O-MISC O-MISC
mannose O-MISC O-MISC
- O-MISC O-MISC
capped O-MISC O-MISC
lipoarabinomannan O-MISC O-MISC
can O-MISC O-MISC
induce O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
human B-MISC O-MISC
immunodeficiency I-MISC O-MISC
virus I-MISC O-MISC
type I-MISC O-MISC
1 I-MISC O-MISC
long I-MISC O-MISC
terminal I-MISC I-MISC
repeat I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Tuberculosis O-MISC O-MISC
has O-MISC O-MISC
emerged O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
epidemic O-MISC O-MISC
, O-MISC O-MISC
extended O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
large O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
individuals O-MISC O-MISC
infected O-MISC O-MISC
with O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
major O-MISC O-MISC
goal O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
was O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
the O-MISC O-MISC
mycobacterial O-MISC O-MISC
cell O-MISC O-MISC
wall O-MISC O-MISC
component O-MISC O-MISC
mannose O-MISC O-MISC
- O-MISC O-MISC
capped O-MISC O-MISC
lipoarabinomannan O-MISC O-MISC
( O-MISC O-MISC
ManLAM O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
Mycobacterium O-MISC O-MISC
tuberculosis O-MISC O-MISC
( O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC
tuberculosis O-MISC O-MISC
) O-MISC O-MISC
could O-MISC O-MISC
activate O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
cell O-MISC O-MISC
culture O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
experiments O-MISC O-MISC
are O-MISC O-MISC
of O-MISC O-MISC
prime O-MISC O-MISC
importance O-MISC O-MISC
considering O-MISC O-MISC
that O-MISC O-MISC
CD4 B-MISC B-MISC
- O-MISC O-MISC
expressing O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
represent O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
virus O-MISC O-MISC
reservoir O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
of O-MISC O-MISC
infected O-MISC O-MISC
individuals O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
the O-MISC O-MISC
1G5 O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
harbouring O-MISC O-MISC
the O-MISC O-MISC
luciferase O-MISC B-MISC
reporter O-MISC I-MISC
gene O-MISC I-MISC
under O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
LTR I-MISC I-MISC
, O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
first O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
culture O-MISC O-MISC
protein O-MISC O-MISC
filtrates O-MISC O-MISC
( O-MISC O-MISC
CFP O-MISC O-MISC
) O-MISC O-MISC
from O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC
tuberculosis O-MISC O-MISC
or O-MISC O-MISC
purified O-MISC O-MISC
ManLAM O-MISC O-MISC
could O-MISC O-MISC
activate O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
LTR I-MISC I-MISC
- I-MISC O-MISC
dependent I-MISC O-MISC
gene I-MISC O-MISC
expression O-MISC O-MISC
unlike O-MISC O-MISC
similarly O-MISC O-MISC
prepared O-MISC O-MISC
CFP O-MISC O-MISC
extracts O-MISC O-MISC
devoid O-MISC O-MISC
of O-MISC O-MISC
ManLAM O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
implication O-MISC O-MISC
of O-MISC O-MISC
protein B-MISC B-MISC
tyrosine I-MISC I-MISC
kinase I-MISC I-MISC
( I-MISC I-MISC
s I-MISC I-MISC
) I-MISC I-MISC
, O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
A I-MISC I-MISC
and O-MISC O-MISC
/ O-MISC I-MISC
or O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
was O-MISC O-MISC
highlighted O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
abrogation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
ManLAM O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
LTR O-MISC I-MISC
- O-MISC O-MISC
driven O-MISC I-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
using O-MISC O-MISC
herbimycin O-MISC O-MISC
A O-MISC O-MISC
and O-MISC O-MISC
H7 O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
determined O-MISC O-MISC
, O-MISC O-MISC
using O-MISC O-MISC
electrophoresis O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC
tuberculosis O-MISC O-MISC
ManLAM O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
. O-MISC O-MISC

M O-MISC O-MISC
. O-MISC O-MISC
tuberculosis O-MISC O-MISC
ManLAM O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
clear O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
luciferase B-MISC B-MISC
gene I-MISC I-MISC
placed O-MISC O-MISC
under O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
wild B-MISC B-MISC
- I-MISC I-MISC
type I-MISC I-MISC
, I-MISC O-MISC
but I-MISC O-MISC
not I-MISC O-MISC
the I-MISC O-MISC
kappaB I-MISC B-MISC
- I-MISC I-MISC
mutated I-MISC I-MISC
, I-MISC I-MISC
HIV I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
LTR I-MISC I-MISC
region I-MISC I-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
ManLAM O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
LTR O-MISC I-MISC
transcription O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
autocrine O-MISC O-MISC
or O-MISC O-MISC
paracrine O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
endogenous B-MISC O-MISC
TNF I-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC
tuberculosis O-MISC O-MISC
can O-MISC O-MISC
upregulate O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
could O-MISC O-MISC
thus O-MISC O-MISC
have O-MISC O-MISC
the O-MISC O-MISC
potential O-MISC O-MISC
to O-MISC O-MISC
influence O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
. O-MISC O-MISC

Human B-MISC B-MISC
immunodeficiency I-MISC I-MISC
virus I-MISC I-MISC
type I-MISC I-MISC
1 I-MISC I-MISC
long I-MISC I-MISC
terminal I-MISC I-MISC
repeat I-MISC I-MISC
quasispecies O-MISC I-MISC
differ O-MISC O-MISC
in O-MISC O-MISC
basal O-MISC O-MISC
transcription O-MISC B-MISC
and O-MISC O-MISC
nuclear O-MISC B-MISC
factor O-MISC I-MISC
recruitment O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
glial O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
genomic O-MISC O-MISC
diversity O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
course O-MISC O-MISC
of O-MISC O-MISC
infection O-MISC O-MISC
has O-MISC O-MISC
the O-MISC O-MISC
potential O-MISC O-MISC
to O-MISC O-MISC
affect O-MISC O-MISC
all O-MISC O-MISC
aspects O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
replication O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proviral O-MISC O-MISC
genome O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
gain O-MISC O-MISC
a O-MISC O-MISC
better O-MISC O-MISC
understanding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
impact O-MISC O-MISC
of O-MISC O-MISC
long B-MISC B-MISC
terminal I-MISC I-MISC
repeat I-MISC I-MISC
( O-MISC O-MISC
LTR B-MISC B-MISC
) O-MISC O-MISC
sequence O-MISC O-MISC
diversity O-MISC O-MISC
on O-MISC O-MISC
LTR B-MISC B-MISC
- I-MISC O-MISC
directed I-MISC O-MISC
gene I-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
central O-MISC O-MISC
nervous O-MISC O-MISC
system O-MISC O-MISC
( O-MISC O-MISC
CNS O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
amplified O-MISC O-MISC
and O-MISC O-MISC
cloned O-MISC B-MISC
LTRs B-MISC B-MISC
from O-MISC O-MISC
proviral O-MISC O-MISC
DNA O-MISC O-MISC
in O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
. O-MISC O-MISC

Sequence O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
nineteen O-MISC O-MISC
LTRs B-MISC B-MISC
cloned O-MISC O-MISC
from O-MISC O-MISC
2 O-MISC O-MISC
adult O-MISC O-MISC
and O-MISC O-MISC
3 O-MISC O-MISC
pediatric O-MISC O-MISC
patients O-MISC O-MISC
revealed O-MISC O-MISC
an O-MISC O-MISC
average O-MISC O-MISC
of O-MISC O-MISC
33 O-MISC O-MISC
nucleotide O-MISC O-MISC
changes O-MISC O-MISC
( O-MISC O-MISC
with O-MISC O-MISC
respect O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
sequence O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
LAI B-MISC B-MISC
LTR I-MISC I-MISC
) O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
455 B-MISC B-MISC
- I-MISC I-MISC
bp I-MISC I-MISC
U3 I-MISC I-MISC
region I-MISC I-MISC
. O-MISC O-MISC

Transient O-MISC O-MISC
expression O-MISC O-MISC
analyses O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
neuroglial O-MISC O-MISC
and O-MISC O-MISC
lymphocytic O-MISC O-MISC
origin O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
some O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
LTRs B-MISC B-MISC
had O-MISC O-MISC
activities O-MISC O-MISC
which O-MISC O-MISC
varied O-MISC O-MISC
significantly O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
LAI B-MISC B-MISC
LTR I-MISC I-MISC
in O-MISC O-MISC
U O-MISC O-MISC
- O-MISC O-MISC
373 O-MISC O-MISC
MG O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
an O-MISC O-MISC
astrocytoma O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
) O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
a O-MISC O-MISC
CD4 O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
lymphocyte O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

While O-MISC O-MISC
LTRs B-MISC B-MISC
which O-MISC O-MISC
demonstrated O-MISC O-MISC
the O-MISC O-MISC
highest O-MISC O-MISC
activities O-MISC O-MISC
in O-MISC O-MISC
U O-MISC O-MISC
- O-MISC O-MISC
373 O-MISC O-MISC
MG O-MISC O-MISC
cells O-MISC O-MISC
also O-MISC O-MISC
yielded O-MISC O-MISC
high O-MISC O-MISC
activities O-MISC O-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
LTRs B-MISC B-MISC
were O-MISC O-MISC
generally O-MISC O-MISC
more O-MISC O-MISC
active O-MISC O-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
when O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
LAI B-MISC B-MISC
LTR I-MISC I-MISC
. O-MISC O-MISC

Differences O-MISC O-MISC
in O-MISC O-MISC
LTR B-MISC B-MISC
sequence I-MISC I-MISC
also O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
transcription O-MISC B-MISC
factor O-MISC I-MISC
recruitment O-MISC O-MISC
to O-MISC O-MISC
cis B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
sites I-MISC I-MISC
within O-MISC O-MISC
the O-MISC O-MISC
U3 B-MISC B-MISC
region I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
LTR B-MISC B-MISC
, O-MISC O-MISC
as O-MISC O-MISC
demonstrated O-MISC O-MISC
by O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
particular O-MISC O-MISC
, O-MISC O-MISC
naturally O-MISC O-MISC
occurring O-MISC O-MISC
sequence O-MISC O-MISC
variation O-MISC O-MISC
impacted O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
activating B-MISC B-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
/ O-MISC I-MISC
cAMP B-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
binding I-MISC I-MISC
( O-MISC I-MISC
ATF B-MISC B-MISC
/ O-MISC I-MISC
CREB B-MISC I-MISC
) O-MISC I-MISC
binding O-MISC I-MISC
site O-MISC I-MISC
( O-MISC O-MISC
located O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
LEF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC O-MISC
distal I-MISC B-MISC
NF I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
) O-MISC O-MISC
that O-MISC O-MISC
we O-MISC O-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
previous O-MISC O-MISC
studies O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
LTR I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
LTR B-MISC B-MISC
sequence I-MISC I-MISC
changes O-MISC O-MISC
can O-MISC O-MISC
significantly O-MISC O-MISC
affect O-MISC O-MISC
basal O-MISC O-MISC
LTR O-MISC B-MISC
function O-MISC O-MISC
and O-MISC O-MISC
transcription O-MISC B-MISC
factor O-MISC I-MISC
recruitment O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
may O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
turn O-MISC O-MISC
, O-MISC O-MISC
alter O-MISC O-MISC
the O-MISC O-MISC
course O-MISC O-MISC
of O-MISC O-MISC
viral O-MISC O-MISC
replication O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
CNS O-MISC O-MISC
and O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
origin O-MISC O-MISC
. O-MISC O-MISC

HMG B-MISC B-MISC
box I-MISC I-MISC
containing I-MISC O-MISC
transcription I-MISC B-MISC
factors I-MISC I-MISC
in O-MISC O-MISC
lymphocyte O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
identification O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mammalian B-MISC B-MISC
sex I-MISC I-MISC
- I-MISC I-MISC
determining I-MISC I-MISC
gene I-MISC I-MISC
Sry I-MISC I-MISC
has O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
discovery O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
large O-MISC O-MISC
family O-MISC O-MISC
of O-MISC O-MISC
related O-MISC O-MISC
( O-MISC O-MISC
' O-MISC I-MISC
HMG B-MISC I-MISC
box I-MISC I-MISC
' O-MISC I-MISC
) O-MISC I-MISC
transcription B-MISC I-MISC
factors I-MISC I-MISC
that O-MISC O-MISC
control O-MISC O-MISC
developmental O-MISC O-MISC
events O-MISC O-MISC
in O-MISC O-MISC
yeast O-MISC O-MISC
, O-MISC O-MISC
C O-MISC O-MISC
. O-MISC O-MISC
elegans O-MISC O-MISC
, O-MISC O-MISC
Drosophila O-MISC O-MISC
and O-MISC O-MISC
vertebrates O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
lymphocyte O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
several O-MISC O-MISC
HMG B-MISC B-MISC
box I-MISC I-MISC
proteins I-MISC I-MISC
play O-MISC O-MISC
a O-MISC O-MISC
decisive O-MISC O-MISC
role O-MISC O-MISC
. O-MISC O-MISC

Sox B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
is O-MISC O-MISC
important O-MISC O-MISC
for O-MISC O-MISC
very O-MISC O-MISC
early O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
/ O-MISC I-MISC
LEF B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
play O-MISC O-MISC
a O-MISC O-MISC
crucial O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
early O-MISC O-MISC
thymocyte O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

TCF B-MISC B-MISC
/ I-MISC I-MISC
LEF I-MISC I-MISC
proteins I-MISC I-MISC
have O-MISC O-MISC
recently O-MISC O-MISC
been O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
constitute O-MISC O-MISC
a O-MISC O-MISC
downstream O-MISC O-MISC
component O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Wingless O-MISC O-MISC
/ O-MISC O-MISC
Wnt O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
flies O-MISC O-MISC
, O-MISC O-MISC
this O-MISC O-MISC
pathway O-MISC O-MISC
controls O-MISC O-MISC
segment O-MISC O-MISC
polarity O-MISC O-MISC
; O-MISC O-MISC
in O-MISC O-MISC
Xenopus O-MISC O-MISC
it O-MISC O-MISC
controls O-MISC O-MISC
the O-MISC O-MISC
definition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
body O-MISC O-MISC
axis O-MISC O-MISC
. O-MISC O-MISC

Deregulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
pathway O-MISC O-MISC
occurs O-MISC O-MISC
in O-MISC O-MISC
several O-MISC O-MISC
human O-MISC O-MISC
tumors O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
insights O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
events O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
TCF B-MISC B-MISC
/ I-MISC I-MISC
LEF I-MISC I-MISC
function O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
organisms O-MISC O-MISC
may O-MISC O-MISC
eventually O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
understanding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
HMG B-MISC B-MISC
box I-MISC I-MISC
proteins I-MISC I-MISC
in O-MISC O-MISC
lymphoid O-MISC O-MISC
development O-MISC O-MISC

Transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
by O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
alpha I-MISC I-MISC
and I-MISC O-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
gene O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
MRP14 B-MISC B-MISC
myeloid I-MISC O-MISC
calcium I-MISC O-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

Transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
gene O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
myeloid B-MISC O-MISC
calcium I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
MRP14 B-MISC B-MISC
, O-MISC O-MISC
was O-MISC O-MISC
investigated O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytic O-MISC O-MISC
leukemia O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
MRP14 B-MISC B-MISC
gene I-MISC I-MISC
was O-MISC O-MISC
not O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
monoblastic O-MISC O-MISC
ML O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
promonocytic O-MISC O-MISC
U O-MISC O-MISC
- O-MISC O-MISC
937 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
promyelocytic O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
hand O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
gene O-MISC O-MISC
was O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
monocytic O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
dihydroxyvitamin O-MISC O-MISC
D3 O-MISC O-MISC
( O-MISC O-MISC
VD3 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
MRP14 B-MISC B-MISC
in O-MISC O-MISC
VD3 O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
two O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
higher O-MISC O-MISC
than O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Among O-MISC O-MISC
several O-MISC O-MISC
known O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
binding I-MISC I-MISC
motifs I-MISC I-MISC
, O-MISC O-MISC
nuclear B-MISC B-MISC
protein I-MISC I-MISC
( I-MISC O-MISC
s I-MISC O-MISC
) I-MISC O-MISC
of O-MISC O-MISC
VD3 O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
bound O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
CCAAT B-MISC B-MISC
/ I-MISC I-MISC
enhancer I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( I-MISC I-MISC
C I-MISC I-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
motif I-MISC I-MISC
that O-MISC O-MISC
was O-MISC O-MISC
located O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
upstream B-MISC O-MISC
region I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
MRP14 B-MISC B-MISC
gene I-MISC I-MISC
( O-MISC O-MISC
- O-MISC O-MISC
81 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
evidenced O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
competitive O-MISC O-MISC
gel O-MISC O-MISC
mobility O-MISC O-MISC
- O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

An O-MISC O-MISC
antibody O-MISC B-MISC
for O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
alpha I-MISC I-MISC
super O-MISC I-MISC
- O-MISC I-MISC
shifted O-MISC I-MISC
the O-MISC O-MISC
nucleoprotein B-MISC B-MISC
complex I-MISC I-MISC
in O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
VD3 O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
an O-MISC O-MISC
antibody O-MISC O-MISC
for O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
beta I-MISC I-MISC
blocked O-MISC O-MISC
the O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
complex O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
with O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

An O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
C I-MISC I-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
delta I-MISC I-MISC
antibody I-MISC I-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
complex O-MISC O-MISC
in O-MISC O-MISC
either O-MISC O-MISC
cell O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
concluded O-MISC O-MISC
that O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
alpha I-MISC I-MISC
and I-MISC I-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
were O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
motif I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
alpha I-MISC I-MISC
bound O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
motif O-MISC O-MISC
in O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
C B-MISC O-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
beta I-MISC I-MISC
bound O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
VD3 O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
to O-MISC O-MISC
examine O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
motif I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
transfected O-MISC O-MISC
several O-MISC O-MISC
constructed O-MISC O-MISC
luciferase B-MISC B-MISC
reporter I-MISC I-MISC
DNAs I-MISC I-MISC
into O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
luciferase O-MISC B-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
motif I-MISC I-MISC
in O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
increased O-MISC O-MISC
by O-MISC O-MISC
VD3 O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
motif I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
MRP14 B-MISC B-MISC
gene I-MISC I-MISC
was O-MISC O-MISC
confirmed O-MISC O-MISC
to O-MISC O-MISC
function O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
regulatory O-MISC O-MISC
region O-MISC I-MISC
in O-MISC O-MISC
VD3 O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

Since O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
beta I-MISC I-MISC
was O-MISC O-MISC
also O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
VD3 O-MISC O-MISC
- O-MISC O-MISC
untreated O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
immunoblotting O-MISC O-MISC
, O-MISC O-MISC
VD3 O-MISC B-MISC
activated O-MISC I-MISC
C B-MISC I-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
beta I-MISC I-MISC
to O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
motif O-MISC I-MISC
, O-MISC O-MISC
probably O-MISC O-MISC
through O-MISC O-MISC
post O-MISC O-MISC
- O-MISC O-MISC
translational O-MISC O-MISC
modification O-MISC O-MISC
. O-MISC O-MISC

Patients O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
risk O-MISC O-MISC
myelodysplastic O-MISC O-MISC
syndrome O-MISC O-MISC
can O-MISC O-MISC
have O-MISC O-MISC
polyclonal O-MISC O-MISC
or O-MISC O-MISC
clonal O-MISC O-MISC
haemopoiesis O-MISC O-MISC
in O-MISC O-MISC
complete O-MISC O-MISC
haematological O-MISC O-MISC
remission O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
clonality O-MISC O-MISC
of O-MISC O-MISC
mature O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
myeloid O-MISC O-MISC
and O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
haemopoietic O-MISC O-MISC
progenitors O-MISC O-MISC
from O-MISC O-MISC
18 O-MISC O-MISC
females O-MISC O-MISC
with O-MISC O-MISC
myelodysplasia O-MISC O-MISC
( O-MISC O-MISC
MDS O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
five O-MISC O-MISC
refractory O-MISC O-MISC
anaemia O-MISC O-MISC
, O-MISC O-MISC
RA O-MISC O-MISC
; O-MISC O-MISC
one O-MISC O-MISC
RA O-MISC O-MISC
with O-MISC O-MISC
ringed O-MISC O-MISC
sideroblasts O-MISC O-MISC
, O-MISC O-MISC
RARS O-MISC O-MISC
; O-MISC O-MISC
three O-MISC O-MISC
chronic O-MISC O-MISC
myelomonocytic O-MISC O-MISC
leukaemia O-MISC O-MISC
, O-MISC O-MISC
CMML O-MISC O-MISC
; O-MISC O-MISC
four O-MISC O-MISC
RA O-MISC O-MISC
with O-MISC O-MISC
excess O-MISC O-MISC
of O-MISC O-MISC
blasts O-MISC O-MISC
, O-MISC O-MISC
RAEB O-MISC B-MISC
; O-MISC O-MISC
five O-MISC O-MISC
RAEB O-MISC O-MISC
in O-MISC O-MISC
transformation O-MISC O-MISC
, O-MISC O-MISC
RAEB O-MISC B-MISC
- O-MISC I-MISC
t O-MISC I-MISC
) O-MISC O-MISC
was O-MISC O-MISC
studied O-MISC O-MISC
by O-MISC O-MISC
X B-MISC B-MISC
- I-MISC I-MISC
chromosome I-MISC I-MISC
inactivation O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
the O-MISC O-MISC
human O-MISC B-MISC
androgen O-MISC I-MISC
- O-MISC I-MISC
receptor O-MISC I-MISC
( O-MISC O-MISC
HUMARA O-MISC B-MISC
) O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
analysed O-MISC O-MISC
the O-MISC O-MISC
clonal O-MISC O-MISC
patterns O-MISC O-MISC
of O-MISC O-MISC
highly O-MISC O-MISC
purified O-MISC O-MISC
immature O-MISC O-MISC
CD34 O-MISC O-MISC
+ O-MISC O-MISC
38 O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
committed O-MISC O-MISC
CD34 O-MISC O-MISC
+ O-MISC O-MISC
38 O-MISC O-MISC
+ O-MISC O-MISC
marrow O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
progenitors O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
CD16 O-MISC O-MISC
+ O-MISC O-MISC
14 O-MISC O-MISC
- O-MISC O-MISC
granulocytes O-MISC O-MISC
, O-MISC O-MISC
CD14 O-MISC O-MISC
+ O-MISC O-MISC
monocytes O-MISC O-MISC
, O-MISC O-MISC
CD3 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
CD19 O-MISC O-MISC
+ O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
risk O-MISC O-MISC
patients O-MISC O-MISC
( O-MISC O-MISC
RAEB O-MISC O-MISC
, O-MISC O-MISC
RAEB O-MISC O-MISC
- O-MISC O-MISC
t O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
clonality O-MISC O-MISC
analysis O-MISC O-MISC
was O-MISC O-MISC
performed O-MISC O-MISC
before O-MISC O-MISC
and O-MISC O-MISC
after O-MISC O-MISC
intensive O-MISC O-MISC
remission O-MISC O-MISC
- O-MISC O-MISC
induction O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

All O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
except O-MISC O-MISC
one O-MISC O-MISC
with O-MISC O-MISC
RA O-MISC O-MISC
, O-MISC O-MISC
had O-MISC O-MISC
predominance O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
clone O-MISC O-MISC
in O-MISC O-MISC
their O-MISC O-MISC
granulocytes O-MISC O-MISC
and O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
same O-MISC O-MISC
clonal O-MISC O-MISC
pattern O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
CD34 O-MISC O-MISC
+ O-MISC O-MISC
progenitor O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
CD3 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
were O-MISC O-MISC
polyclonal O-MISC O-MISC
or O-MISC O-MISC
oligoclonal O-MISC O-MISC
in O-MISC O-MISC
14 O-MISC O-MISC
/ O-MISC O-MISC
18 O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

X B-MISC B-MISC
- I-MISC I-MISC
chromosome I-MISC I-MISC
inactivation O-MISC O-MISC
patterns O-MISC O-MISC
of O-MISC O-MISC
CD19 O-MISC B-MISC
+ O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
highly O-MISC O-MISC
concordant O-MISC O-MISC
with O-MISC O-MISC
CD3 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
except O-MISC O-MISC
for O-MISC O-MISC
two O-MISC O-MISC
patients O-MISC O-MISC
( O-MISC O-MISC
one O-MISC O-MISC
RA O-MISC O-MISC
, O-MISC O-MISC
one O-MISC O-MISC
CMML O-MISC O-MISC
) O-MISC O-MISC
with O-MISC O-MISC
monoclonal O-MISC O-MISC
B O-MISC O-MISC
and O-MISC O-MISC
polyclonal O-MISC B-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
therefore O-MISC O-MISC
suggesting O-MISC O-MISC
a O-MISC O-MISC
clonal O-MISC O-MISC
mutation O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
progenitor O-MISC O-MISC
common O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
myeloid O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphoid O-MISC O-MISC
lineages O-MISC O-MISC
or O-MISC O-MISC
the O-MISC O-MISC
coexistence O-MISC O-MISC
of O-MISC O-MISC
MDS O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
disorder O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
particular O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
dose O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
myeloablative O-MISC O-MISC
chemotherapy O-MISC O-MISC
, O-MISC O-MISC
polyclonal O-MISC O-MISC
haemopoiesis O-MISC O-MISC
was O-MISC O-MISC
reinstalled O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
mature O-MISC O-MISC
myeloid O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
immature O-MISC O-MISC
and O-MISC O-MISC
committed O-MISC O-MISC
marrow O-MISC O-MISC
progenitors O-MISC O-MISC
in O-MISC O-MISC
three O-MISC O-MISC
of O-MISC O-MISC
four O-MISC O-MISC
patients O-MISC O-MISC
achieving O-MISC O-MISC
complete O-MISC O-MISC
haematological O-MISC O-MISC
remission O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
we O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
most O-MISC O-MISC
haematological O-MISC O-MISC
remissions O-MISC O-MISC
in O-MISC O-MISC
MDS O-MISC O-MISC
are O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
restoration O-MISC O-MISC
of O-MISC O-MISC
polyclonal O-MISC O-MISC
haemopoiesis O-MISC O-MISC
. O-MISC O-MISC

Prominent O-MISC O-MISC
sex O-MISC O-MISC
steroid O-MISC O-MISC
metabolism O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Steroid O-MISC O-MISC
metabolism O-MISC O-MISC
was O-MISC O-MISC
investigated O-MISC O-MISC
in O-MISC O-MISC
cultured O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphoblastoid O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
LCL O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Gene O-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
examined O-MISC O-MISC
by O-MISC O-MISC
reverse O-MISC O-MISC
- O-MISC O-MISC
transcription O-MISC O-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
amplification O-MISC O-MISC
( O-MISC O-MISC
RT O-MISC O-MISC
- O-MISC O-MISC
PCR O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Appropriate O-MISC O-MISC
sized O-MISC I-MISC
transcripts B-MISC I-MISC
were O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
cultured O-MISC O-MISC
and O-MISC O-MISC
fresh O-MISC O-MISC
peripheral O-MISC O-MISC
lymphocytes O-MISC O-MISC
for O-MISC O-MISC
CYP11A B-MISC O-MISC
, O-MISC O-MISC
CYP17 B-MISC B-MISC
, O-MISC O-MISC
HSD11L B-MISC B-MISC
( O-MISC O-MISC
11beta B-MISC O-MISC
- I-MISC O-MISC
hydroxysteroid I-MISC O-MISC
dehydrogenase I-MISC O-MISC
I I-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
HSD17B1 B-MISC B-MISC
( O-MISC O-MISC
17beta B-MISC B-MISC
- I-MISC I-MISC
hydroxysteroid I-MISC I-MISC
dehydrogenase I-MISC I-MISC
type I-MISC I-MISC
I I-MISC I-MISC
) O-MISC I-MISC
and O-MISC O-MISC
SRD5A1 B-MISC B-MISC
( O-MISC O-MISC
5alpha B-MISC B-MISC
- I-MISC I-MISC
reductase I-MISC I-MISC
I I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

B O-MISC O-MISC
- O-MISC I-MISC
LCL O-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
expressed O-MISC O-MISC
CYP11B B-MISC B-MISC
. O-MISC O-MISC

There O-MISC O-MISC
was O-MISC O-MISC
minimal O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
HSD3B1 B-MISC B-MISC
and O-MISC O-MISC
HSD3B2 B-MISC B-MISC
( O-MISC I-MISC
3beta B-MISC O-MISC
- I-MISC I-MISC
hydroxysteroid I-MISC I-MISC
dehydrogenase I-MISC I-MISC
I I-MISC I-MISC
and I-MISC O-MISC
II I-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
LCL O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Transcripts O-MISC O-MISC
for O-MISC O-MISC
CYP19 B-MISC B-MISC
and O-MISC O-MISC
HSD11K B-MISC B-MISC
were O-MISC O-MISC
not O-MISC O-MISC
detected O-MISC O-MISC
. O-MISC O-MISC

Corresponding O-MISC O-MISC
enzymatic O-MISC O-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
detectable O-MISC O-MISC
only O-MISC O-MISC
for O-MISC O-MISC
17 B-MISC B-MISC
- I-MISC I-MISC
hydroxysteroid I-MISC I-MISC
dehydrogenase I-MISC I-MISC
and O-MISC O-MISC
5alpha B-MISC B-MISC
- I-MISC I-MISC
reductase I-MISC I-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
producing O-MISC O-MISC
testosterone O-MISC O-MISC
and O-MISC O-MISC
5alpha O-MISC O-MISC
- O-MISC O-MISC
dihydrotestosterone O-MISC O-MISC
. O-MISC O-MISC

Steroid O-MISC O-MISC
identities O-MISC O-MISC
were O-MISC O-MISC
confirmed O-MISC O-MISC
by O-MISC O-MISC
gas O-MISC O-MISC
chromatography O-MISC O-MISC
/ O-MISC O-MISC
mass O-MISC O-MISC
spectrometry O-MISC O-MISC
( O-MISC O-MISC
GC O-MISC O-MISC
/ O-MISC O-MISC
MS O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

One O-MISC O-MISC
metabolite O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
deoxycorticosterone O-MISC O-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
by O-MISC O-MISC
GC O-MISC O-MISC
/ O-MISC O-MISC
MS O-MISC O-MISC
as O-MISC O-MISC
6alpha O-MISC O-MISC
- O-MISC O-MISC
hydroxypregnanolone O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
was O-MISC O-MISC
concluded O-MISC O-MISC
that O-MISC O-MISC
sex O-MISC O-MISC
hormone O-MISC O-MISC
metabolism O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
androgen O-MISC O-MISC
synthesis O-MISC O-MISC
, O-MISC O-MISC
occurs O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
may O-MISC O-MISC
modulate O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
white O-MISC O-MISC
blood O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
hair O-MISC O-MISC
follicles O-MISC O-MISC
are O-MISC O-MISC
good O-MISC O-MISC
sources O-MISC O-MISC
of O-MISC O-MISC
mRNA B-MISC B-MISC
for O-MISC O-MISC
the O-MISC O-MISC
pterin B-MISC B-MISC
carbinolamine I-MISC I-MISC
dehydratase I-MISC I-MISC
/ I-MISC I-MISC
dimerization I-MISC I-MISC
cofactor I-MISC O-MISC
of O-MISC O-MISC
HNF1 B-MISC B-MISC
for O-MISC O-MISC
mutation O-MISC O-MISC
detection O-MISC O-MISC
. O-MISC O-MISC

Pterin B-MISC B-MISC
carbinolamine I-MISC I-MISC
dehydratase I-MISC I-MISC
/ I-MISC I-MISC
dimerization I-MISC I-MISC
cofactor I-MISC I-MISC
of O-MISC O-MISC
HNF1 B-MISC B-MISC
( O-MISC O-MISC
PCD B-MISC I-MISC
/ I-MISC I-MISC
DCoH I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
protein O-MISC O-MISC
that O-MISC O-MISC
has O-MISC O-MISC
a O-MISC O-MISC
dual O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
pterin B-MISC B-MISC
4alpha I-MISC I-MISC
- I-MISC I-MISC
carbinolamine I-MISC I-MISC
dehydratase I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regeneration O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cofactor B-MISC B-MISC
tetrahydrobiopterin I-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
phenylalanine O-MISC I-MISC
hydroxylase O-MISC B-MISC
- O-MISC O-MISC
catalyzed O-MISC B-MISC
hydroxylation O-MISC B-MISC
of O-MISC O-MISC
phenylalanine O-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
dimerization O-MISC O-MISC
cofactor O-MISC I-MISC
of O-MISC O-MISC
HNF1 B-MISC B-MISC
that O-MISC O-MISC
is O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
HNF1 B-MISC B-MISC
. O-MISC O-MISC

Deficiencies O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
gene O-MISC O-MISC
for O-MISC O-MISC
this O-MISC O-MISC
dual B-MISC O-MISC
functional I-MISC O-MISC
protein I-MISC O-MISC
result O-MISC O-MISC
in O-MISC O-MISC
hyperphenylalaninemi O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
time O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
PCD B-MISC B-MISC
/ I-MISC I-MISC
DCoH I-MISC I-MISC
mRNA I-MISC I-MISC
is O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
white O-MISC O-MISC
blood O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
hair O-MISC O-MISC
follicles O-MISC O-MISC
. O-MISC O-MISC

Taking O-MISC O-MISC
advantage O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
finding O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
sensitive O-MISC O-MISC
, O-MISC O-MISC
rapid O-MISC O-MISC
and O-MISC O-MISC
convenient O-MISC O-MISC
method O-MISC O-MISC
for O-MISC O-MISC
screening O-MISC O-MISC
mutations O-MISC O-MISC
occurring O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
coding O-MISC O-MISC
region O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
gene O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
described O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
1998 O-MISC O-MISC
Academic O-MISC O-MISC
Press O-MISC O-MISC
. O-MISC O-MISC

Biochemical O-MISC O-MISC
characterization O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
complex I-MISC I-MISC
during O-MISC O-MISC
B O-MISC O-MISC
lymphocyte O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
, O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
, O-MISC O-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
tissue O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC I-MISC
major B-MISC I-MISC
histocompatibility I-MISC I-MISC
complex I-MISC I-MISC
class I-MISC I-MISC
II I-MISC I-MISC
gene I-MISC I-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
report O-MISC O-MISC
the O-MISC O-MISC
biochemical O-MISC O-MISC
properties O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
heterotrimeric B-MISC B-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
complex I-MISC I-MISC
have O-MISC O-MISC
been O-MISC O-MISC
characterized O-MISC O-MISC
during O-MISC O-MISC
stage O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
several O-MISC O-MISC
class O-MISC O-MISC
II O-MISC O-MISC
- O-MISC O-MISC
mutant O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
represent O-MISC O-MISC
distinct O-MISC O-MISC
bare O-MISC O-MISC
lymphocyte O-MISC O-MISC
syndrome O-MISC O-MISC
class O-MISC O-MISC
II O-MISC O-MISC
genetic O-MISC O-MISC
complementation O-MISC O-MISC
groups O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
complex I-MISC I-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
class O-MISC O-MISC
II O-MISC I-MISC
+ O-MISC O-MISC
mature O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
bound O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
to O-MISC O-MISC
anion B-MISC O-MISC
exchangers I-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
eluted O-MISC B-MISC
as O-MISC O-MISC
an O-MISC O-MISC
intact O-MISC B-MISC
trimeric B-MISC I-MISC
complex I-MISC I-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
, O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
derived O-MISC I-MISC
from O-MISC O-MISC
class O-MISC B-MISC
II O-MISC I-MISC
- O-MISC O-MISC
plasma O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
from O-MISC O-MISC
bare O-MISC O-MISC
lymphocyte O-MISC O-MISC
syndrome O-MISC O-MISC
group O-MISC O-MISC
II O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
RJ2 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
and O-MISC O-MISC
RM3 O-MISC O-MISC
, O-MISC O-MISC
dissociated O-MISC O-MISC
into O-MISC O-MISC
discrete O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
YA I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
YB I-MISC I-MISC
: I-MISC O-MISC
C I-MISC O-MISC
subunit B-MISC I-MISC
fractions I-MISC O-MISC
. O-MISC O-MISC

Recombination O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
MPC11 B-MISC O-MISC
plasma I-MISC B-MISC
B I-MISC I-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
derived I-MISC I-MISC
NF I-MISC I-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
A I-MISC I-MISC
: I-MISC O-MISC
B I-MISC O-MISC
: I-MISC O-MISC
C I-MISC B-MISC
complex I-MISC I-MISC
with O-MISC O-MISC
the O-MISC O-MISC
low O-MISC O-MISC
molecular O-MISC O-MISC
mass O-MISC O-MISC
protein O-MISC O-MISC
fraction O-MISC O-MISC
, O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
- I-MISC I-MISC
associated I-MISC I-MISC
factors I-MISC I-MISC
( O-MISC O-MISC
YAFs B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
mature O-MISC O-MISC
A20 O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
nuclei O-MISC O-MISC
, O-MISC O-MISC
conferred O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
anion O-MISC O-MISC
exchange O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
as O-MISC O-MISC
an O-MISC O-MISC
intact B-MISC B-MISC
trimeric I-MISC I-MISC
complex I-MISC I-MISC
. O-MISC O-MISC

Recombination O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
native B-MISC B-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
YA I-MISC I-MISC
: I-MISC O-MISC
B I-MISC I-MISC
: I-MISC O-MISC
C I-MISC B-MISC
complex I-MISC I-MISC
with O-MISC O-MISC
the O-MISC O-MISC
transcriptional B-MISC O-MISC
cofactor I-MISC I-MISC
, O-MISC O-MISC
PC4 B-MISC O-MISC
, O-MISC O-MISC
likewise O-MISC O-MISC
conferred O-MISC O-MISC
high B-MISC O-MISC
affinity I-MISC O-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
anion B-MISC O-MISC
exchangers I-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
stabilized O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
CCAAT B-MISC B-MISC
- I-MISC I-MISC
box I-MISC I-MISC
DNA I-MISC I-MISC
motifs I-MISC I-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

Interaction O-MISC O-MISC
between O-MISC O-MISC
PC4 B-MISC O-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
was O-MISC O-MISC
mapped O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
C B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
region I-MISC I-MISC
of O-MISC O-MISC
PC4 B-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
subunit B-MISC O-MISC
interaction I-MISC O-MISC
subdomain I-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
highly B-MISC B-MISC
conserved I-MISC I-MISC
DNA I-MISC I-MISC
binding I-MISC I-MISC
- I-MISC I-MISC
subunit I-MISC I-MISC
interaction I-MISC I-MISC
domain I-MISC I-MISC
( O-MISC O-MISC
DBD B-MISC B-MISC
) O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
YA I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
class O-MISC O-MISC
II O-MISC O-MISC
+ O-MISC O-MISC
mature O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC I-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
Y I-MISC I-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
protein O-MISC O-MISC
cofactor O-MISC O-MISC
, O-MISC O-MISC
PC4 B-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
may O-MISC O-MISC
play O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
Y O-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
transcriptional O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
class B-MISC B-MISC
II I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Arrest O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
lymphocyte O-MISC O-MISC
terminal O-MISC I-MISC
differentiation O-MISC O-MISC
by O-MISC O-MISC
CD40 O-MISC B-MISC
signaling O-MISC O-MISC
: O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
lack O-MISC O-MISC
of O-MISC O-MISC
antibody O-MISC O-MISC
- O-MISC O-MISC
secreting O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
germinal O-MISC O-MISC
centers O-MISC O-MISC
. O-MISC O-MISC

Despite O-MISC O-MISC
extensive O-MISC O-MISC
research O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
CD40 B-MISC B-MISC
signaling O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
terminal O-MISC O-MISC
differentiation O-MISC O-MISC
remains O-MISC O-MISC
controversial O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
CD40 B-MISC B-MISC
engagement O-MISC O-MISC
arrests O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
prior O-MISC O-MISC
to O-MISC O-MISC
plasma O-MISC O-MISC
cell O-MISC O-MISC
formation O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
arrest O-MISC O-MISC
is O-MISC O-MISC
manifested O-MISC O-MISC
at O-MISC O-MISC
a O-MISC O-MISC
molecular O-MISC O-MISC
level O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
mRNA O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
secretory O-MISC O-MISC
immunoglobulin O-MISC B-MISC
gene O-MISC I-MISC
products O-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
mu O-MISC B-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
J O-MISC B-MISC
chain O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcriptional B-MISC B-MISC
regulator I-MISC I-MISC
BLIMP B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
by O-MISC O-MISC
CD40 B-MISC B-MISC
engagement O-MISC O-MISC
could O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
overcome O-MISC O-MISC
by O-MISC O-MISC
either O-MISC O-MISC
mitogens B-MISC B-MISC
or O-MISC O-MISC
cytokines B-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
reversed O-MISC O-MISC
by O-MISC O-MISC
antibodies O-MISC O-MISC
that O-MISC O-MISC
interfere O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
CD40 B-MISC B-MISC
/ O-MISC I-MISC
gp39 B-MISC O-MISC
interaction O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
secretory O-MISC O-MISC
immunoglobulin O-MISC B-MISC
is O-MISC O-MISC
not O-MISC O-MISC
produced O-MISC O-MISC
by O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
actively O-MISC O-MISC
engaged O-MISC O-MISC
by O-MISC O-MISC
gp39 O-MISC O-MISC
- O-MISC O-MISC
expressing O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
positively O-MISC O-MISC
charged O-MISC O-MISC
alpha O-MISC O-MISC
- O-MISC O-MISC
lipoic O-MISC O-MISC
acid O-MISC O-MISC
analogue O-MISC O-MISC
with O-MISC O-MISC
increased O-MISC O-MISC
cellular O-MISC O-MISC
uptake O-MISC O-MISC
and O-MISC O-MISC
more O-MISC O-MISC
potent O-MISC O-MISC
immunomodulatory O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

alpha O-MISC O-MISC
- O-MISC I-MISC
Lipoic O-MISC I-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
LA O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
taken O-MISC O-MISC
up O-MISC O-MISC
by O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
reduced O-MISC O-MISC
to O-MISC O-MISC
its O-MISC O-MISC
potent O-MISC O-MISC
dithiol O-MISC O-MISC
form O-MISC O-MISC
, O-MISC O-MISC
dihydrolipoate O-MISC O-MISC
( O-MISC O-MISC
DHLA O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
much O-MISC O-MISC
of O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
rapidly O-MISC O-MISC
effluxed O-MISC O-MISC
out O-MISC O-MISC
from O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
improve O-MISC O-MISC
retention O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
LA O-MISC B-MISC
molecule O-MISC I-MISC
was O-MISC O-MISC
modified O-MISC O-MISC
to O-MISC O-MISC
confer O-MISC O-MISC
a O-MISC O-MISC
positive O-MISC O-MISC
charge O-MISC O-MISC
at O-MISC O-MISC
physiological O-MISC O-MISC
pH O-MISC O-MISC
. O-MISC O-MISC

N O-MISC B-MISC
, O-MISC I-MISC
N O-MISC I-MISC
- O-MISC I-MISC
dimethyl O-MISC I-MISC
, O-MISC O-MISC
N O-MISC B-MISC
' O-MISC I-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC I-MISC
amidoethyl O-MISC I-MISC
- O-MISC I-MISC
lipoate O-MISC I-MISC
was O-MISC O-MISC
synthesized O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
protonated O-MISC B-MISC
form O-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
new O-MISC O-MISC
molecule O-MISC O-MISC
is O-MISC O-MISC
referred O-MISC O-MISC
to O-MISC O-MISC
as O-MISC O-MISC
LA O-MISC B-MISC
- O-MISC I-MISC
Plus O-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
uptake O-MISC O-MISC
of O-MISC O-MISC
LA O-MISC B-MISC
- O-MISC I-MISC
Plus O-MISC I-MISC
by O-MISC O-MISC
human O-MISC O-MISC
Wurzburg O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
higher O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
LA O-MISC O-MISC
. O-MISC O-MISC

Several O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
higher O-MISC O-MISC
amounts O-MISC O-MISC
of O-MISC O-MISC
DHLA O-MISC B-MISC
- O-MISC I-MISC
Plus O-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
corresponding O-MISC O-MISC
reduced O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
LA O-MISC B-MISC
- O-MISC I-MISC
Plus O-MISC I-MISC
, O-MISC O-MISC
were O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
LA O-MISC O-MISC
- O-MISC O-MISC
Plus O-MISC O-MISC
treated O-MISC O-MISC
cells O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
DHLA O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
LA O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
100 O-MISC O-MISC
microM O-MISC O-MISC
, O-MISC O-MISC
LA O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
but O-MISC O-MISC
LA O-MISC O-MISC
- O-MISC O-MISC
Plus O-MISC O-MISC
inhibited O-MISC O-MISC
H2O2 O-MISC O-MISC
induced O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
directed O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
LA O-MISC O-MISC
and O-MISC O-MISC
LA O-MISC B-MISC
- O-MISC I-MISC
Plus O-MISC O-MISC
synergised O-MISC O-MISC
with O-MISC O-MISC
selenium O-MISC O-MISC
in O-MISC O-MISC
inhibiting O-MISC O-MISC
H2O2 O-MISC O-MISC
induced O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
150 O-MISC O-MISC
microM O-MISC O-MISC
LA O-MISC B-MISC
- O-MISC O-MISC
Plus O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
LA O-MISC O-MISC
, O-MISC O-MISC
inhibited O-MISC O-MISC
TNFalpha B-MISC B-MISC
induced O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
5 O-MISC O-MISC
microM O-MISC O-MISC
LA O-MISC O-MISC
- O-MISC O-MISC
Plus O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
LA O-MISC O-MISC
, O-MISC O-MISC
protected O-MISC O-MISC
against O-MISC O-MISC
both O-MISC O-MISC
spontaneous O-MISC O-MISC
and O-MISC O-MISC
etoposide O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
rat O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

LA O-MISC B-MISC
- O-MISC I-MISC
Plus O-MISC I-MISC
is O-MISC O-MISC
thus O-MISC O-MISC
an O-MISC O-MISC
improved O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
LA O-MISC O-MISC
with O-MISC O-MISC
increased O-MISC O-MISC
therapeutic O-MISC O-MISC
potential O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
1998 O-MISC O-MISC
Academic O-MISC O-MISC
Press O-MISC O-MISC
. O-MISC O-MISC

Carrier O-MISC O-MISC
identification O-MISC O-MISC
in O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
immunodeficiency O-MISC O-MISC
diseases O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
Carrier O-MISC O-MISC
identification O-MISC O-MISC
in O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
immunodeficiency O-MISC O-MISC
disorders O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
based O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
demonstration O-MISC O-MISC
of O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
random O-MISC O-MISC
X O-MISC O-MISC
inactivation O-MISC O-MISC
( O-MISC O-MISC
NRXI O-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
affected O-MISC O-MISC
blood O-MISC O-MISC
cell O-MISC O-MISC
lineages O-MISC O-MISC
when O-MISC O-MISC
growth O-MISC O-MISC
is O-MISC O-MISC
impaired O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
expressing O-MISC O-MISC
the O-MISC O-MISC
abnormal B-MISC B-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
utility O-MISC O-MISC
of O-MISC O-MISC
seeking O-MISC O-MISC
evidence O-MISC O-MISC
of O-MISC O-MISC
NRXI O-MISC B-MISC
to O-MISC O-MISC
test O-MISC O-MISC
the O-MISC O-MISC
carrier O-MISC O-MISC
status O-MISC O-MISC
of O-MISC O-MISC
women O-MISC O-MISC
in O-MISC O-MISC
families O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
severe O-MISC O-MISC
combined O-MISC O-MISC
immunodeficiency O-MISC O-MISC
( O-MISC O-MISC
XSCID O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
hypogammaglobulinaem O-MISC B-MISC
( O-MISC O-MISC
XLH O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
to O-MISC O-MISC
identify O-MISC O-MISC
as O-MISC O-MISC
carriers O-MISC O-MISC
the O-MISC O-MISC
mothers O-MISC O-MISC
of O-MISC O-MISC
boys O-MISC O-MISC
with O-MISC O-MISC
SCID O-MISC B-MISC
or O-MISC O-MISC
hypogammaglobulinaem O-MISC B-MISC
whose O-MISC O-MISC
phenotype O-MISC O-MISC
suggested O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linkage O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
infer O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linkage O-MISC O-MISC
in O-MISC O-MISC
boys O-MISC O-MISC
with O-MISC O-MISC
SCID O-MISC O-MISC
or O-MISC O-MISC
hypogammaglobulinaem O-MISC O-MISC
whose O-MISC O-MISC
disease O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
clearly O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
basis O-MISC O-MISC
either O-MISC O-MISC
of O-MISC O-MISC
family O-MISC O-MISC
history O-MISC O-MISC
or O-MISC O-MISC
clinical O-MISC O-MISC
and O-MISC O-MISC
immunological O-MISC O-MISC
characteristics O-MISC O-MISC
. O-MISC O-MISC

METHODOLOGY O-MISC O-MISC
: O-MISC O-MISC
A O-MISC O-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
- O-MISC O-MISC
based O-MISC O-MISC
method O-MISC O-MISC
was O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
amplify O-MISC O-MISC
a O-MISC O-MISC
polymorphic O-MISC B-MISC
CAG B-MISC I-MISC
repeat I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
first B-MISC O-MISC
exon I-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
androgen B-MISC O-MISC
receptor I-MISC I-MISC
gene I-MISC I-MISC
after O-MISC O-MISC
selective O-MISC O-MISC
digestion O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
active B-MISC O-MISC
X I-MISC B-MISC
chromosome I-MISC I-MISC
with O-MISC O-MISC
a O-MISC O-MISC
methylation B-MISC O-MISC
- I-MISC I-MISC
sensitive I-MISC I-MISC
enzyme I-MISC I-MISC
, O-MISC O-MISC
HpaII B-MISC B-MISC
to O-MISC O-MISC
distinguish O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
paternal B-MISC O-MISC
and I-MISC O-MISC
maternal I-MISC B-MISC
alleles I-MISC I-MISC
and O-MISC O-MISC
to O-MISC O-MISC
identify O-MISC O-MISC
their O-MISC O-MISC
methylation O-MISC O-MISC
status O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Heterozygosity O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
24 O-MISC O-MISC
of O-MISC O-MISC
31 O-MISC O-MISC
female O-MISC O-MISC
subjects O-MISC O-MISC
( O-MISC O-MISC
77 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
anticipated O-MISC O-MISC
, O-MISC O-MISC
NRXI O-MISC B-MISC
could O-MISC O-MISC
be O-MISC O-MISC
demonstrated O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
studied O-MISC O-MISC
from O-MISC O-MISC
obligate O-MISC O-MISC
carriers O-MISC O-MISC
of O-MISC O-MISC
XSCID O-MISC O-MISC
and O-MISC O-MISC
an O-MISC O-MISC
obligate O-MISC O-MISC
carrier O-MISC I-MISC
of O-MISC O-MISC
XLH O-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
on O-MISC O-MISC
a O-MISC O-MISC
carrier O-MISC O-MISC
of O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
immunodeficiency O-MISC O-MISC
with O-MISC O-MISC
hyper B-MISC O-MISC
- I-MISC I-MISC
IgM I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
finding O-MISC O-MISC
of O-MISC O-MISC
NRXI O-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
mother O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
boy O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
SCID O-MISC O-MISC
variant O-MISC O-MISC
showed O-MISC O-MISC
her O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
carrier O-MISC O-MISC
of O-MISC O-MISC
XSCID O-MISC O-MISC
and O-MISC O-MISC
establishes O-MISC O-MISC
that O-MISC O-MISC
her O-MISC O-MISC
son O-MISC O-MISC
has O-MISC O-MISC
XSCID O-MISC O-MISC
, O-MISC O-MISC
not O-MISC O-MISC
otherwise O-MISC O-MISC
evident O-MISC O-MISC
from O-MISC O-MISC
available O-MISC O-MISC
data O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
This O-MISC O-MISC
PCR O-MISC O-MISC
assay O-MISC O-MISC
provides O-MISC O-MISC
a O-MISC O-MISC
rapid O-MISC O-MISC
method O-MISC O-MISC
for O-MISC O-MISC
carrier O-MISC O-MISC
detection O-MISC O-MISC
of O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
immunodeficiencies O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
has O-MISC O-MISC
allowed O-MISC O-MISC
us O-MISC O-MISC
to O-MISC O-MISC
expand O-MISC O-MISC
the O-MISC O-MISC
phenotype O-MISC O-MISC
of O-MISC O-MISC
XSCID O-MISC O-MISC

Leukocyte O-MISC O-MISC
- O-MISC O-MISC
endothelial O-MISC O-MISC
interaction O-MISC O-MISC
is O-MISC O-MISC
augmented O-MISC O-MISC
by O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
concentrations O-MISC O-MISC
and O-MISC O-MISC
hyperglycemia O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kB O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
fashion O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
addressed O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
hyperglycemia O-MISC O-MISC
in O-MISC O-MISC
leukocyte O-MISC O-MISC
- O-MISC O-MISC
endothelium O-MISC O-MISC
interaction O-MISC O-MISC
under O-MISC O-MISC
flow O-MISC O-MISC
conditions O-MISC O-MISC
by O-MISC O-MISC
exposing O-MISC O-MISC
human O-MISC O-MISC
umbilical O-MISC O-MISC
vein O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
for O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
to O-MISC O-MISC
normal O-MISC O-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
mM O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
high O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
glucose O-MISC O-MISC
( O-MISC O-MISC
30 O-MISC O-MISC
mM O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
advanced O-MISC O-MISC
glycosylation O-MISC B-MISC
end O-MISC B-MISC
product B-MISC I-MISC
- I-MISC O-MISC
albumin I-MISC I-MISC
( O-MISC O-MISC
100 O-MISC O-MISC
microg O-MISC O-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
hyperglycemic O-MISC O-MISC
( O-MISC O-MISC
174 O-MISC O-MISC
- O-MISC O-MISC
316 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
dl O-MISC O-MISC
) O-MISC O-MISC
sera O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
diabetes O-MISC O-MISC
and O-MISC O-MISC
abnormal O-MISC O-MISC
hemoglobin O-MISC B-MISC
A1c O-MISC I-MISC
( O-MISC O-MISC
8 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
the O-MISC O-MISC
end O-MISC O-MISC
of O-MISC O-MISC
incubation O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
perfused O-MISC O-MISC
with O-MISC O-MISC
total O-MISC O-MISC
leukocyte O-MISC O-MISC
suspension O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
parallel O-MISC O-MISC
plate O-MISC O-MISC
flow O-MISC O-MISC
chamber O-MISC O-MISC
under O-MISC O-MISC
laminar O-MISC O-MISC
flow O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
dyn O-MISC O-MISC
/ O-MISC O-MISC
cm2 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Rolling O-MISC O-MISC
and O-MISC O-MISC
adherent O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
evaluated O-MISC O-MISC
by O-MISC O-MISC
digital O-MISC O-MISC
image O-MISC O-MISC
processing O-MISC O-MISC
. O-MISC O-MISC

Results O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
30 O-MISC O-MISC
mM O-MISC O-MISC
glucose O-MISC O-MISC
significantly O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
adherent O-MISC O-MISC
leukocytes O-MISC O-MISC
to O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
respect O-MISC O-MISC
to O-MISC O-MISC
control O-MISC O-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
mM O-MISC O-MISC
glucose O-MISC O-MISC
; O-MISC O-MISC
151 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
19 O-MISC O-MISC
versus O-MISC O-MISC
33 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
cells O-MISC O-MISC
/ O-MISC O-MISC
mm2 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
similar O-MISC O-MISC
response O-MISC O-MISC
was O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
endothelial O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
, O-MISC O-MISC
here O-MISC O-MISC
used O-MISC O-MISC
as O-MISC O-MISC
positive O-MISC O-MISC
control O-MISC O-MISC
( O-MISC O-MISC
195 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
20 O-MISC O-MISC
cells O-MISC O-MISC
/ O-MISC O-MISC
mm2 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
rolling O-MISC O-MISC
cells O-MISC O-MISC
on O-MISC O-MISC
endothelial O-MISC O-MISC
surface O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
level O-MISC O-MISC
. O-MISC O-MISC

Stable O-MISC O-MISC
adhesion O-MISC O-MISC
of O-MISC O-MISC
leukocytes O-MISC O-MISC
to O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
to O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
1beta O-MISC I-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
preceded O-MISC O-MISC
by O-MISC O-MISC
short O-MISC O-MISC
interaction O-MISC O-MISC
of O-MISC O-MISC
leukocytes O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
endothelial O-MISC O-MISC
surface O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
distance O-MISC O-MISC
travelled O-MISC O-MISC
by O-MISC O-MISC
leukocytes O-MISC O-MISC
before O-MISC O-MISC
arrest O-MISC O-MISC
on O-MISC O-MISC
30 O-MISC O-MISC
mM O-MISC O-MISC
glucose O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
on O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
1beta O-MISC I-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
higher O-MISC O-MISC
than O-MISC O-MISC
that O-MISC O-MISC
observed O-MISC O-MISC
for O-MISC O-MISC
leukocytes O-MISC O-MISC
adhering O-MISC O-MISC
on O-MISC O-MISC
control O-MISC O-MISC
endothelium O-MISC O-MISC
( O-MISC O-MISC
30 O-MISC O-MISC
mM O-MISC O-MISC
glucose O-MISC O-MISC
: O-MISC O-MISC
76 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC I-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
; O-MISC O-MISC
IL1beta O-MISC B-MISC
: O-MISC O-MISC
69 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
versus O-MISC O-MISC
5 O-MISC O-MISC
mM O-MISC O-MISC
glucose O-MISC O-MISC
: O-MISC O-MISC
21 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
5 O-MISC O-MISC
microm O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Functional O-MISC O-MISC
blocking O-MISC O-MISC
of O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
selectin I-MISC I-MISC
, O-MISC O-MISC
intercellular B-MISC B-MISC
cell I-MISC I-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
vascular B-MISC B-MISC
cell I-MISC I-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
on O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
corresponding O-MISC O-MISC
mouse B-MISC O-MISC
mAb I-MISC I-MISC
significantly O-MISC O-MISC
inhibited O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
leukocyte O-MISC O-MISC
adhesion O-MISC O-MISC
( O-MISC O-MISC
67 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
16 O-MISC O-MISC
, O-MISC O-MISC
83 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
12 O-MISC O-MISC
, O-MISC O-MISC
62 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
versus O-MISC O-MISC
144 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
21 O-MISC O-MISC
cells O-MISC O-MISC
/ O-MISC O-MISC
mm2 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Confocal O-MISC O-MISC
fluorescence O-MISC O-MISC
microscopy O-MISC O-MISC
studies O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
30 O-MISC O-MISC
mM O-MISC O-MISC
glucose O-MISC O-MISC
induced O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
endothelial O-MISC O-MISC
surface O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
selectin I-MISC I-MISC
, O-MISC O-MISC
intercellular B-MISC B-MISC
cell I-MISC I-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
vascular B-MISC B-MISC
cell I-MISC I-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
of O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
umbilical O-MISC O-MISC
vein O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
HUVEC O-MISC O-MISC
) O-MISC O-MISC
exposed O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
h O-MISC O-MISC
to O-MISC O-MISC
30 O-MISC O-MISC
mM O-MISC O-MISC
glucose O-MISC O-MISC
revealed O-MISC O-MISC
an O-MISC O-MISC
intense O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kB I-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
HUVEC O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kB I-MISC I-MISC
inhibitors I-MISC O-MISC
pyrrolidinedithiocar O-MISC O-MISC
( O-MISC O-MISC
100 O-MISC O-MISC
microM O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
tosyl O-MISC O-MISC
- O-MISC O-MISC
phe O-MISC O-MISC
- O-MISC O-MISC
chloromethylketone O-MISC O-MISC
( O-MISC O-MISC
25 O-MISC O-MISC
microM O-MISC O-MISC
) O-MISC O-MISC
significantly O-MISC O-MISC
reduced O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
05 O-MISC O-MISC
) O-MISC O-MISC
leukocyte O-MISC O-MISC
adhesion O-MISC O-MISC
in O-MISC O-MISC
respect O-MISC O-MISC
to O-MISC O-MISC
HUVEC O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
glucose O-MISC O-MISC
alone O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
significant O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
leukocyte O-MISC O-MISC
adhesion O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
after O-MISC O-MISC
blocking O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
activity O-MISC O-MISC
with O-MISC O-MISC
staurosporine O-MISC O-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
nM O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

When O-MISC O-MISC
HUVEC O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
specific O-MISC O-MISC
antisense O-MISC O-MISC
oligodesoxynucleotid O-MISC O-MISC
against O-MISC O-MISC
PKCalpha B-MISC B-MISC
and I-MISC O-MISC
PKCepsilon I-MISC B-MISC
isoforms I-MISC O-MISC
before O-MISC O-MISC
the O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
30 O-MISC O-MISC
mM O-MISC O-MISC
glucose O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
( O-MISC O-MISC
P O-MISC B-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
05 O-MISC O-MISC
) O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
adhesion O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
seen O-MISC O-MISC
. O-MISC O-MISC

Advanced O-MISC O-MISC
glycosylation O-MISC B-MISC
end O-MISC B-MISC
product B-MISC I-MISC
- I-MISC I-MISC
albumin I-MISC I-MISC
significantly O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
adhering O-MISC O-MISC
leukocytes O-MISC O-MISC
in O-MISC O-MISC
respect O-MISC O-MISC
to O-MISC O-MISC
native B-MISC O-MISC
albumin I-MISC O-MISC
used O-MISC O-MISC
as O-MISC O-MISC
control O-MISC O-MISC
( O-MISC O-MISC
110 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
16 O-MISC O-MISC
versus O-MISC O-MISC
66 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Sera O-MISC O-MISC
from O-MISC O-MISC
diabetic O-MISC O-MISC
patients O-MISC O-MISC
significantly O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
enhanced O-MISC O-MISC
leukocyte O-MISC O-MISC
adhesion O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
controls O-MISC O-MISC
, O-MISC O-MISC
despite O-MISC O-MISC
normal O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
and O-MISC O-MISC
TNFalpha B-MISC B-MISC
in O-MISC O-MISC
these O-MISC O-MISC
sera O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
concentration O-MISC O-MISC
and O-MISC O-MISC
hyperglycemia O-MISC O-MISC
promote O-MISC O-MISC
leukocyte O-MISC O-MISC
adhesion O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
endothelium O-MISC O-MISC
through O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
surface O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
adhesive O-MISC B-MISC
proteins O-MISC I-MISC
, O-MISC O-MISC
possibly O-MISC O-MISC
depending O-MISC O-MISC
on O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kB I-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Ikaros B-MISC B-MISC
in O-MISC O-MISC
hemopoietic O-MISC O-MISC
lineage O-MISC O-MISC
determination O-MISC O-MISC
and O-MISC O-MISC
homeostasis O-MISC O-MISC
. O-MISC O-MISC

Studies O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
mechanisms O-MISC O-MISC
that O-MISC O-MISC
control O-MISC O-MISC
hemopoietic O-MISC O-MISC
differentiation O-MISC O-MISC
have O-MISC O-MISC
focused O-MISC O-MISC
on O-MISC O-MISC
signaling O-MISC O-MISC
cascades O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
effectors O-MISC O-MISC
that O-MISC O-MISC
drive O-MISC O-MISC
this O-MISC O-MISC
complex O-MISC O-MISC
developmental O-MISC O-MISC
system O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
regulated O-MISC O-MISC
fashion O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
review O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
Ikaros B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
founding O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
unique O-MISC O-MISC
family O-MISC O-MISC
of O-MISC O-MISC
zinc B-MISC B-MISC
finger I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
in O-MISC O-MISC
this O-MISC O-MISC
developmental O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

Studies O-MISC O-MISC
on O-MISC O-MISC
an O-MISC O-MISC
Ikaros B-MISC B-MISC
null O-MISC O-MISC
mutation O-MISC O-MISC
have O-MISC O-MISC
revealed O-MISC O-MISC
an O-MISC O-MISC
essential O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
this O-MISC O-MISC
factor O-MISC O-MISC
in O-MISC O-MISC
lymphoid O-MISC O-MISC
cell O-MISC O-MISC
fate O-MISC O-MISC
determination O-MISC O-MISC
and O-MISC O-MISC
at O-MISC O-MISC
subsequent O-MISC O-MISC
branch O-MISC O-MISC
points O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

Differences O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
phenotypes O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
null O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
dominant B-MISC B-MISC
negative I-MISC I-MISC
( I-MISC I-MISC
DN I-MISC I-MISC
) I-MISC I-MISC
Ikaros I-MISC I-MISC
mutation I-MISC O-MISC
provide O-MISC O-MISC
insight O-MISC O-MISC
into O-MISC O-MISC
a O-MISC O-MISC
regulatory O-MISC O-MISC
network O-MISC I-MISC
through O-MISC O-MISC
which O-MISC O-MISC
Ikaros B-MISC B-MISC
proteins I-MISC I-MISC
exert O-MISC O-MISC
their O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
a O-MISC O-MISC
comparative O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
hemopoietic O-MISC O-MISC
stem O-MISC O-MISC
cell O-MISC O-MISC
and O-MISC O-MISC
precursor O-MISC O-MISC
compartment O-MISC O-MISC
resulting O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
Ikaros B-MISC B-MISC
mutations I-MISC O-MISC
reveals O-MISC O-MISC
a O-MISC O-MISC
profound O-MISC O-MISC
yet O-MISC O-MISC
not O-MISC O-MISC
absolute O-MISC O-MISC
requirement O-MISC O-MISC
for O-MISC O-MISC
Ikaros B-MISC B-MISC

Induction O-MISC O-MISC
of O-MISC O-MISC
early B-MISC B-MISC
B I-MISC I-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC I-MISC
EBF B-MISC I-MISC
) O-MISC I-MISC
and O-MISC O-MISC
multiple B-MISC O-MISC
B I-MISC I-MISC
lineage I-MISC I-MISC
genes I-MISC I-MISC
by O-MISC O-MISC
the O-MISC O-MISC
basic B-MISC B-MISC
helix I-MISC I-MISC
- I-MISC I-MISC
loop I-MISC I-MISC
- I-MISC I-MISC
helix I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
E12 B-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
encoded O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
E2A B-MISC B-MISC
and O-MISC I-MISC
early B-MISC I-MISC
B I-MISC I-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC I-MISC
EBF B-MISC I-MISC
) O-MISC I-MISC
genes O-MISC I-MISC
are O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
proper O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
E2A O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
EBF O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mice O-MISC O-MISC
has O-MISC O-MISC
made O-MISC O-MISC
it O-MISC O-MISC
difficult O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
function O-MISC O-MISC
or O-MISC O-MISC
relationship O-MISC O-MISC
between O-MISC O-MISC
these O-MISC O-MISC
proteins O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
the O-MISC O-MISC
identification O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
model O-MISC O-MISC
system O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
E2A B-MISC B-MISC
and O-MISC O-MISC
EBF B-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
multiple O-MISC O-MISC
B O-MISC O-MISC
lineage O-MISC O-MISC
traits O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
studied O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
conversion O-MISC O-MISC
of O-MISC O-MISC
70Z O-MISC B-MISC
/ O-MISC I-MISC
3 O-MISC I-MISC
pre O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
to O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
macrophage O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
phenotype O-MISC O-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
E2A B-MISC B-MISC
and O-MISC O-MISC
EBF B-MISC B-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
ectopic O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
E2A B-MISC B-MISC
protein O-MISC I-MISC
E12 B-MISC I-MISC
in O-MISC O-MISC
this O-MISC O-MISC
macrophage O-MISC O-MISC
line O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
many B-MISC O-MISC
B I-MISC B-MISC
lineage I-MISC I-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
including O-MISC O-MISC
EBF B-MISC B-MISC
, O-MISC O-MISC
IL7Ralpha B-MISC B-MISC
, O-MISC O-MISC
lambda5 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Rag O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
kappa B-MISC B-MISC
light I-MISC I-MISC
chain I-MISC I-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
mitogen O-MISC B-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
EBF B-MISC B-MISC
may O-MISC O-MISC
be O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
critical O-MISC O-MISC
functions O-MISC O-MISC
of O-MISC O-MISC
E12 B-MISC B-MISC
in O-MISC O-MISC
regulating O-MISC O-MISC
the O-MISC O-MISC
B O-MISC O-MISC
lineage O-MISC O-MISC
phenotype O-MISC O-MISC
since O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
EBF B-MISC B-MISC
alone O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
subset O-MISC O-MISC
of O-MISC O-MISC
E12 B-MISC B-MISC
- O-MISC I-MISC
inducible O-MISC I-MISC
traits O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
data O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
context O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
macrophage O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
E12 B-MISC O-MISC
induces O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
EBF B-MISC B-MISC
and O-MISC O-MISC
together O-MISC O-MISC
these O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
coordinately O-MISC O-MISC
regulate O-MISC O-MISC
numerous O-MISC O-MISC
B B-MISC B-MISC
lineage I-MISC I-MISC
- I-MISC I-MISC
associated I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
retinoid B-MISC B-MISC
receptor I-MISC I-MISC
RXRalpha I-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Role O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
regulation O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
5 B-MISC B-MISC
. I-MISC I-MISC
4 I-MISC I-MISC
- I-MISC I-MISC
kilobase I-MISC I-MISC
mRNA I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
after O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
PBMCs O-MISC O-MISC
) O-MISC O-MISC
with O-MISC O-MISC
various O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
activating O-MISC O-MISC
agents O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
isolated O-MISC O-MISC
using O-MISC O-MISC
an O-MISC O-MISC
mRNA O-MISC B-MISC
differential O-MISC O-MISC
display O-MISC O-MISC
method O-MISC O-MISC
. O-MISC O-MISC

Nucleotide O-MISC B-MISC
sequence O-MISC O-MISC
analysis O-MISC O-MISC
identified O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
end I-MISC I-MISC
of O-MISC O-MISC
this O-MISC O-MISC
RNA B-MISC B-MISC
as O-MISC O-MISC
human B-MISC B-MISC
retinoid I-MISC I-MISC
receptor I-MISC I-MISC
RXRalpha I-MISC I-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
the O-MISC O-MISC
nucleotide O-MISC B-MISC
sequence O-MISC I-MISC
of O-MISC O-MISC
3 B-MISC I-MISC
. I-MISC I-MISC
6 I-MISC I-MISC
kilobases I-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
RNA O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
represents O-MISC O-MISC
the O-MISC O-MISC
3 B-MISC O-MISC
' I-MISC O-MISC
end I-MISC O-MISC
of O-MISC O-MISC
RXRalpha B-MISC B-MISC
mRNA I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
sequence O-MISC O-MISC
of O-MISC O-MISC
which O-MISC O-MISC
has O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
previously O-MISC O-MISC
described O-MISC O-MISC
. O-MISC O-MISC

Activated O-MISC O-MISC
PBMCs O-MISC O-MISC
also O-MISC O-MISC
expressed O-MISC O-MISC
lower O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
RXRalpha B-MISC B-MISC
protein O-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
assay O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
RXRalpha B-MISC B-MISC
mRNA I-MISC I-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
expression O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
protein O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
present O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
transition O-MISC O-MISC
from O-MISC O-MISC
G0 O-MISC B-MISC
/ O-MISC I-MISC
G1 O-MISC I-MISC
to O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
RXRalpha B-MISC B-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
inhibitors O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
block O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
G1 O-MISC O-MISC
phase O-MISC O-MISC
, O-MISC O-MISC
prevent O-MISC O-MISC
this O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
RXRalpha B-MISC B-MISC
mRNA I-MISC I-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
regulated O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
post O-MISC O-MISC
- O-MISC O-MISC
transcriptional O-MISC O-MISC
level O-MISC O-MISC
and O-MISC O-MISC
involved O-MISC O-MISC
new O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
observations O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
RXRalpha B-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
are O-MISC O-MISC
coupled O-MISC O-MISC
to O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
progression O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
there O-MISC O-MISC
is O-MISC O-MISC
tight O-MISC O-MISC
regulatory O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
RXRalpha B-MISC B-MISC
expression O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
transition O-MISC O-MISC
from O-MISC O-MISC
G0 O-MISC B-MISC
/ O-MISC I-MISC
G1 O-MISC I-MISC
to O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
. O-MISC O-MISC

Epidemiology O-MISC O-MISC
and O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
AIDS O-MISC O-MISC
- O-MISC O-MISC
related O-MISC O-MISC
lymphomas O-MISC O-MISC
. O-MISC O-MISC

Among O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
congenital O-MISC O-MISC
and O-MISC O-MISC
acquired O-MISC O-MISC
immunodeficiencies O-MISC O-MISC
, O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
Hodgkin O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
lymphoma O-MISC O-MISC
( O-MISC O-MISC
NHLs O-MISC O-MISC
) O-MISC O-MISC
are O-MISC O-MISC
the O-MISC O-MISC
most O-MISC O-MISC
common O-MISC O-MISC
tumors O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
setting O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
HIV O-MISC O-MISC
) O-MISC O-MISC
infection O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
many O-MISC O-MISC
as O-MISC O-MISC
10 O-MISC O-MISC
% O-MISC O-MISC
to O-MISC O-MISC
20 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
people O-MISC O-MISC
ultimately O-MISC O-MISC
developed O-MISC O-MISC
NHLs O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
tumors O-MISC O-MISC
are O-MISC O-MISC
clinically O-MISC O-MISC
aggressive O-MISC O-MISC
, O-MISC O-MISC
frequently O-MISC O-MISC
involve O-MISC O-MISC
extranodal O-MISC O-MISC
sites O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
often O-MISC O-MISC
exhibit O-MISC O-MISC
unique O-MISC O-MISC
features O-MISC O-MISC
that O-MISC O-MISC
distinguish O-MISC O-MISC
them O-MISC O-MISC
from O-MISC O-MISC
NHL O-MISC O-MISC
arising O-MISC O-MISC
in O-MISC O-MISC
individuals O-MISC O-MISC
with O-MISC O-MISC
other O-MISC O-MISC
forms O-MISC O-MISC
of O-MISC O-MISC
immunosuppression O-MISC O-MISC
. O-MISC O-MISC

Important O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
NHL O-MISC O-MISC
are O-MISC O-MISC
cytokines B-MISC B-MISC
and O-MISC O-MISC
other O-MISC O-MISC
factors O-MISC O-MISC
that O-MISC O-MISC
induce O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
increase O-MISC O-MISC
the O-MISC O-MISC
likelihood O-MISC O-MISC
of O-MISC O-MISC
mutations O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
myc I-MISC I-MISC
, O-MISC I-MISC
bcl B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
other O-MISC O-MISC
tumor B-MISC B-MISC
- I-MISC I-MISC
suppressor I-MISC I-MISC
genes I-MISC I-MISC
with O-MISC O-MISC
carcinogenic O-MISC O-MISC
potential O-MISC O-MISC
. O-MISC O-MISC

Specific O-MISC O-MISC
forms O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
NHL O-MISC O-MISC
are O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Epstein B-MISC O-MISC
- I-MISC O-MISC
Barr I-MISC O-MISC
virus I-MISC O-MISC
( I-MISC O-MISC
EBV I-MISC O-MISC
) I-MISC O-MISC
- I-MISC I-MISC
latent I-MISC I-MISC
proteins I-MISC I-MISC
; O-MISC O-MISC
the O-MISC O-MISC
newly O-MISC O-MISC
described O-MISC O-MISC
DNA O-MISC O-MISC
virus O-MISC O-MISC
, O-MISC O-MISC
Karposi O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
sarcoma O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
herpesvirus O-MISC O-MISC
/ O-MISC O-MISC
human O-MISC O-MISC
herpesvirus O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
( O-MISC O-MISC
KSHV O-MISC O-MISC
/ O-MISC O-MISC
HHV O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
) O-MISC O-MISC
; O-MISC O-MISC
and O-MISC O-MISC
perhaps O-MISC O-MISC
HIV O-MISC O-MISC
. O-MISC O-MISC

Elucidation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
factors O-MISC O-MISC
that O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
high O-MISC O-MISC
incidence O-MISC O-MISC
of O-MISC O-MISC
NHL O-MISC O-MISC
among O-MISC O-MISC
patients O-MISC O-MISC
infected O-MISC O-MISC
with O-MISC O-MISC
HIV O-MISC O-MISC
provides O-MISC O-MISC
insights O-MISC O-MISC
into O-MISC O-MISC
important O-MISC O-MISC
elements O-MISC O-MISC
of O-MISC O-MISC
lymphomagenesis O-MISC O-MISC
. O-MISC O-MISC

Matrix B-MISC B-MISC
metalloproteinase I-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
: O-MISC O-MISC
an O-MISC O-MISC
immunohistochemical O-MISC O-MISC
study O-MISC O-MISC
including O-MISC O-MISC
correlation O-MISC O-MISC
with O-MISC O-MISC
cathepsin B-MISC B-MISC
D I-MISC I-MISC
, O-MISC O-MISC
type B-MISC B-MISC
IV I-MISC I-MISC
collagen I-MISC I-MISC
, O-MISC O-MISC
laminin B-MISC O-MISC
, O-MISC O-MISC
fibronectin B-MISC B-MISC
, O-MISC O-MISC
EGFR B-MISC I-MISC
, O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
erbB I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
oncoprotein I-MISC I-MISC
, O-MISC O-MISC
p53 B-MISC B-MISC
, O-MISC O-MISC
steroid O-MISC B-MISC
receptors O-MISC I-MISC
status O-MISC O-MISC
and O-MISC O-MISC
proliferative O-MISC O-MISC
indices O-MISC O-MISC
. O-MISC O-MISC

Matrix B-MISC B-MISC
metalloproteinase I-MISC B-MISC
s O-MISC I-MISC
( O-MISC O-MISC
MMPs B-MISC B-MISC
) O-MISC O-MISC
are O-MISC O-MISC
a O-MISC O-MISC
group O-MISC O-MISC
of O-MISC O-MISC
enzymes O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
both O-MISC O-MISC
normal O-MISC O-MISC
connective O-MISC O-MISC
tissue O-MISC O-MISC
matrix O-MISC O-MISC
remodelling O-MISC O-MISC
and O-MISC O-MISC
accelerated O-MISC O-MISC
breakdown O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
tumour O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
current O-MISC O-MISC
study O-MISC O-MISC
aimed O-MISC O-MISC
to O-MISC O-MISC
investigate O-MISC O-MISC
the O-MISC O-MISC
immunohistochemical O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
matrix B-MISC B-MISC
metalloproteinase I-MISC I-MISC
3 I-MISC I-MISC
( O-MISC O-MISC
MMP B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
stromelysin B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
correlation O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Basement B-MISC O-MISC
Membrane I-MISC B-MISC
( I-MISC I-MISC
BM I-MISC I-MISC
) I-MISC I-MISC
antigen I-MISC I-MISC
( O-MISC O-MISC
type B-MISC I-MISC
IV I-MISC I-MISC
collagen I-MISC I-MISC
, O-MISC O-MISC
laminin B-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
fibronectin B-MISC O-MISC
, O-MISC O-MISC
cathepsin B-MISC B-MISC
D I-MISC I-MISC
, O-MISC O-MISC
p53 B-MISC B-MISC
, O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
erbB I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
proliferative O-MISC O-MISC
activity O-MISC O-MISC
( O-MISC O-MISC
Ki B-MISC B-MISC
- I-MISC I-MISC
67 I-MISC I-MISC
, O-MISC I-MISC
PCNA B-MISC I-MISC
) O-MISC I-MISC
, O-MISC O-MISC
steroid O-MISC B-MISC
receptor O-MISC I-MISC
content O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
conventional O-MISC O-MISC
clinicopathological O-MISC O-MISC
parameters O-MISC O-MISC
in O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
was O-MISC O-MISC
performed O-MISC O-MISC
on O-MISC O-MISC
a O-MISC O-MISC
series O-MISC O-MISC
of O-MISC O-MISC
frozen O-MISC O-MISC
and O-MISC O-MISC
paraffin O-MISC O-MISC
sections O-MISC O-MISC
from O-MISC O-MISC
84 O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
specimens O-MISC O-MISC
by O-MISC O-MISC
immunohistochemistry O-MISC O-MISC
using O-MISC O-MISC
the O-MISC O-MISC
monoclonal B-MISC B-MISC
antibody I-MISC I-MISC
MMP I-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
( O-MISC O-MISC
Ab B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Stromelysin B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
ST1 B-MISC B-MISC
) O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
about O-MISC O-MISC
10 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
groups O-MISC O-MISC
( O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
fibrocystic O-MISC O-MISC
and O-MISC O-MISC
benign O-MISC O-MISC
proliferative O-MISC O-MISC
breast O-MISC O-MISC
disease O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
expression O-MISC O-MISC
( O-MISC O-MISC
> O-MISC O-MISC
10 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
expression O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
89 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
tumours O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
ST1 B-MISC B-MISC
in O-MISC O-MISC
carcinoma O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
strongly O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
its O-MISC O-MISC
presence O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
stroma O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
significantly O-MISC O-MISC
positive O-MISC O-MISC
correlation O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
between O-MISC O-MISC
ST1 B-MISC B-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
p53 B-MISC B-MISC
tumour O-MISC I-MISC
suppressor O-MISC I-MISC
gene O-MISC I-MISC
product O-MISC I-MISC
( O-MISC O-MISC
p O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
004 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
relationship O-MISC O-MISC
with O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
erbB I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
protein O-MISC I-MISC
and O-MISC O-MISC
progesterone O-MISC B-MISC
receptor O-MISC I-MISC
status O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
indicated O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
ST1 B-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
tissue O-MISC O-MISC
is O-MISC O-MISC
irrespective O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
extracellular O-MISC O-MISC
matrix O-MISC O-MISC
component O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
proteolytic B-MISC O-MISC
enzyme I-MISC I-MISC
cathepsin B-MISC I-MISC
D I-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
growth O-MISC O-MISC
fraction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tumour O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
it O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
potential O-MISC O-MISC
new O-MISC O-MISC
prognostic O-MISC O-MISC
marker O-MISC O-MISC
in O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
. O-MISC O-MISC

Use O-MISC O-MISC
of O-MISC O-MISC
transfected O-MISC O-MISC
liver O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
evaluate O-MISC O-MISC
potential O-MISC O-MISC
mechanisms O-MISC O-MISC
of O-MISC O-MISC
alcohol O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
liver O-MISC O-MISC
injury O-MISC O-MISC
[ O-MISC O-MISC
see O-MISC O-MISC
comments O-MISC O-MISC
] O-MISC O-MISC

There O-MISC O-MISC
is O-MISC O-MISC
increased O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proinflammatory B-MISC B-MISC
cytokine I-MISC I-MISC
, O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
alcoholic O-MISC O-MISC
liver O-MISC O-MISC
disease O-MISC O-MISC
( O-MISC O-MISC
ALD O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Hepatic O-MISC O-MISC
neutrophil O-MISC O-MISC
infiltration O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
principal O-MISC O-MISC
injurious O-MISC O-MISC
manifestation O-MISC O-MISC
of O-MISC O-MISC
ALD O-MISC O-MISC
. O-MISC O-MISC

TNF B-MISC B-MISC
can O-MISC O-MISC
induce O-MISC O-MISC
cellular O-MISC O-MISC
oxidative O-MISC O-MISC
injury O-MISC O-MISC
directly O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
indirectly O-MISC O-MISC
by O-MISC O-MISC
inducing O-MISC O-MISC
neutrophil O-MISC O-MISC
chemotactic O-MISC B-MISC
factor O-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
) O-MISC O-MISC
production O-MISC O-MISC
by O-MISC O-MISC
hepatocytes O-MISC O-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
activates O-MISC O-MISC
and O-MISC O-MISC
chemotactically O-MISC O-MISC
attracts O-MISC O-MISC
neutrophils O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
where O-MISC O-MISC
they O-MISC O-MISC
release O-MISC O-MISC
oxidizing O-MISC O-MISC
substances O-MISC O-MISC
. O-MISC O-MISC

Patients O-MISC O-MISC
with O-MISC O-MISC
ALD O-MISC O-MISC
also O-MISC O-MISC
have O-MISC O-MISC
decreased O-MISC O-MISC
protective B-MISC B-MISC
factors I-MISC I-MISC
for O-MISC O-MISC
cellular O-MISC O-MISC
oxidative O-MISC O-MISC
injury O-MISC O-MISC
. O-MISC O-MISC

Manganous B-MISC O-MISC
superoxide I-MISC I-MISC
dismutase I-MISC I-MISC
( O-MISC O-MISC
MnSOD B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
antioxidant B-MISC B-MISC
protective I-MISC I-MISC
factor I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
objectives O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
studies O-MISC O-MISC
were O-MISC O-MISC
to O-MISC O-MISC
investigate O-MISC O-MISC
mechanisms O-MISC O-MISC
for O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
injurious B-MISC B-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
protective B-MISC B-MISC
factor I-MISC O-MISC
( O-MISC O-MISC
MnSOD B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
HepG2 O-MISC O-MISC
human O-MISC O-MISC
hepatoma O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
set O-MISC O-MISC
of O-MISC O-MISC
experiments O-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
gene I-MISC I-MISC
reporter I-MISC I-MISC
constructs I-MISC I-MISC
were O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
transiently O-MISC O-MISC
transfect O-MISC O-MISC
a O-MISC O-MISC
derivative O-MISC O-MISC
( O-MISC O-MISC
MVh2E1 O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
HepG2 O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
which O-MISC O-MISC
expresses O-MISC O-MISC
P B-MISC B-MISC
- I-MISC I-MISC
4502E1 I-MISC I-MISC
and O-MISC O-MISC
metabolizes O-MISC O-MISC
ethanol O-MISC O-MISC
. O-MISC O-MISC

Inactivation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and I-MISC I-MISC
3 I-MISC I-MISC
' I-MISC I-MISC
NF I-MISC I-MISC
- I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
DNA I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
decreased O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
gene I-MISC I-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
TNF B-MISC B-MISC
while O-MISC O-MISC
inactivation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
NF I-MISC I-MISC
- I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
increased O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
gene I-MISC I-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
TNF B-MISC B-MISC
. O-MISC O-MISC

This O-MISC O-MISC
system O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
useful O-MISC O-MISC
to O-MISC O-MISC
assess O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
ethanol O-MISC O-MISC
on O-MISC O-MISC
TNF B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
hepatocyte O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
production O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
second O-MISC O-MISC
set O-MISC O-MISC
of O-MISC O-MISC
experiments O-MISC O-MISC
, O-MISC O-MISC
HepG2 O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
cultured O-MISC O-MISC
in O-MISC O-MISC
25 O-MISC O-MISC
to O-MISC O-MISC
100 O-MISC O-MISC
mmol O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
ethanol O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
TNF B-MISC B-MISC
and O-MISC O-MISC
ethanol O-MISC O-MISC
increased O-MISC O-MISC
HepG2 O-MISC O-MISC
cell O-MISC O-MISC
MnSOD B-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
short O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
( O-MISC O-MISC
72 O-MISC O-MISC
hr O-MISC O-MISC
) O-MISC O-MISC
cultures O-MISC O-MISC
with O-MISC O-MISC
ethanol O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
after O-MISC O-MISC
long O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
( O-MISC O-MISC
10 O-MISC O-MISC
weeks O-MISC O-MISC
) O-MISC O-MISC
culture O-MISC O-MISC
with O-MISC O-MISC
ethanol O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
no O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
MnSOD B-MISC B-MISC
by O-MISC O-MISC
ethanol O-MISC O-MISC
and O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
diminished O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
MnSOD B-MISC B-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
TNF B-MISC B-MISC
. O-MISC O-MISC

Further O-MISC O-MISC
studies O-MISC O-MISC
are O-MISC O-MISC
needed O-MISC O-MISC
to O-MISC O-MISC
assess O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
diminished O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
MnSOD B-MISC B-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
ethanol O-MISC O-MISC
culture O-MISC O-MISC
on O-MISC O-MISC
HepG2 O-MISC O-MISC
cell O-MISC O-MISC
susceptibility O-MISC O-MISC
to O-MISC O-MISC
TNF O-MISC B-MISC
cytotoxicity O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
transfected O-MISC O-MISC
liver O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
evaluate O-MISC O-MISC
mechanisms O-MISC O-MISC
for O-MISC O-MISC
increased O-MISC O-MISC
injurious B-MISC O-MISC
factors I-MISC I-MISC
and O-MISC O-MISC
decreased O-MISC O-MISC
protective B-MISC B-MISC
factors I-MISC O-MISC
in O-MISC O-MISC
alcoholic O-MISC O-MISC
liver O-MISC O-MISC
injury O-MISC O-MISC
. O-MISC O-MISC

Tissue O-MISC B-MISC
factor O-MISC I-MISC
transcription O-MISC O-MISC
driven O-MISC O-MISC
by O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
murine B-MISC O-MISC
pulmonary I-MISC O-MISC
fibrin I-MISC O-MISC
deposition O-MISC O-MISC
in O-MISC O-MISC
hypoxia O-MISC O-MISC
. O-MISC O-MISC

Local O-MISC O-MISC
hypoxemia O-MISC O-MISC
and O-MISC O-MISC
stasis O-MISC O-MISC
trigger O-MISC O-MISC
thrombosis O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
demonstrated O-MISC O-MISC
previously O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
murine O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
normobaric O-MISC O-MISC
hypoxia O-MISC O-MISC
pulmonary O-MISC O-MISC
fibrin B-MISC O-MISC
deposition O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
result O-MISC O-MISC
of O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
tissue B-MISC B-MISC
factor I-MISC I-MISC
, O-MISC O-MISC
especially O-MISC O-MISC
in O-MISC O-MISC
oxygen B-MISC O-MISC
- I-MISC O-MISC
deprived I-MISC O-MISC
mononuclear I-MISC O-MISC
phagocytes I-MISC O-MISC
( O-MISC O-MISC
MPs B-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
now O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
early I-MISC I-MISC
- I-MISC I-MISC
growth I-MISC I-MISC
- I-MISC I-MISC
response I-MISC I-MISC
gene I-MISC I-MISC
product I-MISC I-MISC
( O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
rapidly O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
hypoxia O-MISC O-MISC
, O-MISC O-MISC
both O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
transcription O-MISC O-MISC
and O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
tissue B-MISC B-MISC
factor I-MISC I-MISC
in O-MISC O-MISC
hypoxic O-MISC O-MISC
lung O-MISC O-MISC
. O-MISC O-MISC

MPs B-MISC O-MISC
and O-MISC O-MISC
HeLa O-MISC O-MISC
cells O-MISC O-MISC
subjected O-MISC O-MISC
to O-MISC O-MISC
hypoxia O-MISC O-MISC
( O-MISC O-MISC
pO2 O-MISC O-MISC
approximately O-MISC O-MISC
13 O-MISC O-MISC
torr O-MISC O-MISC
) O-MISC O-MISC
had O-MISC O-MISC
increased O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
tissue B-MISC B-MISC
factor I-MISC I-MISC
transcripts I-MISC I-MISC
( O-MISC O-MISC
approximately O-MISC O-MISC
18 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
an O-MISC O-MISC
increased O-MISC O-MISC
rate O-MISC O-MISC
of O-MISC O-MISC
transcription O-MISC O-MISC
( O-MISC O-MISC
approximately O-MISC O-MISC
15 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
based O-MISC O-MISC
on O-MISC O-MISC
nuclear O-MISC O-MISC
run O-MISC O-MISC
- O-MISC O-MISC
on O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

Gel O-MISC O-MISC
- O-MISC O-MISC
shift O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
hypoxic B-MISC O-MISC
MPs I-MISC O-MISC
and O-MISC O-MISC
HeLa O-MISC O-MISC
cells O-MISC O-MISC
demonstrated O-MISC O-MISC
increased O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
serum B-MISC B-MISC
response I-MISC I-MISC
region I-MISC I-MISC
( O-MISC O-MISC
SRR O-MISC B-MISC
; O-MISC O-MISC
- O-MISC O-MISC
111 O-MISC O-MISC
/ O-MISC O-MISC
+ O-MISC O-MISC
14 O-MISC I-MISC
bp O-MISC I-MISC
) O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tissue B-MISC B-MISC
factor I-MISC I-MISC
promoter I-MISC I-MISC
at O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
motifs I-MISC I-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
32P O-MISC B-MISC
- O-MISC I-MISC
labeled O-MISC I-MISC
Egr O-MISC B-MISC
consensus O-MISC I-MISC
oligonucleotide O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
observed O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
hypoxic O-MISC O-MISC
lung O-MISC O-MISC
and O-MISC O-MISC
HeLa O-MISC O-MISC
cells O-MISC O-MISC
because O-MISC O-MISC
of O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
by O-MISC O-MISC
means O-MISC O-MISC
of O-MISC O-MISC
supershift O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

Transient O-MISC O-MISC
transfection O-MISC O-MISC
of O-MISC O-MISC
HeLa O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
chimeric B-MISC B-MISC
plasmids I-MISC I-MISC
containing O-MISC O-MISC
wild B-MISC B-MISC
- I-MISC I-MISC
type I-MISC I-MISC
or I-MISC O-MISC
mutant I-MISC O-MISC
SRR I-MISC I-MISC
from O-MISC O-MISC
the O-MISC O-MISC
tissue B-MISC B-MISC
factor I-MISC I-MISC
promoter I-MISC I-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
intact B-MISC O-MISC
Sp1 I-MISC I-MISC
sites I-MISC I-MISC
are O-MISC O-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
basal O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
the O-MISC O-MISC
integrity O-MISC O-MISC
of O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
sites I-MISC I-MISC
was O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
hypoxia O-MISC O-MISC
- O-MISC O-MISC
enhanced O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
central O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
hypoxia O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
tissue O-MISC O-MISC
factor O-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
confirmed O-MISC O-MISC
by O-MISC O-MISC
experiments O-MISC O-MISC
with O-MISC O-MISC
homozygous O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC O-MISC
1 I-MISC O-MISC
null O-MISC O-MISC
mice O-MISC O-MISC
; O-MISC O-MISC
wild O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
mice O-MISC O-MISC
subjected O-MISC O-MISC
to O-MISC O-MISC
oxygen B-MISC O-MISC
deprivation I-MISC O-MISC
expressed I-MISC O-MISC
tissue I-MISC B-MISC
factor I-MISC I-MISC
and O-MISC O-MISC
showed O-MISC O-MISC
fibrin B-MISC B-MISC
deposition O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
hypoxic O-MISC O-MISC
homozygous O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
null O-MISC O-MISC
mice O-MISC O-MISC
displayed O-MISC O-MISC
neither O-MISC O-MISC
tissue B-MISC B-MISC
factor I-MISC O-MISC
nor O-MISC O-MISC
fibrin B-MISC B-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
delineate O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
biology O-MISC O-MISC
for O-MISC O-MISC
hypoxia O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
fibrin B-MISC O-MISC
deposition O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
oxygen O-MISC O-MISC
deprivation O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
resulting O-MISC O-MISC
in O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
tissue B-MISC B-MISC
factor I-MISC I-MISC
, O-MISC O-MISC
has O-MISC O-MISC
an O-MISC O-MISC
unexpected O-MISC O-MISC
and O-MISC O-MISC
central O-MISC O-MISC
role O-MISC O-MISC
. O-MISC O-MISC

Kinetics O-MISC O-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
and O-MISC O-MISC
NFAT O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
interleukin O-MISC I-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
T O-MISC O-MISC
lymphoblasts O-MISC O-MISC
stimulated O-MISC O-MISC
via O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cells O-MISC O-MISC
respond O-MISC O-MISC
to O-MISC O-MISC
mitogenic O-MISC O-MISC
or O-MISC O-MISC
antigenic O-MISC O-MISC
stimulation O-MISC O-MISC
by O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
by O-MISC O-MISC
turning O-MISC O-MISC
on O-MISC O-MISC
cytokine O-MISC B-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
analysed O-MISC O-MISC
the O-MISC O-MISC
kinetics O-MISC O-MISC
and O-MISC O-MISC
nature O-MISC O-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
production O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
T O-MISC O-MISC
lymphoblasts O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
antibodies I-MISC I-MISC
or O-MISC O-MISC
Lens B-MISC O-MISC
culinaris I-MISC O-MISC
lectin I-MISC O-MISC
( O-MISC O-MISC
LCL B-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
purified O-MISC O-MISC
from O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
PBMC O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
primarily O-MISC O-MISC
activated O-MISC O-MISC
with O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
antibodies I-MISC I-MISC
and O-MISC O-MISC
cultured O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Anti O-MISC O-MISC
- O-MISC O-MISC
CD3 O-MISC O-MISC
- O-MISC O-MISC
restimulated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
mainly O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
produced O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
interferon B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
( O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
tumour B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
low O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
and I-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
transcripts I-MISC I-MISC
and O-MISC O-MISC
proteins O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
gene I-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
LCL O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
cells O-MISC O-MISC
the O-MISC O-MISC
cytokine O-MISC B-MISC
production O-MISC O-MISC
pattern O-MISC O-MISC
was O-MISC O-MISC
very O-MISC O-MISC
similar O-MISC O-MISC
. O-MISC O-MISC

Steady O-MISC O-MISC
- O-MISC O-MISC
state O-MISC O-MISC
mRNA O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
and O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
peaked O-MISC O-MISC
at O-MISC O-MISC
3 O-MISC O-MISC
hr O-MISC O-MISC
after O-MISC O-MISC
anti O-MISC B-MISC
- O-MISC I-MISC
CD3 O-MISC I-MISC
stimulation O-MISC O-MISC
and O-MISC O-MISC
declined O-MISC O-MISC
rapidly O-MISC O-MISC
thereafter O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
kinetics O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
mRNA I-MISC I-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
faster O-MISC O-MISC
, O-MISC O-MISC
being O-MISC O-MISC
at O-MISC O-MISC
its O-MISC O-MISC
peak O-MISC O-MISC
level O-MISC O-MISC
1 O-MISC O-MISC
hr O-MISC O-MISC
after O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Anti O-MISC O-MISC
- O-MISC O-MISC
CD3 O-MISC I-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
inhibitor O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
, I-MISC O-MISC
IFN I-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
and I-MISC I-MISC
TNF I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
genes I-MISC I-MISC
were O-MISC O-MISC
readily O-MISC O-MISC
induced O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
ongoing O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
. O-MISC O-MISC

T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
stimulation O-MISC O-MISC
also O-MISC O-MISC
induced O-MISC O-MISC
a O-MISC O-MISC
very O-MISC O-MISC
rapid O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
jun I-MISC I-MISC
, I-MISC I-MISC
c I-MISC I-MISC
- I-MISC I-MISC
fos I-MISC I-MISC
and I-MISC I-MISC
NFATc1 I-MISC B-MISC
( I-MISC I-MISC
NFATc I-MISC I-MISC
) I-MISC I-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
gene O-MISC O-MISC
products O-MISC I-MISC
of O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
cytokine O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
conclusion O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
cytokines B-MISC B-MISC
synthesized O-MISC O-MISC
by O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
predominantly O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

An O-MISC O-MISC
animal O-MISC O-MISC
model O-MISC O-MISC
to O-MISC O-MISC
study O-MISC O-MISC
local O-MISC O-MISC
oxidation O-MISC O-MISC
of O-MISC O-MISC
LDL O-MISC B-MISC
and O-MISC O-MISC
its O-MISC O-MISC
biological O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
arterial O-MISC O-MISC
wall O-MISC O-MISC
. O-MISC O-MISC

Oxidized O-MISC O-MISC
LDL O-MISC B-MISC
( O-MISC O-MISC
oxLDL O-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
atherosclerotic O-MISC O-MISC
lesions O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
believed O-MISC O-MISC
to O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
key O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
atherogenesis O-MISC O-MISC
. O-MISC O-MISC

Mainly O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
basis O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
culture O-MISC O-MISC
studies O-MISC O-MISC
, O-MISC O-MISC
oxLDL O-MISC B-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
produce O-MISC O-MISC
many O-MISC O-MISC
biological O-MISC O-MISC
effects O-MISC O-MISC
that O-MISC O-MISC
influence O-MISC O-MISC
the O-MISC O-MISC
atherosclerotic O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
study O-MISC O-MISC
LDL O-MISC O-MISC
oxidation O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
established O-MISC O-MISC
a O-MISC O-MISC
model O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
Sprague O-MISC O-MISC
- O-MISC O-MISC
Dawley O-MISC O-MISC
rats O-MISC O-MISC
are O-MISC O-MISC
given O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
injection O-MISC O-MISC
of O-MISC O-MISC
unmodified O-MISC O-MISC
human O-MISC O-MISC
LDL O-MISC O-MISC
( O-MISC O-MISC
> O-MISC O-MISC
or O-MISC O-MISC
= O-MISC O-MISC
4 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
body O-MISC O-MISC
weight O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Within O-MISC O-MISC
6 O-MISC O-MISC
hours O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
apolipoprotein O-MISC O-MISC
B O-MISC I-MISC
and O-MISC O-MISC
epitopes B-MISC B-MISC
present O-MISC O-MISC
on O-MISC O-MISC
oxLDL O-MISC B-MISC
are O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
arterial O-MISC O-MISC
endothelium O-MISC O-MISC
and O-MISC O-MISC
media O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
oxLDL O-MISC B-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
nuclear B-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
endothelium O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
endothelial O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Injection O-MISC O-MISC
of O-MISC O-MISC
LDL O-MISC B-MISC
enriched O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
antioxidant O-MISC O-MISC
probucol O-MISC I-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
arterial O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
apolipoprotein O-MISC O-MISC
B O-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
oxLDL O-MISC B-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
epitopes O-MISC O-MISC
was O-MISC O-MISC
reduced O-MISC O-MISC
at O-MISC O-MISC
24 O-MISC B-MISC
hours O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
this O-MISC O-MISC
simple O-MISC O-MISC
model O-MISC O-MISC
has O-MISC O-MISC
the O-MISC O-MISC
potential O-MISC O-MISC
to O-MISC O-MISC
analyze O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
behind O-MISC O-MISC
and O-MISC O-MISC
biological O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
LDL O-MISC B-MISC
oxidation O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

Molecular O-MISC O-MISC
mechanisms O-MISC O-MISC
of O-MISC O-MISC
promoter O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
gp34 B-MISC B-MISC
gene I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
trans O-MISC O-MISC
- O-MISC I-MISC
activated O-MISC I-MISC
by O-MISC O-MISC
an O-MISC O-MISC
oncoprotein B-MISC B-MISC
Tax I-MISC B-MISC
of O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
I O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
gp34 B-MISC B-MISC
gene I-MISC I-MISC
by O-MISC O-MISC
the O-MISC O-MISC
Tax B-MISC B-MISC
oncoprotein I-MISC B-MISC
of O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
I O-MISC O-MISC
( O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
I O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

gp34 B-MISC B-MISC
is O-MISC O-MISC
a O-MISC O-MISC
type B-MISC B-MISC
II I-MISC I-MISC
transmembrane I-MISC I-MISC
molecule I-MISC I-MISC
belonging O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC B-MISC
necrosis O-MISC I-MISC
factor O-MISC I-MISC
family O-MISC I-MISC
and O-MISC O-MISC
is O-MISC O-MISC
constitutively O-MISC O-MISC
expressed O-MISC O-MISC
on O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
I O-MISC O-MISC
- O-MISC O-MISC
producing O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
normal O-MISC O-MISC
resting O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcriptional O-MISC O-MISC
regulatory O-MISC I-MISC
region O-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
gp34 B-MISC B-MISC
gene I-MISC I-MISC
was O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
HTLV O-MISC B-MISC
- O-MISC I-MISC
I O-MISC I-MISC
Tax B-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
Jurkat O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
endogenous O-MISC O-MISC
gp34 B-MISC O-MISC
is O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
Tax B-MISC B-MISC
. O-MISC O-MISC

Sequence O-MISC O-MISC
analysis O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
two O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
elements I-MISC I-MISC
( O-MISC O-MISC
1 O-MISC I-MISC
and O-MISC O-MISC
2 O-MISC I-MISC
) O-MISC O-MISC
were O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulatory B-MISC B-MISC
region I-MISC I-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
elements I-MISC I-MISC
were O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
or O-MISC O-MISC
its O-MISC O-MISC
related O-MISC O-MISC
factor O-MISC O-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
Tax B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
. O-MISC O-MISC

Chloramphenicol B-MISC B-MISC
acetyltransferase I-MISC I-MISC
assays O-MISC O-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
element I-MISC I-MISC
1 I-MISC I-MISC
was O-MISC O-MISC
Tax B-MISC B-MISC
- O-MISC I-MISC
responsive O-MISC I-MISC
, O-MISC O-MISC
although O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
lower O-MISC O-MISC
than O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
native B-MISC O-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- O-MISC I-MISC
like O-MISC I-MISC
element O-MISC I-MISC
2 O-MISC I-MISC
elevated O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
when O-MISC O-MISC
combined O-MISC O-MISC
with O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
element I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
cooperative O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
elements O-MISC O-MISC
for O-MISC O-MISC
maximum O-MISC O-MISC
promoter O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

Unlike O-MISC O-MISC
typical O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
elements I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
elements I-MISC I-MISC
in O-MISC O-MISC
gp34 B-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
phorbol O-MISC O-MISC
ester O-MISC O-MISC
despite O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- O-MISC O-MISC
like O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Chloramphenicol B-MISC B-MISC
acetyltransferase I-MISC I-MISC
reporter O-MISC O-MISC
assays O-MISC O-MISC
using O-MISC O-MISC
the O-MISC O-MISC
region O-MISC O-MISC
upstream O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
elements I-MISC I-MISC
identified O-MISC O-MISC
an O-MISC O-MISC
upstream O-MISC O-MISC
region O-MISC I-MISC
that O-MISC O-MISC
reduced O-MISC O-MISC
transcription O-MISC O-MISC
from O-MISC O-MISC
cognate B-MISC O-MISC
and I-MISC O-MISC
noncognate I-MISC O-MISC
core I-MISC O-MISC
promoters I-MISC I-MISC
in O-MISC O-MISC
a O-MISC O-MISC
Tax O-MISC B-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
manner O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
imply O-MISC O-MISC
complex O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
gp34 B-MISC B-MISC
gene I-MISC I-MISC
and O-MISC O-MISC
suggest O-MISC O-MISC
implication O-MISC O-MISC
of O-MISC O-MISC
gp34 B-MISC O-MISC
in O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
I O-MISC O-MISC
infected O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

beta B-MISC O-MISC
- I-MISC O-MISC
Amyloid I-MISC O-MISC
fibrils I-MISC O-MISC
activate O-MISC O-MISC
parallel O-MISC O-MISC
mitogen B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
pathways O-MISC O-MISC
in O-MISC O-MISC
microglia O-MISC O-MISC
and O-MISC O-MISC
THP1 O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
senile O-MISC O-MISC
plaques O-MISC O-MISC
of O-MISC O-MISC
Alzheimer O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
disease O-MISC O-MISC
are O-MISC O-MISC
foci O-MISC O-MISC
of O-MISC O-MISC
local O-MISC O-MISC
inflammatory O-MISC O-MISC
responses O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
evidenced O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
acute B-MISC O-MISC
phase I-MISC O-MISC
proteins I-MISC O-MISC
and O-MISC O-MISC
oxidative O-MISC O-MISC
damage O-MISC O-MISC
. O-MISC O-MISC

Fibrillar B-MISC O-MISC
forms I-MISC O-MISC
of O-MISC O-MISC
beta B-MISC B-MISC
- I-MISC O-MISC
amyloid I-MISC O-MISC
( O-MISC O-MISC
Abeta B-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
the O-MISC O-MISC
primary O-MISC O-MISC
constituents O-MISC O-MISC
of O-MISC O-MISC
senile O-MISC O-MISC
plaques O-MISC O-MISC
, O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
tyrosine O-MISC B-MISC
kinase O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
cascades O-MISC O-MISC
, O-MISC O-MISC
resulting O-MISC O-MISC
in O-MISC O-MISC
inflammatory O-MISC O-MISC
responses O-MISC O-MISC
in O-MISC O-MISC
microglia O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
downstream O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
mediating O-MISC O-MISC
Abeta B-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
inflammatory O-MISC O-MISC
events O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
well O-MISC O-MISC
characterized O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
that O-MISC O-MISC
exposure O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
rat O-MISC O-MISC
microglia O-MISC O-MISC
and O-MISC O-MISC
human O-MISC O-MISC
THP1 O-MISC O-MISC
monocytes O-MISC O-MISC
to O-MISC O-MISC
fibrillar B-MISC B-MISC
Abeta I-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
tyrosine B-MISC O-MISC
kinase I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
two O-MISC O-MISC
parallel O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
cascades O-MISC O-MISC
involving O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mitogen B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
( I-MISC O-MISC
MAPK I-MISC I-MISC
) I-MISC I-MISC
superfamily I-MISC I-MISC
. O-MISC O-MISC

Abeta B-MISC O-MISC
stimulated O-MISC O-MISC
the O-MISC O-MISC
rapid O-MISC O-MISC
, O-MISC O-MISC
transient O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
extracellular B-MISC B-MISC
signal I-MISC I-MISC
- I-MISC I-MISC
regulated I-MISC I-MISC
kinase I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
ERK1 B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
ERK2 B-MISC B-MISC
in O-MISC O-MISC
microglia O-MISC O-MISC
and O-MISC O-MISC
ERK2 B-MISC B-MISC
in O-MISC O-MISC
THP1 O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
second O-MISC O-MISC
superfamily B-MISC B-MISC
member I-MISC I-MISC
, O-MISC O-MISC
p38 B-MISC B-MISC
MAPK I-MISC I-MISC
, O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
activated O-MISC O-MISC
with O-MISC O-MISC
similar O-MISC O-MISC
kinetics O-MISC O-MISC
. O-MISC O-MISC

Scavenger B-MISC O-MISC
receptor I-MISC I-MISC
and O-MISC O-MISC
receptor B-MISC O-MISC
for I-MISC O-MISC
advanced I-MISC O-MISC
glycated I-MISC B-MISC
end I-MISC I-MISC
products I-MISC I-MISC
( O-MISC O-MISC
RAGE B-MISC O-MISC
) O-MISC O-MISC
ligands O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
ERK B-MISC B-MISC
and O-MISC O-MISC
p38 B-MISC B-MISC
MAPK I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
significant O-MISC O-MISC
increases O-MISC O-MISC
in O-MISC O-MISC
protein O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
, O-MISC O-MISC
demonstrating O-MISC O-MISC
that O-MISC O-MISC
scavenger B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
RAGE B-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
these O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

Importantly O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
stress B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinases I-MISC I-MISC
( O-MISC O-MISC
SAPKs B-MISC B-MISC
) O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
significantly O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
Abeta B-MISC O-MISC
. O-MISC O-MISC

Downstream O-MISC O-MISC
effectors O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
MAPK O-MISC B-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
cascades O-MISC O-MISC
include O-MISC O-MISC
MAPKAP B-MISC B-MISC
kinases I-MISC I-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
RSK1 B-MISC B-MISC
and O-MISC O-MISC
RSK2 B-MISC B-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

Exposure O-MISC O-MISC
of O-MISC O-MISC
microglia O-MISC O-MISC
and O-MISC O-MISC
THP1 O-MISC O-MISC
monocytes O-MISC O-MISC
to O-MISC O-MISC
Abeta B-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
RSK1 B-MISC B-MISC
and O-MISC O-MISC
RSK2 B-MISC B-MISC
and O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
cAMP B-MISC B-MISC
response I-MISC I-MISC
element I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC O-MISC
protein I-MISC O-MISC
at O-MISC O-MISC
Ser133 O-MISC O-MISC
, O-MISC O-MISC
providing O-MISC O-MISC
a O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
Abeta B-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC

Regulation O-MISC O-MISC
of O-MISC O-MISC
cellular B-MISC O-MISC
retinoic I-MISC O-MISC
acid I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
CRABP B-MISC B-MISC
II I-MISC I-MISC
) O-MISC O-MISC
during O-MISC O-MISC
human O-MISC O-MISC
monocyte O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

Cellular B-MISC O-MISC
retinoic I-MISC O-MISC
acid I-MISC I-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
( O-MISC O-MISC
CRABP B-MISC B-MISC
) O-MISC O-MISC
are O-MISC O-MISC
low B-MISC O-MISC
molecular I-MISC O-MISC
weight I-MISC I-MISC
proteins I-MISC I-MISC
whose O-MISC O-MISC
precise O-MISC O-MISC
function O-MISC O-MISC
remains O-MISC O-MISC
unknown O-MISC O-MISC
. O-MISC O-MISC

They O-MISC O-MISC
bind O-MISC O-MISC
retinoids O-MISC O-MISC
and O-MISC O-MISC
may O-MISC O-MISC
thereby O-MISC O-MISC
modulate O-MISC O-MISC
the O-MISC O-MISC
intracellular O-MISC O-MISC
steady O-MISC O-MISC
- O-MISC O-MISC
state O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
retinoids O-MISC O-MISC
. O-MISC O-MISC

Whereas O-MISC O-MISC
CRABP B-MISC B-MISC
I I-MISC I-MISC
is O-MISC O-MISC
ubiquitously O-MISC O-MISC
expressed O-MISC O-MISC
, O-MISC O-MISC
CRABP B-MISC B-MISC
II I-MISC I-MISC
is O-MISC O-MISC
mainly O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
various O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
skin O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
representative O-MISC O-MISC
difference O-MISC O-MISC
analysis O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
CRABP B-MISC B-MISC
II I-MISC I-MISC
is O-MISC O-MISC
also O-MISC O-MISC
strongly O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocyte O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
macrophages O-MISC O-MISC
( O-MISC O-MISC
MAC O-MISC O-MISC
) O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
freshly O-MISC O-MISC
isolated O-MISC O-MISC
monocytes O-MISC O-MISC
( O-MISC O-MISC
MO O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
CRABP B-MISC B-MISC
II I-MISC I-MISC
mRNA I-MISC I-MISC
was O-MISC O-MISC
gradually O-MISC O-MISC
upregulated O-MISC O-MISC
during O-MISC O-MISC
differentiation O-MISC O-MISC
from O-MISC O-MISC
MO O-MISC O-MISC
to O-MISC O-MISC
MAC O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
2 O-MISC O-MISC
% O-MISC O-MISC
serum O-MISC O-MISC
. O-MISC O-MISC

Adherence O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
important O-MISC O-MISC
for O-MISC O-MISC
MO O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
induced O-MISC O-MISC
CRABP B-MISC B-MISC
II I-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
7 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
CRABP B-MISC B-MISC
II I-MISC I-MISC
expression O-MISC O-MISC
during O-MISC O-MISC
MO O-MISC O-MISC
/ O-MISC O-MISC
MAC O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
MO O-MISC O-MISC
can O-MISC O-MISC
differentiate O-MISC O-MISC
along O-MISC O-MISC
the O-MISC O-MISC
classical O-MISC O-MISC
pathway O-MISC O-MISC
not O-MISC O-MISC
only O-MISC O-MISC
to O-MISC O-MISC
MAC O-MISC O-MISC
but O-MISC O-MISC
also O-MISC O-MISC
to O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
we O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
CRABP B-MISC B-MISC
II I-MISC I-MISC
in O-MISC O-MISC
MO O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
cultured O-MISC O-MISC
with O-MISC O-MISC
10 O-MISC O-MISC
% O-MISC O-MISC
FCS B-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
MAC O-MISC O-MISC
, O-MISC O-MISC
MO O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
showed O-MISC O-MISC
an O-MISC O-MISC
extremely O-MISC O-MISC
low O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
CRABP B-MISC B-MISC
II I-MISC I-MISC
. O-MISC O-MISC

From O-MISC O-MISC
these O-MISC O-MISC
results O-MISC O-MISC
we O-MISC O-MISC
conclude O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
availability O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
metabolism O-MISC O-MISC
of O-MISC O-MISC
retinoids O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
different O-MISC O-MISC
in O-MISC O-MISC
MAC O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
MO O-MISC O-MISC
and O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
may O-MISC O-MISC
influence O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
those O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Transcription B-MISC B-MISC
factor I-MISC I-MISC
B I-MISC I-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
activator I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
BSAP B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
differentially O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
subsets O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphomas O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
paired B-MISC B-MISC
box I-MISC I-MISC
containing I-MISC O-MISC
gene I-MISC O-MISC
PAX B-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
encodes O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
BSAP B-MISC B-MISC
( O-MISC O-MISC
B B-MISC I-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
activator I-MISC I-MISC
protein I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
key O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphocyte O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

Despite O-MISC O-MISC
its O-MISC O-MISC
known O-MISC O-MISC
involvement O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
rare O-MISC O-MISC
subtype O-MISC O-MISC
of O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
Hodgkin O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
lymphoma O-MISC O-MISC
( O-MISC O-MISC
NHL O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
detailed O-MISC O-MISC
examination O-MISC O-MISC
of O-MISC O-MISC
BSAP B-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
NHL O-MISC O-MISC
has O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
previously O-MISC O-MISC
reported O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
analyzed O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
lymphoid O-MISC O-MISC
tissues O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
102 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
NHL O-MISC O-MISC
, O-MISC O-MISC
23 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
null O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
NHL O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
18 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
Hodgkin O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

Normal O-MISC O-MISC
lymphoid O-MISC O-MISC
tissues O-MISC O-MISC
showed O-MISC O-MISC
strong O-MISC O-MISC
nuclear O-MISC O-MISC
BSAP B-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
mantle O-MISC O-MISC
zone O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
less O-MISC O-MISC
intense O-MISC O-MISC
reactivity O-MISC O-MISC
in O-MISC O-MISC
follicular O-MISC O-MISC
center O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
no O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T O-MISC B-MISC
- O-MISC I-MISC
cell O-MISC I-MISC
- O-MISC I-MISC
rich O-MISC I-MISC
zones O-MISC I-MISC
. O-MISC O-MISC

Monocytoid O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
showed O-MISC O-MISC
weak O-MISC O-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
plasma O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
extrafollicular O-MISC O-MISC
large O-MISC O-MISC
transformed O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
negative O-MISC O-MISC
. O-MISC O-MISC

Of O-MISC O-MISC
the O-MISC O-MISC
102 O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
NHLs O-MISC O-MISC
, O-MISC O-MISC
83 O-MISC O-MISC
( O-MISC O-MISC
81 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
demonstrated O-MISC O-MISC
BSAP B-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

All O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
13 O-MISC O-MISC
( O-MISC O-MISC
100 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
chronic O-MISC O-MISC
lymphocytic O-MISC O-MISC
leukemias O-MISC O-MISC
( O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
CLLs O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
21 O-MISC O-MISC
of O-MISC O-MISC
( O-MISC O-MISC
100 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
mantle O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
MCLs O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
20 O-MISC O-MISC
of O-MISC O-MISC
21 O-MISC O-MISC
( O-MISC O-MISC
95 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
follicular O-MISC O-MISC
lymphomas O-MISC O-MISC
( O-MISC O-MISC
FLs O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
positive O-MISC O-MISC
. O-MISC O-MISC

Moderate O-MISC O-MISC
staining O-MISC O-MISC
intensities O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
most O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
CLL O-MISC O-MISC
and O-MISC O-MISC
FL O-MISC O-MISC
cases O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
most O-MISC O-MISC
MCLs O-MISC O-MISC
showed O-MISC O-MISC
strong O-MISC O-MISC
reactions O-MISC O-MISC
, O-MISC O-MISC
paralleling O-MISC O-MISC
the O-MISC O-MISC
strong O-MISC O-MISC
reactivity O-MISC O-MISC
of O-MISC O-MISC
nonmalignant O-MISC O-MISC
mantle O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Eight O-MISC O-MISC
of O-MISC O-MISC
12 O-MISC O-MISC
( O-MISC O-MISC
67 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
marginal O-MISC O-MISC
zone O-MISC O-MISC
lymphoma O-MISC O-MISC
cases O-MISC O-MISC
showed O-MISC O-MISC
negative O-MISC O-MISC
or O-MISC O-MISC
low O-MISC O-MISC
BSAP B-MISC B-MISC
levels O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
17 O-MISC O-MISC
of O-MISC O-MISC
24 O-MISC O-MISC
( O-MISC O-MISC
71 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
large O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphomas O-MISC O-MISC
displayed O-MISC O-MISC
moderate O-MISC O-MISC
to O-MISC O-MISC
strong O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

None O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
23 O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
null O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphomas O-MISC O-MISC
reacted O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
BSAP B-MISC B-MISC
antisera O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
in O-MISC O-MISC
Hodgkin O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
disease O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
of O-MISC O-MISC
4 O-MISC O-MISC
( O-MISC O-MISC
50 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
nodular O-MISC O-MISC
lymphocytic O-MISC O-MISC
predominance O-MISC O-MISC
and O-MISC O-MISC
5 O-MISC O-MISC
of O-MISC O-MISC
14 O-MISC O-MISC
( O-MISC O-MISC
36 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
classical O-MISC O-MISC
cases O-MISC O-MISC
showed O-MISC O-MISC
weak O-MISC O-MISC
nuclear O-MISC O-MISC
or O-MISC O-MISC
nucleolar O-MISC O-MISC
BSAP B-MISC I-MISC
reactions O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
fraction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Western O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
showed O-MISC O-MISC
a O-MISC O-MISC
52 O-MISC O-MISC
- O-MISC O-MISC
kD O-MISC I-MISC
BSAP B-MISC B-MISC
band O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
or O-MISC O-MISC
plasma O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
BSAP B-MISC B-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
largely O-MISC O-MISC
restricted O-MISC O-MISC
to O-MISC O-MISC
lymphomas O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lineage O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
BSAP B-MISC B-MISC
expression O-MISC O-MISC
varies O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
subsets O-MISC O-MISC
and O-MISC O-MISC
subtypes O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
NHL O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
BSAP B-MISC B-MISC
, O-MISC O-MISC
especially O-MISC O-MISC
those O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
large O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphomas O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
some O-MISC O-MISC
follicular O-MISC O-MISC
lymphomas O-MISC O-MISC
, O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
consequence O-MISC O-MISC
of O-MISC O-MISC
deregulated O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
suggest O-MISC O-MISC
a O-MISC O-MISC
possible O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
PAX B-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
in O-MISC O-MISC
certain O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
malignancies O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
US O-MISC B-MISC
government O-MISC I-MISC
work O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
are O-MISC O-MISC
no O-MISC O-MISC
restrictions O-MISC O-MISC
on O-MISC O-MISC
its O-MISC O-MISC
use O-MISC O-MISC
. O-MISC O-MISC

Mitogen O-MISC O-MISC
and O-MISC O-MISC
growth O-MISC B-MISC
factor O-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
STAT B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
molecule I-MISC I-MISC
in O-MISC O-MISC
channel O-MISC O-MISC
catfish O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
article O-MISC O-MISC
describes O-MISC O-MISC
the O-MISC O-MISC
identification O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
putative B-MISC B-MISC
STAT I-MISC I-MISC
molecule I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
channel O-MISC B-MISC
catfish O-MISC I-MISC
( O-MISC O-MISC
Ictalurus O-MISC B-MISC
punctatus O-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
report O-MISC O-MISC
of O-MISC O-MISC
such O-MISC O-MISC
a O-MISC O-MISC
molecule O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
' O-MISC O-MISC
lower O-MISC O-MISC
' O-MISC O-MISC
vertebrate O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
monoclonal B-MISC B-MISC
antibody I-MISC I-MISC
against O-MISC O-MISC
human B-MISC B-MISC
STAT6 I-MISC I-MISC
recognizes O-MISC O-MISC
an O-MISC O-MISC
approximately O-MISC O-MISC
100 B-MISC B-MISC
kDa I-MISC I-MISC
molecule I-MISC I-MISC
that O-MISC O-MISC
becomes O-MISC O-MISC
activated O-MISC O-MISC
and O-MISC O-MISC
translocates O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
upon O-MISC O-MISC
both O-MISC O-MISC
growth O-MISC B-MISC
factor O-MISC I-MISC
and O-MISC O-MISC
mitogen O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
catfish O-MISC O-MISC
leukocytes O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
presumed O-MISC O-MISC
catfish B-MISC B-MISC
STAT I-MISC I-MISC
binds O-MISC O-MISC
the O-MISC O-MISC
mammalian B-MISC B-MISC
interferon I-MISC I-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
activation I-MISC I-MISC
site I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
known O-MISC O-MISC
motif O-MISC O-MISC
of O-MISC O-MISC
mammalian O-MISC B-MISC
STAT O-MISC I-MISC
binding O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
shown O-MISC O-MISC
by O-MISC O-MISC
electromobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
. O-MISC O-MISC

Purification O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proteins O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
DNA B-MISC B-MISC
complexes I-MISC I-MISC
confirms O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
catfish O-MISC B-MISC
reactive O-MISC I-MISC
molecule O-MISC I-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
interferon B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
activation I-MISC I-MISC
site I-MISC I-MISC
sequence I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
STAT B-MISC B-MISC
molecules I-MISC I-MISC
have O-MISC O-MISC
been O-MISC O-MISC
highly O-MISC O-MISC
conserved O-MISC O-MISC
in O-MISC O-MISC
vertebrate O-MISC O-MISC
evolution O-MISC O-MISC
. O-MISC O-MISC

Isolation O-MISC O-MISC
and O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
clone O-MISC O-MISC
variant O-MISC O-MISC
exhibiting O-MISC O-MISC
constitutively O-MISC O-MISC
phosphorylated B-MISC O-MISC
Ser133 I-MISC B-MISC
cAMP I-MISC B-MISC
response I-MISC I-MISC
element I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
driving O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
stimulates O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
program O-MISC O-MISC
of O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
that O-MISC O-MISC
includes O-MISC O-MISC
proliferating B-MISC O-MISC
cell I-MISC O-MISC
nuclear I-MISC O-MISC
antigen I-MISC I-MISC
( O-MISC O-MISC
PCNA B-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
requisite O-MISC O-MISC
processivity O-MISC I-MISC
factor O-MISC I-MISC
for O-MISC O-MISC
DNA B-MISC B-MISC
polymerase I-MISC I-MISC
delta I-MISC I-MISC
. O-MISC O-MISC

PCNA B-MISC O-MISC
transcription O-MISC O-MISC
is O-MISC O-MISC
regulated O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
through O-MISC O-MISC
tandem O-MISC B-MISC
CRE B-MISC I-MISC
sequences I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
promoter B-MISC B-MISC
and I-MISC O-MISC
CRE I-MISC B-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
; O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
stimulates O-MISC O-MISC
CREB O-MISC B-MISC
phosphorylation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
resting O-MISC O-MISC
cloned O-MISC O-MISC
T O-MISC O-MISC
lymphocyte O-MISC O-MISC
, O-MISC O-MISC
L2 O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
culturing O-MISC O-MISC
L2 O-MISC O-MISC
cells O-MISC O-MISC
for O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
91 O-MISC O-MISC
days O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
consistently O-MISC O-MISC
isolate O-MISC O-MISC
a O-MISC O-MISC
stable O-MISC O-MISC
variant O-MISC O-MISC
that O-MISC O-MISC
exhibits O-MISC O-MISC
constitutive O-MISC O-MISC
CREB O-MISC B-MISC
phosphorylation O-MISC O-MISC
. O-MISC O-MISC

L2 O-MISC O-MISC
and O-MISC O-MISC
L2 O-MISC O-MISC
variant O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
tested O-MISC O-MISC
for O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
responsiveness O-MISC O-MISC
and O-MISC O-MISC
rapamycin O-MISC O-MISC
sensitivity O-MISC O-MISC
with O-MISC O-MISC
respect O-MISC O-MISC
to O-MISC O-MISC
specific O-MISC O-MISC
kinase O-MISC O-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
PCNA O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
L2 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
stimulated O-MISC O-MISC
and O-MISC O-MISC
rapamycin O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
following O-MISC O-MISC
: O-MISC O-MISC
cAMP O-MISC O-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
CREB B-MISC B-MISC
kinase I-MISC I-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
PCNA O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
L2 O-MISC O-MISC
variant O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
CREB B-MISC B-MISC
kinase I-MISC I-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
constitutively O-MISC O-MISC
high O-MISC O-MISC
; O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
stimulated O-MISC O-MISC
and O-MISC O-MISC
rapamycin O-MISC O-MISC
blocked O-MISC O-MISC
PCNA O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
induces O-MISC O-MISC
a O-MISC O-MISC
rapamycin O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
, O-MISC O-MISC
cAMP O-MISC O-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
CREB B-MISC B-MISC
kinase I-MISC I-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
L2 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
alone O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
drive O-MISC O-MISC
PCNA B-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
L2 O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

Serotonin O-MISC O-MISC
derivative O-MISC O-MISC
, O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
- O-MISC O-MISC
coumaroyl O-MISC O-MISC
) O-MISC O-MISC
serotonin O-MISC O-MISC
, O-MISC O-MISC
inhibits O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
by O-MISC O-MISC
endotoxin O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
human O-MISC O-MISC
blood O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
reported O-MISC O-MISC
that O-MISC O-MISC
N O-MISC B-MISC
- O-MISC I-MISC
( O-MISC O-MISC
p O-MISC O-MISC
- O-MISC O-MISC
coumaroyl O-MISC O-MISC
) O-MISC O-MISC
serotonin O-MISC O-MISC
( O-MISC O-MISC
CS O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
derivatives O-MISC O-MISC
with O-MISC O-MISC
antioxidative O-MISC O-MISC
activity O-MISC O-MISC
are O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
safflower O-MISC O-MISC
seeds O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
species O-MISC O-MISC
( O-MISC O-MISC
ROS O-MISC O-MISC
) O-MISC O-MISC
are O-MISC O-MISC
implicated O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
signaling O-MISC O-MISC
of O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
( O-MISC O-MISC
LPS O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
examined O-MISC O-MISC
whether O-MISC O-MISC
CS O-MISC B-MISC
has O-MISC O-MISC
a O-MISC O-MISC
suppressive O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
inflammatory B-MISC B-MISC
cytokine I-MISC I-MISC
generation O-MISC O-MISC
from O-MISC O-MISC
human O-MISC O-MISC
monocyte O-MISC O-MISC
s O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

CS O-MISC O-MISC
at O-MISC O-MISC
50 O-MISC O-MISC
- O-MISC O-MISC
200 O-MISC O-MISC
microM O-MISC O-MISC
reduced O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
activities O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
culture O-MISC O-MISC
supernatants O-MISC O-MISC
from O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
human O-MISC O-MISC
blood O-MISC O-MISC
monocytes O-MISC O-MISC
without O-MISC O-MISC
cytotoxicity O-MISC O-MISC
. O-MISC O-MISC

ELISA O-MISC O-MISC
assay O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
CS O-MISC B-MISC
. O-MISC O-MISC

Northern O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
cytokine B-MISC B-MISC
mRNA I-MISC I-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
was O-MISC O-MISC
suppressed O-MISC O-MISC
by O-MISC O-MISC
CS O-MISC O-MISC
. O-MISC O-MISC

NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
CS O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
CS O-MISC B-MISC
has O-MISC O-MISC
a O-MISC O-MISC
suppressive O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
proinflammatory O-MISC O-MISC
cytokine O-MISC I-MISC
production O-MISC O-MISC
from O-MISC O-MISC
monocytes O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
this O-MISC O-MISC
effect O-MISC O-MISC
is O-MISC O-MISC
based O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
cytokine B-MISC B-MISC
mRNA I-MISC O-MISC
expression O-MISC O-MISC
through O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Elevated O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
differentiation B-MISC B-MISC
inhibitory I-MISC I-MISC
factor I-MISC I-MISC
nm23 I-MISC I-MISC
mRNA I-MISC I-MISC
in O-MISC O-MISC
monoblastic O-MISC O-MISC
crisis O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
patient O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
myelogenous O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Differentiation B-MISC O-MISC
inhibitory I-MISC B-MISC
factor I-MISC I-MISC
nm23 B-MISC I-MISC
gene I-MISC I-MISC
has O-MISC O-MISC
been O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
high O-MISC O-MISC
quantities O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
myelogenous O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
AML O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
especially O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
monocytic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
AML O-MISC O-MISC
- O-MISC O-MISC
M5 O-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
suggested O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
prognostic O-MISC O-MISC
factor O-MISC O-MISC
in O-MISC O-MISC
AML O-MISC O-MISC
- O-MISC O-MISC
M5 O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
an O-MISC O-MISC
example O-MISC O-MISC
of O-MISC O-MISC
elevated O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
nm23 B-MISC B-MISC
mRNA I-MISC I-MISC
in O-MISC O-MISC
a O-MISC O-MISC
patient O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
myelogenous O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
CML O-MISC O-MISC
) O-MISC O-MISC
who O-MISC O-MISC
developed O-MISC O-MISC
monoblastic O-MISC O-MISC
crisis O-MISC O-MISC
. O-MISC O-MISC

Relative O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
nm23 B-MISC B-MISC
- I-MISC I-MISC
H1 I-MISC I-MISC
and I-MISC I-MISC
- I-MISC I-MISC
H2 I-MISC I-MISC
mRNA I-MISC I-MISC
extracted O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
quantitative O-MISC O-MISC
reverse O-MISC O-MISC
transcriptase O-MISC B-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
nm23 B-MISC B-MISC
- I-MISC I-MISC
H1 I-MISC I-MISC
mRNA I-MISC I-MISC
in O-MISC O-MISC
CML O-MISC O-MISC
cells O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
chronic O-MISC O-MISC
phase O-MISC O-MISC
was O-MISC O-MISC
as O-MISC O-MISC
high O-MISC O-MISC
as O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
healthy O-MISC O-MISC
volunteers O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mRNA O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
nm23 B-MISC B-MISC
- I-MISC I-MISC
H2 I-MISC I-MISC
was O-MISC O-MISC
slightly O-MISC O-MISC
below O-MISC O-MISC
the O-MISC O-MISC
normal O-MISC O-MISC
level O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
blastic O-MISC O-MISC
crisis O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
nm23 B-MISC B-MISC
- I-MISC I-MISC
H1 I-MISC I-MISC
and I-MISC I-MISC
- I-MISC I-MISC
H2 I-MISC I-MISC
mRNA I-MISC I-MISC
was O-MISC O-MISC
elevated O-MISC O-MISC
to O-MISC O-MISC
about O-MISC O-MISC
three O-MISC O-MISC
to O-MISC O-MISC
nine O-MISC O-MISC
times O-MISC O-MISC
of O-MISC O-MISC
that O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
chronic O-MISC O-MISC
phase O-MISC O-MISC
. O-MISC O-MISC

Proliferated O-MISC O-MISC
blastic O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
positive O-MISC O-MISC
for O-MISC O-MISC
non B-MISC O-MISC
- I-MISC O-MISC
specific I-MISC O-MISC
esterase I-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
serum O-MISC B-MISC
lysozyme O-MISC I-MISC
level O-MISC O-MISC
was O-MISC O-MISC
elevated O-MISC O-MISC
and O-MISC O-MISC
diagnosed O-MISC O-MISC
as O-MISC O-MISC
monoblastic O-MISC O-MISC
crisis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
patient O-MISC O-MISC
received O-MISC O-MISC
combined O-MISC O-MISC
chemotherapy O-MISC O-MISC
but O-MISC O-MISC
response O-MISC O-MISC
was O-MISC O-MISC
partial O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
are O-MISC O-MISC
compatible O-MISC O-MISC
with O-MISC O-MISC
our O-MISC O-MISC
previous O-MISC O-MISC
report O-MISC O-MISC
that O-MISC O-MISC
nm23 B-MISC B-MISC
gene I-MISC I-MISC
is O-MISC O-MISC
overexpressed O-MISC O-MISC
in O-MISC O-MISC
monocytic O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Increased O-MISC O-MISC
transcription O-MISC O-MISC
decreases O-MISC O-MISC
the O-MISC O-MISC
spontaneous O-MISC O-MISC
mutation O-MISC O-MISC
rate O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
thymidine B-MISC B-MISC
kinase I-MISC I-MISC
locus I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Transcription O-MISC O-MISC
increases O-MISC O-MISC
DNA O-MISC O-MISC
repair O-MISC O-MISC
efficiency O-MISC O-MISC
and O-MISC O-MISC
modulates O-MISC O-MISC
the O-MISC O-MISC
distribution O-MISC O-MISC
of O-MISC O-MISC
certain O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
DNA O-MISC O-MISC
damage O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
increased O-MISC O-MISC
transcription O-MISC O-MISC
level O-MISC O-MISC
stimulates O-MISC O-MISC
spontaneous O-MISC O-MISC
mutation O-MISC O-MISC
rate O-MISC O-MISC
in O-MISC O-MISC
yeast O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
explored O-MISC O-MISC
whether O-MISC O-MISC
transcription O-MISC O-MISC
level O-MISC O-MISC
affects O-MISC O-MISC
spontaneous O-MISC O-MISC
mutation O-MISC O-MISC
rate O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
first O-MISC O-MISC
developed O-MISC O-MISC
two O-MISC O-MISC
thymidine O-MISC B-MISC
kinase O-MISC I-MISC
( O-MISC O-MISC
tk O-MISC I-MISC
) O-MISC O-MISC
inducible O-MISC O-MISC
human O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
using O-MISC O-MISC
the O-MISC O-MISC
Gal4 O-MISC B-MISC
- O-MISC I-MISC
Estrogen O-MISC I-MISC
receptor O-MISC I-MISC
system O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
our O-MISC O-MISC
TK6i O-MISC B-MISC
- O-MISC I-MISC
G3 O-MISC I-MISC
and O-MISC O-MISC
G9 O-MISC B-MISC
tk O-MISC O-MISC
heterozygous O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
active O-MISC O-MISC
tk B-MISC B-MISC
allele I-MISC I-MISC
is O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
inducible O-MISC B-MISC
promoter B-MISC I-MISC
element I-MISC I-MISC
. O-MISC O-MISC

Tk B-MISC B-MISC
mRNA I-MISC I-MISC
is O-MISC O-MISC
induced O-MISC O-MISC
following O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
estrogen O-MISC O-MISC
. O-MISC O-MISC

Spontaneous O-MISC O-MISC
mutation O-MISC O-MISC
rate O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
decreased O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
after O-MISC O-MISC
induction O-MISC O-MISC
in O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
report O-MISC O-MISC
in O-MISC O-MISC
yeast O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
humans O-MISC O-MISC
may O-MISC O-MISC
have O-MISC O-MISC
evolved O-MISC O-MISC
different O-MISC O-MISC
or O-MISC O-MISC
additional O-MISC O-MISC
mechanisms O-MISC O-MISC
to O-MISC O-MISC
deal O-MISC O-MISC
with O-MISC O-MISC
transcription O-MISC O-MISC
related O-MISC O-MISC
spontaneous O-MISC O-MISC
mutagenesis O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
1998 O-MISC O-MISC
Elsevier O-MISC O-MISC
Science O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
V O-MISC O-MISC
. O-MISC O-MISC

All O-MISC O-MISC
rights O-MISC O-MISC
reserved O-MISC O-MISC
. O-MISC O-MISC

Mutation O-MISC O-MISC
of O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
process O-MISC O-MISC
of O-MISC O-MISC
somatic O-MISC O-MISC
hypermutation O-MISC O-MISC
of O-MISC O-MISC
Ig B-MISC B-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Immunoglobulin B-MISC O-MISC
( I-MISC I-MISC
Ig I-MISC I-MISC
) I-MISC I-MISC
genes I-MISC I-MISC
are O-MISC O-MISC
hypermutated O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
the O-MISC O-MISC
precursors O-MISC O-MISC
to O-MISC O-MISC
memory O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mutations O-MISC O-MISC
are O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
transcription O-MISC O-MISC
initiation O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
non B-MISC B-MISC
- I-MISC I-MISC
Ig I-MISC I-MISC
promoters I-MISC I-MISC
are O-MISC O-MISC
permissible O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
mutation O-MISC O-MISC
process O-MISC O-MISC
; O-MISC O-MISC
thus O-MISC O-MISC
, O-MISC O-MISC
other O-MISC O-MISC
genes O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
mutating O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
may O-MISC O-MISC
also O-MISC O-MISC
be O-MISC O-MISC
subject O-MISC O-MISC
to O-MISC O-MISC
somatic O-MISC O-MISC
hypermutation O-MISC O-MISC
. O-MISC O-MISC

Significant O-MISC O-MISC
mutations O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
MYC I-MISC I-MISC
, I-MISC I-MISC
S14 I-MISC B-MISC
, I-MISC I-MISC
or I-MISC I-MISC
alpha I-MISC B-MISC
- I-MISC I-MISC
fetoprotein I-MISC I-MISC
( I-MISC I-MISC
AFP I-MISC I-MISC
) I-MISC I-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
was O-MISC O-MISC
highly O-MISC O-MISC
mutated O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
large O-MISC O-MISC
proportion O-MISC O-MISC
of O-MISC O-MISC
memory O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
individuals O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mutation O-MISC O-MISC
pattern O-MISC O-MISC
was O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
Ig B-MISC B-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

CD28 O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
: O-MISC O-MISC
enhanced O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
intermediates O-MISC O-MISC
and O-MISC O-MISC
c O-MISC B-MISC
- O-MISC I-MISC
Rel O-MISC I-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
complete O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
( O-MISC O-MISC
anti O-MISC B-MISC
- O-MISC I-MISC
CD3 O-MISC I-MISC
plus O-MISC O-MISC
anti O-MISC B-MISC
- O-MISC I-MISC
CD28 O-MISC I-MISC
) O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
( O-MISC O-MISC
naive O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
( O-MISC O-MISC
memory O-MISC O-MISC
/ O-MISC O-MISC
effector O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Long O-MISC O-MISC
exposure O-MISC O-MISC
( O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
) O-MISC O-MISC
induced O-MISC O-MISC
stronger O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nuclear B-MISC B-MISC
c I-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
protein I-MISC I-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
after O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC I-MISC
CD3 O-MISC I-MISC
+ O-MISC I-MISC
anti O-MISC O-MISC
- O-MISC I-MISC
CD28 O-MISC I-MISC
stimulation O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
was O-MISC O-MISC
higher O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cytoplasmic B-MISC B-MISC
inhibitor I-MISC I-MISC
IkappaBalpha B-MISC I-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
anti O-MISC B-MISC
- O-MISC I-MISC
CD3 O-MISC I-MISC
+ O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
CD28 O-MISC I-MISC
stimulation O-MISC O-MISC
induced O-MISC O-MISC
a O-MISC O-MISC
long O-MISC O-MISC
- O-MISC O-MISC
lasting O-MISC O-MISC
degradation O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
in O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
the O-MISC O-MISC
degradation O-MISC O-MISC
process O-MISC O-MISC
was O-MISC O-MISC
more O-MISC O-MISC
rapid O-MISC O-MISC
. O-MISC O-MISC

Because O-MISC O-MISC
the O-MISC O-MISC
CD28 B-MISC B-MISC
costimulus O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
intermediates O-MISC O-MISC
( O-MISC O-MISC
ROIs O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
intracellular O-MISC O-MISC
ROI O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
compared O-MISC O-MISC
by O-MISC O-MISC
flow O-MISC O-MISC
cytometry O-MISC O-MISC
. O-MISC O-MISC

ROIs O-MISC O-MISC
were O-MISC O-MISC
produced O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
more O-MISC O-MISC
strongly O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
data O-MISC O-MISC
presented O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
further O-MISC O-MISC
emphasize O-MISC O-MISC
the O-MISC O-MISC
differences O-MISC O-MISC
between O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
in O-MISC O-MISC
ROI O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

Non O-MISC O-MISC
- O-MISC O-MISC
Hodgkin O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
lymphoma O-MISC O-MISC
involving O-MISC O-MISC
bilateral O-MISC O-MISC
breasts O-MISC O-MISC
[ O-MISC O-MISC
see O-MISC O-MISC
comments O-MISC O-MISC
] O-MISC O-MISC

We O-MISC O-MISC
describe O-MISC O-MISC
here O-MISC O-MISC
two O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
diffuse O-MISC O-MISC
large O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
Hodgkin O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
lymphoma O-MISC O-MISC
affecting O-MISC O-MISC
the O-MISC O-MISC
bilateral O-MISC O-MISC
breasts O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
contralateral O-MISC O-MISC
tumor O-MISC O-MISC
in O-MISC O-MISC
one O-MISC O-MISC
case O-MISC O-MISC
appeared O-MISC O-MISC
17 O-MISC O-MISC
months O-MISC O-MISC
after O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
mastectomy O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
the O-MISC O-MISC
bilateral O-MISC O-MISC
tumors O-MISC O-MISC
occurred O-MISC O-MISC
concurrently O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
patient O-MISC O-MISC
who O-MISC O-MISC
was O-MISC O-MISC
pregnant O-MISC O-MISC
and O-MISC O-MISC
showed O-MISC O-MISC
widespread O-MISC O-MISC
dissemination O-MISC O-MISC
at O-MISC O-MISC
initial O-MISC O-MISC
presentation O-MISC O-MISC
. O-MISC O-MISC

Lymphoma O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
both O-MISC O-MISC
cases O-MISC O-MISC
showed O-MISC O-MISC
the O-MISC O-MISC
mature O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
immunophenotype O-MISC O-MISC
and O-MISC O-MISC
had O-MISC O-MISC
rearrangements O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
BCL6 B-MISC B-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
patients O-MISC O-MISC
developed O-MISC O-MISC
progressive O-MISC O-MISC
disease O-MISC O-MISC
despite O-MISC O-MISC
chemo O-MISC O-MISC
- O-MISC O-MISC
radiotherapy O-MISC O-MISC
and O-MISC O-MISC
died O-MISC O-MISC
of O-MISC O-MISC
leukemic O-MISC O-MISC
manifestations O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
were O-MISC O-MISC
no O-MISC O-MISC
apparent O-MISC O-MISC
pathological O-MISC O-MISC
features O-MISC O-MISC
of O-MISC O-MISC
lymphomas O-MISC O-MISC
of O-MISC O-MISC
mucosa O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
lymphoid O-MISC O-MISC
tissue O-MISC O-MISC
origin O-MISC O-MISC

Biochemical O-MISC O-MISC
characterization O-MISC O-MISC
of O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
alpha I-MISC I-MISC
nuclear I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

A O-MISC O-MISC
family O-MISC O-MISC
of O-MISC O-MISC
hematopoietic B-MISC B-MISC
specific I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
, O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
alpha I-MISC I-MISC
nuclear I-MISC I-MISC
protein I-MISC I-MISC
( I-MISC I-MISC
MNP I-MISC I-MISC
) I-MISC I-MISC
family I-MISC I-MISC
, O-MISC O-MISC
has O-MISC O-MISC
recently O-MISC O-MISC
been O-MISC O-MISC
identified O-MISC O-MISC
. O-MISC O-MISC

They O-MISC O-MISC
are O-MISC O-MISC
intimately O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
regulating O-MISC O-MISC
the O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
huMIP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
alpha I-MISC I-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
transformed O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

One O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
family O-MISC O-MISC
( O-MISC O-MISC
MNP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
another O-MISC O-MISC
( O-MISC O-MISC
MNP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
full O-MISC O-MISC
promotor O-MISC B-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
third O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
family O-MISC O-MISC
( O-MISC O-MISC
MNP B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
PMA O-MISC O-MISC
induced O-MISC O-MISC
HL60 O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
probably O-MISC O-MISC
has O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
monocyte O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
communication O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
by O-MISC O-MISC
two O-MISC O-MISC
techniques O-MISC O-MISC
that O-MISC O-MISC
MNP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
MNP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
are O-MISC O-MISC
distinct O-MISC O-MISC
but O-MISC O-MISC
related O-MISC O-MISC
factors O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
we O-MISC O-MISC
present O-MISC O-MISC
further O-MISC O-MISC
evidence O-MISC O-MISC
to O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
MNP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
acts O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
heterodimer B-MISC B-MISC
. O-MISC O-MISC

Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
are O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
granulocyte B-MISC B-MISC
- I-MISC I-MISC
macrophage I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
and O-MISC O-MISC
erythropoietin B-MISC B-MISC
in O-MISC O-MISC
proliferating O-MISC O-MISC
human O-MISC O-MISC
erythroid O-MISC O-MISC
precursors O-MISC O-MISC
. O-MISC O-MISC

Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
proto B-MISC B-MISC
- I-MISC I-MISC
oncogene I-MISC I-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
chromosomal O-MISC O-MISC
translocation O-MISC O-MISC
t B-MISC O-MISC
( I-MISC O-MISC
14 I-MISC O-MISC
; I-MISC O-MISC
19 I-MISC O-MISC
) I-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
some O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
lymphocytic O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
shares O-MISC O-MISC
structural O-MISC O-MISC
similarities O-MISC O-MISC
with O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IkappaB B-MISC B-MISC
family I-MISC I-MISC
of O-MISC O-MISC
proteins O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
report O-MISC O-MISC
, O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
in O-MISC O-MISC
hematopoietic O-MISC O-MISC
growth O-MISC I-MISC
factor O-MISC I-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
erythroid O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
was O-MISC O-MISC
examined O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
TF O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
erythroleukemia O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
granulocyte B-MISC O-MISC
- I-MISC O-MISC
macrophage I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
erythropoietin B-MISC B-MISC
( O-MISC O-MISC
Epo B-MISC B-MISC
) O-MISC O-MISC
greatly O-MISC O-MISC
enhanced O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
at O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
protein O-MISC O-MISC
and O-MISC O-MISC
mRNA O-MISC B-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
association O-MISC O-MISC
with O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
protein O-MISC I-MISC
was O-MISC O-MISC
also O-MISC O-MISC
highly O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
early O-MISC O-MISC
burst O-MISC O-MISC
- O-MISC O-MISC
forming O-MISC O-MISC
unit O-MISC O-MISC
- O-MISC O-MISC
erythroid O-MISC O-MISC
( O-MISC O-MISC
BFU O-MISC B-MISC
- O-MISC O-MISC
E O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
erythroid O-MISC O-MISC
precursors O-MISC O-MISC
( O-MISC O-MISC
day O-MISC O-MISC
7 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
decreased O-MISC O-MISC
during O-MISC O-MISC
maturation O-MISC O-MISC
( O-MISC O-MISC
days O-MISC O-MISC
10 O-MISC O-MISC
and O-MISC O-MISC
14 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
erythroid O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
these O-MISC O-MISC
hematopoietic O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
was O-MISC O-MISC
hyperphosphorylated O-MISC O-MISC
. O-MISC O-MISC

GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
and O-MISC O-MISC
Epo B-MISC B-MISC
modulated O-MISC O-MISC
the O-MISC O-MISC
subcellular O-MISC O-MISC
localization O-MISC O-MISC
of O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
. O-MISC O-MISC

Upon O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
TF O-MISC B-MISC
- O-MISC O-MISC
1 O-MISC I-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
or O-MISC O-MISC
Epo B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
was O-MISC O-MISC
dramatically O-MISC O-MISC
enhanced O-MISC O-MISC
. O-MISC O-MISC

Overexpression O-MISC O-MISC
of O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
in O-MISC O-MISC
TF O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
transient O-MISC O-MISC
transfection O-MISC O-MISC
along O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
factors I-MISC I-MISC
p50 I-MISC B-MISC
or I-MISC O-MISC
p52 I-MISC B-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
significant O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
human B-MISC B-MISC
immunodeficiency I-MISC I-MISC
virus I-MISC I-MISC
- I-MISC I-MISC
type I-MISC I-MISC
1 I-MISC I-MISC
( I-MISC I-MISC
HIV I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
TATA I-MISC I-MISC
- I-MISC I-MISC
luceriferase I-MISC I-MISC
reporter I-MISC I-MISC
plasmid I-MISC I-MISC
, O-MISC O-MISC
demonstrating O-MISC O-MISC
that O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
has O-MISC O-MISC
a O-MISC O-MISC
positive O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
transactivation O-MISC O-MISC
of O-MISC O-MISC
kappaB B-MISC B-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
erythroid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Stimulation O-MISC O-MISC
with O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
enhanced O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
myb I-MISC I-MISC
mRNA I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
in O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
of O-MISC O-MISC
TF O-MISC B-MISC
- O-MISC O-MISC
1 O-MISC I-MISC
cells O-MISC O-MISC
bound O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
kappaB B-MISC B-MISC
enhancer I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
myb I-MISC I-MISC
promoter I-MISC I-MISC
together O-MISC O-MISC
with O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB2 I-MISC I-MISC
/ I-MISC I-MISC
p52 I-MISC I-MISC
and O-MISC O-MISC
this O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
enhanced O-MISC O-MISC
by O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
cotransfection O-MISC O-MISC
of O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
with O-MISC O-MISC
p52 B-MISC B-MISC
or O-MISC O-MISC
p50 B-MISC B-MISC
in O-MISC O-MISC
TF O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
significant O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
myb I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
TATA I-MISC I-MISC
- I-MISC I-MISC
luceriferase I-MISC I-MISC
reporter I-MISC I-MISC
plasmid I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
may O-MISC O-MISC
participate O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
certain O-MISC O-MISC
kappaB B-MISC B-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
genes I-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
hematopoiesis O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
myb I-MISC I-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
1998 O-MISC O-MISC
by O-MISC O-MISC
The O-MISC O-MISC
American O-MISC O-MISC
Society O-MISC O-MISC
of O-MISC O-MISC
Hematology O-MISC O-MISC
. O-MISC O-MISC

5 B-MISC O-MISC
- I-MISC O-MISC
Lipoxygenase I-MISC O-MISC
compartmentalization O-MISC O-MISC
in O-MISC O-MISC
granulocytic O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
modulated O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
internal B-MISC O-MISC
bipartite I-MISC O-MISC
nuclear I-MISC O-MISC
localizing I-MISC I-MISC
sequence I-MISC I-MISC
and O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
complex I-MISC I-MISC
formation O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
region O-MISC O-MISC
of O-MISC O-MISC
basic O-MISC B-MISC
amino O-MISC I-MISC
acids O-MISC I-MISC
spanning O-MISC O-MISC
residues B-MISC O-MISC
639 I-MISC B-MISC
- I-MISC I-MISC
656 I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
5 I-MISC I-MISC
- I-MISC I-MISC
lipoxygenase I-MISC I-MISC
sequence I-MISC I-MISC
resembles O-MISC O-MISC
a O-MISC O-MISC
consensus B-MISC B-MISC
bipartite I-MISC O-MISC
nuclear I-MISC O-MISC
localizing I-MISC O-MISC
sequence I-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
synthetic O-MISC O-MISC
peptide O-MISC O-MISC
consisting O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Kaposi B-MISC O-MISC
fibroblast I-MISC O-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
signal I-MISC I-MISC
sequence I-MISC I-MISC
fused O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC B-MISC
- I-MISC I-MISC
lipoxygenase639 I-MISC I-MISC
- I-MISC I-MISC
656 I-MISC I-MISC
bipartite I-MISC O-MISC
nuclear I-MISC O-MISC
localizing I-MISC O-MISC
sequence I-MISC O-MISC
has O-MISC O-MISC
a O-MISC O-MISC
prominent O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
5 B-MISC B-MISC
- I-MISC I-MISC
lipoxygenase I-MISC I-MISC
catalysis O-MISC I-MISC
in O-MISC O-MISC
granulocytic O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
calcium O-MISC O-MISC
ionophor O-MISC O-MISC
A23187 O-MISC O-MISC
. O-MISC O-MISC

Recombinant O-MISC B-MISC
5 B-MISC I-MISC
- I-MISC I-MISC
lipoxygenase I-MISC I-MISC
was O-MISC O-MISC
not O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
peptide O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
peptide O-MISC O-MISC
also O-MISC O-MISC
inhibited O-MISC O-MISC
redistribution O-MISC O-MISC
of O-MISC O-MISC
5 B-MISC B-MISC
- I-MISC I-MISC
lipoxygenase I-MISC I-MISC
from O-MISC O-MISC
the O-MISC O-MISC
cytosol O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
membrane O-MISC O-MISC
of O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
stimulated O-MISC O-MISC
by O-MISC O-MISC
A23187 O-MISC O-MISC
. O-MISC O-MISC

5 B-MISC O-MISC
- I-MISC I-MISC
Lipoxygenase I-MISC I-MISC
protein I-MISC I-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
kappaB I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) I-MISC I-MISC
p65 I-MISC I-MISC
subunit I-MISC I-MISC
immunoprecipitate O-MISC O-MISC
fractions O-MISC O-MISC
prepared O-MISC O-MISC
from O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cell O-MISC O-MISC
lysates O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
5 B-MISC B-MISC
- I-MISC I-MISC
lipoxygenase I-MISC I-MISC
protein I-MISC I-MISC
coimmunoprecipitated O-MISC O-MISC
by O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
antiserum O-MISC O-MISC
was O-MISC O-MISC
increased O-MISC O-MISC
following O-MISC O-MISC
A23187 O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
cells O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
agents O-MISC O-MISC
that O-MISC O-MISC
block O-MISC O-MISC
5 B-MISC B-MISC
- I-MISC I-MISC
lipoxygenase I-MISC I-MISC
translocation O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
, O-MISC O-MISC
5 B-MISC B-MISC
- I-MISC I-MISC
lipoxygenase I-MISC I-MISC
protein O-MISC I-MISC
appearing O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
immunoprecipitate O-MISC O-MISC
was O-MISC O-MISC
diminished O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
implicate O-MISC O-MISC
an O-MISC O-MISC
internal B-MISC O-MISC
bipartite I-MISC B-MISC
nuclear I-MISC I-MISC
localizing I-MISC I-MISC
sequence I-MISC I-MISC
as O-MISC O-MISC
a O-MISC O-MISC
regulatory O-MISC B-MISC
domain O-MISC I-MISC
that O-MISC O-MISC
modulates O-MISC O-MISC
5 B-MISC B-MISC
- I-MISC I-MISC
lipoxygenase I-MISC I-MISC
redistribution O-MISC O-MISC
and O-MISC O-MISC
catalysis O-MISC O-MISC
in O-MISC O-MISC
granulocytic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Additionally O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
molecular O-MISC O-MISC
determinants O-MISC O-MISC
which O-MISC O-MISC
govern O-MISC O-MISC
5 O-MISC B-MISC
- O-MISC I-MISC
lipoxygenase O-MISC I-MISC
and O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
redistribution O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
coordinately O-MISC O-MISC
controlled O-MISC O-MISC
in O-MISC O-MISC
granulocytic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
1998 O-MISC O-MISC
Academic O-MISC O-MISC
Press O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
CD28 O-MISC B-MISC
/ O-MISC I-MISC
CD3 O-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
costimulation O-MISC O-MISC
of O-MISC O-MISC
naive O-MISC O-MISC
and O-MISC O-MISC
memory O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
by O-MISC O-MISC
intracellular O-MISC O-MISC
incorporation O-MISC O-MISC
of O-MISC O-MISC
polyclonal B-MISC B-MISC
antibodies I-MISC I-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
activator B-MISC B-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
transcriptional I-MISC I-MISC
complex I-MISC I-MISC
. O-MISC O-MISC

A O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
indirect O-MISC O-MISC
methods O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
utilized O-MISC O-MISC
in O-MISC O-MISC
demonstrating O-MISC O-MISC
activator B-MISC B-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
transcription O-MISC I-MISC
factor O-MISC I-MISC
function O-MISC O-MISC
in O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
promoter O-MISC I-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
no O-MISC O-MISC
direct O-MISC O-MISC
demonstration O-MISC O-MISC
that O-MISC O-MISC
activator B-MISC O-MISC
protein I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
CD28 O-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
costimulation O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
transcription O-MISC O-MISC
in O-MISC O-MISC
freshly O-MISC O-MISC
isolated O-MISC O-MISC
naive O-MISC O-MISC
and O-MISC O-MISC
memory O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
address O-MISC O-MISC
this O-MISC O-MISC
issue O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
method O-MISC O-MISC
of O-MISC O-MISC
scrape O-MISC B-MISC
loading O-MISC O-MISC
was O-MISC O-MISC
applied O-MISC O-MISC
to O-MISC O-MISC
purified O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Since O-MISC O-MISC
scrape O-MISC O-MISC
loading O-MISC O-MISC
relies O-MISC O-MISC
on O-MISC O-MISC
adherent O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
( O-MISC O-MISC
PB O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
immobilized O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
nonspecific O-MISC B-MISC
cell O-MISC I-MISC
attachment O-MISC I-MISC
factor O-MISC I-MISC
poly O-MISC I-MISC
- O-MISC I-MISC
L O-MISC I-MISC
- O-MISC I-MISC
lysine O-MISC O-MISC
. O-MISC O-MISC

Cells O-MISC O-MISC
scraped O-MISC O-MISC
off O-MISC O-MISC
poly O-MISC B-MISC
- O-MISC I-MISC
L O-MISC I-MISC
- O-MISC O-MISC
lysine O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
Ig B-MISC B-MISC
FITC I-MISC I-MISC
efficiently O-MISC O-MISC
incorporated O-MISC O-MISC
Ig O-MISC B-MISC
, O-MISC O-MISC
with O-MISC O-MISC
relatively O-MISC O-MISC
uniform O-MISC O-MISC
fluorescence O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cells O-MISC O-MISC
retained O-MISC O-MISC
their O-MISC O-MISC
physical O-MISC O-MISC
parameters O-MISC O-MISC
as O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
forward O-MISC O-MISC
and O-MISC O-MISC
side O-MISC O-MISC
light O-MISC O-MISC
scatter O-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
functional O-MISC O-MISC
activity O-MISC O-MISC
as O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
costimulation O-MISC O-MISC
of O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
production O-MISC O-MISC
after O-MISC O-MISC
being O-MISC O-MISC
scraped O-MISC O-MISC
off O-MISC O-MISC
this O-MISC O-MISC
substrate O-MISC O-MISC
. O-MISC O-MISC

CD28 O-MISC B-MISC
/ O-MISC I-MISC
CD3 O-MISC I-MISC
- O-MISC O-MISC
costimulated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
produced O-MISC O-MISC
intracellular O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
from O-MISC O-MISC
all O-MISC O-MISC
subsets O-MISC O-MISC
measured O-MISC O-MISC
( O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
CD4 O-MISC O-MISC
- O-MISC O-MISC
, O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
CD45RO O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
production O-MISC O-MISC
and O-MISC O-MISC
intracellular O-MISC O-MISC
accumulation O-MISC O-MISC
in O-MISC O-MISC
nonscraped O-MISC O-MISC
PB O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
activated O-MISC O-MISC
with O-MISC O-MISC
CD28 O-MISC B-MISC
/ O-MISC O-MISC
CD3 O-MISC O-MISC
coligation O-MISC O-MISC
were O-MISC O-MISC
skewed O-MISC O-MISC
favoring O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
subsets O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
was O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
production O-MISC O-MISC
in O-MISC O-MISC
scraped O-MISC O-MISC
PB O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
intracellular O-MISC O-MISC
incorporation O-MISC O-MISC
of O-MISC O-MISC
Abs O-MISC B-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Fos I-MISC I-MISC
and I-MISC I-MISC
c I-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
family I-MISC I-MISC
members I-MISC I-MISC
by O-MISC O-MISC
scrape O-MISC O-MISC
loading O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
and O-MISC O-MISC
intracellular O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
within O-MISC O-MISC
6 O-MISC O-MISC
h O-MISC O-MISC
of O-MISC O-MISC
costimulation O-MISC O-MISC
with O-MISC O-MISC
PMA O-MISC O-MISC
/ O-MISC O-MISC
ionomycin O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
costimulation O-MISC O-MISC
by O-MISC O-MISC
CD28 O-MISC B-MISC
and O-MISC O-MISC
CD3 O-MISC B-MISC
ligation O-MISC O-MISC
. O-MISC O-MISC

Scrape O-MISC O-MISC
loading O-MISC O-MISC
thus O-MISC O-MISC
provides O-MISC O-MISC
an O-MISC O-MISC
efficient O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
intracellular O-MISC O-MISC
incorporation O-MISC O-MISC
of O-MISC O-MISC
macromolecules O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
direct O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Fos I-MISC I-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
are O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
within O-MISC O-MISC
its O-MISC O-MISC
correct O-MISC O-MISC
chromosomal O-MISC O-MISC
context O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
resting O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
lymphocyte O-MISC O-MISC
subpopulations O-MISC O-MISC
. O-MISC O-MISC

Differential O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Nur77 B-MISC B-MISC
family I-MISC I-MISC
members I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lymphotropic O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
: O-MISC O-MISC
transactivation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
TR3 B-MISC B-MISC
/ I-MISC I-MISC
nur77 I-MISC I-MISC
gene I-MISC I-MISC
by O-MISC O-MISC
Tax B-MISC B-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
differential O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
three O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Nur77 B-MISC B-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
family I-MISC I-MISC
by O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lymphotropic O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
Tax B-MISC B-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
Tax O-MISC O-MISC
- O-MISC O-MISC
expressing O-MISC O-MISC
JPX O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
TR3 B-MISC B-MISC
/ I-MISC I-MISC
nur77 I-MISC I-MISC
is O-MISC O-MISC
highly O-MISC O-MISC
expressed O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
neither O-MISC O-MISC
NOR O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
nor O-MISC O-MISC
NOT O-MISC O-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
detectable O-MISC O-MISC
. O-MISC O-MISC

Transient O-MISC O-MISC
transfection O-MISC O-MISC
analysis O-MISC O-MISC
further O-MISC O-MISC
confirmed O-MISC O-MISC
the O-MISC O-MISC
Tax B-MISC B-MISC
transactivation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
TR3 B-MISC B-MISC
/ I-MISC I-MISC
nur77 I-MISC I-MISC
promoter O-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
NOR B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
promoter I-MISC I-MISC
in O-MISC O-MISC
different O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
luciferase B-MISC B-MISC
reporter I-MISC I-MISC
gene I-MISC I-MISC
driven O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
NGFI B-MISC B-MISC
- I-MISC I-MISC
B I-MISC I-MISC
( I-MISC O-MISC
rat I-MISC O-MISC
homolog I-MISC O-MISC
of I-MISC O-MISC
TR3 I-MISC B-MISC
/ I-MISC I-MISC
Nur77 I-MISC I-MISC
) I-MISC O-MISC
response I-MISC I-MISC
element I-MISC I-MISC
( O-MISC O-MISC
NBRE B-MISC B-MISC
) O-MISC O-MISC
provided O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
Tax B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
transactivation O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
functional O-MISC O-MISC
protein O-MISC O-MISC
. O-MISC O-MISC

Cotransfection O-MISC O-MISC
assays O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
TR3 B-MISC B-MISC
/ I-MISC I-MISC
nur77 I-MISC I-MISC
promoter I-MISC I-MISC
sequence I-MISC I-MISC
or O-MISC O-MISC
the O-MISC O-MISC
NBRE B-MISC B-MISC
binding O-MISC I-MISC
motif O-MISC I-MISC
together O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
series O-MISC O-MISC
of O-MISC O-MISC
Tax B-MISC B-MISC
mutants O-MISC I-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
Tax B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
TR3 B-MISC B-MISC
/ I-MISC I-MISC
nur77 I-MISC I-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
CREB B-MISC B-MISC
/ I-MISC I-MISC
ATF I-MISC I-MISC
- I-MISC I-MISC
related I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

Negative O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
heat O-MISC O-MISC
shock O-MISC O-MISC
transcriptional O-MISC O-MISC
response O-MISC O-MISC
by O-MISC O-MISC
HSBP1 B-MISC B-MISC
. O-MISC O-MISC

In O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
stress O-MISC O-MISC
, O-MISC O-MISC
heat B-MISC B-MISC
shock I-MISC I-MISC
factor I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
HSF1 B-MISC B-MISC
) O-MISC O-MISC
acquires O-MISC O-MISC
rapid O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
and O-MISC O-MISC
transient O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
while O-MISC O-MISC
undergoing O-MISC O-MISC
conformational O-MISC O-MISC
transition O-MISC O-MISC
from O-MISC O-MISC
an O-MISC O-MISC
inert O-MISC O-MISC
non B-MISC B-MISC
- I-MISC I-MISC
DNA I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
monomer I-MISC I-MISC
to O-MISC O-MISC
active O-MISC O-MISC
functional O-MISC O-MISC
trimers O-MISC O-MISC
. O-MISC O-MISC

Attenuation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inducible O-MISC O-MISC
transcriptional O-MISC O-MISC
response O-MISC O-MISC
occurs O-MISC O-MISC
during O-MISC O-MISC
heat O-MISC O-MISC
shock O-MISC O-MISC
or O-MISC O-MISC
upon O-MISC O-MISC
recovery O-MISC O-MISC
at O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
stress O-MISC O-MISC
conditions O-MISC O-MISC
and O-MISC O-MISC
involves O-MISC O-MISC
dissociation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
HSF1 B-MISC B-MISC
trimer I-MISC O-MISC
and O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
used O-MISC O-MISC
the O-MISC O-MISC
hydrophobic B-MISC B-MISC
repeats I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
HSF1 B-MISC B-MISC
trimerization O-MISC I-MISC
domain O-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
yeast O-MISC O-MISC
two O-MISC O-MISC
- O-MISC O-MISC
hybrid O-MISC I-MISC
protein O-MISC O-MISC
interaction O-MISC O-MISC
assay O-MISC O-MISC
to O-MISC O-MISC
identify O-MISC O-MISC
heat B-MISC B-MISC
shock I-MISC B-MISC
factor I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
HSBP1 B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
, O-MISC O-MISC
conserved O-MISC B-MISC
, O-MISC O-MISC
76 B-MISC B-MISC
- I-MISC I-MISC
amino I-MISC I-MISC
- I-MISC I-MISC
acid I-MISC I-MISC
protein I-MISC I-MISC
that O-MISC O-MISC
contains O-MISC O-MISC
two O-MISC O-MISC
extended O-MISC O-MISC
arrays O-MISC O-MISC
of O-MISC O-MISC
hydrophobic B-MISC B-MISC
repeats I-MISC I-MISC
that O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
HSF1 B-MISC B-MISC
heptad I-MISC I-MISC
repeats I-MISC I-MISC
. O-MISC O-MISC

HSBP1 B-MISC B-MISC
is O-MISC O-MISC
nuclear O-MISC O-MISC
- O-MISC O-MISC
localized O-MISC O-MISC
and O-MISC O-MISC
interacts O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
active O-MISC O-MISC
trimeric O-MISC O-MISC
state O-MISC O-MISC
of O-MISC O-MISC
HSF1 B-MISC B-MISC
that O-MISC O-MISC
appears O-MISC O-MISC
during O-MISC O-MISC
heat O-MISC O-MISC
shock O-MISC O-MISC
. O-MISC O-MISC

During O-MISC O-MISC
attenuation O-MISC O-MISC
of O-MISC O-MISC
HSF1 B-MISC B-MISC
to O-MISC O-MISC
the O-MISC O-MISC
inert O-MISC O-MISC
monomer O-MISC O-MISC
, O-MISC O-MISC
HSBP1 B-MISC B-MISC
associates O-MISC O-MISC
with O-MISC O-MISC
Hsp70 O-MISC B-MISC
. O-MISC O-MISC

HSBP1 B-MISC B-MISC
negatively O-MISC O-MISC
affects O-MISC O-MISC
HSF1 B-MISC B-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
HSBP1 B-MISC B-MISC
in O-MISC O-MISC
mammalian O-MISC O-MISC
cells O-MISC O-MISC
represses O-MISC O-MISC
the O-MISC O-MISC
transactivation O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
HSF1 B-MISC B-MISC
. O-MISC O-MISC

To O-MISC O-MISC
establish O-MISC O-MISC
a O-MISC O-MISC
biological O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
HSBP1 B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
homologous O-MISC O-MISC
Caenorhabditis B-MISC B-MISC
elegans I-MISC O-MISC
protein I-MISC O-MISC
was O-MISC O-MISC
overexpressed O-MISC O-MISC
in O-MISC O-MISC
body O-MISC O-MISC
wall O-MISC O-MISC
muscle O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
block O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
heat O-MISC O-MISC
shock O-MISC O-MISC
response O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
heat B-MISC B-MISC
shock I-MISC I-MISC
promoter I-MISC I-MISC
- I-MISC I-MISC
reporter I-MISC I-MISC
construct I-MISC I-MISC
. O-MISC O-MISC

Alteration O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
HSBP1 B-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
C O-MISC B-MISC
. O-MISC O-MISC
elegans O-MISC O-MISC
has O-MISC O-MISC
severe O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
survival O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
animals O-MISC O-MISC
after O-MISC O-MISC
thermal O-MISC O-MISC
and O-MISC O-MISC
chemical O-MISC O-MISC
stress O-MISC O-MISC
, O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
HSBP1 B-MISC B-MISC
as O-MISC O-MISC
a O-MISC O-MISC
negative O-MISC O-MISC
regulator O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
heat O-MISC O-MISC
shock O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Long O-MISC O-MISC
- O-MISC O-MISC
range O-MISC O-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Most O-MISC O-MISC
studies O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
have O-MISC O-MISC
involved O-MISC O-MISC
the O-MISC O-MISC
functional O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
proximal B-MISC B-MISC
promoters I-MISC I-MISC
. O-MISC O-MISC

Recent O-MISC O-MISC
work O-MISC O-MISC
has O-MISC O-MISC
identified O-MISC O-MISC
distal B-MISC B-MISC
elements I-MISC I-MISC
that O-MISC O-MISC
mediate O-MISC O-MISC
long O-MISC I-MISC
- O-MISC I-MISC
range O-MISC O-MISC
cytokine O-MISC B-MISC
gene O-MISC I-MISC
regulation O-MISC O-MISC
and O-MISC O-MISC
has O-MISC O-MISC
implicated O-MISC O-MISC
chromatin O-MISC O-MISC
reorganization O-MISC O-MISC
in O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
cytokine B-MISC B-MISC
gene I-MISC I-MISC
loci I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
studies O-MISC O-MISC
have O-MISC O-MISC
begun O-MISC O-MISC
to O-MISC O-MISC
elucidate O-MISC O-MISC
the O-MISC O-MISC
basis O-MISC O-MISC
for O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
specificity O-MISC O-MISC
and O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
level O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
cytokine B-MISC B-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

A O-MISC O-MISC
signaling O-MISC O-MISC
complex O-MISC O-MISC
of O-MISC O-MISC
Ca2 B-MISC B-MISC
+ I-MISC I-MISC
- I-MISC I-MISC
calmodulin I-MISC I-MISC
- I-MISC I-MISC
dependent I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
IV I-MISC I-MISC
and O-MISC O-MISC
protein B-MISC B-MISC
phosphatase I-MISC B-MISC
2A I-MISC I-MISC
[ O-MISC O-MISC
see O-MISC O-MISC
comments O-MISC O-MISC
] O-MISC O-MISC

Stimulation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
rapid O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
intracellular O-MISC O-MISC
calcium O-MISC O-MISC
concentration O-MISC O-MISC
( O-MISC O-MISC
[ O-MISC O-MISC
Ca2 O-MISC O-MISC
+ O-MISC O-MISC
] O-MISC O-MISC
i O-MISC O-MISC
) O-MISC O-MISC
that O-MISC O-MISC
parallels O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Ca2 B-MISC B-MISC
+ I-MISC I-MISC
- I-MISC I-MISC
calmodulin I-MISC I-MISC
- I-MISC I-MISC
dependent I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
IV I-MISC I-MISC
( O-MISC O-MISC
CaMKIV B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
nuclear B-MISC O-MISC
enzyme I-MISC I-MISC
that O-MISC O-MISC
can O-MISC O-MISC
phosphorylate O-MISC O-MISC
and O-MISC O-MISC
activate O-MISC O-MISC
the O-MISC O-MISC
cyclic B-MISC O-MISC
adenosine I-MISC I-MISC
monophosphate I-MISC I-MISC
( I-MISC I-MISC
cAMP I-MISC I-MISC
) I-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
CREB B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
inactivation O-MISC O-MISC
of O-MISC O-MISC
CaMKIV B-MISC B-MISC
occurs O-MISC O-MISC
despite O-MISC O-MISC
the O-MISC O-MISC
sustained O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
[ O-MISC O-MISC
Ca2 O-MISC O-MISC
+ O-MISC O-MISC
] O-MISC O-MISC
i O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
stable O-MISC O-MISC
and O-MISC O-MISC
stoichiometric O-MISC B-MISC
complex O-MISC I-MISC
of O-MISC O-MISC
CaMKIV B-MISC B-MISC
with O-MISC O-MISC
protein B-MISC O-MISC
serine I-MISC O-MISC
- I-MISC I-MISC
threonine I-MISC I-MISC
phosphatase I-MISC I-MISC
2A I-MISC I-MISC
( O-MISC O-MISC
PP2A B-MISC B-MISC
) O-MISC O-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
PP2A B-MISC B-MISC
dephosphorylates O-MISC O-MISC
CaMKIV B-MISC B-MISC
and O-MISC O-MISC
functions O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
negative O-MISC O-MISC
regulator O-MISC O-MISC
of O-MISC O-MISC
CaMKIV B-MISC B-MISC
signaling O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
PP2A B-MISC B-MISC
activity O-MISC O-MISC
by O-MISC O-MISC
small O-MISC O-MISC
t O-MISC O-MISC
antigen O-MISC O-MISC
enhanced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
transcription O-MISC O-MISC
by O-MISC O-MISC
CaMKIV B-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
reveal O-MISC O-MISC
an O-MISC O-MISC
intracellular O-MISC O-MISC
signaling O-MISC O-MISC
mechanism O-MISC O-MISC
whereby O-MISC O-MISC
a O-MISC O-MISC
protein B-MISC B-MISC
serine I-MISC B-MISC
- I-MISC I-MISC
threonine I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
CaMKIV B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
tightly O-MISC O-MISC
associated O-MISC O-MISC
protein B-MISC I-MISC
serine I-MISC I-MISC
- I-MISC I-MISC
threonine I-MISC I-MISC
phosphatase I-MISC B-MISC
( O-MISC O-MISC
PP2A B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Hypoxia O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulates O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
: O-MISC O-MISC
implications O-MISC O-MISC
for O-MISC O-MISC
macrophage O-MISC O-MISC
distribution O-MISC O-MISC
in O-MISC O-MISC
tumors O-MISC O-MISC
. O-MISC O-MISC

Monocyte B-MISC O-MISC
chemoattractant I-MISC B-MISC
protein I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
likely O-MISC O-MISC
to O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
macrophage O-MISC O-MISC
infiltrate O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
ovarian O-MISC O-MISC
carcinomas O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
predominantly O-MISC O-MISC
expressed O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC O-MISC
parenchyma O-MISC O-MISC
, O-MISC O-MISC
macrophages O-MISC O-MISC
accumulate O-MISC O-MISC
at O-MISC O-MISC
highest O-MISC O-MISC
density O-MISC O-MISC
in O-MISC O-MISC
necrotic O-MISC O-MISC
regions O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
low O-MISC O-MISC
oxygen O-MISC O-MISC
tensions O-MISC O-MISC
. O-MISC O-MISC

Tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
can O-MISC O-MISC
stimulate O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
production O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
present O-MISC O-MISC
within O-MISC O-MISC
ovarian O-MISC O-MISC
carcinomas O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
hypoxia O-MISC O-MISC
both O-MISC O-MISC
on O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
ovarian O-MISC O-MISC
cancer O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
and O-MISC O-MISC
monocyte O-MISC O-MISC
migration O-MISC O-MISC
. O-MISC O-MISC

Hypoxia O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- I-MISC O-MISC
induced I-MISC O-MISC
MCP I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
production O-MISC O-MISC
by O-MISC O-MISC
ovarian O-MISC O-MISC
cancer O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effect O-MISC O-MISC
was O-MISC O-MISC
mimicked O-MISC O-MISC
by O-MISC O-MISC
cobalt O-MISC O-MISC
chloride O-MISC O-MISC
and O-MISC O-MISC
desferrioxamine O-MISC O-MISC
, O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC O-MISC
oxygen O-MISC O-MISC
- O-MISC O-MISC
sensing O-MISC O-MISC
mechanism O-MISC O-MISC
. O-MISC O-MISC

Unlike O-MISC O-MISC
antioxidants O-MISC O-MISC
, O-MISC O-MISC
hypoxia O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
inhibit O-MISC O-MISC
nuclear O-MISC B-MISC
factor O-MISC I-MISC
KB O-MISC I-MISC
mobilization O-MISC O-MISC
. O-MISC O-MISC

Monocyte O-MISC O-MISC
migration O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
was O-MISC O-MISC
also O-MISC O-MISC
diminished O-MISC O-MISC
under O-MISC O-MISC
hypoxic O-MISC O-MISC
conditions O-MISC O-MISC
. O-MISC O-MISC

Down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
monocyte O-MISC O-MISC
migration O-MISC O-MISC
are O-MISC O-MISC
independent O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
hypoxia O-MISC O-MISC
that O-MISC O-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
distribution O-MISC O-MISC
of O-MISC O-MISC
macrophages O-MISC O-MISC
within O-MISC O-MISC
ovarian O-MISC O-MISC
tumors O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
inflammatory O-MISC O-MISC
bowel O-MISC O-MISC
disease O-MISC O-MISC
[ O-MISC O-MISC
see O-MISC O-MISC
comments O-MISC O-MISC
] O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
Expression O-MISC O-MISC
of O-MISC O-MISC
pro B-MISC B-MISC
- I-MISC I-MISC
inflammatory I-MISC I-MISC
cytokines I-MISC I-MISC
is O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
intestinal O-MISC O-MISC
lamina O-MISC O-MISC
propria O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
inflammatory O-MISC O-MISC
bowel O-MISC O-MISC
disease O-MISC O-MISC
( O-MISC O-MISC
IBD O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Nuclear B-MISC B-MISC
factor I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
) O-MISC O-MISC
controls O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
inflammation B-MISC O-MISC
genes I-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
is O-MISC O-MISC
rapidly O-MISC O-MISC
released O-MISC O-MISC
from O-MISC O-MISC
its O-MISC O-MISC
cytoplasmic B-MISC O-MISC
inhibitor I-MISC I-MISC
( O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
transmigrates O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
DNA B-MISC B-MISC
response I-MISC I-MISC
elements I-MISC I-MISC
in O-MISC I-MISC
gene O-MISC I-MISC
promoter O-MISC I-MISC
regions O-MISC I-MISC
. O-MISC O-MISC

AIMS O-MISC O-MISC
: O-MISC O-MISC
To O-MISC O-MISC
investigate O-MISC O-MISC
whether O-MISC O-MISC
increased O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
is O-MISC O-MISC
important O-MISC O-MISC
in O-MISC O-MISC
IBD O-MISC B-MISC
and O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
was O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
western O-MISC O-MISC
blot O-MISC O-MISC
assessment O-MISC O-MISC
and O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
of O-MISC O-MISC
colonic O-MISC O-MISC
biopsy O-MISC O-MISC
samples O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
lamina O-MISC O-MISC
propria O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Nuclear O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
p65 B-MISC B-MISC
are O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
lamina O-MISC O-MISC
propria O-MISC O-MISC
biopsy O-MISC O-MISC
specimens O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
Crohn O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
disease O-MISC O-MISC
in O-MISC O-MISC
comparison O-MISC O-MISC
with O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
ulcerative O-MISC O-MISC
colitis O-MISC O-MISC
and O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

Increased O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
lamina O-MISC O-MISC
propria O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
active O-MISC O-MISC
IBD O-MISC B-MISC
. O-MISC O-MISC

Corticosteroids O-MISC O-MISC
strongly O-MISC O-MISC
inhibit O-MISC O-MISC
intestinal O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
IBD O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
by O-MISC O-MISC
stabilising O-MISC O-MISC
the O-MISC O-MISC
cytosolic B-MISC O-MISC
inhibitor I-MISC I-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha O-MISC I-MISC
against O-MISC O-MISC
activation O-MISC O-MISC
induced O-MISC O-MISC
degradation O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
In O-MISC O-MISC
both O-MISC O-MISC
IBDs O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
particularly O-MISC O-MISC
Crohn O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
disease O-MISC O-MISC
, O-MISC O-MISC
increased O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
may O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
may O-MISC O-MISC
represent O-MISC O-MISC
a O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
steroids O-MISC O-MISC
exert O-MISC O-MISC
an O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
effect O-MISC O-MISC
in O-MISC O-MISC
IBD O-MISC B-MISC

Insufficient O-MISC O-MISC
glycemic O-MISC O-MISC
control O-MISC O-MISC
increases O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
diabetes O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
The O-MISC O-MISC
redox B-MISC B-MISC
- I-MISC I-MISC
sensitive I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
nuclear I-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
believed O-MISC O-MISC
to O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
late O-MISC O-MISC
diabetic O-MISC O-MISC
complications O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
unknown O-MISC O-MISC
whether O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
is O-MISC O-MISC
influenced O-MISC O-MISC
by O-MISC O-MISC
glycemic O-MISC O-MISC
control O-MISC O-MISC
. O-MISC O-MISC

RESEARCH O-MISC O-MISC
DESIGN O-MISC O-MISC
AND O-MISC O-MISC
METHODS O-MISC O-MISC
: O-MISC O-MISC
To O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
is O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
insufficient O-MISC O-MISC
glycemic O-MISC O-MISC
control O-MISC O-MISC
( O-MISC O-MISC
HbA1c O-MISC O-MISC
> O-MISC O-MISC
10 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
developed O-MISC O-MISC
a O-MISC O-MISC
tissue O-MISC O-MISC
culture O-MISC O-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
( O-MISC O-MISC
EMSA O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
based O-MISC O-MISC
semiquantitative O-MISC O-MISC
detection O-MISC O-MISC
system O-MISC O-MISC
that O-MISC O-MISC
allowed O-MISC O-MISC
us O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
ex O-MISC O-MISC
vivo O-MISC O-MISC
- O-MISC O-MISC
isolated O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
PBMCs O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
included O-MISC O-MISC
43 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
diabetes O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
sectional O-MISC O-MISC
study O-MISC O-MISC
. O-MISC O-MISC

10 O-MISC O-MISC
of O-MISC O-MISC
those O-MISC O-MISC
received O-MISC O-MISC
the O-MISC O-MISC
antioxidant O-MISC O-MISC
thioctic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
600 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
day O-MISC O-MISC
p O-MISC O-MISC
. O-MISC O-MISC
o O-MISC O-MISC
. O-MISC O-MISC
) O-MISC O-MISC
for O-MISC O-MISC
2 O-MISC O-MISC
weeks O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Monocytes O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
HbA1c O-MISC B-MISC
levels O-MISC O-MISC
> O-MISC O-MISC
10 O-MISC O-MISC
% O-MISC O-MISC
demonstrated O-MISC O-MISC
significantly O-MISC O-MISC
higher O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
an O-MISC O-MISC
EMSA O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
stronger O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
staining O-MISC O-MISC
in O-MISC O-MISC
immunohistochemistry O-MISC O-MISC
than O-MISC O-MISC
monocytes O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
HbA1c O-MISC B-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
% O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
plasmatic O-MISC O-MISC
markers O-MISC O-MISC
of O-MISC O-MISC
lipid O-MISC O-MISC
peroxidation O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
antioxidant O-MISC O-MISC
thioctic O-MISC O-MISC
acid O-MISC O-MISC
decreased O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
Hyperglycemia O-MISC O-MISC
induces O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription O-MISC B-MISC
factor O-MISC I-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
in O-MISC O-MISC
ex O-MISC O-MISC
vivo O-MISC O-MISC
- O-MISC O-MISC
isolated O-MISC O-MISC
PBMCs O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
diabetes O-MISC O-MISC
. O-MISC O-MISC

NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
is O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
partially O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
oxidative O-MISC O-MISC
stress O-MISC O-MISC
, O-MISC O-MISC
since O-MISC O-MISC
the O-MISC O-MISC
antioxidant O-MISC O-MISC
thioctic O-MISC O-MISC
acid O-MISC O-MISC
significantly O-MISC O-MISC
lowered O-MISC O-MISC
the O-MISC O-MISC
extent O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Synergistic O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
MAP B-MISC B-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
ERK1 B-MISC B-MISC
/ I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
by O-MISC O-MISC
erythropoietin B-MISC O-MISC
and O-MISC O-MISC
stem B-MISC B-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
expanded O-MISC O-MISC
erythropoiesis O-MISC O-MISC
. O-MISC O-MISC

Stem B-MISC B-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
SCF B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
erythropoietin B-MISC B-MISC
( O-MISC O-MISC
EPO B-MISC B-MISC
) O-MISC O-MISC
work O-MISC O-MISC
synergistically O-MISC O-MISC
to O-MISC O-MISC
support O-MISC O-MISC
erythropoiesis O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
this O-MISC O-MISC
synergism O-MISC O-MISC
is O-MISC O-MISC
unknown O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
using O-MISC O-MISC
purified O-MISC O-MISC
human O-MISC O-MISC
erythroid O-MISC O-MISC
colony O-MISC O-MISC
- O-MISC O-MISC
forming O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
ECFC O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
SCF B-MISC B-MISC
and O-MISC O-MISC
EPO B-MISC B-MISC
synergistically O-MISC O-MISC
activate O-MISC O-MISC
MAP B-MISC B-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
MAPK B-MISC B-MISC
, O-MISC O-MISC
ERK1 B-MISC B-MISC
/ I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
correlates O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
and O-MISC O-MISC
thus O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
synergistic O-MISC O-MISC
effects O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
PD98059 O-MISC O-MISC
and O-MISC O-MISC
wortmannin O-MISC O-MISC
, O-MISC O-MISC
inhibitors O-MISC O-MISC
of O-MISC O-MISC
MEK B-MISC B-MISC
and O-MISC O-MISC
PI B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
kinase I-MISC I-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
, O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
synergistic O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
MAPK B-MISC B-MISC
and O-MISC O-MISC
also O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
, O-MISC O-MISC
further O-MISC O-MISC
supporting O-MISC O-MISC
this O-MISC O-MISC
conclusion O-MISC O-MISC
. O-MISC O-MISC

Wortmannin O-MISC O-MISC
only O-MISC O-MISC
inhibits O-MISC O-MISC
MAPK B-MISC B-MISC
activation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
EPO B-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
that O-MISC O-MISC
by O-MISC O-MISC
SCF B-MISC B-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
SCF B-MISC B-MISC
and O-MISC O-MISC
EPO B-MISC B-MISC
may O-MISC O-MISC
activate O-MISC O-MISC
MAPK B-MISC B-MISC
through O-MISC O-MISC
different O-MISC O-MISC
pathways O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
would O-MISC O-MISC
facilitate O-MISC O-MISC
synergy O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
EPO B-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
SCF B-MISC B-MISC
, O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT5 B-MISC B-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
SCF B-MISC B-MISC
and O-MISC O-MISC
wortmannin O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
EPO B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
STAT5 B-MISC B-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
STAT5 B-MISC B-MISC
is O-MISC O-MISC
not O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
synergistic O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
SCF B-MISC B-MISC
and O-MISC O-MISC
EPO B-MISC B-MISC
. O-MISC O-MISC

Together O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
synergistic O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
MAPK B-MISC B-MISC
by O-MISC O-MISC
SCF B-MISC B-MISC
and O-MISC O-MISC
EPO B-MISC B-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
expanded O-MISC O-MISC
erythropoiesis O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
1998 O-MISC O-MISC
by O-MISC O-MISC
The O-MISC O-MISC
American O-MISC O-MISC
Society O-MISC O-MISC
of O-MISC O-MISC
Hematology O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
molecular O-MISC O-MISC
and O-MISC O-MISC
phenotypic O-MISC O-MISC
profile O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
central O-MISC O-MISC
nervous O-MISC O-MISC
system O-MISC O-MISC
lymphoma O-MISC O-MISC
identifies O-MISC O-MISC
distinct O-MISC O-MISC
categories O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
disease O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
histogenetic O-MISC B-MISC
derivation O-MISC O-MISC
from O-MISC O-MISC
germinal O-MISC O-MISC
center O-MISC O-MISC
- O-MISC O-MISC
related O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Primary O-MISC O-MISC
central O-MISC O-MISC
nervous O-MISC O-MISC
system O-MISC O-MISC
lymphoma O-MISC O-MISC
( O-MISC O-MISC
PCNSL O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
cause O-MISC O-MISC
of O-MISC O-MISC
morbidity O-MISC O-MISC
and O-MISC O-MISC
mortality O-MISC O-MISC
among O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
HIV O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
individuals O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
precise O-MISC O-MISC
histogenetic O-MISC O-MISC
derivation O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
PCNSL O-MISC O-MISC
is O-MISC O-MISC
poorly O-MISC O-MISC
understood O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
an O-MISC O-MISC
attempt O-MISC O-MISC
to O-MISC O-MISC
clarify O-MISC O-MISC
the O-MISC O-MISC
histogenesis O-MISC O-MISC
and O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
lymphomas O-MISC O-MISC
, O-MISC O-MISC
49 O-MISC O-MISC
PCNSL O-MISC O-MISC
( O-MISC O-MISC
26 O-MISC O-MISC
acquired O-MISC O-MISC
immunodeficiency O-MISC O-MISC
syndrome O-MISC O-MISC
[ O-MISC O-MISC
AIDS O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
related O-MISC O-MISC
and O-MISC O-MISC
23 O-MISC O-MISC
AIDS O-MISC O-MISC
- O-MISC O-MISC
unrelated O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
analyzed O-MISC O-MISC
for O-MISC O-MISC
multiple O-MISC B-MISC
biologic O-MISC B-MISC
markers O-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
bear O-MISC B-MISC
histogenetic O-MISC B-MISC
and O-MISC O-MISC
pathogenetic O-MISC O-MISC
significance O-MISC O-MISC
for O-MISC O-MISC
mature O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
neoplasms O-MISC O-MISC
. O-MISC O-MISC

PCNSL O-MISC O-MISC
associated O-MISC O-MISC
frequently O-MISC O-MISC
( O-MISC O-MISC
50 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
with O-MISC O-MISC
mutations O-MISC O-MISC
of O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
5 I-MISC I-MISC
' I-MISC I-MISC
noncoding I-MISC I-MISC
regions I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
regarded O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
marker O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
transition O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
germinal O-MISC O-MISC
center O-MISC O-MISC
( O-MISC O-MISC
GC O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
restricted O-MISC O-MISC
to O-MISC O-MISC
GC O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
throughout O-MISC O-MISC
physiologic O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
maturation O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
100 O-MISC O-MISC
% O-MISC O-MISC
AIDS O-MISC O-MISC
- O-MISC O-MISC
unrelated O-MISC O-MISC
PCNSL O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
56 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
% O-MISC O-MISC
AIDS O-MISC O-MISC
- O-MISC O-MISC
related O-MISC O-MISC
cases O-MISC O-MISC
. O-MISC O-MISC

Notably O-MISC O-MISC
, O-MISC O-MISC
among O-MISC O-MISC
AIDS O-MISC O-MISC
- O-MISC O-MISC
related O-MISC O-MISC
PCNSL O-MISC O-MISC
, O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
was O-MISC O-MISC
mutually O-MISC O-MISC
exclusive O-MISC O-MISC
with O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Epstein B-MISC B-MISC
- I-MISC I-MISC
Barr I-MISC I-MISC
virus I-MISC I-MISC
( I-MISC I-MISC
EBV I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
encoded I-MISC I-MISC
latent I-MISC I-MISC
membrane I-MISC I-MISC
protein I-MISC I-MISC
( I-MISC I-MISC
LMP I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
few O-MISC O-MISC
exceptions O-MISC O-MISC
, O-MISC O-MISC
also O-MISC O-MISC
of O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

All O-MISC O-MISC
but O-MISC O-MISC
one O-MISC O-MISC
PCNSL O-MISC O-MISC
expressed O-MISC O-MISC
hMSH2 O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
among O-MISC O-MISC
mature O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
selectively O-MISC O-MISC
stains O-MISC O-MISC
GC O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
PCNSL O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
frequently O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
GC O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
segregated O-MISC O-MISC
into O-MISC O-MISC
two O-MISC O-MISC
major O-MISC O-MISC
biologic O-MISC O-MISC
categories O-MISC O-MISC
based O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
pattern O-MISC O-MISC
of O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
, O-MISC O-MISC
LMP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
( O-MISC O-MISC
+ O-MISC I-MISC
) O-MISC O-MISC
/ O-MISC I-MISC
LMP B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
- O-MISC I-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
BCL B-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
PCNSL O-MISC O-MISC
occur O-MISC O-MISC
both O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC O-MISC
infection O-MISC O-MISC
and O-MISC O-MISC
consistently O-MISC O-MISC
display O-MISC O-MISC
a O-MISC O-MISC
large O-MISC O-MISC
noncleaved O-MISC O-MISC
cell O-MISC O-MISC
morphology O-MISC O-MISC
. O-MISC O-MISC

Conversely O-MISC O-MISC
, O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
( O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
LMP B-MISC I-MISC
- I-MISC O-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
BCL B-MISC O-MISC
- I-MISC O-MISC
2 I-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
PCNSL O-MISC O-MISC
are O-MISC O-MISC
restricted O-MISC O-MISC
to O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
hosts O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
represented O-MISC O-MISC
by O-MISC O-MISC
lymphomas O-MISC O-MISC
with O-MISC O-MISC
immunoblastic O-MISC O-MISC
features O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
are O-MISC O-MISC
relevant O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
and O-MISC O-MISC
histogenesis O-MISC O-MISC
of O-MISC O-MISC
PCNSL O-MISC O-MISC
and O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
helpful O-MISC O-MISC
to O-MISC O-MISC
segregate O-MISC O-MISC
distinct O-MISC O-MISC
biologic O-MISC O-MISC
and O-MISC O-MISC
prognostic O-MISC O-MISC
categories O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
lymphomas O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
1998 O-MISC O-MISC
by O-MISC O-MISC
The O-MISC O-MISC
American O-MISC O-MISC
Society O-MISC O-MISC
of O-MISC O-MISC
Hematology O-MISC O-MISC
. O-MISC O-MISC

Antioxidant O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
phorbol O-MISC O-MISC
ester O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
adhesion O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Regulation O-MISC O-MISC
of O-MISC O-MISC
adhesion O-MISC B-MISC
molecule O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
function O-MISC O-MISC
by O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
species O-MISC O-MISC
via O-MISC O-MISC
specific O-MISC O-MISC
redox O-MISC O-MISC
sensitive O-MISC O-MISC
mechanisms O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
reported O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
clinically O-MISC O-MISC
safe O-MISC O-MISC
antioxidants O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
adhesion O-MISC B-MISC
molecule O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
ECV O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
adherence O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
ECV O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
investigated O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
thiol O-MISC O-MISC
antioxidant O-MISC O-MISC
, O-MISC O-MISC
alpha O-MISC O-MISC
- O-MISC O-MISC
lipoate O-MISC O-MISC
, O-MISC O-MISC
at O-MISC O-MISC
clinically O-MISC O-MISC
relevant O-MISC O-MISC
doses O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
phorbol O-MISC O-MISC
12 O-MISC O-MISC
- O-MISC O-MISC
myristate O-MISC O-MISC
13 O-MISC O-MISC
- O-MISC O-MISC
acetate O-MISC O-MISC
( O-MISC O-MISC
PMA O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
adhesion O-MISC O-MISC
molecule O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
adhesion O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
PMA O-MISC O-MISC
- O-MISC I-MISC
induced O-MISC O-MISC
ICAM O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
and O-MISC O-MISC
VCAM O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
expression O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
PMA O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
adhesion O-MISC O-MISC
of O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
ECV O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
alpha O-MISC O-MISC
- O-MISC O-MISC
lipoate O-MISC O-MISC
was O-MISC O-MISC
dose O-MISC O-MISC
dependent O-MISC O-MISC
( O-MISC O-MISC
50 O-MISC O-MISC
- O-MISC O-MISC
250 O-MISC O-MISC
microM O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effect O-MISC O-MISC
was O-MISC O-MISC
significant O-MISC O-MISC
for O-MISC O-MISC
ICAM B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
VCAM B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
pretreated O-MISC O-MISC
with O-MISC O-MISC
100 O-MISC O-MISC
microM O-MISC B-MISC
alpha O-MISC I-MISC
- O-MISC O-MISC
lipoate O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
PMA O-MISC O-MISC
- O-MISC O-MISC
activated O-MISC O-MISC
untreated O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
PMA O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
adhesion O-MISC B-MISC
molecule O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
adhesion O-MISC O-MISC
was O-MISC O-MISC
more O-MISC O-MISC
pronounced O-MISC O-MISC
when O-MISC O-MISC
a O-MISC O-MISC
combination O-MISC O-MISC
of O-MISC O-MISC
antioxidants O-MISC O-MISC
, O-MISC O-MISC
alpha O-MISC O-MISC
- O-MISC O-MISC
lipoate O-MISC O-MISC
and O-MISC O-MISC
alpha O-MISC O-MISC
- O-MISC O-MISC
tocopherol O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
antioxidant O-MISC O-MISC
alone O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
adhesion O-MISC B-MISC
molecule O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
function O-MISC O-MISC
by O-MISC O-MISC
low O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
antioxidants O-MISC O-MISC
investigated O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
regulated O-MISC O-MISC
or O-MISC O-MISC
transcription O-MISC O-MISC
dependent O-MISC O-MISC
because O-MISC O-MISC
no O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
mRNA O-MISC B-MISC
response O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

Protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
( O-MISC O-MISC
PKC B-MISC B-MISC
) O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
suggested O-MISC O-MISC
to O-MISC O-MISC
regulate O-MISC O-MISC
PMA O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
adhesion O-MISC O-MISC
molecule O-MISC I-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
post O-MISC O-MISC
- O-MISC O-MISC
transcriptional O-MISC O-MISC
stabilization O-MISC O-MISC
of O-MISC O-MISC
adhesion B-MISC B-MISC
molecule I-MISC I-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

Alpha O-MISC O-MISC
- O-MISC O-MISC
lipoate O-MISC O-MISC
pretreatment O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
influence O-MISC O-MISC
the O-MISC O-MISC
response O-MISC O-MISC
of O-MISC O-MISC
PKC B-MISC B-MISC
activity O-MISC O-MISC
to O-MISC O-MISC
PMA O-MISC O-MISC
. O-MISC O-MISC

Oxidants O-MISC O-MISC
are O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
adhesion O-MISC O-MISC
processes O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
ECV O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
PMA O-MISC O-MISC
induced O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
intracellular O-MISC O-MISC
oxidants O-MISC O-MISC
. O-MISC O-MISC

Alpha O-MISC O-MISC
- O-MISC O-MISC
lipoate O-MISC O-MISC
( O-MISC O-MISC
100 O-MISC O-MISC
or O-MISC O-MISC
250 O-MISC O-MISC
microM O-MISC O-MISC
) O-MISC O-MISC
treatment O-MISC O-MISC
decreased O-MISC O-MISC
PMA O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
intracellular O-MISC O-MISC
oxidants O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
low O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
alpha O-MISC B-MISC
- O-MISC I-MISC
lipaote O-MISC I-MISC
alone O-MISC O-MISC
or O-MISC O-MISC
in O-MISC O-MISC
combination O-MISC O-MISC
with O-MISC O-MISC
alpha O-MISC O-MISC
- O-MISC O-MISC
tocopherol O-MISC I-MISC
on O-MISC O-MISC
agonist O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
adhesion O-MISC O-MISC
processes O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
of O-MISC O-MISC
potential O-MISC O-MISC
therapeutic O-MISC O-MISC
value O-MISC O-MISC
. O-MISC O-MISC

Binding O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC I-MISC
virus O-MISC I-MISC
type O-MISC I-MISC
1 O-MISC I-MISC
to O-MISC I-MISC
CD4 B-MISC B-MISC
and I-MISC I-MISC
CXCR4 I-MISC I-MISC
receptors I-MISC I-MISC
differentially O-MISC O-MISC
regulates O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
inflammatory B-MISC B-MISC
genes I-MISC I-MISC
and O-MISC O-MISC
activates O-MISC O-MISC
the O-MISC O-MISC
MEK B-MISC B-MISC
/ O-MISC O-MISC
ERK O-MISC I-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
previously O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
virions O-MISC O-MISC
to O-MISC O-MISC
CD4 B-MISC B-MISC
receptors I-MISC I-MISC
stimulates O-MISC O-MISC
association O-MISC O-MISC
of O-MISC O-MISC
Lck B-MISC B-MISC
with O-MISC O-MISC
Raf B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Raf B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
kinase O-MISC I-MISC
in O-MISC O-MISC
a O-MISC O-MISC
Ras O-MISC B-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
manner O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
envelope I-MISC I-MISC
glycoproteins I-MISC I-MISC
of O-MISC O-MISC
both O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
tropic O-MISC O-MISC
and O-MISC O-MISC
macrophagetropic O-MISC O-MISC
strains O-MISC O-MISC
rapidly O-MISC O-MISC
activate O-MISC O-MISC
the O-MISC O-MISC
ERK O-MISC B-MISC
/ O-MISC O-MISC
mitogen O-MISC I-MISC
- O-MISC O-MISC
activated O-MISC B-MISC
protein O-MISC I-MISC
( O-MISC I-MISC
MAP O-MISC I-MISC
) O-MISC I-MISC
kinase O-MISC I-MISC
pathway O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
( O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
stimulate O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
cytokine B-MISC B-MISC
and I-MISC I-MISC
chemokine I-MISC B-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
requires O-MISC O-MISC
functional O-MISC O-MISC
CD4 B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
is O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
CXCR4 B-MISC B-MISC
. O-MISC O-MISC

Binding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
natural O-MISC O-MISC
ligand O-MISC B-MISC
stromal B-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
derived I-MISC I-MISC
factor I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
SDF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
to O-MISC O-MISC
CXCR4 B-MISC B-MISC
, O-MISC O-MISC
which O-MISC O-MISC
inhibits O-MISC O-MISC
entry O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
tropic O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
activates O-MISC O-MISC
also O-MISC O-MISC
the O-MISC O-MISC
ERK O-MISC B-MISC
/ O-MISC B-MISC
MAP B-MISC I-MISC
kinase I-MISC I-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
SDF B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
did O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
the O-MISC O-MISC
CD4 O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
cytokine B-MISC B-MISC
and I-MISC I-MISC
chemokine I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
provide O-MISC O-MISC
firm O-MISC O-MISC
molecular O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
envelope I-MISC I-MISC
glycoproteins I-MISC I-MISC
to O-MISC O-MISC
CD4 B-MISC B-MISC
receptor I-MISC I-MISC
initiates O-MISC O-MISC
a O-MISC O-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
chemokine B-MISC B-MISC
receptor I-MISC I-MISC
that O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
aberrant O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
inflammatory B-MISC B-MISC
genes I-MISC I-MISC
and O-MISC O-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
significantly O-MISC O-MISC
to O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
replication O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
to O-MISC O-MISC
deregulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

Antigen O-MISC O-MISC
receptor O-MISC I-MISC
signaling O-MISC O-MISC
induces O-MISC O-MISC
MAP O-MISC B-MISC
kinase O-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
phosphorylation O-MISC O-MISC
and O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
transcription B-MISC I-MISC
factor I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
bcl B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
proto I-MISC I-MISC
- I-MISC I-MISC
oncogene I-MISC I-MISC
encodes O-MISC O-MISC
a O-MISC O-MISC
POZ B-MISC B-MISC
/ I-MISC I-MISC
zinc I-MISC I-MISC
finger I-MISC I-MISC
transcriptional I-MISC I-MISC
repressor I-MISC I-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
germinal O-MISC O-MISC
center O-MISC O-MISC
( O-MISC O-MISC
GC O-MISC O-MISC
) O-MISC O-MISC
B O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
GC O-MISC O-MISC
formation O-MISC O-MISC
and O-MISC O-MISC
antibody O-MISC O-MISC
affinity O-MISC O-MISC
maturation O-MISC O-MISC
. O-MISC O-MISC

Deregulation O-MISC O-MISC
of O-MISC O-MISC
bcl B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
chromosomal O-MISC O-MISC
rearrangements O-MISC O-MISC
and O-MISC O-MISC
point O-MISC O-MISC
mutations O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
bcl B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
promoter I-MISC I-MISC
region I-MISC I-MISC
are O-MISC O-MISC
implicated O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphoma O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
signals O-MISC O-MISC
regulating O-MISC O-MISC
bcl B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
expression O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
known O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
antigen O-MISC B-MISC
receptor O-MISC I-MISC
activation O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
phosphorylation O-MISC O-MISC
by O-MISC O-MISC
mitogen B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
MAPK B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Phosphorylation O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
turn O-MISC O-MISC
, O-MISC O-MISC
targets O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
for O-MISC O-MISC
rapid O-MISC O-MISC
degradation O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
ubiquitin B-MISC B-MISC
/ O-MISC I-MISC
proteasome B-MISC I-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
directly O-MISC O-MISC
controlled O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
antigen O-MISC B-MISC
receptor O-MISC I-MISC
via O-MISC O-MISC
MAPK B-MISC B-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
crucial O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
antibody O-MISC O-MISC
response O-MISC O-MISC
and O-MISC O-MISC
has O-MISC O-MISC
implications O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
other O-MISC O-MISC
POZ B-MISC B-MISC
/ I-MISC I-MISC
zinc I-MISC I-MISC
finger I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
in O-MISC O-MISC
other O-MISC O-MISC
tissues O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
are O-MISC O-MISC
differentially O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
tissues O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

Cytosolic B-MISC O-MISC
glucocorticoid I-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
binding O-MISC O-MISC
studies O-MISC O-MISC
on O-MISC O-MISC
immune O-MISC O-MISC
tissues O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
exhibits O-MISC O-MISC
three O-MISC O-MISC
to O-MISC O-MISC
four O-MISC O-MISC
times O-MISC O-MISC
higher O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
protein I-MISC I-MISC
than O-MISC O-MISC
the O-MISC O-MISC
spleen O-MISC O-MISC
. O-MISC O-MISC

High O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
are O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
exquisite O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
to O-MISC O-MISC
glucocorticoid O-MISC O-MISC
exposure O-MISC O-MISC
. O-MISC O-MISC

Nevertheless O-MISC O-MISC
, O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
binding O-MISC O-MISC
studies O-MISC O-MISC
reveal O-MISC O-MISC
similar O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
in O-MISC O-MISC
immature O-MISC O-MISC
thymic O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
more O-MISC O-MISC
mature O-MISC O-MISC
, O-MISC O-MISC
splenic O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
binding O-MISC O-MISC
techniques O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
neutrophils O-MISC O-MISC
( O-MISC O-MISC
which O-MISC O-MISC
represent O-MISC O-MISC
roughly O-MISC O-MISC
30 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
splenic O-MISC O-MISC
leukocytes O-MISC O-MISC
) O-MISC O-MISC
exhibit O-MISC O-MISC
higher O-MISC O-MISC
GR B-MISC B-MISC
than O-MISC O-MISC
both O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
further O-MISC O-MISC
contradicting O-MISC O-MISC
results O-MISC O-MISC
from O-MISC O-MISC
cytosolic O-MISC O-MISC
binding O-MISC O-MISC
studies O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
address O-MISC O-MISC
these O-MISC O-MISC
inconsistencies O-MISC O-MISC
, O-MISC O-MISC
GR B-MISC B-MISC
protein I-MISC I-MISC
was O-MISC O-MISC
assessed O-MISC O-MISC
in O-MISC O-MISC
immune O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
tissues O-MISC O-MISC
using O-MISC O-MISC
cytosolic O-MISC O-MISC
radioligand O-MISC O-MISC
binding O-MISC O-MISC
. O-MISC O-MISC

Western O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
immunocytochemistry O-MISC O-MISC
. O-MISC O-MISC

Consistent O-MISC O-MISC
with O-MISC O-MISC
previous O-MISC O-MISC
cytosolic O-MISC B-MISC
receptor O-MISC I-MISC
binding O-MISC O-MISC
studies O-MISC O-MISC
on O-MISC O-MISC
immune O-MISC O-MISC
tissue O-MISC O-MISC
homogenates O-MISC O-MISC
, O-MISC O-MISC
thymic O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
higher O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
than O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
spleen O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
neutrophils O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
fewer O-MISC O-MISC
GR B-MISC B-MISC
than O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
a O-MISC O-MISC
meaningful O-MISC O-MISC
relationship O-MISC O-MISC
between O-MISC O-MISC
receptor O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
known O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

Functional O-MISC O-MISC
replacement O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mouse B-MISC B-MISC
E2A I-MISC I-MISC
gene I-MISC I-MISC
with O-MISC O-MISC
a O-MISC O-MISC
human B-MISC B-MISC
HEB I-MISC I-MISC
cDNA I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mammalian B-MISC B-MISC
E2A I-MISC I-MISC
, I-MISC O-MISC
HEB I-MISC B-MISC
, I-MISC O-MISC
and I-MISC I-MISC
E2 I-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
genes I-MISC I-MISC
encode O-MISC O-MISC
a O-MISC O-MISC
unique O-MISC O-MISC
class O-MISC O-MISC
of O-MISC O-MISC
basic B-MISC B-MISC
helix I-MISC I-MISC
- I-MISC I-MISC
loop I-MISC I-MISC
- I-MISC I-MISC
helix I-MISC I-MISC
( I-MISC I-MISC
bHLH I-MISC B-MISC
) I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
that O-MISC O-MISC
are O-MISC O-MISC
evolutionarily O-MISC O-MISC
conserved O-MISC O-MISC
and O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
embryonic O-MISC O-MISC
and O-MISC O-MISC
postnatal O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

While O-MISC O-MISC
the O-MISC O-MISC
structural O-MISC O-MISC
and O-MISC O-MISC
functional O-MISC O-MISC
similarities O-MISC O-MISC
among O-MISC O-MISC
the O-MISC O-MISC
gene B-MISC B-MISC
products I-MISC I-MISC
are O-MISC O-MISC
well O-MISC O-MISC
demonstrated O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
clear O-MISC O-MISC
why O-MISC O-MISC
deletion O-MISC O-MISC
of O-MISC O-MISC
E2A B-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
HEB B-MISC B-MISC
or O-MISC O-MISC
E2 B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
complete O-MISC O-MISC
arrest O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphocyte O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
understand O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
basis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
functional O-MISC O-MISC
specificity O-MISC O-MISC
between O-MISC O-MISC
E2A B-MISC B-MISC
and O-MISC O-MISC
HEB B-MISC B-MISC
/ O-MISC I-MISC
E2 B-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
in O-MISC O-MISC
mammalian O-MISC O-MISC
development O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
generated O-MISC O-MISC
and O-MISC O-MISC
tested O-MISC O-MISC
a O-MISC O-MISC
panel O-MISC O-MISC
of O-MISC O-MISC
E2A B-MISC B-MISC
knockin O-MISC O-MISC
mutations O-MISC O-MISC
including O-MISC O-MISC
subtle O-MISC O-MISC
mutations O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
E12 B-MISC B-MISC
and I-MISC O-MISC
E47 I-MISC B-MISC
exons I-MISC O-MISC
and O-MISC O-MISC
substitution O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
E12 B-MISC B-MISC
and I-MISC O-MISC
E47 I-MISC B-MISC
exons I-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
human B-MISC B-MISC
HEB I-MISC I-MISC
cDNA I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
find O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
alternatively O-MISC O-MISC
spliced O-MISC I-MISC
E12 B-MISC I-MISC
and I-MISC I-MISC
E47 I-MISC I-MISC
bHLH I-MISC I-MISC
proteins I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
E2A B-MISC B-MISC
gene I-MISC I-MISC
play O-MISC O-MISC
similar O-MISC O-MISC
and O-MISC O-MISC
additive O-MISC O-MISC
roles O-MISC O-MISC
in O-MISC O-MISC
supporting O-MISC O-MISC
B O-MISC O-MISC
lymphopoiesis O-MISC O-MISC
. O-MISC O-MISC

Further O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
find O-MISC O-MISC
that O-MISC O-MISC
HEB B-MISC B-MISC
driven O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
endogenous B-MISC B-MISC
E2A I-MISC B-MISC
promoter I-MISC I-MISC
can O-MISC O-MISC
functionally O-MISC O-MISC
replace O-MISC O-MISC
E2A B-MISC B-MISC
in O-MISC O-MISC
supporting O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
commitment O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
toward O-MISC O-MISC
completion O-MISC O-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
postnatal O-MISC O-MISC
lethality O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
E2A B-MISC B-MISC
disruption O-MISC O-MISC
is O-MISC O-MISC
fully O-MISC O-MISC
rescued O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
HEB B-MISC B-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
functional O-MISC O-MISC
divergence O-MISC O-MISC
among O-MISC O-MISC
E12 B-MISC B-MISC
, O-MISC O-MISC
E47 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
HEB B-MISC B-MISC
in O-MISC O-MISC
different O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
is O-MISC O-MISC
partially O-MISC O-MISC
defined O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
context O-MISC O-MISC
of O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Biased O-MISC O-MISC
dependency O-MISC O-MISC
of O-MISC O-MISC
CD80 B-MISC B-MISC
versus O-MISC O-MISC
CD86 B-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
regulating O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
signals O-MISC O-MISC
obtained O-MISC O-MISC
by O-MISC O-MISC
ligation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
TCR O-MISC B-MISC
, O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
need O-MISC O-MISC
additional O-MISC O-MISC
, O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulatory O-MISC O-MISC
signals O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
activated O-MISC O-MISC
. O-MISC O-MISC

One O-MISC O-MISC
such O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulatory O-MISC I-MISC
signal O-MISC O-MISC
is O-MISC O-MISC
delivered O-MISC O-MISC
when O-MISC O-MISC
CD28 B-MISC B-MISC
on O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
CD80 B-MISC B-MISC
or O-MISC O-MISC
CD86 B-MISC B-MISC
on O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
presenting O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
APC O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
CD80 B-MISC B-MISC
and O-MISC O-MISC
CD86 B-MISC O-MISC
to O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulate O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
superantigen O-MISC B-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
the O-MISC O-MISC
Raji O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
lymphoma O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
express O-MISC O-MISC
similar O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
CD80 B-MISC B-MISC
and O-MISC O-MISC
CD86 B-MISC B-MISC
, O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
was O-MISC O-MISC
mainly O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
by O-MISC O-MISC
CD80 B-MISC B-MISC
. O-MISC O-MISC

To O-MISC O-MISC
further O-MISC O-MISC
characterize O-MISC O-MISC
the O-MISC O-MISC
consequences O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
biased O-MISC B-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulatory O-MISC O-MISC
dependency O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
employed O-MISC O-MISC
a O-MISC O-MISC
well O-MISC O-MISC
- O-MISC O-MISC
defined O-MISC O-MISC
system O-MISC O-MISC
of O-MISC O-MISC
transfected O-MISC O-MISC
CHO O-MISC O-MISC
cells O-MISC O-MISC
expressing O-MISC O-MISC
human B-MISC O-MISC
MHC I-MISC O-MISC
class I-MISC O-MISC
II I-MISC O-MISC
together O-MISC O-MISC
with O-MISC O-MISC
CD80 B-MISC B-MISC
, O-MISC O-MISC
CD86 B-MISC B-MISC
or O-MISC O-MISC
CD80 B-MISC B-MISC
and O-MISC O-MISC
CD86 B-MISC B-MISC
. O-MISC O-MISC

Proliferation O-MISC O-MISC
of O-MISC O-MISC
freshly O-MISC O-MISC
prepared O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
required O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
CD80 B-MISC B-MISC
or O-MISC O-MISC
CD86 B-MISC B-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
production O-MISC O-MISC
reached O-MISC O-MISC
only O-MISC O-MISC
suboptimal O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
CD86 B-MISC B-MISC
but O-MISC O-MISC
optimal O-MISC O-MISC
levels O-MISC O-MISC
with O-MISC O-MISC
CD80 B-MISC B-MISC
. O-MISC O-MISC

To O-MISC O-MISC
analyze O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
CD80 B-MISC O-MISC
and O-MISC O-MISC
CD86 B-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
we O-MISC O-MISC
used O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
transfected O-MISC O-MISC
with O-MISC O-MISC
luciferase B-MISC B-MISC
reporter I-MISC I-MISC
gene I-MISC I-MISC
constructs I-MISC I-MISC
. O-MISC O-MISC

CD80 B-MISC B-MISC
induced O-MISC O-MISC
higher O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
- O-MISC I-MISC
enhancer O-MISC I-MISC
activity O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
CD86 B-MISC B-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
regulating O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
- I-MISC I-MISC
enhancer I-MISC I-MISC
region I-MISC I-MISC
including O-MISC O-MISC
activation B-MISC O-MISC
protein I-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
CD28 B-MISC B-MISC
response I-MISC I-MISC
element I-MISC I-MISC
and O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
kappaB I-MISC B-MISC
were O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
times O-MISC O-MISC
higher O-MISC O-MISC
after O-MISC O-MISC
CD80 B-MISC B-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
CD86 B-MISC B-MISC
ligation O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
eventual O-MISC O-MISC
appearance O-MISC O-MISC
of O-MISC O-MISC
CD80 B-MISC B-MISC
on O-MISC O-MISC
recently O-MISC O-MISC
activated O-MISC O-MISC
CD86 O-MISC O-MISC
+ O-MISC O-MISC
APC O-MISC O-MISC
is O-MISC O-MISC
important O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
superinduction O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
production O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
support O-MISC O-MISC
vigorous O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Duplication O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
DR3 B-MISC B-MISC
gene I-MISC I-MISC
on O-MISC O-MISC
human B-MISC B-MISC
chromosome I-MISC I-MISC
1p36 I-MISC I-MISC
and O-MISC O-MISC
its O-MISC O-MISC
deletion O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
neuroblastoma O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
human B-MISC B-MISC
DR3 I-MISC I-MISC
gene I-MISC I-MISC
, O-MISC O-MISC
whose O-MISC O-MISC
product O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
known O-MISC O-MISC
as O-MISC O-MISC
Wsl B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
APO I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
/ I-MISC O-MISC
TRAMP I-MISC O-MISC
/ I-MISC O-MISC
LARD I-MISC O-MISC
, O-MISC O-MISC
encodes O-MISC O-MISC
a O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
related I-MISC I-MISC
receptor I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
expressed O-MISC O-MISC
primarily O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
surface O-MISC O-MISC
of O-MISC O-MISC
thymocytes O-MISC O-MISC
and O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

DR3 B-MISC B-MISC
is O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
inducing O-MISC O-MISC
both O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
apoptosis O-MISC O-MISC
when O-MISC O-MISC
overexpressed O-MISC O-MISC
in O-MISC O-MISC
mammalian O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
its O-MISC O-MISC
ligand O-MISC O-MISC
has O-MISC O-MISC
not O-MISC O-MISC
yet O-MISC O-MISC
been O-MISC O-MISC
identified O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
DR3 B-MISC B-MISC
gene I-MISC I-MISC
locus I-MISC I-MISC
is O-MISC O-MISC
tandemly O-MISC O-MISC
duplicated O-MISC O-MISC
on O-MISC O-MISC
human B-MISC B-MISC
chromosome I-MISC I-MISC
band I-MISC I-MISC
1p36 I-MISC I-MISC
. I-MISC I-MISC
2 I-MISC I-MISC
- I-MISC I-MISC
p36 I-MISC I-MISC
. I-MISC I-MISC
3 I-MISC I-MISC
and O-MISC O-MISC
that O-MISC O-MISC
these O-MISC O-MISC
genes O-MISC O-MISC
are O-MISC O-MISC
hemizygously O-MISC O-MISC
deleted O-MISC O-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
translocated O-MISC O-MISC
to O-MISC O-MISC
another O-MISC O-MISC
chromosome O-MISC B-MISC
in O-MISC O-MISC
neuroblastoma O-MISC O-MISC
( O-MISC O-MISC
NB O-MISC O-MISC
) O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
with O-MISC O-MISC
amplified O-MISC O-MISC
MYCN O-MISC B-MISC
. O-MISC O-MISC

Duplication O-MISC O-MISC
of O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
a O-MISC O-MISC
portion O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
DR3 B-MISC B-MISC
gene I-MISC I-MISC
, O-MISC O-MISC
including O-MISC O-MISC
the O-MISC O-MISC
extracellular B-MISC B-MISC
and I-MISC I-MISC
transmembrane I-MISC I-MISC
regions I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
cytoplasmic B-MISC B-MISC
domain I-MISC I-MISC
, O-MISC O-MISC
was O-MISC O-MISC
demonstrated O-MISC O-MISC
by O-MISC O-MISC
both O-MISC O-MISC
fluorescence O-MISC O-MISC
in O-MISC O-MISC
situ O-MISC O-MISC
hybridization O-MISC O-MISC
and O-MISC O-MISC
genomic O-MISC B-MISC
Southern O-MISC O-MISC
blotting O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
most O-MISC O-MISC
NB O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
DR3 B-MISC B-MISC
and I-MISC O-MISC
the I-MISC O-MISC
DR3L I-MISC B-MISC
sequences I-MISC I-MISC
are O-MISC O-MISC
simultaneously O-MISC O-MISC
deleted O-MISC O-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
translocated O-MISC O-MISC
to O-MISC O-MISC
another O-MISC O-MISC
chromosome B-MISC O-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
DR3 B-MISC B-MISC
/ I-MISC I-MISC
Wsl I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
protein I-MISC I-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
quite O-MISC O-MISC
variable O-MISC O-MISC
among O-MISC O-MISC
these O-MISC O-MISC
NB O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
very O-MISC O-MISC
low O-MISC O-MISC
or O-MISC O-MISC
undetectable O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
7 O-MISC O-MISC
of O-MISC O-MISC
17 O-MISC O-MISC
NB O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC

Differential O-MISC O-MISC
protection O-MISC O-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
human O-MISC O-MISC
myeloid O-MISC O-MISC
progenitors O-MISC O-MISC
( O-MISC O-MISC
CFU O-MISC O-MISC
- O-MISC O-MISC
GM O-MISC O-MISC
) O-MISC O-MISC
from O-MISC O-MISC
Ara O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
toxicity O-MISC O-MISC
using O-MISC O-MISC
cycloheximide O-MISC O-MISC
. O-MISC O-MISC

Cycloheximide O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
reversible O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
inhibitor O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
block O-MISC O-MISC
DNA O-MISC O-MISC
replication O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
preventing O-MISC O-MISC
synthesis O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
labile B-MISC B-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
animal O-MISC O-MISC
systems O-MISC O-MISC
, O-MISC O-MISC
cycloheximide O-MISC O-MISC
protects O-MISC O-MISC
normal O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
cytotoxic O-MISC O-MISC
S O-MISC O-MISC
- O-MISC O-MISC
phase O-MISC O-MISC
specific O-MISC O-MISC
agents O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
cytosine O-MISC O-MISC
arabinoside O-MISC O-MISC
( O-MISC O-MISC
Ara O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Malignant O-MISC O-MISC
cells O-MISC O-MISC
appear O-MISC O-MISC
not O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
susceptible O-MISC O-MISC
to O-MISC O-MISC
cycloheximide O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cycle O-MISC O-MISC
arrest O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
subsequently O-MISC O-MISC
, O-MISC O-MISC
may O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
protected O-MISC O-MISC
from O-MISC O-MISC
Ara O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
cytotoxicity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
cycloheximide O-MISC O-MISC
on O-MISC O-MISC
granulocyte O-MISC O-MISC
/ O-MISC O-MISC
macrophage O-MISC O-MISC
progenitors O-MISC O-MISC
( O-MISC O-MISC
CFU O-MISC O-MISC
- O-MISC O-MISC
GM O-MISC O-MISC
) O-MISC O-MISC
after O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
Ara O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
exposure O-MISC O-MISC
was O-MISC O-MISC
examined O-MISC O-MISC
using O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
, O-MISC O-MISC
malignant O-MISC O-MISC
progenitors O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
myelogenous O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
CML O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
clonogenic O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
acute O-MISC O-MISC
nonlymphocytic O-MISC O-MISC
leukemia O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
and O-MISC O-MISC
KG O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC

Mononuclear O-MISC O-MISC
or O-MISC O-MISC
clonogenic O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
incubated O-MISC O-MISC
for O-MISC O-MISC
one O-MISC O-MISC
hour O-MISC O-MISC
with O-MISC O-MISC
cycloheximide O-MISC O-MISC
, O-MISC O-MISC
followed O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
for O-MISC O-MISC
three O-MISC O-MISC
or O-MISC O-MISC
17 O-MISC O-MISC
hours O-MISC O-MISC
, O-MISC O-MISC
of O-MISC O-MISC
Ara O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
before O-MISC O-MISC
being O-MISC O-MISC
plated O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
methylcellulose O-MISC O-MISC
culture O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

CFU O-MISC O-MISC
- O-MISC O-MISC
GM O-MISC O-MISC
survival O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
increase O-MISC O-MISC
if O-MISC O-MISC
normal O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
cycloheximide O-MISC O-MISC
before O-MISC O-MISC
Ara O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
exposure O-MISC O-MISC
. O-MISC O-MISC

Similar O-MISC O-MISC
cycloheximide O-MISC O-MISC
pretreatment O-MISC O-MISC
of O-MISC O-MISC
CML O-MISC O-MISC
progenitors O-MISC O-MISC
and O-MISC O-MISC
clonogenic O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
and O-MISC O-MISC
KG O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
protect O-MISC O-MISC
CFU O-MISC O-MISC
- O-MISC O-MISC
GM O-MISC O-MISC
from O-MISC O-MISC
Ara O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cytotoxicity O-MISC O-MISC
. O-MISC O-MISC

Primary O-MISC O-MISC
cortisol O-MISC O-MISC
resistance O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
two O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
family O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
report O-MISC O-MISC
describes O-MISC O-MISC
studies O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
man O-MISC O-MISC
suspected O-MISC O-MISC
of O-MISC O-MISC
having O-MISC O-MISC
primary O-MISC O-MISC
cortisol O-MISC O-MISC
resistance O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
conclusion O-MISC O-MISC
is O-MISC O-MISC
based O-MISC O-MISC
on O-MISC O-MISC
his O-MISC O-MISC
high O-MISC O-MISC
plasma O-MISC O-MISC
cortisol O-MISC O-MISC
levels O-MISC O-MISC
and O-MISC O-MISC
high O-MISC O-MISC
24 O-MISC O-MISC
- O-MISC O-MISC
h O-MISC O-MISC
urinary O-MISC O-MISC
17 O-MISC O-MISC
- O-MISC O-MISC
hydroxycorticosteroi O-MISC O-MISC
and O-MISC O-MISC
cortisol O-MISC O-MISC
excretion O-MISC O-MISC
, O-MISC O-MISC
plus O-MISC O-MISC
the O-MISC O-MISC
fact O-MISC O-MISC
that O-MISC O-MISC
he O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
manifestations O-MISC O-MISC
of O-MISC O-MISC
Cushing O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
syndrome O-MISC O-MISC
. O-MISC O-MISC

Among O-MISC O-MISC
family O-MISC O-MISC
members O-MISC O-MISC
tested O-MISC O-MISC
, O-MISC O-MISC
his O-MISC O-MISC
mother O-MISC O-MISC
also O-MISC O-MISC
had O-MISC O-MISC
hypercortisolemia O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
mother O-MISC O-MISC
and O-MISC O-MISC
son O-MISC O-MISC
had O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
unbound O-MISC O-MISC
plasma O-MISC O-MISC
cortisol O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
their O-MISC O-MISC
plasma O-MISC O-MISC
ACTH O-MISC O-MISC
concentrations O-MISC O-MISC
were O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
normal O-MISC O-MISC
range O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
were O-MISC O-MISC
partially O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
dexamethasone O-MISC O-MISC
adrenal O-MISC O-MISC
suppression O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
both O-MISC O-MISC
had O-MISC O-MISC
mild O-MISC O-MISC
hypertension O-MISC O-MISC
without O-MISC O-MISC
hypokalemia O-MISC B-MISC
. O-MISC O-MISC

To O-MISC O-MISC
study O-MISC O-MISC
this O-MISC O-MISC
apparent O-MISC O-MISC
end O-MISC O-MISC
- O-MISC O-MISC
organ O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
cortisol O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
assays O-MISC O-MISC
, O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
both O-MISC O-MISC
patients O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
reduced O-MISC O-MISC
total O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
these O-MISC O-MISC
two O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
family O-MISC O-MISC
, O-MISC O-MISC
have O-MISC O-MISC
primary O-MISC O-MISC
cortisol O-MISC O-MISC
resistance O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
reduced O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

[ O-MISC O-MISC
Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
polychemotherapy O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
lymphatic O-MISC O-MISC
leukemia O-MISC O-MISC
] O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
levels O-MISC O-MISC
were O-MISC O-MISC
quantified O-MISC O-MISC
in O-MISC O-MISC
leukemic O-MISC O-MISC
blasts O-MISC O-MISC
from O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
of O-MISC O-MISC
86 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
subsequent O-MISC O-MISC
achievement O-MISC O-MISC
of O-MISC O-MISC
complete O-MISC O-MISC
remission O-MISC O-MISC
after O-MISC O-MISC
combination O-MISC O-MISC
chemotherapy O-MISC O-MISC
was O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
receptor O-MISC O-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

Forty O-MISC O-MISC
- O-MISC O-MISC
seven O-MISC O-MISC
of O-MISC O-MISC
50 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
containing O-MISC O-MISC
more O-MISC O-MISC
than O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
receptor O-MISC I-MISC
sites O-MISC I-MISC
and O-MISC O-MISC
22 O-MISC O-MISC
of O-MISC O-MISC
36 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
cells O-MISC O-MISC
containing O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
receptor O-MISC O-MISC
sites O-MISC I-MISC
achieved O-MISC O-MISC
remission O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
study O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
may O-MISC O-MISC
predict O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
combination O-MISC O-MISC
chemotherapy O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Specific O-MISC O-MISC
uptake O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
dihydroxycholecalcif O-MISC O-MISC
by O-MISC O-MISC
human O-MISC O-MISC
chronic O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
examined O-MISC O-MISC
mononuclear O-MISC O-MISC
cell O-MISC O-MISC
preparations O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
[ O-MISC O-MISC
CML O-MISC O-MISC
] O-MISC O-MISC
for O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
and O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
dihydroxycholecalcif O-MISC O-MISC
[ O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
] O-MISC O-MISC
. O-MISC O-MISC

Whole O-MISC O-MISC
cells O-MISC O-MISC
specifically O-MISC O-MISC
took O-MISC O-MISC
up O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
( O-MISC O-MISC
Kd O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
11 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
low O-MISC O-MISC
capacity O-MISC O-MISC
. O-MISC O-MISC

Subcellular O-MISC O-MISC
fractionation O-MISC O-MISC
of O-MISC O-MISC
labeled O-MISC O-MISC
cells O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
binding O-MISC O-MISC
was O-MISC O-MISC
restricted O-MISC O-MISC
to O-MISC O-MISC
cytosols O-MISC O-MISC
and O-MISC O-MISC
nuclei O-MISC O-MISC
. O-MISC O-MISC

Sucrose O-MISC O-MISC
gradient O-MISC O-MISC
centrifugation O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
preincubated O-MISC O-MISC
with O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
revealed O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
6S O-MISC O-MISC
peak O-MISC O-MISC
which O-MISC O-MISC
was O-MISC O-MISC
totally O-MISC O-MISC
displaced O-MISC O-MISC
with O-MISC O-MISC
100 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
excess O-MISC O-MISC
nonradioactive O-MISC O-MISC
hormone O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
were O-MISC O-MISC
unable O-MISC O-MISC
to O-MISC O-MISC
demonstrate O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
by O-MISC O-MISC
postlabeling O-MISC O-MISC
standard O-MISC O-MISC
cytosol O-MISC O-MISC
preparations O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
cytosols O-MISC O-MISC
prepared O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
mixture O-MISC O-MISC
of O-MISC O-MISC
CML O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
receptor O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
T47D O-MISC O-MISC
( O-MISC O-MISC
human O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
had O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
10 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
measured O-MISC O-MISC
in O-MISC O-MISC
T47D O-MISC O-MISC
cytosol O-MISC B-MISC
alone O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
T47D O-MISC O-MISC
cytosols O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
reduced O-MISC O-MISC
if O-MISC O-MISC
the O-MISC O-MISC
receptors O-MISC O-MISC
were O-MISC O-MISC
occupied O-MISC O-MISC
with O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
prior O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CML O-MISC O-MISC
cytosols O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
CML O-MISC O-MISC
cells O-MISC O-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
contain O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
and O-MISC O-MISC
an O-MISC O-MISC
unknown O-MISC O-MISC
substance O-MISC O-MISC
which O-MISC O-MISC
prevents O-MISC O-MISC
its O-MISC O-MISC
detection O-MISC O-MISC
following O-MISC O-MISC
the O-MISC O-MISC
preparation O-MISC O-MISC
of O-MISC O-MISC
cytosol O-MISC O-MISC
. O-MISC O-MISC

Cells O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
CML O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
chronic O-MISC O-MISC
phase O-MISC O-MISC
specifically O-MISC O-MISC
bound O-MISC O-MISC
more O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
[ O-MISC O-MISC
18 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
( O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
E O-MISC O-MISC
. O-MISC O-MISC
) O-MISC O-MISC
fmol O-MISC O-MISC
/ O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
7 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
] O-MISC O-MISC
than O-MISC O-MISC
did O-MISC O-MISC
those O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
myeloid O-MISC O-MISC
transformation O-MISC O-MISC
[ O-MISC O-MISC
7 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
] O-MISC O-MISC
or O-MISC O-MISC
than O-MISC O-MISC
did O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
[ O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
] O-MISC O-MISC
. O-MISC O-MISC

Only O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
group O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
responded O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
by O-MISC O-MISC
differentiating O-MISC O-MISC
along O-MISC O-MISC
the O-MISC O-MISC
monocyte O-MISC O-MISC
- O-MISC O-MISC
macrophage O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
- O-MISC O-MISC
induction O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
is O-MISC O-MISC
likely O-MISC O-MISC
to O-MISC O-MISC
depend O-MISC O-MISC
on O-MISC O-MISC
adequate O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
receptor O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
intact O-MISC O-MISC
cells O-MISC O-MISC
rather O-MISC O-MISC
than O-MISC O-MISC
cytosol O-MISC O-MISC
preparations O-MISC O-MISC
should O-MISC O-MISC
be O-MISC O-MISC
studied O-MISC O-MISC
before O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
particular O-MISC O-MISC
tissue O-MISC O-MISC
are O-MISC O-MISC
designated O-MISC O-MISC
as O-MISC O-MISC
receptor O-MISC O-MISC
negative O-MISC O-MISC
. O-MISC O-MISC

Effect O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
position O-MISC O-MISC
on O-MISC O-MISC
dexamethasone O-MISC O-MISC
binding O-MISC O-MISC
by O-MISC O-MISC
mouse O-MISC O-MISC
and O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
: O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
dexamethasone O-MISC O-MISC
binding O-MISC O-MISC
during O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
and O-MISC O-MISC
dexamethasone O-MISC O-MISC
sensitivity O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
determined O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
position O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
that O-MISC O-MISC
was O-MISC O-MISC
specifically O-MISC O-MISC
bound O-MISC O-MISC
by O-MISC O-MISC
mouse O-MISC O-MISC
and O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

Cell O-MISC O-MISC
lines O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
either O-MISC O-MISC
sensitive O-MISC O-MISC
or O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
growth O-MISC O-MISC
inhibition O-MISC O-MISC
by O-MISC O-MISC
dexamethasone O-MISC O-MISC
were O-MISC O-MISC
compared O-MISC O-MISC
. O-MISC O-MISC

Exponentially O-MISC O-MISC
growing O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
separated O-MISC O-MISC
by O-MISC O-MISC
centrifugal O-MISC O-MISC
elutriation O-MISC O-MISC
into O-MISC O-MISC
fractions O-MISC O-MISC
that O-MISC O-MISC
corresponded O-MISC O-MISC
to O-MISC O-MISC
different O-MISC O-MISC
positions O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
phase O-MISC O-MISC
distribution O-MISC O-MISC
of O-MISC O-MISC
each O-MISC O-MISC
fraction O-MISC O-MISC
was O-MISC O-MISC
estimated O-MISC O-MISC
by O-MISC O-MISC
flow O-MISC O-MISC
cytometry O-MISC O-MISC
and O-MISC O-MISC
autoradiography O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
bound O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
in O-MISC O-MISC
each O-MISC O-MISC
fraction O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
binding O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
three O-MISC O-MISC
dexamethasone O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
( O-MISC O-MISC
two O-MISC O-MISC
mouse O-MISC O-MISC
and O-MISC O-MISC
one O-MISC O-MISC
human O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
bound O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
increased O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
between O-MISC O-MISC
G1 O-MISC O-MISC
phase O-MISC O-MISC
and O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
then O-MISC O-MISC
decreased O-MISC O-MISC
during O-MISC O-MISC
G2 O-MISC O-MISC
/ O-MISC O-MISC
M O-MISC O-MISC
phase O-MISC O-MISC
. O-MISC O-MISC

Results O-MISC O-MISC
were O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
when O-MISC O-MISC
the O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
bound O-MISC O-MISC
per O-MISC O-MISC
milligram O-MISC O-MISC
of O-MISC O-MISC
cell B-MISC O-MISC
protein I-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
. O-MISC O-MISC

Binding O-MISC O-MISC
affinity O-MISC O-MISC
was O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
during O-MISC O-MISC
G1 O-MISC O-MISC
phase O-MISC O-MISC
and O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
proportion O-MISC O-MISC
of O-MISC O-MISC
bound O-MISC O-MISC
dexamethasone O-MISC O-MISC
that O-MISC O-MISC
translocated O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
was O-MISC O-MISC
greater O-MISC O-MISC
during O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
bound O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
by O-MISC O-MISC
three O-MISC O-MISC
dexamethasone O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
( O-MISC O-MISC
two O-MISC O-MISC
mouse O-MISC O-MISC
and O-MISC O-MISC
one O-MISC O-MISC
human O-MISC O-MISC
) O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
increase O-MISC O-MISC
during O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
dexamethasone O-MISC O-MISC
binding O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
simply O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
cell B-MISC O-MISC
protein I-MISC O-MISC
or O-MISC O-MISC
cell O-MISC O-MISC
volume O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
. O-MISC O-MISC

An O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
dexamethasone O-MISC O-MISC
binding O-MISC O-MISC
during O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
dexamethasone O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
failure O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
increase O-MISC O-MISC
during O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
might O-MISC O-MISC
represent O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
resistance O-MISC O-MISC
in O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Presence O-MISC O-MISC
and O-MISC O-MISC
steroid O-MISC O-MISC
inducibility O-MISC O-MISC
of O-MISC O-MISC
glutamine B-MISC B-MISC
synthetase I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Glutamine B-MISC B-MISC
synthetase I-MISC I-MISC
( O-MISC O-MISC
EC O-MISC B-MISC
6 O-MISC I-MISC
. O-MISC I-MISC
3 O-MISC I-MISC
. O-MISC I-MISC
1 O-MISC I-MISC
. O-MISC I-MISC
2 O-MISC I-MISC
; O-MISC O-MISC
GS O-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
lymphoblasts O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
ALL O-MISC O-MISC
) O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
16 O-MISC O-MISC
out O-MISC O-MISC
of O-MISC O-MISC
20 O-MISC O-MISC
ALL O-MISC O-MISC
patients O-MISC O-MISC
studied O-MISC O-MISC
exposure O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
physiological O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
increased O-MISC O-MISC
enzyme B-MISC O-MISC
activity O-MISC O-MISC
above O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
increase O-MISC O-MISC
was O-MISC O-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
ligands O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
direct O-MISC O-MISC
correlation O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
magnitude O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
increase O-MISC O-MISC
of O-MISC O-MISC
GS O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
specific O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
assayed O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
cell O-MISC O-MISC
specimen O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
basal O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
enzyme B-MISC O-MISC
measured O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
prior O-MISC O-MISC
to O-MISC O-MISC
exposure O-MISC O-MISC
to O-MISC O-MISC
dexamethasone O-MISC O-MISC
correlated O-MISC O-MISC
negatively O-MISC O-MISC
with O-MISC O-MISC
receptor O-MISC O-MISC
density O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
suggested O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
steroid B-MISC O-MISC
- I-MISC O-MISC
inducible I-MISC O-MISC
GS I-MISC O-MISC
in O-MISC O-MISC
ALL O-MISC O-MISC
cells O-MISC O-MISC
may O-MISC O-MISC
prove O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
marker O-MISC O-MISC
for O-MISC O-MISC
functional B-MISC O-MISC
receptor I-MISC B-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

Binding O-MISC O-MISC
of O-MISC O-MISC
progestins O-MISC B-MISC
to O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Correlation O-MISC O-MISC
to O-MISC O-MISC
their O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
functions O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
physiological O-MISC O-MISC
and O-MISC O-MISC
synthetic O-MISC B-MISC
progestins O-MISC B-MISC
were O-MISC O-MISC
tested O-MISC O-MISC
for O-MISC O-MISC
their O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
compete O-MISC O-MISC
with O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
of O-MISC O-MISC
human O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
and O-MISC O-MISC
their O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
elicit O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
reference O-MISC O-MISC
compound O-MISC O-MISC
dexamethasone O-MISC O-MISC
( O-MISC O-MISC
relative O-MISC O-MISC
receptor O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
defined O-MISC O-MISC
as O-MISC O-MISC
100 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
two O-MISC O-MISC
potent O-MISC O-MISC
synthetic O-MISC O-MISC
progestins O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
pregnane O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
structure O-MISC O-MISC
, O-MISC O-MISC
megestrol O-MISC O-MISC
acetate O-MISC O-MISC
and O-MISC O-MISC
medroxyprogesterone O-MISC O-MISC
acetate O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
display O-MISC O-MISC
a O-MISC O-MISC
considerable O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
towards O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
( O-MISC O-MISC
46 O-MISC O-MISC
and O-MISC O-MISC
42 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
relative O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
naturally O-MISC O-MISC
occurring O-MISC O-MISC
ligand O-MISC O-MISC
, O-MISC O-MISC
cortisol O-MISC O-MISC
, O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
was O-MISC O-MISC
clearly O-MISC O-MISC
lower O-MISC O-MISC
( O-MISC O-MISC
25 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effective O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
medroxyprogesterone O-MISC O-MISC
acetate O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
was O-MISC O-MISC
confirmed O-MISC O-MISC
by O-MISC O-MISC
direct O-MISC O-MISC
binding O-MISC O-MISC
studies O-MISC O-MISC
utilizing O-MISC O-MISC
a O-MISC O-MISC
tritiated O-MISC O-MISC
derivative O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
steroid O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC O-MISC
progesterone B-MISC B-MISC
receptor I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
was O-MISC O-MISC
obtained O-MISC O-MISC
as O-MISC O-MISC
judged O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
of O-MISC O-MISC
competition O-MISC O-MISC
experiments O-MISC O-MISC
where O-MISC O-MISC
a O-MISC O-MISC
progesterone O-MISC B-MISC
receptor O-MISC I-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
ligand O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
Org O-MISC O-MISC
2058 O-MISC O-MISC
was O-MISC O-MISC
used O-MISC O-MISC
. O-MISC O-MISC

Medroxyprogesterone O-MISC O-MISC
acetate O-MISC O-MISC
and O-MISC O-MISC
megestrol O-MISC O-MISC
acetate O-MISC O-MISC
also O-MISC O-MISC
induced O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
lymphocyte O-MISC O-MISC
functions O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
included O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proliferative O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
mitogens I-MISC I-MISC
concanavalin B-MISC O-MISC
A I-MISC I-MISC
and O-MISC O-MISC
phytohaemagglutinin B-MISC B-MISC
and O-MISC O-MISC
an O-MISC O-MISC
enhanced O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin O-MISC B-MISC
secreting O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
pokeweed O-MISC B-MISC
mitogen O-MISC B-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
cultures O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
progestin O-MISC B-MISC
effect O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
mediated O-MISC O-MISC
through O-MISC O-MISC
a O-MISC O-MISC
radiosensitive O-MISC O-MISC
( O-MISC O-MISC
suppressor O-MISC O-MISC
) O-MISC O-MISC
subpopulation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
synthetic O-MISC O-MISC
progestins O-MISC B-MISC
related O-MISC O-MISC
structurally O-MISC O-MISC
to O-MISC O-MISC
19 O-MISC O-MISC
- O-MISC O-MISC
nortestosterone O-MISC O-MISC
, O-MISC O-MISC
norethisterone O-MISC O-MISC
and O-MISC O-MISC
d O-MISC O-MISC
- O-MISC O-MISC
norgestrel O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
virtually O-MISC O-MISC
devoid O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
towards O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC O-MISC
receptor I-MISC O-MISC
nor O-MISC O-MISC
did O-MISC O-MISC
they O-MISC O-MISC
measurably O-MISC O-MISC
influence O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
lymphocyte O-MISC O-MISC
functions O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
studies O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
certain O-MISC O-MISC
progestins O-MISC B-MISC
in O-MISC O-MISC
common O-MISC O-MISC
clinical O-MISC O-MISC
use O-MISC O-MISC
probably O-MISC O-MISC
possess O-MISC O-MISC
inherent O-MISC O-MISC
glucocorticoid O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
side O-MISC O-MISC
effects O-MISC O-MISC
attributable O-MISC O-MISC
to O-MISC O-MISC
this O-MISC O-MISC
character O-MISC O-MISC
( O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
g O-MISC O-MISC
. O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
pituitary O-MISC O-MISC
- O-MISC O-MISC
adrenal O-MISC O-MISC
axis O-MISC O-MISC
) O-MISC O-MISC
might O-MISC O-MISC
be O-MISC O-MISC
expected O-MISC O-MISC
when O-MISC O-MISC
these O-MISC O-MISC
compounds O-MISC O-MISC
are O-MISC O-MISC
used O-MISC O-MISC
in O-MISC O-MISC
pharmacological O-MISC O-MISC
doses O-MISC O-MISC
. O-MISC O-MISC

Metabolic O-MISC O-MISC
and O-MISC O-MISC
ultrastructural O-MISC O-MISC
aspects O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
lysis O-MISC O-MISC
of O-MISC O-MISC
chronic O-MISC O-MISC
lymphocytic O-MISC O-MISC
leukemia O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
chronic O-MISC O-MISC
lymphocytic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
CLL O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
like O-MISC O-MISC
prothymocytes O-MISC O-MISC
and O-MISC O-MISC
immunoactivated O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lymphocytes O-MISC O-MISC
are O-MISC O-MISC
readily O-MISC O-MISC
lysed O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
by O-MISC O-MISC
pharmacological O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
cortisol O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
thymocytes O-MISC O-MISC
are O-MISC O-MISC
unaffected O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
hormone B-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
metabolic O-MISC O-MISC
and O-MISC O-MISC
ultrastructural O-MISC O-MISC
aspects O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cortisol O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
killing O-MISC O-MISC
process O-MISC O-MISC
of O-MISC O-MISC
CLL O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
recorded O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
vitro O-MISC O-MISC
lysis O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
temperature O-MISC O-MISC
dependent O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
only O-MISC O-MISC
after O-MISC O-MISC
6 O-MISC O-MISC
to O-MISC O-MISC
8 O-MISC O-MISC
hr O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
cortisol O-MISC O-MISC
by O-MISC O-MISC
means O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
trypan O-MISC O-MISC
blue O-MISC O-MISC
exclusion O-MISC O-MISC
test O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
30 O-MISC O-MISC
min O-MISC O-MISC
of O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
cortisol O-MISC O-MISC
at O-MISC O-MISC
either O-MISC O-MISC
37 O-MISC O-MISC
degrees O-MISC O-MISC
or O-MISC O-MISC
4 O-MISC O-MISC
degrees O-MISC O-MISC
followed O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
removal O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
hormone B-MISC O-MISC
was O-MISC O-MISC
still O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
the O-MISC O-MISC
lytic O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

Ultrastructural O-MISC O-MISC
studies O-MISC O-MISC
demonstrated O-MISC O-MISC
sequential O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytoplasm O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
swelling O-MISC O-MISC
of O-MISC O-MISC
mitochondria O-MISC O-MISC
and O-MISC O-MISC
cytoplasmic O-MISC O-MISC
decompartmentalizati O-MISC O-MISC
, O-MISC O-MISC
followed O-MISC O-MISC
by O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
surface O-MISC O-MISC
microvilli O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
appearance O-MISC O-MISC
of O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
holes O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
membrane O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
subsequent O-MISC O-MISC
condensation O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
chromatin I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
large O-MISC O-MISC
holes O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
membrane O-MISC O-MISC
appearing O-MISC O-MISC
after O-MISC O-MISC
6 O-MISC O-MISC
hr O-MISC O-MISC
of O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
hormone B-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
the O-MISC O-MISC
cause O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
penetration O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
viable O-MISC O-MISC
stain O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
dead O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
seen O-MISC O-MISC
by O-MISC O-MISC
light O-MISC O-MISC
microscopy O-MISC O-MISC
. O-MISC O-MISC

Addition O-MISC O-MISC
of O-MISC O-MISC
metabolic O-MISC O-MISC
inhibitors O-MISC O-MISC
including O-MISC O-MISC
actinomycin O-MISC O-MISC
D O-MISC O-MISC
, O-MISC O-MISC
puromycin O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
cycloheximide O-MISC O-MISC
following O-MISC O-MISC
administration O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
lysis O-MISC O-MISC
. O-MISC O-MISC

An O-MISC O-MISC
excess O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
antagonist O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
cortexolone O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
the O-MISC O-MISC
cortisol O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cytolysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CLL O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
suggested O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
lysis O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
CLL O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
phenomenon O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
rat O-MISC O-MISC
or O-MISC O-MISC
murine O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
interaction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
steroid O-MISC B-MISC
molecule O-MISC I-MISC
with O-MISC O-MISC
the O-MISC O-MISC
cytoplasmic B-MISC B-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
resulting O-MISC O-MISC
complex O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
specific O-MISC O-MISC
gene B-MISC O-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
the O-MISC O-MISC
products O-MISC O-MISC
of O-MISC O-MISC
which O-MISC O-MISC
eventually O-MISC O-MISC
cause O-MISC O-MISC
cytolysis O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
lymphoid O-MISC O-MISC
tumors O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
range O-MISC O-MISC
of O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
numbers O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
various O-MISC O-MISC
subclasses O-MISC O-MISC
of O-MISC O-MISC
acute O-MISC O-MISC
lymphatic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
ALL O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
variability O-MISC O-MISC
can O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
explained O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
known O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
active O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
receptors O-MISC O-MISC
, O-MISC O-MISC
since O-MISC O-MISC
the O-MISC O-MISC
tumors O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
highest O-MISC O-MISC
growth O-MISC O-MISC
fraction O-MISC O-MISC
( O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Burkitt O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
lymphoma O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
) O-MISC O-MISC
tend O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
lower O-MISC O-MISC
average O-MISC O-MISC
receptor O-MISC O-MISC
numbers O-MISC O-MISC
than O-MISC O-MISC
do O-MISC O-MISC
tumors O-MISC O-MISC
with O-MISC O-MISC
lower O-MISC O-MISC
growth O-MISC O-MISC
fractions O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
common O-MISC O-MISC
ALL O-MISC O-MISC
. O-MISC O-MISC

All O-MISC O-MISC
clinical O-MISC O-MISC
specimens O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
lymphatic O-MISC O-MISC
leukemia O-MISC O-MISC
have O-MISC O-MISC
some O-MISC O-MISC
measurable O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
; O-MISC O-MISC
therefore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
resistance O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
can O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
explained O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
lack O-MISC O-MISC
of O-MISC O-MISC
receptors O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
a O-MISC O-MISC
positive O-MISC O-MISC
correlation O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
our O-MISC O-MISC
hands O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
receptor O-MISC O-MISC
level O-MISC O-MISC
and O-MISC O-MISC
prognosis O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
the O-MISC O-MISC
basis O-MISC O-MISC
of O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
models O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
proposed O-MISC O-MISC
that O-MISC O-MISC
perhaps O-MISC O-MISC
the O-MISC O-MISC
high O-MISC O-MISC
receptor O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
( O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
common O-MISC O-MISC
ALL O-MISC O-MISC
of O-MISC O-MISC
childhood O-MISC O-MISC
) O-MISC O-MISC
have O-MISC O-MISC
relative O-MISC O-MISC
stability O-MISC O-MISC
of O-MISC O-MISC
their O-MISC O-MISC
genetic O-MISC O-MISC
material O-MISC O-MISC
making O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
mutations O-MISC O-MISC
less O-MISC O-MISC
likely O-MISC O-MISC
to O-MISC O-MISC
occur O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
low O-MISC B-MISC
- O-MISC O-MISC
receptor O-MISC I-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
( O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
greater O-MISC O-MISC
genetic O-MISC O-MISC
variability O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
low O-MISC O-MISC
- O-MISC O-MISC
receptor O-MISC O-MISC
lines O-MISC O-MISC
could O-MISC O-MISC
account O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
earlier O-MISC O-MISC
emergence O-MISC O-MISC
of O-MISC O-MISC
clinical O-MISC O-MISC
glucocorticoid O-MISC O-MISC
resistance O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

[ O-MISC O-MISC
Tumor O-MISC B-MISC
histology O-MISC I-MISC
and O-MISC I-MISC
steroid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
breast O-MISC O-MISC
carcinoma O-MISC O-MISC
] O-MISC O-MISC

In O-MISC O-MISC
Specimens O-MISC O-MISC
of O-MISC O-MISC
115 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
4 O-MISC O-MISC
tumorparameters O-MISC O-MISC
( O-MISC O-MISC
tumorsize O-MISC O-MISC
, O-MISC O-MISC
tumorboder O-MISC O-MISC
, O-MISC O-MISC
nucleargrade O-MISC O-MISC
, O-MISC O-MISC
lymphocytic O-MISC O-MISC
stromal O-MISC O-MISC
reaction O-MISC O-MISC
) O-MISC O-MISC
3 O-MISC O-MISC
features O-MISC O-MISC
of O-MISC O-MISC
regional O-MISC O-MISC
lymphnodes O-MISC O-MISC
( O-MISC O-MISC
sinushistiocytosis O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cellreaction O-MISC O-MISC
, O-MISC O-MISC
lymphnode O-MISC O-MISC
metastases O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
estrogen B-MISC O-MISC
and I-MISC I-MISC
progesteron I-MISC B-MISC
receptors I-MISC I-MISC
were O-MISC O-MISC
determined O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
strong O-MISC O-MISC
sinushistiocytosis O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cellreaction O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
verified O-MISC O-MISC
mainly O-MISC O-MISC
in O-MISC O-MISC
metastases O-MISC O-MISC
in O-MISC O-MISC
free O-MISC O-MISC
lymphnodes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
steroid B-MISC B-MISC
receptor I-MISC I-MISC
content O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
correlate O-MISC O-MISC
with O-MISC O-MISC
histological O-MISC O-MISC
parameters O-MISC O-MISC

Aldosterone B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
deficiency O-MISC O-MISC
in O-MISC O-MISC
pseudohypoaldosteron O-MISC O-MISC
. O-MISC O-MISC

Pseudohypoaldosteron O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
syndrome O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
salt O-MISC O-MISC
wasting O-MISC O-MISC
and O-MISC O-MISC
failure O-MISC O-MISC
to O-MISC O-MISC
thrive O-MISC O-MISC
, O-MISC O-MISC
usually O-MISC O-MISC
presents O-MISC O-MISC
in O-MISC O-MISC
infancy O-MISC O-MISC
as O-MISC O-MISC
high O-MISC O-MISC
urinary O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
sodium O-MISC O-MISC
despite O-MISC O-MISC
hyponatremia O-MISC O-MISC
, O-MISC O-MISC
hyperkalemia O-MISC O-MISC
, O-MISC O-MISC
hyperreninemia O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
elevated O-MISC O-MISC
aldosterone O-MISC O-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
investigated O-MISC O-MISC
this O-MISC O-MISC
syndrome O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
possibility O-MISC O-MISC
of O-MISC O-MISC
abnormal B-MISC O-MISC
Type I-MISC O-MISC
I I-MISC O-MISC
or O-MISC O-MISC
` B-MISC O-MISC
` I-MISC O-MISC
mineralocorticoid I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
' I-MISC I-MISC
' I-MISC I-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
have O-MISC O-MISC
intrinsic O-MISC O-MISC
steroid O-MISC O-MISC
specificity O-MISC O-MISC
indistinguishable O-MISC O-MISC
from O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
renal B-MISC B-MISC
mineralocorticoid I-MISC I-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
are O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
many O-MISC O-MISC
tissues O-MISC O-MISC
and O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
studied O-MISC O-MISC
three O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
pseudohypoaldosteron O-MISC O-MISC
: O-MISC O-MISC
the O-MISC O-MISC
28 O-MISC O-MISC
- O-MISC O-MISC
year O-MISC O-MISC
- O-MISC O-MISC
old O-MISC O-MISC
index O-MISC O-MISC
case O-MISC O-MISC
in O-MISC O-MISC
Melbourne O-MISC O-MISC
( O-MISC O-MISC
Patient O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
two O-MISC O-MISC
siblings O-MISC O-MISC
in O-MISC O-MISC
Munich O-MISC O-MISC
, O-MISC O-MISC
eight O-MISC O-MISC
and O-MISC O-MISC
two O-MISC O-MISC
years O-MISC O-MISC
of O-MISC O-MISC
age O-MISC O-MISC
( O-MISC O-MISC
Patients O-MISC O-MISC
2 O-MISC O-MISC
and O-MISC O-MISC
3 O-MISC O-MISC
) O-MISC O-MISC
; O-MISC O-MISC
clinically O-MISC O-MISC
, O-MISC O-MISC
Patient O-MISC O-MISC
3 O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
less O-MISC O-MISC
severe O-MISC O-MISC
case O-MISC O-MISC
than O-MISC O-MISC
his O-MISC O-MISC
sister O-MISC O-MISC
. O-MISC O-MISC

Percoll O-MISC O-MISC
- O-MISC O-MISC
separated O-MISC O-MISC
control O-MISC O-MISC
monocytes O-MISC O-MISC
bound O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
aldosterone O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
( O-MISC O-MISC
Kd O-MISC O-MISC
approximately O-MISC O-MISC
3 O-MISC O-MISC
nM O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
limited O-MISC O-MISC
capacity O-MISC O-MISC
( O-MISC O-MISC
150 O-MISC O-MISC
to O-MISC O-MISC
600 O-MISC O-MISC
sites O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
repeated O-MISC O-MISC
examination O-MISC O-MISC
, O-MISC O-MISC
no O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
aldosterone O-MISC O-MISC
binding O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
from O-MISC O-MISC
Patients O-MISC O-MISC
1 O-MISC O-MISC
and O-MISC O-MISC
2 O-MISC O-MISC
; O-MISC O-MISC
in O-MISC O-MISC
Patient O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
levels O-MISC O-MISC
were O-MISC O-MISC
62 O-MISC O-MISC
sites O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
, O-MISC O-MISC
more O-MISC O-MISC
than O-MISC O-MISC
2 O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
D O-MISC O-MISC
. O-MISC O-MISC
below O-MISC O-MISC
those O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
. O-MISC O-MISC

Levels O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
parents O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Munich O-MISC O-MISC
patients O-MISC O-MISC
( O-MISC O-MISC
first O-MISC O-MISC
cousins O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
normal O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
appears O-MISC O-MISC
that O-MISC O-MISC
pseudohypoaldosteron O-MISC O-MISC
is O-MISC O-MISC
caused O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
Type O-MISC B-MISC
I O-MISC I-MISC
receptor O-MISC I-MISC
defect O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
defect O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
complete O-MISC O-MISC
or O-MISC O-MISC
partial O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
transmission O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
autosomal O-MISC O-MISC
recessive O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
study O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
pseudohypoaldosteron O-MISC O-MISC
may O-MISC O-MISC
indicate O-MISC O-MISC
physiologic O-MISC O-MISC
roles O-MISC O-MISC
for O-MISC O-MISC
Type B-MISC B-MISC
I I-MISC I-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
nonepithelial O-MISC O-MISC
tissues O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
urokinase B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
plasminogen I-MISC I-MISC
activators I-MISC I-MISC
in O-MISC O-MISC
cultured O-MISC O-MISC
human O-MISC O-MISC
lymphoblasts O-MISC O-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
human O-MISC O-MISC
lymphoblast O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
LICR O-MISC O-MISC
- O-MISC O-MISC
LON O-MISC O-MISC
- O-MISC O-MISC
HMy2 O-MISC O-MISC
( O-MISC O-MISC
HMy2 O-MISC O-MISC
cells O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
GM4672A O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
are O-MISC O-MISC
moderately O-MISC O-MISC
growth O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
dexamethasone O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
pregnadien O-MISC B-MISC
- O-MISC I-MISC
9 O-MISC I-MISC
- O-MISC I-MISC
fluoro O-MISC I-MISC
- O-MISC I-MISC
16 O-MISC I-MISC
alpha O-MISC I-MISC
- O-MISC I-MISC
methyl O-MISC I-MISC
- O-MISC I-MISC
11 O-MISC I-MISC
beta O-MISC I-MISC
, O-MISC O-MISC
17 O-MISC O-MISC
alpha O-MISC I-MISC
, O-MISC O-MISC
21 O-MISC O-MISC
- O-MISC O-MISC
triol O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
20 O-MISC O-MISC
- O-MISC O-MISC
dione O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
Dex O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
secrete O-MISC O-MISC
a O-MISC O-MISC
urokinase B-MISC B-MISC
( I-MISC I-MISC
UK I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
plasminogen I-MISC I-MISC
activator I-MISC I-MISC
( O-MISC O-MISC
PA B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
HMy2 O-MISC O-MISC
and O-MISC O-MISC
GM4672A O-MISC B-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
Dex O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
days O-MISC O-MISC
inhibits O-MISC O-MISC
extracellular O-MISC O-MISC
PA B-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
concentration O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
, O-MISC O-MISC
being O-MISC O-MISC
half O-MISC O-MISC
- O-MISC O-MISC
maximal O-MISC O-MISC
at O-MISC O-MISC
approximately O-MISC O-MISC
1 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
PA B-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
is O-MISC O-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
active O-MISC O-MISC
glucocorticoids O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
this O-MISC O-MISC
specificity O-MISC O-MISC
parallels O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
various O-MISC O-MISC
steroids O-MISC O-MISC
to O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

HMy2 O-MISC O-MISC
cell O-MISC O-MISC
PA B-MISC O-MISC
is O-MISC O-MISC
fully O-MISC O-MISC
suppressible O-MISC O-MISC
by O-MISC O-MISC
Dex O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
up O-MISC O-MISC
to O-MISC O-MISC
one O-MISC O-MISC
third O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
activator O-MISC O-MISC
expressed O-MISC O-MISC
by O-MISC O-MISC
GM4672A O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
glucocorticoid O-MISC O-MISC
inhibition O-MISC O-MISC
. O-MISC O-MISC

Mixing O-MISC O-MISC
experiments O-MISC O-MISC
using O-MISC O-MISC
a O-MISC O-MISC
UK O-MISC O-MISC
standard O-MISC O-MISC
and O-MISC O-MISC
conditioned O-MISC O-MISC
media O-MISC O-MISC
from O-MISC O-MISC
Dex O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
cells O-MISC O-MISC
suggest O-MISC O-MISC
an O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC O-MISC
- I-MISC O-MISC
inducible I-MISC O-MISC
inhibitors I-MISC O-MISC
to O-MISC O-MISC
UK B-MISC O-MISC
or O-MISC O-MISC
plasmin B-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
conditioned O-MISC O-MISC
media O-MISC O-MISC
from O-MISC O-MISC
Dex O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
GM4672A O-MISC O-MISC
cells O-MISC O-MISC
inhibits O-MISC O-MISC
a O-MISC O-MISC
portion O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
homologous O-MISC O-MISC
cellular O-MISC O-MISC
activator O-MISC O-MISC
in O-MISC O-MISC
conditioned O-MISC O-MISC
media O-MISC O-MISC
from O-MISC O-MISC
control O-MISC O-MISC
GM4672A O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
low O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC O-MISC
- I-MISC O-MISC
inducible I-MISC O-MISC
inhibitors I-MISC O-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
can O-MISC O-MISC
not O-MISC O-MISC
fully O-MISC O-MISC
account O-MISC O-MISC
for O-MISC O-MISC
, O-MISC O-MISC
Dex O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
GM4672A B-MISC O-MISC
PA I-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC O-MISC
- I-MISC O-MISC
inducible I-MISC O-MISC
inhibitors I-MISC O-MISC
in O-MISC O-MISC
HMy2 O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
either O-MISC O-MISC
totally O-MISC O-MISC
absent O-MISC O-MISC
or O-MISC O-MISC
are O-MISC O-MISC
present O-MISC O-MISC
at O-MISC O-MISC
undetectable O-MISC O-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
UK B-MISC O-MISC
- I-MISC O-MISC
like I-MISC O-MISC
PAs I-MISC O-MISC
in O-MISC O-MISC
HMy2 O-MISC O-MISC
and O-MISC O-MISC
GM4672A O-MISC O-MISC
cells O-MISC O-MISC
differs O-MISC O-MISC
with O-MISC O-MISC
respect O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
extent O-MISC O-MISC
to O-MISC O-MISC
which O-MISC O-MISC
glucocorticoids O-MISC O-MISC
inhibit O-MISC O-MISC
constitutively B-MISC O-MISC
expressed I-MISC O-MISC
activator I-MISC O-MISC
levels O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
possible O-MISC O-MISC
contribution O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC O-MISC
- I-MISC O-MISC
inducible I-MISC O-MISC
inhibitors I-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
regulatory O-MISC O-MISC
process O-MISC O-MISC
in O-MISC O-MISC
GM4672A O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Characterization O-MISC O-MISC
of O-MISC O-MISC
aldosterone O-MISC B-MISC
binding O-MISC I-MISC
sites O-MISC I-MISC
in O-MISC O-MISC
circulating O-MISC O-MISC
human O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
. O-MISC O-MISC

Aldosterone O-MISC B-MISC
binding O-MISC I-MISC
sites O-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
were O-MISC O-MISC
characterized O-MISC O-MISC
after O-MISC O-MISC
separation O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
blood O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
Percoll O-MISC O-MISC
gradient O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
washing O-MISC O-MISC
and O-MISC O-MISC
resuspension O-MISC O-MISC
in O-MISC O-MISC
RPMI O-MISC O-MISC
- O-MISC O-MISC
1640 O-MISC O-MISC
medium O-MISC O-MISC
, O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
incubated O-MISC O-MISC
at O-MISC O-MISC
37 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
h O-MISC O-MISC
with O-MISC O-MISC
different O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
aldosterone O-MISC O-MISC
plus O-MISC O-MISC
a O-MISC O-MISC
100 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
RU O-MISC O-MISC
- O-MISC O-MISC
26988 O-MISC O-MISC
( O-MISC O-MISC
11 O-MISC O-MISC
alpha O-MISC O-MISC
, O-MISC O-MISC
17 O-MISC O-MISC
alpha O-MISC O-MISC
- O-MISC O-MISC
dihydroxy O-MISC O-MISC
- O-MISC O-MISC
17 O-MISC O-MISC
beta O-MISC O-MISC
- O-MISC O-MISC
propynylandrost O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
trien O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
one O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
or O-MISC O-MISC
without O-MISC O-MISC
an O-MISC O-MISC
excess O-MISC O-MISC
of O-MISC O-MISC
unlabeled O-MISC O-MISC
aldosterone O-MISC O-MISC
. O-MISC O-MISC

Aldosterone O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
class O-MISC O-MISC
of O-MISC O-MISC
receptors O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
nM O-MISC O-MISC
( O-MISC O-MISC
means O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
SD O-MISC O-MISC
, O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
14 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
capacity O-MISC O-MISC
of O-MISC O-MISC
290 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
108 O-MISC O-MISC
sites O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
14 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
specificity O-MISC O-MISC
data O-MISC O-MISC
show O-MISC O-MISC
a O-MISC O-MISC
hierarchy O-MISC O-MISC
of O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
desoxycorticosterone O-MISC O-MISC
= O-MISC O-MISC
corticosterone O-MISC O-MISC
= O-MISC O-MISC
aldosterone O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
hydrocortisone O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
dexamethasone O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
useful O-MISC O-MISC
for O-MISC O-MISC
studying O-MISC O-MISC
the O-MISC O-MISC
physiological O-MISC O-MISC
significance O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
mineralocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
their O-MISC O-MISC
regulation O-MISC O-MISC
in O-MISC O-MISC
humans O-MISC O-MISC
. O-MISC O-MISC

Mineralocorticoid B-MISC O-MISC
and I-MISC O-MISC
glucocorticoid I-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
circulating O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
primary O-MISC O-MISC
hyperaldosteronism O-MISC O-MISC
. O-MISC O-MISC

Mineralocorticoid B-MISC O-MISC
and I-MISC O-MISC
glucocorticoid I-MISC B-MISC
receptors I-MISC I-MISC
were O-MISC O-MISC
measured O-MISC O-MISC
in O-MISC O-MISC
circulating O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
in O-MISC O-MISC
5 O-MISC O-MISC
patients O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
Conn O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
syndrome O-MISC O-MISC
( O-MISC O-MISC
3 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
bilateral O-MISC O-MISC
adrenal O-MISC O-MISC
hyperplasia O-MISC O-MISC
and O-MISC O-MISC
2 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
adenoma O-MISC O-MISC
plus O-MISC O-MISC
unilateral O-MISC O-MISC
hyperplasia O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC B-MISC
sites O-MISC I-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
resulted O-MISC O-MISC
significantly O-MISC O-MISC
lower O-MISC O-MISC
( O-MISC O-MISC
189 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
114 O-MISC O-MISC
, O-MISC O-MISC
mean O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
SD O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
normal O-MISC O-MISC
controls O-MISC O-MISC
( O-MISC O-MISC
298 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
105 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
aldosterone O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
not O-MISC O-MISC
different O-MISC O-MISC
than O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
healthy O-MISC O-MISC
control O-MISC O-MISC
subjects O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
capacity O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
for O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
ranged O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
normal O-MISC O-MISC
values O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
a O-MISC O-MISC
possible O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
mineralocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
humans O-MISC O-MISC
. O-MISC O-MISC

Short O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
and O-MISC O-MISC
long O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
estrogen O-MISC O-MISC
on O-MISC O-MISC
lymphoid O-MISC O-MISC
tissues O-MISC O-MISC
and O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
some O-MISC O-MISC
remarks O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
significance O-MISC O-MISC
for O-MISC O-MISC
carcinogenesis O-MISC O-MISC
. O-MISC O-MISC

Estrogens O-MISC O-MISC
have O-MISC O-MISC
long O-MISC O-MISC
been O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
regulating O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
some O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
between O-MISC O-MISC
males O-MISC O-MISC
and O-MISC O-MISC
females O-MISC O-MISC
is O-MISC O-MISC
well O-MISC O-MISC
- O-MISC O-MISC
known O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
pronounced O-MISC O-MISC
thymic O-MISC O-MISC
involution O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
exogenous O-MISC O-MISC
estrogens O-MISC O-MISC
. O-MISC O-MISC

Estrogens O-MISC O-MISC
stimulate O-MISC O-MISC
some O-MISC O-MISC
aspects O-MISC O-MISC
of O-MISC O-MISC
macrophage O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
depending O-MISC O-MISC
on O-MISC O-MISC
dose O-MISC O-MISC
and O-MISC O-MISC
mitogen B-MISC O-MISC
, O-MISC O-MISC
inhibit O-MISC O-MISC
or O-MISC O-MISC
stimulate O-MISC O-MISC
lymphocyte O-MISC O-MISC
proliferative O-MISC O-MISC
response O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

Another O-MISC O-MISC
example O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
estrogen O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
delayed O-MISC O-MISC
type O-MISC O-MISC
hypersensitivity O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
broad O-MISC O-MISC
review O-MISC O-MISC
is O-MISC O-MISC
given O-MISC O-MISC
of O-MISC O-MISC
such O-MISC O-MISC
estrogen O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
lymphoid O-MISC O-MISC
tissue O-MISC O-MISC
and O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Most O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
studies O-MISC O-MISC
published O-MISC O-MISC
so O-MISC O-MISC
far O-MISC O-MISC
are O-MISC O-MISC
phenomenological O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
recent O-MISC O-MISC
description O-MISC O-MISC
of O-MISC O-MISC
estrogen B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
some O-MISC O-MISC
lymphocyte O-MISC O-MISC
subpopulations O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
deeper O-MISC O-MISC
understanding O-MISC O-MISC
of O-MISC O-MISC
regulating O-MISC O-MISC
factors O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
, O-MISC O-MISC
open O-MISC O-MISC
the O-MISC O-MISC
possibility O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
more O-MISC O-MISC
detailed O-MISC O-MISC
understanding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
estrogen O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
interference O-MISC O-MISC
. O-MISC O-MISC

Estrogen O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
adults O-MISC O-MISC
are O-MISC O-MISC
reversible O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
treating O-MISC O-MISC
neonatal O-MISC O-MISC
mice O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
synthetic O-MISC O-MISC
estrogen O-MISC O-MISC
diethylstilbestrol O-MISC O-MISC
( O-MISC O-MISC
DES O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
disturbances O-MISC O-MISC
are O-MISC O-MISC
induced O-MISC O-MISC
in O-MISC O-MISC
lymphocyte O-MISC O-MISC
populations O-MISC O-MISC
and O-MISC O-MISC
lymphocyte O-MISC O-MISC
functions O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
permanent O-MISC O-MISC
and O-MISC O-MISC
irreversible O-MISC O-MISC
. O-MISC O-MISC

Lymphocytes O-MISC O-MISC
from O-MISC O-MISC
adult O-MISC O-MISC
, O-MISC O-MISC
neonatally O-MISC O-MISC
DES O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
female O-MISC O-MISC
mice O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
reduced O-MISC O-MISC
mitogen O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
ConA B-MISC O-MISC
and O-MISC O-MISC
LPS B-MISC O-MISC
( O-MISC O-MISC
T B-MISC B-MISC
and I-MISC O-MISC
B I-MISC B-MISC
cell I-MISC I-MISC
mitogen I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
delayed O-MISC O-MISC
type O-MISC O-MISC
hypersensitivity O-MISC O-MISC
response O-MISC O-MISC
is O-MISC O-MISC
depressed O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
detailed O-MISC O-MISC
analysis O-MISC O-MISC
demonstrated O-MISC O-MISC
a O-MISC O-MISC
decreased O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
cell O-MISC O-MISC
population O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
Natural O-MISC O-MISC
Killer O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
permanently O-MISC O-MISC
reduced O-MISC O-MISC
and O-MISC O-MISC
this O-MISC O-MISC
functional O-MISC O-MISC
impairment O-MISC O-MISC
is O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
decreased O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
turn O-MISC O-MISC
determined O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
level O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
same O-MISC O-MISC
animals O-MISC O-MISC
have O-MISC O-MISC
an O-MISC O-MISC
increased O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
chemical O-MISC O-MISC
carcinogens O-MISC O-MISC
( O-MISC O-MISC
methylcholanthrene O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
they O-MISC O-MISC
spontaneously O-MISC O-MISC
develop O-MISC O-MISC
epithelial O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
uterine O-MISC O-MISC
cervix O-MISC O-MISC
which O-MISC O-MISC
morphologically O-MISC O-MISC
are O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
adenocarcinoma O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
association O-MISC O-MISC
between O-MISC O-MISC
estrogen O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
malignancy O-MISC O-MISC
and O-MISC O-MISC
estrogen O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
lymphocyte O-MISC O-MISC
functions O-MISC O-MISC
deserves O-MISC O-MISC
further O-MISC O-MISC
study O-MISC O-MISC
. O-MISC O-MISC

Drugs O-MISC O-MISC
affecting O-MISC O-MISC
the O-MISC O-MISC
hormonal O-MISC B-MISC
receptors O-MISC I-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
leukaemic O-MISC O-MISC
peripheral O-MISC O-MISC
leucocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
authors O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
behaviour O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
hormone O-MISC O-MISC
uptake O-MISC O-MISC
in O-MISC O-MISC
leukaemic O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
CML O-MISC O-MISC
, O-MISC O-MISC
CLL O-MISC O-MISC
, O-MISC O-MISC
AML O-MISC O-MISC
, O-MISC O-MISC
ALL O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
basal O-MISC O-MISC
conditions O-MISC O-MISC
and O-MISC O-MISC
after O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
drugs O-MISC O-MISC
which O-MISC O-MISC
modify O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
cAMP O-MISC O-MISC
, O-MISC O-MISC
PGE O-MISC O-MISC
and O-MISC O-MISC
PGF O-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
demonstrated O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
in O-MISC O-MISC
leukaemic O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
alteration O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
incorporation O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
hormones O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
alteration O-MISC O-MISC
was O-MISC O-MISC
scarcely O-MISC O-MISC
modified O-MISC O-MISC
by O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
theophylline B-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
increases O-MISC O-MISC
cellular O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
cAMP O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
hand O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
moderately O-MISC O-MISC
counteracted O-MISC O-MISC
by O-MISC O-MISC
thioproline O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
evidently O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
flurbiprofen O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
also O-MISC O-MISC
reduced O-MISC O-MISC
cellular O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
prostaglandins O-MISC B-MISC
, O-MISC O-MISC
particularly O-MISC O-MISC
PGE2 O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
exception O-MISC O-MISC
of O-MISC O-MISC
PGF2 O-MISC B-MISC
which O-MISC O-MISC
showed O-MISC O-MISC
a O-MISC O-MISC
poor O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Differences O-MISC O-MISC
were O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
behavior O-MISC O-MISC
of O-MISC O-MISC
hormonal O-MISC O-MISC
uptake O-MISC O-MISC
of O-MISC O-MISC
CML O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
AML O-MISC O-MISC
, O-MISC O-MISC
CLL O-MISC O-MISC
and O-MISC O-MISC
ALL O-MISC O-MISC
peripheral O-MISC O-MISC
leucocytes O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
and O-MISC O-MISC
impaired O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

Recent O-MISC O-MISC
advances O-MISC O-MISC
in O-MISC O-MISC
tumor O-MISC O-MISC
immunology O-MISC O-MISC
have O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
discovery O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
lymphoid O-MISC O-MISC
cell O-MISC O-MISC
with O-MISC O-MISC
unique O-MISC O-MISC
antitumor O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Natural O-MISC O-MISC
killer O-MISC O-MISC
( O-MISC O-MISC
NK O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
form O-MISC O-MISC
an O-MISC O-MISC
antitumor O-MISC O-MISC
surveillance O-MISC O-MISC
system O-MISC O-MISC
and O-MISC O-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
vital O-MISC O-MISC
in O-MISC O-MISC
preventing O-MISC O-MISC
tumor O-MISC O-MISC
growth O-MISC O-MISC
and O-MISC O-MISC
metastasis O-MISC O-MISC
in O-MISC O-MISC
animal O-MISC O-MISC
models O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
studied O-MISC O-MISC
NK O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
benign O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
breast O-MISC O-MISC
disease O-MISC O-MISC
, O-MISC O-MISC
using O-MISC O-MISC
a O-MISC O-MISC
chromium O-MISC O-MISC
- O-MISC O-MISC
51 O-MISC O-MISC
release O-MISC O-MISC
microtiter O-MISC B-MISC
cytotoxicity O-MISC O-MISC
assay O-MISC O-MISC
with O-MISC O-MISC
K562 O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
targets O-MISC O-MISC
. O-MISC O-MISC

Compared O-MISC O-MISC
with O-MISC O-MISC
benign O-MISC O-MISC
controls O-MISC O-MISC
, O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
malignancies O-MISC O-MISC
had O-MISC O-MISC
significantly O-MISC O-MISC
depressed O-MISC O-MISC
NK O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
lysis O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
lysis O-MISC O-MISC
in O-MISC O-MISC
those O-MISC O-MISC
with O-MISC O-MISC
advanced O-MISC O-MISC
disease O-MISC O-MISC
( O-MISC O-MISC
stages O-MISC O-MISC
II O-MISC O-MISC
, O-MISC O-MISC
III O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IV O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
those O-MISC O-MISC
with O-MISC O-MISC
limited O-MISC O-MISC
disease O-MISC O-MISC
( O-MISC O-MISC
stage O-MISC O-MISC
I O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

NK O-MISC B-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
correlated O-MISC O-MISC
to O-MISC O-MISC
estrogen O-MISC O-MISC
or O-MISC O-MISC
progesterone O-MISC B-MISC
receptor O-MISC I-MISC
states O-MISC O-MISC
. O-MISC O-MISC

Positive O-MISC O-MISC
correlation O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
depressed O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
activity O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
extent O-MISC O-MISC
of O-MISC O-MISC
tumor O-MISC O-MISC
spread O-MISC O-MISC
supports O-MISC O-MISC
the O-MISC O-MISC
concept O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
immune O-MISC O-MISC
surveillance O-MISC O-MISC
system O-MISC O-MISC
in O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
and O-MISC O-MISC
emphasizes O-MISC O-MISC
its O-MISC O-MISC
importance O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
malignancy O-MISC O-MISC
. O-MISC O-MISC

Immunosuppressive O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
serum O-MISC O-MISC
progesterone O-MISC O-MISC
during O-MISC O-MISC
pregnancy O-MISC O-MISC
depends O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
progesterone O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Cytotoxic O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
progesterone O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
together O-MISC O-MISC
with O-MISC O-MISC
serum O-MISC O-MISC
progesterone O-MISC O-MISC
concentrations O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
determined O-MISC O-MISC
in O-MISC O-MISC
women O-MISC O-MISC
with O-MISC O-MISC
normal O-MISC O-MISC
pregnancy O-MISC O-MISC
or O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
clinical O-MISC O-MISC
diagnosis O-MISC O-MISC
of O-MISC O-MISC
threatened O-MISC O-MISC
abortion O-MISC O-MISC
or O-MISC O-MISC
threatened O-MISC O-MISC
premature O-MISC O-MISC
labour O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
lymphocytes O-MISC O-MISC
of O-MISC O-MISC
women O-MISC O-MISC
with O-MISC O-MISC
threatened O-MISC O-MISC
abortion O-MISC O-MISC
or O-MISC O-MISC
threatened O-MISC O-MISC
premature O-MISC O-MISC
labour O-MISC O-MISC
showed O-MISC O-MISC
significantly O-MISC O-MISC
higher O-MISC O-MISC
cytotoxic O-MISC O-MISC
activity O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
significantly O-MISC O-MISC
lower O-MISC O-MISC
progesterone O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
) O-MISC O-MISC
than O-MISC O-MISC
did O-MISC O-MISC
lymphocytes O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
healthy O-MISC O-MISC
pregnant O-MISC O-MISC
women O-MISC O-MISC
. O-MISC O-MISC

Significant O-MISC O-MISC
inverse O-MISC O-MISC
correlation O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
between O-MISC O-MISC
progesterone O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
and O-MISC O-MISC
cytotoxic O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
lymphocytes O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
progesterone O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
pregnancy O-MISC O-MISC
serum O-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
no O-MISC O-MISC
influence O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
two O-MISC O-MISC
parameters O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
findings O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
intact O-MISC O-MISC
progesterone O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
lymphocytes O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
essential O-MISC O-MISC
factor O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
manifestation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
blocking O-MISC O-MISC
effect O-MISC O-MISC
exerted O-MISC O-MISC
by O-MISC O-MISC
pregnancy O-MISC O-MISC
serum O-MISC O-MISC
on O-MISC O-MISC
lymphocyte O-MISC O-MISC
cytotoxicity O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

Serum O-MISC O-MISC
sex O-MISC O-MISC
steroid O-MISC O-MISC
and O-MISC O-MISC
peptide O-MISC O-MISC
hormone O-MISC O-MISC
concentrations O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
endometrial O-MISC O-MISC
estrogen O-MISC I-MISC
and O-MISC O-MISC
progestin O-MISC B-MISC
receptor O-MISC I-MISC
levels O-MISC O-MISC
during O-MISC O-MISC
administration O-MISC O-MISC
of O-MISC O-MISC
human B-MISC O-MISC
leukocyte I-MISC O-MISC
interferon I-MISC I-MISC
. O-MISC O-MISC

Five O-MISC O-MISC
normally O-MISC O-MISC
cycling O-MISC O-MISC
healthy O-MISC O-MISC
women O-MISC O-MISC
were O-MISC O-MISC
given O-MISC O-MISC
daily O-MISC O-MISC
subcutaneous O-MISC O-MISC
injections O-MISC O-MISC
of O-MISC O-MISC
human B-MISC O-MISC
leukocyte I-MISC O-MISC
interferon I-MISC I-MISC
( O-MISC O-MISC
3 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
units O-MISC O-MISC
/ O-MISC O-MISC
day O-MISC O-MISC
) O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
3rd O-MISC O-MISC
through O-MISC O-MISC
23rd O-MISC O-MISC
day O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
menstrual O-MISC O-MISC
cycle O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
serum O-MISC O-MISC
steroid O-MISC O-MISC
and O-MISC O-MISC
peptide O-MISC O-MISC
hormone O-MISC O-MISC
concentrations O-MISC O-MISC
monitored O-MISC O-MISC
at O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
day O-MISC O-MISC
intervals O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
preceding O-MISC O-MISC
control O-MISC O-MISC
cycle O-MISC O-MISC
. O-MISC O-MISC

Concentrations O-MISC O-MISC
of O-MISC O-MISC
cytosol B-MISC B-MISC
and I-MISC O-MISC
nuclear I-MISC B-MISC
estrogen I-MISC I-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
ERC B-MISC B-MISC
and O-MISC O-MISC
ERN B-MISC B-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
progestin B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
PRC B-MISC B-MISC
and O-MISC O-MISC
PRN B-MISC B-MISC
) O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
measured O-MISC O-MISC
from O-MISC O-MISC
endometrial O-MISC O-MISC
biopsies O-MISC O-MISC
taken O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
24th O-MISC O-MISC
day O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
and O-MISC O-MISC
treatment O-MISC O-MISC
cycle O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
extensive O-MISC O-MISC
monitoring O-MISC O-MISC
of O-MISC O-MISC
clinical O-MISC O-MISC
chemical O-MISC O-MISC
and O-MISC O-MISC
hematological O-MISC O-MISC
tests O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
blood O-MISC O-MISC
samples O-MISC O-MISC
were O-MISC O-MISC
performed O-MISC O-MISC
. O-MISC O-MISC

Serum O-MISC O-MISC
estradiol O-MISC O-MISC
and O-MISC O-MISC
progesterone O-MISC O-MISC
concentrations O-MISC O-MISC
were O-MISC O-MISC
significantly O-MISC O-MISC
decreased O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
cycle O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
interferon B-MISC B-MISC
interacts O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
FSH O-MISC O-MISC
and O-MISC O-MISC
LH O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
significant O-MISC O-MISC
changes O-MISC O-MISC
were O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
serum O-MISC O-MISC
peptide O-MISC O-MISC
hormone O-MISC O-MISC
concentrations O-MISC O-MISC
measured O-MISC O-MISC
( O-MISC O-MISC
FSH O-MISC O-MISC
, O-MISC O-MISC
LH O-MISC O-MISC
, O-MISC O-MISC
prolactin O-MISC O-MISC
, O-MISC O-MISC
insulin O-MISC O-MISC
, O-MISC O-MISC
growth O-MISC O-MISC
hormone O-MISC O-MISC
and O-MISC O-MISC
TSH O-MISC O-MISC
) O-MISC O-MISC
; O-MISC O-MISC
neither O-MISC O-MISC
were O-MISC O-MISC
the O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
endometrial B-MISC O-MISC
ERC I-MISC B-MISC
, I-MISC O-MISC
ERN I-MISC B-MISC
, I-MISC O-MISC
PRC I-MISC B-MISC
and I-MISC O-MISC
PRN I-MISC B-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
interferon B-MISC B-MISC
administration O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
expected O-MISC O-MISC
, O-MISC O-MISC
interferon B-MISC B-MISC
administration O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
decreased O-MISC O-MISC
leukocyte O-MISC O-MISC
counts O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
increasing O-MISC O-MISC
tendency O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
serum B-MISC B-MISC
alkaline I-MISC I-MISC
phosphatase I-MISC I-MISC
and O-MISC O-MISC
gamma B-MISC B-MISC
- I-MISC I-MISC
glutamyltransferase I-MISC I-MISC
during O-MISC O-MISC
the O-MISC O-MISC
interferon B-MISC B-MISC
therapy O-MISC O-MISC
shows O-MISC O-MISC
that O-MISC O-MISC
interferon B-MISC B-MISC
may O-MISC O-MISC
slightly O-MISC O-MISC
interfere O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
interferon B-MISC B-MISC
treatment O-MISC O-MISC
may O-MISC O-MISC
affect O-MISC O-MISC
the O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
hormone O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
neoplasms O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
the O-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
production O-MISC O-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
circulating O-MISC O-MISC
hormonal O-MISC O-MISC
compounds O-MISC O-MISC
. O-MISC O-MISC

[ O-MISC O-MISC
Glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
level O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
blood O-MISC O-MISC
leukocytes O-MISC O-MISC
in O-MISC O-MISC
different O-MISC O-MISC
acute O-MISC O-MISC
diseases O-MISC O-MISC
] O-MISC O-MISC

Content O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
cytosol O-MISC O-MISC
of O-MISC O-MISC
blood O-MISC O-MISC
leukocytes O-MISC O-MISC
, O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
and O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
leukocytes O-MISC O-MISC
in O-MISC O-MISC
blood O-MISC O-MISC
were O-MISC O-MISC
studied O-MISC O-MISC
in O-MISC O-MISC
20 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
impairments O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
second O-MISC O-MISC
day O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

Content O-MISC O-MISC
of O-MISC O-MISC
receptors O-MISC O-MISC
in O-MISC O-MISC
cytosol O-MISC O-MISC
of O-MISC O-MISC
blood O-MISC O-MISC
leukocytes O-MISC O-MISC
was O-MISC O-MISC
studied O-MISC O-MISC
using O-MISC O-MISC
3H O-MISC O-MISC
- O-MISC O-MISC
triamcinolone O-MISC O-MISC
acetonide O-MISC O-MISC
. O-MISC O-MISC

Distinct O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
leukocyte B-MISC B-MISC
glucocorticoid I-MISC I-MISC
receptors I-MISC I-MISC
was O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
poisoning O-MISC O-MISC
by O-MISC O-MISC
dichlorethane O-MISC O-MISC
and O-MISC O-MISC
hypnotic O-MISC O-MISC
drugs O-MISC O-MISC
under O-MISC O-MISC
conditions O-MISC O-MISC
of O-MISC O-MISC
acute O-MISC O-MISC
myocardial O-MISC O-MISC
infarction O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
acute O-MISC O-MISC
pancreatitis O-MISC O-MISC
content O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
leukocyte B-MISC B-MISC
receptors I-MISC I-MISC
was O-MISC O-MISC
not O-MISC O-MISC
altered O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

Concentration O-MISC O-MISC
of O-MISC O-MISC
endogenous O-MISC O-MISC
cortisol O-MISC O-MISC
was O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
blood O-MISC O-MISC
of O-MISC O-MISC
all O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
except O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
acetate O-MISC O-MISC
intoxication O-MISC O-MISC
. O-MISC O-MISC

Reverse O-MISC O-MISC
correlation O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
between O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
in O-MISC O-MISC
blood O-MISC O-MISC
and O-MISC O-MISC
content O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC B-MISC
receptors O-MISC I-MISC
in O-MISC O-MISC
leukocytes O-MISC O-MISC
. O-MISC O-MISC

But O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
pancreatitis O-MISC O-MISC
the O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
content O-MISC O-MISC
of O-MISC O-MISC
leukocyte B-MISC B-MISC
glucocorticoid I-MISC I-MISC
receptors I-MISC I-MISC
was O-MISC O-MISC
not O-MISC O-MISC
observed O-MISC O-MISC
although O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
cortisol O-MISC O-MISC
concentration O-MISC O-MISC
in O-MISC O-MISC
blood O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
immunological O-MISC O-MISC
processes O-MISC O-MISC
under O-MISC O-MISC
conditions O-MISC O-MISC
of O-MISC O-MISC
purulent O-MISC O-MISC
complications O-MISC O-MISC
and O-MISC O-MISC
possibility O-MISC O-MISC
to O-MISC O-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
metabolism O-MISC O-MISC
in O-MISC O-MISC
leukocytes O-MISC O-MISC

Therapeutic O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
suppress O-MISC O-MISC
the O-MISC O-MISC
antimicrobial O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
macrophages O-MISC O-MISC
without O-MISC O-MISC
impairing O-MISC O-MISC
their O-MISC O-MISC
responsiveness O-MISC O-MISC
to O-MISC O-MISC
gamma B-MISC B-MISC
interferon I-MISC B-MISC
. O-MISC O-MISC

By O-MISC O-MISC
exposing O-MISC O-MISC
human O-MISC O-MISC
blood O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
macrophages O-MISC O-MISC
and O-MISC O-MISC
alveolar O-MISC O-MISC
macrophages O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
to O-MISC O-MISC
dexamethasone O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
showed O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
studies O-MISC O-MISC
that O-MISC O-MISC
glucocorticoids O-MISC O-MISC
markedly O-MISC O-MISC
suppress O-MISC O-MISC
the O-MISC O-MISC
antimicrobial O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
macrophages O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
macrophage O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
lymphokines O-MISC B-MISC
. O-MISC O-MISC

As O-MISC O-MISC
little O-MISC O-MISC
as O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
) O-MISC O-MISC
mol O-MISC O-MISC
/ O-MISC O-MISC
liter O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
prevented O-MISC O-MISC
macrophages O-MISC O-MISC
from O-MISC O-MISC
inhibiting O-MISC O-MISC
germination O-MISC O-MISC
of O-MISC O-MISC
Aspergillus O-MISC O-MISC
spores O-MISC O-MISC
or O-MISC O-MISC
from O-MISC O-MISC
eliminating O-MISC O-MISC
ingested O-MISC O-MISC
bacteria O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
Listeria O-MISC O-MISC
, O-MISC O-MISC
Nocardia O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
Salmonella O-MISC O-MISC
. O-MISC O-MISC

Damage O-MISC O-MISC
to O-MISC O-MISC
macrophage O-MISC O-MISC
function O-MISC O-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
progesterone O-MISC O-MISC
and O-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
receptor O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
accordance O-MISC O-MISC
with O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
observations O-MISC O-MISC
, O-MISC O-MISC
dexamethasone O-MISC O-MISC
required O-MISC O-MISC
24 O-MISC O-MISC
- O-MISC O-MISC
36 O-MISC O-MISC
h O-MISC O-MISC
to O-MISC O-MISC
suppress O-MISC O-MISC
antimicrobial O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

While O-MISC O-MISC
glucocorticoids O-MISC O-MISC
interfered O-MISC O-MISC
with O-MISC O-MISC
base O-MISC O-MISC
- O-MISC O-MISC
line O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
macrophages O-MISC O-MISC
, O-MISC O-MISC
dexamethasone O-MISC O-MISC
concentrations O-MISC O-MISC
comparable O-MISC O-MISC
to O-MISC O-MISC
drug O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
macrophage O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Proliferating O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
gamma B-MISC B-MISC
- I-MISC I-MISC
interferon I-MISC I-MISC
thus O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
antimicrobial O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
phagocytes O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
over O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
control O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Macrophage O-MISC O-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
correction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
dexamethasone O-MISC O-MISC
effect O-MISC O-MISC
by O-MISC O-MISC
gamma B-MISC B-MISC
- I-MISC I-MISC
interferon I-MISC I-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
pathogen O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
lymphokine B-MISC B-MISC
enhanced O-MISC O-MISC
the O-MISC O-MISC
antimicrobial O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
macrophages O-MISC O-MISC
against O-MISC O-MISC
Listeria O-MISC O-MISC
and O-MISC O-MISC
Salmonella O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
against O-MISC O-MISC
Aspergillus O-MISC O-MISC
or O-MISC O-MISC
Nocardia O-MISC O-MISC
. O-MISC O-MISC

Dexamethasone O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
damage O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
antimicrobial O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
macrophages O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
parallels O-MISC O-MISC
observations O-MISC O-MISC
that O-MISC O-MISC
glucocorticoids O-MISC O-MISC
render O-MISC O-MISC
laboratory O-MISC O-MISC
animals O-MISC O-MISC
susceptible O-MISC O-MISC
to O-MISC O-MISC
listeriosis O-MISC O-MISC
and O-MISC O-MISC
aspergillosis O-MISC O-MISC
by O-MISC O-MISC
damaging O-MISC O-MISC
resident O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

Suppression O-MISC O-MISC
of O-MISC O-MISC
macrophage O-MISC O-MISC
antimicrobial O-MISC O-MISC
activity O-MISC O-MISC
should O-MISC O-MISC
thus O-MISC O-MISC
be O-MISC O-MISC
considered O-MISC O-MISC
when O-MISC O-MISC
treating O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
glucocorticoids O-MISC O-MISC
; O-MISC O-MISC
its O-MISC O-MISC
prevention O-MISC O-MISC
by O-MISC O-MISC
gamma B-MISC B-MISC
- I-MISC I-MISC
interferon I-MISC I-MISC
might O-MISC O-MISC
be O-MISC O-MISC
beneficial O-MISC O-MISC
for O-MISC O-MISC
some O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
all O-MISC O-MISC
pathogens O-MISC O-MISC
. O-MISC O-MISC

Interleukin B-MISC B-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
Tac B-MISC B-MISC
antigen I-MISC I-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
I O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
adult O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Interleukin B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
lymphokine B-MISC B-MISC
synthesized O-MISC O-MISC
by O-MISC O-MISC
some O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
following O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Resting O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
express O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
receptors O-MISC O-MISC
are O-MISC O-MISC
rapidly O-MISC O-MISC
expressed O-MISC O-MISC
on O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
following O-MISC O-MISC
interaction O-MISC O-MISC
of O-MISC O-MISC
antigens O-MISC B-MISC
, O-MISC O-MISC
mitogens O-MISC B-MISC
, O-MISC O-MISC
or O-MISC O-MISC
monoclonal B-MISC B-MISC
antibodies I-MISC I-MISC
with O-MISC O-MISC
the O-MISC O-MISC
antigen B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
T I-MISC I-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
complex I-MISC I-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
Tac I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
monoclonal B-MISC B-MISC
antibody I-MISC I-MISC
that O-MISC O-MISC
recognizes O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
purified O-MISC O-MISC
and O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
Mr O-MISC O-MISC
33 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
peptide O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
posttranslationally O-MISC O-MISC
glycosylated O-MISC I-MISC
to O-MISC O-MISC
a O-MISC O-MISC
Mr O-MISC O-MISC
55 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
mature O-MISC O-MISC
form O-MISC O-MISC
. O-MISC O-MISC

Normal O-MISC O-MISC
resting O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
most O-MISC O-MISC
leukemic O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
populations O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
express O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptors I-MISC I-MISC
; O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
11 O-MISC O-MISC
patients O-MISC O-MISC
examined O-MISC O-MISC
who O-MISC O-MISC
had O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphotropic O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
adult O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
expressed O-MISC O-MISC
the O-MISC O-MISC
Tac B-MISC B-MISC
antigen I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphotropic O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
I O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
Mr O-MISC B-MISC
42 O-MISC I-MISC
, O-MISC I-MISC
000 O-MISC I-MISC
long O-MISC I-MISC
open B-MISC I-MISC
reading I-MISC I-MISC
frame I-MISC I-MISC
protein I-MISC I-MISC
encoded O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
pX B-MISC B-MISC
region I-MISC I-MISC
of O-MISC O-MISC
this O-MISC O-MISC
virus O-MISC O-MISC
may O-MISC O-MISC
act O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
transacting B-MISC O-MISC
transcriptional I-MISC I-MISC
activator I-MISC I-MISC
that O-MISC O-MISC
induces O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
gene I-MISC I-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
thus O-MISC O-MISC
providing O-MISC O-MISC
an O-MISC O-MISC
explanation O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
constant O-MISC O-MISC
association O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
expression O-MISC O-MISC
with O-MISC O-MISC
adult O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphotropic O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
I O-MISC O-MISC
infection O-MISC O-MISC
of O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
constant O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
large O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptors I-MISC I-MISC
which O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
aberrant O-MISC O-MISC
may O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
uncontrolled O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
adult O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
Tac O-MISC B-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
adult O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
Tac I-MISC I-MISC
. O-MISC O-MISC

One O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
had O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
mo O-MISC O-MISC
remissions O-MISC O-MISC
of O-MISC O-MISC
his O-MISC O-MISC
leukemia O-MISC O-MISC
following O-MISC O-MISC
two O-MISC O-MISC
courses O-MISC O-MISC
of O-MISC O-MISC
therapy O-MISC O-MISC
with O-MISC O-MISC
this O-MISC O-MISC
monoclonal B-MISC B-MISC
antibody I-MISC I-MISC
directed O-MISC O-MISC
toward O-MISC O-MISC
this O-MISC O-MISC
growth B-MISC B-MISC
factor I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Lymphocyte O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
depressed O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
hypercortisolemia O-MISC O-MISC
. O-MISC O-MISC

Despite O-MISC O-MISC
elevated O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
serum O-MISC O-MISC
and O-MISC O-MISC
urinary O-MISC O-MISC
cortisol O-MISC O-MISC
, O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
depressive O-MISC O-MISC
illness O-MISC O-MISC
manifest O-MISC O-MISC
none O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
clinical O-MISC O-MISC
stigmata O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
excess O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
hypercortisolemia O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
clinical O-MISC O-MISC
effects O-MISC O-MISC
suggests O-MISC O-MISC
a O-MISC O-MISC
state O-MISC O-MISC
of O-MISC O-MISC
hormone O-MISC O-MISC
resistance O-MISC O-MISC
and O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
alterations O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Earlier O-MISC O-MISC
studies O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
small O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
cause O-MISC O-MISC
a O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

White O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
depressed O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
significant O-MISC O-MISC
hypercortisolemia O-MISC O-MISC
would O-MISC O-MISC
be O-MISC O-MISC
expected O-MISC O-MISC
to O-MISC O-MISC
show O-MISC O-MISC
a O-MISC O-MISC
similar O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
if O-MISC O-MISC
peripheral O-MISC O-MISC
tissues O-MISC O-MISC
are O-MISC O-MISC
adequately O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
and O-MISC O-MISC
sensitive O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
hormone O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
we O-MISC O-MISC
compared O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
to O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
and O-MISC O-MISC
depressed O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
hypercortisolemia O-MISC O-MISC
. O-MISC O-MISC

Lymphocytes O-MISC O-MISC
from O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
mean O-MISC O-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
10 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
66 O-MISC O-MISC
fm O-MISC O-MISC
/ O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
E O-MISC O-MISC
. O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
dissociation O-MISC O-MISC
constant O-MISC O-MISC
of O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
47 O-MISC O-MISC
nM O-MISC O-MISC
. O-MISC O-MISC

Lymphocytes O-MISC O-MISC
from O-MISC O-MISC
depressed O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
abnormal O-MISC O-MISC
0800 O-MISC O-MISC
h O-MISC O-MISC
serum O-MISC O-MISC
cortisol O-MISC O-MISC
after O-MISC O-MISC
dexamethasone O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
mean O-MISC O-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
8 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
75 O-MISC O-MISC
fm O-MISC O-MISC
/ O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
significantly O-MISC O-MISC
different O-MISC O-MISC
from O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
or O-MISC O-MISC
from O-MISC O-MISC
depressed O-MISC O-MISC
subjects O-MISC O-MISC
with O-MISC O-MISC
normal O-MISC O-MISC
post O-MISC O-MISC
- O-MISC O-MISC
dexamethasone O-MISC O-MISC
cortisol O-MISC O-MISC
levels O-MISC O-MISC
( O-MISC O-MISC
9 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
95 O-MISC O-MISC
fm O-MISC O-MISC
/ O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Lymphocytes O-MISC O-MISC
from O-MISC O-MISC
depressed O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
elevated O-MISC O-MISC
urinary O-MISC O-MISC
free O-MISC O-MISC
cortisol O-MISC O-MISC
excretion O-MISC O-MISC
( O-MISC O-MISC
UFC O-MISC O-MISC
) O-MISC O-MISC
also O-MISC O-MISC
had O-MISC O-MISC
normal O-MISC O-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
and O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
for O-MISC O-MISC
dexamethasone O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
lack O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
lymphocyte O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
concentration O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
excess O-MISC O-MISC
suggests O-MISC O-MISC
the O-MISC O-MISC
possibility O-MISC O-MISC
that O-MISC O-MISC
hypercortisolemia O-MISC O-MISC
in O-MISC O-MISC
depressive O-MISC O-MISC
illness O-MISC O-MISC
represents O-MISC O-MISC
a O-MISC O-MISC
state O-MISC O-MISC
of O-MISC O-MISC
peripheral O-MISC O-MISC
glucocorticoid O-MISC O-MISC
resistance O-MISC O-MISC
. O-MISC O-MISC

Structure O-MISC O-MISC
and O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
hormone I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
is O-MISC O-MISC
an O-MISC O-MISC
intracellular B-MISC B-MISC
protein I-MISC I-MISC
which O-MISC O-MISC
possesses O-MISC O-MISC
three O-MISC O-MISC
distinct O-MISC O-MISC
domains O-MISC O-MISC
, O-MISC O-MISC
one O-MISC O-MISC
that O-MISC O-MISC
binds O-MISC O-MISC
agonist O-MISC O-MISC
and O-MISC O-MISC
antagonist O-MISC O-MISC
steroids O-MISC O-MISC
, O-MISC O-MISC
one O-MISC O-MISC
that O-MISC O-MISC
binds O-MISC O-MISC
DNA O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
one O-MISC O-MISC
that O-MISC O-MISC
binds O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
antibodies I-MISC I-MISC
and O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
glucocorticoid O-MISC O-MISC
modulation O-MISC O-MISC
of O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
intact O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
receptor O-MISC O-MISC
number O-MISC O-MISC
, O-MISC O-MISC
affinity O-MISC O-MISC
and O-MISC O-MISC
activity O-MISC O-MISC
can O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
factors O-MISC O-MISC
that O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
that O-MISC O-MISC
act O-MISC O-MISC
indirectly O-MISC O-MISC
through O-MISC O-MISC
ill O-MISC O-MISC
- O-MISC O-MISC
defined O-MISC O-MISC
mechanisms O-MISC O-MISC
which O-MISC O-MISC
may O-MISC O-MISC
include O-MISC O-MISC
resumption O-MISC O-MISC
or O-MISC O-MISC
arrest O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
cycling O-MISC O-MISC
and O-MISC O-MISC
variations O-MISC O-MISC
in O-MISC O-MISC
intracellular O-MISC O-MISC
calcium O-MISC O-MISC
ion O-MISC O-MISC
concentrations O-MISC O-MISC
. O-MISC O-MISC

Some O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
factors O-MISC O-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
exert O-MISC O-MISC
their O-MISC O-MISC
effect O-MISC O-MISC
by O-MISC O-MISC
controlling O-MISC O-MISC
critical O-MISC O-MISC
receptor O-MISC O-MISC
properties O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
ATP O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
phosphorylation O-MISC O-MISC
, O-MISC O-MISC
integrity O-MISC O-MISC
of O-MISC O-MISC
thiol B-MISC O-MISC
groups I-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
exposure O-MISC O-MISC
of O-MISC O-MISC
key B-MISC O-MISC
amino I-MISC O-MISC
acid I-MISC O-MISC
residues I-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid O-MISC O-MISC
agonists O-MISC O-MISC
promote O-MISC O-MISC
the O-MISC O-MISC
' O-MISC O-MISC
transformation O-MISC O-MISC
' O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
state O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
competent O-MISC O-MISC
for O-MISC O-MISC
modulating O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid O-MISC O-MISC
antagonists O-MISC O-MISC
are O-MISC O-MISC
steroids O-MISC O-MISC
that O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
but O-MISC O-MISC
either O-MISC O-MISC
fail O-MISC O-MISC
to O-MISC O-MISC
produce O-MISC O-MISC
a O-MISC O-MISC
stable B-MISC O-MISC
complex I-MISC O-MISC
or O-MISC O-MISC
produce O-MISC O-MISC
a O-MISC O-MISC
stable B-MISC O-MISC
but I-MISC O-MISC
inefficient I-MISC O-MISC
complex I-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
substituent O-MISC O-MISC
groups O-MISC O-MISC
that O-MISC O-MISC
confer O-MISC O-MISC
agonist O-MISC O-MISC
or O-MISC O-MISC
antagonist O-MISC O-MISC
activity O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
steroid O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
identified O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
determinants O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
difference O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
level O-MISC O-MISC
remain O-MISC O-MISC
unknown O-MISC O-MISC
. O-MISC O-MISC

Most O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
data O-MISC O-MISC
on O-MISC O-MISC
receptor O-MISC O-MISC
regulation O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
accommodated O-MISC O-MISC
by O-MISC O-MISC
postulating O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
intracellular O-MISC O-MISC
cycle O-MISC O-MISC
that O-MISC O-MISC
involves O-MISC O-MISC
five O-MISC O-MISC
states O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
active O-MISC B-MISC
free O-MISC I-MISC
receptor O-MISC I-MISC
is O-MISC O-MISC
phosphorylated O-MISC O-MISC
, O-MISC O-MISC
reduced O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
presumably O-MISC O-MISC
oligomeric O-MISC O-MISC
( O-MISC O-MISC
state O-MISC O-MISC
A O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Following O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
agonist O-MISC O-MISC
( O-MISC O-MISC
state O-MISC O-MISC
B O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
can O-MISC O-MISC
become O-MISC O-MISC
transformed O-MISC O-MISC
by O-MISC O-MISC
dissociation O-MISC O-MISC
into O-MISC O-MISC
its O-MISC O-MISC
subunits O-MISC O-MISC
and O-MISC O-MISC
dephosphorylation O-MISC O-MISC
( O-MISC O-MISC
state O-MISC O-MISC
C O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transformed B-MISC O-MISC
receptor I-MISC O-MISC
then O-MISC O-MISC
interacts O-MISC O-MISC
with O-MISC O-MISC
chromatin B-MISC B-MISC
( O-MISC O-MISC
state O-MISC O-MISC
D O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Dissociation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
steroid O-MISC O-MISC
and O-MISC O-MISC
oxidation O-MISC O-MISC
of O-MISC O-MISC
receptor B-MISC O-MISC
thiol I-MISC O-MISC
group I-MISC O-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
inactive O-MISC B-MISC
receptor O-MISC I-MISC
form O-MISC O-MISC
( O-MISC O-MISC
state O-MISC O-MISC
E O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Reduction O-MISC O-MISC
and O-MISC O-MISC
rephosphorylation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
enable O-MISC O-MISC
it O-MISC O-MISC
to O-MISC O-MISC
bind O-MISC O-MISC
steroids O-MISC O-MISC
again O-MISC O-MISC
so O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
cycle O-MISC O-MISC
is O-MISC O-MISC
closed O-MISC O-MISC
. O-MISC O-MISC

Thermodynamics O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
glucocorticoid I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
thermodynamics O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
interaction O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
with O-MISC O-MISC
their O-MISC O-MISC
receptor O-MISC O-MISC
were O-MISC O-MISC
studied O-MISC O-MISC
in O-MISC O-MISC
cytosol O-MISC O-MISC
from O-MISC O-MISC
human O-MISC O-MISC
lymphoblastoid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
rate O-MISC O-MISC
and O-MISC O-MISC
affinity O-MISC O-MISC
constants O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
and O-MISC O-MISC
cortisol O-MISC O-MISC
between O-MISC O-MISC
0 O-MISC O-MISC
degree O-MISC O-MISC
and O-MISC O-MISC
25 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
were O-MISC O-MISC
calculated O-MISC O-MISC
by O-MISC O-MISC
curve O-MISC O-MISC
- O-MISC O-MISC
fitting O-MISC O-MISC
from O-MISC O-MISC
time O-MISC O-MISC
- O-MISC O-MISC
course O-MISC O-MISC
and O-MISC O-MISC
equilibrium O-MISC O-MISC
kinetics O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
data O-MISC O-MISC
were O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
simple O-MISC O-MISC
reversible O-MISC O-MISC
bimolecular O-MISC O-MISC
interaction O-MISC O-MISC
. O-MISC O-MISC

Arrhenius O-MISC O-MISC
and O-MISC O-MISC
Va O-MISC O-MISC
n O-MISC O-MISC
' O-MISC O-MISC
t O-MISC O-MISC
Hoff O-MISC O-MISC
plots O-MISC O-MISC
were O-MISC O-MISC
curvilinear O-MISC O-MISC
for O-MISC O-MISC
both O-MISC O-MISC
steroids O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
equilibrium O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
solution O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
equation O-MISC O-MISC
delta O-MISC O-MISC
G O-MISC O-MISC
= O-MISC O-MISC
delta O-MISC O-MISC
H O-MISC O-MISC
- O-MISC I-MISC
T O-MISC I-MISC
X O-MISC I-MISC
delta O-MISC I-MISC
S O-MISC I-MISC
( O-MISC O-MISC
eqn O-MISC B-MISC
. O-MISC I-MISC
1 O-MISC I-MISC
) O-MISC O-MISC
was O-MISC O-MISC
( O-MISC O-MISC
in O-MISC O-MISC
kJ O-MISC O-MISC
X O-MISC O-MISC
mol O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
47 O-MISC O-MISC
= O-MISC O-MISC
36 O-MISC O-MISC
- O-MISC O-MISC
83 O-MISC O-MISC
( O-MISC O-MISC
dexamethasone O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
- O-MISC O-MISC
42 O-MISC O-MISC
= O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
33 O-MISC O-MISC
( O-MISC O-MISC
cortisol O-MISC O-MISC
) O-MISC O-MISC
at O-MISC O-MISC
0 O-MISC O-MISC
degree O-MISC O-MISC
C O-MISC O-MISC
. O-MISC O-MISC

Enthalpy O-MISC O-MISC
and O-MISC O-MISC
entropy O-MISC O-MISC
changes O-MISC O-MISC
decreased O-MISC O-MISC
quasi O-MISC O-MISC
- O-MISC O-MISC
linearly O-MISC O-MISC
with O-MISC O-MISC
temperature O-MISC O-MISC
such O-MISC O-MISC
that O-MISC O-MISC
, O-MISC O-MISC
at O-MISC O-MISC
25 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
respective O-MISC O-MISC
values O-MISC O-MISC
were O-MISC O-MISC
- O-MISC O-MISC
50 O-MISC O-MISC
= O-MISC O-MISC
- O-MISC O-MISC
75 O-MISC O-MISC
+ O-MISC O-MISC
25 O-MISC O-MISC
and O-MISC O-MISC
- O-MISC O-MISC
43 O-MISC O-MISC
= O-MISC O-MISC
- O-MISC O-MISC
48 O-MISC O-MISC
+ O-MISC O-MISC
5 O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
for O-MISC O-MISC
both O-MISC O-MISC
steroids O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
interaction O-MISC O-MISC
was O-MISC O-MISC
entropy O-MISC O-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
at O-MISC O-MISC
low O-MISC O-MISC
temperature O-MISC O-MISC
and O-MISC O-MISC
became O-MISC O-MISC
entirely O-MISC O-MISC
enthalpy O-MISC O-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
at O-MISC O-MISC
20 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
. O-MISC O-MISC

Thermodynamic O-MISC O-MISC
values O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
transition O-MISC O-MISC
state O-MISC O-MISC
were O-MISC O-MISC
calculated O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
rate O-MISC O-MISC
constants O-MISC O-MISC
. O-MISC O-MISC

For O-MISC O-MISC
the O-MISC O-MISC
forward O-MISC O-MISC
reaction O-MISC O-MISC
, O-MISC O-MISC
eqn O-MISC B-MISC
. O-MISC I-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
gave O-MISC O-MISC
45 O-MISC O-MISC
= O-MISC O-MISC
84 O-MISC O-MISC
- O-MISC O-MISC
39 O-MISC O-MISC
( O-MISC O-MISC
dexamethasone O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
46 O-MISC O-MISC
= O-MISC O-MISC
60 O-MISC O-MISC
- O-MISC O-MISC
14 O-MISC O-MISC
( O-MISC O-MISC
cortisol O-MISC O-MISC
) O-MISC O-MISC
at O-MISC O-MISC
0 O-MISC O-MISC
degree O-MISC O-MISC
C O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
44 O-MISC O-MISC
= O-MISC O-MISC
24 O-MISC O-MISC
+ O-MISC O-MISC
20 O-MISC O-MISC
( O-MISC O-MISC
dexamethasone O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
46 O-MISC O-MISC
= O-MISC O-MISC
28 O-MISC O-MISC
+ O-MISC O-MISC
18 O-MISC O-MISC
( O-MISC O-MISC
cortisol O-MISC O-MISC
) O-MISC O-MISC
at O-MISC O-MISC
25 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
fit O-MISC O-MISC
quite O-MISC O-MISC
well O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
two O-MISC O-MISC
- O-MISC O-MISC
step O-MISC O-MISC
model O-MISC O-MISC
[ O-MISC O-MISC
Ross O-MISC O-MISC
& O-MISC O-MISC
Subramanian O-MISC O-MISC
( O-MISC O-MISC
1981 O-MISC O-MISC
) O-MISC O-MISC
Biochemistry O-MISC O-MISC
20 O-MISC O-MISC
, O-MISC O-MISC
3096 O-MISC O-MISC
- O-MISC O-MISC
3102 O-MISC O-MISC
] O-MISC O-MISC
proposed O-MISC O-MISC
for O-MISC O-MISC
ligand O-MISC B-MISC
- O-MISC I-MISC
protein O-MISC I-MISC
interactions O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
involves O-MISC O-MISC
a O-MISC O-MISC
partial O-MISC O-MISC
immobilization O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
reacting O-MISC O-MISC
species O-MISC O-MISC
governed O-MISC O-MISC
by O-MISC O-MISC
hydrophobic O-MISC O-MISC
forces O-MISC O-MISC
, O-MISC O-MISC
followed O-MISC O-MISC
by O-MISC O-MISC
stabilization O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
complex O-MISC O-MISC
by O-MISC O-MISC
short O-MISC O-MISC
- O-MISC O-MISC
range O-MISC O-MISC
interactions O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
the O-MISC O-MISC
basis O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
model O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transition O-MISC O-MISC
- O-MISC O-MISC
state O-MISC O-MISC
thermodynamics O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
conclusion O-MISC O-MISC
that O-MISC O-MISC
no O-MISC O-MISC
more O-MISC O-MISC
than O-MISC O-MISC
half O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
steroid O-MISC O-MISC
molecular O-MISC O-MISC
area O-MISC O-MISC
is O-MISC O-MISC
engaged O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

Cell O-MISC O-MISC
cycle O-MISC O-MISC
- O-MISC O-MISC
related O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
lymphocyte I-MISC I-MISC
receptors I-MISC I-MISC
for O-MISC O-MISC
glucocorticoids O-MISC O-MISC
and O-MISC O-MISC
insulin O-MISC O-MISC
. O-MISC O-MISC

Enriched O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lymphocytes O-MISC O-MISC
were O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
PHA O-MISC B-MISC
and O-MISC O-MISC
examined O-MISC O-MISC
for O-MISC O-MISC
variations O-MISC O-MISC
in O-MISC O-MISC
insulin O-MISC O-MISC
and O-MISC O-MISC
glucocorticoid O-MISC O-MISC
( O-MISC O-MISC
dexamethasone O-MISC O-MISC
) O-MISC O-MISC
receptor O-MISC O-MISC
numbers O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
early O-MISC O-MISC
phases O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
. O-MISC O-MISC

Cells O-MISC O-MISC
in O-MISC O-MISC
G0 O-MISC O-MISC
, O-MISC O-MISC
G1a O-MISC O-MISC
and O-MISC O-MISC
G1b O-MISC B-MISC
phases O-MISC O-MISC
, O-MISC O-MISC
where O-MISC O-MISC
the O-MISC O-MISC
G1a O-MISC B-MISC
- O-MISC I-MISC
G1b O-MISC I-MISC
transition O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
Interleukin B-MISC B-MISC
2 I-MISC I-MISC
dependent O-MISC O-MISC
event O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
quantitated O-MISC O-MISC
by O-MISC O-MISC
flow O-MISC O-MISC
cytometry O-MISC O-MISC
. O-MISC O-MISC

Few O-MISC O-MISC
but O-MISC O-MISC
significant O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
2700 O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
no O-MISC O-MISC
insulin B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
resting O-MISC O-MISC
( O-MISC O-MISC
G0 O-MISC O-MISC
) O-MISC O-MISC
phase O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
cells O-MISC O-MISC
entered O-MISC O-MISC
the O-MISC O-MISC
G1a O-MISC B-MISC
phase O-MISC O-MISC
the O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
increased O-MISC O-MISC
and O-MISC O-MISC
of O-MISC O-MISC
insulin O-MISC O-MISC
took O-MISC O-MISC
place O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
the O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
further O-MISC O-MISC
increased O-MISC O-MISC
as O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
entered O-MISC O-MISC
the O-MISC O-MISC
G1b O-MISC B-MISC
phase O-MISC O-MISC
( O-MISC O-MISC
as O-MISC O-MISC
measured O-MISC O-MISC
at O-MISC O-MISC
44 O-MISC O-MISC
h O-MISC O-MISC
of O-MISC O-MISC
incubation O-MISC O-MISC
and O-MISC O-MISC
using O-MISC O-MISC
hydroxyurea O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
cells O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
took O-MISC O-MISC
place O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
period O-MISC O-MISC
16 O-MISC O-MISC
- O-MISC O-MISC
20 O-MISC O-MISC
h O-MISC O-MISC
after O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Based O-MISC O-MISC
on O-MISC O-MISC
these O-MISC O-MISC
findings O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
concluded O-MISC O-MISC
that O-MISC O-MISC
both O-MISC O-MISC
receptor O-MISC O-MISC
types O-MISC O-MISC
( O-MISC O-MISC
cell B-MISC O-MISC
membrane I-MISC I-MISC
and I-MISC I-MISC
cytoplasmic I-MISC B-MISC
receptors I-MISC I-MISC
) O-MISC O-MISC
are O-MISC O-MISC
being O-MISC O-MISC
formed O-MISC O-MISC
and O-MISC O-MISC
increased O-MISC O-MISC
at O-MISC O-MISC
G1 O-MISC O-MISC
phase O-MISC O-MISC
prior O-MISC O-MISC
to O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
the O-MISC O-MISC
importance O-MISC O-MISC
of O-MISC O-MISC
G1 O-MISC O-MISC
phase O-MISC O-MISC
in O-MISC O-MISC
immunoregulation O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
cortico O-MISC O-MISC
- O-MISC O-MISC
sensitivity O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
human O-MISC O-MISC
clonal O-MISC O-MISC
monocytic O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
CM O-MISC O-MISC
- O-MISC O-MISC
SM O-MISC O-MISC
. O-MISC O-MISC

CM O-MISC O-MISC
- O-MISC O-MISC
SM O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
clonal O-MISC O-MISC
line O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
precursor O-MISC O-MISC
mononuclear O-MISC O-MISC
phagocytes O-MISC O-MISC
inducible O-MISC O-MISC
to O-MISC O-MISC
macrophage O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC B-MISC
promoter O-MISC I-MISC
phorbol O-MISC O-MISC
ester O-MISC O-MISC
12 O-MISC I-MISC
- O-MISC O-MISC
O O-MISC O-MISC
- O-MISC O-MISC
tetradecanoyl O-MISC O-MISC
- O-MISC O-MISC
phorbol O-MISC B-MISC
- O-MISC I-MISC
13 O-MISC I-MISC
- O-MISC O-MISC
acetate O-MISC O-MISC
( O-MISC O-MISC
TPA O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Untreated O-MISC O-MISC
CM O-MISC O-MISC
- O-MISC O-MISC
SM O-MISC O-MISC
cells O-MISC O-MISC
contain O-MISC O-MISC
single O-MISC O-MISC
class O-MISC O-MISC
, O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
affinity O-MISC O-MISC
( O-MISC O-MISC
KD O-MISC O-MISC
= O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
) O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC I-MISC
receptor O-MISC I-MISC
sites O-MISC O-MISC
( O-MISC O-MISC
approximately O-MISC O-MISC
60 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
at O-MISC O-MISC
37 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
, O-MISC O-MISC
using O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
triamcinolone O-MISC O-MISC
acetonide O-MISC O-MISC
( O-MISC O-MISC
TA O-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Exposure O-MISC O-MISC
of O-MISC O-MISC
CM O-MISC O-MISC
- O-MISC O-MISC
SM O-MISC O-MISC
to O-MISC O-MISC
dexamethasone O-MISC O-MISC
( O-MISC O-MISC
DEX O-MISC O-MISC
) O-MISC O-MISC
produced O-MISC O-MISC
a O-MISC O-MISC
progressive O-MISC O-MISC
, O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
time O-MISC O-MISC
- O-MISC O-MISC
related O-MISC O-MISC
series O-MISC O-MISC
of O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
CM O-MISC O-MISC
- O-MISC O-MISC
SM O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
, O-MISC O-MISC
saturation O-MISC O-MISC
density O-MISC O-MISC
, O-MISC O-MISC
morphology O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
functional O-MISC O-MISC
properties O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
half O-MISC O-MISC
- O-MISC O-MISC
maximal O-MISC O-MISC
effects O-MISC O-MISC
at O-MISC O-MISC
about O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
for O-MISC O-MISC
DEX O-MISC O-MISC
. O-MISC O-MISC

TA O-MISC B-MISC
- O-MISC I-MISC
receptor O-MISC I-MISC
sites O-MISC I-MISC
rapidly O-MISC O-MISC
decreased O-MISC O-MISC
( O-MISC O-MISC
about O-MISC O-MISC
70 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
after O-MISC O-MISC
DEX O-MISC O-MISC
treatment O-MISC O-MISC
, O-MISC O-MISC
without O-MISC O-MISC
any O-MISC O-MISC
apparent O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
steroid O-MISC O-MISC
specificity O-MISC O-MISC
and O-MISC O-MISC
affinity O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
5 O-MISC O-MISC
days O-MISC O-MISC
in O-MISC O-MISC
culture O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
saturating O-MISC O-MISC
concentration O-MISC O-MISC
( O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
hormone O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
reached O-MISC O-MISC
a O-MISC O-MISC
saturation O-MISC O-MISC
density O-MISC O-MISC
of O-MISC O-MISC
about O-MISC O-MISC
9 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
viable O-MISC O-MISC
cells O-MISC O-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
( O-MISC O-MISC
about O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
viable O-MISC O-MISC
cells O-MISC O-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
controls O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
modal O-MISC O-MISC
volume O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
resulting O-MISC O-MISC
cell O-MISC O-MISC
population O-MISC O-MISC
was O-MISC O-MISC
approximately O-MISC O-MISC
60 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
volume O-MISC O-MISC
of O-MISC O-MISC
untreated O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

DEX O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
cells O-MISC O-MISC
appeared O-MISC O-MISC
less O-MISC O-MISC
differentiated O-MISC O-MISC
than O-MISC O-MISC
controls O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
combined O-MISC O-MISC
morphologic O-MISC O-MISC
, O-MISC O-MISC
antigenic O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
cytoenzymatic O-MISC B-MISC
analyses O-MISC O-MISC
. O-MISC O-MISC

DEX O-MISC O-MISC
almost O-MISC O-MISC
completely O-MISC O-MISC
inhibited O-MISC O-MISC
TPA O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
following O-MISC O-MISC
macrophage O-MISC O-MISC
functions O-MISC O-MISC
: O-MISC O-MISC
adherency O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
culture O-MISC O-MISC
plate O-MISC O-MISC
, O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
lysosomal B-MISC B-MISC
enzymes I-MISC I-MISC
, O-MISC O-MISC
Fc B-MISC B-MISC
and I-MISC I-MISC
C3 I-MISC I-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
phagocytosis O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
removal O-MISC O-MISC
of O-MISC O-MISC
DEX O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
within O-MISC O-MISC
a O-MISC O-MISC
few O-MISC O-MISC
passages O-MISC O-MISC
, O-MISC O-MISC
returned O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
state O-MISC O-MISC
apparently O-MISC O-MISC
identical O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
untreated O-MISC O-MISC
controls O-MISC O-MISC
and O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
induced O-MISC O-MISC
to O-MISC O-MISC
macrophage O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
TPA O-MISC O-MISC
. O-MISC O-MISC

Acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
in O-MISC O-MISC
children O-MISC O-MISC
: O-MISC O-MISC
current O-MISC O-MISC
status O-MISC O-MISC
, O-MISC O-MISC
controversies O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
future O-MISC O-MISC
perspective O-MISC O-MISC
. O-MISC O-MISC

Disease O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
survival O-MISC O-MISC
( O-MISC O-MISC
DFS O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
childhood O-MISC O-MISC
ALL O-MISC O-MISC
is O-MISC O-MISC
60 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
survival O-MISC O-MISC
in O-MISC O-MISC
good O-MISC O-MISC
, O-MISC O-MISC
average O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
poor O-MISC O-MISC
prognostic O-MISC O-MISC
groups O-MISC O-MISC
defined O-MISC O-MISC
by O-MISC O-MISC
initial O-MISC O-MISC
WBC O-MISC B-MISC
and O-MISC O-MISC
age O-MISC O-MISC
is O-MISC O-MISC
90 O-MISC O-MISC
, O-MISC O-MISC
60 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
45 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

Additional O-MISC O-MISC
immunological O-MISC O-MISC
, O-MISC O-MISC
morphological O-MISC O-MISC
, O-MISC O-MISC
biochemical O-MISC O-MISC
, O-MISC O-MISC
cytokinetic O-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
cytogenetic O-MISC B-MISC
factors O-MISC I-MISC
have O-MISC O-MISC
been O-MISC O-MISC
identified O-MISC O-MISC
, O-MISC O-MISC
illustrating O-MISC O-MISC
the O-MISC O-MISC
heterogeneity O-MISC O-MISC
of O-MISC O-MISC
ALL O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
derivation O-MISC O-MISC
from O-MISC O-MISC
malignant O-MISC O-MISC
clones O-MISC O-MISC
at O-MISC O-MISC
various O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
with O-MISC O-MISC
varying O-MISC O-MISC
rates O-MISC O-MISC
of O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Of O-MISC O-MISC
biologic O-MISC O-MISC
importance O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
factors O-MISC O-MISC
may O-MISC O-MISC
refine O-MISC O-MISC
further O-MISC O-MISC
the O-MISC O-MISC
characteristic O-MISC O-MISC
features O-MISC O-MISC
of O-MISC O-MISC
clinically O-MISC O-MISC
- O-MISC O-MISC
determined O-MISC O-MISC
prognostic O-MISC O-MISC
groups O-MISC O-MISC
. O-MISC O-MISC

Multivariate O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
large O-MISC O-MISC
prospective O-MISC O-MISC
trials O-MISC O-MISC
with O-MISC O-MISC
homogeneous O-MISC O-MISC
therapy O-MISC O-MISC
will O-MISC O-MISC
be O-MISC O-MISC
required O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
independent O-MISC O-MISC
prognostic O-MISC O-MISC
importance O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
factors O-MISC O-MISC
. O-MISC O-MISC

Current O-MISC O-MISC
treatment O-MISC O-MISC
strategies O-MISC O-MISC
in O-MISC O-MISC
ALL O-MISC B-MISC
include O-MISC I-MISC
( O-MISC I-MISC
1 O-MISC I-MISC
) O-MISC I-MISC
tailoring O-MISC I-MISC
therapy O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
intensity O-MISC O-MISC
to O-MISC O-MISC
prognostic O-MISC O-MISC
groups O-MISC O-MISC
; O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
multiple O-MISC O-MISC
- O-MISC O-MISC
drug O-MISC O-MISC
combinations O-MISC O-MISC
in O-MISC O-MISC
induction O-MISC O-MISC
; O-MISC O-MISC
( O-MISC O-MISC
3 O-MISC O-MISC
) O-MISC O-MISC
early O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
intrathecal O-MISC O-MISC
( O-MISC O-MISC
IT O-MISC O-MISC
) O-MISC O-MISC
methotrexate O-MISC O-MISC
( O-MISC O-MISC
MTX O-MISC O-MISC
) O-MISC O-MISC
; O-MISC O-MISC
( O-MISC O-MISC
4 O-MISC O-MISC
) O-MISC O-MISC
CNS O-MISC O-MISC
prophylaxis O-MISC O-MISC
with O-MISC O-MISC
IT O-MISC O-MISC
MTX O-MISC O-MISC
alone O-MISC O-MISC
in O-MISC O-MISC
good O-MISC O-MISC
prognosis O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
combined O-MISC O-MISC
cranial O-MISC O-MISC
radiation O-MISC O-MISC
( O-MISC O-MISC
CXRT O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
1800 O-MISC O-MISC
rads O-MISC O-MISC
plus O-MISC O-MISC
IT O-MISC O-MISC
MTX O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
average O-MISC O-MISC
and O-MISC O-MISC
poor O-MISC O-MISC
prognosis O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Current O-MISC O-MISC
studies O-MISC O-MISC
show O-MISC O-MISC
a O-MISC O-MISC
CNS O-MISC O-MISC
relapse O-MISC O-MISC
rate O-MISC O-MISC
of O-MISC O-MISC
5 O-MISC O-MISC
% O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
prognostic O-MISC O-MISC
groups O-MISC O-MISC
. O-MISC O-MISC

Late O-MISC O-MISC
neuropsychological O-MISC O-MISC
defects O-MISC O-MISC
caused O-MISC O-MISC
by O-MISC O-MISC
cranial O-MISC O-MISC
XRT O-MISC O-MISC
and O-MISC O-MISC
IT O-MISC O-MISC
MTX O-MISC O-MISC
have O-MISC O-MISC
prompted O-MISC O-MISC
programs O-MISC O-MISC
designed O-MISC O-MISC
to O-MISC O-MISC
reduce O-MISC O-MISC
the O-MISC O-MISC
potential O-MISC O-MISC
late O-MISC O-MISC
toxicity O-MISC O-MISC
of O-MISC O-MISC
CNS O-MISC O-MISC
prophylaxis O-MISC O-MISC
. O-MISC O-MISC

More O-MISC O-MISC
pronounced O-MISC O-MISC
in O-MISC O-MISC
younger O-MISC O-MISC
children O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
abnormalities O-MISC O-MISC
include O-MISC O-MISC
decreased O-MISC O-MISC
IQ O-MISC B-MISC
, O-MISC O-MISC
visual O-MISC O-MISC
- O-MISC I-MISC
motor O-MISC I-MISC
incoordination O-MISC O-MISC
, O-MISC O-MISC
poor O-MISC O-MISC
performance O-MISC O-MISC
in O-MISC O-MISC
mathematics O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
memory O-MISC O-MISC
dysfunction O-MISC O-MISC
. O-MISC O-MISC

Until O-MISC O-MISC
1980 O-MISC O-MISC
, O-MISC O-MISC
more O-MISC O-MISC
intensive O-MISC O-MISC
induction O-MISC O-MISC
, O-MISC O-MISC
consolidation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
maintenance O-MISC O-MISC
therapy O-MISC O-MISC
had O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
prolong O-MISC O-MISC
DFS O-MISC O-MISC
in O-MISC O-MISC
children O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
poor O-MISC O-MISC
prognosis O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
West O-MISC O-MISC
Germany O-MISC O-MISC
( O-MISC O-MISC
Berlin O-MISC O-MISC
- O-MISC O-MISC
Frankfurt O-MISC O-MISC
- O-MISC O-MISC
Muenster O-MISC I-MISC
protocol O-MISC O-MISC
) O-MISC O-MISC
a O-MISC O-MISC
70 O-MISC O-MISC
to O-MISC O-MISC
75 O-MISC O-MISC
% O-MISC O-MISC
DFS O-MISC O-MISC
is O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
patients O-MISC O-MISC
regardless O-MISC O-MISC
of O-MISC O-MISC
initial O-MISC O-MISC
WBC O-MISC B-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
effective O-MISC O-MISC
therapy O-MISC O-MISC
will O-MISC O-MISC
override O-MISC O-MISC
prognostic O-MISC O-MISC
factors O-MISC I-MISC
. O-MISC O-MISC

Ultra O-MISC O-MISC
- O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
dose O-MISC O-MISC
MTX O-MISC O-MISC
, O-MISC O-MISC
without O-MISC O-MISC
cranial O-MISC O-MISC
radiation O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
showing O-MISC O-MISC
promise O-MISC O-MISC
in O-MISC O-MISC
poor O-MISC O-MISC
prognosis O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Other O-MISC O-MISC
issues O-MISC O-MISC
include O-MISC O-MISC
the O-MISC O-MISC
optimal O-MISC O-MISC
duration O-MISC O-MISC
of O-MISC O-MISC
therapy O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
testicular O-MISC O-MISC
biopsies O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
prophylactic O-MISC O-MISC
testicular O-MISC O-MISC
radiation O-MISC O-MISC
. O-MISC O-MISC

Recent O-MISC O-MISC
studies O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
prognostic O-MISC O-MISC
factors O-MISC I-MISC
lose O-MISC O-MISC
their O-MISC O-MISC
significance O-MISC O-MISC
after O-MISC O-MISC
2 O-MISC O-MISC
years O-MISC O-MISC
of O-MISC O-MISC
continuous O-MISC O-MISC
complete O-MISC O-MISC
remission O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
2 O-MISC O-MISC
years O-MISC O-MISC
of O-MISC O-MISC
maintenance O-MISC O-MISC
therapy O-MISC O-MISC
is O-MISC O-MISC
adequate O-MISC O-MISC
. O-MISC O-MISC

Bilateral O-MISC O-MISC
open O-MISC O-MISC
- O-MISC O-MISC
wedge O-MISC O-MISC
testicular O-MISC O-MISC
biopsies O-MISC O-MISC
have O-MISC O-MISC
identified O-MISC O-MISC
occult O-MISC O-MISC
testicular O-MISC O-MISC
disease O-MISC O-MISC
in O-MISC O-MISC
8 O-MISC O-MISC
to O-MISC O-MISC
10 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
males O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
unified O-MISC O-MISC
approach O-MISC O-MISC
to O-MISC O-MISC
children O-MISC O-MISC
with O-MISC O-MISC
leukemia O-MISC O-MISC
/ O-MISC O-MISC
lymphoma O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
group O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
particularly O-MISC O-MISC
poor O-MISC O-MISC
prognosis O-MISC O-MISC
, O-MISC O-MISC
utilizing O-MISC O-MISC
NHL O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
therapy O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
more O-MISC O-MISC
effective O-MISC O-MISC
than O-MISC O-MISC
conventional O-MISC O-MISC
ALL O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

( O-MISC O-MISC
ABSTRACT O-MISC O-MISC
TRUNCATED O-MISC O-MISC
AT O-MISC O-MISC
400 O-MISC O-MISC
WORDS O-MISC O-MISC
) O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
steroid O-MISC O-MISC
hormones O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphoproliferative O-MISC O-MISC
diseases O-MISC O-MISC
and O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
quantitation O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
whole O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
assay O-MISC O-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
cytosol O-MISC O-MISC
technique O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
steroids O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
assessed O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
normal O-MISC O-MISC
donors O-MISC O-MISC
and O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
lymphatic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
CLL O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
ALL O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
lymphosarcoma O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
LSCL O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
acute O-MISC O-MISC
nonlymphatic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
ANLL O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
chronic O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
CML O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Within O-MISC O-MISC
the O-MISC O-MISC
lymphoproliferative O-MISC O-MISC
diseases O-MISC O-MISC
, O-MISC O-MISC
ALL O-MISC O-MISC
cells O-MISC O-MISC
exhibited O-MISC O-MISC
the O-MISC O-MISC
highest O-MISC O-MISC
GR B-MISC B-MISC
concentration O-MISC O-MISC
( O-MISC O-MISC
regardless O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
method O-MISC O-MISC
used O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
highest O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
spontaneous O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
thymidine O-MISC O-MISC
( O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
TdR O-MISC O-MISC
) O-MISC O-MISC
uptake O-MISC O-MISC
by O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
significant O-MISC O-MISC
relationship O-MISC O-MISC
between O-MISC O-MISC
GR B-MISC B-MISC
concentration O-MISC O-MISC
( O-MISC O-MISC
whole O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
assay O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
dexamethasone O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
found O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
the O-MISC O-MISC
contrary O-MISC O-MISC
, O-MISC O-MISC
CLL O-MISC O-MISC
cells O-MISC O-MISC
presented O-MISC O-MISC
the O-MISC O-MISC
highest O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
in O-MISC O-MISC
PHA O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
cell O-MISC O-MISC
cultures O-MISC O-MISC
. O-MISC O-MISC

Cells O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
only O-MISC O-MISC
two O-MISC O-MISC
ALL O-MISC O-MISC
patients O-MISC O-MISC
who O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
undergo O-MISC O-MISC
a O-MISC O-MISC
remission O-MISC O-MISC
after O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
inclusive O-MISC O-MISC
chemotherapy O-MISC O-MISC
had O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
lowest O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
dexamethasone O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
lowest O-MISC O-MISC
GR O-MISC B-MISC
concentration O-MISC O-MISC
with O-MISC O-MISC
whole O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

Concerning O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
, O-MISC O-MISC
ANLL O-MISC O-MISC
patients O-MISC O-MISC
had O-MISC O-MISC
GR B-MISC B-MISC
concentrations O-MISC O-MISC
slightly O-MISC O-MISC
higher O-MISC O-MISC
than O-MISC O-MISC
those O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
ALL O-MISC O-MISC
group O-MISC O-MISC
but O-MISC O-MISC
exhibited O-MISC O-MISC
the O-MISC O-MISC
lowest O-MISC O-MISC
degree O-MISC O-MISC
of O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
spontaneous O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
TdR O-MISC B-MISC
uptake O-MISC O-MISC
by O-MISC O-MISC
dexamethasone O-MISC O-MISC
( O-MISC O-MISC
stimulatory O-MISC O-MISC
effects O-MISC O-MISC
occurred O-MISC O-MISC
in O-MISC O-MISC
some O-MISC O-MISC
cases O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

CML O-MISC O-MISC
cells O-MISC O-MISC
exhibited O-MISC O-MISC
an O-MISC O-MISC
inhibition O-MISC O-MISC
degree O-MISC O-MISC
by O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
glucocorticoids O-MISC O-MISC
significantly O-MISC O-MISC
higher O-MISC O-MISC
than O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
ANLL O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
different O-MISC O-MISC
from O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
lymphoproliferative O-MISC O-MISC
diseases O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
clear O-MISC O-MISC
relationship O-MISC O-MISC
among O-MISC O-MISC
GR O-MISC B-MISC
pattern O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
cell O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
clinicohematologic O-MISC O-MISC
parameters O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
- O-MISC O-MISC
bearing O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
corticosensitivity O-MISC O-MISC
of O-MISC O-MISC
peanut O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
and O-MISC O-MISC
peanut O-MISC O-MISC
- O-MISC O-MISC
negative O-MISC O-MISC
human O-MISC O-MISC
thymocyte O-MISC O-MISC
subpopulations O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
6 O-MISC O-MISC
human O-MISC O-MISC
thymus O-MISC O-MISC
glands O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
immature O-MISC O-MISC
subset O-MISC O-MISC
of O-MISC O-MISC
thymocytes O-MISC O-MISC
was O-MISC O-MISC
separated O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
more O-MISC O-MISC
mature O-MISC O-MISC
one O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
differential O-MISC O-MISC
peanut O-MISC B-MISC
lectin O-MISC B-MISC
agglutination O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
2 O-MISC O-MISC
cell O-MISC O-MISC
subpopulations O-MISC O-MISC
were O-MISC O-MISC
analyzed O-MISC O-MISC
for O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
content O-MISC O-MISC
by O-MISC O-MISC
using O-MISC O-MISC
a O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
( O-MISC O-MISC
3H O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
triamcinolone O-MISC O-MISC
acetonide O-MISC O-MISC
as O-MISC O-MISC
tracer O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
unagglutinated O-MISC O-MISC
thymocytes O-MISC O-MISC
( O-MISC O-MISC
peanut O-MISC O-MISC
negative O-MISC O-MISC
) O-MISC O-MISC
contained O-MISC O-MISC
about O-MISC O-MISC
2 O-MISC O-MISC
times O-MISC O-MISC
more O-MISC O-MISC
receptor O-MISC O-MISC
sites O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
than O-MISC O-MISC
agglutinated O-MISC O-MISC
( O-MISC O-MISC
peanut O-MISC O-MISC
positive O-MISC O-MISC
) O-MISC O-MISC
ones O-MISC O-MISC
( O-MISC O-MISC
7650 O-MISC O-MISC
+ O-MISC I-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1550 O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
D O-MISC O-MISC
. O-MISC O-MISC
verus O-MISC O-MISC
3195 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
896 O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
D O-MISC O-MISC
. O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
affinity O-MISC O-MISC
for O-MISC O-MISC
steroid O-MISC O-MISC
was O-MISC O-MISC
similar O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
cell O-MISC O-MISC
subsets O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
was O-MISC O-MISC
the O-MISC O-MISC
stereospecificity O-MISC O-MISC
for O-MISC O-MISC
glucocorticoids O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
time O-MISC O-MISC
- O-MISC O-MISC
course O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC B-MISC
- O-MISC I-MISC
receptor O-MISC I-MISC
association O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
cytoplasmic O-MISC O-MISC
to O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
. O-MISC O-MISC

Despite O-MISC O-MISC
the O-MISC O-MISC
greater O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
sites O-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
peanut O-MISC O-MISC
- O-MISC O-MISC
negative O-MISC O-MISC
thymocyte O-MISC O-MISC
subpopulation O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
differ O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
peanut O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
one O-MISC O-MISC
in O-MISC O-MISC
its O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
triamcinolone O-MISC O-MISC
acetonide O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
measurements O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
incorporation O-MISC O-MISC
of O-MISC O-MISC
radiolabeled O-MISC O-MISC
precursors O-MISC O-MISC
of O-MISC O-MISC
protein O-MISC B-MISC
and O-MISC O-MISC
DNA O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
peanut O-MISC O-MISC
- O-MISC O-MISC
negative O-MISC O-MISC
subset O-MISC O-MISC
appeared O-MISC O-MISC
more O-MISC O-MISC
resistant O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
steroid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
lysis O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
peanut O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
one O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
glucocorticoid O-MISC B-MISC
receptor O-MISC I-MISC
density O-MISC O-MISC
and O-MISC O-MISC
corticosensitivity O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
directly O-MISC O-MISC
correlated O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
sites O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
degree O-MISC O-MISC
of O-MISC O-MISC
immunologic O-MISC O-MISC
maturation O-MISC O-MISC

Defective O-MISC O-MISC
binding O-MISC O-MISC
and O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
1 B-MISC B-MISC
, I-MISC I-MISC
25 I-MISC I-MISC
- I-MISC I-MISC
dihydroxyvitamin I-MISC I-MISC
D3 I-MISC I-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
end O-MISC O-MISC
- O-MISC O-MISC
organ O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
dihydroxyvitamin O-MISC O-MISC
D O-MISC O-MISC
. O-MISC O-MISC

Lectin O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
DNA O-MISC O-MISC
synthesis O-MISC O-MISC
by O-MISC O-MISC
peripheral O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
17 O-MISC O-MISC
normal O-MISC O-MISC
donors O-MISC O-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
( O-MISC O-MISC
40 O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
by O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
dihydroxyvitamin O-MISC O-MISC
D3 O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
[ O-MISC O-MISC
OH O-MISC O-MISC
] O-MISC O-MISC
2D3 O-MISC O-MISC
) O-MISC O-MISC
at O-MISC O-MISC
physiological O-MISC O-MISC
concentrations O-MISC O-MISC
( O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
10 O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
lymphocytes O-MISC O-MISC
acquire O-MISC O-MISC
specific O-MISC I-MISC
receptors O-MISC I-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
upon O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
lectins B-MISC B-MISC
. O-MISC O-MISC

This O-MISC O-MISC
process O-MISC O-MISC
precedes O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
studied O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
six O-MISC O-MISC
patients O-MISC O-MISC
from O-MISC O-MISC
four O-MISC O-MISC
different O-MISC O-MISC
kindreds O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
syndrome O-MISC O-MISC
of O-MISC O-MISC
hereditary O-MISC O-MISC
end O-MISC O-MISC
- O-MISC O-MISC
organ O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D O-MISC O-MISC
( O-MISC O-MISC
the O-MISC O-MISC
so O-MISC O-MISC
- O-MISC O-MISC
called O-MISC O-MISC
vitamin O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
rickets O-MISC O-MISC
type O-MISC O-MISC
II O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
five O-MISC O-MISC
patients O-MISC O-MISC
( O-MISC O-MISC
three O-MISC O-MISC
kindreds O-MISC O-MISC
) O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
acquire O-MISC O-MISC
receptors O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
upon O-MISC O-MISC
phytohemagglutinin O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
normal O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
mitogenic O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
patients O-MISC O-MISC
' O-MISC O-MISC
lymphocytes O-MISC O-MISC
by O-MISC O-MISC
phytohemagglutinin B-MISC B-MISC
and O-MISC O-MISC
concanavalin O-MISC O-MISC
A O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
. O-MISC O-MISC

Activated O-MISC O-MISC
lymphocytes O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
sixth O-MISC O-MISC
patient O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
fourth O-MISC O-MISC
kindred O-MISC O-MISC
exhibited O-MISC O-MISC
normal O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
hormone O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
the O-MISC O-MISC
mitogenic O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
similar O-MISC O-MISC
pattern O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
vitamin O-MISC O-MISC
D O-MISC O-MISC
effector O-MISC O-MISC
system O-MISC O-MISC
was O-MISC O-MISC
previously O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
fibroblasts O-MISC O-MISC
cultured O-MISC O-MISC
from O-MISC O-MISC
skin O-MISC O-MISC
biopsies O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
group O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
conclusions O-MISC O-MISC
from O-MISC O-MISC
these O-MISC O-MISC
findings O-MISC O-MISC
are O-MISC O-MISC
: O-MISC O-MISC
( O-MISC O-MISC
a O-MISC O-MISC
) O-MISC O-MISC
the O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
mitogenic O-MISC O-MISC
stimulation O-MISC O-MISC
by O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
specific B-MISC O-MISC
functional I-MISC B-MISC
receptors I-MISC I-MISC
to O-MISC O-MISC
the O-MISC O-MISC
hormone O-MISC O-MISC
; O-MISC I-MISC
and O-MISC O-MISC
( O-MISC O-MISC
b O-MISC I-MISC
) O-MISC O-MISC
the O-MISC O-MISC
receptors O-MISC B-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
in O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
probably O-MISC O-MISC
controlled O-MISC O-MISC
genetically O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
mechanisms O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
effector O-MISC O-MISC
system O-MISC O-MISC
in O-MISC O-MISC
well O-MISC O-MISC
- O-MISC O-MISC
characterized O-MISC O-MISC
target O-MISC O-MISC
organs O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
hormone O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
intestine O-MISC O-MISC
and O-MISC O-MISC
kidney O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
of O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
from O-MISC O-MISC
myasthenia O-MISC O-MISC
gravis O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
was O-MISC O-MISC
performed O-MISC O-MISC
to O-MISC O-MISC
analyse O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
( O-MISC O-MISC
MNL O-MISC O-MISC
) O-MISC O-MISC
from O-MISC O-MISC
39 O-MISC O-MISC
myasthenia O-MISC O-MISC
gravis O-MISC O-MISC
( O-MISC O-MISC
MG O-MISC O-MISC
) O-MISC O-MISC
patients O-MISC O-MISC
( O-MISC O-MISC
unoperated O-MISC O-MISC
patients O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
13 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
thymectomized O-MISC O-MISC
patients O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
14 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
patients O-MISC O-MISC
receiving O-MISC O-MISC
glucocorticoids O-MISC O-MISC
: O-MISC O-MISC
thymectomized O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
11 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
unoperated O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
6 O-MISC O-MISC
] O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
binding O-MISC O-MISC
assay O-MISC O-MISC
with O-MISC O-MISC
3 O-MISC O-MISC
( O-MISC O-MISC
H O-MISC O-MISC
) O-MISC O-MISC
dexamethasone O-MISC O-MISC
was O-MISC O-MISC
used O-MISC O-MISC
. O-MISC O-MISC

GR B-MISC B-MISC
mean O-MISC O-MISC
values O-MISC O-MISC
were O-MISC O-MISC
significantly O-MISC O-MISC
higher O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
MNL O-MISC O-MISC
of O-MISC O-MISC
MG O-MISC O-MISC
patients O-MISC O-MISC
( O-MISC O-MISC
thymectomized O-MISC O-MISC
or O-MISC O-MISC
not O-MISC O-MISC
) O-MISC O-MISC
not O-MISC O-MISC
receiving O-MISC O-MISC
glucocorticoid O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
MNL O-MISC O-MISC
of O-MISC O-MISC
healthy O-MISC O-MISC
donors O-MISC O-MISC
. O-MISC O-MISC

Affinity O-MISC O-MISC
was O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
normal O-MISC O-MISC
range O-MISC O-MISC
. O-MISC O-MISC

Sex O-MISC O-MISC
, O-MISC O-MISC
age O-MISC O-MISC
or O-MISC O-MISC
clinical O-MISC O-MISC
forms O-MISC O-MISC
of O-MISC O-MISC
illness O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
influence O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
patients O-MISC O-MISC
receiving O-MISC O-MISC
prednisone O-MISC O-MISC
( O-MISC O-MISC
Pd O-MISC B-MISC
) O-MISC O-MISC
the O-MISC O-MISC
GR B-MISC B-MISC
values O-MISC O-MISC
were O-MISC O-MISC
significantly O-MISC O-MISC
lower O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
MG O-MISC O-MISC
patients O-MISC O-MISC
without O-MISC O-MISC
Pd O-MISC O-MISC
therapy O-MISC O-MISC
, O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
Pd O-MISC O-MISC
dose O-MISC O-MISC
or O-MISC O-MISC
time O-MISC O-MISC
of O-MISC O-MISC
administration O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
binding O-MISC O-MISC
between O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
and O-MISC O-MISC
MG O-MISC O-MISC
patients O-MISC O-MISC
receiving O-MISC O-MISC
Pd O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
found O-MISC O-MISC
. O-MISC O-MISC

Immunological O-MISC O-MISC
interference O-MISC O-MISC
of O-MISC O-MISC
high O-MISC O-MISC
dose O-MISC O-MISC
corticosteroids O-MISC O-MISC
. O-MISC O-MISC

High O-MISC O-MISC
- O-MISC O-MISC
dose O-MISC O-MISC
corticosteroids O-MISC O-MISC
( O-MISC O-MISC
HDC O-MISC O-MISC
) O-MISC O-MISC
will O-MISC O-MISC
influence O-MISC O-MISC
cellular O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
humoral O-MISC O-MISC
participants O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
lymphoid O-MISC O-MISC
tissue O-MISC O-MISC
will O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
size O-MISC O-MISC
and O-MISC O-MISC
weight O-MISC O-MISC
after O-MISC O-MISC
prolonged O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
HDC O-MISC O-MISC
. O-MISC O-MISC

Lymphocyte O-MISC O-MISC
functions O-MISC O-MISC
will O-MISC O-MISC
be O-MISC O-MISC
impaired O-MISC O-MISC
. O-MISC O-MISC

Reduced O-MISC O-MISC
synthesis O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lymphocytes O-MISC O-MISC
will O-MISC O-MISC
be O-MISC O-MISC
seen O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
observed O-MISC O-MISC
both O-MISC O-MISC
as O-MISC O-MISC
decreased O-MISC O-MISC
serum O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
immunoglobulins B-MISC B-MISC
and O-MISC O-MISC
as O-MISC O-MISC
impaired O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
antibodies B-MISC B-MISC
and O-MISC O-MISC
complement O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC O-MISC
surface O-MISC O-MISC
. O-MISC O-MISC

Reduced O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
indicated O-MISC O-MISC
by O-MISC O-MISC
impaired O-MISC O-MISC
stimulation O-MISC O-MISC
by O-MISC O-MISC
PHA B-MISC B-MISC
and O-MISC O-MISC
porkweed B-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
by O-MISC O-MISC
impaired O-MISC O-MISC
lymphokinin O-MISC B-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
leukocyte O-MISC O-MISC
migration O-MISC O-MISC
inhibition O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
reported O-MISC O-MISC
. O-MISC O-MISC

Reduced O-MISC O-MISC
lymphocyte O-MISC O-MISC
adherence O-MISC O-MISC
to O-MISC O-MISC
antigen O-MISC O-MISC
and O-MISC O-MISC
suppressed O-MISC O-MISC
lymphocyte O-MISC O-MISC
reaction O-MISC O-MISC
have O-MISC O-MISC
also O-MISC O-MISC
been O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

Humoral O-MISC B-MISC
factors O-MISC I-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
chemotaxis O-MISC O-MISC
, O-MISC O-MISC
opsonisation O-MISC O-MISC
, O-MISC O-MISC
phagocytosis O-MISC O-MISC
, O-MISC O-MISC
vascular O-MISC O-MISC
permeability O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
leakage O-MISC O-MISC
of O-MISC O-MISC
fluid O-MISC O-MISC
and O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
factors O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
lysis O-MISC O-MISC
of O-MISC O-MISC
antigens O-MISC O-MISC
are O-MISC O-MISC
impaired O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
explained O-MISC O-MISC
partly O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
observed O-MISC O-MISC
reduced O-MISC O-MISC
complement O-MISC O-MISC
activation O-MISC O-MISC
via O-MISC O-MISC
the O-MISC O-MISC
alternative O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
classical O-MISC O-MISC
pathway O-MISC O-MISC
in O-MISC O-MISC
association O-MISC O-MISC
with O-MISC O-MISC
HDC O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

Acute O-MISC O-MISC
processes O-MISC O-MISC
with O-MISC O-MISC
increased O-MISC O-MISC
vascular O-MISC B-MISC
permeability O-MISC I-MISC
and O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
leukocytes O-MISC O-MISC
as O-MISC O-MISC
impairing O-MISC O-MISC
factors O-MISC I-MISC
could O-MISC O-MISC
be O-MISC O-MISC
influenced O-MISC O-MISC
beneficially O-MISC O-MISC
by O-MISC O-MISC
HDC O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
positive O-MISC O-MISC
effect O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
septic O-MISC O-MISC
shock O-MISC O-MISC
or O-MISC O-MISC
rejection O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
transplant O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
if O-MISC O-MISC
sepsis O-MISC O-MISC
or O-MISC O-MISC
rejection O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
rapidly O-MISC O-MISC
reversed O-MISC O-MISC
, O-MISC O-MISC
complications O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
multisystem O-MISC O-MISC
organ O-MISC O-MISC
failure O-MISC O-MISC
and O-MISC O-MISC
bacteremia O-MISC O-MISC
are O-MISC O-MISC
prone O-MISC O-MISC
to O-MISC O-MISC
appear O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
of O-MISC O-MISC
human B-MISC B-MISC
leukemic I-MISC I-MISC
glucocorticoid I-MISC I-MISC
receptors I-MISC I-MISC
using O-MISC O-MISC
affinity O-MISC O-MISC
labeling O-MISC O-MISC
and O-MISC O-MISC
anti B-MISC O-MISC
- I-MISC O-MISC
human I-MISC O-MISC
glucocorticoid I-MISC B-MISC
receptor I-MISC I-MISC
antibodies I-MISC I-MISC
. O-MISC O-MISC

Antisera O-MISC O-MISC
raised O-MISC O-MISC
against O-MISC O-MISC
human B-MISC B-MISC
lymphoid I-MISC I-MISC
glucocorticoid I-MISC I-MISC
receptors I-MISC I-MISC
were O-MISC O-MISC
used O-MISC O-MISC
in O-MISC O-MISC
combination O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid O-MISC B-MISC
receptor O-MISC I-MISC
affinity O-MISC O-MISC
label O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
21 O-MISC O-MISC
- O-MISC O-MISC
mesylate O-MISC O-MISC
[ O-MISC O-MISC
( O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
DM O-MISC O-MISC
) O-MISC O-MISC
to O-MISC O-MISC
identify O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphoblastoid O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
IM O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemic O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
CEM O-MISC O-MISC
- O-MISC O-MISC
C7 O-MISC O-MISC
. O-MISC O-MISC

Antisera O-MISC O-MISC
were O-MISC O-MISC
obtained O-MISC O-MISC
following O-MISC O-MISC
immunization O-MISC O-MISC
of O-MISC O-MISC
New O-MISC O-MISC
Zealand O-MISC O-MISC
White O-MISC O-MISC
rabbits O-MISC O-MISC
with O-MISC O-MISC
[ B-MISC O-MISC
3H I-MISC O-MISC
] I-MISC O-MISC
triamcinolone I-MISC O-MISC
acetonide I-MISC O-MISC
[ I-MISC O-MISC
( I-MISC O-MISC
3H I-MISC O-MISC
] I-MISC O-MISC
TA I-MISC O-MISC
) I-MISC O-MISC
- I-MISC O-MISC
glucocorticoid I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC O-MISC
partially O-MISC O-MISC
purified O-MISC O-MISC
by O-MISC O-MISC
two O-MISC O-MISC
- O-MISC O-MISC
stage O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
cellulose O-MISC O-MISC
chromatography O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
human I-MISC I-MISC
glucocorticoid I-MISC I-MISC
receptor I-MISC I-MISC
antibodies I-MISC I-MISC
was O-MISC O-MISC
verified O-MISC O-MISC
by O-MISC O-MISC
: O-MISC O-MISC
( O-MISC O-MISC
a O-MISC O-MISC
) O-MISC O-MISC
adsorption O-MISC O-MISC
of O-MISC O-MISC
[ B-MISC B-MISC
3H I-MISC I-MISC
] I-MISC I-MISC
TA I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
- I-MISC I-MISC
antibody I-MISC I-MISC
complexes I-MISC I-MISC
to O-MISC O-MISC
Protein B-MISC O-MISC
A I-MISC O-MISC
; O-MISC O-MISC
( O-MISC O-MISC
b O-MISC O-MISC
) O-MISC O-MISC
a O-MISC O-MISC
shift O-MISC O-MISC
to O-MISC O-MISC
higher O-MISC O-MISC
apparent O-MISC O-MISC
molecular O-MISC O-MISC
weight O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
elution O-MISC O-MISC
position O-MISC O-MISC
from O-MISC O-MISC
Sephacryl O-MISC O-MISC
S300 O-MISC B-MISC
of O-MISC O-MISC
[ B-MISC B-MISC
3H I-MISC I-MISC
] I-MISC I-MISC
TA I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
immune O-MISC O-MISC
serum O-MISC O-MISC
; O-MISC O-MISC
and O-MISC O-MISC
( O-MISC O-MISC
c O-MISC O-MISC
) O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
immune O-MISC O-MISC
serum O-MISC O-MISC
to O-MISC O-MISC
displace O-MISC O-MISC
[ B-MISC O-MISC
3H I-MISC O-MISC
] I-MISC I-MISC
TA I-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
on O-MISC O-MISC
sucrose O-MISC O-MISC
gradients O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
antibodies B-MISC O-MISC
also O-MISC O-MISC
recognized O-MISC O-MISC
rat O-MISC O-MISC
liver O-MISC O-MISC
and O-MISC O-MISC
murine B-MISC O-MISC
S49 I-MISC I-MISC
cell I-MISC I-MISC
glucocorticoid I-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

Sodium O-MISC O-MISC
dodecyl O-MISC O-MISC
sulfate O-MISC O-MISC
- O-MISC O-MISC
polyacrylamide O-MISC O-MISC
gel O-MISC O-MISC
electrophoresis O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
DM O-MISC O-MISC
- O-MISC O-MISC
labeled O-MISC O-MISC
IM O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
cytosol O-MISC O-MISC
identified O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
competable O-MISC O-MISC
band O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
molecular O-MISC O-MISC
weight O-MISC O-MISC
of O-MISC O-MISC
approximately O-MISC O-MISC
90 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
, O-MISC O-MISC
three O-MISC O-MISC
minor O-MISC O-MISC
competable O-MISC O-MISC
components O-MISC O-MISC
with O-MISC O-MISC
molecular O-MISC O-MISC
weights O-MISC O-MISC
of O-MISC O-MISC
approximately O-MISC O-MISC
78 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
, O-MISC O-MISC
approximately O-MISC O-MISC
51 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
approximately O-MISC O-MISC
38 O-MISC O-MISC
, O-MISC O-MISC
500 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
21 O-MISC O-MISC
other O-MISC O-MISC
noncompetable O-MISC O-MISC
components O-MISC O-MISC
. O-MISC O-MISC

Following O-MISC O-MISC
immunoprecipitation O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
DM O-MISC O-MISC
- O-MISC O-MISC
labeled O-MISC O-MISC
cytosol O-MISC O-MISC
with O-MISC O-MISC
immune O-MISC O-MISC
serum O-MISC O-MISC
, O-MISC O-MISC
only O-MISC O-MISC
the O-MISC O-MISC
Mr O-MISC O-MISC
90 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
and O-MISC O-MISC
78 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
components O-MISC O-MISC
were O-MISC O-MISC
seen O-MISC O-MISC
. O-MISC O-MISC

Sodium O-MISC O-MISC
dodecyl O-MISC O-MISC
sulfate O-MISC O-MISC
- O-MISC O-MISC
polyacrylamide O-MISC O-MISC
gel O-MISC O-MISC
electrophoresis O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
DM O-MISC O-MISC
- O-MISC O-MISC
labeled O-MISC O-MISC
CEM O-MISC O-MISC
- O-MISC O-MISC
C7 O-MISC O-MISC
cytosol O-MISC O-MISC
revealed O-MISC O-MISC
a O-MISC O-MISC
larger O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
DM O-MISC O-MISC
- O-MISC O-MISC
labeled O-MISC O-MISC
components O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
after O-MISC O-MISC
immunoprecipitation O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
DM O-MISC O-MISC
- O-MISC O-MISC
labeled O-MISC O-MISC
CEM O-MISC O-MISC
- O-MISC O-MISC
C7 O-MISC O-MISC
cytosol O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
predominant O-MISC O-MISC
competable O-MISC O-MISC
component O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
molecular O-MISC O-MISC
weight O-MISC O-MISC
of O-MISC O-MISC
90 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
was O-MISC O-MISC
easily O-MISC O-MISC
identified O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
component O-MISC O-MISC
was O-MISC O-MISC
markedly O-MISC O-MISC
diminished O-MISC O-MISC
when O-MISC O-MISC
cytosols O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid O-MISC O-MISC
receptor O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
ICR O-MISC O-MISC
- O-MISC O-MISC
27 O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
combination O-MISC O-MISC
of O-MISC O-MISC
affinity O-MISC O-MISC
labeling O-MISC O-MISC
and O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
human I-MISC I-MISC
glucocorticoid I-MISC I-MISC
receptor I-MISC I-MISC
antibodies I-MISC I-MISC
is O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
providing O-MISC O-MISC
direct O-MISC O-MISC
physical O-MISC O-MISC
identification O-MISC O-MISC
of O-MISC O-MISC
human B-MISC O-MISC
lymphoid I-MISC O-MISC
glucocorticoid I-MISC I-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

Effect O-MISC O-MISC
of O-MISC O-MISC
thymosin O-MISC O-MISC
on O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
glucocorticoid O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

Incubation O-MISC O-MISC
with O-MISC O-MISC
thymosin O-MISC O-MISC
fraction O-MISC O-MISC
5 O-MISC O-MISC
, O-MISC O-MISC
( O-MISC O-MISC
TMS O-MISC O-MISC
F5 O-MISC O-MISC
at O-MISC O-MISC
300 O-MISC O-MISC
micrograms O-MISC O-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
) O-MISC O-MISC
a O-MISC O-MISC
partially O-MISC O-MISC
purified O-MISC O-MISC
thymic O-MISC B-MISC
factor O-MISC I-MISC
, O-MISC O-MISC
reduced O-MISC O-MISC
the O-MISC O-MISC
steroid O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
infant O-MISC O-MISC
thymocytes O-MISC O-MISC
from O-MISC O-MISC
9 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
fmole O-MISC O-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
to O-MISC O-MISC
5 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
fmole O-MISC O-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
infant O-MISC O-MISC
thymocytes O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
146 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
726 O-MISC O-MISC
( O-MISC O-MISC
s O-MISC O-MISC
. O-MISC O-MISC
d O-MISC O-MISC
. O-MISC O-MISC
) O-MISC O-MISC
sites O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
with O-MISC O-MISC
dissociation O-MISC O-MISC
constant O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC

TMS O-MISC O-MISC
F5 O-MISC O-MISC
also O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
resistance O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
thymocytes O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
cytolytic O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
) O-MISC O-MISC
to O-MISC O-MISC
168 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
30 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
control O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
animals O-MISC O-MISC
, O-MISC O-MISC
medullary O-MISC O-MISC
and O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
more O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
than O-MISC O-MISC
immature O-MISC O-MISC
thymic O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
thymosin O-MISC O-MISC
can O-MISC O-MISC
induce O-MISC O-MISC
changes O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
results O-MISC O-MISC
are O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
physiological O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
thymosin O-MISC O-MISC
in O-MISC O-MISC
intrathymic O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
maturation O-MISC O-MISC
in O-MISC O-MISC
man O-MISC O-MISC
. O-MISC O-MISC

Incubation O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
human O-MISC O-MISC
malignant O-MISC O-MISC
thymus O-MISC O-MISC
derived O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
( O-MISC O-MISC
MOLT O-MISC O-MISC
3 O-MISC O-MISC
) O-MISC O-MISC
with O-MISC O-MISC
TMS O-MISC O-MISC
F5 O-MISC O-MISC
also O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
reduction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC O-MISC
to O-MISC O-MISC
44 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
15 O-MISC O-MISC
. O-MISC O-MISC
3 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
control O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
05 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
TMS O-MISC O-MISC
F5 O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
significantly O-MISC O-MISC
reduce O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
MOLT O-MISC O-MISC
3 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Specific B-MISC O-MISC
high I-MISC B-MISC
- I-MISC I-MISC
affinity I-MISC I-MISC
receptors I-MISC I-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
dihydroxyvitamin O-MISC O-MISC
D3 O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
: O-MISC O-MISC
presence O-MISC O-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
induction O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
following O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
monocytes O-MISC O-MISC
have O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
binding O-MISC I-MISC
sites O-MISC I-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
( O-MISC O-MISC
Kd O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
14 O-MISC O-MISC
nM O-MISC O-MISC
, O-MISC O-MISC
sedimentation O-MISC O-MISC
coefficient O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
7S O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Resting O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
demonstrable O-MISC B-MISC
1 B-MISC O-MISC
, I-MISC I-MISC
25 I-MISC I-MISC
- I-MISC I-MISC
( I-MISC I-MISC
OH I-MISC I-MISC
) I-MISC I-MISC
2D3 I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

After O-MISC O-MISC
activation O-MISC O-MISC
with O-MISC O-MISC
phytohemagglutinin B-MISC B-MISC
the O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
exhibit O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
within O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
this O-MISC O-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
cycloheximide O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
receptor O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
has O-MISC O-MISC
a O-MISC O-MISC
sedimentation O-MISC O-MISC
coefficient O-MISC O-MISC
of O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
7S O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
( O-MISC O-MISC
Kd O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
10 O-MISC O-MISC
nM O-MISC O-MISC
) O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
ligand O-MISC O-MISC
. O-MISC O-MISC

Effects O-MISC O-MISC
of O-MISC O-MISC
chronic O-MISC O-MISC
glucocorticoid O-MISC O-MISC
excess O-MISC O-MISC
in O-MISC O-MISC
man O-MISC O-MISC
on O-MISC O-MISC
insulin O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
circulating O-MISC O-MISC
cells O-MISC O-MISC
: O-MISC O-MISC
differences O-MISC O-MISC
between O-MISC O-MISC
endogenous O-MISC O-MISC
and O-MISC O-MISC
exogenous O-MISC O-MISC
hypercorticism O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
measured O-MISC O-MISC
[ O-MISC O-MISC
125I O-MISC O-MISC
] O-MISC O-MISC
insulin O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
circulating O-MISC O-MISC
monocytes O-MISC O-MISC
or O-MISC O-MISC
erythrocytes O-MISC O-MISC
from O-MISC O-MISC
16 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
glucocorticoid O-MISC O-MISC
excess O-MISC O-MISC
, O-MISC O-MISC
9 O-MISC O-MISC
chronically O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
prednisone O-MISC O-MISC
and O-MISC O-MISC
7 O-MISC O-MISC
with O-MISC O-MISC
adrenocortical O-MISC O-MISC
hyperfunction O-MISC O-MISC
. O-MISC O-MISC

With O-MISC O-MISC
monocytes O-MISC O-MISC
, O-MISC O-MISC
[ O-MISC O-MISC
125I O-MISC O-MISC
] O-MISC O-MISC
insulin O-MISC O-MISC
binding O-MISC O-MISC
was O-MISC O-MISC
iincreased O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
data O-MISC O-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
increased O-MISC O-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
prednisone O-MISC O-MISC
was O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
ncrease O-MISC B-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
adrenocortical O-MISC O-MISC
hyperfunction O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
affinity O-MISC O-MISC
. O-MISC O-MISC

With O-MISC O-MISC
erythrocytes O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
adrenocortical O-MISC O-MISC
hyperfunction O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
affinity O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
, O-MISC O-MISC
so O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
125I O-MISC O-MISC
] O-MISC O-MISC
insulin O-MISC O-MISC
was O-MISC O-MISC
normal O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
disparity O-MISC O-MISC
of O-MISC O-MISC
results O-MISC O-MISC
between O-MISC O-MISC
endogenous O-MISC O-MISC
and O-MISC O-MISC
exogenous O-MISC O-MISC
hypercorticism O-MISC O-MISC
, O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
studies O-MISC O-MISC
and O-MISC O-MISC
previous O-MISC O-MISC
studies O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
excess O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
insulin B-MISC B-MISC
receptor I-MISC I-MISC
are O-MISC O-MISC
extremely O-MISC O-MISC
complex O-MISC O-MISC
and O-MISC O-MISC
wide O-MISC O-MISC
- O-MISC O-MISC
ranging O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
condition O-MISC O-MISC
, O-MISC O-MISC
extrapolations O-MISC O-MISC
in O-MISC O-MISC
humans O-MISC O-MISC
from O-MISC O-MISC
data O-MISC O-MISC
with O-MISC O-MISC
circulating O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
liver O-MISC O-MISC
and O-MISC O-MISC
muscle O-MISC O-MISC
may O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
appropriate O-MISC O-MISC
. O-MISC O-MISC

Reduced O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
cellular B-MISC O-MISC
glucocorticoid I-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
anorexia O-MISC O-MISC
nervosa O-MISC O-MISC
. O-MISC O-MISC

Specific O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
were O-MISC O-MISC
measured O-MISC O-MISC
in O-MISC O-MISC
circulating O-MISC O-MISC
mononuclear O-MISC O-MISC
leukocytes O-MISC O-MISC
from O-MISC O-MISC
12 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
anorexia O-MISC O-MISC
nervosa O-MISC O-MISC
and O-MISC O-MISC
21 O-MISC O-MISC
healthy O-MISC O-MISC
control O-MISC O-MISC
subjects O-MISC O-MISC
. O-MISC O-MISC

Cells O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
contain O-MISC O-MISC
a O-MISC O-MISC
significantly O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
lower O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
3830 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
210 O-MISC O-MISC
sites O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
, O-MISC O-MISC
mean O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
SE O-MISC O-MISC
) O-MISC O-MISC
than O-MISC O-MISC
those O-MISC O-MISC
from O-MISC O-MISC
controls O-MISC O-MISC
( O-MISC O-MISC
4930 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
250 O-MISC O-MISC
sites O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
partial O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
defect O-MISC O-MISC
may O-MISC O-MISC
well O-MISC O-MISC
explain O-MISC O-MISC
the O-MISC O-MISC
abnormal O-MISC O-MISC
cortisol O-MISC O-MISC
metabolism O-MISC O-MISC
and O-MISC O-MISC
glucocorticoid O-MISC O-MISC
resistance O-MISC O-MISC
commonly O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
anorexia O-MISC O-MISC
nervosa O-MISC O-MISC
. O-MISC O-MISC

Regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
is O-MISC O-MISC
well O-MISC O-MISC
established O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
factors O-MISC O-MISC
affecting O-MISC O-MISC
its O-MISC O-MISC
regulation O-MISC O-MISC
have O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
described O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
a O-MISC O-MISC
competitive O-MISC O-MISC
binding O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
dexamethasone O-MISC O-MISC
at O-MISC O-MISC
24 O-MISC O-MISC
and O-MISC O-MISC
37 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
in O-MISC O-MISC
untreated O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
healthy O-MISC O-MISC
subjects O-MISC O-MISC
taking O-MISC O-MISC
various O-MISC O-MISC
glucocorticoid O-MISC O-MISC
preparations O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
24 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
had O-MISC O-MISC
6000 O-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
dissociation O-MISC O-MISC
constant O-MISC O-MISC
of O-MISC O-MISC
4 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
administration O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
mg O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
mg O-MISC O-MISC
of O-MISC O-MISC
prednisone O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
37 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
mg O-MISC O-MISC
of O-MISC O-MISC
cortisone O-MISC O-MISC
acetate O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
30 O-MISC O-MISC
% O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC O-MISC
after O-MISC O-MISC
1 O-MISC O-MISC
week O-MISC O-MISC
with O-MISC O-MISC
no O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC B-MISC
sites O-MISC I-MISC
was O-MISC O-MISC
noted O-MISC O-MISC
before O-MISC O-MISC
1 O-MISC O-MISC
week O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
diminished O-MISC O-MISC
number O-MISC O-MISC
persisted O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
week O-MISC O-MISC
after O-MISC O-MISC
discontinuation O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

Lymphocytes O-MISC O-MISC
from O-MISC O-MISC
hospitalized O-MISC O-MISC
patients O-MISC O-MISC
taking O-MISC O-MISC
40 O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
mg O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
daily O-MISC O-MISC
demonstrated O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC B-MISC
sites O-MISC I-MISC
that O-MISC O-MISC
was O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
taking O-MISC O-MISC
1 O-MISC O-MISC
mg O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
. O-MISC O-MISC

When O-MISC O-MISC
binding O-MISC O-MISC
assays O-MISC O-MISC
were O-MISC O-MISC
carried O-MISC O-MISC
out O-MISC O-MISC
at O-MISC O-MISC
physiologic O-MISC O-MISC
temperature O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC O-MISC
after O-MISC O-MISC
dexamethasone O-MISC O-MISC
administration O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
two O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid O-MISC O-MISC
administration O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
time O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
lymphocyte O-MISC O-MISC
glucocorticoid O-MISC B-MISC
binding O-MISC I-MISC
sites O-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
type O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
administered O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
demonstration O-MISC O-MISC
that O-MISC O-MISC
glucocorticoids O-MISC O-MISC
modulate O-MISC O-MISC
their O-MISC O-MISC
own O-MISC O-MISC
receptors O-MISC O-MISC
in O-MISC O-MISC
man O-MISC O-MISC
. O-MISC O-MISC

Immunoglobulin O-MISC O-MISC
localization O-MISC O-MISC
in O-MISC O-MISC
benign O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
lesions O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
mammary O-MISC O-MISC
gland O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
direct O-MISC O-MISC
imunofluorescence O-MISC O-MISC
, O-MISC O-MISC
lesions O-MISC O-MISC
from O-MISC O-MISC
266 O-MISC O-MISC
human O-MISC O-MISC
breast O-MISC O-MISC
specimens O-MISC O-MISC
were O-MISC O-MISC
studied O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
IgA O-MISC B-MISC
, O-MISC O-MISC
IgM O-MISC B-MISC
, O-MISC O-MISC
or O-MISC O-MISC
IgG O-MISC B-MISC
localization O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
lesions O-MISC O-MISC
included O-MISC O-MISC
benign O-MISC B-MISC
elements O-MISC I-MISC
from O-MISC O-MISC
66 O-MISC O-MISC
subcutaneous O-MISC O-MISC
mastectomy O-MISC O-MISC
specimens O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
simultaneous O-MISC O-MISC
breast O-MISC O-MISC
malignancy O-MISC O-MISC
was O-MISC O-MISC
documented O-MISC O-MISC
, O-MISC O-MISC
primary O-MISC O-MISC
breast O-MISC O-MISC
carcinomas O-MISC O-MISC
from O-MISC O-MISC
153 O-MISC O-MISC
mastectomy O-MISC O-MISC
specimens O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
47 O-MISC O-MISC
biopsies O-MISC O-MISC
containing O-MISC O-MISC
metastatic O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
statistically O-MISC O-MISC
significant O-MISC O-MISC
association O-MISC O-MISC
of O-MISC O-MISC
IgA B-MISC B-MISC
and O-MISC O-MISC
IgM B-MISC B-MISC
with O-MISC O-MISC
benign O-MISC O-MISC
lesions O-MISC O-MISC
was O-MISC O-MISC
contrasted O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
association O-MISC O-MISC
of O-MISC O-MISC
IgG B-MISC B-MISC
with O-MISC O-MISC
malignant O-MISC O-MISC
lesions O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
both O-MISC O-MISC
primary O-MISC O-MISC
and O-MISC O-MISC
metastatic O-MISC O-MISC
lesions O-MISC O-MISC
, O-MISC O-MISC
IgG B-MISC B-MISC
localization O-MISC O-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
estrogen O-MISC B-MISC
- O-MISC I-MISC
receptor O-MISC I-MISC
- O-MISC O-MISC
poor O-MISC O-MISC
primary O-MISC O-MISC
cancers O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
estrogen O-MISC B-MISC
- O-MISC I-MISC
receptor O-MISC I-MISC
- O-MISC O-MISC
rich O-MISC O-MISC
primary O-MISC O-MISC
cancers O-MISC O-MISC
. O-MISC O-MISC

Among O-MISC O-MISC
primary O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
IgG B-MISC B-MISC
localization O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
relative O-MISC O-MISC
lymphopenia O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
shorter O-MISC O-MISC
disease O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
interval O-MISC O-MISC
was O-MISC O-MISC
noted O-MISC O-MISC
in O-MISC O-MISC
association O-MISC O-MISC
with O-MISC O-MISC
IgG B-MISC B-MISC
localization O-MISC O-MISC
among O-MISC O-MISC
the O-MISC O-MISC
metastatic O-MISC O-MISC
breast O-MISC O-MISC
lesions O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
statistically O-MISC O-MISC
significant O-MISC O-MISC
association O-MISC O-MISC
between O-MISC O-MISC
stage O-MISC O-MISC
of O-MISC O-MISC
disease O-MISC O-MISC
and O-MISC O-MISC
immunoglobulin O-MISC B-MISC
presence O-MISC O-MISC
was O-MISC O-MISC
demonstrable O-MISC O-MISC
. O-MISC O-MISC

Moderate O-MISC O-MISC
- O-MISC O-MISC
to O-MISC O-MISC
- O-MISC O-MISC
severe O-MISC O-MISC
intraductal O-MISC O-MISC
epithelial O-MISC O-MISC
hyperplasias O-MISC O-MISC
were O-MISC O-MISC
more O-MISC O-MISC
often O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
immunoglobulin B-MISC B-MISC
G I-MISC O-MISC
localization O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
other O-MISC O-MISC
benign O-MISC O-MISC
lesions O-MISC O-MISC

Correlation O-MISC O-MISC
of O-MISC O-MISC
steroid B-MISC B-MISC
receptors I-MISC I-MISC
with O-MISC O-MISC
histologic O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
mammary O-MISC O-MISC
carcinoma O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
Singapore O-MISC O-MISC
experience O-MISC O-MISC
. O-MISC O-MISC

Cancer O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
breast O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
most O-MISC O-MISC
common O-MISC O-MISC
tumor O-MISC O-MISC
in O-MISC O-MISC
females O-MISC O-MISC
in O-MISC O-MISC
Singapore O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
rate O-MISC O-MISC
of O-MISC O-MISC
20 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
per O-MISC O-MISC
100 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
per O-MISC O-MISC
year O-MISC O-MISC
( O-MISC O-MISC
1977 O-MISC O-MISC
estimate O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
predicted O-MISC O-MISC
to O-MISC O-MISC
increase O-MISC O-MISC
to O-MISC O-MISC
29 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
per O-MISC O-MISC
100 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
women O-MISC O-MISC
per O-MISC O-MISC
year O-MISC O-MISC
by O-MISC O-MISC
1995 O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
detailed O-MISC O-MISC
histopathologic O-MISC O-MISC
review O-MISC O-MISC
of O-MISC O-MISC
50 O-MISC O-MISC
primary O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
tumors O-MISC O-MISC
analyzed O-MISC O-MISC
for O-MISC O-MISC
estrogen B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
ER B-MISC B-MISC
) O-MISC O-MISC
level O-MISC O-MISC
was O-MISC O-MISC
carried O-MISC O-MISC
out O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
morphologic O-MISC O-MISC
features O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
ER B-MISC B-MISC
results O-MISC I-MISC
to O-MISC O-MISC
identify O-MISC O-MISC
any O-MISC O-MISC
factors O-MISC I-MISC
that O-MISC O-MISC
will O-MISC O-MISC
improve O-MISC O-MISC
the O-MISC O-MISC
management O-MISC O-MISC
and O-MISC O-MISC
prognosis O-MISC O-MISC
for O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
. O-MISC O-MISC

Cytosol O-MISC O-MISC
was O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
3H O-MISC O-MISC
- O-MISC O-MISC
estradiol O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
and O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
cold O-MISC O-MISC
diethylstilbestrol O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
bound O-MISC O-MISC
and O-MISC O-MISC
free O-MISC O-MISC
hormone O-MISC O-MISC
were O-MISC O-MISC
separated O-MISC O-MISC
by O-MISC O-MISC
Dextran O-MISC O-MISC
- O-MISC O-MISC
coated O-MISC O-MISC
charcoal O-MISC O-MISC
method O-MISC O-MISC
. O-MISC O-MISC

Tumors O-MISC O-MISC
binding O-MISC O-MISC
more O-MISC O-MISC
than O-MISC O-MISC
5 O-MISC O-MISC
fmol O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
cytosol B-MISC B-MISC
protein I-MISC I-MISC
were O-MISC O-MISC
classified O-MISC O-MISC
as O-MISC O-MISC
ER B-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
. O-MISC O-MISC

Progesterone B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
PR B-MISC B-MISC
) O-MISC O-MISC
level O-MISC O-MISC
was O-MISC O-MISC
analyzed O-MISC O-MISC
in O-MISC O-MISC
some O-MISC O-MISC
specimens O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
similar O-MISC O-MISC
method O-MISC O-MISC
. O-MISC O-MISC

Most O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
were O-MISC O-MISC
Chinese O-MISC O-MISC
( O-MISC O-MISC
90 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Three O-MISC O-MISC
patients O-MISC O-MISC
were O-MISC O-MISC
Malays O-MISC O-MISC
, O-MISC O-MISC
one O-MISC O-MISC
was O-MISC O-MISC
Indian O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
one O-MISC O-MISC
was O-MISC O-MISC
European O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
series O-MISC O-MISC
. O-MISC O-MISC

Results O-MISC O-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
strong O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
ER B-MISC B-MISC
level O-MISC O-MISC
, O-MISC O-MISC
age O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
histologic O-MISC O-MISC
grade O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tumors O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
correlation O-MISC O-MISC
existed O-MISC O-MISC
between O-MISC O-MISC
absence O-MISC O-MISC
or O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
lymph O-MISC O-MISC
node O-MISC O-MISC
metastases O-MISC O-MISC
and O-MISC O-MISC
ER B-MISC B-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
trend O-MISC O-MISC
for O-MISC O-MISC
ER B-MISC B-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
tumors O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
low O-MISC O-MISC
- O-MISC O-MISC
grade O-MISC O-MISC
lymphocytic O-MISC O-MISC
infiltration O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
difference O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
statistically O-MISC O-MISC
significant O-MISC O-MISC
. O-MISC O-MISC

Mononuclear O-MISC O-MISC
cells O-MISC O-MISC
infiltrating O-MISC O-MISC
human O-MISC O-MISC
mammary O-MISC O-MISC
carcinomas O-MISC O-MISC
: O-MISC O-MISC
immunohistochemical O-MISC O-MISC
analysis O-MISC O-MISC
with O-MISC O-MISC
monoclonal B-MISC B-MISC
antibodies I-MISC I-MISC
. O-MISC O-MISC

Breast O-MISC O-MISC
carcinomas O-MISC O-MISC
were O-MISC O-MISC
examined O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
immunoperoxidase O-MISC O-MISC
technique O-MISC O-MISC
using O-MISC O-MISC
antisera O-MISC O-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
lymphocyte O-MISC O-MISC
subsets O-MISC O-MISC
, O-MISC O-MISC
monocytes O-MISC O-MISC
, O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
major B-MISC O-MISC
histocompatibility I-MISC O-MISC
antigens I-MISC O-MISC
( O-MISC O-MISC
HLA B-MISC O-MISC
- I-MISC O-MISC
A I-MISC O-MISC
, O-MISC O-MISC
- B-MISC B-MISC
B I-MISC I-MISC
, O-MISC I-MISC
- O-MISC I-MISC
C O-MISC I-MISC
; O-MISC I-MISC
Ia B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Sixty O-MISC O-MISC
- O-MISC O-MISC
four O-MISC O-MISC
per O-MISC O-MISC
cent O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
moderate O-MISC O-MISC
or O-MISC O-MISC
strong O-MISC O-MISC
mononuclear O-MISC O-MISC
cell O-MISC O-MISC
infiltration O-MISC O-MISC
, O-MISC O-MISC
77 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
without O-MISC O-MISC
mononuclear O-MISC O-MISC
cell O-MISC O-MISC
infiltration O-MISC O-MISC
had O-MISC O-MISC
receptors O-MISC O-MISC
for O-MISC O-MISC
estrogens O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
51 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
infiltration O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
majority O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
infiltrating O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
; O-MISC O-MISC
generally O-MISC O-MISC
the O-MISC O-MISC
OKT8 O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
predominant O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Leu O-MISC O-MISC
3A O-MISC O-MISC
/ O-MISC O-MISC
OKT8 O-MISC O-MISC
cell O-MISC O-MISC
ratio O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
histological O-MISC O-MISC
type O-MISC O-MISC
, O-MISC O-MISC
tumor O-MISC O-MISC
size O-MISC O-MISC
, O-MISC O-MISC
age O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
or O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
metastases O-MISC O-MISC
. O-MISC O-MISC

Some O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
had O-MISC O-MISC
the O-MISC O-MISC
Ia B-MISC B-MISC
antigen I-MISC I-MISC
and O-MISC O-MISC
were O-MISC O-MISC
thus O-MISC O-MISC
probably O-MISC O-MISC
activated O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
either O-MISC O-MISC
absent O-MISC O-MISC
or O-MISC O-MISC
less O-MISC O-MISC
numerous O-MISC O-MISC
than O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
was O-MISC O-MISC
no O-MISC O-MISC
relation O-MISC O-MISC
between O-MISC O-MISC
their O-MISC O-MISC
distribution O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
various O-MISC O-MISC
parameters O-MISC O-MISC
studied O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
few O-MISC O-MISC
monocytes O-MISC O-MISC
were O-MISC O-MISC
heterogeneous O-MISC O-MISC
according O-MISC O-MISC
to O-MISC O-MISC
their O-MISC O-MISC
markers O-MISC O-MISC
( O-MISC O-MISC
OKM B-MISC B-MISC
I I-MISC I-MISC
and O-MISC O-MISC
acid O-MISC I-MISC
phosphatase O-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
6 O-MISC O-MISC
cases O-MISC O-MISC
only O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
strong O-MISC O-MISC
infiltration O-MISC O-MISC
of O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
positive O-MISC O-MISC
for O-MISC O-MISC
acid B-MISC O-MISC
phosphatase I-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
low O-MISC O-MISC
. O-MISC O-MISC

Only O-MISC O-MISC
a O-MISC O-MISC
few O-MISC O-MISC
mononuclear O-MISC O-MISC
infiltrating O-MISC O-MISC
cells O-MISC O-MISC
had O-MISC O-MISC
receptors O-MISC O-MISC
for O-MISC O-MISC
transferrin O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
positive O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
inflammatory O-MISC O-MISC
infiltration O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
HLA B-MISC B-MISC
class I-MISC I-MISC
- I-MISC I-MISC
I I-MISC I-MISC
antigens I-MISC I-MISC
on O-MISC O-MISC
tumor O-MISC O-MISC
cell O-MISC O-MISC
s O-MISC O-MISC
. O-MISC O-MISC

Some O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
antisera O-MISC O-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
lymphocyte O-MISC O-MISC
subsets O-MISC O-MISC
also O-MISC O-MISC
stained O-MISC O-MISC
the O-MISC O-MISC
breast O-MISC O-MISC
carcinoma O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
great O-MISC O-MISC
variations O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
subsets O-MISC O-MISC
of O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
breast O-MISC O-MISC
carcinomas O-MISC O-MISC
may O-MISC O-MISC
correspond O-MISC O-MISC
to O-MISC O-MISC
various O-MISC O-MISC
systems O-MISC O-MISC
of O-MISC O-MISC
defense O-MISC O-MISC
against O-MISC O-MISC
neoplasm O-MISC B-MISC
. O-MISC O-MISC

A O-MISC O-MISC
case O-MISC O-MISC
of O-MISC O-MISC
male O-MISC O-MISC
pseudohermaphroditis O-MISC O-MISC
with O-MISC O-MISC
normal O-MISC B-MISC
androgen B-MISC O-MISC
receptor I-MISC I-MISC
binding O-MISC O-MISC
and O-MISC O-MISC
47 O-MISC O-MISC
, O-MISC O-MISC
XYY O-MISC O-MISC
karyotype O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
case O-MISC O-MISC
of O-MISC O-MISC
male O-MISC O-MISC
pseudohermaphroditis O-MISC O-MISC
with O-MISC O-MISC
47 O-MISC O-MISC
, O-MISC O-MISC
XYY O-MISC B-MISC
karyotype O-MISC O-MISC
in O-MISC O-MISC
blood O-MISC O-MISC
and O-MISC O-MISC
cutaneous O-MISC O-MISC
fibroblasts O-MISC O-MISC
is O-MISC O-MISC
described O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
plasma O-MISC O-MISC
testosterone O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
HCG O-MISC O-MISC
stimulation O-MISC O-MISC
was O-MISC O-MISC
slightly O-MISC O-MISC
below O-MISC O-MISC
the O-MISC O-MISC
normal O-MISC O-MISC
range O-MISC O-MISC
on O-MISC O-MISC
two O-MISC O-MISC
occasions O-MISC O-MISC
suggesting O-MISC O-MISC
a O-MISC O-MISC
deficit O-MISC O-MISC
of O-MISC O-MISC
gonadal O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
study O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptors O-MISC O-MISC
for O-MISC O-MISC
dihydrotestosterone O-MISC O-MISC
in O-MISC O-MISC
fibroblasts O-MISC O-MISC
of O-MISC O-MISC
genital O-MISC O-MISC
and O-MISC O-MISC
nongenital O-MISC O-MISC
skin O-MISC O-MISC
showed O-MISC O-MISC
a O-MISC O-MISC
normal O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
receptors O-MISC O-MISC
in O-MISC O-MISC
genital O-MISC O-MISC
skin O-MISC O-MISC
; O-MISC O-MISC
5 B-MISC O-MISC
- I-MISC I-MISC
alpha I-MISC O-MISC
- I-MISC O-MISC
reductase I-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
fibroblasts O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
genital O-MISC O-MISC
skin O-MISC O-MISC
was O-MISC O-MISC
low O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
plasma O-MISC O-MISC
relationship O-MISC O-MISC
testosterone O-MISC O-MISC
/ O-MISC O-MISC
dihydrotestosterone O-MISC O-MISC
under O-MISC O-MISC
HCG O-MISC O-MISC
stimulation O-MISC O-MISC
was O-MISC O-MISC
normal O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
diagnostic O-MISC O-MISC
possibility O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
complete O-MISC O-MISC
testicular O-MISC O-MISC
feminization O-MISC O-MISC
syndrome O-MISC O-MISC
with O-MISC O-MISC
normal O-MISC B-MISC
receptors O-MISC I-MISC
for O-MISC O-MISC
dihydrotestosterone O-MISC O-MISC
is O-MISC O-MISC
commented O-MISC O-MISC
on O-MISC O-MISC
. O-MISC O-MISC

1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
Dihydroxyvitamin O-MISC O-MISC
D3 O-MISC O-MISC
inhibits O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
proliferative O-MISC O-MISC
response O-MISC O-MISC
of O-MISC O-MISC
murine O-MISC O-MISC
spleen O-MISC O-MISC
and O-MISC O-MISC
thymus O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
antigen B-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
to O-MISC O-MISC
lectin B-MISC B-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
active O-MISC O-MISC
metabolite O-MISC O-MISC
of O-MISC O-MISC
vitamin O-MISC O-MISC
D3 O-MISC O-MISC
, O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
directly O-MISC O-MISC
examine O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
on O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
other O-MISC O-MISC
complicating O-MISC O-MISC
interactions O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
utilized O-MISC O-MISC
a O-MISC O-MISC
panel O-MISC O-MISC
of O-MISC O-MISC
cloned O-MISC O-MISC
Ia O-MISC O-MISC
- O-MISC O-MISC
restricted O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
hybridomas O-MISC O-MISC
that O-MISC O-MISC
secrete O-MISC O-MISC
IL B-MISC B-MISC
2 I-MISC I-MISC
on O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
cloned O-MISC O-MISC
Ia O-MISC O-MISC
- O-MISC O-MISC
bearing O-MISC O-MISC
stimulator O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
TA3 O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
when O-MISC O-MISC
stimulated O-MISC O-MISC
by O-MISC O-MISC
mitogen O-MISC O-MISC
. O-MISC O-MISC

Physiologic O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
to O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
nm O-MISC O-MISC
) O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
IL O-MISC B-MISC
2 O-MISC I-MISC
by O-MISC O-MISC
several O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
hybridomas O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
inhibition O-MISC O-MISC
was O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
free O-MISC O-MISC
hormone O-MISC O-MISC
and O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
overcome O-MISC O-MISC
by O-MISC O-MISC
increasing O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
Ia O-MISC O-MISC
- O-MISC O-MISC
bearing O-MISC O-MISC
stimulator O-MISC O-MISC
cells O-MISC O-MISC
used O-MISC O-MISC
. O-MISC O-MISC

Pretreatment O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
hybridoma O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
TA3 O-MISC O-MISC
stimulator O-MISC O-MISC
cell O-MISC O-MISC
with O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
are O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
finding O-MISC O-MISC
that O-MISC O-MISC
specific O-MISC B-MISC
1 B-MISC I-MISC
, I-MISC I-MISC
25 I-MISC I-MISC
- I-MISC I-MISC
( I-MISC I-MISC
OH I-MISC I-MISC
) I-MISC I-MISC
2D3 I-MISC I-MISC
receptors I-MISC I-MISC
are O-MISC O-MISC
present O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
hybridomas O-MISC O-MISC
but O-MISC O-MISC
are O-MISC O-MISC
lacking O-MISC O-MISC
in O-MISC O-MISC
TA3 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
failed O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
hybridomas O-MISC O-MISC
by O-MISC O-MISC
lectin B-MISC B-MISC
or O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
Thy I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
antibody I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
interfering O-MISC O-MISC
with O-MISC O-MISC
early O-MISC O-MISC
events O-MISC O-MISC
of O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
perhaps O-MISC O-MISC
by O-MISC O-MISC
hindering O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
recognition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
relevant O-MISC O-MISC
antigen O-MISC O-MISC
on O-MISC O-MISC
stimulator O-MISC O-MISC
cell O-MISC O-MISC
surfaces O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
system O-MISC O-MISC
should O-MISC O-MISC
prove O-MISC O-MISC
useful O-MISC O-MISC
in O-MISC O-MISC
studying O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
mechanisms O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
acts O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
subsequent O-MISC O-MISC
IL B-MISC B-MISC
2 I-MISC I-MISC
production O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
steroid O-MISC O-MISC
sensitivity O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
neoplastic O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
tissues O-MISC O-MISC
: O-MISC O-MISC
a O-MISC O-MISC
review O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
determination O-MISC O-MISC
of O-MISC O-MISC
estrogen B-MISC B-MISC
and I-MISC I-MISC
progesterone I-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
useful O-MISC O-MISC
in O-MISC O-MISC
predicting O-MISC O-MISC
the O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
endocrine O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

Given O-MISC O-MISC
their O-MISC O-MISC
well O-MISC O-MISC
- O-MISC O-MISC
known O-MISC O-MISC
inhibitory O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
lymphoid O-MISC O-MISC
tissue O-MISC O-MISC
, O-MISC O-MISC
glucocorticoids O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
used O-MISC O-MISC
widely O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Given O-MISC O-MISC
these O-MISC O-MISC
facts O-MISC O-MISC
, O-MISC O-MISC
over O-MISC O-MISC
the O-MISC O-MISC
last O-MISC O-MISC
10 O-MISC O-MISC
years O-MISC O-MISC
, O-MISC O-MISC
several O-MISC O-MISC
investigators O-MISC O-MISC
have O-MISC O-MISC
measured O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
neoplastic O-MISC O-MISC
lymphoid O-MISC O-MISC
tissue O-MISC O-MISC
to O-MISC O-MISC
see O-MISC O-MISC
whether O-MISC O-MISC
their O-MISC O-MISC
number O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
glucocorticoid O-MISC O-MISC
responsiveness O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
or O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
clear O-MISC O-MISC
correlation O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
established O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
steroids O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
neoplastic O-MISC O-MISC
lymphoid O-MISC O-MISC
tissue O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
attempts O-MISC O-MISC
to O-MISC O-MISC
correlate O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
lymphocytic O-MISC O-MISC
leukemia O-MISC O-MISC
to O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
steroid O-MISC O-MISC
responsiveness O-MISC O-MISC
and O-MISC O-MISC
immunological O-MISC O-MISC
type O-MISC O-MISC
using O-MISC O-MISC
the O-MISC O-MISC
whole O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
assay O-MISC O-MISC
for O-MISC O-MISC
receptor O-MISC O-MISC
determination O-MISC O-MISC
and O-MISC O-MISC
selecting O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
according O-MISC O-MISC
to O-MISC O-MISC
age O-MISC O-MISC
and O-MISC O-MISC
immunological O-MISC O-MISC
criteria O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
more O-MISC O-MISC
successful O-MISC O-MISC
. O-MISC O-MISC

[ O-MISC O-MISC
Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
] O-MISC O-MISC

Glucocorticoid O-MISC O-MISC
( O-MISC I-MISC
GC O-MISC B-MISC
) O-MISC I-MISC
receptors O-MISC I-MISC
were O-MISC O-MISC
studied O-MISC O-MISC
in O-MISC O-MISC
intact O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
11 O-MISC O-MISC
donors O-MISC O-MISC
. O-MISC O-MISC

GC O-MISC O-MISC
binding O-MISC O-MISC
parameters O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
highly O-MISC O-MISC
reproducible O-MISC O-MISC
in O-MISC O-MISC
repeated O-MISC O-MISC
experiments O-MISC O-MISC
with O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
was O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
GC B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
donors O-MISC O-MISC
' O-MISC O-MISC
lymphocytes O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
distributed O-MISC O-MISC
into O-MISC O-MISC
two O-MISC O-MISC
different O-MISC O-MISC
classes O-MISC O-MISC
similarly O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
pattern O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
skin O-MISC O-MISC
fibroblasts O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
lymphocytes O-MISC O-MISC
are O-MISC O-MISC
an O-MISC O-MISC
adequate O-MISC O-MISC
object O-MISC O-MISC
for O-MISC O-MISC
studying O-MISC O-MISC
genetically O-MISC O-MISC
determined O-MISC O-MISC
variability O-MISC O-MISC
of O-MISC O-MISC
GC B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
its O-MISC O-MISC
clinical O-MISC O-MISC
importance O-MISC O-MISC
. O-MISC O-MISC

Specific O-MISC O-MISC
estrogen B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
thymic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
estrogen O-MISC O-MISC
in O-MISC O-MISC
preparations O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
by O-MISC O-MISC
splenic O-MISC O-MISC
and O-MISC O-MISC
thymic O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
demonstrated O-MISC O-MISC
by O-MISC O-MISC
three O-MISC O-MISC
different O-MISC O-MISC
approaches O-MISC O-MISC
( O-MISC O-MISC
Dextran O-MISC O-MISC
- O-MISC O-MISC
coated O-MISC O-MISC
charcoal O-MISC O-MISC
method O-MISC O-MISC
, O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
gel O-MISC O-MISC
filtration O-MISC O-MISC
on O-MISC O-MISC
a O-MISC O-MISC
sepharose O-MISC O-MISC
4B O-MISC O-MISC
column O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Scatchard O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
moxestrol O-MISC O-MISC
( O-MISC O-MISC
R2858 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
estradiol O-MISC O-MISC
binding O-MISC O-MISC
proves O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
class O-MISC O-MISC
of O-MISC O-MISC
receptor B-MISC O-MISC
sites I-MISC I-MISC
having O-MISC O-MISC
a O-MISC O-MISC
dissociation O-MISC O-MISC
constant O-MISC O-MISC
of O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
18 O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC

Physicochemical O-MISC O-MISC
properties O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
binder O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
and O-MISC O-MISC
steroid O-MISC O-MISC
specificity O-MISC O-MISC
, O-MISC O-MISC
are O-MISC O-MISC
quite O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
those O-MISC O-MISC
reported O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
of O-MISC O-MISC
small O-MISC O-MISC
mammalian O-MISC O-MISC
species O-MISC O-MISC
or O-MISC O-MISC
human O-MISC O-MISC
thymoma O-MISC O-MISC
. O-MISC O-MISC

Administration O-MISC O-MISC
of O-MISC O-MISC
fibroblast B-MISC O-MISC
interferon I-MISC B-MISC
to O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
advanced O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
: O-MISC O-MISC
possible O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
skin O-MISC O-MISC
metastasis O-MISC O-MISC
and O-MISC O-MISC
on O-MISC O-MISC
hormone B-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

Eleven O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
metastasized O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
received O-MISC O-MISC
8 O-MISC O-MISC
intramuscular O-MISC O-MISC
injections O-MISC O-MISC
of O-MISC O-MISC
6 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
units O-MISC O-MISC
of O-MISC O-MISC
human B-MISC O-MISC
fibroblast I-MISC O-MISC
interferon I-MISC O-MISC
over O-MISC O-MISC
a O-MISC O-MISC
period O-MISC O-MISC
of O-MISC O-MISC
40 O-MISC O-MISC
days O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
injections O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
cause O-MISC O-MISC
local O-MISC O-MISC
irritation O-MISC O-MISC
or O-MISC O-MISC
inflammation O-MISC O-MISC
. O-MISC O-MISC

Fever O-MISC O-MISC
occurred O-MISC O-MISC
in O-MISC O-MISC
only O-MISC O-MISC
1 O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
11 O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
several O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
metastases O-MISC O-MISC
were O-MISC O-MISC
monitored O-MISC O-MISC
, O-MISC O-MISC
only O-MISC O-MISC
skin O-MISC O-MISC
nodules O-MISC O-MISC
consistently O-MISC O-MISC
( O-MISC O-MISC
10 O-MISC O-MISC
out O-MISC O-MISC
of O-MISC O-MISC
11 O-MISC O-MISC
patients O-MISC O-MISC
) O-MISC O-MISC
exhibited O-MISC O-MISC
changes O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
suggestive O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
therapeutic O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
regimen O-MISC O-MISC
: O-MISC O-MISC
either O-MISC O-MISC
a O-MISC O-MISC
simple O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
size O-MISC O-MISC
of O-MISC O-MISC
some O-MISC O-MISC
nodules O-MISC O-MISC
or O-MISC O-MISC
central O-MISC O-MISC
necrosis O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
inflammatory O-MISC O-MISC
reaction O-MISC O-MISC
. O-MISC O-MISC

NK O-MISC O-MISC
- O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
leukocytes O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
increased O-MISC O-MISC
after O-MISC O-MISC
administration O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
dose O-MISC O-MISC
; O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
subsequent O-MISC O-MISC
injections O-MISC O-MISC
was O-MISC O-MISC
less O-MISC O-MISC
clear O-MISC O-MISC
. O-MISC O-MISC

Receptors O-MISC O-MISC
for O-MISC O-MISC
estrogens O-MISC O-MISC
and O-MISC O-MISC
progestogens O-MISC B-MISC
were O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC O-MISC
biopsies O-MISC O-MISC
of O-MISC O-MISC
2 O-MISC O-MISC
out O-MISC O-MISC
of O-MISC O-MISC
2 O-MISC O-MISC
and O-MISC O-MISC
5 O-MISC O-MISC
out O-MISC O-MISC
of O-MISC O-MISC
6 O-MISC O-MISC
patients O-MISC O-MISC
tested O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

Decreased O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
adrenal O-MISC O-MISC
insufficiency O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
examine O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
deficiency O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
examine O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
to O-MISC O-MISC
lymphocytes O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
and O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
adrenal O-MISC O-MISC
insufficiency O-MISC O-MISC
before O-MISC O-MISC
and O-MISC O-MISC
after O-MISC O-MISC
glucocorticoid O-MISC O-MISC
replacement O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
a O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
competitive O-MISC O-MISC
binding O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
had O-MISC O-MISC
5977 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1487 O-MISC O-MISC
( O-MISC O-MISC
mean O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
SD O-MISC O-MISC
) O-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
dissociation O-MISC O-MISC
constant O-MISC O-MISC
of O-MISC O-MISC
10 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
nM O-MISC O-MISC
. O-MISC O-MISC

Lymphocytes O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
untreated O-MISC O-MISC
adrenal O-MISC O-MISC
insufficiency O-MISC O-MISC
had O-MISC O-MISC
fewer O-MISC O-MISC
binding B-MISC O-MISC
sites I-MISC O-MISC
( O-MISC O-MISC
3364 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
322 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
9 O-MISC O-MISC
mM O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
administration O-MISC O-MISC
of O-MISC O-MISC
conventional O-MISC O-MISC
replacement O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
cortisone O-MISC O-MISC
acetate O-MISC O-MISC
for O-MISC O-MISC
6 O-MISC O-MISC
months O-MISC O-MISC
caused O-MISC O-MISC
no O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
number O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
toward O-MISC O-MISC
normal O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
long O-MISC O-MISC
term O-MISC O-MISC
glucocorticoid O-MISC O-MISC
replacement O-MISC O-MISC
therapy O-MISC O-MISC
, O-MISC O-MISC
binding O-MISC O-MISC
parameters O-MISC O-MISC
were O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
those O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
before O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
physiological O-MISC O-MISC
implications O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
decreased O-MISC O-MISC
receptor O-MISC O-MISC
number O-MISC O-MISC
and O-MISC O-MISC
increased O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
in O-MISC O-MISC
adrenal O-MISC O-MISC
insufficiency O-MISC O-MISC
remain O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
elucidated O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
concentrations O-MISC O-MISC
and O-MISC O-MISC
terminal O-MISC B-MISC
transferase B-MISC I-MISC
activity O-MISC O-MISC
as O-MISC O-MISC
indicators O-MISC O-MISC
of O-MISC O-MISC
prognosis O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
lymphocytic O-MISC O-MISC
leukaemia O-MISC O-MISC
. O-MISC O-MISC

Activity O-MISC O-MISC
of O-MISC O-MISC
terminal B-MISC B-MISC
deoxynucleotidyl I-MISC I-MISC
transferase I-MISC I-MISC
( O-MISC O-MISC
TdT B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
adenosine B-MISC B-MISC
deaminase I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
5 B-MISC O-MISC
' I-MISC O-MISC
nucleotidase I-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC O-MISC
( I-MISC O-MISC
dexamethasone I-MISC O-MISC
) I-MISC O-MISC
receptor I-MISC I-MISC
were O-MISC O-MISC
determined O-MISC O-MISC
in O-MISC O-MISC
25 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
lymphocytic O-MISC O-MISC
leukaemia O-MISC O-MISC
. O-MISC O-MISC

All O-MISC O-MISC
patients O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
according O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
common O-MISC O-MISC
protocol O-MISC O-MISC
. O-MISC O-MISC

Increased O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
TdT B-MISC O-MISC
( O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
unit O-MISC O-MISC
/ O-MISC O-MISC
microgram O-MISC O-MISC
DNA O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
11 O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
group O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
was O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
higher O-MISC O-MISC
remission O-MISC O-MISC
and O-MISC O-MISC
survival O-MISC O-MISC
rates O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
06 O-MISC O-MISC
) O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
low O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
TdT O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
leukaemic O-MISC O-MISC
blast O-MISC O-MISC
cells O-MISC O-MISC
ranged O-MISC O-MISC
from O-MISC O-MISC
0 O-MISC O-MISC
to O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
94 O-MISC O-MISC
fmol O-MISC O-MISC
/ O-MISC O-MISC
microgram O-MISC O-MISC
DNA O-MISC O-MISC
. O-MISC O-MISC

Thirteen O-MISC O-MISC
patients O-MISC O-MISC
had O-MISC O-MISC
blast O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
concentration O-MISC O-MISC
over O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
22 O-MISC O-MISC
fmol O-MISC O-MISC
/ O-MISC O-MISC
microgram O-MISC O-MISC
DNA O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
patients O-MISC O-MISC
had O-MISC O-MISC
significantly O-MISC O-MISC
increased O-MISC O-MISC
remission O-MISC O-MISC
and O-MISC O-MISC
survival O-MISC O-MISC
rates O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
006 O-MISC O-MISC
) O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
those O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
low O-MISC B-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
finding O-MISC O-MISC
can O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
explained O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
sensitivity O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
since O-MISC O-MISC
these O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
used O-MISC O-MISC
as O-MISC O-MISC
therapeutic O-MISC O-MISC
agents O-MISC O-MISC
. O-MISC O-MISC

Adenosine B-MISC O-MISC
deaminase I-MISC O-MISC
and O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
nucleotidase I-MISC I-MISC
activities O-MISC O-MISC
both O-MISC O-MISC
varied O-MISC O-MISC
within O-MISC O-MISC
two O-MISC O-MISC
orders O-MISC O-MISC
of O-MISC O-MISC
magnitude O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
correlation O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
found O-MISC O-MISC
between O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
enzymes O-MISC O-MISC
and O-MISC O-MISC
remission O-MISC O-MISC
or O-MISC O-MISC
survival O-MISC O-MISC
rate O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
measurements O-MISC O-MISC
of O-MISC O-MISC
TdT B-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
concentration O-MISC O-MISC
yield O-MISC O-MISC
valuable O-MISC O-MISC
prognostic O-MISC O-MISC
information O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
lymphocytic O-MISC O-MISC
leukaemia O-MISC O-MISC

[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
cortivazol O-MISC O-MISC
: O-MISC O-MISC
a O-MISC O-MISC
unique O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
ligand O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Cortivazol O-MISC O-MISC
( O-MISC O-MISC
CVZ O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
deacylcortivazol O-MISC O-MISC
( O-MISC O-MISC
DAC O-MISC O-MISC
) O-MISC O-MISC
are O-MISC O-MISC
pyrazolosteroids O-MISC O-MISC
with O-MISC O-MISC
potent O-MISC O-MISC
glucocorticoid O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
previous O-MISC O-MISC
work O-MISC O-MISC
we O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
DAC O-MISC O-MISC
is O-MISC O-MISC
40 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
more O-MISC O-MISC
potent O-MISC O-MISC
than O-MISC O-MISC
dexamethasone O-MISC O-MISC
( O-MISC O-MISC
DEX O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
lysing O-MISC O-MISC
leukemic O-MISC O-MISC
lymphoblasts O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
assess O-MISC O-MISC
the O-MISC O-MISC
interaction O-MISC O-MISC
between O-MISC O-MISC
these O-MISC O-MISC
atypical O-MISC O-MISC
steroids O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
CVZ O-MISC O-MISC
to O-MISC O-MISC
cytosol O-MISC O-MISC
from O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
and O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
variants O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
leukemic O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
CEM O-MISC O-MISC
C7 O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
cells O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
CVZ O-MISC O-MISC
causes O-MISC O-MISC
a O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
glutamine B-MISC B-MISC
synthetase I-MISC I-MISC
and O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
protein O-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC I-MISC
S O-MISC B-MISC
region O-MISC I-MISC
of O-MISC O-MISC
high O-MISC O-MISC
salt O-MISC O-MISC
sucrose O-MISC O-MISC
gradients O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
DEAE O-MISC O-MISC
- O-MISC I-MISC
cellulose O-MISC I-MISC
chromatography O-MISC I-MISC
, O-MISC O-MISC
[ B-MISC B-MISC
3H I-MISC O-MISC
] I-MISC I-MISC
CVZ I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
show O-MISC O-MISC
a O-MISC O-MISC
shift O-MISC O-MISC
from O-MISC O-MISC
high O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
25 O-MISC O-MISC
M O-MISC O-MISC
KP O-MISC O-MISC
) O-MISC O-MISC
to O-MISC O-MISC
low O-MISC O-MISC
salt O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
09 O-MISC O-MISC
M O-MISC B-MISC
KP O-MISC I-MISC
) O-MISC O-MISC
eluting O-MISC O-MISC
forms O-MISC O-MISC
upon O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

CVZ O-MISC O-MISC
competes O-MISC O-MISC
for O-MISC O-MISC
a O-MISC O-MISC
97 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
- O-MISC O-MISC
dalton O-MISC O-MISC
protein O-MISC O-MISC
labeled O-MISC O-MISC
by O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
mesylate O-MISC O-MISC
. O-MISC O-MISC

Scatchard O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
CVZ O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
cells O-MISC O-MISC
revealed O-MISC O-MISC
a O-MISC O-MISC
curvilinear O-MISC O-MISC
plot O-MISC O-MISC
which O-MISC O-MISC
resolved O-MISC O-MISC
into O-MISC O-MISC
high O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
nM O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
low O-MISC B-MISC
( O-MISC I-MISC
11 O-MISC I-MISC
nM O-MISC I-MISC
) O-MISC I-MISC
affinity O-MISC I-MISC
components O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
low O-MISC O-MISC
affinity O-MISC O-MISC
site O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
30 O-MISC O-MISC
pmol O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
protein O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
approximately O-MISC O-MISC
twice O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
high B-MISC O-MISC
affinity I-MISC O-MISC
site I-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
14 O-MISC O-MISC
pmol O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
protein O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Dissociation O-MISC O-MISC
experiments O-MISC O-MISC
with O-MISC O-MISC
dilution O-MISC O-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
excess O-MISC O-MISC
unlabeled O-MISC O-MISC
CVZ O-MISC O-MISC
supported O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
independent O-MISC O-MISC
sites O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
DEX O-MISC O-MISC
to O-MISC O-MISC
C7 O-MISC B-MISC
cytosol O-MISC I-MISC
revealed O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
class O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC B-MISC
sites O-MISC I-MISC
( O-MISC O-MISC
Kd O-MISC O-MISC
= O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
9 O-MISC O-MISC
nM O-MISC O-MISC
; O-MISC O-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
, O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
46 O-MISC O-MISC
pmol O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
protein O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Examination O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
CVZ O-MISC O-MISC
using O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
5 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
DEX O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
competing O-MISC O-MISC
ligand O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
DEX O-MISC O-MISC
binds O-MISC O-MISC
only O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
low O-MISC O-MISC
affinity O-MISC O-MISC
site O-MISC O-MISC
detected O-MISC O-MISC
by O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
CVZ O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
cytosol O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
with O-MISC O-MISC
virtually O-MISC O-MISC
no O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
DEX O-MISC O-MISC
binding O-MISC O-MISC
, O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
CVZ O-MISC O-MISC
detected O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
high B-MISC O-MISC
affinity I-MISC O-MISC
binding I-MISC O-MISC
site I-MISC O-MISC
that O-MISC O-MISC
was O-MISC O-MISC
similar O-MISC O-MISC
in O-MISC O-MISC
dissociation O-MISC O-MISC
constant O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
nM O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
13 O-MISC O-MISC
pmol O-MISC O-MISC
/ O-MISC O-MISC
mg O-MISC O-MISC
protein O-MISC O-MISC
) O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
high B-MISC O-MISC
affinity I-MISC O-MISC
site I-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
C7 O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
controlled O-MISC O-MISC
pore O-MISC O-MISC
glass O-MISC O-MISC
bead O-MISC O-MISC
assay O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
measurement O-MISC O-MISC
of O-MISC O-MISC
cytoplasmic B-MISC O-MISC
and I-MISC O-MISC
nuclear I-MISC O-MISC
glucocorticoid I-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

An O-MISC O-MISC
assay O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
quantitation O-MISC O-MISC
of O-MISC O-MISC
cytoplasmic B-MISC B-MISC
and I-MISC I-MISC
nuclear I-MISC I-MISC
glucocorticoid I-MISC I-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
lymphoid O-MISC O-MISC
tissue O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
developed O-MISC O-MISC
using O-MISC O-MISC
controlled O-MISC O-MISC
pore O-MISC O-MISC
glass O-MISC O-MISC
( O-MISC O-MISC
CPG O-MISC B-MISC
) O-MISC O-MISC
beads O-MISC O-MISC
. O-MISC O-MISC

Soluble O-MISC B-MISC
receptor B-MISC I-MISC
- I-MISC I-MISC
- I-MISC I-MISC
3H I-MISC I-MISC
- I-MISC I-MISC
steroid I-MISC I-MISC
complex I-MISC I-MISC
( O-MISC O-MISC
cytosol O-MISC O-MISC
or O-MISC O-MISC
nuclear O-MISC O-MISC
extract O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
adsorbed O-MISC O-MISC
quantitatively O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
crevasses O-MISC O-MISC
of O-MISC O-MISC
porous O-MISC O-MISC
glass O-MISC O-MISC
beads O-MISC O-MISC
. O-MISC O-MISC

Excess O-MISC O-MISC
labeled O-MISC O-MISC
steroid O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
most O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
specifically O-MISC O-MISC
bound O-MISC O-MISC
steroid O-MISC O-MISC
is O-MISC O-MISC
easily O-MISC O-MISC
washed O-MISC O-MISC
away O-MISC O-MISC
, O-MISC O-MISC
leaving O-MISC O-MISC
the O-MISC O-MISC
hormone B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complex I-MISC I-MISC
retained O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
beads O-MISC O-MISC
. O-MISC O-MISC

Bound O-MISC B-MISC
3H O-MISC I-MISC
- O-MISC I-MISC
steroid O-MISC I-MISC
is O-MISC O-MISC
eluted O-MISC O-MISC
with O-MISC O-MISC
ethanol O-MISC O-MISC
and O-MISC O-MISC
measured O-MISC O-MISC
for O-MISC O-MISC
radioactivity O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
procedure O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
simple O-MISC O-MISC
, O-MISC O-MISC
rapid O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
highly O-MISC O-MISC
reproducible O-MISC O-MISC
is O-MISC O-MISC
carried O-MISC O-MISC
out O-MISC O-MISC
using O-MISC O-MISC
frozen O-MISC O-MISC
samples O-MISC O-MISC
( O-MISC O-MISC
stable O-MISC O-MISC
for O-MISC O-MISC
many O-MISC O-MISC
months O-MISC O-MISC
) O-MISC O-MISC
containing O-MISC O-MISC
as O-MISC O-MISC
few O-MISC O-MISC
as O-MISC O-MISC
1 O-MISC O-MISC
X O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
7 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
comparison O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CPG O-MISC O-MISC
assay O-MISC O-MISC
to O-MISC O-MISC
dextran O-MISC O-MISC
coated O-MISC O-MISC
charcoal O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
assay O-MISC O-MISC
demonstrates O-MISC O-MISC
that O-MISC O-MISC
CPG O-MISC B-MISC
and O-MISC O-MISC
dextran O-MISC B-MISC
coated O-MISC O-MISC
charcoal O-MISC O-MISC
give O-MISC O-MISC
equivalent O-MISC O-MISC
measurements O-MISC O-MISC
of O-MISC O-MISC
cytosolic B-MISC B-MISC
receptor I-MISC I-MISC
concentration O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
CPG O-MISC O-MISC
and O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
assays O-MISC O-MISC
provide O-MISC O-MISC
equivalent O-MISC O-MISC
values O-MISC O-MISC
for O-MISC O-MISC
total O-MISC O-MISC
receptor O-MISC O-MISC
content O-MISC O-MISC
. O-MISC O-MISC

Plasmacytoid O-MISC O-MISC
blast O-MISC O-MISC
crisis O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
chronic O-MISC O-MISC
lymphocytic O-MISC O-MISC
leukemia O-MISC O-MISC
: O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
estradiol O-MISC O-MISC
on O-MISC O-MISC
growth O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

Evolution O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
case O-MISC O-MISC
of O-MISC O-MISC
chronic O-MISC O-MISC
lymphocytic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
CLL O-MISC O-MISC
) O-MISC O-MISC
into O-MISC O-MISC
blast O-MISC O-MISC
crisis O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
three O-MISC O-MISC
unusual O-MISC O-MISC
features O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
the O-MISC O-MISC
phenotype O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
emerging O-MISC O-MISC
blast O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
pre O-MISC O-MISC
- O-MISC O-MISC
plasmacytoid O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
shown O-MISC O-MISC
by O-MISC O-MISC
plasma O-MISC O-MISC
cell O-MISC O-MISC
morphology O-MISC O-MISC
and O-MISC O-MISC
an O-MISC O-MISC
immunological O-MISC O-MISC
phenotype O-MISC O-MISC
corresponding O-MISC O-MISC
partially O-MISC O-MISC
with O-MISC O-MISC
CLL O-MISC O-MISC
- O-MISC O-MISC
or O-MISC O-MISC
intermediate O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
partially O-MISC O-MISC
with O-MISC O-MISC
plasma O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
terminal B-MISC B-MISC
transferase I-MISC I-MISC
- O-MISC O-MISC
, O-MISC O-MISC
common O-MISC O-MISC
acute B-MISC O-MISC
lymphocytic I-MISC O-MISC
leukemia I-MISC O-MISC
antigen I-MISC O-MISC
- O-MISC O-MISC
, O-MISC O-MISC
Ia B-MISC O-MISC
+ I-MISC O-MISC
, O-MISC O-MISC
surface B-MISC O-MISC
immunoglobulin I-MISC B-MISC
heavy I-MISC I-MISC
chains I-MISC I-MISC
- O-MISC I-MISC
, O-MISC O-MISC
surface B-MISC B-MISC
kappa I-MISC I-MISC
light I-MISC I-MISC
chains I-MISC I-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
intracytoplasmic B-MISC O-MISC
immunoglobulin I-MISC B-MISC
A I-MISC O-MISC
+ I-MISC O-MISC
and I-MISC O-MISC
G I-MISC O-MISC
+ I-MISC O-MISC
, O-MISC O-MISC
BA B-MISC O-MISC
- I-MISC O-MISC
1 I-MISC O-MISC
+ I-MISC O-MISC
, O-MISC O-MISC
polyclonal O-MISC B-MISC
gammaglobulin O-MISC I-MISC
production O-MISC O-MISC
) O-MISC O-MISC
; O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
cytogenetic O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
spontaneous O-MISC O-MISC
metaphases O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
addition O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
typical O-MISC O-MISC
CLL O-MISC O-MISC
abnormality O-MISC O-MISC
, O-MISC O-MISC
trisomy O-MISC O-MISC
12 O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
additional O-MISC O-MISC
translocation O-MISC O-MISC
between O-MISC O-MISC
chromosomes B-MISC B-MISC
14 I-MISC O-MISC
and I-MISC O-MISC
17 I-MISC O-MISC
was O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
40 O-MISC O-MISC
% O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
presumptive O-MISC O-MISC
breakpoint O-MISC O-MISC
on O-MISC O-MISC
chromosome B-MISC B-MISC
14 I-MISC I-MISC
( O-MISC O-MISC
q12 O-MISC I-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
) O-MISC O-MISC
never O-MISC O-MISC
described O-MISC O-MISC
before O-MISC O-MISC
( O-MISC O-MISC
commonly O-MISC B-MISC
q32 O-MISC I-MISC
) O-MISC I-MISC
and O-MISC O-MISC
( O-MISC O-MISC
3 O-MISC I-MISC
) O-MISC O-MISC
the O-MISC O-MISC
progression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
disease O-MISC O-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
striking O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
transformed O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
specific O-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC O-MISC
for O-MISC O-MISC
estradiol O-MISC O-MISC
( O-MISC O-MISC
E2 O-MISC O-MISC
) O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
actual O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
total O-MISC O-MISC
cellular B-MISC B-MISC
receptor I-MISC I-MISC
proteins I-MISC I-MISC
and O-MISC O-MISC
not O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
affinity O-MISC O-MISC
for O-MISC O-MISC
E2 O-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
functional O-MISC O-MISC
status O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
steroid B-MISC B-MISC
receptors I-MISC I-MISC
was O-MISC O-MISC
confirmed O-MISC O-MISC
by O-MISC O-MISC
nuclear O-MISC O-MISC
transfer O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cytoplasmic B-MISC B-MISC
hormone I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complex I-MISC I-MISC
upon O-MISC O-MISC
temperature O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Since O-MISC O-MISC
the O-MISC O-MISC
rise O-MISC O-MISC
in O-MISC O-MISC
E2 B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
display O-MISC O-MISC
paralleled O-MISC O-MISC
a O-MISC O-MISC
large O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
proliferative O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
their O-MISC O-MISC
maturation O-MISC O-MISC
status O-MISC O-MISC
the O-MISC O-MISC
question O-MISC O-MISC
was O-MISC O-MISC
raised O-MISC O-MISC
as O-MISC O-MISC
to O-MISC O-MISC
whether O-MISC O-MISC
the O-MISC O-MISC
E2 B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
should O-MISC O-MISC
be O-MISC O-MISC
considered O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
physiological O-MISC O-MISC
marker O-MISC O-MISC
of O-MISC O-MISC
growth O-MISC O-MISC
rate O-MISC O-MISC
or O-MISC O-MISC
of O-MISC O-MISC
cellular O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

Exposure O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
blast O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
E2 O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
cessation O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
following O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
one O-MISC O-MISC
mitosis O-MISC O-MISC
after O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inducer O-MISC O-MISC
as O-MISC O-MISC
seen O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
replacement O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
large O-MISC O-MISC
blasts O-MISC O-MISC
by O-MISC O-MISC
small O-MISC O-MISC
CLL O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
cells O-MISC O-MISC
without O-MISC O-MISC
definite O-MISC O-MISC
signs O-MISC O-MISC
of O-MISC O-MISC
alteration O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
status O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
suggests O-MISC O-MISC
the O-MISC O-MISC
association O-MISC O-MISC
of O-MISC O-MISC
E2 B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
expression O-MISC O-MISC
with O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
growth O-MISC O-MISC
rather O-MISC O-MISC
than O-MISC O-MISC
cell O-MISC O-MISC
maturation O-MISC O-MISC
. O-MISC O-MISC

Multiple O-MISC O-MISC
forms O-MISC O-MISC
and O-MISC O-MISC
fragments O-MISC O-MISC
of O-MISC O-MISC
cytosolic B-MISC B-MISC
glucocorticoid I-MISC I-MISC
receptors I-MISC I-MISC
from O-MISC O-MISC
human O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Therapy O-MISC O-MISC
with O-MISC O-MISC
glucocorticoids O-MISC O-MISC
is O-MISC O-MISC
generally O-MISC O-MISC
more O-MISC O-MISC
effective O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
other O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Previous O-MISC O-MISC
studies O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
have O-MISC O-MISC
not O-MISC O-MISC
revealed O-MISC O-MISC
any O-MISC O-MISC
consistent O-MISC O-MISC
relationship O-MISC O-MISC
between O-MISC O-MISC
clinical O-MISC O-MISC
responsiveness O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC O-MISC
or O-MISC O-MISC
cytosolic O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
objectives O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
were O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
there O-MISC O-MISC
are O-MISC O-MISC
intrinsic O-MISC O-MISC
structural O-MISC O-MISC
differences O-MISC O-MISC
among O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
various O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
investigate O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
endogenous B-MISC B-MISC
peptidases I-MISC I-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
degradation O-MISC O-MISC
. O-MISC O-MISC

Cytosols O-MISC O-MISC
were O-MISC O-MISC
prepared O-MISC O-MISC
from O-MISC O-MISC
fresh O-MISC O-MISC
or O-MISC O-MISC
rapidly O-MISC O-MISC
frozen O-MISC O-MISC
leukocytes O-MISC O-MISC
from O-MISC O-MISC
6 O-MISC O-MISC
healthy O-MISC O-MISC
adults O-MISC O-MISC
and O-MISC O-MISC
35 O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
risk O-MISC O-MISC
leukemia O-MISC O-MISC
patients O-MISC O-MISC
( O-MISC O-MISC
median O-MISC O-MISC
white O-MISC O-MISC
blood O-MISC O-MISC
cell O-MISC O-MISC
count O-MISC O-MISC
, O-MISC O-MISC
150 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
cells O-MISC O-MISC
/ O-MISC O-MISC
microliter O-MISC O-MISC
; O-MISC O-MISC
median O-MISC O-MISC
age O-MISC O-MISC
, O-MISC O-MISC
13 O-MISC O-MISC
years O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Receptors O-MISC O-MISC
were O-MISC O-MISC
labeled O-MISC O-MISC
with O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
triamcinolone O-MISC O-MISC
acetonide O-MISC O-MISC
and O-MISC O-MISC
quantitated O-MISC O-MISC
by O-MISC O-MISC
charcoal O-MISC O-MISC
- O-MISC O-MISC
dextran O-MISC O-MISC
treatment O-MISC O-MISC
or O-MISC O-MISC
Sephadex O-MISC O-MISC
LH O-MISC O-MISC
- O-MISC O-MISC
20 O-MISC O-MISC
chromatography O-MISC O-MISC
. O-MISC O-MISC

Mean O-MISC O-MISC
and O-MISC O-MISC
median O-MISC B-MISC
cytosolic O-MISC B-MISC
receptor O-MISC I-MISC
concentrations O-MISC O-MISC
in O-MISC O-MISC
12 O-MISC O-MISC
acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
specimens O-MISC O-MISC
lacking O-MISC O-MISC
the O-MISC O-MISC
standard O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
or O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
markers O-MISC O-MISC
( O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
null O-MISC O-MISC
cells O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
approximately O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
higher O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
23 O-MISC O-MISC
other O-MISC O-MISC
leukemic O-MISC O-MISC
cell O-MISC O-MISC
specimens O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
other O-MISC O-MISC
consistent O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
content O-MISC O-MISC
were O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

Agarose O-MISC O-MISC
filtration O-MISC O-MISC
and O-MISC O-MISC
ultracentrifugation O-MISC O-MISC
in O-MISC O-MISC
hypotonic O-MISC O-MISC
buffers O-MISC O-MISC
containing O-MISC O-MISC
20 O-MISC O-MISC
mM O-MISC O-MISC
Na2MoO4 O-MISC O-MISC
revealed O-MISC O-MISC
complexes O-MISC O-MISC
of O-MISC O-MISC
similar O-MISC O-MISC
size O-MISC O-MISC
and O-MISC O-MISC
shape O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
clinical O-MISC O-MISC
specimens O-MISC O-MISC
tested O-MISC O-MISC
and O-MISC O-MISC
two O-MISC O-MISC
established O-MISC O-MISC
leukemic O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

They O-MISC O-MISC
had O-MISC O-MISC
Stokes O-MISC O-MISC
radii O-MISC O-MISC
( O-MISC O-MISC
Rs O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
8 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
( O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
D O-MISC O-MISC
. O-MISC O-MISC
) O-MISC O-MISC
nm O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
50 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
sedimentation O-MISC O-MISC
coefficients O-MISC O-MISC
of O-MISC O-MISC
9 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
3S O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
40 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
molecular O-MISC O-MISC
weights O-MISC O-MISC
of O-MISC O-MISC
approximately O-MISC O-MISC
330 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
axial O-MISC O-MISC
ratios O-MISC O-MISC
( O-MISC O-MISC
a O-MISC O-MISC
/ O-MISC O-MISC
b O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
approximately O-MISC O-MISC
12 O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
hypertonic O-MISC O-MISC
, O-MISC O-MISC
molybdate O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
buffer O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
oligomeric B-MISC O-MISC
complexes I-MISC O-MISC
were O-MISC O-MISC
dissociated O-MISC O-MISC
into O-MISC O-MISC
subunits O-MISC O-MISC
with O-MISC O-MISC
Rs O-MISC O-MISC
of O-MISC O-MISC
5 O-MISC O-MISC
. O-MISC O-MISC
9 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
3 O-MISC O-MISC
nm O-MISC O-MISC
( O-MISC O-MISC
n O-MISC O-MISC
= O-MISC O-MISC
12 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
/ O-MISC O-MISC
b O-MISC O-MISC
of O-MISC O-MISC
11 O-MISC O-MISC
to O-MISC O-MISC
12 O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
observed O-MISC O-MISC
previously O-MISC O-MISC
for O-MISC O-MISC
other O-MISC O-MISC
receptors O-MISC O-MISC
. O-MISC O-MISC

Fragmentation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
oligomer B-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
subunit B-MISC O-MISC
was O-MISC O-MISC
evident O-MISC O-MISC
in O-MISC O-MISC
some O-MISC O-MISC
cytosols O-MISC O-MISC
. O-MISC O-MISC

High O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
peptidases B-MISC B-MISC
of O-MISC O-MISC
various O-MISC O-MISC
specificities O-MISC O-MISC
were O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
leukemic O-MISC O-MISC
cell O-MISC O-MISC
cytosols O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
in O-MISC O-MISC
other O-MISC O-MISC
cytosols O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
fluorometric O-MISC O-MISC
assays O-MISC O-MISC
with O-MISC O-MISC
derivatives O-MISC O-MISC
of O-MISC O-MISC
7 O-MISC O-MISC
- O-MISC O-MISC
amino O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
methylcoumarin O-MISC O-MISC
. O-MISC O-MISC

Receptor O-MISC O-MISC
cleavage O-MISC O-MISC
by O-MISC O-MISC
these O-MISC O-MISC
and O-MISC O-MISC
other O-MISC O-MISC
endogenous B-MISC O-MISC
enzymes I-MISC O-MISC
may O-MISC O-MISC
account O-MISC O-MISC
for O-MISC O-MISC
previous O-MISC O-MISC
observations O-MISC O-MISC
of O-MISC O-MISC
` O-MISC B-MISC
` O-MISC I-MISC
abnormal O-MISC I-MISC
' O-MISC I-MISC
' O-MISC I-MISC
receptors O-MISC I-MISC
in O-MISC O-MISC
cytosols O-MISC O-MISC
from O-MISC O-MISC
some O-MISC O-MISC
leukemic O-MISC O-MISC
specimens O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
intrinsic O-MISC O-MISC
structural O-MISC O-MISC
defects O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
receptors O-MISC O-MISC
are O-MISC O-MISC
unlikely O-MISC O-MISC
explanations O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
unresponsiveness O-MISC O-MISC
of O-MISC O-MISC
some O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
leukemia O-MISC O-MISC
to O-MISC O-MISC
steroid O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
number O-MISC O-MISC
and O-MISC O-MISC
intracellular O-MISC O-MISC
water O-MISC O-MISC
space O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
order O-MISC O-MISC
to O-MISC O-MISC
elucidate O-MISC O-MISC
the O-MISC O-MISC
relationship O-MISC O-MISC
between O-MISC O-MISC
cell O-MISC O-MISC
water O-MISC O-MISC
content O-MISC O-MISC
and O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
eleven O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
lymphoid O-MISC O-MISC
or O-MISC O-MISC
myelomonocytic O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
originating O-MISC O-MISC
from O-MISC O-MISC
mouse O-MISC O-MISC
, O-MISC O-MISC
rat O-MISC O-MISC
and O-MISC O-MISC
man O-MISC O-MISC
were O-MISC O-MISC
investigated O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cellular O-MISC O-MISC
water O-MISC O-MISC
space O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
with O-MISC O-MISC
3H2O O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
number O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
whole O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
binding O-MISC O-MISC
assay O-MISC O-MISC
with O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
at O-MISC O-MISC
30 O-MISC O-MISC
and O-MISC O-MISC
37 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
intracellular O-MISC O-MISC
water O-MISC O-MISC
phase O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
around O-MISC O-MISC
40 O-MISC O-MISC
nmol O-MISC O-MISC
/ O-MISC O-MISC
l O-MISC O-MISC
cell O-MISC O-MISC
water O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
dependence O-MISC O-MISC
of O-MISC O-MISC
receptor O-MISC O-MISC
affinity O-MISC O-MISC
on O-MISC O-MISC
temperature O-MISC O-MISC
were O-MISC O-MISC
similar O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
rodent O-MISC O-MISC
and O-MISC O-MISC
human O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
concluded O-MISC O-MISC
that O-MISC O-MISC
comparisons O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
are O-MISC O-MISC
best O-MISC O-MISC
made O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
basis O-MISC O-MISC
of O-MISC O-MISC
intracellular B-MISC B-MISC
receptor I-MISC I-MISC
concentrations O-MISC O-MISC
. O-MISC O-MISC

Covalent O-MISC O-MISC
labeling O-MISC O-MISC
of O-MISC O-MISC
rat O-MISC O-MISC
thymocyte O-MISC O-MISC
and O-MISC I-MISC
human B-MISC B-MISC
lymphoid I-MISC I-MISC
glucocorticoid I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Lymphoid O-MISC O-MISC
cells O-MISC O-MISC
contain O-MISC O-MISC
specific O-MISC O-MISC
receptors B-MISC O-MISC
for O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
used O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
- O-MISC O-MISC
21 O-MISC O-MISC
- O-MISC O-MISC
mesylate O-MISC O-MISC
to O-MISC O-MISC
label O-MISC O-MISC
covalently O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
rat O-MISC O-MISC
thymic O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
neoplastic O-MISC O-MISC
cells O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
lymphoma O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
covalently O-MISC O-MISC
labeled O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
were O-MISC O-MISC
identified O-MISC O-MISC
by O-MISC O-MISC
polyacrylamide O-MISC O-MISC
gel O-MISC O-MISC
electrophoresis O-MISC O-MISC
( O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
% O-MISC O-MISC
sodium O-MISC O-MISC
dodecyl O-MISC O-MISC
sulfate O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
cytosolic O-MISC O-MISC
fractions O-MISC O-MISC
prepared O-MISC O-MISC
from O-MISC O-MISC
rat O-MISC O-MISC
thymic O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
dexamethasone O-MISC O-MISC
- O-MISC O-MISC
21 O-MISC O-MISC
- O-MISC O-MISC
mesylate O-MISC O-MISC
labels O-MISC O-MISC
a O-MISC O-MISC
protein O-MISC O-MISC
( O-MISC O-MISC
Mr O-MISC O-MISC
approximately O-MISC O-MISC
equal O-MISC O-MISC
to O-MISC O-MISC
95 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
) O-MISC O-MISC
which O-MISC O-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
by O-MISC O-MISC
the O-MISC O-MISC
following O-MISC O-MISC
criteria O-MISC O-MISC
: O-MISC O-MISC
( O-MISC O-MISC
a O-MISC O-MISC
) O-MISC O-MISC
labeling O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
moiety O-MISC O-MISC
is O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
100 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
molar O-MISC O-MISC
excess O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
dexamethasone O-MISC O-MISC
and O-MISC O-MISC
triamcinolone O-MISC O-MISC
acetonide O-MISC O-MISC
; O-MISC O-MISC
and O-MISC O-MISC
( O-MISC O-MISC
b O-MISC O-MISC
) O-MISC O-MISC
the O-MISC O-MISC
covalently O-MISC O-MISC
labeled O-MISC O-MISC
Mr O-MISC O-MISC
approximately O-MISC O-MISC
equal O-MISC O-MISC
to O-MISC O-MISC
95 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
protein O-MISC O-MISC
is O-MISC O-MISC
activated O-MISC O-MISC
( O-MISC O-MISC
by O-MISC O-MISC
heating O-MISC O-MISC
at O-MISC O-MISC
20 O-MISC O-MISC
degrees O-MISC O-MISC
for O-MISC O-MISC
30 O-MISC O-MISC
min O-MISC O-MISC
) O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
form O-MISC O-MISC
that O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
cellulose O-MISC O-MISC
. O-MISC O-MISC

When O-MISC O-MISC
intact O-MISC O-MISC
thymocytes O-MISC O-MISC
are O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
- O-MISC O-MISC
21 O-MISC O-MISC
- O-MISC O-MISC
mesylate O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
Mr O-MISC O-MISC
approximately O-MISC O-MISC
equal O-MISC O-MISC
to O-MISC O-MISC
95 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
moiety O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
labeled O-MISC O-MISC
covalently O-MISC O-MISC
. O-MISC O-MISC

Approximately O-MISC O-MISC
35 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
can O-MISC O-MISC
be O-MISC O-MISC
labeled O-MISC O-MISC
covalently O-MISC O-MISC
when O-MISC O-MISC
intact O-MISC O-MISC
thymocytes O-MISC O-MISC
are O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
100 O-MISC O-MISC
nM O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
- O-MISC O-MISC
21 O-MISC O-MISC
- O-MISC O-MISC
mesylate O-MISC O-MISC
for O-MISC O-MISC
30 O-MISC O-MISC
min O-MISC O-MISC
at O-MISC O-MISC
4 O-MISC O-MISC
degrees O-MISC O-MISC
. O-MISC O-MISC

Neoplastic O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
lymphoma O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
- O-MISC O-MISC
21 O-MISC O-MISC
- O-MISC O-MISC
mesylate O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
all O-MISC O-MISC
samples O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
Mr O-MISC O-MISC
approximately O-MISC O-MISC
equal O-MISC O-MISC
to O-MISC O-MISC
95 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
moiety O-MISC O-MISC
was O-MISC O-MISC
labeled O-MISC O-MISC
covalently O-MISC O-MISC
; O-MISC O-MISC
labeling O-MISC O-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
excess O-MISC O-MISC
glucocorticoid O-MISC O-MISC
. O-MISC O-MISC

Smaller B-MISC O-MISC
moieties I-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
identified O-MISC O-MISC
by O-MISC O-MISC
competition O-MISC O-MISC
experiments O-MISC O-MISC
; O-MISC O-MISC
these O-MISC O-MISC
may O-MISC O-MISC
represent O-MISC O-MISC
proteolytic B-MISC O-MISC
fragments I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Mr O-MISC O-MISC
approximately O-MISC O-MISC
equal O-MISC O-MISC
to O-MISC O-MISC
95 O-MISC B-MISC
, O-MISC O-MISC
000 O-MISC I-MISC
receptor O-MISC I-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
rat O-MISC O-MISC
and O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
- O-MISC O-MISC
21 O-MISC O-MISC
- O-MISC O-MISC
mesylate O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
label O-MISC O-MISC
covalently O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
association O-MISC O-MISC
of O-MISC O-MISC
cytosol O-MISC B-MISC
oestrogen B-MISC I-MISC
and I-MISC I-MISC
progesterone I-MISC I-MISC
receptors I-MISC I-MISC
with O-MISC O-MISC
histological O-MISC O-MISC
features O-MISC O-MISC
of O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
and O-MISC O-MISC
early O-MISC O-MISC
recurrence O-MISC O-MISC
of O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
hundred O-MISC O-MISC
and O-MISC O-MISC
eighty O-MISC O-MISC
- O-MISC O-MISC
eight O-MISC O-MISC
primary O-MISC O-MISC
breast O-MISC O-MISC
tumours O-MISC O-MISC
were O-MISC O-MISC
examined O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
or O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
oestrogen B-MISC O-MISC
( I-MISC O-MISC
REc I-MISC O-MISC
) I-MISC O-MISC
and I-MISC O-MISC
progesterone I-MISC B-MISC
( I-MISC I-MISC
RPc I-MISC B-MISC
) I-MISC I-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
has O-MISC O-MISC
shown O-MISC O-MISC
a O-MISC O-MISC
relative O-MISC O-MISC
interdependence O-MISC B-MISC
between O-MISC O-MISC
the O-MISC O-MISC
steroid B-MISC B-MISC
receptor I-MISC I-MISC
status O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
and O-MISC O-MISC
other O-MISC O-MISC
prognostic O-MISC O-MISC
variables O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
histological O-MISC O-MISC
grade O-MISC O-MISC
, O-MISC O-MISC
lymphocytic O-MISC O-MISC
infiltration O-MISC O-MISC
and O-MISC O-MISC
tumour O-MISC O-MISC
elastosis O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
were O-MISC O-MISC
significant O-MISC O-MISC
associations O-MISC O-MISC
between O-MISC O-MISC
epithelial O-MISC O-MISC
cellularity O-MISC O-MISC
, O-MISC O-MISC
stromal O-MISC O-MISC
fibrosis O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
value O-MISC O-MISC
of O-MISC O-MISC
REc B-MISC O-MISC
in O-MISC O-MISC
those O-MISC O-MISC
tumours O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
was O-MISC O-MISC
present O-MISC O-MISC
. O-MISC O-MISC

Cellularity O-MISC O-MISC
and O-MISC O-MISC
fibrosis O-MISC O-MISC
were O-MISC O-MISC
unrelated O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
or O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
oestrogen B-MISC B-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

By O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
neither O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
or O-MISC O-MISC
absence O-MISC O-MISC
nor O-MISC O-MISC
the O-MISC O-MISC
value O-MISC O-MISC
of O-MISC O-MISC
RPc B-MISC B-MISC
could O-MISC O-MISC
be O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
cellularity O-MISC O-MISC
or O-MISC O-MISC
fibrosis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
value O-MISC O-MISC
of O-MISC O-MISC
REc B-MISC B-MISC
and O-MISC O-MISC
RPc B-MISC B-MISC
analysis O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
indicator O-MISC O-MISC
of O-MISC O-MISC
prognosis O-MISC O-MISC
was O-MISC O-MISC
examined O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
sub O-MISC O-MISC
- O-MISC O-MISC
group O-MISC O-MISC
of O-MISC O-MISC
175 O-MISC O-MISC
patients O-MISC O-MISC
receiving O-MISC O-MISC
no O-MISC O-MISC
additional O-MISC O-MISC
treatment O-MISC O-MISC
following O-MISC O-MISC
mastectomy O-MISC O-MISC
. O-MISC O-MISC

Overall O-MISC O-MISC
relapse O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
survival O-MISC O-MISC
( O-MISC O-MISC
RFS O-MISC B-MISC
) O-MISC O-MISC
was O-MISC O-MISC
no O-MISC O-MISC
different O-MISC O-MISC
for O-MISC O-MISC
those O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
receptors O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
those O-MISC O-MISC
without O-MISC O-MISC
them O-MISC O-MISC
( O-MISC O-MISC
REc B-MISC O-MISC
P O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
11 O-MISC O-MISC
, O-MISC O-MISC
RPc O-MISC B-MISC
P O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
was O-MISC O-MISC
no O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
RFS O-MISC B-MISC
of O-MISC O-MISC
receptor O-MISC O-MISC
positive O-MISC O-MISC
and O-MISC O-MISC
negative O-MISC O-MISC
tumours O-MISC O-MISC
when O-MISC O-MISC
the O-MISC O-MISC
axillary O-MISC O-MISC
node O-MISC O-MISC
status O-MISC O-MISC
was O-MISC O-MISC
taken O-MISC O-MISC
into O-MISC O-MISC
account O-MISC O-MISC
. O-MISC O-MISC

Clinical O-MISC O-MISC
implications O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Normal O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
contain O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

A O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
stimuli O-MISC O-MISC
that O-MISC O-MISC
activate O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
also O-MISC O-MISC
induce O-MISC O-MISC
increases O-MISC O-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
concentration O-MISC O-MISC
. O-MISC O-MISC

Similar O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
can O-MISC O-MISC
be O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
ALL O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Absence O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
usually O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
treated O-MISC O-MISC
patients O-MISC O-MISC
) O-MISC O-MISC
predicts O-MISC O-MISC
lack O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
responsiveness O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
our O-MISC O-MISC
hands O-MISC O-MISC
, O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
correlate O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
duration O-MISC O-MISC
of O-MISC O-MISC
complete O-MISC O-MISC
remission O-MISC O-MISC
in O-MISC O-MISC
ALL O-MISC O-MISC
( O-MISC O-MISC
though O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
other O-MISC O-MISC
forms O-MISC O-MISC
of O-MISC O-MISC
leukemia O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
association O-MISC O-MISC
is O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
, O-MISC O-MISC
age O-MISC O-MISC
, O-MISC O-MISC
sex O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
initial O-MISC O-MISC
leukocyte O-MISC O-MISC
count O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
receptor O-MISC O-MISC
shows O-MISC O-MISC
a O-MISC O-MISC
negative O-MISC O-MISC
correlation O-MISC O-MISC
with O-MISC O-MISC
increasing O-MISC O-MISC
aggressiveness O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC O-MISC
( O-MISC O-MISC
null O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
Burkitt O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
lymphoma O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Corticosteroid O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
immunoregulation O-MISC O-MISC
in O-MISC O-MISC
man O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoids O-MISC O-MISC
have O-MISC O-MISC
profound O-MISC O-MISC
and O-MISC O-MISC
complex O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
precise O-MISC O-MISC
mechanisms O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
corticosteroid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
immunoregulation O-MISC O-MISC
in O-MISC O-MISC
man O-MISC O-MISC
have O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
precisely O-MISC O-MISC
defined O-MISC O-MISC
. O-MISC O-MISC

Intracytoplasmic B-MISC O-MISC
corticosteroid I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
receptors I-MISC I-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
common O-MISC O-MISC
pathway O-MISC O-MISC
for O-MISC O-MISC
steroid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
changes O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
variations O-MISC O-MISC
of O-MISC O-MISC
receptor O-MISC O-MISC
parameters O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
account O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
multifaceted O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
circulating O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
redistribute O-MISC O-MISC
out O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
intravascular O-MISC O-MISC
compartment O-MISC O-MISC
following O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
corticosteroids O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
certain O-MISC O-MISC
components O-MISC O-MISC
at O-MISC O-MISC
this O-MISC O-MISC
redistribution O-MISC O-MISC
phenomenon O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
well O-MISC O-MISC
- O-MISC O-MISC
characterized O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
importance O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
compartmental O-MISC O-MISC
cellular O-MISC O-MISC
shift O-MISC O-MISC
with O-MISC O-MISC
respect O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
of O-MISC O-MISC
corticosteroid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
immunoregulation O-MISC O-MISC
are O-MISC O-MISC
less O-MISC O-MISC
well O-MISC O-MISC
- O-MISC O-MISC
defined O-MISC O-MISC
. O-MISC O-MISC

Recent O-MISC O-MISC
observations O-MISC O-MISC
that O-MISC O-MISC
activated O-MISC O-MISC
lymphocytes O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
sensitive O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
lytic O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
under O-MISC O-MISC
certain O-MISC O-MISC
situations O-MISC O-MISC
the O-MISC O-MISC
elimination O-MISC O-MISC
of O-MISC O-MISC
selected O-MISC O-MISC
subsets O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
relevant O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
corticosteroid O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
immunoregulation O-MISC O-MISC
in O-MISC O-MISC
man O-MISC O-MISC
. O-MISC O-MISC

Corticosteroid O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
monocyte O-MISC O-MISC
function O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
drug O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
immunoregulation O-MISC O-MISC
in O-MISC O-MISC
monocyte O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
some O-MISC O-MISC
experimental O-MISC O-MISC
conditions O-MISC O-MISC
, O-MISC O-MISC
corticosteroids O-MISC O-MISC
inhibit O-MISC O-MISC
Interleukin B-MISC B-MISC
1 I-MISC I-MISC
production O-MISC O-MISC
by O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
immunoregulatory O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
corticosteroids O-MISC O-MISC
on O-MISC O-MISC
lymphocyte O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
are O-MISC O-MISC
complex O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
vitro O-MISC O-MISC
corticosteroids O-MISC O-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
selectively O-MISC O-MISC
affect O-MISC O-MISC
early O-MISC O-MISC
immunoregulatory O-MISC O-MISC
events O-MISC O-MISC
as O-MISC O-MISC
opposed O-MISC O-MISC
to O-MISC O-MISC
altering O-MISC O-MISC
an O-MISC O-MISC
established O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Multiple O-MISC O-MISC
sites O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
modulations O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
responses O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
defined O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
lymphoid O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
and O-MISC O-MISC
glucocorticoids O-MISC O-MISC
: O-MISC O-MISC
II O-MISC O-MISC
. O-MISC O-MISC

Whole O-MISC O-MISC
cell O-MISC O-MISC
and O-MISC O-MISC
cytoplasmic O-MISC O-MISC
binding O-MISC O-MISC
properties O-MISC O-MISC
of O-MISC O-MISC
lymphoblastoid O-MISC O-MISC
, O-MISC O-MISC
leukaemia O-MISC O-MISC
and O-MISC O-MISC
lymphoma O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
glucocorticoid O-MISC O-MISC
binding O-MISC O-MISC
properties O-MISC O-MISC
of O-MISC O-MISC
18 O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
( O-MISC O-MISC
HLCL O-MISC O-MISC
) O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
investigated O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
specificity O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
binding O-MISC O-MISC
was O-MISC O-MISC
confirmed O-MISC O-MISC
with O-MISC O-MISC
various O-MISC O-MISC
glucocorticoid O-MISC O-MISC
agonists O-MISC O-MISC
and O-MISC O-MISC
antagonists O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
gradation O-MISC O-MISC
in O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
and O-MISC O-MISC
cytoplasmic O-MISC O-MISC
glucocorticoid O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
different O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
types O-MISC O-MISC
: O-MISC O-MISC
lymphoblastoid O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
lymphoma O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
leukaemia O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cytoplasmic B-MISC B-MISC
receptors I-MISC I-MISC
of O-MISC O-MISC
leukaemia O-MISC O-MISC
and O-MISC O-MISC
lymphoblastoid O-MISC O-MISC
lines O-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
contain O-MISC O-MISC
both O-MISC O-MISC
proteinaceous O-MISC O-MISC
and O-MISC O-MISC
phospholipid O-MISC O-MISC
components O-MISC O-MISC
. O-MISC O-MISC

Cytoplasmic B-MISC B-MISC
steroid I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
exhibited O-MISC O-MISC
a O-MISC O-MISC
wide O-MISC O-MISC
range O-MISC O-MISC
of O-MISC O-MISC
sedimentation O-MISC O-MISC
coefficients O-MISC O-MISC
( O-MISC O-MISC
8 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
11 O-MISC O-MISC
. O-MISC O-MISC
3S O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
low O-MISC O-MISC
ionic O-MISC O-MISC
strength O-MISC O-MISC
buffer O-MISC O-MISC
but O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
no O-MISC O-MISC
correlation O-MISC O-MISC
with O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
type O-MISC O-MISC
or O-MISC O-MISC
glucocorticoid O-MISC O-MISC
sensitivity O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
complexes O-MISC O-MISC
by O-MISC O-MISC
heat O-MISC O-MISC
( O-MISC O-MISC
37 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
exposure O-MISC O-MISC
to O-MISC O-MISC
high O-MISC O-MISC
ionic O-MISC O-MISC
strength O-MISC O-MISC
buffer O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
3 O-MISC O-MISC
M O-MISC O-MISC
NaCl O-MISC O-MISC
) O-MISC O-MISC
induced O-MISC O-MISC
nuclear O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
but O-MISC O-MISC
only O-MISC O-MISC
complexes O-MISC O-MISC
in O-MISC O-MISC
high O-MISC O-MISC
ionic O-MISC O-MISC
strength O-MISC O-MISC
buffer O-MISC O-MISC
manifested O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
sedimentation O-MISC O-MISC
coefficient O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
correlation O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
or O-MISC O-MISC
nature O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
binding O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
cytolethal O-MISC O-MISC
or O-MISC O-MISC
cytostatic O-MISC O-MISC
responsiveness O-MISC O-MISC
of O-MISC O-MISC
HLCL O-MISC O-MISC
to O-MISC O-MISC
glucocorticoid O-MISC O-MISC
treatment O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
cytolethal O-MISC O-MISC
effects O-MISC O-MISC
can O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
ascribed O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
failure O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
take O-MISC O-MISC
up O-MISC O-MISC
and O-MISC O-MISC
bind O-MISC O-MISC
steroid O-MISC O-MISC
or O-MISC O-MISC
to O-MISC O-MISC
significant O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
species O-MISC O-MISC
of O-MISC O-MISC
cytoplasmic B-MISC B-MISC
receptors I-MISC I-MISC
present O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
molecular O-MISC O-MISC
mechanisms O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
glucocorticoids O-MISC O-MISC
achieve O-MISC O-MISC
cytolethal O-MISC O-MISC
responses O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC

CD28 B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
: O-MISC O-MISC
enhanced O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
intermediates O-MISC O-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
complete O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
( O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
plus O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD28 I-MISC I-MISC
) O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
( O-MISC O-MISC
naive O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
( O-MISC O-MISC
memory O-MISC O-MISC
/ O-MISC O-MISC
effector O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Long O-MISC O-MISC
exposure O-MISC O-MISC
( O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
) O-MISC O-MISC
induced O-MISC O-MISC
stronger O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nuclear B-MISC B-MISC
c I-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
protein I-MISC I-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
after O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC I-MISC
CD3 O-MISC I-MISC
+ O-MISC I-MISC
anti O-MISC O-MISC
- O-MISC I-MISC
CD28 O-MISC I-MISC
stimulation O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
was O-MISC O-MISC
higher O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cytoplasmic O-MISC B-MISC
inhibitor O-MISC I-MISC
IkappaBalpha B-MISC I-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
anti O-MISC B-MISC
- O-MISC I-MISC
CD3 O-MISC I-MISC
+ O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
CD28 O-MISC I-MISC
stimulation O-MISC O-MISC
induced O-MISC O-MISC
a O-MISC O-MISC
long O-MISC O-MISC
- O-MISC O-MISC
lasting O-MISC O-MISC
degradation O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
in O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
the O-MISC O-MISC
degradation O-MISC O-MISC
process O-MISC O-MISC
was O-MISC O-MISC
more O-MISC O-MISC
rapid O-MISC O-MISC
. O-MISC O-MISC

Because O-MISC O-MISC
the O-MISC O-MISC
CD28 O-MISC B-MISC
costimulus O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
intermediates O-MISC O-MISC
( O-MISC O-MISC
ROIs O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
intracellular O-MISC O-MISC
ROI O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
compared O-MISC O-MISC
by O-MISC O-MISC
flow O-MISC O-MISC
cytometry O-MISC O-MISC
. O-MISC O-MISC

ROIs O-MISC O-MISC
were O-MISC O-MISC
produced O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
more O-MISC O-MISC
strongly O-MISC O-MISC
in O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
data O-MISC O-MISC
presented O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
further O-MISC O-MISC
emphasize O-MISC O-MISC
the O-MISC O-MISC
differences O-MISC O-MISC
between O-MISC O-MISC
CD45RA O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
in O-MISC O-MISC
ROI O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

Ikaros B-MISC B-MISC
in O-MISC O-MISC
hemopoietic O-MISC O-MISC
lineage O-MISC O-MISC
determination O-MISC O-MISC
and O-MISC O-MISC
homeostasis O-MISC O-MISC
. O-MISC O-MISC

Studies O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
mechanisms O-MISC O-MISC
that O-MISC O-MISC
control O-MISC O-MISC
hemopoietic O-MISC O-MISC
differentiation O-MISC O-MISC
have O-MISC O-MISC
focused O-MISC O-MISC
on O-MISC O-MISC
signaling O-MISC O-MISC
cascades O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
effectors O-MISC O-MISC
that O-MISC O-MISC
drive O-MISC O-MISC
this O-MISC O-MISC
complex O-MISC O-MISC
developmental O-MISC O-MISC
system O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
regulated O-MISC O-MISC
fashion O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
review O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
Ikaros B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
founding O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
unique O-MISC O-MISC
family O-MISC O-MISC
of O-MISC O-MISC
zinc B-MISC B-MISC
finger I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
in O-MISC O-MISC
this O-MISC O-MISC
developmental O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

Studies O-MISC O-MISC
on O-MISC O-MISC
an O-MISC O-MISC
Ikaros B-MISC B-MISC
null O-MISC O-MISC
mutation O-MISC O-MISC
have O-MISC O-MISC
revealed O-MISC O-MISC
an O-MISC O-MISC
essential O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
this O-MISC O-MISC
factor O-MISC O-MISC
in O-MISC O-MISC
lymphoid O-MISC O-MISC
cell O-MISC O-MISC
fate O-MISC O-MISC
determination O-MISC O-MISC
and O-MISC O-MISC
at O-MISC O-MISC
subsequent O-MISC O-MISC
branch O-MISC O-MISC
points O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

Differences O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
phenotypes O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
null O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
dominant O-MISC B-MISC
negative O-MISC I-MISC
( O-MISC I-MISC
DN O-MISC I-MISC
) O-MISC I-MISC
Ikaros O-MISC I-MISC
mutation O-MISC O-MISC
provide O-MISC O-MISC
insight O-MISC O-MISC
into O-MISC O-MISC
a O-MISC O-MISC
regulatory O-MISC O-MISC
network O-MISC I-MISC
through O-MISC O-MISC
which O-MISC O-MISC
Ikaros B-MISC B-MISC
proteins I-MISC I-MISC
exert O-MISC O-MISC
their O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
a O-MISC O-MISC
comparative O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
hemopoietic O-MISC O-MISC
stem O-MISC O-MISC
cell O-MISC O-MISC
and O-MISC O-MISC
precursor O-MISC O-MISC
compartment O-MISC O-MISC
resulting O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
Ikaros B-MISC B-MISC
mutations O-MISC O-MISC
reveals O-MISC O-MISC
a O-MISC O-MISC
profound O-MISC O-MISC
yet O-MISC O-MISC
not O-MISC O-MISC
absolute O-MISC O-MISC
requirement O-MISC O-MISC
for O-MISC O-MISC
Ikaros B-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
populations O-MISC O-MISC
. O-MISC O-MISC

Overexpression O-MISC O-MISC
of O-MISC O-MISC
p65 O-MISC B-MISC
and O-MISC O-MISC
c O-MISC B-MISC
- O-MISC I-MISC
Jun O-MISC I-MISC
substitutes O-MISC O-MISC
for O-MISC O-MISC
B7 O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
costimulation O-MISC O-MISC
by O-MISC O-MISC
targeting O-MISC O-MISC
the O-MISC O-MISC
CD28RE B-MISC B-MISC
within O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
Rel B-MISC B-MISC
and O-MISC O-MISC
activation B-MISC B-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
B7 O-MISC O-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
- O-MISC O-MISC
and O-MISC O-MISC
leukocyte O-MISC O-MISC
function O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
Ag O-MISC O-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
( O-MISC O-MISC
LFA O-MISC B-MISC
. O-MISC I-MISC
3 O-MISC I-MISC
) O-MISC O-MISC
- O-MISC O-MISC
costimulated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
evaluated O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Fos I-MISC I-MISC
increases O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
B7 O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
- O-MISC I-MISC
and O-MISC O-MISC
LFA O-MISC B-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
- O-MISC O-MISC
costimulated O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Cotransfection O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
c O-MISC B-MISC
- O-MISC I-MISC
Jun O-MISC I-MISC
and O-MISC O-MISC
c O-MISC B-MISC
- O-MISC I-MISC
Fos O-MISC I-MISC
substitutes O-MISC O-MISC
for O-MISC O-MISC
B7 O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
costimulation O-MISC O-MISC
in O-MISC O-MISC
driving O-MISC O-MISC
an O-MISC O-MISC
activation B-MISC B-MISC
protein I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Overexpression O-MISC O-MISC
of O-MISC O-MISC
Rel B-MISC B-MISC
proteins I-MISC I-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
p65 O-MISC B-MISC
- O-MISC O-MISC
expressing O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
transcribed O-MISC O-MISC
equally O-MISC O-MISC
well O-MISC O-MISC
a O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
kappabeta I-MISC I-MISC
reporter I-MISC I-MISC
construct I-MISC I-MISC
when O-MISC O-MISC
costimulated O-MISC O-MISC
with O-MISC O-MISC
B7 B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
or O-MISC O-MISC
LFA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
or O-MISC O-MISC
CD28 B-MISC B-MISC
response I-MISC I-MISC
element I-MISC I-MISC
( I-MISC O-MISC
CD28RE I-MISC B-MISC
) I-MISC O-MISC
- I-MISC O-MISC
driven I-MISC O-MISC
reporters I-MISC O-MISC
was O-MISC O-MISC
superior O-MISC O-MISC
in O-MISC O-MISC
B7 O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
costimulated O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Combined O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
and O-MISC O-MISC
p65 B-MISC B-MISC
induced O-MISC O-MISC
vigorous O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
- I-MISC I-MISC
and I-MISC I-MISC
CD28RE I-MISC I-MISC
- I-MISC I-MISC
driven I-MISC I-MISC
reporter I-MISC I-MISC
constructs I-MISC I-MISC
in O-MISC O-MISC
both O-MISC O-MISC
LFA O-MISC B-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
- O-MISC O-MISC
and O-MISC O-MISC
B7 O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
- O-MISC O-MISC
costimulated O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Mutating O-MISC O-MISC
the O-MISC O-MISC
CD28RE B-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
upstream B-MISC B-MISC
nuclear I-MISC I-MISC
factor I-MISC I-MISC
kappabeta I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
reduced O-MISC O-MISC
B7 B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
transcription O-MISC O-MISC
> O-MISC O-MISC
90 O-MISC O-MISC
% O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
implicates O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CD28RE B-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
integration O-MISC O-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
/ O-MISC I-MISC
c B-MISC I-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
transcription O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
transition O-MISC O-MISC
from O-MISC O-MISC
an O-MISC O-MISC
autocrine O-MISC O-MISC
LFA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
B7 O-MISC O-MISC
- O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
paracrine O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
involves O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
and O-MISC O-MISC
p65 B-MISC B-MISC
, O-MISC O-MISC
which O-MISC O-MISC
target O-MISC O-MISC
the O-MISC O-MISC
CD28RE B-MISC B-MISC
region O-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Defects O-MISC O-MISC
in O-MISC O-MISC
actin O-MISC O-MISC
- O-MISC O-MISC
cap O-MISC O-MISC
formation O-MISC O-MISC
in O-MISC O-MISC
Vav O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mice O-MISC O-MISC
implicate O-MISC O-MISC
an O-MISC O-MISC
actin O-MISC O-MISC
requirement O-MISC O-MISC
for O-MISC O-MISC
lymphocyte O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
Antigen O-MISC O-MISC
- O-MISC O-MISC
receptor O-MISC O-MISC
interactions O-MISC O-MISC
on O-MISC O-MISC
lymphocytes O-MISC O-MISC
result O-MISC O-MISC
in O-MISC O-MISC
local O-MISC O-MISC
clustering O-MISC O-MISC
of O-MISC O-MISC
actin B-MISC B-MISC
, O-MISC I-MISC
receptors O-MISC I-MISC
and O-MISC O-MISC
signaling O-MISC B-MISC
molecules O-MISC I-MISC
into O-MISC O-MISC
an O-MISC O-MISC
asymmetric O-MISC O-MISC
membrane O-MISC O-MISC
structure O-MISC O-MISC
termed O-MISC O-MISC
a O-MISC O-MISC
cap O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
actin O-MISC O-MISC
polymerization O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
required O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
underlying O-MISC O-MISC
cap O-MISC O-MISC
formation O-MISC O-MISC
are O-MISC O-MISC
unclear O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
studied O-MISC O-MISC
the O-MISC O-MISC
events O-MISC O-MISC
underlying O-MISC O-MISC
cap O-MISC O-MISC
formation O-MISC O-MISC
using O-MISC O-MISC
mice O-MISC O-MISC
bearing O-MISC O-MISC
a O-MISC O-MISC
null O-MISC O-MISC
mutation O-MISC O-MISC
in O-MISC O-MISC
vav B-MISC O-MISC
( O-MISC O-MISC
vav B-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
gene O-MISC O-MISC
that O-MISC O-MISC
encodes O-MISC O-MISC
a O-MISC O-MISC
guanine B-MISC B-MISC
- I-MISC I-MISC
nucleotide I-MISC I-MISC
exchange I-MISC I-MISC
factor I-MISC I-MISC
for O-MISC O-MISC
the O-MISC O-MISC
GTPase B-MISC B-MISC
Rac I-MISC I-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Lymphocytes O-MISC O-MISC
from O-MISC O-MISC
vav B-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
mice O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
form O-MISC O-MISC
T O-MISC B-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
receptor O-MISC O-MISC
caps O-MISC O-MISC
following O-MISC O-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
defective O-MISC O-MISC
actin O-MISC O-MISC
cytoskeleton O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
vav O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
deficient O-MISC O-MISC
in O-MISC O-MISC
interleukin O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
( O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
) O-MISC O-MISC
production O-MISC O-MISC
and O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
peak O-MISC O-MISC
of O-MISC O-MISC
Ca2 O-MISC O-MISC
+ O-MISC O-MISC
mobilization O-MISC O-MISC
was O-MISC O-MISC
reduced O-MISC O-MISC
although O-MISC O-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
duration O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
Jun B-MISC B-MISC
N I-MISC I-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
kinase I-MISC I-MISC
or O-MISC O-MISC
stress B-MISC O-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
JNK B-MISC B-MISC
or O-MISC O-MISC
SAPK B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
mitogen B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
MAPK B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF B-MISC I-MISC
- I-MISC I-MISC
ATc1 I-MISC I-MISC
and I-MISC I-MISC
egr I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
genes I-MISC I-MISC
was O-MISC O-MISC
normal O-MISC O-MISC
. O-MISC O-MISC

Despite O-MISC O-MISC
the O-MISC O-MISC
reduced O-MISC O-MISC
Ca2 O-MISC O-MISC
+ O-MISC O-MISC
mobilization O-MISC O-MISC
, O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
cytoplasmic B-MISC B-MISC
NF I-MISC I-MISC
- I-MISC I-MISC
ATc I-MISC I-MISC
to O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
was O-MISC O-MISC
normal O-MISC O-MISC
, O-MISC O-MISC
reflecting O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
lower O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
Ca2 O-MISC O-MISC
+ O-MISC O-MISC
in O-MISC O-MISC
vav O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
still O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
calcineurin B-MISC B-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
lymphocytes O-MISC O-MISC
with O-MISC O-MISC
cytochalasin O-MISC O-MISC
D O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
blocks O-MISC O-MISC
actin O-MISC O-MISC
polymerization O-MISC O-MISC
, O-MISC O-MISC
inhibited O-MISC O-MISC
cap O-MISC O-MISC
formation O-MISC O-MISC
and O-MISC O-MISC
produced O-MISC O-MISC
defects O-MISC O-MISC
in O-MISC O-MISC
signaling O-MISC O-MISC
and O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
transcriptional O-MISC O-MISC
induction O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC B-MISC
receptor O-MISC I-MISC
signaling O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
nearly O-MISC O-MISC
identical O-MISC O-MISC
to O-MISC O-MISC
those O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
vav O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
transfection O-MISC O-MISC
studies O-MISC O-MISC
, O-MISC O-MISC
either O-MISC O-MISC
constitutively O-MISC O-MISC
active O-MISC O-MISC
Vav B-MISC B-MISC
or O-MISC O-MISC
Rac B-MISC B-MISC
could O-MISC O-MISC
complement O-MISC O-MISC
constitutively O-MISC O-MISC
active O-MISC O-MISC
calcineurin B-MISC B-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
AT O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
These O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
Vav B-MISC B-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
cap O-MISC O-MISC
formation O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
cap O-MISC O-MISC
formation O-MISC O-MISC
, O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
production O-MISC O-MISC
and O-MISC O-MISC
proliferation O-MISC O-MISC
supports O-MISC O-MISC
the O-MISC O-MISC
hypothesis O-MISC O-MISC
that O-MISC O-MISC
an O-MISC O-MISC
actin O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
pathway O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
source O-MISC O-MISC
of O-MISC O-MISC
specialized O-MISC O-MISC
growth O-MISC O-MISC
regulatory O-MISC O-MISC
signals O-MISC O-MISC
. O-MISC O-MISC

CD14 B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
Bacteroides O-MISC O-MISC
fragilis O-MISC O-MISC
outer O-MISC O-MISC
membrane O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
studied O-MISC O-MISC
the O-MISC O-MISC
capacity O-MISC O-MISC
of O-MISC O-MISC
isolated O-MISC O-MISC
Bacteriodes O-MISC O-MISC
fragilis O-MISC O-MISC
outer O-MISC O-MISC
membrane O-MISC O-MISC
, O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
fragilis O-MISC O-MISC
NCTC9343 O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
( O-MISC O-MISC
LPS O-MISC O-MISC
; O-MISC O-MISC
endotoxin O-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
fragilis O-MISC O-MISC
NCTC9343 O-MISC O-MISC
capsular O-MISC O-MISC
polysaccharides O-MISC O-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
human O-MISC O-MISC
umbilical O-MISC O-MISC
vein O-MISC O-MISC
endothelial O-MISC O-MISC
cell O-MISC O-MISC
( O-MISC O-MISC
HUVEC O-MISC O-MISC
) O-MISC O-MISC
monolayers O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
assess O-MISC O-MISC
HUVEC O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
selectin I-MISC I-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
enzyme O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
immunosorbent O-MISC O-MISC
assay O-MISC O-MISC
( O-MISC O-MISC
ELISA O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
Northern O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
for O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
selectin I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
mRNA I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
electrophoretic O-MISC O-MISC
gel O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
( O-MISC O-MISC
EMSA O-MISC O-MISC
) O-MISC O-MISC
for O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
selectin I-MISC I-MISC
gene I-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Exposure O-MISC O-MISC
of O-MISC O-MISC
HUVECs O-MISC O-MISC
to O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
fragilis O-MISC O-MISC
outer O-MISC O-MISC
membrane O-MISC O-MISC
fractions O-MISC O-MISC
, O-MISC O-MISC
separated O-MISC O-MISC
from O-MISC O-MISC
other O-MISC O-MISC
components O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
fragilis O-MISC O-MISC
cell O-MISC O-MISC
wall O-MISC O-MISC
by O-MISC O-MISC
isopycnic O-MISC O-MISC
, O-MISC O-MISC
sucrose O-MISC O-MISC
gradient O-MISC O-MISC
centrifugation O-MISC O-MISC
, O-MISC O-MISC
significantly O-MISC O-MISC
increased O-MISC O-MISC
surface O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
selectin I-MISC I-MISC
and O-MISC O-MISC
induced O-MISC O-MISC
functional O-MISC O-MISC
endothelial O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
leukocyte O-MISC O-MISC
adhesion O-MISC O-MISC
. O-MISC O-MISC

B O-MISC O-MISC
. O-MISC O-MISC
fragilis O-MISC O-MISC
outer O-MISC O-MISC
membranes O-MISC O-MISC
induced O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
to O-MISC O-MISC
HUVEC O-MISC O-MISC
nuclei O-MISC O-MISC
and O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
selectin I-MISC I-MISC
mRNA I-MISC I-MISC
in O-MISC O-MISC
HUVEC O-MISC O-MISC
cytoplasm O-MISC O-MISC
. O-MISC O-MISC

E O-MISC B-MISC
- O-MISC I-MISC
selectin O-MISC I-MISC
expression O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
B O-MISC B-MISC
. O-MISC I-MISC
fragilis O-MISC I-MISC
outer O-MISC I-MISC
membranes O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
polymixin O-MISC B-MISC
B O-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
E O-MISC B-MISC
- O-MISC I-MISC
selectin O-MISC I-MISC
expression O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
outer O-MISC O-MISC
membrane O-MISC O-MISC
fractions O-MISC O-MISC
purified O-MISC O-MISC
from O-MISC O-MISC
E O-MISC O-MISC
. O-MISC O-MISC
coli O-MISC O-MISC
was O-MISC O-MISC
competitively O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
polymixin O-MISC B-MISC
B O-MISC O-MISC
. O-MISC O-MISC

Neither O-MISC O-MISC
purified O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
fragilis O-MISC O-MISC
LPS O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
prominent O-MISC O-MISC
constituent O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
outer O-MISC O-MISC
membrane O-MISC O-MISC
, O-MISC O-MISC
nor O-MISC O-MISC
purified O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
fragilis O-MISC O-MISC
capsular O-MISC O-MISC
polysaccharides O-MISC O-MISC
induced O-MISC O-MISC
HUVEC O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
different O-MISC O-MISC
monoclonal B-MISC B-MISC
antibodies I-MISC I-MISC
directed O-MISC O-MISC
against O-MISC O-MISC
human B-MISC O-MISC
CD14 I-MISC I-MISC
completely O-MISC O-MISC
inhibited O-MISC O-MISC
B O-MISC B-MISC
. O-MISC O-MISC
fragilis O-MISC O-MISC
outer O-MISC O-MISC
membrane O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
E O-MISC B-MISC
- O-MISC I-MISC
selectin O-MISC I-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
E O-MISC B-MISC
- O-MISC B-MISC
selectin O-MISC I-MISC
surface O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
outer O-MISC O-MISC
membrane O-MISC O-MISC
component O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
fragilis O-MISC O-MISC
cell O-MISC O-MISC
wall O-MISC O-MISC
contains O-MISC O-MISC
a O-MISC O-MISC
proinflammatory O-MISC B-MISC
factor O-MISC I-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
LPS O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
induces O-MISC O-MISC
human O-MISC O-MISC
endothelial O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
soluble O-MISC O-MISC
CD14 B-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
mechanism O-MISC O-MISC
. O-MISC O-MISC

NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
protects O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
myeloid O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
monocytic O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
myeloid O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
sustained O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Recently O-MISC O-MISC
, O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
induction O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
protecting O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
programmed O-MISC O-MISC
cell O-MISC O-MISC
death O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
sought O-MISC O-MISC
to O-MISC O-MISC
investigate O-MISC O-MISC
whether O-MISC O-MISC
constitutive O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
chronically O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
promonocytic O-MISC O-MISC
U937 O-MISC O-MISC
( O-MISC O-MISC
U9 O-MISC O-MISC
- O-MISC O-MISC
IIIB O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
myeloblastic O-MISC O-MISC
PLB O-MISC B-MISC
- O-MISC O-MISC
985 O-MISC O-MISC
( O-MISC O-MISC
PLB O-MISC O-MISC
- O-MISC O-MISC
IIIB O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
affects O-MISC O-MISC
apoptotic O-MISC O-MISC
signaling O-MISC O-MISC
. O-MISC O-MISC

TNFalpha B-MISC B-MISC
and O-MISC O-MISC
cycloheximide O-MISC O-MISC
caused O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
undergo O-MISC O-MISC
apoptosis O-MISC O-MISC
more O-MISC O-MISC
rapidly O-MISC O-MISC
than O-MISC O-MISC
parental O-MISC O-MISC
U937 O-MISC O-MISC
and O-MISC O-MISC
PLB O-MISC O-MISC
- O-MISC O-MISC
985 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
TNFalpha B-MISC B-MISC
- O-MISC I-MISC
induced O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
using O-MISC O-MISC
the O-MISC O-MISC
antioxidant O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
acetylcysteine O-MISC O-MISC
( O-MISC O-MISC
NAC O-MISC O-MISC
) O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
increased O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
U937 O-MISC O-MISC
and O-MISC O-MISC
U9 O-MISC O-MISC
- O-MISC O-MISC
IIIB O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
preactivation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
with O-MISC O-MISC
the O-MISC O-MISC
non B-MISC O-MISC
- I-MISC O-MISC
apoptotic I-MISC O-MISC
inducer I-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
caused O-MISC O-MISC
a O-MISC O-MISC
relative O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
constitutive O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
U9 O-MISC O-MISC
- O-MISC O-MISC
IIIB O-MISC O-MISC
and O-MISC O-MISC
PLB O-MISC O-MISC
- O-MISC O-MISC
IIIB O-MISC O-MISC
cells O-MISC O-MISC
also O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
protects O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
persistent O-MISC O-MISC
apoptotic O-MISC O-MISC
signal O-MISC O-MISC
. O-MISC O-MISC

TNFalpha B-MISC B-MISC
plus O-MISC O-MISC
NAC O-MISC O-MISC
treatment O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
marked O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
protein I-MISC I-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
coupled O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
Bax B-MISC B-MISC
protein I-MISC I-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
uninfected O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
susceptibility O-MISC O-MISC
to O-MISC O-MISC
TNFalpha B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
may O-MISC O-MISC
relate O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
relative O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
Bax B-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
protective O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
blocking O-MISC O-MISC
TNFalpha O-MISC B-MISC
- O-MISC O-MISC
and O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
was O-MISC O-MISC
supported O-MISC O-MISC
by O-MISC O-MISC
studies O-MISC O-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
engineered O-MISC O-MISC
to O-MISC O-MISC
express O-MISC O-MISC
IkappaB B-MISC B-MISC
alpha I-MISC I-MISC
repressor I-MISC I-MISC
mutants I-MISC I-MISC
( O-MISC O-MISC
TD B-MISC B-MISC
- I-MISC I-MISC
IkappaB I-MISC I-MISC
) O-MISC O-MISC
under O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
tetracycline B-MISC B-MISC
- I-MISC I-MISC
responsive I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Cells O-MISC O-MISC
underwent O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
TNFalpha B-MISC B-MISC
only O-MISC O-MISC
when O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
TD B-MISC B-MISC
- I-MISC I-MISC
IkappaB I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
U9 O-MISC O-MISC
- O-MISC O-MISC
IIIB O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
TNFalpha B-MISC B-MISC
treatment O-MISC O-MISC
also O-MISC O-MISC
induced O-MISC O-MISC
a O-MISC O-MISC
marked O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
protein I-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
TD O-MISC O-MISC
- O-MISC O-MISC
IkappaB O-MISC I-MISC
expressing O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
experiments O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
apoptotic O-MISC O-MISC
signaling O-MISC O-MISC
is O-MISC O-MISC
perturbed O-MISC O-MISC
in O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
U9 O-MISC O-MISC
- O-MISC O-MISC
IIIB O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
may O-MISC O-MISC
play O-MISC O-MISC
an O-MISC O-MISC
additional O-MISC O-MISC
protective O-MISC O-MISC
role O-MISC O-MISC
against O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
myeloid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
normal O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphocytes O-MISC O-MISC
are O-MISC O-MISC
deficient O-MISC O-MISC
in O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC I-MISC
protein O-MISC I-MISC
kinase O-MISC I-MISC
activity O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
variant O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ku86 B-MISC B-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
heterodimeric O-MISC B-MISC
Ku B-MISC I-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
comprises O-MISC O-MISC
a O-MISC O-MISC
86 B-MISC O-MISC
kDa I-MISC O-MISC
( I-MISC O-MISC
Ku86 I-MISC I-MISC
) I-MISC O-MISC
amd O-MISC O-MISC
a O-MISC O-MISC
70 B-MISC B-MISC
kDa I-MISC I-MISC
( I-MISC I-MISC
Ku70 I-MISC I-MISC
) I-MISC I-MISC
subunits I-MISC I-MISC
, O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
abundant O-MISC O-MISC
nuclear B-MISC B-MISC
DNA I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
which O-MISC O-MISC
binds O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
to O-MISC O-MISC
DNA B-MISC O-MISC
termini I-MISC O-MISC
without O-MISC O-MISC
sequence O-MISC O-MISC
specificity O-MISC O-MISC
. O-MISC O-MISC

Ku B-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
DNA B-MISC O-MISC
- I-MISC O-MISC
targeting I-MISC O-MISC
component I-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
large O-MISC O-MISC
catalytic B-MISC B-MISC
sub I-MISC O-MISC
- I-MISC O-MISC
unit I-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
DNA B-MISC B-MISC
- I-MISC I-MISC
dependent I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
complex I-MISC I-MISC
( O-MISC O-MISC
DNA B-MISC B-MISC
- I-MISC O-MISC
PK I-MISC I-MISC
[ I-MISC O-MISC
CS I-MISC O-MISC
] I-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
mammalian O-MISC O-MISC
double O-MISC O-MISC
- O-MISC O-MISC
strand O-MISC O-MISC
break O-MISC O-MISC
repair O-MISC O-MISC
and O-MISC O-MISC
lymphoid O-MISC O-MISC
V O-MISC O-MISC
( O-MISC O-MISC
D O-MISC O-MISC
) O-MISC O-MISC
J O-MISC O-MISC
recombination O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
using O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
addition O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
major B-MISC B-MISC
Ku I-MISC B-MISC
x I-MISC I-MISC
DNA I-MISC I-MISC
complex I-MISC I-MISC
usually O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
extracts O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
second O-MISC O-MISC
complex O-MISC O-MISC
with O-MISC O-MISC
faster O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
lymphocytes O-MISC O-MISC
( O-MISC O-MISC
PBL O-MISC O-MISC
) O-MISC O-MISC
extracts O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
faster B-MISC B-MISC
migrating I-MISC I-MISC
complex I-MISC I-MISC
was O-MISC O-MISC
restricted O-MISC O-MISC
to O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
among O-MISC O-MISC
the O-MISC O-MISC
circulating O-MISC O-MISC
lymphocyte O-MISC O-MISC
population O-MISC O-MISC
. O-MISC O-MISC

Western O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
express O-MISC O-MISC
a O-MISC O-MISC
variant O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ku86 B-MISC B-MISC
protein I-MISC I-MISC
with O-MISC O-MISC
an O-MISC O-MISC
apparent O-MISC O-MISC
molecular O-MISC O-MISC
weight O-MISC O-MISC
of O-MISC O-MISC
69 O-MISC B-MISC
kDa O-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
86 B-MISC B-MISC
kDa I-MISC I-MISC
- I-MISC I-MISC
full I-MISC I-MISC
- I-MISC I-MISC
length I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
the O-MISC O-MISC
heterodimer B-MISC B-MISC
Ku70 I-MISC I-MISC
/ I-MISC I-MISC
variant I-MISC I-MISC
- I-MISC I-MISC
Ku86 I-MISC I-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
DNA B-MISC B-MISC
- I-MISC I-MISC
ends I-MISC I-MISC
, O-MISC O-MISC
this O-MISC O-MISC
altered O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ku B-MISC B-MISC
heterodimer I-MISC I-MISC
has O-MISC O-MISC
a O-MISC O-MISC
decreased O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
recruit O-MISC O-MISC
the O-MISC O-MISC
catalytic B-MISC O-MISC
component I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
complex O-MISC O-MISC
, O-MISC O-MISC
DNA B-MISC B-MISC
- I-MISC I-MISC
PK I-MISC I-MISC
( I-MISC O-MISC
CS I-MISC I-MISC
) I-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
contributes O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
detectable O-MISC O-MISC
DNA O-MISC B-MISC
- O-MISC O-MISC
PK O-MISC B-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
provide O-MISC O-MISC
a O-MISC O-MISC
molecular O-MISC O-MISC
basis O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
increased O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
ionizing O-MISC O-MISC
radiation O-MISC O-MISC
and O-MISC O-MISC
identify O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
PK O-MISC B-MISC
activity O-MISC O-MISC
that O-MISC O-MISC
operates O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

Co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
monoclonal I-MISC I-MISC
antibodies I-MISC I-MISC
induces O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
. O-MISC O-MISC

Phosphorylation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cAMP B-MISC B-MISC
- I-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
CREB I-MISC I-MISC
within O-MISC O-MISC
1 O-MISC O-MISC
h O-MISC O-MISC
of O-MISC O-MISC
CD2 B-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
CD3 B-MISC B-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
PBMC O-MISC O-MISC
was O-MISC O-MISC
recently O-MISC O-MISC
demonstrated O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
P B-MISC B-MISC
- I-MISC I-MISC
CREB I-MISC I-MISC
following O-MISC O-MISC
CD3 O-MISC B-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
was O-MISC O-MISC
unexpected O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
other O-MISC O-MISC
laboratories O-MISC O-MISC
reported O-MISC O-MISC
increased O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
following O-MISC O-MISC
CD3 O-MISC B-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Jurkat O-MISC O-MISC
lymphocyte O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

Due O-MISC O-MISC
to O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
being O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
postulated O-MISC O-MISC
that O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
might O-MISC O-MISC
provide O-MISC O-MISC
a O-MISC O-MISC
necessary O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulus O-MISC O-MISC
for O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
P B-MISC B-MISC
- I-MISC I-MISC
CREB I-MISC I-MISC
was O-MISC O-MISC
evaluated O-MISC O-MISC
following O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
PBMC O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and I-MISC O-MISC
CD2 I-MISC B-MISC
or I-MISC O-MISC
CD3 I-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
did O-MISC O-MISC
not O-MISC O-MISC
further O-MISC O-MISC
augment O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
following O-MISC O-MISC
CD2 O-MISC B-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
neither O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
nor O-MISC O-MISC
CD3 O-MISC B-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
alone O-MISC O-MISC
induced O-MISC O-MISC
P B-MISC B-MISC
- I-MISC I-MISC
CREB I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
within O-MISC O-MISC
1 O-MISC O-MISC
h O-MISC O-MISC
of O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
/ O-MISC I-MISC
CD3 O-MISC I-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

Phosphorylation O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
cAMP O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
PKA O-MISC B-MISC
signaling O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
P B-MISC B-MISC
- I-MISC I-MISC
CREB I-MISC I-MISC
. O-MISC O-MISC

Consistent O-MISC O-MISC
with O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
through O-MISC O-MISC
p56lck B-MISC B-MISC
or O-MISC O-MISC
p59fyn B-MISC B-MISC
, O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
PTK O-MISC B-MISC
signaling O-MISC O-MISC
reduced O-MISC O-MISC
phosphorylation O-MISC O-MISC
50 O-MISC O-MISC
% O-MISC O-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
inhibiting O-MISC O-MISC
PKC O-MISC B-MISC
signaling O-MISC O-MISC
with O-MISC O-MISC
calphostin O-MISC O-MISC
C O-MISC O-MISC
further O-MISC O-MISC
increased O-MISC O-MISC
P O-MISC B-MISC
- O-MISC I-MISC
CREB O-MISC I-MISC
levels O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
over O-MISC O-MISC
that O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
/ O-MISC O-MISC
CD3 O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
cells O-MISC O-MISC
not O-MISC O-MISC
pretreated O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
PKC O-MISC B-MISC
inhibitor O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
previous O-MISC O-MISC
studies O-MISC O-MISC
performed O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
exogenous B-MISC B-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
no O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
to O-MISC O-MISC
a O-MISC O-MISC
32P O-MISC O-MISC
- O-MISC O-MISC
labeled O-MISC O-MISC
oligonucleotide O-MISC O-MISC
probe O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
by O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
CD3 B-MISC B-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
provide O-MISC O-MISC
a O-MISC O-MISC
necessary O-MISC O-MISC
and O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
operative O-MISC O-MISC
stimulus O-MISC O-MISC
promoting O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
following O-MISC O-MISC
receptor O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
. O-MISC O-MISC

HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
induces O-MISC O-MISC
a O-MISC O-MISC
selective O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
STAT5 O-MISC B-MISC
protein O-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
is O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
qualitative O-MISC O-MISC
and O-MISC O-MISC
quantitative O-MISC O-MISC
defects O-MISC O-MISC
in O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Loss O-MISC O-MISC
of O-MISC O-MISC
immune O-MISC O-MISC
function O-MISC O-MISC
in O-MISC O-MISC
HIV O-MISC O-MISC
patients O-MISC O-MISC
is O-MISC O-MISC
usually O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
profound O-MISC O-MISC
dysregulation O-MISC O-MISC
of O-MISC O-MISC
cytokine B-MISC B-MISC
production O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
investigate O-MISC O-MISC
whether O-MISC O-MISC
cytokine B-MISC B-MISC
signaling O-MISC O-MISC
defects O-MISC O-MISC
occur O-MISC O-MISC
during O-MISC O-MISC
HIV O-MISC O-MISC
infection O-MISC O-MISC
, O-MISC O-MISC
PHA O-MISC B-MISC
blasts O-MISC O-MISC
from O-MISC O-MISC
healthy O-MISC O-MISC
human O-MISC O-MISC
donors O-MISC O-MISC
were O-MISC O-MISC
infected O-MISC O-MISC
with O-MISC O-MISC
two O-MISC O-MISC
strains O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
and O-MISC O-MISC
screened O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
STAT B-MISC B-MISC
proteins I-MISC I-MISC
used O-MISC O-MISC
in O-MISC O-MISC
cytokine B-MISC B-MISC
signaling O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
selective O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
STAT5B B-MISC B-MISC
was O-MISC O-MISC
seen O-MISC O-MISC
8 O-MISC O-MISC
days O-MISC O-MISC
after O-MISC O-MISC
infection O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
BZ167 O-MISC O-MISC
dual O-MISC O-MISC
- O-MISC O-MISC
tropic O-MISC O-MISC
HIV O-MISC O-MISC
isolate O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
Ba O-MISC O-MISC
- O-MISC O-MISC
L O-MISC O-MISC
, O-MISC O-MISC
M O-MISC O-MISC
- O-MISC O-MISC
tropic O-MISC O-MISC
strain O-MISC O-MISC
. O-MISC O-MISC

Based O-MISC O-MISC
on O-MISC O-MISC
these O-MISC O-MISC
findings O-MISC O-MISC
, O-MISC O-MISC
purified O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
patients O-MISC O-MISC
in O-MISC O-MISC
different O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
disease O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
tested O-MISC O-MISC
for O-MISC O-MISC
STAT O-MISC B-MISC
expression O-MISC O-MISC
; O-MISC O-MISC
decreases O-MISC O-MISC
in O-MISC O-MISC
STAT5A B-MISC B-MISC
, O-MISC O-MISC
STAT5B B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
STAT1alpha B-MISC B-MISC
were O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
STATs B-MISC B-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
after O-MISC O-MISC
HIV O-MISC O-MISC
infection O-MISC O-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
in O-MISC O-MISC
HIV O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

Transcription B-MISC B-MISC
factors I-MISC I-MISC
that O-MISC O-MISC
regulate O-MISC O-MISC
monocyte O-MISC O-MISC
/ O-MISC O-MISC
macrophage O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
all O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
an O-MISC O-MISC
organism O-MISC O-MISC
contain O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
genetic O-MISC O-MISC
information O-MISC O-MISC
, O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
arise O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
lineage B-MISC O-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

During O-MISC O-MISC
myelopoiesis O-MISC O-MISC
, O-MISC O-MISC
external O-MISC O-MISC
differentiating O-MISC O-MISC
signals O-MISC O-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
set O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
combined O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
subsequently O-MISC O-MISC
determines O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
myeloid B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
genes I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
particular O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
PU I-MISC I-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
has O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
review O-MISC O-MISC
the O-MISC O-MISC
contribution O-MISC O-MISC
of O-MISC O-MISC
several O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
to O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
macrophage O-MISC O-MISC
development O-MISC O-MISC

Transcription B-MISC B-MISC
factor I-MISC I-MISC
LKLF I-MISC B-MISC
is O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
program O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
quiescence O-MISC O-MISC
via O-MISC O-MISC
a O-MISC O-MISC
c O-MISC B-MISC
- O-MISC I-MISC
Myc O-MISC I-MISC
- O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
lymphocytes O-MISC O-MISC
circulate O-MISC B-MISC
in O-MISC O-MISC
a O-MISC O-MISC
quiescent O-MISC O-MISC
state O-MISC O-MISC
until O-MISC O-MISC
they O-MISC O-MISC
encounter O-MISC O-MISC
cognate B-MISC O-MISC
antigen I-MISC O-MISC
bound O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
surface O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
presenting O-MISC O-MISC
cell O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
molecular O-MISC O-MISC
pathways O-MISC O-MISC
that O-MISC O-MISC
regulate O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
quiescence O-MISC O-MISC
remain O-MISC O-MISC
largely O-MISC O-MISC
unknown O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
forced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
lung B-MISC B-MISC
Kruppel I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
LKLF B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
program O-MISC O-MISC
a O-MISC O-MISC
quiescent O-MISC O-MISC
phenotype O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
decreased O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
reduced O-MISC O-MISC
cell O-MISC O-MISC
size O-MISC O-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
and O-MISC O-MISC
decreased O-MISC O-MISC
surface O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
activation O-MISC B-MISC
markers O-MISC I-MISC
. O-MISC O-MISC

Conversely O-MISC O-MISC
, O-MISC O-MISC
LKLF O-MISC B-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
peripheral O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
produced O-MISC O-MISC
by O-MISC O-MISC
gene O-MISC O-MISC
targeting O-MISC O-MISC
showed O-MISC O-MISC
increased O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
increased O-MISC O-MISC
cell O-MISC O-MISC
size O-MISC O-MISC
and O-MISC O-MISC
enhanced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
surface O-MISC O-MISC
activation O-MISC O-MISC
markers O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

LKLF B-MISC B-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
function O-MISC O-MISC
, O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
decreasing O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proto B-MISC B-MISC
- I-MISC I-MISC
oncogene I-MISC I-MISC
encoding O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Myc I-MISC I-MISC
. O-MISC O-MISC

Forced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
LKLF B-MISC B-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
markedly O-MISC O-MISC
decreased O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Myc I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
many O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
LKLF B-MISC B-MISC
expression O-MISC O-MISC
were O-MISC O-MISC
mimicked O-MISC O-MISC
by O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
dominant B-MISC B-MISC
- I-MISC I-MISC
negative I-MISC I-MISC
MadMyc I-MISC I-MISC
protein I-MISC I-MISC
and O-MISC O-MISC
rescued O-MISC O-MISC
by O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Myc I-MISC I-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
LKLF B-MISC B-MISC
is O-MISC O-MISC
both O-MISC O-MISC
necessary O-MISC O-MISC
and O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
program O-MISC O-MISC
quiescence O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
functions O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
negatively O-MISC O-MISC
regulating O-MISC O-MISC
a O-MISC O-MISC
c O-MISC B-MISC
- O-MISC I-MISC
Myc O-MISC I-MISC
- O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

HTLV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
p12 I-MISC I-MISC
( I-MISC I-MISC
I I-MISC I-MISC
) I-MISC I-MISC
protein I-MISC I-MISC
enhances O-MISC I-MISC
STAT5 O-MISC B-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
decreases O-MISC O-MISC
the O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
requirement O-MISC O-MISC
for O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
p12 B-MISC B-MISC
( I-MISC I-MISC
I I-MISC I-MISC
) I-MISC I-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
encoded O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
pX B-MISC B-MISC
open I-MISC I-MISC
reading I-MISC I-MISC
frame I-MISC I-MISC
I I-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lymphotropic O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
hydrophobic B-MISC B-MISC
protein I-MISC I-MISC
that O-MISC O-MISC
localizes O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
endoplasmic O-MISC O-MISC
reticulum O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
Golgi O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
p12 B-MISC B-MISC
( I-MISC I-MISC
I I-MISC I-MISC
) I-MISC I-MISC
contains O-MISC O-MISC
4 O-MISC I-MISC
minimal O-MISC I-MISC
proline O-MISC I-MISC
- O-MISC I-MISC
rich O-MISC I-MISC
, O-MISC I-MISC
src B-MISC I-MISC
homology I-MISC I-MISC
3 I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
motifs I-MISC I-MISC
( O-MISC O-MISC
PXXP B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
characteristic O-MISC O-MISC
commonly O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
proteins O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
has O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
known O-MISC O-MISC
whether O-MISC O-MISC
p12 B-MISC B-MISC
( I-MISC I-MISC
I I-MISC I-MISC
) I-MISC O-MISC
has O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
modulating O-MISC O-MISC
intracellular O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
p12 B-MISC B-MISC
( I-MISC I-MISC
I I-MISC I-MISC
) I-MISC I-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
cytoplasmic B-MISC B-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
) I-MISC I-MISC
beta I-MISC I-MISC
chain I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
recruitment O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Jak1 B-MISC B-MISC
and I-MISC I-MISC
Jak3 I-MISC B-MISC
kinases I-MISC I-MISC
. O-MISC O-MISC

As O-MISC O-MISC
a O-MISC O-MISC
result O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
interaction O-MISC O-MISC
, O-MISC O-MISC
p12 B-MISC B-MISC
( I-MISC I-MISC
I I-MISC I-MISC
) I-MISC I-MISC
increases O-MISC O-MISC
signal B-MISC B-MISC
transducers I-MISC I-MISC
and I-MISC I-MISC
activators I-MISC I-MISC
of I-MISC I-MISC
transcription I-MISC I-MISC
5 I-MISC I-MISC
( O-MISC O-MISC
STAT5 B-MISC I-MISC
) O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
and O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
this O-MISC O-MISC
effect O-MISC O-MISC
depends O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
beta I-MISC I-MISC
and I-MISC I-MISC
gamma I-MISC I-MISC
( I-MISC I-MISC
c I-MISC I-MISC
) I-MISC I-MISC
chains I-MISC I-MISC
and O-MISC O-MISC
Jak3 B-MISC B-MISC
. O-MISC O-MISC

Transduction O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
PBMCs O-MISC O-MISC
) O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
human B-MISC O-MISC
immunodeficiency I-MISC O-MISC
virus I-MISC O-MISC
type I-MISC O-MISC
1 I-MISC O-MISC
- I-MISC O-MISC
based I-MISC O-MISC
retroviral I-MISC O-MISC
vector I-MISC I-MISC
expressing O-MISC O-MISC
p12 B-MISC B-MISC
( I-MISC O-MISC
I I-MISC O-MISC
) I-MISC O-MISC
also O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
increased O-MISC O-MISC
STAT5 B-MISC B-MISC
phosphorylation O-MISC O-MISC
and O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
p12 B-MISC B-MISC
( I-MISC I-MISC
I I-MISC I-MISC
) I-MISC I-MISC
could O-MISC O-MISC
increase O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
PBMCs O-MISC O-MISC
only O-MISC O-MISC
after O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
receptors I-MISC I-MISC
by O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
low O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
alphaCD3 B-MISC B-MISC
and I-MISC O-MISC
alphaCD28 I-MISC B-MISC
antibodies I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
proliferative O-MISC O-MISC
advantage O-MISC O-MISC
of O-MISC O-MISC
p12 O-MISC B-MISC
( O-MISC I-MISC
I O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
transduced O-MISC O-MISC
PBMCs O-MISC O-MISC
was O-MISC O-MISC
evident O-MISC O-MISC
mainly O-MISC O-MISC
at O-MISC O-MISC
low O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

Together O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
p12 B-MISC B-MISC
( I-MISC I-MISC
I I-MISC I-MISC
) I-MISC O-MISC
may O-MISC O-MISC
confer O-MISC O-MISC
a O-MISC O-MISC
proliferative O-MISC O-MISC
advantage O-MISC O-MISC
on O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
suboptimal O-MISC O-MISC
antigen O-MISC O-MISC
stimulation O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
event O-MISC O-MISC
may O-MISC O-MISC
account O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
clonal O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
infected O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

( O-MISC O-MISC
Blood O-MISC O-MISC
. O-MISC O-MISC
2001 O-MISC O-MISC
; O-MISC O-MISC
98 O-MISC O-MISC
: O-MISC O-MISC
823 O-MISC O-MISC
- O-MISC O-MISC
829 O-MISC O-MISC
) O-MISC O-MISC

Single O-MISC O-MISC
dose O-MISC O-MISC
intranasal O-MISC O-MISC
administration O-MISC O-MISC
of O-MISC O-MISC
retinal B-MISC B-MISC
autoantigen I-MISC I-MISC
generates O-MISC O-MISC
a O-MISC O-MISC
rapid O-MISC O-MISC
accumulation O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
draining O-MISC O-MISC
lymph O-MISC O-MISC
node O-MISC O-MISC
and O-MISC O-MISC
spleen O-MISC O-MISC
: O-MISC O-MISC
implications O-MISC O-MISC
for O-MISC O-MISC
tolerance O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
/ O-MISC O-MISC
AIMS O-MISC O-MISC
: O-MISC O-MISC
A O-MISC O-MISC
single O-MISC O-MISC
intranasal O-MISC O-MISC
delivery O-MISC O-MISC
of O-MISC O-MISC
retinal B-MISC B-MISC
autoantigen I-MISC I-MISC
suppresses O-MISC O-MISC
effectively O-MISC O-MISC
experimental O-MISC O-MISC
autoimmune O-MISC O-MISC
uveoretinitis O-MISC O-MISC
( O-MISC O-MISC
EAU O-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
further O-MISC O-MISC
unravel O-MISC O-MISC
underlying O-MISC O-MISC
mechanisms O-MISC O-MISC
the O-MISC O-MISC
authors O-MISC O-MISC
wished O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
, O-MISC O-MISC
firstly O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
kinetics O-MISC O-MISC
of O-MISC O-MISC
antigen O-MISC O-MISC
delivery O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
secondly O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
early O-MISC O-MISC
cellular O-MISC O-MISC
responses O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
initial O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
nasal O-MISC O-MISC
mucosal O-MISC O-MISC
tolerance O-MISC O-MISC
induction O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Flow O-MISC O-MISC
cytometry O-MISC O-MISC
, O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
assays O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
microscopy O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
track O-MISC O-MISC
antigen B-MISC O-MISC
following O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
, O-MISC O-MISC
intranasal O-MISC B-MISC
dose O-MISC O-MISC
of O-MISC O-MISC
Alexa B-MISC O-MISC
- I-MISC O-MISC
488 I-MISC O-MISC
labelled I-MISC O-MISC
retinal I-MISC O-MISC
antigen I-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
A O-MISC O-MISC
rapid O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
antigen B-MISC O-MISC
within O-MISC O-MISC
both O-MISC O-MISC
superficial O-MISC O-MISC
cervical O-MISC O-MISC
lymph O-MISC O-MISC
nodes O-MISC O-MISC
( O-MISC O-MISC
SCLN O-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
spleen O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
after O-MISC O-MISC
30 O-MISC O-MISC
minutes O-MISC O-MISC
. O-MISC O-MISC

Significant O-MISC O-MISC
proliferative O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
IRBP O-MISC B-MISC
were O-MISC O-MISC
elicited O-MISC O-MISC
by O-MISC O-MISC
48 O-MISC O-MISC
hours O-MISC O-MISC
indicating O-MISC O-MISC
that O-MISC O-MISC
systemic O-MISC O-MISC
priming O-MISC O-MISC
of O-MISC O-MISC
naive O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
retinal B-MISC B-MISC
antigen I-MISC I-MISC
had O-MISC O-MISC
occurred O-MISC O-MISC
. O-MISC O-MISC

Cell O-MISC O-MISC
activation O-MISC O-MISC
was O-MISC O-MISC
further O-MISC O-MISC
confirmed O-MISC O-MISC
by O-MISC O-MISC
immunoprecipitation O-MISC O-MISC
studies O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
demonstrated O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
STAT4 B-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
STAT6 B-MISC B-MISC
in O-MISC O-MISC
both O-MISC O-MISC
lymph O-MISC O-MISC
nodes O-MISC O-MISC
and O-MISC O-MISC
spleen O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
at O-MISC O-MISC
24 O-MISC O-MISC
hours O-MISC O-MISC
, O-MISC O-MISC
STAT4 O-MISC B-MISC
heterodimerisation O-MISC I-MISC
with O-MISC O-MISC
STAT B-MISC B-MISC
3 I-MISC I-MISC
was O-MISC O-MISC
only O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
spleen O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
The O-MISC O-MISC
results O-MISC O-MISC
provide O-MISC O-MISC
novel O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
following O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
intranasal O-MISC B-MISC
application O-MISC O-MISC
rapid O-MISC O-MISC
transfer O-MISC O-MISC
of O-MISC O-MISC
antigen B-MISC O-MISC
occurs O-MISC O-MISC
. O-MISC O-MISC

Resulting O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
develops O-MISC O-MISC
consequent O-MISC O-MISC
to O-MISC O-MISC
differential O-MISC O-MISC
cell O-MISC O-MISC
signalling O-MISC O-MISC
in O-MISC O-MISC
SCLN O-MISC B-MISC
and O-MISC O-MISC
spleen O-MISC O-MISC
. O-MISC O-MISC

Further O-MISC O-MISC
understanding O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
underlying O-MISC O-MISC
cellular O-MISC O-MISC
mechanisms O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
particular O-MISC O-MISC
as O-MISC O-MISC
is O-MISC O-MISC
inferred O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
the O-MISC O-MISC
contribution O-MISC O-MISC
of O-MISC O-MISC
local O-MISC O-MISC
versus O-MISC O-MISC
systemic O-MISC O-MISC
tolerance O-MISC O-MISC
induction O-MISC O-MISC
, O-MISC O-MISC
may O-MISC O-MISC
assist O-MISC O-MISC
in O-MISC O-MISC
strategies O-MISC O-MISC
to O-MISC O-MISC
clinically O-MISC O-MISC
apply O-MISC O-MISC
mucosal O-MISC O-MISC
tolerance O-MISC O-MISC
therapy O-MISC O-MISC
successfully O-MISC O-MISC
. O-MISC O-MISC

Regulation O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
18 I-MISC I-MISC
receptor I-MISC I-MISC
alpha I-MISC I-MISC
chain I-MISC I-MISC
expression O-MISC O-MISC
on O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
( O-MISC O-MISC
Th O-MISC O-MISC
) O-MISC O-MISC
1 O-MISC O-MISC
/ O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

Critical O-MISC O-MISC
downregulatory O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
. O-MISC O-MISC

Interleukin B-MISC B-MISC
( I-MISC I-MISC
IL I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
18 I-MISC I-MISC
has O-MISC O-MISC
been O-MISC O-MISC
well O-MISC O-MISC
characterized O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
costimulatory B-MISC O-MISC
factor I-MISC I-MISC
for O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
- I-MISC O-MISC
mediated I-MISC O-MISC
interferon I-MISC B-MISC
( I-MISC O-MISC
IFN I-MISC B-MISC
) I-MISC O-MISC
- I-MISC O-MISC
gamma I-MISC I-MISC
production O-MISC O-MISC
by O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
( O-MISC O-MISC
Th O-MISC O-MISC
) O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
also O-MISC O-MISC
can O-MISC O-MISC
induce O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
production O-MISC O-MISC
and O-MISC O-MISC
thus O-MISC O-MISC
facilitate O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
Th2 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18 I-MISC I-MISC
might O-MISC O-MISC
regulate O-MISC O-MISC
these O-MISC O-MISC
diametrically O-MISC O-MISC
distinct O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18 I-MISC I-MISC
receptor I-MISC I-MISC
alpha I-MISC I-MISC
chain I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18Ralpha I-MISC I-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
majority O-MISC O-MISC
of O-MISC O-MISC
peripheral O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
constitutively O-MISC O-MISC
expressed O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18Ralpha I-MISC I-MISC
. O-MISC O-MISC

Upon O-MISC O-MISC
antigen O-MISC O-MISC
stimulation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
, O-MISC O-MISC
marked O-MISC O-MISC
enhancement O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18Ralpha I-MISC I-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18Ralpha I-MISC I-MISC
required O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
. O-MISC O-MISC

Activated O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
expressed O-MISC O-MISC
low O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18Ralpha I-MISC I-MISC
could O-MISC O-MISC
produce O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
when O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
combination O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18 I-MISC I-MISC
, O-MISC O-MISC
while O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
which O-MISC O-MISC
expressed O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18Ralpha I-MISC I-MISC
could O-MISC O-MISC
respond O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18 I-MISC I-MISC
alone O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
stimulation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
downregulation O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18Ralpha I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
( O-MISC I-MISC
- O-MISC I-MISC
/ O-MISC I-MISC
) O-MISC I-MISC
- O-MISC I-MISC
and O-MISC I-MISC
signal O-MISC O-MISC
transducer O-MISC I-MISC
and O-MISC I-MISC
activator O-MISC I-MISC
of O-MISC I-MISC
transcription O-MISC O-MISC
( O-MISC O-MISC
Stat O-MISC B-MISC
) O-MISC O-MISC
6 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
expressed O-MISC O-MISC
higher O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18Ralpha I-MISC I-MISC
after O-MISC O-MISC
TCR O-MISC B-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
Stat6 O-MISC B-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
mice O-MISC O-MISC
produced O-MISC O-MISC
more O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18 I-MISC I-MISC
than O-MISC O-MISC
wild O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
positive O-MISC O-MISC
/ O-MISC O-MISC
negative O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18Ralpha I-MISC I-MISC
by O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
inductive O-MISC O-MISC
cytokines B-MISC B-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
) O-MISC O-MISC
determines O-MISC O-MISC
the O-MISC O-MISC
capacity O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18 I-MISC I-MISC
to O-MISC O-MISC
polarize O-MISC O-MISC
an O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
- I-MISC I-MISC
regulated I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

Glucocorticoids O-MISC O-MISC
are O-MISC O-MISC
the O-MISC O-MISC
most O-MISC O-MISC
effective O-MISC O-MISC
antiinflammatory O-MISC O-MISC
drugs O-MISC O-MISC
used O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
asthma O-MISC O-MISC
. O-MISC O-MISC

They O-MISC O-MISC
act O-MISC O-MISC
by O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC B-MISC
receptor O-MISC I-MISC
( O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
that O-MISC O-MISC
, O-MISC O-MISC
upon O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
translocates O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
and O-MISC O-MISC
either O-MISC O-MISC
increases O-MISC O-MISC
( O-MISC O-MISC
transactivates O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
decreases O-MISC O-MISC
( O-MISC O-MISC
transrepresses O-MISC O-MISC
) O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
pro B-MISC B-MISC
- I-MISC I-MISC
inflammatory I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
activator B-MISC B-MISC
protein I-MISC I-MISC
( I-MISC I-MISC
AP I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC I-MISC
signal B-MISC B-MISC
transducers I-MISC I-MISC
and I-MISC O-MISC
activators I-MISC I-MISC
of I-MISC I-MISC
transcription I-MISC I-MISC
( O-MISC O-MISC
STATs B-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
of I-MISC I-MISC
activated I-MISC I-MISC
T I-MISC I-MISC
cells I-MISC I-MISC
( O-MISC O-MISC
NFAT B-MISC B-MISC
) O-MISC I-MISC
and O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
is O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

Acetylation O-MISC O-MISC
of O-MISC O-MISC
histones B-MISC O-MISC
allows O-MISC O-MISC
unwinding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
local B-MISC O-MISC
DNA I-MISC I-MISC
structure I-MISC I-MISC
and O-MISC O-MISC
enables O-MISC I-MISC
RNA B-MISC B-MISC
polymerase I-MISC I-MISC
II I-MISC I-MISC
to O-MISC I-MISC
enhance O-MISC B-MISC
gene O-MISC O-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

Histone O-MISC O-MISC
acetylation O-MISC O-MISC
is O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
balance O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
histone B-MISC B-MISC
acetyltransferases I-MISC I-MISC
( O-MISC O-MISC
HATs B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
histone B-MISC B-MISC
deacetylases I-MISC I-MISC
( O-MISC O-MISC
HDACs B-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

GR B-MISC B-MISC
acts O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
direct O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
HAT O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
also O-MISC O-MISC
by O-MISC O-MISC
recruiting O-MISC O-MISC
HDAC2 B-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
/ I-MISC I-MISC
HAT I-MISC I-MISC
complex I-MISC I-MISC
. O-MISC O-MISC

A O-MISC O-MISC
sub O-MISC O-MISC
- O-MISC O-MISC
group O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
insensitive O-MISC O-MISC
asthma O-MISC O-MISC
have O-MISC O-MISC
an O-MISC O-MISC
inability O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
histone O-MISC B-MISC
acetylation O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
dexamethasone O-MISC O-MISC
suggesting O-MISC O-MISC
reduced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
GR B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
HAT I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
pharmacological O-MISC O-MISC
manipulation O-MISC O-MISC
of O-MISC O-MISC
specific O-MISC O-MISC
histone O-MISC O-MISC
acetylation O-MISC O-MISC
status O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
potentially O-MISC O-MISC
useful O-MISC O-MISC
approach O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
inflammatory O-MISC O-MISC
diseases O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
precise O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
activated B-MISC O-MISC
GR I-MISC B-MISC
recruits O-MISC O-MISC
HDAC2 B-MISC O-MISC
may O-MISC O-MISC
reveal O-MISC O-MISC
new O-MISC O-MISC
targets O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
drugs O-MISC O-MISC
that O-MISC O-MISC
may O-MISC O-MISC
dissociate O-MISC O-MISC
the O-MISC O-MISC
antiinflammatory O-MISC O-MISC
actions O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
from O-MISC O-MISC
their O-MISC O-MISC
side O-MISC O-MISC
effects O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
largely O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
gene O-MISC O-MISC
induction O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
Academic O-MISC O-MISC
Press O-MISC O-MISC
. O-MISC O-MISC

Differential O-MISC O-MISC
ultraviolet O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
immunomodulation O-MISC O-MISC
in O-MISC O-MISC
XPA O-MISC O-MISC
, O-MISC O-MISC
XPC O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
CSB O-MISC O-MISC
DNA O-MISC O-MISC
repair O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Ultraviolet O-MISC O-MISC
B O-MISC O-MISC
irradiation O-MISC O-MISC
has O-MISC O-MISC
serious O-MISC O-MISC
consequences O-MISC O-MISC
for O-MISC O-MISC
cellular O-MISC O-MISC
immunity O-MISC O-MISC
and O-MISC O-MISC
can O-MISC O-MISC
suppress O-MISC O-MISC
the O-MISC O-MISC
rejection O-MISC O-MISC
of O-MISC O-MISC
skin O-MISC O-MISC
tumors O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
infectious O-MISC O-MISC
diseases O-MISC O-MISC
. O-MISC O-MISC

DNA O-MISC O-MISC
damage O-MISC O-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
crucial O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
immunomodulatory O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
ultraviolet O-MISC O-MISC
B O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
impaired O-MISC O-MISC
repair O-MISC O-MISC
of O-MISC O-MISC
ultraviolet O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
DNA O-MISC O-MISC
damage O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
cause O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
cellular O-MISC O-MISC
immunity O-MISC O-MISC
. O-MISC O-MISC

Ultraviolet O-MISC O-MISC
- O-MISC O-MISC
B O-MISC I-MISC
- O-MISC I-MISC
induced O-MISC O-MISC
DNA O-MISC O-MISC
damage O-MISC O-MISC
is O-MISC O-MISC
repaired O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
nucleotide O-MISC O-MISC
excision O-MISC O-MISC
repair O-MISC O-MISC
mechanism O-MISC O-MISC
very O-MISC O-MISC
efficiently O-MISC O-MISC
. O-MISC O-MISC

Nucleotide O-MISC O-MISC
excision O-MISC O-MISC
repair O-MISC O-MISC
comprises O-MISC O-MISC
two O-MISC O-MISC
subpathways O-MISC O-MISC
: O-MISC O-MISC
transcription O-MISC O-MISC
- O-MISC O-MISC
coupled O-MISC O-MISC
and O-MISC O-MISC
global O-MISC O-MISC
genome O-MISC O-MISC
repair O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
the O-MISC O-MISC
immunologic O-MISC O-MISC
consequences O-MISC O-MISC
of O-MISC O-MISC
specific O-MISC O-MISC
nucleotide O-MISC O-MISC
excision O-MISC O-MISC
repair O-MISC O-MISC
defects O-MISC O-MISC
in O-MISC O-MISC
three O-MISC O-MISC
mouse O-MISC O-MISC
models O-MISC O-MISC
, O-MISC O-MISC
XPA O-MISC O-MISC
, O-MISC O-MISC
XPC O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
CSB O-MISC O-MISC
mutant O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
investigated O-MISC O-MISC
. O-MISC O-MISC

XPA O-MISC O-MISC
mice O-MISC O-MISC
carry O-MISC O-MISC
a O-MISC O-MISC
total O-MISC O-MISC
nucleotide O-MISC O-MISC
excision O-MISC O-MISC
repair O-MISC O-MISC
defect O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
XPC O-MISC O-MISC
and O-MISC O-MISC
CSB O-MISC O-MISC
mice O-MISC O-MISC
only O-MISC O-MISC
lack O-MISC O-MISC
global O-MISC O-MISC
genome O-MISC O-MISC
and O-MISC O-MISC
transcription O-MISC O-MISC
- O-MISC O-MISC
coupled O-MISC O-MISC
nucleotide O-MISC O-MISC
excision O-MISC O-MISC
repair O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
data O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
cellular O-MISC O-MISC
immune O-MISC O-MISC
parameters O-MISC O-MISC
in O-MISC O-MISC
XPA O-MISC O-MISC
, O-MISC O-MISC
XPC O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
CSB O-MISC O-MISC
mice O-MISC O-MISC
are O-MISC O-MISC
normal O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
their O-MISC O-MISC
wild O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
( O-MISC O-MISC
control O-MISC O-MISC
) O-MISC O-MISC
littermates O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
may O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
reported O-MISC O-MISC
altered O-MISC O-MISC
cellular O-MISC O-MISC
responses O-MISC O-MISC
in O-MISC O-MISC
xeroderma O-MISC O-MISC
pigmentosum O-MISC O-MISC
patients O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
constitutive O-MISC O-MISC
but O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
external O-MISC B-MISC
factors O-MISC I-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
ultraviolet O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC

Upon O-MISC O-MISC
exposure O-MISC O-MISC
to O-MISC O-MISC
ultraviolet O-MISC O-MISC
B O-MISC O-MISC
, O-MISC O-MISC
only O-MISC O-MISC
XPA O-MISC O-MISC
mice O-MISC O-MISC
are O-MISC O-MISC
very O-MISC O-MISC
sensitive O-MISC O-MISC
to O-MISC O-MISC
ultraviolet O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
Th1 O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
contact O-MISC O-MISC
hypersensitivity O-MISC O-MISC
responses O-MISC O-MISC
and O-MISC O-MISC
interferon B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
production O-MISC O-MISC
in O-MISC O-MISC
skin O-MISC O-MISC
draining O-MISC O-MISC
lymph O-MISC O-MISC
nodes O-MISC O-MISC
. O-MISC O-MISC

Lipopolysaccharide O-MISC O-MISC
- O-MISC I-MISC
stimulated O-MISC I-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
alpha I-MISC I-MISC
and O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
production O-MISC O-MISC
are O-MISC O-MISC
significantly O-MISC O-MISC
augmented O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
XPA O-MISC O-MISC
and O-MISC O-MISC
CSB O-MISC O-MISC
mice O-MISC O-MISC
after O-MISC O-MISC
ultraviolet O-MISC O-MISC
B O-MISC O-MISC
exposure O-MISC O-MISC
. O-MISC O-MISC

Lymph O-MISC O-MISC
node O-MISC O-MISC
cell O-MISC O-MISC
numbers O-MISC O-MISC
were O-MISC O-MISC
increased O-MISC O-MISC
very O-MISC O-MISC
significantly O-MISC O-MISC
in O-MISC O-MISC
XPA O-MISC O-MISC
, O-MISC O-MISC
mildly O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
CSB O-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
XPC O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
general O-MISC O-MISC
XPC O-MISC O-MISC
mice O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
exhibit O-MISC O-MISC
any O-MISC O-MISC
indication O-MISC O-MISC
of O-MISC O-MISC
enhanced O-MISC O-MISC
ultraviolet O-MISC O-MISC
B O-MISC O-MISC
susceptibility O-MISC O-MISC
with O-MISC O-MISC
regard O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
parameters O-MISC O-MISC
analyzed O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
both O-MISC O-MISC
global O-MISC O-MISC
genome O-MISC O-MISC
repair O-MISC O-MISC
and O-MISC O-MISC
transcription O-MISC O-MISC
- O-MISC O-MISC
coupled O-MISC O-MISC
repair O-MISC O-MISC
are O-MISC O-MISC
needed O-MISC O-MISC
to O-MISC O-MISC
prevent O-MISC O-MISC
immunomodulation O-MISC O-MISC
by O-MISC O-MISC
ultraviolet O-MISC O-MISC
B O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
transcription O-MISC O-MISC
- O-MISC O-MISC
coupled O-MISC O-MISC
repair O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
DNA O-MISC O-MISC
repair O-MISC O-MISC
subpathway O-MISC O-MISC
of O-MISC O-MISC
nucleotide O-MISC O-MISC
excision O-MISC O-MISC
repair O-MISC O-MISC
that O-MISC O-MISC
prevents O-MISC O-MISC
the O-MISC O-MISC
acute O-MISC O-MISC
ultraviolet O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
effects O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
erythema O-MISC O-MISC
. O-MISC O-MISC

Biomechanical O-MISC O-MISC
strain O-MISC O-MISC
induces O-MISC O-MISC
class O-MISC O-MISC
a O-MISC O-MISC
scavenger B-MISC B-MISC
receptor I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocyte O-MISC O-MISC
/ O-MISC O-MISC
macrophages O-MISC O-MISC
and O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
: O-MISC O-MISC
a O-MISC O-MISC
potential O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
increased O-MISC O-MISC
atherosclerosis O-MISC O-MISC
in O-MISC O-MISC
hypertension O-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
Although O-MISC O-MISC
hypertension O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
risk O-MISC O-MISC
factor O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
atherosclerosis O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
for O-MISC O-MISC
this O-MISC O-MISC
interaction O-MISC O-MISC
are O-MISC O-MISC
incompletely O-MISC O-MISC
described O-MISC O-MISC
. O-MISC O-MISC

Previous O-MISC O-MISC
studies O-MISC O-MISC
have O-MISC O-MISC
suggested O-MISC O-MISC
that O-MISC O-MISC
biomechanical O-MISC O-MISC
strain O-MISC O-MISC
regulates O-MISC O-MISC
macrophage O-MISC O-MISC
phenotype O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
tested O-MISC O-MISC
the O-MISC O-MISC
hypothesis O-MISC O-MISC
that O-MISC O-MISC
biomechanical O-MISC O-MISC
strain O-MISC O-MISC
can O-MISC O-MISC
induce O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
class B-MISC B-MISC
A I-MISC I-MISC
scavenger I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
SRA B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
lipoprotein B-MISC B-MISC
receptor I-MISC I-MISC
in O-MISC O-MISC
atherogenesis O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
AND O-MISC O-MISC
RESULTS O-MISC O-MISC
: O-MISC O-MISC
Human O-MISC O-MISC
monocyte O-MISC O-MISC
/ O-MISC O-MISC
macrophages O-MISC O-MISC
or O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
cultured O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
device O-MISC O-MISC
that O-MISC O-MISC
imposes O-MISC O-MISC
uniform O-MISC O-MISC
biaxial O-MISC O-MISC
cyclic O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
Hz O-MISC O-MISC
strains O-MISC O-MISC
of O-MISC O-MISC
0 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
1 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
3 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
SRA B-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
analyzed O-MISC O-MISC
. O-MISC O-MISC

Mechanical O-MISC O-MISC
strains O-MISC O-MISC
induced O-MISC O-MISC
SRA B-MISC B-MISC
mRNA I-MISC I-MISC
( O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
at O-MISC O-MISC
3 O-MISC O-MISC
% O-MISC O-MISC
strain O-MISC O-MISC
for O-MISC O-MISC
48 O-MISC O-MISC
hours O-MISC O-MISC
, O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
SRA B-MISC B-MISC
protein I-MISC I-MISC
in O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
an O-MISC O-MISC
amplitude O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
induction O-MISC O-MISC
was O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
augmented O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
class B-MISC B-MISC
B I-MISC I-MISC
scavenger I-MISC I-MISC
receptor I-MISC I-MISC
CD36 I-MISC B-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
, O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
) O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
by O-MISC O-MISC
increased O-MISC O-MISC
peroxisome B-MISC O-MISC
proliferator I-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
receptor I-MISC I-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
evaluate O-MISC O-MISC
this O-MISC O-MISC
effect O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
, O-MISC O-MISC
apolipoprotein O-MISC O-MISC
E O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
were O-MISC O-MISC
randomly O-MISC O-MISC
assigned O-MISC O-MISC
to O-MISC O-MISC
receive O-MISC O-MISC
standard O-MISC O-MISC
chow O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
cholesterol O-MISC O-MISC
diet O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
cholesterol O-MISC O-MISC
diet O-MISC O-MISC
with O-MISC O-MISC
hypertension O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
angiotensin O-MISC O-MISC
II O-MISC I-MISC
infusion O-MISC O-MISC
for O-MISC O-MISC
8 O-MISC O-MISC
weeks O-MISC O-MISC
. O-MISC O-MISC

Immunohistochemistry O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
among O-MISC O-MISC
macrophages O-MISC O-MISC
in O-MISC O-MISC
atherosclerotic O-MISC O-MISC
lesions O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
aorta O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
proportion O-MISC O-MISC
of O-MISC O-MISC
macrophages O-MISC O-MISC
with O-MISC O-MISC
SRA B-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
highest O-MISC O-MISC
in O-MISC O-MISC
hypertensive O-MISC O-MISC
animals O-MISC O-MISC
on O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
cholesterol O-MISC O-MISC
diet O-MISC O-MISC
( O-MISC O-MISC
43 O-MISC O-MISC
. O-MISC O-MISC
9 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
versus O-MISC O-MISC
12 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
% O-MISC O-MISC
for O-MISC O-MISC
normotensive O-MISC O-MISC
animals O-MISC O-MISC
on O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
cholesterol O-MISC O-MISC
diet O-MISC O-MISC
and O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
% O-MISC O-MISC
for O-MISC O-MISC
animals O-MISC O-MISC
on O-MISC O-MISC
standard O-MISC O-MISC
chow O-MISC O-MISC
; O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
Biomechanical O-MISC O-MISC
strain O-MISC O-MISC
induces O-MISC O-MISC
SRA B-MISC O-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
monocyte O-MISC O-MISC
/ O-MISC O-MISC
macrophages O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
promotion O-MISC O-MISC
of O-MISC O-MISC
atherosclerosis O-MISC O-MISC
in O-MISC O-MISC
hypertensive O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

High O-MISC O-MISC
glucose O-MISC O-MISC
induces O-MISC O-MISC
MCP O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
expression O-MISC O-MISC
partly O-MISC O-MISC
via O-MISC O-MISC
tyrosine O-MISC B-MISC
kinase O-MISC I-MISC
- O-MISC I-MISC
AP O-MISC I-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
pathway O-MISC O-MISC
in O-MISC O-MISC
peritoneal O-MISC O-MISC
mesothelial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
High O-MISC O-MISC
glucose O-MISC O-MISC
in O-MISC O-MISC
peritoneal O-MISC O-MISC
dialysis O-MISC O-MISC
solutions O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
implicated O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
peritoneal O-MISC O-MISC
fibrosis O-MISC O-MISC
in O-MISC O-MISC
chronic O-MISC O-MISC
ambulatory O-MISC O-MISC
peritoneal O-MISC O-MISC
dialysis O-MISC O-MISC
( O-MISC O-MISC
CAPD O-MISC O-MISC
) O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
very O-MISC O-MISC
clear O-MISC O-MISC
. O-MISC O-MISC

Peritoneal O-MISC O-MISC
macrophages O-MISC O-MISC
seem O-MISC O-MISC
to O-MISC O-MISC
participate O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
process O-MISC O-MISC
of O-MISC O-MISC
peritoneal O-MISC O-MISC
fibrosis O-MISC O-MISC
and O-MISC O-MISC
monocyte B-MISC B-MISC
chemoattractant I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
key O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
recruitment O-MISC O-MISC
of O-MISC O-MISC
monocytes O-MISC O-MISC
toward O-MISC O-MISC
the O-MISC O-MISC
peritoneal O-MISC O-MISC
cavity O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
little O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
about O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC B-MISC
on O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
pathway O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
peritoneal O-MISC O-MISC
mesothelial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Mesothelial O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
cultured O-MISC O-MISC
with O-MISC O-MISC
glucose O-MISC O-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
to O-MISC O-MISC
100 O-MISC O-MISC
mmol O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
mannitol O-MISC O-MISC
chronically O-MISC O-MISC
for O-MISC O-MISC
up O-MISC O-MISC
to O-MISC O-MISC
seven O-MISC O-MISC
days O-MISC O-MISC
. O-MISC O-MISC

MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
mRNA O-MISC B-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
Northern O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
and O-MISC O-MISC
enzyme O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
immunosorbent O-MISC O-MISC
assay O-MISC O-MISC
( O-MISC O-MISC
ELISA O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Chemotactic O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
conditioned O-MISC O-MISC
culture O-MISC O-MISC
supernatant O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
chemotactic O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
examine O-MISC O-MISC
the O-MISC O-MISC
roles O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
activator B-MISC B-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
( O-MISC O-MISC
EMSA O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
performed O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Glucose O-MISC O-MISC
induced O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
time O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
. O-MISC O-MISC

MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
protein I-MISC I-MISC
in O-MISC O-MISC
cell O-MISC O-MISC
culture O-MISC O-MISC
supernant O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
increased O-MISC O-MISC
. O-MISC O-MISC

Equivalent O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
mannitol O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
significant O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

High O-MISC O-MISC
- O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
conditioned O-MISC O-MISC
supernatant O-MISC O-MISC
possessed O-MISC O-MISC
an O-MISC O-MISC
increased O-MISC O-MISC
chemotactic O-MISC O-MISC
activity O-MISC O-MISC
for O-MISC O-MISC
monocytes O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
was O-MISC O-MISC
neutralized O-MISC O-MISC
by O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
MCP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
antibody I-MISC I-MISC
. O-MISC O-MISC

EMSA O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
glucose O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
time O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
. O-MISC O-MISC

Curcumin O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
dependently O-MISC O-MISC
suppressed O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
by O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
. O-MISC O-MISC

Tyrosine O-MISC O-MISC
kinase O-MISC I-MISC
inhibitors O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
genistein O-MISC O-MISC
( O-MISC O-MISC
12 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
to O-MISC O-MISC
50 O-MISC O-MISC
micromol O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
herbimycin O-MISC O-MISC
A O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
to O-MISC O-MISC
1 O-MISC O-MISC
micromol O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
) O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
also O-MISC O-MISC
suppressed O-MISC O-MISC
the O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
: O-MISC O-MISC
High O-MISC O-MISC
glucose O-MISC O-MISC
induced O-MISC O-MISC
mesothelial O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
partly O-MISC O-MISC
via O-MISC O-MISC
the O-MISC O-MISC
tyrosine O-MISC B-MISC
kinase O-MISC I-MISC
- O-MISC I-MISC
AP B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

Signal O-MISC O-MISC
thresholds O-MISC O-MISC
and O-MISC O-MISC
modular O-MISC O-MISC
synergy O-MISC O-MISC
during O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
costimulatory O-MISC B-MISC
molecules O-MISC I-MISC
in O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
analyzed O-MISC O-MISC
intracellular O-MISC O-MISC
pathways O-MISC O-MISC
modulating O-MISC O-MISC
surface O-MISC O-MISC
densities O-MISC O-MISC
of O-MISC O-MISC
CD80 B-MISC B-MISC
and O-MISC O-MISC
CD86 B-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
activated O-MISC O-MISC
through O-MISC O-MISC
ligation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ag B-MISC B-MISC
receptor I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
adhesion B-MISC B-MISC
molecule I-MISC I-MISC
CD54 B-MISC I-MISC
. O-MISC O-MISC

Whereas O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
Ag I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
BCR B-MISC B-MISC
) O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
alone O-MISC O-MISC
stimulated O-MISC O-MISC
increased O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
CD86 B-MISC B-MISC
, O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
CD80 B-MISC B-MISC
required O-MISC O-MISC
dual O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
IgM I-MISC I-MISC
and O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD54 I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
principal O-MISC O-MISC
downstream O-MISC O-MISC
component O-MISC O-MISC
contributed O-MISC O-MISC
by O-MISC O-MISC
BCR B-MISC B-MISC
signaling O-MISC O-MISC
, O-MISC O-MISC
toward O-MISC O-MISC
both O-MISC O-MISC
CD80 B-MISC B-MISC
and O-MISC O-MISC
CD86 B-MISC B-MISC
induction O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
the O-MISC O-MISC
elevated O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
free O-MISC O-MISC
cytoplasmic O-MISC O-MISC
Ca O-MISC I-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
recruited O-MISC O-MISC
by O-MISC O-MISC
way O-MISC O-MISC
of O-MISC O-MISC
capacitative O-MISC O-MISC
influx O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
alone O-MISC O-MISC
was O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
generate O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
CD86 B-MISC B-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
CD80 B-MISC B-MISC
enhancement O-MISC I-MISC
required O-MISC O-MISC
the O-MISC O-MISC
concerted O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
intracellular O-MISC O-MISC
Ca O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
concentration O-MISC O-MISC
and O-MISC O-MISC
CD54 O-MISC O-MISC
- O-MISC O-MISC
initiated O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
nexus O-MISC O-MISC
between O-MISC O-MISC
anti O-MISC B-MISC
- O-MISC I-MISC
IgM O-MISC I-MISC
and O-MISC O-MISC
anti O-MISC B-MISC
- O-MISC I-MISC
CD54 O-MISC I-MISC
stimulation O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
context O-MISC O-MISC
of O-MISC O-MISC
CD80 B-MISC B-MISC
regulation O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
to O-MISC O-MISC
involve O-MISC O-MISC
a O-MISC O-MISC
self O-MISC O-MISC
- O-MISC O-MISC
propagating O-MISC O-MISC
process O-MISC O-MISC
of O-MISC O-MISC
sequential O-MISC O-MISC
synergy O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
first O-MISC O-MISC
step O-MISC O-MISC
involved O-MISC O-MISC
amplified O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
intracellular O-MISC O-MISC
cAMP O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
result O-MISC O-MISC
of O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
talk O-MISC O-MISC
between O-MISC O-MISC
BCR B-MISC B-MISC
- O-MISC O-MISC
mobilized O-MISC O-MISC
Ca O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
CD54 O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
signals O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
then O-MISC O-MISC
facilitated O-MISC O-MISC
a O-MISC O-MISC
second O-MISC O-MISC
synergistic O-MISC O-MISC
interaction O-MISC O-MISC
between O-MISC O-MISC
Ca O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
cAMP O-MISC O-MISC
, O-MISC O-MISC
culminating O-MISC O-MISC
in O-MISC O-MISC
CD80 B-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
findings O-MISC O-MISC
of O-MISC O-MISC
distinct O-MISC O-MISC
signal O-MISC B-MISC
transducer O-MISC I-MISC
requirements O-MISC I-MISC
, O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
added O-MISC O-MISC
consequences O-MISC O-MISC
of O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
talk O-MISC O-MISC
, O-MISC O-MISC
offers O-MISC O-MISC
an O-MISC O-MISC
explanation O-MISC O-MISC
for O-MISC O-MISC
variable O-MISC O-MISC
modulation O-MISC O-MISC
of O-MISC O-MISC
costimulatory O-MISC B-MISC
molecule O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
diverse O-MISC O-MISC
physiological O-MISC O-MISC
stimuli O-MISC O-MISC
. O-MISC O-MISC

Importantly O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
results O-MISC O-MISC
also O-MISC O-MISC
reveal O-MISC O-MISC
how O-MISC O-MISC
concentration O-MISC O-MISC
threshold O-MISC O-MISC
barriers O-MISC O-MISC
for O-MISC O-MISC
recruitment O-MISC O-MISC
of O-MISC O-MISC
individual O-MISC O-MISC
second O-MISC O-MISC
messengers O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
overcome O-MISC O-MISC
by O-MISC O-MISC
constructive O-MISC O-MISC
convergence O-MISC O-MISC
of O-MISC O-MISC
signaling O-MISC O-MISC
modules O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
in O-MISC O-MISC
neoplastic O-MISC O-MISC
transformation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
review O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
focus O-MISC O-MISC
on O-MISC O-MISC
new O-MISC O-MISC
data O-MISC O-MISC
from O-MISC O-MISC
basic O-MISC O-MISC
, O-MISC O-MISC
translational O-MISC O-MISC
and O-MISC O-MISC
clinical O-MISC O-MISC
research O-MISC O-MISC
relating O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
EBV O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Beside O-MISC O-MISC
its O-MISC O-MISC
well O-MISC O-MISC
- O-MISC O-MISC
known O-MISC O-MISC
tropism O-MISC O-MISC
for O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
EBV O-MISC O-MISC
also O-MISC O-MISC
infects O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
granulocytes O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
primary O-MISC O-MISC
infection O-MISC O-MISC
, O-MISC O-MISC
EBV O-MISC O-MISC
persists O-MISC O-MISC
throughout O-MISC O-MISC
the O-MISC O-MISC
life O-MISC O-MISC
span O-MISC O-MISC
in O-MISC O-MISC
resting O-MISC O-MISC
memory O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
from O-MISC O-MISC
where O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
reactivated O-MISC O-MISC
upon O-MISC O-MISC
breakdown O-MISC O-MISC
of O-MISC O-MISC
cellular O-MISC O-MISC
immunity O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
process O-MISC O-MISC
of O-MISC O-MISC
neoplastic O-MISC O-MISC
transformation O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
EBV B-MISC B-MISC
- I-MISC I-MISC
encoded I-MISC I-MISC
latent I-MISC I-MISC
membrane I-MISC I-MISC
protein I-MISC I-MISC
1 I-MISC I-MISC
( I-MISC O-MISC
LMP1 I-MISC B-MISC
) I-MISC O-MISC
oncogene I-MISC O-MISC
represents O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
driving O-MISC O-MISC
force O-MISC O-MISC
. O-MISC O-MISC

LMP1 B-MISC B-MISC
acts O-MISC O-MISC
like O-MISC O-MISC
a O-MISC O-MISC
constitutively B-MISC O-MISC
activated I-MISC O-MISC
receptor I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
receptor I-MISC I-MISC
family I-MISC I-MISC
and O-MISC O-MISC
allows O-MISC O-MISC
the O-MISC O-MISC
amplification O-MISC O-MISC
or O-MISC O-MISC
bypassing O-MISC O-MISC
of O-MISC O-MISC
physiological O-MISC O-MISC
regulatory O-MISC O-MISC
signals O-MISC O-MISC
through O-MISC O-MISC
direct O-MISC O-MISC
and O-MISC O-MISC
indirect O-MISC O-MISC
interactions O-MISC O-MISC
with O-MISC O-MISC
proteins O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
receptor I-MISC I-MISC
- I-MISC I-MISC
associated I-MISC I-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
TRAF I-MISC I-MISC
) I-MISC I-MISC
family I-MISC I-MISC
. O-MISC O-MISC

TRAF2 B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
induction O-MISC O-MISC
and O-MISC O-MISC
JAK3 B-MISC B-MISC
/ O-MISC I-MISC
STAT B-MISC I-MISC
activation O-MISC O-MISC
may O-MISC O-MISC
result O-MISC O-MISC
in O-MISC O-MISC
sustained O-MISC O-MISC
proliferation O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
lymphoma O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
LMP1 B-MISC B-MISC
to O-MISC O-MISC
suppress O-MISC O-MISC
germinal O-MISC O-MISC
center O-MISC O-MISC
formation O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
capacity O-MISC O-MISC
to O-MISC O-MISC
mediate O-MISC O-MISC
its O-MISC O-MISC
own O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
shed O-MISC O-MISC
new O-MISC O-MISC
light O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
latency O-MISC O-MISC
type O-MISC O-MISC
II O-MISC O-MISC
lymphoproliferations O-MISC O-MISC
like O-MISC O-MISC
Hodgkin O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
disease O-MISC O-MISC
and O-MISC O-MISC
angioimmunoblastic O-MISC O-MISC
lymphadenopathy O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
carboxy B-MISC B-MISC
terminus I-MISC I-MISC
of O-MISC O-MISC
LMP1 B-MISC B-MISC
is O-MISC O-MISC
also O-MISC O-MISC
a O-MISC O-MISC
reliable O-MISC O-MISC
marker O-MISC O-MISC
for O-MISC O-MISC
individual O-MISC O-MISC
EBV O-MISC O-MISC
strain O-MISC O-MISC
identification O-MISC O-MISC
and O-MISC O-MISC
thus O-MISC O-MISC
offers O-MISC O-MISC
new O-MISC O-MISC
possibilities O-MISC O-MISC
in O-MISC O-MISC
tracing O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
events O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
posttransplant O-MISC O-MISC
lymphoproliferative O-MISC O-MISC
disorders O-MISC O-MISC
( O-MISC O-MISC
PTLDs O-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Cytotoxic O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
directed O-MISC O-MISC
against O-MISC O-MISC
well O-MISC O-MISC
- O-MISC O-MISC
characterized O-MISC O-MISC
epitopes O-MISC O-MISC
of O-MISC O-MISC
EBV B-MISC O-MISC
latency I-MISC O-MISC
genes I-MISC O-MISC
represent O-MISC O-MISC
an O-MISC O-MISC
already O-MISC O-MISC
successful O-MISC O-MISC
and O-MISC O-MISC
promising O-MISC O-MISC
therapeutic O-MISC O-MISC
approach O-MISC O-MISC
to O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
lymphomas O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
particular O-MISC O-MISC
PTLDs O-MISC O-MISC

Interferon B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
drives O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
immunopathology O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
intestine O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
interferon B-MISC B-MISC
( I-MISC I-MISC
IFN I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
autoimmunity O-MISC O-MISC
and O-MISC O-MISC
exacerbate O-MISC O-MISC
Th1 O-MISC O-MISC
diseases O-MISC O-MISC
is O-MISC O-MISC
well O-MISC O-MISC
known O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
recently O-MISC O-MISC
described O-MISC O-MISC
enhanced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
mucosa O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
celiac O-MISC O-MISC
disease O-MISC O-MISC
( O-MISC O-MISC
CD O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
gluten O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
Th1 O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
enteropathy O-MISC O-MISC
, O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
villous O-MISC O-MISC
atrophy O-MISC O-MISC
and O-MISC O-MISC
crypt O-MISC O-MISC
cell O-MISC O-MISC
hyperplasia O-MISC O-MISC
. O-MISC O-MISC

Previous O-MISC O-MISC
studies O-MISC O-MISC
from O-MISC O-MISC
this O-MISC O-MISC
laboratory O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
explant O-MISC O-MISC
cultures O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
fetal O-MISC O-MISC
gut O-MISC O-MISC
can O-MISC O-MISC
also O-MISC O-MISC
result O-MISC O-MISC
in O-MISC O-MISC
villous O-MISC O-MISC
atrophy O-MISC O-MISC
and O-MISC O-MISC
crypt O-MISC O-MISC
cell O-MISC O-MISC
hyperplasia O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
, O-MISC O-MISC
therefore O-MISC O-MISC
, O-MISC O-MISC
examined O-MISC O-MISC
changes O-MISC O-MISC
that O-MISC O-MISC
take O-MISC O-MISC
place O-MISC O-MISC
in O-MISC O-MISC
explant O-MISC O-MISC
cultures O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
fetal O-MISC O-MISC
gut O-MISC O-MISC
after O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
anti B-MISC O-MISC
- I-MISC O-MISC
CD3 I-MISC O-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
alone O-MISC O-MISC
elicits O-MISC O-MISC
a O-MISC O-MISC
small O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
response O-MISC O-MISC
with O-MISC O-MISC
no O-MISC O-MISC
tissue O-MISC O-MISC
injury O-MISC O-MISC
. O-MISC O-MISC

Similarly O-MISC O-MISC
, O-MISC O-MISC
no O-MISC O-MISC
changes O-MISC O-MISC
are O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
explants O-MISC O-MISC
cultured O-MISC O-MISC
with O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
alone O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
with O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
results O-MISC O-MISC
in O-MISC O-MISC
enhanced O-MISC O-MISC
Th1 O-MISC O-MISC
response O-MISC O-MISC
and O-MISC O-MISC
crypt O-MISC O-MISC
cell O-MISC O-MISC
hyperplasia O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
enhanced O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
STAT1 B-MISC B-MISC
, O-MISC O-MISC
STAT3 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Fyn B-MISC B-MISC
, I-MISC O-MISC
a I-MISC O-MISC
Src I-MISC B-MISC
homology I-MISC I-MISC
tyrosine I-MISC I-MISC
kinase I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
interacts O-MISC O-MISC
with O-MISC O-MISC
both O-MISC O-MISC
TCR O-MISC B-MISC
and O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
alpha O-MISC B-MISC
signal O-MISC O-MISC
components O-MISC O-MISC
. O-MISC O-MISC

Together O-MISC O-MISC
these O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
can O-MISC O-MISC
facilitate O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Th1 O-MISC O-MISC
- O-MISC O-MISC
reactive O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
gut O-MISC O-MISC
and O-MISC O-MISC
drive O-MISC O-MISC
immunopathology O-MISC O-MISC
. O-MISC O-MISC

Suppression O-MISC O-MISC
of O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
alpha I-MISC I-MISC
production O-MISC O-MISC
by O-MISC O-MISC
cAMP O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
: O-MISC O-MISC
dissociation O-MISC O-MISC
with O-MISC O-MISC
mRNA O-MISC O-MISC
level O-MISC O-MISC
and O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
Elevation O-MISC O-MISC
of O-MISC O-MISC
cellular O-MISC O-MISC
cAMP O-MISC O-MISC
inhibits O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
( O-MISC O-MISC
LPS O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
production O-MISC O-MISC
and O-MISC O-MISC
increases O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
in O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
gene I-MISC O-MISC
expression O-MISC O-MISC
obligates O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
kappaB I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Exogenous O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
inhibits O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
thus O-MISC O-MISC
attenuates O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
production O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
endogenous O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
production O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
by O-MISC O-MISC
cAMP O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Human O-MISC O-MISC
monocytes O-MISC O-MISC
were O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
Escherichia O-MISC O-MISC
coli O-MISC O-MISC
LPS O-MISC O-MISC
( O-MISC O-MISC
100 O-MISC O-MISC
ng O-MISC O-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
) O-MISC O-MISC
with O-MISC O-MISC
and O-MISC O-MISC
without O-MISC O-MISC
forskolin O-MISC O-MISC
( O-MISC O-MISC
FSK O-MISC O-MISC
, O-MISC O-MISC
50 O-MISC O-MISC
microM O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
dibutyryl O-MISC O-MISC
cyclic O-MISC O-MISC
AMP O-MISC O-MISC
( O-MISC O-MISC
dbcAMP O-MISC O-MISC
, O-MISC O-MISC
100 O-MISC O-MISC
microM O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Cytokine B-MISC B-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
) O-MISC O-MISC
release O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
immunoassay O-MISC O-MISC
. O-MISC O-MISC

TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
mRNA I-MISC I-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
reverse O-MISC O-MISC
transcription O-MISC O-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
gel O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
cAMP O-MISC O-MISC
- O-MISC O-MISC
elevating O-MISC O-MISC
agents O-MISC O-MISC
inhibited O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
release O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
77 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
13 O-MISC O-MISC
ng O-MISC O-MISC
/ O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
LPS O-MISC O-MISC
+ O-MISC O-MISC
dbcAMP O-MISC O-MISC
and O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
68 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
19 O-MISC O-MISC
ng O-MISC O-MISC
/ O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
LPS O-MISC O-MISC
+ O-MISC O-MISC
FSK O-MISC O-MISC
, O-MISC O-MISC
both O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
05 O-MISC O-MISC
vs O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
61 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
34 O-MISC O-MISC
ng O-MISC O-MISC
/ O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
LPS O-MISC O-MISC
alone O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Conversely O-MISC O-MISC
, O-MISC O-MISC
cAMP O-MISC O-MISC
enhanced O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
release O-MISC O-MISC
( O-MISC O-MISC
100 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
21 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
pg O-MISC O-MISC
/ O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
LPS O-MISC O-MISC
+ O-MISC O-MISC
dbcAMP O-MISC O-MISC
and O-MISC O-MISC
110 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
25 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
pg O-MISC B-MISC
/ O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
LPS O-MISC O-MISC
+ O-MISC O-MISC
FSK O-MISC O-MISC
, O-MISC O-MISC
both O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
05 O-MISC O-MISC
vs O-MISC O-MISC
53 O-MISC O-MISC
. O-MISC O-MISC
3 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
12 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
pg O-MISC B-MISC
/ O-MISC I-MISC
10 O-MISC I-MISC
( O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
LPS O-MISC O-MISC
alone O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Neither O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
mRNA I-MISC I-MISC
expression O-MISC O-MISC
nor O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
stimulated O-MISC O-MISC
by O-MISC O-MISC
LPS O-MISC O-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
cAMP O-MISC O-MISC
- O-MISC O-MISC
elevating O-MISC O-MISC
agents O-MISC O-MISC
. O-MISC O-MISC

Neutralization O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
with O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC O-MISC
antibody B-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
attenuate O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
cAMP O-MISC O-MISC
- O-MISC O-MISC
elevating O-MISC O-MISC
agents O-MISC O-MISC
on O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
production O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
The O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
cAMP O-MISC O-MISC
inhibits O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
production O-MISC O-MISC
through O-MISC O-MISC
a O-MISC O-MISC
posttranscriptional O-MISC O-MISC
mechanism O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
endogenous O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
2001 O-MISC O-MISC
Academic O-MISC O-MISC
Press O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
p21 B-MISC B-MISC
( I-MISC I-MISC
CIP1 I-MISC I-MISC
/ I-MISC I-MISC
WAF1 I-MISC I-MISC
) I-MISC I-MISC
promoter I-MISC I-MISC
by O-MISC O-MISC
bone B-MISC O-MISC
morphogenetic I-MISC O-MISC
protein I-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
in O-MISC O-MISC
mouse O-MISC O-MISC
B O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

BMPs B-MISC B-MISC
exert O-MISC O-MISC
a O-MISC O-MISC
negative O-MISC O-MISC
growth O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
various O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
previously O-MISC O-MISC
reported O-MISC O-MISC
that O-MISC O-MISC
BMP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
HS O-MISC O-MISC
- O-MISC O-MISC
72 O-MISC O-MISC
mouse O-MISC O-MISC
hybridoma O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
inducing O-MISC O-MISC
p21 O-MISC B-MISC
( O-MISC O-MISC
CIP1 O-MISC B-MISC
/ O-MISC I-MISC
WAF1 O-MISC I-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
BMP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
activated O-MISC O-MISC
the O-MISC O-MISC
mouse O-MISC B-MISC
p21 B-MISC I-MISC
( I-MISC I-MISC
CIP1 I-MISC B-MISC
/ I-MISC I-MISC
WAF1 I-MISC I-MISC
) I-MISC I-MISC
promoter I-MISC I-MISC
in O-MISC O-MISC
HS O-MISC O-MISC
- O-MISC O-MISC
72 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
29 B-MISC B-MISC
- I-MISC I-MISC
base I-MISC I-MISC
pair I-MISC I-MISC
( I-MISC I-MISC
b I-MISC I-MISC
) I-MISC I-MISC
region I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
promoter O-MISC B-MISC
( O-MISC O-MISC
- O-MISC I-MISC
1928 O-MISC I-MISC
/ O-MISC I-MISC
- O-MISC I-MISC
1900 O-MISC I-MISC
relative O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
TATA B-MISC B-MISC
box I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
conserved O-MISC O-MISC
between O-MISC O-MISC
mice O-MISC O-MISC
and O-MISC O-MISC
humans O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
responsive O-MISC O-MISC
to O-MISC O-MISC
BMP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Smad1 B-MISC B-MISC
, O-MISC O-MISC
Smad4 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
constitutively O-MISC O-MISC
active O-MISC I-MISC
mutants O-MISC I-MISC
of O-MISC O-MISC
BMP B-MISC B-MISC
type I-MISC I-MISC
I I-MISC I-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
oligonucleotide O-MISC O-MISC
containing O-MISC O-MISC
the O-MISC O-MISC
29 B-MISC B-MISC
- I-MISC I-MISC
b I-MISC I-MISC
region I-MISC I-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
Smad4 B-MISC B-MISC
and O-MISC O-MISC
phosphorylated B-MISC O-MISC
Smad1 I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
extract O-MISC O-MISC
of O-MISC O-MISC
BMP B-MISC B-MISC
- I-MISC O-MISC
2 I-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
HS O-MISC O-MISC
- O-MISC O-MISC
72 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggested O-MISC O-MISC
that O-MISC O-MISC
BMP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
might O-MISC O-MISC
activate O-MISC O-MISC
p21 O-MISC B-MISC
( O-MISC O-MISC
CIP1 O-MISC B-MISC
/ O-MISC I-MISC
WAF1 O-MISC I-MISC
) O-MISC O-MISC
transcription O-MISC O-MISC
by O-MISC O-MISC
inducing O-MISC O-MISC
a O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
Smad4 B-MISC B-MISC
and O-MISC O-MISC
Smad1 B-MISC B-MISC
to O-MISC O-MISC
the O-MISC O-MISC
29 B-MISC B-MISC
- I-MISC I-MISC
b I-MISC I-MISC
region I-MISC I-MISC
in O-MISC O-MISC
HS O-MISC O-MISC
- O-MISC O-MISC
72 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Dendritic O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
from O-MISC O-MISC
common O-MISC O-MISC
myeloid O-MISC O-MISC
progenitors O-MISC O-MISC
. O-MISC O-MISC

Dendritic O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
DCs O-MISC O-MISC
) O-MISC O-MISC
are O-MISC O-MISC
professional O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
presenting O-MISC O-MISC
cells O-MISC O-MISC
which O-MISC O-MISC
both O-MISC O-MISC
initiate O-MISC O-MISC
adaptive O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
and O-MISC O-MISC
control O-MISC O-MISC
tolerance O-MISC O-MISC
to O-MISC O-MISC
self B-MISC B-MISC
- I-MISC I-MISC
antigens I-MISC I-MISC
. O-MISC O-MISC

It O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
suggested O-MISC O-MISC
that O-MISC O-MISC
these O-MISC O-MISC
different O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
responder O-MISC O-MISC
cells O-MISC O-MISC
depend O-MISC O-MISC
on O-MISC O-MISC
subsets O-MISC O-MISC
of O-MISC O-MISC
DCs O-MISC O-MISC
arising O-MISC O-MISC
from O-MISC O-MISC
either O-MISC O-MISC
myeloid O-MISC O-MISC
or O-MISC O-MISC
lymphoid O-MISC O-MISC
hematopoietic O-MISC O-MISC
origins O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
model O-MISC O-MISC
, O-MISC O-MISC
CD8 O-MISC B-MISC
alpha O-MISC O-MISC
+ O-MISC O-MISC
Mac O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
DCs O-MISC O-MISC
are O-MISC O-MISC
supposed O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
of O-MISC O-MISC
lymphoid O-MISC O-MISC
while O-MISC O-MISC
CD8 O-MISC B-MISC
alpha O-MISC O-MISC
- O-MISC O-MISC
Mac O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
+ O-MISC O-MISC
DCs O-MISC O-MISC
are O-MISC O-MISC
supposed O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
of O-MISC O-MISC
myeloid O-MISC O-MISC
origin O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
summarize O-MISC O-MISC
our O-MISC O-MISC
findings O-MISC O-MISC
that O-MISC O-MISC
both O-MISC O-MISC
CD8 O-MISC B-MISC
alpha O-MISC I-MISC
+ O-MISC I-MISC
and O-MISC O-MISC
CD8 O-MISC B-MISC
alpha O-MISC I-MISC
- O-MISC I-MISC
DCs O-MISC I-MISC
can O-MISC O-MISC
arise O-MISC O-MISC
from O-MISC O-MISC
clonogenic O-MISC O-MISC
common O-MISC O-MISC
myeloid O-MISC O-MISC
progenitors O-MISC O-MISC
( O-MISC O-MISC
CMPs O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
thymus O-MISC O-MISC
and O-MISC O-MISC
spleen O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
CD8 B-MISC B-MISC
alpha I-MISC I-MISC
expression O-MISC O-MISC
DCs O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
indicate O-MISC O-MISC
a O-MISC O-MISC
lymphoid O-MISC O-MISC
origin O-MISC O-MISC
and O-MISC O-MISC
differences O-MISC O-MISC
among O-MISC O-MISC
CD8 O-MISC B-MISC
alpha O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC B-MISC
alpha O-MISC I-MISC
- O-MISC I-MISC
DCs O-MISC O-MISC
might O-MISC O-MISC
rather O-MISC O-MISC
reflect O-MISC O-MISC
maturation O-MISC O-MISC
status O-MISC O-MISC
than O-MISC O-MISC
ontogeny O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
the O-MISC O-MISC
basis O-MISC O-MISC
of O-MISC O-MISC
transplantation O-MISC O-MISC
studies O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
seems O-MISC O-MISC
likely O-MISC O-MISC
that O-MISC O-MISC
most O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
DCs O-MISC O-MISC
in O-MISC O-MISC
secondary O-MISC O-MISC
lymphoid O-MISC O-MISC
organs O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
substantial O-MISC O-MISC
fraction O-MISC O-MISC
of O-MISC O-MISC
thymic O-MISC O-MISC
DCs O-MISC O-MISC
are O-MISC O-MISC
myeloid O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
. O-MISC O-MISC

Macrophage O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
Murabutide O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
suppressive O-MISC O-MISC
muramyl O-MISC O-MISC
peptide O-MISC O-MISC
derivative O-MISC O-MISC
, O-MISC O-MISC
selectively O-MISC O-MISC
activates O-MISC O-MISC
extracellular B-MISC B-MISC
signal I-MISC I-MISC
- I-MISC I-MISC
regulated I-MISC I-MISC
kinases I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC O-MISC
2 I-MISC O-MISC
, O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBPbeta I-MISC B-MISC
and O-MISC O-MISC
STAT1 B-MISC B-MISC
: O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
CD14 B-MISC B-MISC
and O-MISC I-MISC
Toll B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
receptors I-MISC I-MISC
2 I-MISC I-MISC
and I-MISC O-MISC
4 I-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
smallest O-MISC O-MISC
unit O-MISC O-MISC
of O-MISC O-MISC
bacterial O-MISC O-MISC
peptidoglycans O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
endowed O-MISC O-MISC
with O-MISC O-MISC
biological O-MISC O-MISC
activities O-MISC O-MISC
is O-MISC O-MISC
muramyl O-MISC O-MISC
dipeptide O-MISC O-MISC
( O-MISC O-MISC
MDP O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
clinically O-MISC O-MISC
acceptable O-MISC O-MISC
synthetic O-MISC O-MISC
derivative O-MISC O-MISC
of O-MISC O-MISC
MDP O-MISC O-MISC
, O-MISC O-MISC
namely O-MISC O-MISC
murabutide O-MISC O-MISC
( O-MISC O-MISC
MB O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
present O-MISC O-MISC
interesting O-MISC O-MISC
pharmacological O-MISC O-MISC
properties O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
suppress O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
replication O-MISC O-MISC
in O-MISC O-MISC
monocyte O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
macrophages O-MISC O-MISC
( O-MISC O-MISC
MDM O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
addressed O-MISC O-MISC
the O-MISC O-MISC
signaling O-MISC O-MISC
events O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
MDM O-MISC O-MISC
following O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
either O-MISC O-MISC
MB O-MISC O-MISC
or O-MISC O-MISC
the O-MISC O-MISC
potent O-MISC O-MISC
immunostimulant O-MISC O-MISC
LPS O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
also O-MISC O-MISC
examined O-MISC O-MISC
whether O-MISC O-MISC
signaling O-MISC O-MISC
by O-MISC O-MISC
muramyl O-MISC O-MISC
peptides O-MISC O-MISC
involves O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
cell B-MISC B-MISC
surface I-MISC I-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
including O-MISC O-MISC
CD14 B-MISC B-MISC
and O-MISC O-MISC
Toll B-MISC O-MISC
- I-MISC I-MISC
like I-MISC I-MISC
receptor I-MISC I-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
TLR2 B-MISC B-MISC
) O-MISC O-MISC
or O-MISC O-MISC
TLR4 B-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
signal B-MISC B-MISC
- I-MISC I-MISC
transducing I-MISC I-MISC
receptors I-MISC I-MISC
for O-MISC O-MISC
other O-MISC O-MISC
bacterial O-MISC O-MISC
cell O-MISC O-MISC
wall O-MISC O-MISC
components O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
, O-MISC O-MISC
unlike O-MISC O-MISC
LPS O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
safe O-MISC O-MISC
immunomodulator O-MISC O-MISC
MB O-MISC O-MISC
selectively O-MISC O-MISC
activates O-MISC O-MISC
extracellular B-MISC O-MISC
signal I-MISC I-MISC
- I-MISC I-MISC
regulated I-MISC I-MISC
kinases I-MISC I-MISC
( I-MISC I-MISC
Erk I-MISC B-MISC
) I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
detectable O-MISC O-MISC
Jun B-MISC B-MISC
N I-MISC I-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
JNK B-MISC B-MISC
) O-MISC O-MISC
or O-MISC O-MISC
p38 B-MISC B-MISC
mitogen I-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
kinase I-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
STAT1 B-MISC B-MISC
activation O-MISC O-MISC
but O-MISC O-MISC
weak O-MISC O-MISC
or O-MISC O-MISC
no O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT3 B-MISC B-MISC
or O-MISC O-MISC
STAT5 B-MISC B-MISC
respectively O-MISC O-MISC
, O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
MB O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
MDM O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
MonoMac6 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
observed O-MISC O-MISC
high O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBPbeta I-MISC I-MISC
and O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
but O-MISC O-MISC
weaker O-MISC O-MISC
and O-MISC O-MISC
transient O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
MB O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
truncated O-MISC O-MISC
form O-MISC I-MISC
of O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBPbeta I-MISC I-MISC
, O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
repress O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
MB O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Surprisingly O-MISC O-MISC
, O-MISC O-MISC
neither O-MISC O-MISC
MB O-MISC B-MISC
nor O-MISC O-MISC
MDP O-MISC O-MISC
were O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
transduce O-MISC O-MISC
signals O-MISC O-MISC
via O-MISC O-MISC
CD14 B-MISC B-MISC
and O-MISC O-MISC
TLR2 B-MISC B-MISC
or I-MISC O-MISC
4 I-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
present O-MISC O-MISC
major O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
early O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
process O-MISC O-MISC
between O-MISC O-MISC
LPS O-MISC O-MISC
and O-MISC O-MISC
muramyl O-MISC O-MISC
peptides O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
strongly O-MISC O-MISC
argue O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
implication O-MISC O-MISC
of O-MISC O-MISC
co B-MISC B-MISC
- I-MISC I-MISC
receptors I-MISC I-MISC
other O-MISC O-MISC
than O-MISC O-MISC
TLR2 B-MISC B-MISC
and O-MISC O-MISC
TLR4 B-MISC B-MISC
in O-MISC O-MISC
mediating O-MISC O-MISC
the O-MISC O-MISC
signaling O-MISC O-MISC
events O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
defined O-MISC O-MISC
subunits O-MISC O-MISC
of O-MISC O-MISC
bacterial O-MISC O-MISC
peptidoglycans O-MISC O-MISC
. O-MISC O-MISC

Nuclear B-MISC O-MISC
peroxisome I-MISC O-MISC
proliferator I-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
receptors I-MISC I-MISC
alpha I-MISC I-MISC
and I-MISC O-MISC
gamma I-MISC B-MISC
have O-MISC O-MISC
opposing O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
monocyte O-MISC O-MISC
chemotaxis O-MISC O-MISC
in O-MISC O-MISC
endometriosis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
peroxisome B-MISC B-MISC
proliferator I-MISC I-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
receptors I-MISC I-MISC
( I-MISC I-MISC
PPARs I-MISC I-MISC
) I-MISC I-MISC
alpha I-MISC I-MISC
and I-MISC O-MISC
gamma I-MISC I-MISC
are O-MISC O-MISC
nuclear B-MISC B-MISC
receptors I-MISC I-MISC
that O-MISC O-MISC
play O-MISC O-MISC
important O-MISC O-MISC
roles O-MISC O-MISC
in O-MISC O-MISC
inflammatory O-MISC O-MISC
diseases O-MISC O-MISC
like O-MISC O-MISC
ulcerative O-MISC O-MISC
colitis O-MISC O-MISC
and O-MISC O-MISC
arthritis O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
possible O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
PPARs B-MISC B-MISC
in O-MISC O-MISC
macrophage O-MISC O-MISC
attraction O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
peritoneal O-MISC O-MISC
cavity O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
endometriosis O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
identified O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
and I-MISC I-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
messenger O-MISC I-MISC
RNA O-MISC I-MISC
by O-MISC O-MISC
RT O-MISC B-MISC
- O-MISC O-MISC
PCR O-MISC I-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
by O-MISC O-MISC
immunoblotting O-MISC O-MISC
of O-MISC O-MISC
lysates O-MISC O-MISC
of O-MISC O-MISC
peritoneal O-MISC O-MISC
macrophages O-MISC O-MISC
and O-MISC O-MISC
monocytic O-MISC O-MISC
U937 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
immunocytochemistry O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
localized O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
and I-MISC O-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
within O-MISC O-MISC
the O-MISC O-MISC
nuclei O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
. O-MISC O-MISC

Monocyte O-MISC O-MISC
chemotactic O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
peritoneal O-MISC O-MISC
fluid O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
endometriosis O-MISC O-MISC
was O-MISC O-MISC
quantified O-MISC O-MISC
in O-MISC O-MISC
Boyden O-MISC O-MISC
chambers O-MISC O-MISC
. O-MISC O-MISC

Migration O-MISC O-MISC
of O-MISC O-MISC
U937 O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
increased O-MISC O-MISC
by O-MISC O-MISC
WY O-MISC B-MISC
14643 O-MISC O-MISC
and O-MISC O-MISC
reduced O-MISC O-MISC
by O-MISC O-MISC
rosiglitazone O-MISC O-MISC
. O-MISC O-MISC

Peritoneal O-MISC O-MISC
fluid O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
endometriosis O-MISC O-MISC
activated O-MISC O-MISC
U937 O-MISC O-MISC
cells O-MISC O-MISC
transiently O-MISC O-MISC
transfected O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
/ I-MISC I-MISC
GAL4 I-MISC I-MISC
luciferase I-MISC I-MISC
reporter I-MISC I-MISC
. O-MISC O-MISC

By O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
peritoneal O-MISC O-MISC
fluid O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
cause O-MISC O-MISC
significant O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
/ I-MISC I-MISC
GAL4 I-MISC I-MISC
constructs I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
U937 O-MISC O-MISC
cells O-MISC O-MISC
transiently O-MISC O-MISC
transfected O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
PPAR B-MISC B-MISC
response I-MISC I-MISC
element I-MISC I-MISC
luciferase I-MISC I-MISC
reporter I-MISC I-MISC
showed O-MISC O-MISC
disease O-MISC O-MISC
stage O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
when O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
peritoneal O-MISC O-MISC
fluid O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
endometriosis O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
with O-MISC O-MISC
peritoneal O-MISC O-MISC
fluid O-MISC O-MISC
from O-MISC O-MISC
healthy O-MISC O-MISC
controls O-MISC O-MISC
down O-MISC O-MISC
- O-MISC B-MISC
regulated O-MISC I-MISC
PPAR O-MISC I-MISC
response O-MISC I-MISC
element O-MISC I-MISC
transactivation O-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
peritoneal O-MISC O-MISC
fluid O-MISC O-MISC
of O-MISC O-MISC
endometriosis O-MISC O-MISC
patients O-MISC O-MISC
contains O-MISC O-MISC
activators O-MISC O-MISC
of O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
that O-MISC O-MISC
stimulate O-MISC O-MISC
macrophage O-MISC O-MISC
chemotaxis O-MISC O-MISC
. O-MISC O-MISC

Inhibitors O-MISC O-MISC
of O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
or O-MISC O-MISC
activators O-MISC O-MISC
of O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
could O-MISC O-MISC
be O-MISC O-MISC
developed O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
inflammation O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
endometriosis O-MISC O-MISC
. O-MISC O-MISC

Long O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
- O-MISC O-MISC
impaired O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
and O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
trauma O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Nuclear B-MISC B-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
dimer O-MISC O-MISC
characteristics O-MISC O-MISC
were O-MISC O-MISC
studied O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
PBMCs O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
major O-MISC O-MISC
- O-MISC O-MISC
trauma O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
healthy O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
PBMCs O-MISC O-MISC
on O-MISC O-MISC
days O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
10 O-MISC O-MISC
after O-MISC O-MISC
trauma O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
p65p50 B-MISC B-MISC
heterodimers I-MISC I-MISC
and O-MISC O-MISC
p50p50 B-MISC B-MISC
homodimers I-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
reduced O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
vitro O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
( O-MISC O-MISC
LPS O-MISC O-MISC
) O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
PBMCs O-MISC O-MISC
induced O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
translocation O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
throughout O-MISC O-MISC
the O-MISC O-MISC
survey O-MISC O-MISC
, O-MISC O-MISC
p65p50 O-MISC B-MISC
activation O-MISC O-MISC
remained O-MISC O-MISC
significantly O-MISC O-MISC
lower O-MISC O-MISC
in O-MISC O-MISC
trauma O-MISC O-MISC
patients O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
LPS O-MISC O-MISC
stimulation O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
p65p50 O-MISC B-MISC
/ O-MISC I-MISC
p50p50 O-MISC I-MISC
ratio O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
lower O-MISC O-MISC
in O-MISC O-MISC
PBMCs O-MISC O-MISC
from O-MISC O-MISC
trauma O-MISC O-MISC
patients O-MISC O-MISC
than O-MISC O-MISC
from O-MISC O-MISC
healthy O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ex O-MISC O-MISC
vivo O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
was O-MISC O-MISC
higher O-MISC O-MISC
in O-MISC O-MISC
PBMCs O-MISC O-MISC
of O-MISC O-MISC
controls O-MISC O-MISC
than O-MISC O-MISC
of O-MISC O-MISC
trauma O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

LPS O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
induce O-MISC O-MISC
I O-MISC B-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
PBMCs O-MISC O-MISC
from O-MISC O-MISC
trauma O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
strong O-MISC O-MISC
induction O-MISC O-MISC
was O-MISC O-MISC
obtained O-MISC O-MISC
with O-MISC O-MISC
staphylococci O-MISC B-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
defect O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
universal O-MISC O-MISC
and O-MISC O-MISC
depends O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
nature O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
activating O-MISC O-MISC
signal O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
no O-MISC O-MISC
direct O-MISC O-MISC
correlation O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
between O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
or O-MISC I-MISC
transforming B-MISC B-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
, O-MISC O-MISC
these O-MISC O-MISC
immunosuppressive B-MISC O-MISC
cytokines I-MISC B-MISC
were O-MISC O-MISC
significantly O-MISC O-MISC
elevated O-MISC O-MISC
in O-MISC O-MISC
trauma O-MISC O-MISC
patients O-MISC O-MISC
by O-MISC O-MISC
10 O-MISC O-MISC
days O-MISC O-MISC
after O-MISC O-MISC
admission O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
long O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
low O-MISC O-MISC
- O-MISC O-MISC
basal O-MISC O-MISC
and O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
recalled O-MISC O-MISC
long O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
immunoparalysis O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
severe O-MISC O-MISC
inflammatory O-MISC O-MISC
stress O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
trauma O-MISC O-MISC
. O-MISC O-MISC

Hepatic O-MISC B-MISC
ischemia O-MISC O-MISC
- O-MISC O-MISC
reperfusion O-MISC O-MISC
injury O-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
The O-MISC O-MISC
morbidity O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
liver O-MISC O-MISC
transplantation O-MISC O-MISC
and O-MISC O-MISC
major O-MISC O-MISC
hepatic O-MISC O-MISC
resections O-MISC O-MISC
is O-MISC O-MISC
partly O-MISC O-MISC
a O-MISC O-MISC
result O-MISC O-MISC
of O-MISC O-MISC
ischemia O-MISC O-MISC
- O-MISC O-MISC
reperfusion O-MISC O-MISC
injury O-MISC O-MISC
. O-MISC O-MISC

DATA O-MISC B-MISC
SOURCES O-MISC I-MISC
: O-MISC O-MISC
The O-MISC O-MISC
entire O-MISC O-MISC
world O-MISC O-MISC
literature O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
subject O-MISC O-MISC
was O-MISC O-MISC
searched O-MISC O-MISC
via O-MISC O-MISC
Medline O-MISC O-MISC
. O-MISC O-MISC

Keywords O-MISC O-MISC
included O-MISC O-MISC
reperfusion O-MISC O-MISC
injury O-MISC O-MISC
, O-MISC O-MISC
transplantation O-MISC O-MISC
, O-MISC O-MISC
liver O-MISC O-MISC
resection O-MISC O-MISC
, O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
, O-MISC O-MISC
endothelin O-MISC O-MISC
, O-MISC O-MISC
cytokines B-MISC B-MISC
, O-MISC O-MISC
Kupffer O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
ischemic O-MISC O-MISC
/ O-MISC O-MISC
ischaemic O-MISC O-MISC
preconditioning O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
An O-MISC O-MISC
imbalance O-MISC O-MISC
between O-MISC O-MISC
endothelin O-MISC O-MISC
and O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
levels O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
failure O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
hepatic O-MISC O-MISC
microcirculation O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
onset O-MISC O-MISC
of O-MISC O-MISC
reperfusion O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
promotes O-MISC O-MISC
proinflammatory B-MISC O-MISC
cytokine I-MISC I-MISC
and O-MISC O-MISC
adhesion B-MISC B-MISC
molecule I-MISC I-MISC
synthesis O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
result O-MISC O-MISC
in O-MISC O-MISC
oxygen O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
free O-MISC O-MISC
radical O-MISC O-MISC
production O-MISC O-MISC
and O-MISC O-MISC
neutrophil O-MISC O-MISC
recruitment O-MISC O-MISC
, O-MISC O-MISC
further O-MISC O-MISC
contributing O-MISC O-MISC
to O-MISC O-MISC
cellular O-MISC O-MISC
injury O-MISC O-MISC
. O-MISC O-MISC

Various O-MISC O-MISC
therapeutic O-MISC O-MISC
modalities O-MISC B-MISC
acting O-MISC I-MISC
on O-MISC O-MISC
the O-MISC O-MISC
above O-MISC O-MISC
mediators O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
successfully O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
attenuate O-MISC O-MISC
reperfusion O-MISC O-MISC
injury O-MISC O-MISC
in O-MISC O-MISC
animal O-MISC O-MISC
models O-MISC O-MISC
of O-MISC O-MISC
hepatic O-MISC O-MISC
transplantation O-MISC O-MISC
and O-MISC O-MISC
resection O-MISC O-MISC
. O-MISC O-MISC

Application O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
knowledge O-MISC O-MISC
gained O-MISC O-MISC
from O-MISC O-MISC
animal O-MISC O-MISC
models O-MISC O-MISC
of O-MISC O-MISC
hepatic O-MISC O-MISC
ischemia O-MISC O-MISC
- O-MISC O-MISC
reperfusion O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
clinical O-MISC O-MISC
setting O-MISC O-MISC
will O-MISC O-MISC
improve O-MISC O-MISC
the O-MISC O-MISC
outcome O-MISC O-MISC
of O-MISC O-MISC
hepatic O-MISC O-MISC
surgery O-MISC O-MISC
. O-MISC O-MISC

Down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
p40 I-MISC I-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
Plasmodium O-MISC O-MISC
berghei O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
that O-MISC O-MISC
causes O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
p40 I-MISC I-MISC
gene I-MISC I-MISC
induction O-MISC O-MISC
during O-MISC O-MISC
Plasmodium O-MISC O-MISC
berghei O-MISC O-MISC
infection O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
together O-MISC O-MISC
with O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
plays O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
protection O-MISC O-MISC
against O-MISC O-MISC
pathogenic O-MISC O-MISC
infection O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
p70 I-MISC I-MISC
protein I-MISC I-MISC
production O-MISC O-MISC
of O-MISC O-MISC
infected O-MISC O-MISC
macrophages O-MISC O-MISC
is O-MISC O-MISC
lower O-MISC O-MISC
than O-MISC O-MISC
that O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
uninfected O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
showed O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
p40 I-MISC I-MISC
gene I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
p35 I-MISC I-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
macrophages O-MISC O-MISC
of O-MISC O-MISC
P O-MISC O-MISC
. O-MISC O-MISC
berghei O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
mice O-MISC O-MISC
was O-MISC O-MISC
profoundly O-MISC O-MISC
inhibited O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
inhibition O-MISC O-MISC
was O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
macrophages O-MISC O-MISC
that O-MISC O-MISC
had O-MISC O-MISC
contacted O-MISC O-MISC
with O-MISC O-MISC
P O-MISC O-MISC
. O-MISC O-MISC
berghei O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
erythrocytes O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
soluble O-MISC B-MISC
factor O-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
. O-MISC O-MISC

There O-MISC O-MISC
was O-MISC O-MISC
comparable O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
uninfected O-MISC O-MISC
and O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
regulatory I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
gene I-MISC I-MISC
was O-MISC O-MISC
comparable O-MISC O-MISC
in O-MISC O-MISC
transcription O-MISC O-MISC
level O-MISC O-MISC
in O-MISC O-MISC
uninfected O-MISC O-MISC
and O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
unidentified O-MISC O-MISC
complex O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
regulatory I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
p40 I-MISC I-MISC
gene I-MISC I-MISC
induction O-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
regulated O-MISC O-MISC
at O-MISC O-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
gene O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Friend B-MISC O-MISC
of I-MISC O-MISC
GATA I-MISC B-MISC
proteins I-MISC I-MISC
U O-MISC O-MISC
- O-MISC O-MISC
shaped O-MISC O-MISC
, O-MISC O-MISC
FOG B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
FOG B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
function O-MISC O-MISC
as O-MISC O-MISC
negative O-MISC O-MISC
regulators O-MISC O-MISC
of O-MISC O-MISC
blood O-MISC O-MISC
, O-MISC O-MISC
heart O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
eye O-MISC O-MISC
development O-MISC O-MISC
in O-MISC O-MISC
Drosophila O-MISC O-MISC
. O-MISC O-MISC

Friend B-MISC O-MISC
of I-MISC O-MISC
GATA I-MISC B-MISC
( I-MISC I-MISC
FOG I-MISC I-MISC
) I-MISC I-MISC
proteins I-MISC I-MISC
regulate O-MISC O-MISC
GATA O-MISC B-MISC
factor O-MISC I-MISC
- O-MISC I-MISC
activated O-MISC I-MISC
gene O-MISC I-MISC
transcription O-MISC I-MISC
. O-MISC O-MISC

During O-MISC O-MISC
vertebrate O-MISC O-MISC
hematopoiesis O-MISC O-MISC
, O-MISC O-MISC
FOG B-MISC B-MISC
and I-MISC O-MISC
GATA I-MISC B-MISC
proteins I-MISC I-MISC
cooperate O-MISC O-MISC
to O-MISC O-MISC
promote O-MISC O-MISC
erythrocyte O-MISC O-MISC
and O-MISC O-MISC
megakaryocyte O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Drosophila B-MISC B-MISC
FOG I-MISC I-MISC
homologue I-MISC I-MISC
U I-MISC O-MISC
- I-MISC O-MISC
shaped I-MISC O-MISC
( O-MISC O-MISC
Ush B-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
expressed O-MISC O-MISC
similarly O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
blood O-MISC O-MISC
cell O-MISC O-MISC
anlage O-MISC O-MISC
during O-MISC O-MISC
embryogenesis O-MISC O-MISC
. O-MISC O-MISC

During O-MISC O-MISC
hematopoiesis O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
acute O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
1 O-MISC O-MISC
homologue O-MISC O-MISC
Lozenge O-MISC O-MISC
and O-MISC O-MISC
Glial O-MISC O-MISC
cells O-MISC O-MISC
missing O-MISC O-MISC
are O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
crystal O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
plasmatocytes O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
additional O-MISC O-MISC
factors O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
predicted O-MISC O-MISC
to O-MISC O-MISC
control O-MISC O-MISC
crystal O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
report O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
Ush B-MISC O-MISC
is O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
hemocyte O-MISC O-MISC
precursors O-MISC O-MISC
and O-MISC O-MISC
plasmatocytes O-MISC O-MISC
throughout O-MISC O-MISC
embryogenesis O-MISC O-MISC
and O-MISC O-MISC
larval O-MISC O-MISC
development O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
GATA B-MISC B-MISC
factor I-MISC I-MISC
Serpent I-MISC O-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
Ush B-MISC O-MISC
embryonic O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
ush O-MISC O-MISC
function O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
an O-MISC O-MISC
overproduction O-MISC O-MISC
of O-MISC O-MISC
crystal O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
forced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Ush B-MISC O-MISC
reduces O-MISC O-MISC
this O-MISC O-MISC
cell O-MISC O-MISC
population O-MISC O-MISC
. O-MISC O-MISC

Murine B-MISC B-MISC
FOG I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC O-MISC
FOG I-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
also O-MISC O-MISC
can O-MISC O-MISC
repress O-MISC O-MISC
crystal O-MISC O-MISC
cell O-MISC O-MISC
production O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
a O-MISC O-MISC
mutant O-MISC O-MISC
version O-MISC O-MISC
of O-MISC O-MISC
FOG B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
lacking O-MISC O-MISC
a O-MISC O-MISC
conserved O-MISC B-MISC
motif O-MISC I-MISC
that O-MISC O-MISC
binds O-MISC O-MISC
the O-MISC O-MISC
corepressor B-MISC B-MISC
C I-MISC I-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
fails O-MISC O-MISC
to O-MISC O-MISC
affect O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
lineage O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
GATA B-MISC B-MISC
factor I-MISC I-MISC
Pannier I-MISC B-MISC
( O-MISC O-MISC
Pnr B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
eye O-MISC O-MISC
and O-MISC O-MISC
heart O-MISC O-MISC
development O-MISC O-MISC
in O-MISC O-MISC
Drosophila O-MISC O-MISC
. O-MISC O-MISC

When O-MISC O-MISC
Ush B-MISC O-MISC
, O-MISC O-MISC
FOG B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
FOG B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
or O-MISC O-MISC
mutant B-MISC B-MISC
FOG I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
is O-MISC O-MISC
coexpressed O-MISC O-MISC
with O-MISC O-MISC
Pnr B-MISC B-MISC
during O-MISC O-MISC
these O-MISC O-MISC
developmental O-MISC O-MISC
processes O-MISC O-MISC
, O-MISC O-MISC
severe O-MISC O-MISC
eye O-MISC O-MISC
and O-MISC O-MISC
heart O-MISC O-MISC
phenotypes O-MISC O-MISC
result O-MISC O-MISC
, O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
conserved O-MISC O-MISC
negative O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
Pnr B-MISC B-MISC
function O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
fly O-MISC O-MISC
and O-MISC O-MISC
mouse O-MISC B-MISC
FOG B-MISC I-MISC
proteins I-MISC I-MISC
function O-MISC O-MISC
similarly O-MISC O-MISC
in O-MISC O-MISC
three O-MISC O-MISC
distinct O-MISC O-MISC
cellular O-MISC O-MISC
contexts O-MISC O-MISC
in O-MISC O-MISC
Drosophila O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
may O-MISC O-MISC
use O-MISC O-MISC
different O-MISC O-MISC
mechanisms O-MISC O-MISC
to O-MISC O-MISC
regulate O-MISC O-MISC
genetic O-MISC O-MISC
events O-MISC O-MISC
in O-MISC O-MISC
blood O-MISC O-MISC
vs O-MISC O-MISC
. O-MISC O-MISC
cardial O-MISC O-MISC
or O-MISC O-MISC
eye O-MISC O-MISC
cell O-MISC O-MISC
lineages O-MISC O-MISC

The O-MISC O-MISC
RING B-MISC B-MISC
finger I-MISC I-MISC
protein I-MISC I-MISC
Siah B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
regulates O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcriptional B-MISC B-MISC
coactivator I-MISC I-MISC
OBF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcriptional B-MISC B-MISC
coactivator I-MISC I-MISC
OBF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
interacts O-MISC O-MISC
with O-MISC O-MISC
Oct B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
Oct B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
octamer B-MISC B-MISC
site I-MISC I-MISC
DNA I-MISC I-MISC
, O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
critical O-MISC O-MISC
for O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
normal O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
germinal O-MISC O-MISC
centers O-MISC O-MISC
in O-MISC O-MISC
secondary O-MISC O-MISC
lymphoid O-MISC O-MISC
organs O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
identified O-MISC O-MISC
the O-MISC O-MISC
RING B-MISC B-MISC
finger I-MISC I-MISC
protein I-MISC I-MISC
Siah B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
as O-MISC O-MISC
a O-MISC O-MISC
protein O-MISC O-MISC
interacting O-MISC O-MISC
specifically O-MISC O-MISC
with O-MISC O-MISC
OBF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
interaction O-MISC O-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
C B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
part O-MISC I-MISC
of O-MISC O-MISC
Siah B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
by O-MISC O-MISC
residues O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
N B-MISC B-MISC
- I-MISC I-MISC
terminus I-MISC I-MISC
of O-MISC O-MISC
OBF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
partly O-MISC O-MISC
distinct O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
residues O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
complex O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
Oct B-MISC B-MISC
POU I-MISC I-MISC
domains I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
DNA O-MISC O-MISC
. O-MISC O-MISC

Interaction O-MISC O-MISC
between O-MISC O-MISC
Siah B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
OBF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
downregulation O-MISC O-MISC
of O-MISC O-MISC
OBF O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
protein O-MISC O-MISC
level O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
mRNA O-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
corresponding O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
octamer O-MISC B-MISC
site O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
transcription O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
ubiquitin O-MISC B-MISC
- O-MISC I-MISC
proteasome O-MISC I-MISC
pathway O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
elevated O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
OBF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
immunized O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
OBF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
protein I-MISC I-MISC
amounts O-MISC O-MISC
are O-MISC O-MISC
dramatically O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
activated O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
without O-MISC O-MISC
concomitant O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
OBF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
Siah B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
part O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
regulatory O-MISC O-MISC
loop O-MISC O-MISC
controlling O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
OBF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
protein I-MISC I-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
beta O-MISC B-MISC
- O-MISC I-MISC
catenin O-MISC I-MISC
- O-MISC I-MISC
- O-MISC I-MISC
TCF O-MISC I-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
pathway O-MISC O-MISC
ensures O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
thymocyte O-MISC O-MISC
survival O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
association O-MISC O-MISC
of O-MISC O-MISC
trans B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
T I-MISC I-MISC
cell I-MISC I-MISC
factors I-MISC I-MISC
( O-MISC O-MISC
TCFs B-MISC B-MISC
) O-MISC O-MISC
or O-MISC O-MISC
lymphoid B-MISC B-MISC
enhancer I-MISC I-MISC
factor I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
LEF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
with O-MISC O-MISC
their O-MISC O-MISC
coactivator O-MISC O-MISC
beta O-MISC I-MISC
- O-MISC I-MISC
catenin O-MISC I-MISC
mediates O-MISC O-MISC
transient O-MISC O-MISC
transcriptional O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
extracellular O-MISC O-MISC
Wnt O-MISC O-MISC
signals O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
maturation O-MISC O-MISC
depends O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
beta B-MISC B-MISC
- I-MISC I-MISC
catenin I-MISC I-MISC
- I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
in O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
domain O-MISC O-MISC
is O-MISC O-MISC
necessary O-MISC O-MISC
to O-MISC O-MISC
mediate O-MISC O-MISC
the O-MISC O-MISC
survival O-MISC O-MISC
of O-MISC O-MISC
immature O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
double O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
( O-MISC O-MISC
DP O-MISC O-MISC
) O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

Accelerated O-MISC O-MISC
spontaneous O-MISC O-MISC
thymocyte O-MISC O-MISC
death O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
correlates O-MISC O-MISC
with O-MISC O-MISC
aberrantly O-MISC O-MISC
low O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
apoptotic I-MISC I-MISC
protein I-MISC I-MISC
Bcl B-MISC I-MISC
- I-MISC I-MISC
x I-MISC I-MISC
( I-MISC O-MISC
L I-MISC B-MISC
) I-MISC O-MISC
. O-MISC O-MISC

Increasing O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
apoptotic O-MISC O-MISC
effectors O-MISC O-MISC
in O-MISC O-MISC
thymocytes O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
transgene I-MISC I-MISC
rescued O-MISC O-MISC
TCF O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
DP O-MISC O-MISC
thymocytes O-MISC O-MISC
from O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
upon O-MISC O-MISC
association O-MISC O-MISC
with O-MISC O-MISC
beta O-MISC B-MISC
- O-MISC I-MISC
catenin O-MISC I-MISC
, O-MISC O-MISC
transiently O-MISC O-MISC
ensures O-MISC O-MISC
the O-MISC O-MISC
survival O-MISC O-MISC
of O-MISC O-MISC
immature O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
enables O-MISC O-MISC
them O-MISC O-MISC
to O-MISC O-MISC
generate O-MISC O-MISC
and O-MISC O-MISC
edit O-MISC O-MISC
T B-MISC B-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
( I-MISC I-MISC
TCR I-MISC B-MISC
) I-MISC I-MISC
alpha I-MISC I-MISC
chains I-MISC I-MISC
and O-MISC O-MISC
attempt O-MISC O-MISC
TCR B-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
positive O-MISC O-MISC
selection O-MISC O-MISC
. O-MISC O-MISC

TRAIL B-MISC B-MISC
/ I-MISC I-MISC
Apo2L I-MISC I-MISC
ligand I-MISC I-MISC
selectively O-MISC O-MISC
induces O-MISC O-MISC
apoptosis O-MISC O-MISC
and O-MISC O-MISC
overcomes O-MISC O-MISC
drug O-MISC O-MISC
resistance O-MISC O-MISC
in O-MISC O-MISC
multiple O-MISC O-MISC
myeloma O-MISC O-MISC
: O-MISC O-MISC
therapeutic O-MISC O-MISC
applications O-MISC O-MISC
. O-MISC O-MISC

Multiple O-MISC O-MISC
myeloma O-MISC O-MISC
( O-MISC O-MISC
MM O-MISC O-MISC
) O-MISC O-MISC
remains O-MISC O-MISC
incurable O-MISC O-MISC
and O-MISC O-MISC
novel O-MISC O-MISC
treatments O-MISC O-MISC
are O-MISC O-MISC
urgently O-MISC O-MISC
needed O-MISC O-MISC
. O-MISC O-MISC

Preclinical O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
evaluations O-MISC O-MISC
were O-MISC O-MISC
performed O-MISC O-MISC
to O-MISC O-MISC
assess O-MISC O-MISC
the O-MISC O-MISC
potential O-MISC O-MISC
therapeutic O-MISC O-MISC
applications O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
recombinant O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
( I-MISC O-MISC
TNF I-MISC B-MISC
) I-MISC O-MISC
- I-MISC O-MISC
related I-MISC I-MISC
apoptosis I-MISC O-MISC
- I-MISC I-MISC
inducing I-MISC I-MISC
ligand I-MISC O-MISC
/ I-MISC I-MISC
Apo2 I-MISC I-MISC
ligand I-MISC I-MISC
( O-MISC O-MISC
TRAIL B-MISC B-MISC
/ I-MISC I-MISC
Apo2L I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
MM O-MISC O-MISC
. O-MISC O-MISC

TRAIL B-MISC B-MISC
/ I-MISC I-MISC
Apo2L I-MISC I-MISC
potently O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
of O-MISC O-MISC
MM O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
majority O-MISC O-MISC
of O-MISC O-MISC
MM O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
cells O-MISC O-MISC
sensitive O-MISC O-MISC
or O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
dexamethasone O-MISC O-MISC
( O-MISC O-MISC
Dex O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
doxorubicin O-MISC O-MISC
( O-MISC O-MISC
Dox O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
melphalan O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
mitoxantrone O-MISC O-MISC
. O-MISC O-MISC

TRAIL B-MISC B-MISC
/ I-MISC I-MISC
Apo2L I-MISC I-MISC
also O-MISC O-MISC
overcame O-MISC O-MISC
the O-MISC O-MISC
survival O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
6 I-MISC I-MISC
on O-MISC O-MISC
MM O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
the O-MISC O-MISC
survival O-MISC O-MISC
of O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
and O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
purified O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
healthy O-MISC O-MISC
donors O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
status O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
TRAIL B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
immunoblotting O-MISC O-MISC
and O-MISC O-MISC
flow O-MISC O-MISC
cytometry O-MISC O-MISC
) O-MISC O-MISC
could O-MISC O-MISC
not O-MISC O-MISC
predict O-MISC O-MISC
TRAIL O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
MM O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
MM O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
TRAIL B-MISC B-MISC
/ I-MISC I-MISC
Apo2L I-MISC I-MISC
was O-MISC O-MISC
confirmed O-MISC O-MISC
in O-MISC O-MISC
nu O-MISC O-MISC
/ O-MISC O-MISC
xid O-MISC O-MISC
/ O-MISC O-MISC
bg O-MISC O-MISC
mice O-MISC O-MISC
xenografted O-MISC O-MISC
with O-MISC O-MISC
human O-MISC O-MISC
MM O-MISC O-MISC
cells O-MISC O-MISC
; O-MISC O-MISC
TRAIL B-MISC O-MISC
( O-MISC O-MISC
500 O-MISC O-MISC
microg O-MISC O-MISC
intraperitoneally O-MISC O-MISC
daily O-MISC O-MISC
for O-MISC O-MISC
14 O-MISC O-MISC
days O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
well O-MISC O-MISC
tolerated O-MISC O-MISC
and O-MISC O-MISC
significantly O-MISC O-MISC
suppressed O-MISC O-MISC
the O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
plasmacytomas O-MISC O-MISC
. O-MISC O-MISC

Dox O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
TRAIL B-MISC B-MISC
receptor I-MISC I-MISC
death B-MISC I-MISC
receptor I-MISC I-MISC
5 I-MISC I-MISC
( O-MISC O-MISC
DR5 B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
synergistically O-MISC O-MISC
enhanced O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
TRAIL B-MISC B-MISC
not O-MISC O-MISC
only O-MISC O-MISC
against O-MISC O-MISC
MM O-MISC O-MISC
cells O-MISC O-MISC
sensitive O-MISC O-MISC
to O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
also O-MISC O-MISC
against O-MISC O-MISC
those O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
, O-MISC O-MISC
Dex O-MISC O-MISC
- O-MISC O-MISC
or O-MISC O-MISC
Dox O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Nuclear O-MISC B-MISC
factor O-MISC I-MISC
( O-MISC I-MISC
NF O-MISC B-MISC
) O-MISC I-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
inhibitors O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
SN50 O-MISC B-MISC
( O-MISC O-MISC
a O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
permeable O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
and O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) O-MISC O-MISC
or O-MISC O-MISC
the O-MISC O-MISC
proteasome O-MISC B-MISC
inhibitor O-MISC I-MISC
PS O-MISC I-MISC
- O-MISC I-MISC
341 O-MISC I-MISC
, O-MISC O-MISC
enhanced O-MISC O-MISC
the O-MISC O-MISC
proapoptotic O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
TRAIL B-MISC B-MISC
/ I-MISC I-MISC
Apo2L I-MISC I-MISC
against O-MISC O-MISC
TRAIL O-MISC B-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
MM O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
SN50 O-MISC O-MISC
reversed O-MISC O-MISC
the O-MISC O-MISC
TRAIL O-MISC O-MISC
resistance O-MISC O-MISC
of O-MISC O-MISC
ARH O-MISC O-MISC
- O-MISC O-MISC
77 O-MISC O-MISC
and O-MISC O-MISC
IM O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
MM O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Importantly O-MISC O-MISC
, O-MISC O-MISC
normal O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
sensitized O-MISC O-MISC
to O-MISC O-MISC
TRAIL B-MISC B-MISC
by O-MISC O-MISC
either O-MISC O-MISC
Dox O-MISC O-MISC
, O-MISC O-MISC
SN50 O-MISC B-MISC
, O-MISC O-MISC
or O-MISC O-MISC
PS O-MISC B-MISC
- O-MISC I-MISC
341 O-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
preclinical O-MISC O-MISC
studies O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
TRAIL B-MISC B-MISC
/ I-MISC I-MISC
Apo2L I-MISC I-MISC
can O-MISC O-MISC
overcome O-MISC O-MISC
conventional O-MISC O-MISC
drug O-MISC O-MISC
resistance O-MISC O-MISC
and O-MISC O-MISC
provide O-MISC O-MISC
the O-MISC O-MISC
basis O-MISC O-MISC
for O-MISC O-MISC
clinical O-MISC O-MISC
trials O-MISC O-MISC
of O-MISC O-MISC
TRAIL B-MISC B-MISC
- O-MISC O-MISC
based O-MISC O-MISC
treatment O-MISC O-MISC
regimens O-MISC O-MISC
to O-MISC O-MISC
improve O-MISC O-MISC
outcome O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
MM O-MISC O-MISC
. O-MISC O-MISC

( O-MISC O-MISC
Blood O-MISC O-MISC
. O-MISC O-MISC
2001 O-MISC O-MISC
; O-MISC O-MISC
98 O-MISC O-MISC
: O-MISC O-MISC
795 O-MISC O-MISC
- O-MISC O-MISC
804 O-MISC O-MISC
) O-MISC O-MISC

CD28 B-MISC B-MISC
costimulation O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
not O-MISC O-MISC
only O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
receptor I-MISC I-MISC
but O-MISC O-MISC
also O-MISC O-MISC
to O-MISC O-MISC
render O-MISC O-MISC
janus B-MISC B-MISC
kinases I-MISC I-MISC
/ I-MISC O-MISC
STAT4 I-MISC I-MISC
responsive O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
stimulation O-MISC O-MISC
in O-MISC O-MISC
TCR O-MISC B-MISC
- O-MISC O-MISC
triggered O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
resting O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
acquisition O-MISC O-MISC
of O-MISC O-MISC
various O-MISC O-MISC
functions O-MISC O-MISC
depends O-MISC O-MISC
on O-MISC O-MISC
whether O-MISC O-MISC
CD28 O-MISC B-MISC
costimulatory O-MISC O-MISC
signals O-MISC O-MISC
are O-MISC O-MISC
provided O-MISC O-MISC
upon O-MISC O-MISC
T O-MISC B-MISC
cell O-MISC I-MISC
receptor O-MISC I-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
how O-MISC O-MISC
CD28 O-MISC B-MISC
costimulation O-MISC O-MISC
functions O-MISC O-MISC
to O-MISC O-MISC
allow O-MISC O-MISC
TCR B-MISC B-MISC
- O-MISC O-MISC
triggered O-MISC O-MISC
resting O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
acquire O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
responsiveness O-MISC O-MISC
. O-MISC O-MISC

When O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
low O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
mAb I-MISC I-MISC
, O-MISC O-MISC
CD28 O-MISC B-MISC
costimulation O-MISC O-MISC
was O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
optimal O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12R I-MISC I-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
alone O-MISC O-MISC
induced O-MISC O-MISC
comparable O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12R I-MISC I-MISC
expression O-MISC O-MISC
to O-MISC O-MISC
those O-MISC O-MISC
induced O-MISC O-MISC
upon O-MISC O-MISC
CD28 O-MISC B-MISC
costimulation O-MISC O-MISC
. O-MISC O-MISC

Nevertheless O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
substantial O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
responsiveness O-MISC O-MISC
between O-MISC O-MISC
these O-MISC O-MISC
two O-MISC O-MISC
groups O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
: O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
anti O-MISC B-MISC
- O-MISC O-MISC
CD28 O-MISC I-MISC
- O-MISC O-MISC
costimulated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
costimulated O-MISC O-MISC
with O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD28 I-MISC I-MISC
exhibited O-MISC O-MISC
decreased O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
Janus B-MISC B-MISC
kinases I-MISC I-MISC
( O-MISC O-MISC
JAK B-MISC B-MISC
) O-MISC O-MISC
JAK2 B-MISC B-MISC
/ I-MISC I-MISC
TYK2 I-MISC I-MISC
and O-MISC O-MISC
STAT4 B-MISC B-MISC
phosphorylation O-MISC O-MISC
and O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC O-MISC
y O-MISC O-MISC
production O-MISC O-MISC
following O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Importantly O-MISC O-MISC
, O-MISC O-MISC
STAT6 O-MISC B-MISC
phosphorylation O-MISC O-MISC
following O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
stimulation O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
decreased O-MISC O-MISC
in O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
CD28 O-MISC B-MISC
- O-MISC O-MISC
uncostimulated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
resutls O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
CD28 O-MISC B-MISC
costimulation O-MISC O-MISC
not O-MISC O-MISC
only O-MISC O-MISC
contributes O-MISC O-MISC
to O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulating O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12R I-MISC I-MISC
expression O-MISC O-MISC
but O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
required O-MISC O-MISC
to O-MISC O-MISC
render O-MISC O-MISC
JAKs B-MISC B-MISC
/ I-MISC O-MISC
STAT4 I-MISC I-MISC
responsive O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Constitutively O-MISC O-MISC
activated O-MISC O-MISC
Akt B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
vital O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
survival O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
monocyte O-MISC O-MISC
- O-MISC O-MISC
differentiated O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

Role O-MISC O-MISC
of O-MISC O-MISC
Mcl B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
, O-MISC O-MISC
Bad B-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
caspase O-MISC B-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Recent O-MISC O-MISC
data O-MISC O-MISC
from O-MISC O-MISC
mice O-MISC O-MISC
deficient O-MISC O-MISC
for O-MISC O-MISC
phosphatase B-MISC B-MISC
and O-MISC O-MISC
tensin B-MISC I-MISC
homologue I-MISC I-MISC
deleted O-MISC O-MISC
from O-MISC O-MISC
chromosome B-MISC B-MISC
10 I-MISC I-MISC
or O-MISC O-MISC
src B-MISC B-MISC
homology I-MISC I-MISC
2 I-MISC I-MISC
domain I-MISC I-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
5 I-MISC B-MISC
' I-MISC I-MISC
inositol I-MISC O-MISC
phosphatase I-MISC I-MISC
, O-MISC O-MISC
phosphatases B-MISC B-MISC
that O-MISC O-MISC
negatively O-MISC O-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
phosphatidylinositol B-MISC B-MISC
3 I-MISC I-MISC
- I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
PI3K B-MISC B-MISC
) O-MISC O-MISC
pathway O-MISC O-MISC
, O-MISC O-MISC
revealed O-MISC O-MISC
an O-MISC O-MISC
increased O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
macrophages O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
animals O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
an O-MISC O-MISC
essential O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
PI3K B-MISC B-MISC
pathway O-MISC O-MISC
for O-MISC O-MISC
macro O-MISC O-MISC
- O-MISC O-MISC
phage O-MISC O-MISC
survival O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
focused O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
PI3K B-MISC B-MISC
- I-MISC I-MISC
regulated I-MISC I-MISC
serine I-MISC I-MISC
/ I-MISC I-MISC
threonine I-MISC I-MISC
kinase I-MISC I-MISC
Akt B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
modulating O-MISC O-MISC
macrophage O-MISC O-MISC
survival O-MISC O-MISC
. O-MISC O-MISC

Akt B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
was O-MISC O-MISC
constitutively O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
macrophages O-MISC O-MISC
and O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
PI3K B-MISC B-MISC
inhibitor O-MISC O-MISC
, O-MISC O-MISC
LY294002 O-MISC B-MISC
, O-MISC O-MISC
suppressed O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Akt B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
death O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
Akt B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
by O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
PI3K B-MISC B-MISC
or O-MISC O-MISC
a O-MISC O-MISC
dominant B-MISC O-MISC
negative I-MISC I-MISC
( I-MISC O-MISC
DN I-MISC B-MISC
) I-MISC I-MISC
Akt I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
mitochondrial O-MISC B-MISC
transmembrane O-MISC O-MISC
potential O-MISC O-MISC
, O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
caspases B-MISC B-MISC
- I-MISC I-MISC
9 I-MISC I-MISC
and I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
DNA O-MISC O-MISC
fragmentation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
PI3K B-MISC B-MISC
inhibition O-MISC O-MISC
were O-MISC O-MISC
reversed O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
ectopic O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
constitutively O-MISC O-MISC
activated O-MISC O-MISC
Akt B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
or O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
x I-MISC I-MISC
( I-MISC O-MISC
L I-MISC O-MISC
) I-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
PI3K B-MISC B-MISC
/ O-MISC I-MISC
Akt O-MISC I-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
pathway O-MISC O-MISC
either O-MISC O-MISC
by O-MISC O-MISC
LY294002 O-MISC B-MISC
or O-MISC O-MISC
DN B-MISC B-MISC
Akt I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
constitutive O-MISC O-MISC
or O-MISC O-MISC
inducible O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
after O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
PI3K B-MISC B-MISC
/ O-MISC I-MISC
Akt B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
pathway O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
marked O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
antiapoptotic B-MISC B-MISC
molecule I-MISC I-MISC
Mcl B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
other O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
family I-MISC I-MISC
members I-MISC I-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Mcl B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
rescued O-MISC O-MISC
macrophages O-MISC O-MISC
from O-MISC O-MISC
LY294002 O-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
death O-MISC O-MISC
. O-MISC O-MISC

Further O-MISC O-MISC
, O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
Mcl B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
by O-MISC O-MISC
antisense O-MISC O-MISC
oligonucleotides O-MISC O-MISC
, O-MISC O-MISC
also O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
macrophage O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
findings O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
constitutive O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Akt B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
regulates O-MISC O-MISC
macrophage O-MISC O-MISC
survival O-MISC O-MISC
through O-MISC O-MISC
Mcl B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
caspases B-MISC B-MISC
, O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
, O-MISC O-MISC
or O-MISC O-MISC
Bad B-MISC O-MISC
. O-MISC O-MISC

GRbeta O-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
nasal O-MISC O-MISC
polyp O-MISC O-MISC
inflammatory O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
relationship O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
intranasal O-MISC B-MISC
fluticasone O-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
Nasal O-MISC O-MISC
polyposis O-MISC O-MISC
disease O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
inflammatory O-MISC O-MISC
disorder O-MISC O-MISC
with O-MISC O-MISC
intense O-MISC O-MISC
eosinophilic O-MISC O-MISC
infiltration O-MISC O-MISC
of O-MISC O-MISC
respiratory O-MISC O-MISC
mucosa O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
often O-MISC O-MISC
difficult O-MISC O-MISC
to O-MISC O-MISC
control O-MISC O-MISC
with O-MISC O-MISC
topical O-MISC O-MISC
steroids O-MISC O-MISC
. O-MISC O-MISC

Recent O-MISC O-MISC
evidence O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
splice I-MISC I-MISC
variant I-MISC O-MISC
GRbeta B-MISC B-MISC
in O-MISC O-MISC
inflammatory O-MISC O-MISC
cells O-MISC O-MISC
might O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
steroid O-MISC O-MISC
insensitivity O-MISC O-MISC
in O-MISC O-MISC
diseases O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
asthma O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
The O-MISC O-MISC
purposes O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
investigation O-MISC O-MISC
were O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
nasal O-MISC O-MISC
polyp O-MISC O-MISC
( O-MISC O-MISC
NP O-MISC O-MISC
) O-MISC O-MISC
inflammatory O-MISC O-MISC
cells O-MISC O-MISC
overexpress O-MISC O-MISC
GRbeta B-MISC B-MISC
and O-MISC O-MISC
to O-MISC O-MISC
examine O-MISC O-MISC
whether O-MISC O-MISC
GRbeta B-MISC B-MISC
overexpression O-MISC O-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
insensitivity O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
potent O-MISC O-MISC
topical O-MISC O-MISC
steroid O-MISC O-MISC
fluticasone O-MISC O-MISC
propionate O-MISC O-MISC
( O-MISC O-MISC
FP O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Biopsies O-MISC O-MISC
were O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
10 O-MISC O-MISC
subjects O-MISC O-MISC
with O-MISC O-MISC
NPs O-MISC O-MISC
before O-MISC O-MISC
and O-MISC O-MISC
4 O-MISC O-MISC
weeks O-MISC O-MISC
after O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
intranasal O-MISC O-MISC
FP O-MISC B-MISC
. O-MISC O-MISC

Middle O-MISC O-MISC
turbinates O-MISC O-MISC
biopsies O-MISC O-MISC
from O-MISC O-MISC
6 O-MISC O-MISC
healthy O-MISC O-MISC
, O-MISC O-MISC
nonallergic O-MISC O-MISC
subjects O-MISC O-MISC
served O-MISC O-MISC
as O-MISC O-MISC
normal O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

Biopsies O-MISC O-MISC
were O-MISC O-MISC
immunostained O-MISC B-MISC
for O-MISC O-MISC
inflammatory O-MISC B-MISC
cell O-MISC I-MISC
markers O-MISC I-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
GRbeta B-MISC B-MISC
and O-MISC O-MISC
probed O-MISC O-MISC
for O-MISC O-MISC
various O-MISC O-MISC
cytokine B-MISC B-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
FP O-MISC B-MISC
was O-MISC O-MISC
examined O-MISC O-MISC
in O-MISC O-MISC
relation O-MISC O-MISC
to O-MISC O-MISC
pretreatment O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
GRbeta O-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
The O-MISC O-MISC
total O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
inflammatory O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
NPs O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
percentage O-MISC O-MISC
of O-MISC O-MISC
inflammatory O-MISC O-MISC
cells O-MISC O-MISC
expressing O-MISC O-MISC
GRbeta B-MISC B-MISC
was O-MISC O-MISC
also O-MISC O-MISC
increased O-MISC O-MISC
( O-MISC O-MISC
40 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
% O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
19 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
% O-MISC O-MISC
vs O-MISC O-MISC
16 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
% O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
P O-MISC O-MISC
= O-MISC O-MISC
. O-MISC O-MISC
009 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

GRbeta B-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
NPs O-MISC O-MISC
was O-MISC O-MISC
almost O-MISC O-MISC
exclusive O-MISC O-MISC
to O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
eosinophils O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

An O-MISC O-MISC
inverse O-MISC O-MISC
correlation O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
baseline O-MISC O-MISC
inflammatory O-MISC O-MISC
cell O-MISC O-MISC
GRbeta B-MISC B-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
reduction O-MISC O-MISC
after O-MISC O-MISC
FP O-MISC O-MISC
treatment O-MISC O-MISC
in O-MISC O-MISC
EG2 O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
eosinophils O-MISC O-MISC
, O-MISC O-MISC
CD4 O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
endothelial O-MISC O-MISC
VCAM B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
mRNA O-MISC I-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

NPs O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
FP O-MISC O-MISC
- O-MISC O-MISC
insensitive O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
in O-MISC O-MISC
terms O-MISC O-MISC
of O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
eosinophil O-MISC O-MISC
numbers O-MISC O-MISC
( O-MISC O-MISC
major B-MISC O-MISC
basic I-MISC O-MISC
protein I-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
) O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
significantly O-MISC O-MISC
greater O-MISC O-MISC
percentage O-MISC O-MISC
of O-MISC O-MISC
GRbeta O-MISC B-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
inflammatory O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
higher O-MISC O-MISC
ratio O-MISC O-MISC
of O-MISC O-MISC
GRbeta O-MISC B-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
/ O-MISC O-MISC
GRalpha O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
increased O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
GRbeta O-MISC B-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
eosinophils O-MISC O-MISC
and O-MISC O-MISC
macrophages O-MISC O-MISC
in O-MISC O-MISC
comparison O-MISC O-MISC
with O-MISC O-MISC
those O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
FP O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
. O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC

` O-MISC O-MISC
` O-MISC O-MISC
FP O-MISC O-MISC
- O-MISC O-MISC
insensitive O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
NPs O-MISC O-MISC
also O-MISC O-MISC
demonstrated O-MISC O-MISC
a O-MISC O-MISC
higher O-MISC O-MISC
percentage O-MISC O-MISC
of O-MISC O-MISC
IL O-MISC O-MISC
- O-MISC I-MISC
5 O-MISC I-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
inflammatory O-MISC O-MISC
cells O-MISC O-MISC
expressing O-MISC O-MISC
GRbeta B-MISC B-MISC
before O-MISC O-MISC
and O-MISC O-MISC
after O-MISC O-MISC
FP O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
GRbeta B-MISC B-MISC
expression O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
marker O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
insensitivity O-MISC O-MISC
in O-MISC O-MISC
NPs O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
GRbeta B-MISC B-MISC
by O-MISC O-MISC
NP O-MISC O-MISC
inflammatory O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
particularly O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
eosinophils O-MISC O-MISC
, O-MISC O-MISC
might O-MISC O-MISC
render O-MISC O-MISC
them O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
suppression O-MISC O-MISC
by O-MISC O-MISC
topical O-MISC O-MISC
steroids O-MISC O-MISC
and O-MISC O-MISC
thereby O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
persistent O-MISC O-MISC
NP O-MISC O-MISC
inflammation O-MISC O-MISC
. O-MISC O-MISC

Transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
galectin B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
( O-MISC O-MISC
eosinophil B-MISC I-MISC
Charcot I-MISC I-MISC
- I-MISC I-MISC
Leyden I-MISC I-MISC
crystal I-MISC I-MISC
protein I-MISC I-MISC
) O-MISC O-MISC
: O-MISC O-MISC
a O-MISC O-MISC
GC B-MISC B-MISC
box I-MISC I-MISC
( O-MISC O-MISC
- O-MISC O-MISC
44 O-MISC O-MISC
to O-MISC O-MISC
- O-MISC O-MISC
50 O-MISC O-MISC
) O-MISC O-MISC
controls O-MISC O-MISC
butyric O-MISC O-MISC
acid O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Galectin B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
( O-MISC O-MISC
gal B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
, O-MISC O-MISC
also O-MISC O-MISC
known O-MISC O-MISC
as O-MISC O-MISC
Charcot B-MISC B-MISC
- I-MISC I-MISC
Leyden I-MISC I-MISC
crystal I-MISC I-MISC
protein I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
galectin B-MISC B-MISC
family I-MISC I-MISC
of O-MISC O-MISC
beta B-MISC B-MISC
- I-MISC I-MISC
galactoside I-MISC I-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
expressed O-MISC O-MISC
uniquely O-MISC O-MISC
in O-MISC O-MISC
eosinophilic O-MISC O-MISC
and O-MISC O-MISC
basophilic O-MISC O-MISC
leukocytes O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
gain O-MISC O-MISC
a O-MISC O-MISC
better O-MISC O-MISC
understanding O-MISC O-MISC
of O-MISC O-MISC
galectin O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
present O-MISC O-MISC
an O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
gene O-MISC O-MISC
encoding O-MISC O-MISC
gal B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
minimal B-MISC B-MISC
promoter I-MISC I-MISC
revealed O-MISC O-MISC
nine O-MISC O-MISC
consensus B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
for O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
, O-MISC O-MISC
including O-MISC O-MISC
several O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
also O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
minimal B-MISC B-MISC
promoters I-MISC I-MISC
of O-MISC O-MISC
galectins B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, I-MISC O-MISC
and I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
gal O-MISC B-MISC
- O-MISC I-MISC
10 O-MISC I-MISC
promoter O-MISC I-MISC
activity O-MISC O-MISC
after O-MISC O-MISC
disruption O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
the O-MISC O-MISC
GC B-MISC B-MISC
box I-MISC I-MISC
( O-MISC O-MISC
- O-MISC O-MISC
44 O-MISC O-MISC
to O-MISC O-MISC
- O-MISC O-MISC
50 O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
the O-MISC O-MISC
Oct B-MISC B-MISC
site I-MISC I-MISC
( O-MISC O-MISC
- O-MISC O-MISC
255 O-MISC O-MISC
to O-MISC O-MISC
- O-MISC O-MISC
261 O-MISC O-MISC
) O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
these O-MISC O-MISC
sites O-MISC O-MISC
, O-MISC O-MISC
along O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
previously O-MISC O-MISC
characterized O-MISC O-MISC
GATA B-MISC B-MISC
and I-MISC I-MISC
EoTF I-MISC I-MISC
sites I-MISC I-MISC
, O-MISC O-MISC
are O-MISC O-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
full O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
supershift O-MISC O-MISC
analysis O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
Sp1 B-MISC B-MISC
and O-MISC O-MISC
Oct1 B-MISC B-MISC
to O-MISC O-MISC
the O-MISC O-MISC
consensus B-MISC B-MISC
GC I-MISC I-MISC
box I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
Oct B-MISC B-MISC
site I-MISC I-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

Similar O-MISC O-MISC
to O-MISC O-MISC
gal B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
gal O-MISC B-MISC
- O-MISC I-MISC
10 O-MISC I-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
butyric O-MISC O-MISC
acid O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
effect O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
lost O-MISC O-MISC
upon O-MISC O-MISC
ablation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
GC B-MISC B-MISC
box I-MISC I-MISC
. O-MISC O-MISC

Additionally O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
AML3 O-MISC B-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
consensus B-MISC B-MISC
AML I-MISC I-MISC
site I-MISC I-MISC
and O-MISC O-MISC
YY1 B-MISC B-MISC
binding I-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
Inr B-MISC O-MISC
sequence I-MISC O-MISC
, O-MISC O-MISC
both O-MISC O-MISC
elements O-MISC O-MISC
functioning O-MISC O-MISC
as O-MISC O-MISC
silencers O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
gal B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Tumour O-MISC O-MISC
- O-MISC O-MISC
stromal O-MISC O-MISC
interactions O-MISC O-MISC
. O-MISC O-MISC

Role O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
stroma O-MISC O-MISC
in O-MISC O-MISC
mammary O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

Mammary O-MISC O-MISC
development O-MISC O-MISC
depends O-MISC O-MISC
on O-MISC O-MISC
branching O-MISC O-MISC
morphogenesis O-MISC O-MISC
, O-MISC O-MISC
namely O-MISC O-MISC
the O-MISC O-MISC
bifurcation O-MISC O-MISC
and O-MISC O-MISC
extension O-MISC O-MISC
of O-MISC O-MISC
ductal O-MISC O-MISC
growth O-MISC O-MISC
points O-MISC O-MISC
( O-MISC O-MISC
end O-MISC O-MISC
buds O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
secretory O-MISC O-MISC
lobules O-MISC O-MISC
into O-MISC O-MISC
a O-MISC O-MISC
more O-MISC O-MISC
or O-MISC O-MISC
less O-MISC O-MISC
fatty O-MISC O-MISC
stroma O-MISC O-MISC
. O-MISC O-MISC

Because O-MISC O-MISC
breast O-MISC O-MISC
carcinomas O-MISC O-MISC
are O-MISC O-MISC
overwhelmingly O-MISC O-MISC
ductal O-MISC O-MISC
in O-MISC O-MISC
origin O-MISC O-MISC
, O-MISC O-MISC
this O-MISC O-MISC
review O-MISC O-MISC
focuses O-MISC O-MISC
on O-MISC O-MISC
stromal O-MISC O-MISC
influences O-MISC O-MISC
guiding O-MISC O-MISC
postnatal O-MISC O-MISC
ductal O-MISC O-MISC
development O-MISC O-MISC
and O-MISC O-MISC
there O-MISC O-MISC
is O-MISC O-MISC
only O-MISC O-MISC
the O-MISC O-MISC
briefest O-MISC O-MISC
account O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
embryonic O-MISC B-MISC
stroma O-MISC I-MISC
( O-MISC O-MISC
mesenchyme O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
stroma O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
necessary O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
endocrine O-MISC O-MISC
mammogens O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
source O-MISC O-MISC
of O-MISC O-MISC
stimulatory O-MISC O-MISC
growth O-MISC B-MISC
factors O-MISC I-MISC
is O-MISC O-MISC
described O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
importance O-MISC O-MISC
of O-MISC O-MISC
mammary O-MISC O-MISC
epithelium O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
modifications O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
periductal O-MISC O-MISC
stroma O-MISC B-MISC
is O-MISC O-MISC
emphasized O-MISC O-MISC
. O-MISC O-MISC

Evidence O-MISC O-MISC
is O-MISC O-MISC
presented O-MISC O-MISC
that O-MISC O-MISC
if O-MISC O-MISC
they O-MISC O-MISC
are O-MISC O-MISC
to O-MISC O-MISC
grow O-MISC O-MISC
, O-MISC O-MISC
end O-MISC O-MISC
buds O-MISC O-MISC
must O-MISC O-MISC
condition O-MISC O-MISC
proximal O-MISC O-MISC
fatty O-MISC O-MISC
stroma O-MISC O-MISC
by O-MISC O-MISC
recruiting O-MISC O-MISC
white O-MISC O-MISC
blood O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
inducing O-MISC O-MISC
stromal O-MISC O-MISC
cell O-MISC O-MISC
division O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
possibly O-MISC O-MISC
, O-MISC O-MISC
estrogen B-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
fibrous O-MISC B-MISC
stromal O-MISC I-MISC
tunic O-MISC O-MISC
around O-MISC O-MISC
the O-MISC O-MISC
end O-MISC O-MISC
bud O-MISC O-MISC
is O-MISC O-MISC
described O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
likely O-MISC O-MISC
role O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
complex O-MISC B-MISC
ductal O-MISC O-MISC
morphogen O-MISC I-MISC
is O-MISC O-MISC
discussed O-MISC O-MISC
; O-MISC O-MISC
a O-MISC O-MISC
possible O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
growth O-MISC O-MISC
inhibition O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
considered O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
the O-MISC O-MISC
signals O-MISC O-MISC
governing O-MISC O-MISC
fibrotic O-MISC O-MISC
induction O-MISC O-MISC
, O-MISC O-MISC
ductal O-MISC O-MISC
morphogenesis O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
growth O-MISC O-MISC
inhibition O-MISC O-MISC
are O-MISC O-MISC
unknown O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
transforming O-MISC B-MISC
growth B-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
is O-MISC O-MISC
highly O-MISC O-MISC
likely O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
discussed O-MISC O-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
need O-MISC O-MISC
for O-MISC O-MISC
new O-MISC O-MISC
conceptual O-MISC O-MISC
and O-MISC O-MISC
experimental O-MISC O-MISC
approaches O-MISC O-MISC
to O-MISC O-MISC
understanding O-MISC O-MISC
stromal O-MISC O-MISC
- O-MISC O-MISC
epithelial O-MISC O-MISC
signaling O-MISC O-MISC
is O-MISC O-MISC
discussed O-MISC O-MISC
. O-MISC O-MISC

Adipophilin B-MISC B-MISC
is O-MISC O-MISC
a O-MISC O-MISC
sensitive O-MISC O-MISC
marker O-MISC O-MISC
for O-MISC O-MISC
lipid O-MISC O-MISC
loading O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
blood O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

Adipophilin B-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
marker O-MISC O-MISC
of O-MISC O-MISC
lipid O-MISC O-MISC
accumulation O-MISC O-MISC
initially O-MISC O-MISC
described O-MISC O-MISC
in O-MISC O-MISC
adipocytes O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
recently O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
induced O-MISC O-MISC
in O-MISC O-MISC
macrophage O-MISC O-MISC
foam O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
even O-MISC O-MISC
freshly O-MISC O-MISC
isolated O-MISC O-MISC
blood O-MISC O-MISC
monocytes O-MISC O-MISC
express O-MISC O-MISC
adipophilin B-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
adipophilin B-MISC B-MISC
protein I-MISC I-MISC
is O-MISC O-MISC
variable O-MISC O-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
from O-MISC O-MISC
different O-MISC O-MISC
healthy O-MISC O-MISC
individuals O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
physiological O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
adipophilin B-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
correlate O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
free O-MISC O-MISC
fatty O-MISC O-MISC
acids O-MISC O-MISC
, O-MISC O-MISC
cholesterylesters O-MISC O-MISC
or O-MISC O-MISC
free O-MISC O-MISC
cholesterol O-MISC O-MISC
. O-MISC O-MISC

Enzymatically B-MISC O-MISC
modified I-MISC O-MISC
low I-MISC O-MISC
- I-MISC O-MISC
density I-MISC I-MISC
lipoprotein I-MISC I-MISC
( O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
LDL I-MISC I-MISC
) O-MISC O-MISC
induces O-MISC O-MISC
rapid O-MISC O-MISC
foam O-MISC O-MISC
cell O-MISC O-MISC
formation O-MISC O-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
upregulates O-MISC O-MISC
adipophilin B-MISC O-MISC
mRNA O-MISC I-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
within O-MISC O-MISC
2 O-MISC I-MISC
h O-MISC B-MISC
of O-MISC O-MISC
incubation O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
rapid O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
adipophilin B-MISC B-MISC
is O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
increase O-MISC O-MISC
of O-MISC O-MISC
free O-MISC O-MISC
fatty O-MISC O-MISC
acids O-MISC O-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
LDL I-MISC I-MISC
. O-MISC O-MISC

Adipophilin B-MISC O-MISC
facilitates O-MISC O-MISC
the O-MISC O-MISC
uptake O-MISC O-MISC
of O-MISC O-MISC
free O-MISC O-MISC
fatty O-MISC O-MISC
acids O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
here O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
free O-MISC O-MISC
fatty O-MISC O-MISC
acids O-MISC O-MISC
increase O-MISC O-MISC
is O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
early O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
adipophilin O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
blood O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

Fatty O-MISC O-MISC
acids O-MISC O-MISC
are O-MISC O-MISC
ligands O-MISC O-MISC
for O-MISC O-MISC
peroxisome B-MISC B-MISC
proliferator I-MISC I-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
receptor I-MISC I-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
( O-MISC O-MISC
PPARgamma B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
adipophilin B-MISC B-MISC
mRNA I-MISC I-MISC
by O-MISC O-MISC
PPARgamma B-MISC B-MISC
agonists O-MISC O-MISC
like O-MISC O-MISC
15d O-MISC O-MISC
- O-MISC O-MISC
PGJ O-MISC B-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
ciglitazone O-MISC O-MISC
indicates O-MISC O-MISC
that O-MISC O-MISC
PPARgamma B-MISC B-MISC
may O-MISC O-MISC
mediate O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
adipophilin O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
blood O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

Constitutive O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
MHC B-MISC B-MISC
class I-MISC I-MISC
II I-MISC I-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
melanoma O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
results O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
class B-MISC B-MISC
II I-MISC I-MISC
transactivator I-MISC I-MISC
abnormally O-MISC O-MISC
initiated O-MISC O-MISC
from O-MISC O-MISC
its O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
melanoma O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
two O-MISC O-MISC
different O-MISC O-MISC
patterns O-MISC O-MISC
of O-MISC O-MISC
MHC O-MISC B-MISC
class O-MISC I-MISC
II O-MISC I-MISC
expression O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
described O-MISC O-MISC
, O-MISC O-MISC
either O-MISC O-MISC
an O-MISC O-MISC
IFN O-MISC B-MISC
gamma O-MISC I-MISC
- O-MISC O-MISC
inducible O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
HLA B-MISC B-MISC
- I-MISC I-MISC
DR I-MISC I-MISC
and O-MISC O-MISC
HLA B-MISC B-MISC
- I-MISC I-MISC
DP I-MISC I-MISC
, O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
faint O-MISC O-MISC
or O-MISC O-MISC
null O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
HLA B-MISC B-MISC
- I-MISC I-MISC
DQ I-MISC I-MISC
, O-MISC O-MISC
resembling O-MISC O-MISC
that O-MISC O-MISC
described O-MISC O-MISC
for O-MISC O-MISC
melanocytes O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
a O-MISC O-MISC
constitutive O-MISC O-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
independent O-MISC O-MISC
, O-MISC O-MISC
of O-MISC O-MISC
all O-MISC O-MISC
three O-MISC O-MISC
HLA B-MISC B-MISC
- I-MISC I-MISC
D I-MISC I-MISC
isotypes I-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
this O-MISC O-MISC
latter O-MISC O-MISC
phenotype O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
more O-MISC O-MISC
rapid O-MISC O-MISC
progression O-MISC O-MISC
of O-MISC O-MISC
melanoma O-MISC O-MISC
tumors O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
analyzed O-MISC O-MISC
in O-MISC O-MISC
different O-MISC O-MISC
melanoma O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
mechanisms O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
this O-MISC O-MISC
abnormal O-MISC O-MISC
pattern O-MISC O-MISC
of O-MISC O-MISC
MHC O-MISC B-MISC
class O-MISC I-MISC
II O-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
agreement O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
evidence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
coordinate O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
HLA B-MISC B-MISC
- I-MISC I-MISC
D I-MISC I-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
these O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
the O-MISC O-MISC
constitutive O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
CIITA B-MISC B-MISC
( I-MISC I-MISC
class I-MISC B-MISC
II I-MISC I-MISC
transactivator I-MISC I-MISC
) I-MISC I-MISC
transcripts I-MISC I-MISC
, O-MISC O-MISC
CIITA B-MISC B-MISC
being O-MISC O-MISC
known O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
master O-MISC O-MISC
switch O-MISC O-MISC
of O-MISC O-MISC
MHC O-MISC B-MISC
class O-MISC I-MISC
II O-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Unexpectedly O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
transcripts O-MISC O-MISC
initiate O-MISC O-MISC
from O-MISC O-MISC
promoter B-MISC B-MISC
III I-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CIITA B-MISC B-MISC
gene I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
promoter O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
mainly O-MISC O-MISC
used O-MISC O-MISC
constitutively O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
further O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
occur O-MISC O-MISC
through O-MISC O-MISC
factor O-MISC B-MISC
( O-MISC O-MISC
s O-MISC I-MISC
) O-MISC I-MISC
acting O-MISC I-MISC
on O-MISC O-MISC
the O-MISC O-MISC
enhancer O-MISC B-MISC
located O-MISC O-MISC
upstream O-MISC O-MISC
of O-MISC O-MISC
CIITA B-MISC B-MISC
promoter I-MISC I-MISC
III I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
was O-MISC O-MISC
previously O-MISC O-MISC
described O-MISC O-MISC
in O-MISC O-MISC
epithelioid O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
- O-MISC I-MISC
response O-MISC I-MISC
sequence O-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
hypothesis O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
general O-MISC O-MISC
abnormality O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
transduction O-MISC O-MISC
pathway O-MISC O-MISC
was O-MISC O-MISC
dismissed O-MISC O-MISC
. O-MISC O-MISC

Constitutive O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
CIITA B-MISC B-MISC
from O-MISC O-MISC
promoter B-MISC B-MISC
III I-MISC O-MISC
having O-MISC O-MISC
been O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
unrelated O-MISC O-MISC
melanoma O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
propose O-MISC O-MISC
the O-MISC O-MISC
hypothesis O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
phenomenon O-MISC O-MISC
might O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
random O-MISC O-MISC
event O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
neoplasic O-MISC O-MISC
state O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
melanoma O-MISC O-MISC
cells O-MISC O-MISC

Caspase B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
calcineurin O-MISC B-MISC
activation O-MISC O-MISC
contributes O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
release O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Calcineurin B-MISC B-MISC
, O-MISC O-MISC
a O-MISC O-MISC
Ca B-MISC B-MISC
( I-MISC I-MISC
2 I-MISC I-MISC
+ I-MISC I-MISC
) I-MISC I-MISC
/ I-MISC I-MISC
calmodulin I-MISC I-MISC
- I-MISC I-MISC
dependent I-MISC I-MISC
Ser I-MISC I-MISC
/ I-MISC I-MISC
Thr I-MISC I-MISC
phosphatase I-MISC I-MISC
( I-MISC O-MISC
protein I-MISC I-MISC
phosphatase I-MISC I-MISC
2B I-MISC I-MISC
) I-MISC O-MISC
, O-MISC O-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
production O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
previously O-MISC O-MISC
reported O-MISC O-MISC
that O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
release O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC B-MISC
requires O-MISC O-MISC
caspase O-MISC B-MISC
- O-MISC O-MISC
like O-MISC O-MISC
activity O-MISC O-MISC
( O-MISC O-MISC
Posmantur O-MISC O-MISC
et O-MISC O-MISC
al O-MISC O-MISC
. O-MISC O-MISC
( O-MISC O-MISC
1998 O-MISC O-MISC
) O-MISC O-MISC
Exp O-MISC O-MISC
. O-MISC O-MISC
Cell O-MISC O-MISC
. O-MISC O-MISC
Res O-MISC O-MISC
. O-MISC O-MISC
244 O-MISC O-MISC
, O-MISC O-MISC
302 O-MISC O-MISC
- O-MISC O-MISC
309 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
60 B-MISC B-MISC
- I-MISC I-MISC
kDa I-MISC I-MISC
catalytic I-MISC I-MISC
subunit I-MISC I-MISC
of O-MISC O-MISC
calcineurin B-MISC B-MISC
A I-MISC I-MISC
( O-MISC O-MISC
Cn B-MISC B-MISC
A I-MISC I-MISC
) O-MISC O-MISC
was O-MISC O-MISC
partially O-MISC O-MISC
cleaved O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
45 B-MISC B-MISC
- I-MISC I-MISC
kDa I-MISC I-MISC
form O-MISC O-MISC
in O-MISC O-MISC
phytohemagglutinin O-MISC B-MISC
A O-MISC I-MISC
( O-MISC O-MISC
PHA O-MISC B-MISC
) O-MISC O-MISC
or O-MISC O-MISC
phorbol O-MISC O-MISC
ester O-MISC O-MISC
+ O-MISC O-MISC
ionomycin O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
+ O-MISC O-MISC
I O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
activated O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
parallel O-MISC O-MISC
, O-MISC O-MISC
proteolytic O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
upstream O-MISC O-MISC
caspases B-MISC B-MISC
( O-MISC O-MISC
caspase O-MISC B-MISC
- O-MISC I-MISC
8 O-MISC I-MISC
and O-MISC O-MISC
- O-MISC I-MISC
9 O-MISC I-MISC
) O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
effector B-MISC B-MISC
caspase I-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
was O-MISC O-MISC
also O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

Cn B-MISC B-MISC
A I-MISC I-MISC
cleavage O-MISC O-MISC
was O-MISC O-MISC
caspase O-MISC B-MISC
mediated O-MISC O-MISC
, O-MISC O-MISC
since O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
inhibitable O-MISC O-MISC
by O-MISC O-MISC
pan O-MISC O-MISC
- O-MISC O-MISC
caspase O-MISC I-MISC
inhibitor O-MISC I-MISC
Cbz O-MISC B-MISC
- O-MISC I-MISC
Asp O-MISC I-MISC
- O-MISC I-MISC
CH O-MISC I-MISC
( O-MISC O-MISC
2 O-MISC I-MISC
) O-MISC O-MISC
OC O-MISC O-MISC
( O-MISC O-MISC
O O-MISC B-MISC
) O-MISC O-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
dichlorobenzene O-MISC O-MISC
( O-MISC O-MISC
Z O-MISC O-MISC
- O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
DCB O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Cn B-MISC B-MISC
A I-MISC I-MISC
cleavage O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
observed O-MISC O-MISC
when O-MISC O-MISC
purified O-MISC O-MISC
calcineurin B-MISC B-MISC
was O-MISC O-MISC
digested O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
with O-MISC O-MISC
caspase B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
. O-MISC O-MISC

Truncated B-MISC B-MISC
Cn I-MISC I-MISC
A I-MISC I-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
enhanced O-MISC O-MISC
phosphatase O-MISC B-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
reduced O-MISC O-MISC
calmodulin O-MISC B-MISC
sensitivity O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
PHA O-MISC B-MISC
or O-MISC O-MISC
P O-MISC O-MISC
+ O-MISC O-MISC
I O-MISC O-MISC
- O-MISC O-MISC
activated O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
dephosphorylation O-MISC O-MISC
of O-MISC O-MISC
calcineurin B-MISC B-MISC
substrate O-MISC I-MISC
NFATc B-MISC B-MISC
( O-MISC O-MISC
a O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
transactivation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
suppressed O-MISC O-MISC
by O-MISC O-MISC
Z O-MISC B-MISC
- O-MISC I-MISC
D O-MISC I-MISC
- O-MISC I-MISC
DCB O-MISC I-MISC
. O-MISC O-MISC

Taken O-MISC O-MISC
together O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
caspase O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
cleavage O-MISC O-MISC
of O-MISC O-MISC
Cn B-MISC B-MISC
A I-MISC I-MISC
contributes O-MISC O-MISC
to O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
production O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
2001 O-MISC O-MISC
Academic O-MISC O-MISC
Press O-MISC O-MISC
. O-MISC O-MISC

Maturation O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
sulfasalazine O-MISC O-MISC
target O-MISC O-MISC
. O-MISC O-MISC

AIM O-MISC O-MISC
: O-MISC O-MISC
Sulfasalazine O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
nonsteroidal O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
drug O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
effective O-MISC O-MISC
in O-MISC O-MISC
treating O-MISC O-MISC
some O-MISC O-MISC
autoimmune O-MISC O-MISC
diseases O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
its O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
action O-MISC O-MISC
is O-MISC O-MISC
unclear O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
possible O-MISC O-MISC
target O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
drug O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
studied O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
sulfasalazine O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
metabolites O-MISC O-MISC
, O-MISC O-MISC
aminosalicylate O-MISC O-MISC
and O-MISC O-MISC
sulfapyridine O-MISC O-MISC
, O-MISC O-MISC
on O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
maturation O-MISC O-MISC
( O-MISC O-MISC
terminal O-MISC O-MISC
differentiation O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
myeloid O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
We O-MISC O-MISC
prepared O-MISC O-MISC
immature O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
incubating O-MISC O-MISC
CD14 O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
granulocyte B-MISC B-MISC
- I-MISC I-MISC
macrophage I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
and O-MISC O-MISC
interleukin B-MISC B-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
matured O-MISC O-MISC
by O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
( I-MISC O-MISC
TNF I-MISC B-MISC
) I-MISC O-MISC
- I-MISC O-MISC
a I-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
beta I-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
prostaglandin B-MISC O-MISC
E2 I-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
sulfasalazine O-MISC O-MISC
or O-MISC O-MISC
its O-MISC O-MISC
metabolites O-MISC O-MISC
- O-MISC O-MISC
- O-MISC O-MISC
aminosalicylate O-MISC O-MISC
and O-MISC O-MISC
sulfapyridine O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
their O-MISC O-MISC
combinations O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
quantified O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
drugs O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
dendritic O-MISC O-MISC
cell O-MISC O-MISC
characteristics O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
autologous O-MISC O-MISC
and O-MISC O-MISC
allogeneic O-MISC O-MISC
pan O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
surface O-MISC O-MISC
marker O-MISC O-MISC
phenotype O-MISC O-MISC
, O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC B-MISC
12 O-MISC I-MISC
p40 O-MISC I-MISC
subunit O-MISC I-MISC
secretion O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Dendritic O-MISC O-MISC
cells O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
sulfasalazine O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
25 O-MISC O-MISC
micromol O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
or O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
micromol O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
) O-MISC O-MISC
could O-MISC O-MISC
not O-MISC O-MISC
stimulate O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
028 O-MISC O-MISC
, O-MISC O-MISC
two O-MISC O-MISC
- O-MISC O-MISC
sided O-MISC O-MISC
paired O-MISC O-MISC
t O-MISC O-MISC
- O-MISC O-MISC
test O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
distinction O-MISC O-MISC
to O-MISC O-MISC
drug O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
maturing O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
micromol O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
sulfasalazine O-MISC O-MISC
upregulated O-MISC O-MISC
the O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
CD14 B-MISC B-MISC
and O-MISC O-MISC
CD68 B-MISC B-MISC
and O-MISC O-MISC
downregulated O-MISC O-MISC
the O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
CD40 B-MISC B-MISC
, O-MISC O-MISC
CD80 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
CD83 B-MISC B-MISC
( O-MISC O-MISC
for O-MISC O-MISC
all O-MISC O-MISC
CD O-MISC B-MISC
markers O-MISC I-MISC
, O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
03 O-MISC O-MISC
for O-MISC O-MISC
difference O-MISC O-MISC
between O-MISC O-MISC
measurements O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
sulfasalazine O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

From O-MISC O-MISC
concentration O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
CD83 O-MISC B-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
an O-MISC O-MISC
apparent O-MISC O-MISC
ID50 O-MISC O-MISC
> O-MISC O-MISC
> O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
micromol O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
sulfasalazine O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
apparent O-MISC O-MISC
ID50 O-MISC O-MISC
value O-MISC O-MISC
for O-MISC O-MISC
aminosalicylate O-MISC O-MISC
- O-MISC O-MISC
inhibited O-MISC O-MISC
maturation O-MISC O-MISC
was O-MISC O-MISC
4 O-MISC O-MISC
micromol O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
. O-MISC O-MISC

Sulfapyridine O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
25 O-MISC O-MISC
micromol O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
, O-MISC O-MISC
sulfasalazine O-MISC O-MISC
largely O-MISC O-MISC
inhibited O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kB O-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
Maturing O-MISC O-MISC
human O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
hundred O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
more O-MISC O-MISC
sensitive O-MISC O-MISC
to O-MISC O-MISC
sulfasalazine O-MISC O-MISC
than O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
most O-MISC O-MISC
sensitive O-MISC O-MISC
human O-MISC O-MISC
cells O-MISC O-MISC
described O-MISC O-MISC
so O-MISC O-MISC
far O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
dendritic O-MISC O-MISC
cell O-MISC O-MISC
maturation O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
target O-MISC O-MISC
of O-MISC O-MISC
sulfasalazine O-MISC O-MISC
. O-MISC O-MISC

Because O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
( O-MISC O-MISC
auto O-MISC O-MISC
) O-MISC O-MISC
immunity O-MISC O-MISC
, O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
their O-MISC O-MISC
maturation O-MISC O-MISC
might O-MISC O-MISC
provide O-MISC O-MISC
a O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
further O-MISC O-MISC
optimization O-MISC O-MISC
of O-MISC O-MISC
sulfasalazine O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

Defective O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proteasome B-MISC B-MISC
in O-MISC O-MISC
autoimmunity O-MISC O-MISC
: O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
impaired O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Type O-MISC B-MISC
1 O-MISC I-MISC
diabetes O-MISC O-MISC
( O-MISC O-MISC
also O-MISC O-MISC
known O-MISC O-MISC
as O-MISC O-MISC
insulin O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
diabetes O-MISC O-MISC
mellitus O-MISC O-MISC
or O-MISC O-MISC
juvenile O-MISC O-MISC
- O-MISC O-MISC
onset O-MISC O-MISC
diabetes O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
usually O-MISC O-MISC
caused O-MISC O-MISC
by O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
autoimmunity O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
prediabetic O-MISC O-MISC
state O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
autoantibodies B-MISC B-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
proteins O-MISC O-MISC
expressed O-MISC O-MISC
by O-MISC O-MISC
pancreatic O-MISC O-MISC
beta O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
nonobese O-MISC O-MISC
patient O-MISC O-MISC
with O-MISC O-MISC
diabetes O-MISC O-MISC
( O-MISC O-MISC
NOD O-MISC B-MISC
) O-MISC O-MISC
mouse O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
spontaneous O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
diabetes O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
strong O-MISC O-MISC
genetic O-MISC O-MISC
component O-MISC O-MISC
that O-MISC O-MISC
maps O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
major B-MISC B-MISC
histocompatibility I-MISC I-MISC
complex I-MISC I-MISC
( I-MISC I-MISC
MHC I-MISC I-MISC
) I-MISC I-MISC
region I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
genome B-MISC B-MISC
. O-MISC O-MISC

A O-MISC O-MISC
specific O-MISC O-MISC
proteasome B-MISC O-MISC
defect O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
NOD O-MISC O-MISC
mouse O-MISC O-MISC
in O-MISC O-MISC
select O-MISC O-MISC
lymphocytic O-MISC O-MISC
and O-MISC O-MISC
monocytic O-MISC O-MISC
lineages O-MISC O-MISC
that O-MISC O-MISC
results O-MISC O-MISC
from O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proteasome B-MISC B-MISC
subunit I-MISC I-MISC
LMP2 I-MISC B-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
encoded O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
gene O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
MHC B-MISC B-MISC
genomic I-MISC I-MISC
region I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
defect O-MISC O-MISC
prevents O-MISC O-MISC
the O-MISC O-MISC
proteolytic O-MISC O-MISC
processing O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
nuclear I-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
plays O-MISC O-MISC
important O-MISC O-MISC
roles O-MISC O-MISC
in O-MISC O-MISC
immune O-MISC O-MISC
and O-MISC O-MISC
inflammatory O-MISC O-MISC
responses O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
increases O-MISC O-MISC
the O-MISC O-MISC
susceptibility O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
affected O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
apoptosis O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
novel O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proteasome B-MISC B-MISC
in O-MISC O-MISC
dysfunction O-MISC O-MISC
in O-MISC O-MISC
autoimmunity O-MISC O-MISC
is O-MISC O-MISC
presented O-MISC O-MISC
and O-MISC O-MISC
documented O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
both O-MISC O-MISC
tissue O-MISC O-MISC
and O-MISC O-MISC
developmental O-MISC O-MISC
stage O-MISC O-MISC
specific O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
propose O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proteasome B-MISC B-MISC
as O-MISC O-MISC
a O-MISC O-MISC
step O-MISC O-MISC
in O-MISC O-MISC
disease O-MISC O-MISC
pathogenesis O-MISC O-MISC
and O-MISC O-MISC
tissue O-MISC O-MISC
targeting O-MISC O-MISC
. O-MISC O-MISC

Down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
TDT O-MISC O-MISC
transcription O-MISC O-MISC
in O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
thymocytes O-MISC O-MISC
by O-MISC O-MISC
Ikaros B-MISC B-MISC
proteins I-MISC I-MISC
in O-MISC O-MISC
direct O-MISC O-MISC
competition O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
Ets B-MISC B-MISC
activator I-MISC I-MISC
. O-MISC O-MISC

Ikaros B-MISC B-MISC
is O-MISC O-MISC
a O-MISC O-MISC
unique O-MISC O-MISC
regulator O-MISC O-MISC
of O-MISC O-MISC
lymphopoiesis O-MISC O-MISC
that O-MISC O-MISC
associates O-MISC O-MISC
with O-MISC O-MISC
pericentromeric B-MISC O-MISC
heterochromatin I-MISC O-MISC
and O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
implicated O-MISC O-MISC
in O-MISC O-MISC
heritable O-MISC O-MISC
gene O-MISC O-MISC
inactivation O-MISC O-MISC
. O-MISC O-MISC

Binding O-MISC O-MISC
and O-MISC O-MISC
competition O-MISC O-MISC
experiments O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
Ikaros B-MISC B-MISC
dimers I-MISC I-MISC
compete O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
Ets B-MISC B-MISC
activator I-MISC I-MISC
for O-MISC O-MISC
occupancy O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
lymphocyte B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
TdT I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Mutations O-MISC O-MISC
that O-MISC O-MISC
selectively O-MISC O-MISC
disrupt O-MISC O-MISC
Ikaros O-MISC B-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
integrated B-MISC O-MISC
TdT I-MISC B-MISC
promoter I-MISC I-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
promoter O-MISC O-MISC
function O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
thymocyte O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
mutations O-MISC O-MISC
abolished O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
on O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
providing O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
Ikaros B-MISC B-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
direct O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
repression O-MISC O-MISC
. O-MISC O-MISC

Reduced O-MISC O-MISC
access O-MISC O-MISC
to O-MISC O-MISC
restriction O-MISC O-MISC
enzyme O-MISC I-MISC
cleavage O-MISC O-MISC
suggested O-MISC O-MISC
that O-MISC O-MISC
chromatin O-MISC O-MISC
alterations O-MISC O-MISC
accompany O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Ikaros O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
event O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
observed O-MISC O-MISC
chromatin O-MISC B-MISC
alterations O-MISC O-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
precede O-MISC O-MISC
pericentromeric O-MISC O-MISC
repositioning O-MISC O-MISC
. O-MISC O-MISC

Current O-MISC O-MISC
models O-MISC O-MISC
propose O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
functions O-MISC O-MISC
of O-MISC O-MISC
Ikaros B-MISC B-MISC
should O-MISC O-MISC
be O-MISC O-MISC
disrupted O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
small O-MISC O-MISC
isoform B-MISC O-MISC
that O-MISC O-MISC
retains O-MISC O-MISC
the O-MISC O-MISC
dimerization B-MISC O-MISC
domain I-MISC I-MISC
and O-MISC O-MISC
lacks O-MISC O-MISC
the O-MISC O-MISC
DNA B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
. O-MISC O-MISC

Surprisingly O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
thymocyte O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
small B-MISC B-MISC
Ikaros I-MISC B-MISC
isoform I-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
differentiation O-MISC O-MISC
or O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
pericentromeric O-MISC O-MISC
targeting O-MISC O-MISC
and O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
properties O-MISC O-MISC
of O-MISC O-MISC
Ikaros B-MISC B-MISC
. O-MISC O-MISC

Rather O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
small O-MISC B-MISC
isoform B-MISC I-MISC
assembled O-MISC I-MISC
into O-MISC O-MISC
multimeric B-MISC B-MISC
complexes I-MISC I-MISC
with O-MISC O-MISC
DNA B-MISC B-MISC
- I-MISC I-MISC
bound I-MISC I-MISC
Ikaros I-MISC I-MISC
at O-MISC O-MISC
the O-MISC O-MISC
pericentromeric O-MISC O-MISC
foci O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
capacity O-MISC O-MISC
for O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
multimer O-MISC O-MISC
formation O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
interactions O-MISC O-MISC
between O-MISC O-MISC
Ikaros B-MISC B-MISC
dimers I-MISC I-MISC
bound O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
TdT B-MISC B-MISC
promoter I-MISC I-MISC
and O-MISC O-MISC
those O-MISC O-MISC
bound O-MISC O-MISC
to O-MISC O-MISC
pericentromeric B-MISC B-MISC
repeat I-MISC I-MISC
sequences I-MISC I-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
pericentromeric O-MISC O-MISC
repositioning O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inactive B-MISC B-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

Type B-MISC B-MISC
I I-MISC I-MISC
interferons I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
: O-MISC O-MISC
convergence O-MISC O-MISC
and O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
among O-MISC O-MISC
mediators O-MISC O-MISC
of O-MISC O-MISC
cellular O-MISC O-MISC
immunity O-MISC O-MISC
. O-MISC O-MISC

Therapeutic O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
type B-MISC O-MISC
I I-MISC B-MISC
IFN I-MISC I-MISC
( O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
/ I-MISC I-MISC
beta I-MISC I-MISC
) O-MISC O-MISC
has O-MISC O-MISC
become O-MISC O-MISC
common O-MISC O-MISC
. O-MISC O-MISC

Many O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
diverse O-MISC O-MISC
diseases O-MISC O-MISC
targeted O-MISC O-MISC
are O-MISC O-MISC
marked O-MISC O-MISC
by O-MISC O-MISC
pathogenetic O-MISC O-MISC
abnormalities O-MISC O-MISC
in O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
immunity O-MISC O-MISC
( O-MISC O-MISC
CMI O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
cellular O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
either O-MISC O-MISC
causing O-MISC O-MISC
injury O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
host O-MISC O-MISC
, O-MISC O-MISC
lacking O-MISC O-MISC
sufficient O-MISC O-MISC
vigor O-MISC O-MISC
for O-MISC O-MISC
virus O-MISC O-MISC
or O-MISC O-MISC
tumor O-MISC O-MISC
clearance O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
both O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
general O-MISC O-MISC
, O-MISC O-MISC
therapeutic O-MISC O-MISC
efficacy O-MISC O-MISC
is O-MISC O-MISC
limited O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
thus O-MISC O-MISC
notable O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
pleiotropic O-MISC B-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
type B-MISC O-MISC
I I-MISC O-MISC
IFN I-MISC B-MISC
on O-MISC O-MISC
CMI O-MISC O-MISC
remain O-MISC O-MISC
poorly O-MISC O-MISC
understood O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
characterized O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
type B-MISC O-MISC
I I-MISC O-MISC
IFN I-MISC I-MISC
on O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
central B-MISC O-MISC
immunoregulatory I-MISC O-MISC
cytokine I-MISC B-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CD4 B-MISC B-MISC
( I-MISC O-MISC
+ I-MISC O-MISC
) I-MISC O-MISC
T I-MISC O-MISC
cell I-MISC I-MISC
arm I-MISC O-MISC
of O-MISC O-MISC
CMI O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
type B-MISC O-MISC
I I-MISC B-MISC
IFN I-MISC I-MISC
are O-MISC O-MISC
potent O-MISC O-MISC
inhibitors O-MISC O-MISC
of O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
12 O-MISC I-MISC
production O-MISC O-MISC
by O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
/ O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
underlying O-MISC O-MISC
mechanism O-MISC O-MISC
involves O-MISC O-MISC
transcriptional O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12p40 I-MISC I-MISC
gene I-MISC I-MISC
, O-MISC O-MISC
marked O-MISC O-MISC
by O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
PU O-MISC B-MISC
. O-MISC I-MISC
1 O-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
upstream B-MISC B-MISC
Ets I-MISC B-MISC
site I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12p40 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Type B-MISC B-MISC
I I-MISC I-MISC
IFN I-MISC I-MISC
have O-MISC O-MISC
previously O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
substitute O-MISC O-MISC
for O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
in O-MISC O-MISC
driving O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
production O-MISC O-MISC
from O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
/ I-MISC I-MISC
beta I-MISC I-MISC
to O-MISC O-MISC
suppress O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
12 O-MISC I-MISC
production O-MISC O-MISC
while O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulating O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
production O-MISC O-MISC
suggests O-MISC O-MISC
a O-MISC O-MISC
possible O-MISC O-MISC
mechanistic O-MISC O-MISC
basis O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
difficulties O-MISC O-MISC
of O-MISC O-MISC
employing O-MISC O-MISC
these O-MISC O-MISC
cytokines B-MISC B-MISC
in O-MISC O-MISC
diseases O-MISC O-MISC
involving O-MISC O-MISC
abnormalities O-MISC O-MISC
of O-MISC O-MISC
CMI O-MISC O-MISC
. O-MISC O-MISC

Nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
suppressive O-MISC O-MISC
and O-MISC O-MISC
inhibitor B-MISC O-MISC
- I-MISC I-MISC
kappaB I-MISC O-MISC
stimulatory O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
troglitazone O-MISC O-MISC
in O-MISC O-MISC
obese O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
type O-MISC O-MISC
2 O-MISC O-MISC
diabetes O-MISC O-MISC
: O-MISC O-MISC
evidence O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
antiinflammatory O-MISC O-MISC
action O-MISC O-MISC
? O-MISC O-MISC

It O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
recently O-MISC O-MISC
that O-MISC O-MISC
troglitazone O-MISC O-MISC
exerts O-MISC O-MISC
an O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
effect O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
experimental O-MISC O-MISC
animals O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
test O-MISC O-MISC
these O-MISC O-MISC
properties O-MISC O-MISC
in O-MISC O-MISC
humans O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
troglitazone O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
proinflammatory B-MISC B-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
nuclear I-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
its O-MISC O-MISC
inhibitory B-MISC O-MISC
protein I-MISC I-MISC
IkappaB I-MISC B-MISC
in O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
MNC O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
plasma B-MISC O-MISC
soluble I-MISC O-MISC
intracellular I-MISC O-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
monocyte B-MISC B-MISC
chemoattractant I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
plasminogen B-MISC B-MISC
activator I-MISC I-MISC
inhibitor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
C B-MISC I-MISC
- I-MISC I-MISC
reactive I-MISC O-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
also O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
troglitazone O-MISC O-MISC
on O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
species O-MISC O-MISC
generation O-MISC O-MISC
, O-MISC O-MISC
p47 O-MISC B-MISC
( O-MISC I-MISC
phox O-MISC B-MISC
) O-MISC I-MISC
subunit O-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
hydroxyoctadecadieno O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
HODE O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
13 O-MISC O-MISC
- O-MISC O-MISC
HODE O-MISC O-MISC
, O-MISC O-MISC
o O-MISC O-MISC
- O-MISC O-MISC
tyrosine O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
m O-MISC O-MISC
- O-MISC O-MISC
tyrosine O-MISC O-MISC
in O-MISC O-MISC
obese O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
type O-MISC O-MISC
2 O-MISC O-MISC
diabetes O-MISC O-MISC
. O-MISC O-MISC

Seven O-MISC O-MISC
obese O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
type O-MISC O-MISC
2 O-MISC O-MISC
diabetes O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
troglitazone O-MISC O-MISC
( O-MISC O-MISC
400 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
day O-MISC O-MISC
) O-MISC O-MISC
for O-MISC O-MISC
4 O-MISC O-MISC
weeks O-MISC O-MISC
. O-MISC O-MISC

Blood O-MISC O-MISC
samples O-MISC O-MISC
were O-MISC O-MISC
obtained O-MISC O-MISC
at O-MISC O-MISC
weekly O-MISC O-MISC
intervals O-MISC O-MISC
. O-MISC O-MISC

Nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
MNC O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
inhibited O-MISC O-MISC
after O-MISC O-MISC
troglitazone O-MISC O-MISC
treatment O-MISC O-MISC
at O-MISC O-MISC
week O-MISC O-MISC
1 O-MISC O-MISC
and O-MISC O-MISC
continued O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
inhibited O-MISC O-MISC
up O-MISC O-MISC
to O-MISC O-MISC
week O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
hand O-MISC O-MISC
, O-MISC O-MISC
IkappaB O-MISC B-MISC
protein O-MISC I-MISC
levels O-MISC O-MISC
increased O-MISC O-MISC
significantly O-MISC O-MISC
after O-MISC O-MISC
troglitazone O-MISC O-MISC
treatment O-MISC O-MISC
at O-MISC O-MISC
week O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
this O-MISC O-MISC
increase O-MISC O-MISC
persisted O-MISC O-MISC
throughout O-MISC O-MISC
the O-MISC O-MISC
study O-MISC O-MISC
. O-MISC O-MISC

Plasma B-MISC B-MISC
monocyte I-MISC I-MISC
chemoattractant I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
soluble B-MISC B-MISC
intracellular I-MISC O-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
concentrations O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
decrease O-MISC O-MISC
significantly O-MISC O-MISC
after O-MISC O-MISC
troglitazone O-MISC O-MISC
treatment O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
there O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
trend O-MISC O-MISC
toward O-MISC O-MISC
inhibition O-MISC O-MISC
. O-MISC O-MISC

Reactive O-MISC O-MISC
oxygen O-MISC O-MISC
species O-MISC O-MISC
generation O-MISC O-MISC
by O-MISC O-MISC
polymorphonuclear O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
MNC O-MISC O-MISC
, O-MISC O-MISC
p47 B-MISC B-MISC
( I-MISC I-MISC
phox I-MISC I-MISC
) I-MISC I-MISC
subunit I-MISC I-MISC
protein I-MISC O-MISC
quantities O-MISC O-MISC
, O-MISC O-MISC
plasminogen B-MISC B-MISC
activator I-MISC I-MISC
inhibitor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
C B-MISC O-MISC
- I-MISC I-MISC
reactive I-MISC O-MISC
protein I-MISC I-MISC
levels O-MISC O-MISC
decreased O-MISC O-MISC
significantly O-MISC O-MISC
after O-MISC O-MISC
troglitazone O-MISC O-MISC
intake O-MISC O-MISC
. O-MISC O-MISC

13 O-MISC O-MISC
- O-MISC O-MISC
HODE O-MISC O-MISC
/ O-MISC O-MISC
linoleic O-MISC O-MISC
acid O-MISC O-MISC
and O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
HODE O-MISC O-MISC
/ O-MISC O-MISC
linoleic O-MISC O-MISC
acid O-MISC O-MISC
ratios O-MISC O-MISC
also O-MISC O-MISC
decreased O-MISC O-MISC
after O-MISC O-MISC
troglitazone O-MISC O-MISC
intake O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
o O-MISC O-MISC
- O-MISC O-MISC
tyrosine O-MISC O-MISC
/ O-MISC O-MISC
phenylalanine O-MISC O-MISC
and O-MISC O-MISC
m O-MISC O-MISC
- O-MISC O-MISC
tyrosine O-MISC O-MISC
/ O-MISC O-MISC
phenylalanine O-MISC O-MISC
ratios O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
change O-MISC O-MISC
significantly O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
troglitazone O-MISC O-MISC
has O-MISC O-MISC
profound O-MISC O-MISC
antiinflammatory O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
addition O-MISC O-MISC
to O-MISC O-MISC
antioxidant O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
obese O-MISC O-MISC
type O-MISC O-MISC
2 O-MISC O-MISC
diabetics O-MISC O-MISC
; O-MISC O-MISC
these O-MISC O-MISC
effects O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
relevant O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
recently O-MISC O-MISC
described O-MISC O-MISC
beneficial O-MISC O-MISC
antiatherosclerotic O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
troglitazone O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
vascular O-MISC O-MISC
level O-MISC O-MISC
. O-MISC O-MISC

OX40 O-MISC B-MISC
stimulation O-MISC O-MISC
by O-MISC O-MISC
gp34 B-MISC B-MISC
/ I-MISC I-MISC
OX40 I-MISC I-MISC
ligand I-MISC I-MISC
enhances O-MISC I-MISC
productive O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
. O-MISC O-MISC

OX40 B-MISC B-MISC
is O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
TNF I-MISC I-MISC
) I-MISC I-MISC
receptor I-MISC I-MISC
superfamily I-MISC I-MISC
and O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
costimulatory B-MISC B-MISC
molecule I-MISC I-MISC
expressed O-MISC O-MISC
on O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
investigate O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
costimulation O-MISC O-MISC
of O-MISC O-MISC
OX40 B-MISC B-MISC
in O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
infection O-MISC O-MISC
by O-MISC O-MISC
its O-MISC O-MISC
natural O-MISC O-MISC
ligand O-MISC O-MISC
, O-MISC O-MISC
gp34 B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
OX40 O-MISC B-MISC
- O-MISC O-MISC
transfected O-MISC O-MISC
ACH O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
ACH O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
/ O-MISC O-MISC
OX40 O-MISC O-MISC
, O-MISC O-MISC
chronically O-MISC O-MISC
infected O-MISC O-MISC
with O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
cocultured O-MISC O-MISC
with O-MISC O-MISC
paraformaldehyde O-MISC O-MISC
( O-MISC O-MISC
PFA O-MISC B-MISC
) O-MISC O-MISC
- O-MISC O-MISC
fixed O-MISC O-MISC
gp34 O-MISC O-MISC
- O-MISC O-MISC
transfected O-MISC O-MISC
mouse O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
SV O-MISC O-MISC
- O-MISC O-MISC
T2 O-MISC O-MISC
/ O-MISC O-MISC
gp34 O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
production O-MISC O-MISC
was O-MISC O-MISC
strongly O-MISC O-MISC
induced O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
was O-MISC O-MISC
followed O-MISC O-MISC
by O-MISC O-MISC
apparent O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
both O-MISC O-MISC
processes O-MISC O-MISC
were O-MISC O-MISC
specifically O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
gp34 B-MISC B-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
neutralizing B-MISC I-MISC
monoclonal I-MISC I-MISC
antibody I-MISC I-MISC
5A8 I-MISC O-MISC
. O-MISC O-MISC

Endogenous O-MISC O-MISC
TNF B-MISC B-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
production O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
enhanced O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
production O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
enhanced O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
transcription O-MISC O-MISC
in O-MISC O-MISC
gp34 B-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
ACH O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
/ O-MISC O-MISC
OX40 O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
kappa B-MISC B-MISC
B I-MISC I-MISC
site I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
long I-MISC I-MISC
terminal I-MISC I-MISC
repeat I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
OX40 O-MISC B-MISC
- O-MISC I-MISC
gp34 O-MISC I-MISC
interaction O-MISC O-MISC
activated O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
consisting O-MISC O-MISC
of O-MISC O-MISC
p50 B-MISC B-MISC
and I-MISC I-MISC
p65 I-MISC B-MISC
subunits I-MISC I-MISC
. O-MISC O-MISC

When O-MISC O-MISC
primary O-MISC O-MISC
activated O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
acutely O-MISC O-MISC
infected O-MISC O-MISC
with O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
NL4 O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
CXCR4 O-MISC O-MISC
- O-MISC O-MISC
using O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
line O-MISC O-MISC
- O-MISC O-MISC
tropic O-MISC B-MISC
) O-MISC O-MISC
were O-MISC O-MISC
cocultured O-MISC O-MISC
with O-MISC O-MISC
PFA O-MISC B-MISC
- O-MISC I-MISC
fixed O-MISC I-MISC
gp34 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
bearing O-MISC O-MISC
MT O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
cells O-MISC O-MISC
or O-MISC O-MISC
SV O-MISC O-MISC
- O-MISC O-MISC
T2 O-MISC O-MISC
/ O-MISC O-MISC
gp34 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
production O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
markedly O-MISC O-MISC
enhanced O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
enhancement O-MISC O-MISC
was O-MISC O-MISC
again O-MISC O-MISC
significantly O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
5A8 B-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
first O-MISC O-MISC
shows O-MISC O-MISC
that O-MISC O-MISC
OX40 O-MISC B-MISC
- O-MISC O-MISC
gp34 O-MISC O-MISC
interaction O-MISC O-MISC
stimulates O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
OX40 O-MISC B-MISC
triggering O-MISC O-MISC
by O-MISC O-MISC
gp34 B-MISC B-MISC
may O-MISC O-MISC
play O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
enhancing O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
production O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
acutely O-MISC O-MISC
and O-MISC O-MISC
latently O-MISC O-MISC
infected O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

Troglitazone O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
PPARgamma O-MISC B-MISC
ligand O-MISC O-MISC
, O-MISC O-MISC
inhibits O-MISC O-MISC
osteopontin O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
/ O-MISC O-MISC
macrophage O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Peroxizome B-MISC B-MISC
proliferator I-MISC I-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
receptor I-MISC I-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
( O-MISC I-MISC
PPARgamma B-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nuclear B-MISC B-MISC
receptor I-MISC I-MISC
family I-MISC I-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
that O-MISC O-MISC
regulate O-MISC O-MISC
adipocyte O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

Recent O-MISC O-MISC
studies O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
liganded B-MISC O-MISC
PPARgamma I-MISC B-MISC
not O-MISC O-MISC
only O-MISC O-MISC
promotes O-MISC O-MISC
differentiation O-MISC O-MISC
but O-MISC O-MISC
also O-MISC O-MISC
inhibits O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

Osteopontin B-MISC B-MISC
, O-MISC O-MISC
a O-MISC O-MISC
component O-MISC O-MISC
of O-MISC O-MISC
extracellular O-MISC O-MISC
matrix O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
synthesized O-MISC O-MISC
by O-MISC O-MISC
macrophages O-MISC O-MISC
in O-MISC O-MISC
atherosclerotic O-MISC O-MISC
plaques O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
examined O-MISC O-MISC
whether O-MISC O-MISC
PPARgamma B-MISC B-MISC
ligand O-MISC O-MISC
regulates O-MISC O-MISC
osteopontin O-MISC O-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
human O-MISC O-MISC
monocytic O-MISC O-MISC
leukemia O-MISC O-MISC
cells O-MISC O-MISC
which O-MISC O-MISC
can O-MISC O-MISC
differentiate O-MISC O-MISC
to O-MISC O-MISC
macrophage O-MISC O-MISC
upon O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
phorbol O-MISC O-MISC
ester O-MISC O-MISC
PMA O-MISC O-MISC
. O-MISC O-MISC

Northern O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
osteopontin O-MISC B-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
markedly O-MISC O-MISC
induced O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
PMA O-MISC O-MISC
. O-MISC O-MISC

Troglitazone O-MISC B-MISC
, O-MISC O-MISC
a O-MISC O-MISC
PPARgamma B-MISC B-MISC
ligand O-MISC O-MISC
, O-MISC O-MISC
dramatically O-MISC O-MISC
attenuated O-MISC O-MISC
the O-MISC O-MISC
PMA O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
osteopontin O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Transient O-MISC O-MISC
transfection O-MISC O-MISC
assays O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
osteopontin I-MISC I-MISC
promoter I-MISC I-MISC
/ I-MISC I-MISC
luciferase I-MISC I-MISC
construct I-MISC I-MISC
which O-MISC O-MISC
contains O-MISC O-MISC
a O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
- I-MISC I-MISC
flanking I-MISC I-MISC
region I-MISC I-MISC
between O-MISC O-MISC
- O-MISC O-MISC
1500 O-MISC O-MISC
and O-MISC O-MISC
+ O-MISC O-MISC
87 O-MISC O-MISC
relative O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
start I-MISC I-MISC
site I-MISC I-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
either O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
troglitazone O-MISC O-MISC
or O-MISC O-MISC
cotransfection O-MISC O-MISC
of O-MISC O-MISC
PPARgamma B-MISC B-MISC
expression I-MISC O-MISC
vector I-MISC O-MISC
inhibits O-MISC O-MISC
osteopontin O-MISC B-MISC
promoter O-MISC I-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
troglitazone O-MISC O-MISC
reduces O-MISC O-MISC
osteopontin O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
at O-MISC O-MISC
transcriptional O-MISC O-MISC
level O-MISC O-MISC
through O-MISC O-MISC
PPARgamma B-MISC B-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
suggest O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
troglitazone O-MISC O-MISC
in O-MISC O-MISC
inhibiting O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
macrophages O-MISC O-MISC
to O-MISC O-MISC
produce O-MISC O-MISC
extracellular O-MISC O-MISC
matrix O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
particularly O-MISC O-MISC
relevant O-MISC O-MISC
to O-MISC O-MISC
atherosclerotic O-MISC O-MISC
plaque O-MISC O-MISC
formation O-MISC O-MISC
. O-MISC O-MISC

Transcription B-MISC B-MISC
factor I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
regulates O-MISC O-MISC
Ig B-MISC B-MISC
lambda I-MISC I-MISC
light O-MISC I-MISC
chain O-MISC I-MISC
gene O-MISC I-MISC
rearrangement O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
tissue O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
stage O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
assembly O-MISC O-MISC
of O-MISC O-MISC
Ig B-MISC B-MISC
and I-MISC I-MISC
TCR I-MISC I-MISC
genes I-MISC I-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
common O-MISC O-MISC
V B-MISC B-MISC
( I-MISC O-MISC
D I-MISC O-MISC
) I-MISC O-MISC
J I-MISC B-MISC
recombinase I-MISC I-MISC
complex I-MISC I-MISC
in O-MISC O-MISC
precursor O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Directed O-MISC O-MISC
alterations O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
accessibility O-MISC O-MISC
of O-MISC O-MISC
V B-MISC B-MISC
, I-MISC O-MISC
D I-MISC I-MISC
, I-MISC O-MISC
and I-MISC O-MISC
J I-MISC B-MISC
gene I-MISC I-MISC
segments I-MISC I-MISC
target O-MISC O-MISC
the O-MISC O-MISC
recombinase B-MISC O-MISC
to O-MISC O-MISC
specific O-MISC O-MISC
Ag B-MISC B-MISC
receptor I-MISC I-MISC
loci I-MISC I-MISC
. O-MISC O-MISC

Accessibility O-MISC O-MISC
within O-MISC O-MISC
a O-MISC O-MISC
given O-MISC O-MISC
locus B-MISC O-MISC
is O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
functional O-MISC O-MISC
interaction O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
with O-MISC O-MISC
cognate B-MISC B-MISC
enhancer I-MISC I-MISC
elements I-MISC I-MISC
and O-MISC O-MISC
correlates O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
unrearranged O-MISC O-MISC
gene B-MISC O-MISC
segments I-MISC I-MISC
. O-MISC O-MISC

As O-MISC O-MISC
demonstrated O-MISC O-MISC
in O-MISC O-MISC
our O-MISC O-MISC
prior O-MISC O-MISC
studies O-MISC O-MISC
, O-MISC O-MISC
rearrangement O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Igkappa B-MISC B-MISC
locus I-MISC I-MISC
is O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
inducible B-MISC O-MISC
transcription I-MISC B-MISC
factor I-MISC I-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
Igkappa B-MISC B-MISC
locus I-MISC I-MISC
, O-MISC O-MISC
known O-MISC O-MISC
transcriptional B-MISC B-MISC
control I-MISC I-MISC
elements I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
Iglambda B-MISC B-MISC
locus I-MISC I-MISC
lack O-MISC O-MISC
functional O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

Consistent O-MISC O-MISC
with O-MISC O-MISC
this O-MISC O-MISC
observation O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
assembled O-MISC B-MISC
Iglambda B-MISC I-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
mature O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
independent O-MISC O-MISC
. O-MISC O-MISC

Nonetheless O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
now O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
specific O-MISC O-MISC
repression O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
inhibits O-MISC O-MISC
germline O-MISC O-MISC
transcription O-MISC O-MISC
and O-MISC O-MISC
recombination O-MISC O-MISC
of O-MISC O-MISC
Iglambda B-MISC B-MISC
gene I-MISC I-MISC
segments I-MISC O-MISC
in O-MISC O-MISC
precursor O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Molecular O-MISC O-MISC
analyses O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
block O-MISC O-MISC
in O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
impairs O-MISC O-MISC
Iglambda O-MISC B-MISC
rearrangement O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
recombinase B-MISC O-MISC
accessibility O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
known O-MISC O-MISC
Iglambda B-MISC B-MISC
promoter I-MISC I-MISC
and O-MISC I-MISC
enhancer B-MISC I-MISC
elements I-MISC I-MISC
are O-MISC O-MISC
unaffected O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
cellular O-MISC O-MISC
background O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
expand O-MISC O-MISC
the O-MISC O-MISC
range O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
action O-MISC O-MISC
in O-MISC O-MISC
precursor O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
beyond O-MISC O-MISC
Igkappa B-MISC B-MISC
to O-MISC O-MISC
include O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
recombinational O-MISC O-MISC
accessibility O-MISC O-MISC
at O-MISC O-MISC
both O-MISC O-MISC
L B-MISC B-MISC
chain I-MISC I-MISC
loci I-MISC I-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
results O-MISC O-MISC
strongly O-MISC O-MISC
suggest O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
Iglambda B-MISC B-MISC
regulatory I-MISC I-MISC
element I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
either O-MISC O-MISC
directly O-MISC O-MISC
or O-MISC O-MISC
indirectly O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
during O-MISC O-MISC
the O-MISC O-MISC
early O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

Transcription B-MISC B-MISC
factor I-MISC I-MISC
STAT5A B-MISC B-MISC
is O-MISC O-MISC
a O-MISC O-MISC
substrate O-MISC O-MISC
of O-MISC O-MISC
Bruton B-MISC B-MISC
' I-MISC I-MISC
s I-MISC I-MISC
tyrosine I-MISC I-MISC
kinase I-MISC I-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

STAT5A B-MISC B-MISC
is O-MISC O-MISC
a O-MISC O-MISC
molecular O-MISC O-MISC
regulator O-MISC O-MISC
of O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
lymphohematopoietic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
STAT5A B-MISC B-MISC
can O-MISC O-MISC
serve O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
functional O-MISC O-MISC
substrate O-MISC O-MISC
of O-MISC O-MISC
Bruton B-MISC B-MISC
' I-MISC I-MISC
s I-MISC I-MISC
tyrosine I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
BTK B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Purified B-MISC O-MISC
recombinant I-MISC O-MISC
BTK I-MISC B-MISC
was O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
directly O-MISC O-MISC
binding O-MISC O-MISC
purified B-MISC O-MISC
recombinant I-MISC O-MISC
STAT5A I-MISC B-MISC
with O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
( O-MISC O-MISC
K O-MISC O-MISC
( O-MISC O-MISC
d O-MISC O-MISC
) O-MISC O-MISC
= O-MISC O-MISC
44 O-MISC O-MISC
nm O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
surface O-MISC O-MISC
plasmon O-MISC O-MISC
resonance O-MISC O-MISC
using O-MISC O-MISC
a O-MISC O-MISC
BIAcore O-MISC O-MISC
biosensor O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

BTK B-MISC B-MISC
was O-MISC O-MISC
also O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
tyrosine O-MISC O-MISC
- O-MISC O-MISC
phosphorylating O-MISC O-MISC
ectopically O-MISC O-MISC
expressed O-MISC O-MISC
recombinant B-MISC O-MISC
STAT5A I-MISC B-MISC
on O-MISC O-MISC
Tyr O-MISC B-MISC
( O-MISC O-MISC
694 O-MISC O-MISC
) O-MISC O-MISC
both O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
Janus B-MISC B-MISC
kinase I-MISC I-MISC
3 I-MISC O-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
fashion O-MISC O-MISC
. O-MISC O-MISC

BTK B-MISC O-MISC
phosphorylated O-MISC O-MISC
the O-MISC O-MISC
Y665F B-MISC B-MISC
, I-MISC O-MISC
Y668F I-MISC B-MISC
, I-MISC O-MISC
and I-MISC O-MISC
Y682F I-MISC B-MISC
, I-MISC O-MISC
Y683F I-MISC B-MISC
mutants I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
Y694F B-MISC B-MISC
mutant I-MISC I-MISC
of O-MISC O-MISC
STAT5A B-MISC B-MISC
. O-MISC O-MISC

STAT5A O-MISC B-MISC
mutations O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
Src B-MISC B-MISC
homology I-MISC I-MISC
2 I-MISC I-MISC
( I-MISC I-MISC
SH2 I-MISC I-MISC
) I-MISC I-MISC
and I-MISC O-MISC
SH3 I-MISC I-MISC
domains I-MISC I-MISC
did O-MISC O-MISC
not O-MISC O-MISC
alter O-MISC O-MISC
the O-MISC O-MISC
BTK B-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
. O-MISC O-MISC

Recombinant B-MISC B-MISC
BTK I-MISC I-MISC
proteins I-MISC I-MISC
with O-MISC O-MISC
mutant O-MISC B-MISC
pleckstrin O-MISC I-MISC
homology O-MISC I-MISC
, O-MISC O-MISC
SH2 B-MISC B-MISC
, I-MISC O-MISC
or I-MISC O-MISC
SH3 I-MISC B-MISC
domains I-MISC I-MISC
were O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
phosphorylating O-MISC O-MISC
STAT5A B-MISC B-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
recombinant B-MISC B-MISC
BTK I-MISC B-MISC
proteins I-MISC I-MISC
with O-MISC O-MISC
SH1 O-MISC I-MISC
/ O-MISC I-MISC
kinase O-MISC I-MISC
domain O-MISC I-MISC
mutations O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
pull O-MISC O-MISC
- O-MISC O-MISC
down O-MISC O-MISC
experiments O-MISC O-MISC
, O-MISC O-MISC
only O-MISC O-MISC
full B-MISC O-MISC
- I-MISC B-MISC
length I-MISC I-MISC
BTK I-MISC I-MISC
and O-MISC O-MISC
its O-MISC O-MISC
SH1 B-MISC B-MISC
/ I-MISC I-MISC
kinase I-MISC I-MISC
domain I-MISC I-MISC
( O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
pleckstrin O-MISC B-MISC
homology O-MISC I-MISC
, O-MISC O-MISC
SH2 B-MISC B-MISC
, I-MISC O-MISC
or I-MISC O-MISC
SH3 I-MISC B-MISC
domains I-MISC I-MISC
) O-MISC O-MISC
were O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
STAT5A B-MISC B-MISC
. O-MISC O-MISC

Ectopically O-MISC B-MISC
expressed O-MISC O-MISC
BTK B-MISC B-MISC
kinase I-MISC I-MISC
domain I-MISC I-MISC
was O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
tyrosine O-MISC O-MISC
- O-MISC O-MISC
phosphorylating O-MISC O-MISC
STAT5A B-MISC B-MISC
both O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

BTK B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
ectopically O-MISC O-MISC
expressed O-MISC O-MISC
wild O-MISC O-MISC
type O-MISC I-MISC
( O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
Tyr B-MISC O-MISC
( I-MISC O-MISC
694 I-MISC B-MISC
) I-MISC I-MISC
mutant I-MISC I-MISC
) O-MISC O-MISC
STAT5A B-MISC B-MISC
enhanced O-MISC O-MISC
its O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
BTK B-MISC O-MISC
- O-MISC O-MISC
competent O-MISC O-MISC
chicken O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
IgM O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
STAT5 B-MISC B-MISC
protein I-MISC I-MISC
was O-MISC O-MISC
prevented O-MISC O-MISC
by O-MISC O-MISC
pretreatment O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
BTK B-MISC O-MISC
inhibitor O-MISC O-MISC
LFM O-MISC O-MISC
- O-MISC O-MISC
A13 O-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
by O-MISC O-MISC
pretreatment O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
JAK3 O-MISC B-MISC
inhibitor O-MISC O-MISC
HI O-MISC B-MISC
- O-MISC I-MISC
P131 O-MISC I-MISC
. O-MISC O-MISC

B O-MISC O-MISC
cell O-MISC I-MISC
antigen O-MISC I-MISC
receptor O-MISC I-MISC
ligation O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
enhanced O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
STAT5 B-MISC B-MISC
in O-MISC O-MISC
BTK B-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
chicken O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
reconstituted O-MISC O-MISC
with O-MISC O-MISC
wild B-MISC O-MISC
type I-MISC O-MISC
human I-MISC O-MISC
BTK I-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
BTK B-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
chicken O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
reconstituted O-MISC O-MISC
with O-MISC O-MISC
kinase B-MISC B-MISC
- I-MISC I-MISC
inactive I-MISC I-MISC
mutant I-MISC I-MISC
BTK I-MISC I-MISC
. O-MISC O-MISC

Similarly O-MISC O-MISC
, O-MISC O-MISC
anti O-MISC B-MISC
- O-MISC I-MISC
IgM O-MISC I-MISC
stimulation O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
enhanced O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
STAT5A B-MISC B-MISC
in O-MISC O-MISC
BTK B-MISC O-MISC
- O-MISC O-MISC
competent O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
wild O-MISC O-MISC
type O-MISC O-MISC
mice O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
BTK B-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
XID O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
XID O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
JAK3 O-MISC O-MISC
knockout O-MISC O-MISC
mice O-MISC O-MISC
showed O-MISC O-MISC
a O-MISC O-MISC
normal O-MISC O-MISC
STAT5A O-MISC B-MISC
phosphorylation O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
IgM O-MISC I-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
provide O-MISC O-MISC
unprecedented O-MISC O-MISC
experimental O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
BTK B-MISC B-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
nonredundant O-MISC O-MISC
and O-MISC O-MISC
pivotal O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
antigen O-MISC O-MISC
receptor O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
STAT5A O-MISC B-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC

Role O-MISC O-MISC
of O-MISC O-MISC
T B-MISC O-MISC
- I-MISC O-MISC
bet I-MISC O-MISC
in O-MISC O-MISC
commitment O-MISC O-MISC
of O-MISC O-MISC
TH1 O-MISC O-MISC
cells O-MISC O-MISC
before O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
selection O-MISC O-MISC
. O-MISC O-MISC

How O-MISC O-MISC
cytokines B-MISC B-MISC
control O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
helper O-MISC O-MISC
T O-MISC O-MISC
( O-MISC O-MISC
TH O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
controversial O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
T B-MISC O-MISC
- I-MISC O-MISC
bet I-MISC O-MISC
, O-MISC O-MISC
without O-MISC O-MISC
apparent O-MISC O-MISC
assistance O-MISC O-MISC
from O-MISC O-MISC
interleukin B-MISC B-MISC
12 I-MISC I-MISC
( I-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
) I-MISC O-MISC
/ O-MISC O-MISC
STAT4 B-MISC I-MISC
, O-MISC O-MISC
specifies O-MISC O-MISC
TH1 O-MISC O-MISC
effector O-MISC O-MISC
fate O-MISC O-MISC
by O-MISC O-MISC
targeting O-MISC O-MISC
chromatin O-MISC O-MISC
remodeling O-MISC O-MISC
to O-MISC O-MISC
individual O-MISC O-MISC
interferon B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
( I-MISC I-MISC
IFN I-MISC I-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
) I-MISC I-MISC
alleles I-MISC I-MISC
and O-MISC O-MISC
by O-MISC O-MISC
inducing O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
receptor I-MISC I-MISC
beta2 I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Subsequently O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
appears O-MISC O-MISC
that O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
/ O-MISC B-MISC
STAT4 B-MISC I-MISC
serves O-MISC O-MISC
two O-MISC O-MISC
essential O-MISC O-MISC
functions O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
TH1 O-MISC O-MISC
cells O-MISC O-MISC
: O-MISC O-MISC
as O-MISC O-MISC
growth B-MISC O-MISC
signal I-MISC O-MISC
, O-MISC O-MISC
inducing O-MISC O-MISC
survival O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
division O-MISC O-MISC
; O-MISC O-MISC
and O-MISC O-MISC
as O-MISC O-MISC
trans B-MISC O-MISC
- I-MISC I-MISC
activator I-MISC I-MISC
, O-MISC O-MISC
prolonging O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
synthesis O-MISC O-MISC
through O-MISC O-MISC
a O-MISC O-MISC
genetic O-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
coactivator B-MISC O-MISC
, O-MISC O-MISC
CREB B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
cytokine B-MISC B-MISC
does O-MISC O-MISC
not O-MISC O-MISC
simply O-MISC O-MISC
induce O-MISC O-MISC
TH O-MISC O-MISC
fate O-MISC O-MISC
choice O-MISC O-MISC
but O-MISC O-MISC
instead O-MISC O-MISC
may O-MISC O-MISC
act O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
essential O-MISC O-MISC
secondary O-MISC O-MISC
stimulus O-MISC O-MISC
that O-MISC O-MISC
mediates O-MISC O-MISC
selective O-MISC O-MISC
survival O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
lineage O-MISC O-MISC
. O-MISC O-MISC

Stat6 B-MISC B-MISC
is O-MISC O-MISC
necessary O-MISC O-MISC
and O-MISC O-MISC
sufficient O-MISC O-MISC
for O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
' O-MISC O-MISC
s O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
expansion O-MISC O-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
CR O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
naive O-MISC O-MISC
CD4 O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
Th2 O-MISC O-MISC
phenotype O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4R I-MISC I-MISC
activates O-MISC O-MISC
a O-MISC O-MISC
set O-MISC O-MISC
of O-MISC O-MISC
phosphotyrosine B-MISC O-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
proteins I-MISC I-MISC
, O-MISC O-MISC
including O-MISC O-MISC
insulin B-MISC B-MISC
receptor I-MISC I-MISC
substrate I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
Shc B-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4R I-MISC I-MISC
interacting I-MISC I-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
Stat6 B-MISC B-MISC
. O-MISC O-MISC

Stat6 B-MISC B-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
roles O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
phosphotyrosine B-MISC O-MISC
binding I-MISC O-MISC
adaptors I-MISC O-MISC
in O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
prepared O-MISC O-MISC
a O-MISC O-MISC
retrovirus O-MISC O-MISC
containing O-MISC O-MISC
a O-MISC O-MISC
mutant O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
( I-MISC I-MISC
h I-MISC I-MISC
) I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
4R I-MISC I-MISC
alpha I-MISC I-MISC
- I-MISC I-MISC
chain I-MISC I-MISC
, O-MISC O-MISC
Y497F B-MISC B-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
unable O-MISC O-MISC
to O-MISC O-MISC
recruit O-MISC O-MISC
these O-MISC O-MISC
adaptors O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mutant B-MISC B-MISC
hIL I-MISC I-MISC
- I-MISC I-MISC
4Ralpha I-MISC I-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
wild B-MISC B-MISC
- I-MISC I-MISC
type I-MISC O-MISC
( I-MISC O-MISC
WT I-MISC B-MISC
) I-MISC O-MISC
hIL I-MISC B-MISC
- I-MISC I-MISC
4Ralpha I-MISC I-MISC
, O-MISC O-MISC
was O-MISC O-MISC
introduced O-MISC O-MISC
into O-MISC O-MISC
naive O-MISC O-MISC
CD4 O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Upon O-MISC O-MISC
hIL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
stimulation O-MISC O-MISC
, O-MISC O-MISC
Y497F B-MISC B-MISC
worked O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
WT B-MISC B-MISC
hIL I-MISC B-MISC
- I-MISC I-MISC
4Ralpha I-MISC I-MISC
in O-MISC O-MISC
driving O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
Gata3 O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
and O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
production O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
cell O-MISC O-MISC
expansion O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
normal O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
infected O-MISC O-MISC
with O-MISC O-MISC
Y497F B-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
cells O-MISC O-MISC
infected O-MISC O-MISC
with O-MISC O-MISC
Y497F B-MISC B-MISC
were O-MISC O-MISC
not O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
phosphorylating O-MISC O-MISC
insulin B-MISC B-MISC
receptor I-MISC I-MISC
substrate I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
signal O-MISC O-MISC
pathway O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
Y497 B-MISC O-MISC
is O-MISC O-MISC
dispensable O-MISC O-MISC
for O-MISC O-MISC
both O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
expansion O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
WT B-MISC O-MISC
and I-MISC O-MISC
Y497F I-MISC B-MISC
hIL I-MISC I-MISC
- I-MISC I-MISC
4Ralpha I-MISC I-MISC
lose O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
drive O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
expansion O-MISC O-MISC
in O-MISC O-MISC
Stat6 O-MISC B-MISC
- O-MISC O-MISC
knockout O-MISC O-MISC
CD4 O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
constitutively O-MISC O-MISC
activated O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
Stat6 B-MISC B-MISC
introduced O-MISC O-MISC
into O-MISC O-MISC
CD4 O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
enhanced O-MISC O-MISC
cell O-MISC O-MISC
expansion O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
activated B-MISC O-MISC
Stat6 I-MISC B-MISC
is O-MISC O-MISC
necessary O-MISC O-MISC
and O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
mediate O-MISC O-MISC
both O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
expansion O-MISC O-MISC
in O-MISC O-MISC
CD4 O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
regulatory I-MISC I-MISC
proteins I-MISC I-MISC
on O-MISC O-MISC
cellular O-MISC B-MISC
genes O-MISC I-MISC
: O-MISC O-MISC
derepression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
by O-MISC O-MISC
Tat B-MISC B-MISC
. O-MISC O-MISC

In O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
individuals O-MISC O-MISC
dysregulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
is O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
severe O-MISC O-MISC
disorders O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cytokine O-MISC B-MISC
network O-MISC O-MISC
. O-MISC O-MISC

Increase O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
cytokine B-MISC B-MISC
, O-MISC O-MISC
may O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
decisive O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
sensitization O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
for O-MISC O-MISC
activation O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
and O-MISC O-MISC
indirect O-MISC O-MISC
death O-MISC O-MISC
of O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
through O-MISC O-MISC
augmented O-MISC O-MISC
virus O-MISC O-MISC
replication O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
cause O-MISC O-MISC
of O-MISC O-MISC
enhanced O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
secretion O-MISC O-MISC
and O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
HIV B-MISC B-MISC
Tat I-MISC I-MISC
induces O-MISC O-MISC
this O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
increased O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
secretion O-MISC O-MISC
is O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
Tat B-MISC B-MISC
- O-MISC I-MISC
enhanced O-MISC I-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Tat B-MISC O-MISC
derepresses O-MISC O-MISC
and O-MISC O-MISC
activates O-MISC O-MISC
the O-MISC O-MISC
distal B-MISC B-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
( O-MISC O-MISC
position B-MISC I-MISC
- I-MISC I-MISC
185 I-MISC I-MISC
to I-MISC I-MISC
- I-MISC I-MISC
177 I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
nonstimulated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
a O-MISC O-MISC
repressor O-MISC B-MISC
complex O-MISC I-MISC
containing O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
IL6 I-MISC I-MISC
, O-MISC O-MISC
JunB B-MISC B-MISC
, O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Fos I-MISC I-MISC
and O-MISC O-MISC
Fra B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
formed O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
/ I-MISC I-MISC
d I-MISC I-MISC
) I-MISC I-MISC
site I-MISC I-MISC
and O-MISC O-MISC
represses O-MISC B-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
heterodimeric B-MISC O-MISC
activator I-MISC I-MISC
containing O-MISC O-MISC
p65 B-MISC B-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
/ I-MISC I-MISC
d I-MISC I-MISC
) I-MISC I-MISC
site I-MISC I-MISC
. O-MISC O-MISC

HIV B-MISC B-MISC
Tat I-MISC I-MISC
enhances O-MISC I-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
consequently O-MISC O-MISC
, O-MISC O-MISC
activates O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
/ I-MISC I-MISC
d I-MISC I-MISC
) I-MISC I-MISC
site I-MISC I-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
data O-MISC O-MISC
provide O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
HIV B-MISC O-MISC
Tat I-MISC I-MISC
dysregulates O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
production O-MISC O-MISC
and O-MISC O-MISC
therefore O-MISC O-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
way O-MISC O-MISC
yet O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
clarified O-MISC O-MISC
. O-MISC O-MISC

Transforming B-MISC O-MISC
growth I-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
interferes O-MISC O-MISC
with O-MISC O-MISC
thrombopoietin O-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
in O-MISC O-MISC
megakaryoblastic O-MISC O-MISC
and O-MISC O-MISC
erythroleukemic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
Thrombopoietin B-MISC B-MISC
( O-MISC O-MISC
TPO B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
transforming B-MISC B-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
( I-MISC O-MISC
1 I-MISC I-MISC
) I-MISC O-MISC
( O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
( I-MISC O-MISC
1 I-MISC I-MISC
) I-MISC O-MISC
) O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
exert O-MISC O-MISC
opposite O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
megakaryocytic O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
hematopoietic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
( I-MISC I-MISC
1 I-MISC I-MISC
) I-MISC O-MISC
interferes O-MISC O-MISC
directly O-MISC O-MISC
with O-MISC O-MISC
TPO B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
in O-MISC O-MISC
hematopoietic O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
compared O-MISC O-MISC
the O-MISC O-MISC
regulatory O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
TPO B-MISC O-MISC
- O-MISC O-MISC
responsive O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
Mo O-MISC O-MISC
- O-MISC O-MISC
7e O-MISC O-MISC
and O-MISC O-MISC
HEL O-MISC O-MISC
. O-MISC O-MISC

MATERIALS O-MISC O-MISC
AND O-MISC O-MISC
METHODS O-MISC O-MISC
: O-MISC O-MISC
The O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
stimulated O-MISC O-MISC
by O-MISC O-MISC
100 O-MISC O-MISC
ng O-MISC O-MISC
/ O-MISC O-MISC
mL O-MISC O-MISC
TPO B-MISC O-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
100 O-MISC O-MISC
ng O-MISC O-MISC
/ O-MISC O-MISC
mL O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
and O-MISC O-MISC
analyzed O-MISC O-MISC
for O-MISC O-MISC
proliferation O-MISC O-MISC
( O-MISC O-MISC
3H O-MISC O-MISC
thymidine O-MISC O-MISC
incorporation O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
viability O-MISC O-MISC
( O-MISC O-MISC
trypan O-MISC O-MISC
blue O-MISC O-MISC
exclusion O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
phosphorylation O-MISC O-MISC
( O-MISC O-MISC
Western O-MISC O-MISC
blot O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
TPO B-MISC O-MISC
enhanced O-MISC O-MISC
the O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
Mo O-MISC O-MISC
- O-MISC O-MISC
7e O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
3H O-MISC O-MISC
- O-MISC O-MISC
thymidine O-MISC O-MISC
incorporation O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
suppressed O-MISC O-MISC
baseline O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
and O-MISC O-MISC
antagonized O-MISC O-MISC
the O-MISC O-MISC
proliferative O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
TPO B-MISC B-MISC
. O-MISC O-MISC

TPO B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
proliferation O-MISC O-MISC
also O-MISC O-MISC
was O-MISC O-MISC
reduced O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mitogen B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
MAPK B-MISC B-MISC
) O-MISC O-MISC
pathway O-MISC O-MISC
( O-MISC O-MISC
PD098059 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
inhibits O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
MAPK B-MISC B-MISC
extracellular I-MISC B-MISC
signal I-MISC I-MISC
- I-MISC I-MISC
regulated I-MISC I-MISC
kinases I-MISC I-MISC
( O-MISC O-MISC
ERK B-MISC B-MISC
) O-MISC O-MISC
ERK1 B-MISC B-MISC
and O-MISC O-MISC
ERK2 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
AG490 O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
Janus B-MISC B-MISC
kinase I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
completely O-MISC O-MISC
blocked O-MISC O-MISC
TPO B-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
demonstrated O-MISC O-MISC
by O-MISC O-MISC
Western O-MISC O-MISC
blotting O-MISC O-MISC
, O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
reduced O-MISC O-MISC
the O-MISC O-MISC
TPO B-MISC B-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
ERK1 B-MISC B-MISC
/ O-MISC O-MISC
ERK2 B-MISC I-MISC
and O-MISC O-MISC
STAT5 O-MISC B-MISC
phosphorylation O-MISC O-MISC
in O-MISC O-MISC
Mo O-MISC O-MISC
- O-MISC O-MISC
7e O-MISC O-MISC
and O-MISC O-MISC
HEL O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
effect O-MISC O-MISC
was O-MISC O-MISC
completely O-MISC O-MISC
reversed O-MISC O-MISC
by O-MISC O-MISC
preincubation O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
tyrosine O-MISC B-MISC
phosphatase O-MISC I-MISC
inhibitor O-MISC I-MISC
( O-MISC O-MISC
Na3VO4 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
activated O-MISC O-MISC
a O-MISC O-MISC
phosphatase B-MISC I-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
STAT3 B-MISC B-MISC
also O-MISC O-MISC
was O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
TPO B-MISC B-MISC
, O-MISC O-MISC
STAT3 B-MISC B-MISC
activation O-MISC O-MISC
remained O-MISC O-MISC
unaltered O-MISC O-MISC
by O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
Taken O-MISC O-MISC
together O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
modulates O-MISC I-MISC
TPO B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
megakaryocytic O-MISC O-MISC
proliferation O-MISC O-MISC
by O-MISC O-MISC
interfering O-MISC O-MISC
with O-MISC O-MISC
TPO B-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
, O-MISC O-MISC
particularly O-MISC O-MISC
by O-MISC O-MISC
reducing O-MISC O-MISC
the O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
MAPK B-MISC B-MISC
ERK1 I-MISC B-MISC
/ I-MISC I-MISC
ERK2 I-MISC I-MISC
and I-MISC O-MISC
STAT5 I-MISC B-MISC
. O-MISC O-MISC

Invariant B-MISC O-MISC
chain I-MISC O-MISC
induces O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
maturation O-MISC O-MISC
by O-MISC O-MISC
activating O-MISC O-MISC
a O-MISC O-MISC
TAF B-MISC B-MISC
( I-MISC O-MISC
II I-MISC I-MISC
) I-MISC I-MISC
105 I-MISC O-MISC
- I-MISC I-MISC
NF I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
transcription O-MISC O-MISC
program O-MISC O-MISC
. O-MISC O-MISC

Early O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
occur O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
, O-MISC O-MISC
resulting O-MISC O-MISC
in O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
immature O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

From O-MISC O-MISC
there O-MISC O-MISC
these O-MISC O-MISC
immature O-MISC O-MISC
cells O-MISC O-MISC
migrate O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
spleen O-MISC O-MISC
where O-MISC O-MISC
they O-MISC O-MISC
differentiate O-MISC O-MISC
to O-MISC O-MISC
mature O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
final O-MISC O-MISC
maturation O-MISC O-MISC
step O-MISC O-MISC
is O-MISC O-MISC
crucial O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
become O-MISC O-MISC
responsive O-MISC O-MISC
to O-MISC O-MISC
antigens B-MISC B-MISC
and O-MISC O-MISC
to O-MISC O-MISC
participate O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Recently O-MISC O-MISC
, O-MISC O-MISC
invariant B-MISC B-MISC
chain I-MISC I-MISC
( O-MISC O-MISC
Ii B-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
major B-MISC B-MISC
histocompatibility I-MISC I-MISC
complex I-MISC I-MISC
class I-MISC I-MISC
II I-MISC I-MISC
chaperone I-MISC I-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
and O-MISC O-MISC
p65 B-MISC B-MISC
/ I-MISC I-MISC
RelA I-MISC I-MISC
, O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
final O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
differentiation O-MISC O-MISC
stage O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
spleen O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
a O-MISC O-MISC
possible O-MISC O-MISC
link O-MISC O-MISC
between O-MISC O-MISC
Ii B-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
maturation O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
studies O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
Ii B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
maturation O-MISC O-MISC
involves O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
transcription O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
p65 I-MISC I-MISC
/ I-MISC I-MISC
RelA I-MISC I-MISC
homodimer I-MISC I-MISC
and O-MISC O-MISC
requires O-MISC O-MISC
the O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
enriched I-MISC I-MISC
coactivator I-MISC I-MISC
TBP B-MISC I-MISC
- I-MISC I-MISC
associated I-MISC I-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
II I-MISC I-MISC
) I-MISC I-MISC
105 I-MISC I-MISC
. O-MISC O-MISC

Androgens O-MISC O-MISC
indirectly O-MISC O-MISC
accelerate O-MISC O-MISC
thymocyte O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Apoptotic O-MISC O-MISC
processes O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
the O-MISC O-MISC
disturbance O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
natural O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
processes O-MISC O-MISC
, O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
autoimmune O-MISC O-MISC
diseases O-MISC O-MISC
( O-MISC O-MISC
AID O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Women O-MISC O-MISC
are O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
general O-MISC O-MISC
, O-MISC O-MISC
more O-MISC O-MISC
susceptible O-MISC O-MISC
than O-MISC O-MISC
men O-MISC O-MISC
to O-MISC O-MISC
develop O-MISC O-MISC
AID O-MISC O-MISC
like O-MISC O-MISC
rheumatoid O-MISC O-MISC
arthritis O-MISC O-MISC
. O-MISC O-MISC

Androgens O-MISC O-MISC
and O-MISC O-MISC
glucocorticoids O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
oestrogens O-MISC O-MISC
, O-MISC O-MISC
have O-MISC O-MISC
favourable O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
AID O-MISC O-MISC
models O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
in O-MISC O-MISC
human O-MISC B-MISC
AID O-MISC I-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
that O-MISC O-MISC
glucocorticoids O-MISC O-MISC
( O-MISC O-MISC
GC O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
used O-MISC O-MISC
for O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
AID O-MISC O-MISC
, O-MISC O-MISC
increase O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
resulting O-MISC O-MISC
in O-MISC O-MISC
decreased O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
was O-MISC O-MISC
asked O-MISC O-MISC
whether O-MISC O-MISC
androgens O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
oestrogens O-MISC O-MISC
, O-MISC O-MISC
exert O-MISC O-MISC
their O-MISC O-MISC
favourable O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
AID O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
mechanism O-MISC O-MISC
comparable O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
described O-MISC O-MISC
for O-MISC O-MISC
GC O-MISC O-MISC
by O-MISC O-MISC
eliminating O-MISC O-MISC
the O-MISC O-MISC
apoptosis O-MISC O-MISC
prone O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
population O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
both O-MISC O-MISC
androgens O-MISC O-MISC
and O-MISC O-MISC
oestrogens O-MISC O-MISC
proved O-MISC O-MISC
thymolytic O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
significantly O-MISC O-MISC
decreased O-MISC O-MISC
percentage O-MISC O-MISC
of O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
thymocytes O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
by O-MISC O-MISC
flow O-MISC O-MISC
cytometry O-MISC O-MISC
after O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
mice O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
androgen O-MISC O-MISC
methyltestosterone O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
oestrogen O-MISC O-MISC
ethinylestradiol O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
investigate O-MISC O-MISC
whether O-MISC O-MISC
the O-MISC O-MISC
observed O-MISC O-MISC
thymolytic O-MISC O-MISC
effects O-MISC O-MISC
were O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
hormone B-MISC B-MISC
receptors I-MISC I-MISC
on O-MISC O-MISC
thymocytes O-MISC O-MISC
, O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
and O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
androgens O-MISC O-MISC
or O-MISC O-MISC
oestrogens O-MISC O-MISC
to O-MISC O-MISC
measure O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Several O-MISC O-MISC
techniques O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
thymocyte O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
no O-MISC O-MISC
enhanced O-MISC O-MISC
apoptotic O-MISC O-MISC
signal O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
the O-MISC O-MISC
very O-MISC O-MISC
sensitive O-MISC O-MISC
TUNEL O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
no O-MISC O-MISC
direct O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
androgens O-MISC O-MISC
on O-MISC O-MISC
thymocytes O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
is O-MISC O-MISC
in O-MISC O-MISC
sharp O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
high O-MISC O-MISC
signal O-MISC O-MISC
observed O-MISC O-MISC
with O-MISC O-MISC
GC O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
upon O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
androgen O-MISC O-MISC
treatment O-MISC O-MISC
, O-MISC O-MISC
other O-MISC O-MISC
cells O-MISC O-MISC
containing O-MISC O-MISC
androgen B-MISC B-MISC
receptors I-MISC I-MISC
than O-MISC O-MISC
thymocytes O-MISC O-MISC
are O-MISC O-MISC
probably O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
inducing O-MISC O-MISC
the O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
thymic O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
study O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
androgen B-MISC B-MISC
receptor I-MISC I-MISC
on O-MISC O-MISC
thymocyte O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
androgen B-MISC B-MISC
receptor I-MISC I-MISC
mutant O-MISC I-MISC
( O-MISC O-MISC
Tfm O-MISC O-MISC
/ O-MISC O-MISC
Y O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
androgens O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
alterations O-MISC O-MISC
of O-MISC O-MISC
thymocyte O-MISC O-MISC
subpopulations O-MISC O-MISC
were O-MISC O-MISC
seen O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
percentage O-MISC O-MISC
of O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
thymocytes O-MISC O-MISC
after O-MISC O-MISC
administration O-MISC O-MISC
of O-MISC O-MISC
androgens O-MISC O-MISC
depend O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
functional O-MISC O-MISC
androgen B-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
concluded O-MISC O-MISC
that O-MISC O-MISC
androgens O-MISC O-MISC
indirectly O-MISC O-MISC
accelerate O-MISC O-MISC
thymocyte O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
CD4 O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
peroxisome B-MISC O-MISC
proliferator I-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
receptor I-MISC I-MISC
gamma I-MISC I-MISC
ligands I-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
peroxisome B-MISC O-MISC
proliferator I-MISC I-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
receptor I-MISC I-MISC
gamma I-MISC I-MISC
( O-MISC O-MISC
PPARgamma B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nuclear B-MISC B-MISC
hormone I-MISC I-MISC
receptor I-MISC I-MISC
superfamily I-MISC I-MISC
, O-MISC O-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
adipocyte O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
glucose O-MISC O-MISC
homeostasis O-MISC O-MISC
. O-MISC O-MISC

PPARgamma B-MISC B-MISC
has O-MISC O-MISC
been O-MISC O-MISC
found O-MISC O-MISC
recently O-MISC O-MISC
to O-MISC O-MISC
regulate O-MISC O-MISC
macrophage O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
mitogens B-MISC B-MISC
and O-MISC O-MISC
inflammation O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
study O-MISC O-MISC
shows O-MISC O-MISC
PPARgamma B-MISC B-MISC
to O-MISC O-MISC
be O-MISC O-MISC
preferentially O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
nuclei O-MISC O-MISC
of O-MISC O-MISC
resting O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
increase O-MISC O-MISC
upon O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
either O-MISC O-MISC
anti B-MISC O-MISC
- I-MISC O-MISC
CD3 I-MISC O-MISC
and O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD28 I-MISC I-MISC
or O-MISC O-MISC
phorbol O-MISC O-MISC
myristyl O-MISC O-MISC
acetate O-MISC O-MISC
( O-MISC O-MISC
PMA O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
also O-MISC O-MISC
found O-MISC O-MISC
the O-MISC O-MISC
PPARgamma B-MISC B-MISC
ligand I-MISC I-MISC
ciglitizone O-MISC O-MISC
to O-MISC O-MISC
attenuate O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
inhibiting O-MISC O-MISC
cytokine O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
and O-MISC O-MISC
anti B-MISC O-MISC
- I-MISC O-MISC
CD28 I-MISC B-MISC
or O-MISC O-MISC
PMA O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
proliferative O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
proliferative O-MISC O-MISC
response O-MISC O-MISC
and O-MISC O-MISC
inflammatory O-MISC O-MISC
cytokine O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
CD4 O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
activated O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
AP1 B-MISC B-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
. O-MISC O-MISC

PPARgamma B-MISC B-MISC
ligands I-MISC O-MISC
also O-MISC O-MISC
strongly O-MISC O-MISC
inhibited O-MISC O-MISC
SEA O-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
Vbeta3 O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
, O-MISC O-MISC
together O-MISC O-MISC
with O-MISC O-MISC
previous O-MISC O-MISC
findings O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
PPARgamma B-MISC B-MISC
ligands I-MISC O-MISC
on O-MISC O-MISC
activated O-MISC O-MISC
macrophages O-MISC O-MISC
, O-MISC O-MISC
provide O-MISC O-MISC
clear O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
PPARgamma B-MISC B-MISC
as O-MISC O-MISC
a O-MISC O-MISC
negative B-MISC O-MISC
regulator I-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inflammatory O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
macrophage O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

PPARgamma B-MISC B-MISC
may O-MISC O-MISC
thus O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
potential O-MISC O-MISC
therapeutic O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
autoimmunity O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
prominent O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
activator B-MISC B-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
2B4 I-MISC I-MISC
( I-MISC I-MISC
CD244 I-MISC I-MISC
) I-MISC I-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cell B-MISC B-MISC
surface I-MISC I-MISC
glycoprotein I-MISC I-MISC
2B4 I-MISC I-MISC
( O-MISC O-MISC
CD244 B-MISC B-MISC
) O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ig B-MISC B-MISC
superfamily I-MISC I-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
NK O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
lymphocyte O-MISC O-MISC
functions O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
recently O-MISC O-MISC
identified O-MISC O-MISC
CD48 B-MISC B-MISC
as O-MISC O-MISC
the O-MISC O-MISC
high B-MISC O-MISC
affinity I-MISC O-MISC
counterreceptor I-MISC O-MISC
for O-MISC O-MISC
2B4 B-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
mice O-MISC O-MISC
and O-MISC O-MISC
humans O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cytoplasmic B-MISC B-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
2B4 B-MISC B-MISC
associates O-MISC O-MISC
with O-MISC O-MISC
src B-MISC B-MISC
homology I-MISC I-MISC
2 I-MISC I-MISC
domain I-MISC I-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
protein I-MISC O-MISC
or O-MISC O-MISC
signaling B-MISC O-MISC
lymphocyte I-MISC B-MISC
activation I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
associated I-MISC I-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
whose O-MISC O-MISC
mutation O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
underlying O-MISC O-MISC
genetic O-MISC O-MISC
defect O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
lymphoproliferative O-MISC O-MISC
syndrome O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
cloning O-MISC O-MISC
and O-MISC O-MISC
characterization O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
2B4 I-MISC I-MISC
( I-MISC I-MISC
h2B4 I-MISC I-MISC
) I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Through O-MISC O-MISC
primer O-MISC O-MISC
extension O-MISC O-MISC
analysis O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
h2B4 B-MISC B-MISC
gene I-MISC I-MISC
initiates O-MISC O-MISC
at O-MISC O-MISC
multiple O-MISC O-MISC
start O-MISC O-MISC
sites O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
isolated O-MISC O-MISC
h2B4 B-MISC O-MISC
genomic I-MISC O-MISC
clones I-MISC O-MISC
and O-MISC O-MISC
PCR O-MISC O-MISC
amplified O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
untranslated I-MISC I-MISC
region I-MISC I-MISC
containing O-MISC O-MISC
the O-MISC O-MISC
promoter B-MISC B-MISC
elements I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
identified O-MISC O-MISC
a O-MISC O-MISC
functional O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
that O-MISC O-MISC
lies O-MISC O-MISC
between O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
106 O-MISC O-MISC
to O-MISC O-MISC
- O-MISC O-MISC
100 O-MISC O-MISC
) O-MISC O-MISC
through O-MISC O-MISC
transient O-MISC O-MISC
transfection O-MISC O-MISC
analysis O-MISC O-MISC
in O-MISC O-MISC
YT O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
human O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

EMSAs O-MISC O-MISC
with O-MISC O-MISC
Abs B-MISC B-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
various O-MISC O-MISC
protein B-MISC B-MISC
factors I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
family I-MISC I-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
multiple O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Jun B-MISC B-MISC
family I-MISC I-MISC
are O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
h2B4 B-MISC B-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

Mutation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
not O-MISC O-MISC
only O-MISC O-MISC
abolishes O-MISC O-MISC
protein O-MISC O-MISC
/ O-MISC O-MISC
DNA O-MISC O-MISC
interactions O-MISC O-MISC
but O-MISC O-MISC
also O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
demonstrate O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
h2B4 B-MISC B-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

Functional O-MISC O-MISC
correction O-MISC O-MISC
of O-MISC O-MISC
FA O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
FANCC B-MISC O-MISC
suppresses O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
interferon B-MISC B-MISC
gamma I-MISC I-MISC
- I-MISC I-MISC
inducible I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Because O-MISC O-MISC
hematopoietic O-MISC O-MISC
cells O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
Fanconi O-MISC O-MISC
anemia O-MISC O-MISC
( O-MISC O-MISC
FA O-MISC O-MISC
) O-MISC O-MISC
patients O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
C O-MISC O-MISC
- O-MISC O-MISC
complementation O-MISC O-MISC
group O-MISC O-MISC
( O-MISC O-MISC
FA O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
) O-MISC O-MISC
are O-MISC O-MISC
hypersensitive O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
interferon B-MISC B-MISC
gamma I-MISC I-MISC
( O-MISC I-MISC
IFNgamma B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
products O-MISC O-MISC
of O-MISC O-MISC
certain O-MISC O-MISC
IFNgamma B-MISC B-MISC
- I-MISC I-MISC
inducible I-MISC I-MISC
genes I-MISC I-MISC
known O-MISC O-MISC
to O-MISC O-MISC
influence O-MISC O-MISC
hematopoietic O-MISC O-MISC
cell O-MISC O-MISC
survival O-MISC O-MISC
were O-MISC O-MISC
quantified O-MISC O-MISC
. O-MISC O-MISC

High O-MISC O-MISC
constitutive O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IFNgamma B-MISC B-MISC
- I-MISC I-MISC
inducible I-MISC I-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
stimulated I-MISC I-MISC
gene I-MISC I-MISC
factor I-MISC I-MISC
3 I-MISC I-MISC
gamma I-MISC I-MISC
subunit I-MISC I-MISC
( O-MISC O-MISC
ISGF3gamma B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
IFN B-MISC B-MISC
regulatory I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
IRF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
cyclin B-MISC B-MISC
- I-MISC I-MISC
dependent I-MISC I-MISC
kinase I-MISC I-MISC
inhibitor I-MISC I-MISC
p21 I-MISC I-MISC
( O-MISC I-MISC
WAF1 B-MISC I-MISC
) O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
FANCC B-MISC O-MISC
mutant O-MISC O-MISC
B O-MISC O-MISC
lymphoblasts O-MISC O-MISC
, O-MISC O-MISC
low O-MISC O-MISC
- O-MISC O-MISC
density O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
murine O-MISC O-MISC
embryonic O-MISC O-MISC
fibroblasts O-MISC O-MISC
. O-MISC O-MISC

Paradoxically O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
activate B-MISC O-MISC
signal I-MISC B-MISC
transducer I-MISC I-MISC
and I-MISC I-MISC
activator I-MISC I-MISC
of I-MISC I-MISC
transcription I-MISC I-MISC
( I-MISC I-MISC
STAT I-MISC I-MISC
) I-MISC I-MISC
1 I-MISC I-MISC
properly O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
an O-MISC O-MISC
attempt O-MISC O-MISC
to O-MISC O-MISC
clarify O-MISC O-MISC
mechanisms O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
FA O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
cells O-MISC O-MISC
overexpress O-MISC O-MISC
IFNgamma B-MISC B-MISC
- I-MISC O-MISC
inducible I-MISC O-MISC
genes I-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
face O-MISC O-MISC
of O-MISC O-MISC
defective O-MISC O-MISC
STAT1 O-MISC B-MISC
phosphorylation O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
reasoned O-MISC O-MISC
that O-MISC O-MISC
decreased O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
activated B-MISC O-MISC
STAT1 I-MISC B-MISC
might O-MISC O-MISC
result O-MISC O-MISC
in O-MISC O-MISC
reduced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
hematopoietic B-MISC O-MISC
IFNgamma I-MISC I-MISC
- I-MISC I-MISC
responsive I-MISC I-MISC
protein I-MISC I-MISC
that O-MISC O-MISC
normally O-MISC O-MISC
modulates O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
other O-MISC O-MISC
IFNgamma B-MISC B-MISC
- I-MISC O-MISC
responsive I-MISC O-MISC
genes I-MISC O-MISC
. O-MISC O-MISC

Levels O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IFNgamma B-MISC B-MISC
- O-MISC I-MISC
inducible O-MISC I-MISC
factor O-MISC I-MISC
IFN B-MISC I-MISC
consensus I-MISC I-MISC
sequence I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
ICSBP B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
negative B-MISC B-MISC
trans I-MISC I-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
regulator I-MISC I-MISC
of O-MISC O-MISC
some O-MISC O-MISC
IFNgamma B-MISC B-MISC
- I-MISC I-MISC
inducible I-MISC O-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
were O-MISC O-MISC
quantified O-MISC O-MISC
. O-MISC O-MISC

ICSBP B-MISC B-MISC
levels O-MISC O-MISC
were O-MISC O-MISC
reduced O-MISC O-MISC
in O-MISC O-MISC
FA O-MISC O-MISC
- O-MISC O-MISC
C O-MISC O-MISC
B O-MISC O-MISC
lymphoblasts O-MISC O-MISC
and O-MISC O-MISC
MEFs O-MISC B-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
enforced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
ICSBP B-MISC B-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulate O-MISC O-MISC
IRF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
ISGF3gamma B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
p21 B-MISC B-MISC
( I-MISC O-MISC
WAF1 I-MISC B-MISC
) I-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
FANCC B-MISC B-MISC
protein I-MISC I-MISC
functions O-MISC O-MISC
to O-MISC O-MISC
modulate O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
family O-MISC O-MISC
of O-MISC O-MISC
genes O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
inducible O-MISC O-MISC
only O-MISC O-MISC
by O-MISC O-MISC
specific O-MISC O-MISC
environmental O-MISC O-MISC
cues O-MISC O-MISC
for O-MISC O-MISC
apoptosis O-MISC O-MISC
or O-MISC O-MISC
mitogenic O-MISC O-MISC
inhibition O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
it O-MISC O-MISC
does O-MISC O-MISC
so O-MISC O-MISC
independently O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
classic O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
STAT1 O-MISC I-MISC
pathway O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
direct O-MISC O-MISC
result O-MISC O-MISC
of O-MISC O-MISC
reduced O-MISC O-MISC
ICSBP B-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
genetic O-MISC O-MISC
investigation O-MISC O-MISC
of O-MISC O-MISC
E2A O-MISC B-MISC
function O-MISC O-MISC
in O-MISC O-MISC
lymphocyte O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

Lymphocytes O-MISC O-MISC
are O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
hematopoietic O-MISC O-MISC
stem O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
HSC O-MISC O-MISC
) O-MISC O-MISC
following O-MISC O-MISC
a O-MISC O-MISC
series O-MISC O-MISC
of O-MISC O-MISC
regulated O-MISC O-MISC
differentiation O-MISC O-MISC
events O-MISC O-MISC
. O-MISC O-MISC

Multipotent O-MISC O-MISC
HSCs O-MISC O-MISC
become O-MISC O-MISC
committed O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
lineage O-MISC O-MISC
in O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
lineage O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
after O-MISC O-MISC
receiving O-MISC O-MISC
appropriate O-MISC O-MISC
signals O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
corresponding O-MISC O-MISC
microenvironment O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
committed O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
must O-MISC O-MISC
then O-MISC O-MISC
undergo O-MISC O-MISC
V O-MISC O-MISC
( O-MISC O-MISC
D O-MISC O-MISC
) O-MISC O-MISC
J O-MISC O-MISC
recombination O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
immunoglobulin B-MISC B-MISC
gene I-MISC I-MISC
or O-MISC O-MISC
T B-MISC B-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
gene I-MISC I-MISC
locus I-MISC I-MISC
resulting O-MISC O-MISC
in O-MISC O-MISC
clonal O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
functional O-MISC O-MISC
B O-MISC O-MISC
or O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

Lymphocyte O-MISC O-MISC
commitment O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
are O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
programmed O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
or O-MISC O-MISC
repression O-MISC O-MISC
events O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
driven O-MISC O-MISC
by O-MISC O-MISC
lineage B-MISC O-MISC
and I-MISC O-MISC
stage I-MISC O-MISC
specific I-MISC O-MISC
transcription I-MISC B-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
basic B-MISC B-MISC
- I-MISC I-MISC
helix I-MISC I-MISC
- I-MISC I-MISC
loop I-MISC I-MISC
- I-MISC I-MISC
helix I-MISC I-MISC
( I-MISC I-MISC
bHLH I-MISC I-MISC
) I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
encoded O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
E2A B-MISC B-MISC
gene I-MISC I-MISC
are O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
several O-MISC O-MISC
differentiation O-MISC O-MISC
events O-MISC O-MISC
during O-MISC O-MISC
B O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
lineage O-MISC O-MISC
commitment O-MISC O-MISC
, O-MISC O-MISC
initiation O-MISC O-MISC
of O-MISC O-MISC
V O-MISC O-MISC
( O-MISC O-MISC
D O-MISC O-MISC
) O-MISC O-MISC
J O-MISC O-MISC
recombination O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
antigen O-MISC O-MISC
receptor O-MISC O-MISC
mediated O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

Several O-MISC O-MISC
recent O-MISC O-MISC
reviews O-MISC O-MISC
have O-MISC O-MISC
provided O-MISC O-MISC
a O-MISC O-MISC
comprehensive O-MISC O-MISC
discussion O-MISC O-MISC
of O-MISC O-MISC
biochemical O-MISC O-MISC
, O-MISC O-MISC
cellular O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
genetic O-MISC O-MISC
research O-MISC O-MISC
on O-MISC O-MISC
E2A O-MISC B-MISC
function O-MISC O-MISC
in O-MISC O-MISC
lymphocyte O-MISC O-MISC
development O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
only O-MISC O-MISC
discuss O-MISC O-MISC
some O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
genetic O-MISC O-MISC
approaches O-MISC O-MISC
our O-MISC O-MISC
laboratory O-MISC O-MISC
( O-MISC O-MISC
except O-MISC O-MISC
where O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
noted O-MISC O-MISC
) O-MISC O-MISC
has O-MISC O-MISC
undertaken O-MISC O-MISC
to O-MISC O-MISC
investigate O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
pathways O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
E2A B-MISC B-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
in O-MISC O-MISC
lymphocyte O-MISC O-MISC
development O-MISC O-MISC

D609 O-MISC O-MISC
inhibits O-MISC O-MISC
ionizing O-MISC O-MISC
radiation O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
oxidative O-MISC O-MISC
damage O-MISC O-MISC
by O-MISC O-MISC
acting O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
antioxidant O-MISC O-MISC
. O-MISC O-MISC

Tricyclodecan O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
yl O-MISC O-MISC
- O-MISC O-MISC
xanthogenate O-MISC O-MISC
( O-MISC O-MISC
D609 O-MISC O-MISC
) O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
extensively O-MISC O-MISC
studied O-MISC O-MISC
in O-MISC O-MISC
biological O-MISC O-MISC
systems O-MISC O-MISC
and O-MISC O-MISC
exhibits O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
biological O-MISC O-MISC
functions O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
antiviral O-MISC O-MISC
, O-MISC O-MISC
antitumor O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
activities O-MISC O-MISC
. O-MISC O-MISC

Most O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
activities O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
largely O-MISC O-MISC
attributed O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
D609 O-MISC O-MISC
on O-MISC O-MISC
phosphatidylcholine O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
phospholipase B-MISC O-MISC
C I-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
xanthate O-MISC O-MISC
derivative O-MISC O-MISC
, O-MISC O-MISC
D609 O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
strong O-MISC O-MISC
electrolyte O-MISC O-MISC
and O-MISC O-MISC
readily O-MISC O-MISC
dissociates O-MISC O-MISC
to O-MISC O-MISC
xanthate O-MISC O-MISC
anions O-MISC O-MISC
and O-MISC O-MISC
cations O-MISC O-MISC
of O-MISC O-MISC
alkali O-MISC O-MISC
metals O-MISC O-MISC
in O-MISC O-MISC
solution O-MISC O-MISC
. O-MISC O-MISC

Xanthate O-MISC O-MISC
anions O-MISC O-MISC
and O-MISC O-MISC
protonated O-MISC O-MISC
xanthic O-MISC O-MISC
acid O-MISC O-MISC
contain O-MISC O-MISC
a O-MISC O-MISC
free O-MISC O-MISC
thiol O-MISC O-MISC
moiety O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
highly O-MISC O-MISC
reductive O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
implies O-MISC O-MISC
that O-MISC O-MISC
D609 O-MISC O-MISC
and O-MISC O-MISC
other O-MISC O-MISC
xanthate O-MISC O-MISC
derivatives O-MISC O-MISC
may O-MISC O-MISC
function O-MISC O-MISC
as O-MISC O-MISC
potent O-MISC O-MISC
antioxidants O-MISC O-MISC
. O-MISC O-MISC

Indeed O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
D609 O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
Fenton O-MISC O-MISC
reaction O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
oxidation O-MISC O-MISC
of O-MISC O-MISC
dihydrorhodamine O-MISC O-MISC
123 O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
pyrrolidinedithiocar O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
well O-MISC O-MISC
known O-MISC O-MISC
antioxidant O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
D609 O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
alpha O-MISC O-MISC
- O-MISC O-MISC
phenyl O-MISC O-MISC
- O-MISC O-MISC
tert O-MISC O-MISC
- O-MISC O-MISC
butylnitrone O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
radical O-MISC O-MISC
spin O-MISC O-MISC
adducts O-MISC O-MISC
and O-MISC O-MISC
lipid O-MISC O-MISC
peroxidation O-MISC O-MISC
of O-MISC O-MISC
synaptosomal O-MISC O-MISC
membranes O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
Fenton O-MISC O-MISC
reagents O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
preincubation O-MISC O-MISC
of O-MISC O-MISC
lymphocytes O-MISC O-MISC
with O-MISC O-MISC
D609 O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
diminution O-MISC O-MISC
of O-MISC O-MISC
ionizing O-MISC O-MISC
radiation O-MISC O-MISC
( O-MISC O-MISC
IR O-MISC B-MISC
) O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
species O-MISC O-MISC
; O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
intracellular O-MISC O-MISC
reduced O-MISC O-MISC
glutathione O-MISC O-MISC
; O-MISC O-MISC
3 O-MISC O-MISC
) O-MISC O-MISC
oxidative O-MISC O-MISC
damage O-MISC O-MISC
to O-MISC O-MISC
proteins O-MISC O-MISC
and O-MISC O-MISC
lipids O-MISC O-MISC
; O-MISC O-MISC
and O-MISC O-MISC
4 O-MISC O-MISC
) O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
when O-MISC O-MISC
D609 O-MISC O-MISC
( O-MISC O-MISC
50 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
v O-MISC O-MISC
. O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
administered O-MISC O-MISC
to O-MISC O-MISC
mice O-MISC O-MISC
10 O-MISC O-MISC
min O-MISC O-MISC
prior O-MISC O-MISC
to O-MISC O-MISC
total O-MISC O-MISC
body O-MISC O-MISC
IR O-MISC B-MISC
( O-MISC O-MISC
6 O-MISC I-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
and O-MISC O-MISC
8 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
Gy O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
protected O-MISC O-MISC
the O-MISC O-MISC
mice O-MISC O-MISC
from O-MISC O-MISC
IR O-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
lethality O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
D609 O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
antioxidant O-MISC O-MISC
and O-MISC O-MISC
has O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
IR O-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cellular O-MISC O-MISC
oxidative O-MISC O-MISC
stress O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
by O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid O-MISC B-MISC
- O-MISC I-MISC
inducible O-MISC I-MISC
protein B-MISC I-MISC
GILZ I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
immunosuppressive O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
arise O-MISC O-MISC
largely O-MISC O-MISC
by O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
ascribed O-MISC O-MISC
to O-MISC O-MISC
interference O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC O-MISC
and O-MISC O-MISC
transcription B-MISC O-MISC
factors I-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
by O-MISC O-MISC
competition O-MISC O-MISC
for O-MISC O-MISC
common O-MISC O-MISC
coactivators O-MISC B-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
interleukin O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
mRNA O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
normal O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
required O-MISC O-MISC
new O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
phenomenon O-MISC O-MISC
is O-MISC O-MISC
secondary O-MISC O-MISC
to O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC B-MISC
- O-MISC I-MISC
regulated O-MISC I-MISC
genes B-MISC I-MISC
. O-MISC O-MISC

One O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
most O-MISC O-MISC
prominent O-MISC O-MISC
glucocorticoid O-MISC B-MISC
- O-MISC I-MISC
induced O-MISC I-MISC
genes B-MISC I-MISC
is O-MISC O-MISC
glucocorticoid B-MISC B-MISC
- I-MISC O-MISC
induced I-MISC O-MISC
leucine I-MISC B-MISC
zipper I-MISC I-MISC
( O-MISC O-MISC
GILZ B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
reported O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
activation O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
Fas B-MISC B-MISC
ligand I-MISC I-MISC
( I-MISC I-MISC
FasL I-MISC I-MISC
) I-MISC I-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

Indeed O-MISC O-MISC
, O-MISC O-MISC
transient O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
GILZ B-MISC B-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
blocked O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
reporter B-MISC B-MISC
construct I-MISC I-MISC
driven O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
FasL B-MISC B-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
accounted O-MISC O-MISC
for O-MISC O-MISC
by O-MISC O-MISC
GILZ B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
NFAT B-MISC B-MISC
/ I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- O-MISC O-MISC
inducible O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
that O-MISC O-MISC
bind O-MISC O-MISC
a O-MISC O-MISC
regulatory B-MISC B-MISC
element I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
FasL B-MISC B-MISC
promoter I-MISC I-MISC
and O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulate O-MISC O-MISC
FasL O-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

GILZ B-MISC B-MISC
also O-MISC O-MISC
potently O-MISC O-MISC
inhibited O-MISC O-MISC
AP B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- I-MISC I-MISC
driven I-MISC I-MISC
and I-MISC I-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
- I-MISC I-MISC
driven I-MISC I-MISC
reporter I-MISC I-MISC
constructs I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
recombinant O-MISC B-MISC
GILZ B-MISC I-MISC
specifically O-MISC O-MISC
interacted O-MISC O-MISC
with O-MISC O-MISC
c B-MISC B-MISC
- I-MISC O-MISC
Fos I-MISC O-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
active B-MISC O-MISC
AP I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
to O-MISC O-MISC
its O-MISC O-MISC
target O-MISC O-MISC
DNA O-MISC O-MISC
. O-MISC O-MISC

Whereas O-MISC O-MISC
homodimerization O-MISC O-MISC
of O-MISC O-MISC
GILZ B-MISC B-MISC
required O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
its O-MISC O-MISC
leucine B-MISC B-MISC
zipper I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Fos I-MISC I-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
occurred O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
N B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
60 B-MISC I-MISC
- I-MISC I-MISC
amino I-MISC I-MISC
acid I-MISC I-MISC
region I-MISC I-MISC
of O-MISC O-MISC
GILZ B-MISC B-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
GILZ B-MISC B-MISC
represents O-MISC O-MISC
a O-MISC O-MISC
glucocorticoid O-MISC B-MISC
- O-MISC I-MISC
induced O-MISC I-MISC
gene O-MISC I-MISC
product O-MISC I-MISC
that O-MISC O-MISC
can O-MISC O-MISC
inhibit O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
activation O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
events O-MISC O-MISC
, O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
by O-MISC O-MISC
direct O-MISC O-MISC
interference O-MISC O-MISC
with O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
therefore O-MISC O-MISC
a O-MISC O-MISC
candidate O-MISC O-MISC
for O-MISC O-MISC
a O-MISC O-MISC
mediator O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
immunosuppression O-MISC O-MISC
. O-MISC O-MISC

Pharmacokinetic O-MISC O-MISC
differences O-MISC O-MISC
between O-MISC O-MISC
a O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
tolerizing O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
activating O-MISC O-MISC
peptide O-MISC O-MISC
. O-MISC O-MISC

Vaccination O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
peptide O-MISC O-MISC
representing O-MISC O-MISC
a O-MISC O-MISC
CTL O-MISC B-MISC
epitope O-MISC I-MISC
from O-MISC O-MISC
the O-MISC O-MISC
human O-MISC B-MISC
papillomavirus O-MISC I-MISC
( O-MISC O-MISC
HPV O-MISC O-MISC
) O-MISC O-MISC
16 O-MISC I-MISC
E7 B-MISC B-MISC
protein I-MISC I-MISC
induces O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC O-MISC
CTL O-MISC O-MISC
response O-MISC O-MISC
that O-MISC O-MISC
prevents O-MISC O-MISC
the O-MISC O-MISC
outgrowth O-MISC O-MISC
of O-MISC O-MISC
HPV16 O-MISC O-MISC
E7 O-MISC O-MISC
- O-MISC O-MISC
expressing O-MISC O-MISC
tumors O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
vaccination O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
peptide O-MISC O-MISC
encoding O-MISC O-MISC
an O-MISC O-MISC
adenovirus O-MISC O-MISC
type O-MISC O-MISC
5 O-MISC O-MISC
( O-MISC O-MISC
Ad5 O-MISC O-MISC
) O-MISC O-MISC
E1A O-MISC B-MISC
CTL O-MISC I-MISC
epitope O-MISC I-MISC
results O-MISC O-MISC
in O-MISC O-MISC
CTL O-MISC O-MISC
tolerance O-MISC O-MISC
and O-MISC O-MISC
enhanced O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
Ad5 O-MISC O-MISC
E1A O-MISC O-MISC
- O-MISC O-MISC
expressing O-MISC O-MISC
tumor O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
unclear O-MISC O-MISC
why O-MISC O-MISC
these O-MISC O-MISC
peptides O-MISC O-MISC
induce O-MISC O-MISC
such O-MISC O-MISC
opposite O-MISC O-MISC
effects O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
a O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
pharmacokinetics O-MISC O-MISC
can O-MISC O-MISC
explain O-MISC O-MISC
the O-MISC O-MISC
functional O-MISC O-MISC
contrasts O-MISC O-MISC
, O-MISC O-MISC
tritiated O-MISC O-MISC
Ad5 O-MISC O-MISC
E1A O-MISC B-MISC
and O-MISC O-MISC
HPV16 O-MISC O-MISC
E7 O-MISC O-MISC
peptides O-MISC O-MISC
were O-MISC O-MISC
injected O-MISC O-MISC
into O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Results O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
tolerizing O-MISC O-MISC
peptide O-MISC O-MISC
spread O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
body O-MISC O-MISC
16 O-MISC O-MISC
times O-MISC O-MISC
faster O-MISC O-MISC
than O-MISC O-MISC
the O-MISC O-MISC
activating O-MISC O-MISC
peptide O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
cleared O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
2 O-MISC O-MISC
times O-MISC O-MISC
faster O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
HPV16 O-MISC O-MISC
E7 O-MISC B-MISC
peptide O-MISC O-MISC
kinetics O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
kinetics O-MISC O-MISC
of O-MISC O-MISC
HPV16 B-MISC O-MISC
E7 I-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CTL O-MISC O-MISC
induction O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
Ad5 O-MISC B-MISC
E1A O-MISC I-MISC
peptide O-MISC O-MISC
injection O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
physical O-MISC O-MISC
deletion O-MISC O-MISC
of O-MISC O-MISC
preexisting O-MISC O-MISC
Ad5 B-MISC O-MISC
E1A I-MISC B-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CTLs B-MISC O-MISC
within O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
after O-MISC O-MISC
injection O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
tolerization O-MISC O-MISC
occurred O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
time O-MISC O-MISC
when O-MISC O-MISC
the O-MISC O-MISC
peptide O-MISC O-MISC
reached O-MISC O-MISC
its O-MISC O-MISC
maximum O-MISC O-MISC
peptide O-MISC O-MISC
concentration O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
organs O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
ubiquitous O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tolerizing O-MISC O-MISC
Ad5 O-MISC B-MISC
E1A O-MISC B-MISC
peptide O-MISC O-MISC
within O-MISC O-MISC
a O-MISC O-MISC
short O-MISC O-MISC
period O-MISC O-MISC
of O-MISC O-MISC
time O-MISC O-MISC
causes O-MISC O-MISC
activation O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
death O-MISC O-MISC
of O-MISC O-MISC
Ad5 B-MISC B-MISC
E1A I-MISC B-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CTLs B-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
information O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
pharmacokinetics O-MISC O-MISC
of O-MISC O-MISC
peptides O-MISC O-MISC
is O-MISC O-MISC
vital O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
safety O-MISC O-MISC
and O-MISC O-MISC
efficacy O-MISC O-MISC
of O-MISC O-MISC
peptide O-MISC O-MISC
- O-MISC O-MISC
based O-MISC O-MISC
vaccines O-MISC O-MISC
. O-MISC O-MISC

Smad3 B-MISC B-MISC
and O-MISC O-MISC
Smad4 B-MISC B-MISC
mediate O-MISC O-MISC
transforming B-MISC I-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
IgA O-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
murine O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Transforming B-MISC O-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
TGF I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
is O-MISC O-MISC
well O-MISC O-MISC
established O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
IgA B-MISC B-MISC
isotype I-MISC O-MISC
switching I-MISC O-MISC
factor I-MISC O-MISC
and O-MISC O-MISC
Smad B-MISC B-MISC
molecules I-MISC I-MISC
have O-MISC O-MISC
been O-MISC O-MISC
reported O-MISC O-MISC
to O-MISC O-MISC
act O-MISC O-MISC
as O-MISC O-MISC
transducers B-MISC O-MISC
and O-MISC O-MISC
transcriptional B-MISC B-MISC
factors I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
- O-MISC I-MISC
targeted O-MISC I-MISC
genes B-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
Smad B-MISC B-MISC
proteins I-MISC I-MISC
in O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
IgA O-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

First O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
significantly O-MISC O-MISC
increases O-MISC O-MISC
endogenous B-MISC O-MISC
germ I-MISC I-MISC
- I-MISC O-MISC
line I-MISC I-MISC
( I-MISC O-MISC
GL I-MISC B-MISC
) I-MISC I-MISC
alpha I-MISC I-MISC
transcripts I-MISC I-MISC
by O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
CH12 O-MISC O-MISC
. O-MISC O-MISC
LX O-MISC O-MISC
. O-MISC O-MISC
4933 O-MISC O-MISC
( O-MISC O-MISC
mu O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
B O-MISC O-MISC
lymphoma O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
investigate O-MISC O-MISC
its O-MISC O-MISC
signaling O-MISC O-MISC
mechanisms O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
lymphoma O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
was O-MISC O-MISC
transfected O-MISC O-MISC
with O-MISC O-MISC
pFL3 B-MISC B-MISC
that O-MISC O-MISC
contains O-MISC O-MISC
the O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
- I-MISC I-MISC
responsive I-MISC I-MISC
element I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
GLalpha B-MISC B-MISC
promoter I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
. O-MISC O-MISC

Similar O-MISC O-MISC
to O-MISC O-MISC
endogenous B-MISC O-MISC
GLalpha I-MISC B-MISC
transcripts I-MISC I-MISC
, O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
induces O-MISC O-MISC
GLalpha B-MISC B-MISC
promoter I-MISC I-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
Smad3 B-MISC B-MISC
markedly O-MISC O-MISC
enhances O-MISC O-MISC
the O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
activity O-MISC O-MISC
is O-MISC O-MISC
further O-MISC O-MISC
augmented O-MISC O-MISC
by O-MISC O-MISC
cotransfected B-MISC O-MISC
Smad4 I-MISC B-MISC
. O-MISC O-MISC

On O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
hand O-MISC O-MISC
, O-MISC O-MISC
Smad7 B-MISC B-MISC
substantially O-MISC O-MISC
abrogates O-MISC O-MISC
the O-MISC O-MISC
synergistic O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
Smad3 B-MISC B-MISC
/ I-MISC I-MISC
4 I-MISC I-MISC
on O-MISC O-MISC
GLalpha B-MISC B-MISC
promoter I-MISC I-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
Smad3 B-MISC B-MISC
/ I-MISC I-MISC
4 I-MISC I-MISC
enhances O-MISC I-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
endogenous B-MISC O-MISC
GLalpha I-MISC B-MISC
transcripts I-MISC I-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
spleen O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
s O-MISC O-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
, O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
Smad3 B-MISC B-MISC
/ I-MISC I-MISC
4 I-MISC I-MISC
selectively O-MISC O-MISC
increases O-MISC O-MISC
both O-MISC O-MISC
surface O-MISC O-MISC
IgA O-MISC B-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
IgA O-MISC B-MISC
production O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
Smad3 B-MISC B-MISC
, O-MISC O-MISC
Smad4 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Smad7 B-MISC B-MISC
, O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
, O-MISC O-MISC
serve O-MISC O-MISC
as O-MISC O-MISC
mediators O-MISC O-MISC
linking O-MISC O-MISC
TGF B-MISC B-MISC
- I-MISC I-MISC
beta1 I-MISC I-MISC
to O-MISC O-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
IgA B-MISC B-MISC
switching I-MISC O-MISC
related I-MISC O-MISC
gene I-MISC O-MISC
and O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
IgA O-MISC B-MISC
class O-MISC O-MISC
switching O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
translesion B-MISC O-MISC
DNA I-MISC B-MISC
polymerase I-MISC I-MISC
zeta I-MISC I-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
Ig O-MISC B-MISC
and O-MISC O-MISC
bcl O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
somatic O-MISC O-MISC
hypermutation O-MISC O-MISC
. O-MISC O-MISC

Ig O-MISC B-MISC
somatic O-MISC O-MISC
mutations O-MISC O-MISC
would O-MISC O-MISC
be O-MISC O-MISC
introduced O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
polymerase B-MISC O-MISC
( O-MISC O-MISC
pol B-MISC O-MISC
) O-MISC O-MISC
while O-MISC O-MISC
repairing O-MISC O-MISC
DNA O-MISC O-MISC
outside O-MISC O-MISC
main O-MISC O-MISC
DNA O-MISC O-MISC
replication O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
constitutively O-MISC O-MISC
express O-MISC O-MISC
the O-MISC O-MISC
translesion B-MISC O-MISC
pol I-MISC B-MISC
zeta I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
effectively O-MISC O-MISC
extends O-MISC O-MISC
DNA O-MISC O-MISC
past O-MISC O-MISC
mismatched O-MISC O-MISC
bases O-MISC O-MISC
( O-MISC O-MISC
mispair O-MISC O-MISC
extender O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
pol B-MISC O-MISC
eta I-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
bypasses O-MISC O-MISC
DNA O-MISC O-MISC
lesions O-MISC O-MISC
in O-MISC O-MISC
an O-MISC O-MISC
error O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
fashion O-MISC O-MISC
. O-MISC O-MISC

Upon O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
BCR B-MISC B-MISC
) O-MISC O-MISC
engagement O-MISC O-MISC
and O-MISC O-MISC
coculture O-MISC O-MISC
with O-MISC O-MISC
activated O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
lymphocytes O-MISC O-MISC
upregulated O-MISC O-MISC
pol B-MISC B-MISC
zeta I-MISC I-MISC
, O-MISC O-MISC
downregulated O-MISC O-MISC
pol B-MISC O-MISC
eta I-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
mutated O-MISC O-MISC
the O-MISC O-MISC
Ig B-MISC B-MISC
and I-MISC I-MISC
bcl I-MISC I-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
pol B-MISC B-MISC
zeta I-MISC I-MISC
REV3 B-MISC I-MISC
catalytic I-MISC I-MISC
subunit I-MISC I-MISC
by O-MISC O-MISC
specific O-MISC O-MISC
phosphorothioate O-MISC O-MISC
- O-MISC O-MISC
modified O-MISC O-MISC
oligonucleotides O-MISC O-MISC
impaired O-MISC O-MISC
Ig O-MISC B-MISC
and O-MISC O-MISC
bcl O-MISC O-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
hypermutation O-MISC O-MISC
and O-MISC O-MISC
UV O-MISC O-MISC
damage O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
DNA O-MISC O-MISC
mutagenesis O-MISC O-MISC
, O-MISC O-MISC
without O-MISC O-MISC
affecting O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
or O-MISC O-MISC
viability O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
pol B-MISC B-MISC
zeta I-MISC I-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
Ig O-MISC B-MISC
and O-MISC O-MISC
bcl O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
hypermutation O-MISC O-MISC
, O-MISC O-MISC
perhaps O-MISC O-MISC
facilitated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
downregulation O-MISC O-MISC
of O-MISC O-MISC
pol B-MISC O-MISC
eta I-MISC O-MISC
. O-MISC O-MISC

Molecular O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
progression O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
oncogene B-MISC B-MISC
product I-MISC I-MISC
Tax I-MISC B-MISC
of O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
I O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
trans B-MISC B-MISC
- I-MISC I-MISC
activator I-MISC I-MISC
protein I-MISC I-MISC
Tax I-MISC B-MISC
of O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
I O-MISC O-MISC
( O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
I O-MISC O-MISC
) O-MISC O-MISC
plays O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
adult O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
through O-MISC O-MISC
, O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
, O-MISC O-MISC
its O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
stimulate O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
previously O-MISC O-MISC
reported O-MISC O-MISC
that O-MISC O-MISC
Tax B-MISC B-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
progression O-MISC O-MISC
from O-MISC O-MISC
G0 O-MISC O-MISC
/ O-MISC O-MISC
G1 O-MISC O-MISC
phase O-MISC O-MISC
to O-MISC O-MISC
S O-MISC O-MISC
and O-MISC O-MISC
G2 O-MISC O-MISC
/ O-MISC O-MISC
M O-MISC O-MISC
phases O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
Kit O-MISC O-MISC
225 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
elucidate O-MISC O-MISC
molecular O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
Tax B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
progression O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
systematically O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
Tax B-MISC B-MISC
on O-MISC O-MISC
biochemical O-MISC O-MISC
events O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
progression O-MISC O-MISC
. O-MISC O-MISC

Introduction O-MISC O-MISC
of O-MISC O-MISC
Tax B-MISC B-MISC
into O-MISC O-MISC
resting O-MISC O-MISC
Kit O-MISC O-MISC
225 O-MISC O-MISC
cells O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
G1 O-MISC O-MISC
/ O-MISC O-MISC
S O-MISC O-MISC
transition O-MISC O-MISC
regulation O-MISC O-MISC
cascade O-MISC O-MISC
consisting O-MISC O-MISC
of O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
cyclin B-MISC B-MISC
dependent I-MISC I-MISC
kinase I-MISC I-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
CDK2 B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
CDK4 B-MISC B-MISC
, O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Rb B-MISC B-MISC
family I-MISC I-MISC
proteins I-MISC I-MISC
and O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
free O-MISC O-MISC
E2F B-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
kinase O-MISC O-MISC
activation O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
result O-MISC O-MISC
from O-MISC O-MISC
Tax B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
genes O-MISC O-MISC
for O-MISC O-MISC
cell B-MISC B-MISC
cycle I-MISC I-MISC
regulatory I-MISC I-MISC
molecules I-MISC I-MISC
including O-MISC O-MISC
cyclin B-MISC B-MISC
D2 I-MISC I-MISC
, O-MISC O-MISC
cyclin B-MISC B-MISC
E I-MISC I-MISC
, O-MISC O-MISC
E2F1 B-MISC B-MISC
, O-MISC O-MISC
CDK2 B-MISC B-MISC
, O-MISC O-MISC
CDK4 B-MISC B-MISC
and O-MISC O-MISC
CDK6 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Tax B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
reduction O-MISC O-MISC
of O-MISC O-MISC
CDK B-MISC B-MISC
inhibitors I-MISC O-MISC
p19 I-MISC B-MISC
( O-MISC O-MISC
INK4d B-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
p27 B-MISC B-MISC
( I-MISC O-MISC
Kip1 I-MISC B-MISC
) I-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
modulations O-MISC O-MISC
by O-MISC O-MISC
Tax B-MISC B-MISC
always O-MISC O-MISC
paralleled O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
Tax B-MISC B-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
the O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
transcription O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
the O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
Tax B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
trans O-MISC O-MISC
- O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
genes O-MISC O-MISC
for O-MISC O-MISC
cell B-MISC B-MISC
cycle I-MISC I-MISC
regulatory I-MISC I-MISC
molecules I-MISC I-MISC
in O-MISC O-MISC
Tax B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
progression O-MISC O-MISC
. O-MISC O-MISC

Cot B-MISC B-MISC
kinase I-MISC I-MISC
induces O-MISC O-MISC
cyclooxygenase O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
through O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
of I-MISC I-MISC
activated I-MISC I-MISC
T I-MISC I-MISC
cells I-MISC I-MISC
. O-MISC O-MISC

Cyclooxygenase B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
COX B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
induced O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
upon O-MISC O-MISC
T B-MISC O-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
triggering O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
that O-MISC O-MISC
Cot B-MISC B-MISC
kinase I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
mitogen B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
kinase I-MISC I-MISC
kinase I-MISC I-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulates O-MISC O-MISC
COX B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Induction O-MISC O-MISC
of O-MISC O-MISC
COX O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
promoter O-MISC I-MISC
activity O-MISC O-MISC
by O-MISC O-MISC
Cot B-MISC O-MISC
kinase I-MISC I-MISC
occurred O-MISC O-MISC
mainly O-MISC O-MISC
through O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
of I-MISC I-MISC
activated I-MISC I-MISC
T I-MISC I-MISC
cells I-MISC I-MISC
( O-MISC O-MISC
NFAT B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Mutation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
distal B-MISC B-MISC
( I-MISC I-MISC
- I-MISC I-MISC
105 I-MISC I-MISC
/ I-MISC I-MISC
- I-MISC I-MISC
97 I-MISC I-MISC
) I-MISC I-MISC
and O-MISC I-MISC
proximal B-MISC I-MISC
( I-MISC I-MISC
- I-MISC I-MISC
76 I-MISC I-MISC
/ I-MISC I-MISC
- I-MISC I-MISC
61 I-MISC I-MISC
) I-MISC I-MISC
NFAT B-MISC I-MISC
response I-MISC I-MISC
elements I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
COX B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
abolished O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
Cot B-MISC B-MISC
kinase I-MISC I-MISC
. O-MISC O-MISC

Even O-MISC O-MISC
more O-MISC O-MISC
, O-MISC O-MISC
coexpression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
dominant O-MISC O-MISC
negative O-MISC O-MISC
version O-MISC O-MISC
of O-MISC O-MISC
NFAT B-MISC B-MISC
inhibited O-MISC O-MISC
Cot B-MISC O-MISC
kinase I-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
COX B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
cotransfection O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
constitutively O-MISC O-MISC
active O-MISC O-MISC
version O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
calcium B-MISC O-MISC
- I-MISC O-MISC
dependent I-MISC O-MISC
phosphatase I-MISC B-MISC
calcineurin I-MISC B-MISC
synergizes O-MISC O-MISC
with O-MISC O-MISC
Cot B-MISC O-MISC
kinase I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
COX B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

Strikingly O-MISC O-MISC
, O-MISC O-MISC
Cot B-MISC B-MISC
kinase I-MISC I-MISC
increased O-MISC O-MISC
transactivation O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
GAL4 B-MISC B-MISC
- I-MISC I-MISC
NFAT I-MISC I-MISC
fusion I-MISC I-MISC
protein I-MISC I-MISC
containing O-MISC O-MISC
the O-MISC O-MISC
N B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
transactivation I-MISC I-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
NFATp B-MISC B-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
phorbol O-MISC O-MISC
ester O-MISC O-MISC
plus O-MISC O-MISC
calcium O-MISC O-MISC
ionophore O-MISC O-MISC
A23187 O-MISC O-MISC
, O-MISC O-MISC
Cot B-MISC O-MISC
kinase I-MISC I-MISC
increases O-MISC O-MISC
both O-MISC O-MISC
COX B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
NFAT B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
transactivation O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
cyclosporin O-MISC O-MISC
A O-MISC O-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
manner O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
Cot B-MISC B-MISC
kinase I-MISC I-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulates O-MISC O-MISC
COX B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
transcription O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
NFAT B-MISC B-MISC
response I-MISC I-MISC
elements I-MISC I-MISC
, O-MISC O-MISC
being O-MISC O-MISC
the O-MISC O-MISC
Cot B-MISC O-MISC
kinase I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
NFAT B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
transactivation O-MISC O-MISC
presumably O-MISC O-MISC
implicated O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
. O-MISC O-MISC

Positive O-MISC O-MISC
and O-MISC O-MISC
negative O-MISC O-MISC
roles O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
trans B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
T I-MISC I-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
for O-MISC O-MISC
the O-MISC O-MISC
acquisition O-MISC O-MISC
of O-MISC O-MISC
distinct O-MISC O-MISC
Ly B-MISC B-MISC
- I-MISC I-MISC
49 I-MISC I-MISC
MHC I-MISC I-MISC
class I-MISC I-MISC
I I-MISC I-MISC
receptors I-MISC I-MISC
by O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ly B-MISC B-MISC
- I-MISC I-MISC
49 I-MISC I-MISC
gene I-MISC I-MISC
family I-MISC I-MISC
code O-MISC O-MISC
for O-MISC O-MISC
class B-MISC B-MISC
I I-MISC I-MISC
MHC I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
receptors I-MISC I-MISC
that O-MISC O-MISC
regulate O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

Due O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
combinatorial O-MISC O-MISC
distribution O-MISC O-MISC
of O-MISC O-MISC
Ly B-MISC B-MISC
- I-MISC I-MISC
49 I-MISC I-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
display O-MISC O-MISC
considerable O-MISC O-MISC
clonal O-MISC O-MISC
heterogeneity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
acquisition O-MISC O-MISC
of O-MISC O-MISC
one O-MISC O-MISC
Ly B-MISC B-MISC
- I-MISC O-MISC
49 I-MISC I-MISC
receptor I-MISC I-MISC
, O-MISC O-MISC
Ly B-MISC O-MISC
- I-MISC O-MISC
49A I-MISC O-MISC
is O-MISC O-MISC
strictly O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
transcriptional B-MISC B-MISC
trans I-MISC I-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
factor I-MISC I-MISC
T B-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Indeed O-MISC O-MISC
, O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
two O-MISC O-MISC
sites O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
Ly B-MISC B-MISC
- I-MISC I-MISC
49a I-MISC I-MISC
promoter I-MISC I-MISC
and O-MISC O-MISC
regulates O-MISC O-MISC
its O-MISC O-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
Ly B-MISC B-MISC
- I-MISC I-MISC
49a I-MISC I-MISC
gene I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
direct O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
target O-MISC I-MISC
. O-MISC O-MISC

TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
deficiency O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
altered O-MISC O-MISC
usage O-MISC O-MISC
of O-MISC O-MISC
additional O-MISC O-MISC
Ly B-MISC B-MISC
- I-MISC I-MISC
49 I-MISC I-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
using O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
beta I-MISC I-MISC
( I-MISC O-MISC
2 I-MISC O-MISC
) I-MISC O-MISC
- I-MISC O-MISC
microglobulin I-MISC O-MISC
double O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
these O-MISC O-MISC
repertoire O-MISC O-MISC
alterations O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
Ly O-MISC O-MISC
- O-MISC O-MISC
49 O-MISC O-MISC
/ O-MISC O-MISC
MHC O-MISC O-MISC
class O-MISC O-MISC
I O-MISC O-MISC
interactions O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
findings O-MISC O-MISC
rather O-MISC O-MISC
suggest O-MISC O-MISC
a O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
, O-MISC O-MISC
cell O-MISC O-MISC
autonomous O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
acquisition O-MISC O-MISC
of O-MISC O-MISC
multiple O-MISC O-MISC
Ly B-MISC B-MISC
- I-MISC I-MISC
49 I-MISC I-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

Besides O-MISC O-MISC
reduced O-MISC O-MISC
receptor O-MISC O-MISC
usage O-MISC O-MISC
( O-MISC O-MISC
Ly B-MISC O-MISC
- I-MISC O-MISC
49A I-MISC O-MISC
and I-MISC O-MISC
D I-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
also O-MISC O-MISC
observed O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
( O-MISC O-MISC
Ly B-MISC O-MISC
- I-MISC O-MISC
49C I-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
significantly O-MISC O-MISC
expanded O-MISC O-MISC
( O-MISC O-MISC
Ly B-MISC B-MISC
- I-MISC I-MISC
49G I-MISC I-MISC
and I-MISC I-MISC
I I-MISC I-MISC
) O-MISC I-MISC
receptor O-MISC I-MISC
usage O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
effects O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
cases O-MISC O-MISC
correlate O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
TCF B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
respective O-MISC O-MISC
proximal B-MISC B-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
besides O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
proximal B-MISC B-MISC
promoter I-MISC I-MISC
, O-MISC O-MISC
Ly O-MISC O-MISC
- O-MISC O-MISC
49 O-MISC O-MISC
acquisition O-MISC O-MISC
may O-MISC O-MISC
also O-MISC O-MISC
be O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
more O-MISC O-MISC
distant O-MISC O-MISC
cis B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
elements I-MISC I-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
by O-MISC O-MISC
regulating O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
additional O-MISC O-MISC
trans B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

Consistent O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
observed O-MISC O-MISC
differential O-MISC O-MISC
, O-MISC O-MISC
positive O-MISC O-MISC
or O-MISC O-MISC
negative O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
for O-MISC O-MISC
Ly B-MISC B-MISC
- I-MISC I-MISC
49 I-MISC I-MISC
receptor I-MISC O-MISC
acquisition O-MISC O-MISC
, O-MISC O-MISC
reporter O-MISC O-MISC
gene O-MISC O-MISC
assays O-MISC O-MISC
revealed O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
inducing O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
repressing O-MISC B-MISC
TCF B-MISC I-MISC
site I-MISC I-MISC
in O-MISC O-MISC
certain O-MISC O-MISC
proximal O-MISC B-MISC
Ly B-MISC I-MISC
- I-MISC I-MISC
49 I-MISC I-MISC
promoters I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
reveal O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
for O-MISC O-MISC
the O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NK B-MISC B-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
repertoire O-MISC I-MISC
. O-MISC O-MISC

Ligation O-MISC O-MISC
of O-MISC O-MISC
CD11b B-MISC B-MISC
and O-MISC O-MISC
CD11c B-MISC B-MISC
beta I-MISC I-MISC
( I-MISC I-MISC
2 I-MISC I-MISC
) I-MISC I-MISC
integrins B-MISC I-MISC
by O-MISC O-MISC
antibodies B-MISC O-MISC
or O-MISC O-MISC
soluble B-MISC O-MISC
CD23 I-MISC B-MISC
induces O-MISC O-MISC
macrophage B-MISC O-MISC
inflammatory I-MISC I-MISC
protein I-MISC I-MISC
1alpha I-MISC I-MISC
( O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
MIP B-MISC O-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
production O-MISC O-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
through O-MISC O-MISC
a O-MISC O-MISC
pathway O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
. O-MISC O-MISC

Chemokines B-MISC B-MISC
and O-MISC O-MISC
adhesion B-MISC B-MISC
molecules I-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
integrins B-MISC B-MISC
play O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
part O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
trafficking O-MISC O-MISC
, O-MISC O-MISC
extravasation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
recruitment O-MISC O-MISC
of O-MISC O-MISC
leukocytes O-MISC O-MISC
to O-MISC O-MISC
inflammatory O-MISC O-MISC
sites O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
beta O-MISC B-MISC
( O-MISC I-MISC
2 O-MISC I-MISC
) O-MISC I-MISC
integrin O-MISC I-MISC
engagement O-MISC O-MISC
on O-MISC O-MISC
chemokine O-MISC B-MISC
production O-MISC O-MISC
by O-MISC O-MISC
freshly O-MISC O-MISC
isolated O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
ligation O-MISC O-MISC
of O-MISC O-MISC
CD11b B-MISC B-MISC
or O-MISC O-MISC
CD11c B-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
CD11a B-MISC B-MISC
alpha I-MISC I-MISC
chains I-MISC I-MISC
of O-MISC O-MISC
beta B-MISC B-MISC
( I-MISC O-MISC
2 I-MISC I-MISC
) I-MISC O-MISC
integrins I-MISC O-MISC
by O-MISC O-MISC
antibodies B-MISC B-MISC
or O-MISC O-MISC
soluble B-MISC O-MISC
CD23 I-MISC B-MISC
( I-MISC O-MISC
sCD23 I-MISC I-MISC
) I-MISC O-MISC
fusion I-MISC O-MISC
proteins I-MISC I-MISC
rapidly O-MISC O-MISC
induced O-MISC O-MISC
transcription O-MISC O-MISC
and O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
8 I-MISC I-MISC
, O-MISC O-MISC
macrophage B-MISC B-MISC
inflammatory I-MISC I-MISC
protein I-MISC I-MISC
( I-MISC I-MISC
MIP I-MISC B-MISC
) I-MISC I-MISC
1alpha I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
. O-MISC O-MISC

Because O-MISC O-MISC
the O-MISC O-MISC
promoters B-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
chemokine B-MISC B-MISC
genes I-MISC I-MISC
contain O-MISC O-MISC
kappaB B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
assessed O-MISC O-MISC
the O-MISC O-MISC
possible O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
controlling O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
genes O-MISC O-MISC
through O-MISC O-MISC
beta O-MISC B-MISC
( O-MISC I-MISC
2 O-MISC I-MISC
) O-MISC I-MISC
integrin O-MISC I-MISC
engagement O-MISC O-MISC
. O-MISC O-MISC

Electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
sCD23 B-MISC O-MISC
or O-MISC O-MISC
antibodies B-MISC B-MISC
to O-MISC O-MISC
CD11b B-MISC B-MISC
or O-MISC O-MISC
to O-MISC O-MISC
CD11c B-MISC B-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
was O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
its O-MISC O-MISC
cytosolic B-MISC O-MISC
inhibitor I-MISC O-MISC
IkappaB I-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

Blockade O-MISC O-MISC
of O-MISC O-MISC
depletion O-MISC O-MISC
of O-MISC O-MISC
IkappaB B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
by O-MISC O-MISC
proteasome O-MISC O-MISC
inhibitors O-MISC O-MISC
( O-MISC O-MISC
proteasome O-MISC O-MISC
inhibitor O-MISC O-MISC
I O-MISC O-MISC
or O-MISC O-MISC
acetyl O-MISC O-MISC
- O-MISC O-MISC
leucinyl O-MISC O-MISC
- O-MISC O-MISC
leucinyl O-MISC O-MISC
- O-MISC O-MISC
norleucinal O-MISC O-MISC
) O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
concomitant O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC O-MISC
kappaB O-MISC B-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
and I-MISC O-MISC
MIP I-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
messenger I-MISC I-MISC
RNA I-MISC I-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
beta O-MISC B-MISC
( O-MISC O-MISC
2 O-MISC I-MISC
) O-MISC I-MISC
integrin O-MISC B-MISC
ligation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
triggering O-MISC O-MISC
of O-MISC O-MISC
CD11b B-MISC B-MISC
or O-MISC O-MISC
CD11c B-MISC B-MISC
beta I-MISC I-MISC
( I-MISC I-MISC
2 I-MISC I-MISC
) I-MISC I-MISC
integrin O-MISC O-MISC
on O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
provides O-MISC O-MISC
activation O-MISC O-MISC
signals O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
subsequent O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
and O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
that O-MISC O-MISC
may O-MISC O-MISC
have O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
recruitment O-MISC O-MISC
of O-MISC O-MISC
other O-MISC O-MISC
inflammatory O-MISC O-MISC
cells O-MISC O-MISC
during O-MISC O-MISC
initiation O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC

Synergistic O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
human B-MISC B-MISC
Acyl I-MISC I-MISC
- I-MISC I-MISC
coenzyme I-MISC I-MISC
A I-MISC I-MISC
: I-MISC O-MISC
cholesterol I-MISC O-MISC
acyltransterase I-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
gene I-MISC I-MISC
by O-MISC O-MISC
interferon B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
and O-MISC O-MISC
all O-MISC O-MISC
- O-MISC O-MISC
trans O-MISC O-MISC
- O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC I-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Acyl B-MISC O-MISC
- I-MISC O-MISC
coenzyme I-MISC O-MISC
A I-MISC O-MISC
: I-MISC O-MISC
cholesterol I-MISC O-MISC
acyltransferase I-MISC O-MISC
( O-MISC O-MISC
ACAT B-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
intracellular B-MISC O-MISC
enzyme I-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
cellular O-MISC O-MISC
cholesterol O-MISC O-MISC
homeostasis O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
atherosclerotic O-MISC O-MISC
foam O-MISC O-MISC
cell O-MISC O-MISC
formation O-MISC O-MISC
. O-MISC O-MISC

Human B-MISC B-MISC
ACAT I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
gene I-MISC I-MISC
contains O-MISC O-MISC
two O-MISC O-MISC
promoters B-MISC B-MISC
( O-MISC O-MISC
P1 B-MISC B-MISC
and O-MISC O-MISC
P7 B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
each O-MISC O-MISC
located O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
different O-MISC O-MISC
chromosome B-MISC B-MISC
( I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC O-MISC
7 I-MISC I-MISC
) I-MISC O-MISC
( O-MISC O-MISC
Li O-MISC O-MISC
, O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
L O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Li O-MISC O-MISC
, O-MISC O-MISC
X O-MISC O-MISC
. O-MISC O-MISC
L O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Duan O-MISC O-MISC
, O-MISC O-MISC
Z O-MISC O-MISC
. O-MISC O-MISC
J O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Lee O-MISC O-MISC
, O-MISC O-MISC
O O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Lin O-MISC O-MISC
, O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Ma O-MISC O-MISC
, O-MISC O-MISC
Z O-MISC O-MISC
. O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Chang O-MISC O-MISC
, O-MISC O-MISC
C O-MISC O-MISC
. O-MISC I-MISC
C O-MISC I-MISC
. O-MISC I-MISC
, O-MISC O-MISC
Yang O-MISC O-MISC
, O-MISC O-MISC
X O-MISC B-MISC
. O-MISC I-MISC
Y O-MISC I-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Park O-MISC O-MISC
, O-MISC O-MISC
J O-MISC B-MISC
. O-MISC O-MISC
P O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Mohandas O-MISC B-MISC
, O-MISC O-MISC
T O-MISC B-MISC
. O-MISC O-MISC
K O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Noll O-MISC O-MISC
, O-MISC O-MISC
W O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Chan O-MISC O-MISC
, O-MISC O-MISC
L O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Chang O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
. O-MISC O-MISC
Y O-MISC O-MISC
. O-MISC O-MISC
( O-MISC O-MISC
1999 O-MISC O-MISC
) O-MISC O-MISC
J O-MISC O-MISC
. O-MISC O-MISC
Biol O-MISC O-MISC
Chem O-MISC O-MISC
. O-MISC O-MISC
274 O-MISC O-MISC
, O-MISC O-MISC
11060 O-MISC O-MISC
- O-MISC B-MISC
11071 O-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Interferon B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
( O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
cytokine B-MISC B-MISC
that O-MISC O-MISC
exerts O-MISC O-MISC
many O-MISC O-MISC
pro O-MISC O-MISC
- O-MISC O-MISC
atherosclerotic O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
, O-MISC O-MISC
causes O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
ACAT B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
blood O-MISC O-MISC
monocyte O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
macrophages O-MISC O-MISC
and O-MISC O-MISC
macrophage O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
other O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
examine O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
nature O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
observation O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
identified O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
ACAT B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
P1 I-MISC I-MISC
promoter I-MISC I-MISC
a O-MISC O-MISC
159 B-MISC B-MISC
- I-MISC I-MISC
base I-MISC I-MISC
pair I-MISC I-MISC
core I-MISC I-MISC
region I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
region O-MISC O-MISC
contains O-MISC O-MISC
4 O-MISC B-MISC
Sp1 B-MISC I-MISC
elements I-MISC I-MISC
and O-MISC O-MISC
an O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
activated I-MISC I-MISC
sequence I-MISC I-MISC
( O-MISC O-MISC
GAS B-MISC B-MISC
) O-MISC O-MISC
that O-MISC O-MISC
overlaps O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
second O-MISC O-MISC
Sp1 B-MISC B-MISC
element I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
monocytic O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cell O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
combination O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
and O-MISC O-MISC
all O-MISC O-MISC
- O-MISC O-MISC
trans O-MISC O-MISC
- O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
a O-MISC O-MISC
known O-MISC O-MISC
differentiation O-MISC O-MISC
agent O-MISC O-MISC
) O-MISC O-MISC
enhances O-MISC O-MISC
the O-MISC O-MISC
ACAT B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
P1 I-MISC I-MISC
promoter I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
P7 B-MISC B-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Additional O-MISC O-MISC
experiments O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
all O-MISC O-MISC
- O-MISC O-MISC
trans O-MISC O-MISC
- O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
causes O-MISC O-MISC
large O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
STAT1 I-MISC B-MISC
, O-MISC O-MISC
while O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
causes O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT1 B-MISC B-MISC
such O-MISC O-MISC
that O-MISC O-MISC
it O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
GAS B-MISC B-MISC
/ I-MISC I-MISC
Sp1 I-MISC I-MISC
site I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
ACAT B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
P1 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
work O-MISC O-MISC
provides O-MISC O-MISC
a O-MISC O-MISC
molecular O-MISC O-MISC
mechanism O-MISC O-MISC
to O-MISC O-MISC
account O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
in O-MISC O-MISC
causing O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
ACAT B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
macrophage O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Inhaled O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulates O-MISC O-MISC
intrapulmonary O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
production O-MISC O-MISC
in O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
acute O-MISC O-MISC
lung O-MISC O-MISC
injury O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
To O-MISC O-MISC
examine O-MISC O-MISC
whether O-MISC O-MISC
inhaled O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
( O-MISC O-MISC
NO O-MISC O-MISC
) O-MISC O-MISC
affected O-MISC O-MISC
the O-MISC O-MISC
intrapulmonary O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
NO O-MISC O-MISC
, O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
species O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
a O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
( O-MISC O-MISC
LPS O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
acute O-MISC O-MISC
lung O-MISC O-MISC
injury O-MISC O-MISC
. O-MISC O-MISC

DESIGN O-MISC O-MISC
: O-MISC O-MISC
Prospective O-MISC O-MISC
, O-MISC O-MISC
randomized O-MISC O-MISC
, O-MISC O-MISC
laboratory O-MISC O-MISC
study O-MISC O-MISC
. O-MISC O-MISC

SETTING O-MISC O-MISC
: O-MISC O-MISC
Experimental O-MISC O-MISC
laboratory O-MISC O-MISC
at O-MISC O-MISC
a O-MISC O-MISC
biomedical O-MISC O-MISC
institute O-MISC O-MISC
. O-MISC O-MISC

SUBJECTS O-MISC O-MISC
: O-MISC O-MISC
Twenty O-MISC O-MISC
male O-MISC O-MISC
rabbits O-MISC O-MISC
weighing O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
kg O-MISC O-MISC
. O-MISC O-MISC

INTERVENTIONS O-MISC O-MISC
: O-MISC O-MISC
Saline O-MISC O-MISC
or O-MISC O-MISC
LPS O-MISC O-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
of O-MISC O-MISC
body O-MISC O-MISC
weight O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
administered O-MISC O-MISC
intravenously O-MISC O-MISC
with O-MISC O-MISC
or O-MISC O-MISC
without O-MISC O-MISC
NO O-MISC O-MISC
inhalation O-MISC O-MISC
( O-MISC O-MISC
10 O-MISC O-MISC
ppm O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
each O-MISC O-MISC
group O-MISC O-MISC
of O-MISC O-MISC
five O-MISC O-MISC
rabbits O-MISC O-MISC
. O-MISC O-MISC

MEASUREMENTS O-MISC O-MISC
AND O-MISC O-MISC
MAIN O-MISC B-MISC
RESULTS O-MISC O-MISC
: O-MISC O-MISC
LPS O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
lung O-MISC O-MISC
leak O-MISC O-MISC
index O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
neutrophils O-MISC O-MISC
and O-MISC O-MISC
NO O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
bronchoalveolar O-MISC O-MISC
lavage O-MISC O-MISC
fluid O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
NO O-MISC O-MISC
levels O-MISC O-MISC
produced O-MISC O-MISC
by O-MISC O-MISC
resting O-MISC O-MISC
and O-MISC O-MISC
stimulated O-MISC O-MISC
alveolar O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

Inhaled O-MISC O-MISC
NO O-MISC O-MISC
decreased O-MISC O-MISC
the O-MISC O-MISC
lung O-MISC O-MISC
leak O-MISC O-MISC
index O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
neutrophils O-MISC O-MISC
and O-MISC O-MISC
NO O-MISC O-MISC
levels O-MISC O-MISC
as O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
nitrite O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
lavage O-MISC O-MISC
fluid O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
NO O-MISC O-MISC
produced O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
resting O-MISC O-MISC
and O-MISC O-MISC
stimulated O-MISC O-MISC
alveolar O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

Inhaled O-MISC O-MISC
NO O-MISC O-MISC
also O-MISC O-MISC
blocked O-MISC O-MISC
the O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
species O-MISC O-MISC
and O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
DNA O-MISC O-MISC
in O-MISC O-MISC
lavage O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
alveolar O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
Inhaled O-MISC O-MISC
NO O-MISC O-MISC
attenuates O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
acute O-MISC O-MISC
lung O-MISC O-MISC
injury O-MISC O-MISC
, O-MISC O-MISC
possibly O-MISC O-MISC
by O-MISC O-MISC
decreasing O-MISC O-MISC
NO O-MISC O-MISC
production O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
lungs O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
reducing O-MISC O-MISC
NO O-MISC O-MISC
production O-MISC O-MISC
resulting O-MISC O-MISC
from O-MISC O-MISC
inhaled O-MISC O-MISC
NO O-MISC O-MISC
may O-MISC O-MISC
involve O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
species O-MISC O-MISC
and O-MISC O-MISC
/ O-MISC B-MISC
or O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
allergic O-MISC O-MISC
airway O-MISC O-MISC
inflammation O-MISC O-MISC
and O-MISC O-MISC
hyperresponsiveness O-MISC O-MISC
by O-MISC O-MISC
antisense O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
local O-MISC O-MISC
blockade O-MISC O-MISC
of O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Recent O-MISC O-MISC
studies O-MISC O-MISC
in O-MISC O-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
have O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
dominant O-MISC O-MISC
negative O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
GATA I-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
can O-MISC O-MISC
prevent O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
2 O-MISC O-MISC
( O-MISC O-MISC
Th2 O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
allergic O-MISC O-MISC
airway O-MISC O-MISC
inflammation O-MISC O-MISC
in O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
remains O-MISC O-MISC
unclear O-MISC O-MISC
whether O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
effector O-MISC O-MISC
phase O-MISC O-MISC
of O-MISC O-MISC
allergic O-MISC O-MISC
airway O-MISC O-MISC
inflammation O-MISC O-MISC
and O-MISC O-MISC
whether O-MISC O-MISC
antagonizing O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
can O-MISC O-MISC
be O-MISC O-MISC
used O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
therapy O-MISC O-MISC
of O-MISC O-MISC
allergic O-MISC O-MISC
airway O-MISC O-MISC
inflammation O-MISC O-MISC
and O-MISC O-MISC
hyperresponsiveness O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
locally O-MISC O-MISC
antagonizing O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
function O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
murine O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
asthma O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
could O-MISC O-MISC
suppress O-MISC O-MISC
GATA O-MISC B-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
interleukin B-MISC B-MISC
( I-MISC I-MISC
IL I-MISC B-MISC
) I-MISC I-MISC
- I-MISC O-MISC
4 I-MISC O-MISC
- O-MISC O-MISC
producing O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
antisense O-MISC O-MISC
phosphorothioate O-MISC O-MISC
oligonucleotide O-MISC O-MISC
overlapping O-MISC O-MISC
the O-MISC O-MISC
translation B-MISC B-MISC
start I-MISC I-MISC
site I-MISC I-MISC
of O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
nonsense O-MISC O-MISC
control O-MISC O-MISC
oligonucleotides O-MISC O-MISC
were O-MISC O-MISC
virtually O-MISC O-MISC
inactive O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
a O-MISC O-MISC
murine O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
asthma O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
allergic O-MISC O-MISC
pulmonary O-MISC O-MISC
inflammation O-MISC O-MISC
and O-MISC O-MISC
hyperresponsiveness O-MISC O-MISC
in O-MISC O-MISC
ovalbumin O-MISC O-MISC
( O-MISC O-MISC
OVA O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
sensitized O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
local O-MISC O-MISC
intranasal O-MISC O-MISC
administration O-MISC O-MISC
of O-MISC O-MISC
fluorescein O-MISC O-MISC
isothiocyanate O-MISC O-MISC
- O-MISC O-MISC
labeled O-MISC O-MISC
GATA O-MISC B-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
antisense O-MISC O-MISC
oligonucleotides O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
DNA O-MISC O-MISC
uptake O-MISC O-MISC
in O-MISC O-MISC
lung O-MISC O-MISC
cells O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
reduction O-MISC O-MISC
of O-MISC O-MISC
intracellular O-MISC B-MISC
GATA O-MISC I-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Such O-MISC O-MISC
intrapulmonary O-MISC O-MISC
blockade O-MISC O-MISC
of O-MISC O-MISC
GATA O-MISC B-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
expression O-MISC O-MISC
caused O-MISC O-MISC
an O-MISC O-MISC
abrogation O-MISC O-MISC
of O-MISC O-MISC
signs O-MISC O-MISC
of O-MISC O-MISC
lung O-MISC O-MISC
inflammation O-MISC O-MISC
including O-MISC O-MISC
infiltration O-MISC O-MISC
of O-MISC O-MISC
eosinophils O-MISC O-MISC
and O-MISC O-MISC
Th2 O-MISC B-MISC
cytokine O-MISC B-MISC
production O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
antisense O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
nonsense O-MISC O-MISC
oligonucleotides O-MISC O-MISC
induced O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
reduction O-MISC O-MISC
of O-MISC O-MISC
airway O-MISC O-MISC
hyperresponsiveness O-MISC O-MISC
in O-MISC O-MISC
OVA O-MISC O-MISC
- O-MISC O-MISC
sensitized O-MISC O-MISC
mice O-MISC O-MISC
to O-MISC O-MISC
levels O-MISC O-MISC
comparable O-MISC O-MISC
to O-MISC O-MISC
saline O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
control O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
both O-MISC O-MISC
enhanced O-MISC O-MISC
pause O-MISC O-MISC
( O-MISC O-MISC
PenH O-MISC O-MISC
) O-MISC O-MISC
responses O-MISC O-MISC
and O-MISC O-MISC
pulmonary O-MISC O-MISC
resistance O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
body O-MISC O-MISC
plethysmography O-MISC B-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
effector O-MISC O-MISC
phase O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
murine O-MISC O-MISC
asthma O-MISC O-MISC
model O-MISC O-MISC
and O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
local O-MISC O-MISC
delivery O-MISC O-MISC
of O-MISC O-MISC
GATA O-MISC B-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
antisense O-MISC O-MISC
oligonucleotides O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
approach O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
airway O-MISC O-MISC
hyperresponsiveness O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
in O-MISC O-MISC
asthma O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
approach O-MISC O-MISC
has O-MISC O-MISC
the O-MISC O-MISC
potential O-MISC O-MISC
advantage O-MISC O-MISC
of O-MISC O-MISC
suppressing O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
various O-MISC O-MISC
proinflammatory B-MISC O-MISC
Th2 I-MISC I-MISC
cytokines I-MISC B-MISC
simultaneously O-MISC O-MISC
rather O-MISC O-MISC
than O-MISC O-MISC
suppressing O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
cytokine B-MISC B-MISC
. O-MISC O-MISC

T O-MISC O-MISC
helper O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
regulates O-MISC O-MISC
atherosclerosis O-MISC O-MISC
in O-MISC O-MISC
mice O-MISC O-MISC
under O-MISC O-MISC
conditions O-MISC O-MISC
of O-MISC O-MISC
mild O-MISC O-MISC
hypercholesterolemia O-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
implicated O-MISC O-MISC
in O-MISC O-MISC
atherosclerosis O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
little O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
about O-MISC O-MISC
the O-MISC O-MISC
genetic O-MISC O-MISC
control O-MISC O-MISC
or O-MISC O-MISC
molecular O-MISC O-MISC
pathways O-MISC O-MISC
, O-MISC O-MISC
especially O-MISC O-MISC
under O-MISC O-MISC
conditions O-MISC O-MISC
of O-MISC O-MISC
mild O-MISC O-MISC
hypercholesterolemia O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
AND O-MISC O-MISC
RESULTS O-MISC O-MISC
: O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
making O-MISC O-MISC
a O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
Th2 O-MISC O-MISC
( O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
, O-MISC O-MISC
express O-MISC O-MISC
both O-MISC O-MISC
MHC B-MISC B-MISC
class I-MISC I-MISC
II I-MISC I-MISC
antigens I-MISC O-MISC
( O-MISC O-MISC
IA B-MISC B-MISC
( I-MISC O-MISC
d I-MISC I-MISC
) I-MISC O-MISC
, O-MISC O-MISC
IE B-MISC B-MISC
( I-MISC O-MISC
d I-MISC O-MISC
) I-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
atherosclerosis O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
. O-MISC O-MISC

C57Bl O-MISC O-MISC
/ O-MISC O-MISC
6 O-MISC I-MISC
mice O-MISC O-MISC
produce O-MISC O-MISC
a O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
Th1 O-MISC O-MISC
( O-MISC O-MISC
interferon O-MISC B-MISC
[ O-MISC O-MISC
IFN O-MISC B-MISC
] O-MISC O-MISC
gamma O-MISC I-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
response O-MISC O-MISC
, O-MISC O-MISC
express O-MISC O-MISC
IA B-MISC B-MISC
( I-MISC O-MISC
b I-MISC O-MISC
) I-MISC O-MISC
but O-MISC O-MISC
no O-MISC O-MISC
IE B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
atherosclerosis O-MISC O-MISC
- O-MISC O-MISC
prone O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
evaluate O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
in O-MISC O-MISC
fatty O-MISC O-MISC
streak O-MISC O-MISC
formation O-MISC O-MISC
, O-MISC O-MISC
wild O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
C57Bl O-MISC O-MISC
/ O-MISC O-MISC
6 O-MISC O-MISC
mice O-MISC O-MISC
( O-MISC O-MISC
IA O-MISC O-MISC
( O-MISC O-MISC
b O-MISC O-MISC
) O-MISC O-MISC
+ O-MISC O-MISC
IE O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
either O-MISC O-MISC
AB O-MISC O-MISC
( O-MISC O-MISC
o O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
IA O-MISC B-MISC
( O-MISC I-MISC
b O-MISC I-MISC
) O-MISC I-MISC
- O-MISC I-MISC
IE O-MISC I-MISC
- O-MISC I-MISC
; O-MISC I-MISC
ABEalpha O-MISC I-MISC
, O-MISC O-MISC
IA O-MISC B-MISC
- O-MISC I-MISC
IE O-MISC I-MISC
( O-MISC O-MISC
k O-MISC O-MISC
) O-MISC O-MISC
+ O-MISC O-MISC
; O-MISC O-MISC
or O-MISC O-MISC
BL O-MISC O-MISC
: O-MISC O-MISC
TG O-MISC O-MISC
: O-MISC O-MISC
Ealpha O-MISC O-MISC
, O-MISC O-MISC
IA O-MISC B-MISC
( O-MISC I-MISC
b O-MISC O-MISC
) O-MISC O-MISC
+ O-MISC O-MISC
IE O-MISC O-MISC
( O-MISC O-MISC
k O-MISC O-MISC
) O-MISC O-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
fed O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
cholesterol O-MISC O-MISC
diet O-MISC O-MISC
for O-MISC O-MISC
16 O-MISC O-MISC
weeks O-MISC O-MISC
and O-MISC O-MISC
evaluated O-MISC O-MISC
histomorphometricall O-MISC O-MISC
for O-MISC O-MISC
aortic O-MISC O-MISC
lesions O-MISC O-MISC
. O-MISC O-MISC

Lesion O-MISC O-MISC
size O-MISC O-MISC
in O-MISC O-MISC
AB O-MISC O-MISC
( O-MISC I-MISC
o O-MISC O-MISC
) O-MISC I-MISC
, O-MISC O-MISC
ABEalpha O-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
BL O-MISC O-MISC
: O-MISC O-MISC
TG O-MISC O-MISC
: O-MISC O-MISC
Ealpha O-MISC O-MISC
strains O-MISC O-MISC
was O-MISC O-MISC
decreased O-MISC O-MISC
by O-MISC O-MISC
54 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
79 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
82 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
, O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
wild O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
, O-MISC O-MISC
correlating O-MISC O-MISC
with O-MISC O-MISC
decreased O-MISC O-MISC
Th1 O-MISC O-MISC
and O-MISC O-MISC
increased O-MISC O-MISC
Th2 O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
is O-MISC O-MISC
important O-MISC O-MISC
in O-MISC O-MISC
fatty O-MISC O-MISC
lesion O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

Decreasing O-MISC O-MISC
Th1 O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
antibodies B-MISC B-MISC
( O-MISC O-MISC
alpha B-MISC I-MISC
- I-MISC I-MISC
CD4 I-MISC I-MISC
) O-MISC O-MISC
or O-MISC O-MISC
cytokines B-MISC B-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
) O-MISC O-MISC
also O-MISC O-MISC
caused O-MISC O-MISC
> O-MISC O-MISC
/ O-MISC O-MISC
= O-MISC O-MISC
80 O-MISC O-MISC
% O-MISC O-MISC
reductions O-MISC O-MISC
in O-MISC O-MISC
lesion O-MISC O-MISC
size O-MISC O-MISC
. O-MISC O-MISC

Immunohistology O-MISC O-MISC
revealed O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
colocalized O-MISC O-MISC
with O-MISC O-MISC
activated O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

Confirming O-MISC O-MISC
these O-MISC O-MISC
findings O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
different O-MISC O-MISC
mouse O-MISC O-MISC
strain O-MISC O-MISC
, O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC O-MISC
Stat O-MISC I-MISC
6 O-MISC O-MISC
knockout O-MISC O-MISC
mice O-MISC O-MISC
( O-MISC O-MISC
Th2 O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
) O-MISC O-MISC
developed O-MISC O-MISC
aortic O-MISC O-MISC
lesions O-MISC O-MISC
comparable O-MISC O-MISC
to O-MISC O-MISC
C57Bl O-MISC O-MISC
/ O-MISC O-MISC
6 O-MISC O-MISC
mice O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
diet O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
In O-MISC O-MISC
mildly O-MISC O-MISC
hypercholesterolemic O-MISC O-MISC
C57Bl O-MISC O-MISC
/ O-MISC O-MISC
6 O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
IA B-MISC B-MISC
( I-MISC O-MISC
b I-MISC O-MISC
) I-MISC O-MISC
and O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
IE B-MISC B-MISC
regulated O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
; O-MISC O-MISC
fatty O-MISC O-MISC
lesions O-MISC O-MISC
were O-MISC O-MISC
proportional O-MISC O-MISC
to O-MISC O-MISC
IFNgamma O-MISC B-MISC
+ O-MISC O-MISC
Th1 O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
C57Bl O-MISC O-MISC
/ O-MISC O-MISC
6 O-MISC O-MISC
and O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC O-MISC
strains O-MISC O-MISC
. O-MISC O-MISC

IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
may O-MISC O-MISC
participate O-MISC O-MISC
through O-MISC O-MISC
macrophage O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
may O-MISC O-MISC
act O-MISC O-MISC
to O-MISC O-MISC
limit O-MISC O-MISC
Th1 O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Requirement O-MISC O-MISC
for O-MISC O-MISC
p38 B-MISC B-MISC
and O-MISC O-MISC
p44 B-MISC B-MISC
/ I-MISC I-MISC
p42 I-MISC I-MISC
mitogen B-MISC I-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinases I-MISC I-MISC
in O-MISC O-MISC
RAGE B-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
transcriptional O-MISC I-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
cytokine O-MISC B-MISC
secretion O-MISC O-MISC
. O-MISC O-MISC

Advanced O-MISC O-MISC
glycation O-MISC B-MISC
end O-MISC I-MISC
product O-MISC I-MISC
( O-MISC O-MISC
AGE O-MISC O-MISC
) O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
signal B-MISC B-MISC
- I-MISC I-MISC
transducing I-MISC I-MISC
receptor I-MISC I-MISC
for I-MISC O-MISC
AGE I-MISC O-MISC
( O-MISC O-MISC
RAGE B-MISC O-MISC
) O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
proinflammatory O-MISC O-MISC
phenotypic O-MISC O-MISC
change O-MISC O-MISC
within O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
precise O-MISC O-MISC
intracellular O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
involved O-MISC O-MISC
have O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
elucidated O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
demonstrate O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
human O-MISC B-MISC
serum O-MISC I-MISC
albumin O-MISC I-MISC
modified O-MISC O-MISC
with O-MISC O-MISC
N O-MISC B-MISC
( O-MISC O-MISC
varepsilon O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
carboxymethyl O-MISC O-MISC
) O-MISC O-MISC
lysine O-MISC O-MISC
( O-MISC O-MISC
CML O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
AGE O-MISC O-MISC
adduct O-MISC O-MISC
that O-MISC O-MISC
progressively O-MISC O-MISC
accumulates O-MISC O-MISC
with O-MISC O-MISC
aging O-MISC O-MISC
, O-MISC O-MISC
diabetes O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
renal O-MISC O-MISC
failure O-MISC O-MISC
, O-MISC O-MISC
induced O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- O-MISC I-MISC
driven O-MISC I-MISC
reporter O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytic O-MISC O-MISC
THP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
response O-MISC O-MISC
was O-MISC O-MISC
blocked O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
synthetic O-MISC O-MISC
peptide O-MISC O-MISC
corresponding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
putative B-MISC O-MISC
ligand I-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
RAGE B-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
RAGE B-MISC O-MISC
antiserum O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
by O-MISC O-MISC
coexpression O-MISC O-MISC
of O-MISC O-MISC
truncated B-MISC B-MISC
receptors I-MISC I-MISC
lacking O-MISC O-MISC
the O-MISC O-MISC
intracellular B-MISC B-MISC
domain I-MISC I-MISC
. O-MISC O-MISC

Signal O-MISC O-MISC
transduction O-MISC O-MISC
from O-MISC O-MISC
RAGE B-MISC O-MISC
to O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
involved O-MISC O-MISC
the O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
species O-MISC O-MISC
, O-MISC O-MISC
since O-MISC O-MISC
reporter O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
blocked O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
antioxidant O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
acetyl O-MISC O-MISC
- O-MISC O-MISC
L O-MISC O-MISC
- O-MISC O-MISC
cysteine O-MISC O-MISC
. O-MISC O-MISC

CML B-MISC B-MISC
- I-MISC I-MISC
modified I-MISC I-MISC
albumin I-MISC I-MISC
produced O-MISC O-MISC
rapid O-MISC O-MISC
transient O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
, O-MISC O-MISC
extracellular B-MISC O-MISC
signal I-MISC I-MISC
- I-MISC I-MISC
regulated I-MISC I-MISC
kinase I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC O-MISC
2 I-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
p38 B-MISC B-MISC
mitogen I-MISC I-MISC
- I-MISC I-MISC
activated I-MISC O-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
MAPK B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
NH I-MISC I-MISC
( I-MISC I-MISC
2 I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
kinase I-MISC I-MISC
. O-MISC O-MISC

RAGE B-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
was O-MISC O-MISC
suppressed O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
selective O-MISC O-MISC
p38 B-MISC B-MISC
MAPK I-MISC I-MISC
inhibitor O-MISC O-MISC
SB203580 O-MISC B-MISC
and O-MISC O-MISC
by O-MISC O-MISC
coexpression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
kinase O-MISC B-MISC
- O-MISC O-MISC
dead O-MISC I-MISC
p38 O-MISC I-MISC
dominant O-MISC O-MISC
- O-MISC O-MISC
negative O-MISC O-MISC
mutant O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
by O-MISC O-MISC
CML B-MISC B-MISC
- I-MISC I-MISC
modified I-MISC I-MISC
albumin I-MISC I-MISC
increased O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
proinflammatory B-MISC B-MISC
cytokines I-MISC I-MISC
( O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
monocyte B-MISC B-MISC
chemoattractant I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
severalfold O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
p38 B-MISC B-MISC
MAPK I-MISC I-MISC
blocked O-MISC O-MISC
these O-MISC O-MISC
increases O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
p38 B-MISC B-MISC
MAPK I-MISC I-MISC
activation O-MISC O-MISC
mediates O-MISC O-MISC
RAGE B-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
proinflammatory B-MISC B-MISC
cytokines I-MISC I-MISC
and O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
accelerated O-MISC O-MISC
inflammation O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
consequence O-MISC O-MISC
of O-MISC O-MISC
cellular O-MISC O-MISC
activation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
this O-MISC O-MISC
receptor O-MISC O-MISC
. O-MISC O-MISC

Antigen O-MISC O-MISC
- O-MISC O-MISC
receptor O-MISC I-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
and O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
trigger O-MISC O-MISC
distinct O-MISC O-MISC
phosphoinositide B-MISC O-MISC
3 I-MISC I-MISC
- I-MISC I-MISC
kinase I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
pathways O-MISC O-MISC
to O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
/ I-MISC I-MISC
Rel I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
play O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
genes O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
, O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

Nuclear B-MISC B-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
is O-MISC O-MISC
induced O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
engagement O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
the O-MISC O-MISC
BCR B-MISC B-MISC
or O-MISC O-MISC
CD40 B-MISC B-MISC
or O-MISC O-MISC
by O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
( O-MISC O-MISC
LPS O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Despite O-MISC O-MISC
the O-MISC O-MISC
importance O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
to O-MISC O-MISC
B O-MISC I-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
, O-MISC O-MISC
little O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
about O-MISC O-MISC
the O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
report O-MISC O-MISC
we O-MISC O-MISC
address O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
phosphoinositide B-MISC B-MISC
3 I-MISC I-MISC
' I-MISC I-MISC
- I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
PI B-MISC B-MISC
3 I-MISC I-MISC
- I-MISC I-MISC
kinase I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
BCR B-MISC B-MISC
- O-MISC O-MISC
and O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
using O-MISC O-MISC
populations O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
murine O-MISC O-MISC
resting O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
the O-MISC O-MISC
specific O-MISC O-MISC
pharmacological O-MISC O-MISC
inhibitors O-MISC O-MISC
of O-MISC O-MISC
PI B-MISC B-MISC
3 I-MISC I-MISC
- I-MISC I-MISC
kinase I-MISC I-MISC
, O-MISC O-MISC
Wortmannin O-MISC O-MISC
and O-MISC O-MISC
LY294002 O-MISC B-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
PI B-MISC B-MISC
3 I-MISC I-MISC
- I-MISC I-MISC
kinase I-MISC I-MISC
activity O-MISC O-MISC
is O-MISC O-MISC
vital O-MISC O-MISC
for O-MISC O-MISC
BCR B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
is O-MISC O-MISC
achieved O-MISC O-MISC
via O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
IkappaBalpha B-MISC B-MISC
. O-MISC O-MISC

Similar O-MISC O-MISC
analyses O-MISC O-MISC
reveal O-MISC O-MISC
that O-MISC O-MISC
PI B-MISC B-MISC
3 I-MISC I-MISC
- I-MISC I-MISC
kinase I-MISC I-MISC
is O-MISC O-MISC
also O-MISC O-MISC
critical O-MISC O-MISC
in O-MISC O-MISC
triggering O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
IkappaBalpha B-MISC B-MISC
degradation O-MISC O-MISC
following O-MISC O-MISC
LPS O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
PKC O-MISC B-MISC
inhibitor O-MISC O-MISC
which O-MISC O-MISC
blocked O-MISC O-MISC
the O-MISC O-MISC
BCR B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
IkappaBalpha B-MISC B-MISC
degradation O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
IkappaBalpha B-MISC B-MISC
after O-MISC O-MISC
LPS O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Taken O-MISC O-MISC
together O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
the O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
PI B-MISC B-MISC
3 I-MISC I-MISC
- I-MISC I-MISC
kinase I-MISC I-MISC
in O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
two O-MISC O-MISC
distinct O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Tetramer O-MISC B-MISC
- O-MISC I-MISC
guided O-MISC I-MISC
epitope O-MISC I-MISC
mapping O-MISC O-MISC
: O-MISC O-MISC
rapid O-MISC O-MISC
identification O-MISC O-MISC
and O-MISC O-MISC
characterization O-MISC O-MISC
of O-MISC O-MISC
immunodominant O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
epitopes O-MISC O-MISC
from O-MISC O-MISC
complex O-MISC O-MISC
antigens B-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cell O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
Ags B-MISC B-MISC
involve O-MISC O-MISC
recognition O-MISC O-MISC
of O-MISC O-MISC
selected O-MISC O-MISC
peptide B-MISC O-MISC
epitopes I-MISC I-MISC
contained O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
antigenic B-MISC B-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
report O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
describe O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
approach O-MISC O-MISC
for O-MISC O-MISC
direct O-MISC O-MISC
identification O-MISC O-MISC
of O-MISC O-MISC
CD4 O-MISC B-MISC
+ O-MISC I-MISC
T O-MISC I-MISC
cell O-MISC I-MISC
epitopes O-MISC I-MISC
of O-MISC O-MISC
complex O-MISC B-MISC
Ags B-MISC I-MISC
that O-MISC O-MISC
uses O-MISC O-MISC
human B-MISC B-MISC
class I-MISC I-MISC
II I-MISC I-MISC
tetramers I-MISC I-MISC
to O-MISC O-MISC
identify O-MISC O-MISC
reactive O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

With O-MISC O-MISC
a O-MISC O-MISC
panel O-MISC O-MISC
of O-MISC O-MISC
60 O-MISC O-MISC
overlapping O-MISC O-MISC
peptides O-MISC O-MISC
covering O-MISC O-MISC
the O-MISC O-MISC
entire O-MISC O-MISC
sequence O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
VP16 B-MISC B-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
Ag B-MISC O-MISC
for O-MISC O-MISC
HSV O-MISC O-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
generated O-MISC O-MISC
a O-MISC O-MISC
panel O-MISC O-MISC
of O-MISC O-MISC
class B-MISC B-MISC
II I-MISC I-MISC
MHC I-MISC I-MISC
tetramers I-MISC I-MISC
loaded O-MISC O-MISC
with O-MISC O-MISC
peptide O-MISC O-MISC
pools O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
stain O-MISC O-MISC
peripheral O-MISC O-MISC
lymphocytes O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
HSV O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
infected O-MISC O-MISC
individual O-MISC O-MISC
. O-MISC O-MISC

With O-MISC O-MISC
this O-MISC O-MISC
approach O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
identified O-MISC O-MISC
four O-MISC O-MISC
new O-MISC O-MISC
DRA1 O-MISC B-MISC
* O-MISC I-MISC
0101 O-MISC I-MISC
/ O-MISC I-MISC
DRB1 O-MISC I-MISC
* O-MISC I-MISC
0401 O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
two O-MISC O-MISC
DRA1 O-MISC B-MISC
* O-MISC I-MISC
0101 O-MISC O-MISC
/ O-MISC I-MISC
DRB1 O-MISC I-MISC
* O-MISC O-MISC
0404 O-MISC O-MISC
- O-MISC O-MISC
restricted O-MISC O-MISC
, O-MISC O-MISC
VP16 B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
epitopes I-MISC I-MISC
. O-MISC O-MISC

By O-MISC O-MISC
using O-MISC O-MISC
tetramers B-MISC O-MISC
to O-MISC O-MISC
sort O-MISC O-MISC
individual O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
easily O-MISC O-MISC
obtained O-MISC O-MISC
a O-MISC O-MISC
large O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
clones O-MISC O-MISC
specific O-MISC O-MISC
to O-MISC O-MISC
these O-MISC O-MISC
epitopes B-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
DRA1 O-MISC B-MISC
* O-MISC I-MISC
0101 O-MISC I-MISC
/ O-MISC I-MISC
DRB1 O-MISC I-MISC
* O-MISC I-MISC
0401 O-MISC I-MISC
and O-MISC O-MISC
DRA1 O-MISC B-MISC
* O-MISC I-MISC
0101 O-MISC O-MISC
/ O-MISC I-MISC
DRB1 O-MISC I-MISC
* O-MISC O-MISC
0404 O-MISC O-MISC
are O-MISC O-MISC
structurally O-MISC O-MISC
very O-MISC O-MISC
similar O-MISC O-MISC
, O-MISC O-MISC
nonoverlapping O-MISC O-MISC
VP16 B-MISC B-MISC
epitopes I-MISC O-MISC
were O-MISC O-MISC
identified O-MISC O-MISC
, O-MISC O-MISC
illustrating O-MISC O-MISC
high O-MISC O-MISC
selectivity O-MISC I-MISC
of O-MISC O-MISC
individual O-MISC O-MISC
allele O-MISC O-MISC
polymorphisms O-MISC O-MISC
within O-MISC O-MISC
common O-MISC O-MISC
MHC O-MISC B-MISC
variants O-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
rapid O-MISC O-MISC
approach O-MISC O-MISC
to O-MISC O-MISC
detecting O-MISC O-MISC
CD4 O-MISC B-MISC
+ O-MISC I-MISC
T O-MISC I-MISC
cell O-MISC I-MISC
epitopes O-MISC I-MISC
from O-MISC O-MISC
complex O-MISC O-MISC
Ags B-MISC I-MISC
can O-MISC O-MISC
be O-MISC O-MISC
applied O-MISC O-MISC
to O-MISC O-MISC
any O-MISC O-MISC
known O-MISC O-MISC
Ag B-MISC B-MISC
that O-MISC O-MISC
gives O-MISC O-MISC
a O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Localized O-MISC O-MISC
pancreatic O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
in O-MISC O-MISC
taurocholate O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
pancreatitis O-MISC O-MISC
. O-MISC O-MISC

Transcription B-MISC O-MISC
factor I-MISC I-MISC
nuclear I-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
cerulein O-MISC O-MISC
pancreatitis O-MISC O-MISC
and O-MISC O-MISC
mediates O-MISC O-MISC
cytokine O-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
transcription O-MISC B-MISC
factor O-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
other O-MISC O-MISC
models O-MISC O-MISC
of O-MISC O-MISC
pancreatitis O-MISC O-MISC
has O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
established O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
inflammatory B-MISC B-MISC
molecules I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
their O-MISC O-MISC
correlation O-MISC O-MISC
with O-MISC O-MISC
local O-MISC O-MISC
pancreatic O-MISC O-MISC
injury O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
severe O-MISC O-MISC
pancreatitis O-MISC O-MISC
. O-MISC O-MISC

Rats O-MISC O-MISC
received O-MISC O-MISC
intraductal O-MISC O-MISC
infusion O-MISC O-MISC
of O-MISC O-MISC
taurocholate O-MISC O-MISC
or O-MISC O-MISC
saline O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
pancreatic O-MISC O-MISC
head O-MISC O-MISC
and O-MISC O-MISC
tail O-MISC O-MISC
were O-MISC O-MISC
analyzed O-MISC O-MISC
separately O-MISC O-MISC
. O-MISC O-MISC

NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
activator B-MISC B-MISC
protein I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
activation O-MISC O-MISC
were O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
gel O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
mRNA O-MISC B-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
, O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
KC O-MISC B-MISC
, O-MISC O-MISC
monocyte B-MISC B-MISC
chemoattractant I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
inducible B-MISC O-MISC
nitric I-MISC B-MISC
oxide I-MISC I-MISC
synthase I-MISC I-MISC
was O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
semiquantitative O-MISC O-MISC
RT O-MISC O-MISC
- O-MISC O-MISC
PCR O-MISC O-MISC
. O-MISC O-MISC

Morphological O-MISC O-MISC
damage O-MISC O-MISC
and O-MISC O-MISC
trypsin O-MISC O-MISC
activation O-MISC O-MISC
were O-MISC O-MISC
much O-MISC O-MISC
greater O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
pancreatic O-MISC O-MISC
head O-MISC O-MISC
than O-MISC O-MISC
tail O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
parallel O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
stronger O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and I-MISC O-MISC
cytokine I-MISC B-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

Saline O-MISC O-MISC
infusion O-MISC O-MISC
mildly O-MISC O-MISC
affected O-MISC O-MISC
these O-MISC O-MISC
parameters O-MISC O-MISC
. O-MISC O-MISC

AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
was O-MISC O-MISC
strongly O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
pancreatic O-MISC O-MISC
segments O-MISC O-MISC
after O-MISC O-MISC
either O-MISC O-MISC
taurocholate O-MISC O-MISC
or O-MISC O-MISC
saline O-MISC O-MISC
infusion O-MISC O-MISC
. O-MISC O-MISC

NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
inhibition O-MISC O-MISC
with O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
acetylcysteine O-MISC O-MISC
ameliorated O-MISC O-MISC
the O-MISC O-MISC
local O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Correlation O-MISC O-MISC
between O-MISC O-MISC
localized O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
cytokine O-MISC B-MISC
upregulation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
tissue O-MISC O-MISC
damage O-MISC O-MISC
suggests O-MISC O-MISC
a O-MISC O-MISC
key O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
of O-MISC O-MISC
acute O-MISC O-MISC
pancreatitis O-MISC O-MISC
. O-MISC O-MISC

CD45 B-MISC B-MISC
tyrosine I-MISC O-MISC
phosphatase I-MISC I-MISC
controls O-MISC O-MISC
common O-MISC B-MISC
gamma B-MISC B-MISC
- I-MISC I-MISC
chain I-MISC I-MISC
cytokine I-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
STAT B-MISC B-MISC
and O-MISC O-MISC
extracellular O-MISC B-MISC
signal O-MISC I-MISC
- O-MISC I-MISC
related O-MISC I-MISC
kinase O-MISC I-MISC
phosphorylation O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
human O-MISC O-MISC
lymphoblasts O-MISC O-MISC
: O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
proliferation O-MISC O-MISC
without O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
objective O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
was O-MISC O-MISC
to O-MISC O-MISC
test O-MISC O-MISC
whether O-MISC O-MISC
CD45 O-MISC B-MISC
signals O-MISC O-MISC
can O-MISC O-MISC
influence O-MISC O-MISC
signaling O-MISC O-MISC
processes O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
human O-MISC O-MISC
lymphoblasts O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
this O-MISC O-MISC
end O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
generated O-MISC O-MISC
lymphoblasts O-MISC O-MISC
which O-MISC O-MISC
proliferate O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
common O-MISC O-MISC
gamma B-MISC B-MISC
- I-MISC I-MISC
chain I-MISC I-MISC
cytokines I-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
readily O-MISC O-MISC
undergo O-MISC O-MISC
apoptosis O-MISC O-MISC
after O-MISC O-MISC
cytokine O-MISC B-MISC
withdrawal O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
experiments O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
CD45R0 B-MISC B-MISC
mAb I-MISC I-MISC
UCHL I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
control B-MISC O-MISC
CD45 I-MISC B-MISC
mAbs I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
significant O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
pan B-MISC O-MISC
- I-MISC B-MISC
CD45 I-MISC I-MISC
mAb I-MISC I-MISC
GAP8 I-MISC I-MISC
. I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
most O-MISC O-MISC
effective O-MISC O-MISC
in O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
OKT O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
proliferation O-MISC O-MISC
in O-MISC O-MISC
quiescent O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
ineffective O-MISC O-MISC
in O-MISC O-MISC
lymphoblasts O-MISC O-MISC
. O-MISC O-MISC

Addition O-MISC O-MISC
of O-MISC O-MISC
CD3 B-MISC B-MISC
mAb I-MISC I-MISC
OKT I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
had O-MISC O-MISC
no O-MISC O-MISC
influence O-MISC O-MISC
on O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
proliferation O-MISC O-MISC
( O-MISC O-MISC
with O-MISC O-MISC
or O-MISC O-MISC
without O-MISC O-MISC
UCHL B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
after O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
OKT B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
- O-MISC O-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
7 I-MISC I-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
proliferation O-MISC O-MISC
assays O-MISC O-MISC
, O-MISC O-MISC
UCHL B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
signals O-MISC O-MISC
could O-MISC O-MISC
not O-MISC O-MISC
significantly O-MISC O-MISC
alter O-MISC O-MISC
cellular O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
find O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
following O-MISC O-MISC
CD45R0 O-MISC B-MISC
signaling O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
Western O-MISC O-MISC
blots O-MISC O-MISC
using O-MISC O-MISC
mAbs B-MISC O-MISC
detecting O-MISC O-MISC
phosphorylated B-MISC O-MISC
STAT I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, I-MISC O-MISC
STAT I-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
, I-MISC O-MISC
STAT I-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
, O-MISC O-MISC
or O-MISC O-MISC
extracellular B-MISC O-MISC
signal I-MISC I-MISC
- I-MISC I-MISC
related I-MISC I-MISC
kinase I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
CD45R0 O-MISC B-MISC
signaling O-MISC O-MISC
could O-MISC O-MISC
effectively O-MISC O-MISC
diminish O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
intracellular O-MISC O-MISC
signaling O-MISC O-MISC
components O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
RT O-MISC O-MISC
- O-MISC O-MISC
PCR O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
CD45R0 O-MISC B-MISC
signaling O-MISC O-MISC
inhibited O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
mRNA O-MISC I-MISC
production O-MISC O-MISC
without O-MISC O-MISC
major O-MISC O-MISC
influence O-MISC O-MISC
on O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
, O-MISC O-MISC
or O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
mRNA I-MISC I-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

Costimulation O-MISC O-MISC
with O-MISC O-MISC
OKT B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
optimally O-MISC O-MISC
induced O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
, O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
decreased O-MISC O-MISC
by O-MISC O-MISC
CD45 O-MISC B-MISC
signals O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
conclusion O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
illustrate O-MISC O-MISC
that O-MISC O-MISC
CD45R0 O-MISC B-MISC
signals O-MISC O-MISC
control O-MISC O-MISC
early O-MISC O-MISC
cytokine O-MISC B-MISC
receptor O-MISC I-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
signaling O-MISC O-MISC
processes O-MISC O-MISC
and O-MISC O-MISC
mRNA O-MISC B-MISC
and O-MISC O-MISC
DNA O-MISC O-MISC
synthesis O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
human O-MISC O-MISC
lymphoblasts O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
CD45 B-MISC B-MISC
epitopes I-MISC I-MISC
( O-MISC O-MISC
GAP8 B-MISC B-MISC
. I-MISC I-MISC
3 I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
active O-MISC O-MISC
and O-MISC O-MISC
critical O-MISC O-MISC
for O-MISC O-MISC
signaling O-MISC O-MISC
in O-MISC O-MISC
quiescent O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
are O-MISC O-MISC
nonfunctional O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
human O-MISC O-MISC
lymphoblasts O-MISC O-MISC
. O-MISC O-MISC

Pax5 B-MISC B-MISC
determines O-MISC O-MISC
the O-MISC O-MISC
identity O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
beginning O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
end O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphopoiesis O-MISC O-MISC
. O-MISC O-MISC

Despite O-MISC O-MISC
being O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
most O-MISC O-MISC
intensively O-MISC O-MISC
studied O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
basis O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
specification O-MISC O-MISC
is O-MISC O-MISC
largely O-MISC O-MISC
unknown O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Pax5 B-MISC B-MISC
gene I-MISC I-MISC
encoding O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
BSAP I-MISC B-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
progression O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphopoiesis O-MISC O-MISC
beyond O-MISC O-MISC
the O-MISC O-MISC
pro O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
stage O-MISC O-MISC
. O-MISC O-MISC

Pax5 O-MISC B-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
pro O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
not O-MISC O-MISC
yet O-MISC O-MISC
committed O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphoid O-MISC O-MISC
lineage O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
instead O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
broad O-MISC O-MISC
lymphomyeloid O-MISC O-MISC
developmental O-MISC O-MISC
potential O-MISC O-MISC
. O-MISC O-MISC

Pax5 B-MISC B-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
mediate O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lineage O-MISC O-MISC
commitment O-MISC O-MISC
by O-MISC O-MISC
repressing O-MISC O-MISC
the O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
non B-MISC B-MISC
- I-MISC I-MISC
B I-MISC I-MISC
- I-MISC I-MISC
lymphoid I-MISC I-MISC
genes I-MISC I-MISC
and O-MISC O-MISC
by O-MISC O-MISC
simultaneously O-MISC O-MISC
activating O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
B B-MISC B-MISC
- I-MISC I-MISC
lineage I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Pax5 B-MISC B-MISC
thus O-MISC O-MISC
functions O-MISC O-MISC
both O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
transcriptional O-MISC B-MISC
repressor O-MISC I-MISC
and O-MISC O-MISC
activator O-MISC B-MISC
, O-MISC O-MISC
depending O-MISC O-MISC
on O-MISC O-MISC
its O-MISC O-MISC
interactions O-MISC O-MISC
with O-MISC O-MISC
corepressors B-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Groucho B-MISC B-MISC
protein I-MISC I-MISC
family I-MISC I-MISC
or O-MISC O-MISC
with O-MISC O-MISC
positive O-MISC B-MISC
regulators O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
TATA B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

Once O-MISC O-MISC
committed O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lineage O-MISC O-MISC
, O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
require O-MISC O-MISC
Pax5 B-MISC B-MISC
function O-MISC O-MISC
to O-MISC O-MISC
maintain O-MISC O-MISC
their O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphoid O-MISC O-MISC
identity O-MISC O-MISC
throughout O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC

Partners O-MISC O-MISC
in O-MISC O-MISC
transcription O-MISC O-MISC
: O-MISC O-MISC
NFAT B-MISC B-MISC
and O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Combinatorial O-MISC O-MISC
regulation O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
powerful O-MISC O-MISC
mechanism O-MISC O-MISC
that O-MISC O-MISC
enables O-MISC O-MISC
tight O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
via O-MISC O-MISC
integration O-MISC O-MISC
of O-MISC O-MISC
multiple O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
that O-MISC O-MISC
induce O-MISC O-MISC
different O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
required O-MISC O-MISC
for O-MISC O-MISC
enhanceosome O-MISC O-MISC
assembly O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
four O-MISC O-MISC
calcium O-MISC B-MISC
- O-MISC I-MISC
regulated O-MISC I-MISC
transcription B-MISC I-MISC
factors I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NFAT B-MISC B-MISC
family I-MISC I-MISC
act O-MISC O-MISC
synergistically O-MISC O-MISC
with O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( I-MISC I-MISC
Fos I-MISC I-MISC
/ I-MISC I-MISC
Jun I-MISC I-MISC
) I-MISC I-MISC
proteins I-MISC I-MISC
on O-MISC O-MISC
composite O-MISC B-MISC
DNA O-MISC I-MISC
elements O-MISC I-MISC
which O-MISC O-MISC
contain O-MISC O-MISC
adjacent O-MISC O-MISC
NFAT B-MISC B-MISC
and I-MISC I-MISC
AP I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
, O-MISC O-MISC
where O-MISC O-MISC
they O-MISC O-MISC
form O-MISC O-MISC
highly O-MISC O-MISC
stable O-MISC O-MISC
ternary O-MISC B-MISC
complexes O-MISC I-MISC
to O-MISC O-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
diverse O-MISC O-MISC
inducible O-MISC O-MISC
genes O-MISC I-MISC
. O-MISC O-MISC

Concomitant O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
NFAT B-MISC B-MISC
and O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
requires O-MISC O-MISC
concerted O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
two O-MISC O-MISC
different O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
: O-MISC O-MISC
calcium O-MISC O-MISC
/ O-MISC B-MISC
calcineurin O-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
promotes O-MISC O-MISC
NFAT O-MISC B-MISC
dephosphorylation O-MISC O-MISC
, O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
; O-MISC O-MISC
and O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
( I-MISC O-MISC
PKC I-MISC B-MISC
) I-MISC O-MISC
/ I-MISC I-MISC
Ras I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
promotes O-MISC O-MISC
the O-MISC O-MISC
synthesis O-MISC O-MISC
, O-MISC O-MISC
phosphorylation O-MISC O-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Fos B-MISC B-MISC
and I-MISC O-MISC
Jun I-MISC B-MISC
families I-MISC I-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

A O-MISC O-MISC
fifth O-MISC B-MISC
member O-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NFAT B-MISC B-MISC
family I-MISC I-MISC
, O-MISC O-MISC
NFAT5 B-MISC B-MISC
, O-MISC O-MISC
controls O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
osmotic O-MISC O-MISC
stress O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
mechanism O-MISC O-MISC
that O-MISC O-MISC
requires O-MISC O-MISC
dimer O-MISC O-MISC
formation O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
calcineurin B-MISC B-MISC
or O-MISC O-MISC
of O-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Pharmacological O-MISC O-MISC
interference O-MISC O-MISC
with O-MISC O-MISC
theNFAT O-MISC O-MISC
: O-MISC O-MISC
AP O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
interaction O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
useful O-MISC O-MISC
in O-MISC O-MISC
selective O-MISC O-MISC
manipulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Balanced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NFAT B-MISC B-MISC
and O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
productive O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
NFAT O-MISC B-MISC
: O-MISC O-MISC
AP O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
interactions O-MISC O-MISC
in O-MISC O-MISC
other O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
and O-MISC O-MISC
biological O-MISC O-MISC
processes O-MISC O-MISC
remains O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
understood O-MISC O-MISC
. O-MISC O-MISC

Cytokine O-MISC B-MISC
production O-MISC O-MISC
by O-MISC O-MISC
Vgamma O-MISC B-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
subsets O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
factor O-MISC O-MISC
determining O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
Th O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
and O-MISC O-MISC
susceptibility O-MISC O-MISC
of O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC O-MISC
mice O-MISC O-MISC
to O-MISC O-MISC
coxsackievirus O-MISC O-MISC
B3 O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
myocarditis O-MISC O-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
coxsackievirus O-MISC O-MISC
B3 O-MISC I-MISC
( O-MISC I-MISC
CVB3 O-MISC I-MISC
) O-MISC I-MISC
variants O-MISC I-MISC
( O-MISC O-MISC
H3 O-MISC O-MISC
and O-MISC O-MISC
H310A1 O-MISC O-MISC
) O-MISC O-MISC
differ O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
amino O-MISC O-MISC
acid O-MISC O-MISC
mutation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
VP2 B-MISC B-MISC
capsid I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

H3 O-MISC O-MISC
induces O-MISC O-MISC
severe O-MISC O-MISC
myocarditis O-MISC O-MISC
in O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
H310A1 O-MISC O-MISC
is O-MISC O-MISC
amyocarditic O-MISC O-MISC
. O-MISC O-MISC

Infection O-MISC O-MISC
with O-MISC O-MISC
H3 O-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
H310A1 O-MISC O-MISC
, O-MISC O-MISC
preferentially O-MISC O-MISC
activates O-MISC O-MISC
Vgamma4 O-MISC O-MISC
Vdelta4 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
strongly O-MISC O-MISC
positive O-MISC O-MISC
for O-MISC O-MISC
gamma B-MISC B-MISC
interferon I-MISC B-MISC
( O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
Vgamma1 O-MISC O-MISC
Vdelta4 O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
H3 O-MISC O-MISC
and O-MISC O-MISC
H310A1 O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
animals O-MISC O-MISC
. O-MISC O-MISC

Depletion O-MISC O-MISC
of O-MISC O-MISC
Vgamma1 O-MISC B-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
using O-MISC O-MISC
monoclonal B-MISC B-MISC
anti I-MISC I-MISC
- I-MISC I-MISC
Vgamma1 I-MISC I-MISC
antibody I-MISC I-MISC
enhanced O-MISC O-MISC
myocarditis O-MISC O-MISC
and O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
, O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC O-MISC
gamma I-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
responses O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
H3 O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
H310A1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
mice O-MISC O-MISC
yet O-MISC O-MISC
decreased O-MISC O-MISC
the O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
, O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Depleting O-MISC O-MISC
Vgamma4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
suppressed O-MISC O-MISC
myocarditis O-MISC O-MISC
and O-MISC O-MISC
reduced O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
IFN O-MISC O-MISC
- O-MISC O-MISC
gamma O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
increased O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
IL O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
production O-MISC O-MISC
by O-MISC O-MISC
Vgamma1 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
Vgamma4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
investigated O-MISC O-MISC
by O-MISC O-MISC
adoptively O-MISC O-MISC
transferring O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
H3 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC B-MISC
Stat4 O-MISC I-MISC
knockout O-MISC O-MISC
( O-MISC O-MISC
Stat4ko O-MISC B-MISC
) O-MISC O-MISC
( O-MISC O-MISC
defective O-MISC O-MISC
in O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
expression O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC I-MISC
Stat6ko O-MISC I-MISC
( O-MISC O-MISC
defective O-MISC O-MISC
in O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
expression O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
into O-MISC O-MISC
H3 O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
wild O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC O-MISC
recipients O-MISC O-MISC
. O-MISC O-MISC

Vgamma4 O-MISC B-MISC
and O-MISC O-MISC
Vgamma1 O-MISC B-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
Stat4ko O-MISC B-MISC
mice O-MISC O-MISC
expressed O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
but O-MISC O-MISC
no O-MISC O-MISC
or O-MISC O-MISC
minimal O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
these O-MISC O-MISC
cell O-MISC O-MISC
populations O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
Stat6ko O-MISC B-MISC
mice O-MISC O-MISC
expressed O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
but O-MISC O-MISC
no O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
. O-MISC O-MISC

Stat4ko O-MISC B-MISC
Vgamma1 O-MISC B-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
suppress O-MISC O-MISC
myocarditis O-MISC O-MISC
. O-MISC O-MISC

Stat6ko O-MISC B-MISC
Vgamma1 O-MISC B-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
inhibitory O-MISC O-MISC
. O-MISC O-MISC

Stat6ko O-MISC B-MISC
Vgamma4 O-MISC I-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
significantly O-MISC O-MISC
enhanced O-MISC O-MISC
myocarditis O-MISC O-MISC
. O-MISC O-MISC

Stat4ko O-MISC B-MISC
Vgamma4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
neither O-MISC O-MISC
inhibited O-MISC O-MISC
nor O-MISC O-MISC
enhanced O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
distinct O-MISC O-MISC
gammadelta O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
subsets O-MISC O-MISC
control O-MISC O-MISC
myocarditis O-MISC O-MISC
susceptibility O-MISC O-MISC
and O-MISC O-MISC
bias O-MISC O-MISC
the O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
Th O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cytokines B-MISC B-MISC
produced O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
Vgamma O-MISC B-MISC
subpopulation O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
influence O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
CD4 B-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
Th O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
. O-MISC O-MISC

Plasmin B-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
and O-MISC O-MISC
tissue B-MISC B-MISC
factor I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
involves O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
IKKbeta B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
was O-MISC O-MISC
previously O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
plasmin B-MISC B-MISC
activates O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
monocytes O-MISC O-MISC
in O-MISC O-MISC
terms O-MISC O-MISC
of O-MISC O-MISC
lipid O-MISC O-MISC
mediator O-MISC O-MISC
release O-MISC O-MISC
and O-MISC O-MISC
chemotactic O-MISC O-MISC
migration O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
plasmin B-MISC B-MISC
induces O-MISC O-MISC
proinflammatory B-MISC B-MISC
cytokine I-MISC I-MISC
release O-MISC O-MISC
and O-MISC O-MISC
tissue B-MISC B-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
TF B-MISC B-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

Plasmin B-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
043 O-MISC O-MISC
to O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
43 O-MISC O-MISC
CTA O-MISC O-MISC
U O-MISC O-MISC
/ O-MISC O-MISC
mL O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
active B-MISC O-MISC
site I-MISC O-MISC
- I-MISC O-MISC
blocked I-MISC O-MISC
plasmin I-MISC O-MISC
, O-MISC O-MISC
triggered O-MISC O-MISC
concentration O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
mRNA O-MISC B-MISC
for O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
, O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
TF B-MISC B-MISC
with O-MISC O-MISC
maximum O-MISC O-MISC
responses O-MISC O-MISC
after O-MISC O-MISC
4 O-MISC O-MISC
hours O-MISC O-MISC
. O-MISC O-MISC

Plasmin B-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
mRNA O-MISC B-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
concentration O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
lysine O-MISC O-MISC
analogue O-MISC O-MISC
trans O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
aminomethyl O-MISC O-MISC
) O-MISC O-MISC
cyclohexane O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
carboxylic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
t O-MISC O-MISC
- O-MISC O-MISC
AMCA O-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Increases O-MISC O-MISC
in O-MISC O-MISC
mRNA O-MISC O-MISC
levels O-MISC O-MISC
were O-MISC O-MISC
followed O-MISC O-MISC
by O-MISC O-MISC
concentration O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
time O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
release O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
and O-MISC O-MISC
by O-MISC O-MISC
TF B-MISC B-MISC
expression O-MISC O-MISC
on O-MISC O-MISC
monocyte O-MISC O-MISC
surfaces O-MISC O-MISC
. O-MISC O-MISC

Neither O-MISC O-MISC
cytokines B-MISC B-MISC
nor O-MISC O-MISC
TF B-MISC B-MISC
could O-MISC O-MISC
be O-MISC O-MISC
detected O-MISC O-MISC
when O-MISC O-MISC
monocytes O-MISC O-MISC
were O-MISC O-MISC
preincubated O-MISC O-MISC
with O-MISC O-MISC
actinomycin O-MISC O-MISC
D O-MISC O-MISC
or O-MISC O-MISC
cycloheximide O-MISC O-MISC
. O-MISC O-MISC

Electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
indicated O-MISC O-MISC
plasmin B-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
; O-MISC O-MISC
DNA B-MISC O-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
complexes I-MISC I-MISC
were O-MISC O-MISC
composed O-MISC O-MISC
of O-MISC O-MISC
p50 B-MISC B-MISC
, O-MISC O-MISC
p65 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC B-MISC
, O-MISC O-MISC
as O-MISC O-MISC
shown O-MISC O-MISC
by O-MISC O-MISC
supershift O-MISC O-MISC
experiments O-MISC O-MISC
. O-MISC O-MISC

Nuclear O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
/ I-MISC I-MISC
Rel I-MISC I-MISC
proteins I-MISC I-MISC
coincided O-MISC O-MISC
with O-MISC O-MISC
IkappaBalpha O-MISC B-MISC
degradation O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
variance O-MISC O-MISC
with O-MISC O-MISC
endotoxic O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
, O-MISC O-MISC
plasmin B-MISC O-MISC
elicited O-MISC O-MISC
the O-MISC O-MISC
rapid O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
another O-MISC O-MISC
cytoplasmic B-MISC B-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
inhibitor I-MISC O-MISC
, I-MISC O-MISC
p105 I-MISC O-MISC
. O-MISC O-MISC

Proteolysis O-MISC O-MISC
of O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
inhibitors O-MISC O-MISC
was O-MISC O-MISC
apparently O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
transient O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
IkappaB B-MISC B-MISC
kinase I-MISC I-MISC
( I-MISC O-MISC
IKK I-MISC B-MISC
) I-MISC O-MISC
beta I-MISC O-MISC
that O-MISC O-MISC
reached O-MISC O-MISC
maximum O-MISC O-MISC
activity O-MISC O-MISC
at O-MISC O-MISC
1 O-MISC O-MISC
hour O-MISC O-MISC
after O-MISC O-MISC
plasmin B-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
AP O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
binding O-MISC O-MISC
was O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
plasmin B-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
monocytes O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
most O-MISC O-MISC
complexes O-MISC O-MISC
composed O-MISC O-MISC
of O-MISC O-MISC
JunD B-MISC B-MISC
, O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Fos I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
FosB B-MISC B-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
further O-MISC O-MISC
substantiate O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
plasmin B-MISC B-MISC
as O-MISC O-MISC
a O-MISC O-MISC
proinflammatory O-MISC O-MISC
activator O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
reveal O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
new O-MISC O-MISC
link O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
plasminogen O-MISC B-MISC
- O-MISC O-MISC
plasmin O-MISC B-MISC
system O-MISC O-MISC
and O-MISC O-MISC
inflammation O-MISC O-MISC
. O-MISC O-MISC

( O-MISC O-MISC
Blood O-MISC O-MISC
. O-MISC O-MISC
2001 O-MISC O-MISC
; O-MISC O-MISC
97 O-MISC O-MISC
: O-MISC O-MISC
3941 O-MISC O-MISC
- O-MISC O-MISC
3950 O-MISC O-MISC
) O-MISC O-MISC

STAT3 B-MISC B-MISC
is O-MISC O-MISC
constitutively O-MISC O-MISC
active O-MISC O-MISC
in O-MISC O-MISC
some O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
Polycythemia O-MISC O-MISC
rubra O-MISC O-MISC
vera O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
Polycythemia O-MISC O-MISC
vera O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
clonal O-MISC O-MISC
stem O-MISC O-MISC
cell O-MISC O-MISC
disorder O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
hyperproliferation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
erythroid O-MISC O-MISC
, O-MISC O-MISC
myeloid O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
megakaryocytic O-MISC O-MISC
lineages O-MISC O-MISC
. O-MISC O-MISC

While O-MISC O-MISC
it O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
progenitor O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
P O-MISC O-MISC
. O-MISC O-MISC
vera O-MISC O-MISC
patients O-MISC O-MISC
are O-MISC O-MISC
hypersensitive O-MISC O-MISC
to O-MISC O-MISC
several O-MISC O-MISC
growth O-MISC B-MISC
factors O-MISC I-MISC
including O-MISC O-MISC
erythropoietin B-MISC B-MISC
, O-MISC O-MISC
insulin B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
thrombopoietin B-MISC B-MISC
, O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
granulocyte B-MISC B-MISC
/ I-MISC I-MISC
monocyte I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
disease O-MISC O-MISC
remains O-MISC O-MISC
unknown O-MISC O-MISC
. O-MISC O-MISC

Growth O-MISC B-MISC
factor O-MISC I-MISC
hypersensitivity O-MISC B-MISC
could O-MISC O-MISC
be O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
therefore O-MISC O-MISC
investigated O-MISC O-MISC
a O-MISC O-MISC
common O-MISC O-MISC
downstream O-MISC O-MISC
effector O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
signal B-MISC B-MISC
transducers I-MISC I-MISC
and I-MISC I-MISC
activators I-MISC I-MISC
of I-MISC I-MISC
transcription I-MISC I-MISC
( O-MISC O-MISC
STATs B-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
constitutive O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT B-MISC B-MISC
factors I-MISC I-MISC
could O-MISC O-MISC
explain O-MISC O-MISC
the O-MISC O-MISC
increased O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
P O-MISC O-MISC
. O-MISC O-MISC
vera O-MISC O-MISC
cells O-MISC O-MISC
even O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
growth O-MISC B-MISC
factor O-MISC I-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Peripheral O-MISC O-MISC
granulocytes O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
P O-MISC O-MISC
. O-MISC O-MISC
vera O-MISC O-MISC
and O-MISC O-MISC
from O-MISC O-MISC
healthy O-MISC O-MISC
volunteers O-MISC O-MISC
were O-MISC O-MISC
assayed O-MISC O-MISC
for O-MISC O-MISC
STAT1 B-MISC B-MISC
, I-MISC O-MISC
3 I-MISC O-MISC
, I-MISC O-MISC
and I-MISC O-MISC
5 I-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
by O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Four O-MISC O-MISC
of O-MISC O-MISC
14 O-MISC O-MISC
P O-MISC O-MISC
. O-MISC O-MISC
vera O-MISC O-MISC
patients O-MISC O-MISC
analyzed O-MISC O-MISC
showed O-MISC O-MISC
constitutive O-MISC O-MISC
STAT3 O-MISC B-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
unstimulated O-MISC O-MISC
peripheral O-MISC O-MISC
granulocytes O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
none O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
17 O-MISC O-MISC
healthy O-MISC O-MISC
volunteers O-MISC O-MISC
tested O-MISC O-MISC
did O-MISC O-MISC
. O-MISC O-MISC

None O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
subjects O-MISC O-MISC
showed O-MISC O-MISC
constitutive O-MISC O-MISC
STAT1 B-MISC B-MISC
or O-MISC O-MISC
STAT5 B-MISC B-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Western O-MISC O-MISC
blotting O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
three O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
STAT3 B-MISC B-MISC
is O-MISC O-MISC
constitutively O-MISC O-MISC
phosphorylated O-MISC O-MISC
on O-MISC O-MISC
Tyr O-MISC B-MISC
705 O-MISC I-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
unphosphorylated O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
constitutive O-MISC O-MISC
STAT3 B-MISC B-MISC
activity O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
correlate O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
duration O-MISC O-MISC
of O-MISC O-MISC
disease O-MISC O-MISC
or O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
regimen O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
recently O-MISC O-MISC
diagnosed O-MISC O-MISC
patient O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
two O-MISC O-MISC
patients O-MISC O-MISC
treated O-MISC O-MISC
only O-MISC O-MISC
with O-MISC O-MISC
phlebotomy O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
Our O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
constitutive O-MISC O-MISC
phosphorylation O-MISC O-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT3 B-MISC B-MISC
is O-MISC O-MISC
not O-MISC O-MISC
a O-MISC O-MISC
secondary O-MISC O-MISC
event O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
mutagenizing O-MISC O-MISC
agents O-MISC O-MISC
or O-MISC O-MISC
by O-MISC O-MISC
prolonged O-MISC O-MISC
hyperproliferation O-MISC O-MISC
of O-MISC O-MISC
hematopoietic O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
rather O-MISC O-MISC
represents O-MISC O-MISC
a O-MISC O-MISC
primary O-MISC O-MISC
molecular O-MISC O-MISC
aberration O-MISC O-MISC
. O-MISC O-MISC

Constitutively B-MISC O-MISC
active I-MISC I-MISC
STAT3 I-MISC B-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
growth O-MISC B-MISC
factor O-MISC I-MISC
hypersensitivity O-MISC O-MISC
of O-MISC O-MISC
P O-MISC O-MISC
. O-MISC O-MISC
vera O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
of O-MISC O-MISC
phosphorylation B-MISC B-MISC
sites I-MISC I-MISC
for O-MISC O-MISC
Bruton B-MISC B-MISC
' I-MISC I-MISC
s I-MISC I-MISC
tyrosine I-MISC I-MISC
kinase I-MISC I-MISC
within O-MISC O-MISC
the O-MISC O-MISC
transcriptional B-MISC B-MISC
regulator I-MISC I-MISC
BAP I-MISC B-MISC
/ I-MISC I-MISC
TFII I-MISC I-MISC
- I-MISC I-MISC
I I-MISC I-MISC
. O-MISC O-MISC

Bruton B-MISC B-MISC
' I-MISC I-MISC
s I-MISC I-MISC
tyrosine I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC I-MISC
Btk B-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Tec B-MISC O-MISC
family I-MISC I-MISC
of I-MISC O-MISC
cytosolic I-MISC B-MISC
kinases I-MISC I-MISC
, O-MISC O-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
and O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

BAP B-MISC B-MISC
/ I-MISC I-MISC
TFII I-MISC I-MISC
- I-MISC I-MISC
I I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
protein O-MISC O-MISC
implicated O-MISC O-MISC
in O-MISC O-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
Btk B-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
transiently O-MISC O-MISC
phosphorylated O-MISC O-MISC
on O-MISC O-MISC
tyrosine O-MISC O-MISC
following O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
receptor O-MISC I-MISC
engagement O-MISC O-MISC
. O-MISC O-MISC

BAP B-MISC B-MISC
/ I-MISC I-MISC
TFII I-MISC I-MISC
- I-MISC I-MISC
I I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
substrate O-MISC O-MISC
for O-MISC O-MISC
Btk B-MISC B-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
hyperphosphorylated O-MISC O-MISC
on O-MISC O-MISC
tyrosine O-MISC O-MISC
upon O-MISC O-MISC
coexpression O-MISC O-MISC
with O-MISC O-MISC
Btk B-MISC B-MISC
in O-MISC O-MISC
mammalian O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
an O-MISC O-MISC
effort O-MISC O-MISC
to O-MISC O-MISC
understand O-MISC O-MISC
the O-MISC O-MISC
physiologic O-MISC O-MISC
consequences O-MISC O-MISC
of O-MISC O-MISC
BAP B-MISC B-MISC
/ I-MISC I-MISC
TFII I-MISC I-MISC
- I-MISC I-MISC
I I-MISC I-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
following O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
receptor O-MISC I-MISC
stimulation O-MISC O-MISC
, O-MISC O-MISC
site O-MISC O-MISC
- O-MISC O-MISC
directed O-MISC O-MISC
mutagenesis O-MISC O-MISC
and O-MISC O-MISC
phosphopeptide O-MISC O-MISC
mapping O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
locate O-MISC O-MISC
the O-MISC O-MISC
predominant O-MISC O-MISC
sites O-MISC O-MISC
of O-MISC O-MISC
BAP B-MISC B-MISC
/ I-MISC I-MISC
TFII I-MISC I-MISC
- I-MISC O-MISC
I I-MISC O-MISC
phosphorylation O-MISC O-MISC
by O-MISC O-MISC
Btk B-MISC B-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
residues O-MISC O-MISC
, O-MISC O-MISC
Tyr248 O-MISC B-MISC
, O-MISC O-MISC
Tyr357 O-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Tyr462 O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
sites O-MISC I-MISC
for O-MISC O-MISC
Btk B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
BAP B-MISC O-MISC
/ I-MISC O-MISC
TFII I-MISC B-MISC
- I-MISC O-MISC
I I-MISC B-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

Residues O-MISC O-MISC
Tyr357 O-MISC O-MISC
and O-MISC O-MISC
Tyr462 O-MISC O-MISC
are O-MISC O-MISC
contained O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
loop B-MISC B-MISC
regions I-MISC I-MISC
of O-MISC O-MISC
adjacent O-MISC O-MISC
helix B-MISC B-MISC
- I-MISC I-MISC
loop I-MISC I-MISC
- I-MISC I-MISC
helix I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
repeats I-MISC I-MISC
within O-MISC O-MISC
BAP B-MISC B-MISC
/ I-MISC I-MISC
TFII I-MISC I-MISC
- I-MISC O-MISC
I I-MISC I-MISC
. O-MISC O-MISC

Mutation O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
Tyr248 O-MISC B-MISC
, O-MISC O-MISC
Tyr357 O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
Tyr462 O-MISC O-MISC
to O-MISC O-MISC
phenylalanine O-MISC O-MISC
reduced O-MISC O-MISC
transcription O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
fos I-MISC I-MISC
promoter I-MISC I-MISC
relative O-MISC O-MISC
to O-MISC O-MISC
wild B-MISC O-MISC
- I-MISC O-MISC
type I-MISC O-MISC
BAP I-MISC O-MISC
/ I-MISC O-MISC
TFII I-MISC B-MISC
- I-MISC O-MISC
I I-MISC B-MISC
in O-MISC O-MISC
transfected O-MISC O-MISC
COS O-MISC O-MISC
- O-MISC O-MISC
7 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
interpretation O-MISC O-MISC
that O-MISC O-MISC
phosphorylation O-MISC O-MISC
at O-MISC O-MISC
these O-MISC O-MISC
sites O-MISC O-MISC
contributes O-MISC O-MISC
to O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Phosphorylation O-MISC O-MISC
of O-MISC O-MISC
BAP B-MISC B-MISC
/ I-MISC I-MISC
TFII I-MISC I-MISC
- I-MISC I-MISC
I I-MISC I-MISC
by O-MISC O-MISC
Btk B-MISC B-MISC
may O-MISC O-MISC
link O-MISC O-MISC
engagement O-MISC O-MISC
of O-MISC O-MISC
receptors O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
surface O-MISC O-MISC
immunoglobulin B-MISC B-MISC
to O-MISC O-MISC
modulation O-MISC O-MISC
of O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
interferon B-MISC B-MISC
consensus I-MISC I-MISC
sequence I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
induces O-MISC O-MISC
potent O-MISC O-MISC
immunity O-MISC O-MISC
against O-MISC O-MISC
BCR O-MISC B-MISC
/ O-MISC I-MISC
ABL O-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Mice O-MISC O-MISC
deficient O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
interferon B-MISC B-MISC
consensus I-MISC I-MISC
sequence I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
ICSBP B-MISC B-MISC
) O-MISC O-MISC
develop O-MISC O-MISC
a O-MISC O-MISC
disease O-MISC O-MISC
resembling O-MISC O-MISC
chronic O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
CML O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
in O-MISC O-MISC
humans O-MISC O-MISC
is O-MISC O-MISC
caused O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
BCR B-MISC B-MISC
/ I-MISC I-MISC
ABL I-MISC I-MISC
oncoprotein I-MISC I-MISC
. O-MISC O-MISC

Interferon B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
induces O-MISC O-MISC
ICSBP B-MISC B-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
effective O-MISC O-MISC
therapy O-MISC O-MISC
for O-MISC O-MISC
CML O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
examined O-MISC O-MISC
whether O-MISC O-MISC
enforced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
ICSBP B-MISC B-MISC
might O-MISC O-MISC
antagonize O-MISC O-MISC
BCR O-MISC B-MISC
/ O-MISC I-MISC
ABL O-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
leukemia O-MISC O-MISC
; O-MISC O-MISC
results O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
ICSBP O-MISC B-MISC
- O-MISC O-MISC
modified O-MISC O-MISC
cells O-MISC O-MISC
generated O-MISC O-MISC
a O-MISC O-MISC
protective O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cytotoxic O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
against O-MISC O-MISC
BCR O-MISC B-MISC
/ O-MISC I-MISC
ABL O-MISC I-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
BaF3 O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
murine O-MISC O-MISC
leukemia O-MISC O-MISC
model O-MISC O-MISC
. O-MISC O-MISC

ICSBP B-MISC B-MISC
expression O-MISC O-MISC
represents O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
means O-MISC O-MISC
of O-MISC O-MISC
stimulating O-MISC O-MISC
a O-MISC O-MISC
host O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
BCR O-MISC B-MISC
/ O-MISC I-MISC
ABL O-MISC I-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
leukemia O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
potential O-MISC O-MISC
strategy O-MISC O-MISC
for O-MISC O-MISC
immunotherapy O-MISC O-MISC
of O-MISC O-MISC
CML O-MISC O-MISC
. O-MISC O-MISC

( O-MISC O-MISC
Blood O-MISC O-MISC
. O-MISC O-MISC
2001 O-MISC O-MISC
; O-MISC O-MISC
97 O-MISC O-MISC
: O-MISC O-MISC
3491 O-MISC B-MISC
- O-MISC I-MISC
3497 O-MISC I-MISC
) O-MISC O-MISC

A O-MISC O-MISC
transcriptional O-MISC O-MISC
block O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
at O-MISC O-MISC
the O-MISC O-MISC
- B-MISC B-MISC
150 I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
in O-MISC O-MISC
effector O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
produce O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
Ag O-MISC O-MISC
recognition O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
isolated O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
most O-MISC O-MISC
effector O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
recovered O-MISC O-MISC
after O-MISC O-MISC
exposure O-MISC O-MISC
to O-MISC O-MISC
Ag B-MISC B-MISC
do O-MISC O-MISC
not O-MISC O-MISC
produce O-MISC O-MISC
sufficient O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
to O-MISC O-MISC
sustain O-MISC O-MISC
growth O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
depend O-MISC O-MISC
on O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
cells O-MISC O-MISC
for O-MISC O-MISC
this O-MISC O-MISC
obligate O-MISC B-MISC
growth O-MISC I-MISC
factor O-MISC I-MISC
. O-MISC O-MISC

IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
primarily O-MISC O-MISC
controlled O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
mechanisms O-MISC O-MISC
restricting O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
production O-MISC O-MISC
in O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
have O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
elucidated O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
evaluate O-MISC O-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
stably O-MISC O-MISC
transfected O-MISC O-MISC
reporter B-MISC B-MISC
genes I-MISC I-MISC
into O-MISC O-MISC
Ag B-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
clones O-MISC O-MISC
. O-MISC O-MISC

CD28 O-MISC B-MISC
+ O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
unable O-MISC O-MISC
to O-MISC O-MISC
transcribe O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
antigenic O-MISC O-MISC
stimulation O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
block O-MISC O-MISC
in O-MISC O-MISC
transactivation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
- B-MISC B-MISC
150 I-MISC I-MISC
CD28 I-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
( I-MISC O-MISC
CD28RE I-MISC B-MISC
) I-MISC I-MISC
/ I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
did O-MISC O-MISC
transactivate O-MISC O-MISC
the O-MISC O-MISC
composite O-MISC O-MISC
NFAT B-MISC B-MISC
/ I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC O-MISC
OCT I-MISC B-MISC
/ I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
sites I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
consensus B-MISC B-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
motif I-MISC I-MISC
. O-MISC O-MISC

Mutation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nonconsensus B-MISC B-MISC
- I-MISC I-MISC
150 I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
to O-MISC O-MISC
a O-MISC O-MISC
consensus B-MISC B-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
, O-MISC O-MISC
or O-MISC O-MISC
insertion O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
CD28RE B-MISC B-MISC
/ I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
consensus I-MISC I-MISC
site I-MISC I-MISC
upstream O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
native O-MISC B-MISC
- B-MISC I-MISC
150 I-MISC I-MISC
CD28RE I-MISC I-MISC
/ I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
restored O-MISC O-MISC
transactivation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
altered O-MISC O-MISC
promoter B-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
defect O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
- B-MISC B-MISC
150 I-MISC I-MISC
site I-MISC I-MISC
may O-MISC O-MISC
reflect O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
or O-MISC O-MISC
inactivity O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
required O-MISC O-MISC
factor O-MISC O-MISC
rather O-MISC O-MISC
than O-MISC O-MISC
repression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Stem B-MISC B-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
and O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
induce O-MISC O-MISC
stepwise O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
erythroid O-MISC O-MISC
precursor O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
basic O-MISC O-MISC
fibroblast B-MISC O-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
hematopoietic O-MISC O-MISC
stem O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
A O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
m O-MISC O-MISC
ultipotent O-MISC O-MISC
immature O-MISC O-MISC
myeloid O-MISC O-MISC
cell O-MISC O-MISC
population O-MISC O-MISC
was O-MISC O-MISC
produced O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
basic B-MISC O-MISC
fibroblast I-MISC O-MISC
growth I-MISC B-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
bFGF B-MISC B-MISC
) O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
hematopoietic O-MISC O-MISC
stem O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
A O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
when O-MISC O-MISC
cultured O-MISC O-MISC
with O-MISC O-MISC
stem B-MISC B-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC I-MISC
SCF B-MISC I-MISC
) O-MISC I-MISC
replacing O-MISC I-MISC
bFGF B-MISC I-MISC
. O-MISC O-MISC

Those O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
positive O-MISC O-MISC
for O-MISC O-MISC
stem B-MISC B-MISC
cell I-MISC I-MISC
markers I-MISC I-MISC
, O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
kit I-MISC I-MISC
and O-MISC O-MISC
CD34 B-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
myeloid B-MISC O-MISC
cell I-MISC O-MISC
marker I-MISC O-MISC
, I-MISC O-MISC
F4 I-MISC O-MISC
/ I-MISC O-MISC
80 I-MISC O-MISC
. O-MISC O-MISC

Some O-MISC O-MISC
cell O-MISC O-MISC
fractions O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
positive O-MISC O-MISC
for O-MISC O-MISC
Mac B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, I-MISC O-MISC
a I-MISC O-MISC
macrophage I-MISC O-MISC
marker I-MISC O-MISC
or O-MISC O-MISC
Gr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, I-MISC O-MISC
a I-MISC O-MISC
granulocytic I-MISC O-MISC
maker I-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
negative O-MISC O-MISC
for O-MISC O-MISC
an O-MISC O-MISC
erythroid B-MISC B-MISC
marker I-MISC I-MISC
TER119 I-MISC I-MISC
. O-MISC O-MISC

They O-MISC O-MISC
also O-MISC O-MISC
showed O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
mRNA O-MISC B-MISC
for O-MISC O-MISC
the O-MISC O-MISC
myeloid B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
PU I-MISC I-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
but O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
that O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
erythroid B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
GATA I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Among O-MISC O-MISC
various O-MISC O-MISC
cytokines B-MISC B-MISC
, O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
) O-MISC O-MISC
induced O-MISC O-MISC
erythroid O-MISC O-MISC
precursor O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
expressed O-MISC O-MISC
the O-MISC O-MISC
erythroid B-MISC O-MISC
- I-MISC I-MISC
specific I-MISC O-MISC
GATA I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
beta B-MISC B-MISC
- I-MISC I-MISC
major I-MISC I-MISC
globin I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
quantitative O-MISC O-MISC
analysis O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
erythroid O-MISC O-MISC
precursor O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
newly O-MISC O-MISC
produced O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
immature O-MISC O-MISC
myeloid O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
cultivation O-MISC O-MISC
with O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
. O-MISC O-MISC

SCF B-MISC B-MISC
and O-MISC I-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
induced O-MISC O-MISC
stepwise O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
erythroid O-MISC O-MISC
precursor O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
an O-MISC O-MISC
A O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
hematopoietic O-MISC O-MISC
stem O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
2001 O-MISC O-MISC
Academic O-MISC O-MISC
Press O-MISC O-MISC
. O-MISC O-MISC

Distinct O-MISC O-MISC
BMI B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
EZH2 B-MISC B-MISC
expression O-MISC O-MISC
patterns O-MISC O-MISC
in O-MISC O-MISC
thymocytes O-MISC O-MISC
and O-MISC O-MISC
mature O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
suggest O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
Polycomb B-MISC B-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

BMI B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC I-MISC
EZH2 B-MISC B-MISC
Polycomb B-MISC I-MISC
- I-MISC I-MISC
group I-MISC I-MISC
( I-MISC I-MISC
PcG I-MISC I-MISC
) I-MISC I-MISC
proteins I-MISC I-MISC
belong O-MISC O-MISC
to O-MISC O-MISC
two O-MISC O-MISC
distinct O-MISC O-MISC
protein O-MISC B-MISC
complexes O-MISC I-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
hematopoiesis O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
unique O-MISC O-MISC
PcG O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
antisera O-MISC O-MISC
and O-MISC O-MISC
triple O-MISC O-MISC
immunofluorescence O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
mature O-MISC O-MISC
resting O-MISC O-MISC
peripheral O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
expressed O-MISC O-MISC
BMI B-MISC O-MISC
- I-MISC O-MISC
1 I-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
dividing O-MISC O-MISC
blasts O-MISC O-MISC
were O-MISC O-MISC
EZH2 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
subcapsular O-MISC O-MISC
immature O-MISC O-MISC
double O-MISC O-MISC
- O-MISC O-MISC
negative O-MISC O-MISC
( O-MISC O-MISC
DN O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
coexpressed O-MISC O-MISC
BMI B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
EZH2 B-MISC B-MISC
or O-MISC O-MISC
were O-MISC O-MISC
BMI O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
single O-MISC O-MISC
positive O-MISC O-MISC
. O-MISC O-MISC

Their O-MISC O-MISC
descendants O-MISC O-MISC
, O-MISC O-MISC
double O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
( O-MISC O-MISC
DP O-MISC O-MISC
; O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
cortical O-MISC O-MISC
thymocytes O-MISC O-MISC
, O-MISC O-MISC
expressed O-MISC O-MISC
EZH2 B-MISC B-MISC
without O-MISC O-MISC
BMI B-MISC O-MISC
- I-MISC O-MISC
1 I-MISC O-MISC
. O-MISC O-MISC

Most O-MISC O-MISC
EZH2 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
DN O-MISC O-MISC
and O-MISC O-MISC
DP O-MISC O-MISC
thymocytes O-MISC O-MISC
were O-MISC O-MISC
dividing O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
DN O-MISC O-MISC
BMI O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
EZH2 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
thymocytes O-MISC O-MISC
were O-MISC O-MISC
resting O-MISC O-MISC
and O-MISC O-MISC
proliferation O-MISC O-MISC
was O-MISC O-MISC
occasionally O-MISC O-MISC
noted O-MISC O-MISC
in O-MISC O-MISC
DN O-MISC B-MISC
BMI O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
EZH2 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Maturation O-MISC O-MISC
of O-MISC O-MISC
DP O-MISC O-MISC
cortical O-MISC O-MISC
thymocytes O-MISC O-MISC
to O-MISC O-MISC
single O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
( O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
medullar O-MISC O-MISC
thymocytes O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
decreased O-MISC O-MISC
detectability O-MISC O-MISC
of O-MISC O-MISC
EZH2 B-MISC B-MISC
and O-MISC O-MISC
continued O-MISC O-MISC
relative O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
BMI B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
data O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
BMI B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
EZH2 B-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
mature O-MISC O-MISC
peripheral O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
mutually O-MISC O-MISC
exclusive O-MISC O-MISC
and O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
proliferation O-MISC O-MISC
status O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
pattern O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
yet O-MISC O-MISC
established O-MISC O-MISC
in O-MISC O-MISC
thymocytes O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cortex O-MISC O-MISC
and O-MISC O-MISC
medulla O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cell O-MISC O-MISC
stage O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
PcG O-MISC B-MISC
expression O-MISC O-MISC
profiles O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
PcG B-MISC B-MISC
genes I-MISC I-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

They O-MISC O-MISC
probably O-MISC O-MISC
reflect O-MISC O-MISC
stabilization O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC I-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
irreversibility O-MISC O-MISC
of O-MISC O-MISC
lineage O-MISC O-MISC
choice O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
PcG O-MISC B-MISC
expression O-MISC O-MISC
between O-MISC O-MISC
medullar O-MISC O-MISC
thymocytes O-MISC O-MISC
and O-MISC O-MISC
mature O-MISC O-MISC
interfollicular O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
indicates O-MISC O-MISC
that O-MISC O-MISC
additional O-MISC O-MISC
maturation O-MISC O-MISC
processes O-MISC O-MISC
occur O-MISC O-MISC
after O-MISC O-MISC
thymocyte O-MISC O-MISC
transportation O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
. O-MISC O-MISC

Stepwise O-MISC O-MISC
lineage O-MISC O-MISC
restriction O-MISC O-MISC
of O-MISC O-MISC
progenitors O-MISC O-MISC
in O-MISC O-MISC
lympho O-MISC O-MISC
- O-MISC O-MISC
myelopoiesis O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
has O-MISC O-MISC
long O-MISC O-MISC
been O-MISC O-MISC
controversial O-MISC O-MISC
whether O-MISC O-MISC
hematopoiesis O-MISC O-MISC
progresses O-MISC O-MISC
through O-MISC O-MISC
ordered O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
determination O-MISC O-MISC
as O-MISC O-MISC
in O-MISC O-MISC
embryonic O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
is O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
methodology O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
exactly O-MISC O-MISC
determining O-MISC O-MISC
the O-MISC O-MISC
developmental O-MISC O-MISC
potential O-MISC O-MISC
of O-MISC O-MISC
hematopoietic O-MISC O-MISC
stem O-MISC O-MISC
/ O-MISC O-MISC
progenitor O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
multilineage O-MISC O-MISC
progenitor O-MISC O-MISC
( O-MISC O-MISC
MLP O-MISC B-MISC
) O-MISC O-MISC
assay O-MISC O-MISC
enabled O-MISC O-MISC
us O-MISC O-MISC
to O-MISC O-MISC
discriminate O-MISC O-MISC
among O-MISC O-MISC
seven O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
hematopoietic O-MISC O-MISC
progenitors O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
multipotent O-MISC O-MISC
progenitor O-MISC O-MISC
p O-MISC O-MISC
- O-MISC O-MISC
MTB O-MISC O-MISC
( O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
generating O-MISC O-MISC
myeloid O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
bipotent O-MISC O-MISC
progenitors O-MISC O-MISC
p O-MISC O-MISC
- O-MISC O-MISC
MT O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
- O-MISC O-MISC
MB O-MISC O-MISC
and O-MISC O-MISC
p O-MISC O-MISC
- O-MISC O-MISC
TB O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
unipotent O-MISC O-MISC
progenitors O-MISC O-MISC
p O-MISC O-MISC
- O-MISC O-MISC
M O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
- O-MISC O-MISC
T O-MISC B-MISC
and O-MISC I-MISC
p O-MISC I-MISC
- O-MISC I-MISC
B O-MISC I-MISC
. O-MISC O-MISC

Among O-MISC O-MISC
these O-MISC O-MISC
seven O-MISC O-MISC
types O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
p O-MISC B-MISC
- O-MISC I-MISC
TB O-MISC I-MISC
type O-MISC O-MISC
progenitor O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
absent O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
process O-MISC O-MISC
of O-MISC O-MISC
lineage O-MISC O-MISC
commitment O-MISC O-MISC
proceeds O-MISC O-MISC
through O-MISC O-MISC
an O-MISC O-MISC
ordered O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
random O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
extending O-MISC O-MISC
the O-MISC O-MISC
area O-MISC O-MISC
of O-MISC O-MISC
investigation O-MISC O-MISC
to O-MISC O-MISC
include O-MISC O-MISC
the O-MISC O-MISC
erythroid O-MISC O-MISC
lineage O-MISC O-MISC
, O-MISC O-MISC
more O-MISC O-MISC
convincing O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
ordered O-MISC O-MISC
process O-MISC O-MISC
was O-MISC O-MISC
obtained O-MISC O-MISC
. O-MISC O-MISC

Detailed O-MISC O-MISC
and O-MISC O-MISC
exact O-MISC O-MISC
illustration O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
process O-MISC O-MISC
of O-MISC O-MISC
hematopoiesis O-MISC O-MISC
will O-MISC O-MISC
provide O-MISC O-MISC
an O-MISC O-MISC
opportunity O-MISC O-MISC
to O-MISC O-MISC
revive O-MISC O-MISC
hematopoiesis O-MISC O-MISC
as O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
most O-MISC O-MISC
fascinating O-MISC O-MISC
targets O-MISC O-MISC
of O-MISC O-MISC
research O-MISC O-MISC
in O-MISC O-MISC
developmental O-MISC O-MISC
biology O-MISC O-MISC

Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
Virus O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
glycoprotein B-MISC B-MISC
- I-MISC O-MISC
350 I-MISC O-MISC
upregulate O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphocytes O-MISC O-MISC
via O-MISC O-MISC
CD21 B-MISC B-MISC
, O-MISC O-MISC
involving O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
different O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
EBV O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
ubiquitous O-MISC O-MISC
and O-MISC O-MISC
highly O-MISC O-MISC
immunotropic O-MISC O-MISC
gamma O-MISC O-MISC
herpesvirus O-MISC O-MISC
that O-MISC O-MISC
infects O-MISC O-MISC
more O-MISC O-MISC
than O-MISC O-MISC
90 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
humans O-MISC O-MISC
worldwide O-MISC O-MISC
. O-MISC O-MISC

Its O-MISC O-MISC
pathogenicity O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
diseases O-MISC O-MISC
including O-MISC O-MISC
tumors O-MISC O-MISC
that O-MISC O-MISC
result O-MISC O-MISC
from O-MISC O-MISC
EBV O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
readily O-MISC O-MISC
transform O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
lesser O-MISC O-MISC
extent O-MISC O-MISC
, O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

EBV O-MISC O-MISC
utilizes O-MISC O-MISC
CD21 B-MISC B-MISC
/ I-MISC I-MISC
CR2 I-MISC I-MISC
as O-MISC O-MISC
its O-MISC O-MISC
receptor O-MISC O-MISC
on O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
initiate O-MISC O-MISC
the O-MISC O-MISC
infection O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

EBV O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
CR2 B-MISC O-MISC
through O-MISC O-MISC
its O-MISC O-MISC
major B-MISC O-MISC
envelope I-MISC B-MISC
glycoprotein I-MISC B-MISC
- I-MISC O-MISC
350 I-MISC O-MISC
( O-MISC O-MISC
gp350 B-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
a O-MISC O-MISC
remarkable O-MISC O-MISC
immunomodulating O-MISC O-MISC
agent O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
had O-MISC O-MISC
previously O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
EBV O-MISC O-MISC
is O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
modulating O-MISC O-MISC
the O-MISC O-MISC
synthesis O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
. O-MISC O-MISC

We O-MISC O-MISC
now O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
while O-MISC O-MISC
both O-MISC O-MISC
purified O-MISC O-MISC
recombinant B-MISC O-MISC
gp350 I-MISC I-MISC
( O-MISC O-MISC
rgp350 B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
EBV O-MISC O-MISC
upregulate O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
mRNA I-MISC O-MISC
synthesis O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC O-MISC
6 O-MISC I-MISC
gene O-MISC O-MISC
activation O-MISC O-MISC
occurs O-MISC O-MISC
for O-MISC O-MISC
a O-MISC O-MISC
significantly O-MISC O-MISC
longer O-MISC O-MISC
period O-MISC O-MISC
of O-MISC O-MISC
time O-MISC O-MISC
( O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
12 O-MISC O-MISC
hours O-MISC O-MISC
for O-MISC O-MISC
EBV O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
6 O-MISC O-MISC
hours O-MISC O-MISC
for O-MISC O-MISC
rgp350 B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
half O-MISC O-MISC
- O-MISC O-MISC
life O-MISC O-MISC
of O-MISC O-MISC
EBV O-MISC B-MISC
- O-MISC I-MISC
induced O-MISC I-MISC
IL B-MISC I-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
mRNA I-MISC I-MISC
was O-MISC O-MISC
also O-MISC O-MISC
significantly O-MISC O-MISC
longer O-MISC O-MISC
( O-MISC O-MISC
10 O-MISC O-MISC
hours O-MISC O-MISC
) O-MISC O-MISC
than O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
mRNA O-MISC B-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
rgp350 B-MISC B-MISC
( O-MISC O-MISC
about O-MISC O-MISC
6 O-MISC O-MISC
hours O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
EBV O-MISC O-MISC
and O-MISC O-MISC
gp350 B-MISC B-MISC
enhance O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
, O-MISC O-MISC
as O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
band O-MISC O-MISC
- O-MISC O-MISC
shift O-MISC O-MISC
and O-MISC O-MISC
augment O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
CAT B-MISC B-MISC
reporter I-MISC I-MISC
plasmid I-MISC I-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
gp350 B-MISC B-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
primarily O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
protein O-MISC B-MISC
kinase O-MISC I-MISC
C O-MISC I-MISC
pathway O-MISC O-MISC
, O-MISC O-MISC
EBV O-MISC O-MISC
can O-MISC O-MISC
mediate O-MISC O-MISC
its O-MISC O-MISC
effects O-MISC O-MISC
through O-MISC O-MISC
multiple O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
our O-MISC O-MISC
knowledge O-MISC O-MISC
this O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
report O-MISC O-MISC
showing O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
herpesvirus B-MISC B-MISC
envelope I-MISC I-MISC
glycoprotein I-MISC I-MISC
to O-MISC O-MISC
CR2 B-MISC B-MISC
on O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
2001 O-MISC O-MISC
Academic O-MISC O-MISC
Press O-MISC O-MISC
. O-MISC O-MISC

Gene O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
tissue O-MISC O-MISC
- O-MISC O-MISC
specificity O-MISC O-MISC
of O-MISC O-MISC
mutation O-MISC O-MISC
in O-MISC O-MISC
Big O-MISC O-MISC
Blue O-MISC O-MISC
rats O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
hepatocarcinogen O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
hydroxy O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
acetylaminofluorene O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
a O-MISC O-MISC
previous O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
treating O-MISC O-MISC
transgenic O-MISC O-MISC
Big O-MISC O-MISC
Blue O-MISC O-MISC
rats O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
hepatocarcinogen O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
hydroxy O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
acetylaminofluorene O-MISC O-MISC
( O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
AAF O-MISC O-MISC
) O-MISC O-MISC
produced O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
major O-MISC B-MISC
DNA O-MISC I-MISC
adduct O-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
target O-MISC O-MISC
liver O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
nontarget O-MISC O-MISC
spleen O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
induced O-MISC O-MISC
lacI O-MISC O-MISC
mutants O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
induced O-MISC O-MISC
much O-MISC O-MISC
lower O-MISC O-MISC
frequencies O-MISC O-MISC
of O-MISC O-MISC
l O-MISC O-MISC
acI O-MISC O-MISC
and O-MISC O-MISC
hprt O-MISC O-MISC
mutants O-MISC O-MISC
in O-MISC O-MISC
spleen O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
sequence O-MISC O-MISC
analysis O-MISC O-MISC
was O-MISC O-MISC
conducted O-MISC O-MISC
on O-MISC O-MISC
lacI B-MISC O-MISC
DNA I-MISC I-MISC
and O-MISC O-MISC
hprt B-MISC O-MISC
cDNA I-MISC B-MISC
from O-MISC O-MISC
the O-MISC O-MISC
mutants O-MISC O-MISC
, O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
mutational O-MISC O-MISC
specificity O-MISC O-MISC
of O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
AAF O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
rat O-MISC O-MISC
. O-MISC O-MISC

All O-MISC O-MISC
the O-MISC O-MISC
mutation O-MISC O-MISC
spectra O-MISC O-MISC
from O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
AAF O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
rats O-MISC O-MISC
differed O-MISC O-MISC
significantly O-MISC O-MISC
from O-MISC O-MISC
corresponding O-MISC O-MISC
mutation O-MISC O-MISC
profiles O-MISC O-MISC
from O-MISC O-MISC
untreated O-MISC O-MISC
animals O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
02 O-MISC O-MISC
to O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
0001 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
there O-MISC O-MISC
were O-MISC O-MISC
similarities O-MISC O-MISC
among O-MISC O-MISC
the O-MISC O-MISC
mutational O-MISC O-MISC
patterns O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
AAF O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
rats O-MISC O-MISC
( O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
g O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
G O-MISC O-MISC
: O-MISC O-MISC
C O-MISC O-MISC
- O-MISC O-MISC
- O-MISC O-MISC
> O-MISC O-MISC
T O-MISC O-MISC
: O-MISC O-MISC
A O-MISC O-MISC
transversion O-MISC O-MISC
was O-MISC O-MISC
the O-MISC O-MISC
most O-MISC O-MISC
common O-MISC O-MISC
mutation O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
mutation O-MISC O-MISC
sets O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
were O-MISC O-MISC
significant O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
patterns O-MISC O-MISC
of O-MISC O-MISC
basepair O-MISC O-MISC
substitution O-MISC O-MISC
and O-MISC O-MISC
frameshift O-MISC O-MISC
mutation O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
and O-MISC O-MISC
spleen O-MISC O-MISC
lymphocyte O-MISC O-MISC
lacI O-MISC I-MISC
mutants O-MISC I-MISC
( O-MISC O-MISC
P O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
02 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
spleen O-MISC O-MISC
lymphocyte O-MISC O-MISC
lacI O-MISC O-MISC
and O-MISC O-MISC
hprt O-MISC O-MISC
mutants O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
04 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Also O-MISC O-MISC
, O-MISC O-MISC
multiplex O-MISC O-MISC
PCR O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
genomic B-MISC B-MISC
DNA I-MISC I-MISC
from O-MISC O-MISC
the O-MISC O-MISC
hprt O-MISC O-MISC
mutants O-MISC O-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
12 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
mutants O-MISC O-MISC
from O-MISC O-MISC
treated O-MISC O-MISC
rats O-MISC O-MISC
had O-MISC O-MISC
major O-MISC B-MISC
deletions O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
hprt B-MISC B-MISC
gene I-MISC O-MISC
; O-MISC O-MISC
no O-MISC O-MISC
corresponding O-MISC O-MISC
incidence O-MISC O-MISC
of O-MISC O-MISC
large O-MISC O-MISC
deletions O-MISC O-MISC
was O-MISC O-MISC
evident O-MISC O-MISC
among O-MISC O-MISC
lacI O-MISC O-MISC
mutations O-MISC O-MISC
. O-MISC O-MISC

All O-MISC O-MISC
the O-MISC O-MISC
mutation O-MISC O-MISC
profiles O-MISC O-MISC
reflect O-MISC O-MISC
the O-MISC O-MISC
general O-MISC O-MISC
mutational O-MISC O-MISC
specificity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
DNA O-MISC O-MISC
adduct O-MISC O-MISC
formed O-MISC O-MISC
by O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
AAF O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
differences O-MISC O-MISC
between O-MISC O-MISC
N O-MISC B-MISC
- O-MISC I-MISC
OH O-MISC I-MISC
- O-MISC I-MISC
AAF O-MISC I-MISC
mutation O-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
endogenous B-MISC B-MISC
gene I-MISC I-MISC
and O-MISC O-MISC
transgene B-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
partially O-MISC O-MISC
explained O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
structures O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
genes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
tissue O-MISC O-MISC
- O-MISC O-MISC
specificity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mutation O-MISC O-MISC
spectra O-MISC O-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
targeting O-MISC O-MISC
tumor O-MISC O-MISC
formation O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
. O-MISC O-MISC

Environ O-MISC O-MISC
. O-MISC O-MISC
Mol O-MISC O-MISC
. O-MISC O-MISC
Mutagen O-MISC O-MISC
. O-MISC O-MISC
37 O-MISC O-MISC
: O-MISC O-MISC
203 O-MISC O-MISC
- O-MISC O-MISC
214 O-MISC O-MISC
, O-MISC O-MISC
2001 O-MISC O-MISC
. O-MISC O-MISC

Published O-MISC O-MISC
2001 O-MISC O-MISC
Wiley O-MISC O-MISC
- O-MISC O-MISC
Liss O-MISC O-MISC
, O-MISC O-MISC
Inc O-MISC O-MISC
. O-MISC O-MISC

Caspase B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
cleavage O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
hematopoietic B-MISC B-MISC
specific I-MISC I-MISC
adaptor I-MISC I-MISC
protein I-MISC I-MISC
Gads I-MISC I-MISC
alters O-MISC O-MISC
signalling O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Gads B-MISC B-MISC
is O-MISC O-MISC
a O-MISC O-MISC
SH2 B-MISC B-MISC
and I-MISC I-MISC
SH3 I-MISC I-MISC
domain I-MISC I-MISC
- O-MISC I-MISC
containing O-MISC I-MISC
, O-MISC O-MISC
hematopoietic B-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
adaptor I-MISC I-MISC
protein I-MISC I-MISC
that O-MISC O-MISC
functions O-MISC O-MISC
in O-MISC O-MISC
signalling O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Gads B-MISC O-MISC
acts O-MISC O-MISC
by O-MISC O-MISC
linking O-MISC O-MISC
SLP B-MISC B-MISC
- I-MISC I-MISC
76 I-MISC I-MISC
, O-MISC O-MISC
bound O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
carboxy B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
Gads I-MISC I-MISC
SH3 I-MISC I-MISC
domain I-MISC I-MISC
, O-MISC O-MISC
to O-MISC O-MISC
tyrosine B-MISC O-MISC
phosphorylated I-MISC O-MISC
LAT I-MISC I-MISC
which O-MISC O-MISC
contains O-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
Gads B-MISC B-MISC
SH2 I-MISC I-MISC
domain I-MISC I-MISC
. O-MISC O-MISC

Gads B-MISC O-MISC
is O-MISC O-MISC
distinguished O-MISC O-MISC
from O-MISC O-MISC
Grb2 B-MISC B-MISC
and O-MISC O-MISC
the O-MISC O-MISC
closely O-MISC O-MISC
related O-MISC O-MISC
Grap B-MISC B-MISC
protein I-MISC I-MISC
by O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
120 B-MISC O-MISC
amino I-MISC I-MISC
acid I-MISC I-MISC
unique I-MISC I-MISC
region I-MISC I-MISC
between O-MISC O-MISC
the O-MISC O-MISC
SH2 B-MISC B-MISC
domain I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
carboxy B-MISC B-MISC
terminal I-MISC I-MISC
SH3 I-MISC I-MISC
domain I-MISC I-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
unique O-MISC O-MISC
region O-MISC O-MISC
of O-MISC O-MISC
Gads B-MISC B-MISC
contains O-MISC O-MISC
a O-MISC O-MISC
capase B-MISC B-MISC
cleavage I-MISC I-MISC
site I-MISC I-MISC
. O-MISC O-MISC

Induction O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
detectable O-MISC O-MISC
Gads B-MISC O-MISC
cleavage O-MISC O-MISC
by O-MISC O-MISC
60 O-MISC O-MISC
min O-MISC O-MISC
. O-MISC O-MISC

Gads B-MISC O-MISC
cleavage O-MISC O-MISC
is O-MISC O-MISC
blocked O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
by O-MISC O-MISC
treating O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
caspase O-MISC B-MISC
3 O-MISC I-MISC
inhibitor O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
putative B-MISC O-MISC
caspase I-MISC B-MISC
3 I-MISC I-MISC
cleavage I-MISC I-MISC
site I-MISC I-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
unique O-MISC O-MISC
region O-MISC O-MISC
and O-MISC O-MISC
mutation O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
site O-MISC O-MISC
prevented O-MISC O-MISC
Gads B-MISC O-MISC
cleavage O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Gads B-MISC O-MISC
cleavage O-MISC I-MISC
products O-MISC I-MISC
retained O-MISC O-MISC
the O-MISC O-MISC
predicted O-MISC O-MISC
binding O-MISC O-MISC
specificity O-MISC O-MISC
for O-MISC O-MISC
SLP B-MISC B-MISC
- I-MISC I-MISC
76 I-MISC I-MISC
and O-MISC O-MISC
LAT B-MISC B-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Gads B-MISC B-MISC
cleavage O-MISC I-MISC
products O-MISC I-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
inhibited O-MISC O-MISC
NFAT O-MISC B-MISC
activation O-MISC O-MISC
following O-MISC O-MISC
TCR O-MISC B-MISC
cross O-MISC O-MISC
linking O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
cleavage O-MISC O-MISC
of O-MISC O-MISC
Gads B-MISC B-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
could O-MISC O-MISC
function O-MISC O-MISC
to O-MISC O-MISC
alter O-MISC O-MISC
signalling O-MISC O-MISC
downstream O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
by O-MISC O-MISC
disrupting O-MISC O-MISC
cross O-MISC O-MISC
talk O-MISC O-MISC
between O-MISC O-MISC
SLP B-MISC B-MISC
- I-MISC I-MISC
76 I-MISC I-MISC
and O-MISC O-MISC
LAT B-MISC B-MISC
. O-MISC O-MISC

Targeting O-MISC O-MISC
of O-MISC O-MISC
p300 B-MISC B-MISC
to O-MISC O-MISC
the O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
via O-MISC O-MISC
CREB O-MISC B-MISC
- O-MISC I-MISC
Rel O-MISC I-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
talk O-MISC O-MISC
during O-MISC O-MISC
mitogen B-MISC O-MISC
and O-MISC O-MISC
oncogenic O-MISC O-MISC
molecular O-MISC O-MISC
signaling O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
report O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
explore O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
of O-MISC O-MISC
targeting O-MISC O-MISC
of O-MISC O-MISC
p300 B-MISC B-MISC
to O-MISC O-MISC
the O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) I-MISC I-MISC
promoter I-MISC I-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
mitogenic O-MISC O-MISC
and O-MISC O-MISC
oncogenic O-MISC O-MISC
molecular O-MISC O-MISC
signals O-MISC O-MISC
. O-MISC O-MISC

Recruitment O-MISC O-MISC
of O-MISC O-MISC
p300 B-MISC B-MISC
by O-MISC O-MISC
cAMP B-MISC B-MISC
- I-MISC I-MISC
responsive I-MISC I-MISC
element I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
talk O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
composite B-MISC B-MISC
CD28 I-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
( O-MISC O-MISC
CD28RE B-MISC B-MISC
) O-MISC O-MISC
- O-MISC I-MISC
TRE B-MISC B-MISC
element I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
promoter O-MISC B-MISC
inducibility O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
CD28RE B-MISC B-MISC
- I-MISC O-MISC
TRE I-MISC I-MISC
is O-MISC O-MISC
the O-MISC O-MISC
exclusive O-MISC O-MISC
target O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphotropic O-MISC O-MISC
virus O-MISC B-MISC
type O-MISC I-MISC
I O-MISC I-MISC
oncoprotein B-MISC I-MISC
Tax I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
intrinsic O-MISC B-MISC
histone O-MISC I-MISC
acetyltransferase O-MISC I-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
p300 B-MISC B-MISC
is O-MISC O-MISC
dispensable O-MISC O-MISC
for O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
N B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
743 I-MISC I-MISC
residues I-MISC O-MISC
contain O-MISC O-MISC
the O-MISC O-MISC
minimal O-MISC O-MISC
structural O-MISC O-MISC
requirements O-MISC O-MISC
for O-MISC O-MISC
synergistic O-MISC O-MISC
transactivation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CD28RE B-MISC B-MISC
- I-MISC I-MISC
TRE I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
endogenous O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Mutational O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
p300 B-MISC B-MISC
reveals O-MISC O-MISC
differential O-MISC O-MISC
structural O-MISC O-MISC
requirements O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
N O-MISC B-MISC
- O-MISC I-MISC
terminal O-MISC I-MISC
p300 O-MISC I-MISC
module O-MISC O-MISC
by O-MISC O-MISC
individual O-MISC O-MISC
cis B-MISC B-MISC
- I-MISC I-MISC
elements I-MISC I-MISC
within O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
provide O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
p300 B-MISC B-MISC
assembles O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
to O-MISC O-MISC
form O-MISC O-MISC
an O-MISC O-MISC
enhanceosome O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
target O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
centrally O-MISC O-MISC
integrated O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
CD28RE B-MISC B-MISC
- I-MISC I-MISC
TRE I-MISC I-MISC
element I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
through O-MISC O-MISC
specific O-MISC O-MISC
protein O-MISC O-MISC
module O-MISC O-MISC
- O-MISC O-MISC
targeted O-MISC O-MISC
associations O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Regulation O-MISC O-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
production O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
inhalant O-MISC O-MISC
allergen O-MISC O-MISC
: O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
distinguishes O-MISC O-MISC
between O-MISC O-MISC
Th1 O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
Th2 O-MISC O-MISC
- O-MISC O-MISC
polarized O-MISC O-MISC
immunity O-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
The O-MISC O-MISC
precise O-MISC O-MISC
nature O-MISC O-MISC
of O-MISC O-MISC
allergen O-MISC O-MISC
- O-MISC I-MISC
specific O-MISC I-MISC
cytokine O-MISC B-MISC
responses O-MISC O-MISC
in O-MISC O-MISC
atopics O-MISC O-MISC
versus O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
atopics O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
particular O-MISC O-MISC
the O-MISC O-MISC
' O-MISC O-MISC
Th1 O-MISC O-MISC
polarity O-MISC O-MISC
' O-MISC O-MISC
of O-MISC O-MISC
responses O-MISC O-MISC
in O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
atopics O-MISC O-MISC
, O-MISC O-MISC
remains O-MISC O-MISC
controversial O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
is O-MISC O-MISC
due O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
relative O-MISC O-MISC
insensitivity O-MISC O-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
detection O-MISC O-MISC
systems O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
associated O-MISC O-MISC
variations O-MISC O-MISC
in O-MISC O-MISC
kinetics O-MISC O-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
production O-MISC O-MISC
and O-MISC O-MISC
catabolism O-MISC O-MISC
in O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
culture O-MISC O-MISC
systems O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
an O-MISC O-MISC
alternative O-MISC O-MISC
to O-MISC O-MISC
cytokine O-MISC B-MISC
measurement O-MISC O-MISC
, O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
focuses O-MISC O-MISC
on O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
GATA I-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
for O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
allergen O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
Th O-MISC O-MISC
cell O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Cord O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
Th1 O-MISC O-MISC
- O-MISC O-MISC
or O-MISC O-MISC
Th2 O-MISC O-MISC
- O-MISC O-MISC
polarized O-MISC O-MISC
by O-MISC O-MISC
culture O-MISC O-MISC
in O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
12 O-MISC I-MISC
- O-MISC O-MISC
or O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
- O-MISC O-MISC
employing O-MISC O-MISC
established O-MISC O-MISC
methods O-MISC O-MISC
; O-MISC O-MISC
PBMC O-MISC O-MISC
from O-MISC O-MISC
house O-MISC O-MISC
dust O-MISC O-MISC
mite O-MISC O-MISC
( O-MISC O-MISC
HDM O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
atopics O-MISC O-MISC
and O-MISC O-MISC
controls O-MISC O-MISC
were O-MISC O-MISC
stimulated O-MISC O-MISC
overnight O-MISC O-MISC
with O-MISC O-MISC
HDM O-MISC O-MISC
; O-MISC O-MISC
cytokine O-MISC B-MISC
production O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
ELISA O-MISC B-MISC
and O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
mRNA I-MISC I-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
PCR O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Cytokine B-MISC O-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
Th2 O-MISC O-MISC
polarization O-MISC O-MISC
of O-MISC O-MISC
naive O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
marked O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
a O-MISC O-MISC
reciprocal O-MISC O-MISC
expression O-MISC O-MISC
pattern O-MISC O-MISC
accompanies O-MISC O-MISC
differentiation O-MISC O-MISC
towards O-MISC O-MISC
the O-MISC O-MISC
Th1 O-MISC B-MISC
cytokine O-MISC B-MISC
phenotype O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
HDM O-MISC O-MISC
skin O-MISC O-MISC
prick O-MISC O-MISC
test O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
( O-MISC O-MISC
HDM O-MISC O-MISC
- O-MISC O-MISC
SPT O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
HDM O-MISC O-MISC
- O-MISC O-MISC
IgE O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
volunteers O-MISC O-MISC
, O-MISC O-MISC
overnight O-MISC O-MISC
stimulation O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
marked O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
equally O-MISC O-MISC
marked O-MISC O-MISC
downregulation O-MISC O-MISC
of O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
SPT O-MISC B-MISC
- O-MISC O-MISC
/ O-MISC I-MISC
IgE O-MISC I-MISC
- O-MISC O-MISC
subjects O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
subjects O-MISC O-MISC
who O-MISC O-MISC
are O-MISC O-MISC
HDM O-MISC O-MISC
- O-MISC O-MISC
SPT O-MISC O-MISC
+ O-MISC O-MISC
but O-MISC O-MISC
IgE O-MISC B-MISC
- O-MISC I-MISC
, O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
levels O-MISC O-MISC
remained O-MISC O-MISC
relatively O-MISC O-MISC
stable O-MISC O-MISC
during O-MISC O-MISC
culture O-MISC O-MISC
with O-MISC O-MISC
HDM O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
Upregulation O-MISC O-MISC
of O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
PBMC O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
hallmark O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
early O-MISC O-MISC
phase O-MISC O-MISC
of O-MISC O-MISC
Th2 O-MISC O-MISC
recall O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
specific O-MISC O-MISC
allergen O-MISC O-MISC
in O-MISC O-MISC
atopics O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
reciprocal O-MISC O-MISC
expression O-MISC O-MISC
pattern O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
HDM O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
recall O-MISC O-MISC
responses O-MISC O-MISC
of O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
atopics O-MISC O-MISC
provides O-MISC O-MISC
independent O-MISC O-MISC
confirmation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
underlying O-MISC O-MISC
Th1 O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
immunity O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
subjects O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
parallel O-MISC O-MISC
findings O-MISC O-MISC
in O-MISC O-MISC
neonatal O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
approach O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
utilized O-MISC O-MISC
for O-MISC O-MISC
monitoring O-MISC O-MISC
the O-MISC O-MISC
progress O-MISC O-MISC
of O-MISC O-MISC
allergen O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
Th1 O-MISC O-MISC
/ O-MISC O-MISC
Th2 O-MISC O-MISC
memory O-MISC O-MISC
development O-MISC O-MISC
during O-MISC O-MISC
early O-MISC O-MISC
childhood O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
hence O-MISC O-MISC
in O-MISC O-MISC
assessment O-MISC O-MISC
of O-MISC O-MISC
risk O-MISC O-MISC
for O-MISC O-MISC
future O-MISC O-MISC
allergic O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
2001 O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
Karger O-MISC O-MISC
AG O-MISC O-MISC
, O-MISC O-MISC
Basel O-MISC O-MISC

The O-MISC O-MISC
heat O-MISC O-MISC
shock O-MISC O-MISC
response O-MISC O-MISC
reduces O-MISC O-MISC
myelin B-MISC O-MISC
oligodendrocyte I-MISC O-MISC
glycoprotein I-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
experimental O-MISC O-MISC
autoimmune O-MISC O-MISC
encephalomyelitis O-MISC O-MISC
in O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
stress O-MISC O-MISC
response O-MISC O-MISC
( O-MISC O-MISC
SR O-MISC O-MISC
) O-MISC I-MISC
can O-MISC O-MISC
block O-MISC O-MISC
inflammatory O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
preventing O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
inflammatory O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
contributes O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
demyelinating O-MISC O-MISC
diseases O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
tested O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
SR O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
progression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
demyelinating O-MISC O-MISC
disease O-MISC O-MISC
experimental O-MISC O-MISC
autoimmune O-MISC O-MISC
encephalomyelitis O-MISC O-MISC
( O-MISC O-MISC
EAE O-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

EAE O-MISC B-MISC
was O-MISC O-MISC
actively O-MISC O-MISC
induced O-MISC O-MISC
in O-MISC O-MISC
C57BL O-MISC O-MISC
/ O-MISC O-MISC
6 O-MISC O-MISC
mice O-MISC O-MISC
using O-MISC O-MISC
an O-MISC O-MISC
encephalitogenic O-MISC O-MISC
myelin B-MISC O-MISC
oligodendrocyte I-MISC O-MISC
glycoprotein I-MISC I-MISC
( O-MISC O-MISC
MOG B-MISC B-MISC
( I-MISC O-MISC
35 I-MISC O-MISC
- I-MISC O-MISC
55 I-MISC O-MISC
) I-MISC O-MISC
) O-MISC O-MISC
peptide O-MISC O-MISC
. O-MISC O-MISC

Whole O-MISC O-MISC
body O-MISC O-MISC
hyperthermia O-MISC O-MISC
was O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
a O-MISC O-MISC
heat O-MISC O-MISC
shock O-MISC O-MISC
response O-MISC O-MISC
( O-MISC O-MISC
HSR O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
immunized O-MISC O-MISC
mice O-MISC O-MISC
2 O-MISC O-MISC
days O-MISC O-MISC
after O-MISC O-MISC
the O-MISC O-MISC
booster O-MISC O-MISC
MOG O-MISC O-MISC
( O-MISC O-MISC
35 O-MISC O-MISC
- O-MISC O-MISC
55 O-MISC O-MISC
) O-MISC O-MISC
peptide O-MISC O-MISC
injection O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
HSR O-MISC O-MISC
reduced O-MISC O-MISC
the O-MISC O-MISC
incidence O-MISC O-MISC
of O-MISC O-MISC
EAE O-MISC B-MISC
by O-MISC O-MISC
70 O-MISC O-MISC
% O-MISC O-MISC
, O-MISC O-MISC
delayed O-MISC O-MISC
disease O-MISC O-MISC
onset O-MISC O-MISC
by O-MISC O-MISC
6 O-MISC O-MISC
days O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
attenuated O-MISC O-MISC
disease O-MISC O-MISC
severity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
HSR O-MISC O-MISC
attenuated O-MISC O-MISC
leukocyte O-MISC O-MISC
infiltration O-MISC O-MISC
into O-MISC O-MISC
CNS O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
quantitation O-MISC O-MISC
of O-MISC O-MISC
perivascular O-MISC O-MISC
infiltrates O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
by O-MISC O-MISC
reduced O-MISC O-MISC
staining O-MISC O-MISC
for O-MISC O-MISC
CD4 B-MISC B-MISC
and O-MISC O-MISC
CD25 B-MISC B-MISC
immunopositive O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
interferon B-MISC B-MISC
gamma I-MISC I-MISC
( O-MISC O-MISC
IFNgamma B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
MOG B-MISC O-MISC
( I-MISC O-MISC
35 I-MISC O-MISC
- I-MISC O-MISC
55 I-MISC O-MISC
) I-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
decreased O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
HSR O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
HSR O-MISC O-MISC
reduced O-MISC O-MISC
inflammatory O-MISC O-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
brain O-MISC O-MISC
that O-MISC O-MISC
normally O-MISC O-MISC
occurs O-MISC O-MISC
during O-MISC O-MISC
EAE O-MISC B-MISC
, O-MISC O-MISC
including O-MISC O-MISC
the O-MISC O-MISC
early O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
RANTES B-MISC B-MISC
( O-MISC O-MISC
regulated B-MISC O-MISC
on I-MISC O-MISC
activation I-MISC O-MISC
of I-MISC O-MISC
normal I-MISC O-MISC
T I-MISC O-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
expressed I-MISC I-MISC
and I-MISC O-MISC
secreted I-MISC O-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
later O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inducible O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
nitric B-MISC B-MISC
oxide I-MISC I-MISC
synthase I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
early O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
was O-MISC O-MISC
also O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
HSR O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
finding O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
SR O-MISC O-MISC
reduces O-MISC O-MISC
inflammation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
brain O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
clinical O-MISC O-MISC
severity O-MISC O-MISC
of O-MISC O-MISC
EAE O-MISC B-MISC
opens O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
therapeutic O-MISC O-MISC
approach O-MISC O-MISC
for O-MISC O-MISC
prevention O-MISC O-MISC
of O-MISC O-MISC
autoimmune O-MISC O-MISC
diseases O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
vivo O-MISC O-MISC
detection O-MISC O-MISC
of O-MISC O-MISC
intracellular O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
in O-MISC O-MISC
developing O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

Information O-MISC O-MISC
regarding O-MISC O-MISC
the O-MISC O-MISC
intracellular O-MISC O-MISC
signaling O-MISC O-MISC
processes O-MISC O-MISC
that O-MISC O-MISC
occur O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
has O-MISC O-MISC
largely O-MISC O-MISC
been O-MISC O-MISC
obtained O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
transgenic O-MISC O-MISC
mouse O-MISC O-MISC
models O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
although O-MISC O-MISC
providing O-MISC O-MISC
invaluable O-MISC O-MISC
information O-MISC O-MISC
are O-MISC O-MISC
time O-MISC O-MISC
consuming O-MISC O-MISC
and O-MISC O-MISC
costly O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
this O-MISC O-MISC
end O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
developed O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
system O-MISC O-MISC
that O-MISC O-MISC
facilitates O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
pathways O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lymphocyte O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
approach O-MISC O-MISC
uses O-MISC O-MISC
reporter B-MISC B-MISC
- I-MISC I-MISC
plasmids I-MISC I-MISC
for O-MISC O-MISC
the O-MISC O-MISC
detection O-MISC O-MISC
of O-MISC O-MISC
intracellular O-MISC O-MISC
signals O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
mitogen B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
or O-MISC O-MISC
cyclic B-MISC O-MISC
AMP I-MISC I-MISC
- I-MISC I-MISC
dependent I-MISC I-MISC
protein I-MISC B-MISC
kinase I-MISC I-MISC
. O-MISC O-MISC

Reporter B-MISC B-MISC
- I-MISC I-MISC
plasmids I-MISC I-MISC
are O-MISC O-MISC
transfected O-MISC O-MISC
into O-MISC O-MISC
thymocytes O-MISC O-MISC
in O-MISC O-MISC
fetal O-MISC O-MISC
thymic O-MISC O-MISC
organ O-MISC O-MISC
culture O-MISC O-MISC
by O-MISC O-MISC
accelerated O-MISC O-MISC
DNA O-MISC O-MISC
/ O-MISC O-MISC
particle O-MISC O-MISC
bombardment O-MISC O-MISC
( O-MISC O-MISC
gene O-MISC O-MISC
gun O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
is O-MISC O-MISC
determined O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
standard O-MISC O-MISC
luciferase O-MISC B-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

Importantly O-MISC O-MISC
, O-MISC O-MISC
this O-MISC O-MISC
powerful O-MISC O-MISC
technique O-MISC O-MISC
preserves O-MISC O-MISC
the O-MISC O-MISC
structural O-MISC O-MISC
integrity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
will O-MISC O-MISC
provide O-MISC O-MISC
an O-MISC O-MISC
invaluable O-MISC O-MISC
tool O-MISC O-MISC
to O-MISC O-MISC
study O-MISC O-MISC
how O-MISC O-MISC
thymocytes O-MISC O-MISC
respond O-MISC O-MISC
to O-MISC O-MISC
normal O-MISC O-MISC
environmental O-MISC O-MISC
stimuli O-MISC O-MISC
encountered O-MISC O-MISC
during O-MISC O-MISC
differentiation O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
thymic O-MISC B-MISC
milieu O-MISC I-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
this O-MISC O-MISC
method O-MISC O-MISC
allows O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
monitoring O-MISC O-MISC
of O-MISC O-MISC
signals O-MISC O-MISC
that O-MISC O-MISC
occur O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
biological O-MISC O-MISC
time O-MISC O-MISC
frame O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
during O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
natural O-MISC O-MISC
environment O-MISC O-MISC
of O-MISC O-MISC
differentiating O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Core B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
factor I-MISC I-MISC
beta I-MISC I-MISC
( O-MISC O-MISC
CBFbeta B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
CBFbeta B-MISC B-MISC
- I-MISC I-MISC
smooth I-MISC I-MISC
muscle I-MISC I-MISC
myosin I-MISC I-MISC
heavy I-MISC I-MISC
chain I-MISC I-MISC
, O-MISC O-MISC
rescues O-MISC O-MISC
definitive O-MISC O-MISC
hematopoiesis O-MISC O-MISC
in O-MISC O-MISC
CBFbeta B-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
embryonic O-MISC O-MISC
stem O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Core B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
factor I-MISC I-MISC
beta I-MISC I-MISC
( O-MISC I-MISC
CBFbeta B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
non B-MISC B-MISC
- I-MISC I-MISC
DNA I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
subunit I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
heterodimeric B-MISC B-MISC
CBFs I-MISC I-MISC
. O-MISC O-MISC

Genes B-MISC O-MISC
encoding I-MISC O-MISC
CBFbeta I-MISC B-MISC
( O-MISC O-MISC
CBFB B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
DNA B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
CBFalpha I-MISC I-MISC
subunits I-MISC I-MISC
, I-MISC O-MISC
Runx1 I-MISC B-MISC
( O-MISC O-MISC
also O-MISC O-MISC
known O-MISC O-MISC
as O-MISC O-MISC
CBFalpha2 B-MISC B-MISC
, O-MISC O-MISC
AML1 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
PEBP2alphaB B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
are O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
normal O-MISC O-MISC
hematopoiesis O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
also O-MISC O-MISC
frequent O-MISC O-MISC
targets O-MISC O-MISC
of O-MISC O-MISC
chromosomal O-MISC O-MISC
translocations O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
leukemias O-MISC O-MISC
in O-MISC O-MISC
humans O-MISC O-MISC
. O-MISC O-MISC

Homozygous O-MISC O-MISC
disruption O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
the O-MISC O-MISC
Runx1 B-MISC B-MISC
or I-MISC O-MISC
Cbfb I-MISC B-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
mice O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
embryonic O-MISC O-MISC
lethality O-MISC O-MISC
at O-MISC O-MISC
midgestation O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
hemorrhaging O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
central O-MISC O-MISC
nervous O-MISC O-MISC
system O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
severely O-MISC O-MISC
impairs O-MISC O-MISC
fetal O-MISC O-MISC
liver O-MISC O-MISC
hematopoiesis O-MISC O-MISC
. O-MISC O-MISC

Results O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
Cbfb O-MISC B-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mouse O-MISC O-MISC
embryonic O-MISC O-MISC
stem O-MISC O-MISC
( O-MISC O-MISC
ES O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
can O-MISC O-MISC
differentiate O-MISC O-MISC
into O-MISC O-MISC
primitive O-MISC O-MISC
erythroid O-MISC O-MISC
colonies O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
are O-MISC O-MISC
impaired O-MISC O-MISC
in O-MISC O-MISC
their O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
produce O-MISC O-MISC
definitive O-MISC O-MISC
erythroid O-MISC O-MISC
and O-MISC O-MISC
myeloid O-MISC O-MISC
colonies O-MISC O-MISC
, O-MISC O-MISC
mimicking O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
defect O-MISC O-MISC
. O-MISC O-MISC

Definitive O-MISC O-MISC
hematopoiesis O-MISC O-MISC
is O-MISC O-MISC
restored O-MISC O-MISC
by O-MISC O-MISC
ectopic O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
full B-MISC O-MISC
- I-MISC I-MISC
length I-MISC I-MISC
Cbfb I-MISC B-MISC
transgenes I-MISC I-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
transgene O-MISC O-MISC
encoding O-MISC O-MISC
only O-MISC O-MISC
the O-MISC O-MISC
heterodimerization B-MISC B-MISC
domain I-MISC O-MISC
of O-MISC O-MISC
CBFbeta B-MISC B-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
CBFbeta B-MISC B-MISC
- O-MISC I-MISC
smooth B-MISC I-MISC
muscle I-MISC I-MISC
myosin I-MISC I-MISC
heavy I-MISC I-MISC
chain I-MISC I-MISC
( I-MISC I-MISC
SMMHC I-MISC I-MISC
) I-MISC I-MISC
fusion I-MISC I-MISC
protein I-MISC I-MISC
generated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
inv B-MISC O-MISC
( I-MISC O-MISC
16 I-MISC I-MISC
) I-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
myeloid O-MISC O-MISC
leukemias O-MISC O-MISC
( O-MISC O-MISC
M4Eo O-MISC O-MISC
) O-MISC O-MISC
can O-MISC O-MISC
not O-MISC O-MISC
rescue O-MISC O-MISC
definitive O-MISC O-MISC
hematopoiesis O-MISC O-MISC
by O-MISC O-MISC
Cbfb O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
ES O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Sequences O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
inability O-MISC O-MISC
of O-MISC O-MISC
CBFbeta B-MISC B-MISC
- O-MISC I-MISC
SMMHC O-MISC I-MISC
to O-MISC O-MISC
rescue O-MISC O-MISC
definitive O-MISC O-MISC
hematopoiesis O-MISC O-MISC
reside O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
SMMHC B-MISC B-MISC
portion I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
fusion B-MISC B-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

Results O-MISC O-MISC
also O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
CBFbeta B-MISC B-MISC
- I-MISC I-MISC
SMMHC I-MISC I-MISC
fusion I-MISC I-MISC
protein I-MISC I-MISC
transdominantly O-MISC O-MISC
inhibits O-MISC O-MISC
definitive O-MISC O-MISC
hematopoiesis O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
extent O-MISC O-MISC
as O-MISC O-MISC
homozygous O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
Runx1 B-MISC O-MISC
or O-MISC O-MISC
Cbfb B-MISC O-MISC
. O-MISC O-MISC

CBFbeta B-MISC B-MISC
- I-MISC I-MISC
SMMHC I-MISC I-MISC
preferentially O-MISC O-MISC
inhibits O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
myeloid O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
increasing O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
blastlike O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
culture O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
latency O-MISC O-MISC
pattern O-MISC O-MISC
of O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
infection O-MISC O-MISC
and O-MISC O-MISC
viral O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
cutaneous O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
/ O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphomas O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
nasal O-MISC O-MISC
type O-MISC O-MISC
, O-MISC O-MISC
extranodal O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
or O-MISC O-MISC
T O-MISC O-MISC
( O-MISC O-MISC
NK O-MISC O-MISC
/ O-MISC O-MISC
T O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphoma O-MISC O-MISC
is O-MISC O-MISC
usually O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
latent O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
EBV O-MISC O-MISC
) O-MISC O-MISC
infection O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
order O-MISC O-MISC
to O-MISC O-MISC
elucidate O-MISC O-MISC
the O-MISC O-MISC
EBV O-MISC O-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
patterns O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
examined O-MISC O-MISC
eight O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
cutaneous O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
related O-MISC O-MISC
NK O-MISC O-MISC
/ O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphomas O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
six O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
NK O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
and O-MISC O-MISC
two O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
implication O-MISC O-MISC
of O-MISC O-MISC
EBV O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
skin O-MISC O-MISC
lesions O-MISC O-MISC
was O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
EBV B-MISC O-MISC
- I-MISC I-MISC
DNA I-MISC I-MISC
, O-MISC O-MISC
EBV B-MISC B-MISC
- I-MISC I-MISC
encoded I-MISC I-MISC
nuclear I-MISC I-MISC
RNA I-MISC I-MISC
( O-MISC O-MISC
EBER B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
clonality O-MISC O-MISC
of O-MISC O-MISC
EBV B-MISC B-MISC
- I-MISC I-MISC
DNA I-MISC I-MISC
fragments I-MISC I-MISC
containing O-MISC O-MISC
the O-MISC O-MISC
terminal B-MISC B-MISC
repeats I-MISC I-MISC
. O-MISC O-MISC

Transcripts O-MISC O-MISC
of O-MISC O-MISC
EBV B-MISC B-MISC
- I-MISC I-MISC
encoded I-MISC I-MISC
genes I-MISC I-MISC
were O-MISC O-MISC
screened O-MISC O-MISC
by O-MISC O-MISC
reverse O-MISC O-MISC
transcription O-MISC O-MISC
- O-MISC O-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
( O-MISC O-MISC
RT O-MISC O-MISC
- O-MISC O-MISC
PCR O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
confirmed O-MISC O-MISC
by O-MISC O-MISC
Southern O-MISC O-MISC
blot O-MISC O-MISC
hybridization O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
EBV B-MISC B-MISC
- I-MISC I-MISC
related I-MISC I-MISC
antigens I-MISC I-MISC
was O-MISC O-MISC
examined O-MISC O-MISC
by O-MISC O-MISC
immunostaining O-MISC O-MISC
using O-MISC O-MISC
paraffin O-MISC O-MISC
- O-MISC O-MISC
embedded O-MISC O-MISC
tissue O-MISC O-MISC
sections O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
pellets O-MISC O-MISC
of O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
study O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
all O-MISC O-MISC
samples O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
contained O-MISC O-MISC
EBV B-MISC B-MISC
nuclear I-MISC I-MISC
antigen I-MISC I-MISC
( I-MISC I-MISC
EBNA I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
which O-MISC O-MISC
was O-MISC O-MISC
transcribed O-MISC O-MISC
using O-MISC O-MISC
the O-MISC O-MISC
Q B-MISC B-MISC
promoter I-MISC I-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
Q B-MISC B-MISC
promoter I-MISC I-MISC
and O-MISC O-MISC
another O-MISC O-MISC
upstream B-MISC B-MISC
promoter I-MISC I-MISC
( O-MISC O-MISC
Cp B-MISC B-MISC
/ I-MISC I-MISC
Wp I-MISC I-MISC
) O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
in O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
B95 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
, O-MISC O-MISC
Raji O-MISC O-MISC
and O-MISC O-MISC
Jiyoye O-MISC O-MISC
. O-MISC O-MISC

Latent B-MISC B-MISC
membrane I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( I-MISC I-MISC
LMP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) I-MISC I-MISC
mRNA I-MISC I-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
seven O-MISC O-MISC
of O-MISC O-MISC
eight O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
all O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
EBNA B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
transcripts I-MISC I-MISC
were O-MISC O-MISC
found O-MISC O-MISC
only O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

Immunostaining O-MISC O-MISC
showed O-MISC O-MISC
no O-MISC O-MISC
LMP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, I-MISC O-MISC
EBNA I-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
or I-MISC O-MISC
ZEBRA I-MISC B-MISC
antigens I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
paraffin O-MISC O-MISC
- O-MISC O-MISC
embedded O-MISC O-MISC
tissue O-MISC O-MISC
sections O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
they O-MISC O-MISC
were O-MISC O-MISC
positive O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Latent B-MISC B-MISC
BHRF1 I-MISC I-MISC
transcripts I-MISC I-MISC
encoding O-MISC O-MISC
bcl B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
homologue I-MISC I-MISC
and O-MISC O-MISC
BCRF1 B-MISC B-MISC
transcripts I-MISC I-MISC
encoding O-MISC O-MISC
viral B-MISC B-MISC
interleukin I-MISC B-MISC
( I-MISC O-MISC
vIL I-MISC O-MISC
) I-MISC O-MISC
- I-MISC O-MISC
10 I-MISC O-MISC
were O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
one O-MISC O-MISC
and O-MISC O-MISC
two O-MISC O-MISC
of O-MISC O-MISC
eight O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
patient O-MISC O-MISC
with O-MISC O-MISC
NK O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphoma O-MISC O-MISC
expressing O-MISC O-MISC
both O-MISC O-MISC
transcripts O-MISC O-MISC
died O-MISC O-MISC
of O-MISC O-MISC
rapid O-MISC O-MISC
progression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
illness O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
restricted O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
latency B-MISC B-MISC
- I-MISC I-MISC
associated I-MISC I-MISC
EBV I-MISC I-MISC
genes I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
vIL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
and I-MISC O-MISC
bcl I-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
homologue I-MISC O-MISC
may O-MISC O-MISC
favour O-MISC O-MISC
tumour O-MISC O-MISC
growth O-MISC O-MISC
, O-MISC O-MISC
evading O-MISC O-MISC
the O-MISC O-MISC
host O-MISC O-MISC
immune O-MISC O-MISC
surveillance O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
2001 O-MISC O-MISC
Cancer O-MISC O-MISC
Research O-MISC O-MISC
Campaign O-MISC O-MISC
. O-MISC O-MISC

Oxidized O-MISC O-MISC
alkyl O-MISC O-MISC
phospholipids O-MISC O-MISC
are O-MISC O-MISC
specific O-MISC O-MISC
, O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
peroxisome O-MISC O-MISC
proliferator O-MISC B-MISC
- O-MISC I-MISC
activated O-MISC I-MISC
receptor O-MISC I-MISC
gamma O-MISC I-MISC
ligands O-MISC O-MISC
and O-MISC O-MISC
agonists O-MISC O-MISC
. O-MISC O-MISC

Synthetic O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
peroxisome O-MISC O-MISC
proliferator O-MISC B-MISC
- O-MISC I-MISC
activated O-MISC I-MISC
receptor O-MISC I-MISC
( O-MISC O-MISC
PPAR O-MISC B-MISC
) O-MISC O-MISC
agonists O-MISC O-MISC
are O-MISC O-MISC
known O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
biologic O-MISC O-MISC
ligands O-MISC O-MISC
are O-MISC O-MISC
of O-MISC O-MISC
low O-MISC O-MISC
affinity O-MISC O-MISC
. O-MISC O-MISC

Oxidized B-MISC O-MISC
low I-MISC O-MISC
density I-MISC O-MISC
lipoprotein I-MISC B-MISC
( O-MISC O-MISC
oxLDL B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
inflammatory O-MISC O-MISC
and O-MISC O-MISC
signals O-MISC O-MISC
through O-MISC O-MISC
PPARs B-MISC B-MISC
. O-MISC O-MISC

We O-MISC O-MISC
showed O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
phospholipase O-MISC B-MISC
A O-MISC I-MISC
( O-MISC O-MISC
1 O-MISC I-MISC
) O-MISC O-MISC
digestion O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
PPARgamma O-MISC B-MISC
agonists O-MISC O-MISC
in O-MISC O-MISC
oxLDL B-MISC O-MISC
arise O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
small O-MISC O-MISC
pool O-MISC O-MISC
of O-MISC O-MISC
alkyl O-MISC O-MISC
phosphatidylcholines O-MISC B-MISC
in O-MISC O-MISC
LDL B-MISC B-MISC
. O-MISC O-MISC

We O-MISC O-MISC
identified O-MISC O-MISC
an O-MISC O-MISC
abundant O-MISC O-MISC
oxidatively O-MISC O-MISC
fragmented O-MISC I-MISC
alkyl O-MISC B-MISC
phospholipid O-MISC O-MISC
in O-MISC O-MISC
oxLDL B-MISC O-MISC
, O-MISC O-MISC
hexadecyl O-MISC O-MISC
azelaoyl O-MISC O-MISC
phosphatidylcholine O-MISC O-MISC
( O-MISC O-MISC
azPC O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
ligand O-MISC O-MISC
and O-MISC O-MISC
agonist O-MISC O-MISC
for O-MISC O-MISC
PPARgamma B-MISC B-MISC
. O-MISC O-MISC

[ O-MISC O-MISC
( O-MISC O-MISC
3 O-MISC O-MISC
) O-MISC O-MISC
H O-MISC O-MISC
] O-MISC O-MISC
azPC O-MISC O-MISC
bound O-MISC O-MISC
recombinant B-MISC B-MISC
PPARgamma I-MISC B-MISC
with O-MISC O-MISC
an O-MISC O-MISC
affinity O-MISC O-MISC
( O-MISC O-MISC
K O-MISC O-MISC
( O-MISC O-MISC
d O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
( O-MISC O-MISC
app O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
approximately O-MISC O-MISC
40 O-MISC O-MISC
nm O-MISC O-MISC
) O-MISC O-MISC
that O-MISC O-MISC
was O-MISC O-MISC
equivalent O-MISC O-MISC
to O-MISC O-MISC
rosiglitazone O-MISC O-MISC
( O-MISC O-MISC
BRL49653 O-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
competition O-MISC O-MISC
with O-MISC O-MISC
rosiglitazone O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
binding O-MISC O-MISC
occurred O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
ligand B-MISC O-MISC
- I-MISC O-MISC
binding I-MISC O-MISC
pocket I-MISC O-MISC
. O-MISC O-MISC

azPC O-MISC O-MISC
induced O-MISC O-MISC
PPRE O-MISC B-MISC
reporter O-MISC I-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
did O-MISC O-MISC
rosiglitazone O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
half O-MISC O-MISC
- O-MISC O-MISC
maximal O-MISC O-MISC
effect O-MISC O-MISC
at O-MISC O-MISC
100 O-MISC O-MISC
nm O-MISC O-MISC
. O-MISC O-MISC

Overexpression O-MISC O-MISC
of O-MISC O-MISC
PPARalpha B-MISC B-MISC
or O-MISC O-MISC
PPARgamma B-MISC B-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
azPC O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC O-MISC
PPARgamma O-MISC B-MISC
agonist O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
scavenger B-MISC B-MISC
receptor I-MISC I-MISC
CD36 I-MISC I-MISC
is O-MISC O-MISC
encoded O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
PPRE B-MISC B-MISC
- I-MISC I-MISC
responsive I-MISC I-MISC
gene I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
azPC O-MISC O-MISC
enhanced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
CD36 B-MISC B-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD36 I-MISC I-MISC
inhibited O-MISC O-MISC
azPC O-MISC O-MISC
uptake O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
it O-MISC O-MISC
inhibited O-MISC O-MISC
PPRE O-MISC B-MISC
reporter O-MISC O-MISC
induction O-MISC O-MISC
. O-MISC O-MISC

Results O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
small O-MISC B-MISC
molecule O-MISC I-MISC
phospholipid B-MISC B-MISC
flippase I-MISC O-MISC
mimetic I-MISC O-MISC
suggest O-MISC O-MISC
azPC O-MISC O-MISC
acts O-MISC O-MISC
intracellularly O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
cellular O-MISC O-MISC
azPC O-MISC O-MISC
accumulation O-MISC O-MISC
was O-MISC O-MISC
efficient O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
certain O-MISC O-MISC
alkyl O-MISC B-MISC
phospholipid O-MISC I-MISC
oxidation O-MISC I-MISC
products O-MISC I-MISC
in O-MISC O-MISC
oxLDL B-MISC B-MISC
are O-MISC O-MISC
specific O-MISC O-MISC
, O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
extracellular O-MISC O-MISC
ligands O-MISC O-MISC
and O-MISC O-MISC
agonists O-MISC O-MISC
for O-MISC O-MISC
PPARgamma B-MISC B-MISC
that O-MISC O-MISC
induce O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC O-MISC
responsive I-MISC O-MISC
genes I-MISC I-MISC

Regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
MAT2B I-MISC I-MISC
gene I-MISC I-MISC
encoding O-MISC O-MISC
the O-MISC O-MISC
regulatory B-MISC B-MISC
beta I-MISC I-MISC
subunit I-MISC I-MISC
of O-MISC O-MISC
methionine B-MISC O-MISC
adenosyltransferase I-MISC I-MISC
, O-MISC O-MISC
MAT B-MISC B-MISC
II I-MISC I-MISC
. O-MISC O-MISC

Methionine B-MISC O-MISC
adenosyltransferase I-MISC O-MISC
( O-MISC O-MISC
MAT B-MISC O-MISC
) O-MISC O-MISC
catalyzes O-MISC O-MISC
the O-MISC O-MISC
biosynthesis O-MISC O-MISC
of O-MISC O-MISC
S B-MISC O-MISC
- I-MISC O-MISC
adenosylmethionine I-MISC O-MISC
( O-MISC O-MISC
AdoMet B-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
key O-MISC O-MISC
molecule O-MISC O-MISC
in O-MISC O-MISC
transmethylation O-MISC O-MISC
reactions O-MISC O-MISC
and O-MISC O-MISC
polyamine O-MISC O-MISC
biosynthesis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
MAT B-MISC B-MISC
II I-MISC I-MISC
isozyme I-MISC I-MISC
consists O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
catalytic B-MISC B-MISC
alpha2 I-MISC I-MISC
and I-MISC O-MISC
a I-MISC O-MISC
regulatory I-MISC B-MISC
beta I-MISC I-MISC
subunit I-MISC I-MISC
. O-MISC O-MISC

Down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
MAT B-MISC B-MISC
II I-MISC I-MISC
beta I-MISC I-MISC
subunit I-MISC I-MISC
expression O-MISC O-MISC
causes O-MISC O-MISC
a O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
10 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
intracellular O-MISC O-MISC
AdoMet B-MISC O-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
understand O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
the O-MISC O-MISC
beta B-MISC B-MISC
subunit I-MISC I-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
regulated O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
cloned O-MISC O-MISC
the O-MISC O-MISC
MAT2B B-MISC B-MISC
gene I-MISC I-MISC
, O-MISC O-MISC
determined O-MISC O-MISC
its O-MISC O-MISC
organization O-MISC O-MISC
, O-MISC O-MISC
characterized O-MISC O-MISC
its O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
- I-MISC I-MISC
flanking I-MISC I-MISC
sequences I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
elucidated O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
its O-MISC O-MISC
promoter B-MISC O-MISC
. O-MISC O-MISC

Transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
MAT2B B-MISC B-MISC
gene I-MISC I-MISC
initiates O-MISC O-MISC
at O-MISC O-MISC
position O-MISC B-MISC
- O-MISC I-MISC
203 O-MISC I-MISC
relative O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
translation B-MISC B-MISC
start I-MISC I-MISC
site I-MISC I-MISC
. O-MISC O-MISC

Promoter B-MISC O-MISC
deletion I-MISC O-MISC
analysis I-MISC O-MISC
defined O-MISC O-MISC
a O-MISC O-MISC
minimal B-MISC B-MISC
promoter I-MISC I-MISC
between O-MISC O-MISC
positions B-MISC O-MISC
+ I-MISC O-MISC
52 I-MISC O-MISC
and I-MISC O-MISC
+ I-MISC O-MISC
93 I-MISC I-MISC
base O-MISC O-MISC
pairs O-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
GC B-MISC B-MISC
- I-MISC I-MISC
rich I-MISC I-MISC
region I-MISC I-MISC
. O-MISC O-MISC

Inclusion O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
sequences O-MISC O-MISC
between O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
and O-MISC O-MISC
+ O-MISC O-MISC
52 O-MISC O-MISC
enhanced O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
; O-MISC O-MISC
this O-MISC O-MISC
was O-MISC O-MISC
primarily O-MISC O-MISC
because O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
Sp1 B-MISC B-MISC
recognition I-MISC I-MISC
site I-MISC O-MISC
at O-MISC O-MISC
+ O-MISC O-MISC
9 O-MISC O-MISC
/ O-MISC O-MISC
+ O-MISC O-MISC
15 O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
inclusion O-MISC O-MISC
of O-MISC O-MISC
sequences O-MISC O-MISC
up O-MISC O-MISC
to O-MISC O-MISC
position O-MISC O-MISC
- O-MISC O-MISC
115 O-MISC O-MISC
provided O-MISC O-MISC
full O-MISC O-MISC
activity O-MISC O-MISC
; O-MISC O-MISC
this O-MISC O-MISC
was O-MISC O-MISC
attributed O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
TATA B-MISC O-MISC
at O-MISC O-MISC
- O-MISC O-MISC
32 O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Sp1 B-MISC B-MISC
site I-MISC I-MISC
at O-MISC O-MISC
position O-MISC O-MISC
+ O-MISC O-MISC
9 O-MISC O-MISC
was O-MISC O-MISC
key O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
protein O-MISC B-MISC
. O-MISC O-MISC
DNA O-MISC I-MISC
complexes O-MISC I-MISC
. O-MISC O-MISC

Mutation O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
Sp1 B-MISC B-MISC
site I-MISC I-MISC
at O-MISC O-MISC
+ O-MISC O-MISC
9 O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
TATA B-MISC O-MISC
at O-MISC O-MISC
- O-MISC O-MISC
32 O-MISC O-MISC
reduced O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
to O-MISC O-MISC
its O-MISC O-MISC
minimal O-MISC O-MISC
level O-MISC O-MISC
. O-MISC O-MISC

Supershift O-MISC O-MISC
assays O-MISC O-MISC
showed O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
Sp1 I-MISC I-MISC
antibody I-MISC I-MISC
on O-MISC O-MISC
complex O-MISC O-MISC
formation O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
the O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
Sp3 I-MISC I-MISC
antibody I-MISC I-MISC
had O-MISC O-MISC
a O-MISC O-MISC
strong O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
protein O-MISC B-MISC
. O-MISC O-MISC
DNA O-MISC B-MISC
complex O-MISC I-MISC
formation O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
Sp3 B-MISC B-MISC
is O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
main O-MISC B-MISC
factors O-MISC I-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
this O-MISC O-MISC
Sp1 B-MISC B-MISC
site I-MISC I-MISC
. O-MISC O-MISC

Chromatin O-MISC O-MISC
immunoprecipitation O-MISC O-MISC
assays O-MISC O-MISC
supported O-MISC O-MISC
the O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
Sp1 B-MISC B-MISC
and O-MISC O-MISC
Sp3 B-MISC B-MISC
in O-MISC O-MISC
complexes O-MISC O-MISC
formed O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
MAT2B B-MISC B-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
data O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
- I-MISC I-MISC
untranslated I-MISC I-MISC
sequences I-MISC I-MISC
play O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
regulating O-MISC O-MISC
the O-MISC O-MISC
MAT2B B-MISC B-MISC
gene I-MISC I-MISC
and O-MISC O-MISC
identifies O-MISC O-MISC
the O-MISC O-MISC
Sp1 B-MISC B-MISC
site I-MISC I-MISC
at O-MISC O-MISC
+ O-MISC O-MISC
9 O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
potential O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
modulating O-MISC O-MISC
MAT2B O-MISC B-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
process O-MISC O-MISC
that O-MISC O-MISC
can O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
intracellular O-MISC O-MISC
AdoMet B-MISC O-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

Molecular O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
influenza O-MISC O-MISC
A O-MISC O-MISC
virus O-MISC O-MISC
infection O-MISC O-MISC
and O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
cytokine B-MISC B-MISC
gene I-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Despite O-MISC O-MISC
vaccines O-MISC O-MISC
and O-MISC O-MISC
antiviral O-MISC O-MISC
substances O-MISC O-MISC
influenza O-MISC O-MISC
still O-MISC O-MISC
causes O-MISC O-MISC
significant O-MISC O-MISC
morbidity O-MISC O-MISC
and O-MISC O-MISC
mortality O-MISC O-MISC
world O-MISC O-MISC
wide O-MISC O-MISC
. O-MISC O-MISC

Better O-MISC O-MISC
understanding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
mechanisms O-MISC O-MISC
of O-MISC O-MISC
influenza O-MISC O-MISC
virus O-MISC O-MISC
replication O-MISC O-MISC
, O-MISC O-MISC
pathogenesis O-MISC O-MISC
and O-MISC O-MISC
host O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
more O-MISC O-MISC
efficient O-MISC O-MISC
means O-MISC O-MISC
of O-MISC O-MISC
prevention O-MISC O-MISC
and O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
influenza O-MISC O-MISC
. O-MISC O-MISC

Influenza O-MISC O-MISC
A O-MISC O-MISC
virus O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
replicates O-MISC O-MISC
in O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
leukocytes O-MISC O-MISC
, O-MISC O-MISC
regulates O-MISC O-MISC
host O-MISC O-MISC
cell O-MISC O-MISC
transcriptional O-MISC O-MISC
and O-MISC O-MISC
translational O-MISC O-MISC
systems O-MISC O-MISC
and O-MISC O-MISC
activates O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
downregulates O-MISC O-MISC
apoptotic O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

Influenza O-MISC O-MISC
A O-MISC O-MISC
virus O-MISC O-MISC
infection O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
chemotactic O-MISC B-MISC
( O-MISC O-MISC
RANTES B-MISC B-MISC
, O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IP B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
pro O-MISC I-MISC
- O-MISC I-MISC
inflammatory O-MISC I-MISC
( O-MISC I-MISC
IL B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
beta I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
18 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
antiviral B-MISC B-MISC
( I-MISC O-MISC
IFN I-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
/ I-MISC I-MISC
beta I-MISC I-MISC
) I-MISC O-MISC
cytokines I-MISC B-MISC
. O-MISC O-MISC

Cytokine O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
, O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
STAT B-MISC B-MISC
and O-MISC O-MISC
IRF B-MISC B-MISC
signal I-MISC I-MISC
transducing I-MISC I-MISC
molecules I-MISC I-MISC
in O-MISC O-MISC
influenza O-MISC O-MISC
A O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
upregulating O-MISC O-MISC
cytokine B-MISC B-MISC
gene I-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
influenza O-MISC O-MISC
A O-MISC O-MISC
virus O-MISC O-MISC
infection O-MISC O-MISC
activates O-MISC O-MISC
caspase B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
enzyme I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
proteolytic O-MISC O-MISC
processing O-MISC O-MISC
of O-MISC O-MISC
proIL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
beta I-MISC I-MISC
and O-MISC O-MISC
proIL B-MISC B-MISC
- I-MISC I-MISC
18 I-MISC I-MISC
into O-MISC O-MISC
their O-MISC O-MISC
biologically O-MISC O-MISC
active O-MISC O-MISC
forms O-MISC O-MISC
. O-MISC O-MISC

Influenza O-MISC O-MISC
A O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
/ I-MISC I-MISC
beta I-MISC I-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
in O-MISC O-MISC
host O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
antiviral O-MISC O-MISC
defence O-MISC O-MISC
by O-MISC O-MISC
activating O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
antiviral B-MISC O-MISC
Mx I-MISC O-MISC
, O-MISC O-MISC
PKR B-MISC B-MISC
and I-MISC O-MISC
oligoadenylate I-MISC I-MISC
synthetase I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
/ I-MISC I-MISC
beta I-MISC I-MISC
also O-MISC O-MISC
prolongs O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
survival O-MISC O-MISC
, O-MISC O-MISC
upregulates O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
12 O-MISC I-MISC
and O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
18 O-MISC I-MISC
receptor O-MISC I-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
together O-MISC O-MISC
with O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC O-MISC
18 I-MISC O-MISC
stimulates O-MISC O-MISC
NK O-MISC O-MISC
and O-MISC O-MISC
T O-MISC B-MISC
cell O-MISC I-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
production O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
Th1 O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Comparison O-MISC O-MISC
of O-MISC O-MISC
hprt O-MISC O-MISC
and O-MISC O-MISC
lacI O-MISC O-MISC
mutant O-MISC O-MISC
frequency O-MISC O-MISC
with O-MISC O-MISC
DNA O-MISC O-MISC
adduct O-MISC O-MISC
formation O-MISC O-MISC
in O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
hydroxy O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
acetylaminofluorene O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
Big O-MISC O-MISC
Blue O-MISC O-MISC
rats O-MISC O-MISC
. O-MISC O-MISC

N O-MISC O-MISC
- O-MISC O-MISC
Hydroxy O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
acetylaminofluorene O-MISC O-MISC
( O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
AAF O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
proximate O-MISC O-MISC
carcinogenic O-MISC O-MISC
metabolite O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
powerful O-MISC O-MISC
rat O-MISC O-MISC
liver O-MISC O-MISC
carcinogen O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
acetylaminofluorene O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
transgenic O-MISC O-MISC
Big O-MISC O-MISC
Blue O-MISC O-MISC
( O-MISC O-MISC
R O-MISC O-MISC
) O-MISC O-MISC
rats O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
examine O-MISC O-MISC
the O-MISC O-MISC
relationship O-MISC O-MISC
between O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
mutagenicity O-MISC O-MISC
and O-MISC O-MISC
DNA O-MISC O-MISC
adduct O-MISC O-MISC
formation O-MISC O-MISC
by O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
AAF O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
target O-MISC O-MISC
liver O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
nontarget O-MISC O-MISC
tissues O-MISC O-MISC
. O-MISC O-MISC

Male O-MISC O-MISC
rats O-MISC O-MISC
were O-MISC O-MISC
given O-MISC O-MISC
one O-MISC O-MISC
, O-MISC O-MISC
two O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
four O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
25 O-MISC O-MISC
mg O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
AAF O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
body O-MISC O-MISC
weight O-MISC O-MISC
by O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
p O-MISC O-MISC
. O-MISC O-MISC
injection O-MISC O-MISC
at O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
day O-MISC O-MISC
intervals O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
groups O-MISC O-MISC
of O-MISC O-MISC
treated O-MISC O-MISC
and O-MISC O-MISC
control O-MISC O-MISC
rats O-MISC O-MISC
were O-MISC O-MISC
euthanized O-MISC O-MISC
up O-MISC O-MISC
to O-MISC O-MISC
10 O-MISC O-MISC
weeks O-MISC O-MISC
after O-MISC O-MISC
beginning O-MISC O-MISC
the O-MISC O-MISC
dosing O-MISC O-MISC
. O-MISC O-MISC

Mutant O-MISC O-MISC
frequencies O-MISC O-MISC
were O-MISC O-MISC
measured O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
spleen B-MISC O-MISC
lymphocyte I-MISC O-MISC
hprt I-MISC O-MISC
gene I-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
lacI O-MISC O-MISC
mutant O-MISC O-MISC
frequencies O-MISC O-MISC
were O-MISC O-MISC
determined O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
and O-MISC O-MISC
spleen O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
6 O-MISC O-MISC
weeks O-MISC O-MISC
after O-MISC O-MISC
beginning O-MISC O-MISC
the O-MISC O-MISC
dosing O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
hprt O-MISC O-MISC
mutant O-MISC O-MISC
frequency O-MISC O-MISC
in O-MISC O-MISC
spleen O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
four O-MISC O-MISC
- O-MISC O-MISC
dose O-MISC O-MISC
group O-MISC O-MISC
was O-MISC O-MISC
16 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
control O-MISC O-MISC
animals O-MISC O-MISC
. O-MISC O-MISC

Also O-MISC O-MISC
at O-MISC O-MISC
6 O-MISC O-MISC
weeks O-MISC O-MISC
, O-MISC O-MISC
rats O-MISC O-MISC
given O-MISC O-MISC
one O-MISC O-MISC
, O-MISC O-MISC
two O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
four O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
N O-MISC B-MISC
- O-MISC I-MISC
OH O-MISC I-MISC
- O-MISC I-MISC
AAF O-MISC I-MISC
had O-MISC O-MISC
lacI O-MISC O-MISC
mutant O-MISC O-MISC
frequencies O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
of O-MISC O-MISC
97 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
155 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
406 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
, O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
control O-MISC O-MISC
frequency O-MISC O-MISC
of O-MISC O-MISC
25 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
; O-MISC O-MISC
rats O-MISC O-MISC
given O-MISC O-MISC
four O-MISC O-MISC
doses O-MISC O-MISC
had O-MISC O-MISC
lacI O-MISC O-MISC
mutant O-MISC O-MISC
frequencies O-MISC O-MISC
in O-MISC O-MISC
spleen O-MISC O-MISC
lymphocytes O-MISC O-MISC
of O-MISC O-MISC
55 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
control O-MISC O-MISC
frequency O-MISC O-MISC
of O-MISC O-MISC
20 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Additional O-MISC O-MISC
rats O-MISC O-MISC
were O-MISC O-MISC
evaluated O-MISC O-MISC
for O-MISC O-MISC
DNA O-MISC O-MISC
adduct O-MISC O-MISC
formation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
, O-MISC O-MISC
spleen O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
by O-MISC O-MISC
( O-MISC O-MISC
32 O-MISC O-MISC
) O-MISC O-MISC
P O-MISC O-MISC
- O-MISC O-MISC
postlabeling O-MISC O-MISC
. O-MISC O-MISC

Adduct O-MISC O-MISC
analysis O-MISC O-MISC
was O-MISC O-MISC
conducted O-MISC O-MISC
1 O-MISC O-MISC
day O-MISC O-MISC
after O-MISC O-MISC
one O-MISC O-MISC
, O-MISC O-MISC
two O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
four O-MISC O-MISC
treatments O-MISC O-MISC
with O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
AAF O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
days O-MISC O-MISC
after O-MISC O-MISC
one O-MISC O-MISC
treatment O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
9 O-MISC O-MISC
days O-MISC O-MISC
after O-MISC O-MISC
two O-MISC O-MISC
treatments O-MISC O-MISC
. O-MISC O-MISC

N O-MISC B-MISC
- O-MISC I-MISC
( O-MISC I-MISC
Deoxyguanosin O-MISC I-MISC
- O-MISC I-MISC
8 O-MISC I-MISC
- O-MISC I-MISC
yl O-MISC I-MISC
) O-MISC O-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC I-MISC
aminofluorene O-MISC I-MISC
was O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
DNA O-MISC O-MISC
adduct O-MISC O-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
the O-MISC O-MISC
tissues O-MISC O-MISC
examined O-MISC O-MISC
. O-MISC O-MISC

Adduct O-MISC O-MISC
concentrations O-MISC O-MISC
increased O-MISC O-MISC
with O-MISC O-MISC
total O-MISC O-MISC
dose O-MISC O-MISC
to O-MISC O-MISC
maximum O-MISC O-MISC
values O-MISC O-MISC
in O-MISC O-MISC
samples O-MISC O-MISC
taken O-MISC O-MISC
1 O-MISC O-MISC
day O-MISC O-MISC
after O-MISC O-MISC
two O-MISC O-MISC
doses O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
remained O-MISC O-MISC
essentially O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
after O-MISC O-MISC
four O-MISC O-MISC
doses O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
samples O-MISC O-MISC
taken O-MISC O-MISC
after O-MISC O-MISC
four O-MISC O-MISC
doses O-MISC O-MISC
, O-MISC O-MISC
adduct O-MISC O-MISC
levels O-MISC O-MISC
were O-MISC O-MISC
103 O-MISC O-MISC
, O-MISC O-MISC
28 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
7 O-MISC O-MISC
fmol O-MISC O-MISC
/ O-MISC O-MISC
microg O-MISC O-MISC
of O-MISC O-MISC
DNA O-MISC O-MISC
in O-MISC O-MISC
liver O-MISC O-MISC
, O-MISC O-MISC
spleen O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
extent O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
DNA O-MISC O-MISC
adduct O-MISC O-MISC
formation O-MISC O-MISC
and O-MISC O-MISC
mutant O-MISC O-MISC
induction O-MISC O-MISC
correlates O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
organ O-MISC O-MISC
specificity O-MISC O-MISC
for O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
AAF O-MISC O-MISC
carcinogenesis O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
rat O-MISC O-MISC
. O-MISC O-MISC

Environ O-MISC O-MISC
. O-MISC O-MISC
Mol O-MISC O-MISC
. O-MISC O-MISC
Mutagen O-MISC O-MISC
. O-MISC O-MISC
37 O-MISC O-MISC
: O-MISC O-MISC
195 O-MISC O-MISC
- O-MISC O-MISC
202 O-MISC O-MISC
, O-MISC O-MISC
2001 O-MISC O-MISC
. O-MISC O-MISC

Published O-MISC O-MISC
2001 O-MISC O-MISC
Wiley O-MISC O-MISC
- O-MISC O-MISC
Liss O-MISC O-MISC
, O-MISC O-MISC
Inc O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
Mad1 B-MISC B-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
reduced O-MISC O-MISC
thymic O-MISC O-MISC
cellularity O-MISC O-MISC
and O-MISC O-MISC
impaired O-MISC O-MISC
mitogen O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
investigate O-MISC O-MISC
Mad1 B-MISC O-MISC
function O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
, O-MISC O-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
were O-MISC O-MISC
generated O-MISC O-MISC
that O-MISC O-MISC
express O-MISC O-MISC
a O-MISC O-MISC
Mad1 B-MISC B-MISC
transgene I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
under O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proximal B-MISC B-MISC
lck I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Thymus O-MISC O-MISC
size O-MISC O-MISC
in O-MISC O-MISC
lck O-MISC B-MISC
- O-MISC I-MISC
Mad1 O-MISC I-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
is O-MISC O-MISC
drastically O-MISC O-MISC
reduced O-MISC O-MISC
although O-MISC O-MISC
representation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
various O-MISC O-MISC
thymocyte O-MISC O-MISC
sub O-MISC O-MISC
populations O-MISC O-MISC
appears O-MISC O-MISC
normal O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
investigate O-MISC O-MISC
more O-MISC O-MISC
closely O-MISC O-MISC
any O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
Mad1 O-MISC B-MISC
expression O-MISC O-MISC
on O-MISC O-MISC
thymocytes O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
examined O-MISC O-MISC
thymic O-MISC O-MISC
selection O-MISC O-MISC
using O-MISC O-MISC
MHC O-MISC B-MISC
class O-MISC I-MISC
I O-MISC I-MISC
- O-MISC O-MISC
restricted O-MISC O-MISC
H O-MISC O-MISC
- O-MISC O-MISC
Y O-MISC I-MISC
- O-MISC I-MISC
TCR O-MISC I-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Mad1 O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
reduces O-MISC O-MISC
the O-MISC O-MISC
efficiency O-MISC O-MISC
of O-MISC O-MISC
positive O-MISC O-MISC
selection O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
thymocytes O-MISC O-MISC
and O-MISC O-MISC
splenic O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
lck O-MISC B-MISC
- O-MISC I-MISC
Mad1 O-MISC I-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
display O-MISC O-MISC
a O-MISC O-MISC
profound O-MISC O-MISC
proliferative O-MISC O-MISC
defect O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
activation O-MISC O-MISC
with O-MISC O-MISC
either O-MISC O-MISC
PMA O-MISC O-MISC
/ O-MISC O-MISC
Ionomycin O-MISC O-MISC
or O-MISC O-MISC
immobilized B-MISC B-MISC
anti I-MISC I-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
/ I-MISC I-MISC
CD28 I-MISC I-MISC
antibody I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
proliferative O-MISC O-MISC
defect O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
reversed O-MISC O-MISC
by O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
exogenous B-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
is O-MISC O-MISC
p53 O-MISC B-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
growth O-MISC O-MISC
inhibition O-MISC O-MISC
caused O-MISC O-MISC
by O-MISC O-MISC
Mad1 B-MISC O-MISC
is O-MISC O-MISC
overcome O-MISC O-MISC
by O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
active B-MISC O-MISC
c I-MISC B-MISC
- I-MISC I-MISC
Myc I-MISC I-MISC
. O-MISC O-MISC

Differential O-MISC O-MISC
requirement O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
PU I-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
cells O-MISC O-MISC
versus O-MISC O-MISC
B O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

PU B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ets B-MISC B-MISC
family I-MISC I-MISC
of I-MISC O-MISC
transcription I-MISC B-MISC
factors I-MISC I-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
various O-MISC O-MISC
lymphoid O-MISC O-MISC
and O-MISC O-MISC
myeloid O-MISC O-MISC
cell O-MISC O-MISC
lineages O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
its O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
( O-MISC O-MISC
NK O-MISC O-MISC
) O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
known O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
study O-MISC O-MISC
shows O-MISC O-MISC
that O-MISC O-MISC
PU B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
, O-MISC O-MISC
on O-MISC O-MISC
cell O-MISC O-MISC
transfer O-MISC O-MISC
into O-MISC O-MISC
alymphoid O-MISC O-MISC
Rag2 O-MISC B-MISC
/ O-MISC O-MISC
gammac O-MISC I-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
hematopoietic O-MISC O-MISC
progenitors O-MISC O-MISC
of O-MISC O-MISC
PU O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
fetal O-MISC O-MISC
liver O-MISC O-MISC
cells O-MISC O-MISC
could O-MISC O-MISC
generate O-MISC O-MISC
functional O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
B O-MISC O-MISC
or O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Nevertheless O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
precursors O-MISC O-MISC
and O-MISC O-MISC
splenic O-MISC O-MISC
mature O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
reduced O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
PU O-MISC B-MISC
. O-MISC I-MISC
1 O-MISC I-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
displayed O-MISC O-MISC
reduced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptors O-MISC O-MISC
for O-MISC O-MISC
stem B-MISC B-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
and O-MISC O-MISC
interleukin B-MISC B-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
7 I-MISC I-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
a O-MISC O-MISC
nonredundant O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
PU B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
regulating O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
cytokine B-MISC B-MISC
receptor I-MISC I-MISC
genes I-MISC I-MISC
during O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

PU O-MISC B-MISC
. O-MISC I-MISC
1 O-MISC I-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
also O-MISC O-MISC
showed O-MISC O-MISC
defective O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
inhibitory O-MISC O-MISC
and O-MISC O-MISC
activating O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ly49 B-MISC B-MISC
family I-MISC I-MISC
and O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
proliferate O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
despite O-MISC O-MISC
the O-MISC O-MISC
less O-MISC O-MISC
stringent O-MISC O-MISC
requirement O-MISC O-MISC
for O-MISC O-MISC
PU B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
B O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
PU B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
regulates O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
homeostasis O-MISC O-MISC
. O-MISC O-MISC

Benzene O-MISC O-MISC
- O-MISC O-MISC
extracted O-MISC O-MISC
components O-MISC O-MISC
are O-MISC O-MISC
important O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
diesel O-MISC O-MISC
exhaust O-MISC O-MISC
particles O-MISC O-MISC
: O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
gene I-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
bronchial O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Epidemiologic O-MISC O-MISC
and O-MISC O-MISC
experimental O-MISC O-MISC
studies O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
diesel O-MISC O-MISC
exhaust O-MISC O-MISC
particles O-MISC O-MISC
( O-MISC O-MISC
DEPs O-MISC O-MISC
) O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
increasing O-MISC O-MISC
respiratory O-MISC O-MISC
mortality O-MISC O-MISC
and O-MISC O-MISC
morbidity O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
DEPs O-MISC O-MISC
augmented O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
inflammatory B-MISC B-MISC
cytokines I-MISC I-MISC
by O-MISC O-MISC
human O-MISC O-MISC
airway O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
better O-MISC O-MISC
understand O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
of O-MISC O-MISC
their O-MISC O-MISC
proinflammatory O-MISC O-MISC
activities O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
studied O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
several O-MISC O-MISC
components O-MISC O-MISC
extracted O-MISC O-MISC
from O-MISC O-MISC
DEPs O-MISC O-MISC
on O-MISC O-MISC
interleukin O-MISC B-MISC
( O-MISC I-MISC
IL O-MISC B-MISC
) O-MISC I-MISC
- O-MISC I-MISC
8 O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
bronchial O-MISC O-MISC
epithelial O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
BEAS O-MISC O-MISC
- O-MISC O-MISC
2B O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
airway O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
very O-MISC O-MISC
peripheral O-MISC O-MISC
airways O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
ultrathin O-MISC O-MISC
bronchoscope O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
used O-MISC O-MISC
several O-MISC O-MISC
agents O-MISC O-MISC
active O-MISC O-MISC
on O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
pathways O-MISC O-MISC
in O-MISC O-MISC
cytokine O-MISC B-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
protein O-MISC B-MISC
kinase O-MISC I-MISC
C O-MISC I-MISC
inhibitor O-MISC O-MISC
staurosporin O-MISC O-MISC
, O-MISC O-MISC
antioxidant O-MISC O-MISC
agents O-MISC O-MISC
including O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
acetyl O-MISC O-MISC
cysteine O-MISC O-MISC
( O-MISC O-MISC
NAC O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
pyrrolidine O-MISC O-MISC
dithiocarbamate O-MISC O-MISC
( O-MISC O-MISC
PDTC O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
p38 B-MISC B-MISC
mitogen I-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
MAPK B-MISC B-MISC
) O-MISC O-MISC
inhibitor O-MISC O-MISC
SB203580 O-MISC B-MISC
. O-MISC O-MISC

Benzene O-MISC O-MISC
- O-MISC O-MISC
extracted O-MISC O-MISC
components O-MISC O-MISC
showed O-MISC O-MISC
effects O-MISC O-MISC
mimicking O-MISC O-MISC
DEPs O-MISC O-MISC
on O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
8 O-MISC I-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
release O-MISC O-MISC
of O-MISC O-MISC
several O-MISC O-MISC
cytokines B-MISC B-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
; O-MISC O-MISC
granulocyte B-MISC B-MISC
macrophage I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
; O-MISC O-MISC
and O-MISC O-MISC
regulated O-MISC O-MISC
on O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
normal O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
expressed O-MISC O-MISC
and O-MISC O-MISC
secreted O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC B-MISC
factor O-MISC I-MISC
( O-MISC I-MISC
NF O-MISC B-MISC
) O-MISC I-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
also O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
NAC O-MISC O-MISC
, O-MISC O-MISC
PDTC O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
SB203580 O-MISC O-MISC
suppressed O-MISC O-MISC
the O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
DEPs O-MISC O-MISC
and O-MISC O-MISC
their O-MISC O-MISC
benzene O-MISC O-MISC
extracts O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
the O-MISC O-MISC
roles O-MISC O-MISC
of O-MISC O-MISC
oxidants O-MISC O-MISC
- O-MISC I-MISC
mediated O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC O-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
p38MAPK B-MISC B-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
benzo O-MISC O-MISC
[ O-MISC O-MISC
a O-MISC O-MISC
] O-MISC O-MISC
pyrene O-MISC O-MISC
, O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
important O-MISC O-MISC
compounds O-MISC O-MISC
included O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
benzene O-MISC O-MISC
component O-MISC O-MISC
, O-MISC O-MISC
replicated O-MISC O-MISC
the O-MISC O-MISC
activities O-MISC O-MISC
shown O-MISC O-MISC
by O-MISC O-MISC
DEPs O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
nuclear B-MISC B-MISC
receptor I-MISC I-MISC
PPAR I-MISC I-MISC
gamma I-MISC I-MISC
is O-MISC O-MISC
expressed O-MISC O-MISC
by O-MISC O-MISC
mouse O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
PPAR O-MISC B-MISC
gamma O-MISC I-MISC
agonists O-MISC O-MISC
induce O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Peroxisome B-MISC B-MISC
proliferator I-MISC I-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
receptor I-MISC I-MISC
( I-MISC I-MISC
PPAR I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
nuclear B-MISC B-MISC
hormone I-MISC I-MISC
receptor I-MISC I-MISC
that O-MISC O-MISC
serves O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
trans O-MISC O-MISC
factor O-MISC O-MISC
to O-MISC O-MISC
regulate O-MISC O-MISC
lipid O-MISC O-MISC
metabolism O-MISC O-MISC
. O-MISC O-MISC

Intense O-MISC O-MISC
interest O-MISC O-MISC
is O-MISC O-MISC
focused O-MISC O-MISC
on O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
and O-MISC O-MISC
its O-MISC O-MISC
ligands O-MISC O-MISC
owing O-MISC O-MISC
to O-MISC O-MISC
its O-MISC O-MISC
putative O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
adipocyte O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

Little O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
about O-MISC O-MISC
the O-MISC O-MISC
functions O-MISC O-MISC
of O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
, O-MISC O-MISC
especially O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
both O-MISC O-MISC
naive O-MISC O-MISC
and O-MISC O-MISC
activated O-MISC O-MISC
ovalbumin O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
DO11 O-MISC O-MISC
. O-MISC O-MISC
10 O-MISC O-MISC
- O-MISC O-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
express O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
mRNA O-MISC I-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
order O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
, O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
phorbol O-MISC O-MISC
12 O-MISC O-MISC
- O-MISC O-MISC
myristate O-MISC O-MISC
13 O-MISC O-MISC
- O-MISC O-MISC
acetate O-MISC O-MISC
and O-MISC O-MISC
ionomycin O-MISC O-MISC
or O-MISC O-MISC
antigen O-MISC O-MISC
and O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
presenting O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Simultaneous O-MISC O-MISC
exposure O-MISC O-MISC
to O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
ligands O-MISC O-MISC
( O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
g O-MISC O-MISC
. O-MISC O-MISC
15 O-MISC O-MISC
- O-MISC O-MISC
deoxy O-MISC O-MISC
- O-MISC O-MISC
Delta O-MISC O-MISC
( O-MISC O-MISC
12 O-MISC O-MISC
, O-MISC O-MISC
14 O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
prostaglandin O-MISC O-MISC
J O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
troglitazone O-MISC O-MISC
) O-MISC O-MISC
showed O-MISC O-MISC
drastic O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
significant O-MISC O-MISC
decreases O-MISC O-MISC
in O-MISC O-MISC
cell O-MISC O-MISC
viability O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
cell O-MISC O-MISC
viability O-MISC O-MISC
was O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
apoptosis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
occurred O-MISC O-MISC
only O-MISC O-MISC
when O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
not O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC O-MISC
alpha O-MISC O-MISC
agonists O-MISC O-MISC
, O-MISC O-MISC
revealing O-MISC O-MISC
specificity O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
response O-MISC O-MISC
for O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
observations O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
agonists O-MISC I-MISC
play O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
regulating O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
by O-MISC O-MISC
inducing O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cell O-MISC O-MISC
death O-MISC O-MISC
via O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
ligation O-MISC I-MISC
may O-MISC O-MISC
act O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
signal O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
ligands O-MISC O-MISC
could O-MISC O-MISC
possibly O-MISC O-MISC
be O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
control O-MISC O-MISC
disorders O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
excessive O-MISC O-MISC
inflammation O-MISC O-MISC
occurs O-MISC O-MISC
. O-MISC O-MISC

Suppression O-MISC O-MISC
of O-MISC O-MISC
lung O-MISC O-MISC
inflammation O-MISC O-MISC
in O-MISC O-MISC
rats O-MISC O-MISC
by O-MISC O-MISC
prevention O-MISC O-MISC
of O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- O-MISC I-MISC
dependent O-MISC I-MISC
chemokines B-MISC I-MISC
are O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
neutrophilic O-MISC O-MISC
lung O-MISC O-MISC
inflammation O-MISC O-MISC
. O-MISC O-MISC

Calpain O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
inhibitor O-MISC I-MISC
( O-MISC O-MISC
CI O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
) O-MISC O-MISC
blocks O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
by O-MISC O-MISC
preventing O-MISC O-MISC
proteolysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
protein O-MISC I-MISC
IkappaB B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
by O-MISC O-MISC
the O-MISC O-MISC
ubiquitin O-MISC O-MISC
/ O-MISC O-MISC
proteasome O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
hypothesized O-MISC O-MISC
that O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
proteasome O-MISC B-MISC
function O-MISC O-MISC
with O-MISC O-MISC
CI O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
would O-MISC O-MISC
block O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
after O-MISC O-MISC
intraperitoneal O-MISC O-MISC
( O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
p O-MISC O-MISC
. O-MISC O-MISC
) O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
bacterial O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
( O-MISC O-MISC
LPS O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
inhibition O-MISC O-MISC
would O-MISC O-MISC
be O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
chemokine O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
attenuation O-MISC O-MISC
of O-MISC O-MISC
neutrophilic O-MISC O-MISC
alveolitis O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
treated O-MISC O-MISC
rats O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
p O-MISC O-MISC
. O-MISC O-MISC
injection O-MISC O-MISC
of O-MISC O-MISC
CI O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
10 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
) O-MISC O-MISC
two O-MISC O-MISC
hours O-MISC O-MISC
prior O-MISC O-MISC
to O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
p O-MISC O-MISC
. O-MISC O-MISC
LPS O-MISC O-MISC
( O-MISC O-MISC
7 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
with O-MISC O-MISC
Cl O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
prevented O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
IkappaB B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
LPS O-MISC O-MISC
; O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
Cl O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
treatment O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
detected O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
lung O-MISC O-MISC
tissue O-MISC O-MISC
. O-MISC O-MISC

CI O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
treatment O-MISC O-MISC
prior O-MISC O-MISC
to O-MISC O-MISC
LPS O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
40 O-MISC O-MISC
% O-MISC O-MISC
lower O-MISC O-MISC
MIP O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
concentration O-MISC O-MISC
in O-MISC O-MISC
lung O-MISC O-MISC
lavage O-MISC O-MISC
fluid O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
rats O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
vehicle O-MISC O-MISC
prior O-MISC O-MISC
to O-MISC O-MISC
LPS O-MISC O-MISC
( O-MISC O-MISC
502 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
112 O-MISC O-MISC
pg O-MISC B-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
vs O-MISC O-MISC
. O-MISC O-MISC
859 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
144 O-MISC O-MISC
pg O-MISC O-MISC
/ O-MISC O-MISC
ml O-MISC O-MISC
, O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
05 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
CI O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
treatment O-MISC O-MISC
substantially O-MISC O-MISC
inhibited O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
neutrophilic O-MISC O-MISC
alveolitis O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
) O-MISC O-MISC
vs O-MISC O-MISC
. O-MISC O-MISC
43 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
12 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
) O-MISC O-MISC
lung O-MISC O-MISC
lavage O-MISC O-MISC
neutrophils O-MISC O-MISC
, O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
inhibition O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
liver O-MISC O-MISC
can O-MISC O-MISC
alter O-MISC O-MISC
lung O-MISC O-MISC
inflammation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
systemic O-MISC O-MISC
LPS O-MISC O-MISC
treatment O-MISC O-MISC
and O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
liver O-MISC O-MISC
- O-MISC O-MISC
lung O-MISC O-MISC
interaction O-MISC O-MISC
contributes O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
lung O-MISC O-MISC
. O-MISC O-MISC

Notch1 B-MISC O-MISC
regulates O-MISC O-MISC
maturation O-MISC O-MISC
of O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
thymocytes O-MISC O-MISC
by O-MISC O-MISC
modulating O-MISC O-MISC
TCR O-MISC B-MISC
signal O-MISC O-MISC
strength O-MISC O-MISC
. O-MISC O-MISC

Notch O-MISC O-MISC
signaling O-MISC O-MISC
regulates O-MISC O-MISC
cell O-MISC O-MISC
fate O-MISC O-MISC
decisions O-MISC O-MISC
in O-MISC O-MISC
multiple O-MISC O-MISC
lineages O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
demonstrate O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
report O-MISC O-MISC
that O-MISC O-MISC
retroviral O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
activated O-MISC O-MISC
Notch1 B-MISC O-MISC
in O-MISC O-MISC
mouse O-MISC O-MISC
thymocytes O-MISC O-MISC
abrogates O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
immature O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
thymocytes O-MISC O-MISC
into O-MISC O-MISC
both O-MISC O-MISC
CD4 O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC O-MISC
mature O-MISC O-MISC
single O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
Notch1 B-MISC B-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
with O-MISC O-MISC
both O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
TCR O-MISC B-MISC
transgenic O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

Notch1 B-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
developmental O-MISC O-MISC
arrest O-MISC O-MISC
was O-MISC O-MISC
dose O-MISC O-MISC
dependent O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
impaired O-MISC O-MISC
thymocyte O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
TCR O-MISC B-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Notch1 B-MISC O-MISC
also O-MISC O-MISC
inhibited O-MISC O-MISC
TCR O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
signaling O-MISC O-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
constitutively O-MISC O-MISC
active O-MISC O-MISC
Notch1 B-MISC O-MISC
abrogates O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
maturation O-MISC O-MISC
by O-MISC O-MISC
interfering O-MISC O-MISC
with O-MISC O-MISC
TCR O-MISC B-MISC
signal O-MISC O-MISC
strength O-MISC O-MISC
and O-MISC O-MISC
provide O-MISC O-MISC
an O-MISC O-MISC
explanation O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
physiological O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
Notch O-MISC O-MISC
expression O-MISC O-MISC
during O-MISC O-MISC
thymocyte O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
SART3 B-MISC B-MISC
antigen I-MISC I-MISC
and O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
CTLs O-MISC O-MISC
by O-MISC O-MISC
SART3 O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
peptides O-MISC O-MISC
in O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
recently O-MISC O-MISC
reported O-MISC O-MISC
the O-MISC O-MISC
SART3 B-MISC B-MISC
tumour I-MISC I-MISC
- I-MISC I-MISC
rejection I-MISC I-MISC
antigen I-MISC I-MISC
as O-MISC O-MISC
possessing O-MISC O-MISC
tumour O-MISC I-MISC
epitopes O-MISC I-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
inducing O-MISC O-MISC
HLA O-MISC B-MISC
- O-MISC I-MISC
class O-MISC I-MISC
I O-MISC O-MISC
- O-MISC O-MISC
restricted O-MISC O-MISC
cytotoxic O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
( O-MISC O-MISC
CTLs O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
investigated O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
SART3 B-MISC B-MISC
antigen I-MISC I-MISC
in O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
to O-MISC O-MISC
explore O-MISC O-MISC
an O-MISC O-MISC
appropriate O-MISC O-MISC
molecule O-MISC O-MISC
for O-MISC O-MISC
use O-MISC O-MISC
in O-MISC O-MISC
specific O-MISC O-MISC
immunotherapy O-MISC O-MISC
of O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
SART3 B-MISC B-MISC
antigen I-MISC I-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
tested O-MISC O-MISC
, O-MISC O-MISC
30 O-MISC O-MISC
of O-MISC O-MISC
40 O-MISC O-MISC
( O-MISC O-MISC
75 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
tissue O-MISC O-MISC
samples O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
0 O-MISC O-MISC
of O-MISC O-MISC
3 O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
tumourous O-MISC O-MISC
breast O-MISC O-MISC
tissue O-MISC O-MISC
samples O-MISC O-MISC
. O-MISC O-MISC

SART3 O-MISC O-MISC
derived O-MISC O-MISC
peptides O-MISC O-MISC
at O-MISC O-MISC
positions B-MISC O-MISC
109 I-MISC O-MISC
- I-MISC O-MISC
118 I-MISC O-MISC
and I-MISC O-MISC
315 I-MISC O-MISC
- I-MISC O-MISC
323 I-MISC O-MISC
induced O-MISC O-MISC
HLA O-MISC B-MISC
- O-MISC I-MISC
A24 O-MISC O-MISC
restricted O-MISC O-MISC
CTLs O-MISC O-MISC
that O-MISC O-MISC
reacted O-MISC O-MISC
to O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
PBMCs O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
SART3 B-MISC B-MISC
antigen I-MISC I-MISC
and O-MISC O-MISC
its O-MISC O-MISC
peptides O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
an O-MISC O-MISC
appropriate O-MISC O-MISC
molecule O-MISC O-MISC
for O-MISC O-MISC
use O-MISC O-MISC
in O-MISC O-MISC
specific O-MISC O-MISC
immunotherapy O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
majority O-MISC O-MISC
of O-MISC O-MISC
HLA O-MISC O-MISC
- O-MISC O-MISC
A24 O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
patients O-MISC O-MISC

Autostimulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Epstein O-MISC B-MISC
- O-MISC I-MISC
Barr O-MISC I-MISC
virus O-MISC I-MISC
BRLF1 B-MISC I-MISC
promoter I-MISC I-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
through O-MISC O-MISC
consensus O-MISC B-MISC
Sp1 B-MISC I-MISC
and I-MISC I-MISC
Sp3 I-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

As O-MISC O-MISC
an O-MISC O-MISC
essential O-MISC O-MISC
step O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
lytic O-MISC O-MISC
cascade O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
Rta O-MISC B-MISC
homologues O-MISC I-MISC
of O-MISC O-MISC
gammaherpesviruses O-MISC O-MISC
all O-MISC O-MISC
activate O-MISC O-MISC
their O-MISC O-MISC
own O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Consistent O-MISC O-MISC
with O-MISC O-MISC
this O-MISC O-MISC
biologic O-MISC O-MISC
function O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
EBV O-MISC O-MISC
) O-MISC O-MISC
Rta B-MISC O-MISC
protein I-MISC O-MISC
powerfully O-MISC O-MISC
stimulates O-MISC O-MISC
the O-MISC O-MISC
promoter B-MISC O-MISC
of O-MISC O-MISC
its O-MISC O-MISC
own O-MISC O-MISC
gene O-MISC O-MISC
, O-MISC O-MISC
Rp B-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
transient O-MISC O-MISC
- O-MISC O-MISC
transfection O-MISC O-MISC
reporter O-MISC O-MISC
- O-MISC O-MISC
based O-MISC O-MISC
assays O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
RpCAT B-MISC B-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
Rta B-MISC B-MISC
by O-MISC O-MISC
deletional O-MISC O-MISC
and O-MISC O-MISC
site O-MISC O-MISC
- O-MISC O-MISC
directed O-MISC O-MISC
mutagenesis O-MISC O-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
cognate B-MISC B-MISC
Sp1 I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
located O-MISC O-MISC
at O-MISC O-MISC
- O-MISC O-MISC
279 O-MISC I-MISC
and O-MISC I-MISC
- O-MISC I-MISC
45 O-MISC I-MISC
relative O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
transcriptional B-MISC B-MISC
start I-MISC I-MISC
site I-MISC I-MISC
proved O-MISC O-MISC
crucial O-MISC O-MISC
for O-MISC O-MISC
Rta O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Previously O-MISC O-MISC
described O-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC I-MISC
for O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC B-MISC
transcription B-MISC I-MISC
factor I-MISC I-MISC
Zif268 I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
viral B-MISC B-MISC
transactivator I-MISC I-MISC
ZEBRA I-MISC B-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
dispensable O-MISC O-MISC
for O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
RpCAT B-MISC B-MISC
by O-MISC O-MISC
Rta B-MISC B-MISC
. O-MISC O-MISC

Gel O-MISC O-MISC
shift O-MISC O-MISC
analysis O-MISC O-MISC
, O-MISC O-MISC
using O-MISC O-MISC
extracts O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
latency O-MISC O-MISC
or O-MISC O-MISC
induced O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
lytic O-MISC O-MISC
cycle O-MISC O-MISC
, O-MISC O-MISC
identified O-MISC O-MISC
Sp1 B-MISC B-MISC
and O-MISC O-MISC
Sp3 B-MISC B-MISC
as O-MISC O-MISC
the O-MISC O-MISC
predominant O-MISC O-MISC
cellular B-MISC B-MISC
proteins I-MISC I-MISC
bound O-MISC O-MISC
to O-MISC O-MISC
Rp B-MISC B-MISC
near O-MISC O-MISC
- O-MISC O-MISC
45 O-MISC O-MISC
. O-MISC O-MISC

During O-MISC O-MISC
the O-MISC O-MISC
lytic O-MISC O-MISC
cycle O-MISC O-MISC
, O-MISC O-MISC
ZEBRA B-MISC B-MISC
bound O-MISC O-MISC
Rp B-MISC B-MISC
near O-MISC O-MISC
the O-MISC O-MISC
Sp1 B-MISC B-MISC
/ I-MISC I-MISC
Sp3 I-MISC I-MISC
site I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
Sp1 B-MISC B-MISC
and O-MISC O-MISC
Sp3 B-MISC B-MISC
to O-MISC O-MISC
Rp B-MISC B-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
reporter O-MISC O-MISC
activities O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
mutagenesis O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
establishing O-MISC O-MISC
a O-MISC O-MISC
direct O-MISC O-MISC
link O-MISC O-MISC
between O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Rp B-MISC B-MISC
by O-MISC O-MISC
Rta B-MISC B-MISC
and O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
by O-MISC O-MISC
Sp1 B-MISC B-MISC
and O-MISC O-MISC
/ O-MISC I-MISC
or O-MISC O-MISC
Sp3 B-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
relative O-MISC O-MISC
abundance O-MISC O-MISC
or O-MISC O-MISC
functional O-MISC O-MISC
state O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC B-MISC
Sp1 B-MISC I-MISC
and O-MISC I-MISC
Sp3 B-MISC I-MISC
transcription B-MISC I-MISC
factors I-MISC I-MISC
may O-MISC O-MISC
be O-MISC O-MISC
altered O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
stimuli O-MISC O-MISC
that O-MISC O-MISC
induce O-MISC O-MISC
the O-MISC O-MISC
BRLF1 B-MISC B-MISC
promoter I-MISC I-MISC
and O-MISC O-MISC
thereby O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
viral O-MISC O-MISC
lytic O-MISC O-MISC
cycle O-MISC O-MISC
. O-MISC O-MISC

Gene O-MISC O-MISC
transfer O-MISC O-MISC
of O-MISC O-MISC
antisense O-MISC O-MISC
hypoxia B-MISC O-MISC
inducible I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
alpha I-MISC I-MISC
enhances O-MISC I-MISC
the O-MISC O-MISC
therapeutic O-MISC O-MISC
efficacy O-MISC O-MISC
of O-MISC O-MISC
cancer O-MISC O-MISC
immunotherapy O-MISC O-MISC
. O-MISC O-MISC

Solid O-MISC O-MISC
tumors O-MISC O-MISC
meet O-MISC O-MISC
their O-MISC O-MISC
demands O-MISC O-MISC
for O-MISC O-MISC
nascent O-MISC O-MISC
blood O-MISC O-MISC
vessels O-MISC O-MISC
and O-MISC O-MISC
increased O-MISC O-MISC
glycolysis O-MISC O-MISC
, O-MISC O-MISC
to O-MISC O-MISC
combat O-MISC O-MISC
hypoxia O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
activating O-MISC O-MISC
multiple O-MISC O-MISC
genes O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
angiogenesis O-MISC O-MISC
and O-MISC O-MISC
glucose O-MISC O-MISC
metabolism O-MISC O-MISC
. O-MISC O-MISC

Hypoxia B-MISC O-MISC
inducible I-MISC O-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
HIF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
constitutively O-MISC O-MISC
expressed O-MISC O-MISC
basic O-MISC B-MISC
helix B-MISC B-MISC
- I-MISC I-MISC
loop I-MISC I-MISC
- I-MISC I-MISC
helix I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
, O-MISC O-MISC
formed O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
assembly O-MISC O-MISC
of O-MISC O-MISC
HIF B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
and O-MISC O-MISC
HIF B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
( O-MISC O-MISC
Arnt B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
stablized O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
hypoxia O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
rapidly O-MISC O-MISC
degraded O-MISC O-MISC
under O-MISC O-MISC
normoxic O-MISC O-MISC
conditions O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
activates O-MISC O-MISC
the O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
genes O-MISC O-MISC
important O-MISC O-MISC
for O-MISC O-MISC
maintaining O-MISC O-MISC
oxygen O-MISC O-MISC
homeostasis O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
engineered O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
HIF B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
by O-MISC O-MISC
intratumoral O-MISC O-MISC
gene O-MISC I-MISC
transfer O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
antisense B-MISC B-MISC
HIF I-MISC I-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
plasmid I-MISC I-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
VEGF B-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
decreased O-MISC O-MISC
tumor O-MISC O-MISC
microvessel O-MISC O-MISC
density O-MISC O-MISC
. O-MISC O-MISC

Antisense O-MISC O-MISC
HIF O-MISC B-MISC
- O-MISC I-MISC
1alpha O-MISC I-MISC
monotherapy O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
complete O-MISC O-MISC
and O-MISC O-MISC
permanent O-MISC O-MISC
rejection O-MISC O-MISC
of O-MISC O-MISC
small O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
cm O-MISC O-MISC
in O-MISC O-MISC
diameter O-MISC O-MISC
) O-MISC O-MISC
EL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
tumors O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
unusual O-MISC O-MISC
for O-MISC O-MISC
an O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
angiogenic O-MISC O-MISC
agent O-MISC O-MISC
where O-MISC O-MISC
transient O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
tumor O-MISC O-MISC
growth O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
norm O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
induced O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
rejection O-MISC O-MISC
of O-MISC O-MISC
tumors O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
stimulate O-MISC O-MISC
systemic O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
tumor O-MISC O-MISC
immunity O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
synergized O-MISC O-MISC
with O-MISC O-MISC
B7 O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
immunotherapy O-MISC O-MISC
to O-MISC O-MISC
cause O-MISC O-MISC
the O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
rejection O-MISC O-MISC
of O-MISC O-MISC
larger O-MISC O-MISC
EL O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC O-MISC
tumors O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
cm O-MISC O-MISC
in O-MISC O-MISC
diameter O-MISC O-MISC
) O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
refractory O-MISC O-MISC
to O-MISC O-MISC
monotherapies O-MISC O-MISC
. O-MISC O-MISC

Mice O-MISC O-MISC
cured O-MISC O-MISC
of O-MISC O-MISC
their O-MISC O-MISC
tumors O-MISC O-MISC
by O-MISC O-MISC
combination O-MISC O-MISC
therapy O-MISC O-MISC
resisted O-MISC O-MISC
a O-MISC O-MISC
rechallenge O-MISC O-MISC
with O-MISC O-MISC
parental O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
systemic O-MISC O-MISC
antitumor O-MISC O-MISC
immunity O-MISC O-MISC
had O-MISC O-MISC
been O-MISC O-MISC
achieved O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
summary O-MISC O-MISC
, O-MISC O-MISC
whilst O-MISC O-MISC
intensive O-MISC O-MISC
investigations O-MISC O-MISC
are O-MISC O-MISC
in O-MISC O-MISC
progress O-MISC O-MISC
to O-MISC O-MISC
target O-MISC O-MISC
the O-MISC O-MISC
many O-MISC O-MISC
HIF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
effectors O-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
herein O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
blocking O-MISC O-MISC
hypoxia O-MISC O-MISC
- O-MISC O-MISC
inducible O-MISC O-MISC
pathways O-MISC O-MISC
and O-MISC O-MISC
enhancing O-MISC O-MISC
NK O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
antitumor O-MISC O-MISC
immunity O-MISC O-MISC
by O-MISC O-MISC
targeting O-MISC O-MISC
HIF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
itself O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
advantageous O-MISC O-MISC
, O-MISC O-MISC
especially O-MISC O-MISC
when O-MISC O-MISC
combined O-MISC O-MISC
with O-MISC O-MISC
cancer O-MISC O-MISC
immunotherapy O-MISC O-MISC
. O-MISC O-MISC

Runx2 B-MISC O-MISC
: O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
oncogenic O-MISC O-MISC
effector O-MISC O-MISC
revealed O-MISC O-MISC
by O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
complementation O-MISC O-MISC
and O-MISC O-MISC
retroviral O-MISC O-MISC
tagging O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Runx2 B-MISC B-MISC
( O-MISC I-MISC
Cbfa1 B-MISC B-MISC
, O-MISC I-MISC
Pebp2alphaA B-MISC B-MISC
, O-MISC I-MISC
Aml3 B-MISC B-MISC
) O-MISC I-MISC
gene O-MISC I-MISC
was O-MISC O-MISC
previously O-MISC O-MISC
identified O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
frequent O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
proviral O-MISC O-MISC
insertion O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphomas O-MISC O-MISC
of O-MISC O-MISC
CD2 O-MISC B-MISC
- O-MISC O-MISC
MYC O-MISC O-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
recently O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
over O-MISC O-MISC
- O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
full O-MISC O-MISC
- O-MISC O-MISC
length O-MISC O-MISC
, O-MISC O-MISC
most O-MISC O-MISC
highly O-MISC O-MISC
expressed O-MISC O-MISC
Runx2 B-MISC B-MISC
isoform O-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
perturbs O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
, O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
spontaneous O-MISC O-MISC
lymphomas O-MISC O-MISC
at O-MISC O-MISC
low O-MISC O-MISC
frequency O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
strongly O-MISC O-MISC
synergistic O-MISC O-MISC
with O-MISC O-MISC
Myc B-MISC B-MISC
. O-MISC O-MISC

To O-MISC O-MISC
gain O-MISC O-MISC
further O-MISC O-MISC
insight O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
relationship O-MISC O-MISC
of O-MISC O-MISC
Runx2 B-MISC B-MISC
to O-MISC O-MISC
other O-MISC O-MISC
lymphomagenic O-MISC O-MISC
pathways O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
tested O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
combining O-MISC O-MISC
the O-MISC O-MISC
CD2 B-MISC B-MISC
- I-MISC I-MISC
Runx2 I-MISC I-MISC
transgene I-MISC I-MISC
either O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
Pim1 B-MISC B-MISC
transgene I-MISC I-MISC
( O-MISC O-MISC
E B-MISC B-MISC
( I-MISC I-MISC
mu I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
Pim1 I-MISC I-MISC
) O-MISC O-MISC
or O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
p53 B-MISC B-MISC
null O-MISC O-MISC
genotype O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
each O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
displays O-MISC O-MISC
independent O-MISC O-MISC
synergy O-MISC O-MISC
with O-MISC O-MISC
Myc B-MISC B-MISC
. O-MISC O-MISC

In O-MISC O-MISC
both O-MISC O-MISC
cases O-MISC O-MISC
we O-MISC O-MISC
observed O-MISC O-MISC
synergistic O-MISC O-MISC
tumour O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
Runx2 B-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
dominant O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
tumour O-MISC O-MISC
phenotype O-MISC O-MISC
in O-MISC O-MISC
each O-MISC O-MISC
case O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
most O-MISC O-MISC
tumours O-MISC O-MISC
conforming O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
CD3 O-MISC B-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
phenotype O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
CD2 O-MISC O-MISC
- O-MISC O-MISC
Runx2 O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Neonatal O-MISC O-MISC
infection O-MISC O-MISC
of O-MISC O-MISC
CD2 O-MISC B-MISC
- O-MISC I-MISC
Runx2 O-MISC I-MISC
mice O-MISC O-MISC
with O-MISC O-MISC
Moloney O-MISC O-MISC
murine O-MISC O-MISC
leukaemia O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
Moloney O-MISC O-MISC
MLV O-MISC O-MISC
) O-MISC O-MISC
also O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
dramatic O-MISC O-MISC
acceleration O-MISC O-MISC
of O-MISC O-MISC
tumour O-MISC O-MISC
onset O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
known O-MISC O-MISC
Moloney B-MISC O-MISC
MLV I-MISC B-MISC
target I-MISC I-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
these O-MISC O-MISC
lymphomas O-MISC O-MISC
showed O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
frequency O-MISC O-MISC
of O-MISC O-MISC
rearrangement O-MISC O-MISC
at O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Myc I-MISC I-MISC
or O-MISC O-MISC
N B-MISC B-MISC
- I-MISC I-MISC
Myc I-MISC I-MISC
( O-MISC O-MISC
82 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
number O-MISC O-MISC
at O-MISC O-MISC
Pim1 B-MISC O-MISC
or O-MISC O-MISC
Pim2 B-MISC O-MISC
( O-MISC O-MISC
23 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
at O-MISC O-MISC
Pal1 B-MISC B-MISC
/ I-MISC O-MISC
Gfi1 I-MISC O-MISC
( O-MISC O-MISC
18 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
Runx2 B-MISC B-MISC
makes O-MISC O-MISC
a O-MISC O-MISC
distinct O-MISC O-MISC
contribution O-MISC O-MISC
to O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphoma O-MISC O-MISC
development O-MISC O-MISC
which O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
coincide O-MISC O-MISC
with O-MISC O-MISC
any O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
oncogene O-MISC B-MISC
complementation O-MISC O-MISC
groups O-MISC O-MISC
previously O-MISC O-MISC
identified O-MISC O-MISC
by O-MISC O-MISC
retroviral O-MISC O-MISC
tagging O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
related O-MISC I-MISC
apoptosis O-MISC O-MISC
- O-MISC O-MISC
inducing O-MISC O-MISC
ligand O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
enhanced O-MISC O-MISC
cytotoxicity O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC O-MISC
beta I-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
human O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC I-MISC
related O-MISC I-MISC
apoptosis O-MISC O-MISC
- O-MISC O-MISC
inducing O-MISC I-MISC
ligand O-MISC I-MISC
( O-MISC O-MISC
TRAIL O-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
its O-MISC O-MISC
preferential O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
of O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
normal O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Dendritic O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
DCs O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
besides O-MISC O-MISC
their O-MISC O-MISC
role O-MISC O-MISC
as O-MISC O-MISC
APCs O-MISC O-MISC
, O-MISC O-MISC
now O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
demonstrated O-MISC O-MISC
to O-MISC O-MISC
exert O-MISC O-MISC
cytotoxicity O-MISC O-MISC
or O-MISC O-MISC
cytostasis O-MISC O-MISC
on O-MISC O-MISC
some O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
that O-MISC O-MISC
both O-MISC O-MISC
human O-MISC O-MISC
CD34 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
stem O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
DCs O-MISC O-MISC
( O-MISC O-MISC
CD34DCs O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
human O-MISC O-MISC
CD14 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
monocyte O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
DCs O-MISC O-MISC
( O-MISC O-MISC
MoDCs O-MISC O-MISC
) O-MISC O-MISC
express O-MISC O-MISC
TRAIL O-MISC B-MISC
and O-MISC O-MISC
exhibit O-MISC O-MISC
cytotoxicity O-MISC O-MISC
to O-MISC O-MISC
some O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
partially O-MISC O-MISC
through O-MISC O-MISC
TRAIL O-MISC B-MISC
. O-MISC O-MISC

Moderate O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
TRAIL O-MISC B-MISC
appeared O-MISC O-MISC
on O-MISC O-MISC
CD34DCs O-MISC B-MISC
from O-MISC O-MISC
the O-MISC O-MISC
8th O-MISC O-MISC
day O-MISC O-MISC
of O-MISC O-MISC
culture O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
seen O-MISC O-MISC
on O-MISC O-MISC
freshly O-MISC O-MISC
isolated O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
TRAIL O-MISC B-MISC
expression O-MISC O-MISC
remained O-MISC O-MISC
constant O-MISC O-MISC
until O-MISC O-MISC
DC O-MISC O-MISC
maturation O-MISC O-MISC
. O-MISC O-MISC

TRAIL O-MISC B-MISC
expression O-MISC O-MISC
on O-MISC O-MISC
immature O-MISC O-MISC
CD34DCs O-MISC B-MISC
or O-MISC O-MISC
MoDCs O-MISC O-MISC
was O-MISC O-MISC
greatly O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
after O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
could O-MISC O-MISC
strikingly O-MISC O-MISC
enhance O-MISC I-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
CD34DCs O-MISC B-MISC
or O-MISC O-MISC
MoDCs O-MISC O-MISC
to O-MISC O-MISC
kill O-MISC O-MISC
TRAIL O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
LPS O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
have O-MISC O-MISC
such O-MISC O-MISC
an O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
TRAIL O-MISC B-MISC
on O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
DCs O-MISC O-MISC
partially O-MISC O-MISC
contributed O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
increased O-MISC O-MISC
cytotoxicity O-MISC O-MISC
of O-MISC O-MISC
DCS O-MISC O-MISC
: O-MISC O-MISC
Pretreatment O-MISC O-MISC
of O-MISC O-MISC
TRAIL O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
caspase O-MISC B-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
inhibitor O-MISC O-MISC
could O-MISC O-MISC
significantly O-MISC O-MISC
increase O-MISC O-MISC
their O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
cytotoxicity O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC O-MISC
beta I-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
DCS O-MISC O-MISC
: O-MISC O-MISC
In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
inhibitor O-MISC O-MISC
could O-MISC O-MISC
significantly O-MISC O-MISC
increase O-MISC O-MISC
the O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
killing O-MISC O-MISC
by O-MISC O-MISC
nonstimulated O-MISC O-MISC
or O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
DCS O-MISC O-MISC
: O-MISC O-MISC
Our O-MISC O-MISC
studies O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC O-MISC
beta I-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
DCs O-MISC O-MISC
are O-MISC O-MISC
functionally O-MISC O-MISC
cytotoxic O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
innate O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
DC O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
antitumor O-MISC O-MISC
immunity O-MISC O-MISC
might O-MISC O-MISC
exist O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
DCs O-MISC O-MISC
act O-MISC O-MISC
as O-MISC O-MISC
effectors O-MISC O-MISC
to O-MISC O-MISC
directly O-MISC O-MISC
kill O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
partially O-MISC O-MISC
via O-MISC O-MISC
TRAIL O-MISC B-MISC
. O-MISC O-MISC

Subsequently O-MISC O-MISC
, O-MISC O-MISC
DCs O-MISC O-MISC
act O-MISC O-MISC
as O-MISC O-MISC
APCs O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
uptake O-MISC O-MISC
, O-MISC O-MISC
processing O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
presentation O-MISC O-MISC
of O-MISC O-MISC
apoptotic B-MISC O-MISC
tumor I-MISC O-MISC
Ags I-MISC O-MISC
to O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
prime O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
CTL O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Tumor O-MISC O-MISC
cells O-MISC O-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
lytic O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
tumor O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
cytotoxic O-MISC O-MISC
t O-MISC O-MISC
lymphocytes O-MISC O-MISC
by O-MISC O-MISC
modulating O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
natural O-MISC B-MISC
killer O-MISC I-MISC
receptor O-MISC I-MISC
function O-MISC O-MISC
. O-MISC O-MISC

Tumor O-MISC B-MISC
- O-MISC O-MISC
infiltrating O-MISC O-MISC
p58 O-MISC B-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
renal O-MISC O-MISC
tumor O-MISC O-MISC
were O-MISC O-MISC
specifically O-MISC O-MISC
expanded O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
tumor O-MISC O-MISC
cell O-MISC O-MISC
stimulation O-MISC O-MISC
and O-MISC O-MISC
cloned O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
p58 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
express O-MISC O-MISC
a O-MISC O-MISC
memory O-MISC O-MISC
phenotype O-MISC O-MISC
and O-MISC O-MISC
corresponded O-MISC O-MISC
to O-MISC O-MISC
clonal O-MISC O-MISC
TCRBV3 O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
expansion O-MISC O-MISC
. O-MISC O-MISC

Functionally O-MISC O-MISC
, O-MISC O-MISC
p58 O-MISC B-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
CTLs O-MISC O-MISC
displayed O-MISC O-MISC
a O-MISC O-MISC
low O-MISC O-MISC
lytic O-MISC O-MISC
activity O-MISC O-MISC
for O-MISC O-MISC
HLA O-MISC B-MISC
- O-MISC O-MISC
A2 O-MISC O-MISC
tumor O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
this O-MISC O-MISC
lytic O-MISC O-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
increased O-MISC O-MISC
after O-MISC O-MISC
blockade O-MISC O-MISC
of O-MISC O-MISC
p58 B-MISC B-MISC
with O-MISC O-MISC
specific O-MISC O-MISC
monoclonal B-MISC B-MISC
antibodies I-MISC I-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
stimulation O-MISC O-MISC
by O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
required O-MISC O-MISC
to O-MISC O-MISC
trigger O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
p58 B-MISC B-MISC
on O-MISC O-MISC
the O-MISC O-MISC
lytic O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CTLs O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
p58 B-MISC O-MISC
by O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
nuclear O-MISC B-MISC
factor O-MISC I-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
p58 O-MISC O-MISC
+ O-MISC O-MISC
tumor O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CTLS O-MISC O-MISC
. O-MISC O-MISC

T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
during O-MISC O-MISC
human O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
circulating O-MISC O-MISC
CD56 B-MISC O-MISC
( I-MISC O-MISC
+ I-MISC O-MISC
) I-MISC O-MISC
bright O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Transcription B-MISC B-MISC
factors I-MISC I-MISC
are O-MISC O-MISC
essential O-MISC O-MISC
to O-MISC O-MISC
govern O-MISC O-MISC
differentiation O-MISC O-MISC
along O-MISC O-MISC
the O-MISC O-MISC
lymphoid O-MISC O-MISC
lineage O-MISC O-MISC
from O-MISC O-MISC
uncommitted O-MISC O-MISC
hematopoietic O-MISC O-MISC
stem O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
many O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
have O-MISC O-MISC
putative O-MISC O-MISC
roles O-MISC O-MISC
based O-MISC O-MISC
on O-MISC O-MISC
murine O-MISC O-MISC
knockout O-MISC O-MISC
experiments O-MISC O-MISC
, O-MISC O-MISC
their O-MISC O-MISC
function O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
development O-MISC O-MISC
is O-MISC O-MISC
less O-MISC O-MISC
known O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
studied O-MISC O-MISC
further O-MISC O-MISC
. O-MISC O-MISC

Transcription O-MISC B-MISC
factor O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
fresh O-MISC O-MISC
and O-MISC O-MISC
cultured O-MISC O-MISC
adult O-MISC O-MISC
human O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
and O-MISC O-MISC
umbilical O-MISC O-MISC
cord O-MISC O-MISC
blood O-MISC O-MISC
progenitors O-MISC O-MISC
was O-MISC O-MISC
evaluated O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
fresh O-MISC O-MISC
CD34 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
Lin O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
human O-MISC O-MISC
leukocyte O-MISC I-MISC
antigen O-MISC I-MISC
( O-MISC O-MISC
HLA O-MISC B-MISC
) O-MISC O-MISC
- O-MISC I-MISC
DR O-MISC I-MISC
( O-MISC O-MISC
- O-MISC I-MISC
) O-MISC O-MISC
or O-MISC O-MISC
CD38 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
constitutively O-MISC O-MISC
express O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
or O-MISC O-MISC
Id B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
. O-MISC O-MISC

Culture O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
murine O-MISC O-MISC
fetal O-MISC O-MISC
liver O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
AFT024 O-MISC O-MISC
and O-MISC O-MISC
defined O-MISC O-MISC
cytokines B-MISC B-MISC
was O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
inducing O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
no O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
gene I-MISC I-MISC
rearrangement O-MISC I-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
cultured O-MISC O-MISC
progeny O-MISC O-MISC
. O-MISC O-MISC

Id B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
basic B-MISC B-MISC
helix I-MISC B-MISC
loop I-MISC I-MISC
helix I-MISC I-MISC
factor I-MISC I-MISC
with O-MISC O-MISC
dominant O-MISC O-MISC
negative O-MISC O-MISC
function O-MISC O-MISC
for O-MISC O-MISC
T O-MISC B-MISC
- O-MISC I-MISC
cell O-MISC I-MISC
differentiation O-MISC I-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
, O-MISC O-MISC
also O-MISC O-MISC
was O-MISC O-MISC
upregulated O-MISC O-MISC
and O-MISC O-MISC
may O-MISC O-MISC
explain O-MISC O-MISC
unsuccessful O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
maturation O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
better O-MISC O-MISC
understand O-MISC O-MISC
the O-MISC O-MISC
developmental O-MISC O-MISC
link O-MISC O-MISC
between O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
( O-MISC O-MISC
NK O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
progenitors O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
studied O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
subsets O-MISC O-MISC
circulating O-MISC O-MISC
in O-MISC O-MISC
blood O-MISC O-MISC
. O-MISC O-MISC

CD56 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
bright O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
CD56 O-MISC B-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
dim O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
constitutively O-MISC O-MISC
express O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
by O-MISC O-MISC
reverse O-MISC B-MISC
transcriptase O-MISC I-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
and O-MISC O-MISC
Western O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
isoform I-MISC I-MISC
found O-MISC O-MISC
in O-MISC O-MISC
CD56 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
bright O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
express O-MISC O-MISC
lectin B-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
immunoglobulin B-MISC B-MISC
class I-MISC I-MISC
I I-MISC I-MISC
recognizing O-MISC I-MISC
inhibitory B-MISC I-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
was O-MISC O-MISC
identical O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
induced O-MISC O-MISC
in O-MISC O-MISC
NK O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
culture O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
distinctly O-MISC O-MISC
different O-MISC O-MISC
from O-MISC O-MISC
isoforms O-MISC B-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
does O-MISC O-MISC
not O-MISC O-MISC
target O-MISC O-MISC
human B-MISC B-MISC
killer I-MISC I-MISC
immunoglobulin I-MISC I-MISC
receptor I-MISC I-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
uniquely O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
circulating O-MISC O-MISC
CD56 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
bright O-MISC O-MISC
) O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
specific O-MISC O-MISC
TCF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
isoforms I-MISC I-MISC
may O-MISC O-MISC
play O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
regulating O-MISC O-MISC
NK O-MISC O-MISC
differentiation O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
common O-MISC O-MISC
NK O-MISC O-MISC
/ O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
progenitor O-MISC O-MISC
. O-MISC O-MISC

Transcriptional O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
matrix B-MISC O-MISC
associating I-MISC O-MISC
region I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

contextual O-MISC O-MISC
requirements O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
bright B-MISC O-MISC
. O-MISC O-MISC

Bright B-MISC O-MISC
( O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
regulator I-MISC I-MISC
of I-MISC O-MISC
IgH I-MISC B-MISC
transcription I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
, O-MISC O-MISC
matrix B-MISC O-MISC
associating I-MISC I-MISC
region I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
that O-MISC O-MISC
transactivates O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
IgH B-MISC B-MISC
intronic I-MISC I-MISC
enhancer I-MISC I-MISC
( O-MISC O-MISC
E B-MISC B-MISC
mu I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
Bright B-MISC O-MISC
has O-MISC O-MISC
multiple O-MISC O-MISC
contextual O-MISC O-MISC
requirements O-MISC O-MISC
to O-MISC O-MISC
function O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
transcriptional B-MISC B-MISC
activator I-MISC I-MISC
. O-MISC O-MISC

Bright B-MISC O-MISC
can O-MISC O-MISC
not O-MISC O-MISC
transactivate O-MISC O-MISC
via O-MISC O-MISC
out O-MISC O-MISC
of O-MISC O-MISC
context O-MISC O-MISC
, O-MISC O-MISC
concatenated B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

Transactivation O-MISC O-MISC
is O-MISC O-MISC
maximal O-MISC O-MISC
on O-MISC O-MISC
integrated O-MISC O-MISC
substrates O-MISC O-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
three O-MISC O-MISC
previously O-MISC O-MISC
identified O-MISC O-MISC
binding B-MISC B-MISC
sites I-MISC I-MISC
in O-MISC O-MISC
E B-MISC B-MISC
mu I-MISC I-MISC
are O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
full O-MISC O-MISC
Bright B-MISC O-MISC
transactivation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Bright B-MISC B-MISC
DNA I-MISC I-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
defined O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
family O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
includes O-MISC O-MISC
SWI1 B-MISC B-MISC
, O-MISC O-MISC
a O-MISC O-MISC
component O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
SWI B-MISC B-MISC
. I-MISC O-MISC
SNF I-MISC B-MISC
complex I-MISC I-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
high O-MISC O-MISC
mobility O-MISC O-MISC
group O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
characteristics O-MISC O-MISC
. O-MISC O-MISC

Similar O-MISC O-MISC
to O-MISC O-MISC
one O-MISC O-MISC
group O-MISC O-MISC
of O-MISC O-MISC
high B-MISC B-MISC
mobility I-MISC I-MISC
group I-MISC I-MISC
box I-MISC I-MISC
proteins I-MISC I-MISC
, O-MISC O-MISC
Bright B-MISC O-MISC
distorts O-MISC I-MISC
E B-MISC B-MISC
mu I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
- O-MISC O-MISC
containing O-MISC O-MISC
DNA O-MISC O-MISC
on O-MISC O-MISC
binding O-MISC O-MISC
, O-MISC O-MISC
supporting O-MISC O-MISC
the O-MISC O-MISC
concept O-MISC O-MISC
that O-MISC O-MISC
it O-MISC O-MISC
mediates O-MISC O-MISC
E B-MISC B-MISC
mu I-MISC I-MISC
remodeling O-MISC O-MISC
. O-MISC O-MISC

Transfection O-MISC O-MISC
studies O-MISC O-MISC
further O-MISC O-MISC
implicate O-MISC O-MISC
Bright B-MISC O-MISC
in O-MISC O-MISC
facilitating O-MISC O-MISC
spatially O-MISC O-MISC
separated O-MISC O-MISC
promoter O-MISC B-MISC
- O-MISC I-MISC
enhancer O-MISC I-MISC
interactions O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
transient O-MISC O-MISC
and O-MISC O-MISC
stable O-MISC O-MISC
assays O-MISC O-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
Bright B-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
enhanced O-MISC O-MISC
DNase O-MISC B-MISC
I O-MISC I-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
endogenous O-MISC O-MISC
E B-MISC I-MISC
mu I-MISC I-MISC
matrix O-MISC I-MISC
associating O-MISC I-MISC
regions O-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
further O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
Bright B-MISC O-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
increased O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
remodeling O-MISC O-MISC
the O-MISC O-MISC
immunoglobulin B-MISC B-MISC
locus I-MISC I-MISC
during O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
BCL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
mutations O-MISC O-MISC
in O-MISC O-MISC
classic O-MISC O-MISC
Hodgkin O-MISC O-MISC
disease O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
. O-MISC O-MISC

BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
germinal O-MISC O-MISC
center O-MISC O-MISC
formation O-MISC O-MISC
and O-MISC O-MISC
thus O-MISC O-MISC
for O-MISC O-MISC
affinity O-MISC O-MISC
maturation O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
( I-MISC I-MISC
Ig I-MISC I-MISC
) I-MISC I-MISC
genes I-MISC I-MISC
by O-MISC O-MISC
somatic O-MISC O-MISC
mutations O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
- I-MISC I-MISC
noncoding I-MISC I-MISC
region I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
gene I-MISC I-MISC
is O-MISC O-MISC
even O-MISC O-MISC
a O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
mutation O-MISC O-MISC
machinery O-MISC O-MISC
. O-MISC O-MISC

Translocations O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
gene I-MISC I-MISC
to O-MISC I-MISC
heterologous B-MISC B-MISC
promoters I-MISC I-MISC
and O-MISC O-MISC
mutations O-MISC O-MISC
of O-MISC O-MISC
its O-MISC O-MISC
5 B-MISC O-MISC
' I-MISC I-MISC
- I-MISC I-MISC
noncoding I-MISC I-MISC
regulatory I-MISC I-MISC
region I-MISC I-MISC
were O-MISC O-MISC
reported O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
potential O-MISC O-MISC
mechanisms O-MISC O-MISC
for O-MISC O-MISC
deregulating O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
for O-MISC O-MISC
playing O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
genesis O-MISC O-MISC
of O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
Hodgkin O-MISC O-MISC
lymphoma O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
line O-MISC O-MISC
with O-MISC O-MISC
this O-MISC O-MISC
hypothesis O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
observation O-MISC O-MISC
that O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphoma O-MISC O-MISC
with O-MISC O-MISC
somatic O-MISC O-MISC
mutations O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
diffuse O-MISC O-MISC
large O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lymphoma O-MISC O-MISC
and O-MISC O-MISC
follicular O-MISC O-MISC
lymphoma O-MISC O-MISC
, O-MISC O-MISC
also O-MISC O-MISC
carry O-MISC O-MISC
BCL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
mutations O-MISC O-MISC
, O-MISC O-MISC
some O-MISC O-MISC
of O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
recurrently O-MISC O-MISC
detectable O-MISC O-MISC
. O-MISC O-MISC

Classic O-MISC O-MISC
Hodgkin O-MISC O-MISC
disease O-MISC O-MISC
( O-MISC O-MISC
cHD O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
loads O-MISC O-MISC
of O-MISC O-MISC
somatic O-MISC O-MISC
mutations O-MISC O-MISC
and O-MISC O-MISC
thus O-MISC O-MISC
a O-MISC O-MISC
further O-MISC O-MISC
candidate O-MISC O-MISC
for O-MISC O-MISC
BCL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
mutations O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
and O-MISC O-MISC
potential O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
BCL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
mutations O-MISC O-MISC
in O-MISC O-MISC
cHD O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC O-MISC
' I-MISC O-MISC
- I-MISC O-MISC
noncoding I-MISC O-MISC
BCL I-MISC O-MISC
- I-MISC O-MISC
6 I-MISC O-MISC
proportion O-MISC O-MISC
of O-MISC O-MISC
single O-MISC O-MISC
Hodgkin O-MISC O-MISC
and O-MISC O-MISC
Reed O-MISC O-MISC
- O-MISC O-MISC
Sternberg O-MISC O-MISC
( O-MISC O-MISC
HRS O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
6 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
cHD O-MISC O-MISC
and O-MISC O-MISC
6 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
HD O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
was O-MISC O-MISC
analyzed O-MISC O-MISC
. O-MISC O-MISC

All O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
HD O-MISC O-MISC
cases O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
harbored O-MISC O-MISC
BCL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
mutations O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
both O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
HD O-MISC O-MISC
cases O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
were O-MISC O-MISC
devoid O-MISC O-MISC
of O-MISC O-MISC
BCL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
mutations O-MISC O-MISC
. O-MISC O-MISC

With O-MISC O-MISC
only O-MISC O-MISC
one O-MISC O-MISC
exception O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
were O-MISC O-MISC
no O-MISC O-MISC
lymphoma O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
recurrent O-MISC O-MISC
BCL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
mutations O-MISC O-MISC
detected O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
protein I-MISC O-MISC
was O-MISC O-MISC
absent O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
HRS O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
most O-MISC O-MISC
cases O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
conclusion O-MISC O-MISC
, O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
somatic O-MISC O-MISC
BCL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
mutations O-MISC O-MISC
are O-MISC O-MISC
restricted O-MISC O-MISC
to O-MISC O-MISC
cHD O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
origin O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC I-MISC
) O-MISC O-MISC
the O-MISC O-MISC
BCL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
mutations O-MISC O-MISC
represent O-MISC O-MISC
mostly O-MISC O-MISC
irrelevant O-MISC O-MISC
somatic O-MISC O-MISC
base O-MISC O-MISC
substitutions O-MISC O-MISC
without O-MISC O-MISC
consequences O-MISC O-MISC
for O-MISC O-MISC
BCL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
protein I-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
cHD O-MISC O-MISC
. O-MISC O-MISC

Gadd45gamma B-MISC B-MISC
is O-MISC O-MISC
dispensable O-MISC O-MISC
for O-MISC O-MISC
normal O-MISC O-MISC
mouse O-MISC O-MISC
development O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Gadd45gamma B-MISC B-MISC
, O-MISC O-MISC
a O-MISC O-MISC
family O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
growth B-MISC O-MISC
arrest I-MISC I-MISC
and I-MISC O-MISC
DNA I-MISC B-MISC
damage I-MISC I-MISC
- I-MISC I-MISC
inducible I-MISC I-MISC
gene I-MISC I-MISC
family I-MISC I-MISC
45 I-MISC I-MISC
( O-MISC O-MISC
Gadd45 B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
strongly O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

While O-MISC O-MISC
in O-MISC O-MISC
most O-MISC O-MISC
tissues O-MISC O-MISC
all O-MISC O-MISC
Gadd45 B-MISC B-MISC
family I-MISC I-MISC
members I-MISC I-MISC
are O-MISC O-MISC
expressed O-MISC O-MISC
, O-MISC O-MISC
Gadd45gamma B-MISC B-MISC
is O-MISC O-MISC
the O-MISC O-MISC
only O-MISC O-MISC
member O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Gadd45gamma B-MISC B-MISC
is O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
a O-MISC O-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
tyrosine B-MISC B-MISC
kinase I-MISC I-MISC
Jak3 I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
Stat5a B-MISC B-MISC
and O-MISC O-MISC
Stat5b B-MISC B-MISC
( O-MISC O-MISC
signal B-MISC B-MISC
transducer I-MISC I-MISC
and I-MISC O-MISC
activator I-MISC O-MISC
of I-MISC O-MISC
transcription I-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Previous O-MISC O-MISC
studies O-MISC O-MISC
with O-MISC O-MISC
ectopically O-MISC O-MISC
overexpressed O-MISC O-MISC
Gadd45gamma B-MISC B-MISC
in O-MISC O-MISC
various O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
implicated O-MISC O-MISC
its O-MISC O-MISC
function O-MISC O-MISC
in O-MISC O-MISC
negative O-MISC O-MISC
growth O-MISC O-MISC
control O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
analyze O-MISC O-MISC
the O-MISC O-MISC
physiological O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
Gadd45gamma B-MISC B-MISC
we O-MISC O-MISC
used O-MISC O-MISC
homologous O-MISC O-MISC
recombination O-MISC O-MISC
to O-MISC O-MISC
generate O-MISC O-MISC
mice O-MISC O-MISC
lacking O-MISC O-MISC
Gadd45gamma B-MISC B-MISC
. O-MISC O-MISC

Gadd45gamma B-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mice O-MISC O-MISC
develop O-MISC O-MISC
normally O-MISC O-MISC
, O-MISC O-MISC
are O-MISC O-MISC
indistinguishable O-MISC O-MISC
from O-MISC O-MISC
their O-MISC O-MISC
littermates O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
fertile O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
hematopoiesis O-MISC O-MISC
in O-MISC O-MISC
mice O-MISC O-MISC
lacking O-MISC O-MISC
Gadd45gamma B-MISC B-MISC
is O-MISC O-MISC
not O-MISC O-MISC
impaired O-MISC O-MISC
and O-MISC O-MISC
Gadd45gamma B-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
show O-MISC O-MISC
normal O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
Gadd45gamma B-MISC B-MISC
is O-MISC O-MISC
not O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
normal O-MISC O-MISC
mouse O-MISC O-MISC
development O-MISC O-MISC
and O-MISC O-MISC
hematopoiesis O-MISC O-MISC
, O-MISC O-MISC
possibly O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
functional O-MISC O-MISC
redundancy O-MISC O-MISC
among O-MISC O-MISC
the O-MISC O-MISC
Gadd45 B-MISC B-MISC
family I-MISC I-MISC
members I-MISC O-MISC
. O-MISC O-MISC

Gadd45gamma B-MISC B-MISC
is O-MISC O-MISC
also O-MISC O-MISC
dispensable O-MISC O-MISC
for O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Decreased O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
myc I-MISC I-MISC
family I-MISC I-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
thymuses O-MISC O-MISC
from O-MISC O-MISC
myasthenia O-MISC O-MISC
gravis O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
thymus O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
organ O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
elimination O-MISC O-MISC
of O-MISC O-MISC
autoreactive O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
studied O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
- O-MISC I-MISC
associated O-MISC I-MISC
genes O-MISC I-MISC
, O-MISC O-MISC
bcl B-MISC B-MISC
- I-MISC I-MISC
xL I-MISC I-MISC
, O-MISC O-MISC
bad B-MISC B-MISC
, O-MISC O-MISC
caspase B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
myc I-MISC I-MISC
family I-MISC I-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
myasthenia O-MISC O-MISC
gravis O-MISC I-MISC
( O-MISC O-MISC
MG O-MISC O-MISC
) O-MISC O-MISC
thymuses O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
observed O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
mRNA O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
myc B-MISC B-MISC
family I-MISC I-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
myc I-MISC I-MISC
and O-MISC O-MISC
max B-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
markedly O-MISC O-MISC
reduced O-MISC O-MISC
in O-MISC O-MISC
MG O-MISC O-MISC
thymuses O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
myc I-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
signaling O-MISC O-MISC
is O-MISC O-MISC
abnormal O-MISC O-MISC
in O-MISC O-MISC
MG O-MISC O-MISC
thymuses O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
molecules O-MISC O-MISC
whose O-MISC O-MISC
expressions O-MISC O-MISC
are O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
myc B-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
STAM B-MISC B-MISC
, O-MISC O-MISC
prothymosin B-MISC O-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
NFkappaB B-MISC B-MISC

Immunohistochemical O-MISC O-MISC
detection O-MISC O-MISC
of O-MISC O-MISC
interferon O-MISC B-MISC
- O-MISC O-MISC
gamma O-MISC O-MISC
- O-MISC O-MISC
producing O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
dermatophytosis O-MISC O-MISC
. O-MISC O-MISC

Skin O-MISC O-MISC
lesions O-MISC O-MISC
of O-MISC O-MISC
dermatophytosis O-MISC O-MISC
are O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
result O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
various O-MISC O-MISC
cytokines B-MISC B-MISC
. O-MISC O-MISC

We O-MISC O-MISC
examined O-MISC O-MISC
whether O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
as O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Th1 O-MISC B-MISC
response O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
skin O-MISC O-MISC
lesions O-MISC O-MISC
of O-MISC O-MISC
dermatophytosis O-MISC O-MISC
in O-MISC O-MISC
situ O-MISC O-MISC
by O-MISC O-MISC
immunohistochemical O-MISC O-MISC
techniques O-MISC O-MISC
. O-MISC O-MISC

Mixtures O-MISC O-MISC
of O-MISC O-MISC
CD4 O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
dermal O-MISC O-MISC
infiltrates O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
lesions O-MISC O-MISC
. O-MISC O-MISC

Considerable O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
CD1a O-MISC B-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
upper O-MISC O-MISC
dermis O-MISC O-MISC
and O-MISC O-MISC
epidermis O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
marked O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
CD68 O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
upper O-MISC O-MISC
dermis O-MISC O-MISC
. O-MISC O-MISC

IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
upper O-MISC O-MISC
dermis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
lesions O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
pattern O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
staining O-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
intracellular O-MISC O-MISC
in O-MISC O-MISC
mononuclear O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
staining O-MISC O-MISC
was O-MISC O-MISC
considered O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
highly O-MISC O-MISC
specific O-MISC O-MISC
because O-MISC O-MISC
it O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
completely O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
preabsorption O-MISC O-MISC
with O-MISC O-MISC
recombinant B-MISC O-MISC
IFN I-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
data O-MISC O-MISC
support O-MISC O-MISC
the O-MISC O-MISC
hypothesis O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
skin O-MISC O-MISC
lesions O-MISC O-MISC
of O-MISC O-MISC
dermatophytosis O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
Th1 O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Th1 O-MISC O-MISC
response O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
release O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
host O-MISC O-MISC
defense O-MISC O-MISC
against O-MISC O-MISC
dermatophytes O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
reflect O-MISC O-MISC
cutaneous O-MISC O-MISC
reaction O-MISC O-MISC
in O-MISC O-MISC
dermatophytosis O-MISC O-MISC
. O-MISC O-MISC

Regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
helix B-MISC B-MISC
- I-MISC I-MISC
loop I-MISC I-MISC
- I-MISC I-MISC
helix I-MISC I-MISC
proteins I-MISC I-MISC
, O-MISC O-MISC
E2A B-MISC B-MISC
and O-MISC O-MISC
Id3 B-MISC B-MISC
, O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
Ras B-MISC B-MISC
- O-MISC I-MISC
ERK B-MISC I-MISC
MAPK B-MISC B-MISC
cascade O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
mitogen B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
MAPK B-MISC B-MISC
) O-MISC O-MISC
pathways O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
cellular O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
proliferation O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
wide O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
developing O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
basic B-MISC B-MISC
helix I-MISC I-MISC
- I-MISC I-MISC
loop I-MISC I-MISC
- I-MISC I-MISC
helix I-MISC I-MISC
( I-MISC I-MISC
bHLH I-MISC I-MISC
) I-MISC I-MISC
proteins I-MISC I-MISC
E12 B-MISC B-MISC
and O-MISC O-MISC
E47 B-MISC B-MISC
and O-MISC O-MISC
an O-MISC O-MISC
inhibitor B-MISC O-MISC
HLH I-MISC B-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
Id3 B-MISC B-MISC
, O-MISC O-MISC
play O-MISC O-MISC
key O-MISC O-MISC
roles O-MISC O-MISC
in O-MISC O-MISC
thymocyte O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
E2A B-MISC B-MISC
DNA O-MISC I-MISC
binding O-MISC O-MISC
is O-MISC O-MISC
lowered O-MISC O-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
immature O-MISC O-MISC
thymocytes O-MISC O-MISC
consequent O-MISC O-MISC
to O-MISC O-MISC
T O-MISC B-MISC
cell O-MISC I-MISC
receptor O-MISC I-MISC
( O-MISC O-MISC
TCR O-MISC B-MISC
) O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
ligation O-MISC O-MISC
. O-MISC O-MISC

Whereas O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
E2A O-MISC B-MISC
mRNA O-MISC I-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
are O-MISC O-MISC
unaltered O-MISC O-MISC
, O-MISC O-MISC
Id3 B-MISC B-MISC
transcripts I-MISC I-MISC
are O-MISC O-MISC
rapidly O-MISC O-MISC
induced O-MISC O-MISC
upon O-MISC O-MISC
signaling O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
TCR B-MISC B-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
Id3 O-MISC B-MISC
transcription O-MISC O-MISC
is O-MISC O-MISC
regulated O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
extracellular O-MISC B-MISC
signal O-MISC I-MISC
- O-MISC I-MISC
regulated O-MISC I-MISC
kinase O-MISC I-MISC
( O-MISC O-MISC
ERK B-MISC B-MISC
) O-MISC O-MISC
MAPK B-MISC B-MISC
module O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
observations O-MISC O-MISC
directly O-MISC O-MISC
connect O-MISC O-MISC
the O-MISC O-MISC
ERK B-MISC B-MISC
MAPK B-MISC B-MISC
cascade O-MISC O-MISC
and O-MISC O-MISC
HLH B-MISC B-MISC
proteins I-MISC I-MISC
in O-MISC O-MISC
a O-MISC O-MISC
linear O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

Retinoic O-MISC O-MISC
acid O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulates O-MISC O-MISC
myeloid O-MISC B-MISC
ICAM O-MISC B-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
function O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
fashion O-MISC O-MISC
- O-MISC O-MISC
- O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
retinoid O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
mast O-MISC O-MISC
cell O-MISC O-MISC
lineage O-MISC O-MISC
. O-MISC O-MISC

Investigation O-MISC O-MISC
of O-MISC O-MISC
mast O-MISC O-MISC
cell O-MISC O-MISC
responsiveness O-MISC O-MISC
toward O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
RA O-MISC O-MISC
) O-MISC O-MISC
revealed O-MISC O-MISC
selective O-MISC O-MISC
promotion O-MISC O-MISC
of O-MISC O-MISC
ICAM B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
mast O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
HMC O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
process O-MISC O-MISC
was O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
time O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
and O-MISC O-MISC
detectable O-MISC O-MISC
by O-MISC O-MISC
flow O-MISC O-MISC
cytometry O-MISC O-MISC
, O-MISC O-MISC
Western O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
, O-MISC O-MISC
ELISA O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Northern O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

ICAM B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
modulation O-MISC I-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
dependent O-MISC O-MISC
, O-MISC O-MISC
detectable O-MISC O-MISC
also O-MISC O-MISC
for O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
monocytes O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
U O-MISC O-MISC
- O-MISC O-MISC
937 O-MISC O-MISC
and O-MISC O-MISC
only O-MISC O-MISC
weakly O-MISC O-MISC
for O-MISC O-MISC
KU812 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Terminally O-MISC O-MISC
differentiated O-MISC O-MISC
skin O-MISC O-MISC
mast O-MISC O-MISC
cells O-MISC O-MISC
also O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
modulate O-MISC O-MISC
their O-MISC O-MISC
ICAM B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
the O-MISC O-MISC
requirement O-MISC O-MISC
for O-MISC O-MISC
some O-MISC O-MISC
degree O-MISC O-MISC
of O-MISC O-MISC
immaturity O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

RA O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
ICAM B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
studied O-MISC O-MISC
in O-MISC O-MISC
parallel O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
clearly O-MISC O-MISC
distinct O-MISC O-MISC
from O-MISC O-MISC
those O-MISC O-MISC
on O-MISC O-MISC
ICAM B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
. O-MISC O-MISC

Investigation O-MISC O-MISC
of O-MISC O-MISC
retinoid B-MISC B-MISC
receptor I-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
mediate O-MISC O-MISC
intracellular O-MISC O-MISC
RA O-MISC O-MISC
signaling O-MISC O-MISC
, O-MISC O-MISC
revealed O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
RAR B-MISC B-MISC
alpha I-MISC I-MISC
, I-MISC O-MISC
RAR I-MISC B-MISC
gamma I-MISC I-MISC
, I-MISC O-MISC
RXR I-MISC B-MISC
beta I-MISC I-MISC
, I-MISC O-MISC
and I-MISC O-MISC
RXR I-MISC B-MISC
gamma I-MISC I-MISC
transcripts I-MISC I-MISC
in O-MISC O-MISC
all O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
studied O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
HMC O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
the O-MISC O-MISC
only O-MISC O-MISC
line O-MISC O-MISC
lacking O-MISC O-MISC
RXR B-MISC B-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

RAR B-MISC B-MISC
beta I-MISC I-MISC
, O-MISC O-MISC
not O-MISC O-MISC
expressed O-MISC O-MISC
at O-MISC O-MISC
baseline O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
RA O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
fashion O-MISC O-MISC
obviously O-MISC O-MISC
correlating O-MISC O-MISC
with O-MISC O-MISC
ICAM B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
. O-MISC O-MISC

Increased O-MISC O-MISC
ICAM B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
of O-MISC O-MISC
functional O-MISC O-MISC
significance O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
that O-MISC O-MISC
processes O-MISC O-MISC
stimulated O-MISC O-MISC
or O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
via O-MISC O-MISC
ICAM B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
( O-MISC O-MISC
homotypic O-MISC O-MISC
aggregation O-MISC O-MISC
, O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
8 O-MISC I-MISC
secretion O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
clearly O-MISC O-MISC
enhanced O-MISC O-MISC
upon O-MISC O-MISC
RA O-MISC O-MISC
pretreatment O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
RA O-MISC O-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
via O-MISC O-MISC
hitherto O-MISC O-MISC
unrecognized O-MISC O-MISC
pathways O-MISC O-MISC
to O-MISC O-MISC
immune O-MISC O-MISC
function O-MISC O-MISC
and O-MISC O-MISC
host O-MISC O-MISC
defense O-MISC O-MISC
. O-MISC O-MISC

CD28 B-MISC B-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Over O-MISC O-MISC
the O-MISC O-MISC
last O-MISC O-MISC
decade O-MISC O-MISC
the O-MISC O-MISC
concept O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
has O-MISC O-MISC
emerged O-MISC O-MISC
to O-MISC O-MISC
take O-MISC O-MISC
a O-MISC O-MISC
central O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
process O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
exact O-MISC O-MISC
definition O-MISC O-MISC
of O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
is O-MISC O-MISC
still O-MISC O-MISC
unclear O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
review O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
re O-MISC O-MISC
- O-MISC O-MISC
examine O-MISC O-MISC
the O-MISC O-MISC
concept O-MISC O-MISC
of O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
while O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
is O-MISC O-MISC
important O-MISC O-MISC
, O-MISC O-MISC
there O-MISC O-MISC
is O-MISC O-MISC
little O-MISC O-MISC
evidence O-MISC O-MISC
to O-MISC O-MISC
link O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
anergy O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
then O-MISC O-MISC
suggest O-MISC O-MISC
a O-MISC O-MISC
framework O-MISC O-MISC
for O-MISC O-MISC
studying O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Focusing O-MISC O-MISC
on O-MISC O-MISC
recent O-MISC O-MISC
advances O-MISC O-MISC
in O-MISC O-MISC
our O-MISC O-MISC
understanding O-MISC O-MISC
of O-MISC O-MISC
CD28 B-MISC B-MISC
, O-MISC O-MISC
we O-MISC O-MISC
discuss O-MISC O-MISC
four O-MISC O-MISC
areas O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
where O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
stimulation O-MISC O-MISC
may O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
. O-MISC O-MISC

Regulation O-MISC O-MISC
of O-MISC O-MISC
activator B-MISC B-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
in O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
peripheral B-MISC O-MISC
self I-MISC O-MISC
- I-MISC I-MISC
antigens I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcriptional O-MISC O-MISC
events O-MISC O-MISC
that O-MISC O-MISC
control O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
tolerance O-MISC O-MISC
to O-MISC O-MISC
peripheral B-MISC O-MISC
self I-MISC O-MISC
Ags I-MISC O-MISC
are O-MISC O-MISC
still O-MISC O-MISC
unknown O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- O-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
transcription O-MISC O-MISC
during O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
tolerance O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
self B-MISC B-MISC
Ag I-MISC I-MISC
expressed O-MISC O-MISC
exclusively O-MISC O-MISC
on O-MISC O-MISC
hepatocytes O-MISC O-MISC
. O-MISC O-MISC

Naive O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
Desire O-MISC O-MISC
( O-MISC O-MISC
Des O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
Des O-MISC O-MISC
TCR O-MISC B-MISC
- O-MISC O-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
H B-MISC B-MISC
- I-MISC I-MISC
2K I-MISC I-MISC
( I-MISC O-MISC
b I-MISC I-MISC
) I-MISC O-MISC
class I-MISC I-MISC
I I-MISC I-MISC
Ag I-MISC I-MISC
were O-MISC O-MISC
transferred O-MISC O-MISC
into O-MISC O-MISC
Alb O-MISC B-MISC
- O-MISC I-MISC
K O-MISC I-MISC
( O-MISC O-MISC
b O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
that O-MISC O-MISC
express O-MISC O-MISC
the O-MISC O-MISC
H B-MISC B-MISC
- I-MISC I-MISC
2K I-MISC I-MISC
( I-MISC O-MISC
b I-MISC I-MISC
) I-MISC O-MISC
Ag I-MISC B-MISC
on O-MISC O-MISC
hepatocytes O-MISC O-MISC
only O-MISC O-MISC
. O-MISC O-MISC

Tolerance O-MISC O-MISC
develops O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
self O-MISC O-MISC
- O-MISC O-MISC
reactive O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
Des O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
transiently O-MISC O-MISC
activated O-MISC O-MISC
, O-MISC O-MISC
then O-MISC O-MISC
became O-MISC O-MISC
unresponsive O-MISC O-MISC
and O-MISC O-MISC
were O-MISC O-MISC
further O-MISC O-MISC
deleted O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
Des O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
with O-MISC O-MISC
APCs O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
express O-MISC O-MISC
high O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
high O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
unresponsive O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
Des O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
expressed O-MISC O-MISC
no O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
only O-MISC O-MISC
weak O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
distinct O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
complexes I-MISC I-MISC
. O-MISC O-MISC

Indeed O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
primed O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
predominantly O-MISC O-MISC
express O-MISC O-MISC
p50 B-MISC B-MISC
/ I-MISC I-MISC
p50 I-MISC I-MISC
and I-MISC I-MISC
p65 I-MISC B-MISC
/ I-MISC I-MISC
p50 I-MISC I-MISC
dimers I-MISC I-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
these O-MISC O-MISC
p50 B-MISC B-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
complexes I-MISC I-MISC
are O-MISC O-MISC
barely O-MISC O-MISC
detectable O-MISC O-MISC
in O-MISC O-MISC
tolerant O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
express O-MISC O-MISC
p65 B-MISC B-MISC
- I-MISC I-MISC
and I-MISC I-MISC
c I-MISC I-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
complexes I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
observations O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
fine O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
complex I-MISC I-MISC
formation O-MISC O-MISC
may O-MISC O-MISC
determine O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
fate O-MISC O-MISC
. O-MISC O-MISC

Transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Lymphocytes O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
investigate O-MISC O-MISC
many O-MISC O-MISC
cellular O-MISC O-MISC
processes O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
lineage O-MISC O-MISC
commitment O-MISC O-MISC
, O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
that O-MISC O-MISC
mediate O-MISC O-MISC
these O-MISC O-MISC
processes O-MISC O-MISC
are O-MISC O-MISC
often O-MISC O-MISC
expressed O-MISC O-MISC
broadly O-MISC O-MISC
in O-MISC O-MISC
many O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
emerging O-MISC O-MISC
theme O-MISC O-MISC
is O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
regulation O-MISC O-MISC
, O-MISC O-MISC
affecting O-MISC O-MISC
not O-MISC O-MISC
only O-MISC O-MISC
the O-MISC O-MISC
functional O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
but O-MISC O-MISC
also O-MISC O-MISC
their O-MISC O-MISC
access O-MISC O-MISC
to O-MISC O-MISC
appropriate O-MISC O-MISC
regions O-MISC O-MISC
of O-MISC O-MISC
DNA O-MISC O-MISC
. O-MISC O-MISC

Existence O-MISC O-MISC
of O-MISC O-MISC
retinoic B-MISC B-MISC
acid I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
- O-MISC I-MISC
independent O-MISC I-MISC
retinoid B-MISC I-MISC
X I-MISC I-MISC
- I-MISC O-MISC
receptor I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
pathway O-MISC O-MISC
in O-MISC O-MISC
myeloid O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
previously O-MISC O-MISC
reported O-MISC O-MISC
that O-MISC O-MISC
ER O-MISC B-MISC
- O-MISC I-MISC
27191 O-MISC I-MISC
( O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
[ O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
, O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
8 O-MISC O-MISC
, O-MISC O-MISC
9 O-MISC O-MISC
, O-MISC O-MISC
10 O-MISC O-MISC
- O-MISC O-MISC
hexahydro O-MISC O-MISC
- O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
10 O-MISC O-MISC
, O-MISC O-MISC
10 O-MISC O-MISC
- O-MISC O-MISC
tetramethyl O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
pyridylmethyl O-MISC O-MISC
) O-MISC O-MISC
anthra O-MISC O-MISC
[ O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
b O-MISC O-MISC
] O-MISC O-MISC
pyrrol O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
yl O-MISC O-MISC
] O-MISC O-MISC
benzoic O-MISC O-MISC
acid O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
antagonist O-MISC O-MISC
of O-MISC O-MISC
retinoic B-MISC B-MISC
acid I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
RAR B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
ER O-MISC B-MISC
- O-MISC I-MISC
35795 O-MISC I-MISC
( O-MISC O-MISC
( O-MISC O-MISC
2E O-MISC O-MISC
, O-MISC O-MISC
4E O-MISC O-MISC
, O-MISC O-MISC
6E O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
7 O-MISC O-MISC
- O-MISC O-MISC
[ O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
methylethyl O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
- O-MISC O-MISC
chloro O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
tetrahydroquinolin O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
yl O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
fluoro O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
methyl O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
nonatrienoic O-MISC O-MISC
acid O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
retinoid B-MISC B-MISC
X I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
RXR B-MISC B-MISC
) O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
agonist O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
using O-MISC O-MISC
these O-MISC O-MISC
compounds O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
whether O-MISC O-MISC
distinct O-MISC O-MISC
RAR B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
and O-MISC O-MISC
RXR B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
pathways O-MISC O-MISC
operate O-MISC O-MISC
to O-MISC O-MISC
mediate O-MISC O-MISC
the O-MISC O-MISC
diverse O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
retinoids O-MISC O-MISC
, O-MISC O-MISC
particularly O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
RXR B-MISC B-MISC
pathway O-MISC O-MISC
on O-MISC O-MISC
cellular O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

ER O-MISC B-MISC
- O-MISC I-MISC
27191 O-MISC I-MISC
completely O-MISC O-MISC
antagonized O-MISC O-MISC
HL60 O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
all O-MISC O-MISC
- O-MISC O-MISC
trans O-MISC O-MISC
- O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
atRA O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
ER O-MISC B-MISC
- O-MISC I-MISC
35795 O-MISC I-MISC
was O-MISC O-MISC
not O-MISC O-MISC
antagonized O-MISC O-MISC
at O-MISC O-MISC
all O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
RAR B-MISC B-MISC
antagonist O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
RXR B-MISC B-MISC
homodimer I-MISC I-MISC
antagonist O-MISC O-MISC
( O-MISC O-MISC
LGD100754 O-MISC B-MISC
, O-MISC O-MISC
( O-MISC O-MISC
2E O-MISC O-MISC
, O-MISC O-MISC
4E O-MISC O-MISC
, O-MISC O-MISC
6Z O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
7 O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
n O-MISC O-MISC
- O-MISC O-MISC
propoxy O-MISC O-MISC
- O-MISC O-MISC
5 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
8 O-MISC O-MISC
- O-MISC O-MISC
tetrahydro O-MISC O-MISC
- O-MISC O-MISC
5 O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
, O-MISC O-MISC
8 O-MISC O-MISC
, O-MISC O-MISC
8 O-MISC O-MISC
- O-MISC O-MISC
tetramethylnaphthale O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
yl O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
methylocta O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
trienoic O-MISC O-MISC
acid O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Its O-MISC O-MISC
agonistic O-MISC O-MISC
action O-MISC O-MISC
on O-MISC O-MISC
RXR B-MISC B-MISC
/ I-MISC I-MISC
RAR I-MISC I-MISC
heterodimer I-MISC I-MISC
, O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
hand O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
neutralized O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
RAR B-MISC B-MISC
antagonist O-MISC O-MISC
. O-MISC O-MISC

During O-MISC O-MISC
HL60 O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
atRA O-MISC O-MISC
induced O-MISC O-MISC
RARbeta B-MISC B-MISC
mRNA I-MISC I-MISC
, O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
RXR B-MISC B-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
functional O-MISC O-MISC
RXR B-MISC B-MISC
- O-MISC O-MISC
pathway O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
mouse O-MISC O-MISC
splenocyte O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
strongly O-MISC O-MISC
suggest O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
pharmacological O-MISC O-MISC
RXR B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
pathway O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
ligand O-MISC O-MISC
that O-MISC O-MISC
can O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
RXR B-MISC B-MISC
. O-MISC O-MISC

Targeting O-MISC O-MISC
Src B-MISC B-MISC
homology I-MISC I-MISC
2 I-MISC I-MISC
domain I-MISC I-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
tyrosine I-MISC I-MISC
phosphatase I-MISC I-MISC
( O-MISC O-MISC
SHP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
into O-MISC O-MISC
lipid O-MISC O-MISC
rafts O-MISC O-MISC
inhibits O-MISC O-MISC
CD3 B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
study O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
protein B-MISC O-MISC
tyrosine I-MISC O-MISC
phosphatases I-MISC I-MISC
( O-MISC O-MISC
PTPs B-MISC B-MISC
) O-MISC O-MISC
regulate O-MISC O-MISC
CD3 B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
distribution O-MISC O-MISC
of O-MISC O-MISC
PTPs B-MISC B-MISC
in O-MISC O-MISC
subdomains O-MISC O-MISC
of O-MISC O-MISC
plasma O-MISC O-MISC
membrane O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
bulk O-MISC O-MISC
PTP B-MISC O-MISC
activity O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
membrane O-MISC O-MISC
is O-MISC O-MISC
present O-MISC O-MISC
outside O-MISC O-MISC
the O-MISC O-MISC
lipid O-MISC O-MISC
rafts O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
sucrose O-MISC O-MISC
density O-MISC O-MISC
gradient O-MISC O-MISC
sedimentation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
approximately O-MISC O-MISC
5 O-MISC B-MISC
- O-MISC I-MISC
- O-MISC I-MISC
10 O-MISC I-MISC
% O-MISC O-MISC
of O-MISC O-MISC
Src B-MISC B-MISC
homology I-MISC I-MISC
2 I-MISC I-MISC
domain I-MISC I-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
tyrosine I-MISC O-MISC
phosphatase I-MISC I-MISC
( O-MISC O-MISC
SHP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
constitutively O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
plasma O-MISC O-MISC
membrane O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
nearly O-MISC O-MISC
50 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
SHP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
is O-MISC O-MISC
translocated O-MISC O-MISC
to O-MISC O-MISC
plasma O-MISC O-MISC
membrane O-MISC O-MISC
after O-MISC O-MISC
vanadate O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

Similar O-MISC O-MISC
to O-MISC O-MISC
transmembrane B-MISC O-MISC
PTP I-MISC B-MISC
, O-MISC O-MISC
CD45 B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
membrane O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
populations O-MISC O-MISC
of O-MISC O-MISC
SHP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
SHP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
are O-MISC O-MISC
essentially O-MISC O-MISC
excluded O-MISC O-MISC
from O-MISC O-MISC
lipid O-MISC O-MISC
rafts O-MISC O-MISC
, O-MISC O-MISC
where O-MISC O-MISC
other O-MISC O-MISC
signaling B-MISC B-MISC
molecules I-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
Lck B-MISC B-MISC
, I-MISC O-MISC
linker I-MISC O-MISC
for I-MISC O-MISC
activation I-MISC O-MISC
of I-MISC O-MISC
T I-MISC O-MISC
cells I-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
CD3 B-MISC B-MISC
zeta I-MISC I-MISC
are O-MISC O-MISC
enriched O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
further O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
CD3 B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
substrates O-MISC O-MISC
is O-MISC O-MISC
largely O-MISC O-MISC
restricted O-MISC O-MISC
to O-MISC O-MISC
lipid O-MISC O-MISC
rafts O-MISC O-MISC
, O-MISC O-MISC
unless O-MISC O-MISC
PTPs B-MISC O-MISC
are O-MISC O-MISC
inhibited O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
restricted O-MISC O-MISC
partition O-MISC O-MISC
of O-MISC O-MISC
PTPs B-MISC B-MISC
among O-MISC O-MISC
membrane O-MISC B-MISC
subdomains O-MISC I-MISC
may O-MISC O-MISC
regulate O-MISC O-MISC
protein O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
membrane O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
test O-MISC O-MISC
this O-MISC O-MISC
hypothesis O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
targeted O-MISC O-MISC
SHP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
into O-MISC O-MISC
lipid O-MISC O-MISC
rafts O-MISC I-MISC
by O-MISC O-MISC
using O-MISC O-MISC
the O-MISC O-MISC
N B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
region I-MISC I-MISC
of I-MISC O-MISC
Lck I-MISC B-MISC
( O-MISC I-MISC
residues B-MISC I-MISC
1 I-MISC I-MISC
- I-MISC I-MISC
- I-MISC I-MISC
14 I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Lck B-MISC B-MISC
/ I-MISC I-MISC
SHP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
chimera I-MISC O-MISC
inside O-MISC O-MISC
lipid O-MISC O-MISC
rafts O-MISC O-MISC
profoundly O-MISC O-MISC
inhibits O-MISC O-MISC
CD3 B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
CD3 B-MISC B-MISC
zeta I-MISC O-MISC
/ I-MISC O-MISC
epsilon I-MISC O-MISC
, O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC O-MISC
2 O-MISC I-MISC
generation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
mobilization O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
AT I-MISC I-MISC
. O-MISC O-MISC

Collectively O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
exclusion O-MISC O-MISC
of O-MISC O-MISC
PTPs B-MISC O-MISC
from O-MISC O-MISC
lipid O-MISC O-MISC
rafts O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
mechanism O-MISC O-MISC
that O-MISC O-MISC
potentiates O-MISC O-MISC
TCR B-MISC B-MISC
/ O-MISC I-MISC
CD3 B-MISC I-MISC
activation O-MISC O-MISC

An O-MISC O-MISC
instructive O-MISC O-MISC
component O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
2 O-MISC O-MISC
( O-MISC O-MISC
Th2 O-MISC O-MISC
) O-MISC O-MISC
development O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
interleukin B-MISC B-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
polarize O-MISC O-MISC
naive O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
toward O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
Th1 O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
Th2 O-MISC O-MISC
phenotypes O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
known O-MISC O-MISC
whether O-MISC O-MISC
cytokines B-MISC B-MISC
instruct O-MISC O-MISC
the O-MISC O-MISC
developmental O-MISC O-MISC
fate O-MISC O-MISC
in O-MISC O-MISC
uncommitted O-MISC O-MISC
progenitors O-MISC O-MISC
or O-MISC O-MISC
select O-MISC O-MISC
for O-MISC O-MISC
outgrowth O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
have O-MISC O-MISC
stochastically O-MISC O-MISC
committed O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
particular O-MISC O-MISC
fate O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
distinguish O-MISC O-MISC
these O-MISC O-MISC
instructive O-MISC O-MISC
and O-MISC O-MISC
selective O-MISC O-MISC
models O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
used O-MISC O-MISC
surface O-MISC O-MISC
affinity O-MISC O-MISC
matrix O-MISC O-MISC
technology O-MISC O-MISC
to O-MISC O-MISC
isolate O-MISC O-MISC
committed O-MISC O-MISC
progenitors O-MISC O-MISC
based O-MISC O-MISC
on O-MISC O-MISC
cytokine O-MISC B-MISC
secretion O-MISC O-MISC
phenotype O-MISC O-MISC
and O-MISC O-MISC
developed O-MISC O-MISC
retroviral O-MISC O-MISC
- O-MISC O-MISC
based O-MISC O-MISC
tagging O-MISC O-MISC
approaches O-MISC O-MISC
to O-MISC O-MISC
directly O-MISC O-MISC
monitor O-MISC O-MISC
individual O-MISC O-MISC
progenitor O-MISC O-MISC
fate O-MISC O-MISC
decisions O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
clonal O-MISC O-MISC
and O-MISC O-MISC
population O-MISC O-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
observe O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
redirection O-MISC O-MISC
of O-MISC O-MISC
phenotype O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
have O-MISC O-MISC
already O-MISC O-MISC
committed O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
IL O-MISC O-MISC
- O-MISC O-MISC
4 O-MISC I-MISC
- O-MISC O-MISC
producing O-MISC O-MISC
fate O-MISC O-MISC
, O-MISC O-MISC
inconsistent O-MISC O-MISC
with O-MISC O-MISC
predictions O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
selective O-MISC O-MISC
model O-MISC O-MISC
. O-MISC O-MISC

Further O-MISC O-MISC
, O-MISC O-MISC
retroviral O-MISC O-MISC
tagging O-MISC O-MISC
of O-MISC O-MISC
naive O-MISC O-MISC
progenitors O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
Th2 B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
GATA I-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
provided O-MISC O-MISC
direct O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
instructive O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
no O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
selective O-MISC O-MISC
outgrowth O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
committed O-MISC O-MISC
to O-MISC O-MISC
either O-MISC O-MISC
the O-MISC O-MISC
Th1 O-MISC O-MISC
or O-MISC O-MISC
Th2 O-MISC O-MISC
fate O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
would O-MISC O-MISC
seem O-MISC O-MISC
to O-MISC O-MISC
exclude O-MISC O-MISC
selection O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
exclusive O-MISC O-MISC
mechanism O-MISC O-MISC
in O-MISC O-MISC
Th1 O-MISC O-MISC
/ O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
support O-MISC O-MISC
an O-MISC O-MISC
instructive O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
transcriptional O-MISC O-MISC
programming O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
fate O-MISC O-MISC
decisions O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
vitro O-MISC O-MISC
- O-MISC O-MISC
activated O-MISC O-MISC
human O-MISC O-MISC
lupus O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
express O-MISC O-MISC
normal O-MISC B-MISC
estrogen B-MISC B-MISC
receptor I-MISC I-MISC
proteins I-MISC I-MISC
which O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
estrogen B-MISC B-MISC
response I-MISC I-MISC
element I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
estrogen B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC I-MISC
ERalpha B-MISC B-MISC
, O-MISC O-MISC
ERbeta B-MISC B-MISC
) O-MISC I-MISC
transcripts O-MISC I-MISC
are O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
SLE O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
female O-MISC O-MISC
lupus O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
donors O-MISC O-MISC
were O-MISC O-MISC
tested O-MISC O-MISC
for O-MISC O-MISC
biologically O-MISC O-MISC
active O-MISC O-MISC
ER B-MISC B-MISC
proteins I-MISC I-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
estrogen I-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
( O-MISC O-MISC
hERE B-MISC B-MISC
) O-MISC O-MISC
by O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
. O-MISC O-MISC

When O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
17beta O-MISC O-MISC
- O-MISC O-MISC
estradiol O-MISC O-MISC
( O-MISC O-MISC
E2 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
PMA O-MISC O-MISC
and O-MISC O-MISC
ionomycin O-MISC O-MISC
, O-MISC O-MISC
two O-MISC O-MISC
major O-MISC O-MISC
retarded O-MISC O-MISC
bands O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
exhibited O-MISC O-MISC
a O-MISC O-MISC
migration O-MISC O-MISC
pattern O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
slow O-MISC O-MISC
migrating O-MISC O-MISC
protein B-MISC B-MISC
- I-MISC I-MISC
ERE I-MISC I-MISC
complexes I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
cell O-MISC O-MISC
extracts O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cells O-MISC O-MISC
cultured O-MISC O-MISC
only O-MISC O-MISC
with O-MISC O-MISC
E2 O-MISC B-MISC
did O-MISC O-MISC
not O-MISC O-MISC
have O-MISC O-MISC
these O-MISC O-MISC
complexes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
complexes O-MISC O-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
competition O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
hERE O-MISC O-MISC
cold O-MISC O-MISC
oligonucleotide O-MISC O-MISC
and O-MISC O-MISC
partially O-MISC O-MISC
with O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
ERalpha I-MISC I-MISC
antibodies I-MISC I-MISC
. O-MISC O-MISC

There O-MISC O-MISC
was O-MISC O-MISC
no O-MISC O-MISC
notable O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
migration O-MISC O-MISC
pattern O-MISC O-MISC
of O-MISC O-MISC
ERE B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
between O-MISC O-MISC
the O-MISC O-MISC
SLE O-MISC O-MISC
and O-MISC O-MISC
normal O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
extracts O-MISC O-MISC
. O-MISC O-MISC

Together O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
activated O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
whether O-MISC O-MISC
lupus O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
or O-MISC O-MISC
normal O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
, O-MISC O-MISC
contain O-MISC O-MISC
biologically O-MISC O-MISC
active O-MISC O-MISC
ERalpha B-MISC B-MISC
proteins I-MISC I-MISC
. O-MISC O-MISC

Other O-MISC O-MISC
factors O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
differential O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
lupus O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
estrogen O-MISC O-MISC
. O-MISC O-MISC

Mechanism O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
protease O-MISC B-MISC
inhibitor O-MISC O-MISC
on O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
alpha I-MISC I-MISC
production O-MISC O-MISC
of O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

If O-MISC O-MISC
the O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
becomes O-MISC O-MISC
excessive O-MISC O-MISC
or O-MISC O-MISC
uncontrolled O-MISC O-MISC
by O-MISC O-MISC
some O-MISC O-MISC
stimuli O-MISC O-MISC
, O-MISC O-MISC
inappropriate O-MISC O-MISC
inflammatory O-MISC O-MISC
responses O-MISC O-MISC
occur O-MISC O-MISC
. O-MISC O-MISC

Monocytes O-MISC O-MISC
are O-MISC O-MISC
extremely O-MISC O-MISC
important O-MISC O-MISC
cells O-MISC O-MISC
for O-MISC O-MISC
regulating O-MISC O-MISC
the O-MISC O-MISC
cytokine O-MISC B-MISC
network O-MISC O-MISC
and O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNFalpha B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC B-MISC
) I-MISC I-MISC
10 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
mainly O-MISC O-MISC
synthesized O-MISC O-MISC
by O-MISC O-MISC
monocytes O-MISC O-MISC
, O-MISC O-MISC
are O-MISC O-MISC
representative O-MISC O-MISC
cytokines B-MISC B-MISC
that O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
central O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytokine O-MISC B-MISC
network O-MISC O-MISC
. O-MISC O-MISC

Protease O-MISC O-MISC
inhibitors O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
gabexate O-MISC O-MISC
mesilate O-MISC O-MISC
( O-MISC O-MISC
GM O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
ulinastatin O-MISC B-MISC
( O-MISC O-MISC
UTI O-MISC O-MISC
) O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
various O-MISC O-MISC
beneficial O-MISC O-MISC
effects O-MISC O-MISC
by O-MISC O-MISC
inhibiting O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
leukocytes O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
this O-MISC O-MISC
has O-MISC O-MISC
yet O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
fully O-MISC O-MISC
elucidated O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
protease O-MISC B-MISC
inhibitors O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
proinflammatory O-MISC O-MISC
cytokine O-MISC I-MISC
production O-MISC O-MISC
of O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
LPS O-MISC O-MISC
) O-MISC O-MISC
stimulated O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
monocytes O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
GM O-MISC O-MISC
or O-MISC O-MISC
UTI O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
value O-MISC O-MISC
of O-MISC O-MISC
TNFalpha B-MISC B-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
culture O-MISC O-MISC
medium O-MISC O-MISC
of O-MISC O-MISC
monocytes O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
and O-MISC O-MISC
each O-MISC O-MISC
mRNA O-MISC B-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
assayed O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
protease O-MISC B-MISC
inhibitors O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
intracellular O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
pathways O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
( O-MISC O-MISC
PKC B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
( O-MISC O-MISC
NFkappaB B-MISC B-MISC
) O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
evaluated O-MISC O-MISC
. O-MISC O-MISC

GM O-MISC O-MISC
decreased O-MISC O-MISC
the O-MISC O-MISC
TNFalpha B-MISC B-MISC
production O-MISC O-MISC
of O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
monocytes O-MISC O-MISC
as O-MISC O-MISC
shown O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
mRNA O-MISC B-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
production O-MISC O-MISC
of O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

GM O-MISC O-MISC
also O-MISC O-MISC
suppressed O-MISC O-MISC
the O-MISC O-MISC
NFkappaB B-MISC B-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

UTI O-MISC O-MISC
decreased O-MISC O-MISC
the O-MISC O-MISC
TNFalpha B-MISC B-MISC
production O-MISC O-MISC
of O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
monocytes O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
inhibit O-MISC O-MISC
the O-MISC O-MISC
TNFalpha B-MISC B-MISC
mRNA I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
shows O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
GM O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
TNFalpha B-MISC B-MISC
production O-MISC O-MISC
of O-MISC O-MISC
activated O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
NFkappaB B-MISC B-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
UTI O-MISC O-MISC
inhibiting O-MISC O-MISC
TNFalpha B-MISC B-MISC
production O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
the O-MISC O-MISC
translation O-MISC O-MISC
or O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
TNFalpha B-MISC B-MISC
. O-MISC O-MISC

Homocysteine O-MISC O-MISC
stimulates O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
monocyte B-MISC B-MISC
chemoattractant I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
enhanced O-MISC O-MISC
monocyte O-MISC O-MISC
chemotaxis O-MISC O-MISC
. O-MISC O-MISC

Hyperhomocysteinemia O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
identified O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
independent O-MISC O-MISC
risk O-MISC O-MISC
factor O-MISC O-MISC
for O-MISC O-MISC
atherosclerosis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
infiltration O-MISC O-MISC
of O-MISC O-MISC
monocytes O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
arterial O-MISC O-MISC
wall O-MISC O-MISC
is O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
key O-MISC O-MISC
events O-MISC O-MISC
during O-MISC O-MISC
atherogenesis O-MISC O-MISC
. O-MISC O-MISC

Monocyte B-MISC O-MISC
chemoattractant I-MISC B-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
chemokine B-MISC O-MISC
that O-MISC O-MISC
stimulates O-MISC O-MISC
the O-MISC O-MISC
migration O-MISC O-MISC
of O-MISC O-MISC
monocytes O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
intima O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
arterial O-MISC O-MISC
wall O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
increased O-MISC O-MISC
monocyte O-MISC O-MISC
infiltration O-MISC O-MISC
occurs O-MISC O-MISC
in O-MISC O-MISC
atherosclerotic O-MISC O-MISC
lesions O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
hyperhomocysteinemia O-MISC O-MISC
has O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
delineated O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
objective O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
was O-MISC O-MISC
to O-MISC O-MISC
investigate O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
homocysteine O-MISC O-MISC
on O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
production O-MISC O-MISC
in O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Cells O-MISC O-MISC
were O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
homocysteine O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
protein I-MISC I-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
increased O-MISC O-MISC
( O-MISC O-MISC
195 O-MISC O-MISC
% O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
pathological O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
homocysteine O-MISC O-MISC
. O-MISC O-MISC

Such O-MISC O-MISC
effect O-MISC O-MISC
was O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
increased O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
( O-MISC O-MISC
176 O-MISC O-MISC
% O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
which O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
enhanced O-MISC O-MISC
monocyte O-MISC O-MISC
chemotaxis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
p38 B-MISC B-MISC
MAP I-MISC I-MISC
kinase I-MISC I-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
other O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
p38 O-MISC B-MISC
MAP O-MISC I-MISC
kinase O-MISC I-MISC
pathway O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
MKK3 B-MISC B-MISC
, O-MISC O-MISC
MKK6 B-MISC B-MISC
, O-MISC O-MISC
ATF B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
Elk B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
were O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
homocysteine O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Homocysteine O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
subsequent O-MISC O-MISC
monocyte O-MISC O-MISC
chemotaxis O-MISC O-MISC
were O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
p38 B-MISC B-MISC
MAP I-MISC I-MISC
kinase I-MISC I-MISC
inhibitor O-MISC I-MISC
( O-MISC O-MISC
SB203580 O-MISC B-MISC
) O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
p38 B-MISC O-MISC
MAP I-MISC I-MISC
kinase I-MISC I-MISC
pathway O-MISC O-MISC
might O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
homocysteine O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
staurosporine O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
inhibitor O-MISC O-MISC
, O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
homocysteine O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
conclusion O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
homocysteine O-MISC O-MISC
stimulates O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
enhanced O-MISC O-MISC
monocyte O-MISC O-MISC
chemotaxis O-MISC O-MISC
. O-MISC O-MISC

Inducible O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
Fas O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Apoptosis O-MISC O-MISC
produced O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
through O-MISC O-MISC
Fas B-MISC B-MISC
( O-MISC O-MISC
APO B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
CD95 B-MISC B-MISC
) O-MISC O-MISC
triggering O-MISC O-MISC
is O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
signals O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
other O-MISC O-MISC
surface O-MISC B-MISC
receptors O-MISC I-MISC
: O-MISC O-MISC
CD40 O-MISC B-MISC
engagement O-MISC O-MISC
produces O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
Fas B-MISC B-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
marked O-MISC O-MISC
susceptibility O-MISC O-MISC
to O-MISC O-MISC
Fas B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
death O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
antigen O-MISC O-MISC
receptor O-MISC I-MISC
engagement O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4R O-MISC I-MISC
engagement O-MISC O-MISC
, O-MISC O-MISC
inhibits O-MISC O-MISC
Fas B-MISC B-MISC
killing O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
so O-MISC O-MISC
doing O-MISC O-MISC
induces O-MISC O-MISC
a O-MISC O-MISC
state O-MISC O-MISC
of O-MISC O-MISC
Fas B-MISC B-MISC
- O-MISC I-MISC
resistance O-MISC O-MISC
, O-MISC O-MISC
even O-MISC O-MISC
in O-MISC O-MISC
otherwise O-MISC O-MISC
sensitive O-MISC O-MISC
, O-MISC O-MISC
CD40 B-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
targets O-MISC O-MISC
. O-MISC O-MISC

Surface B-MISC O-MISC
immunoglobulin I-MISC B-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4R I-MISC I-MISC
utilize O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
partially O-MISC O-MISC
distinct O-MISC O-MISC
pathways O-MISC O-MISC
to O-MISC O-MISC
produce O-MISC O-MISC
Fas B-MISC B-MISC
- O-MISC O-MISC
resistance O-MISC O-MISC
that O-MISC O-MISC
differentially O-MISC O-MISC
depend O-MISC O-MISC
on O-MISC O-MISC
PKC B-MISC B-MISC
and O-MISC O-MISC
STAT6 B-MISC B-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

Further O-MISC O-MISC
, O-MISC O-MISC
surface O-MISC O-MISC
immunoglobulin O-MISC B-MISC
signaling O-MISC O-MISC
for O-MISC O-MISC
inducible O-MISC O-MISC
Fas B-MISC B-MISC
- O-MISC O-MISC
resistance O-MISC O-MISC
bypasses O-MISC O-MISC
Btk B-MISC B-MISC
, O-MISC O-MISC
requires O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
entails O-MISC O-MISC
new O-MISC O-MISC
macromolecular O-MISC O-MISC
synthesis O-MISC O-MISC
. O-MISC O-MISC

Terminal O-MISC O-MISC
effectors O-MISC O-MISC
of O-MISC O-MISC
B O-MISC B-MISC
cell O-MISC I-MISC
Fas B-MISC I-MISC
- O-MISC I-MISC
resistance O-MISC I-MISC
include O-MISC O-MISC
the O-MISC O-MISC
known O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
apoptotic I-MISC I-MISC
gene I-MISC I-MISC
products I-MISC I-MISC
, O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
xL I-MISC I-MISC
and O-MISC O-MISC
FLIP B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
apoptotic I-MISC I-MISC
gene I-MISC I-MISC
that O-MISC O-MISC
encodes O-MISC O-MISC
FAIM B-MISC B-MISC
( O-MISC O-MISC
Fas B-MISC B-MISC
Apoptosis I-MISC I-MISC
Inhibitory I-MISC O-MISC
Molecule I-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

faim B-MISC O-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
by O-MISC O-MISC
differential O-MISC O-MISC
display O-MISC O-MISC
and O-MISC O-MISC
exists O-MISC O-MISC
in O-MISC O-MISC
two O-MISC O-MISC
alternatively O-MISC O-MISC
spliced O-MISC B-MISC
forms O-MISC O-MISC
; O-MISC O-MISC
faim B-MISC O-MISC
- I-MISC I-MISC
S I-MISC I-MISC
is O-MISC O-MISC
broadly O-MISC O-MISC
expressed O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
faim O-MISC O-MISC
- O-MISC O-MISC
L O-MISC O-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
tissue O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
FAIM B-MISC B-MISC
sequence I-MISC I-MISC
is O-MISC O-MISC
highly O-MISC O-MISC
evolu O-MISC O-MISC
- O-MISC O-MISC
tionarily O-MISC O-MISC
conserved O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
this O-MISC O-MISC
molecule O-MISC O-MISC
throughout O-MISC O-MISC
phylogeny O-MISC B-MISC
. O-MISC O-MISC

Inducible O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
Fas B-MISC B-MISC
killing O-MISC O-MISC
is O-MISC O-MISC
hypothesized O-MISC O-MISC
to O-MISC O-MISC
protect O-MISC O-MISC
foreign O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
during O-MISC O-MISC
potentially O-MISC O-MISC
hazardous O-MISC O-MISC
interactions O-MISC O-MISC
with O-MISC O-MISC
FasL O-MISC O-MISC
- O-MISC O-MISC
bearing O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
autoreactive O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
fail O-MISC O-MISC
to O-MISC O-MISC
become O-MISC O-MISC
Fas B-MISC B-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
deleted O-MISC O-MISC
via O-MISC O-MISC
Fas B-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
cytotoxicity O-MISC O-MISC
. O-MISC O-MISC

Inadvertent O-MISC O-MISC
or O-MISC O-MISC
aberrant O-MISC O-MISC
acquisition O-MISC O-MISC
of O-MISC O-MISC
Fas B-MISC B-MISC
- O-MISC O-MISC
resistance O-MISC O-MISC
may O-MISC O-MISC
permit O-MISC O-MISC
autoreactive O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
escape O-MISC O-MISC
Fas B-MISC B-MISC
deletion O-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
lymphocytes O-MISC O-MISC
to O-MISC O-MISC
impede O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
tumor O-MISC O-MISC
immunity O-MISC O-MISC
. O-MISC O-MISC

Stromal B-MISC B-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
derived I-MISC I-MISC
factor I-MISC I-MISC
1 I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
chemotaxis O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

Stromal B-MISC B-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
derived I-MISC I-MISC
factor I-MISC I-MISC
1 I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
SDF1 B-MISC B-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
cognate O-MISC O-MISC
chemokine B-MISC B-MISC
receptor I-MISC I-MISC
CXCR4 I-MISC B-MISC
act O-MISC O-MISC
as O-MISC O-MISC
potent O-MISC O-MISC
chemoattractants O-MISC O-MISC
and O-MISC O-MISC
regulate O-MISC O-MISC
trafficking O-MISC O-MISC
and O-MISC O-MISC
homing O-MISC O-MISC
of O-MISC O-MISC
hematopoietic O-MISC O-MISC
progenitor O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
mechanisms O-MISC O-MISC
regulating O-MISC O-MISC
SDF1 B-MISC O-MISC
alpha I-MISC O-MISC
- O-MISC O-MISC
driven O-MISC O-MISC
cell O-MISC O-MISC
migration O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
well O-MISC O-MISC
defined O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
explored O-MISC O-MISC
the O-MISC O-MISC
roles O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
second O-MISC O-MISC
messenger O-MISC O-MISC
NO O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
in O-MISC O-MISC
SDF1 B-MISC O-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
migration O-MISC O-MISC
. O-MISC O-MISC

SDF1 B-MISC B-MISC
alpha I-MISC I-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
NO B-MISC B-MISC
synthase I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
catalyzes O-MISC O-MISC
the O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
NO O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
observed O-MISC O-MISC
that O-MISC O-MISC
pretreatment O-MISC O-MISC
of O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
or O-MISC O-MISC
activated O-MISC O-MISC
PBLs O-MISC O-MISC
with O-MISC O-MISC
several O-MISC O-MISC
NO O-MISC O-MISC
donors O-MISC O-MISC
significantly O-MISC O-MISC
enhanced O-MISC O-MISC
the O-MISC O-MISC
SDF1 B-MISC O-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
migration O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
various O-MISC O-MISC
inhibitors O-MISC O-MISC
of O-MISC O-MISC
NO B-MISC B-MISC
synthase I-MISC I-MISC
markedly O-MISC O-MISC
abrogated O-MISC O-MISC
the O-MISC O-MISC
chemotactic O-MISC O-MISC
response O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
concentration O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
observed O-MISC O-MISC
that O-MISC O-MISC
inhibitors O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
NO O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
, O-MISC O-MISC
also O-MISC O-MISC
significantly O-MISC O-MISC
blocked O-MISC O-MISC
the O-MISC O-MISC
SDF1 B-MISC O-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
chemotactic O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
compounds O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
SDF1 B-MISC B-MISC
alpha I-MISC I-MISC
- O-MISC I-MISC
induced O-MISC I-MISC
mitogen O-MISC I-MISC
- O-MISC I-MISC
activated O-MISC I-MISC
protein O-MISC I-MISC
kinase O-MISC I-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
MAP O-MISC B-MISC
/ O-MISC I-MISC
Erk O-MISC I-MISC
kinase O-MISC I-MISC
kinase O-MISC I-MISC
inhibitor O-MISC O-MISC
PD98059 O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
abrogate O-MISC O-MISC
SDF1 B-MISC O-MISC
alpha I-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
chemotaxis O-MISC O-MISC
. O-MISC O-MISC

AKT B-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
mediate O-MISC O-MISC
NO O-MISC O-MISC
production O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
phosphorylated O-MISC O-MISC
upon O-MISC O-MISC
SDF1 B-MISC B-MISC
alpha I-MISC I-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
studies O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
NO O-MISC O-MISC
- O-MISC O-MISC
related O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
may O-MISC O-MISC
mediate O-MISC O-MISC
SDF1 B-MISC O-MISC
alpha I-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
chemotaxis O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
mitogen B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
lack O-MISC O-MISC
of O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
transactivation O-MISC O-MISC
and O-MISC O-MISC
PKC O-MISC B-MISC
epsilon O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
thymocytes O-MISC O-MISC
correlates O-MISC O-MISC
with O-MISC O-MISC
negative O-MISC O-MISC
selection O-MISC O-MISC
. O-MISC O-MISC

Deletion O-MISC O-MISC
of O-MISC O-MISC
autoreactive O-MISC O-MISC
thymocytes O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
DP O-MISC O-MISC
stage O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
basis O-MISC O-MISC
for O-MISC O-MISC
tolerance O-MISC O-MISC
to O-MISC O-MISC
thymus B-MISC O-MISC
- I-MISC O-MISC
expressed I-MISC I-MISC
self I-MISC B-MISC
antigens I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
whether O-MISC O-MISC
distinct O-MISC O-MISC
signalling O-MISC O-MISC
pathways O-MISC O-MISC
are O-MISC O-MISC
induced O-MISC O-MISC
in O-MISC O-MISC
DP O-MISC O-MISC
thymocytes O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
mature O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
upon O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
antigen O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
triple O-MISC O-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
expressing O-MISC O-MISC
a O-MISC O-MISC
TCR B-MISC B-MISC
transgene I-MISC I-MISC
, O-MISC O-MISC
dominant B-MISC B-MISC
negative I-MISC I-MISC
ras I-MISC I-MISC
/ I-MISC I-MISC
Mek I-MISC I-MISC
proteins I-MISC I-MISC
and O-MISC O-MISC
a O-MISC O-MISC
reporter B-MISC B-MISC
gene I-MISC I-MISC
construct I-MISC I-MISC
with O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
or I-MISC O-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
showed O-MISC O-MISC
a O-MISC O-MISC
complete O-MISC O-MISC
lack O-MISC O-MISC
of O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
DP O-MISC O-MISC
thymocytes O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
both O-MISC O-MISC
were O-MISC O-MISC
transcriptionally O-MISC O-MISC
active O-MISC O-MISC
in O-MISC O-MISC
mature O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
after O-MISC O-MISC
antigenic O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Lack O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
induction O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
increased O-MISC O-MISC
death O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
antigen B-MISC O-MISC
. O-MISC O-MISC

AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
induction O-MISC O-MISC
was O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
integrity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
ras O-MISC B-MISC
/ O-MISC I-MISC
Mek O-MISC I-MISC
pathway O-MISC O-MISC
indicating O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
pathway O-MISC O-MISC
was O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
DP O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
a O-MISC O-MISC
complete O-MISC O-MISC
lack O-MISC O-MISC
of O-MISC O-MISC
constitutive O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
epsilon B-MISC B-MISC
isoform I-MISC I-MISC
of I-MISC O-MISC
Protein I-MISC B-MISC
Kinase I-MISC B-MISC
C I-MISC I-MISC
( O-MISC O-MISC
PKC B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
DP O-MISC O-MISC
thymocytes O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
mature O-MISC O-MISC
thymocytes O-MISC O-MISC
and O-MISC O-MISC
peripheral O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Taken O-MISC O-MISC
together O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
lack O-MISC O-MISC
of O-MISC O-MISC
PKC B-MISC B-MISC
epsilon I-MISC O-MISC
in O-MISC O-MISC
DP O-MISC O-MISC
thymocytes O-MISC O-MISC
could O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activity O-MISC O-MISC
after O-MISC O-MISC
antigenic O-MISC O-MISC
stimulation O-MISC O-MISC
contributing O-MISC O-MISC
to O-MISC O-MISC
negative O-MISC O-MISC
selection O-MISC O-MISC
. O-MISC O-MISC

Cell O-MISC O-MISC
Death O-MISC O-MISC
and O-MISC O-MISC
Differentiation O-MISC O-MISC
( O-MISC O-MISC
2000 O-MISC O-MISC
) O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
1253 O-MISC O-MISC
- O-MISC O-MISC
1262 O-MISC O-MISC
. O-MISC O-MISC

CD2 O-MISC B-MISC
stimulation O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
delayed O-MISC O-MISC
and O-MISC O-MISC
prolonged O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT1 B-MISC B-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
soluble O-MISC B-MISC
factors O-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
cytokines B-MISC B-MISC
or O-MISC O-MISC
through O-MISC O-MISC
direct O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
interactions O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
cytokine B-MISC B-MISC
receptors I-MISC I-MISC
are O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
signal O-MISC O-MISC
through O-MISC O-MISC
STAT B-MISC B-MISC
family I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
other O-MISC O-MISC
cell B-MISC B-MISC
- I-MISC I-MISC
surface I-MISC I-MISC
molecules I-MISC I-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
CD2 B-MISC B-MISC
, O-MISC O-MISC
transduce O-MISC O-MISC
signals O-MISC O-MISC
is O-MISC O-MISC
unclear O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
goal O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
was O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
through O-MISC O-MISC
CD2 B-MISC B-MISC
recapitulates O-MISC O-MISC
aspects O-MISC O-MISC
of O-MISC O-MISC
cytokine B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
STAT B-MISC B-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

MATERIALS O-MISC O-MISC
AND O-MISC O-MISC
METHODS O-MISC O-MISC
: O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD2 I-MISC I-MISC
antibodies I-MISC I-MISC
or O-MISC O-MISC
cells O-MISC O-MISC
bearing O-MISC O-MISC
the O-MISC O-MISC
natural O-MISC O-MISC
CD2 B-MISC B-MISC
ligand I-MISC I-MISC
CD58 I-MISC I-MISC
, O-MISC O-MISC
after O-MISC O-MISC
which O-MISC O-MISC
signaling O-MISC O-MISC
through O-MISC O-MISC
STAT B-MISC B-MISC
transcription I-MISC B-MISC
factors I-MISC I-MISC
was O-MISC O-MISC
assessed O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Stimulation O-MISC O-MISC
of O-MISC O-MISC
CD2 B-MISC B-MISC
on O-MISC O-MISC
primary O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
, O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
STAT1 B-MISC B-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
stimulation O-MISC O-MISC
by O-MISC O-MISC
cytokines B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT1 B-MISC B-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
CD2 O-MISC B-MISC
ligation O-MISC O-MISC
is O-MISC O-MISC
delayed O-MISC O-MISC
and O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
involve O-MISC O-MISC
Jak B-MISC B-MISC
kinases I-MISC I-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
STAT O-MISC B-MISC
phosphorylation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
cytokines B-MISC B-MISC
is O-MISC O-MISC
generally O-MISC O-MISC
transient O-MISC O-MISC
, O-MISC O-MISC
STAT1 O-MISC B-MISC
phosphorylation O-MISC O-MISC
following O-MISC O-MISC
CD2 O-MISC B-MISC
stimulation O-MISC O-MISC
persists O-MISC O-MISC
for O-MISC O-MISC
a O-MISC O-MISC
period O-MISC O-MISC
of O-MISC O-MISC
days O-MISC O-MISC
. O-MISC O-MISC

Transcription O-MISC O-MISC
of O-MISC O-MISC
key O-MISC O-MISC
target O-MISC B-MISC
genes O-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
IRF1 B-MISC B-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
fos I-MISC I-MISC
proceeds O-MISC O-MISC
with O-MISC O-MISC
delayed O-MISC O-MISC
kinetics O-MISC O-MISC
following O-MISC O-MISC
CD2 O-MISC B-MISC
stimulation O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
unique O-MISC O-MISC
pattern O-MISC O-MISC
of O-MISC O-MISC
STAT O-MISC B-MISC
activation O-MISC O-MISC
may O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
distinct O-MISC O-MISC
cellular O-MISC O-MISC
response O-MISC O-MISC
following O-MISC O-MISC
CD2 O-MISC B-MISC
ligation O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
pathway O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
restricted O-MISC O-MISC
to O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
CD2 B-MISC O-MISC
on O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
STAT1 O-MISC B-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
Stimulation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
through O-MISC O-MISC
cell B-MISC B-MISC
- I-MISC I-MISC
surface I-MISC I-MISC
molecules I-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
CD2 B-MISC B-MISC
involves O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT B-MISC B-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
, O-MISC O-MISC
thus O-MISC O-MISC
recapitulating O-MISC O-MISC
elements O-MISC I-MISC
of O-MISC O-MISC
cytokine O-MISC B-MISC
signaling O-MISC O-MISC
. O-MISC O-MISC

NFATc1 B-MISC B-MISC
and O-MISC O-MISC
NFATc2 B-MISC B-MISC
together O-MISC O-MISC
control O-MISC O-MISC
both O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

NFAT B-MISC B-MISC
transcription I-MISC B-MISC
factors I-MISC I-MISC
play O-MISC O-MISC
critical O-MISC O-MISC
roles O-MISC O-MISC
in O-MISC O-MISC
gene O-MISC O-MISC
transcription O-MISC O-MISC
during O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
investigate O-MISC O-MISC
further O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
most O-MISC O-MISC
prominent O-MISC O-MISC
NFAT B-MISC B-MISC
family I-MISC I-MISC
members I-MISC I-MISC
, O-MISC O-MISC
NFATc1 B-MISC B-MISC
and O-MISC O-MISC
NFATc2 B-MISC B-MISC
, O-MISC O-MISC
we O-MISC O-MISC
generated O-MISC O-MISC
mice O-MISC O-MISC
bearing O-MISC O-MISC
lymphoid O-MISC O-MISC
systems O-MISC O-MISC
devoid O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
. O-MISC O-MISC

Doubly O-MISC O-MISC
deficient O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
displayed O-MISC O-MISC
cell O-MISC B-MISC
surface O-MISC I-MISC
markers O-MISC I-MISC
of O-MISC O-MISC
activation O-MISC O-MISC
yet O-MISC O-MISC
were O-MISC O-MISC
significantly O-MISC O-MISC
deficient O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
multiple O-MISC O-MISC
effector O-MISC O-MISC
functions O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
Th B-MISC B-MISC
cytokine I-MISC I-MISC
production O-MISC O-MISC
, O-MISC O-MISC
surface B-MISC B-MISC
effector I-MISC I-MISC
molecule I-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
cytolytic O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Nevertheless O-MISC O-MISC
, O-MISC O-MISC
doubly O-MISC O-MISC
deficient O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
hyperactivated O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
evidenced O-MISC O-MISC
by O-MISC O-MISC
extremely O-MISC O-MISC
elevated O-MISC O-MISC
serum O-MISC B-MISC
IgG1 B-MISC I-MISC
and O-MISC O-MISC
IgE B-MISC B-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
plasma O-MISC O-MISC
cell O-MISC O-MISC
expansion O-MISC O-MISC
and O-MISC O-MISC
infiltration O-MISC O-MISC
of O-MISC O-MISC
end O-MISC O-MISC
organs O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
NFATc1 B-MISC B-MISC
and O-MISC O-MISC
NFATc2 B-MISC B-MISC
are O-MISC O-MISC
dispensable O-MISC O-MISC
for O-MISC O-MISC
inflammatory O-MISC O-MISC
reactivity O-MISC O-MISC
but O-MISC O-MISC
are O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
effector O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
NFATs B-MISC B-MISC
regulate O-MISC O-MISC
both O-MISC O-MISC
normal O-MISC O-MISC
homeostasis O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

Epstein O-MISC B-MISC
- O-MISC I-MISC
barr O-MISC I-MISC
virus O-MISC I-MISC
immediate B-MISC I-MISC
- I-MISC I-MISC
early I-MISC I-MISC
protein I-MISC I-MISC
BZLF1 I-MISC I-MISC
is O-MISC O-MISC
SUMO O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
modified O-MISC O-MISC
and O-MISC O-MISC
disrupts O-MISC O-MISC
promyelocytic O-MISC O-MISC
leukemia O-MISC O-MISC
bodies O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
the O-MISC O-MISC
immediate B-MISC B-MISC
- I-MISC I-MISC
early I-MISC I-MISC
proteins I-MISC I-MISC
of O-MISC O-MISC
both O-MISC O-MISC
herpes O-MISC O-MISC
simplex O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
HSV O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
cytomegalovirus O-MISC O-MISC
( O-MISC O-MISC
CMV O-MISC O-MISC
) O-MISC O-MISC
are O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
modify O-MISC O-MISC
promyelocytic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
PML O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
ND10 O-MISC O-MISC
) O-MISC O-MISC
bodies O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
host O-MISC O-MISC
cell O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
unclear O-MISC O-MISC
whether O-MISC O-MISC
lytic O-MISC O-MISC
infection O-MISC O-MISC
with O-MISC O-MISC
gamma O-MISC O-MISC
herpesviruses O-MISC O-MISC
induces O-MISC O-MISC
a O-MISC O-MISC
similar O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
PML B-MISC B-MISC
protein I-MISC I-MISC
is O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
interferon B-MISC B-MISC
, O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
major B-MISC B-MISC
histocompatibility I-MISC I-MISC
complex I-MISC I-MISC
class I-MISC I-MISC
I I-MISC I-MISC
presentation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
certain O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
likely O-MISC O-MISC
that O-MISC O-MISC
PML O-MISC O-MISC
bodies O-MISC O-MISC
function O-MISC O-MISC
in O-MISC O-MISC
an O-MISC O-MISC
antiviral O-MISC O-MISC
capacity O-MISC O-MISC
. O-MISC O-MISC

SUMO O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
modification O-MISC O-MISC
of O-MISC O-MISC
PML B-MISC B-MISC
is O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
PML O-MISC O-MISC
bodies O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
examine O-MISC O-MISC
whether O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
EBV O-MISC O-MISC
) O-MISC O-MISC
lytic O-MISC O-MISC
replication O-MISC O-MISC
interferes O-MISC O-MISC
with O-MISC O-MISC
PML O-MISC O-MISC
bodies O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
expressed O-MISC O-MISC
the O-MISC O-MISC
EBV B-MISC B-MISC
immediate I-MISC I-MISC
- I-MISC I-MISC
early I-MISC I-MISC
genes I-MISC I-MISC
BZLF1 B-MISC B-MISC
( I-MISC O-MISC
Z I-MISC B-MISC
) I-MISC O-MISC
and O-MISC O-MISC
BRLF1 B-MISC B-MISC
( I-MISC O-MISC
R I-MISC I-MISC
) I-MISC O-MISC
in O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
and O-MISC O-MISC
examined O-MISC O-MISC
PML B-MISC O-MISC
localization O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
Z O-MISC O-MISC
and O-MISC O-MISC
R O-MISC O-MISC
expression O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
PML B-MISC O-MISC
dispersion O-MISC O-MISC
in O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Z O-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
R O-MISC I-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
disrupt O-MISC O-MISC
PML O-MISC O-MISC
bodies O-MISC O-MISC
in O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
negative O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
dispersion O-MISC O-MISC
of O-MISC O-MISC
PML O-MISC O-MISC
bodies O-MISC O-MISC
by O-MISC O-MISC
Z B-MISC B-MISC
requires O-MISC O-MISC
a O-MISC O-MISC
portion O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcriptional B-MISC O-MISC
activation I-MISC O-MISC
domain I-MISC O-MISC
of O-MISC O-MISC
Z B-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
was O-MISC O-MISC
previously O-MISC O-MISC
reported O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
HSV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
ICP0 I-MISC I-MISC
and I-MISC I-MISC
CMV I-MISC I-MISC
IE1 I-MISC I-MISC
proteins I-MISC I-MISC
, O-MISC O-MISC
Z B-MISC B-MISC
reduces O-MISC O-MISC
the O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
SUMO B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- I-MISC O-MISC
modified I-MISC O-MISC
PML I-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
also O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
Z B-MISC B-MISC
itself O-MISC O-MISC
is O-MISC O-MISC
SUMO O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
modified O-MISC O-MISC
( O-MISC O-MISC
through O-MISC O-MISC
amino O-MISC O-MISC
acid O-MISC O-MISC
12 O-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
Z B-MISC B-MISC
competes O-MISC O-MISC
with O-MISC O-MISC
PML B-MISC O-MISC
for O-MISC O-MISC
limiting O-MISC O-MISC
amounts O-MISC O-MISC
of O-MISC O-MISC
SUMO B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
disruption O-MISC O-MISC
of O-MISC O-MISC
PML O-MISC B-MISC
bodies O-MISC I-MISC
is O-MISC O-MISC
important O-MISC O-MISC
for O-MISC O-MISC
efficient O-MISC O-MISC
lytic O-MISC O-MISC
replication O-MISC O-MISC
of O-MISC O-MISC
EBV O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
Z B-MISC O-MISC
may O-MISC O-MISC
potentially O-MISC O-MISC
alter O-MISC O-MISC
the O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
cellular O-MISC B-MISC
proteins O-MISC I-MISC
by O-MISC O-MISC
inhibiting O-MISC O-MISC
SUMO O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
modification O-MISC O-MISC

Suppression O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
inhibitor B-MISC O-MISC
kappaB I-MISC O-MISC
by O-MISC O-MISC
troglitazone O-MISC O-MISC
: O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
an O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
effect O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
potential O-MISC O-MISC
antiatherosclerotic O-MISC O-MISC
effect O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
obese O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
elucidate O-MISC O-MISC
whether O-MISC O-MISC
troglitazone O-MISC O-MISC
exerts O-MISC O-MISC
an O-MISC O-MISC
antiinflammatory O-MISC O-MISC
effect O-MISC O-MISC
in O-MISC O-MISC
humans O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
kappaB I-MISC I-MISC
( O-MISC O-MISC
NFkappaB B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
MNC O-MISC O-MISC
) O-MISC O-MISC
by O-MISC O-MISC
this O-MISC O-MISC
drug O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
measured O-MISC O-MISC
intranuclear B-MISC O-MISC
NFkappaB I-MISC B-MISC
, O-MISC O-MISC
total O-MISC O-MISC
cellular B-MISC O-MISC
NFkappaB I-MISC B-MISC
, O-MISC O-MISC
inhibitor B-MISC O-MISC
kappaB I-MISC I-MISC
( I-MISC O-MISC
IkappaB I-MISC B-MISC
) I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
species O-MISC O-MISC
( O-MISC O-MISC
ROS O-MISC O-MISC
) O-MISC O-MISC
generation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
p47 B-MISC B-MISC
( I-MISC I-MISC
phox I-MISC I-MISC
) I-MISC I-MISC
subunit I-MISC I-MISC
( O-MISC O-MISC
a O-MISC O-MISC
key O-MISC O-MISC
component O-MISC O-MISC
protein O-MISC O-MISC
of O-MISC O-MISC
nicotinamide B-MISC O-MISC
adenine I-MISC O-MISC
dinucleotide I-MISC O-MISC
phosphate I-MISC O-MISC
oxidase I-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
MNC O-MISC O-MISC
. O-MISC O-MISC

Plasma B-MISC B-MISC
tumor I-MISC I-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
TNF I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
soluble B-MISC O-MISC
intercellular I-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
sICAM B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
monocyte B-MISC B-MISC
chemoattractant I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( I-MISC O-MISC
MCP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) I-MISC O-MISC
, O-MISC O-MISC
plasminogen B-MISC B-MISC
activator I-MISC I-MISC
inhibitor I-MISC I-MISC
type I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
PAI B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
C B-MISC B-MISC
- I-MISC I-MISC
reactive I-MISC I-MISC
protein I-MISC I-MISC
( I-MISC O-MISC
CRP I-MISC I-MISC
) I-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
interleukin B-MISC B-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
( O-MISC O-MISC
antiinflammatory B-MISC I-MISC
cytokine I-MISC I-MISC
) O-MISC O-MISC
concentrations O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
measured O-MISC O-MISC
as O-MISC O-MISC
mediators O-MISC O-MISC
of O-MISC O-MISC
inflammatory O-MISC O-MISC
activity O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
proinflammatory B-MISC B-MISC
transcription I-MISC O-MISC
factor I-MISC I-MISC
NFkappaB I-MISC B-MISC
. O-MISC O-MISC

Seven O-MISC O-MISC
nondiabetic O-MISC O-MISC
obese O-MISC O-MISC
patients O-MISC O-MISC
were O-MISC O-MISC
given O-MISC O-MISC
400 O-MISC O-MISC
mg O-MISC O-MISC
troglitazone O-MISC O-MISC
daily O-MISC O-MISC
for O-MISC O-MISC
4 O-MISC O-MISC
weeks O-MISC O-MISC
. O-MISC O-MISC

Blood O-MISC O-MISC
samples O-MISC O-MISC
were O-MISC O-MISC
collected O-MISC O-MISC
before O-MISC O-MISC
and O-MISC O-MISC
at O-MISC O-MISC
weekly O-MISC O-MISC
intervals O-MISC O-MISC
thereafter O-MISC O-MISC
. O-MISC O-MISC

MNC O-MISC O-MISC
were O-MISC O-MISC
separated O-MISC O-MISC
; O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
intranuclear B-MISC O-MISC
NFkappaB I-MISC B-MISC
, O-MISC O-MISC
total O-MISC O-MISC
cellular B-MISC O-MISC
NFkappaB I-MISC B-MISC
, O-MISC O-MISC
IkappaBalpha B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
p47 B-MISC B-MISC
( I-MISC O-MISC
phox I-MISC B-MISC
) I-MISC O-MISC
subunit I-MISC O-MISC
and O-MISC O-MISC
ROS O-MISC O-MISC
generation O-MISC O-MISC
were O-MISC O-MISC
determined O-MISC O-MISC
. O-MISC O-MISC

Plasma O-MISC O-MISC
was O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
measure O-MISC O-MISC
insulin O-MISC O-MISC
glucose O-MISC O-MISC
, O-MISC O-MISC
TNFalpha B-MISC B-MISC
, O-MISC O-MISC
sICAM B-MISC O-MISC
, O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
PAI B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
CRP B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
. O-MISC O-MISC

Plasma O-MISC O-MISC
insulin O-MISC B-MISC
concentrations O-MISC O-MISC
fell O-MISC O-MISC
significantly O-MISC O-MISC
at O-MISC O-MISC
week O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
from O-MISC O-MISC
31 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
29 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
to O-MISC O-MISC
14 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
11 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
mU O-MISC O-MISC
/ O-MISC O-MISC
L O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
remained O-MISC O-MISC
low O-MISC O-MISC
throughout O-MISC O-MISC
4 O-MISC O-MISC
weeks O-MISC O-MISC
. O-MISC O-MISC

Plasma O-MISC O-MISC
glucose O-MISC O-MISC
concentrations O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
alter O-MISC O-MISC
significantly O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
fall O-MISC O-MISC
in O-MISC O-MISC
intranuclear B-MISC O-MISC
NFkappaB I-MISC B-MISC
, O-MISC O-MISC
total O-MISC O-MISC
cellular B-MISC O-MISC
NFkappaB I-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
p47 B-MISC B-MISC
( I-MISC I-MISC
phox I-MISC B-MISC
) I-MISC I-MISC
subunit I-MISC I-MISC
, O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
cellular O-MISC O-MISC
IkappaBalpha B-MISC B-MISC
at O-MISC O-MISC
week O-MISC O-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
persisted O-MISC O-MISC
until O-MISC O-MISC
week O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
was O-MISC O-MISC
a O-MISC O-MISC
parallel O-MISC O-MISC
fall O-MISC O-MISC
in O-MISC O-MISC
ROS O-MISC O-MISC
generation O-MISC O-MISC
by O-MISC O-MISC
MNC O-MISC O-MISC
at O-MISC O-MISC
week O-MISC O-MISC
1 O-MISC O-MISC
; O-MISC O-MISC
this O-MISC O-MISC
progressed O-MISC O-MISC
and O-MISC O-MISC
persisted O-MISC O-MISC
until O-MISC O-MISC
week O-MISC O-MISC
4 O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Plasma O-MISC B-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
sICAM B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
MCP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
PAI B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
concentrations O-MISC O-MISC
fell O-MISC O-MISC
significantly O-MISC O-MISC
at O-MISC O-MISC
week O-MISC O-MISC
4 O-MISC O-MISC
. O-MISC O-MISC

Plasma O-MISC B-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
concentration O-MISC O-MISC
increased O-MISC O-MISC
significantly O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
plasma B-MISC O-MISC
CRP I-MISC O-MISC
concentrations O-MISC O-MISC
decreased O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
troglitazone O-MISC O-MISC
has O-MISC O-MISC
an O-MISC O-MISC
antiinflammatory O-MISC O-MISC
action O-MISC O-MISC
that O-MISC O-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
its O-MISC O-MISC
putative O-MISC O-MISC
antiatherosclerotic O-MISC O-MISC
effects O-MISC O-MISC
. O-MISC O-MISC

Tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
. O-MISC O-MISC

Requirement O-MISC O-MISC
for O-MISC O-MISC
p56 B-MISC B-MISC
LCK I-MISC I-MISC
and I-MISC O-MISC
ZAP I-MISC B-MISC
- I-MISC I-MISC
70 I-MISC I-MISC
protein I-MISC I-MISC
tyrosine I-MISC I-MISC
kinases I-MISC I-MISC
. O-MISC O-MISC

Phosphorylation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
N B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
inhibitory I-MISC I-MISC
subunits I-MISC I-MISC
induces O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
serine O-MISC O-MISC
phosphorylation O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
ubiquitination O-MISC O-MISC
and O-MISC O-MISC
subsequent O-MISC O-MISC
proteasome O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
little O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
about O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
that O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
release O-MISC O-MISC
of O-MISC O-MISC
active O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
consequence O-MISC O-MISC
of O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
[ O-MISC O-MISC
Imbert O-MISC B-MISC
, O-MISC O-MISC
V O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Rupec O-MISC O-MISC
, O-MISC O-MISC
R O-MISC O-MISC
. O-MISC O-MISC
A O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Livolsi O-MISC O-MISC
, O-MISC O-MISC
A O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Pahl O-MISC O-MISC
, O-MISC O-MISC
H O-MISC O-MISC
. O-MISC O-MISC
L O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Traenckner O-MISC O-MISC
, O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Mueller O-MISC O-MISC
- O-MISC O-MISC
Dieckmann O-MISC O-MISC
, O-MISC O-MISC
C O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Farahifar O-MISC O-MISC
, O-MISC O-MISC
D O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Rossi O-MISC O-MISC
, O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Auberger O-MISC O-MISC
, O-MISC O-MISC
P O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Baeuerle O-MISC O-MISC
, O-MISC O-MISC
P O-MISC O-MISC
. O-MISC O-MISC
& O-MISC O-MISC
Peyron O-MISC O-MISC
, O-MISC O-MISC
J O-MISC O-MISC
. O-MISC O-MISC
F O-MISC O-MISC
. O-MISC O-MISC
( O-MISC O-MISC
1996 O-MISC O-MISC
) O-MISC O-MISC
Cell O-MISC O-MISC
86 O-MISC O-MISC
, O-MISC O-MISC
787 O-MISC O-MISC
- O-MISC O-MISC
- O-MISC O-MISC
798 O-MISC O-MISC
] O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tyrosine B-MISC B-MISC
kinases I-MISC I-MISC
p56 B-MISC I-MISC
( I-MISC I-MISC
lck I-MISC I-MISC
) I-MISC I-MISC
and O-MISC O-MISC
ZAP B-MISC B-MISC
- I-MISC I-MISC
70 I-MISC I-MISC
in O-MISC O-MISC
this O-MISC O-MISC
reaction O-MISC O-MISC
is O-MISC O-MISC
demonstrated O-MISC O-MISC
here O-MISC O-MISC
using O-MISC O-MISC
specific O-MISC O-MISC
pharmacological O-MISC O-MISC
inhibitors O-MISC O-MISC
and O-MISC O-MISC
Jurkat O-MISC O-MISC
mutants O-MISC O-MISC
unable O-MISC O-MISC
to O-MISC O-MISC
express O-MISC O-MISC
these O-MISC O-MISC
kinases B-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
the O-MISC O-MISC
inhibitors O-MISC O-MISC
prevented O-MISC O-MISC
both O-MISC O-MISC
pervanadate O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
on O-MISC O-MISC
Tyr42 O-MISC B-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
observed O-MISC O-MISC
that O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
p56 O-MISC O-MISC
( O-MISC O-MISC
lck O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
Jurkat O-MISC O-MISC
mutants O-MISC O-MISC
, O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
could O-MISC O-MISC
still O-MISC O-MISC
associate O-MISC O-MISC
with O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
despite O-MISC O-MISC
phosphorylation O-MISC O-MISC
on O-MISC O-MISC
Tyr42 O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
SH2 B-MISC B-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
p56 B-MISC B-MISC
( I-MISC I-MISC
lck I-MISC I-MISC
) I-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
pervanadate O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
for O-MISC O-MISC
Tyr42 O-MISC O-MISC
phosphorylation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
p56 B-MISC B-MISC
( I-MISC I-MISC
lck I-MISC I-MISC
) I-MISC I-MISC
and O-MISC O-MISC
ZAP B-MISC B-MISC
- I-MISC I-MISC
70 I-MISC I-MISC
are O-MISC O-MISC
key O-MISC O-MISC
components O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
that O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
phosphotyrosine O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
confirm O-MISC O-MISC
that O-MISC O-MISC
tyrosine B-MISC B-MISC
kinases I-MISC I-MISC
must O-MISC O-MISC
control O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
two O-MISC O-MISC
different O-MISC O-MISC
steps O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
H O-MISC B-MISC
( O-MISC I-MISC
2 O-MISC I-MISC
) O-MISC I-MISC
O O-MISC I-MISC
( O-MISC I-MISC
2 O-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
stimulates O-MISC O-MISC
p56 B-MISC B-MISC
( I-MISC I-MISC
lck I-MISC I-MISC
) I-MISC I-MISC
and O-MISC O-MISC
ZAP B-MISC B-MISC
- I-MISC I-MISC
70 I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
activator O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
through O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

Specific O-MISC O-MISC
missense O-MISC O-MISC
mutations O-MISC O-MISC
in O-MISC O-MISC
NEMO B-MISC O-MISC
result O-MISC O-MISC
in O-MISC O-MISC
hyper O-MISC O-MISC
- O-MISC O-MISC
IgM O-MISC I-MISC
syndrome O-MISC O-MISC
with O-MISC O-MISC
hypohydrotic O-MISC O-MISC
ectodermal O-MISC O-MISC
dysplasia O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
gene O-MISC O-MISC
that O-MISC O-MISC
encodes O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
kappaB I-MISC I-MISC
( I-MISC O-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) I-MISC O-MISC
essential I-MISC O-MISC
modulator I-MISC O-MISC
( O-MISC O-MISC
or O-MISC O-MISC
NEMO B-MISC O-MISC
, O-MISC O-MISC
also O-MISC O-MISC
known O-MISC O-MISC
as O-MISC O-MISC
IKKgamma B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
describe O-MISC O-MISC
mutations O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
putative B-MISC O-MISC
zinc I-MISC B-MISC
- I-MISC I-MISC
finger I-MISC I-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
NEMO B-MISC B-MISC
that O-MISC O-MISC
result O-MISC O-MISC
in O-MISC O-MISC
an O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
primary O-MISC O-MISC
immunodeficiency O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
hyper O-MISC O-MISC
- O-MISC O-MISC
IgM O-MISC O-MISC
syndrome O-MISC O-MISC
and O-MISC O-MISC
hypohydrotic O-MISC O-MISC
ectodermal O-MISC O-MISC
dysplasia O-MISC O-MISC
( O-MISC O-MISC
XHM O-MISC O-MISC
- O-MISC O-MISC
ED O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
mutations O-MISC O-MISC
prevent O-MISC O-MISC
CD40 B-MISC B-MISC
ligand I-MISC O-MISC
( O-MISC O-MISC
CD40L B-MISC B-MISC
) O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
IkappaB B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
account O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
following O-MISC O-MISC
observations O-MISC O-MISC
: O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
XHM O-MISC O-MISC
- O-MISC O-MISC
ED O-MISC O-MISC
patients O-MISC O-MISC
are O-MISC O-MISC
unable O-MISC O-MISC
to O-MISC O-MISC
undergo O-MISC O-MISC
immunoglobulin O-MISC B-MISC
class O-MISC I-MISC
- O-MISC O-MISC
switch O-MISC O-MISC
recombination O-MISC O-MISC
and O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
presenting O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
APCs O-MISC O-MISC
) O-MISC O-MISC
are O-MISC O-MISC
unable O-MISC O-MISC
to O-MISC O-MISC
synthesize O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
regulated I-MISC I-MISC
cytokines I-MISC I-MISC
interleukin B-MISC B-MISC
12 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
12 I-MISC I-MISC
) O-MISC O-MISC
or O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
when O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
CD40L B-MISC B-MISC
. O-MISC O-MISC

Nevertheless O-MISC O-MISC
, O-MISC O-MISC
innate O-MISC O-MISC
immunity O-MISC O-MISC
is O-MISC O-MISC
preserved O-MISC O-MISC
in O-MISC O-MISC
XHM O-MISC O-MISC
- O-MISC O-MISC
ED O-MISC O-MISC
patients O-MISC O-MISC
because O-MISC O-MISC
APCs O-MISC O-MISC
retain O-MISC O-MISC
the O-MISC O-MISC
capacity O-MISC O-MISC
to O-MISC O-MISC
respond O-MISC O-MISC
to O-MISC O-MISC
stimulation O-MISC O-MISC
by O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
or O-MISC O-MISC
Staphylococcus B-MISC B-MISC
aureus I-MISC O-MISC
Cowan I-MISC O-MISC
' I-MISC O-MISC
s I-MISC O-MISC
antigen I-MISC O-MISC
( O-MISC O-MISC
SAC B-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Overall O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
phenotype O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
XHM O-MISC O-MISC
- O-MISC O-MISC
ED O-MISC O-MISC
patients O-MISC O-MISC
shows O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
putative B-MISC O-MISC
zinc I-MISC B-MISC
- I-MISC I-MISC
finger I-MISC I-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
NEMO B-MISC O-MISC
has O-MISC O-MISC
a O-MISC O-MISC
regulatory O-MISC O-MISC
function O-MISC O-MISC
and O-MISC O-MISC
demonstrates O-MISC O-MISC
the O-MISC O-MISC
definite O-MISC O-MISC
requirement O-MISC O-MISC
of O-MISC O-MISC
CD40 B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
activation O-MISC O-MISC
for O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
immunoglobulin O-MISC B-MISC
class O-MISC O-MISC
- O-MISC O-MISC
switching O-MISC O-MISC
. O-MISC O-MISC

Granulocytic O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
NB4 O-MISC O-MISC
promyelocytic O-MISC O-MISC
leukemia O-MISC O-MISC
cells O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
all O-MISC O-MISC
- O-MISC O-MISC
trans O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
metabolites O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
metabolism O-MISC O-MISC
of O-MISC O-MISC
all O-MISC O-MISC
- O-MISC O-MISC
trans O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
ATRA O-MISC O-MISC
) O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
reported O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
partly O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
resistance O-MISC O-MISC
to O-MISC O-MISC
ATRA O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
acute O-MISC O-MISC
promyelocytic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
APL O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
ATRA O-MISC O-MISC
metabolism O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
growth O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
several O-MISC O-MISC
cancer O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
purpose O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
was O-MISC O-MISC
to O-MISC O-MISC
evaluate O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
principal O-MISC O-MISC
metabolites O-MISC O-MISC
of O-MISC O-MISC
ATRA O-MISC O-MISC
[ O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
hydroxy O-MISC O-MISC
- O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
RA O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
18 O-MISC O-MISC
- O-MISC O-MISC
hydroxy O-MISC O-MISC
- O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
18 O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
RA O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
oxo O-MISC O-MISC
- O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
oxo O-MISC O-MISC
- O-MISC O-MISC
RA O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
5 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
epoxy O-MISC O-MISC
- O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
epoxy O-MISC O-MISC
- O-MISC O-MISC
RA O-MISC O-MISC
) O-MISC O-MISC
] O-MISC O-MISC
in O-MISC O-MISC
NB4 O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
human O-MISC O-MISC
promyelocytic O-MISC O-MISC
leukemia O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
that O-MISC O-MISC
exhibits O-MISC O-MISC
the O-MISC O-MISC
APL O-MISC B-MISC
diagnostic O-MISC I-MISC
t O-MISC I-MISC
( O-MISC I-MISC
15 O-MISC I-MISC
; O-MISC I-MISC
17 O-MISC I-MISC
) O-MISC I-MISC
chromosomal O-MISC I-MISC
translocation O-MISC O-MISC
and O-MISC O-MISC
expresses O-MISC O-MISC
the O-MISC O-MISC
PML B-MISC B-MISC
- I-MISC I-MISC
RAR I-MISC I-MISC
alpha I-MISC I-MISC
fusion I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
established O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
four O-MISC O-MISC
ATRA O-MISC O-MISC
metabolites O-MISC O-MISC
were O-MISC O-MISC
indeed O-MISC O-MISC
formed O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
NB4 O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

NB4 O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
( O-MISC O-MISC
69 O-MISC O-MISC
- O-MISC O-MISC
78 O-MISC O-MISC
% O-MISC O-MISC
at O-MISC O-MISC
120 O-MISC O-MISC
h O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
progression O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
G1 O-MISC O-MISC
phase O-MISC O-MISC
( O-MISC O-MISC
82 O-MISC O-MISC
- O-MISC O-MISC
85 O-MISC O-MISC
% O-MISC O-MISC
at O-MISC O-MISC
120 O-MISC O-MISC
h O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
ATRA O-MISC O-MISC
and O-MISC O-MISC
all O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
metabolites O-MISC O-MISC
at O-MISC O-MISC
1 O-MISC O-MISC
microM O-MISC O-MISC
concentration O-MISC O-MISC
. O-MISC O-MISC

ATRA O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
metabolites O-MISC O-MISC
could O-MISC O-MISC
induce O-MISC O-MISC
NB4 O-MISC O-MISC
cells O-MISC O-MISC
differentiation O-MISC O-MISC
with O-MISC O-MISC
similar O-MISC O-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
evaluated O-MISC O-MISC
by O-MISC O-MISC
cell O-MISC O-MISC
morphology O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
nitroblue O-MISC O-MISC
tetrazolium O-MISC O-MISC
reduction O-MISC O-MISC
test O-MISC O-MISC
( O-MISC O-MISC
82 O-MISC O-MISC
- O-MISC O-MISC
88 O-MISC O-MISC
% O-MISC O-MISC
at O-MISC O-MISC
120 O-MISC O-MISC
h O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
maturation B-MISC O-MISC
specific I-MISC I-MISC
cell I-MISC I-MISC
surface I-MISC I-MISC
marker I-MISC I-MISC
CD11c I-MISC B-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
nuclear O-MISC O-MISC
body O-MISC O-MISC
reorganization O-MISC O-MISC
to O-MISC O-MISC
macropunctated O-MISC O-MISC
structures O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
PML B-MISC B-MISC
- I-MISC I-MISC
RAR I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
similar O-MISC O-MISC
for O-MISC O-MISC
ATRA O-MISC O-MISC
and O-MISC O-MISC
all O-MISC O-MISC
of O-MISC O-MISC
its O-MISC O-MISC
metabolites O-MISC O-MISC
. O-MISC O-MISC

Comparison O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
relative O-MISC O-MISC
potency O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
retinoids O-MISC O-MISC
using O-MISC O-MISC
the O-MISC O-MISC
nitroblue O-MISC O-MISC
tetrazolium O-MISC O-MISC
reduction O-MISC O-MISC
test O-MISC O-MISC
showed O-MISC O-MISC
effective O-MISC O-MISC
concentrations O-MISC O-MISC
required O-MISC O-MISC
to O-MISC O-MISC
differentiate O-MISC O-MISC
50 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
72 O-MISC O-MISC
h O-MISC O-MISC
as O-MISC O-MISC
follows O-MISC O-MISC
: O-MISC O-MISC
ATRA O-MISC O-MISC
, O-MISC O-MISC
15 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
nM O-MISC O-MISC
; O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
oxo O-MISC O-MISC
- O-MISC O-MISC
RA O-MISC O-MISC
, O-MISC O-MISC
38 O-MISC O-MISC
. O-MISC O-MISC
3 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
3 O-MISC O-MISC
nM O-MISC O-MISC
; O-MISC O-MISC
18 O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
RA O-MISC O-MISC
, O-MISC O-MISC
55 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
nM O-MISC O-MISC
; O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
OH O-MISC O-MISC
- O-MISC O-MISC
RA O-MISC O-MISC
, O-MISC O-MISC
79 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
nM O-MISC O-MISC
; O-MISC O-MISC
and O-MISC O-MISC
5 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
- O-MISC O-MISC
epoxy O-MISC O-MISC
- O-MISC O-MISC
RA O-MISC O-MISC
, O-MISC O-MISC
99 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
nM O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ATRA O-MISC O-MISC
metabolites O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
exert O-MISC O-MISC
their O-MISC O-MISC
differentiation O-MISC O-MISC
effects O-MISC O-MISC
via O-MISC O-MISC
the O-MISC O-MISC
RAR B-MISC B-MISC
alpha I-MISC I-MISC
nuclear I-MISC I-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
because O-MISC O-MISC
the O-MISC O-MISC
RAR O-MISC B-MISC
alpha O-MISC I-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
antagonist O-MISC O-MISC
BMS614 O-MISC O-MISC
blocked O-MISC O-MISC
metabolite O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
CD11c O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
NB4 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
principal O-MISC O-MISC
ATRA O-MISC O-MISC
Phase O-MISC O-MISC
1 O-MISC O-MISC
metabolites O-MISC O-MISC
can O-MISC O-MISC
elicit O-MISC O-MISC
leukemia O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
inhibition O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
RAR O-MISC B-MISC
alpha O-MISC I-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
they O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
these O-MISC O-MISC
metabolites O-MISC O-MISC
may O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
ATRA O-MISC O-MISC
antileukemic O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
oestrogen B-MISC O-MISC
and I-MISC I-MISC
progesterone I-MISC B-MISC
receptors I-MISC I-MISC
by O-MISC O-MISC
mast O-MISC O-MISC
cells O-MISC O-MISC
alone O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
macrophages O-MISC O-MISC
or O-MISC O-MISC
other O-MISC O-MISC
immune O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
upper O-MISC O-MISC
airways O-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
Nasal O-MISC O-MISC
polyposis O-MISC O-MISC
often O-MISC O-MISC
coexists O-MISC O-MISC
with O-MISC O-MISC
asthma O-MISC O-MISC
in O-MISC O-MISC
airway O-MISC O-MISC
inflammatory O-MISC O-MISC
conditions O-MISC O-MISC
characterised O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
infiltration O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
range O-MISC O-MISC
of O-MISC O-MISC
immune O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
potentially O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
ovarian O-MISC O-MISC
hormones O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
implicated O-MISC O-MISC
in O-MISC O-MISC
airway O-MISC O-MISC
inflammation O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
such O-MISC O-MISC
action O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
known O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Expression O-MISC O-MISC
of O-MISC O-MISC
oestrogen B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
ER B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
progesterone B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
PR B-MISC B-MISC
) O-MISC O-MISC
was O-MISC O-MISC
examined O-MISC O-MISC
using O-MISC O-MISC
immunohistochemistry O-MISC O-MISC
in O-MISC O-MISC
formalin O-MISC O-MISC
fixed O-MISC O-MISC
nasal O-MISC O-MISC
polyp O-MISC O-MISC
tissues O-MISC O-MISC
from O-MISC O-MISC
47 O-MISC O-MISC
subjects O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cells O-MISC O-MISC
positive O-MISC O-MISC
for O-MISC O-MISC
ER B-MISC B-MISC
or O-MISC O-MISC
PR B-MISC B-MISC
were O-MISC O-MISC
confirmed O-MISC O-MISC
by O-MISC O-MISC
spatial O-MISC O-MISC
location O-MISC O-MISC
, O-MISC O-MISC
dual O-MISC O-MISC
immunolabelling O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
histochemical O-MISC O-MISC
staining O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Consistent O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
known O-MISC O-MISC
features O-MISC O-MISC
of O-MISC O-MISC
nasal O-MISC O-MISC
polyps O-MISC O-MISC
, O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
( O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
/ O-MISC O-MISC
inducer O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
( O-MISC O-MISC
cytotoxic O-MISC O-MISC
/ O-MISC O-MISC
suppressor O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
CD68 O-MISC O-MISC
+ O-MISC O-MISC
( O-MISC O-MISC
macrophages O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
mast O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
eosinophils O-MISC O-MISC
and O-MISC O-MISC
neutrophils O-MISC O-MISC
were O-MISC O-MISC
all O-MISC O-MISC
clearly O-MISC O-MISC
detected O-MISC O-MISC
by O-MISC O-MISC
their O-MISC O-MISC
relevant O-MISC O-MISC
monoclonal B-MISC B-MISC
antibodies I-MISC I-MISC
or O-MISC O-MISC
appropriate O-MISC O-MISC
histochemical O-MISC O-MISC
staining O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
only O-MISC O-MISC
mast O-MISC O-MISC
cells O-MISC O-MISC
tested O-MISC O-MISC
positive O-MISC O-MISC
for O-MISC O-MISC
ER B-MISC B-MISC
/ O-MISC I-MISC
PR O-MISC I-MISC
labelling O-MISC O-MISC
with O-MISC O-MISC
their O-MISC O-MISC
polyclonal B-MISC B-MISC
and I-MISC O-MISC
monoclonal I-MISC B-MISC
antibodies I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
frequencies O-MISC O-MISC
for O-MISC O-MISC
expression O-MISC O-MISC
were O-MISC O-MISC
61 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
% O-MISC O-MISC
for O-MISC O-MISC
ER O-MISC O-MISC
positive O-MISC O-MISC
and O-MISC O-MISC
59 O-MISC O-MISC
. O-MISC O-MISC
6 O-MISC O-MISC
% O-MISC O-MISC
for O-MISC O-MISC
PR O-MISC O-MISC
positive O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
ER B-MISC B-MISC
/ O-MISC I-MISC
PR B-MISC I-MISC
was O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
patient O-MISC O-MISC
sex O-MISC O-MISC
and O-MISC O-MISC
age O-MISC O-MISC
but O-MISC O-MISC
was O-MISC O-MISC
highly O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
mast O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
r O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
973 O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
for O-MISC O-MISC
ER B-MISC B-MISC
; O-MISC O-MISC
r O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
955 O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
for O-MISC O-MISC
PR B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Fewer O-MISC O-MISC
than O-MISC O-MISC
5 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
mast O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
negative O-MISC O-MISC
for O-MISC O-MISC
ER B-MISC B-MISC
/ O-MISC O-MISC
PR B-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
Mast O-MISC O-MISC
cells O-MISC O-MISC
alone O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
macrophages O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
other O-MISC O-MISC
immune O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
express O-MISC O-MISC
ER B-MISC B-MISC
/ O-MISC I-MISC
PR B-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
upper O-MISC O-MISC
airways O-MISC O-MISC
. O-MISC O-MISC

Numerous O-MISC O-MISC
ER O-MISC O-MISC
/ O-MISC O-MISC
PR O-MISC O-MISC
positive O-MISC O-MISC
mast O-MISC O-MISC
cells O-MISC O-MISC
exist O-MISC O-MISC
in O-MISC O-MISC
nasal O-MISC O-MISC
polyps O-MISC O-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
route O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
sex O-MISC O-MISC
hormones O-MISC O-MISC
in O-MISC O-MISC
airway O-MISC O-MISC
inflammation O-MISC O-MISC
when O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
higher O-MISC O-MISC
and O-MISC O-MISC
varying O-MISC O-MISC
concentration O-MISC O-MISC
of O-MISC O-MISC
oestrogen O-MISC O-MISC
and O-MISC O-MISC
progesterone O-MISC O-MISC
characteristic O-MISC O-MISC
of O-MISC O-MISC
females O-MISC O-MISC
. O-MISC O-MISC

NF O-MISC B-MISC
kappa O-MISC I-MISC
b O-MISC O-MISC
signaling O-MISC O-MISC
in O-MISC O-MISC
posthypoxic O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
: O-MISC O-MISC
relevance O-MISC O-MISC
to O-MISC O-MISC
E O-MISC B-MISC
- O-MISC I-MISC
selectin O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
neutrophil O-MISC O-MISC
adhesion O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
previous O-MISC O-MISC
studies O-MISC O-MISC
have O-MISC O-MISC
implicated O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC B-MISC
transcription O-MISC I-MISC
factor O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
adhesion B-MISC B-MISC
molecule I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
anoxia O-MISC O-MISC
- O-MISC O-MISC
reoxygenation O-MISC O-MISC
( O-MISC O-MISC
A O-MISC O-MISC
/ O-MISC O-MISC
R O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
a O-MISC O-MISC
redox O-MISC O-MISC
imbalance O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
objectives O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
were O-MISC O-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
to O-MISC O-MISC
define O-MISC O-MISC
the O-MISC O-MISC
kinetics O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
examining O-MISC O-MISC
I O-MISC B-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
alpha O-MISC I-MISC
degradation O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
A O-MISC O-MISC
/ O-MISC O-MISC
R O-MISC O-MISC
or O-MISC O-MISC
redox O-MISC O-MISC
imbalance O-MISC O-MISC
( O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
diamide O-MISC O-MISC
and O-MISC O-MISC
buthionine O-MISC O-MISC
sulfoximine O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
the O-MISC O-MISC
signal O-MISC O-MISC
for O-MISC O-MISC
I O-MISC B-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
alpha O-MISC I-MISC
degradation O-MISC O-MISC
, O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
selectin I-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
neutrophil O-MISC O-MISC
adhesion O-MISC O-MISC
is O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
protein B-MISC B-MISC
tyrosine I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
PTK B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
protein B-MISC B-MISC
tyrosine I-MISC I-MISC
phosphatase I-MISC I-MISC
( O-MISC O-MISC
PTPase B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
/ O-MISC B-MISC
or O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
( O-MISC O-MISC
PKC B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
both O-MISC O-MISC
A O-MISC O-MISC
/ O-MISC O-MISC
R O-MISC O-MISC
and O-MISC O-MISC
redox O-MISC O-MISC
imbalance O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
I O-MISC B-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
alpha O-MISC I-MISC
degradation O-MISC O-MISC
within O-MISC O-MISC
30 O-MISC O-MISC
min O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
concomitant O-MISC O-MISC
appearance O-MISC O-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
, O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
rapid O-MISC O-MISC
cytosolic O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
and O-MISC O-MISC
subsequent O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
activated B-MISC O-MISC
p65 I-MISC B-MISC
subunit I-MISC I-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
PKC B-MISC B-MISC
blocked O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
degradation O-MISC O-MISC
and O-MISC O-MISC
p65 B-MISC B-MISC
translocation O-MISC O-MISC
in O-MISC O-MISC
A O-MISC O-MISC
/ O-MISC O-MISC
R O-MISC O-MISC
- O-MISC O-MISC
challenged O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
redox O-MISC O-MISC
- O-MISC O-MISC
altered O-MISC O-MISC
, O-MISC O-MISC
endothelial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
both O-MISC O-MISC
A O-MISC O-MISC
/ O-MISC O-MISC
R O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
redox O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
NF O-MISC B-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
activation O-MISC O-MISC
was O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
PTK B-MISC B-MISC
. O-MISC O-MISC

Similarly O-MISC O-MISC
, O-MISC O-MISC
A O-MISC O-MISC
/ O-MISC O-MISC
R O-MISC O-MISC
- O-MISC I-MISC
induced O-MISC O-MISC
E O-MISC B-MISC
- O-MISC I-MISC
selectin O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
neutrophil O-MISC O-MISC
- O-MISC O-MISC
endothelial O-MISC O-MISC
cell O-MISC O-MISC
adhesion O-MISC O-MISC
were O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
PKC B-MISC B-MISC
or O-MISC O-MISC
PTK B-MISC B-MISC
, O-MISC O-MISC
while O-MISC O-MISC
only O-MISC O-MISC
PTK B-MISC B-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
redox O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
adhesion O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Pretreatment O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
acetyl O-MISC O-MISC
cysteine O-MISC O-MISC
effectively O-MISC O-MISC
blocked O-MISC O-MISC
A O-MISC O-MISC
/ O-MISC O-MISC
R O-MISC O-MISC
- O-MISC O-MISC
or O-MISC O-MISC
redox O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
I O-MISC B-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
degradation O-MISC O-MISC
and O-MISC O-MISC
significantly O-MISC O-MISC
attenuated O-MISC O-MISC
the O-MISC O-MISC
respective O-MISC O-MISC
neutrophil O-MISC O-MISC
adhesion O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

Collectively O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
findings O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
A O-MISC O-MISC
/ O-MISC B-MISC
R O-MISC I-MISC
- O-MISC I-MISC
induced O-MISC I-MISC
E O-MISC B-MISC
- O-MISC I-MISC
selectin O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
neutrophil O-MISC O-MISC
- O-MISC O-MISC
endothelial O-MISC O-MISC
cell O-MISC O-MISC
adhesion O-MISC O-MISC
are O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
both O-MISC O-MISC
PKC B-MISC B-MISC
and O-MISC O-MISC
PTK B-MISC B-MISC
, O-MISC O-MISC
which O-MISC O-MISC
signal O-MISC O-MISC
rapid O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
A O-MISC O-MISC
/ O-MISC O-MISC
R O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
NF B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
signaling O-MISC O-MISC
response O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
mediated O-MISC O-MISC
, O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
intracellular O-MISC O-MISC
redox O-MISC O-MISC
imbalance O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
2001 O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
Karger O-MISC O-MISC
AG O-MISC O-MISC
, O-MISC O-MISC
Basel O-MISC O-MISC

Induction O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
herbicide O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
dichlorophenoxyaceti O-MISC O-MISC
acid O-MISC O-MISC
. O-MISC O-MISC

Dimethylammonium O-MISC O-MISC
salt O-MISC O-MISC
of O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
dichlorophenoxyaceti O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
DMA O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
D O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
widely O-MISC O-MISC
used O-MISC O-MISC
herbicide O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
considered O-MISC O-MISC
moderately O-MISC O-MISC
toxic O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
DMA O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
D O-MISC O-MISC
is O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
cause O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
lymphocytes O-MISC O-MISC
of O-MISC O-MISC
healthy O-MISC O-MISC
individuals O-MISC O-MISC
and O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Apoptosis O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
DMA O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
D O-MISC O-MISC
was O-MISC O-MISC
dose O-MISC O-MISC
and O-MISC O-MISC
time O-MISC O-MISC
dependent O-MISC O-MISC
, O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
Fas B-MISC B-MISC
, O-MISC O-MISC
TNF B-MISC B-MISC
receptor I-MISC I-MISC
1 I-MISC I-MISC
or O-MISC O-MISC
the O-MISC O-MISC
aromatic B-MISC O-MISC
hydrocarbon I-MISC O-MISC
receptor I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
involved O-MISC O-MISC
disruption O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mitochondrial O-MISC B-MISC
transmembrane O-MISC I-MISC
potential O-MISC O-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
caspase B-MISC B-MISC
- I-MISC I-MISC
9 I-MISC I-MISC
. O-MISC O-MISC

ZVAD O-MISC B-MISC
- O-MISC I-MISC
FMK O-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
broad O-MISC O-MISC
- O-MISC O-MISC
spectrum O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
caspases B-MISC B-MISC
, O-MISC O-MISC
blocked O-MISC O-MISC
DMA O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
completely O-MISC O-MISC
. O-MISC O-MISC

While O-MISC O-MISC
an O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
caspase B-MISC B-MISC
- I-MISC I-MISC
9 I-MISC I-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
caspase B-MISC B-MISC
- I-MISC I-MISC
9 I-MISC I-MISC
and O-MISC O-MISC
caspase O-MISC B-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
inhibitors O-MISC O-MISC
in O-MISC O-MISC
combination O-MISC O-MISC
, O-MISC O-MISC
strongly O-MISC O-MISC
blocked O-MISC O-MISC
DMA O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
caspase B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
had O-MISC O-MISC
a O-MISC O-MISC
moderate O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

Unlike O-MISC O-MISC
Fas B-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
initiator B-MISC O-MISC
caspase I-MISC B-MISC
, O-MISC O-MISC
caspase B-MISC B-MISC
- I-MISC I-MISC
8 I-MISC I-MISC
, O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
DMA O-MISC O-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Transfection O-MISC O-MISC
of O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
prevented O-MISC O-MISC
DMA O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
disruption O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mitochondrial O-MISC B-MISC
transmembrane O-MISC I-MISC
potential O-MISC O-MISC
and O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
complete O-MISC O-MISC
blockage O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
DMA O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
D O-MISC O-MISC
kills O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
by O-MISC O-MISC
initiating O-MISC O-MISC
apoptosis O-MISC O-MISC
via O-MISC O-MISC
a O-MISC O-MISC
direct O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
mitochondria O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
caspases B-MISC B-MISC
occurs O-MISC O-MISC
downstream O-MISC O-MISC
of O-MISC O-MISC
mitochondrial O-MISC O-MISC
damage O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
dysfunction O-MISC O-MISC
of O-MISC O-MISC
mitochondria O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
sufficient O-MISC O-MISC
for O-MISC O-MISC
triggering O-MISC O-MISC
all O-MISC O-MISC
downstream O-MISC O-MISC
events O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
Th1 O-MISC O-MISC
differentiation O-MISC O-MISC
by O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
SOCS1 B-MISC B-MISC
. O-MISC O-MISC

Interleukin B-MISC B-MISC
6 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
cytokine B-MISC B-MISC
produced O-MISC O-MISC
by O-MISC O-MISC
immune O-MISC O-MISC
and O-MISC O-MISC
nonimmune O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
exhibits O-MISC O-MISC
functional O-MISC O-MISC
pleiotropy O-MISC O-MISC
and O-MISC O-MISC
redundancy O-MISC O-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
plays O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
several O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
describe O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
: O-MISC O-MISC
the O-MISC O-MISC
negative O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
CD4 B-MISC O-MISC
+ O-MISC O-MISC
Th1 O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

While O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
- O-MISC O-MISC
directed O-MISC O-MISC
CD4 B-MISC O-MISC
+ O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
Th1 O-MISC O-MISC
differentiation O-MISC O-MISC
by O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
is O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
upregulates O-MISC O-MISC
suppressor B-MISC O-MISC
of I-MISC O-MISC
cytokine I-MISC B-MISC
signaling I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
SOCS1 B-MISC B-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
thereby O-MISC O-MISC
interfering O-MISC O-MISC
with O-MISC O-MISC
signal B-MISC B-MISC
transducer I-MISC I-MISC
and I-MISC I-MISC
activator I-MISC I-MISC
of I-MISC I-MISC
transcription I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
STAT1 B-MISC B-MISC
) O-MISC O-MISC
phosphorylation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
interferon B-MISC B-MISC
gamma I-MISC I-MISC
( O-MISC O-MISC
IFNgamma B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
IFNgamma B-MISC B-MISC
receptor O-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
signals O-MISC O-MISC
by O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
prevents O-MISC O-MISC
autoregulation O-MISC O-MISC
of O-MISC O-MISC
IFNgamma B-MISC B-MISC
gene I-MISC O-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
IFNgamma B-MISC B-MISC
during O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
thereby O-MISC O-MISC
preventing O-MISC O-MISC
Th1 O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
promotes O-MISC O-MISC
CD4 B-MISC O-MISC
+ O-MISC O-MISC
Th2 O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
inhibits O-MISC O-MISC
Th1 O-MISC O-MISC
differentiation O-MISC O-MISC
by O-MISC O-MISC
two O-MISC O-MISC
independent O-MISC O-MISC
molecular O-MISC O-MISC
mechanisms O-MISC O-MISC
. O-MISC O-MISC

Interaction O-MISC O-MISC
between O-MISC O-MISC
CCAAT B-MISC B-MISC
/ I-MISC I-MISC
enhancer I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
and O-MISC O-MISC
cyclic B-MISC B-MISC
AMP I-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
1 I-MISC O-MISC
regulates O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
transcription O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
monocyte O-MISC O-MISC
/ O-MISC O-MISC
macrophage O-MISC O-MISC
lineage O-MISC O-MISC
. O-MISC O-MISC

Recent O-MISC O-MISC
observations O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
two O-MISC O-MISC
CCAAT B-MISC B-MISC
/ I-MISC I-MISC
enhancer I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( I-MISC I-MISC
C I-MISC I-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
) I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
to O-MISC O-MISC
be O-MISC O-MISC
critically O-MISC O-MISC
important O-MISC O-MISC
for O-MISC O-MISC
efficient O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
replication O-MISC O-MISC
within O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
monocyte O-MISC O-MISC
/ O-MISC O-MISC
macrophage O-MISC O-MISC
lineage O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
likely O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
transport O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
virus O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
brain O-MISC O-MISC
. O-MISC O-MISC

Additionally O-MISC O-MISC
, O-MISC O-MISC
sequence O-MISC O-MISC
variation O-MISC O-MISC
at O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
site I-MISC I-MISC
I I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
lies O-MISC O-MISC
immediately O-MISC O-MISC
upstream O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
distal B-MISC B-MISC
nuclear I-MISC I-MISC
factor I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
site I-MISC I-MISC
and O-MISC O-MISC
immediately O-MISC O-MISC
downstream O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
binding O-MISC O-MISC
site O-MISC O-MISC
for O-MISC O-MISC
activating B-MISC B-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC I-MISC
ATF B-MISC B-MISC
) O-MISC I-MISC
/ O-MISC I-MISC
cyclic B-MISC I-MISC
AMP I-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
CREB B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
affect O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
long I-MISC I-MISC
terminal I-MISC I-MISC
repeat I-MISC I-MISC
( O-MISC O-MISC
LTR B-MISC B-MISC
) O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Given O-MISC O-MISC
that O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
proteins I-MISC I-MISC
have O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
many O-MISC O-MISC
other O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
including O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
ATF B-MISC B-MISC
/ I-MISC I-MISC
CREB I-MISC I-MISC
family I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
proceeded O-MISC O-MISC
to O-MISC O-MISC
determine O-MISC O-MISC
whether O-MISC O-MISC
an O-MISC O-MISC
adjacent O-MISC O-MISC
ATF B-MISC B-MISC
/ I-MISC I-MISC
CREB I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
could O-MISC O-MISC
affect O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
protein I-MISC I-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
site I-MISC I-MISC
I I-MISC I-MISC
. O-MISC O-MISC

Electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
analyses O-MISC O-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
selected O-MISC O-MISC
ATF B-MISC B-MISC
/ I-MISC I-MISC
CREB I-MISC I-MISC
site I-MISC I-MISC
variants I-MISC O-MISC
assisted O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
recruitment O-MISC O-MISC
of O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
proteins I-MISC I-MISC
to O-MISC O-MISC
an O-MISC O-MISC
adjacent O-MISC O-MISC
, O-MISC O-MISC
naturally O-MISC O-MISC
occurring O-MISC O-MISC
, O-MISC O-MISC
low O-MISC O-MISC
- O-MISC O-MISC
affinity O-MISC B-MISC
C B-MISC I-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
site I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
biophysical O-MISC O-MISC
interaction O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
occur O-MISC O-MISC
via O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
two O-MISC O-MISC
mechanisms O-MISC O-MISC
. O-MISC O-MISC

First O-MISC O-MISC
, O-MISC O-MISC
low O-MISC O-MISC
amounts O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
heterodimerize O-MISC O-MISC
and O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
site O-MISC O-MISC
consisting O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
half O-MISC B-MISC
site O-MISC I-MISC
from O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
ATF B-MISC B-MISC
/ I-MISC I-MISC
CREB I-MISC I-MISC
and I-MISC I-MISC
C I-MISC I-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
CREB B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
homodimers I-MISC I-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
ATF B-MISC B-MISC
/ I-MISC I-MISC
CREB I-MISC I-MISC
site I-MISC I-MISC
and O-MISC O-MISC
recruit O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
dimers I-MISC I-MISC
to O-MISC O-MISC
their O-MISC O-MISC
cognate O-MISC O-MISC
weak B-MISC O-MISC
binding I-MISC O-MISC
sites I-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
interaction O-MISC O-MISC
is O-MISC O-MISC
reciprocal O-MISC O-MISC
, O-MISC O-MISC
since O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
dimer I-MISC I-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
strong O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
site I-MISC I-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
enhanced O-MISC O-MISC
CREB B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
recruitment O-MISC O-MISC
to O-MISC O-MISC
ATF B-MISC B-MISC
/ I-MISC I-MISC
CREB I-MISC I-MISC
sites I-MISC I-MISC
that O-MISC O-MISC
are O-MISC O-MISC
weakly O-MISC O-MISC
bound O-MISC O-MISC
by O-MISC O-MISC
CREB B-MISC B-MISC
. O-MISC O-MISC

Sequence O-MISC O-MISC
variation O-MISC O-MISC
at O-MISC O-MISC
both O-MISC O-MISC
C B-MISC B-MISC
/ I-MISC I-MISC
EBP I-MISC I-MISC
and I-MISC I-MISC
ATF I-MISC I-MISC
/ I-MISC I-MISC
CREB I-MISC I-MISC
sites I-MISC I-MISC
affects O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
interactions O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
mediating O-MISC O-MISC
both O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
mechanisms O-MISC O-MISC
. O-MISC O-MISC

Most O-MISC O-MISC
importantly O-MISC O-MISC
, O-MISC O-MISC
sequence O-MISC O-MISC
variation O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
ATF B-MISC B-MISC
/ I-MISC I-MISC
CREB I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
affected O-MISC O-MISC
basal O-MISC O-MISC
LTR B-MISC B-MISC
activity O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
LTR B-MISC B-MISC
function O-MISC O-MISC
following O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
stimulation O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
treatment O-MISC O-MISC
that O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
increases O-MISC O-MISC
in O-MISC O-MISC
C O-MISC B-MISC
/ O-MISC I-MISC
EBP O-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
LTR I-MISC I-MISC
ATF B-MISC I-MISC
/ I-MISC I-MISC
CREB I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
sequence O-MISC O-MISC
variation O-MISC O-MISC
may O-MISC O-MISC
modulate O-MISC O-MISC
cellular O-MISC O-MISC
signaling O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
viral B-MISC B-MISC
promoter I-MISC I-MISC
through O-MISC O-MISC
the O-MISC O-MISC
C O-MISC B-MISC
/ O-MISC I-MISC
EBP O-MISC I-MISC
pathway O-MISC O-MISC

Selective O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
interleukin O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
aspirin O-MISC O-MISC
. O-MISC O-MISC

Previous O-MISC O-MISC
studies O-MISC O-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
aspirin O-MISC O-MISC
( O-MISC O-MISC
acetylsalicylic O-MISC O-MISC
acid O-MISC O-MISC
[ O-MISC O-MISC
ASA O-MISC O-MISC
] O-MISC O-MISC
) O-MISC O-MISC
can O-MISC O-MISC
have O-MISC O-MISC
profound O-MISC O-MISC
immunomodulatory O-MISC O-MISC
effects O-MISC O-MISC
by O-MISC O-MISC
regulating O-MISC O-MISC
cytokine O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
several O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
ASA O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
therapeutic O-MISC O-MISC
range O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
significantly O-MISC O-MISC
reduce O-MISC O-MISC
interleukin B-MISC B-MISC
( I-MISC I-MISC
IL I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
secretion O-MISC O-MISC
and O-MISC O-MISC
RNA O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
freshly O-MISC O-MISC
isolated O-MISC O-MISC
and O-MISC O-MISC
mitogen O-MISC O-MISC
- O-MISC O-MISC
primed O-MISC O-MISC
human O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
ASA O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
, O-MISC O-MISC
interferon B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

ASA O-MISC O-MISC
inhibited O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
promoter O-MISC B-MISC
- O-MISC I-MISC
driven O-MISC I-MISC
chloramphenicol O-MISC I-MISC
acetyltransferase O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
transiently O-MISC O-MISC
transfected O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
structurally O-MISC O-MISC
unrelated O-MISC O-MISC
nonsteroidal O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
drugs O-MISC O-MISC
indomethacin O-MISC O-MISC
and O-MISC O-MISC
flurbiprofen O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
cytokine O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
the O-MISC O-MISC
weak O-MISC O-MISC
cyclo O-MISC O-MISC
- O-MISC O-MISC
oxygenase O-MISC O-MISC
inhibitor O-MISC O-MISC
salicylic O-MISC O-MISC
acid O-MISC O-MISC
was O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
as O-MISC O-MISC
effective O-MISC O-MISC
as O-MISC O-MISC
ASA O-MISC O-MISC
in O-MISC O-MISC
inhibiting O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
ASA O-MISC O-MISC
on O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
transcription O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
decreased O-MISC O-MISC
nuclear O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
known O-MISC O-MISC
salicylate B-MISC O-MISC
target I-MISC I-MISC
nuclear I-MISC B-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
was O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
reduced O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
inducible O-MISC B-MISC
factor O-MISC I-MISC
to O-MISC O-MISC
an O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
promoter I-MISC I-MISC
region I-MISC I-MISC
upstream O-MISC O-MISC
of O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
overlapping O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
of I-MISC I-MISC
activated I-MISC I-MISC
T I-MISC I-MISC
cells I-MISC I-MISC
- I-MISC O-MISC
and I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
P1 I-MISC I-MISC
element I-MISC I-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
concluded O-MISC O-MISC
that O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
salicylates O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
means O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
previously O-MISC O-MISC
unrecognized O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
action O-MISC O-MISC
, O-MISC O-MISC
can O-MISC O-MISC
influence O-MISC O-MISC
the O-MISC O-MISC
nature O-MISC O-MISC
of O-MISC O-MISC
adaptive O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
by O-MISC O-MISC
selectively O-MISC O-MISC
inhibiting O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
effector O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
responses O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Molecular O-MISC O-MISC
and O-MISC O-MISC
cellular O-MISC O-MISC
mediators O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
acute O-MISC O-MISC
inflammatory O-MISC O-MISC
arthritis O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
To O-MISC O-MISC
examine O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
and O-MISC O-MISC
cellular O-MISC O-MISC
mechanisms O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
acute O-MISC O-MISC
inflammatory O-MISC O-MISC
monarticular O-MISC O-MISC
arthritis O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
methylated B-MISC O-MISC
bovine I-MISC O-MISC
serum I-MISC B-MISC
albumin I-MISC I-MISC
( O-MISC O-MISC
mBSA B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Mice O-MISC O-MISC
were O-MISC O-MISC
injected O-MISC O-MISC
intraarticularly O-MISC O-MISC
with O-MISC O-MISC
mBSA B-MISC B-MISC
on O-MISC O-MISC
day O-MISC O-MISC
0 O-MISC O-MISC
and O-MISC O-MISC
subcutaneously O-MISC O-MISC
with O-MISC O-MISC
recombinant B-MISC B-MISC
human I-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
on O-MISC O-MISC
days O-MISC O-MISC
0 O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC I-MISC
. O-MISC O-MISC

At O-MISC O-MISC
day O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
knee O-MISC O-MISC
joints O-MISC O-MISC
were O-MISC O-MISC
removed O-MISC O-MISC
and O-MISC O-MISC
assessed O-MISC O-MISC
histologically O-MISC O-MISC
. O-MISC O-MISC

Flow O-MISC O-MISC
cytometry O-MISC O-MISC
and O-MISC O-MISC
RNase O-MISC B-MISC
protection O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
analyze O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
events O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
C57BL O-MISC O-MISC
/ O-MISC O-MISC
6 O-MISC O-MISC
( O-MISC O-MISC
B6 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
129 O-MISC O-MISC
/ O-MISC I-MISC
Sv O-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
( O-MISC O-MISC
B6 O-MISC O-MISC
x O-MISC O-MISC
129 O-MISC O-MISC
/ O-MISC O-MISC
Sv O-MISC I-MISC
) O-MISC O-MISC
F1 O-MISC O-MISC
hybrid O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
all O-MISC O-MISC
H O-MISC O-MISC
- O-MISC O-MISC
2b O-MISC O-MISC
strains O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
susceptible O-MISC O-MISC
to O-MISC O-MISC
mBSA B-MISC B-MISC
/ O-MISC I-MISC
IL O-MISC I-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
arthritis O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
C3H O-MISC O-MISC
/ O-MISC O-MISC
HeJ O-MISC O-MISC
( O-MISC O-MISC
H O-MISC O-MISC
- O-MISC O-MISC
2k O-MISC I-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
. O-MISC O-MISC

B6 O-MISC O-MISC
mice O-MISC O-MISC
lacking O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
RAG1 O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
major B-MISC B-MISC
histocompatibility I-MISC I-MISC
complex I-MISC I-MISC
( I-MISC O-MISC
MHC I-MISC B-MISC
) I-MISC I-MISC
class I-MISC I-MISC
II I-MISC I-MISC
antigens I-MISC I-MISC
( O-MISC O-MISC
MHCII O-MISC B-MISC
- O-MISC I-MISC
/ O-MISC I-MISC
- O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
B6 O-MISC O-MISC
mice O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
CD4 B-MISC O-MISC
+ I-MISC O-MISC
T I-MISC O-MISC
cell I-MISC O-MISC
- I-MISC O-MISC
depleting I-MISC O-MISC
monoclonal I-MISC O-MISC
antibody I-MISC I-MISC
, O-MISC O-MISC
were O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
( O-MISC O-MISC
muMT O-MISC O-MISC
/ O-MISC O-MISC
muMT O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
developed O-MISC O-MISC
arthritis O-MISC O-MISC
at O-MISC O-MISC
an O-MISC O-MISC
incidence O-MISC O-MISC
and O-MISC O-MISC
severity O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

RelB O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
( O-MISC O-MISC
RelB O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
chimeric O-MISC O-MISC
mice O-MISC O-MISC
had O-MISC O-MISC
arthritis O-MISC O-MISC
that O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
reduced O-MISC O-MISC
in O-MISC O-MISC
incidence O-MISC O-MISC
and O-MISC O-MISC
severity O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
B6 O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
flow O-MISC O-MISC
cytometry O-MISC O-MISC
demonstrated O-MISC O-MISC
an O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
leukocyte O-MISC O-MISC
infiltration O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
synovial O-MISC O-MISC
compartment O-MISC O-MISC
and O-MISC O-MISC
RNase O-MISC B-MISC
protection O-MISC O-MISC
assays O-MISC O-MISC
revealed O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
messenger B-MISC O-MISC
RNA I-MISC O-MISC
( O-MISC O-MISC
mRNA B-MISC B-MISC
) O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
chemokines B-MISC B-MISC
monocyte B-MISC I-MISC
chemoattractant I-MISC I-MISC
protein I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
macrophage B-MISC O-MISC
inhibitory I-MISC O-MISC
protein I-MISC I-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
RANTES B-MISC B-MISC
, O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
, O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
Arthritis O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
mBSA B-MISC B-MISC
/ O-MISC I-MISC
IL B-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
strain O-MISC O-MISC
specific O-MISC O-MISC
and O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
partially O-MISC O-MISC
on O-MISC O-MISC
RelB B-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
on O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
or O-MISC O-MISC
antibody B-MISC O-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
contributes O-MISC O-MISC
to O-MISC O-MISC
leukocyte O-MISC O-MISC
recruitment O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
synovium O-MISC O-MISC
and O-MISC O-MISC
directly O-MISC O-MISC
induces O-MISC O-MISC
chemokine O-MISC B-MISC
mRNA O-MISC I-MISC
production O-MISC O-MISC
by O-MISC O-MISC
synovial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
acute O-MISC O-MISC
monarticular O-MISC O-MISC
arthritis O-MISC O-MISC
is O-MISC O-MISC
particularly O-MISC O-MISC
suitable O-MISC O-MISC
for O-MISC O-MISC
further O-MISC O-MISC
investigations O-MISC O-MISC
into O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
immunity O-MISC O-MISC
in O-MISC O-MISC
arthritis O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Positive O-MISC O-MISC
and O-MISC O-MISC
negative O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
granulopoiesis O-MISC O-MISC
by O-MISC O-MISC
endogenous B-MISC O-MISC
RARalpha I-MISC B-MISC
. O-MISC O-MISC

Acute O-MISC O-MISC
promyelocytic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
APL O-MISC O-MISC
) O-MISC O-MISC
is O-MISC O-MISC
always O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
chromosomal O-MISC O-MISC
translocations O-MISC O-MISC
that O-MISC O-MISC
disrupt O-MISC O-MISC
the O-MISC O-MISC
retinoic B-MISC B-MISC
acid I-MISC I-MISC
receptor I-MISC I-MISC
alpha I-MISC I-MISC
( I-MISC I-MISC
RARalpha I-MISC B-MISC
) I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

Whether O-MISC O-MISC
these O-MISC O-MISC
translocations O-MISC O-MISC
relate O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
endogenous B-MISC O-MISC
RARalpha I-MISC B-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
granulopoiesis O-MISC O-MISC
remains O-MISC O-MISC
uncertain O-MISC O-MISC
because O-MISC O-MISC
most O-MISC O-MISC
studies O-MISC O-MISC
addressing O-MISC O-MISC
this O-MISC O-MISC
question O-MISC O-MISC
have O-MISC O-MISC
used O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
physiological O-MISC O-MISC
overexpression O-MISC O-MISC
systems O-MISC O-MISC
. O-MISC O-MISC

Granulocyte O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
RARalpha O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
( O-MISC O-MISC
RARalpha O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
was O-MISC O-MISC
studied O-MISC O-MISC
and O-MISC O-MISC
evaluated O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
context O-MISC O-MISC
of O-MISC O-MISC
agonist B-MISC O-MISC
- I-MISC O-MISC
bound I-MISC O-MISC
and I-MISC O-MISC
ligand I-MISC O-MISC
- I-MISC O-MISC
free I-MISC O-MISC
RARalpha I-MISC B-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
RARalpha B-MISC B-MISC
is O-MISC O-MISC
dispensable O-MISC O-MISC
for O-MISC O-MISC
granulopoiesis O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
RARalpha O-MISC B-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
normal O-MISC O-MISC
granulocyte O-MISC O-MISC
population O-MISC O-MISC
despite O-MISC O-MISC
an O-MISC O-MISC
impaired O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
respond O-MISC O-MISC
to O-MISC O-MISC
retinoids O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
absolutely O-MISC O-MISC
required O-MISC O-MISC
, O-MISC O-MISC
RARalpha B-MISC B-MISC
can O-MISC O-MISC
bidirectionally O-MISC O-MISC
modulate O-MISC O-MISC
granulopoiesis O-MISC O-MISC
. O-MISC O-MISC

RARalpha B-MISC B-MISC
stimulates O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
exogenous O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
endogenous O-MISC O-MISC
retinoids O-MISC O-MISC
control O-MISC O-MISC
granulopoiesis O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
either O-MISC O-MISC
vitamin O-MISC O-MISC
A O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mice O-MISC O-MISC
or O-MISC O-MISC
animals O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
RAR O-MISC B-MISC
antagonist O-MISC O-MISC
accumulate O-MISC O-MISC
more O-MISC O-MISC
immature O-MISC O-MISC
granulocytes O-MISC O-MISC
in O-MISC O-MISC
their O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
. O-MISC O-MISC

Conversely O-MISC O-MISC
, O-MISC O-MISC
RARalpha B-MISC B-MISC
acts O-MISC O-MISC
to O-MISC O-MISC
limit O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
ligand B-MISC O-MISC
because O-MISC O-MISC
granulocyte O-MISC O-MISC
precursors O-MISC O-MISC
from O-MISC O-MISC
RARalpha O-MISC B-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
differentiate O-MISC O-MISC
earlier O-MISC O-MISC
in O-MISC O-MISC
culture O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
block O-MISC O-MISC
in O-MISC O-MISC
granulopoiesis O-MISC O-MISC
exerted O-MISC O-MISC
by O-MISC O-MISC
RARalpha B-MISC B-MISC
fusion B-MISC I-MISC
proteins I-MISC I-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
APL O-MISC O-MISC
cells O-MISC O-MISC
may O-MISC O-MISC
correspond O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
amplification O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
normal O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
unliganded B-MISC O-MISC
RARalpha I-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
and O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
stem B-MISC B-MISC
cell I-MISC I-MISC
promoter I-MISC I-MISC
for O-MISC O-MISC
the O-MISC O-MISC
murine B-MISC B-MISC
CBFalpha2 I-MISC I-MISC
gene I-MISC I-MISC
: O-MISC O-MISC
distinct O-MISC O-MISC
roles O-MISC O-MISC
and O-MISC O-MISC
regulation O-MISC O-MISC
in O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Runt B-MISC B-MISC
family I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
CBFalpha2 B-MISC I-MISC
( O-MISC O-MISC
AML1 B-MISC B-MISC
, O-MISC O-MISC
PEBP2alphaB B-MISC B-MISC
, O-MISC O-MISC
or O-MISC O-MISC
Runx1 B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
by O-MISC O-MISC
hematopoietic O-MISC O-MISC
stem O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
expressed O-MISC O-MISC
at O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
CBFalpha2 B-MISC B-MISC
is O-MISC O-MISC
usually O-MISC O-MISC
transcribed O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
different B-MISC O-MISC
promoter I-MISC B-MISC
( O-MISC O-MISC
distal B-MISC B-MISC
promoter I-MISC I-MISC
) O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
myeloid O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
proximal B-MISC B-MISC
promoter I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
developmental O-MISC O-MISC
and O-MISC O-MISC
functional O-MISC O-MISC
significance O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
promoter O-MISC B-MISC
switch O-MISC O-MISC
has O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
known O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
that O-MISC O-MISC
both O-MISC O-MISC
coding B-MISC O-MISC
and I-MISC O-MISC
noncoding I-MISC B-MISC
sequences I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
distal B-MISC B-MISC
5 I-MISC I-MISC
' I-MISC I-MISC
end I-MISC I-MISC
are O-MISC O-MISC
highly O-MISC O-MISC
conserved O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
human B-MISC O-MISC
and I-MISC O-MISC
the I-MISC O-MISC
murine I-MISC B-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
distal B-MISC B-MISC
promoter I-MISC I-MISC
is O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
overwhelming O-MISC O-MISC
majority O-MISC O-MISC
of O-MISC O-MISC
CBFalpha2 O-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
murine O-MISC O-MISC
hematopoietic O-MISC O-MISC
stem O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Distal O-MISC O-MISC
promoter O-MISC I-MISC
activity O-MISC O-MISC
is O-MISC O-MISC
maintained O-MISC O-MISC
throughout O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
and O-MISC O-MISC
at O-MISC O-MISC
lower O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
downregulated O-MISC O-MISC
in O-MISC O-MISC
natural O-MISC O-MISC
killer O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
distal B-MISC B-MISC
N I-MISC I-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
isoform I-MISC I-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
functionally O-MISC O-MISC
important O-MISC I-MISC
regulatory B-MISC I-MISC
sites I-MISC I-MISC
from O-MISC O-MISC
known O-MISC O-MISC
target B-MISC B-MISC
genes I-MISC O-MISC
with O-MISC O-MISC
two O-MISC O-MISC
- O-MISC O-MISC
to O-MISC O-MISC
threefold O-MISC O-MISC
higher O-MISC O-MISC
affinity O-MISC O-MISC
than O-MISC O-MISC
the O-MISC O-MISC
proximal B-MISC B-MISC
N I-MISC I-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
isoform I-MISC I-MISC
. O-MISC O-MISC

Neither O-MISC O-MISC
full B-MISC O-MISC
- I-MISC O-MISC
length I-MISC O-MISC
isoform I-MISC O-MISC
alters O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
myeloid O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
under O-MISC O-MISC
nondifferentiating O-MISC O-MISC
conditions O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
proximal B-MISC O-MISC
isoform I-MISC O-MISC
selectively O-MISC O-MISC
delays O-MISC O-MISC
mitotic O-MISC O-MISC
arrest O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
under O-MISC O-MISC
differentiating O-MISC O-MISC
conditions O-MISC O-MISC
, O-MISC O-MISC
resulting O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
greater O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
neutrophils O-MISC O-MISC
. O-MISC O-MISC

Constitutive O-MISC O-MISC
PI3 O-MISC B-MISC
- O-MISC I-MISC
K O-MISC I-MISC
activity O-MISC O-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
survival O-MISC O-MISC
, O-MISC O-MISC
of O-MISC O-MISC
Theileria O-MISC O-MISC
parva O-MISC O-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Theileria O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
intracellular O-MISC O-MISC
parasite O-MISC O-MISC
that O-MISC O-MISC
causes O-MISC O-MISC
lymphoproliferative O-MISC O-MISC
disorders O-MISC O-MISC
in O-MISC O-MISC
cattle O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
infection O-MISC O-MISC
of O-MISC O-MISC
leucocytes O-MISC O-MISC
induces O-MISC O-MISC
a O-MISC O-MISC
transformed O-MISC O-MISC
phenotype O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
tumour O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
the O-MISC O-MISC
parasite O-MISC O-MISC
induces O-MISC O-MISC
this O-MISC O-MISC
phenotype O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
understood O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
infected O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
display O-MISC O-MISC
constitutive O-MISC O-MISC
phosphoinositide O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC I-MISC
kinase O-MISC I-MISC
( O-MISC O-MISC
PI3 O-MISC B-MISC
- O-MISC I-MISC
K O-MISC O-MISC
) O-MISC O-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
survival O-MISC O-MISC
. O-MISC O-MISC

Importantly O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
one O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
PI3 B-MISC B-MISC
- I-MISC O-MISC
K I-MISC O-MISC
mediates O-MISC O-MISC
the O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
infected O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
is O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
granulocyte B-MISC B-MISC
- I-MISC I-MISC
monocyte I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
) O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
autocrine O-MISC O-MISC
loop O-MISC O-MISC
. O-MISC O-MISC

PI3 B-MISC B-MISC
- I-MISC I-MISC
K I-MISC I-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC O-MISC
level O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
consistently O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
PI3 B-MISC B-MISC
- I-MISC I-MISC
K I-MISC I-MISC
is O-MISC O-MISC
also O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
constitutive O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
characterizes O-MISC O-MISC
Theileria O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
leucocytes O-MISC O-MISC
. O-MISC O-MISC

Taken O-MISC O-MISC
together O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
results O-MISC O-MISC
highlight O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
strategy O-MISC O-MISC
exploited O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
intracellular O-MISC O-MISC
parasite O-MISC O-MISC
Theileria O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
continued O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
its O-MISC O-MISC
host O-MISC O-MISC
leucocyte O-MISC O-MISC
. O-MISC O-MISC

Lymphokine B-MISC B-MISC
dependence O-MISC O-MISC
of O-MISC O-MISC
STAT3 O-MISC B-MISC
activation O-MISC O-MISC
produced O-MISC O-MISC
by O-MISC O-MISC
surface O-MISC O-MISC
immunoglobulin O-MISC B-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
and O-MISC O-MISC
by O-MISC O-MISC
phorbol O-MISC O-MISC
ester O-MISC O-MISC
plus O-MISC O-MISC
calcium O-MISC O-MISC
ionophore O-MISC O-MISC
treatment O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Stimulation O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
surface B-MISC O-MISC
immunoglobulin I-MISC B-MISC
( O-MISC O-MISC
sIg B-MISC B-MISC
) O-MISC O-MISC
triggering O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
mitogenic O-MISC O-MISC
combination O-MISC O-MISC
of O-MISC O-MISC
phorbol O-MISC O-MISC
ester O-MISC O-MISC
and O-MISC O-MISC
calcium O-MISC O-MISC
ionophore O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT B-MISC B-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mechanism O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
delayed O-MISC O-MISC
nuclear O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
phosphorylated B-MISC O-MISC
STAT3 I-MISC B-MISC
was O-MISC O-MISC
examined O-MISC O-MISC
in O-MISC O-MISC
detail O-MISC O-MISC
, O-MISC O-MISC
focusing O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
derived I-MISC I-MISC
lymphokines I-MISC I-MISC
. O-MISC O-MISC

sIg B-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT3 B-MISC B-MISC
was O-MISC O-MISC
partially O-MISC O-MISC
inhibited O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
- O-MISC O-MISC
or O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
10 O-MISC I-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
partially O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
neutralizing B-MISC B-MISC
antibodies I-MISC I-MISC
directed O-MISC O-MISC
against O-MISC O-MISC
either O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
lymphokines B-MISC B-MISC
. O-MISC O-MISC

sIg B-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
STAT3 O-MISC B-MISC
activation O-MISC O-MISC
was O-MISC O-MISC
completely O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
combining O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
- I-MISC I-MISC
and I-MISC I-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
neutralizing I-MISC I-MISC
antibodies I-MISC I-MISC
, O-MISC O-MISC
or O-MISC O-MISC
by O-MISC O-MISC
adding O-MISC O-MISC
individual O-MISC O-MISC
neutralizing B-MISC O-MISC
antibodies I-MISC I-MISC
to O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
lymphokine O-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
animals O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
alone O-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
account O-MISC O-MISC
for O-MISC O-MISC
STAT3 O-MISC B-MISC
activation O-MISC O-MISC
resulting O-MISC O-MISC
from O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
phorbol O-MISC O-MISC
ester O-MISC O-MISC
and O-MISC O-MISC
calcium O-MISC O-MISC
ionophore O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
keeping O-MISC O-MISC
with O-MISC O-MISC
these O-MISC O-MISC
results O-MISC O-MISC
, O-MISC O-MISC
soluble O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
were O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
supernatant O-MISC O-MISC
fluid O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
stimulated O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
work O-MISC O-MISC
indicates O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
lymphokine O-MISC B-MISC
pathway O-MISC O-MISC
is O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
STAT3 O-MISC B-MISC
activation O-MISC O-MISC
that O-MISC O-MISC
occurs O-MISC O-MISC
late O-MISC O-MISC
after O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
stimulation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
points O-MISC O-MISC
out O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
that O-MISC O-MISC
result O-MISC O-MISC
from O-MISC O-MISC
stimulation O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
antigen B-MISC B-MISC
receptor I-MISC I-MISC
and O-MISC O-MISC
through O-MISC O-MISC
pharmacological O-MISC O-MISC
mimicry O-MISC O-MISC
of O-MISC O-MISC
signaling B-MISC B-MISC
mediators I-MISC I-MISC
. O-MISC O-MISC

Transcription B-MISC B-MISC
factor I-MISC I-MISC
AP I-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
ligand B-MISC O-MISC
for O-MISC O-MISC
immunoglobulin B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
promoter I-MISC I-MISC
E I-MISC I-MISC
- I-MISC I-MISC
box I-MISC I-MISC
elements I-MISC I-MISC
. O-MISC O-MISC

Immunoglobulin B-MISC O-MISC
( I-MISC I-MISC
Ig I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
promoters I-MISC I-MISC
from O-MISC O-MISC
humans O-MISC O-MISC
and O-MISC O-MISC
mice O-MISC O-MISC
share O-MISC O-MISC
conserved B-MISC O-MISC
sequences I-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
octamer B-MISC B-MISC
element I-MISC I-MISC
is O-MISC O-MISC
common O-MISC O-MISC
to O-MISC O-MISC
all O-MISC O-MISC
Ig B-MISC B-MISC
promoters I-MISC I-MISC
and O-MISC O-MISC
pivotal O-MISC O-MISC
for O-MISC O-MISC
their O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
other O-MISC O-MISC
conserved B-MISC B-MISC
sequence I-MISC I-MISC
motifs I-MISC I-MISC
, O-MISC O-MISC
that O-MISC O-MISC
differ O-MISC O-MISC
between O-MISC O-MISC
Ig B-MISC B-MISC
variable I-MISC I-MISC
gene I-MISC I-MISC
families I-MISC I-MISC
, O-MISC O-MISC
are O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
normal O-MISC O-MISC
promoter O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
conserved O-MISC O-MISC
motifs O-MISC I-MISC
do O-MISC O-MISC
not O-MISC O-MISC
stimulate O-MISC O-MISC
transcription O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
octamer B-MISC B-MISC
. O-MISC O-MISC

One O-MISC O-MISC
example O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
E B-MISC B-MISC
- I-MISC I-MISC
box I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
E47 B-MISC B-MISC
/ I-MISC I-MISC
E12 I-MISC I-MISC
type I-MISC I-MISC
( I-MISC O-MISC
5 I-MISC B-MISC
' I-MISC I-MISC
- I-MISC I-MISC
CAGCTG I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
' I-MISC O-MISC
) I-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
promoters O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
and I-MISC I-MISC
murine I-MISC I-MISC
Ig I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
gene I-MISC I-MISC
subgroups I-MISC O-MISC
/ I-MISC O-MISC
families I-MISC I-MISC
, O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
exception O-MISC O-MISC
of O-MISC O-MISC
subgroups O-MISC O-MISC
II O-MISC O-MISC
and O-MISC O-MISC
VI O-MISC O-MISC
and O-MISC O-MISC
their O-MISC O-MISC
related O-MISC O-MISC
murine B-MISC O-MISC
families I-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
ubiquitously O-MISC B-MISC
expressed O-MISC I-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
not O-MISC O-MISC
E47 B-MISC B-MISC
, O-MISC O-MISC
interacts O-MISC O-MISC
specifically O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
kappa B-MISC B-MISC
promoter I-MISC I-MISC
E I-MISC I-MISC
- I-MISC I-MISC
boxes I-MISC I-MISC
when O-MISC O-MISC
tested O-MISC O-MISC
in O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
- O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
using O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
human O-MISC O-MISC
and O-MISC O-MISC
murine O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
unlike O-MISC O-MISC
E47 B-MISC B-MISC
, O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
act O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
transactivator B-MISC B-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
in O-MISC O-MISC
agreement O-MISC O-MISC
with O-MISC O-MISC
previous O-MISC O-MISC
studies O-MISC O-MISC
on O-MISC O-MISC
intact O-MISC B-MISC
kappa B-MISC B-MISC
promoters I-MISC I-MISC
, O-MISC O-MISC
showing O-MISC O-MISC
that O-MISC O-MISC
transcription O-MISC O-MISC
is O-MISC O-MISC
absent O-MISC O-MISC
when O-MISC O-MISC
the O-MISC O-MISC
octamer B-MISC B-MISC
element I-MISC I-MISC
has O-MISC O-MISC
been O-MISC O-MISC
mutated O-MISC B-MISC
. O-MISC O-MISC

Based O-MISC O-MISC
on O-MISC O-MISC
these O-MISC O-MISC
data O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
conservation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
- I-MISC I-MISC
CAGCTG I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
' I-MISC I-MISC
motif I-MISC I-MISC
among O-MISC O-MISC
human B-MISC B-MISC
and I-MISC I-MISC
murine I-MISC I-MISC
kappa I-MISC I-MISC
promoters I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
propose O-MISC O-MISC
that O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
is O-MISC O-MISC
the O-MISC O-MISC
major B-MISC O-MISC
ligand I-MISC O-MISC
for O-MISC O-MISC
Ig B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
promoter I-MISC I-MISC
E I-MISC I-MISC
- I-MISC I-MISC
boxes I-MISC I-MISC
. O-MISC O-MISC

A O-MISC O-MISC
16 O-MISC O-MISC
- O-MISC O-MISC
mer O-MISC O-MISC
peptide O-MISC O-MISC
( O-MISC O-MISC
RQIKIWFQNRRMKWKK O-MISC B-MISC
) O-MISC O-MISC
from O-MISC O-MISC
antennapedia O-MISC B-MISC
preferentially O-MISC O-MISC
targets O-MISC O-MISC
the O-MISC O-MISC
Class O-MISC O-MISC
I O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

Translocation O-MISC O-MISC
of O-MISC O-MISC
antigenic O-MISC O-MISC
peptides O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
cytosol O-MISC O-MISC
of O-MISC O-MISC
antigen O-MISC O-MISC
presenting O-MISC O-MISC
cells O-MISC O-MISC
facilitates O-MISC O-MISC
proteosomal O-MISC O-MISC
processing O-MISC O-MISC
and O-MISC O-MISC
loading O-MISC O-MISC
into O-MISC O-MISC
Class B-MISC B-MISC
I I-MISC B-MISC
molecules I-MISC I-MISC
for O-MISC O-MISC
MHC O-MISC B-MISC
presentation O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
surface O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
DNA B-MISC B-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Drosophila B-MISC B-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
Antennapedia B-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
60 B-MISC B-MISC
amino I-MISC I-MISC
acid I-MISC I-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
is O-MISC O-MISC
rapidly O-MISC O-MISC
taken O-MISC O-MISC
up O-MISC O-MISC
by O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
fused O-MISC O-MISC
to O-MISC O-MISC
selected O-MISC O-MISC
antigens B-MISC O-MISC
to O-MISC O-MISC
enhance O-MISC O-MISC
their O-MISC O-MISC
immunogenicity O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
now O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
16 O-MISC O-MISC
amino O-MISC O-MISC
acid O-MISC O-MISC
peptide O-MISC O-MISC
from O-MISC O-MISC
antennapedia O-MISC O-MISC
can O-MISC O-MISC
facilitate O-MISC O-MISC
the O-MISC O-MISC
cytoplasmic O-MISC O-MISC
uptake O-MISC O-MISC
of O-MISC O-MISC
CTL O-MISC B-MISC
epitope O-MISC I-MISC
9 O-MISC I-MISC
- O-MISC O-MISC
mer O-MISC O-MISC
peptides O-MISC O-MISC
. O-MISC O-MISC

Synthetic O-MISC O-MISC
peptides O-MISC O-MISC
were O-MISC O-MISC
made O-MISC O-MISC
containing O-MISC O-MISC
the O-MISC O-MISC
16 O-MISC O-MISC
- O-MISC O-MISC
mer O-MISC O-MISC
antennapedia O-MISC O-MISC
peptide O-MISC O-MISC
linked O-MISC O-MISC
in O-MISC O-MISC
tandem O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
ovalbumin O-MISC O-MISC
SIINFEKL O-MISC B-MISC
CTL O-MISC O-MISC
peptide O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
peptide O-MISC B-MISC
complex O-MISC I-MISC
was O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
rapidly O-MISC O-MISC
internalise O-MISC O-MISC
into O-MISC O-MISC
APCs O-MISC O-MISC
by O-MISC O-MISC
confocal O-MISC O-MISC
microscopy O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
peptide O-MISC O-MISC
induced O-MISC O-MISC
CTL O-MISC O-MISC
in O-MISC O-MISC
C57BL O-MISC O-MISC
/ O-MISC O-MISC
6 O-MISC O-MISC
mice O-MISC O-MISC
and O-MISC O-MISC
protected O-MISC O-MISC
them O-MISC O-MISC
against O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
ovalbumin O-MISC O-MISC
expressing O-MISC O-MISC
tumour O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
( O-MISC O-MISC
E O-MISC O-MISC
. O-MISC O-MISC
G7 O-MISC O-MISC
- O-MISC O-MISC
OVA O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
hybrid O-MISC O-MISC
peptide O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
processed O-MISC O-MISC
and O-MISC O-MISC
presented O-MISC O-MISC
by O-MISC O-MISC
APCs O-MISC O-MISC
was O-MISC O-MISC
similar O-MISC O-MISC
, O-MISC O-MISC
whether O-MISC O-MISC
the O-MISC O-MISC
SIINFEKL O-MISC B-MISC
sequence O-MISC I-MISC
was O-MISC O-MISC
appended O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
C B-MISC B-MISC
- I-MISC I-MISC
terminus I-MISC I-MISC
or O-MISC O-MISC
N B-MISC B-MISC
- I-MISC I-MISC
terminus I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Antennapedia O-MISC O-MISC
peptide O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
synthetic O-MISC O-MISC
peptides O-MISC O-MISC
containing O-MISC O-MISC
other O-MISC O-MISC
CTL O-MISC O-MISC
peptide O-MISC O-MISC
epitopes O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
useful O-MISC O-MISC
for O-MISC O-MISC
priming O-MISC O-MISC
CTLs O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC

Bone O-MISC O-MISC
marrow O-MISC O-MISC
cells O-MISC O-MISC
promote O-MISC O-MISC
TH2 O-MISC O-MISC
polarization O-MISC O-MISC
and O-MISC O-MISC
inhibit O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CTL O-MISC O-MISC
generation O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
laboratory O-MISC O-MISC
recently O-MISC O-MISC
reported O-MISC O-MISC
that O-MISC O-MISC
human O-MISC O-MISC
bone O-MISC O-MISC
marrow O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
BMC O-MISC O-MISC
) O-MISC O-MISC
inhibit O-MISC O-MISC
the O-MISC O-MISC
generation O-MISC O-MISC
of O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CTL O-MISC O-MISC
in O-MISC O-MISC
culture O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
culture O-MISC O-MISC
supernatants O-MISC O-MISC
contained O-MISC O-MISC
increased O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
prostaglandin B-MISC O-MISC
E I-MISC O-MISC
( I-MISC O-MISC
2 I-MISC O-MISC
) I-MISC O-MISC
( I-MISC O-MISC
PGE I-MISC O-MISC
( I-MISC O-MISC
2 I-MISC O-MISC
) I-MISC O-MISC
) I-MISC O-MISC
( O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
favor O-MISC O-MISC
TH2 O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
also O-MISC O-MISC
inhibited O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
CTL O-MISC O-MISC
effector O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
obtained O-MISC O-MISC
PBL O-MISC O-MISC
from O-MISC O-MISC
Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
EBV O-MISC O-MISC
) O-MISC O-MISC
IgG B-MISC O-MISC
antibody I-MISC O-MISC
positive O-MISC O-MISC
kidney O-MISC O-MISC
transplant O-MISC O-MISC
recipients O-MISC O-MISC
( O-MISC O-MISC
R O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
their O-MISC O-MISC
living O-MISC O-MISC
- O-MISC O-MISC
related O-MISC O-MISC
donors O-MISC O-MISC
( O-MISC O-MISC
LRD O-MISC O-MISC
) O-MISC O-MISC
one O-MISC O-MISC
year O-MISC O-MISC
after O-MISC O-MISC
renal O-MISC O-MISC
transplantation O-MISC O-MISC
. O-MISC O-MISC

EBV O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CTL O-MISC O-MISC
were O-MISC O-MISC
then O-MISC O-MISC
generated O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
by O-MISC O-MISC
stimulating O-MISC O-MISC
PBL O-MISC O-MISC
with O-MISC O-MISC
autologous O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
or O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
autologous O-MISC O-MISC
BMC O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
BMC O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
CTL O-MISC O-MISC
generation O-MISC O-MISC
cultures O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
intracellular O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
CD3 O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, I-MISC I-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
, I-MISC O-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
, I-MISC O-MISC
- I-MISC I-MISC
10 I-MISC I-MISC
, I-MISC O-MISC
and I-MISC O-MISC
- I-MISC O-MISC
13 I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
CD3 O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
also O-MISC O-MISC
expressed O-MISC O-MISC
increased O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
TH2 B-MISC B-MISC
associated I-MISC I-MISC
receptor I-MISC I-MISC
CCR3 I-MISC I-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
was O-MISC O-MISC
even O-MISC O-MISC
observed O-MISC O-MISC
by O-MISC O-MISC
preparing O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
CTL O-MISC O-MISC
generating O-MISC O-MISC
cultures O-MISC O-MISC
in O-MISC O-MISC
trans O-MISC O-MISC
- O-MISC O-MISC
wells O-MISC O-MISC
that O-MISC O-MISC
separated O-MISC O-MISC
the O-MISC O-MISC
autologous O-MISC O-MISC
BMC O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
PBL O-MISC O-MISC
+ O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
was O-MISC O-MISC
then O-MISC O-MISC
observed O-MISC O-MISC
that O-MISC O-MISC
CD3 O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
obtained O-MISC O-MISC
after O-MISC O-MISC
7 O-MISC O-MISC
days O-MISC O-MISC
of O-MISC O-MISC
culture O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
autologous O-MISC O-MISC
BMC O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
used O-MISC O-MISC
as O-MISC O-MISC
inhibitors O-MISC O-MISC
of O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
CTL O-MISC O-MISC
generation O-MISC O-MISC
. O-MISC O-MISC

Protein B-MISC O-MISC
Kinase I-MISC B-MISC
A I-MISC I-MISC
( O-MISC O-MISC
PKA B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
cAMP B-MISC B-MISC
kinase I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
TH2 B-MISC B-MISC
cytokine I-MISC I-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
CTL O-MISC O-MISC
cultures O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
BMC O-MISC O-MISC
. O-MISC O-MISC

Additionally O-MISC O-MISC
, O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
transcription O-MISC O-MISC
( O-MISC O-MISC
STAT B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
) O-MISC O-MISC
phosphorylation O-MISC O-MISC
was O-MISC O-MISC
slightly O-MISC O-MISC
increased O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
BMC O-MISC O-MISC
inhibition O-MISC O-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
soluble B-MISC B-MISC
factors I-MISC I-MISC
( O-MISC O-MISC
cytokines B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
contact O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
autologous O-MISC O-MISC
system O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
required O-MISC O-MISC
, O-MISC O-MISC
so O-MISC O-MISC
that O-MISC O-MISC
BMC O-MISC O-MISC
( O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
partially O-MISC O-MISC
, O-MISC O-MISC
via O-MISC O-MISC
cytokine O-MISC B-MISC
production O-MISC O-MISC
) O-MISC O-MISC
promote O-MISC O-MISC
TH2 O-MISC O-MISC
polarization O-MISC O-MISC
in O-MISC O-MISC
culture O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
TH2 O-MISC O-MISC
cells O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
culturing O-MISC O-MISC
with O-MISC O-MISC
autologous O-MISC O-MISC
BMC O-MISC O-MISC
directly O-MISC O-MISC
inhibit O-MISC O-MISC
EBV O-MISC O-MISC
- O-MISC O-MISC
CTL O-MISC O-MISC
generation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
TH2 B-MISC B-MISC
associated O-MISC O-MISC
PKA B-MISC B-MISC
, O-MISC O-MISC
CCR3 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
STAT B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
phosphorylation O-MISC O-MISC
are O-MISC O-MISC
enhanced O-MISC O-MISC
by O-MISC O-MISC
BMC O-MISC O-MISC
. O-MISC O-MISC

Reduction O-MISC O-MISC
in O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5a I-MISC I-MISC
in O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
of O-MISC O-MISC
aged O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Aging O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
intrinsic O-MISC O-MISC
changes O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
humoral O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
may O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
increased O-MISC O-MISC
occurrence O-MISC O-MISC
of O-MISC O-MISC
autoimmune O-MISC O-MISC
disorders O-MISC O-MISC
and O-MISC O-MISC
pathogenic O-MISC O-MISC
susceptibility O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
key O-MISC O-MISC
regulator O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

Pax B-MISC B-MISC
- I-MISC I-MISC
5a I-MISC I-MISC
/ I-MISC I-MISC
B I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
activator I-MISC I-MISC
protein I-MISC I-MISC
and O-MISC O-MISC
an O-MISC O-MISC
alternatively B-MISC O-MISC
spliced I-MISC B-MISC
isoform I-MISC O-MISC
, I-MISC O-MISC
Pax I-MISC B-MISC
- I-MISC I-MISC
5d I-MISC I-MISC
, O-MISC O-MISC
may O-MISC O-MISC
have O-MISC O-MISC
opposing O-MISC O-MISC
functions O-MISC O-MISC
in O-MISC O-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
lack O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
transactivation B-MISC B-MISC
domain I-MISC I-MISC
in O-MISC O-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5d I-MISC I-MISC
. O-MISC O-MISC

To O-MISC O-MISC
study O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
changes O-MISC O-MISC
that O-MISC O-MISC
occur O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
aging O-MISC O-MISC
process O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
expression O-MISC O-MISC
patterns O-MISC O-MISC
of O-MISC O-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5a I-MISC I-MISC
and I-MISC O-MISC
5d I-MISC O-MISC
in O-MISC O-MISC
mature O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
young O-MISC O-MISC
and O-MISC O-MISC
aged O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

RNase O-MISC B-MISC
protection O-MISC O-MISC
assays O-MISC O-MISC
showed O-MISC O-MISC
a O-MISC O-MISC
similar O-MISC O-MISC
transcriptional O-MISC O-MISC
pattern O-MISC O-MISC
for O-MISC O-MISC
both O-MISC O-MISC
age O-MISC O-MISC
groups O-MISC O-MISC
that O-MISC O-MISC
indicates O-MISC O-MISC
that O-MISC O-MISC
aging O-MISC O-MISC
has O-MISC O-MISC
no O-MISC O-MISC
affect O-MISC O-MISC
on O-MISC O-MISC
transcription O-MISC O-MISC
initiation O-MISC O-MISC
or O-MISC O-MISC
alternative O-MISC O-MISC
splicing O-MISC O-MISC
for O-MISC O-MISC
either O-MISC O-MISC
isoform B-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5a I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5d I-MISC I-MISC
protein O-MISC I-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
aged O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
Western O-MISC O-MISC
blot O-MISC O-MISC
analyses O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
similar O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5a I-MISC I-MISC
and I-MISC I-MISC
5d I-MISC B-MISC
proteins O-MISC I-MISC
were O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
age O-MISC O-MISC
groups O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
observed O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5a I-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
two O-MISC O-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
target I-MISC I-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
aged O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ig B-MISC B-MISC
J I-MISC I-MISC
chain I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
secreted O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
Ig B-MISC B-MISC
mu I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
both O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
suppressed O-MISC O-MISC
by O-MISC O-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5a I-MISC I-MISC
in O-MISC O-MISC
mature O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
increased O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
aged O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Together O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
studies O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
changes O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
aging O-MISC O-MISC
phenotype O-MISC O-MISC
cause O-MISC O-MISC
posttranslational O-MISC O-MISC
modification O-MISC O-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5a I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
Pax B-MISC B-MISC
- I-MISC I-MISC
5d I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
may O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
abnormal O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
phenotype O-MISC O-MISC
in O-MISC O-MISC
aged O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
elevated O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
J B-MISC B-MISC
chain I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
IgM B-MISC B-MISC

NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
/ I-MISC I-MISC
Rel I-MISC I-MISC
participation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
lymphokine O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Proliferative O-MISC O-MISC
responses O-MISC O-MISC
of O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
depend O-MISC O-MISC
on O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
activation O-MISC O-MISC
enhances O-MISC O-MISC
cellular O-MISC O-MISC
competence O-MISC O-MISC
to O-MISC O-MISC
respond O-MISC O-MISC
to O-MISC O-MISC
cytokines B-MISC B-MISC
is O-MISC O-MISC
not O-MISC O-MISC
fully O-MISC O-MISC
understood O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
/ I-MISC I-MISC
Rel I-MISC I-MISC
family I-MISC I-MISC
represents O-MISC O-MISC
one O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
pathway O-MISC O-MISC
induced O-MISC O-MISC
during O-MISC O-MISC
such O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
that O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
through O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
IkappaBalpha B-MISC B-MISC
( O-MISC O-MISC
inhibitory B-MISC O-MISC
protein I-MISC O-MISC
that O-MISC O-MISC
dissociates O-MISC O-MISC
from O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) O-MISC O-MISC
mutant O-MISC O-MISC
refractory O-MISC O-MISC
to O-MISC O-MISC
signal O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
degradation O-MISC O-MISC
( O-MISC O-MISC
IkappaBalpha B-MISC B-MISC
( I-MISC O-MISC
DeltaN I-MISC B-MISC
) I-MISC O-MISC
) O-MISC O-MISC
interfered O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
acquisition O-MISC O-MISC
of O-MISC O-MISC
competence O-MISC O-MISC
to O-MISC O-MISC
proliferate O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

Thymocytes O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
IkappaBalpha B-MISC O-MISC
( I-MISC O-MISC
DeltaN I-MISC B-MISC
) I-MISC O-MISC
transgenic O-MISC O-MISC
mice O-MISC O-MISC
expressed O-MISC O-MISC
normal O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
subunits I-MISC I-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
transgenic O-MISC O-MISC
cells O-MISC O-MISC
exhibited O-MISC O-MISC
a O-MISC O-MISC
dramatic O-MISC O-MISC
defect O-MISC O-MISC
in O-MISC O-MISC
Stat5A O-MISC B-MISC
activation O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
similar O-MISC O-MISC
defect O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
for O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
Stat5 B-MISC B-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
showed O-MISC O-MISC
normal O-MISC O-MISC
insulin O-MISC B-MISC
receptor O-MISC I-MISC
substrate O-MISC O-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
phosphorylation O-MISC O-MISC
and O-MISC O-MISC
only O-MISC O-MISC
a O-MISC O-MISC
modest O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
Stat6 O-MISC B-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
insulin O-MISC B-MISC
receptor O-MISC B-MISC
substrate O-MISC I-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
phosphorylation O-MISC O-MISC
after O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
/ O-MISC I-MISC
Rel O-MISC I-MISC
/ O-MISC I-MISC
IkappaBalpha O-MISC I-MISC
system O-MISC O-MISC
can O-MISC O-MISC
regulate O-MISC O-MISC
cytokine B-MISC B-MISC
receptor I-MISC I-MISC
capacitation O-MISC O-MISC
through O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
downstream O-MISC O-MISC
signaling O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
Stat B-MISC B-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
family I-MISC I-MISC
. O-MISC O-MISC

BMS O-MISC O-MISC
- O-MISC O-MISC
189453 O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
retinoid O-MISC B-MISC
receptor O-MISC I-MISC
antagonist O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
testicular O-MISC O-MISC
toxin O-MISC O-MISC
. O-MISC O-MISC

BMS O-MISC O-MISC
- O-MISC O-MISC
189453 O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
synthetic O-MISC O-MISC
retinoid O-MISC O-MISC
that O-MISC O-MISC
acts O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
antagonist O-MISC O-MISC
at O-MISC O-MISC
retinoic B-MISC B-MISC
acid I-MISC I-MISC
receptors I-MISC I-MISC
alpha I-MISC I-MISC
, I-MISC O-MISC
beta I-MISC B-MISC
, I-MISC O-MISC
and I-MISC O-MISC
gamma I-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
Sprague O-MISC O-MISC
Dawley O-MISC O-MISC
rats O-MISC O-MISC
at O-MISC O-MISC
daily O-MISC O-MISC
oral O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
15 O-MISC O-MISC
, O-MISC O-MISC
60 O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
240 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
month O-MISC O-MISC
, O-MISC O-MISC
BMS O-MISC O-MISC
- O-MISC O-MISC
189453 O-MISC I-MISC
produced O-MISC O-MISC
increases O-MISC O-MISC
in O-MISC O-MISC
leukocyte O-MISC O-MISC
counts O-MISC O-MISC
, O-MISC O-MISC
alkaline B-MISC B-MISC
phosphatase I-MISC I-MISC
and O-MISC O-MISC
alanine B-MISC O-MISC
aminotransferase I-MISC B-MISC
levels O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
marked O-MISC O-MISC
testicular O-MISC O-MISC
degeneration O-MISC O-MISC
and O-MISC O-MISC
atrophy O-MISC O-MISC
at O-MISC O-MISC
all O-MISC O-MISC
doses O-MISC O-MISC
. O-MISC O-MISC

Significant O-MISC O-MISC
overt O-MISC O-MISC
signs O-MISC O-MISC
of O-MISC O-MISC
toxicity O-MISC O-MISC
and O-MISC O-MISC
deaths O-MISC O-MISC
occurred O-MISC O-MISC
at O-MISC O-MISC
240 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
body O-MISC O-MISC
- O-MISC O-MISC
weight O-MISC O-MISC
and O-MISC O-MISC
food O-MISC O-MISC
- O-MISC O-MISC
consumption O-MISC O-MISC
decreases O-MISC O-MISC
occurred O-MISC O-MISC
at O-MISC O-MISC
60 O-MISC O-MISC
and O-MISC O-MISC
240 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
. O-MISC O-MISC

When O-MISC O-MISC
BMS O-MISC O-MISC
- O-MISC O-MISC
189453 O-MISC O-MISC
was O-MISC O-MISC
administered O-MISC O-MISC
to O-MISC O-MISC
male O-MISC O-MISC
rats O-MISC O-MISC
at O-MISC O-MISC
daily O-MISC O-MISC
doses O-MISC O-MISC
ranging O-MISC O-MISC
from O-MISC O-MISC
12 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
to O-MISC O-MISC
100 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
week O-MISC O-MISC
, O-MISC O-MISC
only O-MISC O-MISC
minimal O-MISC O-MISC
testicular O-MISC O-MISC
changes O-MISC O-MISC
occurred O-MISC O-MISC
at O-MISC O-MISC
all O-MISC O-MISC
doses O-MISC O-MISC
, O-MISC O-MISC
shortly O-MISC O-MISC
after O-MISC O-MISC
the O-MISC O-MISC
dosing O-MISC O-MISC
period O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
after O-MISC O-MISC
a O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
month O-MISC O-MISC
drug O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
observation O-MISC O-MISC
period O-MISC O-MISC
, O-MISC O-MISC
marked O-MISC O-MISC
testicular O-MISC O-MISC
atrophy O-MISC O-MISC
was O-MISC O-MISC
evident O-MISC O-MISC
at O-MISC O-MISC
all O-MISC O-MISC
doses O-MISC O-MISC
. O-MISC O-MISC

BMS O-MISC O-MISC
- O-MISC O-MISC
189453 O-MISC O-MISC
was O-MISC O-MISC
then O-MISC O-MISC
administered O-MISC O-MISC
at O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
10 O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
50 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
to O-MISC O-MISC
male O-MISC O-MISC
rats O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
7 O-MISC O-MISC
consecutive O-MISC O-MISC
days O-MISC O-MISC
. O-MISC O-MISC

Dose O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
duration O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
testicular O-MISC O-MISC
toxicity O-MISC O-MISC
that O-MISC O-MISC
occurred O-MISC O-MISC
after O-MISC O-MISC
a O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
month O-MISC O-MISC
observation O-MISC O-MISC
period O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
recover O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
some O-MISC O-MISC
cases O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
more O-MISC O-MISC
severe O-MISC O-MISC
4 O-MISC O-MISC
months O-MISC O-MISC
after O-MISC O-MISC
the O-MISC O-MISC
last O-MISC O-MISC
dose O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
rabbits O-MISC O-MISC
administered O-MISC O-MISC
BMS O-MISC O-MISC
- O-MISC O-MISC
189453 O-MISC O-MISC
at O-MISC O-MISC
oral O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
10 O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
50 O-MISC O-MISC
mg O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
week O-MISC O-MISC
, O-MISC O-MISC
testicular O-MISC O-MISC
degeneration O-MISC O-MISC
and O-MISC O-MISC
atrophy O-MISC O-MISC
were O-MISC O-MISC
evident O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
dose O-MISC O-MISC
group O-MISC O-MISC
at O-MISC O-MISC
1 O-MISC O-MISC
month O-MISC O-MISC
following O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
studies O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
retinoid O-MISC O-MISC
antagonists O-MISC O-MISC
can O-MISC O-MISC
selectively O-MISC O-MISC
produce O-MISC O-MISC
progressive O-MISC O-MISC
and O-MISC O-MISC
prolonged O-MISC O-MISC
testicular O-MISC O-MISC
toxicity O-MISC O-MISC
after O-MISC O-MISC
single O-MISC O-MISC
or O-MISC O-MISC
repeated O-MISC O-MISC
oral O-MISC O-MISC
doses O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
otherwise O-MISC O-MISC
well O-MISC O-MISC
tolerated O-MISC O-MISC
. O-MISC O-MISC

Sequential O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
NFAT B-MISC B-MISC
and O-MISC O-MISC
Egr B-MISC B-MISC
transcription B-MISC I-MISC
factors I-MISC I-MISC
in O-MISC O-MISC
FasL O-MISC B-MISC
regulation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
critical O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
NFAT B-MISC B-MISC
proteins I-MISC I-MISC
in O-MISC O-MISC
maintaining O-MISC O-MISC
lymphoid O-MISC O-MISC
homeostasis O-MISC O-MISC
was O-MISC O-MISC
revealed O-MISC O-MISC
in O-MISC O-MISC
mice O-MISC O-MISC
lacking O-MISC O-MISC
both O-MISC O-MISC
NFATp B-MISC B-MISC
and O-MISC O-MISC
NFAT4 B-MISC B-MISC
( O-MISC O-MISC
DKO O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

DKO O-MISC O-MISC
mice O-MISC O-MISC
exhibit O-MISC O-MISC
increased O-MISC O-MISC
lymphoproliferation O-MISC O-MISC
, O-MISC O-MISC
decreased O-MISC O-MISC
activation O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
death O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
impaired O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
FasL B-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
Egr2 B-MISC B-MISC
and O-MISC O-MISC
Egr3 B-MISC B-MISC
are O-MISC O-MISC
potent O-MISC O-MISC
activators O-MISC O-MISC
of O-MISC O-MISC
FasL O-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
find O-MISC O-MISC
that O-MISC O-MISC
Egr2 B-MISC B-MISC
and O-MISC O-MISC
Egr3 B-MISC B-MISC
are O-MISC O-MISC
NFAT B-MISC B-MISC
target I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
FasL B-MISC B-MISC
occurs O-MISC O-MISC
via O-MISC O-MISC
the O-MISC O-MISC
NFAT B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
Egr3 B-MISC B-MISC
, O-MISC O-MISC
as O-MISC O-MISC
demonstrated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
exogenously O-MISC O-MISC
provided O-MISC O-MISC
NFATp B-MISC B-MISC
to O-MISC O-MISC
restore O-MISC O-MISC
Egr B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
FasL O-MISC B-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
DKO O-MISC O-MISC
lymph O-MISC O-MISC
node O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Further O-MISC O-MISC
, O-MISC O-MISC
Egr3 B-MISC B-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
enriched O-MISC O-MISC
in O-MISC O-MISC
Th1 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
a O-MISC O-MISC
molecular O-MISC O-MISC
basis O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
known O-MISC O-MISC
preferential O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
FasL B-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
Th1 O-MISC O-MISC
versus O-MISC O-MISC
Th2 O-MISC O-MISC
subset O-MISC O-MISC
. O-MISC O-MISC

Mechanisms O-MISC O-MISC
and O-MISC O-MISC
clinical O-MISC O-MISC
relevance O-MISC O-MISC
of O-MISC O-MISC
nongenomic O-MISC O-MISC
glucocorticoid O-MISC O-MISC
actions O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoids O-MISC O-MISC
have O-MISC O-MISC
profound O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
and O-MISC O-MISC
immunosuppressive O-MISC O-MISC
actions O-MISC O-MISC
when O-MISC O-MISC
used O-MISC O-MISC
therapeutically O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
therapeutic O-MISC O-MISC
dose O-MISC O-MISC
is O-MISC O-MISC
quite O-MISC O-MISC
variable O-MISC O-MISC
and O-MISC O-MISC
depends O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
disease O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
ranges O-MISC O-MISC
from O-MISC O-MISC
very O-MISC O-MISC
low O-MISC O-MISC
to O-MISC O-MISC
extremely O-MISC O-MISC
high O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
rationale O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
various O-MISC O-MISC
dosage O-MISC O-MISC
regimens O-MISC O-MISC
for O-MISC O-MISC
specific O-MISC O-MISC
clinical O-MISC O-MISC
indications O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
three O-MISC O-MISC
distinct O-MISC O-MISC
, O-MISC O-MISC
therapeutically O-MISC O-MISC
relevant O-MISC O-MISC
effects O-MISC O-MISC
: O-MISC O-MISC
genomic O-MISC O-MISC
, O-MISC O-MISC
specific O-MISC O-MISC
nongenomic O-MISC O-MISC
and O-MISC O-MISC
unspecific O-MISC O-MISC
nongenomic O-MISC O-MISC
. O-MISC O-MISC

Genomic O-MISC O-MISC
effects O-MISC O-MISC
are O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
cytosolic B-MISC B-MISC
receptors I-MISC I-MISC
that O-MISC O-MISC
alter O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
specific O-MISC B-MISC
genes O-MISC I-MISC
. O-MISC O-MISC

Specific O-MISC O-MISC
nongenomic O-MISC O-MISC
effects O-MISC O-MISC
occur O-MISC O-MISC
within O-MISC O-MISC
a O-MISC O-MISC
few O-MISC O-MISC
minutes O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
steroid B-MISC B-MISC
- I-MISC I-MISC
selective I-MISC I-MISC
membrane I-MISC I-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

Unspecific O-MISC O-MISC
nongenomic O-MISC O-MISC
effects O-MISC O-MISC
occur O-MISC O-MISC
within O-MISC O-MISC
seconds O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
only O-MISC O-MISC
at O-MISC O-MISC
high O-MISC O-MISC
glucocorticoid O-MISC O-MISC
dosages O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
seem O-MISC O-MISC
to O-MISC O-MISC
result O-MISC O-MISC
from O-MISC O-MISC
direct O-MISC O-MISC
interactions O-MISC O-MISC
with O-MISC O-MISC
biological O-MISC O-MISC
membranes O-MISC O-MISC
. O-MISC O-MISC

For O-MISC O-MISC
unspecific O-MISC O-MISC
nongenomic O-MISC O-MISC
effects O-MISC O-MISC
, O-MISC O-MISC
methylprednisolone O-MISC O-MISC
and O-MISC O-MISC
other O-MISC O-MISC
glucocorticoids O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
cation O-MISC O-MISC
cycling O-MISC O-MISC
across O-MISC O-MISC
the O-MISC O-MISC
plasma O-MISC O-MISC
membrane O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
little O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
glucocorticoids O-MISC O-MISC
could O-MISC O-MISC
diminish O-MISC O-MISC
or O-MISC O-MISC
prevent O-MISC O-MISC
the O-MISC O-MISC
acute O-MISC O-MISC
immune O-MISC O-MISC
response O-MISC O-MISC
by O-MISC O-MISC
interfering O-MISC O-MISC
with O-MISC O-MISC
processes O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
rise O-MISC O-MISC
in O-MISC O-MISC
intracellular O-MISC O-MISC
Ca2 O-MISC O-MISC
+ O-MISC O-MISC
concentration O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
proposed O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
additional O-MISC O-MISC
therapeutic O-MISC O-MISC
benefit O-MISC O-MISC
of O-MISC O-MISC
higher O-MISC O-MISC
doses O-MISC O-MISC
is O-MISC O-MISC
obtained O-MISC O-MISC
via O-MISC O-MISC
these O-MISC O-MISC
nongenomic O-MISC O-MISC
effects O-MISC O-MISC
. O-MISC O-MISC

High O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
ICAM B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
through O-MISC O-MISC
an O-MISC O-MISC
osmotic O-MISC O-MISC
effect O-MISC O-MISC
in O-MISC O-MISC
rat O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
PKC O-MISC O-MISC
- O-MISC I-MISC
NF O-MISC I-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
. O-MISC O-MISC

AIMS O-MISC O-MISC
/ O-MISC O-MISC
HYPOTHESIS O-MISC O-MISC
: O-MISC O-MISC
Infiltration O-MISC O-MISC
of O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
glomerular O-MISC O-MISC
enlargement O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
glomerular O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
are O-MISC O-MISC
very O-MISC O-MISC
early O-MISC O-MISC
characteristics O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
pathophysiology O-MISC O-MISC
of O-MISC O-MISC
diabetes O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
clarify O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
early O-MISC O-MISC
diabetic O-MISC O-MISC
nephropathy O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
measured O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
thymidine O-MISC O-MISC
incorporation O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
numbers O-MISC O-MISC
to O-MISC O-MISC
show O-MISC O-MISC
the O-MISC O-MISC
influence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
ambient O-MISC O-MISC
glucose O-MISC O-MISC
concentration O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
osmotic O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
rat O-MISC O-MISC
mesangial O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
also O-MISC O-MISC
measured O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
vascular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
by O-MISC O-MISC
flow O-MISC O-MISC
cytometry O-MISC O-MISC
and O-MISC O-MISC
semiquantitative O-MISC O-MISC
RT O-MISC O-MISC
- O-MISC O-MISC
PCR O-MISC O-MISC
in O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
adhesion O-MISC O-MISC
of O-MISC O-MISC
leukocytes O-MISC O-MISC
to O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
/ O-MISC O-MISC
RESULTS O-MISC O-MISC
: O-MISC O-MISC
Cells O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
high O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
glucose O-MISC O-MISC
( O-MISC O-MISC
30 O-MISC O-MISC
mmol O-MISC O-MISC
/ O-MISC O-MISC
l O-MISC O-MISC
) O-MISC O-MISC
caused O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
thymidine O-MISC O-MISC
incorporation O-MISC O-MISC
and O-MISC O-MISC
cell O-MISC O-MISC
numbers O-MISC O-MISC
at O-MISC O-MISC
24 O-MISC O-MISC
and O-MISC O-MISC
48 O-MISC O-MISC
h O-MISC O-MISC
and O-MISC O-MISC
normalized O-MISC O-MISC
at O-MISC O-MISC
72 O-MISC O-MISC
h O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
05 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
these O-MISC O-MISC
changes O-MISC O-MISC
were O-MISC O-MISC
not O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
high O-MISC O-MISC
mannitol O-MISC O-MISC
( O-MISC O-MISC
30 O-MISC O-MISC
mmol O-MISC O-MISC
/ O-MISC O-MISC
l O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
beta I-MISC I-MISC
, O-MISC O-MISC
or O-MISC O-MISC
TNF B-MISC B-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Cells O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
glucose O-MISC O-MISC
( O-MISC O-MISC
15 O-MISC O-MISC
, O-MISC O-MISC
30 O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
60 O-MISC O-MISC
mmol O-MISC O-MISC
/ O-MISC O-MISC
l O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
osmotic O-MISC O-MISC
agents O-MISC O-MISC
( O-MISC O-MISC
L O-MISC O-MISC
- O-MISC O-MISC
glucose O-MISC O-MISC
, O-MISC O-MISC
raffinose O-MISC O-MISC
and O-MISC O-MISC
mannitol O-MISC O-MISC
) O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
began O-MISC O-MISC
to O-MISC O-MISC
increase O-MISC O-MISC
after O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
, O-MISC O-MISC
reached O-MISC O-MISC
its O-MISC O-MISC
maximum O-MISC O-MISC
at O-MISC O-MISC
24 O-MISC O-MISC
and O-MISC O-MISC
48 O-MISC O-MISC
h O-MISC O-MISC
and O-MISC O-MISC
gradually O-MISC O-MISC
decreased O-MISC O-MISC
afterwards O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
stimulatory O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
and O-MISC O-MISC
high O-MISC O-MISC
mannitol O-MISC O-MISC
on O-MISC O-MISC
mRNA O-MISC B-MISC
expression O-MISC O-MISC
were O-MISC O-MISC
observed O-MISC O-MISC
as O-MISC O-MISC
early O-MISC O-MISC
as O-MISC O-MISC
6 O-MISC O-MISC
h O-MISC O-MISC
and O-MISC O-MISC
reached O-MISC O-MISC
its O-MISC O-MISC
maximum O-MISC O-MISC
at O-MISC O-MISC
12 O-MISC O-MISC
h O-MISC O-MISC
. O-MISC O-MISC

Up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
ICAM B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
protein O-MISC I-MISC
and O-MISC O-MISC
mRNA O-MISC B-MISC
was O-MISC O-MISC
also O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- I-MISC O-MISC
beta I-MISC I-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Neither O-MISC O-MISC
vascular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
protein O-MISC I-MISC
nor O-MISC O-MISC
mRNA O-MISC B-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
and O-MISC O-MISC
high O-MISC O-MISC
mannitol O-MISC O-MISC
. O-MISC O-MISC

Notably O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
protein O-MISC B-MISC
kinase O-MISC I-MISC
C O-MISC I-MISC
inhibitors O-MISC O-MISC
calphostin O-MISC O-MISC
C O-MISC O-MISC
and O-MISC O-MISC
staurosporine O-MISC O-MISC
reduced O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
or O-MISC O-MISC
high O-MISC O-MISC
mannitol O-MISC O-MISC
- O-MISC I-MISC
induced O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
inhibitor O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
tosyl O-MISC O-MISC
- O-MISC O-MISC
L O-MISC O-MISC
- O-MISC O-MISC
phenylalanine O-MISC O-MISC
chloromethyl O-MISC O-MISC
ketone O-MISC O-MISC
reduced O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
or O-MISC O-MISC
high O-MISC O-MISC
mannitol O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Results O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
( O-MISC O-MISC
15 O-MISC O-MISC
, O-MISC O-MISC
30 O-MISC O-MISC
mmol O-MISC O-MISC
/ O-MISC O-MISC
l O-MISC O-MISC
) O-MISC O-MISC
or O-MISC O-MISC
high O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
osmotic O-MISC O-MISC
agents O-MISC O-MISC
remarkably O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
adherent O-MISC O-MISC
leukocytes O-MISC O-MISC
to O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
control O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
mmol O-MISC O-MISC
/ O-MISC O-MISC
l O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
glucose O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Functional O-MISC O-MISC
blocking O-MISC O-MISC
of O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
on O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
rat B-MISC O-MISC
intercellular I-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
monoclonal I-MISC I-MISC
antibody I-MISC I-MISC
, O-MISC O-MISC
calphostin O-MISC O-MISC
C O-MISC O-MISC
, O-MISC O-MISC
staurosporine O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
tosyl O-MISC O-MISC
- O-MISC O-MISC
L O-MISC O-MISC
- O-MISC O-MISC
phenylalanine O-MISC O-MISC
chloromethyl O-MISC O-MISC
ketone O-MISC O-MISC
significantly O-MISC O-MISC
inhibited O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
or O-MISC O-MISC
high O-MISC O-MISC
mannitol O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
leukocyte O-MISC O-MISC
adhesion O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
< O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
05 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
/ O-MISC O-MISC
INTERPRETATION O-MISC O-MISC
: O-MISC O-MISC
These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
high O-MISC O-MISC
glucose O-MISC O-MISC
can O-MISC O-MISC
upregulate O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
protein O-MISC I-MISC
and O-MISC O-MISC
mRNA O-MISC B-MISC
expression O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
vascular O-MISC B-MISC
adhesion O-MISC O-MISC
molecule O-MISC I-MISC
- O-MISC O-MISC
1 O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
promote O-MISC O-MISC
leukocyte O-MISC O-MISC
adhesion O-MISC O-MISC
through O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
through O-MISC O-MISC
osmotic O-MISC O-MISC
effect O-MISC O-MISC
, O-MISC O-MISC
possibly O-MISC O-MISC
depending O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
nuclear B-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
( O-MISC O-MISC
PKC B-MISC B-MISC
- O-MISC I-MISC
NF B-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
) O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

High O-MISC O-MISC
glucose O-MISC O-MISC
itself O-MISC O-MISC
can O-MISC O-MISC
also O-MISC O-MISC
promote O-MISC O-MISC
mesangial O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
PKC O-MISC B-MISC
- O-MISC I-MISC
NF O-MISC I-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
hyperglycaemia O-MISC O-MISC
in O-MISC O-MISC
itself O-MISC O-MISC
seems O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
factor O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
early O-MISC O-MISC
diabetic O-MISC O-MISC
nephropathy O-MISC O-MISC
. O-MISC O-MISC

Combined O-MISC O-MISC
corticosteroid O-MISC O-MISC
/ O-MISC I-MISC
granulocyte B-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
) O-MISC O-MISC
therapy O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
severe O-MISC O-MISC
congenital O-MISC O-MISC
neutropenia O-MISC O-MISC
unresponsive O-MISC O-MISC
to O-MISC O-MISC
G B-MISC O-MISC
- I-MISC O-MISC
CSF I-MISC O-MISC
: O-MISC O-MISC
Activated O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
synergize O-MISC O-MISC
with O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
signals O-MISC O-MISC
. O-MISC O-MISC

More O-MISC O-MISC
than O-MISC O-MISC
90 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
severe O-MISC O-MISC
congenital O-MISC O-MISC
neutropenia O-MISC O-MISC
( O-MISC O-MISC
SCN O-MISC B-MISC
) O-MISC O-MISC
respond O-MISC O-MISC
to O-MISC O-MISC
granulocyte B-MISC O-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
) O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
basis O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
refractory O-MISC O-MISC
state O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
remaining O-MISC O-MISC
patients O-MISC O-MISC
is O-MISC O-MISC
unknown O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
address O-MISC O-MISC
this O-MISC O-MISC
issue O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
studied O-MISC O-MISC
a O-MISC O-MISC
child O-MISC O-MISC
with O-MISC O-MISC
SCN O-MISC B-MISC
who O-MISC O-MISC
was O-MISC O-MISC
totally O-MISC O-MISC
unresponsive O-MISC O-MISC
to O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
and O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
point O-MISC O-MISC
mutation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
extracellular B-MISC B-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
GCSF B-MISC B-MISC
- I-MISC I-MISC
R I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Marrow O-MISC O-MISC
stromal O-MISC O-MISC
support O-MISC O-MISC
of O-MISC O-MISC
granulopoiesis O-MISC O-MISC
was O-MISC O-MISC
evaluated O-MISC O-MISC
by O-MISC O-MISC
plating O-MISC O-MISC
CD34 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
on O-MISC O-MISC
preformed O-MISC O-MISC
stromal O-MISC O-MISC
layers O-MISC O-MISC
. O-MISC O-MISC

Nonadherent O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
harvested O-MISC O-MISC
and O-MISC O-MISC
assayed O-MISC O-MISC
in O-MISC O-MISC
clonogenic O-MISC O-MISC
assays O-MISC O-MISC
for O-MISC O-MISC
granulocytic O-MISC O-MISC
colony O-MISC O-MISC
production O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
and O-MISC O-MISC
corticosteroids O-MISC O-MISC
on O-MISC O-MISC
granulopoiesis O-MISC O-MISC
was O-MISC O-MISC
evaluated O-MISC O-MISC
in O-MISC O-MISC
clonogenic O-MISC O-MISC
assays O-MISC O-MISC
of O-MISC O-MISC
marrow O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
proliferation O-MISC O-MISC
studies O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
murine O-MISC O-MISC
myeloid O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
32D O-MISC O-MISC
expressing O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
mutated B-MISC O-MISC
G I-MISC B-MISC
- I-MISC I-MISC
CSFR I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
by O-MISC O-MISC
measuring O-MISC O-MISC
STAT5 O-MISC B-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
stimulated O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Patient O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
stroma O-MISC O-MISC
supported O-MISC O-MISC
granulopoiesis O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
control O-MISC O-MISC
marrow O-MISC O-MISC
CD34 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
normal O-MISC O-MISC
manner O-MISC O-MISC
. O-MISC O-MISC

Normal O-MISC O-MISC
stroma O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
granulopoiesis O-MISC O-MISC
from O-MISC O-MISC
patient O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
CD34 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Clonogenic O-MISC O-MISC
assays O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
marrow O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
incorporating O-MISC O-MISC
either O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
or O-MISC O-MISC
hydrocortisone O-MISC O-MISC
produced O-MISC O-MISC
little O-MISC O-MISC
neutrophil O-MISC O-MISC
growth O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
inclusion O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
and O-MISC O-MISC
hydrocortisone O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytokine B-MISC B-MISC
` I-MISC O-MISC
` I-MISC O-MISC
cocktail I-MISC O-MISC
' I-MISC O-MISC
' I-MISC O-MISC
markedly O-MISC O-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
neutrophil O-MISC O-MISC
numbers O-MISC O-MISC
. O-MISC O-MISC

Proliferation O-MISC O-MISC
of O-MISC O-MISC
32D O-MISC O-MISC
cells O-MISC O-MISC
expressing O-MISC O-MISC
the O-MISC O-MISC
mutated B-MISC B-MISC
receptor I-MISC I-MISC
and O-MISC O-MISC
STAT5 O-MISC B-MISC
activation O-MISC O-MISC
were O-MISC O-MISC
improved O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
combination O-MISC O-MISC
of O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
and O-MISC O-MISC
dexamethasone O-MISC O-MISC
. O-MISC O-MISC

When O-MISC O-MISC
small O-MISC O-MISC
daily O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
oral O-MISC O-MISC
prednisone O-MISC O-MISC
were O-MISC O-MISC
then O-MISC O-MISC
administered O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
with O-MISC O-MISC
conventional O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
subcutaneous B-MISC O-MISC
G I-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
patient O-MISC O-MISC
responded O-MISC O-MISC
with O-MISC O-MISC
increased O-MISC O-MISC
neutrophil O-MISC O-MISC
numbers O-MISC O-MISC
and O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
complete O-MISC O-MISC
reversal O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
infectious O-MISC O-MISC
problems O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
provide O-MISC O-MISC
insight O-MISC O-MISC
into O-MISC O-MISC
SCN O-MISC B-MISC
unresponsive O-MISC O-MISC
to O-MISC O-MISC
standard O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
treatment O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
potential O-MISC O-MISC
corrective O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
combined O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
G B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
and O-MISC O-MISC
corticosteroids O-MISC O-MISC
through O-MISC O-MISC
synergistic O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT5 B-MISC B-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
renal O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
a O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
cis O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
. O-MISC O-MISC

Mesangial O-MISC O-MISC
cells O-MISC O-MISC
play O-MISC O-MISC
an O-MISC O-MISC
active O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
glomerular O-MISC O-MISC
injury O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
studied O-MISC O-MISC
in O-MISC O-MISC
cultured O-MISC O-MISC
human O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
CHMC O-MISC O-MISC
) O-MISC O-MISC
several O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
cis O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
cRA O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
activator O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
retinoic B-MISC B-MISC
acid I-MISC I-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
RARs B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
retinoid B-MISC B-MISC
X I-MISC I-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
RXRs B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

9 O-MISC O-MISC
- O-MISC O-MISC
cRA O-MISC O-MISC
inhibited O-MISC O-MISC
foetal O-MISC O-MISC
calf O-MISC O-MISC
serum O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
CHMC O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
also O-MISC O-MISC
prevented O-MISC O-MISC
CHMC O-MISC O-MISC
death O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
inflammatory O-MISC B-MISC
mediator O-MISC I-MISC
H O-MISC I-MISC
( O-MISC I-MISC
2 O-MISC I-MISC
) O-MISC O-MISC
O O-MISC B-MISC
( O-MISC O-MISC
2 O-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
preventive O-MISC O-MISC
effect O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
any O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
H O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
O O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
catabolism O-MISC O-MISC
and O-MISC O-MISC
it O-MISC O-MISC
persisted O-MISC O-MISC
even O-MISC O-MISC
when O-MISC O-MISC
both O-MISC O-MISC
catalase O-MISC O-MISC
and O-MISC O-MISC
glutathione O-MISC O-MISC
synthesis O-MISC O-MISC
were O-MISC O-MISC
inhibited O-MISC O-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
cRA O-MISC O-MISC
diminished O-MISC O-MISC
monocyte O-MISC O-MISC
adhesion O-MISC O-MISC
to O-MISC O-MISC
FCS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
CHMC O-MISC O-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
retinoid O-MISC O-MISC
also O-MISC O-MISC
inhibited O-MISC O-MISC
in O-MISC O-MISC
FCS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
cells O-MISC O-MISC
the O-MISC O-MISC
protein O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
two O-MISC O-MISC
mesangial B-MISC O-MISC
adhesion I-MISC B-MISC
molecules I-MISC I-MISC
, O-MISC O-MISC
fibronectin B-MISC B-MISC
and O-MISC O-MISC
osteopontin B-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
it O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
modify O-MISC O-MISC
the O-MISC O-MISC
protein O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
vascular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

All O-MISC O-MISC
major O-MISC O-MISC
RARs B-MISC B-MISC
and I-MISC O-MISC
RXRs I-MISC B-MISC
isotypes I-MISC O-MISC
were O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
CHMC O-MISC O-MISC
regardless O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
or O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
cRA O-MISC O-MISC
. O-MISC O-MISC

Transcripts O-MISC O-MISC
to O-MISC O-MISC
RAR B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
RAR B-MISC B-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
and O-MISC I-MISC
RXR B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
increased O-MISC O-MISC
after O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
cRA O-MISC O-MISC
whereas O-MISC O-MISC
RXR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
a O-MISC O-MISC
major O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
RARs B-MISC B-MISC
and O-MISC O-MISC
RXRs B-MISC B-MISC
in O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
cRA O-MISC O-MISC
- O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
effects O-MISC O-MISC
. O-MISC O-MISC

9 O-MISC O-MISC
- O-MISC O-MISC
cRA O-MISC O-MISC
was O-MISC O-MISC
toxic O-MISC O-MISC
only O-MISC O-MISC
at O-MISC O-MISC
50 O-MISC O-MISC
microM O-MISC O-MISC
( O-MISC O-MISC
a O-MISC O-MISC
concentration O-MISC O-MISC
50 O-MISC O-MISC
- O-MISC O-MISC
5000 O-MISC O-MISC
times O-MISC O-MISC
higher O-MISC O-MISC
than O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
above O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Cell O-MISC O-MISC
death O-MISC O-MISC
occurred O-MISC O-MISC
by O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
whose O-MISC O-MISC
onset O-MISC O-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
pronounced O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
catalase O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
reduced O-MISC O-MISC
glutathione O-MISC O-MISC
content O-MISC O-MISC
, O-MISC O-MISC
being O-MISC O-MISC
more O-MISC O-MISC
effectively O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
all O-MISC O-MISC
- O-MISC O-MISC
trans O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
. O-MISC O-MISC

Modulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
oxidant O-MISC O-MISC
/ O-MISC O-MISC
antioxidant O-MISC O-MISC
balance O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
mesangial O-MISC O-MISC
cells O-MISC O-MISC
might O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
inflammatory O-MISC O-MISC
glomerulopathies O-MISC O-MISC
with O-MISC O-MISC
9 O-MISC O-MISC
- O-MISC O-MISC
cRA O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
mammalian B-MISC B-MISC
defensin I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Antimicrobial O-MISC O-MISC
peptides O-MISC O-MISC
are O-MISC O-MISC
a O-MISC O-MISC
prevalent O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
host O-MISC O-MISC
defense O-MISC O-MISC
found O-MISC O-MISC
throughout O-MISC O-MISC
nature O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
mammals O-MISC O-MISC
, O-MISC O-MISC
defensins B-MISC B-MISC
are O-MISC O-MISC
among O-MISC O-MISC
the O-MISC O-MISC
most O-MISC O-MISC
abundant O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
broad O-MISC O-MISC
- O-MISC O-MISC
spectrum O-MISC I-MISC
antibiotics O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
epithelial O-MISC O-MISC
and O-MISC O-MISC
hematopoietic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
defensin O-MISC O-MISC
peptides O-MISC O-MISC
are O-MISC O-MISC
especially O-MISC O-MISC
abundant O-MISC O-MISC
in O-MISC O-MISC
neutrophils O-MISC O-MISC
; O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
limited O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
promyelocyte O-MISC O-MISC
stage O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
defensin B-MISC B-MISC
genes I-MISC I-MISC
are O-MISC O-MISC
found O-MISC O-MISC
as O-MISC O-MISC
both O-MISC O-MISC
constitutively O-MISC O-MISC
expressed O-MISC O-MISC
and O-MISC O-MISC
inducible O-MISC O-MISC
. O-MISC O-MISC

Induction O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
by O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
bacterial O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
inflammatory O-MISC B-MISC
mediators O-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
vivo O-MISC O-MISC
, O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
several O-MISC O-MISC
defensin B-MISC B-MISC
genes I-MISC I-MISC
occurs O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
infectious O-MISC O-MISC
and O-MISC O-MISC
inflammatory O-MISC O-MISC
states O-MISC O-MISC
. O-MISC O-MISC

Gene O-MISC O-MISC
regulation O-MISC O-MISC
occurs O-MISC O-MISC
via O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
pathways O-MISC O-MISC
common O-MISC O-MISC
to O-MISC O-MISC
other O-MISC O-MISC
innate O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
, O-MISC O-MISC
utilizing O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
interleukin I-MISC I-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
. O-MISC O-MISC

Together O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
a O-MISC O-MISC
broad O-MISC O-MISC
- O-MISC O-MISC
based O-MISC O-MISC
innate O-MISC O-MISC
host O-MISC O-MISC
defense O-MISC O-MISC
whereby O-MISC O-MISC
potent O-MISC O-MISC
antimicrobial O-MISC O-MISC
peptides O-MISC O-MISC
are O-MISC O-MISC
present O-MISC O-MISC
to O-MISC O-MISC
prevent O-MISC O-MISC
initial O-MISC O-MISC
colonization O-MISC O-MISC
by O-MISC O-MISC
pathogenic O-MISC O-MISC
microorganisms O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
recognition O-MISC O-MISC
of O-MISC O-MISC
bacteria O-MISC O-MISC
coupled O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
nascent O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
can O-MISC O-MISC
bolster O-MISC O-MISC
this O-MISC O-MISC
defense O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
coordinated O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
peptides O-MISC O-MISC
. O-MISC O-MISC

Multiple O-MISC O-MISC
signals O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
cyclic B-MISC B-MISC
AMP I-MISC I-MISC
- I-MISC I-MISC
responsive I-MISC I-MISC
element I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
CREB B-MISC B-MISC
) O-MISC O-MISC
binding O-MISC O-MISC
protein O-MISC O-MISC
interaction O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
CD3 O-MISC B-MISC
/ O-MISC I-MISC
CD28 O-MISC I-MISC
costimulation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
optimal O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
cAMP B-MISC B-MISC
- I-MISC I-MISC
responsive I-MISC I-MISC
element I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
CREB B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
full O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
requires O-MISC O-MISC
the O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
CD3 B-MISC B-MISC
and O-MISC O-MISC
CD28 B-MISC B-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
a O-MISC O-MISC
reporter O-MISC O-MISC
system O-MISC O-MISC
to O-MISC O-MISC
detect O-MISC O-MISC
interaction O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
and O-MISC O-MISC
CREB B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
CBP B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
CREB B-MISC B-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
CBP B-MISC B-MISC
only O-MISC O-MISC
by O-MISC O-MISC
engagement O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
CD3 B-MISC B-MISC
and O-MISC O-MISC
CD28 B-MISC B-MISC
. O-MISC O-MISC

CD3 B-MISC B-MISC
/ I-MISC O-MISC
CD28 I-MISC I-MISC
- O-MISC O-MISC
promoted O-MISC O-MISC
CREB B-MISC B-MISC
- O-MISC O-MISC
CBP B-MISC I-MISC
interaction O-MISC O-MISC
was O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
p38 B-MISC B-MISC
mitogen I-MISC I-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
MAPK B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
calcium B-MISC B-MISC
/ I-MISC I-MISC
calmodulin I-MISC I-MISC
- I-MISC I-MISC
dependent I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
( I-MISC I-MISC
CaMK I-MISC I-MISC
) I-MISC I-MISC
IV I-MISC I-MISC
in O-MISC O-MISC
addition O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
previously O-MISC O-MISC
identified O-MISC O-MISC
extracellular O-MISC B-MISC
signal O-MISC I-MISC
- O-MISC I-MISC
regulated O-MISC I-MISC
kinase O-MISC I-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

Extracellular B-MISC O-MISC
signal I-MISC B-MISC
- I-MISC I-MISC
regulated I-MISC I-MISC
kinase I-MISC I-MISC
, I-MISC O-MISC
CaMKIV I-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
p38 B-MISC B-MISC
MAPK I-MISC I-MISC
were O-MISC O-MISC
also O-MISC O-MISC
the O-MISC O-MISC
kinases O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
CREB B-MISC B-MISC
Ser O-MISC O-MISC
( O-MISC O-MISC
133 O-MISC O-MISC
) O-MISC O-MISC
phosphorylation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
CD3 B-MISC B-MISC
/ I-MISC O-MISC
CD28 I-MISC B-MISC
. O-MISC O-MISC

A O-MISC O-MISC
reconstitution O-MISC O-MISC
experiment O-MISC O-MISC
illustrated O-MISC O-MISC
that O-MISC O-MISC
optimum O-MISC O-MISC
CREB B-MISC B-MISC
- O-MISC O-MISC
CBP B-MISC I-MISC
interaction O-MISC O-MISC
and O-MISC O-MISC
CREB B-MISC B-MISC
trans O-MISC O-MISC
- O-MISC O-MISC
activation O-MISC O-MISC
were O-MISC O-MISC
attained O-MISC O-MISC
when O-MISC O-MISC
these O-MISC O-MISC
three O-MISC O-MISC
kinase O-MISC O-MISC
pathways O-MISC O-MISC
were O-MISC O-MISC
simultaneously O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
coordinated O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
different O-MISC O-MISC
kinases B-MISC B-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
full O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
CREB B-MISC B-MISC
. O-MISC O-MISC

Notably O-MISC O-MISC
, O-MISC O-MISC
CD28 O-MISC B-MISC
ligation O-MISC O-MISC
activated O-MISC O-MISC
p38 B-MISC B-MISC
MAPK I-MISC I-MISC
and O-MISC O-MISC
CaMKIV B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
kinases B-MISC O-MISC
stimulated O-MISC O-MISC
by O-MISC O-MISC
CD3 O-MISC B-MISC
engagement O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
CD28 B-MISC B-MISC
acts O-MISC O-MISC
by O-MISC O-MISC
increasing O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
extent O-MISC O-MISC
of O-MISC O-MISC
p38 B-MISC B-MISC
MAPK I-MISC B-MISC
and O-MISC O-MISC
CaMKIV B-MISC B-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
support O-MISC O-MISC
the O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
minimum O-MISC O-MISC
activation O-MISC O-MISC
threshold O-MISC O-MISC
for O-MISC O-MISC
CREB B-MISC B-MISC
- O-MISC I-MISC
CBP B-MISC I-MISC
interaction O-MISC O-MISC
that O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
reached O-MISC O-MISC
only O-MISC O-MISC
when O-MISC O-MISC
both O-MISC O-MISC
CD3 B-MISC B-MISC
and O-MISC O-MISC
CD28 B-MISC B-MISC
are O-MISC O-MISC
stimulated O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
murine B-MISC B-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
contains O-MISC O-MISC
distal B-MISC B-MISC
regulatory I-MISC I-MISC
elements I-MISC I-MISC
responsive O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
Ah B-MISC B-MISC
receptor I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
evolutionarily O-MISC B-MISC
conserved O-MISC I-MISC
bHLH B-MISC I-MISC
- I-MISC I-MISC
PAS I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
family I-MISC I-MISC
. O-MISC O-MISC

Signaling O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
TCR B-MISC B-MISC
and O-MISC O-MISC
costimulatory O-MISC O-MISC
signals O-MISC O-MISC
primarily O-MISC O-MISC
control O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
naive O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
minimal B-MISC B-MISC
promoter I-MISC I-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
this O-MISC O-MISC
expression O-MISC O-MISC
lies O-MISC O-MISC
proximal O-MISC O-MISC
, O-MISC O-MISC
between O-MISC O-MISC
- O-MISC O-MISC
300 O-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
start I-MISC I-MISC
site I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
had O-MISC O-MISC
previously O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
arylhydrocarbon B-MISC O-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
AHR B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
bHLH B-MISC B-MISC
- I-MISC I-MISC
PAS I-MISC I-MISC
family I-MISC I-MISC
of I-MISC O-MISC
transcription I-MISC B-MISC
factors I-MISC I-MISC
, O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
increased O-MISC O-MISC
mRNA O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
in O-MISC O-MISC
murine O-MISC O-MISC
fetal O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
AHR B-MISC O-MISC
is O-MISC O-MISC
abundant O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
thymus O-MISC O-MISC
and O-MISC O-MISC
may O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
its O-MISC O-MISC
overactivation O-MISC O-MISC
by O-MISC O-MISC
chemicals O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
dioxins O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
immunosuppression O-MISC O-MISC
and O-MISC O-MISC
thymic O-MISC O-MISC
involution O-MISC O-MISC
. O-MISC O-MISC

Binding O-MISC O-MISC
motifs O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
liganded B-MISC B-MISC
AHR I-MISC I-MISC
can O-MISC O-MISC
be O-MISC O-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
distal B-MISC B-MISC
region I-MISC I-MISC
- I-MISC I-MISC
1300 I-MISC I-MISC
to I-MISC O-MISC
- I-MISC O-MISC
800 I-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mouse B-MISC B-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
these O-MISC O-MISC
DNA B-MISC B-MISC
motifs I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
so O-MISC O-MISC
- O-MISC I-MISC
called O-MISC O-MISC
dioxin B-MISC I-MISC
response I-MISC I-MISC
elements I-MISC I-MISC
, O-MISC O-MISC
after O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
liganded B-MISC B-MISC
AHR I-MISC I-MISC
are O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
transactivate O-MISC O-MISC
luciferase O-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
reporter O-MISC B-MISC
gene O-MISC I-MISC
system O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
can O-MISC O-MISC
be O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
AHR B-MISC O-MISC
also O-MISC O-MISC
in O-MISC O-MISC
thymocytes O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
after O-MISC O-MISC
injection O-MISC O-MISC
of O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
8 O-MISC O-MISC
- O-MISC O-MISC
tetrachlorodibenzo O-MISC O-MISC
- O-MISC O-MISC
p O-MISC O-MISC
- O-MISC O-MISC
dioxin O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
ligand O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
AHR B-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
AHR B-MISC O-MISC
mediates O-MISC O-MISC
the O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
induction O-MISC O-MISC
as O-MISC O-MISC
shown O-MISC O-MISC
with O-MISC O-MISC
AHR B-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
spleen O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
costimulation O-MISC O-MISC
via O-MISC O-MISC
the O-MISC O-MISC
TCR B-MISC B-MISC
is O-MISC O-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
optimal O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
induction O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
region I-MISC I-MISC
contains O-MISC O-MISC
novel O-MISC O-MISC
distal B-MISC B-MISC
regulatory I-MISC I-MISC
elements I-MISC I-MISC
that O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
addressed O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
AHR B-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
can O-MISC O-MISC
cooperate O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
proximal B-MISC B-MISC
promoter I-MISC I-MISC

Visualization O-MISC O-MISC
of O-MISC O-MISC
Syk B-MISC B-MISC
- I-MISC I-MISC
antigen I-MISC I-MISC
receptor I-MISC I-MISC
interactions O-MISC O-MISC
using O-MISC O-MISC
green B-MISC O-MISC
fluorescent I-MISC O-MISC
protein I-MISC O-MISC
: O-MISC O-MISC
differential O-MISC O-MISC
roles O-MISC O-MISC
for O-MISC O-MISC
Syk B-MISC B-MISC
and O-MISC O-MISC
Lyn B-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
receptor O-MISC B-MISC
capping O-MISC I-MISC
and O-MISC O-MISC
internalization O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
Ag I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
BCR B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
coupled O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
multiple O-MISC O-MISC
intracellular O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
cascades O-MISC O-MISC
via O-MISC O-MISC
receptor O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
, O-MISC O-MISC
protein B-MISC B-MISC
tyrosine I-MISC I-MISC
kinases I-MISC I-MISC
of O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
Src B-MISC B-MISC
and I-MISC I-MISC
Syk I-MISC I-MISC
families I-MISC I-MISC
. O-MISC O-MISC

To O-MISC O-MISC
monitor O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
subcellular O-MISC O-MISC
distribution O-MISC O-MISC
of O-MISC O-MISC
Syk B-MISC B-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
responding O-MISC O-MISC
to O-MISC O-MISC
BCR B-MISC B-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
Syk B-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
DT40 O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
a O-MISC O-MISC
fusion B-MISC B-MISC
protein I-MISC I-MISC
consisting O-MISC O-MISC
of O-MISC O-MISC
Syk B-MISC B-MISC
coupled O-MISC O-MISC
to O-MISC O-MISC
green B-MISC I-MISC
fluorescent I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
IgM I-MISC I-MISC
Abs I-MISC I-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
recruitment O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
kinase B-MISC B-MISC
from O-MISC O-MISC
cytoplasmic O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
compartments O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
site O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cross B-MISC B-MISC
- I-MISC I-MISC
linked I-MISC I-MISC
receptor I-MISC I-MISC
at O-MISC O-MISC
the O-MISC O-MISC
plasma O-MISC O-MISC
membrane O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Syk B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
aggregate O-MISC O-MISC
into O-MISC O-MISC
membrane O-MISC O-MISC
patches O-MISC O-MISC
that O-MISC O-MISC
redistribute O-MISC O-MISC
to O-MISC O-MISC
form O-MISC O-MISC
a O-MISC O-MISC
cap O-MISC O-MISC
at O-MISC O-MISC
one O-MISC O-MISC
pole O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
. O-MISC O-MISC

Syk B-MISC B-MISC
is O-MISC O-MISC
not O-MISC O-MISC
demonstrably O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
internalized B-MISC B-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Catalytically O-MISC O-MISC
active O-MISC O-MISC
Syk B-MISC B-MISC
promotes O-MISC O-MISC
and O-MISC O-MISC
stabilizes O-MISC O-MISC
the O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
tightly B-MISC O-MISC
capped I-MISC I-MISC
BCR I-MISC B-MISC
complexes I-MISC I-MISC
at O-MISC O-MISC
the O-MISC O-MISC
plasma O-MISC O-MISC
membrane O-MISC O-MISC
. O-MISC O-MISC

Lyn B-MISC B-MISC
is O-MISC O-MISC
not O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
recruitment O-MISC O-MISC
of O-MISC O-MISC
Syk B-MISC B-MISC
to O-MISC O-MISC
the O-MISC O-MISC
cross B-MISC B-MISC
- I-MISC I-MISC
linked I-MISC I-MISC
receptor I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
internalization O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
clustered O-MISC B-MISC
BCR B-MISC I-MISC
complexes I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
Lyn B-MISC B-MISC
, O-MISC O-MISC
receptor B-MISC I-MISC
- I-MISC I-MISC
Syk I-MISC I-MISC
complexes I-MISC I-MISC
at O-MISC O-MISC
the O-MISC O-MISC
plasma O-MISC O-MISC
membrane O-MISC O-MISC
are O-MISC O-MISC
long O-MISC O-MISC
lived O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
AT I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
is O-MISC O-MISC
enhanced O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
Lyn B-MISC B-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
function O-MISC O-MISC
to O-MISC O-MISC
negatively O-MISC O-MISC
regulate O-MISC O-MISC
aspects O-MISC O-MISC
of O-MISC O-MISC
BCR B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
signaling O-MISC O-MISC
by O-MISC O-MISC
stimulating O-MISC B-MISC
receptor O-MISC I-MISC
internalization O-MISC O-MISC
and O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
. O-MISC O-MISC

Renal O-MISC O-MISC
interstitial O-MISC O-MISC
fibrosis O-MISC O-MISC
is O-MISC O-MISC
reduced O-MISC O-MISC
in O-MISC O-MISC
angiotensin B-MISC O-MISC
II I-MISC O-MISC
type I-MISC O-MISC
1a I-MISC O-MISC
receptor I-MISC O-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Unilateral O-MISC O-MISC
ureteral O-MISC O-MISC
obstruction O-MISC B-MISC
( O-MISC O-MISC
UUO O-MISC O-MISC
) O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
tubulointerstitial O-MISC O-MISC
fibrosis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
affected O-MISC O-MISC
kidney O-MISC O-MISC
by O-MISC O-MISC
stimulating O-MISC O-MISC
the O-MISC O-MISC
renin O-MISC O-MISC
- O-MISC O-MISC
angiotensin O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
established O-MISC O-MISC
a O-MISC O-MISC
UUO O-MISC O-MISC
model O-MISC O-MISC
in O-MISC O-MISC
angiotensin B-MISC O-MISC
type I-MISC B-MISC
1a I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
AT1a B-MISC O-MISC
) O-MISC O-MISC
deficient O-MISC O-MISC
( O-MISC O-MISC
mutant O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
to O-MISC O-MISC
elucidate O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
angiotensin B-MISC O-MISC
II I-MISC I-MISC
through O-MISC O-MISC
AT1a B-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
fibrosis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
obstructed O-MISC B-MISC
kidney O-MISC O-MISC
( O-MISC O-MISC
OBK O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
relative O-MISC O-MISC
volume O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tubulointerstitium O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
image O-MISC O-MISC
analyzer O-MISC O-MISC
; O-MISC O-MISC
deposition O-MISC O-MISC
of O-MISC O-MISC
collagen B-MISC O-MISC
types I-MISC O-MISC
III I-MISC O-MISC
and I-MISC O-MISC
IV I-MISC O-MISC
and O-MISC O-MISC
monocyte O-MISC O-MISC
/ O-MISC O-MISC
macrophage O-MISC O-MISC
infiltration O-MISC O-MISC
were O-MISC O-MISC
histologically O-MISC O-MISC
examined O-MISC O-MISC
using O-MISC O-MISC
specific B-MISC B-MISC
antibodies I-MISC I-MISC
. O-MISC O-MISC

Also O-MISC O-MISC
determined O-MISC O-MISC
were O-MISC O-MISC
the O-MISC O-MISC
mRNA O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
transforming B-MISC B-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
by O-MISC O-MISC
Northern O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

Nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
gel O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

UUO O-MISC O-MISC
in O-MISC O-MISC
wild O-MISC O-MISC
mice O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
marked O-MISC O-MISC
expansion O-MISC O-MISC
of O-MISC O-MISC
relative O-MISC O-MISC
volume O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tubulointerstitium O-MISC O-MISC
, O-MISC O-MISC
together O-MISC O-MISC
with O-MISC O-MISC
increased O-MISC O-MISC
deposition O-MISC O-MISC
of O-MISC O-MISC
collagen B-MISC O-MISC
types I-MISC O-MISC
III I-MISC O-MISC
and I-MISC O-MISC
IV I-MISC O-MISC
and O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
infiltrated O-MISC O-MISC
monocytes O-MISC O-MISC
/ O-MISC O-MISC
macrophages O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
interstitium O-MISC O-MISC
, O-MISC O-MISC
relative O-MISC O-MISC
to O-MISC O-MISC
sham O-MISC O-MISC
- O-MISC O-MISC
operated O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
comparison O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
changes O-MISC O-MISC
were O-MISC O-MISC
significantly O-MISC O-MISC
lower O-MISC O-MISC
in O-MISC O-MISC
mutant O-MISC O-MISC
mice O-MISC O-MISC
with O-MISC O-MISC
UUO O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mRNA O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
transforming B-MISC B-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
beta I-MISC I-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
higher O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
OBK O-MISC O-MISC
of O-MISC O-MISC
wild O-MISC O-MISC
mice O-MISC O-MISC
with O-MISC O-MISC
UUO O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
sham O-MISC O-MISC
- O-MISC O-MISC
operated O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
mRNA O-MISC B-MISC
level O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
OBK O-MISC O-MISC
of O-MISC O-MISC
mutant O-MISC O-MISC
mice O-MISC O-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
in O-MISC O-MISC
wild O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
UUO O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
in O-MISC O-MISC
wild O-MISC O-MISC
mice O-MISC O-MISC
but O-MISC O-MISC
was O-MISC O-MISC
inhibited O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
OBK O-MISC B-MISC
of O-MISC O-MISC
mutant O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
results O-MISC O-MISC
provide O-MISC O-MISC
direct O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
angiotensin B-MISC O-MISC
II I-MISC I-MISC
acting O-MISC I-MISC
via O-MISC O-MISC
the O-MISC O-MISC
AT1a B-MISC B-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
pivotal O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
tubulointerstitial O-MISC O-MISC
fibrosis O-MISC O-MISC
in O-MISC O-MISC
UUO O-MISC O-MISC
. O-MISC O-MISC

HLA B-MISC B-MISC
- I-MISC I-MISC
DQ I-MISC I-MISC
tetramers I-MISC I-MISC
identify O-MISC O-MISC
epitope O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
of O-MISC O-MISC
herpes O-MISC O-MISC
simplex O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
individuals O-MISC O-MISC
: O-MISC O-MISC
direct O-MISC O-MISC
detection O-MISC O-MISC
of O-MISC O-MISC
immunodominant O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
responsive O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Ag O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
in O-MISC O-MISC
low O-MISC O-MISC
frequency O-MISC O-MISC
, O-MISC O-MISC
where O-MISC O-MISC
they O-MISC O-MISC
undergo O-MISC O-MISC
recruitment O-MISC O-MISC
and O-MISC O-MISC
expansion O-MISC O-MISC
during O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
numerous O-MISC O-MISC
autoimmune O-MISC O-MISC
diseases O-MISC O-MISC
. O-MISC O-MISC

MHC B-MISC B-MISC
tetramers I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
constitute O-MISC O-MISC
a O-MISC O-MISC
labeled B-MISC O-MISC
MHC I-MISC O-MISC
- I-MISC O-MISC
peptide I-MISC O-MISC
ligand I-MISC O-MISC
suitable O-MISC O-MISC
for O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
Ag B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
receptor I-MISC I-MISC
on O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
provide O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
approach O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
detection O-MISC O-MISC
and O-MISC O-MISC
characterization O-MISC O-MISC
of O-MISC O-MISC
such O-MISC O-MISC
rare O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
utilized O-MISC O-MISC
this O-MISC O-MISC
technology O-MISC O-MISC
to O-MISC O-MISC
identify O-MISC O-MISC
HLA B-MISC B-MISC
DQ I-MISC I-MISC
- O-MISC I-MISC
restricted O-MISC I-MISC
Ag O-MISC I-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
subjects O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
identify O-MISC O-MISC
immunodominant O-MISC B-MISC
epitopes O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
viral O-MISC O-MISC
infection O-MISC O-MISC
. O-MISC O-MISC

Peptides O-MISC O-MISC
representing O-MISC O-MISC
potential O-MISC O-MISC
epitope B-MISC B-MISC
regions I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
VP16 B-MISC B-MISC
protein I-MISC I-MISC
from O-MISC O-MISC
HSV O-MISC O-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
were O-MISC O-MISC
loaded O-MISC O-MISC
onto O-MISC O-MISC
recombinant B-MISC O-MISC
DQ0602 I-MISC I-MISC
molecules I-MISC I-MISC
to O-MISC O-MISC
generate O-MISC O-MISC
a O-MISC O-MISC
panel O-MISC O-MISC
of O-MISC O-MISC
Ag B-MISC B-MISC
- I-MISC O-MISC
specific I-MISC O-MISC
DQ0602 I-MISC O-MISC
tetramers I-MISC O-MISC
. O-MISC O-MISC

VP16 B-MISC B-MISC
Ag I-MISC I-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
DQ O-MISC O-MISC
- O-MISC O-MISC
restricted O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
identified O-MISC O-MISC
and O-MISC O-MISC
expanded O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
of O-MISC O-MISC
HSV O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
individuals O-MISC O-MISC
, O-MISC O-MISC
representing O-MISC O-MISC
two O-MISC O-MISC
predominant O-MISC O-MISC
epitope O-MISC O-MISC
specificities O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
the O-MISC O-MISC
VP16 O-MISC O-MISC
369 O-MISC O-MISC
- O-MISC O-MISC
380 O-MISC O-MISC
peptide O-MISC O-MISC
has O-MISC O-MISC
a O-MISC O-MISC
lower O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
for O-MISC O-MISC
DQ0602 B-MISC O-MISC
molecules I-MISC O-MISC
than O-MISC O-MISC
the O-MISC O-MISC
VP16 O-MISC O-MISC
33 O-MISC O-MISC
- O-MISC O-MISC
52 O-MISC O-MISC
peptide O-MISC O-MISC
, O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
recognized O-MISC O-MISC
the O-MISC O-MISC
VP16 O-MISC O-MISC
369 O-MISC O-MISC
- O-MISC O-MISC
380 O-MISC O-MISC
peptide O-MISC O-MISC
occurred O-MISC O-MISC
at O-MISC O-MISC
a O-MISC O-MISC
much O-MISC O-MISC
higher O-MISC O-MISC
frequency O-MISC O-MISC
than O-MISC O-MISC
those O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
VP16 O-MISC O-MISC
33 O-MISC O-MISC
- O-MISC O-MISC
52 O-MISC O-MISC
peptide O-MISC O-MISC
. O-MISC O-MISC

Down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
BOB B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
OBF I-MISC I-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
Oct2 B-MISC B-MISC
in O-MISC O-MISC
classical O-MISC O-MISC
Hodgkin O-MISC O-MISC
disease O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
lymphocyte O-MISC O-MISC
predominant O-MISC O-MISC
Hodgkin O-MISC O-MISC
disease O-MISC O-MISC
correlates O-MISC O-MISC
with O-MISC O-MISC
immunoglobulin O-MISC O-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
tumor O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
L O-MISC O-MISC
& O-MISC O-MISC
H O-MISC O-MISC
cells O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
lymphocyte O-MISC O-MISC
predominant O-MISC O-MISC
Hodgkin O-MISC O-MISC
disease O-MISC O-MISC
( O-MISC O-MISC
LPHD O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
Hodgkin O-MISC O-MISC
and O-MISC O-MISC
Reed O-MISC O-MISC
- O-MISC O-MISC
Sternberg O-MISC O-MISC
( O-MISC O-MISC
HRS O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
classical O-MISC O-MISC
Hodgkin O-MISC O-MISC
disease O-MISC O-MISC
( O-MISC O-MISC
cHD O-MISC O-MISC
) O-MISC O-MISC
are O-MISC O-MISC
unable O-MISC O-MISC
to O-MISC O-MISC
transcribe O-MISC O-MISC
immunoglobulin B-MISC B-MISC
, O-MISC O-MISC
despite O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
rearranged B-MISC O-MISC
immunoglobulin I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
initial O-MISC O-MISC
studies O-MISC O-MISC
have O-MISC O-MISC
suggested O-MISC O-MISC
crippling O-MISC O-MISC
immunoglobulin O-MISC B-MISC
gene O-MISC I-MISC
mutations O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
the O-MISC O-MISC
cause O-MISC O-MISC
of O-MISC O-MISC
absent O-MISC O-MISC
immunoglobulin O-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
cHD O-MISC O-MISC
, O-MISC O-MISC
recent O-MISC O-MISC
work O-MISC O-MISC
of O-MISC O-MISC
our O-MISC O-MISC
group O-MISC O-MISC
has O-MISC O-MISC
demonstrated O-MISC O-MISC
an O-MISC O-MISC
impaired O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immunoglobulin B-MISC B-MISC
promoter I-MISC I-MISC
as O-MISC O-MISC
a O-MISC O-MISC
superior O-MISC O-MISC
mechanism O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
immunoglobulin O-MISC B-MISC
transcription O-MISC O-MISC
is O-MISC O-MISC
mainly O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
B B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
Oct2 B-MISC B-MISC
and O-MISC O-MISC
BOB B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
OBF I-MISC I-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
analyzed O-MISC O-MISC
35 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
LPHD O-MISC O-MISC
, O-MISC O-MISC
32 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
cHD O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
2 O-MISC O-MISC
Hodgkin O-MISC O-MISC
disease O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
and O-MISC O-MISC
also O-MISC O-MISC
in O-MISC O-MISC
parallel O-MISC O-MISC
for O-MISC O-MISC
immunoglobulin O-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
demonstrate O-MISC O-MISC
an O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
Oct2 B-MISC B-MISC
and O-MISC I-MISC
/ O-MISC I-MISC
or O-MISC I-MISC
BOB B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
OBF I-MISC I-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
cHD O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
striking O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
Oct2 B-MISC B-MISC
in O-MISC O-MISC
LPHD O-MISC O-MISC
. O-MISC O-MISC

Immunoglobulin O-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
lacking O-MISC O-MISC
in O-MISC O-MISC
cHD O-MISC O-MISC
but O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
LPHD O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
reintroduction O-MISC O-MISC
of O-MISC O-MISC
BOB B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
OBF I-MISC I-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
Oct2 B-MISC B-MISC
into O-MISC O-MISC
cultured O-MISC O-MISC
HRS O-MISC O-MISC
cells O-MISC O-MISC
restored O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
cotransduced O-MISC B-MISC
immunoglobulin B-MISC B-MISC
promoter I-MISC I-MISC
constructs I-MISC I-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
findings O-MISC O-MISC
dismiss O-MISC O-MISC
the O-MISC O-MISC
concept O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
different O-MISC O-MISC
immunoglobulin O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
cHD O-MISC O-MISC
and O-MISC O-MISC
LPHD O-MISC O-MISC
is O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
disrupting O-MISC O-MISC
mutations O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin B-MISC B-MISC
V I-MISC B-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
cHD O-MISC O-MISC
but O-MISC O-MISC
is O-MISC O-MISC
most O-MISC O-MISC
likely O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
Oct2 B-MISC B-MISC
and O-MISC I-MISC
/ O-MISC I-MISC
or O-MISC I-MISC
BOB B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
OBF I-MISC I-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
further O-MISC O-MISC
revealed O-MISC O-MISC
Oct2 B-MISC B-MISC
as O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
and O-MISC O-MISC
valuable O-MISC O-MISC
marker O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
identification O-MISC O-MISC
of O-MISC O-MISC
L O-MISC O-MISC
& O-MISC O-MISC
H O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
their O-MISC O-MISC
distinction O-MISC O-MISC
from O-MISC O-MISC
HRS O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
impairment O-MISC O-MISC
of O-MISC O-MISC
immunoglobulin O-MISC B-MISC
transcription O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
synthesis O-MISC O-MISC
of O-MISC O-MISC
Oct2 B-MISC B-MISC
and O-MISC O-MISC
BOB B-MISC B-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
OBF I-MISC I-MISC
. I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
established O-MISC O-MISC
general O-MISC O-MISC
recurrent O-MISC O-MISC
defect O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
HRS O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Constitutive O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
characteristic O-MISC O-MISC
feature O-MISC O-MISC
of O-MISC O-MISC
mycosis O-MISC O-MISC
fungoides O-MISC O-MISC
: O-MISC O-MISC
implications O-MISC O-MISC
for O-MISC O-MISC
apoptosis O-MISC O-MISC
resistance O-MISC O-MISC
and O-MISC O-MISC
pathogenesis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
family I-MISC I-MISC
of I-MISC O-MISC
transcription I-MISC B-MISC
factors I-MISC I-MISC
is O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
regulator O-MISC O-MISC
of O-MISC O-MISC
genes O-MISC O-MISC
expressed O-MISC O-MISC
during O-MISC O-MISC
inflammatory O-MISC O-MISC
responses O-MISC O-MISC
, O-MISC O-MISC
immunoglobulin O-MISC O-MISC
( O-MISC O-MISC
Ig O-MISC B-MISC
) O-MISC O-MISC
class O-MISC O-MISC
switching O-MISC O-MISC
, O-MISC O-MISC
cellular O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Recently O-MISC O-MISC
, O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
family I-MISC I-MISC
, O-MISC O-MISC
including O-MISC O-MISC
p65 B-MISC B-MISC
( I-MISC O-MISC
Rel I-MISC B-MISC
A I-MISC I-MISC
) I-MISC O-MISC
, O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
implicated O-MISC O-MISC
in O-MISC O-MISC
promoting O-MISC O-MISC
survival O-MISC O-MISC
of O-MISC O-MISC
various O-MISC O-MISC
hematopoeitic O-MISC O-MISC
neoplasms O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
malignancies O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
adult O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
- O-MISC O-MISC
lymphoma O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
active B-MISC O-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
p65 I-MISC I-MISC
( I-MISC O-MISC
Rel I-MISC B-MISC
A I-MISC I-MISC
) I-MISC O-MISC
in O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
mycosis O-MISC O-MISC
fungoides O-MISC O-MISC
( O-MISC O-MISC
MF O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
chemical O-MISC O-MISC
inhibitors O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
on O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
cutaneous O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
lymphoma O-MISC O-MISC
( O-MISC O-MISC
CTCL O-MISC O-MISC
) O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

Paraffin O-MISC O-MISC
- O-MISC O-MISC
embedded O-MISC O-MISC
tissues O-MISC O-MISC
from O-MISC O-MISC
23 O-MISC O-MISC
cutaneous O-MISC O-MISC
lesions O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
lymph O-MISC O-MISC
node O-MISC O-MISC
biopsy O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
diagnosed O-MISC O-MISC
with O-MISC O-MISC
MF O-MISC B-MISC
were O-MISC O-MISC
evaluated O-MISC O-MISC
for O-MISC O-MISC
p65 O-MISC B-MISC
( O-MISC O-MISC
Rel O-MISC B-MISC
A O-MISC I-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
using O-MISC O-MISC
a O-MISC O-MISC
monoclonal B-MISC B-MISC
mouse I-MISC I-MISC
antibody I-MISC I-MISC
that O-MISC O-MISC
detects O-MISC O-MISC
the O-MISC O-MISC
activated O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
( I-MISC O-MISC
Rel I-MISC B-MISC
A I-MISC I-MISC
) I-MISC O-MISC
. O-MISC O-MISC

Apoptosis O-MISC O-MISC
after O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
inhibitors O-MISC O-MISC
gliotoxin O-MISC O-MISC
, O-MISC O-MISC
MG132 O-MISC O-MISC
, O-MISC O-MISC
BAY O-MISC B-MISC
11 O-MISC I-MISC
- O-MISC I-MISC
7082 O-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
BAY O-MISC O-MISC
11 O-MISC O-MISC
- O-MISC I-MISC
7085 O-MISC O-MISC
was O-MISC O-MISC
quantitatively O-MISC O-MISC
measured O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
CTCL O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
HuT O-MISC O-MISC
- O-MISC O-MISC
78 O-MISC O-MISC
and O-MISC O-MISC
HH O-MISC O-MISC
by O-MISC O-MISC
propidium O-MISC O-MISC
iodide O-MISC O-MISC
( O-MISC O-MISC
PI O-MISC O-MISC
) O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
analysis O-MISC O-MISC
for O-MISC O-MISC
detection O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
hypodiploid O-MISC B-MISC
( O-MISC O-MISC
sub O-MISC O-MISC
- O-MISC O-MISC
G O-MISC O-MISC
( O-MISC O-MISC
0 O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
population O-MISC O-MISC
and O-MISC O-MISC
by O-MISC O-MISC
determination O-MISC O-MISC
of O-MISC O-MISC
increased O-MISC O-MISC
Annexin O-MISC O-MISC
V O-MISC O-MISC
/ O-MISC O-MISC
7 O-MISC O-MISC
- O-MISC O-MISC
amino O-MISC O-MISC
- O-MISC O-MISC
actinomycin O-MISC O-MISC
D O-MISC O-MISC
( O-MISC O-MISC
7 O-MISC O-MISC
- O-MISC O-MISC
AAD O-MISC O-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Nuclear O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
CTCL O-MISC O-MISC
cells O-MISC O-MISC
before O-MISC O-MISC
and O-MISC O-MISC
after O-MISC O-MISC
chemical O-MISC O-MISC
inhibition O-MISC O-MISC
were O-MISC O-MISC
analyzed O-MISC O-MISC
for O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
nuclear O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
by O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
( O-MISC O-MISC
EMSA O-MISC O-MISC
) O-MISC O-MISC
with O-MISC O-MISC
quantitative O-MISC O-MISC
densitometry O-MISC O-MISC
. O-MISC O-MISC

Nuclear O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
( I-MISC O-MISC
Rel I-MISC B-MISC
A I-MISC I-MISC
) I-MISC O-MISC
before O-MISC O-MISC
and O-MISC O-MISC
after O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
various O-MISC O-MISC
inhibitory O-MISC O-MISC
compounds O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
by O-MISC O-MISC
immunofluorescence O-MISC O-MISC
staining O-MISC O-MISC
in O-MISC O-MISC
each O-MISC O-MISC
CTCL O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

Neoplastic O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
22 O-MISC O-MISC
of O-MISC O-MISC
24 O-MISC O-MISC
cases O-MISC O-MISC
of O-MISC O-MISC
MF O-MISC B-MISC
showed O-MISC O-MISC
strong O-MISC O-MISC
nuclear O-MISC O-MISC
and O-MISC O-MISC
cytoplasmic O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
active B-MISC O-MISC
p65 I-MISC B-MISC
( I-MISC O-MISC
Rel I-MISC B-MISC
A I-MISC I-MISC
) I-MISC O-MISC
. O-MISC O-MISC

Compared O-MISC O-MISC
with O-MISC O-MISC
untreated O-MISC O-MISC
control O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
marked O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
marked O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC B-MISC
p65 O-MISC I-MISC
( O-MISC I-MISC
Rel O-MISC B-MISC
A O-MISC I-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
were O-MISC O-MISC
seen O-MISC O-MISC
in O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
both O-MISC O-MISC
CTCL O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
after O-MISC O-MISC
chemical O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
inhibition O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
active O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
p65 I-MISC I-MISC
( I-MISC O-MISC
Rel I-MISC B-MISC
A I-MISC I-MISC
) I-MISC O-MISC
is O-MISC O-MISC
commonly O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
neoplastic O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
MF O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
CTCL O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
significant O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
marked O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
spontaneous O-MISC O-MISC
apoptosis O-MISC O-MISC
caused O-MISC O-MISC
by O-MISC O-MISC
chemical O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
inhibition O-MISC O-MISC
suggest O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
and O-MISC O-MISC
tumor O-MISC O-MISC
cell O-MISC O-MISC
maintenance O-MISC O-MISC
of O-MISC O-MISC
CTCLs O-MISC O-MISC
. O-MISC O-MISC

HUM O-MISC O-MISC
PATHOL O-MISC O-MISC
31 O-MISC O-MISC
: O-MISC O-MISC
1482 O-MISC O-MISC
- O-MISC O-MISC
1490 O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
T O-MISC I-MISC
- O-MISC I-MISC
cell O-MISC I-MISC
leukemia O-MISC I-MISC
virus O-MISC I-MISC
type O-MISC I-MISC
1 O-MISC I-MISC
tax B-MISC I-MISC
protein I-MISC I-MISC
activates O-MISC O-MISC
transcription O-MISC O-MISC
through O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
by O-MISC O-MISC
inducing O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
T O-MISC I-MISC
- O-MISC I-MISC
cell O-MISC I-MISC
leukemia O-MISC I-MISC
virus O-MISC I-MISC
type O-MISC I-MISC
1 O-MISC I-MISC
( O-MISC I-MISC
HTLV O-MISC I-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
) O-MISC I-MISC
Tax B-MISC I-MISC
protein I-MISC I-MISC
induces O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
various O-MISC O-MISC
family O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
AP I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
, O-MISC O-MISC
JunD B-MISC B-MISC
, O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Fos I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Fra B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
RNA O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
Tax B-MISC B-MISC
in O-MISC O-MISC
transcription O-MISC O-MISC
through O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
( O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Transient O-MISC O-MISC
transfection O-MISC O-MISC
studies O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
Tax B-MISC B-MISC
activated O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
luciferase B-MISC B-MISC
gene I-MISC I-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
two O-MISC O-MISC
copies O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

Tax B-MISC O-MISC
activates O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
viral B-MISC B-MISC
and I-MISC I-MISC
cellular I-MISC I-MISC
genes I-MISC I-MISC
through O-MISC O-MISC
two O-MISC O-MISC
different O-MISC O-MISC
enhancers O-MISC B-MISC
: O-MISC O-MISC
a O-MISC O-MISC
cAMP B-MISC O-MISC
- I-MISC I-MISC
responsive I-MISC I-MISC
( I-MISC I-MISC
CRE I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
like I-MISC I-MISC
element I-MISC I-MISC
and O-MISC O-MISC
a O-MISC O-MISC
kappaB B-MISC B-MISC
element I-MISC I-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
Tax B-MISC B-MISC
mutants I-MISC I-MISC
differentially O-MISC O-MISC
activated O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
two O-MISC O-MISC
elements O-MISC O-MISC
. O-MISC O-MISC

Tax703 B-MISC B-MISC
preferentially O-MISC O-MISC
activated O-MISC O-MISC
the O-MISC O-MISC
kappaB B-MISC B-MISC
element I-MISC I-MISC
but O-MISC O-MISC
not O-MISC O-MISC
the O-MISC O-MISC
CRE O-MISC B-MISC
- O-MISC O-MISC
like O-MISC O-MISC
one O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
TaxM22 B-MISC B-MISC
showed O-MISC O-MISC
the O-MISC O-MISC
reverse O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
Tax703 B-MISC B-MISC
and O-MISC O-MISC
Tax B-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
TaxM22 B-MISC B-MISC
, O-MISC O-MISC
converted O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
mouse O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
from O-MISC O-MISC
being O-MISC O-MISC
interleukin O-MISC B-MISC
( O-MISC I-MISC
IL O-MISC B-MISC
) O-MISC I-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC I-MISC
dependent O-MISC O-MISC
to O-MISC O-MISC
being O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
. O-MISC O-MISC

Unlike O-MISC O-MISC
the O-MISC O-MISC
wild B-MISC B-MISC
- I-MISC I-MISC
type I-MISC I-MISC
Tax I-MISC I-MISC
, O-MISC O-MISC
Tax703 B-MISC B-MISC
and O-MISC O-MISC
TaxM22 B-MISC B-MISC
only O-MISC O-MISC
weakly O-MISC O-MISC
activated O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
Tax B-MISC B-MISC
seems O-MISC O-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
via O-MISC O-MISC
mechanisms O-MISC O-MISC
distinct O-MISC O-MISC
from O-MISC O-MISC
those O-MISC O-MISC
of O-MISC O-MISC
kappaB B-MISC B-MISC
or I-MISC I-MISC
CRE I-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
elements I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
is O-MISC O-MISC
dispensable O-MISC O-MISC
for O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
CTLL O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC I-MISC
. O-MISC O-MISC

Electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
Tax B-MISC B-MISC
induced O-MISC O-MISC
strong O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
in O-MISC O-MISC
CTLL O-MISC O-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
Tax703 B-MISC B-MISC
did O-MISC O-MISC
not O-MISC O-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
Tax B-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
binding B-MISC O-MISC
complex I-MISC I-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
Tax B-MISC B-MISC
in O-MISC O-MISC
CTLL O-MISC O-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
contained O-MISC O-MISC
JunD B-MISC B-MISC
and O-MISC O-MISC
Fra B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

Other O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
proteins I-MISC I-MISC
were O-MISC O-MISC
undetectable O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
transcription O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
JunD B-MISC B-MISC
and O-MISC O-MISC
/ O-MISC O-MISC
or O-MISC O-MISC
Fra B-MISC O-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
was O-MISC O-MISC
weak O-MISC O-MISC
. O-MISC O-MISC

c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
, O-MISC O-MISC
JunB B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Fos I-MISC I-MISC
activation O-MISC O-MISC
was O-MISC O-MISC
greater O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
was O-MISC O-MISC
still O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
that O-MISC O-MISC
with O-MISC O-MISC
Tax B-MISC B-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
by O-MISC O-MISC
Tax B-MISC B-MISC
may O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
sufficient O-MISC O-MISC
for O-MISC O-MISC
a O-MISC O-MISC
complete O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
by O-MISC O-MISC
Tax B-MISC B-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
Tax B-MISC B-MISC
activates O-MISC O-MISC
the O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
cellular B-MISC B-MISC
genes I-MISC I-MISC
with O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
sites I-MISC I-MISC
by O-MISC O-MISC
inducing O-MISC O-MISC
the O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
proteins I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
mechanism O-MISC O-MISC
distinct O-MISC O-MISC
from O-MISC O-MISC
those O-MISC O-MISC
of O-MISC O-MISC
CRE B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
and I-MISC I-MISC
kappaB I-MISC I-MISC
elements I-MISC I-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
2001 O-MISC O-MISC
Academic O-MISC O-MISC
Press O-MISC O-MISC
. O-MISC O-MISC

Strict O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
replication O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
genetic O-MISC O-MISC
switch O-MISC O-MISC
: O-MISC O-MISC
Tet O-MISC O-MISC
for O-MISC O-MISC
Tat O-MISC B-MISC
. O-MISC O-MISC

Live O-MISC O-MISC
- O-MISC O-MISC
attenuated O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
variants O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
great O-MISC O-MISC
promise O-MISC O-MISC
as O-MISC O-MISC
AIDS O-MISC O-MISC
vaccines O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
continued O-MISC O-MISC
replication O-MISC O-MISC
can O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
selection O-MISC O-MISC
of O-MISC O-MISC
faster O-MISC O-MISC
- O-MISC O-MISC
replicating O-MISC O-MISC
variants O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
pathogenic O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
therefore O-MISC O-MISC
designed O-MISC O-MISC
HIV B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
genomes I-MISC I-MISC
that O-MISC O-MISC
replicate O-MISC O-MISC
exclusively O-MISC O-MISC
upon O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nontoxic O-MISC O-MISC
effector O-MISC O-MISC
doxycycline O-MISC O-MISC
( O-MISC O-MISC
dox O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
was O-MISC O-MISC
achieved O-MISC O-MISC
by O-MISC O-MISC
replacement O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
viral O-MISC B-MISC
TAR O-MISC I-MISC
- O-MISC I-MISC
Tat O-MISC I-MISC
system O-MISC O-MISC
for O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
Escherichia O-MISC O-MISC
coli O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
Tet O-MISC O-MISC
system O-MISC O-MISC
for O-MISC O-MISC
inducible O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
designer O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
rtTA O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
viruses O-MISC O-MISC
replicate O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
strictly O-MISC O-MISC
dox O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
both O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
blood O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
rate O-MISC O-MISC
of O-MISC O-MISC
replication O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
fine O-MISC O-MISC
- O-MISC O-MISC
tuned O-MISC O-MISC
by O-MISC O-MISC
simple O-MISC O-MISC
variation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
dox O-MISC O-MISC
concentration O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
HIV O-MISC B-MISC
- O-MISC I-MISC
rtTA O-MISC I-MISC
viruses O-MISC O-MISC
provide O-MISC O-MISC
a O-MISC O-MISC
tool O-MISC O-MISC
to O-MISC O-MISC
perform O-MISC O-MISC
genetics O-MISC O-MISC
, O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
g O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
selection O-MISC O-MISC
and O-MISC O-MISC
optimization O-MISC O-MISC
experiments O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
E O-MISC O-MISC
. O-MISC O-MISC
coli O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
Tet O-MISC O-MISC
reagents O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
eukaryotic O-MISC O-MISC
background O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
viruses O-MISC O-MISC
may O-MISC O-MISC
represent O-MISC O-MISC
improved O-MISC O-MISC
vaccine O-MISC O-MISC
candidates O-MISC O-MISC
because O-MISC O-MISC
their O-MISC O-MISC
replication O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
turned O-MISC O-MISC
on O-MISC O-MISC
and O-MISC O-MISC
off O-MISC O-MISC
at O-MISC O-MISC
will O-MISC O-MISC
. O-MISC O-MISC

Synovial O-MISC O-MISC
fluid O-MISC O-MISC
induced O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
monocytic O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
To O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
synovial O-MISC O-MISC
fluids O-MISC O-MISC
( O-MISC O-MISC
SF O-MISC O-MISC
) O-MISC O-MISC
on O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
Mono O-MISC O-MISC
Mac O-MISC O-MISC
6 O-MISC O-MISC
monocytic O-MISC O-MISC
/ O-MISC O-MISC
macrophage O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
model O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
interaction O-MISC O-MISC
between O-MISC O-MISC
SF O-MISC O-MISC
and O-MISC O-MISC
synovial O-MISC O-MISC
tissue O-MISC O-MISC
macrophages O-MISC O-MISC
in O-MISC O-MISC
arthritis O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Mono O-MISC O-MISC
Mac O-MISC O-MISC
6 O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
SF O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
knee O-MISC O-MISC
joints O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
subjects O-MISC O-MISC
with O-MISC O-MISC
rheumatoid O-MISC O-MISC
arthritis O-MISC O-MISC
( O-MISC O-MISC
RA O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
undifferentiated O-MISC O-MISC
seronegative O-MISC O-MISC
oligoarthritis O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
osteoarthritis O-MISC O-MISC
( O-MISC O-MISC
OA O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Nuclear O-MISC O-MISC
extracts O-MISC O-MISC
prepared O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
Mono O-MISC O-MISC
Mac O-MISC O-MISC
6 O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
RA O-MISC O-MISC
synovial O-MISC O-MISC
tissue O-MISC O-MISC
were O-MISC O-MISC
analyzed O-MISC O-MISC
by O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
analysis O-MISC O-MISC
( O-MISC O-MISC
EMSA O-MISC O-MISC
) O-MISC O-MISC
for O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
DNA I-MISC I-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Induction O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
p65 B-MISC B-MISC
( I-MISC I-MISC
RelA I-MISC B-MISC
) I-MISC I-MISC
/ I-MISC I-MISC
p50 I-MISC I-MISC
heterodimer I-MISC I-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
incubation O-MISC O-MISC
of O-MISC O-MISC
Mono O-MISC O-MISC
Mac O-MISC O-MISC
6 O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
SF O-MISC O-MISC
( O-MISC O-MISC
20 O-MISC O-MISC
% O-MISC O-MISC
in O-MISC O-MISC
culture O-MISC O-MISC
medium O-MISC O-MISC
) O-MISC O-MISC
from O-MISC O-MISC
5 O-MISC O-MISC
of O-MISC O-MISC
8 O-MISC O-MISC
subjects O-MISC O-MISC
with O-MISC O-MISC
RA O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
of O-MISC O-MISC
5 O-MISC O-MISC
with O-MISC O-MISC
OA O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
none O-MISC O-MISC
of O-MISC O-MISC
3 O-MISC O-MISC
with O-MISC O-MISC
undifferentiated O-MISC O-MISC
seronegative O-MISC O-MISC
oligoarthritis O-MISC O-MISC
. O-MISC O-MISC

Incubation O-MISC O-MISC
of O-MISC O-MISC
SF O-MISC B-MISC
with O-MISC O-MISC
neutralizing B-MISC B-MISC
antibodies I-MISC I-MISC
against O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
( I-MISC O-MISC
TNF I-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) I-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
antibodies B-MISC B-MISC
against O-MISC O-MISC
interleukin B-MISC B-MISC
6 I-MISC I-MISC
( I-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
) I-MISC O-MISC
, O-MISC O-MISC
significantly O-MISC O-MISC
reduced O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
p65 O-MISC B-MISC
/ O-MISC I-MISC
p50 O-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
SF O-MISC O-MISC
from O-MISC O-MISC
subjects O-MISC O-MISC
with O-MISC O-MISC
RA O-MISC O-MISC
and O-MISC O-MISC
OA O-MISC O-MISC
. O-MISC O-MISC

Unexpectedly O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
slowly O-MISC O-MISC
migrating O-MISC O-MISC
SF O-MISC O-MISC
inducible O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- O-MISC I-MISC
binding O-MISC I-MISC
complex O-MISC I-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
EMSA O-MISC O-MISC
of O-MISC O-MISC
Mono O-MISC O-MISC
Mac O-MISC O-MISC
6 O-MISC O-MISC
cells O-MISC O-MISC
after O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
SF O-MISC O-MISC
from O-MISC O-MISC
5 O-MISC O-MISC
of O-MISC O-MISC
8 O-MISC O-MISC
RA O-MISC O-MISC
and O-MISC O-MISC
2 O-MISC O-MISC
of O-MISC O-MISC
5 O-MISC O-MISC
OA O-MISC O-MISC
subjects O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
complex O-MISC O-MISC
by O-MISC O-MISC
SF O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
neutralization O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
or O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
in O-MISC O-MISC
SF O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
complex O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
inducible O-MISC O-MISC
by O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
1beta O-MISC I-MISC
, O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
/ O-MISC I-MISC
IL B-MISC I-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
, O-MISC O-MISC
platelet B-MISC B-MISC
derived I-MISC I-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
, O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
tetradecanoyl O-MISC O-MISC
phorbol O-MISC O-MISC
acetate O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
slowly O-MISC O-MISC
migrating B-MISC O-MISC
complex I-MISC I-MISC
could O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
supershifted O-MISC O-MISC
with O-MISC O-MISC
antibodies B-MISC O-MISC
against O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
, O-MISC O-MISC
Jun B-MISC B-MISC
, O-MISC O-MISC
or O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC B-MISC
coactivators O-MISC I-MISC
p300 B-MISC I-MISC
or O-MISC O-MISC
CBP B-MISC B-MISC
. O-MISC O-MISC

A O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
complex I-MISC I-MISC
with O-MISC O-MISC
similar O-MISC O-MISC
slow O-MISC O-MISC
mobility O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
prepared O-MISC O-MISC
from O-MISC O-MISC
fresh O-MISC O-MISC
human O-MISC O-MISC
RA O-MISC O-MISC
synovial O-MISC O-MISC
tissue O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
Biological O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
in O-MISC O-MISC
SF O-MISC O-MISC
from O-MISC O-MISC
RA O-MISC O-MISC
and O-MISC O-MISC
OA O-MISC O-MISC
subjects O-MISC O-MISC
is O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
inducing O-MISC O-MISC
p65 B-MISC B-MISC
/ I-MISC I-MISC
p50 I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
property O-MISC O-MISC
of O-MISC O-MISC
SF O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
and O-MISC O-MISC
other O-MISC O-MISC
cytokines B-MISC B-MISC
is O-MISC O-MISC
responsible O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
slowly O-MISC O-MISC
migrating O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
complex I-MISC I-MISC
. O-MISC O-MISC

Soluble O-MISC O-MISC
mediators O-MISC O-MISC
in O-MISC O-MISC
SF O-MISC O-MISC
of O-MISC O-MISC
subjects O-MISC O-MISC
with O-MISC O-MISC
RA O-MISC O-MISC
and O-MISC O-MISC
OA O-MISC O-MISC
can O-MISC O-MISC
therefore O-MISC O-MISC
modulate O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
proteins I-MISC I-MISC
to O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
in O-MISC O-MISC
macrophages O-MISC O-MISC
and O-MISC O-MISC
may O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
inflammatory O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
arthritis O-MISC O-MISC
. O-MISC O-MISC

Peroxisome B-MISC B-MISC
proliferator I-MISC I-MISC
activator I-MISC I-MISC
receptor I-MISC I-MISC
- I-MISC O-MISC
gamma I-MISC I-MISC
agonists O-MISC O-MISC
and O-MISC O-MISC
15 O-MISC O-MISC
- O-MISC O-MISC
deoxy O-MISC O-MISC
- O-MISC O-MISC
Delta O-MISC O-MISC
( O-MISC O-MISC
12 O-MISC O-MISC
, O-MISC O-MISC
14 O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
12 O-MISC O-MISC
, O-MISC O-MISC
14 O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
PGJ O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
induce O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
research O-MISC O-MISC
described O-MISC O-MISC
herein O-MISC O-MISC
evaluates O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
functional O-MISC O-MISC
significance O-MISC O-MISC
of O-MISC O-MISC
peroxisome B-MISC B-MISC
proliferator I-MISC I-MISC
activator I-MISC I-MISC
receptor I-MISC I-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
( I-MISC O-MISC
PPAR I-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
) I-MISC O-MISC
on O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Normal O-MISC O-MISC
mouse O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
lymphoma O-MISC O-MISC
cells O-MISC O-MISC
reflective O-MISC O-MISC
of O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
( O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
g O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
70Z O-MISC B-MISC
/ O-MISC I-MISC
3 O-MISC I-MISC
, O-MISC O-MISC
CH31 O-MISC O-MISC
, O-MISC O-MISC
WEHI O-MISC B-MISC
- O-MISC I-MISC
231 O-MISC I-MISC
, O-MISC O-MISC
CH12 O-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
J558 O-MISC B-MISC
) O-MISC O-MISC
express O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
mRNA I-MISC I-MISC
and O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
Western O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
67 B-MISC B-MISC
- I-MISC I-MISC
kDa I-MISC I-MISC
PPAR I-MISC I-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

15 O-MISC B-MISC
- O-MISC I-MISC
Deoxy O-MISC I-MISC
- O-MISC I-MISC
Delta O-MISC I-MISC
( O-MISC O-MISC
12 O-MISC O-MISC
, O-MISC O-MISC
14 O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
PGJ O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
15d O-MISC O-MISC
- O-MISC O-MISC
PGJ O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC O-MISC
gamma O-MISC I-MISC
agonist O-MISC O-MISC
, O-MISC O-MISC
has O-MISC O-MISC
a O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
antiproliferative O-MISC O-MISC
and O-MISC O-MISC
cytotoxic O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
shown O-MISC O-MISC
by O-MISC O-MISC
[ O-MISC O-MISC
( O-MISC O-MISC
3 O-MISC O-MISC
) O-MISC O-MISC
H O-MISC O-MISC
] O-MISC O-MISC
thymidine O-MISC O-MISC
and O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
[ O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
dimethylthiazol O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
yl O-MISC O-MISC
] O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
diphenyltetrazolium O-MISC O-MISC
bromide O-MISC O-MISC
assays O-MISC O-MISC
. O-MISC O-MISC

Only O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
agonists O-MISC O-MISC
( O-MISC O-MISC
thiazolidinediones O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
not O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC O-MISC
alpha O-MISC O-MISC
agonists O-MISC O-MISC
, O-MISC O-MISC
mimicked O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
15d O-MISC O-MISC
- O-MISC O-MISC
PGJ O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
on O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
15d O-MISC O-MISC
- O-MISC O-MISC
PGJ O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
negatively O-MISC O-MISC
affects O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
involves O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
PPAR B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
agonists O-MISC I-MISC
induce O-MISC O-MISC
cytotoxicity O-MISC O-MISC
is O-MISC O-MISC
via O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
shown O-MISC O-MISC
by O-MISC O-MISC
annexin O-MISC O-MISC
V O-MISC O-MISC
staining O-MISC O-MISC
and O-MISC O-MISC
as O-MISC O-MISC
confirmed O-MISC O-MISC
by O-MISC O-MISC
DNA O-MISC O-MISC
fragmentation O-MISC O-MISC
detected O-MISC O-MISC
using O-MISC O-MISC
the O-MISC O-MISC
TUNEL O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
PGF O-MISC B-MISC
( O-MISC I-MISC
2alpha O-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
affect O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
dramatically O-MISC O-MISC
attenuated O-MISC O-MISC
the O-MISC O-MISC
deleterious O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC O-MISC
gamma O-MISC I-MISC
agonists O-MISC O-MISC
on O-MISC O-MISC
B O-MISC O-MISC
lymphomas O-MISC O-MISC
. O-MISC O-MISC

Surprisingly O-MISC O-MISC
, O-MISC O-MISC
15d O-MISC B-MISC
- O-MISC I-MISC
PGJ O-MISC I-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
induced O-MISC O-MISC
a O-MISC O-MISC
massive O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC B-MISC
mitogen O-MISC I-MISC
- O-MISC I-MISC
activated O-MISC I-MISC
protein O-MISC I-MISC
kinase O-MISC I-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
pretreatment O-MISC O-MISC
with O-MISC O-MISC
PGF O-MISC B-MISC
( O-MISC O-MISC
2alpha O-MISC I-MISC
) O-MISC O-MISC
blunted O-MISC O-MISC
the O-MISC O-MISC
mitogen O-MISC B-MISC
- O-MISC I-MISC
activated O-MISC I-MISC
protein O-MISC I-MISC
kinase O-MISC I-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
study O-MISC O-MISC
evaluating O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
significance O-MISC O-MISC
on O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

PPAR O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
agonists O-MISC O-MISC
may O-MISC O-MISC
serve O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
counterbalance O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
stimulating O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
other O-MISC O-MISC
PGs O-MISC O-MISC
, O-MISC O-MISC
namely O-MISC O-MISC
PGE O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
promotes O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

Finally O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
PGs O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
15d O-MISC O-MISC
- O-MISC O-MISC
PGJ O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
synthetic O-MISC O-MISC
PPAR O-MISC B-MISC
- O-MISC O-MISC
gamma O-MISC I-MISC
agonists O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
may O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
novel O-MISC O-MISC
therapies O-MISC O-MISC
for O-MISC O-MISC
fatal O-MISC O-MISC
B O-MISC O-MISC
lymphomas O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
STAT3 O-MISC B-MISC
signaling O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
apoptosis O-MISC O-MISC
of O-MISC O-MISC
leukemic O-MISC O-MISC
large O-MISC O-MISC
granular O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
decreased O-MISC O-MISC
Mcl O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Large O-MISC O-MISC
granular O-MISC O-MISC
lymphocyte O-MISC O-MISC
( O-MISC O-MISC
LGL O-MISC O-MISC
) O-MISC O-MISC
leukemia O-MISC O-MISC
is O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
expansion O-MISC O-MISC
of O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
activated O-MISC O-MISC
cytotoxic O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
Fas O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
apoptosis O-MISC O-MISC
despite O-MISC O-MISC
expressing O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
Fas B-MISC B-MISC
. O-MISC O-MISC

We O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
leukemic O-MISC O-MISC
LGL O-MISC O-MISC
from O-MISC O-MISC
19 O-MISC O-MISC
patients O-MISC O-MISC
displayed O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
activated B-MISC O-MISC
STAT3 I-MISC B-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
leukemic O-MISC O-MISC
LGL O-MISC I-MISC
with O-MISC O-MISC
the O-MISC O-MISC
JAK O-MISC B-MISC
- O-MISC O-MISC
selective O-MISC O-MISC
tyrosine O-MISC I-MISC
kinase O-MISC I-MISC
inhibitor O-MISC O-MISC
AG O-MISC O-MISC
- O-MISC O-MISC
490 O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
corresponding O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
STAT B-MISC B-MISC
- O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
using O-MISC O-MISC
an O-MISC O-MISC
antisense O-MISC O-MISC
oligonucleotide O-MISC O-MISC
approach O-MISC O-MISC
to O-MISC O-MISC
diminish O-MISC O-MISC
STAT3 O-MISC B-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
Fas O-MISC B-MISC
sensitivity O-MISC O-MISC
was O-MISC O-MISC
restored O-MISC O-MISC
in O-MISC O-MISC
leukemic O-MISC O-MISC
LGL O-MISC O-MISC
. O-MISC O-MISC

AG O-MISC O-MISC
- O-MISC O-MISC
490 O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
leukemic O-MISC O-MISC
LGL O-MISC I-MISC
was O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
Bcl O-MISC B-MISC
- O-MISC I-MISC
xL O-MISC I-MISC
or O-MISC O-MISC
Bcl O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
Bcl B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
- I-MISC I-MISC
family I-MISC I-MISC
protein I-MISC I-MISC
Mcl I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
was O-MISC O-MISC
significantly O-MISC O-MISC
reduced O-MISC O-MISC
by O-MISC O-MISC
AG O-MISC O-MISC
- O-MISC O-MISC
490 O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

Activated B-MISC O-MISC
STAT3 I-MISC B-MISC
was O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
bind O-MISC O-MISC
an O-MISC O-MISC
SIE B-MISC B-MISC
- I-MISC I-MISC
related I-MISC I-MISC
element I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
murine B-MISC B-MISC
mcl I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
a O-MISC O-MISC
luciferase O-MISC B-MISC
reporter O-MISC I-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
v O-MISC B-MISC
- O-MISC I-MISC
src O-MISC I-MISC
overexpression O-MISC O-MISC
in O-MISC O-MISC
NIH3T3 O-MISC B-MISC
induced O-MISC O-MISC
STAT3 B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
mcl B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
promoter I-MISC I-MISC
and O-MISC O-MISC
increased O-MISC O-MISC
endogenous O-MISC O-MISC
Mcl O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
protein O-MISC I-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
STAT3 B-MISC B-MISC
activation O-MISC O-MISC
contributed O-MISC O-MISC
to O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
leukemic O-MISC O-MISC
LGL O-MISC O-MISC
clones O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
investigation O-MISC O-MISC
should O-MISC O-MISC
focus O-MISC O-MISC
on O-MISC O-MISC
novel O-MISC O-MISC
strategies O-MISC O-MISC
targeting O-MISC O-MISC
STAT3 B-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
LGL O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Decreased O-MISC O-MISC
immediate O-MISC O-MISC
inflammatory B-MISC I-MISC
gene I-MISC I-MISC
induction O-MISC O-MISC
in O-MISC O-MISC
activating B-MISC O-MISC
transcription I-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
mutant O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Transcription B-MISC B-MISC
factor I-MISC I-MISC
activating I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
ATF I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
is O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
inflammatory O-MISC O-MISC
signals O-MISC O-MISC
transduced O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
JNK O-MISC B-MISC
and O-MISC O-MISC
p38 O-MISC B-MISC
MAP O-MISC I-MISC
kinase O-MISC I-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
better O-MISC O-MISC
define O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
ATF B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
in O-MISC O-MISC
inflammation O-MISC O-MISC
, O-MISC O-MISC
adult O-MISC O-MISC
mice O-MISC O-MISC
expressing O-MISC O-MISC
small O-MISC O-MISC
amounts O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
mutant B-MISC B-MISC
ATF I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
protein I-MISC I-MISC
were O-MISC O-MISC
challenged O-MISC O-MISC
with O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
( O-MISC O-MISC
LPS O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
antibody I-MISC I-MISC
or O-MISC O-MISC
virus O-MISC O-MISC
. O-MISC O-MISC

Within O-MISC O-MISC
3 O-MISC O-MISC
h O-MISC O-MISC
of O-MISC O-MISC
challenge O-MISC O-MISC
by O-MISC O-MISC
LPS O-MISC O-MISC
, O-MISC O-MISC
ATF O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
mutant O-MISC O-MISC
mice O-MISC O-MISC
had O-MISC O-MISC
decreased O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
adhesion B-MISC B-MISC
molecules I-MISC I-MISC
E B-MISC B-MISC
- I-MISC I-MISC
selectin I-MISC I-MISC
, O-MISC O-MISC
P B-MISC B-MISC
- I-MISC I-MISC
selectin I-MISC I-MISC
and O-MISC O-MISC
VCAM B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
cytokines B-MISC B-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
control O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Stimulation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
by O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
antibody I-MISC I-MISC
also O-MISC O-MISC
showed O-MISC O-MISC
less O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
in O-MISC O-MISC
ATF O-MISC O-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
mutant O-MISC O-MISC
tissues O-MISC O-MISC
. O-MISC O-MISC

ATF O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
mutant O-MISC O-MISC
thymocytes O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD3 I-MISC I-MISC
antibody I-MISC I-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
demonstrated O-MISC O-MISC
reduced O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
, O-MISC O-MISC
JunB B-MISC B-MISC
, O-MISC O-MISC
JunD B-MISC B-MISC
and O-MISC O-MISC
Fra B-MISC O-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
similar O-MISC O-MISC
to O-MISC O-MISC
what O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
after O-MISC O-MISC
p38 O-MISC B-MISC
kinase O-MISC I-MISC
inhibition O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
mice O-MISC O-MISC
, O-MISC O-MISC
relative O-MISC O-MISC
ATF O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
deficiency O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
prevent O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
mononuclear O-MISC O-MISC
cell O-MISC O-MISC
infiltrate O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
week O-MISC O-MISC
following O-MISC O-MISC
an O-MISC O-MISC
inflammatory O-MISC O-MISC
stimulus O-MISC O-MISC
. O-MISC O-MISC

ATF O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
mutant O-MISC O-MISC
mice O-MISC O-MISC
proved O-MISC O-MISC
more O-MISC O-MISC
susceptible O-MISC O-MISC
to O-MISC O-MISC
death O-MISC O-MISC
than O-MISC O-MISC
control O-MISC O-MISC
mice O-MISC O-MISC
from O-MISC O-MISC
LPS O-MISC O-MISC
plus O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
galactosamine O-MISC O-MISC
injection O-MISC O-MISC
or O-MISC O-MISC
Coxsackievirus O-MISC O-MISC
B3 O-MISC O-MISC
infection O-MISC O-MISC
and O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
higher O-MISC O-MISC
incidence O-MISC O-MISC
of O-MISC O-MISC
mononuclear O-MISC O-MISC
pulmonary O-MISC O-MISC
infiltrates O-MISC O-MISC
after O-MISC O-MISC
exposure O-MISC O-MISC
to O-MISC O-MISC
Herpes O-MISC O-MISC
simplex O-MISC O-MISC
virus O-MISC O-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
. O-MISC O-MISC

ATF B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
maximal O-MISC O-MISC
immediate O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
adhesion B-MISC B-MISC
molecules I-MISC I-MISC
and O-MISC O-MISC
cytokine B-MISC B-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
at O-MISC O-MISC
later O-MISC O-MISC
time O-MISC O-MISC
points O-MISC O-MISC
may O-MISC O-MISC
even O-MISC O-MISC
protect O-MISC O-MISC
against O-MISC O-MISC
overactive O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

LIGHT B-MISC B-MISC
, O-MISC O-MISC
a O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
molecule I-MISC I-MISC
, O-MISC O-MISC
costimulates O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
dendritic O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
allogeneic O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

LIGHT B-MISC B-MISC
is O-MISC O-MISC
a O-MISC O-MISC
recently O-MISC O-MISC
identified O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
TNF B-MISC B-MISC
superfamily I-MISC I-MISC
and O-MISC O-MISC
its O-MISC O-MISC
receptors O-MISC O-MISC
, O-MISC O-MISC
herpesvirus B-MISC O-MISC
entry I-MISC O-MISC
mediator I-MISC O-MISC
and O-MISC O-MISC
lymphotoxin B-MISC B-MISC
beta I-MISC I-MISC
receptor I-MISC I-MISC
, O-MISC O-MISC
are O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
stromal O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
LIGHT B-MISC B-MISC
is O-MISC O-MISC
selectively O-MISC O-MISC
expressed O-MISC O-MISC
on O-MISC O-MISC
immature O-MISC O-MISC
dendritic O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
DCs O-MISC O-MISC
) O-MISC O-MISC
generated O-MISC O-MISC
from O-MISC O-MISC
human O-MISC O-MISC
PBMCs O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
LIGHT B-MISC B-MISC
is O-MISC O-MISC
not O-MISC O-MISC
detectable O-MISC O-MISC
in O-MISC O-MISC
DCs O-MISC O-MISC
either O-MISC O-MISC
freshly O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
PBMCs O-MISC O-MISC
or O-MISC O-MISC
rendered O-MISC O-MISC
mature O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
by O-MISC O-MISC
LPS O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

Blockade O-MISC O-MISC
of O-MISC O-MISC
LIGHT B-MISC B-MISC
by O-MISC O-MISC
its O-MISC O-MISC
soluble B-MISC B-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
lymphotoxin B-MISC B-MISC
beta I-MISC I-MISC
receptor I-MISC I-MISC
- I-MISC I-MISC
Ig I-MISC I-MISC
or O-MISC O-MISC
HVEM B-MISC O-MISC
- I-MISC O-MISC
Ig I-MISC I-MISC
, O-MISC O-MISC
inhibits O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
DC O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
primary O-MISC O-MISC
allogeneic O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
engagement O-MISC O-MISC
of O-MISC O-MISC
LIGHT B-MISC B-MISC
costimulates O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
amplifies O-MISC O-MISC
the O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappaB O-MISC I-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
preferentially O-MISC O-MISC
induces O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
antigenic O-MISC O-MISC
signal O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
LIGHT B-MISC B-MISC
is O-MISC O-MISC
a O-MISC O-MISC
costimulatory B-MISC O-MISC
molecule I-MISC I-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
DC O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
cellular O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

Suppression O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
replication O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
dominant B-MISC B-MISC
- I-MISC I-MISC
negative I-MISC I-MISC
Ets I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mutant I-MISC I-MISC
. O-MISC O-MISC

Activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
distal B-MISC B-MISC
region I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC B-MISC
immunodeficiency O-MISC I-MISC
virus O-MISC I-MISC
( O-MISC I-MISC
HIV O-MISC I-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
) O-MISC I-MISC
long B-MISC I-MISC
terminal I-MISC I-MISC
repeat I-MISC I-MISC
( O-MISC I-MISC
LTR B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
contains O-MISC O-MISC
binding B-MISC O-MISC
sites I-MISC I-MISC
for O-MISC O-MISC
the O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC I-MISC
USF I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
proteins I-MISC I-MISC
, O-MISC O-MISC
is O-MISC O-MISC
integral O-MISC O-MISC
for O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
replication O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC I-MISC
USF I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
proteins I-MISC I-MISC
play O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
LTR I-MISC I-MISC
distal I-MISC I-MISC
enhancer I-MISC I-MISC
region I-MISC I-MISC
, O-MISC O-MISC
as O-MISC O-MISC
indicated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
potent O-MISC O-MISC
dominant O-MISC O-MISC
negative O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
mutant B-MISC O-MISC
Ets I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
lacking I-MISC O-MISC
trans I-MISC B-MISC
- I-MISC I-MISC
activation I-MISC I-MISC
domains I-MISC I-MISC
on O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
LTR B-MISC B-MISC
. O-MISC O-MISC

To O-MISC O-MISC
determine O-MISC O-MISC
the O-MISC O-MISC
biological O-MISC O-MISC
relevance O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC I-MISC
USF I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
proteins I-MISC I-MISC
in O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
replication O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
dominant O-MISC O-MISC
- O-MISC O-MISC
negative O-MISC O-MISC
mutant O-MISC O-MISC
of O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
dnEts B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
on O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
dnEts B-MISC B-MISC
markedly O-MISC O-MISC
suppressed O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
finding O-MISC O-MISC
indicates O-MISC O-MISC
that O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
transcriptionaly B-MISC O-MISC
active I-MISC O-MISC
USF I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
/ I-MISC I-MISC
Ets I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
complex I-MISC I-MISC
is O-MISC O-MISC
important O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
productive O-MISC O-MISC
infection O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
interaction O-MISC O-MISC
between O-MISC O-MISC
USF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
with O-MISC O-MISC
the O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
LTR I-MISC I-MISC
may O-MISC O-MISC
provide O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
gene O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
eosinophils O-MISC O-MISC
constitutively O-MISC O-MISC
express O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
of I-MISC I-MISC
activated I-MISC I-MISC
T I-MISC I-MISC
cells I-MISC I-MISC
p I-MISC O-MISC
and I-MISC O-MISC
c I-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
: O-MISC O-MISC
Eosinophils O-MISC O-MISC
are O-MISC O-MISC
now O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
produce O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
proinflammatory B-MISC B-MISC
cytokines I-MISC I-MISC
, O-MISC O-MISC
although O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC B-MISC
factors O-MISC I-MISC
that O-MISC O-MISC
regulate O-MISC O-MISC
their O-MISC O-MISC
production O-MISC O-MISC
are O-MISC O-MISC
poorly O-MISC O-MISC
understood O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
almost O-MISC O-MISC
all O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cytokines B-MISC B-MISC
produced O-MISC O-MISC
by O-MISC O-MISC
eosinophils O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
the O-MISC O-MISC
proallergic B-MISC O-MISC
cytokine I-MISC B-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
is O-MISC O-MISC
now O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
regulated O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
transcription O-MISC O-MISC
by O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
of I-MISC I-MISC
activated I-MISC I-MISC
T I-MISC I-MISC
cells I-MISC I-MISC
( O-MISC I-MISC
NFAT B-MISC I-MISC
) O-MISC I-MISC
family O-MISC I-MISC
of O-MISC O-MISC
transcription O-MISC B-MISC
factors O-MISC I-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
We O-MISC O-MISC
sought O-MISC O-MISC
to O-MISC O-MISC
characterize O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
different O-MISC O-MISC
NFAT B-MISC B-MISC
proteins I-MISC I-MISC
in O-MISC O-MISC
resting O-MISC O-MISC
and O-MISC O-MISC
activated O-MISC O-MISC
eosinophils O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Nuclear O-MISC O-MISC
and O-MISC O-MISC
whole O-MISC O-MISC
cell O-MISC O-MISC
extracts O-MISC O-MISC
were O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
both O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
eosinophils O-MISC O-MISC
and O-MISC O-MISC
those O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
bronchoalveolar O-MISC O-MISC
lavage O-MISC O-MISC
fluid O-MISC O-MISC
of O-MISC O-MISC
asthmatic O-MISC O-MISC
subjects O-MISC O-MISC
after O-MISC O-MISC
endobronchial O-MISC O-MISC
allergen O-MISC O-MISC
challenge O-MISC O-MISC
. O-MISC O-MISC

NFAT B-MISC B-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
using O-MISC O-MISC
immunoprecipitation O-MISC O-MISC
and O-MISC O-MISC
Western O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
, O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
assays O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
RT O-MISC O-MISC
- O-MISC O-MISC
PCR O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
eosinophil B-MISC B-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Both O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
and O-MISC O-MISC
bronchoalveolar O-MISC O-MISC
lavage O-MISC O-MISC
fluid O-MISC O-MISC
eosinophils O-MISC O-MISC
expressed O-MISC O-MISC
NFATp B-MISC B-MISC
and I-MISC I-MISC
NFATc I-MISC B-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

Unlike O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
express O-MISC O-MISC
multiple O-MISC O-MISC
NFATc O-MISC B-MISC
isoforms O-MISC I-MISC
, O-MISC O-MISC
eosinophils O-MISC O-MISC
preferentially O-MISC O-MISC
express O-MISC O-MISC
the O-MISC O-MISC
approximately O-MISC O-MISC
85 O-MISC B-MISC
- O-MISC I-MISC
kd O-MISC I-MISC
isoform O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
eosinophils O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
constitutively O-MISC O-MISC
express O-MISC O-MISC
NFATc B-MISC B-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

A O-MISC O-MISC
brief O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
( I-MISC I-MISC
H I-MISC I-MISC
) I-MISC I-MISC
2 I-MISC I-MISC
cytokines I-MISC I-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
was O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
NFATc B-MISC B-MISC
. O-MISC O-MISC

Eosinophil O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
contain O-MISC O-MISC
multiple O-MISC O-MISC
factors O-MISC O-MISC
that O-MISC O-MISC
can O-MISC O-MISC
specifically O-MISC O-MISC
recognize O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
promoter I-MISC I-MISC
P1 I-MISC I-MISC
NFAT I-MISC B-MISC
site I-MISC I-MISC
in O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
assays O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
NFATp B-MISC B-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
NFATp B-MISC B-MISC
and O-MISC O-MISC
NFATc B-MISC B-MISC
can O-MISC O-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
and O-MISC O-MISC
other O-MISC O-MISC
genes O-MISC O-MISC
in O-MISC O-MISC
eosinophils O-MISC O-MISC
but O-MISC O-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
mechanism O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

BLyS B-MISC O-MISC
BINDS O-MISC O-MISC
TO O-MISC O-MISC
B O-MISC O-MISC
CELLS O-MISC O-MISC
WITH O-MISC B-MISC
HIGH O-MISC O-MISC
AFFINITY O-MISC O-MISC
AND O-MISC O-MISC
INDUCES O-MISC O-MISC
ACTIVATION O-MISC O-MISC
OF O-MISC O-MISC
THE O-MISC O-MISC
TRANSCRIPTION B-MISC B-MISC
FACTORS I-MISC B-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
AND O-MISC O-MISC
ELF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

B B-MISC O-MISC
lymphocyte I-MISC I-MISC
stimulator I-MISC I-MISC
( O-MISC O-MISC
BLyS B-MISC B-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
TNF B-MISC B-MISC
family I-MISC I-MISC
of I-MISC O-MISC
proteins I-MISC O-MISC
expressed O-MISC O-MISC
by O-MISC O-MISC
myeloid O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
membrane O-MISC O-MISC
- O-MISC O-MISC
bound O-MISC O-MISC
and O-MISC O-MISC
soluble O-MISC O-MISC
forms O-MISC O-MISC
. O-MISC O-MISC

BLyS B-MISC O-MISC
was O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
act O-MISC O-MISC
specifically O-MISC O-MISC
on O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
inducing O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
immunoglobulin O-MISC B-MISC
production O-MISC O-MISC
both O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
was O-MISC O-MISC
undertaken O-MISC O-MISC
to O-MISC O-MISC
characterize O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
radiolabeled B-MISC B-MISC
BLyS I-MISC I-MISC
to O-MISC O-MISC
its O-MISC O-MISC
cognate B-MISC B-MISC
receptor I-MISC I-MISC
on O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
examine O-MISC O-MISC
intracellular O-MISC O-MISC
events O-MISC O-MISC
initiated O-MISC O-MISC
by O-MISC O-MISC
BLyS B-MISC O-MISC
binding O-MISC O-MISC
. O-MISC O-MISC

Similar O-MISC O-MISC
to O-MISC O-MISC
other O-MISC O-MISC
TNF B-MISC B-MISC
family I-MISC I-MISC
members I-MISC I-MISC
, O-MISC O-MISC
BLyS B-MISC B-MISC
is O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
solution O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
homotrimer B-MISC O-MISC
as O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
gel O-MISC O-MISC
filtration O-MISC O-MISC
chromatography O-MISC O-MISC
and O-MISC O-MISC
light O-MISC O-MISC
scattering O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

BLyS B-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
specific O-MISC O-MISC
as O-MISC O-MISC
other O-MISC O-MISC
TNF B-MISC B-MISC
family I-MISC I-MISC
members I-MISC I-MISC
tested O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
compete O-MISC O-MISC
for O-MISC O-MISC
( O-MISC O-MISC
125 O-MISC O-MISC
) O-MISC O-MISC
I O-MISC O-MISC
- O-MISC O-MISC
BLyS B-MISC O-MISC
binding O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
equilibrium O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
( B-MISC O-MISC
125 I-MISC B-MISC
) I-MISC I-MISC
I I-MISC I-MISC
- I-MISC I-MISC
labeled I-MISC I-MISC
BLyS I-MISC I-MISC
to O-MISC O-MISC
purified O-MISC O-MISC
human O-MISC O-MISC
tonsillar O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
demonstrated O-MISC O-MISC
saturable O-MISC O-MISC
binding O-MISC O-MISC
. O-MISC O-MISC

Scatchard O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
data O-MISC O-MISC
revealed O-MISC O-MISC
a O-MISC O-MISC
single O-MISC O-MISC
class O-MISC O-MISC
of O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
affinity O-MISC O-MISC
binding O-MISC O-MISC
on O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
approximately O-MISC O-MISC
2600 O-MISC B-MISC
binding O-MISC I-MISC
sites O-MISC I-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
and O-MISC O-MISC
an O-MISC O-MISC
apparent O-MISC O-MISC
dissociation O-MISC O-MISC
constant O-MISC O-MISC
( O-MISC O-MISC
K O-MISC O-MISC
( O-MISC O-MISC
D O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
about O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
nM O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
that O-MISC O-MISC
BLyS B-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
Ets B-MISC B-MISC
family I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
, O-MISC O-MISC
ELF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
mRNA O-MISC B-MISC
for O-MISC O-MISC
Polo B-MISC O-MISC
- I-MISC I-MISC
like I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
PLK B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Copyright O-MISC O-MISC
2001 O-MISC O-MISC
Academic O-MISC O-MISC
Press O-MISC O-MISC
. O-MISC O-MISC

Design O-MISC O-MISC
and O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
inducibly O-MISC O-MISC
activated O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC I-MISC
Nef B-MISC B-MISC
to O-MISC O-MISC
study O-MISC O-MISC
immune O-MISC O-MISC
modulation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Nef B-MISC B-MISC
protein I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
enhance O-MISC O-MISC
the O-MISC O-MISC
infectivity O-MISC O-MISC
of O-MISC O-MISC
virus O-MISC O-MISC
particles O-MISC O-MISC
, O-MISC O-MISC
downmodulate O-MISC O-MISC
cell B-MISC B-MISC
surface I-MISC I-MISC
proteins I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
associate O-MISC O-MISC
with O-MISC O-MISC
many O-MISC O-MISC
intracellular B-MISC B-MISC
proteins I-MISC I-MISC
that O-MISC O-MISC
are O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
facilitate O-MISC O-MISC
HIV O-MISC O-MISC
infection O-MISC O-MISC
. O-MISC O-MISC

One O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
challenges O-MISC O-MISC
in O-MISC O-MISC
defining O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
events O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
Nef B-MISC B-MISC
has O-MISC O-MISC
been O-MISC O-MISC
obtaining O-MISC O-MISC
good O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Nef B-MISC B-MISC
protein I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
attributed O-MISC O-MISC
to O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
Nef B-MISC B-MISC
on O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
designed O-MISC O-MISC
a O-MISC O-MISC
Nef B-MISC B-MISC
protein I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
readily O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
and O-MISC O-MISC
whose O-MISC O-MISC
function O-MISC O-MISC
is O-MISC O-MISC
inducibly O-MISC O-MISC
activated O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
composed O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
fusion O-MISC O-MISC
between O-MISC O-MISC
full B-MISC O-MISC
- I-MISC O-MISC
length I-MISC I-MISC
Nef I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
estrogen B-MISC B-MISC
receptor I-MISC I-MISC
hormone I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
( O-MISC O-MISC
Nef B-MISC B-MISC
- I-MISC I-MISC
ER I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Nef B-MISC B-MISC
- I-MISC I-MISC
ER I-MISC I-MISC
is O-MISC O-MISC
kept O-MISC O-MISC
in O-MISC O-MISC
an O-MISC O-MISC
inactive O-MISC O-MISC
state O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
steric O-MISC O-MISC
hindrance O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
membrane O-MISC O-MISC
- O-MISC O-MISC
permeable O-MISC O-MISC
drug O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
hydroxytamoxifen O-MISC O-MISC
( O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
HT O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
ER B-MISC B-MISC
domain I-MISC I-MISC
, O-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
inducible O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Nef B-MISC B-MISC
- I-MISC O-MISC
ER I-MISC O-MISC
within O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
Nef B-MISC B-MISC
- I-MISC I-MISC
ER I-MISC I-MISC
inducibly O-MISC O-MISC
associates O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
62 B-MISC B-MISC
- I-MISC I-MISC
kDa I-MISC I-MISC
Ser I-MISC I-MISC
/ I-MISC I-MISC
Thr I-MISC I-MISC
kinase I-MISC I-MISC
and O-MISC O-MISC
is O-MISC O-MISC
localized O-MISC O-MISC
to O-MISC O-MISC
specific O-MISC O-MISC
membrane O-MISC O-MISC
microdomains O-MISC I-MISC
( O-MISC O-MISC
lipid O-MISC O-MISC
rafts O-MISC O-MISC
) O-MISC O-MISC
only O-MISC O-MISC
after O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
this O-MISC O-MISC
inducible O-MISC O-MISC
Nef B-MISC B-MISC
, O-MISC O-MISC
we O-MISC O-MISC
also O-MISC O-MISC
compared O-MISC O-MISC
the O-MISC O-MISC
specific O-MISC O-MISC
requirements O-MISC O-MISC
for O-MISC O-MISC
CD4 B-MISC B-MISC
and O-MISC O-MISC
HLA B-MISC B-MISC
- I-MISC O-MISC
A2 I-MISC O-MISC
downmodulation O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
SupT1 O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

Half O-MISC O-MISC
- O-MISC O-MISC
maximal O-MISC O-MISC
downmodulation O-MISC O-MISC
of O-MISC O-MISC
cell B-MISC O-MISC
surface I-MISC I-MISC
CD4 I-MISC I-MISC
required O-MISC O-MISC
very O-MISC O-MISC
little O-MISC O-MISC
active O-MISC O-MISC
Nef B-MISC B-MISC
- I-MISC I-MISC
ER I-MISC I-MISC
and O-MISC O-MISC
occurred O-MISC O-MISC
as O-MISC O-MISC
early O-MISC O-MISC
as O-MISC O-MISC
4 O-MISC O-MISC
h O-MISC O-MISC
after O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
HT O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
50 O-MISC O-MISC
% O-MISC O-MISC
downmodulation O-MISC O-MISC
of O-MISC O-MISC
HLA B-MISC B-MISC
- I-MISC I-MISC
A2 I-MISC I-MISC
by O-MISC O-MISC
Nef B-MISC B-MISC
required O-MISC O-MISC
16 O-MISC O-MISC
to O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
and O-MISC O-MISC
about O-MISC O-MISC
50 O-MISC O-MISC
- O-MISC O-MISC
to O-MISC O-MISC
100 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
- O-MISC O-MISC
greater O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
HT O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
HLA B-MISC B-MISC
- I-MISC I-MISC
A2 I-MISC I-MISC
downmodulation O-MISC O-MISC
may O-MISC O-MISC
require O-MISC O-MISC
certain O-MISC O-MISC
threshold O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
active O-MISC O-MISC
Nef B-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
differential O-MISC O-MISC
timing O-MISC O-MISC
of O-MISC O-MISC
CD4 B-MISC B-MISC
and O-MISC O-MISC
HLA B-MISC B-MISC
- I-MISC I-MISC
A2 I-MISC I-MISC
downmodulation O-MISC O-MISC
may O-MISC O-MISC
have O-MISC O-MISC
implications O-MISC O-MISC
for O-MISC O-MISC
HIV O-MISC O-MISC
pathogenesis O-MISC O-MISC
and O-MISC O-MISC
immune O-MISC O-MISC
evasion O-MISC O-MISC
. O-MISC O-MISC

Regulation O-MISC O-MISC
of O-MISC O-MISC
chemokine O-MISC B-MISC
mRNA O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
rat O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
vanadium O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
pulmonary O-MISC O-MISC
inflammation O-MISC O-MISC
. O-MISC O-MISC

Environmental O-MISC O-MISC
and O-MISC O-MISC
occupational O-MISC O-MISC
exposure O-MISC O-MISC
to O-MISC O-MISC
vanadium O-MISC O-MISC
dusts O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
toxic O-MISC O-MISC
effects O-MISC O-MISC
mainly O-MISC O-MISC
confined O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
respiratory O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
a O-MISC O-MISC
rat O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
acute O-MISC O-MISC
lung O-MISC O-MISC
inflammation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
intratracheal O-MISC O-MISC
instillation O-MISC O-MISC
of O-MISC O-MISC
sodium O-MISC O-MISC
metavanadate O-MISC O-MISC
( O-MISC O-MISC
NaVO3 O-MISC O-MISC
) O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
dose O-MISC O-MISC
of O-MISC O-MISC
200 O-MISC O-MISC
microg O-MISC O-MISC
V O-MISC O-MISC
/ O-MISC O-MISC
kg O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
relationship O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
cytologic O-MISC O-MISC
characterization O-MISC O-MISC
of O-MISC O-MISC
pulmonary O-MISC O-MISC
inflammation O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
chemokine B-MISC B-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

Significant O-MISC O-MISC
polymorphonuclear O-MISC O-MISC
leukocyte O-MISC O-MISC
( O-MISC O-MISC
PMN O-MISC O-MISC
) O-MISC O-MISC
influx O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
< O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
01 O-MISC O-MISC
) O-MISC O-MISC
into O-MISC O-MISC
the O-MISC O-MISC
lung O-MISC O-MISC
was O-MISC O-MISC
noted O-MISC O-MISC
4 O-MISC O-MISC
h O-MISC O-MISC
after O-MISC O-MISC
NaVO3 O-MISC O-MISC
instillation O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
alveolar O-MISC O-MISC
macrophages O-MISC O-MISC
( O-MISC O-MISC
AMs O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
bronchoalveolar O-MISC O-MISC
lavage O-MISC O-MISC
( O-MISC O-MISC
BAL O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
decrease O-MISC O-MISC
significantly O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
neither O-MISC O-MISC
PMNs O-MISC B-MISC
nor O-MISC O-MISC
AMs O-MISC O-MISC
changed O-MISC O-MISC
substantially O-MISC O-MISC
1 O-MISC O-MISC
h O-MISC O-MISC
after O-MISC O-MISC
NaVO3 O-MISC O-MISC
instillation O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
Northern O-MISC O-MISC
analysis O-MISC O-MISC
, O-MISC O-MISC
macrophage B-MISC B-MISC
inflammatory I-MISC I-MISC
protein I-MISC I-MISC
( I-MISC I-MISC
MIP I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
mRNA I-MISC I-MISC
in O-MISC O-MISC
BAL O-MISC O-MISC
cells O-MISC O-MISC
increased O-MISC O-MISC
markedly O-MISC O-MISC
1 O-MISC O-MISC
h O-MISC O-MISC
after O-MISC O-MISC
NaVO3 O-MISC O-MISC
instillation O-MISC O-MISC
and O-MISC O-MISC
reduced O-MISC O-MISC
a O-MISC O-MISC
little O-MISC O-MISC
bit O-MISC O-MISC
at O-MISC O-MISC
4 O-MISC O-MISC
h O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
mRNA I-MISC I-MISC
in O-MISC O-MISC
BAL O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
expressed O-MISC O-MISC
relatively O-MISC O-MISC
high O-MISC O-MISC
1 O-MISC O-MISC
h O-MISC O-MISC
after O-MISC O-MISC
NaVO3 O-MISC O-MISC
instillation O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
a O-MISC O-MISC
basal O-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
control O-MISC O-MISC
group O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
returned O-MISC O-MISC
rapidly O-MISC O-MISC
nearly O-MISC O-MISC
to O-MISC O-MISC
control O-MISC O-MISC
level O-MISC O-MISC
at O-MISC O-MISC
4 O-MISC O-MISC
h O-MISC O-MISC
. O-MISC O-MISC

Since O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
PMN O-MISC B-MISC
chemoattractant O-MISC I-MISC
and O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
macrophage O-MISC O-MISC
/ O-MISC I-MISC
monocyte O-MISC I-MISC
chemoattractant O-MISC I-MISC
has O-MISC O-MISC
been O-MISC O-MISC
well O-MISC O-MISC
known O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
facts O-MISC O-MISC
that O-MISC O-MISC
PMN O-MISC O-MISC
influx O-MISC O-MISC
was O-MISC O-MISC
preceded O-MISC O-MISC
by O-MISC O-MISC
increased O-MISC O-MISC
MIP O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
mRNA O-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
NaVO3 O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
pulmonary O-MISC O-MISC
inflammation O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
increased O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
mRNA I-MISC I-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
followed O-MISC O-MISC
by O-MISC O-MISC
decreased O-MISC O-MISC
AMs O-MISC O-MISC
in O-MISC O-MISC
BAL O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
AMs O-MISC O-MISC
might O-MISC O-MISC
be O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
, O-MISC O-MISC
adherent O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
lining O-MISC O-MISC
surface O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
airways O-MISC O-MISC
and O-MISC O-MISC
then O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
washed O-MISC O-MISC
out O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
delineate O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
of O-MISC O-MISC
transcriptional O-MISC O-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
recently O-MISC O-MISC
cloned O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
- I-MISC I-MISC
flanking I-MISC I-MISC
region I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
promotor B-MISC B-MISC
region I-MISC I-MISC
contains O-MISC O-MISC
consensus B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
for O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
nuclear I-MISC I-MISC
factor I-MISC I-MISC
kappaB I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
activator B-MISC B-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
increased O-MISC O-MISC
nuclear O-MISC B-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
, O-MISC O-MISC
not O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
1 O-MISC O-MISC
h O-MISC O-MISC
after O-MISC O-MISC
NaVO3 O-MISC O-MISC
instillation O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

p65 B-MISC B-MISC
( I-MISC I-MISC
Rel I-MISC B-MISC
A I-MISC I-MISC
) I-MISC O-MISC
and O-MISC O-MISC
p50 B-MISC B-MISC
protein I-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
MIP O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
binding O-MISC O-MISC
. O-MISC O-MISC

Taken O-MISC O-MISC
together O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
studies O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
is O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
mediator O-MISC O-MISC
of O-MISC O-MISC
NaVO3 O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
pulmonary O-MISC O-MISC
inflammation O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
rat O-MISC O-MISC
model O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
elevated O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
mRNA I-MISC I-MISC
levels O-MISC O-MISC
are O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
increased O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
BAL O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
possible O-MISC O-MISC
MIP B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
transcriptional O-MISC O-MISC
regulation O-MISC O-MISC
through O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
and O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
healthy O-MISC O-MISC
lymphomonocytes O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
bystander O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Persistent O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
is O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
hallmarks O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
we O-MISC O-MISC
analysed O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
factors O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
cytokine O-MISC B-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
STAT B-MISC B-MISC
1 I-MISC I-MISC
proteins I-MISC I-MISC
and O-MISC O-MISC
IRF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
, O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
PBMC O-MISC O-MISC
) O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

Western O-MISC O-MISC
blot O-MISC O-MISC
analyses O-MISC O-MISC
and O-MISC O-MISC
reverse O-MISC B-MISC
transcriptase O-MISC I-MISC
- O-MISC O-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
both O-MISC O-MISC
cells O-MISC O-MISC
infected O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
X4 O-MISC O-MISC
strain O-MISC O-MISC
and O-MISC O-MISC
cells O-MISC O-MISC
infected O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
R5 O-MISC O-MISC
strain O-MISC O-MISC
are O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
increase O-MISC O-MISC
intracellular O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
STAT B-MISC B-MISC
1alpha I-MISC I-MISC
and I-MISC O-MISC
beta I-MISC B-MISC
proteins O-MISC I-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
IRF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
effect O-MISC O-MISC
was O-MISC O-MISC
prevented O-MISC O-MISC
by O-MISC O-MISC
neutralizing O-MISC B-MISC
antibodies O-MISC I-MISC
against O-MISC O-MISC
interferon B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
dependently O-MISC O-MISC
induced O-MISC O-MISC
apoptotic O-MISC O-MISC
commitment O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
PBMC O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
revealed O-MISC O-MISC
by O-MISC O-MISC
DNA O-MISC B-MISC
fragmentation O-MISC I-MISC
analysis O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
this O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
of O-MISC O-MISC
caspase O-MISC B-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
even O-MISC O-MISC
if O-MISC O-MISC
a O-MISC O-MISC
slight O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1beta I-MISC I-MISC
- I-MISC I-MISC
converting I-MISC I-MISC
enzyme I-MISC I-MISC
mRNA I-MISC I-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
. O-MISC O-MISC

Apoptosis O-MISC O-MISC
induction O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
abrogated O-MISC O-MISC
mainly O-MISC O-MISC
by O-MISC O-MISC
antibodies B-MISC O-MISC
against O-MISC O-MISC
tumour B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
lesser O-MISC O-MISC
extent O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
antibodies B-MISC O-MISC
against O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
. O-MISC O-MISC

All O-MISC O-MISC
these O-MISC O-MISC
findings O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
uninfected O-MISC O-MISC
PBMC O-MISC O-MISC
can O-MISC O-MISC
undergo O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
and O-MISC O-MISC
apoptosis O-MISC O-MISC
after O-MISC O-MISC
exposure O-MISC O-MISC
to O-MISC O-MISC
bystander O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
subsequent O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
such O-MISC O-MISC
as O-MISC O-MISC
IFNs B-MISC B-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
physical O-MISC O-MISC
association O-MISC O-MISC
of O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
theta I-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
lipid O-MISC O-MISC
raft O-MISC O-MISC
- O-MISC O-MISC
associated O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
kappa B-MISC B-MISC
B I-MISC I-MISC
factor I-MISC I-MISC
kinase I-MISC I-MISC
( I-MISC I-MISC
IKK I-MISC B-MISC
) I-MISC I-MISC
complex I-MISC I-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
cascade O-MISC O-MISC
by O-MISC O-MISC
TCR B-MISC B-MISC
and O-MISC O-MISC
CD28 B-MISC B-MISC
. O-MISC O-MISC

We O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
theta I-MISC O-MISC
( O-MISC O-MISC
PKCtheta B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
cascade O-MISC O-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Among O-MISC O-MISC
six O-MISC O-MISC
or O-MISC O-MISC
so O-MISC O-MISC
PKC B-MISC B-MISC
isoforms I-MISC I-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
only O-MISC O-MISC
PKCtheta B-MISC B-MISC
participates O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
assembly O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
supramolecular O-MISC O-MISC
activation O-MISC O-MISC
clusters O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
contact O-MISC O-MISC
site O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
TCR B-MISC B-MISC
with O-MISC O-MISC
Ag B-MISC O-MISC
. O-MISC O-MISC

Signaling O-MISC O-MISC
via O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
TCR B-MISC B-MISC
and O-MISC O-MISC
CD28 B-MISC B-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
optimal O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
multisubunit B-MISC O-MISC
IkappaB I-MISC B-MISC
kinase I-MISC I-MISC
( I-MISC O-MISC
IKK I-MISC B-MISC
) I-MISC O-MISC
complex I-MISC O-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
; O-MISC O-MISC
this O-MISC O-MISC
activation O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
Ca O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
PKC O-MISC B-MISC
isoform O-MISC O-MISC
inhibitor O-MISC O-MISC
, O-MISC O-MISC
rottlerin O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
endogenous O-MISC O-MISC
PKCtheta B-MISC B-MISC
physically O-MISC O-MISC
associates O-MISC O-MISC
with O-MISC O-MISC
activated O-MISC B-MISC
IKK B-MISC I-MISC
complexes I-MISC I-MISC
in O-MISC O-MISC
CD3 O-MISC B-MISC
/ O-MISC O-MISC
CD28 O-MISC I-MISC
- O-MISC O-MISC
costimulated O-MISC O-MISC
primary O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
same O-MISC O-MISC
set O-MISC O-MISC
of O-MISC O-MISC
stimuli O-MISC O-MISC
also O-MISC O-MISC
induced O-MISC O-MISC
relocation O-MISC O-MISC
of O-MISC O-MISC
endogenous O-MISC O-MISC
PKCtheta B-MISC B-MISC
and O-MISC O-MISC
IKKs B-MISC B-MISC
to O-MISC O-MISC
a O-MISC O-MISC
GM1 O-MISC O-MISC
ganglioside O-MISC O-MISC
- O-MISC O-MISC
enriched O-MISC O-MISC
, O-MISC O-MISC
detergent O-MISC O-MISC
- O-MISC O-MISC
insoluble O-MISC O-MISC
membrane O-MISC O-MISC
compartment O-MISC O-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

IKKs B-MISC B-MISC
recruited O-MISC O-MISC
to O-MISC O-MISC
these O-MISC O-MISC
lipid O-MISC O-MISC
rafts O-MISC O-MISC
were O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
phosphorylating O-MISC O-MISC
a O-MISC O-MISC
recombinant O-MISC O-MISC
IkappaBalpha O-MISC B-MISC
sustrate O-MISC O-MISC
. O-MISC O-MISC

Confocal O-MISC O-MISC
microscopy O-MISC O-MISC
further O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
exogenously O-MISC O-MISC
expressed O-MISC O-MISC
PKCtheta B-MISC B-MISC
and O-MISC O-MISC
IKKss B-MISC B-MISC
colocalize O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
membrane O-MISC O-MISC
of O-MISC O-MISC
CD3 O-MISC B-MISC
/ O-MISC O-MISC
CD28 O-MISC I-MISC
- O-MISC O-MISC
costimulated O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Constitutively O-MISC O-MISC
active O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
kinase B-MISC B-MISC
- I-MISC I-MISC
inactive I-MISC I-MISC
PKCtheta I-MISC I-MISC
activated O-MISC O-MISC
IKKbeta B-MISC B-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
dominant B-MISC B-MISC
- I-MISC I-MISC
active I-MISC I-MISC
PKCtheta I-MISC I-MISC
also O-MISC O-MISC
had O-MISC O-MISC
stimulatory O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
CD28 B-MISC B-MISC
response I-MISC I-MISC
element I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Taken O-MISC O-MISC
together O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
data O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
PKCtheta B-MISC B-MISC
by O-MISC O-MISC
the O-MISC O-MISC
TCR B-MISC B-MISC
and O-MISC O-MISC
CD28 B-MISC B-MISC
plays O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
assembly O-MISC O-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
IKK B-MISC B-MISC
complexes I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
membrane O-MISC O-MISC

T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
osteoclastogenesis O-MISC B-MISC
by O-MISC O-MISC
signalling O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
talk O-MISC O-MISC
between O-MISC O-MISC
RANKL B-MISC B-MISC
and O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
. O-MISC O-MISC

Bone O-MISC O-MISC
resorption O-MISC O-MISC
is O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
, O-MISC O-MISC
where O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
RANKL B-MISC B-MISC
( O-MISC O-MISC
receptor B-MISC O-MISC
activator I-MISC O-MISC
of I-MISC O-MISC
nuclear I-MISC B-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC B-MISC
) I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
ligand I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
tumour B-MISC B-MISC
- I-MISC I-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
family I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
osteoclastogenesis O-MISC O-MISC
, O-MISC O-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
pathological O-MISC O-MISC
conditions O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
autoimmune O-MISC O-MISC
arthritis O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
whether O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
maintain O-MISC O-MISC
bone O-MISC O-MISC
homeostasis O-MISC O-MISC
by O-MISC O-MISC
counterbalancing O-MISC O-MISC
the O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
RANKL B-MISC B-MISC
remains O-MISC O-MISC
unknown O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
interferon B-MISC B-MISC
( I-MISC O-MISC
IFN I-MISC B-MISC
) I-MISC O-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
strongly O-MISC O-MISC
suppresses O-MISC O-MISC
osteoclastogenesis O-MISC O-MISC
by O-MISC O-MISC
interfering O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
RANKL B-MISC B-MISC
- O-MISC I-MISC
RANK O-MISC I-MISC
signalling O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
induces O-MISC O-MISC
rapid O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
RANK B-MISC B-MISC
adapter I-MISC I-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
TRAF6 B-MISC B-MISC
( O-MISC O-MISC
tumour B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
receptor I-MISC I-MISC
- I-MISC I-MISC
associated I-MISC I-MISC
factor I-MISC I-MISC
6 I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
strong O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
RANKL B-MISC B-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
JNK B-MISC B-MISC
. O-MISC O-MISC

This O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
osteoclastogenesis O-MISC O-MISC
is O-MISC O-MISC
rescued O-MISC O-MISC
by O-MISC O-MISC
overexpressing O-MISC O-MISC
TRAF6 B-MISC B-MISC
in O-MISC O-MISC
precursor O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
indicates O-MISC O-MISC
that O-MISC O-MISC
TRAF6 B-MISC B-MISC
is O-MISC O-MISC
the O-MISC O-MISC
target O-MISC O-MISC
critical O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
action O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
provide O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
accelerated O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
TRAF6 B-MISC B-MISC
requires O-MISC O-MISC
both O-MISC O-MISC
its O-MISC O-MISC
ubiquitination O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
initiated O-MISC O-MISC
by O-MISC O-MISC
RANKL B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
ubiquitin O-MISC B-MISC
- O-MISC I-MISC
proteasome O-MISC I-MISC
system O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
study O-MISC O-MISC
shows O-MISC O-MISC
that O-MISC O-MISC
there O-MISC O-MISC
is O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
talk O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
tumour B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
and O-MISC O-MISC
IFN B-MISC B-MISC
families I-MISC I-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
, O-MISC O-MISC
through O-MISC O-MISC
which O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
provides O-MISC O-MISC
a O-MISC O-MISC
negative O-MISC O-MISC
link O-MISC O-MISC
between O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
bone O-MISC O-MISC
resorption O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
results O-MISC O-MISC
may O-MISC O-MISC
offer O-MISC O-MISC
a O-MISC O-MISC
therapeutic O-MISC O-MISC
approach O-MISC O-MISC
to O-MISC O-MISC
treat O-MISC O-MISC
the O-MISC O-MISC
inflammation O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
tissue O-MISC O-MISC
breakdown O-MISC O-MISC
. O-MISC O-MISC

Stromal B-MISC B-MISC
- I-MISC I-MISC
derived I-MISC I-MISC
factor I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
thrombopoietin B-MISC B-MISC
regulate O-MISC O-MISC
distinct O-MISC O-MISC
aspects O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
megakaryopoiesis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
chemokine B-MISC B-MISC
binding O-MISC I-MISC
stromal B-MISC I-MISC
- I-MISC I-MISC
derived I-MISC I-MISC
factor I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
SDF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
megakaryopoiesis O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC O-MISC
and O-MISC O-MISC
molecular O-MISC O-MISC
levels O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
comparison O-MISC O-MISC
with O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
thrombopoietin B-MISC B-MISC
( O-MISC O-MISC
TPO B-MISC B-MISC
) O-MISC O-MISC
have O-MISC O-MISC
not O-MISC O-MISC
been O-MISC O-MISC
determined O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
SDF B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
unlike O-MISC O-MISC
TPO B-MISC B-MISC
, O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
stimulate O-MISC O-MISC
alpha O-MISC B-MISC
( O-MISC O-MISC
IIb O-MISC I-MISC
) O-MISC O-MISC
beta O-MISC O-MISC
( O-MISC O-MISC
3 O-MISC O-MISC
) O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
or O-MISC O-MISC
differentiation O-MISC O-MISC
or O-MISC O-MISC
have O-MISC O-MISC
an O-MISC O-MISC
antiapoptotic O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
does O-MISC O-MISC
induce O-MISC O-MISC
chemotaxis O-MISC O-MISC
, O-MISC O-MISC
trans O-MISC O-MISC
- O-MISC O-MISC
Matrigel O-MISC O-MISC
migration O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
matrix O-MISC B-MISC
metalloproteinase B-MISC I-MISC
9 I-MISC I-MISC
( O-MISC I-MISC
MMP B-MISC I-MISC
- I-MISC I-MISC
9 I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
vascular B-MISC B-MISC
endothelial I-MISC B-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
VEGF B-MISC O-MISC
) O-MISC O-MISC
by O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
both O-MISC O-MISC
SDF B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
TPO B-MISC B-MISC
increase O-MISC O-MISC
the O-MISC O-MISC
adhesion O-MISC O-MISC
of O-MISC I-MISC
alpha O-MISC B-MISC
( O-MISC I-MISC
IIb O-MISC I-MISC
) O-MISC I-MISC
beta O-MISC I-MISC
( O-MISC I-MISC
3 O-MISC I-MISC
) O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
fibrinogen B-MISC B-MISC
and O-MISC O-MISC
vitronectin B-MISC B-MISC
. O-MISC O-MISC

Investigating O-MISC O-MISC
the O-MISC O-MISC
intracellular O-MISC O-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
SDF B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
TPO B-MISC B-MISC
revealed O-MISC O-MISC
some O-MISC O-MISC
overlapping O-MISC O-MISC
patterns O-MISC O-MISC
of O-MISC O-MISC
protein O-MISC O-MISC
phosphorylation O-MISC O-MISC
/ O-MISC O-MISC
activation O-MISC O-MISC
( O-MISC O-MISC
mitogen B-MISC B-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
[ I-MISC O-MISC
MAPK I-MISC B-MISC
] I-MISC O-MISC
p42 I-MISC I-MISC
/ I-MISC I-MISC
44 I-MISC I-MISC
, O-MISC O-MISC
MAPK B-MISC B-MISC
p38 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
AKT B-MISC O-MISC
[ I-MISC O-MISC
protein I-MISC B-MISC
kinase I-MISC I-MISC
B I-MISC I-MISC
] I-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
some O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
distinct O-MISC O-MISC
for O-MISC O-MISC
TPO B-MISC B-MISC
( O-MISC O-MISC
eg O-MISC B-MISC
, O-MISC O-MISC
JAK B-MISC B-MISC
- I-MISC I-MISC
STAT I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
for O-MISC O-MISC
SDF B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
eg O-MISC O-MISC
, O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
though O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
phosphatidyl B-MISC B-MISC
- I-MISC I-MISC
inositol I-MISC I-MISC
3 I-MISC I-MISC
- I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
PI B-MISC B-MISC
- I-MISC I-MISC
3K I-MISC I-MISC
) O-MISC O-MISC
by O-MISC O-MISC
LY294002 O-MISC B-MISC
in O-MISC O-MISC
alpha O-MISC B-MISC
( O-MISC O-MISC
IIb O-MISC I-MISC
) O-MISC O-MISC
beta O-MISC I-MISC
( O-MISC O-MISC
3 O-MISC I-MISC
) O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
and O-MISC O-MISC
inhibited O-MISC O-MISC
chemotaxis O-MISC O-MISC
adhesion O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
MMP B-MISC B-MISC
- I-MISC I-MISC
9 I-MISC I-MISC
and O-MISC O-MISC
VEGF B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
MAPK B-MISC B-MISC
p42 I-MISC O-MISC
/ I-MISC O-MISC
44 I-MISC O-MISC
( O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
MEK O-MISC B-MISC
inhibitor O-MISC O-MISC
U0126 O-MISC I-MISC
) O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
survival O-MISC O-MISC
, O-MISC O-MISC
proliferation O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
migration O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Hence O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
suggested O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
proliferative O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
TPO B-MISC B-MISC
is O-MISC O-MISC
more O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
JAK O-MISC B-MISC
- O-MISC O-MISC
STAT O-MISC I-MISC
pathway O-MISC O-MISC
( O-MISC O-MISC
unique O-MISC O-MISC
to O-MISC O-MISC
TPO B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
PI O-MISC B-MISC
- O-MISC I-MISC
3K O-MISC I-MISC
- O-MISC O-MISC
AKT O-MISC O-MISC
axis O-MISC O-MISC
is O-MISC O-MISC
differentially O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
TPO O-MISC B-MISC
- O-MISC I-MISC
and O-MISC O-MISC
SDF O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
signaling O-MISC O-MISC
. O-MISC O-MISC

Accordingly O-MISC O-MISC
, O-MISC O-MISC
PI B-MISC B-MISC
- I-MISC I-MISC
3K I-MISC I-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
TPO B-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
TPO O-MISC B-MISC
- O-MISC I-MISC
and O-MISC O-MISC
SDF O-MISC O-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
adhesion O-MISC O-MISC
to O-MISC O-MISC
fibrinogen B-MISC B-MISC
and O-MISC O-MISC
vitronectin B-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
SDF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
migration O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
study O-MISC O-MISC
expands O-MISC O-MISC
the O-MISC O-MISC
understanding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
SDF B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
TPO B-MISC B-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
megakaryopoiesis O-MISC O-MISC
and O-MISC O-MISC
indicates O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
basis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
observed O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
cellular O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

( O-MISC O-MISC
Blood O-MISC O-MISC
. O-MISC O-MISC
2000 O-MISC O-MISC
; O-MISC O-MISC
96 O-MISC O-MISC
: O-MISC O-MISC
4142 O-MISC B-MISC
- O-MISC I-MISC
4151 O-MISC I-MISC
) O-MISC O-MISC

Adhesion O-MISC O-MISC
of O-MISC O-MISC
immature O-MISC O-MISC
and O-MISC O-MISC
mature O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
induces O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
thymic O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
TEC O-MISC O-MISC
) O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
gene I-MISC I-MISC
trascription I-MISC I-MISC
factors I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
IL6 I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
: O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
alpha3beta1 B-MISC B-MISC
and I-MISC O-MISC
alpha6beta4 I-MISC B-MISC
integrins I-MISC B-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cell O-MISC O-MISC
precursors O-MISC O-MISC
homed O-MISC O-MISC
to O-MISC O-MISC
thymus O-MISC O-MISC
develop O-MISC O-MISC
in O-MISC O-MISC
close O-MISC O-MISC
contact O-MISC O-MISC
with O-MISC O-MISC
stromal O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Among O-MISC O-MISC
them O-MISC O-MISC
, O-MISC O-MISC
thymic O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
TEC O-MISC O-MISC
) O-MISC O-MISC
are O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
exert O-MISC O-MISC
dominant O-MISC O-MISC
roles O-MISC O-MISC
in O-MISC O-MISC
their O-MISC O-MISC
survival O-MISC O-MISC
and O-MISC O-MISC
functional O-MISC O-MISC
shaping O-MISC O-MISC
. O-MISC O-MISC

Key O-MISC O-MISC
molecules O-MISC O-MISC
mediating O-MISC O-MISC
TEC O-MISC O-MISC
/ O-MISC O-MISC
thymocytes O-MISC O-MISC
interactions O-MISC O-MISC
include O-MISC O-MISC
cytokines B-MISC B-MISC
and O-MISC O-MISC
growth B-MISC B-MISC
factors I-MISC I-MISC
secreted O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
and O-MISC O-MISC
adhesion B-MISC B-MISC
receptors I-MISC I-MISC
mediating O-MISC O-MISC
cell O-MISC O-MISC
contact O-MISC O-MISC
. O-MISC O-MISC

Signaling O-MISC O-MISC
events O-MISC O-MISC
triggered O-MISC O-MISC
in O-MISC O-MISC
thymocytes O-MISC O-MISC
by O-MISC O-MISC
adhesion O-MISC O-MISC
to O-MISC O-MISC
epithelial O-MISC O-MISC
cells O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
extensively O-MISC O-MISC
investigated O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
little O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
opposite O-MISC O-MISC
phenomenon O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
previously O-MISC O-MISC
investigated O-MISC O-MISC
this O-MISC O-MISC
issue O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
culture O-MISC O-MISC
system O-MISC O-MISC
composed O-MISC O-MISC
of O-MISC O-MISC
TEC O-MISC O-MISC
cultures O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
human O-MISC O-MISC
normal O-MISC O-MISC
thymus O-MISC O-MISC
and O-MISC O-MISC
heterologous O-MISC O-MISC
thymocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
thymocytes O-MISC O-MISC
adhere O-MISC O-MISC
to O-MISC O-MISC
TEC O-MISC O-MISC
involving O-MISC O-MISC
beta1 B-MISC B-MISC
and I-MISC I-MISC
beta4 I-MISC I-MISC
integrins I-MISC I-MISC
and O-MISC O-MISC
induce O-MISC O-MISC
the O-MISC O-MISC
clustering O-MISC O-MISC
of O-MISC O-MISC
alpha3beta1 B-MISC B-MISC
and I-MISC O-MISC
alpha6beta4 I-MISC B-MISC
heterodimers I-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
TEC O-MISC B-MISC
surface O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
thymocyte O-MISC O-MISC
adhesion O-MISC O-MISC
was O-MISC O-MISC
followed O-MISC O-MISC
by O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
IL6 I-MISC I-MISC
gene B-MISC I-MISC
transcription I-MISC B-MISC
factors I-MISC I-MISC
and O-MISC O-MISC
enhanced O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
production O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
two O-MISC O-MISC
latter O-MISC O-MISC
phenomena O-MISC O-MISC
were O-MISC O-MISC
reproduced O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
alpha3 B-MISC B-MISC
, O-MISC I-MISC
alpha6 B-MISC B-MISC
, O-MISC O-MISC
beta1 B-MISC I-MISC
and I-MISC O-MISC
beta4 I-MISC B-MISC
integrins I-MISC I-MISC
, O-MISC O-MISC
thus O-MISC O-MISC
implying O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
alpha3beta1 B-MISC B-MISC
and I-MISC O-MISC
alpha6beta4 I-MISC B-MISC
heterodimers I-MISC I-MISC
can O-MISC O-MISC
signal O-MISC O-MISC
during O-MISC O-MISC
thymocyte O-MISC O-MISC
adhesion O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
extended O-MISC O-MISC
our O-MISC O-MISC
previous O-MISC O-MISC
work O-MISC O-MISC
investigating O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
experimental O-MISC O-MISC
setting O-MISC O-MISC
the O-MISC O-MISC
inducing O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
non O-MISC O-MISC
stimulated O-MISC O-MISC
or O-MISC O-MISC
activated O-MISC O-MISC
policlonal O-MISC O-MISC
or O-MISC O-MISC
clonal O-MISC O-MISC
mature O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
representative O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
more O-MISC O-MISC
mature O-MISC O-MISC
thymocyte O-MISC O-MISC
subset O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
adhesion O-MISC O-MISC
of O-MISC O-MISC
unstimulated O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
i O-MISC O-MISC
) O-MISC O-MISC
involved O-MISC O-MISC
beta1 O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
beta4 O-MISC B-MISC
integrin O-MISC O-MISC
functions O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
surface O-MISC O-MISC
ii O-MISC O-MISC
) O-MISC O-MISC
induced O-MISC O-MISC
the O-MISC O-MISC
clustering O-MISC O-MISC
of O-MISC O-MISC
alpha3beta1 B-MISC B-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
alpha2beta1 B-MISC B-MISC
heterodimers I-MISC I-MISC
at O-MISC O-MISC
the O-MISC O-MISC
TEC O-MISC O-MISC
surface O-MISC O-MISC
and O-MISC O-MISC
iii O-MISC O-MISC
) O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
secretion O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
propose O-MISC O-MISC
that O-MISC O-MISC
alpha3beta1 B-MISC B-MISC
and I-MISC I-MISC
alpha6beta4 I-MISC B-MISC
heterodimers I-MISC I-MISC
are O-MISC O-MISC
induced O-MISC O-MISC
to O-MISC O-MISC
cluster O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
TEC O-MISC O-MISC
surface O-MISC O-MISC
recognizing O-MISC O-MISC
yet O-MISC O-MISC
unknown O-MISC O-MISC
cellular B-MISC O-MISC
ligands I-MISC O-MISC
differentially O-MISC O-MISC
expressed O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
development O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
and O-MISC O-MISC
characterization O-MISC O-MISC
of O-MISC O-MISC
SKAT B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
Th2 B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
zinc I-MISC I-MISC
finger I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
identified O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
Kruppel B-MISC B-MISC
- I-MISC I-MISC
type I-MISC I-MISC
zinc I-MISC I-MISC
finger I-MISC I-MISC
( I-MISC I-MISC
ZF I-MISC I-MISC
) I-MISC I-MISC
gene I-MISC I-MISC
, O-MISC O-MISC
SKAT B-MISC O-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
selectively O-MISC O-MISC
expressed O-MISC O-MISC
by O-MISC O-MISC
murine O-MISC O-MISC
Th2 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
protein O-MISC O-MISC
encoded O-MISC O-MISC
by O-MISC O-MISC
this O-MISC O-MISC
gene O-MISC O-MISC
has O-MISC O-MISC
14 O-MISC B-MISC
C2H2 O-MISC I-MISC
- O-MISC I-MISC
type O-MISC I-MISC
ZF O-MISC I-MISC
tandemly O-MISC I-MISC
arrayed O-MISC O-MISC
at O-MISC O-MISC
its O-MISC O-MISC
C B-MISC B-MISC
terminus I-MISC I-MISC
and O-MISC O-MISC
N B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
SCAN B-MISC I-MISC
box I-MISC I-MISC
and O-MISC I-MISC
KRAB B-MISC I-MISC
domains I-MISC I-MISC
. O-MISC O-MISC

SKAT B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
is O-MISC O-MISC
tissue O-MISC O-MISC
restricted O-MISC O-MISC
in O-MISC O-MISC
expression O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
RNA O-MISC O-MISC
level O-MISC O-MISC
, O-MISC O-MISC
detectable O-MISC O-MISC
only O-MISC O-MISC
in O-MISC O-MISC
brain O-MISC O-MISC
and O-MISC O-MISC
at O-MISC O-MISC
low O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
kidney O-MISC O-MISC
and O-MISC O-MISC
spleen O-MISC O-MISC
and O-MISC O-MISC
few O-MISC O-MISC
hematopoietic O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
in O-MISC O-MISC
situ O-MISC O-MISC
hybridization O-MISC O-MISC
, O-MISC O-MISC
SKAT B-MISC O-MISC
- I-MISC O-MISC
2 I-MISC O-MISC
expression O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
peak O-MISC O-MISC
in O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
after O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
3 O-MISC O-MISC
days O-MISC O-MISC
of O-MISC O-MISC
culture O-MISC O-MISC
under O-MISC O-MISC
Th2 O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
Th1 O-MISC O-MISC
biasing O-MISC O-MISC
conditions O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
pattern O-MISC O-MISC
of O-MISC O-MISC
expression O-MISC O-MISC
closely O-MISC O-MISC
mirrored O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
transient O-MISC O-MISC
transfection O-MISC O-MISC
experiments O-MISC O-MISC
in O-MISC O-MISC
phorbol O-MISC O-MISC
12 O-MISC O-MISC
- O-MISC O-MISC
myristate O-MISC O-MISC
13 O-MISC O-MISC
- O-MISC O-MISC
acetate O-MISC O-MISC
/ O-MISC O-MISC
ionomycin O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
EL4 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
SKAT B-MISC O-MISC
- I-MISC O-MISC
2 I-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
but I-MISC O-MISC
not I-MISC O-MISC
the I-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
promoter I-MISC I-MISC
, O-MISC O-MISC
contrasting O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
both O-MISC O-MISC
promoters B-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
result O-MISC O-MISC
was O-MISC O-MISC
confirmed O-MISC O-MISC
using O-MISC O-MISC
clones O-MISC O-MISC
of O-MISC O-MISC
EL4 O-MISC O-MISC
cells O-MISC O-MISC
stably O-MISC O-MISC
expressing O-MISC O-MISC
an O-MISC O-MISC
inducible O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
SKAT B-MISC O-MISC
- I-MISC O-MISC
2 I-MISC O-MISC
, O-MISC O-MISC
thus O-MISC O-MISC
SKAT B-MISC O-MISC
- I-MISC O-MISC
2 I-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
Th2 B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
gene I-MISC I-MISC
that O-MISC O-MISC
may O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
selective O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
cytokine B-MISC B-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

hsp70 B-MISC B-MISC
interacting I-MISC I-MISC
protein I-MISC I-MISC
Hip I-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
folding O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
hsp90 O-MISC O-MISC
- O-MISC O-MISC
based O-MISC O-MISC
chaperone O-MISC O-MISC
machinery O-MISC O-MISC
except O-MISC O-MISC
to O-MISC O-MISC
oppose O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
BAG B-MISC O-MISC
- I-MISC O-MISC
1 I-MISC O-MISC
. O-MISC O-MISC

Reticulocyte O-MISC O-MISC
lysate O-MISC O-MISC
contains O-MISC O-MISC
a O-MISC O-MISC
chaperone O-MISC O-MISC
system O-MISC O-MISC
that O-MISC O-MISC
assembles O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
( I-MISC O-MISC
GR I-MISC B-MISC
) I-MISC O-MISC
. I-MISC O-MISC
hsp90 I-MISC O-MISC
heterocomplexes I-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
purified B-MISC B-MISC
proteins I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
prepared O-MISC O-MISC
a O-MISC O-MISC
five O-MISC O-MISC
- O-MISC B-MISC
protein O-MISC I-MISC
heterocomplex O-MISC I-MISC
assembly O-MISC O-MISC
system O-MISC O-MISC
consisting O-MISC O-MISC
of O-MISC O-MISC
two O-MISC O-MISC
proteins O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
heterocomplex O-MISC O-MISC
assembly O-MISC O-MISC
- O-MISC O-MISC
hsp90 B-MISC I-MISC
and O-MISC O-MISC
hsp70 B-MISC B-MISC
- O-MISC I-MISC
and O-MISC O-MISC
three O-MISC O-MISC
proteins O-MISC I-MISC
that O-MISC O-MISC
act O-MISC O-MISC
as O-MISC O-MISC
co O-MISC B-MISC
- O-MISC I-MISC
chaperones O-MISC I-MISC
to O-MISC I-MISC
enhance O-MISC I-MISC
assembly O-MISC O-MISC
- O-MISC O-MISC
Hop B-MISC O-MISC
, O-MISC O-MISC
hsp40 B-MISC B-MISC
, O-MISC O-MISC
p23 B-MISC B-MISC
[ O-MISC O-MISC
Morishima O-MISC O-MISC
, O-MISC O-MISC
Y O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Kanelakis O-MISC O-MISC
, O-MISC O-MISC
K O-MISC O-MISC
. O-MISC O-MISC
C O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Silverstein O-MISC O-MISC
, O-MISC O-MISC
A O-MISC O-MISC
. O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Dittmar O-MISC O-MISC
, O-MISC O-MISC
K O-MISC O-MISC
. O-MISC O-MISC
D O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
Estrada O-MISC B-MISC
, O-MISC O-MISC
L O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Pratt O-MISC O-MISC
, O-MISC O-MISC
W O-MISC O-MISC
. O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
( O-MISC O-MISC
2000 O-MISC O-MISC
) O-MISC O-MISC
J O-MISC O-MISC
. O-MISC O-MISC
Biol O-MISC O-MISC
. O-MISC O-MISC
Chem O-MISC O-MISC
. O-MISC O-MISC
275 O-MISC O-MISC
, O-MISC O-MISC
6894 O-MISC O-MISC
- O-MISC O-MISC
6900 O-MISC O-MISC
] O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
hsp70 B-MISC B-MISC
co I-MISC O-MISC
- I-MISC I-MISC
chaperone I-MISC I-MISC
Hip I-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
recovered O-MISC O-MISC
in O-MISC O-MISC
receptor B-MISC O-MISC
. I-MISC O-MISC
hsp90 I-MISC O-MISC
heterocomplexes I-MISC O-MISC
at O-MISC O-MISC
an O-MISC O-MISC
intermediate O-MISC O-MISC
stage O-MISC O-MISC
of O-MISC O-MISC
assembly O-MISC O-MISC
in O-MISC O-MISC
reticulocyte O-MISC O-MISC
lysate O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Hip B-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
thought O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
an O-MISC O-MISC
intrinsic O-MISC O-MISC
component O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
assembly O-MISC O-MISC
machinery O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
immunodepletion O-MISC O-MISC
of O-MISC O-MISC
Hip B-MISC O-MISC
from O-MISC O-MISC
reticulocyte O-MISC O-MISC
lysate O-MISC O-MISC
or O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
Hip B-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
purified O-MISC O-MISC
five O-MISC O-MISC
- O-MISC O-MISC
protein O-MISC O-MISC
system O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
GR O-MISC B-MISC
. O-MISC O-MISC
hsp90 O-MISC O-MISC
heterocomplex O-MISC O-MISC
assembly O-MISC O-MISC
or O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
that O-MISC O-MISC
occurs O-MISC O-MISC
with O-MISC O-MISC
assembly O-MISC O-MISC
. O-MISC O-MISC

Despite O-MISC O-MISC
the O-MISC O-MISC
fact O-MISC O-MISC
that O-MISC O-MISC
Hip B-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
assembly O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
recovered O-MISC O-MISC
in O-MISC O-MISC
GR B-MISC B-MISC
. I-MISC O-MISC
hsp90 I-MISC B-MISC
heterocomplexes I-MISC O-MISC
assembled O-MISC O-MISC
by O-MISC O-MISC
both O-MISC O-MISC
systems O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
five O-MISC O-MISC
- O-MISC O-MISC
protein O-MISC I-MISC
system O-MISC O-MISC
, O-MISC O-MISC
Hip B-MISC O-MISC
prevents O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
assembly O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
hsp70 B-MISC B-MISC
co I-MISC I-MISC
- I-MISC I-MISC
chaperone I-MISC I-MISC
BAG I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
cotransfection O-MISC O-MISC
of O-MISC O-MISC
Hip B-MISC O-MISC
with O-MISC O-MISC
BAG B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
opposes O-MISC O-MISC
BAG B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
reduction O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
COS O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
Hip B-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
a O-MISC O-MISC
component O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
assembly O-MISC O-MISC
machinery O-MISC O-MISC
but O-MISC O-MISC
that O-MISC O-MISC
it O-MISC O-MISC
could O-MISC O-MISC
play O-MISC O-MISC
a O-MISC O-MISC
regulatory O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
opposition O-MISC O-MISC
to O-MISC O-MISC
BAG B-MISC O-MISC
- I-MISC I-MISC
1 I-MISC O-MISC
. O-MISC O-MISC

Cutting O-MISC O-MISC
edge O-MISC O-MISC
: O-MISC O-MISC
STAT6 O-MISC B-MISC
- O-MISC O-MISC
deficient O-MISC O-MISC
mice O-MISC O-MISC
have O-MISC O-MISC
enhanced O-MISC O-MISC
tumor O-MISC O-MISC
immunity O-MISC O-MISC
to O-MISC O-MISC
primary O-MISC O-MISC
and O-MISC O-MISC
metastatic O-MISC O-MISC
mammary O-MISC O-MISC
carcinoma O-MISC O-MISC
. O-MISC O-MISC

STAT4 B-MISC B-MISC
and O-MISC O-MISC
STAT6 B-MISC B-MISC
are O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
Th1 O-MISC O-MISC
and O-MISC O-MISC
Th2 O-MISC O-MISC
development O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

Tumor O-MISC O-MISC
immunologists O-MISC O-MISC
have O-MISC O-MISC
hypothesized O-MISC O-MISC
that O-MISC O-MISC
Th1 O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
critical O-MISC O-MISC
in O-MISC O-MISC
tumor O-MISC O-MISC
immunity O-MISC O-MISC
because O-MISC O-MISC
they O-MISC O-MISC
facilitate O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
potent O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
tumor O-MISC O-MISC
effectors O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
used O-MISC O-MISC
STAT4 O-MISC B-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
STAT6 O-MISC B-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
to O-MISC O-MISC
test O-MISC O-MISC
this O-MISC O-MISC
hypothesis O-MISC O-MISC
. O-MISC O-MISC

BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC O-MISC
and O-MISC O-MISC
knockout O-MISC O-MISC
mice O-MISC O-MISC
were O-MISC O-MISC
challenged O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
mammary O-MISC O-MISC
gland O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
highly O-MISC O-MISC
malignant O-MISC O-MISC
and O-MISC O-MISC
spontaneously O-MISC O-MISC
metastatic O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
4T1 O-MISC O-MISC
mammary O-MISC O-MISC
carcinoma O-MISC O-MISC
. O-MISC O-MISC

Primary O-MISC O-MISC
tumor O-MISC O-MISC
growth O-MISC O-MISC
and O-MISC O-MISC
metastatic O-MISC O-MISC
disease O-MISC O-MISC
are O-MISC O-MISC
reduced O-MISC O-MISC
in O-MISC O-MISC
STAT6 O-MISC B-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
relative O-MISC O-MISC
to O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC O-MISC
and O-MISC O-MISC
STAT4 O-MISC B-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Ab O-MISC O-MISC
depletions O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
is O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
CD8 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
immunized O-MISC O-MISC
STAT6 O-MISC B-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
have O-MISC O-MISC
higher O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
4T1 O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
CTL O-MISC O-MISC
than O-MISC O-MISC
BALB O-MISC O-MISC
/ O-MISC O-MISC
c O-MISC O-MISC
or O-MISC O-MISC
STAT4 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Surprisingly O-MISC O-MISC
, O-MISC O-MISC
Th1 O-MISC O-MISC
or O-MISC O-MISC
Th2 O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
involved O-MISC O-MISC
, O-MISC O-MISC
because O-MISC O-MISC
CD4 O-MISC O-MISC
depletion O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
diminish O-MISC O-MISC
the O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
tumor O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
deletion O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
STAT6 B-MISC B-MISC
gene I-MISC I-MISC
facilitates O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
potent O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
tumor O-MISC O-MISC
immunity O-MISC O-MISC
via O-MISC O-MISC
a O-MISC O-MISC
CD4 O-MISC O-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
oncogenic B-MISC O-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
AP I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
infected O-MISC O-MISC
with O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
T O-MISC I-MISC
cell O-MISC I-MISC
leukemia O-MISC I-MISC
virus O-MISC I-MISC
type O-MISC I-MISC
1 O-MISC I-MISC
( O-MISC I-MISC
HTLV O-MISC I-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
) O-MISC I-MISC
Tax B-MISC I-MISC
protein I-MISC I-MISC
transforms O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
previously O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
Tax B-MISC B-MISC
induces O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
various O-MISC O-MISC
family O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
, O-MISC O-MISC
JunD B-MISC B-MISC
, O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Fos I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Fra B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
at O-MISC O-MISC
the O-MISC O-MISC
mRNA O-MISC B-MISC
level O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
Tax B-MISC B-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
transcription O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
( O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
transient O-MISC O-MISC
transfection O-MISC O-MISC
study O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
Tax B-MISC B-MISC
can O-MISC O-MISC
activate O-MISC O-MISC
transcription O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
in O-MISC O-MISC
a O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
any O-MISC O-MISC
combination O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
proteins I-MISC I-MISC
did O-MISC O-MISC
so O-MISC O-MISC
much O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
Tax B-MISC B-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
by O-MISC O-MISC
Tax B-MISC B-MISC
may O-MISC O-MISC
require O-MISC O-MISC
a O-MISC O-MISC
mechanism O-MISC O-MISC
other O-MISC O-MISC
than O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
. O-MISC O-MISC

Fresh O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
leukemia O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
all O-MISC O-MISC
surveyed O-MISC O-MISC
ATL O-MISC O-MISC
patients O-MISC O-MISC
displayed O-MISC O-MISC
constitutive O-MISC O-MISC
AP O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
no O-MISC O-MISC
normal O-MISC O-MISC
individuals O-MISC O-MISC
did O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
HTLV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
including O-MISC O-MISC
tax B-MISC B-MISC
, O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
significantly O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
fresh O-MISC O-MISC
leukemia O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
ATL O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
present O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
occurs O-MISC O-MISC
through O-MISC O-MISC
Tax O-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
and O-MISC O-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
mechanisms O-MISC O-MISC
in O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
may O-MISC O-MISC
play O-MISC O-MISC
some O-MISC O-MISC
roles O-MISC O-MISC
in O-MISC O-MISC
dysregulated O-MISC O-MISC
phenotypes O-MISC O-MISC
of O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

2 O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
' O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
' O-MISC O-MISC
- O-MISC O-MISC
pentachlorobiphenyl O-MISC O-MISC
induces O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Polychlorinatedbiphe O-MISC O-MISC
( O-MISC O-MISC
PCBs O-MISC O-MISC
) O-MISC O-MISC
are O-MISC O-MISC
a O-MISC O-MISC
group O-MISC O-MISC
of O-MISC O-MISC
persistent O-MISC O-MISC
and O-MISC O-MISC
widely O-MISC O-MISC
dispersed O-MISC O-MISC
environmental O-MISC O-MISC
pollutants O-MISC O-MISC
, O-MISC O-MISC
some O-MISC O-MISC
of O-MISC O-MISC
which O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
immunotoxic O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
PCBs O-MISC O-MISC
on O-MISC O-MISC
immune O-MISC O-MISC
system O-MISC O-MISC
by O-MISC O-MISC
assessing O-MISC O-MISC
apoptotic O-MISC O-MISC
cell O-MISC O-MISC
death O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytic O-MISC O-MISC
U937 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Among O-MISC O-MISC
the O-MISC O-MISC
various O-MISC O-MISC
congeners O-MISC B-MISC
tested O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
' O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
' O-MISC O-MISC
- O-MISC O-MISC
pentachlorobiphenyl O-MISC O-MISC
( O-MISC O-MISC
PeCB O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
highly O-MISC O-MISC
ortho O-MISC O-MISC
- O-MISC O-MISC
substituted O-MISC O-MISC
congener O-MISC O-MISC
, O-MISC O-MISC
specifically O-MISC O-MISC
induced O-MISC O-MISC
DNA O-MISC O-MISC
fragmentation O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
hallmark O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
examined O-MISC O-MISC
di O-MISC O-MISC
- O-MISC O-MISC
, O-MISC O-MISC
tri O-MISC O-MISC
- O-MISC O-MISC
, O-MISC O-MISC
tetra O-MISC O-MISC
- O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
pentachlorobiphenyls O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
further O-MISC O-MISC
study O-MISC O-MISC
the O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
' O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
' O-MISC O-MISC
- O-MISC O-MISC
PeCB O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
death O-MISC O-MISC
, O-MISC O-MISC
various O-MISC O-MISC
features O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
were O-MISC O-MISC
examined O-MISC O-MISC
. O-MISC O-MISC

2 O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
' O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
' O-MISC O-MISC
- O-MISC O-MISC
PeCB O-MISC O-MISC
caused O-MISC O-MISC
a O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
cell O-MISC O-MISC
viability O-MISC O-MISC
and O-MISC O-MISC
induced O-MISC O-MISC
cellular O-MISC O-MISC
morphologic O-MISC O-MISC
features O-MISC O-MISC
characteristic O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
chromatin O-MISC O-MISC
aggregation O-MISC O-MISC
and O-MISC O-MISC
apoptotic O-MISC O-MISC
bodies O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
caspase B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
an O-MISC O-MISC
executioner O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
activated O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
substrate O-MISC O-MISC
, O-MISC O-MISC
poly B-MISC B-MISC
( I-MISC I-MISC
ADP I-MISC I-MISC
- I-MISC I-MISC
ribose I-MISC I-MISC
) I-MISC I-MISC
polymerase I-MISC I-MISC
( O-MISC O-MISC
PARP B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
cleaved O-MISC O-MISC
during O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
' O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
' O-MISC O-MISC
- O-MISC O-MISC
PeCB O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
3 O-MISC O-MISC
' O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
' O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
PeCB O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
congener O-MISC O-MISC
of O-MISC O-MISC
coplanar O-MISC O-MISC
structure O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
8 O-MISC O-MISC
- O-MISC O-MISC
TCDD O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
induce O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
human O-MISC O-MISC
monocytic O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
they O-MISC O-MISC
potently O-MISC O-MISC
induced O-MISC O-MISC
CYP B-MISC B-MISC
1A1 I-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
hepatoma O-MISC O-MISC
Hep O-MISC O-MISC
G2 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Taken O-MISC O-MISC
together O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
2 O-MISC O-MISC
' O-MISC O-MISC
, O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
6 O-MISC O-MISC
' O-MISC O-MISC
- O-MISC O-MISC
PeCB O-MISC O-MISC
induces O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytic O-MISC O-MISC
cells O-MISC O-MISC
through O-MISC O-MISC
a O-MISC O-MISC
mechanism O-MISC O-MISC
that O-MISC O-MISC
is O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
arylhydrocarbon B-MISC O-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
suggests O-MISC O-MISC
a O-MISC O-MISC
possibly O-MISC O-MISC
separate O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
PCBs O-MISC O-MISC
cause O-MISC O-MISC
immunosuppression O-MISC O-MISC
. O-MISC O-MISC

Effects O-MISC O-MISC
of O-MISC O-MISC
deregulated O-MISC O-MISC
Raf O-MISC B-MISC
activation O-MISC O-MISC
on O-MISC O-MISC
integrin B-MISC B-MISC
, O-MISC O-MISC
cytokine O-MISC B-MISC
- O-MISC I-MISC
receptor O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
hematopoietic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
deregulated O-MISC O-MISC
Raf O-MISC B-MISC
activation O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
growth O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
hematopoietic O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
investigated O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cytokine O-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
murine O-MISC O-MISC
myeloid O-MISC O-MISC
FDC O-MISC I-MISC
- O-MISC I-MISC
P1 O-MISC I-MISC
and O-MISC O-MISC
human O-MISC O-MISC
erythroleukemic O-MISC O-MISC
TF O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
were O-MISC O-MISC
transformed O-MISC O-MISC
to O-MISC O-MISC
grow O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
deregulated O-MISC O-MISC
Raf O-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
exogenous B-MISC O-MISC
cytokines I-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
conditionally O-MISC O-MISC
active O-MISC O-MISC
Raf B-MISC B-MISC
proteins I-MISC I-MISC
were O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
beta O-MISC O-MISC
- O-MISC O-MISC
estradiol O-MISC O-MISC
as O-MISC O-MISC
cDNAs B-MISC B-MISC
containing O-MISC O-MISC
the O-MISC O-MISC
Raf B-MISC B-MISC
catalytic I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
lacking O-MISC O-MISC
negative B-MISC B-MISC
- I-MISC I-MISC
regulatory I-MISC I-MISC
domains I-MISC I-MISC
, O-MISC O-MISC
were O-MISC O-MISC
ligated O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
hormone B-MISC B-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
estrogen B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
deltaRaf B-MISC B-MISC
: I-MISC O-MISC
ER I-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Continuous O-MISC O-MISC
deltaRaf B-MISC B-MISC
expression O-MISC O-MISC
prevented O-MISC O-MISC
apoptosis O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
exogenous B-MISC B-MISC
cytokines I-MISC I-MISC
and O-MISC O-MISC
altered O-MISC O-MISC
the O-MISC O-MISC
morphology O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
FD O-MISC B-MISC
/ O-MISC I-MISC
deltaRaf O-MISC I-MISC
: O-MISC O-MISC
ER O-MISC O-MISC
cells O-MISC O-MISC
as O-MISC O-MISC
they O-MISC O-MISC
grew O-MISC O-MISC
in O-MISC O-MISC
large O-MISC O-MISC
aggregated O-MISC O-MISC
masses O-MISC O-MISC
( O-MISC O-MISC
> O-MISC O-MISC
100 O-MISC O-MISC
cells O-MISC O-MISC
) O-MISC O-MISC
whereas O-MISC O-MISC
the O-MISC O-MISC
parental O-MISC O-MISC
cytokine O-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
FDC O-MISC O-MISC
- O-MISC O-MISC
P1 O-MISC O-MISC
cells O-MISC O-MISC
grew O-MISC O-MISC
in O-MISC O-MISC
smaller O-MISC O-MISC
grape O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
clusters O-MISC O-MISC
( O-MISC O-MISC
< O-MISC O-MISC
10 O-MISC O-MISC
cells O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

FD O-MISC B-MISC
/ O-MISC I-MISC
deltaRaf O-MISC I-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
: O-MISC O-MISC
ER O-MISC O-MISC
cells O-MISC O-MISC
growing O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
Raf O-MISC B-MISC
activation O-MISC O-MISC
displayed O-MISC O-MISC
decreased O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Mac B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and I-MISC I-MISC
Mac I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
molecules I-MISC I-MISC
on O-MISC O-MISC
their O-MISC O-MISC
cell O-MISC O-MISC
surface O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
when O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
cultured O-MISC O-MISC
in O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
higher O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
adhesion B-MISC B-MISC
molecules I-MISC I-MISC
were O-MISC O-MISC
detected O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
activated O-MISC O-MISC
Raf B-MISC B-MISC
oncoproteins I-MISC I-MISC
also O-MISC O-MISC
abrogated O-MISC O-MISC
cytokine O-MISC B-MISC
dependency O-MISC O-MISC
and O-MISC O-MISC
prevented O-MISC O-MISC
apoptosis O-MISC O-MISC
of O-MISC O-MISC
TF O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
status O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
Raf O-MISC B-MISC
- O-MISC O-MISC
responsive O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
more O-MISC O-MISC
immature O-MISC O-MISC
upon O-MISC O-MISC
Raf O-MISC B-MISC
activation O-MISC O-MISC
as O-MISC O-MISC
culture O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
- O-MISC O-MISC
inducing O-MISC O-MISC
agent O-MISC O-MISC
phorbol O-MISC O-MISC
12 O-MISC O-MISC
myristate O-MISC O-MISC
13 O-MISC O-MISC
- O-MISC O-MISC
acetate O-MISC O-MISC
( O-MISC O-MISC
PMA O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
beta O-MISC O-MISC
- O-MISC O-MISC
estradiol O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
decreased O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CD11b B-MISC B-MISC
and I-MISC O-MISC
CD18 I-MISC B-MISC
integrin I-MISC B-MISC
molecules I-MISC I-MISC
on O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
surface O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
when O-MISC O-MISC
the O-MISC O-MISC
Raf O-MISC B-MISC
- O-MISC O-MISC
responsive O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
induced O-MISC O-MISC
to O-MISC O-MISC
differentiate O-MISC O-MISC
with O-MISC O-MISC
PMA O-MISC O-MISC
and O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
, O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
deltaRaf B-MISC B-MISC
: I-MISC O-MISC
ER I-MISC B-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
increased O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CD11b B-MISC B-MISC
and I-MISC I-MISC
CD18 I-MISC I-MISC
molecules I-MISC I-MISC
were O-MISC O-MISC
detected O-MISC O-MISC
. O-MISC O-MISC

Retinoic O-MISC O-MISC
acid O-MISC O-MISC
( O-MISC O-MISC
RA O-MISC O-MISC
) O-MISC O-MISC
inhibited O-MISC O-MISC
3H O-MISC O-MISC
- O-MISC O-MISC
thymidine O-MISC O-MISC
incorporation O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
Raf O-MISC B-MISC
activation O-MISC O-MISC
counterbalanced O-MISC O-MISC
the O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
DNA O-MISC O-MISC
synthesis O-MISC O-MISC
caused O-MISC O-MISC
by O-MISC O-MISC
RA O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
PMA O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
deregulated O-MISC O-MISC
Raf O-MISC B-MISC
expression O-MISC O-MISC
can O-MISC O-MISC
alter O-MISC O-MISC
cytokine O-MISC B-MISC
dependency O-MISC O-MISC
, O-MISC O-MISC
integrin O-MISC B-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
stage O-MISC O-MISC
of O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
Raf O-MISC B-MISC
- O-MISC O-MISC
responsive O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
will O-MISC O-MISC
be O-MISC O-MISC
useful O-MISC O-MISC
in O-MISC O-MISC
elucidating O-MISC O-MISC
the O-MISC O-MISC
roles O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
MAP O-MISC B-MISC
kinase O-MISC I-MISC
cascade O-MISC O-MISC
on O-MISC O-MISC
hematopoietic O-MISC O-MISC
cell O-MISC O-MISC
differentiation O-MISC O-MISC
and O-MISC O-MISC
malignant O-MISC O-MISC
transformation O-MISC O-MISC

Cyclic O-MISC O-MISC
AMP O-MISC O-MISC
activates O-MISC O-MISC
p38 B-MISC B-MISC
mitogen I-MISC I-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
in O-MISC O-MISC
Th2 O-MISC O-MISC
cells O-MISC O-MISC
: O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
and O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
Th2 O-MISC B-MISC
cytokine O-MISC I-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

cAMP O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
important O-MISC O-MISC
second O-MISC O-MISC
messenger O-MISC O-MISC
with O-MISC O-MISC
immunomodulatory O-MISC O-MISC
properties O-MISC O-MISC
. O-MISC O-MISC

Elevation O-MISC O-MISC
of O-MISC O-MISC
intracellular O-MISC O-MISC
cAMP O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
agents O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1alpha I-MISC I-MISC
or O-MISC O-MISC
PGs B-MISC B-MISC
, O-MISC O-MISC
inhibits O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
effector O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
intracellular O-MISC O-MISC
cAMP O-MISC O-MISC
inhibits O-MISC O-MISC
cytokine B-MISC B-MISC
production O-MISC O-MISC
in O-MISC O-MISC
Th1 O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
stimulates O-MISC O-MISC
cytokine B-MISC B-MISC
production O-MISC O-MISC
in O-MISC O-MISC
Th2 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
that O-MISC O-MISC
cAMP O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
Th2 O-MISC O-MISC
cells O-MISC O-MISC
occur O-MISC O-MISC
independently O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
A I-MISC O-MISC
pathway O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
major O-MISC O-MISC
mediator O-MISC O-MISC
of O-MISC O-MISC
cAMP O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
signaling O-MISC O-MISC
events O-MISC O-MISC
in O-MISC O-MISC
most O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
. O-MISC O-MISC

Instead O-MISC O-MISC
, O-MISC O-MISC
cAMP O-MISC O-MISC
stimulates O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
p38 B-MISC B-MISC
mitogen I-MISC I-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
in O-MISC O-MISC
Th2 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
Th2 O-MISC O-MISC
- O-MISC O-MISC
selective O-MISC O-MISC
event O-MISC O-MISC
because O-MISC O-MISC
cAMP O-MISC O-MISC
barely O-MISC O-MISC
increased O-MISC O-MISC
p38 B-MISC O-MISC
phosphorylation O-MISC O-MISC
in O-MISC O-MISC
Th1 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
Th2 O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
cAMP O-MISC O-MISC
promotes O-MISC O-MISC
the O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
play O-MISC O-MISC
distinct O-MISC O-MISC
but O-MISC O-MISC
critical O-MISC O-MISC
roles O-MISC O-MISC
in O-MISC O-MISC
asthma O-MISC O-MISC
pathogenesis O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
data O-MISC O-MISC
also O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
cAMP O-MISC O-MISC
causes O-MISC O-MISC
increased O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
GATA I-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
regulator O-MISC O-MISC
of O-MISC O-MISC
Th2 O-MISC B-MISC
cytokine O-MISC I-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
turn O-MISC O-MISC
, O-MISC O-MISC
of O-MISC O-MISC
airway O-MISC O-MISC
inflammation O-MISC O-MISC
in O-MISC O-MISC
mice O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
Th2 O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
p38 B-MISC B-MISC
mitogen I-MISC I-MISC
- I-MISC I-MISC
activated I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
activation O-MISC O-MISC
together O-MISC O-MISC
provide O-MISC O-MISC
a O-MISC O-MISC
molecular O-MISC O-MISC
basis O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
differential O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
cAMP O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
T O-MISC O-MISC
helper O-MISC O-MISC
cell O-MISC O-MISC
subsets O-MISC O-MISC
. O-MISC O-MISC

Characterization O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
signals O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
receptor I-MISC I-MISC
alpha I-MISC I-MISC
chain I-MISC I-MISC
1 I-MISC I-MISC
: O-MISC O-MISC
redundancy O-MISC O-MISC
of O-MISC O-MISC
requirement O-MISC O-MISC
of O-MISC O-MISC
tyrosine O-MISC O-MISC
residue O-MISC O-MISC
for O-MISC O-MISC
STAT3 O-MISC B-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
are O-MISC O-MISC
pleiotropic B-MISC B-MISC
cytokines I-MISC I-MISC
whose O-MISC O-MISC
biological O-MISC O-MISC
activities O-MISC O-MISC
overlap O-MISC O-MISC
with O-MISC O-MISC
each O-MISC O-MISC
other O-MISC O-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
receptor I-MISC I-MISC
alpha I-MISC I-MISC
chain I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13R I-MISC I-MISC
alpha I-MISC I-MISC
1 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
heterodimer O-MISC O-MISC
composed O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13R I-MISC I-MISC
alpha I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4R I-MISC I-MISC
alpha I-MISC I-MISC
chain I-MISC I-MISC
transduces O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
signals O-MISC O-MISC
; O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
functional O-MISC O-MISC
mapping O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
intracellular B-MISC B-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13R I-MISC I-MISC
alpha I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
not O-MISC O-MISC
fully O-MISC O-MISC
understood O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
constructed O-MISC O-MISC
wild O-MISC O-MISC
and O-MISC O-MISC
mutated O-MISC O-MISC
types O-MISC O-MISC
of O-MISC O-MISC
human B-MISC B-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
13R I-MISC I-MISC
alpha I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
analyzed O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
signals O-MISC O-MISC
using O-MISC O-MISC
an O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13R I-MISC I-MISC
alpha I-MISC I-MISC
1 I-MISC I-MISC
- O-MISC O-MISC
transfected O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13R I-MISC I-MISC
alpha I-MISC I-MISC
1 I-MISC I-MISC
evoked O-MISC O-MISC
STAT3 B-MISC B-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
stimulated O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
on O-MISC O-MISC
which O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13R I-MISC I-MISC
alpha I-MISC I-MISC
1 I-MISC I-MISC
was O-MISC O-MISC
highly O-MISC O-MISC
expressed O-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
induced O-MISC O-MISC
STAT3 B-MISC B-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Replacement O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
tyrosine O-MISC O-MISC
residues O-MISC O-MISC
completely O-MISC O-MISC
abolished O-MISC O-MISC
STAT3 B-MISC B-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
replacing O-MISC O-MISC
either O-MISC O-MISC
tyrosine O-MISC O-MISC
residue O-MISC O-MISC
alone O-MISC O-MISC
retained O-MISC O-MISC
it O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
Box1 B-MISC B-MISC
region I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
C B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
tail I-MISC I-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13R I-MISC I-MISC
alpha I-MISC I-MISC
1 I-MISC I-MISC
were O-MISC O-MISC
critical O-MISC O-MISC
for O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
Tyk2 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Jak1 B-MISC B-MISC
, O-MISC O-MISC
Tyk2 B-MISC B-MISC
, O-MISC O-MISC
the O-MISC O-MISC
insulin B-MISC B-MISC
receptor I-MISC I-MISC
substrate I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
STAT6 B-MISC B-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
STAT3 B-MISC B-MISC
activation O-MISC O-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
with O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13 I-MISC I-MISC
signals O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
along O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
STAT6 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
there O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
unique O-MISC O-MISC
sequence O-MISC O-MISC
in O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
13R I-MISC I-MISC
alpha I-MISC I-MISC
1 I-MISC I-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
STAT3 B-MISC B-MISC
. O-MISC O-MISC

Functional O-MISC O-MISC
uncoupling O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Janus O-MISC B-MISC
kinase O-MISC I-MISC
3 O-MISC I-MISC
- O-MISC I-MISC
Stat5 O-MISC I-MISC
pathway O-MISC O-MISC
in O-MISC O-MISC
malignant O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
) O-MISC O-MISC
transforms O-MISC O-MISC
cytokine B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
causes O-MISC O-MISC
adult O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Janus B-MISC B-MISC
tyrosine I-MISC I-MISC
kinase I-MISC I-MISC
( I-MISC I-MISC
Jak I-MISC I-MISC
) I-MISC I-MISC
3 I-MISC I-MISC
and O-MISC I-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
Stat5a B-MISC B-MISC
and O-MISC O-MISC
Stat5b B-MISC B-MISC
are O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
are O-MISC O-MISC
constitutively O-MISC O-MISC
hyperactivated O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
and O-MISC O-MISC
lymphocytes O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
patients O-MISC O-MISC
; O-MISC O-MISC
therefore O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
critical O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
Jak3 O-MISC B-MISC
- O-MISC I-MISC
Stat5 O-MISC I-MISC
pathway O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
progression O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
disease O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
postulated O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
recently O-MISC O-MISC
reported O-MISC O-MISC
that O-MISC O-MISC
tyrphostin O-MISC O-MISC
AG O-MISC O-MISC
- O-MISC O-MISC
490 O-MISC O-MISC
selectively O-MISC O-MISC
blocked O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Jak3 B-MISC B-MISC
/ I-MISC I-MISC
Stat5 I-MISC I-MISC
and O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
murine O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
disruption O-MISC O-MISC
of O-MISC O-MISC
Jak3 O-MISC B-MISC
/ O-MISC I-MISC
Stat5a O-MISC I-MISC
/ O-MISC I-MISC
b O-MISC O-MISC
signaling O-MISC O-MISC
with O-MISC O-MISC
AG O-MISC O-MISC
- O-MISC O-MISC
490 O-MISC O-MISC
( O-MISC O-MISC
50 O-MISC O-MISC
& O-MISC O-MISC
mgr O-MISC O-MISC
; O-MISC O-MISC
M O-MISC O-MISC
) O-MISC O-MISC
blocked O-MISC O-MISC
the O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
paradoxically O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
inhibit O-MISC O-MISC
the O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
HuT O-MISC O-MISC
- O-MISC O-MISC
102 O-MISC O-MISC
and O-MISC O-MISC
MT O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC

Structural O-MISC O-MISC
homologues O-MISC O-MISC
of O-MISC O-MISC
AG O-MISC O-MISC
- O-MISC O-MISC
490 O-MISC O-MISC
also O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Disruption O-MISC O-MISC
of O-MISC O-MISC
constitutive O-MISC O-MISC
Jak3 O-MISC B-MISC
/ O-MISC I-MISC
Stat5 O-MISC I-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
AG O-MISC O-MISC
- O-MISC O-MISC
490 O-MISC O-MISC
was O-MISC O-MISC
demonstrated O-MISC O-MISC
by O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
Jak3 B-MISC B-MISC
, O-MISC O-MISC
Stat5a B-MISC B-MISC
( O-MISC O-MISC
Tyr O-MISC O-MISC
( O-MISC O-MISC
694 O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Stat5b B-MISC B-MISC
( O-MISC O-MISC
Tyr O-MISC O-MISC
( O-MISC O-MISC
699 O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
; O-MISC O-MISC
2 O-MISC O-MISC
) O-MISC O-MISC
serine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
Stat5a B-MISC B-MISC
( O-MISC O-MISC
Ser O-MISC O-MISC
( O-MISC O-MISC
726 O-MISC O-MISC
) O-MISC O-MISC
) O-MISC O-MISC
as O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
phosphospecific B-MISC O-MISC
Ab I-MISC O-MISC
; O-MISC O-MISC
and O-MISC O-MISC
3 O-MISC O-MISC
) O-MISC O-MISC
Stat5a O-MISC B-MISC
/ O-MISC I-MISC
b O-MISC I-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
Stat5 B-MISC B-MISC
- I-MISC I-MISC
responsive I-MISC I-MISC
beta I-MISC I-MISC
- I-MISC I-MISC
casein I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
AG O-MISC O-MISC
- O-MISC O-MISC
490 O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
by O-MISC O-MISC
p50 B-MISC B-MISC
/ I-MISC I-MISC
p65 I-MISC I-MISC
components I-MISC I-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
HTLV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- I-MISC I-MISC
encoded I-MISC I-MISC
phosphoprotein I-MISC I-MISC
, I-MISC O-MISC
Tax I-MISC B-MISC
. O-MISC O-MISC

Collectively O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
Jak3 O-MISC B-MISC
- O-MISC I-MISC
Stat5 O-MISC I-MISC
pathway O-MISC O-MISC
in O-MISC O-MISC
HTLV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
transformed O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
has O-MISC O-MISC
become O-MISC O-MISC
functionally O-MISC O-MISC
redundant O-MISC O-MISC
for O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Reversal O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
functional O-MISC O-MISC
uncoupling O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
required O-MISC O-MISC
before O-MISC O-MISC
Jak3 O-MISC B-MISC
/ O-MISC I-MISC
Stat5 O-MISC I-MISC
inhibitors O-MISC O-MISC
will O-MISC O-MISC
be O-MISC O-MISC
useful O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
malignancy O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Epstein B-MISC B-MISC
- I-MISC I-MISC
Barr I-MISC I-MISC
virus I-MISC I-MISC
promoter I-MISC I-MISC
initiating O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
transformation O-MISC O-MISC
is O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
RFX B-MISC B-MISC
proteins I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
B B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
activator I-MISC I-MISC
protein I-MISC I-MISC
BSAP I-MISC I-MISC
/ I-MISC I-MISC
Pax5 I-MISC I-MISC
. O-MISC O-MISC

Epstein O-MISC O-MISC
- O-MISC O-MISC
Barr O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
EBV O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
transformation O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
central O-MISC O-MISC
feature O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
virus O-MISC O-MISC
' O-MISC O-MISC
strategy O-MISC O-MISC
for O-MISC O-MISC
colonizing O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
system O-MISC O-MISC
, O-MISC O-MISC
requires O-MISC O-MISC
full O-MISC O-MISC
virus O-MISC O-MISC
latent O-MISC O-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
initiated O-MISC O-MISC
by O-MISC O-MISC
transcription O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
viral B-MISC B-MISC
promoter I-MISC I-MISC
Wp I-MISC I-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
when O-MISC O-MISC
EBV O-MISC O-MISC
accesses O-MISC O-MISC
other O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
, O-MISC O-MISC
this O-MISC O-MISC
growth O-MISC O-MISC
- O-MISC O-MISC
transforming O-MISC O-MISC
program O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
activated O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
present O-MISC O-MISC
work O-MISC O-MISC
focuses O-MISC O-MISC
on O-MISC O-MISC
a O-MISC O-MISC
region O-MISC O-MISC
of O-MISC O-MISC
Wp B-MISC B-MISC
which O-MISC O-MISC
in O-MISC O-MISC
reporter O-MISC O-MISC
assays O-MISC O-MISC
confers O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Bandshift O-MISC O-MISC
studies O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
region O-MISC O-MISC
contains O-MISC O-MISC
three O-MISC O-MISC
factor O-MISC B-MISC
binding O-MISC I-MISC
sites O-MISC I-MISC
, O-MISC O-MISC
termed O-MISC O-MISC
sites B-MISC O-MISC
B I-MISC B-MISC
, I-MISC O-MISC
C I-MISC B-MISC
, I-MISC O-MISC
and I-MISC O-MISC
D I-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
addition O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
previously O-MISC O-MISC
characterized O-MISC O-MISC
CREB B-MISC B-MISC
site I-MISC I-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
site B-MISC O-MISC
C I-MISC I-MISC
binds O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
ubiquitously O-MISC B-MISC
expressed O-MISC O-MISC
RFX B-MISC B-MISC
family I-MISC I-MISC
of I-MISC O-MISC
proteins I-MISC O-MISC
, O-MISC O-MISC
notably O-MISC O-MISC
RFX1 B-MISC B-MISC
, O-MISC O-MISC
RFX3 B-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
associated O-MISC O-MISC
factor O-MISC I-MISC
MIBP1 B-MISC B-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
sites B-MISC O-MISC
B I-MISC O-MISC
and I-MISC O-MISC
D I-MISC O-MISC
both O-MISC O-MISC
bind O-MISC O-MISC
the O-MISC O-MISC
B B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
activator I-MISC I-MISC
protein I-MISC I-MISC
BSAP I-MISC B-MISC
/ I-MISC I-MISC
Pax5 I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
reporter O-MISC O-MISC
assays O-MISC O-MISC
with O-MISC O-MISC
mutant B-MISC B-MISC
Wp I-MISC I-MISC
constructs I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
factor O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
any O-MISC O-MISC
one O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
sites O-MISC O-MISC
severely O-MISC O-MISC
impaired O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
wild B-MISC B-MISC
- I-MISC I-MISC
type I-MISC I-MISC
promoter I-MISC I-MISC
could O-MISC O-MISC
be O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
ectopic O-MISC O-MISC
BSAP O-MISC B-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
Wp B-MISC B-MISC
regulation O-MISC O-MISC
by O-MISC O-MISC
BSAP B-MISC B-MISC
helps O-MISC O-MISC
to O-MISC O-MISC
ensure O-MISC O-MISC
the O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
specificity O-MISC O-MISC
of O-MISC O-MISC
EBV O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
growth O-MISC O-MISC
- O-MISC O-MISC
transforming O-MISC O-MISC
function O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Lck B-MISC B-MISC
tyrosine I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
by O-MISC O-MISC
the O-MISC O-MISC
Herpesvirus O-MISC O-MISC
saimiri O-MISC O-MISC
tip B-MISC O-MISC
protein I-MISC O-MISC
involves O-MISC O-MISC
two O-MISC O-MISC
binding O-MISC O-MISC
interactions O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Tip B-MISC O-MISC
protein I-MISC O-MISC
of O-MISC O-MISC
Herpesvirus O-MISC O-MISC
saimiri O-MISC O-MISC
strain O-MISC O-MISC
484C O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
and O-MISC O-MISC
activates O-MISC O-MISC
the O-MISC O-MISC
Lck B-MISC B-MISC
tyrosine I-MISC I-MISC
protein I-MISC I-MISC
kinase I-MISC I-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
sequences O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
Tip B-MISC B-MISC
protein I-MISC I-MISC
were O-MISC O-MISC
previously O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
Lck B-MISC B-MISC
. O-MISC O-MISC

A O-MISC O-MISC
proline B-MISC B-MISC
- I-MISC I-MISC
rich I-MISC I-MISC
region I-MISC I-MISC
, O-MISC O-MISC
residues O-MISC O-MISC
132 O-MISC I-MISC
- O-MISC I-MISC
141 O-MISC I-MISC
, O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
SH3 B-MISC B-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Lck B-MISC B-MISC
protein I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
Lck B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
, O-MISC O-MISC
residues O-MISC O-MISC
104 O-MISC O-MISC
- O-MISC O-MISC
113 O-MISC I-MISC
, O-MISC O-MISC
binds O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
carboxyl B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
half I-MISC I-MISC
of O-MISC O-MISC
Lck B-MISC B-MISC
and O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
binding O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
require O-MISC O-MISC
the O-MISC O-MISC
Lck B-MISC B-MISC
SH3 I-MISC I-MISC
domain I-MISC I-MISC
. O-MISC O-MISC

Mutated O-MISC O-MISC
Tip B-MISC O-MISC
containing O-MISC O-MISC
only O-MISC O-MISC
one O-MISC O-MISC
functional O-MISC O-MISC
Lck B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
can O-MISC O-MISC
bind O-MISC O-MISC
stably O-MISC O-MISC
to O-MISC O-MISC
Lck B-MISC B-MISC
, O-MISC O-MISC
although O-MISC O-MISC
not O-MISC O-MISC
as O-MISC O-MISC
strongly O-MISC O-MISC
as O-MISC O-MISC
wild B-MISC O-MISC
- I-MISC O-MISC
type I-MISC O-MISC
Tip I-MISC O-MISC
. O-MISC O-MISC

Interaction O-MISC O-MISC
of O-MISC O-MISC
Tip B-MISC O-MISC
with O-MISC O-MISC
Lck B-MISC B-MISC
through O-MISC O-MISC
either O-MISC O-MISC
Lck B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
increases O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
Lck B-MISC B-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

Simultaneous O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
domains O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
maximal O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
Lck B-MISC B-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transient O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Tip B-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
stimulate O-MISC O-MISC
both O-MISC O-MISC
Stat3 B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
AT I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

Mutant O-MISC O-MISC
forms O-MISC O-MISC
of O-MISC O-MISC
Tip B-MISC B-MISC
lacking O-MISC O-MISC
one O-MISC O-MISC
or O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
two O-MISC B-MISC
Lck B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domains I-MISC I-MISC
retained O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
stimulate O-MISC O-MISC
Stat3 B-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

Tip B-MISC O-MISC
lacking O-MISC O-MISC
the O-MISC O-MISC
proline O-MISC B-MISC
- O-MISC I-MISC
rich O-MISC I-MISC
Lck B-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
exhibited O-MISC O-MISC
almost O-MISC O-MISC
wild O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
ablation O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
Lck B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
abolished O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
Tip B-MISC O-MISC
to O-MISC O-MISC
stimulate O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
AT I-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

Full O-MISC O-MISC
biological O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
Tip B-MISC O-MISC
, O-MISC O-MISC
therefore O-MISC O-MISC
, O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
require O-MISC O-MISC
both O-MISC O-MISC
Lck B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
domains I-MISC I-MISC
. O-MISC O-MISC

Accumulation O-MISC O-MISC
of O-MISC O-MISC
RXR B-MISC B-MISC
alpha I-MISC I-MISC
during O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
cycling O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
: O-MISC O-MISC
modulation O-MISC O-MISC
of O-MISC O-MISC
RXRE O-MISC B-MISC
transactivation O-MISC O-MISC
function O-MISC O-MISC
by O-MISC O-MISC
mitogen O-MISC B-MISC
- O-MISC I-MISC
activated O-MISC O-MISC
protein O-MISC B-MISC
kinase O-MISC I-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
previously O-MISC O-MISC
reported O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
resting O-MISC O-MISC
human O-MISC O-MISC
immature O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
( O-MISC O-MISC
PBT O-MISC O-MISC
) O-MISC O-MISC
lymphocytes O-MISC O-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
retinoid B-MISC B-MISC
X I-MISC I-MISC
receptor I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
RXRalpha B-MISC B-MISC
) O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
, O-MISC O-MISC
unlike O-MISC O-MISC
resting O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
cycling O-MISC O-MISC
human O-MISC O-MISC
mature O-MISC O-MISC
PBT O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
lymphocyte O-MISC O-MISC
leukemia O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
is O-MISC O-MISC
accompanied O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
accumulation O-MISC O-MISC
of O-MISC O-MISC
RXRalpha B-MISC B-MISC
mRNA O-MISC I-MISC
and O-MISC O-MISC
protein O-MISC B-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
cyclosporin O-MISC O-MISC
A O-MISC O-MISC
further O-MISC O-MISC
augmented O-MISC O-MISC
RXRalpha B-MISC B-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
the O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
calcineurin O-MISC B-MISC
pathways O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

9 O-MISC O-MISC
- O-MISC O-MISC
cis O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
accumulation O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
retinoids O-MISC O-MISC
can O-MISC O-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
synthesis O-MISC O-MISC
of O-MISC O-MISC
their O-MISC O-MISC
own O-MISC O-MISC
receptors O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Transfection O-MISC O-MISC
analysis O-MISC O-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
using O-MISC O-MISC
RXRE O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
reporter O-MISC O-MISC
assays O-MISC O-MISC
, O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
RXRalpha B-MISC B-MISC
accumulated O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
was O-MISC O-MISC
transcriptionally O-MISC O-MISC
inactive O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
investigate O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
such O-MISC O-MISC
inhibition O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
two O-MISC O-MISC
mitogen O-MISC B-MISC
- O-MISC I-MISC
activated O-MISC I-MISC
protein O-MISC I-MISC
kinase O-MISC I-MISC
pathways O-MISC O-MISC
, O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Jun I-MISC I-MISC
N I-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
JNK B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
extracellular B-MISC B-MISC
signal I-MISC I-MISC
- I-MISC I-MISC
regulated I-MISC I-MISC
kinase I-MISC I-MISC
( O-MISC O-MISC
ERK B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
modulating O-MISC O-MISC
RXRE O-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
explored O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
constitutively O-MISC O-MISC
active O-MISC O-MISC
MAP B-MISC B-MISC
/ I-MISC I-MISC
ERK I-MISC I-MISC
kinase I-MISC I-MISC
kinase I-MISC I-MISC
1 I-MISC I-MISC
( O-MISC O-MISC
MEKK1 B-MISC B-MISC
) O-MISC O-MISC
inhibited O-MISC O-MISC
RXRE O-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
dominant B-MISC O-MISC
negative I-MISC O-MISC
MEKK1 I-MISC B-MISC
increased O-MISC O-MISC
the O-MISC O-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
the O-MISC O-MISC
involvement O-MISC O-MISC
of O-MISC O-MISC
JNK B-MISC B-MISC
signaling O-MISC O-MISC
pathways O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
process O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
constitutively B-MISC O-MISC
active I-MISC O-MISC
MEK1 I-MISC B-MISC
, O-MISC O-MISC
which O-MISC O-MISC
activates O-MISC O-MISC
ERK B-MISC B-MISC
pathway O-MISC O-MISC
, O-MISC O-MISC
enhanced O-MISC O-MISC
RXRE O-MISC B-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

When O-MISC O-MISC
both O-MISC O-MISC
were O-MISC O-MISC
activated O-MISC O-MISC
simultaneously O-MISC O-MISC
, O-MISC O-MISC
JNK B-MISC B-MISC
pathway O-MISC O-MISC
was O-MISC O-MISC
dominant O-MISC O-MISC
over O-MISC O-MISC
ERK B-MISC B-MISC
pathway O-MISC O-MISC
and O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
RXRE O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
demonstrate O-MISC O-MISC
a O-MISC O-MISC
dual O-MISC O-MISC
regulatory O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
RXRalpha B-MISC B-MISC
expression O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
resting O-MISC O-MISC
and O-MISC O-MISC
cycling O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
indicate O-MISC O-MISC
a O-MISC O-MISC
dynamic O-MISC O-MISC
balance O-MISC O-MISC
between O-MISC O-MISC
JNK O-MISC B-MISC
and O-MISC O-MISC
ERK O-MISC B-MISC
pathways O-MISC O-MISC
in O-MISC O-MISC
modulating O-MISC O-MISC
RXRE O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
transactivation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
proteasome B-MISC B-MISC
regulates O-MISC O-MISC
receptor O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
endocytosis O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

Recent O-MISC O-MISC
studies O-MISC O-MISC
have O-MISC O-MISC
increasingly O-MISC O-MISC
implicated O-MISC O-MISC
the O-MISC O-MISC
proteasome B-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
cell B-MISC B-MISC
surface I-MISC I-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proteasome B-MISC B-MISC
for O-MISC O-MISC
ligand O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
endocytosis O-MISC O-MISC
and O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
interleukin I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
) I-MISC I-MISC
complex I-MISC I-MISC
. O-MISC O-MISC

Proteasome O-MISC O-MISC
inhibitors O-MISC O-MISC
impaired O-MISC O-MISC
internalization O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. I-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
and O-MISC O-MISC
prevented O-MISC O-MISC
the O-MISC O-MISC
lysosomal O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
cytokine B-MISC B-MISC
. O-MISC O-MISC

Based O-MISC O-MISC
on O-MISC O-MISC
time O-MISC O-MISC
- O-MISC O-MISC
course O-MISC O-MISC
studies O-MISC O-MISC
, O-MISC O-MISC
proteasome B-MISC B-MISC
activity O-MISC O-MISC
is O-MISC O-MISC
primarily O-MISC O-MISC
required O-MISC O-MISC
after O-MISC O-MISC
initial O-MISC O-MISC
endocytosis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
. I-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
. O-MISC O-MISC

Proteasome O-MISC O-MISC
function O-MISC O-MISC
was O-MISC O-MISC
also O-MISC O-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
lysosomal O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
internalized O-MISC O-MISC
by O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
that O-MISC O-MISC
were O-MISC O-MISC
comprised O-MISC O-MISC
of O-MISC O-MISC
cytoplasmic B-MISC B-MISC
tailless I-MISC I-MISC
beta B-MISC I-MISC
- I-MISC I-MISC
or I-MISC I-MISC
gamma I-MISC I-MISC
c I-MISC I-MISC
- I-MISC I-MISC
subunits I-MISC I-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
target O-MISC O-MISC
protein O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
proteasome B-MISC B-MISC
is O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
the O-MISC O-MISC
cytoplasmic B-MISC B-MISC
tail I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
beta B-MISC I-MISC
- I-MISC I-MISC
or I-MISC I-MISC
gamma I-MISC I-MISC
c I-MISC I-MISC
- I-MISC I-MISC
subunits I-MISC I-MISC
and O-MISC O-MISC
their O-MISC O-MISC
associated O-MISC O-MISC
signaling O-MISC O-MISC
components O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
functional O-MISC O-MISC
proteasome B-MISC B-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
optimal O-MISC O-MISC
endocytosis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
/ I-MISC I-MISC
ligand I-MISC I-MISC
complex I-MISC I-MISC
and O-MISC O-MISC
is O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
subsequent O-MISC O-MISC
lysosomal O-MISC O-MISC
degradation O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
possibly O-MISC O-MISC
by O-MISC O-MISC
regulating O-MISC O-MISC
trafficking O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
lysosome O-MISC O-MISC
. O-MISC O-MISC

Functional O-MISC O-MISC
characterization O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
alternative O-MISC O-MISC
promoters O-MISC I-MISC
of O-MISC O-MISC
human B-MISC B-MISC
p45 I-MISC I-MISC
NF I-MISC I-MISC
- I-MISC I-MISC
E2 I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
The O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF I-MISC I-MISC
- I-MISC I-MISC
E2 I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
heterodimeric B-MISC B-MISC
protein I-MISC I-MISC
complex I-MISC I-MISC
composed O-MISC O-MISC
of O-MISC O-MISC
p45 B-MISC B-MISC
and O-MISC I-MISC
small O-MISC I-MISC
Maf B-MISC I-MISC
family I-MISC I-MISC
proteins I-MISC I-MISC
, O-MISC O-MISC
is O-MISC O-MISC
considered O-MISC O-MISC
crucial O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
proper O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
erythrocytes O-MISC O-MISC
and O-MISC O-MISC
megakaryocytes O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
of O-MISC O-MISC
studies O-MISC O-MISC
aimed O-MISC O-MISC
at O-MISC O-MISC
understanding O-MISC O-MISC
the O-MISC O-MISC
regulatory O-MISC O-MISC
mechanisms O-MISC O-MISC
controlling O-MISC O-MISC
p45 B-MISC B-MISC
gene I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
erythroid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

MATERIALS O-MISC O-MISC
AND O-MISC O-MISC
METHODS O-MISC O-MISC
: O-MISC O-MISC
Human B-MISC B-MISC
p45 I-MISC I-MISC
mRNAs I-MISC I-MISC
have O-MISC O-MISC
two O-MISC O-MISC
alternative O-MISC O-MISC
isoforms O-MISC O-MISC
, O-MISC O-MISC
aNF B-MISC O-MISC
- I-MISC I-MISC
E2 I-MISC I-MISC
and O-MISC O-MISC
fNF B-MISC B-MISC
- I-MISC I-MISC
E2 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
these O-MISC O-MISC
isoforms O-MISC O-MISC
are O-MISC O-MISC
transcribed O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
alternative B-MISC O-MISC
promoters I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
investigated O-MISC O-MISC
lineage O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
isomers O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
erythroid O-MISC O-MISC
and O-MISC O-MISC
megakaryocytic O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
reverse O-MISC B-MISC
transcriptase O-MISC I-MISC
polymerase O-MISC I-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
or O-MISC O-MISC
Northern O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

For O-MISC O-MISC
functional O-MISC O-MISC
characterization O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
promoters O-MISC O-MISC
, O-MISC O-MISC
plasmids O-MISC B-MISC
in O-MISC O-MISC
which O-MISC O-MISC
reporter B-MISC B-MISC
genes I-MISC I-MISC
were O-MISC O-MISC
placed O-MISC O-MISC
under O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
series O-MISC O-MISC
of O-MISC O-MISC
truncated O-MISC O-MISC
or O-MISC O-MISC
mutated O-MISC B-MISC
promoter B-MISC I-MISC
fragments I-MISC I-MISC
were O-MISC O-MISC
transfected O-MISC O-MISC
to O-MISC O-MISC
human O-MISC O-MISC
hematopoietic O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
When O-MISC O-MISC
CD34 O-MISC B-MISC
( O-MISC O-MISC
+ O-MISC O-MISC
) O-MISC O-MISC
cells O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
human O-MISC O-MISC
cord O-MISC O-MISC
blood O-MISC O-MISC
were O-MISC O-MISC
induced O-MISC O-MISC
to O-MISC O-MISC
unilineage O-MISC O-MISC
erythroid O-MISC O-MISC
or O-MISC O-MISC
megakaryocytic O-MISC O-MISC
differentiation O-MISC O-MISC
in O-MISC O-MISC
liquid O-MISC O-MISC
suspension O-MISC O-MISC
culture O-MISC O-MISC
, O-MISC O-MISC
both O-MISC O-MISC
transcripts O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
barely O-MISC O-MISC
detected O-MISC O-MISC
at O-MISC O-MISC
day O-MISC O-MISC
0 O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
induced O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
erythroid O-MISC O-MISC
and O-MISC O-MISC
megakaryocytic O-MISC O-MISC
cultures O-MISC O-MISC
. O-MISC O-MISC

fNF B-MISC B-MISC
- I-MISC I-MISC
E2 I-MISC I-MISC
mRNA I-MISC I-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
more O-MISC O-MISC
abundant O-MISC O-MISC
in O-MISC O-MISC
erythroid O-MISC O-MISC
cells O-MISC O-MISC
than O-MISC O-MISC
megakaryocytic O-MISC O-MISC
cells O-MISC O-MISC
at O-MISC O-MISC
day O-MISC O-MISC
7 O-MISC O-MISC
of O-MISC O-MISC
culture O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
both O-MISC O-MISC
isomers O-MISC O-MISC
were O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
erythroid O-MISC O-MISC
- O-MISC O-MISC
megakaryocytic O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
megakaryocytic O-MISC O-MISC
maturation O-MISC O-MISC
with O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
erythroid O-MISC O-MISC
phenotype O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
phorbol O-MISC O-MISC
12 O-MISC O-MISC
- O-MISC O-MISC
myristate O-MISC O-MISC
13 O-MISC O-MISC
- O-MISC O-MISC
acetate O-MISC O-MISC
( O-MISC O-MISC
PMA O-MISC O-MISC
) O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
exclusive O-MISC O-MISC
downregulation O-MISC O-MISC
of O-MISC O-MISC
fNF B-MISC B-MISC
- I-MISC I-MISC
E2 I-MISC I-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
fNF B-MISC B-MISC
- I-MISC I-MISC
E2 I-MISC I-MISC
promoter I-MISC I-MISC
is O-MISC O-MISC
more O-MISC O-MISC
erythroid O-MISC O-MISC
specific O-MISC O-MISC
. O-MISC O-MISC

Functional O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
fNF B-MISC B-MISC
- I-MISC I-MISC
E2 I-MISC I-MISC
promoter I-MISC I-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
promoter O-MISC B-MISC
is O-MISC O-MISC
active O-MISC O-MISC
only O-MISC O-MISC
in O-MISC O-MISC
erythroid O-MISC O-MISC
- O-MISC O-MISC
megakaryocytic O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
double B-MISC O-MISC
GATA I-MISC B-MISC
sit I-MISC O-MISC
e O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
proximal O-MISC O-MISC
region O-MISC O-MISC
is O-MISC O-MISC
necessary O-MISC O-MISC
for O-MISC O-MISC
its O-MISC O-MISC
efficient O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
GATA B-MISC B-MISC
proteins I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
govern O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
erythroid O-MISC O-MISC
lineage O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
are O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
full O-MISC O-MISC
promoter O-MISC B-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
p45 B-MISC B-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

Transcriptional O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
heme B-MISC B-MISC
oxygenase I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
its O-MISC O-MISC
functional O-MISC O-MISC
significance O-MISC O-MISC
in O-MISC O-MISC
acetaminophen O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
hepatitis O-MISC O-MISC
and O-MISC O-MISC
hepatocellular O-MISC O-MISC
injury O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
rat O-MISC O-MISC
. O-MISC O-MISC

BACKGROUND O-MISC O-MISC
/ O-MISC O-MISC
AIM O-MISC O-MISC
: O-MISC O-MISC
Glutathione O-MISC O-MISC
depletion O-MISC O-MISC
contributes O-MISC O-MISC
to O-MISC O-MISC
acetaminophen O-MISC O-MISC
hepatotoxicity O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
the O-MISC O-MISC
oxidative O-MISC O-MISC
stress O-MISC O-MISC
reactant O-MISC O-MISC
heme B-MISC O-MISC
oxygenase I-MISC O-MISC
- I-MISC O-MISC
1 I-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
metabolites O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
heme O-MISC B-MISC
oxygenase O-MISC I-MISC
pathway O-MISC O-MISC
, O-MISC O-MISC
biliverdin O-MISC O-MISC
, O-MISC O-MISC
carbon O-MISC O-MISC
monoxide O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
iron O-MISC O-MISC
may O-MISC O-MISC
modulate O-MISC O-MISC
acetaminophen O-MISC O-MISC
toxicity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
aim O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
study O-MISC O-MISC
was O-MISC O-MISC
to O-MISC O-MISC
assess O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
heme B-MISC B-MISC
oxygenase I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
its O-MISC O-MISC
impact O-MISC O-MISC
on O-MISC O-MISC
liver O-MISC O-MISC
injury O-MISC O-MISC
and O-MISC O-MISC
microcirculatory O-MISC O-MISC
disturbances O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
acetaminophen O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
hepatitis O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
: O-MISC O-MISC
Gene O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
heme B-MISC B-MISC
oxygenase I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
was O-MISC O-MISC
studied O-MISC O-MISC
by O-MISC O-MISC
Northern O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
Western O-MISC O-MISC
analysis O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
immunohistochemistry O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
time O-MISC O-MISC
course O-MISC O-MISC
of O-MISC O-MISC
heme B-MISC B-MISC
oxygenase I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC O-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
cytokine B-MISC B-MISC
- I-MISC O-MISC
induced I-MISC O-MISC
neutrophil I-MISC O-MISC
chemoattractant I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
was O-MISC O-MISC
studied O-MISC O-MISC
by O-MISC O-MISC
Northern O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

DNA O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
was O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
. O-MISC O-MISC

Sinusoidal O-MISC O-MISC
perfusion O-MISC O-MISC
and O-MISC O-MISC
leukocyte O-MISC O-MISC
- O-MISC O-MISC
endothelial O-MISC O-MISC
interactions O-MISC O-MISC
were O-MISC O-MISC
assessed O-MISC O-MISC
by O-MISC O-MISC
intravital O-MISC O-MISC
microscopy O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
Acetaminophen O-MISC O-MISC
caused O-MISC O-MISC
a O-MISC O-MISC
moderate O-MISC O-MISC
sinusoidal O-MISC O-MISC
perfusion O-MISC O-MISC
failure O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
15 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
infiltration O-MISC O-MISC
of O-MISC O-MISC
neutrophils O-MISC O-MISC
along O-MISC O-MISC
with O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC O-MISC
and O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
cytokine B-MISC B-MISC
- I-MISC O-MISC
induced I-MISC O-MISC
neutrophil I-MISC O-MISC
chemoattractant I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNAs O-MISC I-MISC
. O-MISC O-MISC

Induction O-MISC O-MISC
of O-MISC O-MISC
heme B-MISC B-MISC
oxygenase I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA O-MISC I-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
( O-MISC O-MISC
approximately O-MISC O-MISC
30 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
hepatocytes O-MISC O-MISC
and O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
parenchymal O-MISC O-MISC
cells O-MISC O-MISC
paralleled O-MISC O-MISC
the O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

Blockade O-MISC O-MISC
of O-MISC O-MISC
heme O-MISC B-MISC
oxygenase O-MISC I-MISC
activity O-MISC O-MISC
with O-MISC O-MISC
tin O-MISC O-MISC
- O-MISC I-MISC
protoporphyrin O-MISC I-MISC
- O-MISC O-MISC
IX O-MISC O-MISC
abrogated O-MISC O-MISC
acetaminophen O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
hepatic O-MISC O-MISC
neutrophil O-MISC I-MISC
accumulation O-MISC O-MISC
and O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC B-MISC
activation O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
affect O-MISC O-MISC
sinusoidal O-MISC O-MISC
perfusion O-MISC O-MISC
and O-MISC O-MISC
liver O-MISC O-MISC
injury O-MISC O-MISC
. O-MISC O-MISC

CONCLUSIONS O-MISC O-MISC
: O-MISC O-MISC
The O-MISC O-MISC
inflammatory O-MISC O-MISC
response O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
acetaminophen O-MISC O-MISC
hepatotoxicity O-MISC O-MISC
is O-MISC O-MISC
modulated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
parallel O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
heme B-MISC B-MISC
oxygenase I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
heme B-MISC B-MISC
oxygenase I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
has O-MISC O-MISC
no O-MISC O-MISC
permissive O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
sinusoidal O-MISC O-MISC
perfusion O-MISC O-MISC
and O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
liver O-MISC O-MISC
injury O-MISC O-MISC
in O-MISC O-MISC
this O-MISC O-MISC
model O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
argue O-MISC O-MISC
against O-MISC O-MISC
a O-MISC O-MISC
central O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
neutrophil O-MISC O-MISC
infiltration O-MISC O-MISC
as O-MISC O-MISC
perpetuating O-MISC B-MISC
factors O-MISC I-MISC
of O-MISC O-MISC
liver O-MISC O-MISC
injury O-MISC O-MISC
in O-MISC O-MISC
acetaminophen O-MISC O-MISC
toxicity O-MISC O-MISC
. O-MISC O-MISC

Tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
proliferation O-MISC O-MISC
requires O-MISC O-MISC
synthesis O-MISC O-MISC
of O-MISC O-MISC
granulocyte B-MISC B-MISC
- I-MISC I-MISC
macrophage I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
: O-MISC O-MISC
Tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
induces O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
cellular O-MISC O-MISC
responses O-MISC O-MISC
, O-MISC O-MISC
some O-MISC O-MISC
of O-MISC O-MISC
them O-MISC O-MISC
being O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
seemingly O-MISC O-MISC
contradictory O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
set O-MISC O-MISC
out O-MISC O-MISC
to O-MISC O-MISC
find O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
modes O-MISC O-MISC
of O-MISC O-MISC
proliferative O-MISC O-MISC
and O-MISC O-MISC
apoptotic O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

MATERIALS O-MISC O-MISC
AND O-MISC O-MISC
METHODS O-MISC O-MISC
: O-MISC O-MISC
We O-MISC O-MISC
screened O-MISC O-MISC
a O-MISC O-MISC
panel O-MISC O-MISC
of O-MISC O-MISC
acute O-MISC O-MISC
myeloid O-MISC O-MISC
leukemia O-MISC O-MISC
- O-MISC O-MISC
derived O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
for O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
responsiveness O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
two O-MISC O-MISC
lines O-MISC O-MISC
( O-MISC O-MISC
OCI O-MISC O-MISC
- O-MISC O-MISC
AML O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
OCI O-MISC O-MISC
- O-MISC O-MISC
AML O-MISC I-MISC
- O-MISC I-MISC
11 O-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
acted O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
apoptotic O-MISC O-MISC
agent O-MISC O-MISC
; O-MISC O-MISC
in O-MISC O-MISC
others O-MISC O-MISC
( O-MISC O-MISC
HU O-MISC O-MISC
- O-MISC B-MISC
3 O-MISC I-MISC
, O-MISC O-MISC
M O-MISC B-MISC
- O-MISC I-MISC
07e O-MISC I-MISC
, O-MISC O-MISC
TF O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
had O-MISC O-MISC
the O-MISC O-MISC
opposite O-MISC O-MISC
effect O-MISC O-MISC
, O-MISC O-MISC
preventing O-MISC O-MISC
apoptosis O-MISC O-MISC
and O-MISC O-MISC
inducing O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

Direct O-MISC O-MISC
and O-MISC O-MISC
indirect O-MISC O-MISC
signaling O-MISC O-MISC
mechanisms O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
cytokine O-MISC B-MISC
synthesis O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
analyzed O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
: O-MISC O-MISC
All O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
tested O-MISC O-MISC
expressed O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
receptors I-MISC I-MISC
I I-MISC I-MISC
and I-MISC O-MISC
II I-MISC I-MISC
and O-MISC O-MISC
responded O-MISC O-MISC
to O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
by O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
intercellular B-MISC B-MISC
adhesion I-MISC I-MISC
molecule I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
to O-MISC O-MISC
granulocyte B-MISC B-MISC
- I-MISC I-MISC
macrophage I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
( O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
did O-MISC O-MISC
not O-MISC O-MISC
activate O-MISC O-MISC
the O-MISC O-MISC
MAP B-MISC B-MISC
kinase I-MISC I-MISC
and O-MISC O-MISC
p70S6 O-MISC B-MISC
kinase O-MISC I-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

Nevertheless O-MISC O-MISC
, O-MISC O-MISC
inhibitors O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
pathways O-MISC O-MISC
clearly O-MISC O-MISC
reduced O-MISC O-MISC
the O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
growth O-MISC O-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
that O-MISC O-MISC
TNF O-MISC B-MISC
- O-MISC I-MISC
alpha O-MISC I-MISC
- O-MISC O-MISC
proliferative O-MISC O-MISC
cells O-MISC O-MISC
produced O-MISC O-MISC
a O-MISC O-MISC
growth O-MISC B-MISC
factor O-MISC I-MISC
that O-MISC O-MISC
induced O-MISC O-MISC
proliferation O-MISC O-MISC
upon O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
above O-MISC O-MISC
pathways O-MISC O-MISC
. O-MISC O-MISC

Anti B-MISC O-MISC
- I-MISC I-MISC
GM I-MISC I-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
antibodies I-MISC I-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
growth O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
autocrine O-MISC O-MISC
loop O-MISC O-MISC
for O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
. O-MISC O-MISC

Supporting O-MISC O-MISC
this O-MISC O-MISC
notion O-MISC O-MISC
, O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
upregulation O-MISC O-MISC
of O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
mRNA I-MISC I-MISC
levels O-MISC O-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
secretion O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
proliferative O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
TNF O-MISC B-MISC
- O-MISC I-MISC
alpha O-MISC I-MISC
- O-MISC O-MISC
apoptotic O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
: O-MISC O-MISC
These O-MISC O-MISC
data O-MISC O-MISC
identify O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
synthesis O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
early O-MISC O-MISC
and O-MISC O-MISC
essential O-MISC O-MISC
step O-MISC O-MISC
in O-MISC O-MISC
TNF O-MISC B-MISC
- O-MISC I-MISC
alpha O-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
first O-MISC O-MISC
time O-MISC O-MISC
that O-MISC O-MISC
TNF O-MISC B-MISC
- O-MISC I-MISC
alpha O-MISC I-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
producing O-MISC O-MISC
no O-MISC O-MISC
or O-MISC O-MISC
only O-MISC O-MISC
minimal O-MISC O-MISC
amounts O-MISC O-MISC
of O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
demonstrate O-MISC O-MISC
an O-MISC O-MISC
apoptotic O-MISC O-MISC
phenotype O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
expression O-MISC O-MISC
rates O-MISC O-MISC
can O-MISC O-MISC
escape O-MISC O-MISC
from O-MISC O-MISC
growth O-MISC O-MISC
arrest O-MISC O-MISC
or O-MISC O-MISC
even O-MISC O-MISC
apoptosis O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
context O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
discuss O-MISC O-MISC
arguments O-MISC O-MISC
pointing O-MISC O-MISC
at O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappaB I-MISC I-MISC
as O-MISC O-MISC
regulator O-MISC O-MISC
of O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
synthesis O-MISC O-MISC
and O-MISC O-MISC
thus O-MISC O-MISC
indirectly O-MISC O-MISC
as O-MISC O-MISC
regulator O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
escape O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
apoptosis O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
content O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
: O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
heterogeneity O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
were O-MISC O-MISC
measured O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
by O-MISC O-MISC
either O-MISC O-MISC
nylon O-MISC O-MISC
wool O-MISC O-MISC
filtration O-MISC O-MISC
or O-MISC O-MISC
E O-MISC O-MISC
- O-MISC O-MISC
rosette O-MISC O-MISC
sedimentation O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cells O-MISC O-MISC
isolated O-MISC O-MISC
by O-MISC O-MISC
nylon O-MISC O-MISC
wool O-MISC O-MISC
filtration O-MISC O-MISC
specifically O-MISC O-MISC
bind O-MISC O-MISC
6 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
fmol O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
per O-MISC O-MISC
million O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
equivalent O-MISC O-MISC
to O-MISC O-MISC
4000 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
200 O-MISC O-MISC
receptors O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
isolated O-MISC O-MISC
by O-MISC O-MISC
E O-MISC O-MISC
- O-MISC O-MISC
rosette O-MISC O-MISC
sedimentation O-MISC O-MISC
bind O-MISC O-MISC
12 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
fmol O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
per O-MISC O-MISC
million O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
equivalent O-MISC O-MISC
to O-MISC O-MISC
7200 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
400 O-MISC O-MISC
receptors O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
difference O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
bound O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
two O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
preparations O-MISC O-MISC
was O-MISC O-MISC
significant O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
present O-MISC O-MISC
immediately O-MISC O-MISC
after O-MISC O-MISC
cell O-MISC O-MISC
isolation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
binding O-MISC O-MISC
affinities O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
different O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
preparations O-MISC O-MISC
for O-MISC O-MISC
dexamethasone O-MISC O-MISC
were O-MISC O-MISC
similar O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
isolated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
combination O-MISC O-MISC
of O-MISC O-MISC
nylon O-MISC O-MISC
wool O-MISC O-MISC
filtration O-MISC O-MISC
followed O-MISC O-MISC
by O-MISC O-MISC
E O-MISC O-MISC
- O-MISC O-MISC
rosette O-MISC O-MISC
sedimentation O-MISC O-MISC
bind O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
as O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
isolated O-MISC O-MISC
by O-MISC O-MISC
nylon O-MISC O-MISC
wool O-MISC O-MISC
filtration O-MISC O-MISC
alone O-MISC O-MISC
. O-MISC O-MISC

T O-MISC O-MISC
cells O-MISC O-MISC
isolated O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
combination O-MISC O-MISC
of O-MISC O-MISC
E O-MISC O-MISC
- O-MISC O-MISC
rosette O-MISC O-MISC
sedimentation O-MISC O-MISC
following O-MISC O-MISC
by O-MISC O-MISC
nylon O-MISC O-MISC
wool O-MISC O-MISC
filtration O-MISC O-MISC
bind O-MISC O-MISC
less O-MISC O-MISC
dexamethasone O-MISC O-MISC
than O-MISC O-MISC
do O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
isolated O-MISC O-MISC
by O-MISC O-MISC
E O-MISC O-MISC
- O-MISC O-MISC
rosette O-MISC O-MISC
sedimentation O-MISC O-MISC
alone O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
findings O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
heterogeneous O-MISC O-MISC
with O-MISC O-MISC
respect O-MISC O-MISC
to O-MISC O-MISC
their O-MISC O-MISC
quantity O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

Isolation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
E O-MISC O-MISC
- O-MISC O-MISC
rosette O-MISC O-MISC
sedimentation O-MISC O-MISC
enriches O-MISC O-MISC
for O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
greater O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
isolation O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
nylon O-MISC O-MISC
wool O-MISC O-MISC
filtration O-MISC O-MISC
enriches O-MISC O-MISC
for O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
that O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
lesser O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
glucocorticoid O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
established O-MISC O-MISC
optimal O-MISC O-MISC
conditions O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
measurement O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
white O-MISC O-MISC
cells O-MISC O-MISC
using O-MISC O-MISC
a O-MISC O-MISC
whole O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
binding O-MISC O-MISC
assay O-MISC O-MISC
with O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
ligand O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
subsequent O-MISC O-MISC
determination O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
GR B-MISC B-MISC
content O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
various O-MISC O-MISC
forms O-MISC O-MISC
of O-MISC O-MISC
acute O-MISC O-MISC
and O-MISC O-MISC
chronic O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
leukemia O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
in O-MISC O-MISC
continuous O-MISC O-MISC
culture O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
subjected O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
GR B-MISC B-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
were O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
to O-MISC O-MISC
glucocorticoid O-MISC O-MISC
steroids O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
GR B-MISC B-MISC
content O-MISC O-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
amounted O-MISC O-MISC
to O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
850 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
340 O-MISC O-MISC
( O-MISC O-MISC
mean O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
SD O-MISC O-MISC
) O-MISC O-MISC
receptors O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mean O-MISC O-MISC
equilibrium O-MISC O-MISC
dissociation O-MISC O-MISC
constant O-MISC O-MISC
( O-MISC O-MISC
KD O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
interaction O-MISC O-MISC
of O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
GR B-MISC B-MISC
was O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
2 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
. O-MISC O-MISC

Steroidal O-MISC O-MISC
compounds O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
known O-MISC O-MISC
glucocorticoid O-MISC O-MISC
potency O-MISC O-MISC
effectively O-MISC O-MISC
competed O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
steroids O-MISC O-MISC
devoid O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC O-MISC
activity O-MISC O-MISC
( O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
g O-MISC O-MISC
. O-MISC O-MISC
estradiol O-MISC O-MISC
- O-MISC O-MISC
17 O-MISC O-MISC
beta O-MISC O-MISC
and O-MISC O-MISC
testosterone O-MISC O-MISC
) O-MISC O-MISC
were O-MISC O-MISC
ineffective O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
GR B-MISC O-MISC
content O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
blast O-MISC O-MISC
cells O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
eight O-MISC O-MISC
patients O-MISC O-MISC
suffering O-MISC O-MISC
from O-MISC O-MISC
acute O-MISC O-MISC
leukemia O-MISC O-MISC
and O-MISC O-MISC
four O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
blast O-MISC O-MISC
crisis O-MISC O-MISC
of O-MISC O-MISC
chronic O-MISC O-MISC
myelocytic O-MISC O-MISC
leukemia O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
highly O-MISC O-MISC
variable O-MISC O-MISC
( O-MISC O-MISC
3 O-MISC I-MISC
, O-MISC O-MISC
230 O-MISC I-MISC
- O-MISC I-MISC
29 O-MISC I-MISC
, O-MISC O-MISC
900 O-MISC B-MISC
receptors O-MISC I-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
lymphocytes O-MISC O-MISC
of O-MISC O-MISC
six O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
lymphatic O-MISC O-MISC
leukemia O-MISC O-MISC
contained O-MISC O-MISC
a O-MISC O-MISC
rather O-MISC O-MISC
stable O-MISC O-MISC
GR B-MISC B-MISC
content O-MISC O-MISC
( O-MISC O-MISC
2 O-MISC I-MISC
, O-MISC O-MISC
930 O-MISC B-MISC
- O-MISC I-MISC
5 O-MISC I-MISC
, O-MISC O-MISC
120 O-MISC B-MISC
receptors O-MISC I-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
was O-MISC O-MISC
comparable O-MISC O-MISC
with O-MISC O-MISC
that O-MISC O-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

GR B-MISC B-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
the O-MISC O-MISC
12 O-MISC O-MISC
malignant O-MISC O-MISC
continuous O-MISC O-MISC
white O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
studied O-MISC O-MISC
. O-MISC O-MISC

Large O-MISC O-MISC
cells O-MISC O-MISC
contained O-MISC O-MISC
more O-MISC O-MISC
GR B-MISC B-MISC
than O-MISC O-MISC
the O-MISC O-MISC
smaller O-MISC O-MISC
ones O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
was O-MISC O-MISC
no O-MISC O-MISC
apparent O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
GR B-MISC B-MISC
concentration O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
as O-MISC O-MISC
judged O-MISC O-MISC
by O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
thymidine O-MISC O-MISC
incorporation O-MISC O-MISC
studies O-MISC O-MISC
. O-MISC O-MISC

Distribution O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
surface O-MISC B-MISC
markers O-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
leukemic O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
relate O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
GR B-MISC B-MISC
concentration O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
GR B-MISC B-MISC
is O-MISC O-MISC
probably O-MISC O-MISC
a O-MISC O-MISC
universal O-MISC O-MISC
feature O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
clinical O-MISC O-MISC
standpoint O-MISC O-MISC
, O-MISC O-MISC
probably O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
alone O-MISC O-MISC
imply O-MISC O-MISC
steroid O-MISC O-MISC
responsiveness O-MISC O-MISC
. O-MISC O-MISC

Evidence O-MISC O-MISC
for O-MISC O-MISC
a O-MISC O-MISC
steroid B-MISC B-MISC
receptor I-MISC I-MISC
in O-MISC O-MISC
rheumatoid O-MISC O-MISC
synovial O-MISC O-MISC
tissue O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

One O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
glucocorticoids O-MISC O-MISC
could O-MISC O-MISC
exert O-MISC O-MISC
their O-MISC O-MISC
anti O-MISC O-MISC
- O-MISC O-MISC
inflammatory O-MISC O-MISC
action O-MISC O-MISC
is O-MISC O-MISC
via O-MISC O-MISC
rapidly O-MISC O-MISC
saturable O-MISC O-MISC
, O-MISC O-MISC
stereo B-MISC O-MISC
- I-MISC O-MISC
specific I-MISC O-MISC
cytoplasmic I-MISC B-MISC
protein I-MISC I-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
report O-MISC O-MISC
is O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
investigation O-MISC O-MISC
into O-MISC O-MISC
such O-MISC O-MISC
a O-MISC O-MISC
possibility O-MISC O-MISC
in O-MISC O-MISC
synovial O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Synovium O-MISC O-MISC
, O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
knee O-MISC O-MISC
joints O-MISC O-MISC
of O-MISC O-MISC
rheumatoid O-MISC O-MISC
patients O-MISC O-MISC
undergoing O-MISC O-MISC
surgery O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
clostridiopeptidase B-MISC O-MISC
A I-MISC I-MISC
and O-MISC O-MISC
trypsin B-MISC B-MISC
- I-MISC O-MISC
EDTA I-MISC B-MISC
to O-MISC O-MISC
obtain O-MISC O-MISC
cell O-MISC O-MISC
suspensions O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
, O-MISC O-MISC
together O-MISC O-MISC
with O-MISC O-MISC
cells O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
synovial O-MISC O-MISC
fluid O-MISC O-MISC
aspirated O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
rheumatoid O-MISC O-MISC
arthritis O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
identified O-MISC O-MISC
by O-MISC O-MISC
electron O-MISC O-MISC
microscopy O-MISC O-MISC
. O-MISC O-MISC

Duplicate O-MISC O-MISC
samples O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
cell O-MISC O-MISC
suspensions O-MISC O-MISC
were O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
increasing O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
H3Dexamethasone O-MISC B-MISC
( O-MISC O-MISC
1 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
10 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
) O-MISC O-MISC
for O-MISC O-MISC
30 O-MISC O-MISC
minutes O-MISC O-MISC
at O-MISC O-MISC
37 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
proportion O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
bound O-MISC O-MISC
to O-MISC O-MISC
whole O-MISC O-MISC
cells O-MISC O-MISC
showed O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
specific O-MISC O-MISC
, O-MISC O-MISC
rapidly O-MISC O-MISC
saturable O-MISC O-MISC
, O-MISC O-MISC
receptors O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
synovial O-MISC O-MISC
tissue O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
this O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
synovial O-MISC O-MISC
fluid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Electron O-MISC O-MISC
micrographs O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
cells O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
synovial O-MISC O-MISC
tissue O-MISC O-MISC
consisted O-MISC O-MISC
of O-MISC O-MISC
synovial O-MISC O-MISC
fibroblast O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
macrophage O-MISC O-MISC
- O-MISC O-MISC
types O-MISC O-MISC
, O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

Polymorphonuclear O-MISC O-MISC
leucocytes O-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
absent O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
synovial O-MISC O-MISC
fluid O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
polymorphonuclear O-MISC O-MISC
leucocytes O-MISC O-MISC
were O-MISC O-MISC
the O-MISC O-MISC
predominant O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
concluded O-MISC O-MISC
from O-MISC O-MISC
this O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
one O-MISC O-MISC
or O-MISC O-MISC
more O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
synovial O-MISC O-MISC
tissue O-MISC O-MISC
contain O-MISC O-MISC
a O-MISC O-MISC
specific B-MISC O-MISC
steroid I-MISC B-MISC
receptor I-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
is O-MISC O-MISC
lacking O-MISC O-MISC
in O-MISC O-MISC
synovial O-MISC O-MISC
fluid O-MISC O-MISC
polymorphonuclear O-MISC O-MISC
leucocytes O-MISC O-MISC
. O-MISC O-MISC

Clinical O-MISC O-MISC
implications O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

Glucorticoid B-MISC B-MISC
receptors I-MISC I-MISC
were O-MISC O-MISC
studied O-MISC O-MISC
in O-MISC O-MISC
various O-MISC O-MISC
populations O-MISC O-MISC
of O-MISC O-MISC
normal O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
leukemic O-MISC O-MISC
lymphoblasts O-MISC O-MISC
. O-MISC O-MISC

Normal O-MISC O-MISC
lymphocytes O-MISC O-MISC
contain O-MISC O-MISC
low O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
approximately O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
500 O-MISC O-MISC
sites O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
identical O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
fractions O-MISC O-MISC
. O-MISC O-MISC

Phytohemagglutinin B-MISC O-MISC
treatment O-MISC O-MISC
increases O-MISC O-MISC
levels O-MISC O-MISC
about O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
. O-MISC O-MISC

Leukemic O-MISC O-MISC
lymphoblasts O-MISC O-MISC
contain O-MISC O-MISC
larger O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
receptor O-MISC B-MISC
sites O-MISC I-MISC
. O-MISC O-MISC

Presence O-MISC O-MISC
of O-MISC O-MISC
receptor O-MISC O-MISC
is O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
sensitivitiy O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

Quantity O-MISC O-MISC
of O-MISC O-MISC
receptor O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
complete O-MISC O-MISC
remission O-MISC O-MISC
duration O-MISC O-MISC
independently O-MISC O-MISC
of O-MISC O-MISC
leukemic O-MISC O-MISC
cell O-MISC O-MISC
type O-MISC O-MISC
( O-MISC O-MISC
T O-MISC O-MISC
or O-MISC O-MISC
null O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
initial O-MISC O-MISC
WBC O-MISC B-MISC
, O-MISC O-MISC
or O-MISC O-MISC
age O-MISC O-MISC
of O-MISC O-MISC
patient O-MISC O-MISC
. O-MISC O-MISC

Quantitative O-MISC O-MISC
determination O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
lymphoblastic O-MISC O-MISC
leukemia O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
of O-MISC O-MISC
value O-MISC O-MISC
both O-MISC O-MISC
as O-MISC O-MISC
an O-MISC O-MISC
independent O-MISC O-MISC
prognostic O-MISC O-MISC
variable O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
suggesting O-MISC O-MISC
which O-MISC O-MISC
patients O-MISC O-MISC
should O-MISC O-MISC
receive O-MISC O-MISC
glucocorticoid O-MISC O-MISC
therapy O-MISC O-MISC
. O-MISC O-MISC

Functional O-MISC O-MISC
and O-MISC O-MISC
physical O-MISC O-MISC
interaction O-MISC O-MISC
of O-MISC O-MISC
protein B-MISC B-MISC
- I-MISC I-MISC
tyrosine I-MISC I-MISC
kinases I-MISC I-MISC
Fyn I-MISC B-MISC
and I-MISC O-MISC
Csk I-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
signaling O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Src B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
tyrosine I-MISC I-MISC
kinase I-MISC I-MISC
Fyn B-MISC I-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
antigen I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Transient O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
actively O-MISC O-MISC
mutated O-MISC B-MISC
Fyn B-MISC B-MISC
, O-MISC O-MISC
having O-MISC O-MISC
Phe O-MISC O-MISC
- O-MISC O-MISC
528 O-MISC O-MISC
instead O-MISC O-MISC
of O-MISC O-MISC
Tyr O-MISC O-MISC
- O-MISC O-MISC
528 O-MISC O-MISC
or O-MISC O-MISC
Thr O-MISC O-MISC
- O-MISC O-MISC
338 O-MISC O-MISC
instead O-MISC O-MISC
of O-MISC O-MISC
Ile O-MISC O-MISC
- O-MISC O-MISC
338 O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
stimulated B-MISC O-MISC
the I-MISC O-MISC
serum I-MISC B-MISC
response I-MISC I-MISC
element I-MISC I-MISC
( O-MISC O-MISC
SRE B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
12 B-MISC O-MISC
- I-MISC O-MISC
O I-MISC O-MISC
- I-MISC O-MISC
tetradecanoyl I-MISC O-MISC
- I-MISC O-MISC
phorbol I-MISC O-MISC
- I-MISC O-MISC
13 I-MISC I-MISC
- I-MISC I-MISC
acetate I-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
, O-MISC O-MISC
cyclic B-MISC B-MISC
AMP I-MISC I-MISC
response I-MISC I-MISC
element I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
fos I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
SRE B-MISC B-MISC
was O-MISC O-MISC
particularly O-MISC O-MISC
prominent O-MISC O-MISC
not O-MISC O-MISC
only O-MISC O-MISC
with O-MISC O-MISC
active O-MISC O-MISC
Fyn B-MISC B-MISC
but O-MISC O-MISC
also O-MISC O-MISC
with O-MISC O-MISC
normal B-MISC O-MISC
( I-MISC O-MISC
wild I-MISC B-MISC
- I-MISC I-MISC
type I-MISC I-MISC
) I-MISC O-MISC
Fyn I-MISC B-MISC
. O-MISC O-MISC

SRE B-MISC B-MISC
was O-MISC O-MISC
also O-MISC O-MISC
stimulated O-MISC O-MISC
by O-MISC O-MISC
both O-MISC O-MISC
normal B-MISC O-MISC
and I-MISC O-MISC
active I-MISC O-MISC
Lck I-MISC B-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
normal B-MISC O-MISC
and I-MISC O-MISC
active I-MISC O-MISC
Fyn I-MISC O-MISC
stimulated O-MISC O-MISC
transcription O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
gene I-MISC I-MISC
promoter I-MISC I-MISC
when O-MISC O-MISC
transfected O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
stimulated O-MISC O-MISC
by O-MISC O-MISC
concanavalin B-MISC O-MISC
A I-MISC O-MISC
plus O-MISC O-MISC
12 O-MISC O-MISC
- O-MISC O-MISC
O O-MISC O-MISC
- O-MISC O-MISC
tetradecanoylphorbol O-MISC O-MISC
- O-MISC O-MISC
13 O-MISC O-MISC
- O-MISC O-MISC
acetate O-MISC O-MISC
. O-MISC O-MISC

Under O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
conditions O-MISC O-MISC
, O-MISC O-MISC
Lck B-MISC B-MISC
did O-MISC O-MISC
not O-MISC O-MISC
stimulate O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
unless O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
mutation O-MISC O-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
mutant B-MISC B-MISC
Fyn I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
has O-MISC O-MISC
deletions O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
SH2 B-MISC B-MISC
region I-MISC I-MISC
and O-MISC O-MISC
so O-MISC O-MISC
is O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
transform O-MISC O-MISC
chicken O-MISC O-MISC
embryo O-MISC O-MISC
fibroblasts O-MISC O-MISC
, O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
stimulate O-MISC O-MISC
either O-MISC O-MISC
the O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
fos I-MISC I-MISC
or I-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
the O-MISC O-MISC
importance O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
region O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
signaling O-MISC O-MISC
. O-MISC O-MISC

Csk B-MISC B-MISC
, O-MISC O-MISC
which O-MISC O-MISC
phosphorylates O-MISC O-MISC
tyrosine O-MISC I-MISC
residues O-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
negative O-MISC O-MISC
regulatory O-MISC I-MISC
sites O-MISC I-MISC
of O-MISC O-MISC
Src B-MISC B-MISC
family I-MISC I-MISC
kinases I-MISC I-MISC
, O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
Fyn O-MISC B-MISC
- O-MISC I-MISC
and O-MISC O-MISC
Lck O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
serum B-MISC B-MISC
response I-MISC I-MISC
element I-MISC I-MISC
and O-MISC O-MISC
Fyn O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
enhancement O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
Fyn B-MISC B-MISC
and O-MISC O-MISC
Lck B-MISC B-MISC
, O-MISC O-MISC
whose O-MISC O-MISC
activities O-MISC O-MISC
are O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
Csk B-MISC B-MISC
, O-MISC O-MISC
are O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
different O-MISC O-MISC
phases O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
novel O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
complex I-MISC I-MISC
containing O-MISC I-MISC
p65 B-MISC B-MISC
homodimers I-MISC I-MISC
: O-MISC O-MISC
implications O-MISC O-MISC
for O-MISC O-MISC
transcriptional O-MISC O-MISC
control O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
subunit O-MISC B-MISC
dimerization O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
predominant O-MISC O-MISC
inducible O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
is O-MISC O-MISC
a O-MISC O-MISC
heteromeric B-MISC B-MISC
complex I-MISC I-MISC
containing O-MISC O-MISC
two O-MISC O-MISC
Rel B-MISC B-MISC
- I-MISC I-MISC
related I-MISC I-MISC
DNA I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
subunits I-MISC I-MISC
, O-MISC O-MISC
termed B-MISC O-MISC
p65 I-MISC B-MISC
and O-MISC O-MISC
p50 B-MISC B-MISC
. O-MISC O-MISC

Prior O-MISC O-MISC
transfection O-MISC O-MISC
studies O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
when O-MISC O-MISC
these O-MISC O-MISC
p65 B-MISC B-MISC
and I-MISC I-MISC
p50 I-MISC I-MISC
subunits I-MISC I-MISC
are O-MISC O-MISC
expressed O-MISC O-MISC
independently O-MISC O-MISC
as O-MISC O-MISC
stable B-MISC O-MISC
homodimers I-MISC O-MISC
, O-MISC O-MISC
p65 B-MISC B-MISC
stimulates O-MISC O-MISC
kappa O-MISC B-MISC
B O-MISC I-MISC
- O-MISC O-MISC
directed O-MISC O-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
p50 B-MISC B-MISC
functions O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
kappa O-MISC B-MISC
B O-MISC I-MISC
- O-MISC I-MISC
specific O-MISC I-MISC
repressor O-MISC I-MISC
. O-MISC O-MISC

While O-MISC O-MISC
authentic O-MISC O-MISC
p50 B-MISC B-MISC
homodimers I-MISC I-MISC
( O-MISC O-MISC
previously O-MISC O-MISC
termed O-MISC O-MISC
KBF1 B-MISC B-MISC
) O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
nontransfected O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
experimental O-MISC O-MISC
evidence O-MISC O-MISC
supporting O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
homodimers I-MISC I-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
was O-MISC O-MISC
lacking O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
now O-MISC O-MISC
provide O-MISC O-MISC
direct O-MISC O-MISC
biochemical O-MISC O-MISC
evidence O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
endogenous O-MISC O-MISC
pool O-MISC O-MISC
of O-MISC O-MISC
inducible O-MISC B-MISC
p65 B-MISC B-MISC
homodimers I-MISC I-MISC
in O-MISC O-MISC
intact O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
prototypical O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
p50 I-MISC I-MISC
- I-MISC I-MISC
p65 I-MISC I-MISC
heterodimer I-MISC I-MISC
, O-MISC O-MISC
this O-MISC O-MISC
novel O-MISC O-MISC
p65 B-MISC B-MISC
homodimeric I-MISC I-MISC
form I-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
is O-MISC O-MISC
functionally O-MISC O-MISC
sequestered O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytoplasm O-MISC B-MISC
but O-MISC O-MISC
rapidly O-MISC O-MISC
appears O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
compartment O-MISC O-MISC
following O-MISC O-MISC
cellular O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Site O-MISC O-MISC
- O-MISC O-MISC
directed O-MISC O-MISC
mutagenesis O-MISC O-MISC
studies O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
homodimerization O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
is O-MISC O-MISC
dependent O-MISC O-MISC
upon O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
cysteine O-MISC O-MISC
216 O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
conserved O-MISC O-MISC
recognition O-MISC I-MISC
motif O-MISC I-MISC
for O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
A I-MISC I-MISC
( O-MISC O-MISC
RRPS B-MISC B-MISC
; O-MISC I-MISC
amino O-MISC B-MISC
acids O-MISC I-MISC
273 O-MISC I-MISC
to O-MISC I-MISC
276 O-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
both O-MISC O-MISC
of O-MISC O-MISC
which O-MISC O-MISC
reside O-MISC O-MISC
within O-MISC O-MISC
a O-MISC O-MISC
91 O-MISC B-MISC
- O-MISC I-MISC
amino O-MISC I-MISC
- O-MISC I-MISC
acid O-MISC I-MISC
segment O-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Rel B-MISC B-MISC
homology I-MISC I-MISC
domain I-MISC I-MISC
that O-MISC O-MISC
mediates O-MISC O-MISC
self O-MISC O-MISC
- O-MISC O-MISC
association O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
mutations O-MISC O-MISC
at O-MISC O-MISC
these O-MISC O-MISC
two O-MISC O-MISC
sites O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
heterodimerization O-MISC O-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
with O-MISC O-MISC
p50 B-MISC B-MISC
or O-MISC O-MISC
its O-MISC O-MISC
functional O-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
I O-MISC B-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
alpha O-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
later O-MISC O-MISC
findings O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
neither O-MISC O-MISC
homo O-MISC O-MISC
- O-MISC O-MISC
nor O-MISC O-MISC
heterodimer O-MISC O-MISC
formation O-MISC O-MISC
is O-MISC O-MISC
an O-MISC O-MISC
absolute O-MISC O-MISC
prerequisite O-MISC O-MISC
for O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
recognition O-MISC I-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
. O-MISC O-MISC

Taken O-MISC O-MISC
together O-MISC O-MISC
with O-MISC O-MISC
prior O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
transcription O-MISC O-MISC
studies O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
biological O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
p65 B-MISC B-MISC
and I-MISC I-MISC
p50 I-MISC B-MISC
homodimers I-MISC I-MISC
are O-MISC O-MISC
independently O-MISC O-MISC
regulated O-MISC O-MISC
, O-MISC O-MISC
thereby O-MISC O-MISC
providing O-MISC O-MISC
an O-MISC O-MISC
integrated O-MISC O-MISC
and O-MISC O-MISC
flexible O-MISC O-MISC
control O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
rapid O-MISC O-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
repression O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
/ O-MISC I-MISC
Rel B-MISC I-MISC
- O-MISC O-MISC
directed O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

Carrier O-MISC O-MISC
determination O-MISC O-MISC
for O-MISC O-MISC
X O-MISC B-MISC
- O-MISC I-MISC
linked O-MISC I-MISC
agammaglobulinemia O-MISC I-MISC
using O-MISC O-MISC
X O-MISC O-MISC
inactivation O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
purified O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
the O-MISC O-MISC
development O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
relatively O-MISC O-MISC
quick O-MISC O-MISC
and O-MISC O-MISC
simple O-MISC O-MISC
method O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
assessment O-MISC O-MISC
of O-MISC O-MISC
X O-MISC O-MISC
inactivation O-MISC O-MISC
status O-MISC O-MISC
for O-MISC O-MISC
carrier O-MISC O-MISC
determination O-MISC O-MISC
in O-MISC O-MISC
families O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
X O-MISC B-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
agammaglobulinemia O-MISC O-MISC
( O-MISC O-MISC
XLA O-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
method O-MISC O-MISC
utilises O-MISC O-MISC
an O-MISC O-MISC
immunomagnetic O-MISC O-MISC
separation O-MISC O-MISC
technique O-MISC O-MISC
for O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
purification O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
( O-MISC O-MISC
PCR O-MISC O-MISC
) O-MISC O-MISC
based O-MISC O-MISC
assay O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
determination O-MISC O-MISC
of O-MISC O-MISC
methylation O-MISC O-MISC
status O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
androgen B-MISC O-MISC
receptor I-MISC I-MISC
( I-MISC I-MISC
AR I-MISC B-MISC
) I-MISC I-MISC
gene I-MISC I-MISC
locus I-MISC I-MISC
to O-MISC O-MISC
assess O-MISC O-MISC
whether O-MISC O-MISC
X O-MISC O-MISC
inactivation O-MISC O-MISC
is O-MISC O-MISC
random O-MISC O-MISC
or O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
random O-MISC O-MISC
at O-MISC O-MISC
this O-MISC O-MISC
locus O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
obtained O-MISC O-MISC
using O-MISC O-MISC
this O-MISC O-MISC
assay O-MISC O-MISC
to O-MISC O-MISC
investigate O-MISC O-MISC
females O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
carriers O-MISC O-MISC
of O-MISC O-MISC
various O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
immunodeficiency O-MISC O-MISC
disorders O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
investigated O-MISC O-MISC
four O-MISC O-MISC
females O-MISC O-MISC
from O-MISC O-MISC
different O-MISC O-MISC
families O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
XLA O-MISC B-MISC
, O-MISC O-MISC
two O-MISC O-MISC
of O-MISC O-MISC
whom O-MISC O-MISC
were O-MISC O-MISC
of O-MISC O-MISC
unknown O-MISC O-MISC
carrier O-MISC O-MISC
status O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
we O-MISC O-MISC
discuss O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
obtained O-MISC O-MISC
with O-MISC O-MISC
this O-MISC O-MISC
and O-MISC O-MISC
other O-MISC O-MISC
X O-MISC O-MISC
- O-MISC O-MISC
inactivation O-MISC O-MISC
assays O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
similar O-MISC O-MISC
assay O-MISC O-MISC
has O-MISC O-MISC
recently O-MISC O-MISC
been O-MISC O-MISC
described O-MISC O-MISC
by O-MISC O-MISC
Allen O-MISC O-MISC
et O-MISC O-MISC
al O-MISC O-MISC
. O-MISC O-MISC
( O-MISC O-MISC
1992 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
applied O-MISC O-MISC
to O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
one O-MISC O-MISC
family O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
XLA O-MISC B-MISC
. O-MISC O-MISC

Effects O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
and O-MISC O-MISC
Fc B-MISC B-MISC
gamma I-MISC I-MISC
receptor I-MISC I-MISC
II I-MISC I-MISC
engagement O-MISC O-MISC
on O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC O-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
during O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
by O-MISC O-MISC
membrane O-MISC O-MISC
immunoglobulin O-MISC I-MISC
crosslinking O-MISC O-MISC
. O-MISC O-MISC

Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
an O-MISC O-MISC
immediate B-MISC B-MISC
early I-MISC I-MISC
gene I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
rapidly O-MISC O-MISC
upregulated O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
mitogenic O-MISC O-MISC
signals O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
antigen O-MISC B-MISC
receptor O-MISC I-MISC
crosslinking O-MISC O-MISC
on O-MISC O-MISC
murine O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
expression O-MISC O-MISC
are O-MISC O-MISC
closely O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
in O-MISC O-MISC
several O-MISC O-MISC
models O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
tolerance O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
compared O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
during O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
Fab B-MISC O-MISC
' I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
IgG B-MISC B-MISC
anti I-MISC O-MISC
- I-MISC I-MISC
immunoglobulin I-MISC I-MISC
( O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
Ig I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
since O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
that O-MISC O-MISC
Fab B-MISC B-MISC
' I-MISC I-MISC
2 I-MISC I-MISC
anti I-MISC B-MISC
- I-MISC I-MISC
Ig I-MISC I-MISC
is O-MISC O-MISC
mitogenic O-MISC O-MISC
while O-MISC O-MISC
IgG B-MISC B-MISC
anti I-MISC I-MISC
- I-MISC I-MISC
Ig I-MISC I-MISC
is O-MISC O-MISC
not O-MISC O-MISC
, O-MISC O-MISC
owing O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
dominant O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
crosslinking O-MISC O-MISC
the O-MISC O-MISC
B B-MISC B-MISC
cell I-MISC I-MISC
Fc I-MISC I-MISC
gamma I-MISC I-MISC
RII I-MISC I-MISC
to O-MISC O-MISC
membrane B-MISC B-MISC
Ig I-MISC I-MISC
. O-MISC O-MISC

While O-MISC O-MISC
mitogenic O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
Fab B-MISC B-MISC
' I-MISC I-MISC
2 I-MISC I-MISC
anti I-MISC I-MISC
- I-MISC I-MISC
Ig I-MISC I-MISC
induce O-MISC O-MISC
large O-MISC O-MISC
and O-MISC O-MISC
rapid O-MISC O-MISC
increases O-MISC O-MISC
in O-MISC O-MISC
Egr O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
IgG B-MISC B-MISC
anti I-MISC I-MISC
- I-MISC I-MISC
Ig I-MISC I-MISC
results O-MISC O-MISC
in O-MISC O-MISC
smaller O-MISC O-MISC
increases O-MISC O-MISC
in O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
, O-MISC O-MISC
comparable O-MISC O-MISC
to O-MISC O-MISC
that O-MISC O-MISC
seen O-MISC O-MISC
with O-MISC O-MISC
submitogenic O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
Fab B-MISC B-MISC
' I-MISC I-MISC
2 I-MISC I-MISC
anti I-MISC I-MISC
- I-MISC I-MISC
Ig I-MISC I-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
Egr O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
breaks O-MISC O-MISC
down O-MISC O-MISC
when O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
is O-MISC O-MISC
added O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
co O-MISC O-MISC
- O-MISC I-MISC
mitogen O-MISC I-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
with O-MISC O-MISC
IgG B-MISC B-MISC
anti I-MISC I-MISC
- I-MISC I-MISC
Ig I-MISC I-MISC
or O-MISC O-MISC
submitogenic O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
Fab B-MISC O-MISC
' I-MISC I-MISC
2 I-MISC I-MISC
anti I-MISC I-MISC
- I-MISC I-MISC
Ig I-MISC I-MISC
. O-MISC O-MISC

No O-MISC O-MISC
corresponding O-MISC O-MISC
increases O-MISC O-MISC
in O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
levels O-MISC O-MISC
are O-MISC O-MISC
observed O-MISC O-MISC
when O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
is O-MISC O-MISC
added O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
overcomes O-MISC O-MISC
Fc O-MISC B-MISC
receptor O-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
without O-MISC O-MISC
affecting O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
Egr B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
mRNA I-MISC I-MISC
induction O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
demonstrated O-MISC O-MISC
earlier O-MISC O-MISC
for O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
myc I-MISC I-MISC
mRNA I-MISC I-MISC
in O-MISC O-MISC
this O-MISC O-MISC
system O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
cyclosporin B-MISC B-MISC
- I-MISC I-MISC
sensitive I-MISC I-MISC
element I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
tumor I-MISC I-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
alpha I-MISC I-MISC
gene I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

Tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
alpha I-MISC I-MISC
( O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
cytokine B-MISC B-MISC
with O-MISC O-MISC
pleiotropic O-MISC O-MISC
biological O-MISC O-MISC
effects O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
produced O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
variety O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
induction O-MISC O-MISC
by O-MISC O-MISC
diverse O-MISC O-MISC
stimuli O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
paper O-MISC O-MISC
, O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
mRNA I-MISC I-MISC
is O-MISC O-MISC
shown O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
highly O-MISC O-MISC
induced O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
murine O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
clone O-MISC O-MISC
by O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
T B-MISC B-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
TCR B-MISC B-MISC
) O-MISC O-MISC
ligands O-MISC O-MISC
or O-MISC O-MISC
by O-MISC O-MISC
calcium O-MISC O-MISC
ionophores O-MISC O-MISC
alone O-MISC O-MISC
. O-MISC O-MISC

Induction O-MISC O-MISC
is O-MISC O-MISC
rapid O-MISC O-MISC
, O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
require O-MISC O-MISC
de O-MISC O-MISC
novo O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
completely O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
immunosuppressant O-MISC O-MISC
cyclosporin O-MISC O-MISC
A O-MISC O-MISC
( O-MISC O-MISC
CsA O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
identified O-MISC O-MISC
a O-MISC O-MISC
human B-MISC B-MISC
TNF I-MISC I-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
promoter I-MISC I-MISC
element I-MISC I-MISC
, O-MISC O-MISC
kappa B-MISC B-MISC
3 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
plays O-MISC O-MISC
a O-MISC O-MISC
key O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
calcium O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
inducibility O-MISC O-MISC
and O-MISC O-MISC
CsA O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
gene O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
, O-MISC O-MISC
an O-MISC O-MISC
oligonucleotide O-MISC O-MISC
containing O-MISC O-MISC
kappa B-MISC B-MISC
3 I-MISC I-MISC
forms O-MISC O-MISC
two O-MISC O-MISC
DNA O-MISC B-MISC
protein O-MISC I-MISC
complexes O-MISC I-MISC
with O-MISC O-MISC
proteins O-MISC O-MISC
that O-MISC O-MISC
are O-MISC O-MISC
present O-MISC O-MISC
in O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
unstimulated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
complexes O-MISC O-MISC
appear O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
only O-MISC O-MISC
after O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Induction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inducible O-MISC B-MISC
nuclear B-MISC I-MISC
complexes I-MISC I-MISC
is O-MISC O-MISC
rapid O-MISC O-MISC
, O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
CsA O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
thus O-MISC O-MISC
, O-MISC O-MISC
exactly O-MISC O-MISC
parallels O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
mRNA I-MISC I-MISC
by O-MISC O-MISC
TCR O-MISC B-MISC
ligands O-MISC O-MISC
or O-MISC O-MISC
by O-MISC O-MISC
calcium O-MISC O-MISC
ionophore O-MISC O-MISC
. O-MISC O-MISC

Our O-MISC O-MISC
studies O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
kappa B-MISC B-MISC
3 I-MISC I-MISC
binding I-MISC I-MISC
factor I-MISC I-MISC
resembles O-MISC O-MISC
the O-MISC O-MISC
preexisting O-MISC O-MISC
component O-MISC I-MISC
of O-MISC I-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
of O-MISC I-MISC
activated O-MISC I-MISC
T O-MISC I-MISC
cells O-MISC I-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
gene I-MISC I-MISC
is O-MISC O-MISC
an O-MISC O-MISC
immediate O-MISC B-MISC
early O-MISC I-MISC
gene O-MISC I-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
provides O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
model O-MISC O-MISC
system O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
to O-MISC O-MISC
study O-MISC O-MISC
CsA B-MISC B-MISC
- I-MISC I-MISC
sensitive I-MISC I-MISC
gene I-MISC I-MISC
induction O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Differences O-MISC O-MISC
in O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
AP I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
promyelocytic O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
during O-MISC O-MISC
differentiation O-MISC O-MISC
towards O-MISC O-MISC
macrophages O-MISC O-MISC
versus O-MISC O-MISC
granulocytes O-MISC O-MISC
. O-MISC O-MISC

Commitment O-MISC O-MISC
of O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
macrophage O-MISC O-MISC
or O-MISC O-MISC
granulocytic O-MISC O-MISC
differentiation O-MISC O-MISC
was O-MISC O-MISC
achieved O-MISC O-MISC
by O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
4 O-MISC O-MISC
beta O-MISC O-MISC
- O-MISC O-MISC
phorbol O-MISC O-MISC
12 O-MISC O-MISC
- O-MISC O-MISC
myristate O-MISC O-MISC
13 O-MISC O-MISC
- O-MISC O-MISC
acetate O-MISC O-MISC
( O-MISC O-MISC
PMA O-MISC O-MISC
) O-MISC O-MISC
for O-MISC O-MISC
30 O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
min O-MISC O-MISC
or O-MISC O-MISC
with O-MISC O-MISC
dimethyl O-MISC O-MISC
sulphoxide O-MISC O-MISC
( O-MISC O-MISC
DMSO O-MISC O-MISC
) O-MISC O-MISC
for O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
commitment O-MISC O-MISC
stage O-MISC O-MISC
towards O-MISC O-MISC
PMA O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
macrophage O-MISC O-MISC
differentiation O-MISC O-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
increases O-MISC O-MISC
in O-MISC O-MISC
jun O-MISC B-MISC
B O-MISC I-MISC
and O-MISC I-MISC
c O-MISC B-MISC
- O-MISC I-MISC
fos O-MISC I-MISC
mRNA O-MISC I-MISC
levels O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
AP I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Nevertheless O-MISC O-MISC
, O-MISC O-MISC
gel O-MISC O-MISC
retardation O-MISC O-MISC
analysis O-MISC O-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
activity O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
untreated O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
drastically O-MISC O-MISC
reduced O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
commitment O-MISC O-MISC
stage O-MISC O-MISC
of O-MISC O-MISC
DMSO O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
differentiation O-MISC O-MISC
towards O-MISC O-MISC
granulocytes O-MISC O-MISC
. O-MISC O-MISC

When O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
sodium O-MISC O-MISC
butyrate O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
induced O-MISC O-MISC
monocytic O-MISC O-MISC
differentiation O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
remarkable O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
AP O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
1 O-MISC O-MISC
alpha O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
dihydroxyvitamin O-MISC O-MISC
D3 O-MISC O-MISC
, O-MISC O-MISC
another O-MISC O-MISC
monocytic O-MISC O-MISC
differentiation O-MISC O-MISC
agent O-MISC O-MISC
, O-MISC O-MISC
induced O-MISC O-MISC
a O-MISC O-MISC
weak O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
appreciable O-MISC O-MISC
, O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
sodium O-MISC O-MISC
butyrate O-MISC O-MISC
or O-MISC O-MISC
1 O-MISC O-MISC
alpha O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
- O-MISC O-MISC
dihydroxyvitamin O-MISC O-MISC
D3 O-MISC O-MISC
to O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
induced O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
fos I-MISC I-MISC
, I-MISC O-MISC
c I-MISC B-MISC
- I-MISC I-MISC
jun I-MISC I-MISC
, I-MISC I-MISC
jun I-MISC I-MISC
B I-MISC I-MISC
and I-MISC I-MISC
jun I-MISC I-MISC
D I-MISC I-MISC
proto I-MISC I-MISC
- I-MISC I-MISC
oncogenes I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
when O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
retinoic O-MISC O-MISC
acid O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
granulocytic O-MISC O-MISC
differentiation O-MISC O-MISC
inducer O-MISC O-MISC
, O-MISC O-MISC
no O-MISC O-MISC
enhanced O-MISC O-MISC
AP O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
only O-MISC O-MISC
a O-MISC O-MISC
weak O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
jun B-MISC B-MISC
D I-MISC I-MISC
mRNA I-MISC I-MISC
level O-MISC O-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
is O-MISC O-MISC
not O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
differentiation O-MISC O-MISC
towards O-MISC O-MISC
granulocytes O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
monocytic O-MISC O-MISC
differentiation O-MISC O-MISC
is O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
differential O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
activity O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
critical O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
differentiation O-MISC O-MISC
of O-MISC O-MISC
HL O-MISC O-MISC
- O-MISC O-MISC
60 O-MISC O-MISC
cells O-MISC O-MISC
towards O-MISC O-MISC
monocytic O-MISC O-MISC
or O-MISC O-MISC
granulocytic O-MISC O-MISC
lineages O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
sensitivity O-MISC O-MISC
in O-MISC O-MISC
leukemias O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
an O-MISC O-MISC
attempt O-MISC O-MISC
to O-MISC O-MISC
investigate O-MISC O-MISC
the O-MISC O-MISC
utility O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
determination O-MISC O-MISC
to O-MISC O-MISC
predict O-MISC O-MISC
clinical O-MISC O-MISC
responsiveness O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
leukemias O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
studied O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
46 O-MISC O-MISC
patients O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
18 O-MISC O-MISC
normal O-MISC O-MISC
donors O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
normal O-MISC O-MISC
lymphocytes O-MISC O-MISC
there O-MISC O-MISC
were O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
875 O-MISC O-MISC
( O-MISC O-MISC
Median O-MISC O-MISC
) O-MISC I-MISC
specific O-MISC I-MISC
binding O-MISC I-MISC
sites O-MISC I-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
blasts O-MISC O-MISC
from O-MISC O-MISC
17 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
ANLL O-MISC O-MISC
had O-MISC O-MISC
on O-MISC O-MISC
average O-MISC O-MISC
higher O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
binding B-MISC O-MISC
sites I-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
( O-MISC O-MISC
Median O-MISC O-MISC
= O-MISC O-MISC
7 O-MISC O-MISC
, O-MISC O-MISC
250 O-MISC O-MISC
, O-MISC O-MISC
range O-MISC O-MISC
: O-MISC O-MISC
0 O-MISC O-MISC
to O-MISC O-MISC
15 O-MISC O-MISC
, O-MISC O-MISC
295 O-MISC O-MISC
) O-MISC O-MISC
than O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
leukemias O-MISC O-MISC
. O-MISC O-MISC

Of O-MISC O-MISC
the O-MISC O-MISC
15 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
CLL O-MISC O-MISC
, O-MISC O-MISC
six O-MISC O-MISC
had O-MISC O-MISC
received O-MISC O-MISC
glucocorticoid O-MISC O-MISC
treatment O-MISC O-MISC
for O-MISC O-MISC
3 O-MISC O-MISC
to O-MISC O-MISC
5 O-MISC O-MISC
years O-MISC O-MISC
. O-MISC O-MISC

Their O-MISC O-MISC
lymphocytes O-MISC O-MISC
had O-MISC O-MISC
lower O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
receptors O-MISC B-MISC
( O-MISC O-MISC
Median O-MISC O-MISC
= O-MISC O-MISC
2 O-MISC O-MISC
, O-MISC O-MISC
000 O-MISC O-MISC
) O-MISC O-MISC
than O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
cases O-MISC O-MISC
which O-MISC O-MISC
were O-MISC O-MISC
newly O-MISC O-MISC
diagnosed O-MISC O-MISC
( O-MISC O-MISC
Median O-MISC O-MISC
= O-MISC O-MISC
4 O-MISC O-MISC
, O-MISC O-MISC
500 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Four O-MISC O-MISC
patients O-MISC O-MISC
had O-MISC O-MISC
ALL O-MISC O-MISC
/ O-MISC O-MISC
AUL O-MISC O-MISC
, O-MISC O-MISC
three O-MISC O-MISC
patients O-MISC O-MISC
had O-MISC O-MISC
blast O-MISC O-MISC
crisis O-MISC O-MISC
as O-MISC O-MISC
terminal O-MISC O-MISC
phase O-MISC O-MISC
of O-MISC O-MISC
CML O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
seven O-MISC O-MISC
had O-MISC O-MISC
leukemic O-MISC O-MISC
Non O-MISC O-MISC
- O-MISC O-MISC
Hodgkin O-MISC O-MISC
lymphomas O-MISC O-MISC
( O-MISC O-MISC
Median O-MISC O-MISC
= O-MISC O-MISC
3 O-MISC O-MISC
, O-MISC O-MISC
500 O-MISC O-MISC
sites O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
24 O-MISC O-MISC
patients O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
also O-MISC O-MISC
studied O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
leukemic O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
dexamethasone O-MISC O-MISC
. O-MISC O-MISC

There O-MISC O-MISC
was O-MISC O-MISC
no O-MISC O-MISC
marked O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
sensitivity O-MISC O-MISC
. O-MISC O-MISC

An O-MISC O-MISC
attempt O-MISC O-MISC
to O-MISC O-MISC
correlate O-MISC O-MISC
receptor O-MISC O-MISC
levels O-MISC O-MISC
with O-MISC O-MISC
clinical O-MISC O-MISC
responsiveness O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
determination O-MISC O-MISC
might O-MISC O-MISC
be O-MISC O-MISC
of O-MISC O-MISC
value O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
lymphoid O-MISC O-MISC
malignancies O-MISC O-MISC
but O-MISC O-MISC
probably O-MISC O-MISC
not O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
other O-MISC O-MISC
leukemias O-MISC O-MISC
. O-MISC O-MISC

' B-MISC O-MISC
Activation I-MISC O-MISC
- I-MISC I-MISC
labile I-MISC I-MISC
' I-MISC I-MISC
glucocorticoid I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
of O-MISC O-MISC
a O-MISC O-MISC
steroid O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
variant O-MISC O-MISC
of O-MISC O-MISC
CEM O-MISC O-MISC
- O-MISC O-MISC
C7 O-MISC O-MISC
human O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

For O-MISC O-MISC
cytoplasmic B-MISC B-MISC
glucocorticoid I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
to O-MISC O-MISC
enter O-MISC O-MISC
and O-MISC O-MISC
accumulate O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
a O-MISC O-MISC
temperature O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
event O-MISC O-MISC
, O-MISC O-MISC
' O-MISC O-MISC
activation O-MISC O-MISC
' O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
. O-MISC O-MISC

Activation O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
achieved O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
by O-MISC O-MISC
increased O-MISC O-MISC
ionic O-MISC O-MISC
strength O-MISC O-MISC
, O-MISC O-MISC
dilution O-MISC O-MISC
or O-MISC O-MISC
gel O-MISC O-MISC
filtration O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
manifested O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
increased O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
steroid B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complex I-MISC O-MISC
for O-MISC O-MISC
DNA B-MISC O-MISC
and O-MISC O-MISC
an O-MISC O-MISC
altered O-MISC O-MISC
elution O-MISC O-MISC
profile O-MISC O-MISC
from O-MISC O-MISC
ion O-MISC O-MISC
- O-MISC O-MISC
exchange O-MISC O-MISC
resins O-MISC O-MISC
. O-MISC O-MISC

Munck O-MISC O-MISC
and O-MISC O-MISC
Foley O-MISC O-MISC
have O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
activated B-MISC B-MISC
complexes I-MISC I-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
thymocytes O-MISC O-MISC
elute O-MISC O-MISC
from O-MISC O-MISC
DEAE O-MISC O-MISC
- O-MISC O-MISC
cellulose O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
manner O-MISC O-MISC
identical O-MISC O-MISC
to O-MISC O-MISC
complexes O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
report O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
DEAE O-MISC O-MISC
- O-MISC O-MISC
cellulose O-MISC O-MISC
chromatography O-MISC O-MISC
of O-MISC O-MISC
steroid B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
from O-MISC O-MISC
CEM O-MISC O-MISC
- O-MISC O-MISC
C7 O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
cloned O-MISC O-MISC
human O-MISC O-MISC
leukaemic O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
sensitive O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
cytolytic O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
its O-MISC O-MISC
steroid O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
subclone O-MISC O-MISC
4R4 O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
steroid B-MISC B-MISC
receptors I-MISC I-MISC
of O-MISC O-MISC
clone O-MISC B-MISC
4R4 O-MISC I-MISC
can O-MISC O-MISC
not O-MISC O-MISC
form O-MISC O-MISC
stable O-MISC O-MISC
activated O-MISC O-MISC
complexes O-MISC I-MISC
. O-MISC O-MISC

This O-MISC O-MISC
defines O-MISC O-MISC
a O-MISC O-MISC
new O-MISC O-MISC
defect O-MISC O-MISC
in O-MISC O-MISC
receptor O-MISC O-MISC
action O-MISC O-MISC
, O-MISC O-MISC
activation O-MISC O-MISC
lability O-MISC O-MISC
( O-MISC O-MISC
r O-MISC B-MISC
+ O-MISC I-MISC
act1 O-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
unlike O-MISC O-MISC
either O-MISC O-MISC
the O-MISC O-MISC
r O-MISC B-MISC
- O-MISC I-MISC
, O-MISC O-MISC
r O-MISC O-MISC
+ O-MISC I-MISC
nt O-MISC I-MISC
- O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
r O-MISC O-MISC
+ O-MISC O-MISC
nti O-MISC O-MISC
phenotypes O-MISC O-MISC
previously O-MISC O-MISC
described O-MISC O-MISC
for O-MISC O-MISC
mouse O-MISC B-MISC
lymphoid O-MISC I-MISC
variants O-MISC I-MISC
. O-MISC O-MISC

Granulocytes O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
endometrium O-MISC O-MISC
of O-MISC O-MISC
post O-MISC O-MISC
- O-MISC O-MISC
partum O-MISC O-MISC
women O-MISC O-MISC
. O-MISC O-MISC

Endometrial O-MISC O-MISC
samples O-MISC O-MISC
of O-MISC O-MISC
women O-MISC O-MISC
at O-MISC O-MISC
various O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
gonadal O-MISC O-MISC
activity O-MISC O-MISC
after O-MISC O-MISC
parturition O-MISC O-MISC
were O-MISC O-MISC
examined O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
and O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
endometrial O-MISC O-MISC
granulocytes O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
samples O-MISC O-MISC
at O-MISC O-MISC
all O-MISC O-MISC
the O-MISC O-MISC
stages O-MISC O-MISC
contained O-MISC O-MISC
significant O-MISC O-MISC
numbers O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
granulocytes O-MISC O-MISC
( O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
greater O-MISC O-MISC
than O-MISC O-MISC
7 O-MISC O-MISC
/ O-MISC O-MISC
high O-MISC O-MISC
- O-MISC O-MISC
power O-MISC O-MISC
field O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
100 O-MISC O-MISC
% O-MISC O-MISC
values O-MISC O-MISC
for O-MISC O-MISC
late O-MISC O-MISC
- O-MISC O-MISC
proliferative O-MISC O-MISC
and O-MISC O-MISC
adaptation O-MISC O-MISC
hyperplasia O-MISC O-MISC
were O-MISC O-MISC
significantly O-MISC O-MISC
higher O-MISC O-MISC
than O-MISC O-MISC
the O-MISC O-MISC
values O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
resting O-MISC O-MISC
( O-MISC O-MISC
81 O-MISC O-MISC
. O-MISC O-MISC
8 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
early O-MISC O-MISC
( O-MISC O-MISC
82 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
mid O-MISC O-MISC
- O-MISC O-MISC
( O-MISC O-MISC
87 O-MISC O-MISC
. O-MISC O-MISC
9 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
proliferative O-MISC O-MISC
and O-MISC O-MISC
secretory O-MISC O-MISC
( O-MISC O-MISC
83 O-MISC O-MISC
. O-MISC O-MISC
3 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
phases O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
correlates O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
suggestion O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
granulocytes O-MISC O-MISC
constitute O-MISC O-MISC
a O-MISC O-MISC
receptor O-MISC O-MISC
system O-MISC O-MISC
for O-MISC O-MISC
oestrogens O-MISC O-MISC
. O-MISC O-MISC

Interaction O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
with O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
macrophages O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid O-MISC O-MISC
binding O-MISC O-MISC
was O-MISC O-MISC
measured O-MISC O-MISC
in O-MISC O-MISC
resident O-MISC O-MISC
and O-MISC O-MISC
thioglycollate O-MISC O-MISC
- O-MISC O-MISC
elicited O-MISC O-MISC
mouse O-MISC O-MISC
peritoneal O-MISC O-MISC
macrophages O-MISC O-MISC
, O-MISC O-MISC
rabbit O-MISC O-MISC
alveolar O-MISC O-MISC
macrophages O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
assays O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
were O-MISC O-MISC
used O-MISC O-MISC
- O-MISC O-MISC
- O-MISC O-MISC
an O-MISC O-MISC
assay O-MISC O-MISC
with O-MISC O-MISC
intact O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
suspension O-MISC O-MISC
or O-MISC O-MISC
monolayers O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
an O-MISC O-MISC
assay O-MISC O-MISC
of O-MISC O-MISC
cytosol O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
forms O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mononuclear O-MISC O-MISC
phagocytes O-MISC O-MISC
contained O-MISC O-MISC
approximately O-MISC O-MISC
equal O-MISC O-MISC
to O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC I-MISC
- O-MISC I-MISC
10 O-MISC I-MISC
X O-MISC I-MISC
10 O-MISC I-MISC
( O-MISC I-MISC
3 O-MISC O-MISC
) O-MISC I-MISC
high B-MISC I-MISC
affinity I-MISC I-MISC
receptor I-MISC I-MISC
sites I-MISC I-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
, O-MISC O-MISC
with O-MISC O-MISC
dissociation O-MISC O-MISC
constants O-MISC O-MISC
of O-MISC O-MISC
approximately O-MISC O-MISC
equal O-MISC O-MISC
to O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
nM O-MISC O-MISC
dexamethasone O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
saturable B-MISC O-MISC
sites I-MISC I-MISC
was O-MISC O-MISC
specific O-MISC O-MISC
for O-MISC O-MISC
steroids O-MISC O-MISC
with O-MISC O-MISC
glucocorticoid O-MISC O-MISC
or O-MISC O-MISC
antiglucocorticoid O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Cortisol O-MISC O-MISC
, O-MISC O-MISC
corticosterone O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
progesterone O-MISC O-MISC
competed O-MISC O-MISC
with O-MISC O-MISC
dexamethasone O-MISC O-MISC
for O-MISC O-MISC
binding O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
estradiol O-MISC O-MISC
, O-MISC O-MISC
dihydrotestosterone O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
11 O-MISC O-MISC
- O-MISC O-MISC
epicortisol O-MISC O-MISC
competed O-MISC O-MISC
very O-MISC O-MISC
little O-MISC O-MISC
. O-MISC O-MISC

Binding O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
to O-MISC O-MISC
cytosol O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
forms O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptor B-MISC B-MISC
complex I-MISC O-MISC
and O-MISC O-MISC
temperature O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
translocation O-MISC O-MISC
of O-MISC O-MISC
cytosol O-MISC O-MISC
forms O-MISC O-MISC
to O-MISC O-MISC
nuclear O-MISC O-MISC
forms O-MISC O-MISC
were O-MISC O-MISC
shown O-MISC O-MISC
. O-MISC O-MISC

At O-MISC O-MISC
37 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
the O-MISC O-MISC
predominant O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
hormone B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complex I-MISC I-MISC
was O-MISC O-MISC
nuclear O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
corticosteroids O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
macrophages O-MISC O-MISC
at O-MISC O-MISC
physiological O-MISC O-MISC
concentrations O-MISC O-MISC
. O-MISC O-MISC

Nitric O-MISC O-MISC
oxide O-MISC O-MISC
signaling O-MISC O-MISC
: O-MISC O-MISC
a O-MISC O-MISC
possible O-MISC O-MISC
role O-MISC O-MISC
for O-MISC O-MISC
G B-MISC B-MISC
proteins I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
previously O-MISC O-MISC
reported O-MISC O-MISC
various O-MISC O-MISC
inductive O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
on O-MISC O-MISC
human O-MISC O-MISC
PBMC O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
describe O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
and O-MISC O-MISC
potentially O-MISC O-MISC
important O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
signaling O-MISC O-MISC
- O-MISC O-MISC
through O-MISC O-MISC
direct O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
guanine B-MISC O-MISC
nucleotide I-MISC O-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
( O-MISC O-MISC
G B-MISC B-MISC
proteins I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
membranes O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
fresh O-MISC O-MISC
human O-MISC B-MISC
PBMC O-MISC I-MISC
enhances O-MISC I-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
membranes O-MISC O-MISC
to O-MISC O-MISC
hydrolyze O-MISC O-MISC
[ O-MISC O-MISC
gamma O-MISC O-MISC
- O-MISC O-MISC
32P O-MISC O-MISC
] O-MISC O-MISC
GTP O-MISC O-MISC
and O-MISC O-MISC
bind O-MISC O-MISC
[ O-MISC O-MISC
gamma O-MISC B-MISC
- O-MISC I-MISC
35S O-MISC I-MISC
] O-MISC O-MISC
GTP O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
whole O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
yielded O-MISC O-MISC
membranes O-MISC O-MISC
with O-MISC O-MISC
enhanced O-MISC O-MISC
GTPase O-MISC B-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
GTPase O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
pure O-MISC O-MISC
, O-MISC O-MISC
recombinant O-MISC B-MISC
Gs B-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
Gi B-MISC B-MISC
alpha I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
p21ras B-MISC B-MISC
was O-MISC O-MISC
greatly O-MISC O-MISC
enhanced O-MISC O-MISC
by O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
support O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
pathway O-MISC O-MISC
in O-MISC O-MISC
whole O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
G O-MISC B-MISC
protein O-MISC I-MISC
inhibitor O-MISC O-MISC
, O-MISC O-MISC
GDP O-MISC O-MISC
- O-MISC O-MISC
beta O-MISC I-MISC
- O-MISC I-MISC
S O-MISC O-MISC
, O-MISC O-MISC
blocked O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
translocation O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
or O-MISC O-MISC
LPS O-MISC O-MISC
in O-MISC O-MISC
permeabilized O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
nitric O-MISC O-MISC
oxide O-MISC O-MISC
greatly O-MISC O-MISC
reduced O-MISC O-MISC
the O-MISC O-MISC
pertussis O-MISC O-MISC
toxin O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
ADP O-MISC O-MISC
- O-MISC O-MISC
ribosylation O-MISC O-MISC
of O-MISC O-MISC
45 B-MISC O-MISC
- I-MISC O-MISC
and I-MISC I-MISC
41 I-MISC B-MISC
- I-MISC I-MISC
kDa I-MISC I-MISC
proteins I-MISC I-MISC
in O-MISC O-MISC
membranes O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Because O-MISC O-MISC
G B-MISC B-MISC
proteins I-MISC I-MISC
play O-MISC O-MISC
a O-MISC O-MISC
central O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
many O-MISC O-MISC
diverse O-MISC O-MISC
signaling O-MISC O-MISC
systems O-MISC O-MISC
, O-MISC O-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
an O-MISC O-MISC
endogenous O-MISC O-MISC
and O-MISC O-MISC
inducible O-MISC O-MISC
oxidant O-MISC O-MISC
may O-MISC O-MISC
represent O-MISC O-MISC
a O-MISC O-MISC
novel O-MISC O-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
granulocyte B-MISC B-MISC
- I-MISC I-MISC
macrophage I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
promoter I-MISC I-MISC
cis I-MISC I-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
element I-MISC I-MISC
CLE0 B-MISC B-MISC
mediates O-MISC O-MISC
induction O-MISC O-MISC
signals O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
recognized O-MISC O-MISC
by O-MISC O-MISC
factors O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
AP1 B-MISC B-MISC
and O-MISC O-MISC
NFAT B-MISC B-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
granulocyte B-MISC B-MISC
- I-MISC I-MISC
macrophage I-MISC I-MISC
colony I-MISC I-MISC
- I-MISC I-MISC
stimulating I-MISC I-MISC
factor I-MISC I-MISC
( I-MISC I-MISC
GM I-MISC I-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
) I-MISC I-MISC
gene I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
combination O-MISC O-MISC
of O-MISC O-MISC
phorbol O-MISC O-MISC
ester O-MISC O-MISC
( O-MISC O-MISC
phorbol O-MISC O-MISC
myristate O-MISC O-MISC
acetate O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
calcium O-MISC O-MISC
ionophore O-MISC O-MISC
( O-MISC O-MISC
A23187 O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
mimic O-MISC O-MISC
antigen O-MISC O-MISC
stimulation O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
previously O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
fragment O-MISC O-MISC
containing O-MISC O-MISC
bp B-MISC B-MISC
- I-MISC I-MISC
95 I-MISC O-MISC
to I-MISC O-MISC
+ I-MISC O-MISC
27 I-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mouse B-MISC B-MISC
GM I-MISC I-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
promoter I-MISC I-MISC
can O-MISC O-MISC
confer O-MISC O-MISC
inducibility O-MISC O-MISC
to O-MISC O-MISC
reporter B-MISC B-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
Jurkat O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
use O-MISC O-MISC
an O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
transcription O-MISC O-MISC
system O-MISC O-MISC
to O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
cis B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
element I-MISC I-MISC
( O-MISC O-MISC
positions B-MISC O-MISC
- I-MISC O-MISC
54 I-MISC O-MISC
to I-MISC O-MISC
- I-MISC O-MISC
40 I-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
referred O-MISC O-MISC
to O-MISC O-MISC
as O-MISC O-MISC
CLE0 B-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
target O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
signals O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
observed O-MISC O-MISC
induction O-MISC O-MISC
with O-MISC O-MISC
templates O-MISC O-MISC
containing O-MISC O-MISC
intact O-MISC O-MISC
CLE0 B-MISC B-MISC
but O-MISC O-MISC
not O-MISC O-MISC
with O-MISC O-MISC
templates O-MISC O-MISC
with O-MISC O-MISC
deleted B-MISC O-MISC
or I-MISC O-MISC
mutated I-MISC B-MISC
CLE0 I-MISC B-MISC
. O-MISC O-MISC

We O-MISC O-MISC
also O-MISC O-MISC
observed O-MISC O-MISC
that O-MISC O-MISC
two O-MISC O-MISC
distinct O-MISC O-MISC
signals O-MISC O-MISC
were O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
stimulation O-MISC O-MISC
through O-MISC O-MISC
CLE0 B-MISC B-MISC
, O-MISC O-MISC
since O-MISC O-MISC
only O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
cells O-MISC O-MISC
treated O-MISC O-MISC
with O-MISC O-MISC
both O-MISC O-MISC
phorbol O-MISC O-MISC
myristate O-MISC O-MISC
acetate O-MISC O-MISC
and O-MISC O-MISC
A23187 O-MISC O-MISC
supported O-MISC O-MISC
optimal O-MISC O-MISC
induction O-MISC O-MISC
. O-MISC O-MISC

Stimulation O-MISC O-MISC
probably O-MISC O-MISC
was O-MISC O-MISC
mediated O-MISC O-MISC
by O-MISC O-MISC
CLE0 B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
proteins I-MISC I-MISC
because O-MISC O-MISC
depletion O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
proteins O-MISC O-MISC
specifically O-MISC O-MISC
reduced O-MISC O-MISC
GM B-MISC B-MISC
- I-MISC O-MISC
CSF I-MISC I-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

One O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
binding B-MISC B-MISC
factors I-MISC I-MISC
possessed O-MISC O-MISC
biochemical O-MISC O-MISC
and O-MISC O-MISC
immunological O-MISC O-MISC
features O-MISC O-MISC
identical O-MISC O-MISC
to O-MISC O-MISC
those O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
AP1 I-MISC B-MISC
. O-MISC O-MISC

Another O-MISC O-MISC
factor O-MISC O-MISC
resembled O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
factor I-MISC I-MISC
NFAT I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
characteristics O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
two O-MISC O-MISC
factors O-MISC O-MISC
are O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
their O-MISC O-MISC
involvement O-MISC O-MISC
in O-MISC O-MISC
GM O-MISC B-MISC
- O-MISC I-MISC
CSF O-MISC I-MISC
induction O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
CLE0 B-MISC B-MISC
- I-MISC I-MISC
like I-MISC I-MISC
elements I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
promoters B-MISC B-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
) I-MISC O-MISC
, I-MISC O-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, I-MISC I-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
5 I-MISC I-MISC
, I-MISC I-MISC
GM I-MISC B-MISC
- I-MISC I-MISC
CSF I-MISC I-MISC
, I-MISC O-MISC
and I-MISC O-MISC
NFAT I-MISC B-MISC
sites I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
factors O-MISC O-MISC
we O-MISC O-MISC
detected O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
related O-MISC O-MISC
factors O-MISC O-MISC
that O-MISC O-MISC
recognize O-MISC O-MISC
these O-MISC O-MISC
sites O-MISC O-MISC
, O-MISC O-MISC
may O-MISC O-MISC
account O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
coordinate O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
genes O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
and O-MISC O-MISC
characterization O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
Alu B-MISC B-MISC
- I-MISC I-MISC
containing I-MISC I-MISC
, I-MISC O-MISC
T I-MISC I-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
enhancer I-MISC I-MISC
located O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
last O-MISC O-MISC
intron B-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
CD8 I-MISC I-MISC
alpha I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
CD8 I-MISC I-MISC
alpha I-MISC I-MISC
gene I-MISC I-MISC
is O-MISC O-MISC
restricted O-MISC O-MISC
to O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
lymphoid O-MISC O-MISC
lineage O-MISC O-MISC
and O-MISC O-MISC
developmentally O-MISC O-MISC
regulated O-MISC O-MISC
during O-MISC O-MISC
thymopoiesis O-MISC O-MISC
. O-MISC O-MISC

As O-MISC O-MISC
an O-MISC O-MISC
initial O-MISC O-MISC
step O-MISC O-MISC
towards O-MISC O-MISC
understanding O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
basis O-MISC O-MISC
for O-MISC O-MISC
tissue O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
gene O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
surveyed O-MISC O-MISC
the O-MISC O-MISC
surrounding O-MISC O-MISC
chromatin O-MISC O-MISC
structure O-MISC O-MISC
for O-MISC O-MISC
potential O-MISC O-MISC
cis B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
regulatory I-MISC I-MISC
regions I-MISC I-MISC
by O-MISC O-MISC
DNase B-MISC B-MISC
I I-MISC I-MISC
hypersensitivity O-MISC I-MISC
mapping O-MISC O-MISC
and O-MISC O-MISC
found O-MISC O-MISC
four O-MISC O-MISC
hypersensitive O-MISC O-MISC
sites O-MISC I-MISC
, O-MISC O-MISC
three O-MISC O-MISC
of O-MISC O-MISC
which O-MISC O-MISC
were O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
restricted O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
using O-MISC O-MISC
a O-MISC O-MISC
reporter O-MISC O-MISC
- O-MISC O-MISC
based O-MISC O-MISC
expression O-MISC O-MISC
approach O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
enhancer I-MISC I-MISC
was O-MISC O-MISC
identified O-MISC O-MISC
by O-MISC O-MISC
its O-MISC O-MISC
close O-MISC O-MISC
association O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
prominent O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
restricted I-MISC I-MISC
hypersensitive I-MISC I-MISC
sites I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
last O-MISC B-MISC
intron O-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CD8 B-MISC B-MISC
alpha I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

Deletion O-MISC O-MISC
studies O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
minimal O-MISC B-MISC
enhancer O-MISC I-MISC
is O-MISC O-MISC
adjacent O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
negative O-MISC B-MISC
regulatory O-MISC I-MISC
element O-MISC I-MISC
. O-MISC O-MISC

DNA O-MISC O-MISC
sequence O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
minimal B-MISC B-MISC
enhancer I-MISC I-MISC
revealed O-MISC O-MISC
a O-MISC O-MISC
striking O-MISC O-MISC
cluster O-MISC O-MISC
of O-MISC O-MISC
consensus B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
for O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, I-MISC O-MISC
TCF I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, I-MISC O-MISC
CRE I-MISC B-MISC
, I-MISC I-MISC
GATA I-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, I-MISC I-MISC
LyF I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, I-MISC O-MISC
and I-MISC O-MISC
bHLH I-MISC B-MISC
proteins I-MISC I-MISC
which O-MISC O-MISC
were O-MISC O-MISC
verified O-MISC O-MISC
by O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
end I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
enhancer B-MISC B-MISC
was O-MISC O-MISC
composed O-MISC O-MISC
of O-MISC O-MISC
an O-MISC O-MISC
Alu O-MISC B-MISC
repeat O-MISC I-MISC
which O-MISC O-MISC
contained O-MISC O-MISC
the O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
, I-MISC I-MISC
bHLH I-MISC I-MISC
, I-MISC I-MISC
and I-MISC I-MISC
LyF I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

Site O-MISC O-MISC
- O-MISC O-MISC
directed O-MISC O-MISC
mutation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC I-MISC
GATA I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
sites I-MISC I-MISC
dramatically O-MISC O-MISC
reduced O-MISC O-MISC
enhancer O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
functional O-MISC O-MISC
importance O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
binding O-MISC B-MISC
sites O-MISC I-MISC
only O-MISC O-MISC
became O-MISC O-MISC
apparent O-MISC O-MISC
when O-MISC O-MISC
combinations O-MISC O-MISC
of O-MISC O-MISC
mutations O-MISC O-MISC
were O-MISC O-MISC
analyzed O-MISC O-MISC
. O-MISC O-MISC

Taken O-MISC O-MISC
together O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
CD8 I-MISC I-MISC
alpha I-MISC I-MISC
gene I-MISC I-MISC
is O-MISC O-MISC
regulated O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
interaction O-MISC O-MISC
of O-MISC O-MISC
multiple O-MISC O-MISC
T B-MISC O-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
nuclear I-MISC I-MISC
proteins I-MISC I-MISC
with O-MISC O-MISC
a O-MISC O-MISC
transcriptional O-MISC B-MISC
enhancer O-MISC I-MISC
located O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
last O-MISC B-MISC
intron B-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
gene O-MISC O-MISC
. O-MISC O-MISC

Comparison O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CD8 B-MISC B-MISC
alpha I-MISC I-MISC
enhancer I-MISC I-MISC
with O-MISC O-MISC
other O-MISC O-MISC
recently O-MISC O-MISC
identified O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
regulatory I-MISC I-MISC
elements I-MISC I-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
common O-MISC O-MISC
set O-MISC O-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
regulates O-MISC O-MISC
several O-MISC O-MISC
T B-MISC B-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
genes I-MISC I-MISC
. O-MISC O-MISC

Molecular O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
gene I-MISC I-MISC
: O-MISC O-MISC
inducible O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
restricted O-MISC O-MISC
expression O-MISC O-MISC
requires O-MISC O-MISC
intact O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC O-MISC
Elf I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
nuclear I-MISC I-MISC
protein I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

Interleukin B-MISC B-MISC
3 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
) O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
hematopoietic B-MISC O-MISC
stem I-MISC I-MISC
- I-MISC I-MISC
cell I-MISC I-MISC
growth I-MISC I-MISC
and I-MISC O-MISC
differentiation I-MISC B-MISC
factor I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
expressed O-MISC O-MISC
solely O-MISC O-MISC
in O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
NK O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Studies O-MISC O-MISC
to O-MISC O-MISC
date O-MISC O-MISC
have O-MISC O-MISC
identified O-MISC O-MISC
elements O-MISC O-MISC
5 O-MISC O-MISC
' O-MISC I-MISC
to O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
coding I-MISC I-MISC
sequences I-MISC I-MISC
that O-MISC O-MISC
regulate O-MISC O-MISC
its O-MISC O-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
the O-MISC O-MISC
sequences O-MISC O-MISC
that O-MISC O-MISC
confer O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
remain O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
clearly O-MISC O-MISC
defined O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
now O-MISC O-MISC
identified O-MISC O-MISC
DNA B-MISC B-MISC
sequences I-MISC I-MISC
that O-MISC O-MISC
are O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
restricted O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
gene I-MISC I-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
series O-MISC O-MISC
of O-MISC O-MISC
transient O-MISC O-MISC
transfections O-MISC O-MISC
performed O-MISC O-MISC
with O-MISC O-MISC
human B-MISC B-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
- I-MISC I-MISC
chloramphenicol I-MISC I-MISC
acetyltransferase I-MISC I-MISC
( I-MISC I-MISC
CAT I-MISC I-MISC
) I-MISC I-MISC
reporter I-MISC I-MISC
plasmids I-MISC I-MISC
in O-MISC O-MISC
T O-MISC O-MISC
and O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
plasmid B-MISC B-MISC
containing O-MISC O-MISC
319 O-MISC O-MISC
bp O-MISC I-MISC
of O-MISC I-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
flanking I-MISC I-MISC
sequences I-MISC I-MISC
was O-MISC O-MISC
active O-MISC O-MISC
exclusively O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Deletion O-MISC O-MISC
analysis O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
specificity O-MISC O-MISC
was O-MISC O-MISC
conferred O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
49 B-MISC B-MISC
- I-MISC I-MISC
bp I-MISC I-MISC
fragment I-MISC I-MISC
( O-MISC O-MISC
bp B-MISC B-MISC
- I-MISC O-MISC
319 I-MISC O-MISC
to I-MISC O-MISC
- I-MISC O-MISC
270 I-MISC O-MISC
) O-MISC O-MISC
that O-MISC O-MISC
included O-MISC O-MISC
a O-MISC O-MISC
potential B-MISC O-MISC
binding I-MISC O-MISC
site I-MISC O-MISC
for O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
6 O-MISC I-MISC
bp O-MISC I-MISC
upstream O-MISC I-MISC
of O-MISC O-MISC
a O-MISC O-MISC
binding B-MISC B-MISC
site I-MISC I-MISC
for I-MISC O-MISC
Elf I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
member O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Ets B-MISC B-MISC
family I-MISC I-MISC
of O-MISC O-MISC
transcription B-MISC B-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

DNaseI B-MISC B-MISC
footprint O-MISC O-MISC
and O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
analyses O-MISC O-MISC
performed O-MISC O-MISC
with O-MISC O-MISC
MLA O-MISC O-MISC
- O-MISC O-MISC
144 O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
49 B-MISC O-MISC
- I-MISC I-MISC
bp I-MISC I-MISC
region I-MISC I-MISC
contains O-MISC O-MISC
a O-MISC O-MISC
nuclear B-MISC B-MISC
protein I-MISC I-MISC
binding I-MISC I-MISC
region I-MISC I-MISC
that O-MISC O-MISC
includes O-MISC O-MISC
consensus B-MISC B-MISC
AP I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC I-MISC
Elf I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
extracts O-MISC O-MISC
prepared O-MISC O-MISC
from O-MISC O-MISC
purified O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
contained O-MISC O-MISC
proteins O-MISC O-MISC
that O-MISC O-MISC
bound O-MISC O-MISC
to O-MISC O-MISC
synthetic O-MISC O-MISC
oligonucleotides O-MISC O-MISC
corresponding O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC O-MISC
Elf I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
vitro O-MISC O-MISC
- O-MISC O-MISC
transcribed O-MISC O-MISC
and O-MISC O-MISC
- O-MISC B-MISC
translated O-MISC I-MISC
Elf B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
protein I-MISC I-MISC
bound O-MISC O-MISC
specifically O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
Elf B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
Elf O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
antisera O-MISC O-MISC
competed O-MISC O-MISC
and O-MISC O-MISC
super O-MISC O-MISC
shifted O-MISC O-MISC
nuclear O-MISC O-MISC
protein O-MISC B-MISC
complexes O-MISC I-MISC
present O-MISC O-MISC
in O-MISC O-MISC
MLA O-MISC O-MISC
- O-MISC O-MISC
144 O-MISC O-MISC
nuclear O-MISC O-MISC
extracts O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
anti O-MISC B-MISC
- O-MISC I-MISC
Jun O-MISC I-MISC
family O-MISC I-MISC
antiserum O-MISC I-MISC
in O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
reactions O-MISC O-MISC
completely O-MISC O-MISC
blocked O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
- I-MISC I-MISC
related I-MISC I-MISC
complexes I-MISC I-MISC
. O-MISC O-MISC

Transient O-MISC O-MISC
transfection O-MISC O-MISC
studies O-MISC O-MISC
in O-MISC O-MISC
MLA O-MISC O-MISC
- O-MISC O-MISC
144 O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
constructs O-MISC O-MISC
containing O-MISC O-MISC
mutations O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
almost O-MISC O-MISC
completely O-MISC O-MISC
abolished O-MISC O-MISC
CAT O-MISC B-MISC
activity O-MISC O-MISC
while O-MISC O-MISC
mutation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Elf B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
site I-MISC I-MISC
or O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
site I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
previously O-MISC O-MISC
described O-MISC O-MISC
nuclear B-MISC B-MISC
protein I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
( O-MISC O-MISC
bp B-MISC B-MISC
. I-MISC O-MISC
- I-MISC I-MISC
155 I-MISC I-MISC
to I-MISC I-MISC
- I-MISC I-MISC
148 I-MISC I-MISC
) O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
promoter I-MISC I-MISC
, O-MISC O-MISC
reduced O-MISC O-MISC
CAT O-MISC B-MISC
activity O-MISC O-MISC
to O-MISC O-MISC
< O-MISC O-MISC
25 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
given O-MISC O-MISC
by O-MISC O-MISC
wild O-MISC B-MISC
- O-MISC I-MISC
type O-MISC I-MISC
constructs O-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
conclude O-MISC O-MISC
that O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
gene I-MISC I-MISC
requires O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC I-MISC
Elf I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
; O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
unlike O-MISC O-MISC
other O-MISC O-MISC
previously O-MISC O-MISC
characterized O-MISC O-MISC
cytokine B-MISC B-MISC
genes I-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and I-MISC I-MISC
Elf I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
factors I-MISC I-MISC
can O-MISC O-MISC
bind O-MISC O-MISC
independently O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

( O-MISC O-MISC
ABSTRACT O-MISC O-MISC
TRUNCATED O-MISC O-MISC
AT O-MISC O-MISC
400 O-MISC O-MISC
WORDS O-MISC O-MISC
) O-MISC O-MISC

Combination O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
reduces O-MISC O-MISC
glucocorticoid O-MISC O-MISC
receptor O-MISC I-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
mechanisms O-MISC O-MISC
contributing O-MISC O-MISC
to O-MISC O-MISC
persistent O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
poor O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
in O-MISC O-MISC
chronic O-MISC O-MISC
inflammatory O-MISC O-MISC
illnesses O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
steroid O-MISC O-MISC
resistant O-MISC O-MISC
( O-MISC O-MISC
SR O-MISC O-MISC
) O-MISC O-MISC
asthma O-MISC O-MISC
are O-MISC O-MISC
poorly O-MISC O-MISC
defined O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
possibility O-MISC O-MISC
that O-MISC O-MISC
certain O-MISC O-MISC
cytokines O-MISC B-MISC
, O-MISC O-MISC
specifically O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
, O-MISC O-MISC
could O-MISC O-MISC
affect O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
dexamethasone O-MISC O-MISC
radioligand O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
assay O-MISC O-MISC
was O-MISC O-MISC
used O-MISC O-MISC
to O-MISC O-MISC
measure O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
( O-MISC O-MISC
GR B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
dissociation O-MISC O-MISC
constant O-MISC O-MISC
( O-MISC O-MISC
Kd O-MISC O-MISC
) O-MISC O-MISC
in O-MISC O-MISC
PBMC O-MISC O-MISC
from O-MISC O-MISC
normal O-MISC O-MISC
donors O-MISC O-MISC
and O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
SR O-MISC O-MISC
asthma O-MISC O-MISC
, O-MISC O-MISC
cultured O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
absence O-MISC O-MISC
and O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
cytokines B-MISC B-MISC
. O-MISC O-MISC

PBMC O-MISC O-MISC
from O-MISC O-MISC
normal O-MISC O-MISC
donors O-MISC O-MISC
incubated O-MISC O-MISC
for O-MISC O-MISC
48 O-MISC O-MISC
h O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
combination O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
+ O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
had O-MISC O-MISC
nuclear O-MISC O-MISC
GR O-MISC B-MISC
with O-MISC O-MISC
significantly O-MISC O-MISC
reduced O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
( O-MISC O-MISC
GR O-MISC B-MISC
Kd O-MISC O-MISC
= O-MISC O-MISC
36 O-MISC O-MISC
. O-MISC O-MISC
1 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
63 O-MISC O-MISC
nM O-MISC O-MISC
, O-MISC O-MISC
mean O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
SEM O-MISC O-MISC
; O-MISC O-MISC
p O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
0001 O-MISC O-MISC
) O-MISC O-MISC
as O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
PBMC O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
medium O-MISC O-MISC
alone O-MISC O-MISC
( O-MISC O-MISC
GR O-MISC B-MISC
Kd O-MISC I-MISC
= O-MISC O-MISC
6 O-MISC O-MISC
. O-MISC O-MISC
74 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
46 O-MISC O-MISC
nM O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cytosolic O-MISC B-MISC
GR O-MISC I-MISC
Kd O-MISC I-MISC
remained O-MISC O-MISC
unchanged O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
when O-MISC O-MISC
PBMC O-MISC O-MISC
were O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
alone O-MISC O-MISC
or O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
alone O-MISC O-MISC
, O-MISC O-MISC
no O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
GR O-MISC B-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
when O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
non O-MISC O-MISC
- O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
individually O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
combination O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
+ O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
GR O-MISC B-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
only O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
population O-MISC O-MISC
( O-MISC O-MISC
p O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
0001 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
+ O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
alteration O-MISC O-MISC
in O-MISC O-MISC
PBMC O-MISC O-MISC
GR O-MISC B-MISC
Kd O-MISC I-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
GR O-MISC B-MISC
number O-MISC O-MISC
( O-MISC O-MISC
8348 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
964 O-MISC O-MISC
vs O-MISC O-MISC
1710 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
228 O-MISC O-MISC
sites O-MISC O-MISC
/ O-MISC O-MISC
cell O-MISC O-MISC
; O-MISC O-MISC
p O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
0003 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

More O-MISC O-MISC
importantly O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
alteration O-MISC O-MISC
in O-MISC O-MISC
PBMC O-MISC O-MISC
GR O-MISC B-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
with O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
+ O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
functional O-MISC O-MISC
change O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
methylprednisolone O-MISC O-MISC
MPN O-MISC O-MISC
, O-MISC O-MISC
i O-MISC O-MISC
. O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
reduced O-MISC O-MISC
inhibitory O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
MPN O-MISC O-MISC
on O-MISC O-MISC
PMA O-MISC O-MISC
/ O-MISC O-MISC
ionomycin O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
+ O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
on O-MISC O-MISC
PBMC O-MISC O-MISC
GR B-MISC B-MISC
affinity O-MISC O-MISC
and O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
MPN O-MISC O-MISC
were O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
co O-MISC O-MISC
- O-MISC O-MISC
incubation O-MISC O-MISC
with O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
. O-MISC O-MISC

Freshly O-MISC O-MISC
isolated O-MISC O-MISC
PBMC O-MISC O-MISC
from O-MISC O-MISC
four O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
SR O-MISC O-MISC
asthma O-MISC O-MISC
had O-MISC O-MISC
a O-MISC O-MISC
significantly O-MISC O-MISC
reduced O-MISC O-MISC
GR O-MISC B-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
( O-MISC O-MISC
Kd O-MISC O-MISC
= O-MISC O-MISC
40 O-MISC O-MISC
. O-MISC O-MISC
0 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
2 O-MISC O-MISC
. O-MISC O-MISC
68 O-MISC O-MISC
nM O-MISC O-MISC
; O-MISC O-MISC
p O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
0001 O-MISC O-MISC
) O-MISC O-MISC
when O-MISC O-MISC
compared O-MISC O-MISC
with O-MISC O-MISC
seven O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
( O-MISC O-MISC
7 O-MISC O-MISC
. O-MISC O-MISC
15 O-MISC O-MISC
+ O-MISC O-MISC
/ O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
41 O-MISC O-MISC
nM O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
altered O-MISC O-MISC
PBMC O-MISC O-MISC
GR O-MISC B-MISC
binding O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
SR O-MISC O-MISC
asthma O-MISC O-MISC
reversed O-MISC O-MISC
to O-MISC O-MISC
normal O-MISC O-MISC
when O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
medium O-MISC O-MISC
alone O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
was O-MISC O-MISC
sustained O-MISC O-MISC
with O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
+ O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
observations O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
with O-MISC O-MISC
persistent O-MISC O-MISC
inflammation O-MISC O-MISC
certain O-MISC O-MISC
cytokines B-MISC B-MISC
may O-MISC O-MISC
contribute O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
impaired O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
were O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
. O-MISC O-MISC

Characterization O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
CD4 I-MISC I-MISC
gene I-MISC I-MISC
promoter I-MISC I-MISC
: O-MISC O-MISC
transcription O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
CD4 B-MISC B-MISC
gene I-MISC I-MISC
core I-MISC I-MISC
promoter I-MISC I-MISC
is O-MISC O-MISC
tissue O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
Ets B-MISC B-MISC
proteins I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
transcription I-MISC I-MISC
control I-MISC I-MISC
sequences I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
CD4 I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
located O-MISC O-MISC
the O-MISC O-MISC
transcription B-MISC B-MISC
initiation I-MISC I-MISC
site I-MISC I-MISC
and O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
CD4 B-MISC B-MISC
core I-MISC I-MISC
promoter I-MISC I-MISC
( O-MISC O-MISC
positions B-MISC O-MISC
- I-MISC I-MISC
40 I-MISC I-MISC
to I-MISC I-MISC
+ I-MISC I-MISC
16 I-MISC I-MISC
) O-MISC O-MISC
lacks O-MISC O-MISC
a O-MISC O-MISC
classical O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
TATA O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
or O-MISC O-MISC
initiator B-MISC O-MISC
positioning I-MISC O-MISC
consensus I-MISC B-MISC
sequence I-MISC I-MISC
but O-MISC O-MISC
directs O-MISC O-MISC
precise O-MISC O-MISC
and O-MISC O-MISC
efficient O-MISC O-MISC
transcription O-MISC O-MISC
when O-MISC O-MISC
coupled O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
ubiquitously O-MISC B-MISC
active O-MISC I-MISC
simian B-MISC I-MISC
virus I-MISC I-MISC
40 I-MISC I-MISC
enhancer I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CD4 B-MISC B-MISC
gene I-MISC I-MISC
promoter I-MISC I-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
CD4 O-MISC B-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
various O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
. O-MISC O-MISC

Interestingly O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
CD4 B-MISC B-MISC
core I-MISC I-MISC
promoter I-MISC I-MISC
also O-MISC O-MISC
displayed O-MISC O-MISC
a O-MISC O-MISC
tissue O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
transcriptional O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

Within O-MISC O-MISC
this O-MISC O-MISC
fragment O-MISC O-MISC
, O-MISC O-MISC
three O-MISC O-MISC
nucleic O-MISC B-MISC
acid O-MISC I-MISC
sequences O-MISC I-MISC
are O-MISC O-MISC
completely O-MISC O-MISC
conserved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
murine B-MISC B-MISC
CD4 I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

One O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
sequences O-MISC O-MISC
contains O-MISC O-MISC
a O-MISC O-MISC
perfect B-MISC O-MISC
ETS I-MISC B-MISC
consensus I-MISC I-MISC
sequence I-MISC I-MISC
. O-MISC O-MISC

Another O-MISC O-MISC
ETS B-MISC B-MISC
consensus I-MISC I-MISC
sequence I-MISC I-MISC
is O-MISC O-MISC
located O-MISC O-MISC
1060 O-MISC O-MISC
nt O-MISC I-MISC
upstream O-MISC I-MISC
. O-MISC O-MISC

Electrophoretic O-MISC O-MISC
- O-MISC O-MISC
mobility O-MISC O-MISC
- O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
core O-MISC B-MISC
promoter O-MISC I-MISC
ETS O-MISC I-MISC
motif O-MISC I-MISC
binds O-MISC O-MISC
an O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
related I-MISC I-MISC
protein I-MISC I-MISC
specifically O-MISC O-MISC
expressed O-MISC O-MISC
at O-MISC O-MISC
high O-MISC O-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
CD4 O-MISC O-MISC
+ O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Moreover O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
CD4 O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
or O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
efficiently O-MISC O-MISC
and O-MISC O-MISC
specifically O-MISC O-MISC
activated O-MISC O-MISC
transcription O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
CD4 B-MISC B-MISC
promoter I-MISC I-MISC
and O-MISC O-MISC
core B-MISC B-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
Ets B-MISC B-MISC
transcription I-MISC I-MISC
factors I-MISC I-MISC
play O-MISC O-MISC
a O-MISC O-MISC
central O-MISC O-MISC
role O-MISC O-MISC
in O-MISC O-MISC
controlling O-MISC O-MISC
CD4 O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
by O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
both O-MISC O-MISC
a O-MISC O-MISC
classical B-MISC O-MISC
remote I-MISC B-MISC
site I-MISC I-MISC
and O-MISC O-MISC
an O-MISC O-MISC
unusual O-MISC O-MISC
proximal B-MISC B-MISC
activator I-MISC I-MISC
sequence I-MISC I-MISC

Glucocorticoid O-MISC B-MISC
receptor O-MISC I-MISC
activation O-MISC O-MISC
and O-MISC O-MISC
inactivation O-MISC O-MISC
in O-MISC O-MISC
c O-MISC O-MISC
ultured O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
glucocorticoids O-MISC O-MISC
are O-MISC O-MISC
not O-MISC O-MISC
cytolytic O-MISC O-MISC
for O-MISC O-MISC
and O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
inhibit O-MISC O-MISC
the O-MISC O-MISC
growth O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IM O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
line O-MISC O-MISC
of O-MISC O-MISC
cultured O-MISC O-MISC
human O-MISC O-MISC
lymphoblasts O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
have O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
steroid O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
used O-MISC O-MISC
IM O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
order O-MISC O-MISC
to O-MISC O-MISC
examine O-MISC O-MISC
whether O-MISC O-MISC
unoccupied B-MISC B-MISC
glucocorticoid I-MISC I-MISC
receptors I-MISC I-MISC
are O-MISC O-MISC
inactivated O-MISC O-MISC
and O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
intact O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

when O-MISC O-MISC
IM O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
incubated O-MISC O-MISC
in O-MISC O-MISC
glucose O-MISC O-MISC
- O-MISC O-MISC
free O-MISC O-MISC
medium O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
nitrogen O-MISC O-MISC
atmosphere O-MISC O-MISC
, O-MISC O-MISC
both O-MISC O-MISC
their O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
bind O-MISC O-MISC
triamcinolone O-MISC O-MISC
acetonide O-MISC O-MISC
and O-MISC O-MISC
their O-MISC O-MISC
ATP O-MISC O-MISC
levels O-MISC O-MISC
decline O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
when O-MISC O-MISC
glucose O-MISC O-MISC
and O-MISC O-MISC
oxygen O-MISC O-MISC
are O-MISC O-MISC
reintroduced O-MISC O-MISC
, O-MISC O-MISC
ATP O-MISC O-MISC
levels O-MISC O-MISC
and O-MISC O-MISC
receptor O-MISC O-MISC
activity O-MISC O-MISC
return O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
specific O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
cytosol O-MISC O-MISC
prepared O-MISC O-MISC
from O-MISC O-MISC
cells O-MISC O-MISC
exposed O-MISC O-MISC
to O-MISC O-MISC
various O-MISC O-MISC
degrees O-MISC O-MISC
of O-MISC O-MISC
energy O-MISC O-MISC
limitation O-MISC O-MISC
is O-MISC O-MISC
directly O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
ATP O-MISC O-MISC
content O-MISC O-MISC
. O-MISC O-MISC

Receptor O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
intact O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
rapid O-MISC O-MISC
and O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
protein O-MISC O-MISC
synthesis O-MISC O-MISC
. O-MISC O-MISC

Cytosol O-MISC O-MISC
prepared O-MISC O-MISC
from O-MISC O-MISC
inactivated O-MISC O-MISC
cells O-MISC O-MISC
can O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
activated O-MISC O-MISC
by O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
ATP O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
inactivation O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
that O-MISC O-MISC
occurs O-MISC O-MISC
when O-MISC O-MISC
cytosol O-MISC O-MISC
from O-MISC O-MISC
normal O-MISC O-MISC
IM O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
incubated O-MISC O-MISC
at O-MISC O-MISC
25 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
is O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
molybdate O-MISC O-MISC
, O-MISC O-MISC
vanadate O-MISC O-MISC
, O-MISC O-MISC
fluoride O-MISC O-MISC
, O-MISC O-MISC
ATP O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
several O-MISC O-MISC
other O-MISC O-MISC
nucleotides O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
experiments O-MISC O-MISC
with O-MISC O-MISC
intact O-MISC O-MISC
human O-MISC O-MISC
lymphoblasts O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
assays O-MISC O-MISC
of O-MISC O-MISC
specific O-MISC O-MISC
glucocorticoid O-MISC O-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
necessarily O-MISC O-MISC
reflect O-MISC O-MISC
the O-MISC O-MISC
cellular O-MISC O-MISC
content O-MISC O-MISC
of O-MISC O-MISC
receptor B-MISC B-MISC
protein I-MISC O-MISC
. O-MISC O-MISC

Glucocorticoids O-MISC O-MISC
and O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

II O-MISC O-MISC
. O-MISC O-MISC

Cell O-MISC O-MISC
cycle O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
content O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
study O-MISC O-MISC
variations O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
during O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
separated O-MISC O-MISC
mitogen O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
rat O-MISC O-MISC
lymph O-MISC O-MISC
node O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
unit O-MISC O-MISC
gravity O-MISC O-MISC
sedimentation O-MISC O-MISC
and O-MISC O-MISC
measured O-MISC O-MISC
glucocorticoid O-MISC O-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
resultant O-MISC O-MISC
fractions O-MISC O-MISC
. O-MISC O-MISC

By O-MISC O-MISC
morphologic O-MISC O-MISC
criteria O-MISC O-MISC
and O-MISC O-MISC
thymidine O-MISC O-MISC
incorporation O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
fractions O-MISC O-MISC
were O-MISC O-MISC
separated O-MISC O-MISC
into O-MISC O-MISC
populations O-MISC O-MISC
of O-MISC O-MISC
G0 O-MISC O-MISC
and O-MISC O-MISC
G1 O-MISC O-MISC
phase O-MISC O-MISC
and O-MISC O-MISC
S O-MISC O-MISC
and O-MISC O-MISC
post O-MISC O-MISC
- O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
to O-MISC O-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid O-MISC B-MISC
receptor O-MISC I-MISC
sites O-MISC I-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
, O-MISC O-MISC
for O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
S O-MISC O-MISC
and O-MISC O-MISC
post O-MISC O-MISC
- O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
over O-MISC O-MISC
those O-MISC O-MISC
in O-MISC O-MISC
G0 O-MISC O-MISC
and O-MISC O-MISC
G1 O-MISC B-MISC
, O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
with O-MISC O-MISC
both O-MISC O-MISC
nonstimulated O-MISC O-MISC
rat O-MISC O-MISC
lymph O-MISC O-MISC
node O-MISC O-MISC
cell O-MISC O-MISC
suspensions O-MISC O-MISC
and O-MISC O-MISC
concanavalin O-MISC O-MISC
A O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
observations O-MISC O-MISC
together O-MISC O-MISC
with O-MISC O-MISC
those O-MISC O-MISC
from O-MISC O-MISC
other O-MISC O-MISC
studies O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
formation O-MISC O-MISC
of O-MISC O-MISC
new O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
near O-MISC O-MISC
the O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
general O-MISC O-MISC
phenomenon O-MISC O-MISC
in O-MISC O-MISC
proliferating O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
propose O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
during O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
may O-MISC O-MISC
explain O-MISC O-MISC
the O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
mitogen O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
leukocyte O-MISC O-MISC
migration O-MISC O-MISC
inhibition O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
certain O-MISC O-MISC
breast B-MISC O-MISC
cancer I-MISC O-MISC
- I-MISC B-MISC
related I-MISC I-MISC
antigens I-MISC I-MISC
( O-MISC O-MISC
MCF B-MISC B-MISC
- I-MISC I-MISC
7 I-MISC I-MISC
and O-MISC O-MISC
MuMTV B-MISC O-MISC
) O-MISC O-MISC
: O-MISC O-MISC
their O-MISC O-MISC
potential O-MISC O-MISC
as O-MISC O-MISC
discriminants O-MISC O-MISC
. O-MISC O-MISC

Certain O-MISC O-MISC
oncogenic O-MISC O-MISC
viruses O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
implicated O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
the O-MISC O-MISC
murine O-MISC O-MISC
mammary O-MISC O-MISC
tumor O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
MuMTV O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
Mason O-MISC O-MISC
- O-MISC O-MISC
Pfizer O-MISC O-MISC
monkey O-MISC O-MISC
virus O-MISC O-MISC
( O-MISC O-MISC
MPMV O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
used O-MISC O-MISC
the O-MISC O-MISC
leukocyte O-MISC O-MISC
migration O-MISC O-MISC
inhibition O-MISC O-MISC
( O-MISC O-MISC
LMI O-MISC O-MISC
) O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
assay O-MISC O-MISC
the O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
several O-MISC O-MISC
potential O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
- O-MISC O-MISC
related O-MISC I-MISC
antigens O-MISC B-MISC
, O-MISC O-MISC
including O-MISC O-MISC
MuMTV B-MISC O-MISC
, O-MISC O-MISC
MPMV B-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
cultured O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
MCF O-MISC B-MISC
- O-MISC I-MISC
7 O-MISC I-MISC
, O-MISC O-MISC
in O-MISC O-MISC
96 O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
32 O-MISC O-MISC
women O-MISC O-MISC
with O-MISC O-MISC
benign O-MISC O-MISC
breast O-MISC O-MISC
disease O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
67 O-MISC O-MISC
normal O-MISC O-MISC
women O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
lowest O-MISC O-MISC
tenth O-MISC O-MISC
percentile O-MISC O-MISC
of O-MISC O-MISC
control O-MISC O-MISC
( O-MISC O-MISC
LMI O-MISC O-MISC
) O-MISC O-MISC
responses O-MISC O-MISC
was O-MISC O-MISC
used O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
cutoff O-MISC O-MISC
point O-MISC O-MISC
to O-MISC O-MISC
designate O-MISC O-MISC
responders O-MISC O-MISC
. O-MISC O-MISC

Breast O-MISC O-MISC
cancer O-MISC O-MISC
patients O-MISC O-MISC
showed O-MISC O-MISC
significant O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
MuMTV B-MISC O-MISC
( O-MISC O-MISC
49 O-MISC O-MISC
% O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
MCF O-MISC O-MISC
- O-MISC O-MISC
7 O-MISC O-MISC
( O-MISC O-MISC
50 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
to O-MISC O-MISC
MPMV B-MISC O-MISC
( O-MISC O-MISC
29 O-MISC O-MISC
% O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
a O-MISC O-MISC
paired O-MISC B-MISC
- O-MISC I-MISC
antigen O-MISC I-MISC
study O-MISC O-MISC
using O-MISC O-MISC
MuMTV B-MISC O-MISC
and O-MISC O-MISC
MCF B-MISC O-MISC
- I-MISC O-MISC
7 I-MISC O-MISC
, O-MISC O-MISC
75 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
patients O-MISC O-MISC
responded O-MISC O-MISC
, O-MISC O-MISC
versus O-MISC O-MISC
18 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
normal O-MISC O-MISC
women O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
0050 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
potential O-MISC O-MISC
for O-MISC O-MISC
this O-MISC O-MISC
assay O-MISC O-MISC
to O-MISC O-MISC
distinguish O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
normal O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
from O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
was O-MISC O-MISC
analyzed O-MISC O-MISC
using O-MISC O-MISC
a O-MISC O-MISC
migration O-MISC O-MISC
index O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
discriminant O-MISC O-MISC
analysis O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
assay O-MISC O-MISC
to O-MISC O-MISC
discriminate O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
normal O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
from O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
cancer O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
was O-MISC O-MISC
significant O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
001 O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
showed O-MISC O-MISC
a O-MISC O-MISC
sensitivity O-MISC O-MISC
of O-MISC O-MISC
detecting O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
cancer O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
of O-MISC O-MISC
75 O-MISC O-MISC
% O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
overall O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
MuMTV B-MISC O-MISC
and O-MISC O-MISC
MCF B-MISC B-MISC
- I-MISC I-MISC
7 I-MISC I-MISC
were O-MISC O-MISC
analyzed O-MISC O-MISC
with O-MISC O-MISC
reference O-MISC O-MISC
to O-MISC O-MISC
certain O-MISC O-MISC
prognostic O-MISC B-MISC
factors O-MISC I-MISC
, O-MISC O-MISC
but O-MISC O-MISC
showed O-MISC O-MISC
no O-MISC O-MISC
relation O-MISC O-MISC
to O-MISC O-MISC
age O-MISC O-MISC
, O-MISC O-MISC
menstrual O-MISC O-MISC
status O-MISC O-MISC
, O-MISC O-MISC
estrogen O-MISC B-MISC
receptor O-MISC I-MISC
status O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
stage O-MISC O-MISC
of O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
above O-MISC O-MISC
reactions O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
large O-MISC O-MISC
proportion O-MISC O-MISC
of O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
patients O-MISC O-MISC
exhibit O-MISC O-MISC
presensitization O-MISC O-MISC
to O-MISC O-MISC
antigenfs O-MISC O-MISC
found O-MISC O-MISC
in O-MISC O-MISC
MuMTV B-MISC O-MISC
and O-MISC O-MISC
MCF B-MISC O-MISC
- I-MISC O-MISC
7 I-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
reactive O-MISC O-MISC
with O-MISC O-MISC
antigens O-MISC B-MISC
in O-MISC O-MISC
the O-MISC O-MISC
primary O-MISC O-MISC
cancer O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
responses O-MISC O-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
independent O-MISC O-MISC
of O-MISC O-MISC
major O-MISC O-MISC
prognostic O-MISC O-MISC
variables O-MISC O-MISC
. O-MISC O-MISC

Further O-MISC O-MISC
refinement O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
assay O-MISC O-MISC
may O-MISC O-MISC
yield O-MISC O-MISC
one O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
more O-MISC O-MISC
highly O-MISC O-MISC
discriminating O-MISC O-MISC
for O-MISC O-MISC
breast O-MISC O-MISC
cancer O-MISC O-MISC
. O-MISC O-MISC

Chronic O-MISC O-MISC
lymphatic O-MISC O-MISC
leukaemia O-MISC O-MISC
: O-MISC O-MISC
cellular O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
glucocorticoids O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
and O-MISC O-MISC
steroid O-MISC O-MISC
induced O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
nucleic O-MISC O-MISC
acid O-MISC O-MISC
precursors O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
examined O-MISC O-MISC
in O-MISC O-MISC
lymphocytes O-MISC O-MISC
from O-MISC O-MISC
27 O-MISC O-MISC
patients O-MISC O-MISC
at O-MISC O-MISC
different O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
chronic O-MISC O-MISC
lymphatic O-MISC O-MISC
leukaemia O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
correlation O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
found O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
stage O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

On O-MISC O-MISC
the O-MISC O-MISC
other O-MISC O-MISC
hand O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
significant O-MISC O-MISC
difference O-MISC O-MISC
( O-MISC O-MISC
P O-MISC O-MISC
less O-MISC O-MISC
than O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
02 O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
between O-MISC O-MISC
stage O-MISC O-MISC
O O-MISC O-MISC
and O-MISC O-MISC
stage O-MISC O-MISC
III O-MISC O-MISC
/ O-MISC O-MISC
IV O-MISC O-MISC
patients O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
terms O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
on O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
uridine O-MISC O-MISC
incorporation O-MISC O-MISC
. O-MISC O-MISC

Pyrrolidine O-MISC O-MISC
dithiocarbamate O-MISC O-MISC
inhibits O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
mobilization O-MISC O-MISC
and O-MISC O-MISC
TNF O-MISC B-MISC
production O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
human B-MISC B-MISC
TNF I-MISC I-MISC
promoter I-MISC I-MISC
contains O-MISC O-MISC
four O-MISC O-MISC
potential O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
( I-MISC I-MISC
NF I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
) I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
, O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
strongest O-MISC O-MISC
binding O-MISC O-MISC
seen O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
- O-MISC O-MISC
605 O-MISC B-MISC
motif O-MISC I-MISC
. O-MISC O-MISC

Nuclear O-MISC O-MISC
extracts O-MISC O-MISC
from O-MISC O-MISC
unstimulated O-MISC O-MISC
cells O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human O-MISC O-MISC
monocytic O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
, O-MISC O-MISC
Mono O-MISC O-MISC
Mac O-MISC O-MISC
6 O-MISC O-MISC
, O-MISC O-MISC
contain O-MISC O-MISC
one O-MISC O-MISC
specific B-MISC O-MISC
binding I-MISC B-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
complex B-MISC I-MISC
II I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
constitutive B-MISC O-MISC
p50 I-MISC I-MISC
homodimer I-MISC I-MISC
. O-MISC O-MISC

Stimulation O-MISC O-MISC
of O-MISC O-MISC
Mono O-MISC O-MISC
Mac O-MISC O-MISC
6 O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
LPS O-MISC O-MISC
will O-MISC O-MISC
increase O-MISC O-MISC
complex B-MISC O-MISC
II I-MISC I-MISC
and O-MISC O-MISC
will O-MISC O-MISC
strongly O-MISC O-MISC
induce O-MISC O-MISC
a O-MISC O-MISC
second O-MISC O-MISC
specific O-MISC O-MISC
complex O-MISC O-MISC
( O-MISC I-MISC
complex B-MISC I-MISC
I I-MISC I-MISC
) O-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
represents O-MISC O-MISC
the O-MISC O-MISC
p50 B-MISC B-MISC
/ I-MISC I-MISC
65 I-MISC I-MISC
heterodimer I-MISC I-MISC
. O-MISC O-MISC

Treatment O-MISC O-MISC
of O-MISC O-MISC
Mono O-MISC O-MISC
Mac O-MISC O-MISC
6 O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
pyrrolidine O-MISC O-MISC
- O-MISC O-MISC
dithiocarbamate O-MISC O-MISC
( O-MISC O-MISC
PDTC O-MISC O-MISC
) O-MISC O-MISC
at O-MISC O-MISC
300 O-MISC O-MISC
microM O-MISC O-MISC
will O-MISC O-MISC
block O-MISC O-MISC
the O-MISC O-MISC
LPS B-MISC O-MISC
- I-MISC O-MISC
induced I-MISC O-MISC
complex I-MISC O-MISC
I I-MISC O-MISC
almost O-MISC O-MISC
completely O-MISC O-MISC
and O-MISC O-MISC
will O-MISC O-MISC
reduce O-MISC O-MISC
complex B-MISC B-MISC
II I-MISC I-MISC
to O-MISC O-MISC
the O-MISC O-MISC
constitutive O-MISC O-MISC
level O-MISC O-MISC
. O-MISC O-MISC

Binding O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
other O-MISC O-MISC
nuclear B-MISC B-MISC
factors I-MISC I-MISC
that O-MISC O-MISC
recognize O-MISC O-MISC
the O-MISC O-MISC
SP O-MISC I-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
and O-MISC I-MISC
c O-MISC I-MISC
/ O-MISC I-MISC
EBP O-MISC I-MISC
motifs O-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
human B-MISC B-MISC
TNF I-MISC I-MISC
promoter I-MISC I-MISC
is O-MISC O-MISC
not O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
such O-MISC O-MISC
treatment O-MISC O-MISC
. O-MISC O-MISC

Northern O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
demonstrates O-MISC O-MISC
that O-MISC O-MISC
PDTC O-MISC O-MISC
treatment O-MISC O-MISC
will O-MISC O-MISC
strongly O-MISC O-MISC
reduce O-MISC O-MISC
LPS B-MISC O-MISC
- I-MISC O-MISC
induced I-MISC I-MISC
TNF I-MISC B-MISC
transcripts I-MISC I-MISC
. O-MISC O-MISC

Secreted O-MISC O-MISC
TNF B-MISC B-MISC
protein I-MISC I-MISC
as O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
Wehi O-MISC O-MISC
164S O-MISC I-MISC
/ O-MISC I-MISC
ActD O-MISC I-MISC
bioassay O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
sandwich O-MISC O-MISC
immunoassay O-MISC O-MISC
was O-MISC O-MISC
similarly O-MISC O-MISC
reduced O-MISC O-MISC
by O-MISC O-MISC
PDTC O-MISC O-MISC
. O-MISC O-MISC

Kinetic O-MISC O-MISC
analyses O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
after O-MISC O-MISC
LPS O-MISC O-MISC
stimulation O-MISC O-MISC
, O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
will O-MISC O-MISC
peak O-MISC O-MISC
at O-MISC O-MISC
1 O-MISC O-MISC
h O-MISC O-MISC
, O-MISC O-MISC
TNF O-MISC B-MISC
transcript O-MISC I-MISC
prevalence O-MISC O-MISC
at O-MISC O-MISC
2 O-MISC O-MISC
h O-MISC B-MISC
, O-MISC O-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
protein I-MISC I-MISC
at O-MISC O-MISC
4 O-MISC O-MISC
h O-MISC O-MISC
. O-MISC O-MISC

PDTC O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
shift O-MISC O-MISC
this O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
LPS O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
later O-MISC O-MISC
time O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
suppressed O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
mobilization O-MISC O-MISC
, O-MISC O-MISC
TNF B-MISC B-MISC
transcripts I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
protein I-MISC I-MISC
over O-MISC O-MISC
the O-MISC O-MISC
entire O-MISC O-MISC
8 O-MISC O-MISC
- O-MISC O-MISC
h O-MISC O-MISC
observation O-MISC O-MISC
period O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
freshly O-MISC O-MISC
isolated O-MISC O-MISC
, O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
blood O-MISC O-MISC
monocytes O-MISC O-MISC
showed O-MISC O-MISC
a O-MISC O-MISC
similar O-MISC O-MISC
blockade O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
these O-MISC O-MISC
primary O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
transcripts I-MISC I-MISC
, O-MISC O-MISC
as O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
Northern O-MISC O-MISC
blot O-MISC O-MISC
analysis O-MISC O-MISC
and O-MISC O-MISC
by O-MISC O-MISC
quantitative O-MISC O-MISC
polymerase O-MISC O-MISC
chain O-MISC O-MISC
reaction O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
prevented O-MISC O-MISC
by O-MISC O-MISC
PDTC O-MISC O-MISC
as O-MISC O-MISC
was O-MISC O-MISC
TNF B-MISC B-MISC
protein I-MISC I-MISC
production O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
dithiocarbamates O-MISC O-MISC
can O-MISC O-MISC
profoundly O-MISC O-MISC
affect O-MISC O-MISC
cytokine O-MISC B-MISC
expression O-MISC O-MISC
and O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
is O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
TNF O-MISC B-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

Comparing O-MISC O-MISC
regions O-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Epstein B-MISC B-MISC
- I-MISC I-MISC
Barr I-MISC I-MISC
virus I-MISC I-MISC
ZEBRA I-MISC I-MISC
protein I-MISC I-MISC
which O-MISC O-MISC
function O-MISC O-MISC
as O-MISC O-MISC
transcriptional B-MISC O-MISC
activating I-MISC O-MISC
sequences I-MISC I-MISC
in O-MISC O-MISC
Saccharomyces O-MISC O-MISC
cerevisiae O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
ZEBRA B-MISC B-MISC
protein I-MISC I-MISC
activates O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
Epstein O-MISC B-MISC
- O-MISC I-MISC
Barr O-MISC I-MISC
virus O-MISC I-MISC
early B-MISC I-MISC
- I-MISC I-MISC
lytic I-MISC I-MISC
- I-MISC I-MISC
cycle I-MISC I-MISC
genes I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
ZEBRA B-MISC B-MISC
also O-MISC O-MISC
behaves O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
sequence B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
transcriptional I-MISC I-MISC
activator I-MISC I-MISC
in O-MISC O-MISC
Saccharomyces O-MISC O-MISC
cerevisiae O-MISC O-MISC
. O-MISC O-MISC

Deletional O-MISC O-MISC
mutagenesis O-MISC O-MISC
defined O-MISC O-MISC
three O-MISC O-MISC
regions O-MISC O-MISC
of O-MISC O-MISC
ZEBRA B-MISC B-MISC
that O-MISC O-MISC
participate O-MISC O-MISC
in O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
cerevisiae O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
regions O-MISC O-MISC
are O-MISC O-MISC
designated O-MISC O-MISC
YI B-MISC B-MISC
( O-MISC I-MISC
amino B-MISC I-MISC
acids I-MISC I-MISC
[ I-MISC O-MISC
aa I-MISC O-MISC
] I-MISC O-MISC
1 I-MISC I-MISC
to I-MISC O-MISC
25 I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
YII B-MISC B-MISC
( O-MISC O-MISC
aa B-MISC O-MISC
51 I-MISC O-MISC
to I-MISC O-MISC
102 I-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
YIII B-MISC B-MISC
( O-MISC O-MISC
aa B-MISC O-MISC
228 I-MISC I-MISC
to I-MISC I-MISC
245 I-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Two O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
three O-MISC O-MISC
regions O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
native O-MISC B-MISC
ZEBRA B-MISC B-MISC
protein I-MISC I-MISC
act O-MISC O-MISC
together O-MISC O-MISC
to O-MISC O-MISC
mediate O-MISC O-MISC
activation O-MISC O-MISC
when O-MISC O-MISC
assayed O-MISC O-MISC
on O-MISC O-MISC
ZEBRA B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
when O-MISC O-MISC
fused O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
DNA B-MISC B-MISC
binding I-MISC I-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
GAL B-MISC B-MISC
4 O-MISC I-MISC
and O-MISC O-MISC
assayed O-MISC O-MISC
on O-MISC O-MISC
GAL4 B-MISC B-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
, O-MISC O-MISC
regions B-MISC O-MISC
YII I-MISC B-MISC
and I-MISC O-MISC
YIII I-MISC B-MISC
were O-MISC O-MISC
each O-MISC O-MISC
sufficient O-MISC O-MISC
to O-MISC O-MISC
confer O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
cerevisiae O-MISC O-MISC
. O-MISC O-MISC

Regions O-MISC O-MISC
of O-MISC O-MISC
ZEBRA B-MISC B-MISC
which O-MISC O-MISC
affected O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
cerevisiae O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
required O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
amino B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
region I-MISC I-MISC
of O-MISC O-MISC
ZEBRA B-MISC B-MISC
( O-MISC O-MISC
aa B-MISC O-MISC
1 I-MISC I-MISC
to I-MISC O-MISC
98 I-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
activation O-MISC O-MISC
both O-MISC O-MISC
in O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
cerevisiae O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
; O-MISC O-MISC
deletion O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
carboxy B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
18 I-MISC I-MISC
aa I-MISC O-MISC
also O-MISC O-MISC
significantly O-MISC O-MISC
reduced O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
cell O-MISC O-MISC
types O-MISC O-MISC
. O-MISC O-MISC

Thus O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
behavior O-MISC O-MISC
of O-MISC O-MISC
ZEBRA B-MISC B-MISC
in O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
cerevisiae O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
protein O-MISC O-MISC
contains O-MISC O-MISC
universal B-MISC O-MISC
activation I-MISC B-MISC
motifs I-MISC I-MISC
that O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
conserved O-MISC O-MISC
components O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
transcription O-MISC O-MISC
machinery O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
certain O-MISC O-MISC
deletion B-MISC O-MISC
mutants I-MISC O-MISC
of O-MISC O-MISC
ZEBRA B-MISC B-MISC
containing O-MISC O-MISC
mutations O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
N B-MISC B-MISC
- I-MISC I-MISC
terminal I-MISC I-MISC
region I-MISC I-MISC
exhibited O-MISC O-MISC
discordant O-MISC O-MISC
behaviors O-MISC O-MISC
in O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
cerevisiae O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

For O-MISC O-MISC
example O-MISC O-MISC
, O-MISC O-MISC
deletion O-MISC O-MISC
of O-MISC O-MISC
ZEBRA B-MISC B-MISC
aa I-MISC O-MISC
26 I-MISC O-MISC
to I-MISC O-MISC
51 I-MISC O-MISC
impaired O-MISC O-MISC
activation O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
great O-MISC O-MISC
extent O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
but O-MISC O-MISC
had O-MISC O-MISC
little O-MISC O-MISC
or O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
in O-MISC O-MISC
S O-MISC O-MISC
. O-MISC O-MISC
cerevisiae O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
discordant O-MISC O-MISC
mutants O-MISC O-MISC
may O-MISC O-MISC
reflect O-MISC O-MISC
interactions O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
variable B-MISC O-MISC
domain I-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
conserved O-MISC O-MISC
component O-MISC O-MISC
or O-MISC O-MISC
unique O-MISC O-MISC
interactions O-MISC O-MISC
with O-MISC O-MISC
specialized O-MISC O-MISC
components O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
basal O-MISC O-MISC
transcription O-MISC O-MISC
apparatus O-MISC O-MISC
in O-MISC O-MISC
different O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Functional O-MISC O-MISC
interaction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
v B-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
and I-MISC O-MISC
c I-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
oncoproteins I-MISC I-MISC
with O-MISC O-MISC
the O-MISC O-MISC
TATA B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
and O-MISC O-MISC
association O-MISC O-MISC
with O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
IIB I-MISC I-MISC
. O-MISC O-MISC

Rel B-MISC B-MISC
family I-MISC I-MISC
proteins I-MISC I-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
genes O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
kappa O-MISC B-MISC
B O-MISC I-MISC
- O-MISC I-MISC
binding O-MISC I-MISC
motifs O-MISC I-MISC
. O-MISC O-MISC

Little O-MISC O-MISC
is O-MISC O-MISC
known O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mechanism O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
they O-MISC O-MISC
enhance O-MISC O-MISC
transcription O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
investigated O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
v B-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
and I-MISC O-MISC
c I-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
oncoproteins I-MISC I-MISC
to O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
components O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
basal O-MISC O-MISC
transcription O-MISC O-MISC
machinery O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
report O-MISC O-MISC
that O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
acidic O-MISC B-MISC
transcription O-MISC I-MISC
activation O-MISC I-MISC
domain O-MISC I-MISC
mapping O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
unique O-MISC O-MISC
C B-MISC B-MISC
terminus I-MISC I-MISC
of O-MISC O-MISC
chicken B-MISC B-MISC
c I-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
F9 B-MISC B-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
activation I-MISC I-MISC
region I-MISC I-MISC
common O-MISC O-MISC
to O-MISC O-MISC
both O-MISC O-MISC
v B-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
and O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
TATA B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
( O-MISC O-MISC
TBP B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
IIB I-MISC I-MISC
( O-MISC O-MISC
TFIIB B-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
also O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
TPB B-MISC B-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
Rel B-MISC B-MISC
activation I-MISC O-MISC
regions I-MISC O-MISC
leads O-MISC O-MISC
to O-MISC O-MISC
synergistic O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
kappa B-MISC B-MISC
B I-MISC I-MISC
- I-MISC I-MISC
linked I-MISC I-MISC
reporter I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

Combined O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
observation O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
mouse B-MISC B-MISC
c I-MISC I-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
and I-MISC I-MISC
human I-MISC B-MISC
RelA I-MISC I-MISC
proteins I-MISC I-MISC
also O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
TBP B-MISC B-MISC
and O-MISC O-MISC
TFIIB B-MISC B-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
association O-MISC O-MISC
with O-MISC O-MISC
basal B-MISC O-MISC
transcription I-MISC B-MISC
factors I-MISC I-MISC
is O-MISC O-MISC
important O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
transcriptional O-MISC O-MISC
activities O-MISC O-MISC
of O-MISC O-MISC
Rel B-MISC B-MISC
family I-MISC I-MISC
proteins I-MISC I-MISC
. O-MISC O-MISC

p21ras B-MISC B-MISC
and O-MISC O-MISC
calcineurin O-MISC B-MISC
synergize O-MISC O-MISC
to O-MISC O-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
of O-MISC I-MISC
activated O-MISC I-MISC
T O-MISC I-MISC
cells O-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
triggering O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
cell I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
TCR B-MISC B-MISC
) O-MISC O-MISC
induces O-MISC O-MISC
several O-MISC O-MISC
signaling O-MISC O-MISC
cascades O-MISC O-MISC
which O-MISC O-MISC
ultimately O-MISC O-MISC
synergize O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
of O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC I-MISC
( O-MISC O-MISC
NFAT O-MISC B-MISC
) O-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
DNA B-MISC B-MISC
binding I-MISC I-MISC
complex I-MISC I-MISC
critical O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
inducibility O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
specificity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
T B-MISC B-MISC
cell I-MISC I-MISC
growth I-MISC I-MISC
factor I-MISC I-MISC
interleukin B-MISC I-MISC
2 I-MISC I-MISC
. O-MISC O-MISC

One O-MISC O-MISC
immediate O-MISC O-MISC
consequence O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
via O-MISC O-MISC
the O-MISC O-MISC
TCR B-MISC B-MISC
is O-MISC O-MISC
an O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
cytosolic O-MISC O-MISC
calcium O-MISC O-MISC
. O-MISC O-MISC

Calcium O-MISC O-MISC
signals O-MISC O-MISC
are O-MISC O-MISC
important O-MISC O-MISC
for O-MISC O-MISC
NFAT O-MISC B-MISC
induction O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
recent O-MISC O-MISC
studies O-MISC O-MISC
have O-MISC O-MISC
identified O-MISC O-MISC
calcineurin B-MISC B-MISC
, O-MISC O-MISC
a O-MISC O-MISC
calcium B-MISC B-MISC
- I-MISC I-MISC
calmodulin I-MISC I-MISC
dependent I-MISC I-MISC
serine I-MISC I-MISC
- I-MISC I-MISC
threonine I-MISC I-MISC
phosphatase I-MISC I-MISC
, O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
prominent O-MISC O-MISC
component O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
calcium O-MISC O-MISC
signaling O-MISC O-MISC
pathway O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
second O-MISC O-MISC
important O-MISC O-MISC
molecule O-MISC O-MISC
in O-MISC O-MISC
TCR O-MISC B-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
is O-MISC O-MISC
the O-MISC O-MISC
guanine B-MISC O-MISC
nucleotide I-MISC I-MISC
binding I-MISC I-MISC
protein I-MISC I-MISC
, O-MISC O-MISC
p21ras B-MISC B-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
coupled O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
TCR B-MISC B-MISC
by O-MISC O-MISC
a O-MISC O-MISC
protein B-MISC B-MISC
tyrosine I-MISC O-MISC
kinase I-MISC I-MISC
dependent O-MISC O-MISC
mechanism O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
experiments O-MISC O-MISC
presented O-MISC O-MISC
here O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
transfection O-MISC O-MISC
of O-MISC O-MISC
mutationally O-MISC O-MISC
activated O-MISC O-MISC
calcineurin B-MISC B-MISC
or O-MISC O-MISC
activated O-MISC O-MISC
p21ras B-MISC B-MISC
alone O-MISC O-MISC
is O-MISC O-MISC
insufficient O-MISC O-MISC
for O-MISC O-MISC
NFAT O-MISC B-MISC
transactivation O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
coexpression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
activated O-MISC O-MISC
calcineurin O-MISC B-MISC
with O-MISC O-MISC
activated O-MISC O-MISC
p21ras O-MISC B-MISC
could O-MISC O-MISC
mimic O-MISC O-MISC
TCR O-MISC B-MISC
signals O-MISC O-MISC
in O-MISC O-MISC
NFAT O-MISC B-MISC
induction O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
data O-MISC O-MISC
identify O-MISC O-MISC
calcineurin B-MISC B-MISC
and O-MISC O-MISC
p21ras B-MISC B-MISC
as O-MISC O-MISC
cooperative O-MISC O-MISC
partners O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
activation O-MISC O-MISC
. O-MISC O-MISC

Expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
chicken B-MISC B-MISC
GATA I-MISC I-MISC
factor I-MISC I-MISC
family I-MISC I-MISC
during O-MISC O-MISC
early O-MISC O-MISC
erythroid O-MISC O-MISC
development O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
DNA O-MISC B-MISC
motif O-MISC I-MISC
WGATAR O-MISC B-MISC
has O-MISC O-MISC
been O-MISC O-MISC
identified O-MISC O-MISC
within O-MISC O-MISC
transcriptional B-MISC B-MISC
regulatory I-MISC I-MISC
domains I-MISC I-MISC
of O-MISC O-MISC
globin B-MISC B-MISC
and O-MISC O-MISC
other O-MISC O-MISC
erythroid B-MISC B-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
genes I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
activator B-MISC B-MISC
proteins I-MISC I-MISC
that O-MISC O-MISC
bind O-MISC O-MISC
to O-MISC O-MISC
this O-MISC O-MISC
regulatory B-MISC B-MISC
element I-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
GATA B-MISC B-MISC
factors I-MISC I-MISC
, O-MISC O-MISC
belong O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
multi B-MISC B-MISC
- I-MISC I-MISC
gene I-MISC I-MISC
family I-MISC I-MISC
that O-MISC O-MISC
is O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
chicken O-MISC O-MISC
erythroid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
in O-MISC O-MISC
chickens O-MISC O-MISC
, O-MISC O-MISC
multiple O-MISC O-MISC
members O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
GATA B-MISC B-MISC
factor I-MISC I-MISC
family I-MISC I-MISC
are O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
and O-MISC O-MISC
murine O-MISC O-MISC
erythroid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

During O-MISC O-MISC
the O-MISC O-MISC
early O-MISC O-MISC
stages O-MISC O-MISC
of O-MISC O-MISC
chicken O-MISC O-MISC
embryogenesis O-MISC O-MISC
( O-MISC O-MISC
well O-MISC O-MISC
before O-MISC O-MISC
blood O-MISC O-MISC
island O-MISC O-MISC
formation O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
each O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
GATA B-MISC B-MISC
family I-MISC I-MISC
members I-MISC I-MISC
is O-MISC O-MISC
transcribed O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
unique O-MISC O-MISC
temporal O-MISC O-MISC
and O-MISC O-MISC
spatial O-MISC O-MISC
pattern O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
the O-MISC O-MISC
primitive O-MISC O-MISC
erythroid O-MISC O-MISC
lineage O-MISC O-MISC
, O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
embryonic B-MISC B-MISC
epsilon I-MISC I-MISC
- I-MISC I-MISC
globin I-MISC I-MISC
gene I-MISC I-MISC
parallels O-MISC O-MISC
GATA O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
expression O-MISC O-MISC
while O-MISC O-MISC
the O-MISC O-MISC
switch O-MISC O-MISC
to O-MISC O-MISC
beta O-MISC B-MISC
- O-MISC I-MISC
globin O-MISC I-MISC
transcription O-MISC O-MISC
in O-MISC O-MISC
definitive O-MISC O-MISC
erythroid O-MISC O-MISC
cells O-MISC O-MISC
is O-MISC O-MISC
directly O-MISC O-MISC
preceded O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
pronounced O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
GATA B-MISC B-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
accumulation O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
timing O-MISC O-MISC
and O-MISC O-MISC
pattern O-MISC O-MISC
of O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
different O-MISC O-MISC
mRNAs B-MISC B-MISC
during O-MISC O-MISC
avian O-MISC O-MISC
erythroid O-MISC O-MISC
development O-MISC O-MISC
and O-MISC O-MISC
differentiation O-MISC O-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
temporally O-MISC O-MISC
regulated O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
GATA B-MISC B-MISC
factor I-MISC I-MISC
expression O-MISC O-MISC
are O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
vertebrate O-MISC O-MISC
hematopoiesis O-MISC O-MISC
. O-MISC O-MISC

Molecular O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
human B-MISC B-MISC
interleukin I-MISC I-MISC
2 I-MISC I-MISC
and O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
function O-MISC O-MISC
by O-MISC O-MISC
interleukin B-MISC B-MISC
4 I-MISC I-MISC
. O-MISC O-MISC

Distinct O-MISC O-MISC
functional O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
subsets O-MISC O-MISC
, O-MISC O-MISC
differing O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
patterns O-MISC O-MISC
of O-MISC O-MISC
lymphokines B-MISC B-MISC
produced O-MISC O-MISC
, O-MISC O-MISC
regulate O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
and O-MISC O-MISC
humoral O-MISC O-MISC
immune O-MISC O-MISC
responses O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
two O-MISC O-MISC
major O-MISC O-MISC
types O-MISC O-MISC
and O-MISC O-MISC
their O-MISC O-MISC
principal O-MISC B-MISC
products O-MISC I-MISC
, O-MISC O-MISC
interleukin B-MISC B-MISC
4 I-MISC I-MISC
and O-MISC O-MISC
interferon B-MISC B-MISC
gamma I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
and O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
are O-MISC O-MISC
reciprocally O-MISC O-MISC
negatively O-MISC O-MISC
interactive O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
analyze O-MISC O-MISC
the O-MISC O-MISC
molecular O-MISC O-MISC
mechanism O-MISC O-MISC
of O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
immunity O-MISC O-MISC
we O-MISC O-MISC
studied O-MISC O-MISC
its O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
interleukin B-MISC B-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
and O-MISC O-MISC
IFN B-MISC B-MISC
- I-MISC I-MISC
gamma I-MISC I-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
pretreatment O-MISC O-MISC
of O-MISC O-MISC
Jurkat O-MISC O-MISC
cells O-MISC O-MISC
prior O-MISC O-MISC
to O-MISC O-MISC
stimulation O-MISC O-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
decrease O-MISC O-MISC
in O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL2 B-MISC B-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
suppressed O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
and O-MISC O-MISC
IFN O-MISC B-MISC
- O-MISC I-MISC
gamma O-MISC I-MISC
mRNA O-MISC I-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
CD28 I-MISC I-MISC
antibodies I-MISC I-MISC
relieved O-MISC O-MISC
this O-MISC O-MISC
suppression O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
enhancer B-MISC B-MISC
- I-MISC I-MISC
reporter I-MISC I-MISC
constructs I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
specifically O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
the O-MISC O-MISC
NFIL B-MISC B-MISC
- I-MISC I-MISC
2B I-MISC I-MISC
element I-MISC I-MISC
. O-MISC O-MISC

Electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
using O-MISC O-MISC
a O-MISC O-MISC
DNA O-MISC O-MISC
oligomer O-MISC O-MISC
containing O-MISC O-MISC
the O-MISC O-MISC
NFIL B-MISC B-MISC
- I-MISC I-MISC
2B I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
indicated O-MISC O-MISC
that O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
NFIL B-MISC B-MISC
- I-MISC I-MISC
2B I-MISC I-MISC
complex I-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
NFIL B-MISC B-MISC
- I-MISC I-MISC
2B I-MISC I-MISC
DNA I-MISC I-MISC
binding I-MISC I-MISC
factor I-MISC I-MISC
is O-MISC O-MISC
distinct O-MISC O-MISC
from O-MISC O-MISC
AP B-MISC B-MISC
- I-MISC I-MISC
1 O-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
may O-MISC O-MISC
regulate O-MISC O-MISC
development O-MISC O-MISC
and O-MISC O-MISC
function O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
subsets O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
immunity O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
by O-MISC O-MISC
inhibiting B-MISC O-MISC
factors I-MISC I-MISC
required O-MISC O-MISC
for O-MISC O-MISC
transcription O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
IL2 B-MISC B-MISC
gene I-MISC I-MISC

Immunochemical O-MISC O-MISC
differences O-MISC O-MISC
between O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
from O-MISC O-MISC
corticoid O-MISC O-MISC
- O-MISC O-MISC
sensitive O-MISC O-MISC
and O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
malignant O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
explored O-MISC O-MISC
the O-MISC O-MISC
possibility O-MISC O-MISC
of O-MISC O-MISC
using O-MISC O-MISC
antibodies B-MISC O-MISC
against O-MISC O-MISC
purified O-MISC O-MISC
rat O-MISC O-MISC
liver O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
to O-MISC O-MISC
study O-MISC O-MISC
the O-MISC O-MISC
immunochemical O-MISC O-MISC
properties O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
from O-MISC O-MISC
murine O-MISC O-MISC
and O-MISC O-MISC
human O-MISC O-MISC
malignant O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

For O-MISC O-MISC
this O-MISC O-MISC
purpose O-MISC O-MISC
, O-MISC O-MISC
purified B-MISC O-MISC
immune I-MISC O-MISC
immunoglobulin I-MISC B-MISC
G I-MISC B-MISC
was O-MISC O-MISC
covalently O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
Sepharose B-MISC O-MISC
CL I-MISC B-MISC
- I-MISC I-MISC
4B I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
then O-MISC O-MISC
examined O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
affinity O-MISC O-MISC
gel O-MISC O-MISC
to O-MISC O-MISC
recognize O-MISC O-MISC
cytosolic B-MISC O-MISC
[ I-MISC I-MISC
3H I-MISC O-MISC
] I-MISC I-MISC
triamcinolone I-MISC I-MISC
acetonide I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
from O-MISC O-MISC
the O-MISC O-MISC
corticoid O-MISC O-MISC
- O-MISC I-MISC
sensitive O-MISC O-MISC
( O-MISC O-MISC
CS O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
strains O-MISC O-MISC
of O-MISC O-MISC
mouse O-MISC O-MISC
lymphoma O-MISC O-MISC
P1798 O-MISC B-MISC
, O-MISC O-MISC
from O-MISC O-MISC
CS O-MISC O-MISC
lymphocytes O-MISC O-MISC
of O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
chronic O-MISC O-MISC
lymphatic O-MISC O-MISC
leukemia O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
from O-MISC O-MISC
a O-MISC O-MISC
CS O-MISC O-MISC
clone O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
leukemic O-MISC O-MISC
lymphoblasts O-MISC O-MISC
in O-MISC O-MISC
tissue O-MISC O-MISC
culture O-MISC O-MISC
( O-MISC O-MISC
CH6 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Mouse O-MISC O-MISC
thymus O-MISC O-MISC
was O-MISC O-MISC
used O-MISC O-MISC
as O-MISC O-MISC
a O-MISC O-MISC
source O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
from O-MISC O-MISC
normal O-MISC O-MISC
CS O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Whereas O-MISC O-MISC
the O-MISC O-MISC
immunoaffinity O-MISC O-MISC
column O-MISC O-MISC
retained O-MISC O-MISC
70 O-MISC O-MISC
to O-MISC O-MISC
84 O-MISC O-MISC
% O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
58 O-MISC O-MISC
- O-MISC O-MISC
to O-MISC O-MISC
62 O-MISC O-MISC
- O-MISC O-MISC
A O-MISC O-MISC
( O-MISC O-MISC
Stokes O-MISC O-MISC
radius O-MISC O-MISC
) O-MISC O-MISC
[ B-MISC O-MISC
3H I-MISC O-MISC
] I-MISC O-MISC
triamcinolone I-MISC O-MISC
acetonide I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
characteristic O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
CS O-MISC O-MISC
mouse O-MISC O-MISC
and O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
recognize O-MISC O-MISC
the O-MISC O-MISC
27 O-MISC O-MISC
- O-MISC O-MISC
to O-MISC O-MISC
28 O-MISC O-MISC
- O-MISC O-MISC
A O-MISC O-MISC
( O-MISC O-MISC
Stokes O-MISC O-MISC
radius O-MISC O-MISC
) O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
present O-MISC O-MISC
in O-MISC O-MISC
corticoid O-MISC O-MISC
- O-MISC O-MISC
resistant O-MISC O-MISC
mouse O-MISC O-MISC
lymphoma O-MISC O-MISC
P1798 O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Therefore O-MISC O-MISC
, O-MISC O-MISC
under O-MISC O-MISC
appropriate O-MISC O-MISC
experimental O-MISC O-MISC
conditions O-MISC O-MISC
, O-MISC O-MISC
it O-MISC O-MISC
was O-MISC O-MISC
possible O-MISC O-MISC
to O-MISC O-MISC
demonstrate O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
reactivity O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
antiserum O-MISC O-MISC
against O-MISC O-MISC
rat B-MISC O-MISC
liver I-MISC O-MISC
glucocorticoid I-MISC B-MISC
receptor I-MISC I-MISC
and O-MISC O-MISC
the O-MISC O-MISC
58 O-MISC O-MISC
- O-MISC O-MISC
to O-MISC O-MISC
62 O-MISC O-MISC
- O-MISC O-MISC
A O-MISC O-MISC
( O-MISC O-MISC
Stokes O-MISC O-MISC
radius O-MISC O-MISC
) O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
from O-MISC O-MISC
species O-MISC O-MISC
as O-MISC O-MISC
diverse O-MISC O-MISC
as O-MISC O-MISC
mouse O-MISC O-MISC
and O-MISC O-MISC
humans O-MISC O-MISC
. O-MISC O-MISC

Heterogeneity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
responses O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
in O-MISC O-MISC
acute O-MISC O-MISC
leukemia O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
leukocyte O-MISC O-MISC
population O-MISC O-MISC
freshly O-MISC O-MISC
isolated O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
blood O-MISC O-MISC
of O-MISC O-MISC
26 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
acute O-MISC O-MISC
leukemia O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
measured O-MISC O-MISC
several O-MISC O-MISC
parameters O-MISC O-MISC
including O-MISC O-MISC
glucocorticoid B-MISC O-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
nucleoside O-MISC O-MISC
incorporation O-MISC O-MISC
, O-MISC O-MISC
percentage O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
steroid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
lysis O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
some O-MISC O-MISC
cases O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
short O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
steroid O-MISC O-MISC
therapy O-MISC O-MISC
was O-MISC O-MISC
determined O-MISC O-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
, O-MISC O-MISC
in O-MISC O-MISC
all O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
studied O-MISC O-MISC
, O-MISC O-MISC
leukocytes O-MISC O-MISC
were O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
contain O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
, O-MISC O-MISC
we O-MISC O-MISC
failed O-MISC O-MISC
to O-MISC O-MISC
demonstrate O-MISC O-MISC
any O-MISC O-MISC
correlation O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
or O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
correlation O-MISC O-MISC
could O-MISC O-MISC
be O-MISC O-MISC
in O-MISC O-MISC
part O-MISC O-MISC
explained O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
marked O-MISC O-MISC
heterogeneity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
steroid O-MISC O-MISC
response O-MISC O-MISC
demonstrated O-MISC O-MISC
in O-MISC O-MISC
leukocyte O-MISC O-MISC
subpopulations O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
appears O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
degree O-MISC O-MISC
of O-MISC O-MISC
steroid O-MISC O-MISC
action O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
extent O-MISC O-MISC
of O-MISC O-MISC
spontaneous O-MISC O-MISC
and O-MISC O-MISC
dexamethasone O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
cell O-MISC O-MISC
death O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
S O-MISC O-MISC
phase O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
cytosol O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
extract O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
leukocytes O-MISC O-MISC
. O-MISC O-MISC

Cortisol O-MISC O-MISC
binding O-MISC O-MISC
by O-MISC O-MISC
cytosol O-MISC O-MISC
and O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
4 O-MISC O-MISC
M O-MISC O-MISC
KCl O-MISC O-MISC
extract O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
nuclear O-MISC O-MISC
fraction O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
leukocytes O-MISC O-MISC
were O-MISC O-MISC
studied O-MISC O-MISC
by O-MISC O-MISC
gel O-MISC O-MISC
chromatography O-MISC O-MISC
and O-MISC O-MISC
ion O-MISC O-MISC
exchange O-MISC O-MISC
filtration O-MISC O-MISC
on O-MISC O-MISC
DEAE O-MISC O-MISC
cellulose O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
cytoplasmic B-MISC O-MISC
cortisol I-MISC O-MISC
binding I-MISC O-MISC
protein I-MISC O-MISC
has O-MISC O-MISC
a O-MISC O-MISC
molecular O-MISC O-MISC
weight O-MISC O-MISC
95 O-MISC O-MISC
000 O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
soluble B-MISC O-MISC
nuclear I-MISC O-MISC
binding I-MISC I-MISC
protein I-MISC O-MISC
50 O-MISC O-MISC
000 O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
absence O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
uptake O-MISC O-MISC
of O-MISC O-MISC
radioactive O-MISC O-MISC
cortisol O-MISC O-MISC
by O-MISC O-MISC
isolated O-MISC O-MISC
nuclei O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
apparent O-MISC O-MISC
requirement O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cytosol O-MISC O-MISC
for O-MISC O-MISC
glucocorticoid O-MISC O-MISC
specific O-MISC I-MISC
binding O-MISC I-MISC
in O-MISC I-MISC
nuclear O-MISC B-MISC
receptor O-MISC I-MISC
sites O-MISC I-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
association O-MISC O-MISC
constant O-MISC O-MISC
characterising O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
cortisol O-MISC O-MISC
to O-MISC O-MISC
cytosol O-MISC O-MISC
was O-MISC O-MISC
KA O-MISC O-MISC
= O-MISC O-MISC
3 O-MISC O-MISC
. O-MISC O-MISC
5 O-MISC O-MISC
. O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
9 O-MISC O-MISC
) O-MISC O-MISC
l O-MISC O-MISC
/ O-MISC O-MISC
mol O-MISC O-MISC
. O-MISC O-MISC

Corticosteroid O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
lymphopenia O-MISC O-MISC
, O-MISC O-MISC
immunosuppression O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
body O-MISC O-MISC
defense O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
apparent O-MISC O-MISC
paradox O-MISC O-MISC
of O-MISC O-MISC
heightened O-MISC O-MISC
adrenal O-MISC O-MISC
corticosteroid O-MISC O-MISC
levels O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
reduction O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
competence O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
body O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
defensive O-MISC O-MISC
apparatus O-MISC O-MISC
to O-MISC O-MISC
cope O-MISC O-MISC
with O-MISC O-MISC
exposure O-MISC O-MISC
to O-MISC O-MISC
new O-MISC O-MISC
microbial B-MISC B-MISC
antigens I-MISC O-MISC
is O-MISC O-MISC
considered O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
question O-MISC O-MISC
is O-MISC O-MISC
asked O-MISC O-MISC
how O-MISC O-MISC
this O-MISC O-MISC
lowered O-MISC O-MISC
defensive O-MISC O-MISC
capability O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
occurs O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
face O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
threat O-MISC O-MISC
to O-MISC O-MISC
body O-MISC O-MISC
integrity O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
Cannon O-MISC O-MISC
' O-MISC O-MISC
s O-MISC O-MISC
principals O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
wisdom O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
body O-MISC O-MISC
. O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC

The O-MISC O-MISC
suggestion O-MISC O-MISC
is O-MISC O-MISC
offered O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
immunologic O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
self B-MISC B-MISC
- I-MISC I-MISC
antigens I-MISC I-MISC
exposed O-MISC O-MISC
by O-MISC O-MISC
disease O-MISC O-MISC
or O-MISC O-MISC
trauma O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
suppressed O-MISC O-MISC
by O-MISC O-MISC
corticosteroid O-MISC O-MISC
to O-MISC O-MISC
offset O-MISC O-MISC
the O-MISC O-MISC
likelihood O-MISC O-MISC
of O-MISC O-MISC
autoimmune O-MISC O-MISC
attack O-MISC O-MISC
. O-MISC O-MISC

Protein B-MISC O-MISC
tyrosine I-MISC B-MISC
kinase I-MISC I-MISC
activation O-MISC O-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
in O-MISC O-MISC
human O-MISC O-MISC
blood O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

Bacterial O-MISC O-MISC
LPS O-MISC O-MISC
induce O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
such O-MISC O-MISC
as O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
in O-MISC O-MISC
mononuclear O-MISC O-MISC
phagocytes O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
this O-MISC O-MISC
represents O-MISC O-MISC
a O-MISC O-MISC
central O-MISC O-MISC
component O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
pathogenesis O-MISC O-MISC
of O-MISC O-MISC
septic O-MISC O-MISC
shock O-MISC O-MISC
syndrome O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
by O-MISC O-MISC
which O-MISC O-MISC
LPS O-MISC O-MISC
activates O-MISC O-MISC
these O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
express O-MISC O-MISC
cytokines B-MISC B-MISC
are O-MISC O-MISC
not O-MISC O-MISC
completely O-MISC O-MISC
characterized O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
addressed O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
different O-MISC O-MISC
protein B-MISC B-MISC
kinases I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
LPS O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
LPS O-MISC O-MISC
induced O-MISC O-MISC
a O-MISC O-MISC
12 O-MISC O-MISC
- O-MISC O-MISC
to O-MISC O-MISC
16 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
beta O-MISC I-MISC
, O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
TNF O-MISC B-MISC
- O-MISC I-MISC
alpha O-MISC I-MISC
mRNA O-MISC I-MISC
levels O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
this O-MISC O-MISC
was O-MISC O-MISC
completely O-MISC O-MISC
or O-MISC O-MISC
more O-MISC O-MISC
than O-MISC O-MISC
80 O-MISC O-MISC
% O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
protein O-MISC B-MISC
tyrosine O-MISC I-MISC
kinase O-MISC I-MISC
specific O-MISC O-MISC
inhibitors O-MISC O-MISC
herbimycin O-MISC O-MISC
A O-MISC O-MISC
and O-MISC O-MISC
genistein O-MISC O-MISC
at O-MISC O-MISC
the O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
1 O-MISC O-MISC
. O-MISC O-MISC
7 O-MISC O-MISC
and O-MISC O-MISC
37 O-MISC O-MISC
microM O-MISC O-MISC
, O-MISC O-MISC
respectively O-MISC O-MISC
. O-MISC O-MISC

Protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
inhibition O-MISC O-MISC
by O-MISC O-MISC
staurosporine O-MISC O-MISC
reduced O-MISC O-MISC
LPS O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
it O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effects O-MISC O-MISC
on O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
and O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
beta O-MISC I-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
A I-MISC I-MISC
by O-MISC O-MISC
H89 O-MISC O-MISC
reduced O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
mRNA I-MISC I-MISC
levels O-MISC O-MISC
but O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
detectably O-MISC O-MISC
change O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
1 O-MISC I-MISC
beta O-MISC I-MISC
or O-MISC O-MISC
TNF O-MISC B-MISC
- O-MISC I-MISC
alpha O-MISC I-MISC
mRNA O-MISC I-MISC
levels O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
contrast O-MISC O-MISC
, O-MISC O-MISC
LPS O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
increase O-MISC O-MISC
leukemia B-MISC B-MISC
inhibitory I-MISC I-MISC
factor I-MISC I-MISC
mRNA I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
was O-MISC O-MISC
constitutively O-MISC O-MISC
expressed O-MISC O-MISC
and O-MISC O-MISC
not O-MISC O-MISC
significantly O-MISC O-MISC
reduced O-MISC O-MISC
by O-MISC O-MISC
these O-MISC O-MISC
inhibitors O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
to O-MISC O-MISC
cytokine B-MISC B-MISC
mRNA I-MISC I-MISC
levels O-MISC O-MISC
, O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
protein O-MISC I-MISC
synthesis O-MISC O-MISC
and O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
6 O-MISC I-MISC
bioactivity O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
reduced O-MISC O-MISC
to O-MISC O-MISC
baseline O-MISC O-MISC
levels O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
PTK O-MISC O-MISC
inhibitors O-MISC O-MISC
herbimycin O-MISC O-MISC
A O-MISC O-MISC
and O-MISC O-MISC
genistein O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
PTK O-MISC O-MISC
inhibitors O-MISC O-MISC
also O-MISC O-MISC
reduced O-MISC O-MISC
the O-MISC O-MISC
LPS O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
factor I-MISC I-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
( O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
cytokine B-MISC B-MISC
genes I-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
6 I-MISC I-MISC
and O-MISC O-MISC
TNF B-MISC B-MISC
- I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
was O-MISC O-MISC
also O-MISC O-MISC
reduced O-MISC O-MISC
by O-MISC O-MISC
H89 O-MISC O-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
staurosporine O-MISC O-MISC
had O-MISC O-MISC
no O-MISC O-MISC
effect O-MISC O-MISC
on O-MISC O-MISC
this O-MISC O-MISC
response O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
summary O-MISC O-MISC
, O-MISC O-MISC
these O-MISC O-MISC
findings O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
C I-MISC I-MISC
and O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
A I-MISC I-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
have O-MISC O-MISC
selective O-MISC O-MISC
effects O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
LPS O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
, O-MISC O-MISC
whereas O-MISC O-MISC
PTK B-MISC B-MISC
is O-MISC O-MISC
required O-MISC O-MISC
for O-MISC O-MISC
LPS O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
broad O-MISC O-MISC
spectrum O-MISC O-MISC
of O-MISC O-MISC
cytokines B-MISC B-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
vivo O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activation O-MISC O-MISC
by O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
is O-MISC O-MISC
stored O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytoplasm O-MISC B-MISC
in O-MISC O-MISC
complexes O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
inhibitor B-MISC O-MISC
protein I-MISC O-MISC
I I-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

It O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
shown O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
that O-MISC O-MISC
dissociation O-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
from O-MISC O-MISC
these O-MISC O-MISC
complexes O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
active B-MISC O-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
report O-MISC O-MISC
we O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
lipopolysaccharide O-MISC O-MISC
( O-MISC O-MISC
LPS O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
B O-MISC O-MISC
or O-MISC O-MISC
pre O-MISC O-MISC
- O-MISC O-MISC
B O-MISC O-MISC
cells O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
loss O-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
from O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
complexes I-MISC I-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
. O-MISC O-MISC

Many O-MISC O-MISC
liberated O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
dimers I-MISC I-MISC
reached O-MISC O-MISC
the O-MISC O-MISC
nucleus O-MISC O-MISC
, O-MISC O-MISC
where O-MISC O-MISC
increased O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
rel I-MISC I-MISC
, O-MISC O-MISC
p65 O-MISC B-MISC
and O-MISC O-MISC
p50 O-MISC B-MISC
were O-MISC O-MISC
detected O-MISC O-MISC
by O-MISC O-MISC
immunoblotting O-MISC O-MISC
and O-MISC O-MISC
by O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
assays O-MISC O-MISC
. O-MISC O-MISC

Some O-MISC O-MISC
liberated B-MISC O-MISC
dimers I-MISC O-MISC
were O-MISC O-MISC
retained O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytoplasm O-MISC O-MISC
, O-MISC O-MISC
however O-MISC O-MISC
, O-MISC O-MISC
through O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
newly O-MISC O-MISC
synthesized O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
finding O-MISC O-MISC
which O-MISC O-MISC
strongly O-MISC O-MISC
suggests O-MISC O-MISC
( O-MISC O-MISC
i O-MISC O-MISC
) O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
LPS O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
signal O-MISC O-MISC
causes O-MISC O-MISC
dissociation O-MISC O-MISC
of O-MISC O-MISC
complexes O-MISC O-MISC
rather O-MISC O-MISC
than O-MISC O-MISC
preventing O-MISC O-MISC
their O-MISC O-MISC
association O-MISC O-MISC
and O-MISC O-MISC
( O-MISC O-MISC
ii O-MISC O-MISC
) O-MISC O-MISC
that O-MISC O-MISC
dissociation O-MISC O-MISC
results O-MISC O-MISC
from O-MISC O-MISC
modification O-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
and O-MISC O-MISC
not O-MISC O-MISC
of O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
rel I-MISC I-MISC
or O-MISC O-MISC
p65 B-MISC B-MISC
. O-MISC O-MISC

No O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
LPS O-MISC O-MISC
treatment O-MISC O-MISC
was O-MISC O-MISC
detected O-MISC O-MISC
on O-MISC O-MISC
p105 B-MISC B-MISC
or O-MISC I-MISC
p100 B-MISC B-MISC
, O-MISC O-MISC
which O-MISC O-MISC
also O-MISC O-MISC
retain O-MISC O-MISC
rel B-MISC B-MISC
family I-MISC I-MISC
members I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
cytoplasm O-MISC O-MISC
. O-MISC O-MISC

Quite O-MISC O-MISC
unexpectedly O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
also O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
in O-MISC O-MISC
unstimulated O-MISC O-MISC
cells O-MISC O-MISC
there O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
constant O-MISC O-MISC
ongoing O-MISC O-MISC
process O-MISC O-MISC
of O-MISC O-MISC
degradation O-MISC O-MISC
and O-MISC O-MISC
replacement O-MISC O-MISC
of O-MISC O-MISC
complexed B-MISC B-MISC
I I-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
propose O-MISC O-MISC
that O-MISC O-MISC
this O-MISC O-MISC
turnover O-MISC O-MISC
results O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
low O-MISC O-MISC
level O-MISC O-MISC
of O-MISC O-MISC
active B-MISC O-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
presumably O-MISC O-MISC
necessary O-MISC O-MISC
even O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
unstimulated O-MISC O-MISC
cell O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
high O-MISC O-MISC
rate O-MISC O-MISC
of O-MISC O-MISC
synthesis O-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
provides O-MISC O-MISC
the O-MISC O-MISC
ability O-MISC O-MISC
to O-MISC O-MISC
turn O-MISC O-MISC
off O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
activity O-MISC O-MISC
rapidly O-MISC O-MISC
as O-MISC O-MISC
soon O-MISC O-MISC
as O-MISC O-MISC
the O-MISC O-MISC
activating O-MISC O-MISC
signal O-MISC O-MISC
ceases O-MISC O-MISC
. O-MISC O-MISC

Identification O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
killer B-MISC B-MISC
cell I-MISC I-MISC
- I-MISC I-MISC
specific I-MISC I-MISC
regulatory I-MISC I-MISC
element I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mouse B-MISC B-MISC
perforin I-MISC I-MISC
gene I-MISC I-MISC
: O-MISC O-MISC
an O-MISC O-MISC
Ets O-MISC B-MISC
- O-MISC I-MISC
binding O-MISC I-MISC
site O-MISC I-MISC
- O-MISC I-MISC
homologous O-MISC I-MISC
motif O-MISC I-MISC
that O-MISC O-MISC
interacts O-MISC O-MISC
with O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
related I-MISC I-MISC
proteins I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
gene O-MISC O-MISC
encoding O-MISC O-MISC
the O-MISC O-MISC
cytolytic B-MISC B-MISC
protein I-MISC I-MISC
perforin B-MISC I-MISC
is O-MISC O-MISC
selectively O-MISC O-MISC
expressed O-MISC O-MISC
by O-MISC O-MISC
activated O-MISC O-MISC
killer O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
understand O-MISC O-MISC
the O-MISC O-MISC
mechanisms O-MISC O-MISC
underlying O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
type O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
gene O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
characterized O-MISC O-MISC
the O-MISC O-MISC
regulatory O-MISC O-MISC
functions O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
DNA O-MISC O-MISC
- O-MISC O-MISC
protein O-MISC O-MISC
interactions O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
5 B-MISC B-MISC
' I-MISC I-MISC
- I-MISC I-MISC
flanking I-MISC I-MISC
region I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
mouse B-MISC B-MISC
perforin I-MISC I-MISC
gene I-MISC I-MISC
( O-MISC O-MISC
Pfp B-MISC B-MISC
) O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
region O-MISC O-MISC
extending O-MISC O-MISC
from O-MISC O-MISC
residues B-MISC O-MISC
+ I-MISC O-MISC
62 I-MISC O-MISC
through I-MISC O-MISC
- I-MISC B-MISC
141 I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
possesses O-MISC O-MISC
the O-MISC O-MISC
essential O-MISC O-MISC
promoter O-MISC O-MISC
activity O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
regions O-MISC O-MISC
further O-MISC O-MISC
upstream O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
are O-MISC O-MISC
able O-MISC O-MISC
to O-MISC O-MISC
either O-MISC O-MISC
enhance O-MISC O-MISC
or O-MISC O-MISC
suppress O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
identified O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
region O-MISC O-MISC
between O-MISC O-MISC
residues B-MISC O-MISC
- I-MISC O-MISC
411 I-MISC O-MISC
and I-MISC O-MISC
- I-MISC O-MISC
566 I-MISC O-MISC
was O-MISC O-MISC
chosen O-MISC O-MISC
for O-MISC O-MISC
further O-MISC O-MISC
characterization O-MISC O-MISC
, O-MISC O-MISC
since O-MISC O-MISC
it O-MISC O-MISC
contains O-MISC O-MISC
an O-MISC O-MISC
enhancer O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
identified O-MISC O-MISC
a O-MISC O-MISC
32 O-MISC B-MISC
- O-MISC I-MISC
mer O-MISC I-MISC
sequence O-MISC I-MISC
( O-MISC O-MISC
residues B-MISC I-MISC
- I-MISC I-MISC
491 I-MISC I-MISC
to I-MISC I-MISC
- I-MISC I-MISC
522 I-MISC I-MISC
) O-MISC O-MISC
which O-MISC O-MISC
appeared O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
capable O-MISC O-MISC
of O-MISC O-MISC
enhancing O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
killer O-MISC O-MISC
cell O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
manner O-MISC O-MISC
. O-MISC O-MISC

Within O-MISC O-MISC
this O-MISC O-MISC
segment O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
9 O-MISC B-MISC
- O-MISC I-MISC
mer O-MISC I-MISC
motif O-MISC I-MISC
( O-MISC O-MISC
5 O-MISC O-MISC
' O-MISC O-MISC
- O-MISC I-MISC
ACAGGAAGT O-MISC I-MISC
- O-MISC I-MISC
3 O-MISC I-MISC
' O-MISC O-MISC
, O-MISC O-MISC
residues B-MISC O-MISC
- I-MISC O-MISC
505 I-MISC O-MISC
to I-MISC O-MISC
- I-MISC O-MISC
497 I-MISC O-MISC
; O-MISC O-MISC
designated O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
P O-MISC I-MISC
motif O-MISC I-MISC
) O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
highly O-MISC O-MISC
homologous O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
Ets B-MISC B-MISC
proto I-MISC I-MISC
- I-MISC I-MISC
oncoprotein I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
, O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
interact O-MISC O-MISC
with O-MISC O-MISC
two O-MISC O-MISC
proteins O-MISC O-MISC
, O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P1 I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P2 I-MISC I-MISC
. O-MISC O-MISC

NF B-MISC B-MISC
- I-MISC I-MISC
P2 I-MISC I-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
reagents O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulate O-MISC O-MISC
the O-MISC O-MISC
perforin O-MISC B-MISC
message O-MISC O-MISC
level O-MISC O-MISC
and O-MISC O-MISC
is O-MISC O-MISC
present O-MISC O-MISC
exclusively O-MISC O-MISC
in O-MISC O-MISC
killer O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assay O-MISC O-MISC
and O-MISC O-MISC
UV O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
linking O-MISC O-MISC
experiments O-MISC O-MISC
revealed O-MISC O-MISC
that O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P1 I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P2 I-MISC I-MISC
may O-MISC O-MISC
possess O-MISC O-MISC
common O-MISC O-MISC
DNA B-MISC B-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
subunits I-MISC I-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
larger O-MISC O-MISC
native O-MISC O-MISC
molecular O-MISC O-MISC
mass O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P1 I-MISC I-MISC
suggests O-MISC O-MISC
that O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P1 I-MISC I-MISC
contains O-MISC O-MISC
an O-MISC O-MISC
additional O-MISC O-MISC
non B-MISC B-MISC
- I-MISC I-MISC
DNA I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
subunit I-MISC I-MISC
( O-MISC O-MISC
s O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
view O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
homology O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P I-MISC I-MISC
motif I-MISC I-MISC
and O-MISC O-MISC
other O-MISC O-MISC
Ets B-MISC B-MISC
proto I-MISC I-MISC
- I-MISC I-MISC
oncoprotein I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
, O-MISC O-MISC
it O-MISC O-MISC
is O-MISC O-MISC
postulated O-MISC O-MISC
that O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P1 I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P2 I-MISC I-MISC
belong O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
Ets B-MISC B-MISC
protein I-MISC I-MISC
family I-MISC I-MISC
. O-MISC O-MISC

Results O-MISC O-MISC
obtained O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
competition O-MISC O-MISC
assay O-MISC O-MISC
, O-MISC O-MISC
nevertheless O-MISC O-MISC
, O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P1 I-MISC I-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
P2 I-MISC I-MISC
are O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
but O-MISC O-MISC
distinct O-MISC O-MISC
from O-MISC O-MISC
Ets B-MISC B-MISC
proteins I-MISC I-MISC
, O-MISC O-MISC
e O-MISC O-MISC
. O-MISC O-MISC
g O-MISC B-MISC
. O-MISC I-MISC
, O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
Ets B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
AT I-MISC I-MISC
/ I-MISC I-MISC
Elf I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
, O-MISC O-MISC
known O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
expressed O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B1 I-MISC I-MISC
( I-MISC I-MISC
p50 I-MISC I-MISC
/ I-MISC I-MISC
p105 I-MISC I-MISC
) I-MISC I-MISC
gene I-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lymphocytes O-MISC O-MISC
via O-MISC O-MISC
CD2 B-MISC B-MISC
and I-MISC O-MISC
CD28 I-MISC B-MISC
adhesion I-MISC I-MISC
molecules I-MISC I-MISC
. O-MISC O-MISC

Stimulation O-MISC O-MISC
of O-MISC O-MISC
primary O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lymphocytes O-MISC O-MISC
via O-MISC O-MISC
CD2 B-MISC B-MISC
and I-MISC O-MISC
CD28 I-MISC B-MISC
adhesion I-MISC I-MISC
molecules I-MISC I-MISC
induces O-MISC O-MISC
a O-MISC O-MISC
long O-MISC O-MISC
- O-MISC O-MISC
lasting O-MISC O-MISC
proliferation O-MISC O-MISC
( O-MISC O-MISC
> O-MISC O-MISC
3 O-MISC O-MISC
weeks O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
potent O-MISC O-MISC
activation O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
require O-MISC O-MISC
accessory O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
such O-MISC O-MISC
as O-MISC O-MISC
monocytes O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
depends O-MISC O-MISC
on O-MISC O-MISC
persistent O-MISC O-MISC
interleukin B-MISC B-MISC
2 I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
) O-MISC O-MISC
secretion O-MISC O-MISC
and O-MISC O-MISC
receptivity O-MISC O-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
and O-MISC O-MISC
prolonged O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
inducible O-MISC B-MISC
CD25 B-MISC I-MISC
/ I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
alpha I-MISC I-MISC
( I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
alpha I-MISC I-MISC
) I-MISC I-MISC
chain I-MISC I-MISC
gene I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
transcription B-MISC B-MISC
factor I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
participates O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
regulation O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
and I-MISC I-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
alpha I-MISC I-MISC
genes I-MISC I-MISC
, O-MISC O-MISC
as O-MISC O-MISC
well O-MISC O-MISC
as O-MISC O-MISC
multiple B-MISC O-MISC
cellular I-MISC B-MISC
genes I-MISC I-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
evaluate O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
lymphocytes O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
previously O-MISC O-MISC
analyzed O-MISC O-MISC
the O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
- I-MISC I-MISC
related I-MISC I-MISC
complexes I-MISC I-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
CD2 O-MISC O-MISC
+ O-MISC O-MISC
CD28 O-MISC B-MISC
costimulation O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
demonstrated O-MISC O-MISC
a O-MISC O-MISC
long O-MISC O-MISC
- O-MISC O-MISC
term O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
p50 B-MISC B-MISC
/ I-MISC I-MISC
p65 I-MISC I-MISC
heterodimer I-MISC I-MISC
, O-MISC O-MISC
a O-MISC O-MISC
putative B-MISC O-MISC
p65 I-MISC B-MISC
/ I-MISC I-MISC
c I-MISC I-MISC
- I-MISC I-MISC
Rel I-MISC I-MISC
heterodimer I-MISC I-MISC
, O-MISC O-MISC
and O-MISC O-MISC
a O-MISC O-MISC
constitutive O-MISC O-MISC
nuclear O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
KBF1 B-MISC B-MISC
/ I-MISC I-MISC
p50 I-MISC I-MISC
homodimers I-MISC I-MISC
. I-MISC O-MISC

As O-MISC O-MISC
the O-MISC O-MISC
role O-MISC O-MISC
of O-MISC O-MISC
p50 B-MISC B-MISC
remains O-MISC O-MISC
unclear O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
focused O-MISC O-MISC
our O-MISC O-MISC
present O-MISC O-MISC
study O-MISC O-MISC
on O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B1 I-MISC I-MISC
( O-MISC I-MISC
p50 B-MISC B-MISC
/ I-MISC I-MISC
p105 I-MISC I-MISC
) O-MISC I-MISC
gene O-MISC I-MISC
regulation O-MISC O-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
electrophoretic O-MISC O-MISC
mobility O-MISC O-MISC
shift O-MISC O-MISC
assays O-MISC O-MISC
and O-MISC O-MISC
Western O-MISC O-MISC
and O-MISC O-MISC
Northern O-MISC O-MISC
blot O-MISC O-MISC
analyses O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
studied O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B1 I-MISC I-MISC
gene I-MISC I-MISC
expression O-MISC O-MISC
during O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
stimulation O-MISC O-MISC
via O-MISC O-MISC
CD2 B-MISC B-MISC
+ I-MISC O-MISC
CD28 I-MISC B-MISC
. O-MISC O-MISC

We O-MISC O-MISC
observed O-MISC O-MISC
a O-MISC O-MISC
transient O-MISC O-MISC
4 O-MISC O-MISC
- O-MISC O-MISC
to O-MISC O-MISC
5 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
increase O-MISC O-MISC
of O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B1 O-MISC I-MISC
gene O-MISC I-MISC
expression O-MISC O-MISC
at O-MISC O-MISC
both O-MISC O-MISC
the O-MISC O-MISC
mRNA O-MISC B-MISC
and O-MISC O-MISC
protein O-MISC O-MISC
levels O-MISC O-MISC
, O-MISC O-MISC
lasting O-MISC O-MISC
for O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
. O-MISC O-MISC

p50 O-MISC B-MISC
DNA O-MISC I-MISC
- O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
apparently O-MISC O-MISC
stays O-MISC O-MISC
highly O-MISC O-MISC
controlled O-MISC O-MISC
when O-MISC O-MISC
p105 O-MISC B-MISC
expression O-MISC O-MISC
is O-MISC O-MISC
enhanced O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
physiological O-MISC O-MISC
stimulus O-MISC O-MISC
of O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Partial O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
p50 O-MISC B-MISC
and O-MISC O-MISC
p105 O-MISC B-MISC
expression O-MISC O-MISC
by O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B1 I-MISC I-MISC
antisense O-MISC O-MISC
oligonucleotides O-MISC O-MISC
significantly O-MISC O-MISC
reduced O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
CD25 B-MISC B-MISC
/ I-MISC I-MISC
IL I-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
alpha I-MISC I-MISC
cell O-MISC O-MISC
surface O-MISC O-MISC
expression O-MISC O-MISC
. O-MISC O-MISC

( O-MISC O-MISC
ABSTRACT O-MISC O-MISC
TRUNCATED O-MISC O-MISC
AT O-MISC O-MISC
250 O-MISC O-MISC
WORDS O-MISC O-MISC
) O-MISC O-MISC

Vitamin B-MISC B-MISC
D I-MISC I-MISC
receptor I-MISC I-MISC
quantitation O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
in O-MISC O-MISC
health O-MISC O-MISC
and O-MISC O-MISC
disease O-MISC O-MISC
. O-MISC O-MISC

Vitamin B-MISC B-MISC
D I-MISC I-MISC
receptor I-MISC I-MISC
( O-MISC O-MISC
VDR O-MISC B-MISC
) O-MISC O-MISC
concentration O-MISC O-MISC
was O-MISC O-MISC
quantitated O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
mononuclear O-MISC O-MISC
cells O-MISC O-MISC
( O-MISC O-MISC
PBMC O-MISC O-MISC
) O-MISC O-MISC
from O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
absorptive O-MISC O-MISC
hypercalciuria O-MISC O-MISC
( O-MISC O-MISC
AH O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
high O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
acquired O-MISC O-MISC
or O-MISC O-MISC
transient O-MISC O-MISC
disease O-MISC O-MISC
states O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
compared O-MISC O-MISC
to O-MISC O-MISC
those O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
subjects O-MISC O-MISC
. O-MISC O-MISC

VDR O-MISC B-MISC
concentration O-MISC O-MISC
in O-MISC O-MISC
resting O-MISC O-MISC
cells O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
different O-MISC O-MISC
between O-MISC O-MISC
the O-MISC O-MISC
three O-MISC O-MISC
groups O-MISC O-MISC
and O-MISC O-MISC
represented O-MISC O-MISC
constitutive O-MISC O-MISC
receptor O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
monocytes O-MISC O-MISC
. O-MISC O-MISC

Following O-MISC O-MISC
activation O-MISC O-MISC
with O-MISC O-MISC
phytohemagglutinin B-MISC B-MISC
, O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
hypercalcitriolemia O-MISC O-MISC
demonstrated O-MISC O-MISC
significantly O-MISC O-MISC
greater O-MISC O-MISC
VDR O-MISC B-MISC
concentrations O-MISC O-MISC
. O-MISC O-MISC

Patients O-MISC O-MISC
with O-MISC O-MISC
AH O-MISC O-MISC
demonstrated O-MISC O-MISC
a O-MISC O-MISC
normal O-MISC O-MISC
value O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
group O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
6 O-MISC O-MISC
patients O-MISC O-MISC
had O-MISC O-MISC
significantly O-MISC O-MISC
greater O-MISC O-MISC
concentrations O-MISC O-MISC
of O-MISC O-MISC
VDR B-MISC B-MISC
despite O-MISC O-MISC
normal O-MISC O-MISC
plasma O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
in O-MISC O-MISC
four O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
patients O-MISC O-MISC
. O-MISC O-MISC

Proliferation O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
assessed O-MISC O-MISC
from O-MISC O-MISC
[ O-MISC O-MISC
3H O-MISC O-MISC
] O-MISC O-MISC
thymidine O-MISC O-MISC
incorporation O-MISC O-MISC
was O-MISC O-MISC
inversely O-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
serum O-MISC O-MISC
1 O-MISC O-MISC
, O-MISC O-MISC
25 O-MISC O-MISC
( O-MISC O-MISC
OH O-MISC O-MISC
) O-MISC O-MISC
2D3 O-MISC O-MISC
and O-MISC O-MISC
was O-MISC O-MISC
significant O-MISC O-MISC
( O-MISC O-MISC
R O-MISC O-MISC
= O-MISC O-MISC
- O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
299 O-MISC O-MISC
, O-MISC O-MISC
p O-MISC O-MISC
= O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
048 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Taken O-MISC O-MISC
together O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
results O-MISC O-MISC
suggest O-MISC O-MISC
that O-MISC O-MISC
PBMC O-MISC O-MISC
provide O-MISC O-MISC
a O-MISC O-MISC
useful O-MISC O-MISC
system O-MISC O-MISC
for O-MISC O-MISC
studying O-MISC O-MISC
VDR B-MISC B-MISC
status O-MISC O-MISC
in O-MISC O-MISC
transient O-MISC O-MISC
or O-MISC O-MISC
acquired O-MISC O-MISC
states O-MISC O-MISC
of O-MISC O-MISC
hypercalcitriolemia O-MISC O-MISC
. O-MISC O-MISC

Furthermore O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
studies O-MISC O-MISC
in O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
absorptive O-MISC O-MISC
hypercalciuria O-MISC O-MISC
disclosed O-MISC O-MISC
it O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
a O-MISC O-MISC
heterogeneous O-MISC O-MISC
disorder O-MISC O-MISC
, O-MISC O-MISC
characterized O-MISC O-MISC
by O-MISC O-MISC
both O-MISC O-MISC
vitamin O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
and O-MISC O-MISC
D O-MISC O-MISC
- O-MISC O-MISC
independent O-MISC O-MISC
forms O-MISC O-MISC
of O-MISC O-MISC
receptor O-MISC O-MISC
up O-MISC O-MISC
- O-MISC O-MISC
regulation O-MISC O-MISC
. O-MISC O-MISC

Reactive O-MISC O-MISC
oxygen O-MISC O-MISC
intermediates O-MISC O-MISC
activate O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
in O-MISC O-MISC
a O-MISC O-MISC
tyrosine O-MISC B-MISC
kinase O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
mechanism O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
combination O-MISC O-MISC
with O-MISC O-MISC
vanadate O-MISC O-MISC
activate O-MISC O-MISC
the O-MISC O-MISC
p56lck B-MISC B-MISC
and I-MISC O-MISC
p59fyn I-MISC B-MISC
tyrosine I-MISC O-MISC
kinases I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
previously O-MISC O-MISC
observed O-MISC O-MISC
that O-MISC O-MISC
ionizing O-MISC O-MISC
radiation O-MISC O-MISC
induces O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
B O-MISC O-MISC
- O-MISC O-MISC
lymphocyte O-MISC O-MISC
precursors O-MISC O-MISC
by O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
unidentified O-MISC O-MISC
tyrosine B-MISC O-MISC
kinases I-MISC I-MISC
and O-MISC O-MISC
this O-MISC O-MISC
phosphorylation O-MISC O-MISC
is O-MISC O-MISC
substantially O-MISC O-MISC
augmented O-MISC O-MISC
by O-MISC O-MISC
vanadate O-MISC O-MISC
. O-MISC O-MISC

Ionizing O-MISC O-MISC
radiation O-MISC O-MISC
generates O-MISC O-MISC
reactive O-MISC O-MISC
oxygen O-MISC O-MISC
intermediates O-MISC O-MISC
( O-MISC O-MISC
ROI O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Because O-MISC O-MISC
H2O2 O-MISC O-MISC
is O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
ROI O-MISC O-MISC
generator O-MISC O-MISC
that O-MISC O-MISC
readily O-MISC O-MISC
crosses O-MISC O-MISC
the O-MISC O-MISC
plasma O-MISC O-MISC
membrane O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
used O-MISC O-MISC
H2O2 O-MISC O-MISC
to O-MISC O-MISC
examine O-MISC O-MISC
the O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
ROI O-MISC O-MISC
on O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
now O-MISC O-MISC
provide O-MISC O-MISC
evidence O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
tyrosine O-MISC B-MISC
kinase O-MISC I-MISC
inhibitor O-MISC O-MISC
herbimycin O-MISC O-MISC
A O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
free O-MISC O-MISC
radical O-MISC O-MISC
scavenger O-MISC O-MISC
N O-MISC O-MISC
- O-MISC O-MISC
acetyl O-MISC O-MISC
- O-MISC O-MISC
cysteine O-MISC O-MISC
inhibit O-MISC O-MISC
both O-MISC O-MISC
radiation O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
and O-MISC O-MISC
H2O2 O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
, O-MISC O-MISC
indicating O-MISC O-MISC
that O-MISC O-MISC
activation O-MISC O-MISC
triggered O-MISC O-MISC
by O-MISC O-MISC
ROI O-MISC O-MISC
is O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
tyrosine O-MISC B-MISC
kinase O-MISC I-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

H2O2 O-MISC B-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
stimulate O-MISC O-MISC
Ins B-MISC O-MISC
- I-MISC B-MISC
1 I-MISC I-MISC
, I-MISC O-MISC
4 I-MISC O-MISC
, I-MISC O-MISC
5 I-MISC B-MISC
- I-MISC I-MISC
P3 I-MISC I-MISC
production O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
tyrosine O-MISC B-MISC
kinase O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
manner O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
calcium O-MISC O-MISC
signals O-MISC O-MISC
that O-MISC O-MISC
were O-MISC O-MISC
greatly O-MISC O-MISC
augmented O-MISC O-MISC
by O-MISC O-MISC
vanadate O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
synergistic O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
by O-MISC O-MISC
H2O2 O-MISC O-MISC
plus O-MISC O-MISC
vanadate O-MISC O-MISC
included O-MISC O-MISC
physiologically O-MISC O-MISC
relevant O-MISC O-MISC
proteins O-MISC I-MISC
such O-MISC O-MISC
as O-MISC O-MISC
PLC B-MISC B-MISC
gamma I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Although O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
with O-MISC O-MISC
H2O2 O-MISC O-MISC
alone O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
src B-MISC B-MISC
family I-MISC I-MISC
kinases I-MISC I-MISC
, O-MISC O-MISC
treatment O-MISC O-MISC
with O-MISC O-MISC
H2O2 O-MISC O-MISC
plus O-MISC O-MISC
vanadate O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
p56lck B-MISC B-MISC
and I-MISC I-MISC
p59fyn I-MISC B-MISC
tyrosine I-MISC I-MISC
kinases I-MISC I-MISC
. O-MISC O-MISC

The O-MISC O-MISC
combined O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
phosphatases B-MISC B-MISC
and O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
kinases B-MISC O-MISC
provides O-MISC O-MISC
a O-MISC O-MISC
potent O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
synergistic O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
H2O2 O-MISC B-MISC
plus O-MISC O-MISC
vanadate O-MISC O-MISC
. O-MISC O-MISC

Induction O-MISC O-MISC
of O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
by O-MISC O-MISC
ROI O-MISC O-MISC
may O-MISC O-MISC
thus O-MISC O-MISC
lead O-MISC O-MISC
to O-MISC O-MISC
many O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
pleiotropic O-MISC B-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
ROI O-MISC B-MISC
in O-MISC O-MISC
lymphoid O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
including O-MISC O-MISC
downstream O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
PLC B-MISC B-MISC
gamma I-MISC I-MISC
1 I-MISC O-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC

Influence O-MISC O-MISC
of O-MISC O-MISC
sex B-MISC B-MISC
hormone I-MISC I-MISC
binding I-MISC I-MISC
globulin I-MISC I-MISC
and O-MISC O-MISC
serum B-MISC B-MISC
albumin I-MISC I-MISC
on O-MISC O-MISC
the O-MISC O-MISC
conversion O-MISC O-MISC
of O-MISC O-MISC
androstenedione O-MISC O-MISC
to O-MISC O-MISC
testosterone O-MISC O-MISC
by O-MISC O-MISC
human O-MISC O-MISC
erythrocytes O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
influence O-MISC O-MISC
of O-MISC O-MISC
human B-MISC B-MISC
serum I-MISC I-MISC
albumin I-MISC I-MISC
and O-MISC O-MISC
sex B-MISC I-MISC
hormone I-MISC I-MISC
binding I-MISC I-MISC
globulin I-MISC I-MISC
( O-MISC O-MISC
SHBG B-MISC B-MISC
) O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
enzymic O-MISC O-MISC
conversion O-MISC O-MISC
of O-MISC O-MISC
androstenedione O-MISC O-MISC
to O-MISC O-MISC
testosterone O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
erythrocytes O-MISC O-MISC
was O-MISC O-MISC
investigated O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
. O-MISC O-MISC

Total O-MISC O-MISC
plasma O-MISC O-MISC
and O-MISC O-MISC
albumin B-MISC B-MISC
delayed O-MISC O-MISC
the O-MISC O-MISC
conversion O-MISC O-MISC
rate O-MISC O-MISC
of O-MISC O-MISC
androstenedione O-MISC O-MISC
, O-MISC O-MISC
while O-MISC O-MISC
SHBG B-MISC B-MISC
increased O-MISC O-MISC
it O-MISC O-MISC
markedly O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
SHBG B-MISC B-MISC
was O-MISC O-MISC
largely O-MISC O-MISC
abolished O-MISC O-MISC
by O-MISC O-MISC
heating O-MISC O-MISC
to O-MISC O-MISC
60 O-MISC O-MISC
degrees O-MISC O-MISC
C O-MISC O-MISC
for O-MISC O-MISC
1 O-MISC O-MISC
h O-MISC O-MISC
and O-MISC O-MISC
by O-MISC O-MISC
saturating O-MISC O-MISC
its O-MISC O-MISC
binding O-MISC B-MISC
sites O-MISC I-MISC
by O-MISC O-MISC
DHT O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
effect O-MISC O-MISC
of O-MISC O-MISC
both O-MISC O-MISC
proteins O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
related O-MISC O-MISC
to O-MISC O-MISC
their O-MISC O-MISC
concentration O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
appears O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC B-MISC
sites O-MISC I-MISC
of O-MISC O-MISC
albumin B-MISC B-MISC
provide O-MISC O-MISC
a O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
retarding O-MISC O-MISC
androstenedione O-MISC O-MISC
uptake O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
erythrocytes O-MISC O-MISC
and O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
high O-MISC O-MISC
binding O-MISC O-MISC
affinity O-MISC O-MISC
of O-MISC O-MISC
SHBG B-MISC B-MISC
for O-MISC O-MISC
testosterone O-MISC O-MISC
facilitates O-MISC O-MISC
the O-MISC O-MISC
diffusion O-MISC O-MISC
of O-MISC O-MISC
this O-MISC O-MISC
steroid O-MISC O-MISC
out O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
and O-MISC O-MISC
thus O-MISC O-MISC
, O-MISC O-MISC
displaces O-MISC O-MISC
the O-MISC O-MISC
chemical O-MISC O-MISC
equilibrium O-MISC O-MISC
within O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoids O-MISC O-MISC
and O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

I O-MISC O-MISC
. O-MISC O-MISC

Increased O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
levels O-MISC O-MISC
in O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Recently O-MISC O-MISC
a O-MISC O-MISC
2 O-MISC O-MISC
- O-MISC O-MISC
to O-MISC I-MISC
3 O-MISC O-MISC
- O-MISC O-MISC
fold O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
lymphocytes O-MISC O-MISC
has O-MISC O-MISC
been O-MISC O-MISC
noted O-MISC O-MISC
after O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
mitogen O-MISC O-MISC
stimulation O-MISC O-MISC
. O-MISC O-MISC

Here O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
extend O-MISC O-MISC
these O-MISC O-MISC
observations O-MISC O-MISC
to O-MISC O-MISC
in O-MISC O-MISC
vivo O-MISC O-MISC
immunization O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
unilateral O-MISC O-MISC
immunization O-MISC O-MISC
of O-MISC O-MISC
adrenalectomized O-MISC O-MISC
male O-MISC O-MISC
rats O-MISC O-MISC
, O-MISC O-MISC
a O-MISC O-MISC
50 O-MISC O-MISC
% O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
glucocorticoid O-MISC B-MISC
receptor O-MISC I-MISC
sites O-MISC O-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
, O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
, O-MISC O-MISC
was O-MISC O-MISC
observed O-MISC O-MISC
in O-MISC O-MISC
cell O-MISC O-MISC
suspensions O-MISC O-MISC
of O-MISC O-MISC
homolateral O-MISC O-MISC
lymph O-MISC O-MISC
nodes O-MISC O-MISC
over O-MISC O-MISC
those O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
contralateral O-MISC O-MISC
nonimmunized O-MISC O-MISC
side O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
same O-MISC O-MISC
animal O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
association O-MISC O-MISC
constant O-MISC O-MISC
for O-MISC O-MISC
dexamethasone O-MISC O-MISC
was O-MISC O-MISC
similar O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
groups O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
was O-MISC O-MISC
the O-MISC O-MISC
stereospecificity O-MISC O-MISC
for O-MISC O-MISC
various O-MISC O-MISC
steroids O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
time O-MISC O-MISC
course O-MISC O-MISC
of O-MISC O-MISC
cytoplasmic O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
association O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
cytoplasmic O-MISC O-MISC
- O-MISC O-MISC
to O-MISC O-MISC
- O-MISC O-MISC
nuclear O-MISC O-MISC
translocation O-MISC O-MISC
. O-MISC O-MISC

Despite O-MISC O-MISC
a O-MISC O-MISC
50 O-MISC O-MISC
% O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC B-MISC
receptor O-MISC I-MISC
sites O-MISC I-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
homolateral O-MISC O-MISC
and O-MISC O-MISC
controlateral O-MISC O-MISC
lymph O-MISC O-MISC
nodes O-MISC O-MISC
were O-MISC O-MISC
equally O-MISC O-MISC
sensitive O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
inhibitory O-MISC O-MISC
effects O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
, O-MISC O-MISC
as O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
measurements O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
incorporation O-MISC O-MISC
of O-MISC O-MISC
radiolabeled O-MISC O-MISC
precursors O-MISC O-MISC
of O-MISC O-MISC
protein O-MISC O-MISC
, O-MISC O-MISC
RNA O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
DNA O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
measurements O-MISC O-MISC
of O-MISC O-MISC
in O-MISC O-MISC
vitro O-MISC O-MISC
cell O-MISC O-MISC
survival O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoid O-MISC B-MISC
receptors O-MISC I-MISC
and O-MISC O-MISC
actions O-MISC O-MISC
in O-MISC O-MISC
rat O-MISC O-MISC
thymocytes O-MISC O-MISC
and O-MISC O-MISC
immunologically O-MISC O-MISC
stimulated O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

After O-MISC O-MISC
reviewing O-MISC O-MISC
briefly O-MISC O-MISC
our O-MISC O-MISC
earlier O-MISC O-MISC
studies O-MISC O-MISC
on O-MISC O-MISC
glucocorticoid O-MISC B-MISC
receptors O-MISC I-MISC
and O-MISC O-MISC
mechanisms O-MISC O-MISC
in O-MISC O-MISC
thymus O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
have O-MISC O-MISC
outlined O-MISC O-MISC
results O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
following O-MISC O-MISC
two O-MISC O-MISC
areas O-MISC O-MISC
of O-MISC O-MISC
current O-MISC O-MISC
interest O-MISC O-MISC
in O-MISC O-MISC
our O-MISC O-MISC
laboratories O-MISC O-MISC
: O-MISC O-MISC
the O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
life O-MISC O-MISC
- O-MISC O-MISC
cycle O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC B-MISC
receptors O-MISC I-MISC
and O-MISC O-MISC
complexes O-MISC O-MISC
in O-MISC O-MISC
thymus O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid O-MISC B-MISC
receptors O-MISC I-MISC
and O-MISC O-MISC
sensitivity O-MISC O-MISC
in O-MISC O-MISC
immunologically O-MISC O-MISC
stimulated O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Several O-MISC O-MISC
of O-MISC O-MISC
our O-MISC O-MISC
results O-MISC O-MISC
on O-MISC O-MISC
energetics O-MISC O-MISC
and O-MISC O-MISC
kinetics O-MISC O-MISC
of O-MISC O-MISC
hormone O-MISC O-MISC
binding O-MISC O-MISC
to O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptors I-MISC I-MISC
in O-MISC O-MISC
rat O-MISC O-MISC
thymus O-MISC O-MISC
cells O-MISC O-MISC
seem O-MISC O-MISC
to O-MISC O-MISC
require O-MISC O-MISC
extension O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
simplest O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
hormone O-MISC B-MISC
- O-MISC O-MISC
receptor O-MISC I-MISC
transformations O-MISC O-MISC
in O-MISC O-MISC
intact O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

ATP O-MISC O-MISC
- O-MISC O-MISC
depletion O-MISC O-MISC
experiments O-MISC O-MISC
suggest O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
nonbinding O-MISC O-MISC
form O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
receptor O-MISC O-MISC
; O-MISC O-MISC
` O-MISC O-MISC
` O-MISC O-MISC
chase O-MISC O-MISC
' O-MISC O-MISC
' O-MISC O-MISC
experiments O-MISC O-MISC
suggest O-MISC O-MISC
reaction O-MISC O-MISC
of O-MISC O-MISC
hormone O-MISC O-MISC
directly O-MISC O-MISC
with O-MISC O-MISC
nuclear O-MISC O-MISC
- O-MISC O-MISC
bound O-MISC O-MISC
receptor O-MISC O-MISC
; O-MISC O-MISC
experiments O-MISC O-MISC
on O-MISC O-MISC
depletion O-MISC O-MISC
and O-MISC O-MISC
replenishment O-MISC O-MISC
of O-MISC O-MISC
cytoplasmic B-MISC B-MISC
receptor I-MISC I-MISC
using O-MISC O-MISC
cortisol O-MISC O-MISC
and O-MISC O-MISC
dexamethasone O-MISC O-MISC
suggest O-MISC O-MISC
the O-MISC O-MISC
existence O-MISC O-MISC
of O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
two O-MISC O-MISC
subpopulations O-MISC O-MISC
of O-MISC O-MISC
nuclear B-MISC B-MISC
- I-MISC I-MISC
bound I-MISC I-MISC
hormone I-MISC I-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complex I-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
found O-MISC O-MISC
that O-MISC O-MISC
mitogen O-MISC O-MISC
or O-MISC O-MISC
immunologic O-MISC O-MISC
stimulation O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
peripheral O-MISC O-MISC
lymphocytes O-MISC O-MISC
in O-MISC O-MISC
culture O-MISC O-MISC
leads O-MISC O-MISC
within O-MISC O-MISC
24 O-MISC O-MISC
h O-MISC O-MISC
or O-MISC O-MISC
so O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
striking O-MISC O-MISC
increase O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
number O-MISC O-MISC
of O-MISC O-MISC
glucocorticoid B-MISC B-MISC
receptor I-MISC I-MISC
sites O-MISC I-MISC
per O-MISC O-MISC
cell O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
believe O-MISC O-MISC
this O-MISC O-MISC
increase O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
partial O-MISC O-MISC
synchronization O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
population O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
phase O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
in O-MISC O-MISC
which O-MISC O-MISC
receptor O-MISC O-MISC
content O-MISC O-MISC
is O-MISC O-MISC
high O-MISC O-MISC
. O-MISC O-MISC

Contrary O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
widely O-MISC O-MISC
held O-MISC O-MISC
view O-MISC O-MISC
that O-MISC O-MISC
mitogen O-MISC O-MISC
- O-MISC O-MISC
stimulated O-MISC O-MISC
cells O-MISC O-MISC
become O-MISC O-MISC
insensitive O-MISC O-MISC
to O-MISC O-MISC
glucocorticoids O-MISC O-MISC
, O-MISC O-MISC
our O-MISC O-MISC
experiments O-MISC O-MISC
show O-MISC O-MISC
that O-MISC O-MISC
with O-MISC O-MISC
respect O-MISC O-MISC
to O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
thymidine O-MISC O-MISC
and O-MISC O-MISC
uridine O-MISC O-MISC
incorporation O-MISC O-MISC
and O-MISC O-MISC
glucose O-MISC O-MISC
uptake O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
cells O-MISC O-MISC
are O-MISC O-MISC
highly O-MISC O-MISC
sensitive O-MISC O-MISC
to O-MISC O-MISC
dexamethasone O-MISC O-MISC
at O-MISC O-MISC
24 O-MISC O-MISC
, O-MISC O-MISC
48 O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
72 O-MISC O-MISC
h O-MISC O-MISC
after O-MISC O-MISC
stimulation O-MISC O-MISC
with O-MISC O-MISC
concanavalin B-MISC O-MISC
A I-MISC O-MISC
. O-MISC O-MISC

Nuclear O-MISC O-MISC
glucocorticoid O-MISC O-MISC
binding O-MISC O-MISC
in O-MISC O-MISC
chronic O-MISC O-MISC
lymphatic O-MISC O-MISC
leukemia O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

A O-MISC O-MISC
reliable O-MISC O-MISC
procedure O-MISC O-MISC
is O-MISC O-MISC
described O-MISC O-MISC
for O-MISC O-MISC
isolating O-MISC O-MISC
3H B-MISC O-MISC
- I-MISC I-MISC
triamcinolone I-MISC I-MISC
acetonide I-MISC I-MISC
( I-MISC I-MISC
3H I-MISC O-MISC
- I-MISC I-MISC
TA I-MISC I-MISC
) I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
from O-MISC O-MISC
purified O-MISC O-MISC
chronic O-MISC O-MISC
lymphatic O-MISC O-MISC
leukemia O-MISC O-MISC
( O-MISC O-MISC
CLL O-MISC O-MISC
) O-MISC O-MISC
lymphocyte O-MISC O-MISC
nuclei O-MISC O-MISC
, O-MISC O-MISC
based O-MISC O-MISC
on O-MISC O-MISC
the O-MISC O-MISC
use O-MISC O-MISC
of O-MISC O-MISC
carbobenzoxy O-MISC O-MISC
- O-MISC O-MISC
L O-MISC O-MISC
- O-MISC O-MISC
phenylalanine O-MISC O-MISC
( O-MISC O-MISC
CBZ O-MISC B-MISC
- O-MISC O-MISC
L O-MISC O-MISC
- O-MISC O-MISC
phe O-MISC O-MISC
) O-MISC O-MISC
to O-MISC O-MISC
prevent O-MISC O-MISC
breakdown O-MISC O-MISC
of O-MISC O-MISC
hormone B-MISC B-MISC
- I-MISC I-MISC
receptor I-MISC I-MISC
complexes I-MISC I-MISC
during O-MISC O-MISC
extraction O-MISC O-MISC
of O-MISC O-MISC
nuclei O-MISC O-MISC
with O-MISC O-MISC
0 O-MISC O-MISC
. O-MISC O-MISC
6M O-MISC O-MISC
KCl O-MISC B-MISC
. O-MISC O-MISC

Using O-MISC O-MISC
this O-MISC O-MISC
method O-MISC O-MISC
, O-MISC O-MISC
specific O-MISC O-MISC
nuclear O-MISC O-MISC
glucocorticoid O-MISC O-MISC
binding O-MISC O-MISC
was O-MISC O-MISC
demonstrated O-MISC O-MISC
in O-MISC O-MISC
14 O-MISC O-MISC
/ O-MISC O-MISC
14 O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
untreated O-MISC O-MISC
CLL O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
correlation O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
between O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
nuclear O-MISC B-MISC
- O-MISC I-MISC
associated O-MISC I-MISC
3H O-MISC I-MISC
- O-MISC O-MISC
TA O-MISC O-MISC
and O-MISC O-MISC
peripheral O-MISC O-MISC
white O-MISC O-MISC
blood O-MISC O-MISC
cell O-MISC O-MISC
count O-MISC O-MISC
or O-MISC O-MISC
rosetting O-MISC O-MISC
ability O-MISC O-MISC
of O-MISC O-MISC
circulating O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Multiple O-MISC O-MISC
closely O-MISC O-MISC
- O-MISC O-MISC
linked O-MISC O-MISC
NFAT B-MISC B-MISC
/ I-MISC I-MISC
octamer I-MISC I-MISC
and O-MISC I-MISC
HMG B-MISC I-MISC
I I-MISC I-MISC
( I-MISC I-MISC
Y I-MISC I-MISC
) I-MISC I-MISC
binding I-MISC I-MISC
sites I-MISC I-MISC
are O-MISC O-MISC
part O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
interleukin O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
promoter O-MISC I-MISC
. O-MISC O-MISC

We O-MISC O-MISC
show O-MISC O-MISC
here O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
immediate B-MISC B-MISC
upstream I-MISC I-MISC
region I-MISC I-MISC
( O-MISC O-MISC
from O-MISC O-MISC
position O-MISC O-MISC
- O-MISC O-MISC
12 O-MISC I-MISC
to O-MISC O-MISC
- O-MISC O-MISC
270 O-MISC O-MISC
) O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
murine B-MISC O-MISC
interleukin I-MISC I-MISC
4 I-MISC I-MISC
( I-MISC I-MISC
Il I-MISC I-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
) I-MISC I-MISC
gene I-MISC I-MISC
harbors O-MISC O-MISC
a O-MISC O-MISC
strong O-MISC B-MISC
cell O-MISC I-MISC
- O-MISC I-MISC
type O-MISC I-MISC
specific O-MISC I-MISC
transcriptional B-MISC I-MISC
enhancer I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
T O-MISC O-MISC
lymphoma O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Il B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
promoter I-MISC I-MISC
/ I-MISC I-MISC
enhancer I-MISC I-MISC
is O-MISC O-MISC
stimulated O-MISC O-MISC
by O-MISC O-MISC
phorbol O-MISC O-MISC
esters O-MISC O-MISC
, O-MISC O-MISC
Ca O-MISC O-MISC
+ O-MISC O-MISC
+ O-MISC O-MISC
ionophores O-MISC O-MISC
and O-MISC O-MISC
agonists O-MISC O-MISC
of O-MISC O-MISC
protein B-MISC B-MISC
kinase I-MISC I-MISC
A I-MISC I-MISC
and O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
low O-MISC O-MISC
doses O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
immunosuppressant O-MISC O-MISC
cyclosporin O-MISC O-MISC
A O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
Il B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
promoter I-MISC I-MISC
/ I-MISC I-MISC
enhancer I-MISC I-MISC
is O-MISC O-MISC
transcriptionally O-MISC O-MISC
inactive O-MISC O-MISC
in O-MISC O-MISC
B O-MISC O-MISC
lymphoma O-MISC O-MISC
cells O-MISC O-MISC
and O-MISC O-MISC
HeLa O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

DNase O-MISC B-MISC
I O-MISC I-MISC
footprint O-MISC O-MISC
protection O-MISC O-MISC
experiments O-MISC O-MISC
revealed O-MISC O-MISC
six O-MISC O-MISC
sites O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Il B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
promoter I-MISC I-MISC
/ I-MISC I-MISC
enhancer I-MISC I-MISC
to O-MISC O-MISC
be O-MISC O-MISC
bound O-MISC O-MISC
by O-MISC O-MISC
nuclear B-MISC B-MISC
proteins I-MISC I-MISC
from O-MISC O-MISC
lymphoid O-MISC O-MISC
and O-MISC O-MISC
myeloid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Among O-MISC O-MISC
them O-MISC O-MISC
are O-MISC O-MISC
four O-MISC O-MISC
purine O-MISC B-MISC
boxes O-MISC I-MISC
which O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
described O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
important O-MISC O-MISC
sequence O-MISC O-MISC
motifs O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Il B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
promoter I-MISC I-MISC
. O-MISC O-MISC

They O-MISC O-MISC
contain O-MISC O-MISC
the O-MISC O-MISC
motif O-MISC O-MISC
GGAAA O-MISC B-MISC
and O-MISC O-MISC
are O-MISC O-MISC
recognized O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
inducible B-MISC O-MISC
and I-MISC O-MISC
cyclosporin I-MISC O-MISC
A I-MISC O-MISC
- I-MISC I-MISC
sensitive I-MISC I-MISC
transcription I-MISC I-MISC
factor I-MISC I-MISC
NFAT I-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

Three O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Il B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
NFAT I-MISC I-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
sites I-MISC I-MISC
are O-MISC O-MISC
closely O-MISC O-MISC
linked O-MISC O-MISC
to O-MISC O-MISC
weak O-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC O-MISC
of O-MISC O-MISC
Octamer B-MISC B-MISC
factors I-MISC I-MISC
. O-MISC O-MISC

Several O-MISC O-MISC
purine O-MISC B-MISC
boxes O-MISC I-MISC
and O-MISC O-MISC
an O-MISC O-MISC
AT B-MISC B-MISC
- I-MISC I-MISC
rich I-MISC I-MISC
protein I-MISC I-MISC
- I-MISC I-MISC
binding I-MISC I-MISC
site I-MISC I-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Il O-MISC B-MISC
- O-MISC I-MISC
4 O-MISC I-MISC
promoter O-MISC I-MISC
are O-MISC O-MISC
also O-MISC O-MISC
recognized O-MISC O-MISC
by O-MISC O-MISC
the O-MISC O-MISC
high B-MISC B-MISC
mobility I-MISC I-MISC
group I-MISC I-MISC
protein I-MISC I-MISC
HMG B-MISC I-MISC
I I-MISC I-MISC
( I-MISC O-MISC
Y I-MISC I-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Whereas O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
NFAT B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
and O-MISC O-MISC
Octamer B-MISC B-MISC
factors I-MISC I-MISC
enhance O-MISC O-MISC
the O-MISC O-MISC
activity O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
Il B-MISC B-MISC
- I-MISC I-MISC
4 I-MISC I-MISC
promoter I-MISC I-MISC
, O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
HMG O-MISC B-MISC
I O-MISC I-MISC
( O-MISC I-MISC
Y O-MISC I-MISC
) O-MISC O-MISC
suppresses O-MISC O-MISC
its O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
, O-MISC O-MISC
therefore O-MISC O-MISC
, O-MISC O-MISC
appears O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
involved O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
suppression O-MISC O-MISC
of O-MISC O-MISC
Il B-MISC O-MISC
- I-MISC O-MISC
4 I-MISC O-MISC
transcription O-MISC O-MISC
in O-MISC O-MISC
resting O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

Reversibility O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
differentiated O-MISC O-MISC
state O-MISC O-MISC
in O-MISC O-MISC
somatic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Analysis O-MISC O-MISC
of O-MISC O-MISC
de O-MISC O-MISC
novo O-MISC O-MISC
gene O-MISC O-MISC
activation O-MISC O-MISC
in O-MISC O-MISC
multinucleated O-MISC O-MISC
heterokaryons O-MISC O-MISC
has O-MISC O-MISC
shown O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
differentiated O-MISC O-MISC
state O-MISC O-MISC
, O-MISC O-MISC
although O-MISC O-MISC
stable O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
not O-MISC O-MISC
irreversible O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
can O-MISC O-MISC
be O-MISC O-MISC
reprogrammed O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
appropriate O-MISC O-MISC
combinations O-MISC O-MISC
of O-MISC O-MISC
trans B-MISC B-MISC
- I-MISC I-MISC
acting I-MISC I-MISC
regulatory I-MISC I-MISC
molecules I-MISC I-MISC
. O-MISC O-MISC

These O-MISC O-MISC
properties O-MISC O-MISC
have O-MISC O-MISC
been O-MISC O-MISC
exploited O-MISC O-MISC
to O-MISC O-MISC
design O-MISC O-MISC
strategies O-MISC O-MISC
for O-MISC O-MISC
identifying O-MISC O-MISC
novel O-MISC O-MISC
regulators O-MISC O-MISC
of O-MISC O-MISC
cellular O-MISC O-MISC
differentiation O-MISC O-MISC
. O-MISC O-MISC

Phosphatidylcholine O-MISC O-MISC
hydrolysis O-MISC O-MISC
activates O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
and O-MISC O-MISC
increases O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
replication O-MISC O-MISC
in O-MISC O-MISC
human O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
have O-MISC O-MISC
tested O-MISC O-MISC
whether O-MISC O-MISC
breakdown O-MISC O-MISC
of O-MISC O-MISC
phosphatidylcholine O-MISC O-MISC
( O-MISC O-MISC
PC O-MISC O-MISC
) O-MISC O-MISC
initiated O-MISC O-MISC
by O-MISC O-MISC
exogenous O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
PC B-MISC O-MISC
- I-MISC O-MISC
specific I-MISC O-MISC
phospholipase I-MISC O-MISC
C I-MISC O-MISC
( O-MISC O-MISC
PC B-MISC O-MISC
- I-MISC O-MISC
PLC I-MISC O-MISC
) O-MISC O-MISC
from O-MISC O-MISC
Bacillus O-MISC O-MISC
cereus O-MISC O-MISC
or O-MISC O-MISC
by O-MISC O-MISC
endogenous O-MISC O-MISC
overexpression O-MISC O-MISC
of O-MISC O-MISC
PC B-MISC O-MISC
- I-MISC O-MISC
PLC I-MISC I-MISC
induces O-MISC O-MISC
functional O-MISC O-MISC
activation O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
and O-MISC O-MISC
increases O-MISC O-MISC
human B-MISC O-MISC
immunodeficiency I-MISC O-MISC
virus I-MISC O-MISC
( I-MISC O-MISC
HIV I-MISC O-MISC
) I-MISC O-MISC
enhancer I-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

PC O-MISC O-MISC
- O-MISC O-MISC
PLC O-MISC O-MISC
- O-MISC O-MISC
activated O-MISC O-MISC
hydrolysis O-MISC O-MISC
of O-MISC O-MISC
PC O-MISC O-MISC
was O-MISC O-MISC
found O-MISC O-MISC
to O-MISC O-MISC
induce O-MISC O-MISC
bona O-MISC O-MISC
fide O-MISC O-MISC
p50 B-MISC B-MISC
/ I-MISC I-MISC
p65 I-MISC I-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
in O-MISC O-MISC
three O-MISC O-MISC
different O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
or O-MISC O-MISC
murine O-MISC O-MISC
origin O-MISC O-MISC
. O-MISC O-MISC

No O-MISC O-MISC
significant O-MISC O-MISC
changes O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
turnover O-MISC O-MISC
of O-MISC O-MISC
other O-MISC O-MISC
cellular O-MISC O-MISC
phospholipids O-MISC O-MISC
were O-MISC O-MISC
detected O-MISC O-MISC
in O-MISC O-MISC
PC O-MISC O-MISC
- O-MISC O-MISC
PLC O-MISC O-MISC
- O-MISC O-MISC
treated O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Induction O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
by O-MISC O-MISC
PC B-MISC O-MISC
- I-MISC O-MISC
PLC I-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
depend O-MISC O-MISC
on O-MISC O-MISC
de O-MISC O-MISC
novo O-MISC O-MISC
synthesis O-MISC O-MISC
of O-MISC O-MISC
proteins O-MISC O-MISC
or O-MISC O-MISC
autocrine O-MISC O-MISC
secretion O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
or O-MISC O-MISC
interleukin B-MISC B-MISC
1 I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
human O-MISC O-MISC
monocytic O-MISC O-MISC
and O-MISC O-MISC
lymphoblastoid O-MISC O-MISC
T O-MISC O-MISC
- O-MISC O-MISC
cell O-MISC O-MISC
lines O-MISC O-MISC
, O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
by O-MISC O-MISC
PC B-MISC O-MISC
- I-MISC O-MISC
PLC I-MISC I-MISC
resulted O-MISC O-MISC
in O-MISC O-MISC
clear O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
luciferase B-MISC B-MISC
expression O-MISC O-MISC
vectors O-MISC I-MISC
placed O-MISC O-MISC
under O-MISC O-MISC
the O-MISC O-MISC
control O-MISC O-MISC
of O-MISC O-MISC
synthetic B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
enhancers I-MISC I-MISC
or O-MISC O-MISC
wild O-MISC O-MISC
type O-MISC O-MISC
, O-MISC O-MISC
but O-MISC O-MISC
not O-MISC O-MISC
kappa O-MISC B-MISC
B O-MISC I-MISC
- O-MISC I-MISC
mutated O-MISC I-MISC
, O-MISC O-MISC
HIV B-MISC B-MISC
long I-MISC I-MISC
terminal I-MISC I-MISC
repeat I-MISC I-MISC
constructs I-MISC I-MISC
. O-MISC O-MISC

HIV O-MISC O-MISC
replication O-MISC O-MISC
was O-MISC O-MISC
increased O-MISC O-MISC
by O-MISC O-MISC
PC B-MISC O-MISC
- I-MISC O-MISC
PLC I-MISC O-MISC
in O-MISC O-MISC
chronically O-MISC O-MISC
infected O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
. O-MISC O-MISC

NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
activation O-MISC O-MISC
promoted O-MISC O-MISC
by O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
exogenous B-MISC O-MISC
PC I-MISC O-MISC
- I-MISC O-MISC
PLC I-MISC O-MISC
correlated O-MISC O-MISC
with O-MISC O-MISC
an O-MISC O-MISC
intense O-MISC O-MISC
production O-MISC O-MISC
of O-MISC O-MISC
diacylglycerol O-MISC O-MISC
. O-MISC O-MISC

However O-MISC O-MISC
, O-MISC O-MISC
addition O-MISC O-MISC
of O-MISC O-MISC
a O-MISC O-MISC
phosphatidylinositol B-MISC O-MISC
- I-MISC O-MISC
specific I-MISC O-MISC
PLC I-MISC O-MISC
from O-MISC O-MISC
B O-MISC O-MISC
. O-MISC O-MISC
cereus O-MISC O-MISC
also O-MISC O-MISC
induced O-MISC O-MISC
diacylglycerol O-MISC O-MISC
but O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
activate O-MISC O-MISC
kappa B-MISC B-MISC
B I-MISC I-MISC
enhancer I-MISC I-MISC
- I-MISC I-MISC
directed I-MISC O-MISC
vectors I-MISC I-MISC
. O-MISC O-MISC

PC O-MISC O-MISC
- O-MISC O-MISC
PLC O-MISC O-MISC
- O-MISC O-MISC
induced O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
activation O-MISC O-MISC
could O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
blocked O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC O-MISC
phorbol B-MISC O-MISC
ester I-MISC O-MISC
- I-MISC O-MISC
inducible I-MISC O-MISC
protein I-MISC B-MISC
kinases I-MISC I-MISC
C I-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
indicate O-MISC O-MISC
that O-MISC O-MISC
a O-MISC O-MISC
cellular O-MISC O-MISC
transduction O-MISC O-MISC
pathway O-MISC O-MISC
, O-MISC O-MISC
dependent O-MISC O-MISC
on O-MISC O-MISC
specific O-MISC O-MISC
PC O-MISC O-MISC
breakdown O-MISC O-MISC
, O-MISC O-MISC
is O-MISC O-MISC
functional O-MISC O-MISC
in O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
and O-MISC O-MISC
monocytes O-MISC O-MISC
and O-MISC O-MISC
may O-MISC O-MISC
be O-MISC O-MISC
used O-MISC O-MISC
by O-MISC O-MISC
various O-MISC O-MISC
transmembrane O-MISC B-MISC
receptors O-MISC I-MISC
to O-MISC O-MISC
activate O-MISC O-MISC
HIV O-MISC O-MISC
transcription O-MISC O-MISC
through O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
HIV B-MISC B-MISC
enhancer I-MISC I-MISC
. O-MISC O-MISC

Novel O-MISC O-MISC
mechanism O-MISC O-MISC
for O-MISC O-MISC
inhibition O-MISC O-MISC
of O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
glucocorticoids O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoids O-MISC O-MISC
inhibit O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
through O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
receptor I-MISC I-MISC
. O-MISC O-MISC

Interaction O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
with O-MISC O-MISC
its O-MISC O-MISC
high B-MISC O-MISC
affinity I-MISC I-MISC
membrane I-MISC I-MISC
receptor I-MISC I-MISC
complex I-MISC I-MISC
( O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
) O-MISC O-MISC
present O-MISC O-MISC
on O-MISC O-MISC
activated O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
induces O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
and O-MISC O-MISC
mediates O-MISC O-MISC
effector O-MISC O-MISC
functions O-MISC O-MISC
. O-MISC O-MISC

Glucocorticoids O-MISC O-MISC
inhibit O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
production O-MISC O-MISC
by O-MISC O-MISC
inhibiting O-MISC O-MISC
TCR O-MISC B-MISC
- O-MISC O-MISC
mediated O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
. O-MISC O-MISC

We O-MISC O-MISC
asked O-MISC O-MISC
whether O-MISC O-MISC
they O-MISC O-MISC
also O-MISC O-MISC
inhibit O-MISC O-MISC
the O-MISC O-MISC
action O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
by O-MISC O-MISC
inhibiting O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
through O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
. O-MISC O-MISC

Human O-MISC O-MISC
peripheral O-MISC O-MISC
blood O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
stimulated O-MISC O-MISC
with O-MISC O-MISC
PMA O-MISC O-MISC
for O-MISC O-MISC
48 O-MISC O-MISC
h O-MISC O-MISC
( O-MISC O-MISC
PMA O-MISC O-MISC
blasts O-MISC O-MISC
) O-MISC O-MISC
, O-MISC O-MISC
were O-MISC O-MISC
incubated O-MISC O-MISC
with O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
in O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
incremental O-MISC O-MISC
dosages O-MISC O-MISC
of O-MISC O-MISC
dexamethasone O-MISC O-MISC
( O-MISC O-MISC
Dex O-MISC O-MISC
; O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
5 O-MISC O-MISC
) O-MISC O-MISC
- O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
9 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Dex O-MISC O-MISC
inhibited O-MISC O-MISC
the O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
proliferation O-MISC O-MISC
of O-MISC O-MISC
PMA O-MISC O-MISC
blasts O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
dose O-MISC O-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
fashion O-MISC O-MISC
( O-MISC O-MISC
IC50 O-MISC O-MISC
, O-MISC O-MISC
5 O-MISC O-MISC
x O-MISC O-MISC
10 O-MISC O-MISC
( O-MISC O-MISC
- O-MISC O-MISC
8 O-MISC O-MISC
) O-MISC O-MISC
M O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Cell O-MISC O-MISC
surface O-MISC O-MISC
expression O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
alpha I-MISC I-MISC
- I-MISC I-MISC
and I-MISC I-MISC
beta I-MISC I-MISC
- I-MISC I-MISC
chains I-MISC I-MISC
as O-MISC O-MISC
determined O-MISC O-MISC
by O-MISC O-MISC
immunofluorescence O-MISC O-MISC
analysis O-MISC O-MISC
was O-MISC O-MISC
not O-MISC O-MISC
affected O-MISC O-MISC
by O-MISC O-MISC
Dex O-MISC O-MISC
. O-MISC O-MISC

In O-MISC O-MISC
addition O-MISC O-MISC
, O-MISC O-MISC
Scatchard O-MISC O-MISC
plot O-MISC O-MISC
analysis O-MISC O-MISC
of O-MISC O-MISC
125I B-MISC B-MISC
- I-MISC I-MISC
labeled I-MISC I-MISC
IL I-MISC I-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
showed O-MISC O-MISC
that O-MISC O-MISC
Dex O-MISC O-MISC
did O-MISC O-MISC
not O-MISC O-MISC
affect O-MISC O-MISC
the O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2 I-MISC I-MISC
, O-MISC O-MISC
thus O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
inhibition O-MISC O-MISC
is O-MISC O-MISC
due O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
postreceptor O-MISC O-MISC
effect O-MISC O-MISC
. O-MISC O-MISC

Inhibition O-MISC O-MISC
of O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
proliferation O-MISC O-MISC
by O-MISC O-MISC
Dex O-MISC O-MISC
was O-MISC O-MISC
associated O-MISC O-MISC
with O-MISC O-MISC
decreased O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
tyrosine O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
several O-MISC O-MISC
intracellular B-MISC B-MISC
proteins I-MISC I-MISC
and O-MISC O-MISC
decreased O-MISC O-MISC
phosphorylation O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
retinoblastoma B-MISC B-MISC
gene I-MISC I-MISC
product I-MISC I-MISC
Rb I-MISC B-MISC
, O-MISC O-MISC
a O-MISC O-MISC
protein O-MISC O-MISC
essential O-MISC O-MISC
for O-MISC O-MISC
controlling O-MISC O-MISC
the O-MISC O-MISC
progression O-MISC O-MISC
of O-MISC O-MISC
cells O-MISC O-MISC
through O-MISC O-MISC
the O-MISC O-MISC
cell O-MISC O-MISC
cycle O-MISC O-MISC
. O-MISC O-MISC

IL O-MISC B-MISC
- O-MISC I-MISC
2 O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
IL O-MISC B-MISC
- O-MISC I-MISC
2R O-MISC I-MISC
alpha O-MISC I-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
PMA O-MISC O-MISC
blasts O-MISC O-MISC
and O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kB I-MISC I-MISC
induction O-MISC O-MISC
in O-MISC O-MISC
resting O-MISC O-MISC
human O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
Dex O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
results O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
glucocorticoids O-MISC O-MISC
inhibit O-MISC O-MISC
preactivated O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
by O-MISC O-MISC
down O-MISC O-MISC
- O-MISC O-MISC
regulating O-MISC O-MISC
signal O-MISC O-MISC
transduction O-MISC O-MISC
through O-MISC O-MISC
IL B-MISC B-MISC
- I-MISC I-MISC
2R I-MISC I-MISC
. O-MISC O-MISC

Chronic O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
stimulates O-MISC O-MISC
distinct O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
/ O-MISC O-MISC
rel O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activities O-MISC O-MISC
in O-MISC O-MISC
myelomonoblastic O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
relationship O-MISC O-MISC
between O-MISC O-MISC
human O-MISC O-MISC
immunodeficiency O-MISC O-MISC
virus O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
) O-MISC O-MISC
infection O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
induction O-MISC O-MISC
of O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
was O-MISC O-MISC
examined O-MISC O-MISC
in O-MISC O-MISC
a O-MISC O-MISC
myeloid O-MISC O-MISC
cell O-MISC O-MISC
model O-MISC O-MISC
of O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
derived O-MISC O-MISC
from O-MISC O-MISC
the O-MISC O-MISC
PLB O-MISC O-MISC
- O-MISC O-MISC
985 O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

Chronic O-MISC O-MISC
infection O-MISC O-MISC
of O-MISC O-MISC
PLB O-MISC O-MISC
- O-MISC O-MISC
985 O-MISC O-MISC
cells O-MISC O-MISC
led O-MISC O-MISC
to O-MISC O-MISC
increased O-MISC O-MISC
monocyte O-MISC O-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
surface O-MISC O-MISC
marker O-MISC O-MISC
expression O-MISC O-MISC
, O-MISC O-MISC
increased O-MISC O-MISC
c O-MISC B-MISC
- O-MISC I-MISC
fms O-MISC I-MISC
gene O-MISC I-MISC
transcription O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
morphological O-MISC O-MISC
alterations O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
differentiation O-MISC O-MISC
along O-MISC O-MISC
the O-MISC O-MISC
monocytic O-MISC O-MISC
pathway O-MISC O-MISC
. O-MISC O-MISC

PLB O-MISC O-MISC
- O-MISC O-MISC
IIIB O-MISC O-MISC
cells O-MISC O-MISC
displayed O-MISC O-MISC
a O-MISC O-MISC
constitutive O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
- O-MISC O-MISC
like O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
that O-MISC O-MISC
was O-MISC O-MISC
distinct O-MISC O-MISC
from O-MISC O-MISC
that O-MISC O-MISC
induced O-MISC O-MISC
by O-MISC O-MISC
tumor B-MISC B-MISC
necrosis I-MISC I-MISC
factor I-MISC I-MISC
alpha I-MISC I-MISC
or O-MISC O-MISC
phorbol O-MISC O-MISC
12 O-MISC O-MISC
- O-MISC O-MISC
myristate O-MISC O-MISC
13 O-MISC O-MISC
- O-MISC O-MISC
acetate O-MISC O-MISC
treatment O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
parental O-MISC O-MISC
PLB O-MISC O-MISC
- O-MISC O-MISC
985 O-MISC O-MISC
cell O-MISC O-MISC
line O-MISC O-MISC
. O-MISC O-MISC

This O-MISC O-MISC
unique O-MISC O-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
consisted O-MISC O-MISC
of O-MISC O-MISC
proteins O-MISC O-MISC
of O-MISC O-MISC
70 B-MISC O-MISC
, I-MISC O-MISC
90 I-MISC O-MISC
, I-MISC O-MISC
and I-MISC O-MISC
100 I-MISC O-MISC
kDa I-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
high O-MISC O-MISC
degree O-MISC O-MISC
of O-MISC O-MISC
binding O-MISC O-MISC
specificity O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
site I-MISC I-MISC
within O-MISC O-MISC
the O-MISC O-MISC
PRDII B-MISC B-MISC
domain I-MISC I-MISC
of O-MISC O-MISC
beta B-MISC B-MISC
interferon I-MISC I-MISC
. O-MISC O-MISC

In O-MISC O-MISC
this O-MISC O-MISC
report O-MISC O-MISC
, O-MISC O-MISC
we O-MISC O-MISC
characterize O-MISC O-MISC
the O-MISC O-MISC
nature O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
proteins O-MISC O-MISC
and O-MISC O-MISC
demonstrate O-MISC O-MISC
that O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
these O-MISC O-MISC
proteins O-MISC O-MISC
is O-MISC O-MISC
also O-MISC O-MISC
induced O-MISC O-MISC
following O-MISC O-MISC
Sendai O-MISC O-MISC
paramyxovirus O-MISC O-MISC
infection O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
70 B-MISC B-MISC
- I-MISC I-MISC
kDa I-MISC I-MISC
protein I-MISC I-MISC
corresponds O-MISC O-MISC
to O-MISC O-MISC
the O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
RelA I-MISC I-MISC
( I-MISC I-MISC
p65 I-MISC I-MISC
) I-MISC I-MISC
subunit I-MISC I-MISC
, O-MISC O-MISC
which O-MISC O-MISC
is O-MISC O-MISC
activated O-MISC O-MISC
in O-MISC O-MISC
response O-MISC O-MISC
to O-MISC O-MISC
an O-MISC O-MISC
acute O-MISC O-MISC
paramyxovirus O-MISC O-MISC
infection O-MISC O-MISC
or O-MISC O-MISC
a O-MISC O-MISC
chronic O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
infection O-MISC O-MISC
. O-MISC O-MISC

Virus O-MISC O-MISC
infection O-MISC O-MISC
does O-MISC O-MISC
not O-MISC O-MISC
appear O-MISC O-MISC
to O-MISC O-MISC
alter O-MISC O-MISC
the O-MISC O-MISC
amount O-MISC O-MISC
of O-MISC O-MISC
RelA B-MISC B-MISC
( O-MISC I-MISC
p65 B-MISC I-MISC
) O-MISC I-MISC
or O-MISC O-MISC
NFKB1 B-MISC B-MISC
( O-MISC O-MISC
p50 B-MISC B-MISC
) O-MISC O-MISC
but O-MISC O-MISC
rather O-MISC O-MISC
affects O-MISC O-MISC
the O-MISC O-MISC
capacity O-MISC O-MISC
of O-MISC O-MISC
I B-MISC B-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
to O-MISC O-MISC
sequester O-MISC O-MISC
RelA B-MISC B-MISC
( I-MISC O-MISC
p65 I-MISC B-MISC
) I-MISC I-MISC
, O-MISC O-MISC
therefore O-MISC O-MISC
leading O-MISC O-MISC
to O-MISC O-MISC
constitutive O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
RelA O-MISC B-MISC
DNA O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
and O-MISC O-MISC
to O-MISC O-MISC
increased O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
- O-MISC O-MISC
dependent O-MISC O-MISC
gene O-MISC O-MISC
activity O-MISC O-MISC
. O-MISC O-MISC

The O-MISC O-MISC
virally O-MISC O-MISC
induced O-MISC O-MISC
90 B-MISC B-MISC
- I-MISC I-MISC
to I-MISC I-MISC
100 I-MISC I-MISC
- I-MISC I-MISC
kDa I-MISC I-MISC
proteins I-MISC I-MISC
have O-MISC O-MISC
a O-MISC O-MISC
distinct O-MISC O-MISC
binding O-MISC O-MISC
specificity O-MISC O-MISC
for O-MISC O-MISC
the O-MISC O-MISC
PRDII B-MISC B-MISC
domain I-MISC I-MISC
and O-MISC O-MISC
an O-MISC O-MISC
AT B-MISC B-MISC
- I-MISC I-MISC
rich I-MISC I-MISC
sequence I-MISC I-MISC
but O-MISC O-MISC
do O-MISC O-MISC
not O-MISC O-MISC
cross O-MISC O-MISC
- O-MISC O-MISC
react O-MISC O-MISC
with O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
subunit O-MISC I-MISC
- O-MISC O-MISC
specific O-MISC O-MISC
antisera O-MISC O-MISC
directed O-MISC O-MISC
against O-MISC O-MISC
NFKB1 B-MISC B-MISC
( O-MISC O-MISC
p105 B-MISC B-MISC
or O-MISC O-MISC
p50 B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
NFKB2 B-MISC B-MISC
( O-MISC O-MISC
p100 B-MISC B-MISC
or O-MISC O-MISC
p52 B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
RelA B-MISC B-MISC
( O-MISC O-MISC
p65 B-MISC B-MISC
) O-MISC O-MISC
, O-MISC O-MISC
or O-MISC O-MISC
c B-MISC B-MISC
- I-MISC I-MISC
rel I-MISC I-MISC
. O-MISC O-MISC

DNA O-MISC O-MISC
binding O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
90 B-MISC B-MISC
- I-MISC I-MISC
to I-MISC I-MISC
100 I-MISC I-MISC
- I-MISC I-MISC
kDa I-MISC I-MISC
proteins I-MISC I-MISC
was O-MISC O-MISC
not O-MISC O-MISC
inhibited O-MISC O-MISC
by O-MISC O-MISC
recombinant B-MISC B-MISC
I I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
alpha I-MISC I-MISC
/ I-MISC I-MISC
MAD I-MISC I-MISC
- I-MISC I-MISC
3 I-MISC I-MISC
and O-MISC O-MISC
was O-MISC O-MISC
resistant O-MISC O-MISC
to O-MISC O-MISC
tryptic O-MISC O-MISC
digestion O-MISC O-MISC
, O-MISC O-MISC
suggesting O-MISC O-MISC
that O-MISC O-MISC
these O-MISC O-MISC
proteins O-MISC O-MISC
may O-MISC O-MISC
not O-MISC O-MISC
be O-MISC O-MISC
NF B-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
related I-MISC O-MISC
. O-MISC O-MISC

Transient O-MISC O-MISC
cotransfection O-MISC O-MISC
experiments O-MISC O-MISC
demonstrated O-MISC O-MISC
that O-MISC O-MISC
RelA O-MISC B-MISC
and O-MISC O-MISC
NFKB1 O-MISC B-MISC
expression O-MISC O-MISC
maximally O-MISC O-MISC
stimulated O-MISC O-MISC
HIV B-MISC B-MISC
- I-MISC I-MISC
1 I-MISC I-MISC
LTR I-MISC I-MISC
- I-MISC I-MISC
and I-MISC O-MISC
NF I-MISC B-MISC
- I-MISC I-MISC
kappa I-MISC I-MISC
B I-MISC I-MISC
- I-MISC I-MISC
dependent I-MISC I-MISC
reporter I-MISC I-MISC
genes I-MISC I-MISC
; O-MISC O-MISC
differences O-MISC O-MISC
in O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC O-MISC
kappa O-MISC B-MISC
B O-MISC I-MISC
- O-MISC O-MISC
like O-MISC O-MISC
binding O-MISC O-MISC
activity O-MISC O-MISC
were O-MISC O-MISC
also O-MISC O-MISC
reflected O-MISC O-MISC
in O-MISC O-MISC
higher O-MISC O-MISC
constitutive O-MISC O-MISC
levels O-MISC O-MISC
of O-MISC O-MISC
NF O-MISC B-MISC
- O-MISC I-MISC
kappa O-MISC I-MISC
B O-MISC I-MISC
- O-MISC O-MISC
regulated O-MISC O-MISC
gene O-MISC O-MISC
expression O-MISC O-MISC
in O-MISC O-MISC
HIV O-MISC O-MISC
- O-MISC O-MISC
1 O-MISC O-MISC
- O-MISC O-MISC
infected O-MISC O-MISC
myeloid O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

Presence O-MISC O-MISC
of O-MISC O-MISC
estrogen O-MISC B-MISC
- O-MISC I-MISC
binding O-MISC I-MISC
sites O-MISC I-MISC
on O-MISC O-MISC
macrophage O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
synoviocytes O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
CD29 O-MISC O-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
in O-MISC O-MISC
normal O-MISC O-MISC
and O-MISC O-MISC
rheumatoid O-MISC O-MISC
synovium O-MISC O-MISC
. O-MISC O-MISC

OBJECTIVE O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
study O-MISC O-MISC
the O-MISC O-MISC
presence O-MISC O-MISC
of O-MISC O-MISC
estrogen O-MISC B-MISC
- O-MISC I-MISC
binding O-MISC I-MISC
sites O-MISC I-MISC
( O-MISC O-MISC
EBS O-MISC B-MISC
) O-MISC O-MISC
in O-MISC O-MISC
the O-MISC O-MISC
synovial O-MISC O-MISC
tissues O-MISC O-MISC
of O-MISC O-MISC
male O-MISC O-MISC
and O-MISC O-MISC
female O-MISC O-MISC
patients O-MISC O-MISC
with O-MISC O-MISC
rheumatoid O-MISC O-MISC
arthritis O-MISC O-MISC
( O-MISC O-MISC
RA O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
age O-MISC O-MISC
- O-MISC O-MISC
and O-MISC O-MISC
sex O-MISC O-MISC
- O-MISC O-MISC
matched O-MISC O-MISC
healthy O-MISC O-MISC
controls O-MISC O-MISC
. O-MISC O-MISC

METHODS O-MISC O-MISC
. O-MISC O-MISC

Both O-MISC O-MISC
type O-MISC O-MISC
1 O-MISC O-MISC
( O-MISC O-MISC
high O-MISC O-MISC
affinity O-MISC O-MISC
, O-MISC O-MISC
low O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
) O-MISC O-MISC
and O-MISC O-MISC
type O-MISC O-MISC
2 O-MISC O-MISC
( O-MISC O-MISC
reduced O-MISC O-MISC
affinity O-MISC O-MISC
, O-MISC O-MISC
higher O-MISC O-MISC
binding O-MISC O-MISC
capacity O-MISC O-MISC
) O-MISC O-MISC
EBS O-MISC B-MISC
were O-MISC O-MISC
investigated O-MISC O-MISC
in O-MISC O-MISC
both O-MISC O-MISC
soluble O-MISC O-MISC
and O-MISC O-MISC
nuclear O-MISC O-MISC
fractions O-MISC O-MISC
of O-MISC O-MISC
homogenized O-MISC O-MISC
synovial O-MISC O-MISC
tissue O-MISC O-MISC
samples O-MISC O-MISC
by O-MISC O-MISC
a O-MISC O-MISC
dextran O-MISC O-MISC
- O-MISC O-MISC
coated O-MISC O-MISC
charcoal O-MISC O-MISC
method O-MISC O-MISC
. O-MISC O-MISC

To O-MISC O-MISC
determine O-MISC O-MISC
what O-MISC O-MISC
type O-MISC O-MISC
of O-MISC O-MISC
synovial O-MISC O-MISC
cell O-MISC O-MISC
was O-MISC O-MISC
positive O-MISC O-MISC
for O-MISC O-MISC
EBS O-MISC B-MISC
, O-MISC O-MISC
cryosections O-MISC O-MISC
of O-MISC O-MISC
synovial O-MISC O-MISC
tissues O-MISC O-MISC
were O-MISC O-MISC
immunostained O-MISC O-MISC
with O-MISC O-MISC
a O-MISC O-MISC
specific O-MISC O-MISC
monoclonal B-MISC B-MISC
anti I-MISC I-MISC
- I-MISC I-MISC
estrogen I-MISC I-MISC
receptor I-MISC I-MISC
antibody I-MISC O-MISC
( O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
ER I-MISC I-MISC
MAb I-MISC I-MISC
) O-MISC O-MISC
using O-MISC O-MISC
both O-MISC O-MISC
immunofluorescence O-MISC O-MISC
and O-MISC O-MISC
immunoperoxidase O-MISC B-MISC
techniques O-MISC O-MISC
. O-MISC O-MISC

Double O-MISC O-MISC
immunostaining O-MISC O-MISC
with O-MISC O-MISC
the O-MISC O-MISC
anti B-MISC B-MISC
- I-MISC I-MISC
ER I-MISC I-MISC
MAb I-MISC I-MISC
and O-MISC O-MISC
with O-MISC O-MISC
specific B-MISC O-MISC
MAb I-MISC B-MISC
to O-MISC O-MISC
detect O-MISC O-MISC
different O-MISC O-MISC
macrophage B-MISC O-MISC
antigens I-MISC I-MISC
( O-MISC O-MISC
Ber B-MISC B-MISC
- I-MISC I-MISC
MAC3 I-MISC I-MISC
, O-MISC O-MISC
MAC387 B-MISC O-MISC
, O-MISC O-MISC
CD68 B-MISC B-MISC
) O-MISC O-MISC
and O-MISC O-MISC
CD8 O-MISC B-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cell O-MISC O-MISC
subsets O-MISC O-MISC
( O-MISC O-MISC
CD29 O-MISC O-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC
and O-MISC O-MISC
CD29 O-MISC O-MISC
- O-MISC O-MISC
, O-MISC O-MISC
CD45RO O-MISC O-MISC
- O-MISC O-MISC
) O-MISC O-MISC
was O-MISC O-MISC
performed O-MISC O-MISC
. O-MISC O-MISC

RESULTS O-MISC O-MISC
. O-MISC O-MISC

Higher O-MISC O-MISC
affinity O-MISC I-MISC
EBS O-MISC B-MISC
were O-MISC O-MISC
found O-MISC O-MISC
mostly O-MISC O-MISC
in O-MISC O-MISC
nuclear O-MISC O-MISC
cell O-MISC O-MISC
fractions O-MISC O-MISC
of O-MISC O-MISC
either O-MISC O-MISC
RA O-MISC O-MISC
or O-MISC O-MISC
control O-MISC O-MISC
synovial O-MISC O-MISC
tissues O-MISC O-MISC
( O-MISC O-MISC
28 O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
33 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

These O-MISC O-MISC
EBS O-MISC B-MISC
were O-MISC O-MISC
present O-MISC O-MISC
to O-MISC O-MISC
a O-MISC O-MISC
lesser O-MISC O-MISC
extent O-MISC O-MISC
in O-MISC O-MISC
soluble O-MISC O-MISC
cell O-MISC O-MISC
fractions O-MISC O-MISC
( O-MISC O-MISC
11 O-MISC O-MISC
of O-MISC O-MISC
the O-MISC O-MISC
33 O-MISC O-MISC
) O-MISC O-MISC
. O-MISC O-MISC

Immunostaining O-MISC O-MISC
showed O-MISC O-MISC
the O-MISC O-MISC
estrogen O-MISC B-MISC
receptor O-MISC I-MISC
- O-MISC O-MISC
positive O-MISC O-MISC
cells O-MISC O-MISC
to O-MISC O-MISC
be O-MISC O-MISC
the O-MISC O-MISC
macrophage O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
synoviocytes O-MISC O-MISC
and O-MISC O-MISC
the O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
CD29 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
both O-MISC O-MISC
in O-MISC O-MISC
RA O-MISC O-MISC
and O-MISC O-MISC
in O-MISC O-MISC
control O-MISC O-MISC
synovial O-MISC O-MISC
tissues O-MISC O-MISC
. O-MISC O-MISC

Higher O-MISC O-MISC
nuclear O-MISC O-MISC
content O-MISC O-MISC
of O-MISC O-MISC
EBS O-MISC B-MISC
was O-MISC O-MISC
consistent O-MISC O-MISC
with O-MISC O-MISC
more O-MISC O-MISC
intense O-MISC O-MISC
nuclear O-MISC O-MISC
staining O-MISC O-MISC
of O-MISC O-MISC
synoviocytes O-MISC O-MISC
and O-MISC O-MISC
T O-MISC O-MISC
cells O-MISC O-MISC
. O-MISC O-MISC

CONCLUSION O-MISC O-MISC
. O-MISC O-MISC

It O-MISC O-MISC
is O-MISC O-MISC
conceivable O-MISC O-MISC
that O-MISC O-MISC
the O-MISC O-MISC
immunomodulatory O-MISC O-MISC
activity O-MISC O-MISC
exerted O-MISC O-MISC
by O-MISC O-MISC
estrogens O-MISC O-MISC
is O-MISC O-MISC
at O-MISC O-MISC
least O-MISC O-MISC
partly O-MISC O-MISC
mediated O-MISC O-MISC
through O-MISC O-MISC
their O-MISC O-MISC
interaction O-MISC O-MISC
with O-MISC O-MISC
EBS O-MISC B-MISC
that O-MISC O-MISC
are O-MISC O-MISC
present O-MISC O-MISC
on O-MISC O-MISC
macrophage O-MISC O-MISC
- O-MISC O-MISC
like O-MISC O-MISC
synoviocytes O-MISC O-MISC
, O-MISC O-MISC
functioning O-MISC O-MISC
as O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
processing O-MISC O-MISC
and O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
presenting O-MISC O-MISC
cells O-MISC O-MISC
, O-MISC O-MISC
and O-MISC O-MISC
on O-MISC O-MISC
antigen O-MISC O-MISC
- O-MISC O-MISC
experienced O-MISC O-MISC
( O-MISC O-MISC
memory O-MISC O-MISC
) O-MISC O-MISC
CD8 O-MISC O-MISC
+ O-MISC O-MISC
T O-MISC O-MISC
lymphocytes O-MISC O-MISC
( O-MISC O-MISC
CD29 O-MISC O-MISC
+ O-MISC O-MISC
, O-MISC O-MISC
CD45RO O-MISC O-MISC
+ O-MISC O-MISC

